<SEC-DOCUMENT>0001558370-22-003614.txt : 20220315
<SEC-HEADER>0001558370-22-003614.hdr.sgml : 20220315
<ACCEPTANCE-DATETIME>20220315074930
ACCESSION NUMBER:		0001558370-22-003614
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		115
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220315
DATE AS OF CHANGE:		20220315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entrada Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001689375
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813983399
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40969
		FILM NUMBER:		22739146

	BUSINESS ADDRESS:	
		STREET 1:		6 TIDE STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		857-305-1825

	MAIL ADDRESS:	
		STREET 1:		6 TIDE STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CycloPorters, Inc.
		DATE OF NAME CHANGE:	20161104
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>trda-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/15/2022 11:35:26 AM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: 5cffa737-7507-4d83-bb90-2f6d69ec0d6a -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:trda="http://www.entradatx.com/20211231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" xs:nil="true" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Of58JJxZ4keNwMsnoEV_Hw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" xs:nil="true" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_UbgNrvtLyUiiH7YvL8dZzg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" xs:nil="true" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" name="us-gaap:CommonStockValue" id="Hidden_2ziGg0HHdkeDmqmrnAviXg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_drr4vLhnZUCSHDjSts1PsA">8.16</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_NTFV33O3hk6TxzH7NJ9c5g">24.00</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_3VJWT4ngp0aczaFLk0nApg">6267776</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_saaCB_HxK0Gfhe0kWokcQA">1105260</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_NJwUPpejpEG2GASt6Z9RoA">6267776</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_x-mNzE4UUkGBx0e3FnoP8A">1105260</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_JFF1gzEYxkmqNACNSLO4fA">8.16</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_KRMqqkYCvkiUV0MKGa8Rag">24.00</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityCentralIndexKey" id="Tc_fV_WLEBahE6doBQcQvAU4Q_2_1">0001689375</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:DocumentFiscalYearFocus" id="Tc_ag9IyKqV4UWAyY1Fzexp2g_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_gVLyzqVObEWjzwPXAFxHaA_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:AmendmentFlag" id="Tc_5i7nXnmtfE-rsTyJ45mPAQ_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" xs:nil="true" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Hidden_EcmWlvh2TEiknBczU408Mg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" xs:nil="true" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Hidden_-KTlssYZZU-m9cyJXvqw1g"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_10_22_2021_To_10_22_2021_uQZsCRIxnUqAluL0h4RX7Q" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_w1M_9o9Q5kO5Amu-2DsMtA">0.1382</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" xs:nil="true" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" name="us-gaap:DeferredTaxAssetsNet" id="Hidden_HodcTs_FvES0HiIzmfy6sw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" xs:nil="true" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" name="us-gaap:DeferredTaxAssetsNet" id="Hidden_x7heNc3It0iVSYbvysmtSA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_BSNci6dkMUiwQdU7Toounw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_nO6qA4U-90qR30UGTnbjfg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" id="Hidden_pW9XlBHI-0ycz6y8QY0knQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_mKo_OzFuf0iQHjQHrOziTg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_Q1xy7BMWbEaf-hfVggNTxg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" id="Hidden_MKSePaSzEkGUhAEuj95QSg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" id="Hidden_rEQdZS50-kOSKfpodxCC5Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" id="Hidden_55OB18X63USdH30lIVVNWA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" id="Hidden_Ga0buu0SgUSrUdG99nJxqA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" id="Hidden_s0CI3ABO1UOwyiaMjM21WQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" id="Hidden_STNba99TEE2P8TlOmIf09w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" id="Hidden_bdDNugQjEkeWGJ5RRTmMeQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" id="Hidden_rAODftV1WkevOqiQBf1HaA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" id="Hidden_Lf1kOd_TBEa3WfZ4jJXYSA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" id="Hidden_hbAR-Fm85kGGPUqDJIMHMA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" id="Hidden_Y9_kSFxPbUCICwx3C4cQwQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" id="Hidden_t79w48C3NUGADeWiFga7Hg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_ym4vD8Ib1EeCt_yPBK0BDg">2420746</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_UU486mV8PEqPdC425qxydw">82879139</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_YSRag8nKMEqb6M9fhWc-MQ">85299885</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:IcfrAuditorAttestationFlag" id="Hidden_wvP2J5Tt3UeeM1ma9KGLpQ">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="trda-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_O8pVP4l75kOdx-yCEK8aZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_zP_saBrSuEeXS1wmFBKk8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_aj5kvebNtEaEwVM3errF3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_7VWTG_vPyUKvAaUWm3BT8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_22_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_epyOIcPzq0SVrlfXNg7yEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tYP56ACKCEObErEOejmqsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_16_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_xATBx4mlJkO_FY67Y7xj6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_3_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_0aluTUFCZU6jYAc_CRSl2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_27_2016_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_GsM3bvleAkui8rQ0h-Ql9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_dnx581iJhk-tByLmAfE2iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_22_2021_To_10_22_2021_uQZsCRIxnUqAluL0h4RX7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-22</xbrli:startDate><xbrli:endDate>2021-10-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fIyU3F2ce0eWRga502fJBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3Evel5BXlU2Nkn6JOeAzkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O7xm61cRg0K4Na8wCgmpSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpyy8MnVM0KmlsYrfZMTyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I9FjEp0tz0WGNpk85jBJ1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kycqBPxOmUOgzZHFE2RRRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_78VjKUVPTEe0xf_MNsF1lA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l9HKPBpFZ0iNKAGeJGZG1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BuEOalfyI0u2lwqzpEOfWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_jPFYwfOyHkibNEeOW_EYTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_q07zOZMvO0O0qAOZXAgC6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2016Member_WSANhifLkU2A9s4mVWiePw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:StockPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_eX6Qkp3pp0eD-g-WpjcsYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_trda_StockPlan2021Member_XN77OWOzXkC7szS4MrVGTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:StockPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_Tt00y1mV6kiK5B4cvFJE-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_RWcJH0PTE0iREP0s53rf8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_djIfGJUG3UerKSFCe6I17g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_nCvXJPkm-EeVgL-HAKzWCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:StockPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_rM6lo0glkkSHK6fx56dohQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:OfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_-28m7dTNPU20dkA6HHUEeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_G0o0UYvQV06N8dmtQoWrUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:OfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_iH0SLfAWbk6jaf3g4ibe_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_nypqQlrtZE6lptm3mK1OuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_iZZ8FczNTU2tGeemyaYEYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_fyE8largOkCW__YS3RTN3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wcmbqMPhOU6rzqEZYMNIYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QYNTB61VYUat6jQAfNj3sA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Ue4SlaWOQ0KyF4HIsqdP3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3wtllMeGF0-uvRoiD-yA9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_QjA51H3Ah0aFo7MeOknVsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__p-8KrZhskSQeQtAxAXVcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DeQYlMJLU0-AyRtM2oqjfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_22_2020_To_1_22_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_-1_Yd9urDk-m9ncpSMWkLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-22</xbrli:startDate><xbrli:endDate>2020-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_27_2016_To_5_16_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_4mA-_qHs2kGfQFglJrYgww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-27</xbrli:startDate><xbrli:endDate>2017-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_y8-ETpe8yUaoJwpU5roQfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_a53NGrxD4kSTEvV0srI_NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kbIUpMM9tU6Bw1ItzOX4kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_skLgUvkO-UWUx7Bti_R8Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_K6kVW2WPBE-kg0DD1wJujA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:OfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_1fQTtTn9-E69-ajeccNB9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2021_a0-v3caGu0mm1ZtiJx365w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_5fShMvZuL0CBikfxgEmhJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:StockPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_WfsWIAfNmE2sstVPNwOq4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BPELmQx4xEiCTW0PJ5snKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RedeemableConvertiblePreferredStockMember_6iNejRF2DEGk6tYe2YQoHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JkQZPPgBBUGf-humPcfAMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_trda_StockPlan2016Member_AiSU5Z1vhEGHTV-J1QFVng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:StockPlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_0F7kyPmgPE6NFo60sAPzEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HJgZfqoHTEiB7zwNlTcURQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ehK6rCutpEqfLe84L0CqtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-qOWEZ-lG0Wgp-Dc-_n5tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4PqQOnDumkefao8imFFhKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BPCLjgwbAkKCfg-NbETCtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P198-NvWk0W9y94TBotMiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_L_Yrm18-ZEq_KotDl6_Nmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_voVae7De2EOf0pczy20g7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_kcauchfWnUmJP3dujL0p2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_29_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_jhtKcYUrGUeXiu8kysHe4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:OfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_aI2VmsKba02tMKmJCqhsEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:OfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VeWTpBES60mrDvFGp33DJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_trda_UnvestedSharesMember_Yg75Vq-JeUiuqL-_773DFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">trda:UnvestedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BrM28n-jyUOi_DtOIFHwAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_Yg0eRdnrPE6oZY0L97BMQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_EMioRKOEOUuK6W_DHnQC0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_trda_UnvestedSharesMember_ONz4dFb4f0-msro3DrkJBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">trda:UnvestedSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W6iQ9yRAYE2F1wZofX493A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_F-9SRQC7hkatUiZQujCAMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tD1C2qFg_0-xasA5fL3IOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_zsGA-ZYjak2Nkhe-ZCUNNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_l7f8215TfUmkc3xqHhvUwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynIvbasOrkmhLq6FFmJ_CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_ydttNEUZL0mEntDbye7NGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_29_2021_To_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_EV4uTuzkYE6h_aLfr9tQpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-29</xbrli:startDate><xbrli:endDate>2021-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_12_2020_To_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_z6226-NgvE6yUlb-QpUJqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-12</xbrli:startDate><xbrli:endDate>2020-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_22_2020_To_1_22_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_xzJvCpIB60egOnueDPk1DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-22</xbrli:startDate><xbrli:endDate>2020-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_16_2017_To_5_16_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_2d5Zkg5ROU2FOzEjN1-Wlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-16</xbrli:startDate><xbrli:endDate>2017-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_3_2017_To_3_3_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_3gJUFiFT7E-8naW-uk6dqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-03</xbrli:startDate><xbrli:endDate>2017-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_27_2016_To_10_27_2016_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_-En8tjRnnUC9eKmjOLrxDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-27</xbrli:startDate><xbrli:endDate>2016-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_u1sl4JaoEU2V5L65kkaVfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_494Nn9bt3E65r2GvytHiBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_rXp55kz8m0-Oy4jN90htNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_603nz09bmES_5kNTHFmsAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f79AwiNGhE-sfsUO9KmsTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_LGXl_iZN7E6dEJSRz6h1QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-14</xbrli:startDate><xbrli:endDate>2018-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2019_To_6_30_2020_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Hf7j2O4nM06-u1HOfsgByg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Cy9RrUM470ieiIVBwGRytQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_RYC5_ZIHMEyAEsk0XkA_Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_FM5MwYyCLk66BYx1-YT-iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_WDhCcPxYokqoE__Xm560JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tneHEayNbkCaFY8W_qAw-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_jxCvIM-1WEOJ9WQF7LNJvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_-TdaxQCqC0-mYAk7Hd2Eow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_5_2021_klmSXHbwckOZOadD2UgSvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2022_1msmRA4SCkq2Cr9ERvHZHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001689375</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_z46z-AyIh0iy55GSvWd0bw"><xbrli:measure>trda:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_qXeWDqcza0Kv2YWLNzbANQ"><xbrli:measure>trda:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw"><xbrli:measure>trda:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_rx7LKou9MUKld2X7S962qQ"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_3f14ddb0_c5c9_4cad_8b5f_e49223443fa0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:15pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:15pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:15pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:DocumentType" id="Narr_rRhc2Fb5Wkug2-7VSQS25g"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_03a1632d_5b6c_4388_a332_80b08944919b"></a><div style="padding-left:36pt;"><a id="Tc_E0WPRQBqZk60DYqLytBGHQ_1_0"></a><a id="Tc_lUmGQKCeWEitcCjD18fpFA_2_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:88.28%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:90.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">(Mark&#160;One)</b></p></td><td style="vertical-align:top;width:90.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:DocumentAnnualReport" id="Tc_ly_3_2Vksk-8YgkE_ZmbJA_2_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:90.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;"> ANNUAL&#160;REPORT&#160;PURSUANT&#160;TO&#160;SECTION&#160;13&#160;OR&#160;15(d)&#160;OF&#160;THE&#160;SECURITIES EXCHANGE&#160;ACT OF 1934</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:DocumentPeriodEndDate" id="Narr_YYUW0mnnD0mzTGCdIEli8w"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:CurrentFiscalYearEndDate" id="Narr_qEJUA_NscEqEZBG3jwGeXQ"><b style="font-size:7pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">or</b></p><a id="_397d23bb_7603_43ea_849f_ea1f28eaa192"></a><div style="padding-left:36pt;"><a id="Tc_1mEZbVPLkEqlKH2GhdPB0A_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:89.01%;"><tr style="height:1pt;"><td style="vertical-align:top;width:9.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:90.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:DocumentTransitionReport" id="Tc_00HvY3o5ekOJRpDj5FoRUA_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:90.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION&#160;REPORT&#160;PURSUANT&#160;TO&#160;SECTION&#160;13&#160;OR&#160;15(d)&#160;OF&#160;THE&#160;SECURITIES EXCHANGE&#160;ACT OF 1934</b></p></td></tr><tr style="height:3.2pt;"><td style="vertical-align:top;width:9.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><span style="font-size:9pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;"> to </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityFileNumber" id="Narr_uTH8Kq4rLEumernYnRcYKw"><b style="font-size:7pt;font-weight:bold;">001-40969</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> </b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:21pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityRegistrantName" id="Narr_H-fgWQLDdE-1NEv4gQQgWA"><b style="font-weight:bold;">ENTRADA THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_3126735a_55c1_4237_95e6_48d0d5e71cc7"></a><a id="Tc_lxpw1turbE2UcXNTE0lV8Q_2_0"></a><a id="Tc_Ud04MF51GUiRa6-xIE-i0A_2_1"></a><a id="Tc_JtpKwG84CUOmMmfiYnKjEg_4_0"></a><a id="Tc_-JaD7wuZE0uAF29hEo8h-Q_5_0"></a><a id="Tc_tbn2Y6DD3EqbxPi1yM-MRw_6_0"></a><a id="Tc_qLwyLiuCvUC1fUXow3bAFQ_6_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:89.01%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_JFpL1Nh-v0efRi4eFho9DQ_1_0"><b style="font-size:7pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityTaxIdentificationNumber" id="Tc_Boba7Qt4XUWQ6MyQ0st28w_1_1"><b style="font-size:7pt;font-weight:bold;">81-3983399</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other&#160;jurisdiction of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification Number)</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityAddressAddressLine1" id="Narr_sj5YdNvbo0uggZ_YZy0L8Q"><b style="font-size:7pt;font-weight:bold;">6 Tide Street</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityAddressCityOrTown" id="Narr_x8W7MSvSWkCZn5x_i8frXQ"><b style="font-size:7pt;font-weight:bold;">Boston</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityAddressStateOrProvince" id="Narr_hmEu1AtUrUygGx7_YnuNgg"><b style="font-size:7pt;font-weight:bold;">MA</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityAddressPostalZipCode" id="Tc_Y2mOe8DDgEekdaDV1LRP6Q_5_1"><b style="font-size:7pt;font-weight:bold;">02210</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of Principal Executive Offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:CityAreaCode" id="Narr_CdpeunhQk06Uk8bxLXk8qw"><b style="font-size:7pt;font-weight:bold;">857</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:LocalPhoneNumber" id="Narr__smCWVeYsk2eR0Ded3vizA"><b style="font-size:7pt;font-weight:bold;">520-9158</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_a158e9ad_1a85_44ae_baf3_03a8e94f4bfd"></a><a id="Tc_6h_2PSS3dECeo9CePshoww_1_0"></a><a id="Tc_9xdTKuxKzEubG01M-rp2OQ_1_1"></a><a id="Tc_t4avKpLCZEmBlKnwjEpBbw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:96.43%;"><tr style="height:0.55pt;"><td style="vertical-align:top;width:38.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:0.55pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:23.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:0.55pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:38.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:0.55pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:38.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title of Each Class</b></p></td><td style="vertical-align:top;width:23.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:38.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Name of each exchange on which registered</b></p></td></tr><tr style="height:22.05pt;"><td style="vertical-align:top;width:38.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:Security12bTitle" id="Tc_c8_doWk920mjZt7HtDkhvQ_2_0"><b style="font-size:7pt;font-weight:bold;">Common Stock, par value $0.0001 per share</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:23.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:TradingSymbol" id="Tc_-THN0Cw5yUi6O97WNaBsvw_2_1"><b style="font-size:7pt;font-weight:bold;">TRDA</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:SecurityExchangeName" id="Tc_iYXBnQI7-U6qkoQOGIFwEQ_2_2"><b style="font-size:7pt;font-weight:bold;">The Nasdaq Global Market</b></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;">Securities registered pursuant to Section 12(g) of the Act: None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_iyiCx97i-0KfESIZ6YqNLw"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;white-space:pre-wrap;">   </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityVoluntaryFilers" id="Narr_KbhZqXnkQEGJ7ROxGEusdA"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityCurrentReportingStatus" id="Narr_HNBcD1ki4EeuKr_9SdE2aQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityInteractiveDataCurrent" id="Narr_08HRlrpklE-rZiT5NYQ_rw"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_9e756c58_62d7_4a23_870d_80a36c507334"></a><a id="Tc_Q7QQS42P-EejpHIADgp8Bg_1_0"></a><a id="Tc_3SQPbhvGi0WEme_GNq2F2g_1_1"></a><a id="Tc_t2lQiG-_o0CKn2e5xx4O8Q_1_2"></a><a id="Tc_7tYKb_g7jE-YMyOm1i7BHQ_1_3"></a><a id="Tc_Czz4hayjzE-qnsvpkLoXEQ_3_1"></a><a id="Tc_6A1PltSRsESW7cIrms0xMA_3_2"></a><a id="Tc_62-nAvJF00-Bgo7N8Ap6NQ_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1.9pt;"><td style="vertical-align:bottom;width:26.45%;margin:0pt;padding:0pt;"><div style="height:1.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><div style="height:1.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:32.19%;margin:0pt;padding:0pt;"><div style="height:1.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:32.19%;margin:0pt;padding:0pt;"><div style="height:1.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1.9pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:7.05pt;"><td style="vertical-align:bottom;width:26.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Wingdings';">&#168;</span></p></td><td style="vertical-align:bottom;width:32.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Wingdings';">&#168;</span></p></td><td style="vertical-align:top;width:32.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:26.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:32.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.85pt;"><td style="vertical-align:bottom;width:26.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityFilerCategory" id="Tc_r6uOWJsA_k-8YRh-oNmqpw_3_0"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span>&#160;&#160;</p></td><td style="vertical-align:bottom;width:32.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntitySmallBusiness" id="Tc_8c0bfDPseU-xABtZo3nhUg_3_3"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:32.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Emerging&#160;growth&#160;company</p></td><td style="vertical-align:bottom;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityEmergingGrowthCompany" id="Tc_DE8fbUnACUShackwPnMepA_3_5"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityExTransitionPeriod" id="Narr_Xlhmul0PnESaHNvcAh8RIg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;"> </span><span style="-sec-ix-hidden:Hidden_wvP2J5Tt3UeeM1ma9KGLpQ;"><span style="font-family:'Wingdings';font-size:7pt;font-style:normal;font-weight:normal;">&#168;</span></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:EntityShellCompany" id="Narr_kirHdxZPD06GfVKLmsnyjQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 5pt 0pt;">The aggregate market value of registrant&#8217;s common equity held by non-affiliates of registrant on November 5, 2021 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_11_5_2021_klmSXHbwckOZOadD2UgSvg" decimals="-5" name="dei:EntityPublicFloat" id="Narr_wyLTzTYyLkS9iwCVWLnsMQ">474.9</ix:nonFraction> million based upon the closing sale price of the common stock as reported on The Nasdaq Global Market as of such date. <span style="background:#ffffff;">The registrant has elected to use </span>November 5<span style="background:#ffffff;">, 2021, which was the final closing date of the Company&#8217;s initial public offering, including the </span><span style="letter-spacing:-0.1pt;">full exercise of the underwriters&#8217; option to purchase additional shares&#160;</span><span style="background:#ffffff;">on the Nasdaq Global Market, as the calculation date because on June 30, 2021 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) the registrant was a privately held company.&#160;</span>In determining the market value of non-affiliate common stock, shares of the registrant&#8217;s common stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">As of February 28, 2022, the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_28_2022_1msmRA4SCkq2Cr9ERvHZHg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_GCpR3Z5lh0yj7ELrkzPGfQ">31,251,484</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Portions of the registrant&#39;s definitive Proxy Statement for its 2022 Annual Meeting of Stockholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#39;s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f1207078_71cd_45f8_a994_67fe56b75254"></a><a id="TableofContents"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_266dacd1_fd10_498a_998b_3cdfe81c532d"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;white-space:normal;width:87.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt 51pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTI"><b style="font-style:normal;font-weight:bold;">PART I</b></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:87.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_606971"><span style="font-style:normal;font-weight:normal;">Item 1. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Business</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_796330"><span style="font-style:normal;font-weight:normal;">Item 1A. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk Factors</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">64</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_342067"><span style="font-style:normal;font-weight:normal;">Item 1B. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unresolved Staff Comments</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">130</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_998237"><span style="font-style:normal;font-weight:normal;">Item 2. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Properties</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">130</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_466085"><span style="font-style:normal;font-weight:normal;">Item 3. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal Proceedings</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">130</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_423594"><span style="font-style:normal;font-weight:normal;">Item 4. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Mine Safety Disclosures</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">130</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:87.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTII_277737"><b style="font-style:normal;font-weight:bold;">PART II</b></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:87.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item 5. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">131</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_268516"><span style="font-style:normal;font-weight:normal;">Item 6. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reserved</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">132</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Item 7. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">133</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item 7A. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 0.05pt;">Quantitative and Qualitative Disclosures About Market Risk</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">143</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item 8. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial Statements and Supplementary Data</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">144</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item 9. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">168</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_447228"><span style="font-style:normal;font-weight:normal;">Item 9A. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Controls and Procedures</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">168</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_773499"><span style="font-style:normal;font-weight:normal;">Item 9B. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Information</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">168</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">168</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:87.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIII_735359"><b style="font-style:normal;font-weight:bold;">PART III</b></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:87.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item 10. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Directors, Executive Officers and Corporate Governance</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">169</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_320836"><span style="font-style:normal;font-weight:normal;">Item 11. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Executive Compensation</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">169</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item 12. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">169</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item 13. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certain Relationships and Related Transactions, and Director Independence</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">169</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountingFeesandServices"><span style="font-style:normal;font-weight:normal;">Item 14. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal Accounting Fees and Services</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">169</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:87.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="4" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><a href="#PARTIV_938268"><b style="font-style:normal;font-weight:bold;">PART IV</b></a></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:87.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item 15. </span></a></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibits and Financial Statement Schedules</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">170</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a> </p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Form 10-K Summary</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">171</p></td></tr><tr><td style="vertical-align:top;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:77.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">172</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_caf59ca1_4a10_4631_a72d_3af4ec21e29a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk88575512"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">This Annual Report on Form 10-K (Annual Report) contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), that are based on our management&#8217;s belief and assumptions and on information currently available to our management. These statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, timing, progress, results and costs of conducting our research and development programs and our current and future preclinical studies and anticipated clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our current and future programs;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of our preclinical studies and clinical trials to demonstrate safety and efficacy of our therapeutic candidates, and other positive results;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of our therapeutic candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, scope and likelihood of regulatory filings and approvals, including timing of Investigational New Drug applications (INDs) and final U.S. Food and Drug Administration (FDA) approval of our current therapeutic candidates or any future therapeutic candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, scope or likelihood of foreign regulatory filings and approvals;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to leverage our proprietary EEV Platform to efficiently develop additional therapeutic candidates, including by applying learnings from one program to other programs and from </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one indication to our other indications;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates of the number of patients that we will enroll and our ability to initiate, recruit and enroll patients in and conduct and successfully complete clinical trials at the pace that we project;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing and our ability to scale-up our manufacturing and processing approaches to appropriately address our anticipated commercial needs, which will require significant resources;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish or maintain collaborations or strategic relationships and the ability and willingness of our third-party strategic collaborators to undertake research and development activities relating to our therapeutic candidates and discovery programs;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our therapeutic candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to take advantage of expedited regulatory pathways for our therapeutic candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory approval of our therapeutic candidates;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the implementation of our business model, and strategic plans for our business, therapeutic candidates, and technology;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of protection we are able to establish and maintain for intellectual property rights covering our therapeutic candidates and other therapeutic candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 2.9pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our financial performance and estimates of our future expenses, revenues, capital requirements, use of our cash reserves, and our needs for additional financing;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future agreements with third parties in connection with the development and commercialization of our therapeutic candidates and any other approved product;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rate and degree of market acceptance and the size and growth potential of the markets for our therapeutic candidates, and our ability to serve those markets;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to produce our therapeutic candidates with advantages in turnaround times or manufacturing cost;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitive position and the success of competing therapies that are or may become available;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our need for and ability to attract and retain key scientific, management and other personnel and to identify, hire and retain additional qualified professionals;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the period during which we will remain an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the JOBS Act);</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our anticipated use of our existing resources;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of the ongoing coronavirus, or COVID-19, pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;background:#ffffff;margin:0pt;">In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;seek,&#8221; &#8220;predict,&#8221; &#8220;future,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; or the negative of these terms or other comparable terminology, and similar expressions, although not all forward-looking statements contain these identifying words. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. You should read this Annual Report and the documents that we reference in this Annual Report and have filed with the Securities and Exchange Commission (the SEC) thereto completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">You should read this Annual Report on Form 10-K and the documents that we reference herein and have filed or incorporated by reference as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">This Annual Report also contains estimates, projections and other information concerning our industry, our business and the markets for our product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. All of the market data used in this Annual Report involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions<span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7ae205d5_413b_4eb0_b7e8_598e970e5edd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUMMARY OF MATERIAL AND OTHER RISKS ASSOCIATED WITH OUR BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our business is subject to numerous risks and uncertainties and are subject to change based on various factors, including those highlighted in the section entitled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K (Annual Report). These risks include, but are not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are early in our development efforts. We have not initiated clinical studies, and as a result it will be years before we commercialize a therapeutic candidate, if ever. If we are unable to identify and advance therapeutic candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business is highly dependent on the clinical advancement of our programs and modalities and is especially dependent on the success of our lead EEV therapeutic candidate, ENTR-601-44. Delay or failure to advance programs or modalities, including ENTR-601-44 could adversely impact our business.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our EEV therapeutic candidates are based on a novel therapeutic approach, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies are not necessarily predictive of the results of later preclinical studies and any clinical trials of our therapeutic candidates. We have not tested any of our therapeutic candidates in clinical trials and our therapeutic candidates may not have favorable results in clinical trials, if any, or receive regulatory approval on a timely basis, if at all.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Substantial delays in the commencement, enrollment or completion of our planned clinical trials or failure to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities could prevent us from commercializing any therapeutic candidates we determine to develop on a timely basis, if at all.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our approach to the discovery and development of therapeutic candidates based on our EEV Platform is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our therapeutic candidates or render our EEV Platform obsolete.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily or, dedicate adequate resources to meet our needs, or may be unable to acquire the necessary supplies to perform successfully.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition, and if our competitors develop technologies or therapeutic candidates more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">While we will attempt to diversify our risks by developing one or more programs in each modality, there are risks that are unique to each modality and risks that are applicable across modalities. These risks may impair our ability to advance one or more of our programs in clinical development, obtain regulatory approval, or ultimately commercialize our programs, or cause us to experience significant delays in doing so, any of which may materially harm our business. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain patent protection for our EEV Platform, therapeutic development programs and other proprietary technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our therapeutic programs and other proprietary technologies we may develop may be adversely affected.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our future success depends on our ability to retain key employees and to attract, retain and motivate qualified personnel. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unstable market and economic conditions may have adverse consequences for our business, financial condition and stock price.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The material and other risks summarized above should be read together with the text of the full risk factors and in the other information set forth in this Annual Report, including our consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange Commission (the SEC). If any such material and other risks and uncertainties actually occur, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks summarized above or described in full are not the only risks that we face. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, prospects, financial condition and results of operations.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2d0565f1_d2b7_4306_a79e_66c32c291abb"></a><a id="PARTI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART I</b></p><a id="Item1Business_606971"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1. Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We aim to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV) therapeutics as a new class of medicines and we aim to become the world&#8217;s foremost intracellular therapeutics company. EEV therapeutics are comprised of small cyclic peptides that are chemically conjugated to a wide range of specific and active biological therapeutics. Our EEV therapeutics are designed to engage intracellular targets that have long been considered inaccessible and undruggable. Through our proprietary, highly versatile and modular EEV platform (EEV Platform), we are building a robust development portfolio of EEV therapeutic candidates designed to enable the efficient intracellular delivery of therapeutics in various organs and tissues with an improved therapeutic index. We believe that the potential success of our early programs can translate into the efficient development of additional EEV therapeutic candidates and allow us to build portfolios in rare disease, immunology and oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are initially focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). DMD is caused by genetic mutations that prevent the creation of functional dystrophin, a protein required to maintain the structural integrity of muscle cells. In our neuromuscular disease programs, we link EEVs to small strands of nucleic acids called oligonucleotides, including phosphorodiamidate morpholino oligomers (PMOs). We are developing EEV-PMOs that promote the skipping of these mutations associated with DMD. We believe that our EEV-PMO exon-skipping therapy will enable the production of functional dystrophin to slow, stop or even reverse disease progression. Our most advanced therapeutic candidate, ENTR-601-44, is being developed for patients with DMD that are exon 44 skipping amenable. We plan to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ENTR-601-44 in 2022. We are developing a second lead program, EEV-PMO-CAG, for patients with DM1. Patients with DM1 carry extra cytosine-uracil-guanine (CUG) triplet repeats that result in misprocessing of several proteins and multisystemic clinical manifestations. Our EEV-PMO-CAG for DM1 is designed to block the triplet repeats in the messenger RNA (mRNA) that sequesters these critical proteins and restore muscle function. We plan to submit an IND to the FDA for EEV-PMO-CAG, for the treatment of DM1, in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Approximately 75% of all disease-causing targets are located inside cells. Intracellular therapeutics are designed to correct disease-causing dysfunction inside cells, addressing targets at the level of DNA, RNA or protein. In order to do so, these therapeutics need to first get through the cell&#8217;s membrane, which is a phospholipid bilayer, and then escape from the cell&#8217;s transportation and sorting vehicle, known as the early endosome, in order to reach and engage with their intended targets. Small molecules can permeate cell membranes but tend to be rapidly cleared by the body before they reach the intended tissue and can be associated with off-target effects. These limitations often necessitate high therapeutic doses and can be associated with less-than-optimal therapeutic activity. Biological therapeutics are generally potent and specific with respect to their intracellular targets of interest but limited in their ability to reach such targets, often lacking the ability to efficiently penetrate the cell membrane and then escape from the early endosome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe our EEV Platform can enable the efficient intracellular delivery of specific and potent therapeutics. The following key attributes of our EEV Platform have allowed us to develop broadly distributed, EEV therapeutic candidates, which have been observed to be pharmacologically or biologically active and targeted with respect to the engagement or involvement with a desired intracellular target of interest.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Serum stability and extended half-life:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Based on preclinical studies, we have observed that EEVs have increased stability and extended half-life due to their unique cyclic structure, which limits protease-mediated degradation. We believe this may enable increased systemic exposure.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Broad biodistribution:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> EEVs target phospholipid bilayers, which we believe can enable delivery to any cell in the body, regardless of route of administration. We have shown biodistribution to a wide range of organs, tissues and cells in our preclinical studies, including cardiac muscle, the cerebellum and macrophages, among many others.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:160.7pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Active uptake and drug release:</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> EEVs generally avoid being trapped in the cell membrane and are instead taken up into the cell by the early endosome. EEVs then enable budding of vesicles from the early endosome, which we believe substantially increase the level of therapeutics reaching intended targets within the cell.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe our EEV Platform can offer meaningful advantages over existing therapeutic approaches, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Broad potential therapeutic index</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> based on observations in preclinical studies. We believe EEV therapeutic candidates can engage targets across various organs and tissues with up to 50 times greater intracellular target exposure compared with a similar dose regimen of an unconjugated therapeutic.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Potential utility across multiple modalities</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> due to the ability of EEVs to facilitate intracellular uptake of proprietary therapeutic candidates ranging in size from 1 kDa to 600 kDa, including oligonucleotides, peptides, antibodies and larger multimeric proteins.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Potential applicability to a wide range of diseases</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> as we believe EEVs can enter cells by binding with the phospholipid bilayer which is common to all cells, tissues and organs in the body. This may imply an ability to achieve both systemic and specific delivery of potential therapeutic candidates for a wide range of diseases.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Multiple delivery routes</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> possible including intravenous (IV), intramuscular (IM), subcutaneous (SQ) and intrathecal (IT) injections to deliver our EEV therapeutic candidates and generate functional outcomes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Modular approach supports efficient expansion of development into multiple therapeutic areas,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> including oligonucleotide therapies in rare disease and immunology, antibody-based protein degraders in oncology and enzyme replacement therapy in rare disease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">A simple and scalable construct designed to translate from preclinical to clinical development</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> as EEVs have been manufactured efficiently to clinical scale and the small size of EEVs may limit the risk of immunogenicity. In addition, acute and chronic toxicology studies in the ENTR-501 program have demonstrated the potential to deliver clinically-relevant doses in a non-human primate (NHP) with favorable tolerability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Through our EEV Platform, we aim to create a diverse and expanding development portfolio of oligonucleotide, antibody and enzyme-based programs as summarized in the graphic below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k006.jpg" alt="A screenshot of a computer&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:160.7pt;width:436.8pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Neuromuscular Diseases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In neuromuscular disease, we are initially focused on the development of disease-modifying treatments for DMD. DMD is a monogenic X-linked disease caused by mutations in the DMD gene, which encodes for the protein dystrophin. We estimate that DMD occurs in approximately one in every 3,500 to 5,000 live male births and that the </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">patient population is approximately 30,000 patients in the aggregate in the United States and Europe. Approximately 80% of patients have mutations amenable to exon skipping in the nucleus. We are developing therapeutic candidates to address the genetic basis, at the exon-specific level, of DMD. EEV oligonucleotides are designed to promote the skipping of exon mutations associated with DMD, enabling muscle cells to create a functional dystrophin at a level that we believe may slow, stop or even reverse DMD progression. We are initially focusing on the development of an EEV-PMO, ENTR-601-44, for patients with DMD that are exon 44 skipping amenable, who represent approximately 7.6% of the total DMD population with significant unmet medical need. We have observed substantial exon skipping (50%-100%) and dystrophin production of up to approximately 70% of wild-type levels in mice, which is durable at eight weeks. Our preclinical studies have also demonstrated reductions in serum creatine kinase (CK), which is a commonly-used biomarker of muscle breakdown, to wild-type levels. Correction of CK is believed to be a strong indicator of pharmacodynamic activity throughout the body and has been described in medical literature as a marker of muscle integrity. We have observed corresponding and significant improvements in functional outcomes as measured in the D2-mdx mouse. In particular, we have observed meaningful tissue uptake and exon skipping, ranging from approximately 60% to over 95% depending on the tissue, in the D2-mdx mouse.<span style="color:#231f20;"> In this model, in EEV-PMO treated tissues we observed substantial restoration of both dystrophin and alpha sarcoglycan. In striated muscle, sarcoglycans interact with dystrophin and other dystrophin-associated proteins to form the dystrophin-associated glycoprotein complex which protects the sarcolemma from contraction-induced injury. Finally, we have observed extended</span> PK and high levels (almost 90% in the biceps) of exon skipping in a NHP with ENTR-601-44. We are also developing an EEV-PMO for patients with exon 45 skipping amenable mutations, which population represents approximately 8% of the total DMD population. We plan to submit an IND to the FDA for ENTR-601-44 in 2022 and to select an exon 45 skipping candidate in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are developing a second lead program for patients with DM1. DM1 is a rare disease caused by a mutation driven alteration of normal RNA structure manifesting as an increase in the number of CTG triplet repeats found in the 3&#8217; non-coding region of the DM1 protein kinase (DMPK) gene. The resulting transcripts, which contain an expanded CUG tract, aggregate in discrete foci in the nuclei of DM patient cells. The excessive number of CUG repeats impart toxic activity, referred to as a toxic gain-of-function. Multiple key proteins are misprocessed, and this contributes to the multisystemic nature of the disease, which includes generalized limb weakness, respiratory muscle impairment, cardiac abnormalities, fatigue, gastrointestinal complications, cataracts, incontinence and excessive daytime sleepiness. DM1 is commonly estimated to affect over 40,000 people in the United States and over 50,000 in Europe. Our approach is intended to address the underlying cause of the disease by targeting the extra CUG triplet repeats responsible for the downstream misprocessing of proteins important to cell growth, metabolism and function. <span style="color:#231f20;">EEV-PMO-CAG is designed to block the triplet repeats and correct the mis-splicing and aberrant expression of downstream transcripts in order to restore tissue function. Our preclinical studies have resulted in </span><i style="color:#231f20;font-style:italic;">in vitro</i><span style="color:#231f20;"> and </span><i style="color:#231f20;font-style:italic;">in vivo</i><span style="color:#231f20;"> data where we have observed splicing correction across multiple transcripts, durable DMPK mRNA knockdown, reduction of foci, rapid phenotypic correction, and tolerability in murine models of DM1 which exhibit expanded CTG and CUG repeats. We expect to announce a candidate for the potential treatment of DM1 and additional supporting data in early 2022, and expect to submit an IND for such therapeutic candidate to the FDA in 2023</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We believe our EEV Platform has broad applicability across multiple neuromuscular diseases. In addition to DMD and DM1, we are leveraging this platform to explore EEV oligonucleotides for the potential treatment of Pompe disease. Pompe disease is a rare, autosomal recessive lysosomal storage disease caused by a mutation in the gene that encodes for glucosidase alpha acid (GAA), which results in an absence or deficiency of GAA protein that is essential to the breakdown of complex sugar, glycogen. Excess glycogen in the muscle cell leads to tissue damage and loss of function. Pompe disease is commonly estimated to affect between 5,000 and 10,000 patients in the aggregate in the United States and Europe; however, the advent of newborn screening suggests the disease is underdiagnosed. Our Pompe disease program focuses on the development of a potentially disease-modifying treatment by utilizing an EEV therapeutic candidate that targets and degrades the mRNA-encoding glycogen synthetase 1 (GYS1), a protein required for the synthesis of glycogen which powers in muscle cells. Our preclinical data has shown superior and dose-dependent EEV-PMO knockdown of GYS1 gene expression (approximately 95%) and protein production in skeletal and cardiac muscles versus PMO alone. Further, protein level reductions were durable to eight weeks post IV dose of 13.5 mg/kg EEV-PMO.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immunology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">In immunology, we are currently leveraging multiple oligonucleotide strategies to downregulate the expression of Interferon Regulatory Factor 5 (IRF5). IRF5 activation is a master switch implicated in the inflammatory and fibrotic </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">processes associated with non-alcoholic steatohepatitis, systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, type 2 diabetes, asthma and neuropathic pain, among many others. We have observed knockdown of the problematic IRF5 protein both </span><i style="color:#231f20;font-style:italic;">in vitro </i><span style="color:#231f20;">and </span><i style="color:#231f20;font-style:italic;">in vivo</i><span style="color:#231f20;">. We are currently optimizing the EEV-PMO constructs and conducting experiments evaluating the delivery of IRF5-targeting EEV-PMOs in disease models. Results from these experiments, including potential proof-in-concept are expected in 2022. Pending positive results, we plan to select our first immunology therapeutic candidate by the end of 2023</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Oncology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">In oncology, we believe our EEV Platform has the potential to deliver highly selective large molecule protein degraders against disease-causing proteins. We are actively working towards an oncology therapeutic candidate selection for biologically validated targets that have been undruggable or have been sub-optimally drugged. We are initially focused on &#946;-catenin, a protein which contributes to the carcinogenesis, tumor progression and metastasis of several cancers, including colon, liver, pancreatic, lung, breast and ovarian cancer. We have observed that EEV conjugation to a receptor-targeted antibody enhances meaningful modulation of intracellular signaling</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Metabolic Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ENTR-501, an intracellular thymidine phosphorylase (TP) enzyme replacement therapy (ERT), program is in development for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). MNGIE is a slowly progressive, rare disease characterized by elevated levels of thymidine. Preliminary preclinical studies have demonstrated that ENTR-501 reduces toxic thymidine levels below those observed in wild-type mice. We have completed IND-enabling studies for the MNGIE program, including pharmacodynamic and pharmacokinetic studies in mice, and pharmacokinetic and chronic toxicology in NHPs. In 2020, we made the strategic decision to focus the majority of our immediate efforts on EEV-oligonucleotide opportunities. In order to support ENTR-501 progress, we are exploring partnership opportunities with organizations that have the resources and expertise to continue the development of ENTR-501 into and through clinical development. We continue to believe that the program will have an important role in the future treatment of patients with MNGIE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional Discovery Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">We</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">leveraging</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">modularity</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">our</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">EEV</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">Platform</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">develop</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">opportunities</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">as</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">diverse</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">as EEV-CRISPR-Cas</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">delivery</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">gene</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">editing,</span><span style="color:#231f20;letter-spacing:-0.55pt;"> EEV-antibody drug conjugates, </span><span style="color:#231f20;">EEV-oligonucleotide</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">opportunities</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">for</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">central</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">nervous system (CNS) and peripheral nervous system (PNS) disorders, EEV-antibody oligonucleotide conjugates for enhanced tissue tropism and blood brain barrier carriage, as well as novel EEV-ERT therapies. We regularly explore strategic opportunities to develop therapies where we believe our EEV Platform will make a difference for patients with devastating diseases</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We aim to transform the lives of patients by establishing EEV therapeutics as a new class of medicines and we aim to become the world&#8217;s foremost intracellular therapeutics company. To achieve this, the key pillars of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Rapidly advance EEV-PMO therapeutic candidates into clinical development in patients with DMD and DM1.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our DMD portfolio is comprised of exon-skipping </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">EEV-PMO </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapies that aim to restore functional dystrophin production. We have initially prioritized our DMD development efforts on exon 44 and 45 skipping amenable mutations, due to the profound unmet need in these respective patient populations. We plan to advance our most advanced lead </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;">EEV-PMO </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapeutic candidate, ENTR-601-44, which targets the skipping of exon 44,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.5pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to Investigational New Drug (IND) filing with the FDA in 2022. Following proof-of-concept of ENTR-601-44</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">plan</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DMD</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">franchise</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discovering</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapeutic candidates for additional patient subpopulations. We are developing a second program</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for patients with DM1 and plan to submit an IND to the FDA for an EEV-PMO-CAG</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> candidate </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2023.</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">believe</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">can</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leverage</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">EEV,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">linker</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">oligonucleotide optimization process and build upon the potential success of each exon skipping therapeutic candidate. For example, we believe that potential technical success in DM1, which involves correcting for a toxic gain of function, could be broadly applicable within and beyond neuromuscular</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diseases</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Leverage the modularity of our platform to advance a broad development portfolio of EEV therapeutic candidates across multiple devastating diseases</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We believe our modular EEV Platform can enable us to advance therapeutic candidates for the treatment of additional</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">neuromuscular</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.3pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diseases</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.3pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.3pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">which</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.3pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.3pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">biophysical</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.3pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">properties,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.3pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapeutic</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.3pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approaches, and development strategies are similar to DMD which involves upregulating gene and protein expression and DM1 which involves downregulating protein expression through the normalization of alternate splicing. Initially we intend to broaden our disease portfolio into Pompe</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disease,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">while</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assessing</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">same</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapeutic</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">candidate</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">multiple glycogen storage disorders. We plan to advance additional programs outside of neuromuscular diseases leveraging a variety of EEV-PMO strategies to downregulate gene expression with a focus on broadly applicable intracellular targets central to a variety of indications beyond neuromuscular disease</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Continue to invest in and build upon our EEV Platform to extend our pioneering position in developing novel EEV-based therapeutic candidates. </b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We plan to continue to invest in our platform and expand our library of EEVs by optimizing the EEV chemistry for specific modalities, including oligonucleotide, antibody and enzyme-based therapeutic candidates. We are also leveraging the modularity of the platform to combine different elements such as antibody-guided oligonucleotide constructs to enhance tissue tropism and enzyme and guide RNA associations to enable gene editing. We further plan to explore the flexibility</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">platform</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pursue</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">alternative</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapeutic</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approaches</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">same</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fundamental challenges;</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">example,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">EEV</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">antibodies</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">degrade</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pathogenic</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protein</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">to</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">use</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;">EEV- </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PMO approaches to prevent the production of that same</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protein</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Selectively evaluate strategic partnerships to maximize the therapeutic potential of our EEV Platform</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We aim to improve patients&#8217; lives and plan to utilize our library of EEVs to enable strategic partnerships with the goal of expanding our therapeutic footprint, and to accelerate the development of certain programs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Team and Culture</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our patient-focused culture drives our shared mission of developing intracellular therapeutics for patients with devastating diseases. We are committed to building and maintaining a deep connection with the patients, caregivers, research community and physicians that we serve.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management team brings a depth of experience and knowledge base in platform research, drug discovery and development and commercialization. The team is led by Dipal Doshi, our President and Chief Executive Officer, who brings over 20 years of leadership experience within life sciences companies; Natarajan Sethuraman, Ph.D., our Chief Scientific Officer, who is an expert in large molecule therapeutic development and delivery platforms with over 30 years of experience across pharmaceutical and biotechnology companies; Nerissa Kreher, M.D., our Chief Medical Officer, a physician executive with a 15-year record of driving growth at start-ups and larger biotech/pharma companies and with extensive experience in rare disease research; Nathan Dowden, our Chief Operating Officer, who has almost three decades of experience leading corporate strategy, portfolio management, business planning and operations; Kory Wentworth, our Chief Financial Officer, who has 20 years of public accounting and global biopharmaceutical experience<span style="color:#231f20;"> and our General Counsel, Jared Cohen Ph.D., J.D., who has 20 years of both external and in-house experience at a range of mature and early stage biopharmaceutical companies. Our leadership team also includes, Karla MacDonald, our Vice President of Corporate Communications, and Kerry Robert, M.S., our Vice President of People. As of December 31, 2021, our organization was comprised of 102 talented individuals with significant experience across</span><span style="color:#231f20;letter-spacing:-1.55pt;"> </span><span style="color:#231f20;">discovery,</span><span style="color:#231f20;letter-spacing:-1.5pt;"> </span><span style="color:#231f20;">preclinical</span><span style="color:#231f20;letter-spacing:-1.5pt;"> </span><span style="color:#231f20;">research,</span><span style="color:#231f20;letter-spacing:-1.5pt;"> </span><span style="color:#231f20;">manufacturing,</span><span style="color:#231f20;letter-spacing:-1.5pt;"> </span><span style="color:#231f20;">clinical</span><span style="color:#231f20;letter-spacing:-1.5pt;"> </span><span style="color:#231f20;">development</span><span style="color:#231f20;letter-spacing:-1.5pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-1.5pt;"> </span><span style="color:#231f20;">operations.</span><span style="color:#231f20;letter-spacing:-1.5pt;"> </span>We are supported by leading scientific and clinical experts in the fields of peptide chemistry, oligonucleotide and protein optimization, disease specific pathophysiology and clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">Since our inception, we have raised over $400 million in private and public capital from leading biotechnology investors</span>.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:201pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Platform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biology of Intracellular Trafficking</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each person&#8217;s genetic material, or genome, consists of DNA in sequences of genetic code called genes. Many diseases, including rare genetic diseases, immune-mediated disorders and cancers, are caused by a mutation in an individual&#8217;s DNA sequence, as compared to a healthy individual. These mutations can be in a single gene, and result in monogenic disorders, or in multiple genes. This genetic dysregulation can be inherited or can be caused by damage to the DNA. In each case, a mutation results in a change in the information that DNA provides to the cell&#8217;s protein manufacturing and processing functions, which in turn result in either a lack of useful protein, an excess of toxic protein, or a dysregulation of cell signaling mechanisms. These changes manifest in pathological dysfunction at the cellular, tissue, organ and potentially systemic level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As pathological dysfunction occurs inside the cell, intracellular therapeutics are designed to correct disease-causing dysfunction at either the level of DNA, RNA, or protein. Therapeutic modalities which prevent or enhance protein production include small molecules, viral gene therapies and oligonucleotide therapeutics, including anti-sense oligonucleotides (ASOs) and small interfering RNAs (siRNAs). Therapeutic modalities which target aberrant proteins include small molecules, enzymes, antibodies and peptides.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Despite significant advances in understanding disease drivers, obstacles to effective treatment remain, in part because approximately 75% of all disease-causing targets are located inside of cells. Small molecules can permeate cell membranes but tend to be rapidly cleared by the body before they reach the intended tissue and can be associated with off-target effects. These limitations often necessitate high therapeutic doses and can be associated with less-than-optimal therapeutic activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the other hand, biological therapeutics are highly targeted and potent but are limited in their ability to reach intracellular targets of interest. The first challenge is to get biological therapeutics, such as proteins and nucleic acids, through the phospholipid bilayer. Proteins and nucleic acids can be internalized through endocytosis, a natural process by which substances are brought into the cell. Once endocytosis begins, the cell membrane folds around the biological therapeutic and internalizes it, fusing with it and trapping it in a structure called the early endosome. The early endosome serves as a sorting vehicle, either returning its contents back to the cell membrane or transporting and slowly degrading them in the late endosome and, ultimately, in the lysosome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k007.jpg" alt="Graphic" style="display:inline-block;height:200.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:455.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The second challenge is achieving endosomal escape, wherein the biological therapeutic is released in functional form from the early endosome. Even when a therapeutic is successful in penetrating a cell, only about 1% of the drug will escape the early endosome to reach its intended intracellular targets. As a result, high doses of drug product are often needed to produce a therapeutic effect, which could potentially cause systemic dose-related toxicity. While scientific advances using lipid particles, viral vectors, antibodies and prior generations of cell-penetrating peptides to </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:198.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">deliver biological therapeutics have been made, these vehicles are often relatively toxic, limited in their applicability and/or difficult to manufacture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To effectively capitalize on both known biology and future discoveries, a better way of targeted intracellular delivery of therapeutics is needed. We believe we have discovered a potential solution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Approach</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An ideal therapeutic platform enables the efficient intracellular delivery of highly targeted and potent therapeutics throughout the body. The cornerstone of our platform, our proprietary EEVs are comprised of small cyclic peptides of approximately 10 amino acid residues or fewer. EEVs bind with low affinity, at normal serum pH levels, directly to the phospholipid bilayer of all cells and trigger the natural process of endocytosis. EEVs are chemically conjugated to a wide range of specific and potent biological therapeutics, including, for example, small snippets of therapeutic RNA (ASOs), antibodies and large enzymes, to create EEV therapeutic candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="trda-20211231x10k008.jpg" alt="Graphic" style="display:inline-block;height:198.25pt;width:452.2pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once the EEV-conjugated material binds to the phospholipid bilayer, the cell engulfs the conjugate and brings it inside. EEVs are designed to enable cellular uptake into every type of tissue in the body. In addition to the potential for broad cellular distribution, we believe EEVs can also, if needed, be tailored to specific cell types or tissues through the conjugation of high affinity cell-receptor antibodies, wherein the picomolar to nanomolar level receptor binding affinity would be expected to easily out-compete the low affinity phospholipid binding activity of the EEV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In our preclinical studies, we have observed, based on mass balance analysis, that greater than 90% of EEV-conjugated material is taken up by the tissues of the body. Once inside the cell, these studies indicate that the EEV-conjugated material rapidly escapes from the early endosome. Because of the low-pH conditions in the early endosome, the binding affinity of the EEV to the inner endosome wall increases, resulting in the successful formation and budding of unstable vesicles which then collapse and release their contents into the cell cytosol. In our preclinical studies, we observed that approximately 50% of the EEV-conjugated material escaped the endosome to reach the intracellular disease target as compared to the &lt;2% observed in prior studies of current biologics. While these preclinical studies were not designed as head-to-head comparisons to current biologics, these data generally compare favorably to historical published data regarding the percentage, of current biologics that have been observed to reach their designed intracellular disease target. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:192.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="trda-20211231x10k009.jpg" alt="Graphic" style="display:inline-block;height:192.25pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:446.95pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Key attributes of our EEV Platform include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Serum stability and extended half-life:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The cyclic structure of EEVs is designed to limit protease-mediated degradation, resulting in increased stability and extended half-life. In contrast, linear cell-penetrating peptides are rapidly degraded in human serum.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Broad biodistribution:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> EEVs target phospholipid bilayers and can therefore potentially be delivered to any cell in the body, regardless of route of administration. Additionally, and importantly, cyclization confers unique biophysiochemical properties to EEVs, optimally positioning side chains for membrane association and enabling the use of fewer positively charged cationic residues, which we believe could reduce potential toxicities of EEVs relative to linear peptides which rely on chemistries with a high positive charge.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Active uptake and drug release:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> EEVs bind to membrane phospholipids but not proteoglycans and thus avoid being trapped in the cell membrane. The low affinity binding to the cell surface triggers endocytosis and we have observed that 90% of the EEV-conjugated material was taken up in tissue in our preclinical studies. The low pH enhanced affinity of EEVs triggers the budding of vesicles from the early endosome and we have observed the subsequent release of approximately 50% of this material into the cytosol in our preclinical studies. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="trda-20211231x10k010.jpg" alt="Graphic" style="display:inline-block;height:192.25pt;width:434.05pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:172.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have developed a proprietary library of EEVs to enable the intracellular engagement of therapeutics against previously inaccessible and undruggable disease-causing targets. EEVs are broadly distributed, highly targeted, designed to have a wide therapeutic index and can be chronically dosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Key advantages of our platform include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Broad potential therapeutic index:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our EEV Platform is designed to allow specific biological therapeutics to engage targets across every cell in the body. In our preclinical studies, we observed that approximately 50% of the EEV-conjugated material escaped the endosome to reach the intracellular disease target as compared to the &lt;2% observed in prior studies of current biologics. While these preclinical studies were not designed as head-to-head comparisons to current biologics, these data generally compare favorably to historical published data regarding the percentage of current biologics that have been observed to reach their designed intracellular disease target. We therefore believe that our EEV Platform can enable greater target exposure with an unconjugated therapeutic and similar dose regimen.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential across multiple modalities:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our EEV Platform is designed to enable the development of intracellular therapeutic candidates that modulate, inhibit, degrade or replace an intracellular target to correct the underlying disease pathophysiology. In our preclinical studies of EEVs, we observed intracellular uptake of unique therapeutic candidates ranging in size from 1 kDa to 600 kDa, including oligonucleotides, antibodies and larger multimeric proteins. Unlike viral vectors or certain lipids and nanoparticle constructs, EEVs do not appear to be hampered by &#8220;packaging limits&#8221;. For example, adeno-associated viruses constructs are limited to 5 kb in length, dramatically restricting both the size of genes and complexity of regulatory sequences that can be delivered. Importantly, our preclinical studies support the concept of modularity in that we can use similar EEV structures across the portfolio. EEVs are then further optimized to the specific application of interest. Each program advanced contributes to a foundation upon which our development portfolio can continue to expand. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="trda-20211231x10k011.jpg" alt="Graphical user interface, application&#10;&#10;Description automatically generated" style="display:inline-block;height:171.85pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:410.95pt;" /></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Potential across tissue types:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our EEV Platform is not limited to a particular tissue type. Because</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">every</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cell</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">human</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">body</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">surrounded</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">by</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">phospholipid</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">bilayer,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">this</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enables</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;">the </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">systemic delivery of potential therapeutic candidates for a wide range of diseases. We have seen potentially clinically relevant uptake of EEV-PMOs across a wide range of organs, tissue and cell types, including skeletal and cardiac muscle, monocytes and macrophages, and both the cerebellum and dorsal root ganglia.</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">also</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">shown</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">studies</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">need</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">be,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;">we </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">can target our EEV-conjugated nucleotides by adding tissue-targeting moieties</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or organelle-targeting sequences, including, for example, nucleus, mitochondria and peroxisome</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Multiple delivery routes:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In our preclinical studies, we have generated functional outcomes systemically using IV, IM and SQ injections. Preclinical studies have also demonstrated what we believe to be therapeutically relevant concentrations of product uptake in the cerebellum and dorsal root ganglia via IT administration.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:63.5pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Modular approach that enables efficient expansion into multiple therapeutic areas:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a wide variety of programs in discovery and preclinical development, including oligonucleotide therapies in rare disease and immunology, antibody-based protein degraders in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">oncology</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enzyme</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">replacement</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">therapy</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rare</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disease.</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">EEV</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Platform</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilitates the effectiveness of the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">modality, which in turn produces the translational output</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="trda-20211231x10k012.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:63.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:435.85pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Oligonucleotide programs:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In our neuromuscular programs, we chemically link EEVs to oligonucleotides . EEV-PMOs are highly programmable and can upregulate or downregulate gene expression. We are developing a potential therapy for patients with DMD as our most advanced lead program. In patients with DMD, there are mutations in or deletions of regions in the genetic code responsible for dystrophin production. These mutations or deletions result in the creation of incomplete RNA sequences, which fail to create functional dystrophin. By using our EEV-PMO, we have demonstrated in animal models that we can skip mutated sequences, allowing the cell to create functional dystrophin. Our second lead program is an EEV-PMO for the treatment of DM1, where we aim to correct mRNA splicing defects associated with muscle tissue development and insulin response to prevent the mistranslation of proteins. </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We plan to follow this DM1 program with neuromuscular development programs for additional exon skipping amenable populations in DMD and other neuromuscular diseases and in the downregulation of gene expression for a range of non-neuromuscular diseases. The backbone EEV and oligonucleotide chemistries are the same</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">across the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">various</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">applications,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">and</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">anticipate</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">that</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.8pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">can</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leverage</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approach across a wide range of diseases by simply coding the sequence needed to impact gene expression</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Antibody programs:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our approach relies on leveraging an EEV-antibody, which binds to a protein of interest. This complex is then marked by an endogenous protein within the cell for degradation, mimicking a way that the body disposes of viral intruders. Preclinical studies have demonstrated intracellular delivery of a variety of full and partial domain antibodies and we have observed target engagement and a meaningful modulation of downstream signaling.</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">antibody</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">degraders</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">follow</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">same</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">basic</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">design,</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">with</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">only</span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant change being the antibody sequence needed to target the disease-causing protein of interest</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Enzyme/protein related programs:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> EEVs can be linked to an enzyme critical to maintaining specific steps in a cell&#8217;s metabolic processes. Patients lacking a given enzyme will fail to produce proteins needed to maintain the viability of cells in the body or will suffer a buildup of toxic byproducts, either of which can result in disease and potentially death. We have generated a number of EEV-enzyme conjugates, including ENTR-501 for MNGIE, a fatal mitochondrial disease, for which we have completed IND-enabling studies. NHP pharmacokinetic and acute and chronic toxicology studies indicated both a long circulating half-life and a favorable tolerability profile, which may serve as a foundation upon which our ERT programs can later build. We are also exploring the use of EEVs as a novel non-viral vector for the delivery of CRISPR-Cas to enable highly efficient approaches to gene editing.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">A simple and scalable construct designed to translate from preclinical to clinical development across our therapeutic programs:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">   EEVs are comprised of small serum-stable cyclic peptides of approximately 10 amino acid residues or fewer produced via synthetic chemistry.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">EEVs have been manufactured efficiently to clinical scale and, because we use well-understood chemical conjugation methods to link EEVs to our oligonucleotides, antibodies and enzymes of interest, we believe manufacturing the final drug product can be optimized. We have experience manufacturing an EEV therapeutic candidate, ENTR-501, under Good Manufacturing Practices (GMP).</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:160.8pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The size of EEVs implies that they are unlikely to be presented on the surface of immune cells, and therefore we believe the risk of immunogenicity is low and limited to the conjugate of the EEV therapeutic candidate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Ultimately, we believe that the significant increase in intracellular target exposure enabled by EEV conjugation has the potential to translate into substantial improvements to the efficacy, safety, tolerability, manufacturability and cost of future medicines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Development Portfolio</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are leveraging our EEV Platform to create a diverse and expanding development portfolio of oligonucleotide-, antibody- and enzyme-based programs. Included in this development portfolio are several of our oligonucleotide programs for the treatment of multiple neuromuscular diseases, including DMD, DM1 and additional preclinical and discovery programs. In addition, we are exploring oligonucleotide opportunities in immune mediated diseases and oncology. The development portfolio also includes antibody based intracellular protein degradation programs for oncology. Research efforts include enzyme replacement therapies, targeting moieties and CRISPR-Cas. The chart below represents a summary of our initial development programs, each of which are wholly owned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k013.jpg" alt="A screenshot of a computer&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:160.8pt;width:436.85pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Neuromuscular Diseases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Duchenne Muscular Dystrophy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are initially focused on the development of disease-modifying treatments for patients with DMD. We are developing therapeutic candidates to address the genetic basis, at the exon-specific level, of DMD. EEV oligonucleotides are designed to promote the skipping of exon mutations associated with DMD, enabling muscle cells to create a functional dystrophin at a level that we believe may slow, stop or even reverse DMD progression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are prioritizing the development of an EEV-PMO, ENTR-601-44, for patients with DMD that are exon 44 skipping amenable. This patient population represents approximately 7.6% of patients with DMD with substantial unmet medical need, due to the lack of approved disease-modifying therapies available. Furthermore, there are also no ongoing clinical trials for patients with DMD that are exon 44 skipping amenable in the United States or Europe, and we believe we have the potential to be first to market. We believe that the high unmet need combined with the lack of alternative therapeutics will support rapid clinical trial enrollment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are also developing an EEV-PMO for patients with DMD that are exon 45 skipping amenable, who account for approximately 8% of patients with DMD. In the United States alone, there is currently only one product approved for patients amenable to exon 45 skipping, which has demonstrated an increase in dystrophin of less than 2% in clinical trials. The product has not yet demonstrated a clinical benefit in confirmatory trials, which are ongoing. We plan to leverage our preclinical and regulatory experience with the ENTR-601-44 program in developing the EEV-PMO candidate, given the substantially similar preclinical and clinical development paths of these therapeutic candidates, with the goal of efficiently advancing this program.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:187.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We plan to submit an IND to the FDA for ENTR-601-44 in 2022 and, pending authorization to proceed from the FDA, to report initial clinical data in 2023, and to advance a potential EEV-PMO candidate for patients with DMD that are exon 45 skipping amenable thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">DMD Background and Market Opportunity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">DMD is a monogenic, X-linked disease caused by mutations in the DMD gene, which encodes for the dystrophin protein. Dystrophin is essential to maintaining the structural integrity and normal function of muscle cells for walking, breathing and cardiac function. In patients with DMD, mutations in the DMD gene can lead to certain exons being misread, resulting in a failure to produce sufficient functional dystrophin. The reduction or absence of functional dystrophin leads to damage to muscle cell membranes, resulting in muscle cell death and progressive loss of muscle function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The symptoms of DMD typically manifest in the first few years of life. Patients experience progressive muscle weakness and muscle wasting and have difficulty standing up, climbing stairs, running, breathing and performing daily functions. As the disease progresses, the severity of damage to skeletal and cardiac muscles results in most patients experiencing total loss of ambulation in the pre-teenage or early teenage years. Progressive loss of upper extremity function is often observed in the mid-to-late teens followed by paralysis, respiratory and/or cardiac failure, resulting in early mortality in the third or fourth decade of life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We estimate that DMD occurs in approximately one in every 3,500 to 5,000 patients and that the patient population is approximately 30,000 patients in the aggregate in the United States and Europe. Approximately 80% of patients have mutations amenable to exon skipping in the nucleus. Approximately 40% of patients with DMD have mutations amenable to exon skipping of exons 44, 45, 51 and 53, as illustrated in the figure below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k014.jpg" alt="Graphic" style="display:inline-block;height:187.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:434.7pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Current Treatment Landscape and Limitations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Corticosteroids are the current standard of care. However, chronic use of corticosteroids, particularly in pediatric populations, is challenging due to side effects including growth impairment, immune suppression, obesity and other endocrine-related disorders. There are four FDA-approved PMO-based oligonucleotide skipping therapies, each addressing a specific mutation: casimersen (exon 45), eteplirsen (exon 51), golodirsen (exon 53) and viltolarsen (exon 53). These products have all been approved using the accelerated approval pathway on the basis of dystrophin production. Currently approved exon skipping therapeutics have demonstrated a modest improvement in dystrophin levels ranging from approximately 1-6%. However, the FDA-approved labels for all four drugs state that continued approval may be contingent upon the verification of a clinical benefit in confirmatory clinical trials. None of the products are approved by the European Medicines Agency due to insufficient evidence of clinical benefit. A fifth drug, ataluren, has only been conditionally approved outside of the United States in certain territories for nonsense mutations in ambulatory patients with DMD aged five years and older. Finally, these therapies require weekly intravenous infusions which is suboptimal from a patient perspective. In summary, each of these approved products also seeks to address DMD through exon skipping, but to date, the clinical benefits of these products have not been confirmed.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:183pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Our Solution</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our DMD program is designed to address the genetic basis of DMD by promoting the skipping of specific DMD exons in the nucleus, allowing muscle cells to create a functional dystrophin protein. Our EEV Platform is designed to enable high cellular uptake and robust cytosolic delivery of EEV therapeutic candidates, resulting in a greater amount of the oligonucleotide being able to reach its intended target in the nucleus. Based on preclinical data, we have shown that our proprietary oligonucleotide is then able to promote enhanced exon skipping and dystrophin production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preclinical models, we have observed that conjugation of an oligonucleotide to our EEV results in multi-fold greater exon skipping and dystrophin production than the oligonucleotide alone, with such results indicating dystrophin production comparable to wild-type levels in certain tissues. We have observed substantial improvement in dystrophin production in both skeletal and cardiac muscle, as well as uniform dystrophin production within tissues that we believe may be attributable to the unique mechanism of action of our EEV Platform and the broad biodistribution of our oligonucleotide conjugates. We have observed deep and uniform penetration of EEV-PMOs as compared to unconjugated oligonucleotides in our preclinical models, as illustrated below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k015.jpg" alt="Graphic" style="display:inline-block;height:182.7pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:455.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Importantly, we believe an increased level of dystrophin production in the heart may translate to improved cardiac function in patients with DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our preclinical data have demonstrated 50% to 100% correction of exon skipping in the D2-mdx model, which mimics human disease, and in a human dystrophin mouse model which enables us to evaluate our lead sequence directly. In an initial NHP model, we have observed almost 90% target exon skipping in skeletal muscles. We have generated promising <i style="font-style:italic;">in vivo</i> data in cardiac and skeletal muscles (including the diaphragm) across a range of disease and wild-type models (both murine and NHP). We believe the observed increase in dystrophin production is sufficient to protect muscle from progressive functional decline in treated mice and the improvement in functional outcomes versus controls observed in the D2-mdx model supports this belief.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Summary of Preclinical Data</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our early data in mouse and NHP models have been consistent and robust. We have observed substantial exon skipping and dystrophin production in various tissues of mdx mice. The mdx mouse is the canonical model used in DMD research and carries a spontaneous nonsense mutation in exon 23 of the DMD gene. Although this does not allow for the testing of oligonucleotides specific to human mutations, it does enable measurement of tissue concentration of oligonucleotides, exon 23 skipping levels and the corresponding dystrophin production. This allowed us to extrapolate anticipated dystrophin production from exon-skipping observations as we move to NHP models. We were also able to show in both single-dose and multiple-dose experiments that the EEV-PMOs has greater activity than unconjugated PMOs. <span style="color:#231f20;">Similarly, EEV-PMOs had greater activity than alternative cell-penetrating peptide conjugates in our preclinical studies. We also observed corresponding and significant improvements in functional outcomes as measured in the exon 23 specific D2-mdx mouse. In particular, we observed meaningful tissue uptake and exon skipping, ranging from </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:175.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">approximately 60% to 95% depending on the tissue In this model, EEV-PMO treated tissues have substantial restoration of both dystrophin and alpha sarcoglycan. Our preclinical studies have also demonstrated reductions in serum CK to wild-type levels in D2-mdx model. Serum CK is a commonly-used biomarker of systemic muscle breakdown. Correction of CK is believed to be a strong indicator of pharmacodynamic activity and a marker of muscle integrity restoration. Finally, we observed extended half-life and high levels (almost 90% in the biceps) of exon skipping in a NHP with ENTR-601-44</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the data below, unless otherwise noted, we used reverse transcription-polymerase chain reaction to assess exon skipping and Western Blot to assess dystrophin production. Our preclinical studies have demonstrated durable dystrophin production over a period of up to eight weeks, suggesting the possibility of infrequent dosing. Immunohistochemistry and morphometric analysis confirm that the protein is broadly distributed across tissues, which is necessary if the muscle is to maintain function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For each of our preclinical studies that were powered for statistical significance, we have so indicated with the p or p-values presented. In the description of our preclinical studies below and elsewhere in this prospectus, p or p-values represent the probability that random chance caused the result. For instance, a p-value of 0.001 means that there is a 0.1% probability that the difference between the placebo group and the treatment group is purely due to random chance. A p-value of less than or equal to 0.05 is a commonly used threshold for identifying statistically significant outcomes. Except with respect to ENTR-501, our preclinical studies to date have not been designed as toxicology studies and therefore we have not collected safety data from such studies. We plan to conduct toxicology studies in compliance with Good Laboratory Practices in advance of submitting an IND for any of our therapeutic-candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">mdx Mouse Dystrophin Distribution Analyzed via Immunofluorescence After Four Injections of EEV-PMO at 10 mg/kg</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k016.jpg" alt="Graphic" style="display:inline-block;height:175.9pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:455.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the experiment above, mdx mice were injected with weekly doses of either saline, unconjugated exon 23 skipping PMO or an EEV conjugated to the same exon 23 skipping PMO over the course of four weeks. Samples were taken one week after the fourth dose. The EEV-PMO-DMD substantially increased dystrophin production and accumulation in the heart, with approximately 40% of the cardiac tissue staining positive for dystrophin (in red). This compares favorably to the PMO alone, where at even double the dose virtually no dystrophin can be seen. Endothelial cells are stained green, and as shown in the image, dystrophin can be observed distributing broadly and deep into the cardiac tissue. We believe this experiment suggests that at low doses an EEV oligonucleotide has the potential to substantially improve on treatment with unconjugated oligonucleotides. We also believe these heart results suggest the possibility that EEV-PMOs may address cardiomyopathy in patients with DMD, which is a major complication and leading cause of death associated with the disease. We believe this could therefore potentially improve survival rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">This improvement in dystrophin production at 10 mg/kg is also associated with an observed improvement in measured serum creatin kinase (CK) levels. Serum CK is a commonly-used biomarker for systemic muscle breakdown. CK is released from muscles with damaged and porous sarcolemma, which, in the case of DMD, is due to a lack of </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:231pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">functional dystrophin. Normalization of serum CK indicates broad correction of dystrophin and protection of the sarcolemma throughout the body, which can further imply a potential restoration of function. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Normalization of Serum CK Levels in mdx and Wild-Type (BL10) Mice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k017.jpg" alt="Graphic" style="display:inline-block;height:230.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:275.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the experiment above mdx mice were injected with weekly doses of either saline, unconjugated exon 23 skipping PMO or an EEV conjugated to the same exon 23 skipping PMO over the course of four weeks. Samples were taken one week after the fourth dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have also observed that tissue concentration of EEV-PMO in the cell correlates with the level of exon skipping, which correlates with dystrophin production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">High Levels of Exon 23 Skipping and Tissue Concentration Observed in Various Muscle Groups at Three Different Doses of EEV-PMO in mdx Mice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k018.jpg" alt="Graphic" style="display:inline-block;height:93.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:446.95pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the mdx mouse model illustrated above, exon skipping and tissue concentration in various muscle groups have been quantified one week after a single 20, 30 or 40 mg/kg intravenous (IV) dose of an EEV conjugate to an exon 23 skipping PMO in mdx mice. A dose-dependent effect was seen, both with respect to tissue concentrations and exon 23 skipping levels, which ranged from approximately 80%-100% at the highest IV dose of 40 mg/kg, depending on the tissue sampled. These dose-dependent tissue concentrations and the correlation with exon skipping suggest active target engagement in heart, diaphragm and other skeletal muscles. </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:204.45pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">High Levels of Exon 23 Skipping and Dystrophin Correction Observed up to 8 Weeks After a Single IV Dose of EEV-PMO in mdx Mice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k019.jpg" alt="Graphic" style="display:inline-block;height:159.6pt;width:455.1pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following dose-ranging experiments, exon 23 skipping and dystrophin production in various muscle groups were quantified one week, two weeks, four weeks and eight weeks after a single IV dosage of 40 mg/kg in mdx mice. We selected the highest dose based on the magnitude of exon skipping observed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Normalization of Serum CK Levels in mdx and Wild-Type (BL10) Mice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k020.jpg" alt="Graphic" style="display:inline-block;height:204.45pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:347.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In this experiment, untreated wild-type (BL10) mice were compared to mdx mice treated with EEV-PMO and mdx mice treated with phosphate-buffered saline (PBS). Serum CK from mdx mice was analyzed one week after a single 40 mg/kg IV dose of EEV-PMO skipping exon 23 or of PBS. Treatment with EEV-PMO normalized serum CK levels in the mdx mice, suggesting restoration of muscle integrity. In contrast, no significant correction of serum CK was seen in the PBS control arm. </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:130.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">EEV-PMO Significantly Improved Exon 23 Skipping After 3 Days in mdx Mice as Compared to R6-PMO</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k021.jpg" alt="Graphic" style="display:inline-block;height:129.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:455.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To compare the exon 23 skipping of an EEV against an alternative published linear peptide, we synthesized a 6 arginine (R6) cell-penetrating peptide and conjugated it to the exon 23 skipping oligonucleotide. We then compared the activity of this molecule to EEV-PMO, by conjugating the same oligonucleotide to one of our EEVs. After a single 40 mg/kg IV dose of the EEV-PMO or the R6-PMO, the EEV-PMO exhibited profound effects, with near complete exon skipping in the diaphragm and the quadriceps and approximately 60% exon skipping in the heart. The R6-PMO results were very limited in the skeletal muscle and virtually no pharmacodynamic effects were seen in the heart.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Superior Correction of Exon 23 Skipping in the D2-mdx Model Versus Unconjugated PMO</i><i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k022.jpg" alt="Graphic" style="display:inline-block;height:129.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:452.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have employed a methodical and robust approach to candidate qualification by generating data in the canonical mdx mouse, as well as in a mouse model with a more severe phenotype known as the D2-mdx mouse. While the approach remains focused on exon 23 skipping, the D2-mdx mouse model more closely represents human disease as these animals develop more inflammation, fibrosis and exhibit less muscle regeneration over time when compared to the mdx model. In the study above, we compare exon skipping in the quadriceps, diaphragm and heart as generated by either the EEV-PMO skipping exon 23 or the PMO alone skipping exon 23. The lack of response from unconjugated PMO illustrates the difficulty in generating pharmacodynamic responses in the D2-mdx model, and further reinforces the importance of EEV conjugation. The animals were given a single 40 mg/kg IV dose of either the PMO or the EEV-PMO. We were able to demonstrate approximately 50% to 95% exon skipping from the mice dosed with EEV-PMO, depending on the tissue sampled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to the single dose study above, a separate repeat dose study was conducted as shown below. D2-mdx mice were treated with three IV doses at monthly intervals of either 20 mg/kg of a saline vehicle, PMO-23, or EEV-PMO-23 (n=6 per cohort). We compared exon skipping by one-step reverse transcription-polymerase chain reaction in the heart, diaphragm, tibialis anterior (TiA) and triceps as generated by either the EEV-PMO-23 skipping exon 23 or the PMO-23 alone skipping exon 23. We believe the significant difference in exon skipping observed between the EEV-PMO-23 and the PMO-23 in the D2-mdx model at a lower dose further reinforces the potential importance of EEV conjugation. We were able to demonstrate approximately 60% to over 95% exon skipping from the mice dosed with EEV-PMO-23 depending on the tissue sampled.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:137.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Superior Correction of Exon 23 Skipping at 22 Weeks Using an EEV-PMO in the D2-mdx Model Versus an Unconjugated PMO At 20 mg/kg</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k023.jpg" alt="Graphic" style="display:inline-block;height:100.95pt;width:469.45pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A durable CK response was observed in EEV-PMO-23 treated mice versus both vehicle and PMO-23 treated mice. In this experiment D2-mdx mice were treated with 4 monthly doses of either vehicle, 20 mg/kg PMO or 20 mg/kg PMO equivalent of EEV-PMO, and the data were collected 4 weeks after the last dose. No significant difference was seen between CK levels measured in wild type control mice and EEV-PMO-23 treated mice. We believe that this observation of reduced skeletal muscle breakdown resulted in improved functional outcomes for EEV-PMO-23 treated mice as evidenced by measurement of both wire hang time and a normalization of grip strength. In each case a significant difference (p&lt;0.05 for wire hang time, p&lt;0.001 for grip strength) between PMO-23 treated mice and EEV-PMO-23 treated mice was observed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Repeat EEV-PMO-23 Treatment Normalized Serum CK Levels and Showed Significant Improvements in Muscle Function When Compared to PMO Alone After Four Monthly IV Doses in D2-mdx Mice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k024.jpg" alt="A picture containing graphical user interface&#10;&#10;Description automatically generated" style="display:inline-block;height:137.9pt;width:470.7pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the same experiment, dystrophin expression was assessed four weeks post last injection via immunofluorescent staining, shown in the representative gastrocnemius sections shown in bright green below. The untreated wild type mice and the EEV-PMO-23 treated D2-mdx mice show broad and appropriate dystrophin expression, while the D2-mdx mice treated with vehicle control and the D2-mdx animals treated with PMO-23 show little to no dystrophin expression.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:133.95pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">D2-mdx Mouse Dystrophin Expression Analyzed via Immunofluorescence Is Enhanced After IV Administration of EEV-PMO Versus PMO Alone at 20 mg/kg</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k025.jpg" alt="A screenshot of a map&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:133.95pt;width:460.85pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Muscle histopathology was also assessed four weeks after the last injection. The D2-mdx animals treated with vehicle control and those treated with PMO-23 show clear signs of fibrosis and muscle damage. This stands in contrast to healthy samples from both the normal, wild type mice and the EEV-PMO-23 treated D2-mdx mice shown on the far left and far right panels below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Correction of D2-mdx Mouse Histopathology is Enhanced after IV Administration of EEV-PMO Versus PMO Alone at 20 mg/kg</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k026.jpg" alt="A screenshot of a computer&#10;&#10;Description automatically generated with low confidence" style="display:inline-block;height:129.7pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:448pt;" /> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">In the same experiment we also observed similarly dramatic results when comparing the wild type, control and treated images of both dystrophin and histology in the heart, as shown below. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:249pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">Repeat EEV-PMO-23 Treatment Corrected Dystrophin Expression and Pathology in the Heart After Four Monthly IV Doses in D2-mdx Mice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#231f20;"><img src="trda-20211231x10k027.jpg" alt="Graphical user interface&#10;&#10;Description automatically generated with low confidence" style="display:inline-block;height:183.01pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:447.84pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">Further analysis of the previous experiment showed EEV-PMO treated tissues have almost normalized the level and the localization of both dystrophin and &#945;-sarcoglycan. In striated muscle, sarcoglycans interact with dystrophin and other dystrophin-associated proteins to form the dystrophin-associated glycoprotein complex which protects the sarcolemma from contraction-induced injury. In the absence of dystrophin, &#945;-sarcoglycan fails to correctly&#160;localize to&#160;the dystrophin-glycoprotein complex (DGC) causing weakening of the plasma membrane. Loss of dystrophin leads to loss in alpha-sarcoglycan in the D2-</span><i style="color:#231f20;font-style:italic;">mdx</i><span style="color:#231f20;"> tissue. In the figure below PMO treated mice had limited restoration of dystrophin as well as </span><span style="color:#231f20;font-family:'Symbol';">a</span><span style="color:#231f20;">-sarcoglycan. In contrast, EEV-PMO treated tissues have almost complete restoration of both dystrophin and alpha-sarcoglycan.</span><span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:19.95pt;margin:5.75pt 66.7pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">Repeat EEV-PMO-23 Treatment Resulted in Functional Restoration of Dystrophin and DGC Protein &#945;-sarcoglycan After Four Monthly IV Doses in D2-mdx Mice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:19.95pt;margin:5.75pt 66.7pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;"> </i><i style="color:#231f20;font-style:italic;"><img src="trda-20211231x10k028.jpg" alt="Graphical user interface, application&#10;&#10;Description automatically generated" style="display:inline-block;height:248.5pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:460.5pt;" /></i></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:135.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The mdx mouse model, the most commonly used mouse model for DMD, carries a spontaneous nonsense mutation in exon 23 of the DMD gene. While this model has been useful to show proof-of-concept of the exon skipping approach <i style="font-style:italic;">in vivo</i>, it does not allow for the testing of human-specific oligonucleotides. Consequently, we also used transgenic mice carrying an integrated copy of the full-length human DMD gene with an exon 44 skipping amenable mutation. While these mice do not exhibit the DMD phenotype, the model does allow for an assessment of exon skipping levels. The mice were given a single IV dose of an EEV conjugated to an exon 44 skipping PMO (a combination thereof defined as EEV-PMO-44) at 15 mg/kg and near 100% exon skipping was observed. This result is notable because the mice in this model have intact muscle cells, which have historically been more difficult for therapeutics to access than the damaged cells seen in a mdx model. We believe that these robust exon skipping results suggest the potential for our EEV-PMO to expand into additional neuromuscular diseases in which uptake into intact muscle is crucial to demonstrating clinical activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exon 44 Skipping Activity of EEV-PMO-44 as Compared to a R6 Conjugated Exon 44 Skipping PMO (Single IV Dose of 15 mg/kg in hDystrophin Mice)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k029.jpg" alt="Graphic" style="display:inline-block;height:128.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:446.95pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We conjugated our lead exon 44 skipping sequence to an EEV from our candidate library, which we refer to as EEV-PMO-44, as mentioned above. Human dystrophic mice were IV dosed with 15 mg/kg of either EEV-PMO-44 or a R6 linear peptide conjugated to the same exon 44 skipping PMO. We observed exon skipping of between 60% to approximately 95% in the EEV-PMO-DMD-44 mice, compared to exon skipping of less than 20% in the R6-PMO-44-dosed mice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following the exon 44 skipping preclinical work depicted above, we completed lead optimization work and initiated experiments for ENTR-601-44 in patient derived cells, humanized mice, and NHPs. The results of these studies are described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dose-Dependent Levels of Exon Skipping and Significant Dystrophin Restoration Observed in Patient Derived Cells Treated With ENTR-601-44</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k030.jpg" alt="Graphic" style="display:inline-block;height:135.15pt;width:435.4pt;" /> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the experiment depicted above, patient derived cells were treated with the EEV-PMO-44, or ENTR-601-44. Dose-dependent exon 44 skipping and dystrophin protein restoration was observed (up to 100% and 43.7% respectively) in DMD patient-derived muscle cells treated with ENTR-601-44 compared with both untreated patient derived cells and </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:174.55pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">healthy cells. ENTR-601-44 was then studied in the humanized mouse model to assess uptake in tissue and exon skipping potential. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ENTR-601-44 Associated Dose (IV)-Dependent Tissue Exposure and Exon Skipping in a Transgenic Murine Model Carrying the Full-Length Human DMD Gene</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k031.jpg" alt="Graphic" style="display:inline-block;height:125pt;width:444.25pt;" /> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In this experiment, the transgenic mice carrying an integrated copy of the full- length human DMD gene were administered ascending IV doses of ENTR-601-44 at various levels ranging from 10 mg/kg to 80 mg/kg. Exon skipping and tissue exposure were each assessed five days after dosing. We observed dose dependent levels of tissue exposure of up to 80% and exon skipping up to 100% with translationally relevant doses. Following the results from our transgenic mouse study, we initiated studies in NHPs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Extended Circulating Half-Life for ENTR-601-44 Observed in Non-Human Primate Model</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k032.jpg" alt="Graphic" style="display:inline-block;height:174.55pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:213.95pt;" /> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the study depicted above, an IV dose of 30 mg/kg was administered over the course of one hour. The NHP was assessed at regular intervals, and an extended circulating half-life was observed. ENTR-601-44 was detectable in plasma up to 50 hours later. This pharmacokinetic profile suggests an opportunity for intended tissue exposure, target engagement and pharmacodynamic effects. </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:204.45pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Meaningful Levels of Exon Skipping Observed After 7 Days in NHP after IV Administration of</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ENTR-601-44 at a dose of 30 mg/kg</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k033.jpg" alt="Graphic" style="display:inline-block;height:204.45pt;width:447.6pt;" /> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A single 30 mg/kg IV dose of ENTR-601-44 resulted in meaningful levels of exon skipping in both skeletal and heart muscles. These levels of exon skipping appear to correlate with the exon skipping observed with ENTR-601-44 in the transgenic mouse and the exon 23 skipping observed in the mdx and the D2-mdx mouse. We believe that these data, together with the correlation between exon skipping and dystrophin production in PPMO clinical trials, are encouraging in the translational potential of ENTR-601-44. We further believe that these data provide support for the potential of the EEV Platform to address additional DMD populations. We expect to complete GLP toxicology studies to support an IND filing in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Development Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We plan to study our ENTR-601-44 in healthy adult volunteers initially and leverage the regulatory precedents set by exon skipping programs both in the clinic and on the market in the United States. We plan to initiate ascending dose studies, beginning with a single ascending dose in healthy volunteers, to assess safety and tolerability as well as evaluate pharmacokinetics (PK), and potentially exon skipping at the highest doses tested. Pending the outcome of these studies, and subsequent regulatory feedback we plan to initiate an MAD/Phase 2b study, in which we intend to assess tolerability, safety and PK in the ascending dose portion of the study. We expect the MAD/Phase 2b study will measure changes in dystrophin levels as the primary endpoint, and a variety of clinical measures as secondary endpoints. We also plan to conduct exploratory assessments of cardiac and pulmonary function as part of this study. We plan to study a second program for patients with DMD that are exon 45 skipping amenable and follow a similar clinical development plan. We believe that generating clinical proof-of-concept in these underserved populations will create translational, regulatory and clinical development synergies, and improve our potential to create meaningful treatment for these patients and those patients with DMD that are exon 51 and exon 53 skipping amenable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We plan to submit an IND to the FDA for ENTR-601-44 in the second half of 2022 and, pending authorization to proceed from the FDA, to report initial clinical data in 2023. We plan to submit an IND to the FDA for a potential EEV-PMO candidate for patients with DMD that are exon 45 skipping amenable thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">DM1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">DM1 is a rare disease, commonly estimated to affect over 40,000 people in the United States and over 50,000 in Europe. The disease is caused by a mutation driven alteration of normal RNA structure manifesting as an increase in the number of CTG triplet repeats found in the 3&#8217; non-coding region of the DM1 protein kinase (DMPK) gene. The number of repeats ranges from up to approximately 35 copies in healthy individuals to many thousands in patients with DM1. The resulting transcripts, which contain an expanded CUG tract, aggregate in discrete foci in the nuclei of DM patient cells. The excessive number of CUG repeats form large hairpin loops that entrap the DMPK pre-mRNA in the nucleus </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and impart toxic activity, referred to as a toxic gain-of-function. Specifically, mutant DMPK pre-mRNA sequesters a critical CUG-binding protein, muscle blind-like protein 1 (MBNL1), forming nuclear foci and inhibiting its ability to perform its normal function of guiding pre-mRNA processing of gene transcription for many other genes. These genes, among others, include insulin receptor signaling (INSR), Ras receptor signaling which is implicated in cell growth (SOS1), Bridging Integrator-1 (BIN1) which is implicated in cardiac development, and LIM domain binding 3 (LDB3) which plays a role in stabilizing the sarcomere (the basic units of muscles) during contraction. As a result, multiple pre-mRNAs that encode key proteins are misprocessed and this contributes to the multisystemic nature of the disease. These abnormal proteins ultimately cause DM1. The progression of DM1 may depend on the growth of the expanded repeat over time, suggesting that stabilization of the repeat is a means to postpone the onset or slow the progression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">DM1 is typically categorized based on age of onset and severity of symptoms into various phenotypes: 75% classical (adult-onset in the second to fourth decade of life); 10% childhood; and 15% congenital. All forms of DM1, except the late-onset form, are associated with high levels of disease burden and in the most severe cases can be associated with premature mortality. Life expectancy ranges from 45 years to 60 years. Seventy percent of early mortality is caused by cardiorespiratory complications. Respiratory failure due to muscle weakness (especially diaphragmatic weakness) causes at least 40% of early mortality, and cardiac abnormalities account for approximately 30%. The clinical course of DM1 is usually slowly progressive, but may become extremely disabling, especially when more generalized limb weakness and respiratory muscle impairment develops. Systemic manifestations such as fatigue, gastrointestinal (GI) complications, cataracts, incontinence and excessive daytime sleepiness greatly impact a patient&#8217;s quality of life. As a result, DM1 leads to physical impairment, activity limitations and decreased participation in social activities and work.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Current Treatment Landscape and Limitations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are currently no approved therapies to treat DM1 and treatment is focused largely on symptom management, which is tailored to the system affected and can therefore range from diet modification and physical therapy to surgery and ventilatory support. A previous attempt at treating patients with DM1 with an unconjugated antisense oligonucleotide was discontinued due to lack of efficacy. Therefore, there remains a high unmet medical need for new disease modifying therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Solution</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our approach intends to address the underlying cause of the disease by targeting and blocking the extra CUG triplet repeats occurring in the DMPK mRNA. CAG-repeat antisense oligonucleotides are designed to bind CUG repeat RNA and have been shown to block RNA-protein interactions as well as reduce the level of CUG transcription. We are using a PMO, which we would expect to sterically block CUG repeats and relieve or prevent the sequestration MBNL1 while leaving DMPK mRNA unaffected and leaving healthy levels of DMPK intact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Summary of Preclinical Data</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our initial <i style="font-style:italic;">in vitro</i> work was conducted in cell lines engineered to display a very high number of CUG repeats to generate foci, as a model for testing the potential for foci reduction. In our preclinical studies, we observed dose-dependent downregulation of target gene splicing and RNA foci formation in a Hela480 cell line with <span style="color:#231f20;">a high CTG and CUG repeat load and splicing defects knocked in. In a separate </span><i style="color:#231f20;font-style:italic;">in vitro</i><span style="color:#231f20;"> experiment, we observed free uptake of CUG-targeting EEV-PMO, EEV-PMO-CAG, (doses from 0-20 </span><span style="color:#231f20;font-family:'Symbol';">m</span><span style="color:#231f20;">M) resulted in dose dependent splice correction as well as selective and significant knock down of high triplet repeat load (CUG)480 DMPK mRNA transcripts while control (CUG)0 DMPK mRNA transcripts were unaffected</span>. </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:166.95pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">EEV-PMO-CAG Showed Dose-Dependent Correction of RNA Splicing and Selectively Knocked Down CUG-repeat Containing DMPK Transcript in a HeLa480 Cell Line</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k034.jpg" alt="Graphical user interface, application&#10;&#10;Description automatically generated" style="display:inline-block;height:150.95pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:466.2pt;" /> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">Following success in the knock-in model we then assessed the performance of EEV-PMO-CAG in patient derived cell lines.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">EEV-PMO-CAG Treatment in a DM1 Patient-Derived Cell Line Resulted in Significant RNA Foci Reduction and Dose-Dependent Changes in MBNL1 and Downstream Gene Splicing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k035.jpg" alt="Graphical user interface&#10;&#10;Description automatically generated" style="display:inline-block;height:166.95pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:448.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the above experiment <span style="color:#231f20;">immortalized DM1 patient-derived (2,600 CUG repeats) muscle cell line were treated with EEV-PMO and analyzed for correction of aberrant splicing and foci quantification. Administration of EEV-PMO-CAG resulted in a significant dose dependent decrease in MBNL1 exon 5 inclusion. Corrections of other downstream mis-splicings including SOS1 were also observed. Following successful correction </span><i style="color:#231f20;font-style:italic;">in vitro</i><span style="color:#231f20;"> we dosed a DM1 murine model with EEV-PMO-CAG</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">The</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">human</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">skeletal</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">actin</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">&#8212;</span><span style="color:#231f20;letter-spacing:-0.15pt;"> </span><span style="color:#231f20;">long</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">repeat</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">(HSA-LR)</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">transgenic</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">mouse</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">contains</span><span style="color:#231f20;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;">long</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;letter-spacing:-0.25pt;">CUG</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">repeats</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">has a myotonia</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">phenotype</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">DM1-relevant</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">splicing</span><span style="color:#231f20;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;">defects.</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">As</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">such, this</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">one</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">standard</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">most</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">frequent</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">mouse</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">models</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">used</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">assess</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">potential</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:-0.5pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:-0.55pt;"> </span><span style="color:#231f20;white-space:pre-wrap;">preclinical candidate for DM1.  In the experiment below HSA-LR mice were dosed once with vehicle or 15, 30, 60 or 90 mg/kg of EEV-PMO-CAG via IV injections. Healthy wildtype animals were used as controls.</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:216.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-align:center;text-indent:20.15pt;margin:0pt 68.4pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">EEV-PMO-CAG Treatment Corrected Aberrant Splicing, Knocked Down CUG-repeat Expansion Transcript And Reduced Nuclear Foci In HSA-LR mice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-align:center;text-indent:19.95pt;margin:2.29pt 68.75pt 12pt 0pt;"><img src="trda-20211231x10k036.jpg" alt="A screenshot of a computer&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:169.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:461.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-indent:19.95pt;margin:2.29pt 3.8pt 12pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;">In this model, EEV-PMO-CAG corrected DM1 relevant splicing defects (Atp2a1 exon 22, Nfix exon 7, Clcn1 exon 7a, Mbnl1 exon 5) at 1-week post injection in the quadriceps, gastrocnemius, triceps and tibialis anterior in a dose dependent manner with higher doses approaching or equivalent to those observed in the control wild type mice.  Similarly, we observed approximately 50% human skeletal actin RNA knockdown in HSA-LR mice at drug concentrations that achieved near complete splicing correction. Finally, we also observed a reduction of over 60% in the number of nuclei with CUG-foci (stained red in above left panel).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-indent:19.95pt;margin:2.29pt 3.8pt 12pt 0pt;"><span style="color:#231f20;">We believe that a steric block of CUG repeats may result in destabilization of HSA mRNA and degradation of a certain percentage of HSA mRNA, allowing for tissue-specific differences. Further </span><i style="color:#231f20;font-style:italic;">in vivo</i><span style="color:#231f20;white-space:pre-wrap;"> experiments focused on dosing EEV-PMO-CAG at 60 mg/kg are depicted below.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-align:center;text-indent:19.95pt;margin:2.29pt 68.75pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">EEV-PMO-CAG Dosed at 60 mg/kg Corrected Multiple MBNL1-responsive Splicing Biomarkers in HSA-LR Mice</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-align:center;text-indent:19.95pt;margin:2.29pt 68.75pt 12pt 0pt;"><img src="trda-20211231x10k037.jpg" alt="A picture containing outdoor, light&#10;&#10;Description automatically generated" style="display:inline-block;height:216.5pt;width:460.55pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-indent:19.95pt;margin:2.29pt 3.8pt 0pt 0pt;"><span style="color:#231f20;">In the above experiment HSA-LR mice received a single dose of EEV-PMO-CAG at 60 mg/kg. The choice of MBNL1 dependent biomarkers were selected based on the dynamic range between the wildtype and disease groups as described in medical literature. As noted, EEV-PMO-CAG treatment restored splicing to baseline WT levels, as shown </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:234.85pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;margin:0pt 3.8pt 12pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;">by the percent spliced in (PSI) values.  Going one step further, transcriptomic analysis confirmed normalization at both expression and splicing levels in HSA-LR mice, as illustrated below.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-align:center;text-indent:19.95pt;margin:2.29pt 68.75pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">Normalized Global Transcriptome Following a Single IV Injection of EEV-PMO-CAG at 60 mg/kg</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-align:center;text-indent:19.95pt;margin:2.29pt 68.75pt 12pt 0pt;"><span style="color:#231f20;"><img src="trda-20211231x10k038.jpg" alt="A picture containing graphical user interface&#10;&#10;Description automatically generated" style="display:inline-block;height:234.85pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:254.75pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.2;text-indent:19.95pt;margin:2.29pt 0pt 12pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;">In the experiment above HSA-LR mice were dosed with 60 mg/kg EEV-PMO-CAG via IV injection. Gastronemius muscles were assessed on Day 7 via RNA-seq analysis (956 differentially expressed genes; adj. p&lt;0.05).  Treatment with EEV-PMO-CAG (HSA-LR (+,+) above) resulted in global gene expression correction, shifting away from a disease profile (in red, HSA-LR (-,-) above) and toward that of wild type mice (in green, WT above).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:19.95pt;margin:0pt;"><span style="color:#231f20;">In summary, we observed that EEV-PMO-CAG treatment across a variety of models resulted in highly specific, significant and durable splice correction, and a substantial shift in the transcriptome. Collectively, these experiments suggest the potential for improved functional outcomes. We believe that a steric blocker of CUG repeats that leaves healthy levels of DMPK intact has the potential to be both efficacious and safer than less discriminate approaches</span><span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical Development Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following regulatory feedback and potential authorization to proceed from the FDA based on our IND submission, which we would expect to seek in 2023, we plan to initiate ascending dose studies of EEV-PMO-CAG to assess safety and tolerability and evaluate PKs, mRNA knockdown and spliceopathy in adult patients with DM1. We also plan to explore various measures of clinical activity and quality of life metrics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Additional Preclinical Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Neuromuscular Diseases</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Pompe Disease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pompe disease is a rare, autosomal recessive lysosomal storage disease caused by a mutation in the gene that encodes for glucosidase alpha acid (GAA), which results in an absence or deficiency of GAA protein. Normally, the body uses GAA to break down the complex carbohydrate glycogen and convert it into glucose. Failure to achieve proper breakdown and abnormalities in glycogen metabolism result in the excessive accumulation of glycogen in the body&#8217;s cells, particularly in cardiac, smooth, and skeletal muscle cells, which can lead to impairment and degradation of normal tissue and organ function. Patients with Pompe disease experience serious muscle-related problems, including </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">progressive muscle weakness throughout the body, especially in the legs, trunk and diaphragm. As the disorder progresses, breathing problems can lead to respiratory failure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, more than 300 pathogenic mutations have been identified in GAA. Pompe disease is commonly estimated to affect between 5,000 and 10,000 patients in the aggregate in the United States and Europe; however, the advent of newborn screening suggests the disease is underdiagnosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the age of onset and severity of symptoms, Pompe disease is typically classified as either infantile-onset Pompe disease (IOPD) or late-onset Pompe disease (LOPD). IOPD is characterized by severe muscle weakness and abnormally diminished muscle tone and usually manifests within the first few months of life. If left untreated, IOPD is often fatal due to progressive cardiac failure, respiratory distress or malnutrition resulting from feeding difficulties. LOPD presents in childhood, adolescence or adulthood. Patients with LOPD typically have milder symptoms, such as reduced mobility and respiratory problems. Patients with LOPD experience progressive difficulty walking and respiratory decline. Initial symptoms of LOPD may be subtle and go unrecognized for years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Current Treatment Landscape and Limitations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The only currently approved therapies for Pompe disease are alglucosidase alfa (Lumizyme in the United States, Myozyme in other geographies) and avalglucosidase alfa-ngpt (Nexviazyme in the United States), which are both forms of ERT delivered via IV infusions. Although infantile patients treated with ERT for Pompe disease have demonstrated improved survival, ERT is not curative, and many patients in long-term observational studies continue to have increased risk of both cardiomyopathy and heart failure. These patients also experience residual muscle weakness, including difficulties swallowing and the attendant increased risk of aspiration. ERT is particularly limited in its ability to improve skeletal muscle myopathy and respiratory dysfunction, primarily due to its inability to penetrate key tissues affected by the disease, a lack of activity in the cytosol and potential immunogenicity. Despite the availability of ERT, there remains significant unmet medical need in patients with either IOPD or LOPD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Our Solution</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Pompe disease program focuses on the development of a potentially disease-modifying treatment, which mitigates the production of glycogen in the cytosol of the cell. Leveraging the modularity of our EEV Platform, we are utilizing EEV-PMOs that target the mRNA that encodes glycogen synthetase 1 (GYS1), a protein required for the synthesis of glycogen in muscle cells. Our EEV-PMO is expected to provide a complementary mechanism of action to GAA replacement, which increases glycogen processing in the lysosome. Together these therapies may improve therapeutic outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that an EEV-PMO based approach is well suited for the treatment of patients with either IOPD or LOPD because of the ability to specifically inhibit GYS1 in the muscle.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Summary of Preclinical Data</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our therapeutic strategy involves EEV-PMO induced exon skipping, which is similar to our DMD strategy. We believe the more advanced DMD programs lay the foundation for the potential clinical success of our Pompe disease program. The approach in Pompe disease involves knockdown of GYS1 expression by inducing exon skipping to shift the reading frame and induce the reading of a premature stop codon, as illustrated below, resulting in subsequent nonsense-mediated mRNA decay (NMD). NMD prevents the translation of protein production.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:251.45pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:center;text-indent:20.15pt;margin:0pt 64.1pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">GYS1 Knockdown Via Exon Skipping, To Drive Premature Stop Codon</i><i style="color:#231f20;font-style:italic;"><br /></i><i style="color:#231f20;font-style:italic;">Presentation And mRNA Decay</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="trda-20211231x10k039.jpg" alt="Timeline&#10;&#10;Description automatically generated" style="display:inline-block;height:182.2pt;width:354.6pt;" /> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">GYS1/GAA double knockout mice, when compared to the GAA single knockout mice, have exhibited a profound reduction in the amount of glycogen in the heart and skeletal muscles, a significant decrease in lysosomal swelling and autophagic build-up. These cellular-level changes lead to cardiomegaly correction, normalization of glucose metabolism and correction of muscle atrophy. We believe, and medical literature suggests, that, despite the absence of GAA, the elimination of GYS1 plays an important role in glycogen metabolism. Furthermore, this mouse model allows us to test the more general utility of NMD and the more specific goal of GYS1 knockdown by an EEV-PMO <i style="font-style:italic;">in vivo</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Dose-Dependent EEV-PMO Knockdown of GYS1 Gene Expression and Protein Production in Skeletal and Cardiac Muscles Versus PMO Alone</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"> <img src="trda-20211231x10k040.jpg" alt="A picture containing graphical user interface&#10;&#10;Description automatically generated" style="display:inline-block;height:251.45pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:396.8pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the experiment above, GAA knockout mice (GAA-/-) were injected with a single IV dose of either 13.5 mg/kg of EEV-PMO, 27 mg/kg of EEV-PMO, 27 mg/kg of PMO or a negative control (vehicle). GYS1 mRNA and </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:99.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">protein levels were measured one-week post-injection and a significant knockdown of both was observed in both the EEV-PMO arms, but not in the unconjugated PMO arm. This pharmacodynamic result is notable given that this is a single dose experiment administered at very low doses, and it suggests that GYS1 is an addressable target. We further demonstrated that these protein level reductions were durable up to eight weeks post IV dose of 13.5 mg/kg EEV-PMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k041.jpg" alt="Graphic" style="display:inline-block;height:99.15pt;width:432pt;" /> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe this result demonstrates the potential of using exon skipping to drive NMD, which potentially opens a broad range of therapeutic indications where a downregulation of gene expression is needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Development considerations for GYS1 (Pompe disease and beyond)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We plan to continue studying Pompe disease and select our first Pompe EEV-PMO therapeutic candidate for patients with LOPD by the end of 2023. Although ERT is an effective treatment for some patients, many will fail to adequately respond, or appear to lose response over time. Pending completion of IND-enabling studies, submission of an IND and obtaining regulatory feedback, we expect to initiate trials in combination with ERT to assess safety, tolerability and PK in patients with LOPD. Additionally, we plan to initiate clinical trials involving pediatric patients with IOPD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Beyond Pompe disease, we continue to explore a number of additional diseases where GYS1 knockdown is relevant. <span style="color:#231f20;">In addition, we continue to assess other neuromuscular diseases such as FSHD</span>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Immunology / Oligonucleotides</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interferon Regulatory Factors (IRFs) are a family of transcription factors that regulate transcription of interferons, which are associated with both innate and adaptive immunity pathways. IRF5 in particular operates as a master switch in macrophages and is implicated in proinflammatory cytokine release and fibrosis formation across a range of high unmet need diseases, making this an attractive potential &#8220;pipeline in a product.&#8221; <span style="color:#231f20;">IRF5 polymorphisms related to higher expression have been associated with susceptibility to inflammatory and autoimmune diseases. Increased IRF5 mRNA level is strongly correlated with disease pathology. </span>IRF5 knockout mice have been shown to have reduced inflammatory phenotype and relevant fibrosis in many disease models including non-alcoholic steatohepatitis (NASH), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), asthma and neuropathic pain, among many others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Downregulating IRF5 represents a promising treatment strategy for multiple immune-mediated and inflammatory diseases. We are currently leveraging multiple oligonucleotide strategies for IRF5 downregulation. In preclinical studies, we have demonstrated knockdown of IRF5 protein levels as well as knocking down downstream expression of the pro-inflammatory cytokines.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:150.65pt;"><a id="_Hlk95667262"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:center;text-indent:20.15pt;margin:0pt 64.1pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">Downregulation Of IRF5 Via Exon Skipping To Drive Premature Stop Codon</i><i style="color:#231f20;font-style:italic;"><br /></i><i style="color:#231f20;font-style:italic;">Presentation And mRNA Decay</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:center;text-indent:19.95pt;margin:3.4pt 64.35pt 12pt 0pt;"><span style="color:#231f20;"><img src="trda-20211231x10k042.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="display:inline-block;height:142.9pt;width:282.45pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">Initial results suggest that EEV-PMO-mediated downregulation of IRF5 mRNA expression in different tissue-resident macrophages has the potential to target multiple disease areas, such as NASH, IBD, SLE and RA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:center;text-indent:19.95pt;margin:3.4pt 64.35pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">IRF5 Knockdown In Vivo (WT Model)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:center;text-indent:19.95pt;margin:3.4pt 64.35pt 12pt 0pt;"><span style="color:#231f20;"><img src="trda-20211231x10k043.jpg" alt="A picture containing chart&#10;&#10;Description automatically generated" style="display:inline-block;height:93.6pt;width:446.4pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-indent:19.95pt;margin:3.4pt 3.8pt 12pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;">In the experiment above, wild type mice were treated with two doses of EEV #1-PMO on Days 0 and 3. Samples were collected on Day 7 for qPCR to measure mRNA levels. In each of the tissues evaluated, a dramatic and dose dependent reduction in relative IRF5 mRNA was observed, as compared with a negative control.  Following a screening process, several high potential constructs were tested </span><i style="color:#231f20;font-style:italic;">in vitro</i><span style="color:#231f20;">. We are working to optimize the construct in order to identify a potential clinical candidate. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:center;text-indent:19.95pt;margin:3.4pt 64.35pt 12pt 0pt;"><i style="color:#231f20;font-style:italic;">Optimization of EEV-PMO Targeting IRF5</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-align:center;text-indent:19.95pt;margin:3.4pt 64.35pt 12pt 0pt;"><span style="color:#231f20;"><img src="trda-20211231x10k044.jpg" alt="Graphical user interface&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:150.65pt;width:340.6pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:19.95pt;margin:0pt;"><span style="color:#231f20;">In the left panel above, mouse macrophage cells treated with</span><span style="color:#231f20;letter-spacing:-0.25pt;"> the EEV #1-PMO </span><span style="color:#231f20;">showed a statistically significant reduction of IRF5 protein levels at doses of 30, 10 and 3 uM. In the right panel mouse macrophage cells were pre-treated with 2 &#956;M of EEV-PMOs #1-4 for 4 hours, followed by stimulation with R848, an imidazoquinoline compound that is a specific activator of toll-like receptor (TLR) 7/8, overnight. At 24 hours post treatment, cells were harvested and </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#231f20;">evaluated by Western Blot. When compared to the initial EEV #1-PMO which was depicted in the prior </span><i style="color:#231f20;font-style:italic;">in vivo</i><span style="color:#231f20;"> model and in the left panel of the </span><i style="color:#231f20;font-style:italic;">in vitro</i><span style="color:#231f20;"> data above, we observed a significant improvement in relative potency, as measured by IRF5 protein expression. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.21;text-indent:19.95pt;margin:7.69pt 3.8pt 12pt 0pt;"><span style="color:#231f20;">We are currently conducting preclinical studies evaluating the delivery of IRF5-targeting EEV- PMOs in disease mouse models with the expectation of </span><i style="color:#231f20;font-style:italic;">in vivo </i><span style="color:#231f20;">proof of concept in 2022 and the potential for candidate selection as early as 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0.05pt 0pt 12pt 0pt;"><span style="color:#231f20;">Protein Inhibition and Degradation Therapeutics</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:19.95pt;margin:0.05pt 8.3pt 12pt 0pt;"><span style="color:#231f20;">When proteins become old, mutated, misfolded or expended, they are degraded by the body through the ubiquitin proteasome system in which cells mark or tag a particular protein for disposal by attaching several molecules of the small regulatory protein ubiquitin.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:19.95pt;margin:8.69pt 8.3pt 12pt 0pt;"><span style="color:#231f20;">Several therapeutic approaches are designed to work at the protein level by modulating the ubiquitin proteasome system to harness the cell&#8217;s natural protein disposal system to degrade and remove a protein. Unlike more traditional signaling inhibitors that need a 1:1 inhibitor-to-target activity ratio,</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">degraders</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">can</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">continuously</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">function</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">show</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">sub-stoichiometric</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">properties.</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">We</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">believe</span><span style="color:#231f20;letter-spacing:-1.15pt;"> </span><span style="color:#231f20;">this</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">means that potentially lower doses and a wider therapeutic index may be possible. This benefit may be enhanced if a higher percentage of the degrader can access the protein in the</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">cell.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:19.95pt;margin:8.69pt 8.3pt 12pt 0pt;"><span style="color:#231f20;">Our EEV Platform has the potential to deliver highly selective large molecule protein degraders with activity against disease-causing proteins. Our constructs are designed to induce the ubiquitination and subsequent degradation of proteins in one step, without the need for a separate E3 recruiting moiety or a molecular glue. Furthermore, large molecules are generally more selective than small molecules.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:19.95pt;margin:8.64pt 8.3pt 12pt 0pt;"><span style="color:#231f20;white-space:pre-wrap;">We are exploring biologically validated targets that have been undruggable or have been suboptimally drugged. We have initially focused on &#946;-catenin, a protein which is implicated in both mutagenesis and in immune resistance. This contributes to the carcinogenesis, tumor progression and metastasis of several cancers, including hepatocellular carcinoma, pancreatic, lung, breast, ovarian and colon cancers. We believe a &#946;-catenin degrader may both mitigate tumor progression and (re)sensitize the tumor to immunotherapy. We are currently conducting preclinical studies and have observed both intracellular uptake and downstream signal inhibition.  We are expecting </span><i style="color:#231f20;font-style:italic;">in vivo </i><span style="color:#231f20;">proof of concept in 2022 and the potential for candidate selection as early as 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 8.3pt 0pt 0pt;"><i style="color:#231f20;font-style:italic;">Our Solution</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 8.3pt 0pt 50.5pt;"><span style="font-style:italic;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-indent:19.95pt;margin:0pt 8.3pt 12pt 0pt;"><span style="color:#231f20;">We are currently developing a library of high affinity intracellular antibodies using </span><i style="color:#231f20;font-style:italic;">in vitro </i><span style="color:#231f20;">phage selection of an alpaca immune library and are screening for target engagement, degradation and downstream signal inhibition. We have observed ERK / c-Myc pathway modulation</span><span style="font-size:11pt;"> in an </span><span style="color:#231f20;">HCT116 xenograft colorectal cancer model. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:2.29pt 0pt 12pt 0pt;"><span style="color:#231f20;">Protein- and Enzyme-Based Therapeutic Candidates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="color:#231f20;font-style:italic;">Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE): ENTR 501</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:19.95pt;margin:7.94pt 3.8pt 12pt 0pt;"><span style="color:#231f20;">MNGIE is a slowly progressive, rare autosomal recessive disease caused by mutations in the TYMP</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">gene</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">encoding</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">thymidine</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">phosphorylase</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">(TP).</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">MNGIE</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">a</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">clinically</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">distinct</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;">disorder</span><span style="color:#231f20;letter-spacing:-0.65pt;"> </span><span style="color:#231f20;letter-spacing:-0.15pt;">characterized </span><span style="color:#231f20;">by extraocular muscle weakness, peripheral neuropathy, progressive gastrointestinal dysmotility, severe cachexia, leukoencephalopathy, and mitochondrial defects including abnormalities of mitochondrial</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">DNA</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">(mtDNA).</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">The</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">disease</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">is</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">highly</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">variable</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">presentation</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">relentlessly</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">progressive and fatal, with an average age-at-onset of around 18-years-old and an average age-at-death</span><span style="color:#231f20;letter-spacing:-1.9pt;"> </span><span style="color:#231f20;">of 35-years-old. Studies in MNGIE patients have shown that biallelic TYMP mutations cause severe loss of TP activity and dramatic elevation of TP substrates, the pyrimidine nucleosides thymidine (Thd) and deoxyuridine (dUrd) in tissues and plasma. Increased Thd and dUrd leads to deoxynucleoside triphosphate (dNTP) pool imbalance, instability of mtDNA, mitochondrial damage, and, consequently, the resulting MNGIE</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">phenotype.</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="color:#231f20;font-weight:normal;">Our Solution</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:19.95pt;margin:6.44pt 8.3pt 12pt 0pt;"><span style="color:#231f20;">Our ENTR-501, an intracellular TP ERT, program is in development for the treatment of MNGIE. ENTR-501 has shown robust reduction in the accumulation of thymidine in animal models. Preliminary preclinical studies have also demonstrated that ENTR-501 can reduce toxic TP substrate accumulation below the levels observed in wild-type mice. We believe that ENTR-501 could reduce plasma and tissue levels of toxic TP substrates in patients with MNGIE (both adults and children) to sub-pathogenic levels with the potential to improve clinical symptoms and impact the progression of disease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:19.95pt;margin:7.84pt 8.3pt 12pt 0pt;"><span style="color:#231f20;">We have completed IND-enabling studies for the MNGIE program. In 2020, we made the strategic decision to focus the majority of our immediate efforts on EEV-oligonucleotide opportunities. In order to support ENTR-501 progress, we are exploring partnership opportunities with organizations that have the resources and expertise to continue the development of ENTR-501 into and through clinical development.</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">We</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">continue</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">to</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">believe</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">that</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">program</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">may have</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">an</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">important</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">role</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">future</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;letter-spacing:-0.2pt;">treatment </span><span style="color:#231f20;">of patients with</span><span style="color:#231f20;letter-spacing:-0.2pt;"> </span><span style="color:#231f20;">MNGIE.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Central Nervous System / Oligonucleotides</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Neurodegenerative diseases are generally progressive in nature and can result in cognitive decline, functional impairment and eventually death. The rapidly growing patient population represents one of the largest unmet medical needs of our time. We have successfully demonstrated delivery to a wide variety of structures, including the cerebellum, cortex, and hippocampus in the brain, as well as the dorsal root ganglia, the spinal cord, and cells within the nervous system. Importantly, we have observed EEV-PMO concentrations in these tissues up to 60-fold higher when compared with PMO alone. Disease targets we are interested in potentially pursuing include Alzheimer&#8217;s disease, glucocerebrosidase administration or GBA gene upregulation for Gaucher&#8217;s Disease, glucocerebrosidase administration or GBA gene upregulation for Parkinson&#8217;s Disease and CAG trinucleotide repeat modulation for Huntington&#8217;s Disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our most advanced CNS focused program is being developed for the treatment of Alzheimer&#8217;s disease. The Alzheimer&#8217;s Association estimates that in 2021 there are approximately 6.2 million Americans who have Alzheimer&#8217;s disease. We are not aware of any inhibitor-based therapies targeting the proteins thought to be the cause of these neurodegenerative diseases that have shown clinical benefits to date and only one, aducanumab, has received an accelerated approval from the FDA on the basis of reducing amyloid beta plaques in the brain. While some existing products provide symptomatic relief to Alzheimer&#8217;s patients, they have significant side effect risks and over time gradually lose their effectiveness in treating the symptoms of the disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Our Solution</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Genome-wide association studies have identified many Alzheimer&#8217;s disease risk genes related to immune response and microglia including the phagocytic receptor CD33 and two single nucleotide polymorphisms (rs3826656 and rs3865444) appear to confer increased risk for late onset Alzheimer&#8217;s disease and show increased CD33 levels. CD33 otherwise known as siglec-3, is a membrane-bound receptor which regulates innate immune function by limiting the downstream signaling of SHP1 and blocking the inhibition of PI3K. In the CNS, expression is restricted to microglia and macrophages. CD33 mRNA and protein expression is elevated in brains of sporadic Alzheimer&#8217;s disease patients and evidence suggests CD33 increases may reduce microglial phagocytosis and inhibit amyloid-beta clearance, potentially driving disease progression. We have employed an exon skipping approach in NHPs to generate an impaired isoform of the CD33 receptor. We believe that our EEV-CD33 may enable activation of otherwise quiescent microglia in the brain to clear amyloid-beta.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Additional Platform Applications</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">There are a number of additional EEV conjugates that are in discovery. We are leveraging the modularity of the platform to develop opportunities as diverse as EEV-CRISPR-Cas delivery for gene editing, EEV-antibody oligonucleotide conjugates for enhanced tissue tropism and blood brain barrier carriage, as well as novel EEV-ERT </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:190.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">therapies. We continually explore strategic opportunities to develop therapies wherever the EEV Platform provides us with the ability to make a difference for patients with devastating diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="trda-20211231x10k045.jpg" alt="Graphical user interface&#10;&#10;Description automatically generated with medium confidence" style="display:inline-block;height:190.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:426.9pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and biopharmaceutical industries generally, and the neuromuscular disease field specifically, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our team, and our development experience and scientific knowledge in the field of muscle diseases, oligonucleotide therapeutics and manufacturing provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Any therapeutic candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA (deflazacort) is an FDA-approved corticosteroid marketed by PTC Therapeutics, Inc. (PTC). In addition, there are four FDA-approved exon skipping drugs: EXONDYS 51 (eteplirsen), VYONDYS 53 (golodirsen), and AMONDYS 45 (casimersen), which are PMOs approved for the treatment of patients with DMD who are amenable to exon 51, exon 53 and exon 45 skipping, respectively, and are marketed by Sarepta Therapeutics, Inc. (Sarepta), and VILTEPSO (vitolarsen), a PMO approved for the treatment of patients with DMD who are amenable to exon 53 skipping, which is marketed by Nippon Shinyaku Co. Ltd. Companies focused on developing treatments for DMD that target dystrophin mechanisms, as does our DMD program, include Sarepta with SRP-5051, a peptide-linked PMO currently being evaluated following a Phase 2 clinical trial for patients amenable to exon 51 skipping <span style="color:#231f20;">along with SRP-5053,SRP-5045 and SRP-5044 in preclinical development</span>, PTC with ataluren, a small molecule targeting nonsense mutations in a Phase 3 clinical trial, Avidity Biosciences, Inc. (Avidity), which is in preclinical development with an antibody oligonucleotide conjugate for exons 44 (AOC-1044), 45 and 51 that targets dystrophin production, Wave Life Sciences Ltd., which is clinically evaluating WVE-N531, a splicing candidate that is designed to target exon 53 within the dystrophin gene, Dyne Therapeutics, Inc. (Dyne), which is pursuing antibody fragment-oligonucleotide conjugates for exons 44, 45, 51 (DYNE-251), and 53, PepGen, Inc. with PGN-EDO51, a preclinical candidate designed to address exon 51, and BioMarin Pharmaceutical Inc., which is in preclinical development with BMN 351, an antisense oligonucleotide therapy for exon 51. In addition, several companies are developing gene therapies to treat DMD, including Audentes Therapeutics, Inc. (AT466 AAV antisense exon 2 skipping candidate, and AT751 and AT753, AAV-antisense exon 51 and 53 skipping candidates, respectively), Pfizer Inc. (PF 06939926), Sarepta (SRP-9001 and Galgt2 gene therapy program), and Solid Biosciences Inc. (SGT-001). Gene editing treatments that are in preclinical development are also being pursued by Vertex Pharmaceuticals, Inc. (Vertex) and Sarepta. We are also aware of several companies targeting non-dystrophin mechanisms for the treatment of DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">There are currently no approved therapies to treat the underlying cause of DM1. Therapeutic candidates currently in development to treat DM1 include: tideglusib, a GSK3-&#223; inhibitor in late-stage clinical</span><span style="color:#231f20;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;">development</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">by</span><span style="color:#231f20;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;">AMO</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">Pharma</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">Ltd.</span><span style="color:#231f20;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;">For</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;">congenital</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">phenotype</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">of</span><span style="color:#231f20;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;">DM1;</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">AOC-1001,</span><span style="color:#231f20;letter-spacing:-0.45pt;"> </span><span style="color:#231f20;">an</span><span style="color:#231f20;letter-spacing:-0.4pt;"> </span><span style="color:#231f20;">antibody linked siRNA in clinical development </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">by Avidity; DYNE-101, an antibody fragment conjugated to an ASO targeting DM1 protein kinase knockdown in preclinical development by Dyne; a peptide-nucleic acid targeting CUG repeats in development by NeuBase Therapeutics, Inc.; EDOMD1, a linear peptide conjugated to a PMO targeting CUG repeats in preclinical development by PepGen, Inc.; a small molecule targeting GTG repeats in preclinical development by Design Therapeutics, Inc.; gene editing treatments in preclinical development by Vertex; an RNA-targeting gene therapy in preclinical development by Locana, Inc.; and small molecules interacting with RNA in preclinical development by Expansion Therapeutics,</span><span style="color:#231f20;letter-spacing:-1.2pt;"> </span><span style="color:#231f20;">Inc</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">The only currently-approved therapies for Pompe disease are alglucosidase alfa (Lumizyme in the </span><span style="color:#231f20;letter-spacing:-0.15pt;">United</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">States,</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">Myozyme</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">other</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">geographies)</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">avalglucosidase</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">alfa-ngpt</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">(Nexviazyme</span><span style="color:#231f20;letter-spacing:-0.3pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;">the</span><span style="color:#231f20;letter-spacing:-0.25pt;"> </span><span style="color:#231f20;letter-spacing:-0.3pt;">United </span><span style="color:#231f20;">States), which are both forms of ERT delivered via IV infusions. There is one next-generation GAA enzyme in registration from Amicus Therapeutics Inc. (Amicus), and there are four gene therapies in the early stages of clinical development from Astellas Pharma Inc., Bayer AG, Roche Holding AG and Lacerta</span><span style="color:#231f20;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;">Therapeutics,</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">Inc.</span><span style="color:#231f20;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;">There</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">are</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">five</span><span style="color:#231f20;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;">gene</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">therapies</span><span style="color:#231f20;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">preclinical</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">development</span><span style="color:#231f20;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;">from</span><span style="color:#231f20;letter-spacing:-0.7pt;"> </span><span style="color:#231f20;">AVROBIO,</span><span style="color:#231f20;letter-spacing:-0.75pt;"> </span><span style="color:#231f20;">Inc., Amicus, Provention Bio Inc., Selecta Biosciences, Inc. and Sarepta. There are two preclinical therapies targeting GYS1 inhibition from Maze Therapeutics, Inc. and Avidity, respectively. Denali has an ERT in preclinical</span><span style="color:#231f20;letter-spacing:-1.95pt;"> </span><span style="color:#231f20;">development.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Many of our competitors, either independently or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than we are in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approval for treatments and achieving widespread market acceptance. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial potential could be substantially limited if our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than any products we may develop. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products. In addition, our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of other drugs. The key competitive factors affecting the success of any products we may develop are likely to be their efficacy, safety, convenience, price and availability of reimbursement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We strive to protect our proprietary technology, inventions, improvements, platforms, program candidates, therapeutic candidates and components thereof, their methods of use and processes for their manufacture that we believe are important to our business, including by obtaining, maintaining, defending and enforcing patent and other intellectual property rights for the foregoing in the United States and in foreign jurisdictions. We also rely on trade secrets and confidentiality agreements to protect our confidential information and know-how and other aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future commercial success depends in part on our ability to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain, maintain, enforce and defend patent and other intellectual property rights for our important technology, inventions and know-how; preserve the confidentiality of our trade secrets and other confidential information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain and maintain licenses to use and exploit intellectual property owned or controlled by third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">operate without infringing, misappropriating or otherwise violating any valid and enforceable patents and other intellectual property rights of third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defend against challenges and assertions by third parties challenging the validity or enforceability of our intellectual property rights, or our rights in our intellectual property, or asserting that the operation of our business infringes, misappropriates or otherwise violates their intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our portfolio consists of owned and exclusively licensed patents and applications. As of February 28, 2022, there are 38 distinct patent families (21 families with non-provisional applications and 17 families with pending provisional applications) covering compositions of matter, manufacturing and uses related to our business. Among these patent families, we have 75 pending applications (including PCT, provisional and non-provisional applications) in the U.S., European Patent Convention, China, Canada, Hong Kong, Japan, and Taiwan; and 61 granted patents in the U.S., European Patent Convention, India, Japan, and Hong Kong (including a total of 45 member state validations of three European patents). Of these pending applications and granted patents, the licensed patent applications are pending in U.S., European Patent Convention, China, Canada, Hong Kong, Japan, and Taiwan; and licensed patents are granted in the U.S., European Patent Convention, China, India, Japan, and Hong Kong.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our owned and licensed patent estate covers various aspects of our programs and technology, including various embodiments of our EEV Platform; proprietary enzyme, peptide, oligonucleotide and CRISPR conjugates; methods of treatment; and aspects of manufacturing. The portfolio includes patents covering certain embodiments of the EEV Platform that don&#8217;t relate to our lead therapeutic candidates with granted patents in the U.S. (3), India, Japan, China, Hong Kong and Europe (including 37 European validation states). The extent to which any patents, if and when granted, will cover our therapeutic candidates is uncertain. Any U.S. or foreign patents issued from national stage filings of our PCT patent applications and any U.S. patents issued from non-provisional applications we have filed or may file in connection with our provisional patent applications would be scheduled to expire on various dates from 2036 through 2042, without taking into account any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity and other governmental fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Patent Prosecution</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A PCT patent application is not eligible to become an issued patent until, among other things, we file one or more national stage patent applications in the jurisdictions in which we seek patent protection and do so within prescribed timelines of the PCT patent application&#8217;s priority date. These prescribed timelines are generally 30 months, 31 months or 32 months, depending on the jurisdiction. If we do not timely file any national stage patent applications, we may lose our priority date and any potential patent protection on the inventions disclosed in such PCT patent application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, a provisional patent application is not eligible to become an issued patent. A provisional patent application may serve as a priority filing for a non-provisional patent application we file within 12 months of such provisional patent application. If we do not timely file non-provisional patent applications, we may lose our priority date with respect to our existing provisional patent applications and any potential patent protection on the inventions disclosed in our provisional patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we intend to timely file additional provisional patent applications, as well as national stage and non-provisional patent applications relating to our provisional applications or PCT patent applications, we cannot predict whether any of our patent applications will result in the issuance of patents. If we do not successfully obtain patent protection, or if the scope of the patent protection we or our licensors obtain with respect to our therapeutic candidates or technology is insufficient, we will be unable to use patent protection to prevent others from using our technology or from developing or commercializing technology and products similar or identical to ours or other similar competing products and technologies. Our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our technology, inventions and improvements, either directly or indirectly, will depend in part on our success in obtaining, maintaining, defending and enforcing patent claims that cover our technology, inventions and improvements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. The protection afforded by a patent varies on a product-by-product basis, from jurisdiction-to-jurisdiction, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of patent term adjustments and regulatory-related patent term extensions, the availability of legal remedies in a particular jurisdiction, and the validity and enforceability of the patent. Patent laws and related enforcement in various jurisdictions outside of the United States are uncertain and may not protect our rights to the same extent as the laws of the United States. Changes in the patent laws and rules, whether by legislation, judicial decisions or regulatory interpretation, in the United States and other jurisdictions may have uncertain affects that could improve or diminish our ability to protect our inventions and obtain, maintain, defend and enforce our patent rights, and could therefore affect the value of our business in uncertain ways.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The area of patent and other intellectual property rights in biotechnology is evolving and has many risks and uncertainties, and third parties may have blocking patents and other intellectual property that could be used to prevent us from commercializing our platform and therapeutic candidates and practicing our proprietary technology. Our patent rights may be challenged, narrowed, circumvented, invalidated or ruled unenforceable, which could limit our ability to stop third parties from marketing and commercializing related platforms or therapeutic candidates or limit the term of patents that cover our platform and any therapeutic candidates. In addition, the rights granted under any issued patents may not provide us with protection or competitive advantages against third parties with similar technology, and third parties may independently develop similar technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before any of our therapeutic candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any competitive advantage provided by the patent. For this and other risks related to our proprietary technology, inventions, improvements, platforms and therapeutic candidates and intellectual property rights related to the foregoing, please see the section entitled &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Patent Term</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term of individual patents depends upon the laws of the jurisdictions in which they are obtained. In most jurisdictions in which we file, the patent term is 20 years from the filing date of a PCT patent application or, if a PCT application is not filed, the earliest date of filing of the first non-provisional patent application to which the patent claims priority. However, the term of U.S. patents may be extended or adjusted for delays incurred due to compliance with FDA requirements or by delays encountered during prosecution that are caused by the United States Patent and Trademark Office (USPTO). For example, in the United States, a patent claiming a new chemical entity or biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) for up to five years beyond the normal expiration date of the patent. Patent term extension cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought and within 60 days of FDA approval of the product. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. During the period of extension, if granted, the scope of exclusivity is limited to the approved product for approved uses. Some foreign jurisdictions, including Europe and Japan, have analogous patent term extension provisions, which allow for extension of the term of a patent that covers a drug approved by the applicable foreign regulatory agency. For more information on patent term extensions, see &#8220;Business&#8212;Government Regulation&#8212;Patent Term Restoration and Extension and Marketing Exclusivity.&#8221; In the future, if and when any therapeutic candidates we may develop receive FDA approval, we expect to apply for patent term extensions on issued patents covering those therapeutic candidates. Moreover, we intend to seek patent term adjustments and extensions for any of our issued patents in any jurisdiction where such adjustments and extensions are available. However, there is no guarantee that the applicable authorities, including the USPTO and the FDA, will agree with our assessment of whether such adjustments and extensions should be granted, and even if granted, the length of such adjustments and extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Trade Secrets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition to patent protection, we also rely on trade secrets, know-how, unpatented technology and other proprietary information to strengthen our competitive position. We currently, and may continue in the future continue to, rely on third parties to assist us in developing and manufacturing our products. Accordingly, we must, at times, share trade secrets, know-how, unpatented technology and other proprietary information, including those related to our platform, with them. We may in the future also enter into research and development collaborations with third parties that may require us to share trade secrets, know-how, unpatented technology and other proprietary information under the terms of research and development partnerships or similar agreements. Nonetheless, we take steps to protect and preserve our trade secrets and other confidential and proprietary information and prevent the unauthorized disclosure of the foregoing, including by entering into non-disclosure and invention assignment agreements with parties who have access to our trade secrets or other confidential and proprietary information, such as employees, consultants, outside scientific collaborators, contract research and manufacturing organizations, sponsored researchers and other advisors, at the commencement of their employment, consulting or other relationships with us. In addition, we take other appropriate precautions, such as maintaining physical security of our premises and physical and electronic security of our </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">information technology systems, to guard against any misappropriation or unauthorized disclosure of our trade secrets and other confidential and proprietary information by third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Despite these efforts, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or other confidential or proprietary information. In addition, we cannot provide any assurances that all of the foregoing non-disclosure and invention assignment agreements have been duly executed, and any of the counterparties to such agreements may breach them and disclose our trade secrets and other confidential and proprietary information. Although we have confidence in the measures we take to protect and preserve our trade secrets and other confidential and proprietary information, they may be inadequate, our agreements or security measures may be breached, and we may not have adequate remedies for such breaches. Moreover, to the extent that our employees, contractors, consultants, collaborators and advisors use intellectual property owned by others in their work for us, disputes may arise as to our rights in any know-how or inventions arising out of such work. For more information, please see the section entitled &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">License Agreement with The Ohio State University</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 12, 2017, we entered into an option agreement with Ohio State Innovation Foundation (OSIF), an affiliate of The Ohio State University (OSU) responsible for the commercialization of technology developed at or created by or for OSU, in which the Company obtained an option (OSIF Option Agreement) to license all patents and patent applications involving technologies using cell-penetrating peptides arising out of or related to specified invention disclosures or through a sponsored research agreement executed with OSU on the same date (OSU SRA). On September 26, 2018, we exercised our option pursuant to the terms of the OSIF Option Agreement, and on December 14, 2018, we entered into a license agreement (OSIF License Agreement) for an exclusive, worldwide, sublicensable license under these patents and patent rights, and a non-exclusive, worldwide, sublicensable license under certain related know-how, to develop, commercialize or otherwise exploit products based on these cell-penetrating technologies for the treatment, prevention and diagnosis of any and all diseases or conditions. In addition, the OSIF License Agreement grants a worldwide, perpetual, irrevocable, fully-paid, royalty-free, sublicensable, exclusive license to any rights held by OSIF, OSU or its affiliates covering specifically identified cell-penetrating platform technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The term of the OSIF License Agreement will continue until the later of (a) the expiration of the last to expire of the exclusively licensed patent rights, or (b) the end of our obligation to pay royalties under the OSIF License Agreement. Such obligation ends, on a licensed product-by-licensed product and country-by-country basis, on the later of (1) expiration of the last to expire of the valid claims of the exclusively licensed patent rights covering such licensed product in such country, or (2) ten (10) years after the first commercial sale of such licensed product in such country. The last to expire exclusively licensed patent rights and valid claim of such exclusively licensed patent rights are estimated to expire by 2042, excluding any patent term adjustments or extensions. Upon expiration of the OSIF License Agreement at the end of the royalty term, the Company will maintain all license rights as a perpetual and fully paid-up license. Both parties have the right to terminate under certain enumerated circumstances. At our option, we may terminate the OSIF License Agreement for any reason with ninety days&#8217; (90) written notice, or if OSIF is in material breach, after providing thirty (30) days&#8217; notice of termination. OSIF may terminate the agreement at its option immediately upon delivery of written notice if any specified events occur, including failure by the Company to make payments due under the agreement and if the Company is in material breach, in each case pursuant to specified cure periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have typical diligence obligations under the OSIF License Agreement, including the obligation to use commercially reasonable efforts to develop and commercialize at least one licensed product. We may also be obligated to pay aggregate milestone payments of up to $7,950,000, tiered royalties on sales at low single digit percentages, a license maintenance fee of $25,000 per year beginning in 2021 and continuing until the first year in which commercial sales of a licensed product pursuant to the agreement commence. After such commercialization, we are required to make minimum annual payments of $125,000. In addition, in the event of a sublicense, under certain circumstances we may be required to pay up to 15% of non-royalty sublicensing consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Commercialization</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Excluding ENTR-501, we intend to retain significant development and commercial rights to our potential therapeutic candidates and, if marketing approval is obtained, to commercialize our therapeutic candidates on our own, or potentially with a partner, in the United States and other regions. We currently have no sales, marketing, or </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">commercial product distribution capabilities. We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following further advancement of our therapeutic candidates. We believe that such a focused sales and marketing organization will be able to address the key specialists in treating the patient populations for which our therapeutic candidates are being developed. Clinical data, the size of the addressable patient population, and the size of the commercial infrastructure and manufacturing needs may all influence or alter our commercialization plans. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing relationships with researchers and practitioners in relevant fields of medicine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not own or operate manufacturing facilities. We currently rely on third-party contract manufacturing organizations (CMOs), and suppliers for EEVs, linkers and nucleotides that comprise ENTR-601-44, EEV-PMO-CAG and our potential therapeutic candidates and the conjugation of these components, and we expect to continue to do so to support our IND-enabling studies and our clinical trials and commercial activities; however, we may seek to establish our own manufacturing facility for IND-enabling studies, clinical studies and long-term commercial supply. As we scale manufacturing, we intend to continue to expand and strengthen our network of CMOs. We believe there are multiple sources for all of the materials required for the manufacture of our therapeutic candidates, as well as multiple CMOs who could assemble the aforementioned components that comprise ENTR-601-44 and our potential therapeutic candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Manufacturing is subject to extensive regulations that impose procedural and documentation requirements. These regulations govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance. Our CMOs are required to comply with these regulations and are assessed through regular monitoring and formal audits. Our third-party manufacturers are required to manufacture any therapeutic candidates we develop under current Good Manufacturing Practice (cGMP), requirements and other applicable laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have personnel with extensive technical, manufacturing, analytical and quality experience to oversee all contracted manufacturing and testing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Government authorities in the United States, at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting and import and export of drugs and biological products such as those we are developing. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licensure and Regulation of Drugs and Biologics in the United States</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, where we are initially focusing our product development, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA), and biologics under the FDCA and the Public Health Service Act (PHSA), and their implementing regulations. Both drugs and biologics are also subject to other federal, state and local statutes and regulations. Our therapeutic candidates are early-stage and have not been approved by the FDA for marketing in the United States. Based on our novel therapeutic approach and the broad potential applicability of our EEV Platform to deliver a variety of therapeutic modalities into cells, we are developing therapeutic candidates that would be regulated under the FDCA, and/or the PHSA, and their implementing regulations, as drugs or biologics, depending on the modality of each product candidate. The failure to comply with the applicable U.S. requirements at any time during the product development process, including preclinical testing, clinical testing, the approval process, or post-approval process, may subject an applicant to delays in the conduct of the study, regulatory review and approval and/or administrative or judicial sanctions. These sanctions may include, but are not limited to, the FDA&#8217;s refusal to allow an applicant to proceed with clinical testing, refusal to approve pending applications, license suspension, or revocation, withdrawal of an approval, warning letters, adverse publicity, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines and civil or criminal investigations and penalties brought by the FDA or the Department of Justice (DOJ), and other governmental entities, including state agencies.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An applicant seeking approval to market and distribute a new drug or biologic in the United States generally must satisfactorily complete each of the following steps: preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the FDA&#8217;s Good Laboratory Practices (GLP) regulations, as applicable; completion of the manufacture, under current Good Manufacturing Practices (cGMP) conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; submission to the FDA of an Investigational New Drug application (IND), for human clinical testing, which must become effective before human clinical trials may begin; approval by an independent institutional review board (IRB), representing each clinical trial site before each clinical trial site may be initiated; performance of adequate and well-controlled human clinical trials, in accordance with current Good Clinical Practices (GCP), and any additional nonclinical studies required to establish the safety, efficacy, potency and purity of the product candidate for each proposed indication; preparation and submission to the FDA of a new drug application (NDA), or a Biologics License Application (BLA), for a biologic product, requesting marketing for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development and proposed labelling; review of the product by an FDA advisory committee, where appropriate or if applicable; satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; satisfactory completion of any FDA audits of the preclinical studies and clinical trial sites to assure compliance with GLP, as applicable, and GCP, and the integrity of clinical data in support of the NDA or BLA; payment of user fees under the Prescription Drug User Fee Act (PDUFA); securing FDA approval of the NDA or BLA; and compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (REMS), and any post-approval studies or other post-marketing commitments required by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Studies and Investigational New Drug Application</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before testing any therapeutic product candidate in humans, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in a clinical trial and a request for FDA authorization to administer such investigational product to humans. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin or recommence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result, submission of the IND may result in the FDA not allowing the trials to commence or allowing the trial to commence on the terms originally specified by the sponsor in the IND. If the FDA raises concerns or questions either during this initial 30-day period, or at any time during the IND review process, it may choose to impose a partial or complete clinical hold. Clinical holds may be imposed by the FDA when there is concern for patient safety, and may be a result of new data, findings, or developments in clinical, preclinical and/or chemistry, manufacturing and controls or where there is non-compliance with regulatory requirements. This order issued by the FDA would delay either a proposed clinical trial or cause suspension of an ongoing trial, until all outstanding concerns have been adequately addressed and the FDA has notified the company that investigations may proceed. A separate submission to an existing IND must also be made for each successive clinical trial conducted during drug development, and the FDA must grant permission, either explicitly or implicitly by not objecting, before each clinical trial can begin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Human Clinical Trials in Support of an NDA or BLA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision of qualified investigators in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. The FDA will accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. The GCP requirements encompass both ethical and data integrity standards for clinical trials. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign trials are conducted in a manner comparable to that required for clinical trials in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with GCP requirements or that the participants are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board (DSMB), or data monitoring committee (DMC). This group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on certain available data from the trial to which only the DSMB/DMC has access. Finally, certain clinical trials involving recombinant or synthetic nucleic acid molecules may be subject to review and approval of an Institutional Biosafety Committee (IBC), in accordance with NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines). An IBC is a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding for recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1 clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy subjects or patients.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2 clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3 clinical trials typically proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are generally undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a therapeutic.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In some cases, the FDA may approve an NDA or BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit for products approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement or to request a change in the product labeling. The failure to exercise due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information about applicable clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Pediatric Research Equity Act of 2003, an NDA, BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDCA requires that a sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan (PSP), within sixty days of an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The sponsor and the FDA must reach agreement on the PSP. The FDA or the applicant may request an amendment to the plan at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in the Food and Drug Administration Safety and Innovation Act. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expanded Access to an Investigational Drug for Treatment Use</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expanded access may be appropriate when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; patient enrollment in a clinical trial is not possible; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product. There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by the 21<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> Century Cures Act (Cures Act), a sponsor must make its policy regarding evaluating and responding to expanded access requests publicly available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Compliance with cGMP Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Before approving an NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">required specifications. The PHSA emphasizes the importance of manufacturing controls for products like biologics whose attributes cannot be precisely defined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Noncompliance with such requirements can lead to adverse findings by the FDA during these inspections; in instances of significant or continued noncompliance, such adverse findings can serve as the basis for additional regulatory action by the FDA, including but not limited to warning and &#8220;untitled&#8221; letters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Review and Approval of an NDA or BLA</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of product candidate development, preclinical testing and clinical trials, including negative or ambiguous results as well as positive findings, are submitted to the FDA as part of an NDA or BLA requesting approval to market the product. The NDA or BLA must contain extensive manufacturing information and detailed information on the composition of the product and proposed labeling as well as payment of a user fee. Under federal law, the submission of most NDAs and BLAs are subject to an application user fee. The sponsor of an approved NDA or BLA is also subject to an annual program fee. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has 60 days after submission of the application to conduct an initial review to determine whether to accept it for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission has been accepted for filing, the FDA begins an in-depth review of the application. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months in which to complete its initial review of a standard application and respond to the applicant, and six months for a priority review of the application. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs and BLAs. The review process may be significantly extended by FDA requests for additional information or clarification. The review process and the PDUFA goal date may be extended by three months if the FDA requests or if the applicant otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA reviews an NDA or BLA to determine, among other things, whether the product is safe and effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity. On the basis of the FDA&#8217;s evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities and any FDA audits of preclinical and clinical trial sites to assure compliance with GCPs, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. If the application is not approved, the FDA will issue a complete response letter, which will contain the conditions that must be met in order to secure final approval of the application, and when possible, will outline recommended actions the sponsor might take to obtain approval of the application. Sponsors that receive a complete response letter have one year to submit to the FDA information that represents a complete response to the issues identified by the FDA. The FDA will then re-review the application, taking into consideration the response. Failure to respond to a complete response letter will serve as a withdrawal of an application. The FDA will not approve an application until issues identified in any complete response letters have been addressed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may also refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. In particular, the FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the FDA approves a new product, it may limit the approved indication(s) for use of the product. It may also require that contraindications, warnings, or precautions be included in the product labeling. In addition, the FDA may call for post-approval studies, including Phase 4 clinical trials, to further assess the product&#8217;s efficacy and/or safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including a REMS program, to help ensure that the benefits of the product outweigh the potential risks. A REMS can include medication guides, communication plans for healthcare professionals and elements to assure safe use (ETASU). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Fast Track, Breakthrough Therapy and Priority Review</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA provides programs intended to facilitate and expedite development and review of new products that are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as fast track designation, breakthrough therapy designation, and priority review designation. These designations are not mutually exclusive, and a product candidate may qualify for one or more of these programs. While these programs are intended to expedite product development and approval, they do not alter the standards for FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may designate a product for fast track designation if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For products with fast track designation, sponsors may have greater interactions with the FDA, the product is potentially eligible for accelerated approval and priority review, if relevant criteria are met, and the FDA may initiate review of sections of a product with fast track designation application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a product with fast track designation may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#8217;s time period goal for reviewing a fast track application does not begin until the last section of the application is submitted. In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A product may be designated as a breakthrough therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving senior managers in the review process; assigning a cross-disciplinary lead for the review team; and taking other steps to design the clinical trials in an efficient manner. Breakthrough designation may be rescinded if a product no longer meets the qualifying criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months. Priority review designation may be rescinded if a product no longer meets the qualifying criteria.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Accelerated Approval Pathway</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (IMM), and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, confirm a clinical benefit during post-marketing studies or dissemination of false or misleading promotional materials would allow the FDA to withdraw the product from the market on an expedited basis. In addition, for products being considered for accelerated approval, the FDA generally requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Drug Designation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects 200,000 or more individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#8217;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. After the FDA grants orphan designation, the product must then go through the review and approval process like any other product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">another sponsor&#8217;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the same use. The FDA cannot, however, approve the same product made by another manufacturer for the same indication during the market exclusivity period unless it has the consent of the sponsor, or the sponsor is unable to provide sufficient quantities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pediatric Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including orphan exclusivity. This six-month exclusivity may be granted if an NDA or BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity that cover the product are extended by six months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">U.S. Patent Term Restoration and Extension and Marketing Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND and the submission date of the NDA or BLA, plus the time between the submission date of the NDA or BLA and the ultimate approval date, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketing exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (ANDA), or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Biosimilars and Exclusivity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), which was signed into law in March 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA). The BPCIA established a regulatory scheme authorizing the FDA to approve biosimilars and interchangeable biosimilars. A biosimilar is a biological product that is highly similar to an existing FDA-licensed &#8220;reference product.&#8221; The FDA has issued multiple guidance documents outlining an approach to review and approval of biosimilars. Under the BPCIA, a manufacturer may submit an application for licensure of a biologic product that is &#8220;biosimilar to&#8221; or &#8220;interchangeable with&#8221; a previously approved biological product or &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and proposed biosimilar product in terms of safety, purity and potency. For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product, and (for products administered multiple times) that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date of approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. Since the passage of the BPCIA, many states have passed laws or amendments to laws, including laws governing pharmacy practices, which are state regulated, to regulate the use of biosimilars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Post-Approval Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA have imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information, and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers, and applicable product tracking and tracing requirements. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A biological product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency and effectiveness of pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recall, seizure or detention, or refusal to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses or patient populations that are not approved by the FDA, as reflected in the product&#8217;s prescribing information (known as &#8220;off-label&#8221; use). In the United States, healthcare professionals are generally permitted to prescribe drugs for such off-label uses because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of off-label uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a company, including any agent of the company or anyone speaking on behalf of the company, is found to have promoted off-label uses, the company may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the DOJ, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Federal and State Data Privacy and Security Laws</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), the U.S. Department of Health and Human Services (HHS), has issued regulations to protect the privacy and security of protected health information (PHI), used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 or HITECH, and their regulations, including the final omnibus rule published on January 25, 2013, also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that are applicable to our business. In addition to possible federal administrative, civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. Accordingly, state attorneys general have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. New laws and regulations governing privacy and security may be adopted in the future as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, states, such as California, Virginia and Colorado have recently enacted the consumer privacy laws that grant rights to data subjects and place increased privacy and security obligations on entities handling personal data of consumers or households. While we are not currently subject to laws such as the California Consumer Privacy Act </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(CCPA), some observers note that the CCPA and similar legislation could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions under such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that we may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any applicable privacy or data security laws or regulations, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that we collect or otherwise process personal information, we may be subject to privacy or data protection laws that are in effect in such third countries foreign laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Regulation and Procedures Governing Approval of Medicinal Products Outside the United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. For example, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application (MAA) and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Clinical Trial Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In April 2014, the European Union adopted the new Clinical Trials Regulation (EU) No 536/2014, which came into effect on January 31, 2022 and repealed the Clinical Trials Directive 2001/20/EC. The transitory provisions of the Clinical Trials Regulation offer sponsors the possibility to choose between the requirements of the previous Clinical Trials Directive and the new Clinical Trials Regulation if the request for authorization of a clinical trial is submitted in the year after the Clinical Trials Regulation became applicable. If the sponsor chooses to submit under the Clinical Trials Directive, the clinical trial continues to be governed by the Clinical Trial Directive until three years after the Clinical Trials Regulation became applicable. If a clinical trial continues for more than three years after the Clinical Trial Regulation became applicable, the Clinical Trial Regulation will at that time begin to apply to the clinical trial. The Clinical Trial Regulation overhauls the current system of approvals for clinical trials in the European Union. Specifically, the new legislation, which is directly applicable in all EU Member States (meaning no national implementing legislation in each Member State is required), aims at simplifying and streamlining the approval of clinical trials in the European Union, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point through the Clinical Trials Information System (CTIS); a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned) of a draft report prepared by a Reference Member State. Part II is assessed separately by each Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned EU Member State. However, overall related timelines will </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">be defined by the Clinical Trials Regulation. Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the European Union at the EudraCT website: https://eudract.ema.europa.eu.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">PRIME Designation in the European Union</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2016, the European Medicines Agency (EMA) launched an initiative to facilitate development of therapeutic candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines (PRIME), scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the European Economic Area (EEA) or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods of therapy or improving existing ones. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of therapeutic candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from the Committee for Human Medicinal Products (CHMP), or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at the EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Marketing Authorization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To obtain a marketing authorization for a product under the European Union regulatory system, an applicant must submit a Marketing Authorization Application (MAA), either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in European Union Member States (decentralized procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the European Union. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, an applicant must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan (PIP), covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or a deferral for one or more of the measures included in the PIP. The Paediatric Committee of the EMA (PDCO), may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. The respective requirements for all marketing authorization procedures are laid down in Regulation (EC) No 1901/2006, the so-called Paediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP (even where such results are negative) are eligible for six months&#8217; supplementary protection certificate extension. In the case of orphan medicinal products, a two-year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. The centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the European Union. Manufacturers must demonstrate the quality, safety and efficacy of their products to the EMA, which provides an opinion regarding the MAA. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting an initial assessment of a product. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Clock stops may extend the timeframe of evaluation of a Marketing Authorization (MA) application considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the centralized procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this national MA can be recognized in other Member States through the mutual recognition procedure. If the product has not received a national MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (RMS). The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics (SmPC), and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Concerned Member States (CMSs)) for their approval. If the CMSs raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling, or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States (i.e., in the RMS and the CMSs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Now that the UK (which comprises Great Britain and Northern Ireland) has left the European Union, Great Britain will no longer be covered by centralized MAs (under the Northern Irish Protocol, centralized MAs will continue to be recognized in Northern Ireland). All medicinal products with a current centralized MA were automatically converted to Great Britain MAs on January 1, 2021. For a period of two years from January 1, 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain MA. A separate application will, however, still be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Regulatory Data Protection in the European Union</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the European Union, new chemical entities approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Regulation (EC) No 726/2004, as amended, and Directive 2001/83/EC, as amended. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic (abbreviated) application for a period of eight years. During the additional two-year period of market exclusivity, a generic marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Patent Term Extensions in the European Union and Other Jurisdictions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The European Union also provides for patent term extension through Supplementary Protection Certificates (SPCs). The rules and requirements for obtaining a SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">fifteen years of marketing exclusivity for a drug. In certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained; and in the case of orphan medicinal products, a two-year extension of the orphan market exclusivity may be available. Although SPCs are available throughout the European Union, sponsors must apply on a country-by-country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the European Union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Periods of Authorization and Renewals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the drug on the European Union market (in the case of the centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Regulatory Requirements After Marketing Authorization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product, and must adhere in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These include compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the EMA&#8217;s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and identity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Much like the Anti-Kickback Statue prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to induce or reward improper performance generally is usually governed by the national anti-bribery laws of European Union Member States, and the Bribery Act 2010 in the UK. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the European Union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments made to physicians in certain European Union Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Orphan Drug Designation and Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">drug in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An orphan drug designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized European Union marketing authorization. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity being granted following marketing approval of the orphan product. During this market exclusivity period, neither the EMA nor the European Commission or the member states may only grant marketing authorization to a &#8220;similar medicinal product&#8221; for the same therapeutic indication if: (i) a second applicant can establish that its product, although similar to the authorized product, is safer, more effective or otherwise clinically superior; (ii) the marketing authorization holder for the authorized product consents to a second orphan medicinal product application; or (iii) the marketing authorization holder for the authorized product cannot supply enough orphan medicinal product. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity. Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aforementioned EU rules are generally applicable in the European Economic Area (EEA), which consists of the EU Member States, plus Norway, Liechtenstein and Iceland.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Brexit and the Regulatory Framework in the United Kingdom</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the electorate in the UK voted in favor of leaving the European Union (commonly referred to as Brexit). Thereafter, in March 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty and the UK formally left the European Union on January 31, 2020. A transition period began on February 1, 2020, during which EU pharmaceutical law remained applicable to the UK, which ended on December 31, 2020. Since the regulatory framework in the UK covering the quality, safety and efficacy of medicinal products, clinical trials, marketing authorization, commercial sales and distribution of medicinal products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of therapeutic candidates in the UK, as UK legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for therapeutic candidates and products in the UK in the long-term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since the regulatory framework for pharmaceutical products in the United Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from European Union directives and regulations, Brexit could materially impact the future regulatory regime that applies to products and the approval of therapeutic candidates in the United Kingdom. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for any therapeutic candidates we may develop, which could significantly and materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, once we begin to conduct business in the United Kingdom, we will be subject to stringent data protection laws that are in effect in the United Kingdom. As of January 1, 2021, the United Kingdom&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December 31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the United Kingdom&#8217;s data protection regime, which is independent from but aligned to the European Union&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General Data Protection Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Once we begin processing of personal data regarding individuals in the European Union, including personal health data, our activities will be subject to the GDPR, which became effective on May 25, 2018. The GDPR is wide-</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require us to change our business practices to ensure full compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Coverage, Pricing and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any therapeutic candidates for which we may seek regulatory approval by the FDA or other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payers to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any therapeutic candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such therapeutic candidates. Even if any therapeutic candidates we may develop are approved, sales of such therapeutic candidates will depend, in part, on the extent to which third-party payers, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for, such therapeutic candidates. The process for determining whether a payer will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payers are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payers may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. For more information, see &#8220;Risks Related to Commercialization of Our Therapeutic Candidates&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, therapeutic candidates may not be considered medically necessary or cost effective. A decision by a third-party payer not to cover any therapeutic candidates we may develop could reduce physician utilization of such therapeutic candidates once approved and have a material adverse effect on our sales, results of operations and financial condition. Additionally, a payer&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payer&#8217;s determination to provide coverage for a product does not assure that other payers will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payer to payer. Third-party reimbursement and coverage may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, any companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to any companion diagnostics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Outside the United States, ensuring adequate coverage and payment for any therapeutic candidates we may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any therapeutic candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Healthcare Law and Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business that may constrain the financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing authorization. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, and transparency laws and regulations related to drug pricing and payments and other transfers of value made to physicians and other healthcare providers. If our operations are found to be in violation of any such laws or any other governmental regulations that apply, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment. For more information, see &#8220;Risks Related to Our Business Operations and Industry&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. For more information, see &#8220;Risks Related to Our Business Operations and Industry&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">By way of example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government healthcare programs. The ACA, among other things, subjected biologic products to potential competition by lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new annual </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since enactment of the ACA, there have been, and continue to be, numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administrations or other efforts, if any, to challenge repeal or replace the ACA, will impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments, will remain in effect through 2030 unless additional Congressional action is taken. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act, as well as subsequent legislation, these reductions have been suspended from May 1, 2020 through March 31, 2022 due to the ongoing COVID-19 pandemic. Following the temporary suspension, a 1% payment reduction will occur beginning April 1, 2022 through June 30, 2022, and the 2% payment reduction will resume on July 1, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 28, 2022, we had 114 full-time employees, including a total of 47 employees with Ph.D. degrees. Of these full-time employees, 86 employees are engaged in research and development. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel, whether existing employees or new hires, through the granting of stock-based and cash-based compensation awards. We believe that this increases value to our stockholders and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have, since our inception, worked to create a high-performing, inclusive and diverse workforce, which is a core element of our operating culture. We have deliberately sought to secure top talent with a diversity of thought, experiences and backgrounds who are committed to making a difference in the lives of patients with neuroscience diseases. We believe that, by embracing differences, we have a unique advantage in challenging the status quo to apply innovative thinking to long-existing medical challenges. As of February 28, 2022, our workforce was self-reportedly approximately 49% women and approximately 52% Asian, Hispanic, Latino, Black or African American, and our senior leadership was 68% women or minorities, reflecting the workforce we strive to create throughout the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As the success of our business is fundamentally connected to the well-being of our employees, we are committed to their health, safety and wellness. We provide our employees and their families with access to convenient health and wellness programs, including benefits that provide protection and security giving them peace of mind concerning events that may require time away from work or that impact their financial well-being; and that offer choices where possible so they can customize their benefits to meet their needs and the needs of their families. In response to the ongoing COVID-19 pandemic, we implemented significant changes that we determined were in the best interest of our </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">employees, as well as the community in which we operate, and which comply with government regulations, including working in a remote environment where appropriate or required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Available Information </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We maintain an internet website at www.entradatx.com and make available free of charge through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act of 1934, or the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. You can review our electronically filed reports and other information that we file with the SEC on the SEC&#8217;s web site at http://www.sec.gov. We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. In addition, we regularly use our website to post information regarding our business, product development programs and governance, and we encourage investors to use our website, particularly the information in the section entitled &#8220;Investor Relations,&#8221; as a source of information about us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information on our website is not incorporated by reference into this Annual Report on Form 10-K and should not be considered to be a part of this Annual Report on Form 10-K. Our website address is included in this Annual Report on Form 10-K as an inactive technical reference only. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note Regarding Trademarks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>We have applied for various trademarks that we use in connection with the operation of our business. This Annual Report may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#8217; trademarks, service marks, trade names or products in this Annual Report is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Annual Report may appear without the &#174;, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner of these trademarks, service marks and trade names will not assert, to the fullest extent under applicable law, its rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_7fe3aefc_d722_4712_b239_a10c4d1fe87b"></a><a id="_Hlk94011437_0"></a><a id="_4540e59a_b225_4f14_8599_d523b40a02cf"></a><a id="Item1ARiskFactors_796330"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1A. Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In evaluating the Company and our business, careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report on Form 10-K (Annual Report) and in other documents that we file with the SEC. </i><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline and you could lose part or all of your investment. Unless otherwise indicated, reference in this section and elsewhere in this Annual Report to our business being adversely affected, negatively impacted or harmed will include an adverse effect on, or a negative impact or harm to, the business, reputation, financial condition, results of operations, revenue and our future prospects. The material and other risks and uncertainties summarized above and described below are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Annual Report also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See the section titled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</i> <span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Risks Related to Our Limited Operating History, Financial Position and Capital Requirements</b><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a preclinical-stage biopharmaceutical company with a limited operating history upon which our stockholders can evaluate our business and prospects. All of our development programs, including our lead therapeutic candidate, ENTR-601-44, are in preclinical development or in the drug discovery stage. We commenced operations in 2016, and to date, we have focused primarily on organizing and staffing our company, business planning, raising capital, developing our proprietary, highly versatile and modular EEV platform (EEV Platform), identifying EEV therapeutic candidates, establishing our intellectual property portfolio and conducting research and preclinical studies. Our approach to the discovery and development of therapeutic candidates based on our EEV Platform is unproven, and we do not know whether we will be able to conduct clinical studies on our therapeutic candidates, develop any therapeutic candidates that succeed in clinical development or produce products of commercial value. As an organization, we have not yet initiated or completed any clinical trials, obtained regulatory approvals, manufactured a clinical- or commercial-scale product, or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.</span><span style="letter-spacing:0.2pt;"> </span></p><a id="_d6dadbf7_42f8_49c2_8887_3e5065ab3f91"></a><a id="_8789982e_2193_43ed_ac7b_c8aa90fdd83c"></a><a id="_1b19a73c_6f6a_4f75_80d6_ddf936f1294c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We have incurred significant operating losses since our inception. We do not have any products approved for sale and have not generated any product revenue since our inception. If our therapeutic candidates are not successfully developed and approved, we may never generate any significant revenue. Our net losses were </span><span style="letter-spacing:-0.1pt;">$51.2</span><span style="letter-spacing:-0.1pt;"> million and </span><span style="letter-spacing:-0.1pt;">$26.5</span><span style="letter-spacing:-0.1pt;"> million for the years ended December 31, 2021 and December 31, 2020, respectively. As of December 31, 2021, we had an accumulated deficit of </span><span style="letter-spacing:-0.1pt;">$93.7</span><span style="letter-spacing:-0.1pt;"> million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. All of our therapeutic candidates will require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory approval for and potentially commercialize any of our therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our therapeutic candidates, identifying lead therapeutic candidates, discovering additional therapeutic candidates, conducting preclinical studies prior to submitting an Investigational New Drug application (IND), obtaining clearance for an IND, obtaining regulatory approval for these therapeutic candidates and manufacturing, marketing and selling any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable may have an adverse effect on the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our therapeutic candidates or even continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">Our limited operating history may make it difficult to evaluate our technology and industry and predict our future performance. Though several groups have conducted or are conducting studies involving the intracellular delivery of therapeutic molecules, the relevance of those studies to the evaluation of therapeutic candidates developed using our EEV Platform may be difficult to ascertain. Our short history as an operating company and novel therapeutic approach make any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. Failure to address these risks successfully will cause our business to suffer. Similarly, we expect that our financial condition and operating results will fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. As a </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">result, our stockholders should not rely upon the results of any quarterly or annual period as an indicator of future operating performance.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, as an early-stage company, we have encountered unforeseen expenses, difficulties, complications, delays and other known and unknown circumstances. As we advance our EEV therapeutic candidates, we will need to transition from a company with a research focus to a company capable of supporting clinical development and if successful, commercial activities. We may not be successful in such a transition.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The development of biopharmaceutical therapeutic candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned preclinical studies of our development programs, initiate clinical trials for our therapeutic candidates and seek regulatory approval for our current therapeutic candidates and any future therapeutic candidates we may develop. If we obtain regulatory approval for any of our therapeutic candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any preclinical study or clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our therapeutic candidates. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. Failing to raise capital when needed or on attractive terms could force us to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We believe that the net proceeds from our initial public offering completed in November 2021, together with our existing cash, cash equivalents and marketable securities, will enable us to fund our operations into the second half of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other capital sources, including potentially additional collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.1pt;">Our future capital requirements will depend on many factors, including, but not limited to:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the type, number, scope, progress, expansions, results, costs and timing of our preclinical studies and any clinical trials of the therapeutic candidates that we are pursuing or may choose to pursue in the future;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the clinical development plans we establish for our EEV therapeutic candidates;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the costs and timing of manufacturing for our therapeutic candidates and commercial manufacturing if any therapeutic candidate is approved;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the costs of establishing and maintaining clinical and commercial supply for the development and manufacture of our therapeutic candidates;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the costs, timing and outcome of regulatory review of our therapeutic candidates;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">t</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">he achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements, if any;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the costs and timing of establishing or securing sales and marketing capabilities if any therapeutic candidate is approved;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">subject to receipt of regulatory approval, revenue, if any, received from commercial sales of our therapeutic candidates;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property related claims; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the ongoing costs of operating as a public company.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Identifying potential therapeutic candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and commercialize our therapeutic candidates. In addition, our therapeutic candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the timing and cost of, and level of investment in, research and development activities relating to our programs, which will change from time to time;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our ability to enroll patients in clinical trials and the timing of enrollment;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the cost of manufacturing our current therapeutic candidates and any future therapeutic candidates, which may vary depending on FDA, EMA or other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">expenditures that we will or may incur to acquire or develop additional therapeutic candidates and technologies or other assets;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the timing and outcomes of preclinical studies and clinical trials for ENTR-601-44 and any therapeutic candidates from our discovery programs, or competing therapeutic candidates;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">competition from existing and potential future products that compete with ENTR-601-44 or any of our discovery programs, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">any delays in regulatory review or approval of ENTR-601-44 or therapeutic candidates from any of our discovery programs;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the level of demand for any of our therapeutic candidates, if approved, which may fluctuate significantly and be difficult to predict;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the risk/benefit profile, cost and reimbursement policies with respect to our therapeutic candidates, if approved, and existing and potential future products that compete with ENTR-601-44 or any of our discovery programs;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our ability to commercialize ENTR-601-44 or therapeutic candidates from any of our discovery programs, if approved, inside and outside of the U.S., either independently or working with third parties;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our ability to establish and maintain collaborations, licensing or other arrangements;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our ability to adequately support future growth;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">potential unforeseen business disruptions that increase our costs or expenses;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">future accounting pronouncements or changes in our accounting policies; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the changing and volatile global economic and political environment.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Risks Related to the Discovery, Development and Regulatory Approval of Our Therapeutic Candidates</b><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We are early in our development efforts. We have not initiated clinical studies, and as a result it will be years before we commercialize a therapeutic candidate, if ever. If we are unable to identify and advance therapeutic candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We are early in our development efforts and all our development programs, including our lead therapeutic candidate ENTR-601-44, are in the preclinical or drug discovery stage. We have invested substantially all of our research efforts to date in developing our EEV Platform, identifying potential therapeutic candidates and conducting preclinical studies. As an organization, we have never conducted any clinical trials or submitted an application for regulatory approval, and we may be unable to do so for our therapeutic candidates. We have not yet completed IND-enabling studies for ENTR-601-44, our lead candidate, and we will need to do so to support submission of an IND and progress ENTR-601-44 into and through clinical studies. In addition, we have a development portfolio of programs that are in earlier stages of development and have not yet initiated or completed IND-enabling studies. We may never advance any therapeutic candidates through IND-enabling studies and receive authorization from the U.S. Food and Drug Administration (FDA), to proceed under an IND prior to initiating their clinical-stage development. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our therapeutic candidates, which may never occur. We currently generate no revenue from sales of any product, and we may never be able to develop or commercialize a marketable product.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Commencing clinical trials in the United States is subject to acceptance by the FDA of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities. For the FDA to accept an IND, we must complete Good Laboratory Practices (GLP) studies, which may not be successful or may take longer than we expect. The FDA may require us to complete additional preclinical studies or we may be required to satisfy other FDA requests prior to commencing clinical trials, and such requests may not currently be known or anticipated, which may cause the start of our first clinical trials to be delayed or prevent us from conducting clinical trials. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials, impose stricter approval conditions than we currently expect or may prevent us from conducting clinical trials. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union (EU).</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Commercialization of any therapeutic candidates we may develop will require preclinical and clinical development; regulatory and marketing approval in multiple jurisdictions, including by the FDA and the European Medicines Agency (EMA); manufacturing supply, capacity and expertise; a commercial organization; and significant marketing efforts. The success of therapeutic candidates we may identify and develop will depend on many factors, including:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for any therapeutic candidates we may develop;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">successful enrollment and completion of clinical trials, including under the FDA&#8217;s current Good Clinical Practices (cGCPs), current Good Laboratory Practices (cGLPs) and any additional regulatory requirements from foreign regulatory authorities;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">positive results from our future clinical trials that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended populations;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">receipt of regulatory marketing approvals from applicable regulatory authorities;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">establishment of arrangements with third-party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property protection or regulatory exclusivity for any therapeutic candidates we may develop;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">patient recruitment and enrollment;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">commercial launch of any therapeutic candidates we may develop, if approved, whether alone or in collaboration with others;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">acceptance of the benefits and use of our therapeutic candidates we may develop, including method of administration, if and when approved, by patients, the medical community and third-party payors;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our ability to compete effectively with other therapies and treatment options;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">maintenance of a continued acceptable safety, tolerability and efficacy profile of any therapeutic candidates we may develop following approval; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">establishment and maintenance of healthcare coverage and adequate reimbursement by payors.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any therapeutic candidates we may develop, which would materially harm our business. If we are unable to advance our therapeutic candidates to clinical development, obtain regulatory approval and ultimately commercialize our therapeutic candidates, or experience significant delays in doing so, our business will be materially harmed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our business is highly dependent on the clinical advancement of our programs and modalities and is especially dependent on the success of our lead EEV therapeutic candidate, ENTR-601-44. Delay or failure to advance programs or modalities, including ENTR-601-44 could adversely impact our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Using our platform, we are developing product features for medicines based on EEVs. Over time, our platform work led to commonalities, where a specific combination of EEV technologies, delivery technologies, and manufacturing processes generated a set of product features shared by multiple programs, for example, oligonucleotide-conjugated EEVs and antibody-conjugated EEVs. This is what we call a &#8220;modality.&#8221; We are utilizing early programs in a modality, such as ENTR-601-44 for oligonucleotide-conjugated EEVs, to understand the technology risks within the modality, including manufacturing and pharmaceutical properties. Our lead therapeutic candidate, ENTR-601-44, is being developed to address Duchenne muscular dystrophy (DMD) and we are highly dependent on the success of the future clinical trials of ENTR-601-44, the outcomes of which are uncertain, to further develop a second lead therapeutic candidate for patients with DMD with exon 45 skipping amenable mutations. Because ENTR-601-44 is our first EEV therapeutic candidate, if ENTR-601-44 encounters safety, efficacy, supply or manufacturing problems, developmental delays, regulatory or commercialization issues or other problems, the value of our EEV Platform could be greatly diminished and our development plans and business would be significantly harmed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Even if our earlier programs in a modality are successful in any phase of development any of such earlier programs may fail at a later phase of development, and other programs within the same modality may still fail at any phase of development including at phases where earlier programs in that modality were successful. This may be a result of technical challenges unique to that program or due to biology risk, which is unique to every program. As we progress our programs through clinical development, there may be new technical challenges that arise that cause an entire modality to fail.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our EEV therapeutic candidates are based on a novel therapeutic approach, which makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval, if at all.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">Using EEV technology to develop therapeutic candidates is a new therapeutic approach and no products based on EEVs have been approved to date in the United States, the United Kingdom or the EU. As such, it is difficult to accurately </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">predict the developmental challenges we may face for our EEV therapeutic candidates as they proceed through development. In addition, because we have not yet commenced any clinical trials with our EEV therapeutic candidates, we have not yet been able to assess safety in humans and there may be short-term or long-term effects from treatment with any therapeutic candidates that we develop that we cannot predict at this time. Also, animal models may not exist for some of the diseases we choose to pursue in our programs. As a result of these factors, it is more difficult for us to predict the time and cost of therapeutic candidate development and we cannot predict whether our EEV Platform, or any similar or competitive intracellular delivery technologies, will enable the identification, development and regulatory approval of any products. There can be no assurance that any development problems we experience in the future related to our EEV Platform or any of our research programs will not cause significant delays or unanticipated costs or that such development problems can be solved. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any therapeutic candidates we may develop on a timely or profitable basis, if at all.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The clinical trial requirements of the FDA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a therapeutic candidate vary substantially according to the type, complexity, novelty and intended use and market of the therapeutic candidate. No products based on EEVs have been approved to date by regulators. As a result, the regulatory approval process for therapeutic candidates such as ours is uncertain and may be more expensive and take longer than the approval process for therapeutic candidates based on other, better known or more extensively studied technologies. For example, the general approach for FDA approval of a new biologic or drug is for sponsors to seek licensure or approval based on dispositive data from well-controlled, Phase 3 clinical trials of the relevant therapeutic candidate in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our therapeutic candidates in the U.S., the UK, the EU or other regions of the world or how long it will take to commercialize our therapeutic candidates. Delay or failure to obtain or unexpected costs in obtaining the regulatory approvals necessary to bring a potential therapeutic candidate to market could decrease our ability to generate sufficient product revenue and our business, financial condition, results of operations and prospects may be harmed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Preclinical and clinical development involves a lengthy and expensive process with an uncertain outcome, and the results of preclinical studies are not necessarily predictive of the results of later preclinical studies and any clinical trials of our therapeutic candidates. We have not tested any of our therapeutic candidates in clinical trials and our therapeutic candidates may not have favorable results in clinical trials, if any, or receive regulatory approval on a timely basis, if at all.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Preclinical and clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any preclinical studies or clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. Any positive results from our preclinical studies of our EEV therapeutic candidates may not necessarily be predictive of the results in later preclinical studies and clinical trials. Similarly, even if we are able to complete our planned preclinical studies or clinical trials of our therapeutic candidates according to our current development timeline, the positive results from such preclinical studies and clinical trials may not be replicated in our subsequent preclinical studies or later-stage clinical trials. Despite promising preclinical or clinical results, any therapeutic candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for therapeutic candidates in our industry is high.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">The results from preclinical studies or clinical trials of a therapeutic candidate may not predict the results of later clinical trials of the therapeutic candidate, and interim, topline, or preliminary results of a clinical trial are not necessarily indicative of final results. Therapeutic candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. In particular, while we have conducted certain preclinical studies of ENTR-601-44 and other potential therapeutic candidates, we do not know whether ENTR-601-44 or the other potential therapeutic candidates will perform in future clinical trials as they have performed in these prior studies. The positive results we have observed for our therapeutic candidates in early, non-GLP preclinical studies and animal models may not be predictive of our future clinical trials in humans. Furthermore, for some indications that we are pursuing there are no animal models that adequately mirror the human disease to predict any level of positive results. It is not uncommon to observe results in clinical trials that are unexpected based on preclinical studies and early clinical trials, and many therapeutic candidates fail in clinical trials despite very promising early results. We are currently conducting IND-enabling studies for ENTR-601-44. Unexpected observations or toxicities observed in these studies, or in IND-enabling studies for any of our other development programs, could delay clinical trials for ENTR-601-44 or our other development programs. Moreover, preclinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the biopharmaceutical and biotechnology industries have suffered significant </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">setbacks in clinical development even after achieving promising results in earlier studies, and companies that have believed their therapeutic candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain FDA approval. Additionally, we may conduct clinical trials that utilize an &#8220;open-label&#8221; trial design. An &#8220;open-label&#8221; clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational therapeutic candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational therapeutic candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results with any of our therapeutic candidates for which we include an open-label clinical trial when studied in a controlled environment with a placebo or active control.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">For the foregoing reasons, we cannot be certain that our ongoing and planned preclinical studies and planned clinical trials will be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our therapeutic candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Substantial delays in the commencement, enrollment or completion of our planned clinical trials or failure to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities could prevent us from commercializing any therapeutic candidates we determine to develop on a timely basis, if at all.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The risk of failure in developing therapeutic candidates is high. It is impossible to predict when or if any therapeutic candidate would prove effective or safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any therapeutic candidate, we must complete preclinical development, submit an IND or foreign equivalent to permit initiation of clinical studies, and then conduct extensive clinical trials to demonstrate the safety and efficacy of therapeutic candidates in humans. We have not yet conducted a clinical trial of any therapeutic candidate. As an organization, we plan to advance ENTR-601-44 to IND submission in 2022 and to advance our EEV therapeutic candidate targeting exon 45 to IND submission in 2023. We have not previously conducted any clinical trials of any therapeutic candidates, have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not previously submitted an IND, NDA or BLA or other comparable foreign regulatory submission for any therapeutic candidate. In addition, we have had limited interactions with the FDA and cannot be certain how many clinical trials of ENTR-601-44 or any other therapeutic candidates will be required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of any of our therapeutic candidates. Clinical trials may fail to demonstrate that our therapeutic candidates are safe for humans and effective for indicated uses. Even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Before we can commence clinical trials for a therapeutic candidate, we must complete extensive preclinical testing and studies that support our INDs and other regulatory filings. We cannot be certain of the timely identification of a therapeutic candidate or the completion or outcome of our preclinical testing and studies and cannot predict whether the FDA will accept our proposed clinical programs or whether the outcome of our preclinical testing and studies will ultimately support the further development of any therapeutic candidates. Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. As a result, we cannot be sure that we will be able to submit INDs for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs will result in the FDA allowing clinical trials to begin.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Furthermore, therapeutic candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not limited to, flaws in trial design, dose selection issues, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Other events that may prevent successful enrollment, initiation or timely completion of clinical development include:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">we may be unable to generate sufficient preclinical, toxicology or other </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:-0.1pt;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:-0.1pt;">in vitro</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> data to support the initiation of clinical trials;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">delays in reaching a consensus with regulatory authorities on trial design;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">delays in reaching agreement on acceptable terms with prospective clinical research organizations (CROs) and clinical trial sites;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">delays in opening clinical trial sites or obtaining required institutional review board (IRB) or independent ethics committee approval, or the equivalent review groups for sites outside the United States, at each clinical trial site;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">we may need to add new or additional clinical trial sites;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or after an inspection of our clinical trial operations or trial sites;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">negative or inconclusive results observed in clinical trials, including failure to demonstrate statistical significance, safety, purity or potency, which could lead us, or cause regulators to require us, to conduct additional clinical trials or abandon product development programs;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">positive results from our preclinical studies of our therapeutic candidates may not necessarily be predictive of the results from required later preclinical studies and clinical trials and positive results from such preclinical studies and clinical trials of our therapeutic candidates may not be replicated in subsequent preclinical studies or clinical trial results;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">failure to perform in accordance with applicable cGCPs;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">failure by investigators to adhere to clinical trial protocols leading to variable results;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">delays in the testing, validation, manufacturing and delivery of any therapeutic candidates we may develop to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">failure of our third-party contractors to comply with regulatory requirements or to meet their contractual obligations to us in a timely manner, or at all;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">clinical trial sites or patients dropping out of a trial;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">occurrence of serious adverse events associated with the therapeutic candidate that are viewed to outweigh its potential benefits;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">occurrence of serious adverse events associated with a therapeutic candidate in development by another company, which are viewed to outweigh its potential benefits, and which may negatively impact the perception of our product due to a similarity in technology or approach;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies or impose other requirements before permitting us to initiate a clinical trial;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">changes in the legal or regulatory regimes domestically or internationally related to patient rights and privacy; or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">lack of adequate funding to continue the clinical trial.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We could also encounter delays if a clinical trial is suspended, placed on clinical hold or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA or other regulatory authorities or recommended for suspension or termination by the Data Safety Monitoring Board (DSMB) for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our therapeutic candidates. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their therapeutic candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA approval.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Any inability to successfully complete preclinical studies and clinical trials could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, manufacturing or formulation changes to any therapeutic candidates we may develop may require us to conduct additional studies or trials to bridge our modified therapeutic candidates to earlier versions. Clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize any therapeutic candidates we may develop or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize any therapeutic candidates we may develop and may harm our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Additionally, if the results of future clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with any therapeutic candidates we may develop, we may:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">be delayed in obtaining marketing approval for therapeutic candidates, if at all;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">be subject to changes in the way the product is administered;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">be subject to the addition of labeling statements, such as warnings or contraindications;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">be sued; or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">experience damage to our reputation.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Delays or difficulties in the enrollment of patients in clinical trials could delay or prevent our receipt of necessary regulatory approvals.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Failure to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the U.S. may delay or prevent us from initiating or continuing clinical trials for our therapeutic candidates. Because the target patient populations for some of our therapeutic candidates are relatively small, it may be difficult to successfully identify patients. Although we may enter into agreements with third parties to develop companion diagnostic tests for use in some of our future clinical trials in order to help identify eligible patients in certain indications, we may experience delays in reaching, or fail to reach, agreement on acceptable terms to develop such companion diagnostic tests. Any third parties whom we engage to develop companion diagnostic tests may experience delays or may not be successful in developing such companion diagnostic tests, furthering the difficulty in identifying patients for our clinical trials. In addition, current commercially available diagnostic tests to identify appropriate patients for our clinical trials or any approved therapeutic candidates may become unavailable in the future.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, we may experience delays or disruptions in the initiation of or enrollment in our planned clinical trials due to the ongoing COVID-19 pandemic and changes in local site or IRB policies, availabilities of site staff, reprioritization of hospital resources, restricted access to healthcare professionals and testing sites and other containment measures or concerns among patients about participating in clinical trials during a pandemic. Furthermore, some of our competitors have ongoing clinical trials for therapeutic candidates that treat the same indications as our therapeutic candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, the pediatric population is an important patient population for certain of the indications we are targeting, including DMD, and our addressable patient population estimates include pediatric populations. However, it may be more challenging to conduct studies in this population, and to locate and enroll pediatric patients. Additionally, it may be challenging to ensure that pediatric or adolescent patients adhere to clinical trial protocols.</span><span style="letter-spacing:0.2pt;"> </span><span style="letter-spacing:-0.1pt;">Patient enrollment and trial competition may be affected by other factors including:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">clinicians&#8217; and patients&#8217; perceived risks and benefits of the therapeutic candidate under trial, particularly therapeutic candidates developed using a novel and unproven therapeutic approach, like our EEV therapeutic candidates in relation to available or investigational drugs;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">size of the patient population, in particular for rare diseases such as the diseases on which we are initially focused, and process for identifying patients;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">design of the trial protocol;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">efforts to facilitate timely enrollment in clinical trials;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">eligibility and exclusion criteria;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">availability of competing therapies and clinical trials;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">severity of the disease or disorder under investigation;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">proximity and availability of clinical trial sites for prospective patients;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">ability to obtain and maintain patient consent;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">risk that enrolled patients will drop out before completion of the trial;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">patient referral practices of physicians; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">ability to monitor patients adequately during and after treatment.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our inability to identify patients appropriate for enrollment in our clinical trials, or to enroll a sufficient number of patients in our clinical trials, would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our therapeutic candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. If we are unable to include patients with the driver of the disease, including the applicable genomic alteration for diseases in genomically defined patient populations, this could limit our ability to seek participation in the FDA&#8217;s expedited development programs, including Breakthrough Therapy Designation and Fast Track Designation, or otherwise to seek to accelerate clinical development and regulatory timelines.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining patients in our clinical trials. In our planned clinical trials that will include a placebo group, some of the patients who end up receiving placebo may perceive that they are not receiving the therapeutic candidate being tested, and they may decide to withdraw from our clinical trials to pursue other alternative therapies rather than continue the trial with the perception that they are receiving placebo. Difficulty enrolling or maintaining a sufficient number of patients to conduct our clinical trials, may require us to delay, limit or terminate clinical trials, any of which would harm our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Use of our therapeutic candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a therapeutic candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, prospects, operating results and financial condition.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We have not evaluated any therapeutic candidates in human clinical trials, and we have not yet completed preclinical studies to assess the safety of our lead candidate, ENTR-601-44. Although other oligonucleotide therapeutics, enzyme replacement therapies and gene therapies have received regulatory approval, our EEV-based therapeutics are a novel approach to the delivery of biological therapeutics, which may present enhanced uncertainty associated with the safety profile of ENTR-601-44 and other EEV-based therapeutics compared to more well-established classes of therapies. Moreover, it is impossible to predict when or if any therapeutic candidates we may develop will prove safe in humans. As is the case with biopharmaceuticals generally, it is likely that there may be side effects and adverse events associated with our therapeutic candidates&#8217; use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our therapeutic candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our therapeutic candidates may only be uncovered with a significantly larger number of patients exposed to the therapeutic candidate. Any undesirable side effects or unexpected characteristics associated with our therapeutic candidates in clinical trials may lead us to elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the therapeutic candidate if approved. We may also be required to modify our study plans based on findings after we commence our clinical trials. Many compounds that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">It is possible that as we test our therapeutic candidates in larger, longer and more extensive clinical trials, or as the use of these therapeutic candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, may be reported by subjects. Any findings of such side effects later in development or upon approval, if any, may harm our business, financial condition and prospects significantly.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Patients treated with our therapeutics, if approved, may experience previously unreported adverse reactions, and it is possible that the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our therapeutic candidates. If safety problems occur or are identified after our therapeutics, if any, reach the market, we may make the decision or be required by regulatory authorities to amend the labeling of our therapeutics, recall our therapeutics or even withdraw approval for our therapeutics.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our therapeutic candidates are subject to extensive regulation and compliance, which is costly and time-consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The clinical development, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, import, export, marketing, distribution and adverse event reporting, including the submission of safety and other information, of our therapeutic candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. In the United States, we are not permitted to market our therapeutic candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the therapeutic candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a therapeutic candidate for many reasons. Despite the time and expense invested in clinical development of therapeutic candidates, regulatory approval is never guaranteed. Neither we nor any current or future collaborator is permitted to market any of our therapeutic candidates in the United States until we receive approval from the FDA.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Prior to obtaining approval to commercialize a therapeutic candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such therapeutic candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our therapeutic candidates are promising, such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or clinical trials for our therapeutic candidates either prior to or post-approval, or may object to elements of our clinical development program.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a therapeutic candidate for many reasons, including:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">such authorities may disagree with the design or implementation of our or our current or future collaborators&#8217; clinical trials;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs similar to our therapeutic candidates;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">we or any of our current or future collaborators may be unable to demonstrate that a therapeutic candidate is safe and effective, and that therapeutic candidate&#8217;s clinical and other benefits outweigh its safety risks;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">such authorities may not agree that the data collected from clinical trials of our therapeutic candidates are acceptable or sufficient to support the submission of an NDA or BLA or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">such authorities may disagree regarding the formulation, labeling and/or the specifications of our therapeutic candidates;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">such authorities may find deficiencies in the manufacturing processes, approval policies or facilities of our third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#8217; clinical data insufficient for approval; or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed biopharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our approach to the discovery and development of therapeutic candidates based on our EEV Platform is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing technological approaches will limit the commercial value of our therapeutic candidates or render our EEV Platform obsolete.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our proprietary EEV Platform, which leverages a novel and unproven approach. While we have observed favorable preclinical study results based on our EEV Platform, we have not yet succeeded and may not succeed in demonstrating efficacy and safety for any therapeutic candidates in clinical trials or in obtaining marketing approval thereafter. Our lead therapeutic candidate, ENTR-601-44, is in preclinical development and we have not yet submitted an IND or initiated any clinical trials for any therapeutic candidate. Our research methodology and novel approach to intracellular therapeutics may be unsuccessful in identifying additional therapeutic candidates, and any therapeutic candidates based on our EEV Platform may be shown to have harmful side effects or may have other characteristics that may necessitate additional clinical testing, or make the therapeutic candidates unmarketable or unlikely to receive marketing approval. Further, because all of our therapeutic candidates and development programs are based on our EEV Platform, adverse developments with respect to one of our programs may have a significant adverse impact on the actual or perceived likelihood of success and value of our other programs.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, the biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies. Our future success will depend in part on our ability to maintain a competitive position with our EEV approach. Failure to stay at the forefront of technological change in utilizing our EEV Platform to create and develop therapeutic candidates may prevent us from competing effectively. Our competitors may render our EEV approach obsolete, or limit the commercial value of our therapeutic candidates, by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and proprietary technologies. By contrast, adverse developments with respect to other companies that attempt to use a similar approach to our approach may adversely impact the actual or perceived value of our EEV Platform and potential of our therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The occurrence of any of these events may force us to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Interim, topline and preliminary data from our preclinical studies and planned clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">From time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies and planned clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim, preliminary or topline data from our clinical studies. Interim, topline or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, topline or interim data and final data could significantly harm our business prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular therapeutic candidate or product and the value of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial will be based on what is typically extensive information, and our stockholders or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, therapeutic candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our therapeutic candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may expend our limited resources to pursue a particular therapeutic candidate or indication, such as our initial focus on developing ENTR-601-44, and fail to capitalize on therapeutic candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Because we have limited human capital and financial resources, we focus on research programs and therapeutic candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and therapeutic candidates for specific indications may not yield any commercially viable therapeutic candidates. If we do not accurately evaluate the commercial potential or target market for a particular therapeutic candidate, we may relinquish valuable rights to that therapeutic candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such therapeutic candidate.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">At any time and for any reason, we may determine that one or more of our discovery programs or pre-clinical or clinical therapeutic candidates or programs does not have sufficient potential to warrant the allocation of resources toward such program or therapeutic candidate. Accordingly, we may choose not to develop a potential therapeutic candidate or elect to suspend, deprioritize or terminate one or more of our discovery programs or pre-clinical or clinical therapeutic candidates or programs. Suspending, deprioritizing or terminating a program or therapeutic candidate in which we have invested significant resources, we will have expended resources on a program that will not provide a full return on our investment and may have missed the opportunity to have allocated those resources to potentially more productive uses, including existing or future programs or therapeutic candidates. For example, in 2020, we made the strategic decision to focus the majority of our immediate efforts on EEV-oligonucleotide opportunities. In order to support ENTR-501 progress, we are exploring partnership opportunities with organizations that have the resources and expertise to continue the development of ENTR-501 into and through clinical development. We continue to believe that the program will have an important role in the future treatment of patients with MNGIE.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may not be successful in our efforts to expand our development portfolio of therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">A key element of our strategy is to use our novel EEV Platform to address intracellular targets that are drivers of diseases in genomically defined patient populations with high unmet medical need in order to build a development portfolio of therapeutic candidates. Although our research and development efforts to date have resulted in a development portfolio of potential programs and therapeutic candidates, we may not be able to continue to identify intracellular disease targets and develop therapeutic candidates. We may also pursue opportunities to acquire or in-license additional businesses, technologies or products, form strategic alliances or create joint ventures with third parties to complement or augment our existing business. However, we may not be able to identify any therapeutic candidates for our development portfolio through such acquisition or in-license.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Even if we are successful in continuing to build and expand our development portfolio, the potential therapeutic candidates that we identify may not be suitable for clinical development. For example, they may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will be successful in clinical trials or receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize therapeutic candidates, we will not be able to obtain drug revenues in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Where appropriate, we plan to secure approval from the FDA, EMA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA or comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, EMA or such other regulatory authorities may seek to withdraw accelerated approval.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Where possible, we plan to pursue accelerated development strategies in areas of high unmet need. We may seek an accelerated approval pathway for our one or more of our therapeutic candidates from the FDA, EMA or comparable foreign regulatory authorities. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA&#8217;s implementing regulations, the FDA may grant accelerated approval to a therapeutic candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the therapeutic candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">Prior to seeking accelerated approval, we will seek feedback from the FDA, EMA or comparable foreign regulatory authorities and will otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA or BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, EMA or comparable foreign regulatory authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA, EMA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA to full approval. </span><span style="letter-spacing:-0.1pt;">In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of any of our products. </span><span style="letter-spacing:-0.1pt;">A failure to obtain accelerated approval or </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">any other form of expedited development, review or approval for our therapeutic candidate would result in a longer time period to commercialization of such therapeutic candidate, could increase the cost of development of such therapeutic candidate and could harm our competitive position in the marketplace.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may seek Fast Track designation, Breakthrough Therapy designation and/or orphan drug designation from the FDA or similar designations from other regulatory authorities for one or more of our therapeutic candidates. Even if one or more of our therapeutic candidates receive any of these designations, we may be unable to obtain or maintain the benefits associated with such designation.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The FDA has established various designations to facilitate more rapid and efficient development and approval of certain types of drugs. Such designations include Fast Track designation, Breakthrough Therapy designation, and orphan drug designation. Fast Track designation is designed to facilitate the development and expedite the review of therapies for serious conditions that fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review and the ability to submit a rolling application for regulatory review. Fast Track designation applies to both the therapeutic candidate and the specific indication for which it is being studied. If any of our therapeutic candidates receive Fast Track designation but do not continue to meet the criteria for Fast Track designation, or if our clinical trials are delayed, suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply, we will not receive the benefits associated with the Fast Track program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">A Breakthrough Therapy, on the other hand, is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For therapeutic candidates that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Designation as a Breakthrough Therapy is within the discretion of the FDA, and drugs designated as Breakthrough Therapies by the FDA may also be eligible for other expedited approval programs, including accelerated approval. Even if one or more of our therapeutic candidates qualify as Breakthrough Therapies pursuant to FDA standards, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we may seek Breakthrough Therapy designation for one or more of our current or future therapeutic candidates, there can be no assurance that we will receive Breakthrough Therapy designation.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Regulatory authorities in some jurisdictions, including the United States and the EU, may also designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a therapeutic candidate as an orphan drug if it is a drug intended to treat a rare condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA&#8217;s Committee for Orphan Medicinal Products (COMP) evaluates orphan designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five (5) in ten thousand (10,000) persons in the EU, or where the product, without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary investment in its development. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers, and it may entitle the therapeutic to exclusivity in the United States and the EU. Even if we obtain orphan drug designation for a therapeutic candidate, we may not be able to obtain or maintain orphan drug exclusivity for that therapeutic candidate</span><span style="letter-spacing:-0.1pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If any of our programs or therapeutic candidates receive Fast Track, Breakthrough Therapy or orphan drug designation by the FDA or similar designations by other regulatory authorities, there is no assurance that we will receive any benefits from such programs or that we will continue to meet the criteria to maintain such designation. Even if we obtain such designations, we may not experience a faster development process, review or approval compared to conventional FDA procedures. A Fast Track, Breakthrough Therapy, or orphan drug designation does not ensure that a therapeutic candidate will receive marketing approval or that approval will be granted within any particular timeframe.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Obtaining and maintaining marketing approval or commercialization of our therapeutic candidates in the United States does not mean that we will be successful in obtaining marketing approval of our therapeutic candidates in other jurisdictions. Failure to obtain marketing approval in foreign jurisdictions would prevent any therapeutic candidates we may develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In order to market and sell any therapeutic candidates we may develop in the EU and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our medicines in any jurisdiction, which would materially impair our ability to generate revenue.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the withdrawal of the United Kingdom from the EU, commonly referred to as Brexit. On December 24, 2020, the United Kingdom and the EU entered into a Trade and Cooperation Agreement, which became provisionally applicable on January 1, 2021 and has been formally applicable since May 1, 2021. This agreement is comprehensive and provides some details on how aspects of the United Kingdom and EU&#8217;s relationship regarding medicinal products will operate, particularly in relation to Good Manufacturing Practice, however it does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. Great Britain is therefore no longer covered by the centralized procedure for obtaining EU-wide marketing authorizations from the EMA for medicinal products (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland and centralized EU authorizations will continue to be recognized) and a separate process for authorization of drug products will be required in Great Britain</span><span style="letter-spacing:-0.1pt;">. For a period of two years from January 1, 2021, the Medicines and Healthcare Products Regulatory Agency may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization, however a separate application will still be required.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of the Trade and Cooperation Agreement or otherwise, would prevent us from commercializing any therapeutic candidates in the United Kingdom and/or the EU and restrict our ability to generate revenue and achieve or sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or the EU for any therapeutic candidates that we may develop, which could significantly and materially harm our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We anticipate we will initially conduct clinical trials of our therapeutic candidates in the United States and we may choose to conduct our clinical trials internationally as well. The acceptance of study data by the FDA, EMA or other comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions. In cases where data from United States clinical trials are intended to serve as the basis for marketing approval in the foreign countries outside the United States, the standards for clinical trials and approval may be different. There can be no assurance that any United States or foreign regulatory authority would accept data from trials conducted outside of its applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our therapeutic candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Changes in methods of therapeutic candidate manufacturing or formulation may result in additional costs or delay, which could adversely affect our business, results of operations and financial condition.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">As therapeutic candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. For example, we may introduce an alternative formulation of one or more of our therapeutic candidates during the course of our planned clinical trials. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our therapeutic candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our therapeutic candidates and jeopardize our ability to commercialize our therapeutic candidates, if approved, and generate revenue.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Even if we, or any collaborators we may have, obtain marketing approvals for any therapeutic candidates we may develop, the terms of approvals and ongoing regulation of our therapeutics could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our therapeutics, which could materially impair our ability to generate revenue.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Any therapeutic candidate for which we obtain marketing approval, if ever, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such medicine, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, compliance with applicable product tracking and tracing requirements, and requirements regarding the distribution of samples to physicians and recordkeeping. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The FDA typically advises that patients treated with genetic medicine undergo follow-up observations for potential adverse events for a 15-year period. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Even if marketing approval of a therapeutic candidate is granted, the approval may be subject to limitations on the indicated uses for which the medicine may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Accordingly, assuming we, or any third parties we may collaborate with, receive marketing approval for one or more therapeutic candidates we may develop, we, and such collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we and such collaborators are not able to comply with post-approval regulatory requirements, we and such collaborators could have the marketing approvals for our therapeutics withdrawn by regulatory authorities and our, or such collaborators&#8217;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial condition and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If we fail to comply with applicable regulatory requirements following approval of any therapeutic candidates we may develop, a regulatory agency may:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">issue a warning letter asserting that we are in violation of the law;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">seek an injunction or impose civil or criminal penalties or monetary fines;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">suspend or withdraw regulatory approval;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">suspend any ongoing clinical trials;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">refuse to approve a pending BLA or supplements to a BLA submitted by us;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">seize product; or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">refuse to allow us to enter into supply contracts, including government contracts.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any therapeutic candidates we may develop and generate revenues.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Clinical trial and product liability lawsuits against us could divert our resources, could cause us to incur substantial liabilities and could limit commercialization of any therapeutic candidates we may develop.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We will face an inherent risk of clinical trial and product liability exposure related to the testing of any therapeutic candidates we may develop in clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have no therapeutic candidates in clinical trials or that have been approved for commercial sale, the future use of therapeutic candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our therapeutic candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">decreased demand for any therapeutic candidates we may develop;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">injury to our reputation and significant negative media attention;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">withdrawal of clinical trial participants and inability to continue clinical trials;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">initiation of investigations by regulators;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">significant costs to defend any related litigation;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">substantial monetary awards to trial participants or patients;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">loss of revenue;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">exhaustion of any available insurance and our capital resources;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">decline in our stock price;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">reduced resources of our management to pursue our business strategy; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the inability to commercialize any therapeutic candidates we may develop.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We will need to increase our insurance coverage if we commence clinical trials or if we commence commercialization of any therapeutic candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If and when coverage is secured, our insurance policies may also have various exclusions and we may be subject to a product liability claim for which we have no coverage. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may develop our current or future therapeutic candidates in combination with other therapies, which would expose us to additional risks.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We may develop our current or potential future therapeutic candidates in combination with one or more currently approved therapies or therapies in development. Even if any of our current or future therapeutic candidates were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA, EMA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of our therapeutic candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our therapeutic candidates are approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our therapeutic candidates or our own products being removed from the market or being less successful commercially.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We may also evaluate our current or future therapeutic candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA, EMA or comparable foreign regulatory authorities. We will not be able to market and sell any therapeutic candidate in combination with any such unapproved therapies that do not ultimately obtain marketing approval.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Furthermore, we cannot be certain that we will be able to obtain a steady supply of such therapies for use in developing combinations with our therapeutic candidates on commercially reasonable terms or at all. Any failure to obtain such therapies for use in clinical development and the expense of purchasing therapies in the market may delay our development timelines, increase our costs and jeopardize our ability to develop our therapeutic candidates as commercially viable therapies. If the FDA, EMA or other comparable foreign regulatory authorities do not approve or withdraw their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with any of our current or future therapeutic candidates, we may be unable to obtain approval of or successfully market any one or all of the current or future therapeutic candidates we develop. Additionally, if the third-party providers of therapies or therapies in development used in combination with our current or future therapeutic candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our current or future therapeutic candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Risks Related to Our Reliance on Third Parties</b><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We do not expect to independently conduct all aspects of our product manufacturing, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to many of these items, including contract manufacturing organizations (CMOs) for the manufacturing of any therapeutic candidates we test in preclinical or clinical development, as well as CROs for the conduct of our animal testing and research and CROs for the conduct of our planned clinical trials. Any of these third parties may terminate their engagements with us at any time. A need to enter into alternative arrangements could delay our product development </span><span style="letter-spacing:-0.1pt;">activities, and we may not be able to enter into alternative arrangements on reasonable terms, if at all</span><span style="letter-spacing:-0.1pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For example, for therapeutic candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols. Moreover, the FDA requires us to comply with cGCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, clinicaltrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. If we or any of our CROs or other third parties, including trial sites, fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure our stockholders that upon inspection by a given </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">regulatory authority, such regulatory authority will determine that any of our clinical trials complies with cGCP regulations. In addition, our clinical trials must be conducted with product produced under conditions that comply with the FDA&#8217;s current Good Manufacturing Practices. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Although we intend to design the clinical trials for any therapeutic candidates we may develop, CROs will conduct some or all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future preclinical studies and clinical trials will also result in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">have staffing difficulties;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">be unable to acquire the necessary supplies to perform successfully;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">fail to comply with contractual obligations;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">experience regulatory compliance issues;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">undergo changes in priorities or become financially distressed; or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">form relationships with other entities, some of which may be our competitors.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. We expect to have to negotiate budgets and contracts with CROs and trial sites, which may result in delays to our development timelines and increased costs. In addition, any third parties conducting our clinical trials will not be our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our clinical programs. If these CROs, and any other third parties we engage do not perform preclinical studies and future clinical trials in a satisfactory manner, if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, or if they breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of any therapeutic candidates we may develop may be delayed, we may not be able to obtain regulatory approval and commercialize our therapeutic candidates or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs and other third parties, we could be required to repeat, extend the duration of or increase the size of any preclinical studies or clinical trials we conduct and this could significantly delay commercialization and require greater expenditures.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and other regulatory authorities for therapeutic candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or other regulatory authorities may require us to suspend, place on clinical hold or terminate these trials or perform additional preclinical studies or clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP requirements. In addition, our clinical trials must be conducted with biologic product produced under cGMP requirements and may require a large number of patients. In the U.S., we also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our therapeutic candidates. As a result, our financial results and the commercial prospects for our therapeutic candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. For any violations of laws and regulations during the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. If third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the preclinical studies and clinical trials required to support future IND submissions and approval of any therapeutic candidates we may develop.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We are dependent on third-party vendors to provide certain licenses, products and services and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We engage a number of third-party suppliers and service providers to supply critical goods and services, such as contract research services, contract manufacturing services and IT services. Disruptions to the business, financial stability or operations of these suppliers and service providers, including due to strikes, labor disputes or other disruptions to the workforce, for instance, if, as a result of the ongoing COVID-19 pandemic, employees are not able to come to work, or to their willingness and ability to produce or deliver such products or provide such services in a manner that satisfies the requirements put forth by the authorities, or in a manner that satisfies our own requirements, could affect our ability to develop and market our future therapeutic candidates on a timely basis. If these suppliers and service providers were unable or unwilling to continue to provide their products or services in the manner expected, or at all, we could encounter difficulty finding alternative suppliers. Even if we are able to secure appropriate alternative suppliers in a timely manner, costs for such products or services could increase significantly. </span><span style="letter-spacing:-0.1pt;">Additionally, since the beginning of the pandemic, three vaccines for COVID-19 were granted Emergency Use Authorization by the FDA, and two of those later received marketing approval. Additional vaccines may be authorized in the future. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. Any of these events could adversely affect our results of operations and our business</span><span style="letter-spacing:-0.1pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our EEV-based therapeutic candidates are based on novel technologies and any therapeutic candidates we develop may be complex and difficult to manufacture. We may encounter difficulties in manufacturing, product release, shelf life, testing, storage, supply chain management or shipping. If we or any of our third-party manufacturers encounter such difficulties, our ability to supply material for clinical trials or any approved product could be delayed or stopped.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">The manufacturing processes for our therapeutic candidates are novel. There are no medicines incorporating or utilizing our EEV Platform that have been commercialized to date or manufactured at such scale. Due to the novel nature of this technology and limited experience at larger scale production, we may encounter difficulties in manufacturing, product release, shelf life, testing, storage and supply chain management, or shipping. These difficulties could be due to any number of reasons including, but not limited to, complexities of producing batches at larger scale, equipment failure, choice and quality of raw materials and excipients, analytical testing technology, and product instability. In an effort to optimize product features, we have in the past and may in the future make changes to our therapeutic candidates in their manufacturing and stability formulation and conditions. This has in the past resulted in and may in the future result in our </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">having to resupply batches for preclinical or clinical activities when there is insufficient product stability during storage and insufficient supply. Insufficient stability or shelf life of our therapeutic candidates could materially delay our or our strategic collaborators&#8217; ability to continue the clinical trial for that therapeutic candidate or require us to begin a new clinical trial with a newly formulated drug product, due to the need to manufacture additional preclinical or clinical supply.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our rate of innovation is high, which has resulted in and will continue to cause a high degree of technology change that can negatively impact product comparability during and after clinical development. Furthermore, technology changes may drive the need for changes in, modification to, or the sourcing of new manufacturing infrastructure or may adversely affect third-party relationships.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The process to generate our EEV-based therapeutics is complex and, if not developed and manufactured under well-controlled conditions, can adversely impact pharmacological activity. Furthermore, we have not manufactured our EEV-based therapeutics at commercial scale. We may encounter difficulties in scaling up our manufacturing process, thereby potentially impacting clinical and commercial supply.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">During clinical development of our EEV-based therapeutics, in many cases, we may have to utilize multiple batches of drug substance and drug product to meet the clinical supply requirement of a single clinical trial. Failure in our ability to scale up batch size or failure in any batch may lead to a substantial delay in our clinical trials.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">As we continue developing new manufacturing processes for our drug substance and drug product, the changes we implement to manufacturing process may in turn impact specification and stability of the drug product. Changes in our manufacturing processes may lead to failure of lots and this could lead to a substantial delay in our clinical trials. Our EEV-based therapeutic candidates may prove to have a stability profile that leads to a lower than desired shelf life of our final approved EEV-based product. This poses risk in supply requirements, wasted stock, and higher cost of goods.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Due to the number of different programs, we may have cross contamination of products inside of our factories, CROs, suppliers, or in the clinic that affect the integrity of our therapeutics.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">As we scale the manufacturing output for particular programs, we plan to continuously improve yield, purity, and the pharmaceutical properties of our development candidates from IND-enabling studies through commercial launch, including shelf life stability, and solubility properties of drug product and drug substance. Because of continuous improvement in manufacturing processes, we may switch processes for a particular program during development. However, after the change in process, more time is required for pharmaceutical property testing, such as 6 or 12 month stability testing. That may require resupplying clinical material, or making additional cGMP batches to keep up with clinical trial demand before such pharmaceutical property testing is completed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We are utilizing a number of raw materials and excipients that are either new to the pharmaceutical industry or are being employed in a novel manner. Some of these raw materials and excipients have not been scaled to a level to support commercial supply and could experience unexpected manufacturing or testing failures, or supply shortages. Such issues with raw materials and excipients could cause delays or interruptions to clinical and commercial supply of our therapeutic candidates. Further, now and in the future one or more of our programs may have a single source of supply for raw materials and excipients.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We may establish a number of analytical assays to assess the quality of our EEV-based therapeutic candidates. We may identify gaps in our analytical testing strategy that might prevent release of product or could require product withdrawal or recall. For example, we may discover new impurities that have an impact on product safety, efficacy, or stability. This may lead to an inability to release our therapeutic candidates until the manufacturing or testing process is rectified.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We may find that our therapeutic candidates are extremely temperature sensitive, and we may learn that any or all of our therapeutics are less stable than desired. We may also find that transportation conditions negatively impact product quality. This may require changes to the formulation or manufacturing process for one or more of our therapeutic candidates and result in delays or interruptions to clinical or commercial supply. In addition, the cost associated with such transportation services and the limited pool of vendors may also add additional risks of supply disruptions.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Because we currently rely on third parties to manufacture our therapeutic candidates and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements, and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets and despite our efforts to protect our trade secrets, a competitor&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may from time to time be dependent on single-source suppliers for some of the components and materials used in the therapeutic candidates we may develop.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We may from time to time depend on single-source suppliers for some of the components and materials used in any therapeutic candidates we may develop. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and finished goods could expose us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If we have to switch to a replacement supplier, the manufacture and delivery of any therapeutic candidates we may develop could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our therapeutics, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our investigational medicines.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may enter into collaborations, licenses and other similar arrangements with third parties for the research, development and commercialization of certain of the therapeutic candidates we may develop. If any such arrangements are not successful, we may not be able to capitalize on the market potential of those therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We may seek third-party collaborators for the research, development and commercialization of certain of the therapeutic candidates we may develop. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our partners dedicate to the development or commercialization of any therapeutic candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our abilities to successfully perform the functions assigned to them in these arrangements. We cannot predict the success of any arrangement that we enter into.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Collaborations involving our research programs or any therapeutic candidates we may develop pose numerous risks to us, including the following:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaborators would have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaborators may not perform their obligations as expected;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaborators may not pursue development and commercialization of any therapeutic candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaborators may delay programs, preclinical studies or clinical trials, provide insufficient funding for programs, preclinical studies or clinical trials, stop a preclinical study or clinical trial or abandon a therapeutic candidate, repeat or conduct new clinical trials or require a new formulation of a therapeutic candidate for clinical testing;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with any therapeutic candidates we may develop if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaborators may be acquired by a third party having competitive products or different priorities, causing the emphasis on our product development or commercialization program under such collaboration to be delayed, diminished or terminated;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaborators may not properly obtain, maintain, enforce or defend our intellectual property or proprietary rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any therapeutic candidate licensed to it by us;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our collaborators&#8217; business or operations could be disrupted due to the ongoing COVID-19 pandemic or other reasons outside of our control, which could have an adverse impact on their development and commercialization efforts or the prospects of our collaboration;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development, or commercialization of any therapeutic candidates we may develop or that result in costly litigation or arbitration that diverts management attention and resources; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">we may lose certain valuable rights under certain circumstances, including if we undergo a change of control;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable therapeutic candidates we may develop; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">collaboration agreements may not lead to development or commercialization of therapeutic candidates in the most efficient manner or at all.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If our collaborations do not result in the successful development and commercialization of therapeutic candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of therapeutic candidates could be delayed, and we may need additional resources to develop therapeutic candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report apply to the activities of our collaborators.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">These relationships, or those like them, may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of several factors. If we license rights to any therapeutic candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">If conflicts arise between us and our potential collaborators, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If conflicts arise between us and our potential collaborators, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Our collaborators may develop, either alone or with others, products in related fields that are competitive with the therapeutic candidates we may develop that are the subject of these collaborations with us. Competing products, either developed by the collaborators or to which the collaborators have rights, may result in the withdrawal of support for our therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Some of our future collaborators could also become our competitors. Our collaborators could develop competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, fail to devote sufficient resources to the development and commercialization of products, or merge with or be acquired by a third party who may do any of these things. Any of these developments could harm our product development efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our product development and research programs and the potential commercialization of any therapeutic candidates we may develop will require substantial additional cash to fund expenses. For some of the therapeutic candidates we may develop, we may decide to collaborate with other pharmaceutical and biotechnology companies for the development and potential commercialization of those therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, the EMA or similar regulatory authorities outside the United States, the potential market for the subject therapeutic candidate, the costs and complexities of manufacturing and delivering such therapeutic candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative therapeutic candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the therapeutic candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization, reduce the scope of any sales or marketing activities, or increase our own expenditures on the development of the therapeutic candidate. </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Risks Related to Commercialization of Our Therapeutic Candidates</b><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">The commercial success of our therapeutic candidates will depend upon the degree of market acceptance of such therapeutic candidates by physicians, patients, healthcare payors and others in the medical community.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our therapeutic candidates may not be commercially successful. Even if any of our therapeutic candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. The commercial success of any of our current or future therapeutic candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. The degree of market acceptance of our therapeutics will depend on a number of factors, including:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">demonstration of clinical efficacy and safety compared to other more-established products;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the indications for which our therapeutic candidates are approved;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">acceptance of a new drug for the relevant indication by healthcare providers and their patients;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the pricing and cost-effectiveness of our therapeutics, as well as the cost of treatment with our therapeutics in relation to alternative treatments and therapies;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and Medicaid, private health insurers and other third-party payors;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our therapeutics in the absence of sufficient third-party coverage and adequate reimbursement;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">any restrictions on the use of our therapeutics, and the prevalence and severity of any adverse effects;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">potential product liability claims;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the timing of market introduction of our therapeutics as well as competitive drugs;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the effectiveness of our or any of our current or potential future collaborators&#8217; sales and marketing strategies; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">unfavorable publicity relating to the product.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If any therapeutic candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our therapeutics may require significant resources and may never be successful.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Even if we are able to commercialize any of our therapeutic candidates, if approved, such therapeutic candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">The regulations that govern regulatory approvals, pricing and reimbursement for new products vary widely from country to country. Some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a therapeutic candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the therapeutic candidate, possibly for lengthy time periods, and negatively </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">impact the revenues we are able to generate from the sale of the therapeutic candidate in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more therapeutic candidates, even if our therapeutic candidates obtain marketing approval.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our ability to commercialize any therapeutic candidates successfully also will depend in part on the extent to which coverage and reimbursement for these therapeutic candidates and related treatments will be available from government authorities, private health insurers and other organizations. In the U.S. and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services (HHS). CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. The availability of coverage and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford treatments. Sales of these or other products that we may identify will depend substantially, both domestically and abroad, on the extent to which the costs of our therapeutics will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our therapeutics. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Factors payors consider in determining reimbursement are based on whether the product is:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">a covered benefit under its health plan;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">safe, effective and medically necessary;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">appropriate for the specific patient;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">cost-effective; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">neither experimental nor investigational.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for products. We cannot be sure that coverage will be available for any therapeutic candidate that we commercialize and, if coverage is available, the level of reimbursement.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any therapeutic candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price (ASP) and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular therapeutic candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our therapeutic candidates. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We face significant competition, and if our competitors develop technologies or therapeutic candidates more rapidly than we do or their technologies are more effective, our business and our ability to develop and successfully commercialize products may be adversely affected.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The biotechnology and biopharmaceutical industries are characterized by rapid advancing technologies, intense competition and a strong emphasis on proprietary and novel products and therapeutic candidates. Our competitors have developed, are developing or may develop products, therapeutic candidates and processes competitive with our therapeutic candidates. Any therapeutic candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop therapeutic candidates. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and in-licensing new therapeutic candidates. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Currently, patients with DMD are treated with corticosteroids to manage the inflammatory component of the disease. EMFLAZA (deflazacort) is an FDA-approved corticosteroid marketed by PTC Therapeutics, Inc. (PTC). In addition, there are four FDA-approved exon skipping drugs: EXONDYS 51 (eteplirsen), VYONDYS 53 (golodirsen), and AMONDYS 45 (casimersen), which are PMOs approved for the treatment of patients with DMD who are amenable to exon 51, exon 53 and exon 45 skipping, respectively, and are marketed by Sarepta Therapeutics, Inc. (Sarepta), and VILTEPSO (vitolarsen), a PMO approved for the treatment of patients with DMD who are amenable to exon 53 skipping, which is marketed by Nippon Shinyaku Co. Ltd. Companies focused on developing treatments for DMD that target dystrophin mechanisms, as does our DMD program, include Sarepta with SRP-5051, a peptide-linked PMO currently being evaluated following a Phase 2 clinical trial for patients amenable to exon 51 skipping along with SRP-5053,SRP-5045 and SRP-5044 in preclinical development, PTC with ataluren, a small molecule targeting nonsense mutations in a Phase 3 clinical trial, Avidity Biosciences, Inc. (Avidity), which is in preclinical development with an antibody oligonucleotide conjugate for exons 44 (AOC-1044), 45 and 51 that targets dystrophin production, Wave Life Sciences Ltd., which is clinically evaluating WVE-N531, a splicing candidate that is designed to target exon 53 within the dystrophin gene, Dyne Therapeutics, Inc. (Dyne), which is pursuing antibody fragment-oligonucleotide conjugates for exons 44, 45, 51 (DYNE-251), and 53, PepGen, Inc. with PGN-EDO51, a preclinical candidate designed to address exon 51, and BioMarin Pharmaceutical Inc., which is in preclinical development with BMN 351, an antisense oligonucleotide therapy for exon 51. In addition, several companies are developing gene therapies to treat DMD, including Audentes Therapeutics, Inc. (AT466 AAV antisense exon 2 skipping candidate, and AT751 and AT753, AAV-antisense exon 51 and 53 skipping candidates, respectively), Pfizer Inc. (PF-06939926), Sarepta (SRP-9001 and Galgt2 gene therapy program), and Solid Biosciences Inc. (SGT-001). Gene editing treatments that are in preclinical development are also being pursued by Vertex Pharmaceuticals, Inc. (Vertex) and Sarepta. We are also aware of several companies targeting non-dystrophin mechanisms for the treatment of DMD.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:8pt 0pt 0pt 0pt;"><span style="letter-spacing:-0.1pt;">We expect to face competition from existing products and products in development for each of our therapeutic candidates. There are currently no approved therapies to treat the underlying cause of DM1. Therapeutic candidates currently in development to treat DM1 include: tideglusib, a GSK3-&#223; inhibitor in late-stage clinical development by AMO Pharma Ltd. for the congenital phenotype of DM1; AOC-1001, an antibody linked siRNA in clinical development by Avidity; DYNE-101, an antibody fragment conjugated to an ASO targeting DM1 protein kinase knockdown in preclinical development by Dyne; a peptide-nucleic acid targeting CUG repeats in development by NeuBase Therapeutics, Inc.; EDODM1, a linear peptide conjugated to a PMO targeting CUG repeats in preclinical development by PepGen, Inc.; a small molecule targeting GTG repeats in preclinical development by Design Therapeutics, Inc.; gene editing treatments in preclinical development by Vertex; an RNA-targeting gene therapy in preclinical development by Locana, Inc.; and small molecules interacting with RNA in preclinical development by Expansion Therapeutics, Inc.</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The only currently-approved therapies for Pompe&#160; disease are alglucosidase alfa (Lumizyme in the United States, Myozyme in other geographies) and avalglucosidase alfa-ngpt (Nexviazyme in the United States), which are both forms of ERT delivered via IV infusions. There is one next-generation GAA enzyme in registration from Amicus Therapeutics Inc. (Amicus), and there are four gene therapies in the early stages of clinical development from Astellas Pharma Inc., Bayer AG, Roche Holding AG and Lacerta Therapeutics, Inc. There are five gene therapies in preclinical development from AVROBIO, Inc., Amicus, Provention Bio Inc., Selecta Biosciences, Inc. and Sarepta. There are two preclinical therapies targeting GYS1 inhibition from Maze Therapeutics, Inc. and Avidity, respectively. Denali has an ERT in preclinical development</span><span style="letter-spacing:-0.1pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any therapeutic candidate, we will face competition based on many different factors, including the safety and effectiveness of our therapeutics, the ease with which our therapeutics can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competitive products or technological approaches may make any products we develop, or our EEV Platform, obsolete or noncompetitive before we recover the expense of developing and commercializing our therapeutic candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our therapeutics we may develop, if approved, could be adversely affected.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Risks Related to Our Business Operations and Industry</b><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our future success depends on our ability to retain key employees and to attract, retain and motivate qualified personnel.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We are highly dependent on the research expertise of Natarajan Sethuraman, Ph.D., our Chief Scientific Officer, and the development and management expertise of Dipal Doshi, our President and Chief Executive Officer, as well as the other principal members of our management, scientific and clinical team. Although we have entered into employment agreements and/or offer letters with our executive officers, each of them may terminate their employment with us at any time.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our industry has experienced a high rate of turnover in recent years. Our ability to compete in the highly competitive pharmaceuticals industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, clinical, regulatory, manufacturing and management skills and experience. We conduct our operations in the Boston area, a region that is home to many other pharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. We may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among pharmaceutical companies. Many of the other pharmaceutical companies against which we compete have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. Any or all of these competing factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize our therapeutic candidates and to grow our business and operations as currently contemplated.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. For example, employment of our key employees is at-will, which means that any of our employees could leave our employment at any time, with or without notice.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">As of February 28, 2022, we had 114 full-time employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of clinical development, clinical operations, manufacturing, regulatory affairs and, if any of our therapeutic candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth and with developing sales, marketing and distribution infrastructure, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Further, we currently rely, and for the foreseeable future will continue to rely, in substantial part on certain third-party contract organizations, advisors and consultants to provide certain services, including assuming substantial responsibilities for the conduct of our clinical trials and the manufacture of ENTR-601-44 or any future therapeutic candidates. We cannot assure our stockholders that the services of such third-party contract organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by our vendors or consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of ENTR-601-44 or any future therapeutic candidates or otherwise advance our business. We cannot assure our stockholders that we will be able to properly manage our existing vendors or consultants or find other competent outside vendors and consultants on economically reasonable terms, or at all.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If we are not able to effectively manage growth and expand our organization, we may not be able to successfully implement the tasks necessary to further develop and commercialize ENTR-601-44, our other development portfolio therapeutic candidates or any future therapeutic candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our therapeutic candidates and decrease the prices we may obtain.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our therapeutic candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any therapeutic candidates for which we obtain marketing approval.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">For example, the ACA was passed in March 2010 and substantially changed the way healthcare is financed by both governmental and private insurers, and continues to significantly impact the U.S. pharmaceutical industry.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Among the provisions of the ACA of importance to our potential therapeutic candidates are the following:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">annual fees and taxes on manufacturers of certain branded prescription drugs;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">expansion of healthcare fraud and abuse laws, including the False Claims Act and the federal Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">extension of manufacturers&#8217; Medicaid rebate liability;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">expansion of eligibility criteria for Medicaid programs;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">requirements to report financial arrangements with physicians and teaching hospitals;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">a requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administrations or other efforts, if any, to challenge repeal or replace the ACA, will impact our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals for spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction, triggering the legislation&#8217;s automatic reduction to several government programs. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, starting in 2013, and due to subsequent legislative amendments to the statute, will remain in effect through 2030, except for a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Following the temporary suspension, a 1% payment reduction will occur beginning April 1, 2022 through June 30, 2022, and the 2% payment reduction will resume on July 1, 2022. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. In addition, on December 20, 2019, former President Trump signed into law the Further Consolidated Appropriations Act (H.R. 1865), which repeals the Cadillac tax, the health insurance provider tax, and the medical device excise tax. It is impossible to determine whether similar taxes could be instated in the future. Further, CMS published a final rule that would give states greater flexibility as of 2020 in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. Additionally, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020. However, it is unclear whether the Biden administration will challenge, reverse, revoke or otherwise modify these executive and administrative actions</span><span style="letter-spacing:-0.1pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Further, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, President Biden signed an Executive Order on July 9, 2021 affirming the administration&#8217;s policy to (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs HHS to provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#8217;s implementing regulations. FDA released such implementing regulations on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation (MFN) Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. However, CMS published a final rule in the Federal Register on December 27, 2021 that rescinds the November 27, 2020 MFN Model interim final rule. Additionally, on December 2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that it will continue to seek new legislative measures to control drug costs</span><span style="letter-spacing:-0.1pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our therapeutics. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our therapeutic candidates, if any, may be. It is also possible that additional governmental action is taken in response to the ongoing COVID-19 pandemic</span><span style="letter-spacing:-0.1pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Failure or security breaches, loss or leakage of data and other disruptions of our internal information technology systems, or those of our third-party CROs or other vendors, contractors or consultants could result in material disruption of our development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">elements of our operations to third parties, and as a result we manage a number of third-party CROs, vendors, and other contractors and consultants who have access to our confidential information.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Despite the implementation of security measures, given their size and complexity and the increasing amounts of confidential information that they maintain, our internal information technology systems and those of our third-party CROs, vendors and other contractors and consultants are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, third-party CROs, vendors, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our system infrastructure, or that of our third-party CROs, vendors and other contractors and consultants, or lead to data leakage. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all types of security threats, nor may we be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or those of our third-party CROs, vendors and other contractors and consultants, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization of ENTR-601-44 or any future therapeutic candidates could be delayed. The costs related to significant security breaches or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against such risks. If the information technology systems of our third-party CROs, vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems, or those of our third-party CROs, vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or financial condition. For example, if such an event were to occur and cause interruptions in our operations, or those of our third-party CROs, vendors and other contractors and consultants, it could result in a material disruption of our programs and the development of our therapeutic candidates could be delayed. In addition, the loss of clinical trial data for ENTR-601-44 or any other therapeutic candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of our internal information technology systems or those of our third-party CROs, vendors and other contractors and consultants, or security breaches could result in the loss, misappropriation and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), which could result in financial, legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and could cause a disruption to the development of our therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">The ongoing COVID-19 pandemic continues to rapidly evolve and has broadly affected the global economy, resulted in significant travel and work restrictions in many regions and has put a significant strain on healthcare resources. The ultimate extent of the impact of the COVID-19 pandemic on our business, preclinical studies and planned clinical trials, financial condition and results of operations is highly uncertain and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the identification of new variants of the virus, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. The continuation of the worldwide COVID-19 pandemic may affect our ability to initiate and complete preclinical studies, </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">delay the initiation of our planned clinical trials, disrupt regulatory activities or have other adverse effects on our business, results of operations, financial condition and prospects. In addition, the ongoing COVID-19 pandemic has adversely impacted economies worldwide and may cause substantial disruption in the financial markets, both of which could adversely affect our business, operations and ability to raise funds to support our operations</span><span style="letter-spacing:-0.1pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">To date, we have not experienced a material financial impact or significant business disruptions, including with our vendors, or impairments of any of our assets as a result of the ongoing COVID-19 pandemic. We are following, and plan to continue to follow, recommendations from federal, state and local governments regarding workplace policies, practices and procedures. We have taken temporary precautionary measures intended to help minimize the risk of the virus to our employees, including limiting on-site presence to essential employees, providing for social distancing, increased sanitization of our facilities and providing personal protective equipment for our employees. We expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and other business partners. We are continuing to monitor the potential impact of the ongoing COVID-19 pandemic, but we cannot be certain what the overall impact of the COVID-19 pandemic will be on our business, financial condition, results of operations and prospects</span><span style="letter-spacing:-0.1pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Failure to comply with environmental, health and safety laws and regulations could subject us to fines or penalties or incur costs that could harm our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We are subject to numerous foreign, federal, state and local environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources, including any available insurance.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, our leasing and operation of real property may subject us to liability pursuant to certain of these laws or regulations. Under existing U.S. environmental laws and regulations, current or previous owners or operators of real property and entities that disposed or arranged for the disposal of hazardous substances may be held strictly, jointly and severally liable for the cost of investigating or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We could incur significant costs and liabilities which may adversely affect our financial condition and operating results for failure to comply with such laws and regulations, including, among other things, civil or criminal fines and penalties, property damage and personal injury claims, costs associated with upgrades to our facilities or changes to our operating procedures, or injunctions limiting or altering our operations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations, which are becoming increasingly more stringent, may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our relationships with customers, third-party payors, physicians and healthcare providers will be subject to applicable anti-kickback, fraud and abuse, and other laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any therapeutic candidates for which we obtain regulatory approval. Our current and future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research and would market, sell and distribute our therapeutics. As a pharmaceutical company, even though we do not and will not </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. Restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate include the following:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil money penalties;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the federal civil and criminal false claims laws and civil monetary penalty laws, such as the federal False Claims Act, which impose criminal and civil penalties and authorize civil whistleblower or qui tam actions, against individuals or entities for, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent; knowingly making, using or causing to be made or used, a false statement of record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. Manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The federal False Claims Act also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the federal False Claims Act and to share in any monetary recovery;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal statutes that prohibit a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates, independent contractors or agents of covered entities, that perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and non-U.S. laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the U.S. federal transparency requirements under the ACA, including the provision commonly referred to as the Physician Payments Sunshine Act, and its implementing regulations, which requires applicable manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Effective January 1, 2022, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">obligations extend to include transfers of value made to certain non-physician providers (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants and certified-nurse midwives)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the federal Anti-Kickback Statute and False Claims Act, and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Healthcare Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state and require the registration of pharmaceutical sales representatives. State and foreign laws, including for example the European Union General Data Protection Regulation, which became effective on May 25, 2018 also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement we could be subject to penalties. Finally, there are state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time and resource consuming and can divert a company&#8217;s attention from the business. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment, reputational harm, and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate: (i) the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, including cGMP requirements, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or (iv) laws that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We are subject to certain U.S. and certain foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations prohibit, among other things, companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of these laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase over time. We expect to rely on third parties for research, preclinical studies and clinical trials and/or to obtain necessary permits, licenses, patent registrations and other marketing approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and out-licensing or in-licensing of intellectual property, products or technologies. Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired in-process research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">successful and may require significant time and attention of our management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Legislation or other changes in U.S. tax law could adversely affect our business and financial condition.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. For example, the Tax Cuts and Jobs Act (the TCJA) was enacted in 2017 and made significant changes to corporate taxation, including the reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses to 80% of current year taxable income and the elimination of net operating loss carrybacks (though any such net operating losses may be carried forward indefinitely) and the modification or repeal of many business deductions and credits, in each case, as modified by the CARES Act (as defined below). In addition, on March 27, 2020, former President Trump signed into law the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act), which included certain changes in tax law intended to stimulate the U.S. economy in light of the ongoing COVID-19 coronavirus pandemic, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. Under the CARES Act, the limitation of the tax deduction for net operating losses to 80% of taxable income applies only to taxable years beginning after December 31, 2020 and net operating losses generated in 2018, 2019 and 2020 may be carried back five taxable years. Further, under the CARES Act, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income is increased to 50% of adjusted taxable income for 2019 and 2020. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our ability to use our U.S. net operating loss carryforwards and certain other U.S. tax attributes may be limited.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our ability to use our U.S. federal and state net operating losses to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our net operating losses.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Under current law, unused U.S. federal net operating losses generated for tax years beginning after December 31, 2017 are not subject to expiration and may be carried forward indefinitely. Such U.S. federal net operating losses generally may not be carried back to prior taxable years, except that, net operating losses generated in 2018, 2019 and 2020 may be carried back to each of the five tax years preceding the tax years of such losses. Additionally, for taxable years beginning after December 31, 2020, the deductibility of such U.S. federal net operating losses is limited to 80% of our taxable income in any future taxable year. In addition, both our current and our future unused U.S. federal net operating losses and tax credits may be subject to limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (Code), if we undergo an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. Our net operating losses and tax credits may also be impaired or restricted under state law. As of December 31, 2021, we had U.S. federal net operating loss carryforwards of approximately $93.1 million, and our ability to utilize those net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above, which could result in increased tax liability to us.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We plan to distribute our technology, biology, execution and financing risks across a wide variety of therapeutic areas, disease states, programs, and technologies. However, our assessment of, and approach to, risk may not be comprehensive or effectively avoid delays or failures in one or more of our programs or modalities. Failures in one or more of our programs or modalities could adversely impact other programs or modalities in our development portfolio and have a material adverse impact on our business, results of operations and ability to fund our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We are creating a new category of potential therapeutics based on EEVs to improve the lives of patients. We have designed our strategy and operations to realize the full potential value and impact of EEVs over a long time horizon across a broad array of human diseases. We have made investments in our platform, infrastructure, and clinical capabilities that have enabled us to establish a development portfolio of several programs in development. As our therapeutic candidates and discovery programs progress, we or others may determine: that certain of our risk allocation decisions were incorrect or insufficient; that we made platform level technology mistakes; that individual programs or our EEV science in general has technology or biology risks that were unknown or underappreciated; that our choices on how to develop our infrastructure to support our scale will result in an inability to manufacture our therapeutics for clinical trials or otherwise impair our manufacturing; or that we have allocated resources in such a way that large investments are not recovered and capital allocation is not subject to rapid re-direction. All of these risks may relate to our current and future programs sharing similar science (including EEV science) and infrastructure, and in the event material decisions in any of these areas turn out to have been incorrect or under-optimized, we may experience a material adverse impact on our business and ability to fund our operations and we may never realize what we believe is the potential of EEVs.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">While we will attempt to diversify our risks by developing one or more programs in each modality, there are risks that are unique to each modality and risks that are applicable across modalities. These risks may impair our ability to advance one or more of our programs in clinical development, obtain regulatory approval, or ultimately commercialize our programs, or cause us to experience significant delays in doing so, any of which may materially harm our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Certain features in our therapeutic candidates, including those related to large enzymes, antibodies and oligonucleotides, and their components, may result in foreseen and unforeseen risks that are active across some or all of our modalities. In addition, the biology risk across much of our development portfolio represents targets and pathways not clinically validated by one or more approved drugs. While we believe we have made progress in seeking to reduce biology risk in certain settings, the risk that the targets or pathways that we have selected may not be effective could continue to apply across our current and future programs. Any such portfolio spanning risks, whether known or unknown, if realized in any one of our programs would have a material and adverse effect on our other programs and on our business as a whole.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Successful development of intracellular therapeutics is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Intracellular therapeutics that appear promising in the early phases of development may fail to reach the market for several reasons, including: </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">nonclinical or preclinical testing or study results may show our EEV-therapeutics to be less effective than desired or to have harmful or problematic side effects or toxicities;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">clinical trial results may show our oligonucleotides to be less effective than expected (e.g., a clinical trial could fail to meet its primary endpoint(s)) or to have unacceptable side effects or toxicities;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">failure to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused by slow enrollment in clinical trials, patients dropping out of trials, length of time to achieve trial endpoints, additional time requirements for data analysis, NDA or BLA preparation, discussions with the FDA, an FDA request for additional nonclinical or clinical data, or unexpected safety or manufacturing issues;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">manufacturing costs, formulation issues, pricing or reimbursement issues, or other factors that make our EEV-therapeutics uneconomical; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">proprietary rights of others and their competing products and technologies that may prevent our EEV-therapeutics from being commercialized.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Risks Related to Our Intellectual Property</b><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">If we are unable to obtain and maintain patent protection for our therapeutic programs and other proprietary technologies we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our therapeutic programs and other proprietary technologies we may develop may be adversely affected.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our therapeutic programs and other proprietary technologies we may develop. In order to protect our proprietary position, we have filed or intend to file patent applications in the United States and abroad relating to our therapeutic programs and other proprietary technologies we may develop; however, there can be no assurance that any such patent applications will issue as granted patents. If we are unable to obtain or maintain patent protection with respect to our therapeutic programs and other proprietary technologies we may develop, our business, financial condition, results of operations and prospects could be materially harmed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our inventions, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our protection. In addition, we may rely on third-party collaborators or licensors to file patent applications relating to therapeutic programs or proprietary technology that may be developed or in-licensed. We cannot predict whether the patent applications we are currently pursuing, or that we or our third-party collaborators or licensors may pursue, will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection against competitors or other third parties.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">No consistent policy regarding the scope of claims allowable in patents in the biotechnology field has emerged in the United States, and the patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our patent applications may not result in patents being issued which protect our therapeutic programs and other proprietary technologies we may develop or which effectively prevent others from commercializing competitive technologies and products. In particular, our ability to stop third parties from making, using, selling, offering to sell, or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements. We do not currently have issued patents that cover all of our technology or therapeutic candidates. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future. Moreover, even issued patents do not provide us with the right to practice our technology in relation to the commercialization of our therapeutics. The area of patent and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, and third parties may have blocking patents that could be used to prevent us from commercializing our patented therapeutic candidates and practicing our proprietary technology. Our issued patents, those that may issue in the future and those that we in-license may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or limit the length of the term of patent protection that we may have for our therapeutic candidates. Furthermore, our competitors may independently develop similar technologies.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Moreover, the claim coverage in a patent application can be significantly reduced before the patent is granted. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Any patents issuing from our patent applications may be challenged, narrowed, circumvented or invalidated by third parties. Consequently, we do not know whether our therapeutic programs and other proprietary technology will be protectable or remain protected by valid and enforceable patents. For example, we do not currently have any issued patents covering any of our oligonucleotide therapeutic candidates. The extent to which any patents, if and when granted, will cover our therapeutic candidates is uncertain. Even if a patent is granted, our competitors or other third parties may be able to circumvent the patent by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects. In addition, given the amount of time required for the development, testing and regulatory review of our therapeutic programs and eventual therapeutic candidates, patents protecting the therapeutic candidates might expire before or shortly after such therapeutic candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability and our patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third-party pre-issuance submission of prior art to the United States Patent and Trademark Office (USPTO) or in other jurisdictions, or become involved in opposition, derivation, revocation, reexamination, post-grant and </span><i style="font-style:italic;letter-spacing:-0.1pt;">inter partes</i><span style="letter-spacing:-0.1pt;"> review, or other similar proceedings challenging our patent rights. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our therapeutic programs and other proprietary technologies we may develop and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our rights to develop and commercialize any therapeutic candidates are subject and may in the future be subject, in part, to the terms and conditions of licenses granted to us by third parties. If we fail to comply with our obligations under our current or future intellectual property license agreements or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We are and expect to continue to be reliant upon third-party licensors for certain patent and other intellectual property rights that are important or necessary to the development of our therapeutic programs, eventual therapeutic candidates, and proprietary technologies. For example, we rely on a license from Ohio State Innovation Foundation (OSIF), an affiliate of The Ohio State University (OSU) to certain patent rights and know-how of OSU. Our license agreement with OSIF imposes, and we expect that any future license agreement will impose, specified diligence, milestone payments, royalty payments, commercialization, development and other obligations on us and require us to meet development timelines, or to exercise diligent or commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. These milestone payments, and other payments associated with the license, will make it less profitable for us to develop and potentially commercialize our therapeutic candidate. If this agreement is terminated, we could lose intellectual property rights that may be important to our business, potentially be liable for damages to the licensor or potentially be prevented from developing and commercializing our therapeutic candidate. Termination of the agreement or reduction or elimination of our rights under the agreement may also potentially result in us being required to negotiate a new or reinstated agreement with less favorable terms, and it is possible that we may be unable to obtain any such additional license at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to spend significant time and resources to redesign our therapeutic candidate or the method for manufacturing it or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. For more information on the terms of the license agreement with OSIF, see &#8220;Business-Intellectual Property-License Agreement with The Ohio State University&#8221; in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on November 1, 2021.</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Furthermore, our licensors have, or may in the future have, the right to terminate a license if we materially breach the agreement and fail to cure such breach within a specified period or in the event we undergo certain bankruptcy events. In spite of our best efforts, our current or any future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements. If our license agreements are terminated, we may lose our rights to develop and commercialize therapeutic candidates and technology, lose patent protection, experience significant delays in the development and commercialization of our therapeutic candidates and technology, and incur liability for damages. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, our competitors or other third parties could have the freedom to seek regulatory approval of, and to market, products and technologies identical or competitive to ours and we may be required to cease our development and commercialization of certain of our therapeutic candidates and technology. In addition, we may seek to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with any therapeutic candidates we may develop and our technology. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the scope of rights granted and obligations imposed under the license agreement and other interpretation-related issues;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our or our licensors&#8217; ability to obtain, maintain and defend intellectual property and to enforce intellectual property rights against third parties;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the extent to which our technology, therapeutic candidates and processes infringe, misappropriate or otherwise violate the intellectual property of the licensor that is not subject to the license agreement;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the sublicensing of patent and other intellectual property rights under our license agreements;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our diligence, development, regulatory, commercialization, financial or other obligations under the license agreement and what activities satisfy those diligence obligations;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and us and our partners; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the priority of invention of patented technology.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, any current or future license agreements to which we are a party, including our license agreement with OSIF, are likely to be, complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our diligence, development, regulatory, commercialization, financial or other obligations under the relevant agreement. In addition, if disputes over intellectual property that we have licensed or any other dispute related to our license agreements prevent or impair our ability to maintain our current license agreements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates and technology. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">License agreements we may enter into in the future may be non-exclusive. Accordingly, third parties may also obtain non-exclusive licenses from such licensors with respect to the intellectual property licensed to us under such license agreements. Accordingly, these license agreements may not provide us with exclusive rights to use such licensed patent and other intellectual property rights, or may not provide us with exclusive rights to use such patent and other intellectual property rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and any therapeutic candidates we may develop in the future.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">Moreover, some of our in-licensed patent and other intellectual property rights may in the future be subject to third party interests such as co-ownership. If we are unable to obtain an exclusive license to such third-party co-owners&#8217; interest, </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">in such patent and other intellectual property rights, such third-party co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We or our licensors may need the cooperation of any such co-owners of our licensed patent and other intellectual property rights in order to enforce them against third parties, and such cooperation may not be provided to us or our licensors.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Additionally, we may not have complete control over the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. It is possible that our licensors&#8217; filing, prosecution and maintenance of the licensed patents and patent applications, enforcement of patents against infringers or defense of such patents against challenges of validity or claims of enforceability may be less vigorous than if we had conducted them ourselves, and accordingly, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our licensors fail to file, prosecute, maintain, enforce and defend such patents and patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of our technology and any therapeutic candidates we may develop that are the subject of such licensed rights could be adversely affected and we may not be able to prevent competitors or other third parties from making, using and selling competing products.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Furthermore, our owned and in-licensed patent rights may be subject to a reservation of rights by one or more third parties, including the U.S. government. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. When new technologies are developed with government funding, in order to secure ownership of patent rights related to the technologies, the recipient of such funding is required to comply with certain government regulations, including timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such inventions. A failure to meet these obligations may lead to a loss of rights or the unenforceability of relevant patents or patent applications. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). If the U.S. government exercised its march-in rights in our current or future intellectual property rights that are generated through the use of U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S. government for the exercise of such rights. If the U.S. government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The U.S. government&#8217;s rights may also permit it to disclose the funded inventions and technology, which may include our confidential information, to third parties and to exercise march-in rights to use or allow third parties to use the technology that was developed using U.S. government funding. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. Any of the foregoing could harm our business, financial condition, results of operations and prospects significantly.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may not be able to protect our intellectual property rights throughout the world.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">Filing, prosecuting, maintaining, enforcing and defending patents and other intellectual property rights on our technology and any therapeutic candidates we may develop in all jurisdictions throughout the world would be prohibitively expensive, and accordingly, our intellectual property rights in some jurisdictions outside the United States could be less extensive than those in the United States. In some cases, we or our licensors may not be able to obtain patent or other intellectual property protection for certain technology and therapeutic candidates outside the United States. In addition, the laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our licensors may not be able to obtain issued patents or other intellectual property rights covering any therapeutic candidates we may develop and our technology in all jurisdictions outside the United States and, as a result, may not be able to prevent third parties from practicing our and our licensors&#8217; inventions in all countries </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Third parties may use our technologies in jurisdictions where we and our licensors have not pursued and obtained patent or other intellectual property protection to develop their own products and, further, may export otherwise infringing, misappropriating or violating products to territories where we have patent or other intellectual property protection, but enforcement is not as strong as that in the United States. These products may compete with any therapeutic candidates we may develop and our technology and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Additionally, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain jurisdictions, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement, misappropriation or other violation of our patent and other intellectual property rights or marketing of competing products in violation of our intellectual property rights generally. For example, an April 2019 report from the Office of the United States Trade Representative identified a number of countries, including China, Russia, Argentina, Chile and India, where challenges to the procurement and enforcement of patent rights have been reported. Proceedings to enforce our or our licensors&#8217; patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patent and other intellectual property rights at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our licensors initiate and, if we or our licensors prevail, the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Many jurisdictions have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many jurisdictions limit the enforceability of patents against government agencies or government contractors. In these jurisdictions, the patent owner may have limited remedies, which could materially diminish the value of such patents. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and we will not have the benefit of patent protection in such countries.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Issued patents covering any therapeutic candidates we may develop could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our owned and licensed patent rights may be subject to priority, validity, inventorship and enforceability disputes. If we or our licensors are unsuccessful in any of these proceedings, such patent rights may be narrowed, invalidated or held unenforceable, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or we may be required to cease the development, manufacture and commercialization of one or more of our therapeutic candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">If we or one of our licensors initiate legal proceedings against a third party to enforce a patent covering any of any therapeutic candidates we may develop or our technology, the defendant could counterclaim that the patent covering the therapeutic candidate or technology is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, interference proceedings, derivation proceedings, post grant review, </span><i style="font-style:italic;letter-spacing:-0.1pt;">inter partes</i><span style="letter-spacing:-0.1pt;"> review and equivalent proceedings such as opposition, invalidation and revocation proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover any therapeutic candidates we may develop or our technology or no longer prevent third parties from competing with any therapeutic candidates we may develop or our technology. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Defense of these </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">claims, regardless of their merit, would involve substantial litigation expense and would be a distraction to management and other employees. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our therapeutic candidates or technology. Such a loss of patent protection could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Changes in patent law in the United States or worldwide could diminish the value of patents in general, thereby impairing our ability to protect any therapeutic candidates we may develop and our technology.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Changes in either the patent laws or interpretation of patent laws in the United States and worldwide, including patent reform legislation such as the Leahy-Smith America Invents Act (the Leahy-Smith Act), could increase the uncertainties and costs surrounding the prosecution of any owned or in-licensed patent applications and the maintenance, enforcement or defense of any current in-licensed issued patents and issued patents we may own or in-license in the future. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, </span><i style="font-style:italic;letter-spacing:-0.1pt;">inter partes</i><span style="letter-spacing:-0.1pt;"> review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our in-licensed issued patents and issued patents we may own or in-license in the future, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our therapeutic candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><i style="font-style:italic;letter-spacing:-0.1pt;">inter partes</i><span style="letter-spacing:-0.1pt;"> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim unpatentable even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to review patentability of our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Therefore, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. As one example, in the case </span><i style="font-style:italic;letter-spacing:-0.1pt;">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</i><span style="letter-spacing:-0.1pt;">, the U.S. Supreme Court held that certain claims to DNA molecules are not patentable simply because they have been isolated from surrounding material. Moreover, in 2012, the USPTO issued a guidance memo to patent examiners indicating that process claims directed to a law of nature, a natural phenomenon or a naturally occurring relation or correlation that do not include additional elements or steps that integrate the natural principle into the claimed invention such that the natural principle is practically applied and the claim amounts to significantly more than the natural principle itself should be rejected as directed to patent-ineligible subject matter. Accordingly, in view of the guidance memo, there can be no assurance that claims in our patent rights covering any therapeutic candidates we may develop or our technology will be held by the USPTO or equivalent foreign patent offices or by courts in the United States or in foreign jurisdictions to cover patentable subject matter. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">If we do not obtain patent term extension and data exclusivity for any therapeutic candidates we may develop, our business may be harmed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Depending upon the timing, duration and specifics of any FDA marketing approval of any therapeutic candidates we may develop and our technology, one or more of our U.S. patents that we license or may own in the future may be eligible for limited patent term extension under Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. The application for the extension must be submitted prior to the expiration of the patent for which extension is sought and within 60 days of FDA approval. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. In addition, to the extent we wish to pursue patent term extension based on a patent that we in-license from a third party, we would need the cooperation of that third party. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may be subject to claims challenging the inventorship or ownership of our patent and other intellectual property rights.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patent rights, trade secrets or other intellectual property as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our therapeutic candidates or technology. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patent rights, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of or right to use intellectual property that is important to any therapeutic candidates we may develop or our technology. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition to seeking patent protection for our therapeutic programs and other proprietary technologies we may develop, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. With respect to our EEV Platform and development programs, we consider trade secrets and know-how to be one of our important sources of intellectual property, including our extensive knowledge of oligonucleotide drug delivery techniques and antibody conjugation. Trade secrets and know-how can be difficult to protect. In particular, the trade secrets and know-how in connection with our EEV Platform, development programs and other proprietary technology we may develop may over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel with scientific positions in academic and industry.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We seek to protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We may be subject to claims that third parties have an ownership interest in our trade secrets. For example, we may have disputes arise from conflicting obligations of our employees, consultants or others who are involved in developing our therapeutic candidate. Litigation may be necessary to defend against these and other claims challenging ownership of our trade secrets. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable trade secret rights, such as exclusive ownership of, or right to use, trade secrets that are important to our therapeutic programs and other proprietary technologies we may develop. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may not be successful in obtaining necessary rights to any therapeutic candidate we may develop through acquisitions and in-licenses.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We currently own or exclusively license intellectual property rights covering certain aspects of our therapeutic programs. Other pharmaceutical companies and academic institutions may also have filed or are planning to file patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain licenses to such patents from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for our therapeutic programs and other proprietary technologies we may develop. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or therapeutic candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Some of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Third-party claims of intellectual property infringement, misappropriation or other violations against us or our collaborators may prevent or delay the development and commercialization of our therapeutic programs and other proprietary technologies we may develop.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our commercial success depends in part on our ability to avoid infringing, misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. As discussed above, recently, due to changes in U.S. law referred to as patent reform, new procedures including </span><i style="font-style:italic;letter-spacing:-0.1pt;">inter partes</i><span style="letter-spacing:-0.1pt;"> review and post-grant review have also been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are commercializing or plan to commercialize our therapeutic programs and in which we are developing other proprietary technologies. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our therapeutic programs and commercializing activities may give rise to claims of infringement of the patent rights of others. We are aware of third party patents that cover certain aspects of therapeutic candidates that we may develop. We cannot assure our stockholders that our therapeutic programs and other proprietary technologies we may develop will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing our therapeutic programs, might assert as infringed by us. It is also possible that patents owned by third parties of which we are aware, but which we do not believe we infringe or that we believe we have valid defenses to any claims of patent infringement, could be found to be infringed by us. It is not unusual that corresponding patents issued in different countries have different scopes of coverage, such that in one country a third-party patent does not pose a material risk, but in another country, the corresponding third-party patent may pose a material risk to our planned products. As such, we review third-party patents in the relevant pharmaceutical markets. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that we may infringe.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">In the event that any third party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by us. In this case, the holders of such patents may be able to block our ability to commercialize the infringing products or technologies unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize the infringing products or technologies or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing the infringing products or technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our therapeutic candidate or technologies, which could harm our business significantly. Further, we cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. In the event that we could not obtain a license, we may be unable to further develop our therapeutic candidate and commercialize our product, if approved, which could harm our business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Engaging in litigation defending against third parties alleging infringement of patent and other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We may in the future pursue invalidity proceedings with respect to third-party patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in our favor, these legal proceedings may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such proceedings adequately. Some of these third parties may be able to sustain the costs of such proceedings more effectively than we can because of their greater financial resources. If we do not prevail in the patent proceedings the third parties may assert a claim of patent infringement directed at our therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Third parties, such as a competitor, may infringe our patent rights. In an infringement proceeding, a court may decide that a patent owned by us is invalid or unenforceable or may refuse to stop the other party from using the invention at issue on the grounds that the patent does not cover the technology in question. In addition, our patent rights may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time-consuming. An adverse result in any litigation proceeding could put our patent rights at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings. Moreover, any name we have proposed to use with our therapeutic candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA or equivalent body. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Furthermore, assertions of potential trademark infringement or possible market confusion may lead to coexistence agreements in order to avoid costly disputes related to our trademarks. As a consequence, we may be forced to amend the list of goods and services covered by our trademarks more narrowly than as originally filed and intended, which could adversely affect our ability to establish name recognition. For example, the description of goods and services for our Entrada trademark was amended twice to settle potential disputes with two other biopharmaceutical companies as part of coexistence agreements. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain name or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Intellectual property rights do not necessarily address all potential threats.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">others may be able to make products that are similar to our therapeutic candidate or utilize similar technology but that are not covered by the claims of the patents that we license or may own;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">we might not have been the first to make the inventions covered by our current or future patent applications;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">we might not have been the first to file patent applications covering our inventions;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">it is possible that our current or future patent applications will not lead to issued patents;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">any patent issuing from our current or future patent applications may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">we may not develop additional proprietary technologies that are patentable;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the patents of others may harm our business; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">we may choose not to file for patent protection in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent application covering such intellectual property.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The occurrence of any of these events would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We partially depend on intellectual property licensed from third parties, and our licensors may not always act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated or if disputes regarding these licenses arise, we could lose significant rights that are important to our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We are dependent, in part, on patents, know-how and proprietary technology licensed from others. Our licenses to such patents, know-how and proprietary technology may not provide exclusive rights in all relevant fields of use and in all territories in which we may wish to develop or commercialize our therapeutics in the future. The agreements under which we license patents, know-how and proprietary technology from others are complex, and certain provisions in such agreements may be susceptible to multiple interpretations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If we fail to comply with obligations under any license agreements, our licensors may have the right to terminate our license, in which event we would not be able to develop or market technology or therapeutic candidates covered by the intellectual property licensed under these agreements. In addition, we may need to obtain additional licenses from our existing licensors and others to advance our research or allow commercialization of therapeutic candidates we may develop. It is possible that we may be unable to obtain any additional licenses at a reasonable cost or on reasonable terms, if at all. In either event, we may be required to expend significant time and resources to redesign our technology, therapeutic candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology or therapeutic candidates. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If we or our licensors fail to adequately protect our licensed intellectual property, our ability to commercialize therapeutic candidates could suffer. We do not have complete control over the maintenance, prosecution and litigation of our in-licensed patents and patent applications and may have limited control over future intellectual property that may be in-licensed. For example, we cannot be certain that activities such as the maintenance and prosecution by our licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. It is possible that our licensors&#8217; infringement proceedings or defense activities may be less vigorous than had we conducted them ourselves, or may not be conducted in accordance with our best interests.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, the resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant patents, know-how and proprietary technology, or increase what we believe to be our financial or other obligations under the relevant agreement. Disputes that may arise between us and our licensors regarding intellectual property subject to a license agreement could include disputes regarding:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our therapeutic candidates and what activities satisfy those diligence obligations; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected technology or therapeutic candidates. As a result, any termination of or disputes over our intellectual property licenses could result in the loss of our ability to develop and commercialize our EEV Platform, or EEV products, or we could lose other significant rights, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">For example, our agreements with certain of our third-party research partners provide that improvements developed in the course of our relationship may be owned solely by either us or our third-party research partner, or jointly between us and the third party. If we determine that rights to such improvements owned solely by a research partner or other third party with whom we collaborate are necessary to commercialize our therapeutic candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue developing, manufacturing or marketing our therapeutic candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our therapeutic candidates or allow our competitors or others the chance to access technology that is important to our business. We also may need the cooperation of any co-owners of our intellectual property in order to enforce such intellectual property against third parties, and such cooperation may not be provided to us.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development portfolio through acquisitions and in-licenses.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The growth of our business may depend in part on our ability to acquire, in-license or use third-party proprietary rights. For example, our therapeutic candidates may require specific formulations to work effectively and efficiently, we may develop therapeutic candidates containing our compounds and pre-existing pharmaceutical compounds, or we may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our therapeutic candidates, any of which could require us to obtain rights to use intellectual property held by third parties. In addition, with respect to any patents we may co-own with third parties, we may require licenses to such co-owners interest to such patents. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods covered by those third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on those intellectual property rights, which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, which means that our competitors may also receive access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies that may be more established or have greater resources than we do may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our therapeutic candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">may be unwilling to assign or license rights to us. There can be no assurance that we will be able to successfully complete these types of negotiations and ultimately acquire the rights to the intellectual property surrounding the additional therapeutic candidates that we may seek to develop or market. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of certain programs and our business financial condition, results of operations and prospects could suffer.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We, our collaborators and our service providers may be subject to a variety of privacy and data security laws and contractual obligations, which could increase compliance costs and our failure to comply with them could subject us to potentially significant fines or penalties and otherwise harm our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We maintain a large quantity of sensitive information, including confidential business and patient health information in connection with our preclinical studies, and are subject to laws and regulations governing the privacy and security of such information. The global data protection landscape is rapidly evolving, and we may be affected by or subject to new, amended or existing laws and regulations in the future, including as our operations continue to expand or if we operate in foreign jurisdictions. These laws and regulations may be subject to differing interpretations, which adds to the complexity of processing personal data. Guidance on implementation and compliance practices are often updated or otherwise revised.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws and federal and state consumer protection laws. Each of these laws is subject to varying interpretations and constantly evolving. By way of example, HIPAA imposes privacy and security requirements and breach reporting obligations with respect to individually identifiable health information upon &#8220;covered entities&#8221; &#8203;(health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or entities that create, received, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of health information to the U.S. Department of Health and Human Services (HHS), affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations. Even when HIPAA does not apply, failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act (FTCA), 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. By way of example, the California Consumer Privacy Act (CCPA), which went into effect on January 1, 2020, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:8pt 0pt 0pt 0pt;"><span style="white-space:pre-wrap;">Further, a new California privacy law, the California Privacy Rights Act (CPRA), was passed by California voters on November 3, 2020. The CPRA will create additional obligations with respect to processing and storing personal information that are scheduled to take effect on January 1, 2023 (with certain provisions having retroactive effect to January 1, 2022). Additionally,  some observers have noted that the CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. Already, in the United States, we have witnessed significant developments at the state level. For example, on March 2, 2021, Virginia enacted the Consumer Data Protection Act (CDPA) and, on July 8, 2021, Colorado&#8217;s governor signed the Colorado Privacy Act (CPA), into law. The CDPA and the CPA will both become effective January 1, 2023. While the CDPA and CPA incorporate many similar concepts of the CCPA and CPRA, there are also several key differences in the scope, application, and enforcement of the law that will change the operational practices of regulated businesses. The new laws will, among other things, impact how regulated businesses collect and </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requests.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:8pt 0pt 0pt 0pt;">A number of other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:8pt 0pt 0pt 0pt;"><span style="letter-spacing:-0.1pt;">In the EU, on May 25 2018, a new privacy regime, the General Data Protection Regulation, the GDPR, took effect in the European Economic Area (EEA). The GDPR governs the collection, use, disclosure, transfer or other processing of personal data of European persons. Among other things, the GDPR imposes new requirements regarding the security of personal data and notification of data processing obligations to the competent national data processing authorities, changes the lawful bases on which personal data can be processed, expands the definition of personal data and requires changes to informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws, and imposes substantial fines for breaches and violations (up to the greater of &#8364;20 million or 4% of our consolidated annual worldwide gross revenue). The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Moreover, the United Kingdom leaving the EU could also lead to further legislative and regulatory changes. In addition, further to the U.K.&#8217;s exit from the EU on January 31, 2020, the GDPR ceased to apply in the U.K. at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the U.K.&#8217;s European Union (Withdrawal) Act 2018 incorporated the U.K. GDPR into U.K. law. The U.K. GDPR and the U.K. Data Protection Act 2018 set out the U.K.&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Non-compliance with the U.K. GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. </span><span style="letter-spacing:-0.1pt;">Although the UK is regarded as a third country under the EU&#8217;s GDPR, the European Commission (EC) has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:8pt 0pt 0pt 0pt;"><span style="letter-spacing:-0.1pt;">To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards must be implemented in compliance with European and UK data protection laws. On June 4, 2021, the EC issued new forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EU/EEA (and not subject to the GDPR). The new standard contractual clauses replace the standard contractual clauses that were adopted previously under the EU Data Protection Directive. The UK is not subject to the EC&#8217;s new standard contractual clauses but has published a draft version of a UK-specific transfer mechanism, which, once finalized, will enable transfers from the UK. We will be required to implement these new safeguards when conducting restricted data transfers under the EU and UK GDPR and doing so will require significant effort and cost.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:8pt 0pt 0pt 0pt;"><span style="letter-spacing:-0.1pt;">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:8pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Use of open source software could impose limitations on us that may adversely affect our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:8pt 0pt 0pt 0pt;"><span style="letter-spacing:-0.1pt;">Should use of open source software be necessary for commercialization of our therapeutic candidates, such use could impose limitations on our ability to commercialize. As a result, as we seek to use our platform in connection with commercially available products, we may be required to license software under different license terms, which may not be possible on commercially reasonable terms, if at all. If we are unable to license software components on terms that permit its use for commercial purposes, we may be required to replace those software components, which could result in delays, additional cost and additional regulatory approvals.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:8pt 0pt 0pt 0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the software code. Some open source licenses contain requirements that we make available source code for modifications or derivative works we create based upon the type of open source software we use. If we combine our proprietary software with open source software in a certain manner, we could, under certain of the open source licenses, be required to release the source code of our proprietary software to the public. This could allow our competitors to create similar products with lower development effort and time, and ultimately could result in a loss of product sales for us. Although we monitor our use of open source software, the terms of many open source licenses have not been interpreted by U.S. courts, and there is a risk that those licenses could be construed in a manner that could impose unanticipated conditions or restrictions on our ability to commercialize our therapeutic candidates. We could be required to seek licenses from third parties in order to continue offering our therapeutic candidates, to re-engineer our therapeutic candidates or to discontinue the sale of our therapeutic candidates in the event re-engineering cannot be accomplished on a timely basis, any of which could materially and adversely affect our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor or other third party will discover our trade secrets or that our trade secrets will be misappropriated or disclosed.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Because we currently rely on certain third parties to manufacture all or part of our drug product and to perform quality testing, and because we collaborate with various organizations and academic institutions for the advancement of our product engine and development portfolio, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements and other similar agreements with our collaborators, advisors, employees, consultants and contractors prior to beginning research or disclosing any proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors or other third parties, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements, independent development or publication of information including our trade secrets by third parties. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s or other third party&#8217;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure would impair our competitive position and may harm our business, financial condition, results of operations and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Rights to improvements to our therapeutic candidates may be held by third parties.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In the course of testing our therapeutic candidates, we may enter into agreements with third parties to conduct clinical testing, which may provide that improvements to our therapeutic candidates may be owned solely by a party or jointly between the parties. If we determine that rights to such improvements owned solely by a third party are necessary to commercialize our therapeutic candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to use the improvements and continue developing, manufacturing or marketing the therapeutic candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain such a license, it could be granted on non-exclusive terms, thereby giving our competitors and other third parties access to the same technologies licensed to us. Failure to obtain a license on commercially reasonable terms or at all, or to obtain an exclusive license, could prevent us from commercializing our therapeutic candidates or force us to cease some of our business operations, which could materially harm our business. If we determine that rights to improvements jointly owned between us and a third party are necessary to commercialize our therapeutic candidates or maintain our competitive advantage, we may need to obtain an exclusive license from such third party. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such improvements, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our intellectual property in order to enforce such intellectual property against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our therapeutic candidate, and other proprietary technologies. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Risks Related to Ownership of Our Common Stock</b><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We do not know whether an active, liquid and orderly trading market will develop for our common stock and as a result it may be difficult for our stockholders to sell their shares of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Prior to our initial public offering, no market for shares of our common stock existed and an active trading market for our shares may never develop or be sustained. The lack of an active market may impair our stockholders&#8217; ability to sell their shares at the time they wish to sell them or at a price that they consider reasonable. The lack of an active market may also reduce the fair market value of our stockholders&#8217; shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic collaborations or acquire companies, technologies or other assets by using our shares of common stock as consideration.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">The market price of our common stock may be volatile, and investors could lose all or part of their investment.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The trading price of our common stock is likely to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report, these factors include:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the timing and results of INDs, preclinical studies and clinical trials of our therapeutic candidates or those of our competitors;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the success of competitive products or announcements by potential competitors of their product development efforts;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">any delay in our regulatory filings for our therapeutic candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">adverse developments concerning our potential future in-house manufacturing facilities or CMOs;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">regulatory actions with respect to our therapeutics or therapeutic candidates or our competitors&#8217; products or therapeutic candidates;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">actual or anticipated changes in our growth rate relative to our competitors;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the size and growth of our initial target markets;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">unanticipated serious safety concerns related to the use of our therapeutic candidates;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">regulatory or legal developments in the U.S. and other countries;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">significant lawsuits, including patent or stockholder litigation;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">publication of research reports about us or our industry, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the recruitment or departure of key personnel;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">market conditions in the pharmaceutical and biotechnology sector;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">changes in the structure of healthcare payment systems;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">announcement or expectation of additional financing efforts;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">sales of our common stock by us, our insiders or our other stockholders;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">expiration of market stand-off or lock-up agreements;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the impact of any natural disasters or public health emergencies, such as the ongoing COVID-19 pandemic;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">general economic, political, industry and market conditions; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">other events or factors, many of which are beyond our control.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. In the event that one or more of the analysts who covers us issues adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. </span><span style="letter-spacing:-0.1pt;">If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">As widely reported, global credit and financial markets have experienced extreme volatility and disruptions in the past several years, most recently due to the evolving ongoing COVID-19 pandemic, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions, whether due to the evolving effects of the COVID-19 pandemic or otherwise, will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse event on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our stock price may decline due in part to the volatility of the stock market and the general economic downturn.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 87.4% of our outstanding voting stock as of December 31, 2021. These stockholders, acting together, may be able to impact matters requiring stockholder approval. For example, they may be able to impact elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that investors may feel are in their best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with each investor&#8217;s interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our 2021 Plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We expect that significant additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Pursuant to our 2021 Plan, our management is authorized to grant stock options to our employees, directors and consultants. If the number of shares reserved under our 2021 Plan is increased pursuant to the terms of the 2021 Plan, our stockholders may experience additional dilution, which could cause our stock price to fall.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or therapeutic candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">We do not have any committed external source of funds or other support for our development and commercialization efforts, and we cannot be certain that additional funding will be available on acceptable terms, or at all. </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Any future debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">As a result of our recurring losses from operations and recurring negative cash flows from operations, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively. If we raise additional funds through future collaborations, licenses and other similar arrangements, we may have to relinquish valuable rights to our future revenue streams, research programs, therapeutic candidates or EEV Platform, or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market therapeutic candidates that we would otherwise prefer to develop and market ourselves. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We are an &#8220;emerging growth company&#8221; and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). For as long as we continue to be an emerging growth company, we intend to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in our periodic reports;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (Sarbanes-Oxley Act);</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">We will remain an emerging growth company until the earliest to occur of: (i) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; (ii) the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700.0 million of equity securities held by non-affiliates; (iii) the date on which we have issued more than $1.0 billion in </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">non-convertible debt securities during the prior three-year period; and (iv) the last day of the fiscal year ending after the fifth anniversary of our initial public offering.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to continue to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of their stock.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Anti-takeover provisions in our certificate of incorporation, our bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our fourth amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions include, among other things:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">a prohibition on stockholder actions through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a requirement of approval by the affirmative vote of a majority of the outstanding shares of our voting stock to amend or repeal specified provisions of our certificate of incorporation, and the affirmative vote of a majority of the outstanding shares of each class entitled to vote thereon as a class, at a duly constituted meeting of stockholders called expressly for such purpose; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, Section 203 of the General Corporation Law of the State of Delaware (DGCL) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Any provision of our fourth amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein (Delaware Forum Provision). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the U.S. shall be the sole and exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act (Federal Forum Provision). In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders&#8217; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court ruled in March 2020 that federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court were &#8220;facially valid&#8221; under Delaware law, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the U.S. may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of our common stock.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If we fail to satisfy Nasdaq&#8217;s continued listing requirements, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair our stockholders&#8217; ability to sell or purchase our common stock when our stockholders wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">General Risk Factors</b><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to related compliance initiatives.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company, and these expenses may increase even more after we are no longer an &#8220;emerging growth company.&#8221; We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (Exchange Act), the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain sufficient coverage, particularly in light of recent cost increases related to coverage. We cannot accurately predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In addition, as a public company we will be required to incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act. Under these rules, beginning with our second annual report on Form 10-K after we become a public company, we will be required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we may be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaging in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We may in the future discover material weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We, and our independent registered public accounting firm, were not required to perform an evaluation of our internal control over financial reporting as of December 31, 2021 in accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we cannot assure our stockholders that we will not in the future identify material weaknesses. Material weaknesses may exist when we become required to report on the effectiveness of our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial information, the market price of our stock could decline, and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">We may be subject to securities litigation, which is expensive and could divert management attention.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include property, general liability, employment benefits liability, business automobile, workers&#8217; compensation, and directors&#8217; and officers&#8217;, employment practices and fiduciary liability insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</span><span style="letter-spacing:0.2pt;"> </span></p><a id="_Hlk88565326"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.</span><span style="letter-spacing:0.2pt;"> </span></p><a id="_Hlk88565266"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">Most recently, the ongoing COVID-19 pandemic created a shortage of available resources at the FDA. Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. </span><span style="letter-spacing:-0.1pt;">Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Ongoing travel restrictions and other uncertainties continue to impact oversight operations both domestic and abroad and it is unclear when standard operational levels will resume. The FDA is continuing to complete mission-critical work, prioritize other higher-tiered inspectional needs (e.g., for-cause inspections), and carry out surveillance inspections using risk-based approaches for evaluating public health. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. </span> </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">Additionally, during the COVID-19 pandemic, the FDA has stated that it is working to ensure timely reviews of applications for medical products in line with its user fee performance goals. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period</span><span style="letter-spacing:-0.1pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:8pt 0pt 0pt 0pt;"><span style="letter-spacing:-0.1pt;">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the ongoing COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, including formal and informal interactions with product developers, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our future regulatory submissions, which could have a material adverse effect on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><a id="_1e7f7484_b8c9_478b_8427_57e34cc9e160"></a><a id="Item1BUnresolvedStaffComments_342067"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1B. Unresolved Staff Comments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f897345a_689a_4231_b7fc_ef55f77a6456"></a><a id="Item2Properties_998237"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 2. Properties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters are located in Boston, Massachusetts, where we lease a facility containing approximately 34,866 square feet of office, research and development and laboratory space. The lease expires on November 30, 2025, subject to an option to terminate the lease after November 30, 2023 without penalty or to extend for three additional years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We believe our facilities are adequate and suitable for our current needs and that should it be needed, suitable additional or alternative space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ccb43922_4265_4b04_8ad4_e90a304d7527"></a><a id="Item3LegalProceedings_466085"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 3. Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of our business. While the outcome of any such proceedings cannot be predicted with certainty, as of December 31, 2021, we were not a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors</span>.</p><a id="_912d372c_670a_4248_88a2_8b4d6ea3c1b1"></a><a id="Item4MineSafetyDisclosures_423594"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 4. Mine Safety Disclosures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a8cbdf87_c8b8_4d24_92ee_52a9b7e08c61"></a><a id="PARTII_277737"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II</b></p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity </b><b style="font-weight:bold;">Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock has traded on the Nasdaq Global Market under the symbol &#8220;TRDA&#8221; since October 29, 2021. Prior to that date, there was no public trading market for our common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders of Our Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 28, 2022, there were approximately 65 stockholders of record of our common stock.<b style="font-weight:bold;"> </b>The actual number of stockholders is greater than the number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. The number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common stock.<span style="letter-spacing:-0.1pt;"> We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future.</span> <b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Securities Authorized for Issuance Under Equity Compensation Plans </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The information required by Item 701 of Regulation S-K was previously included in Quarterly Report on Form 10-Q filed on December 9, 2021 (File No. 001-40969).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Proceeds from our Initial Public Offering of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In November 2021, the Company completed its initial public offering (IPO) in which the Company issued and sold&#160;</span>10,436,250<span style="background:#ffffff;">&#160;shares of its common stock, including&#160;</span>1,361,250<span style="background:#ffffff;">&#160;shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $</span>20.00<span style="background:#ffffff;">&#160;per share</span>. All of the shares of common stock issued and sold in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-260160), which was declared effective by the Securities and Exchange Commission (the SEC) on October 28, 2021. Goldman Sachs &amp; Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C. acted as joint book-running managers for the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate net proceeds received by the Company from the IPO were approximately $190.7 million, after deducting underwriting discounts and commissions of $14.6 million, and offering expenses payable by the Company of $3.4 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There has been no material change in our planned use of the net proceeds from the offering as described in our final prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Purchases of Equity Securities by the Issuer or Affiliated Purchasers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4e9a953b_6155_4a9d_a241_dd948080b4a2"></a><a id="Item6SelectedFinancialData_268516"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 6. </b><span style="font-style:italic;font-weight:bold;">Reserved</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Not Applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_bbe2eaea_9a4f_4e1b_98fe_a333913efa61"></a><a id="Item7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 7.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS</b><b style="font-weight:bold;"> OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K (Annual Report). Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis. You should carefully read the &#8220;Cautionary Note Regarding Forward Looking Statements&#8221; and &#8220;Risk Factors&#8221; sections of this Annual Report to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a biotechnology company that aims to transform the lives of patients by establishing EEV therapeutics as a new class of medicines and we aim to become the world&#8217;s foremost intracellular therapeutics company. Through our proprietary, highly versatile and modular EEV platform (EEV Platform), we are building a robust development portfolio of EEV therapeutic candidates designed to enable the efficient intracellular delivery of therapeutics in various organs and tissues with an improved therapeutic index.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we ha<span style="background:#ffffff;">ve devoted substantially all our resources to research and development efforts relating to our</span> EEV <span style="background:#ffffff;">Platform, advancing development of our portfolio of programs and general and administrative support for these operations, including raising capital. </span>To date, we have financed our operations primarily through the sales of our preferred stock, and most recently, with proceeds from the sale of our common stock in our initial public offering (IPO). In November 2021, we completed our IPO pursuant to which we issued and sold 10,436,250 shares of our common stock, including 1,361,250 shares of common stock pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares at a public offering price of $20.00 per share. We received aggregate net proceeds from our IPO of $190.7 million after deducting underwriting discounts and commissions of $14.6 million and offering expenses payable of $3.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred losses since our inception. Our net losses were $51.2 million and $26.5 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $93.7 million. We expect to continue to generate operating losses and negative operating cash flows for the foreseeable future as we advance our platform and EEV therapeutic candidates into later stages of preclinical development and, if successful, clinical development. We will not generate any revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for one or more therapeutic candidates, if ever. If we obtain regulatory approval for any therapeutic candidates, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy, as we advance therapeutic candidates through preclinical and, if successful, into clinical development, seek regulatory approval, prepare for and, if any therapeutic candidates are approved, proceed to commercialization and operate as a public company. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain funding, we will be forced to delay, reduce, or eliminate some or all of our research and development programs, product portfolio expansion and ultimate commercialization efforts, which would adversely affect our business prospects, or we may be unable to continue operations. Although we continue to pursue these plans, we may not be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we can generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we had cash and cash equivalents of $291.1&#160;million. We believe that our cash and cash equivalents as of December 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources.&#8221; To finance our operations beyond that point we will need to raise additional capital, which cannot be assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Impact of the Ongoing COVID-19 Pandemic on Our Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The duration of the ongoing COVID-19 pandemic and the extent to which it may directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and difficult to predict, including the duration of the outbreak, new information that may emerge concerning the severity of COVID-19, such as new strains of the virus, including the Delta and Omicron variants and any future variants that may emerge, which may impact rates of infection and vaccination efforts, developments or perceptions regarding the safety of vaccines and the extent and effectiveness of actions to contain COVID-19 or treat its impact, including vaccination campaigns and lockdown measures, among others. At times during the pandemic, we, our contract manufacturing organizations (CMOs), and our contract research organizations (CROs), experienced temporary reductions in certain operations that have since normalized. We, together with our CMOs and CROs, are closely monitoring the impact of the ongoing COVID-19 pandemic on these operations. Additionally, to provide a safe work environment for our employees, we have implemented various measures including limiting on-site presence to essential employees, providing for social distancing, increased sanitization of our facilities and providing personal protective equipment for our employees. We are continuing to monitor the impact and effects of the ongoing COVID-19 pandemic and our response to it, and we expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and other business partners in light of the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not incurred any significant impairment losses in the carrying values of our assets as a result of the pandemic and we are not aware of any specific related event or circumstance that would require us to revise our estimates reflected in our audited consolidated financial statements included elsewhere in this Annual Report. Our estimates of the impact on our business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Components of Our Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have not generated any revenue. We do not expect to generate any revenue from the sale of products for the foreseeable future. If our development efforts for our therapeutic candidates are successful and result in regulatory approval or we successfully enter into collaboration or license arrangements with third parties, we may generate revenue in the future from product sales, payments from collaboration or license arrangements that we may enter into with third parties, or any combination thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Operating Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our programs. These expenses include:</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expenses, including salaries, related benefits, and stock-based compensation expense for individuals engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred in connection with the discovery and preclinical development of our therapeutic candidates and research programs, including under agreements with third parties, such as consultants, contractors, and CROs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of developing and validating our manufacturing process for use in our preclinical studies and potential future clinical trials, including the cost of raw materials used in our research and development activities, and engaging with third party CMOs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of laboratory supplies and research materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of payments made under third-party licensing agreements and related future payments should certain development and regulatory milestones be achieved; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facilities, depreciation and other direct and allocated expenses, including rent and other operating costs, incurred as a result of our research and development activities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred. Non-refundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered or the services rendered. Upfront payments under license agreements are expensed upon receipt of the license and annual maintenance fees under license agreements are expensed in the period in which they are incurred. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a preclinical-stage company in the early phases of development, our research and development costs are often devoted to proof-of-concept studies and our overall EEV Platform that underpins our therapeutic candidates. <span style="background:#ffffff;">Our direct, external research and development expenses consist primarily of fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our process development, manufacturing and clinical development activities. Our direct external research and development expenses also include fees incurred under license and intellectual property purchase agreements. We expect to track these external research and development costs on a program-by-program basis as we identify specific programs and product candidates to advance into clinical development</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We do not allocate employee costs, costs associated with our development efforts and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources and third-party consultants primarily to conduct our research and development activities as well as for managing our process development, manufacturing and clinical development activities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Therapeutic candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in connection with our platform development efforts and planned preclinical and clinical development activities in the near term and in the future. We expect that the research and development expenses of our programs will increase in the near term as we initiate investigational new drug (IND)-enabling activities for our therapeutic candidates. Therefore, we cannot reasonably estimate or know the nature, timing, and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our therapeutic candidates. The successful development of our therapeutic candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development, including the following:</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing, rate of progress and expenses of our ongoing and potential future research activities, including preclinical and IND-enabling studies, clinical trials and other research and development activities we decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the successful initiation, enrollment, and completion of clinical trials under current good clinical practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of filing and acceptance of INDs or comparable foreign applications that allow commencement of future clinical trials for our therapeutic candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether our therapeutic candidates show safety and efficacy in our clinical trials and an acceptable risk-benefit profile in the intended populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to hire and retain key research and development personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully develop, obtain regulatory and marketing approvals of our therapeutic candidates for the expected indications and patient populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our therapeutic candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercializing therapeutic candidates, if and when approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain a continued acceptable safety, tolerability, and efficacy profile of our therapeutic candidates following approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish new licensing or collaboration arrangements to support our potential therapeutic candidates on favorable business terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any decisions we make to discontinue, delay or modify our programs to focus on others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining, maintaining, protecting and enforcing patent and trade secret protection and regulatory exclusivity for our therapeutic candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining adequate coverage and reimbursement from third party payors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.15pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of the ongoing COVID-19 pandemic.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of any of our therapeutic candidates could significantly change the costs and timing associated with the development of that therapeutic candidate. We may never succeed in obtaining regulatory approval for any of our therapeutic candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of salaries and personnel-related costs, including stock-based compensation, for our personnel in executive, legal, finance and accounting, corporate and business development, human resources, and other administrative functions. General and administrative expenses also include: legal fees relating to intellectual property and corporate matters; professional fees paid for accounting, auditing, consulting, and tax services; insurance costs; travel expenses; and facility costs not otherwise included in research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our programs and EEV Platform. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance, and investor and public relations expenses associated with operating as a public company.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Income (Expense)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Interest Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest income consists of interest earned on our invested cash and cash equivalents balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Income (Expense), Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other income (expense), net consists primarily of gains and losses on disposal of fixed assets and gains and losses on foreign currency transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have not recorded any income tax benefits for the net losses we have incurred or for the research and development tax credits earned in each&#160;year and interim period as we believe, based upon the weight of available evidence, that it is more likely than not that all our net operating loss carryforwards and tax credit carryforwards will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021, we had federal net operating loss carryforwards of $93.1 million, which may be available to offset future taxable income, of which $3.2 million expire at various dates beginning in 2036 and the remaining $89.9 million do not expire but are limited in their usage to an annual deduction equal to 80% of annual taxable income. In addition, as of December 31, 2021, we had state net operating loss carryforwards of $88.0 million, which may be available to offset future taxable income and expire at various dates beginning in 2036. As of December 31, 2021, we also had federal and state research and development tax credit carryforwards of $2.3 million and $1.2 million, respectively, which may be available to reduce future tax liabilities and expire at various dates beginning in 2039 and 2034, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Accrued Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">vendors in connection with discovery and preclinical development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CROs in connection with preclinical studies and testing; and</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party manufacturers in connection with the development and scale up activities and the production of materials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We base the expense recorded related to contract research and manufacturing on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple service providers that conduct services and supply materials. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. In accruing service fees, we estimate the time period over which services were performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. While the majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met, some require advance payments. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. We record these as prepaid expenses on our consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We account for all stock-based compensation awards granted as stock-based compensation expense at fair value <span style="background:#ffffff;">in accordance with FASB ASC Topic 718,&#160;</span><i style="font-style:italic;background:#ffffff;">Compensation&#8212;Stock Compensation</i><span style="background:#ffffff;"> (ASC 718)</span>. Our stock-based payments include stock options and grants of common stock restricted for vesting conditions. The measurement date for awards is the date of grant, and stock-based compensation costs are recognized as expense over the requisite service period, which is generally the vesting period, on a straight-line basis. Stock-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided. Forfeitures are recorded as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected share price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and our expected dividend yield. Prior to our IPO, there was no public market for our common stock, and consequently, the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant, with input from management, considering third-party valuations of our common stock as well as our board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;<i style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </i>(Practice Aid). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of our common stock at each valuation date. Since our IPO, we have determined the fair market value of our common stock using the closing price of our common stock as reported on the Nasdaq Global Market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Subsequent to the IPO, the fair value of the common stock underlying our stock-based awards is the closing price of our common stock on the date of grant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Note&#160;2, <i style="font-style:italic;">Summary of Significant Accounting Policies</i>, in the notes to our consolidated financial statements for a description of recent accounting pronouncements applicable to our business.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Comparison of the years ended December 31, 2021 and 2020</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:61.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:23.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:23.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:middle;width:61.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:61.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,926</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,102</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,824</span></p></td></tr><tr><td style="vertical-align:middle;width:61.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,201</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,565</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,636</span></p></td></tr><tr><td style="vertical-align:middle;width:61.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 51,127</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,667</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,460</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (51,127)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (26,667)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (24,460)</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest and other income (expense), net</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (31)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 144</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (175)</span></p></td></tr><tr><td style="vertical-align:middle;width:61.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income (expense), net</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (31)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 144</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (175)</span></p></td></tr><tr><td style="vertical-align:bottom;width:61.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (51,158)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (26,523)</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (24,635)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:22.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:22.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">External fees for outside research and consulting services (including third-party CROs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,973</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,713</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,260</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Personnel related (including stock&#8209;based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,187</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,106</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,081</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lab supplies used in research and development activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,873</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,470</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,403</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Facility and equipment related costs (including depreciation) and other unallocated costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,893</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,813</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,080</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35,926</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,102</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,824</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $35.9&#160;million for the&#160;year ended December 31,&#160;2021, compared to $21.1&#160;million for the&#160;year ended December&#160;31,&#160;2020. The increase of $14.8&#160;million in research and development expenses was primarily attributable to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $7.1&#160;million in personnel-related costs driven by increased headcount in our research and development function, inclusive of stock-based compensation expense of $0.9 million and $0.1 million for the years ended December 31, 2021 and 2020, respectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $4.1&#160;million in facility and equipment-related costs, including depreciation, and other allocated miscellaneous expenses in connection with the operating lease for our corporate headquarters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $2.2 million in external expenses associated with discovery and preclinical studies performed by outside consulting services, including third party CROs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase of $1.4 million in lab supplies due to the increased investment in research and development activities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect our research and development expenses will continue to increase as we continue our current research and development activities, initiate new research programs, continue our preclinical development of therapeutic candidates and progress ENTR-601-44, and future product candidates, into clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the&#160;year ended December 31, 2021 were $15.2&#160;million, compared to $5.6&#160;million for the year&#160;ended December 31, 2020. The increase of $9.6 million was primarily attributable to the following:</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a $5.2&#160;million increase in personnel-related costs, primarily as a result of the increase in headcount in our general and administrative function, inclusive of stock-based compensation expense of $1.6 million and $0.2 million for the years ended December 31, 2021 and 2020, respectively; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a $2.1 million increase in professional services costs, primarily attributable to legal and outside consulting services to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">support our continued research activities and development of our programs</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a $1.3 million increase in other miscellaneous expenses, including fees attributable to operating as a public company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a $1.0&#160;million increase in facility and equipment-related expenses in connection with the operating lease for our corporate headquarters.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Total other expense was less than $0.1 million for the year ended December 31, 2021, compared to total other income of $0.1&#160;million for the year ended December 31, 2020. Total other income included interest income on our cash equivalents, which are primarily invested in money market funds which decreased less than $0.1 million from December 31, 2020 to December 31, 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sources of Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2016, we have incurred significant operating losses. Our net losses were $51.2 million and $26.5 million for the years ended December 31, 2021 and 2020, respectively<span style="white-space:pre-wrap;">. As of December 31, 2021 and December 31, 2020, we had an accumulated deficit of $93.7 million and $42.5 million, respectively. We expect to incur significant expenses and operating losses for the foreseeable future as we further our platform development and advance the preclinical and, if successful, the clinical development of our programs. To date, we have funded our operations primarily with $201.8 million in proceeds from the sale of preferred stock, and most recently, with  proceeds from the sale of common stock in our IPO completed in November 2021, including the underwriters&#8217; exercise of their over-allotment option to purchase additional shares of common stock. As of December&#160;31,&#160;2021, we had cash and cash equivalents of $291.1&#160;million. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cash Flows</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows for each of the periods presented:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.14%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:23.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:23.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (50,862)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25,570)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,580)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,318)</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 307,461</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,089</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 252,019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,201</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December 31,&#160;2021, net cash used in operating activities was $50.9 million, consisting primarily of our net loss of $51.2&#160;million, partially offset by stock-based compensation expense of $2.5 million, depreciation expense of $1.1 million, loss on disposal of assets of $0.1 million, and net cash used in our operating assets and liabilities of $3.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31,&#160;2020, net cash used in operating activities was $25.6 million, consisting primarily of our net loss of $26.5&#160;million, partially offset by stock-based compensation expense of $0.3 million, depreciation expense of $0.3 million, and net cash provided by changes in our operating assets and liabilities of $0.3 million.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Net cash used in investing activities was $4.6&#160;million and $2.3&#160;million for the years ended December&#160;31, 2021 and 2020, respectively, and resulted from our purchases of property and equipment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $307.5 million for the year ended December&#160;31, 2021, consisting of $115.8 million of net proceeds from the sale of our Series B Preferred Stock in March 2021 and $190.7 million of aggregate net proceeds from our IPO in November 2021, and stock option exercises, inclusive of early exercises of stock options, of $1.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $50.1 million for the year ended December 31, 2020, consisting of $49.8 million of net proceeds from the sale of our Series A Preferred Stock in January 2020 and August 2020, and stock option exercises, inclusive of early exercises of stock options, of $0.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Funding Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and, if successful, the clinical development of our programs. In addition, we expect to incur additional costs associated with operating as a public company. Our operating expenses and future funding requirements are expected to increase substantially as we continue to advance our portfolio of programs. We believe that our cash and cash equivalents as of December 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with research, development, and commercialization of our candidates, we are unable to estimate the exact amount of our working capital requirements. Our future capital requirements will depend on many factors, including costs associated with:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the continuation of our current research programs and our preclinical development of therapeutic candidates from our current research programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking to identify additional research programs and additional therapeutic candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advancing our existing and future therapeutic candidates into clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiating preclinical studies and clinical trials for any therapeutic candidates we identify and develop or expand development of existing programs into additional indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, expanding, enforcing, defending and protecting our intellectual property portfolio and providing reimbursement of third-party expenses related to our patent portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing of manufacturing for our therapeutic candidates and commercial manufacturing if any therapeutic candidate is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing and maintaining clinical and commercial supply for the development and manufacture of our therapeutic candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking regulatory and marketing approvals for any of our therapeutic candidates that we develop, if any;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking to identify, establish and maintain additional collaborations and license agreements, and the success of those collaborations and license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ultimately establishing a sales, marketing, and distribution infrastructure to commercialize any platforms for which we may obtain marketing approval, either by ourselves or in collaboration with others;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">generating revenue from commercial sales of therapeutic candidates we may develop for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hiring additional personnel including research and development, clinical, and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding operational, financial, and management information systems and personnel, including personnel to support our product development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquiring or in-licensing products, intellectual property, and technologies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ongoing costs of operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenue to support our cost structure, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise funds through collaborations or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or therapeutic candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our therapeutic candidates even if we would otherwise prefer to develop and market such therapeutic candidates ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Contractual Obligations and Commitments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our contractual obligations as of December 31, 2021:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:48.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Payments&#160;Due&#160;by&#160;Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less&#160;Than&#160;1&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">1&#160;to&#160;3&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">4&#160;to&#160;5&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More&#160;Than&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">5&#160;Years</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease obligations (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,910</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,526</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,384</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,910</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,526</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,384</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td colspan="16" style="vertical-align:middle;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(1) We have the option to terminate our Boston, Massachusetts office and lab space lease after November 30, 2023 upon proper notice without penalty.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with CROs, third-party manufacturers, and other third parties for preclinical research studies and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation. These payments are not included in the preceding table as the amount and timing of such payments are not known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have also entered into license agreements under which we are obligated to make certain payments. The table above does not include potential success payments, sublicense fees, royalty fees, licensing maintenance fees and reimbursement of patent maintenance costs that we may be required to pay under license agreements. For additional information about our license agreement and amounts that could become payable in the future under such agreements, see &#8220;Business&#8212;Intellectual property&#8212; License agreement with The Ohio State University&#8221; and Note&#160;9 Commitments and Contingencies to our consolidated financial statements.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Emerging Growth Company and Smaller Reporting Company Status</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; or EGC, under the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Section&#160;107 of the JOBS Act provides that an EGC can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B)&#160;of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of delayed adoption of new or revised accounting standards and, therefore, we will be subject to the same requirements to adopt new or revised accounting standards as private entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As an EGC, we may, and intend to, take advantage of certain exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an EGC:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may present only two&#160;years of audited financial statements and only two&#160;years of related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may avail ourselves of the exemption from providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section&#160;404(b)&#160;of the Sarbanes-Oxley Act of 2002, as amended (the Sarbanes-Oxley Act);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may avail ourselves of the exemption from complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (PCAOB) regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may provide reduced disclosure about our executive compensation arrangements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not require nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will remain an EGC until the earliest to occur of (i)&#160;the last day of the fiscal&#160;year following the fifth anniversary of the completion of our IPO, (ii)&#160;the last day of the fiscal&#160;year in which we have total annual gross revenues of $1.07 billion or more, (iii)&#160;the date on which we have issued more than $1.0 billion in non-convertible debt during the previous rolling three-year period or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the Securities Exchange Act of 1934, as amended (the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal&#160;year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250 million or (ii)&#160;our annual revenue was less than $100 million during the most recently completed fiscal&#160;year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c50d60ac_ebdd_4efe_8de0_ccda31e4cc3c"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Item 7A.</b> <b style="font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk</b></p><a id="_Hlk96510009"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3f6bb1be_79dc_45b8_a1c8_7fc29bf09599"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 8. Financial Statements and Supplementary Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:91.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:8.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:91.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#ReportofIndependent"><span style="font-style:normal;font-weight:normal;">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</span></a> (PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:AuditorFirmId" id="Narr_tbEqwkb3lkyqlp02qtfLzw">42</ix:nonNumeric>)</p></td><td style="vertical-align:top;width:8.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">145</p></td></tr><tr><td style="vertical-align:top;width:91.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#BALANCESHEETS_206978"><span style="font-style:normal;font-weight:normal;">Consolidated balance sheets</span></a></p></td><td style="vertical-align:top;width:8.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">146</p></td></tr><tr><td style="vertical-align:top;width:91.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#STATEMENTSOFOPERATIONS_447754"><span style="font-style:normal;font-weight:normal;">Consolidated statements of operations</span></a></p></td><td style="vertical-align:top;width:8.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">147</p></td></tr><tr><td style="vertical-align:top;width:91.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#STATEMENTSOFREDEEMABLECONVERTIBLE_786859"><span style="font-style:normal;font-weight:normal;">Consolidated statements of redeemable convertible preferred stock and stockholders&#8217; (deficit) equity</span></a></p></td><td style="vertical-align:top;width:8.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">148</p></td></tr><tr><td style="vertical-align:top;width:91.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#STATEMENTSOFCASHFLOWS_974455"><span style="font-style:normal;font-weight:normal;">Consolidated statements of cash flows</span></a></p></td><td style="vertical-align:top;width:8.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">149</p></td></tr><tr><td style="vertical-align:top;width:91.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#NOTES"><span style="font-style:normal;font-weight:normal;">Notes to consolidated financial statements</span></a></p></td><td style="vertical-align:top;width:8.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;">150</p></td></tr><tr><td style="vertical-align:top;width:91.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.09%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 9pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2173204a_60b8_4a54_9e21_c01ea5bffca5"></a><a id="ReportofIndependent"></a><a id="_636181"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;">To the Stockholders and the Board of Directors of Entrada Therapeutics, Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#333333;font-weight:bold;">Opinion on the Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;">We have audited the accompanying consolidated balance sheets of Entrada Therapeutics, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, redeemable convertible preferred stock and stockholders&#39; (deficit) equity and cash flows for the years then ended, and the related notes</span><sup style="color:#333333;font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#f4f4f4;"> </sup><span style="color:#333333;">(collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="color:#333333;font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk64312489"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;">These financial statements are the responsibility of the Company&#39;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;white-space:pre-wrap;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.  Accordingly, we express no such opinion.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="color:#333333;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;">/s/ </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:AuditorName" id="Narr_Lv8dU-Y-DUGoMsp1kYAvew"><span style="color:#333333;">Ernst &amp; Young LLP</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;">We have served as the Company&#8217;s auditor since 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="dei:AuditorLocation" id="Narr_LpEzv___dkupwQf_GyWMMA"><span style="color:#333333;">Boston, Massachusetts</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#333333;">March 15, 2022</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_06ed730c_9997_4917_af39_3b99ec1134c8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ENTRADA THERAPEUTICS, INC.</b></p><a id="BALANCESHEETS_206978"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_80c9371b_962c_4cd9_9ef1_94231f7d92ef"></a><a id="Tc_vKYFn3PIXEiJVWoPYSPL2g_1_3"></a><a id="Tc_gYajetN8B0K_K1nIAP58Ew_1_6"></a><a id="Tc_cxiKblbAz0GfvQKkmwlkNg_2_2"></a><a id="Tc_KHgWm1ZK5kO6YrOiDzUNng_2_5"></a><a id="Tc_sU_9RCmKHUOvwmi31tnjrw_3_0"></a><a id="Tc_DBNlIOV5bk6-gYkeOLMgzg_4_0"></a><a id="Tc_gs_eZRcAo0WfWZ9zBaqw6g_5_0"></a><a id="Tc_WW9e2WgibEusQkwujo9g2A_5_2"></a><a id="Tc_lQAafqu-bkW3mehDaPUKGA_5_5"></a><a id="Tc_s6fGFIYjDEevCgsblsuadw_6_0"></a><a id="Tc_kRqn9wWUy0aFp1u1PBLP0Q_7_0"></a><a id="Tc_bSc-a9XuhEymi65ytkvNSA_8_0"></a><a id="Tc_MlCiTxv2qEeMuZXRE3xtNg_9_0"></a><a id="Tc_v0JQVGXFSEWSC_8D-dKHIQ_10_0"></a><a id="Tc_xFkZpztzT0Wp2r6wMrg6DA_10_2"></a><a id="Tc_18nOWeCV8EGNP1_nsMypYg_10_5"></a><a id="Tc_lGwGcyL4zkyuqpRxkX50fg_11_0"></a><a id="Tc_uNSh1bzE8EWh7hTdS4hAqw_12_0"></a><a id="Tc_5kZkT2hYPkmEmIAAU03Ixg_13_0"></a><a id="Tc_Qg79-Ffnc0SEwVz_Z9LIiw_13_2"></a><a id="Tc_6YSR-Y4o3kWfJtnC3G10UQ_13_5"></a><a id="Tc_XjsNsLrAI0-EPStC1_otVA_14_0"></a><a id="Tc_I15JWIZWEkeNinEGDDRV8A_15_0"></a><a id="Tc_mHBwegooMEKK8qtk5qlCwA_16_0"></a><a id="Tc_IId3E6oTm0qUlP9U0AV3Wg_16_6"></a><a id="Tc_3V_FtezDXEqj8-0Ixo9aQA_17_0"></a><a id="Tc_b8o2m1NwCkqj8as_UGvQFw_18_0"></a><a id="Tc_f1WeL8ONIE2uko63Ry9raw_19_0"></a><a id="Tc_yePoLTc4REexpnu_tbWbIg_19_3"></a><a id="Tc_wDr-eL5mW0uxyJhj-PpMUQ_20_0"></a><a id="Tc_UApHp4YJ00-jL0id1jw4GA_21_0"></a><a id="Tc_VfL7dQCHIEKxkLEmuDxxiA_22_0"></a><a id="Tc_Sz02X4a8vU6VH0vG7ndUCw_23_0"></a><a id="Tc_PdQPFrsIXUGHuFMVLIQIgw_24_0"></a><a id="Tc_jueEibwDU0mz4AaEjnj4Ug_25_0"></a><a id="Tc_wfPbaeqdKUi6BgWzgQuzfQ_25_2"></a><a id="Tc_3DCtW3fNk0mbaWhwTBoLyg_25_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_YC2pk23Fv0iKCbYbJ7elqA_5_3">291,064</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_UIPHQUjK60OjBzx-uWcCOg_5_6">39,045</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_EsQgL5nUhUevoJHTLXUz4Q_6_3">7,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_4mmrfxMBVkaXc6yUBgLWaA_6_6">904</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_5M2igIMuoU-fB0P6NybYgw_7_3">298,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_ya9RYTkEw0av-gTTNUuFnA_7_6">39,949</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_L8Abny57Gku5uSiajhIA0g_8_3">6,261</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_MB_aIoESdkeV9xBHr5AGmA_8_6">3,037</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_rxoaCSCLaES4vAnYBcXW-w_9_3">872</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_jhUWWACy3kiYVvBPWlue7Q_9_6">541</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_SO-H6JTrM0efa5uIyxVhhA_10_3">305,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_6199Rfy_WE-Z51pCIbECVA_10_6">43,527</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217; (Deficit) Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_ALXDIFZ0IUaTfNsXdDxANw_13_3">706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_FF_OHbZ5WUmyvLz38zps3A_13_6">1,602</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_q0841-UhLkiuvY02Q6EE3g_14_3">6,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Mffc3he5q0utINORykHpxg_14_6">1,757</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_CTZHcaWEgkyjpEPK0IHxfg_15_3">6,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_zxV0OwVbtU214g3tgrOKMA_15_6">3,359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred rent, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="Tc_2R2cqCDVT0Kd7A1uljZOZA_16_3">396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212; </p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_hLN8BPcw0U6BJBrIJ3dK5Q_17_3">7,115</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_qCRdj9Mvo0KL153YS8ayOw_17_6">3,359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Redeemable convertible preferred stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_4PfnsgxMWE-tqu7rbK2tVg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_8SEVFFQNVE6OQN4D6upzCA">0.0001</ix:nonFraction></ix:nonFraction> (Note 6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212; </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_SoPBMUgqRk6zuv3-LFnoMA_19_6">81,658</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; (deficit) equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_YmXsJ5RW90WerYJq-cMlYA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_5RFZUWklcEydCxN1Ypbv9g">0.0001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_L6SXid1S1keb3sbW_ZGThw">150,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_XSZ0wMm520-prCHmnRDnqg">113,259,306</ix:nonFraction> shares authorized as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_KPEF6e4dvkOVMcMHWZTzNA">31,336,092</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_jNV0Pkgpa0-ISKTNjiZnFA">1,283,545</ix:nonFraction> shares issued as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively; <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_Wyo0DBolakimCrBHHERCrw">31,224,336</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_7Jx3Oy7HOUqpv0fONkwtuQ">1,244,139</ix:nonFraction> shares outstanding as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_3r1csMLn-kqu65RfqubVDg_21_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_2ziGg0HHdkeDmqmrnAviXg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212; </span></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid&#8209;in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_bDaD1oYc00uMnJKjdrPeMQ_22_3">392,384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_pl-W08GCGUuausQcDQrJ9A_22_6">1,021</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_6mDDCMjj30-yT65MPGd5eg_23_3">93,669</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_oNzr4ZCcKUSh3eWHU-WVQw_23_6">42,511</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6UvE1dqSYEOL0J-CSwjgMQ_24_3">298,718</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_vZUb_DGtm0yAJSzQxnxO4w_24_6">41,490</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; (deficit) equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_xgbn072hD0Km8U4L5SY1vA_25_3">305,833</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_l76Q5-RG-k2Vr7WxcxtlNw_25_6">43,527</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a746545e_e3d8_4c9b_a35a_54e91de514bc"></a><a id="_12661"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ENTRADA THERAPEUTICS, INC.</p><a id="STATEMENTSOFOPERATIONS_447754"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_87ae280a_6b01_41b3_a015_c53d6417f102"></a><a id="Tc_9M2ixuvBHUWc2dfamdtOJQ_1_2"></a><a id="Tc_m0I2d7O7EEu4K-s8N6mUkA_2_2"></a><a id="Tc_Nq2rggANq06KCa4WfmRZSA_2_5"></a><a id="Tc_3sXSf2Tb_UuCh2mtg8CT3Q_4_0"></a><a id="Tc_Kl-XlYSShk2QpW1VByiTfw_5_0"></a><a id="Tc_iijUPE2ePkuQUXNKB9vhFA_5_2"></a><a id="Tc_nX-498YJVk-xYeLB0iWjzw_5_5"></a><a id="Tc_nDCf_1H9CEWRP7sV1y9qQg_6_0"></a><a id="Tc_H7SkVIVkkEuKRqTp_J4oXw_7_0"></a><a id="Tc_ReGi7vHklUip53a2BbaFaw_8_0"></a><a id="Tc_XmPS8XE6YEWeWJCW1MK_LA_9_0"></a><a id="Tc_ngY4ul9OJkO5RtnETWHmwg_10_0"></a><a id="Tc_2t-TU5jRqUuxCywN94SZmA_11_0"></a><a id="Tc_wxeUKxuIsUW98C-J-xDzeQ_12_0"></a><a id="Tc_0Vre9_qdYkOh0992jMB2GA_12_2"></a><a id="Tc_GSPsJTgT9kGTaDB27uy3DQ_12_5"></a><a id="Tc_IPRCVFmI7kmX9E9PusfhKA_13_0"></a><a id="Tc_Mhczz_dliUSipX-rYSE2lg_14_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_han1bwOp60uxwW5PrzbpRw_5_3">35,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_W9MG9ZQMxEyn0me046d4bQ_5_6">21,102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_kQs25rFTDECxdO7IpPKKVQ_6_3">15,201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_mnkhJm5hU0mJf_oqsoUyiw_6_6">5,565</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_2GPgEdefQEeufSr4IJKV4A_7_3">51,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_XMRwH0hzK0moCsM3qGcgrA_7_6">26,667</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_wIoDSfGpF0WE46rs4kCp9Q_8_3">51,127</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_MiMnto8M7E2I4K2dcawsrQ_8_6">26,667</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other (expense) income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest and other (expense) income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="trda:InterestAndOtherIncomeExpenseNet" sign="-" scale="3" id="Tc__QqRdg5Z1kKDHhePTk7OBQ_10_3">31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="trda:InterestAndOtherIncomeExpenseNet" scale="3" id="Tc_AoJtjM3VkEOgZL_NYj6PPA_10_6">144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other (expense) income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_7lJiIpi5l0-HnFNBaFsvjg_11_3">31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_c92t7GJM7EqMgULBouxDUQ_11_6">144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_2ScpIb7YVkagsltX9-ZzjA_12_3">51,158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_2V47968seE2qa1DGEBooEg_12_6">26,523</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_drr4vLhnZUCSHDjSts1PsA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_myq2k-5tUE6NtDsXfrpyAw_13_3">8.16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_NTFV33O3hk6TxzH7NJ9c5g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Qso2n8BkU0CREUYRXv_Wrw_13_6">24.00</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted&#8209;average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Tb4i8xRddUq3iVulW38P0Q_14_3">6,267,776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Kor8OCWzIUeqWZJS_upwSA_14_6">1,105,260</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b5fc05fc_7ac3_454f_b81c_e7a4159529ec"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">ENTRADA THERAPEUTICS, INC.</p><a id="STATEMENTSOFREDEEMABLECONVERTIBLE_786859"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">PREFERRED STOCK AND STOCKHOLDERS&#8217; (DEFICIT) EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_88fd860a_fa31_47d9_8205_7e78bb56a2ae"></a><a id="Tc_6vh0NPOENkqHqHjJYBcorA_1_2"></a><a id="Tc_0bVyrxwLrUiuUYoRysLWOg_1_13"></a><a id="Tc__h1GutydvEacXF72KcfMnA_1_19"></a><a id="Tc_WcaJWxwUikaW5_2CSrNEkQ_2_2"></a><a id="Tc_M4ZciGPZPUKz1BOD7bwXLQ_2_8"></a><a id="Tc_9m6KWf5h5UyQD5hyU99xug_2_13"></a><a id="Tc_9dfhEw5d8keSP4YWuZDoRw_2_16"></a><a id="Tc_RunffvyecEukmFGqprYEVg_2_19"></a><a id="Tc_9Qyq8AyQ2kKaJQktpHeBlg_3_2"></a><a id="Tc_Vw53LTkNGE2YINbLTFkSkg_3_4"></a><a id="Tc_TJ7bR8Mz_0uIsIc3WeVzYQ_3_8"></a><a id="Tc_3CM6AjbBpUCPreo9jfWL6Q_3_10"></a><a id="Tc_Yp9e4He57U6rbQfeKcLdLg_3_13"></a><a id="Tc_gs9dKOU2IU-EcL6XkQCrnQ_3_16"></a><a id="Tc_g-3aWk6JCUONu-12k6ZIJw_3_19"></a><a id="Tc_vtVpiGmLfkOkSRE6VW5prg_4_0"></a><a id="Tc_DBJ9OWb1cEW0nBkHFd95eQ_4_4"></a><a id="Tc_UJeqxgMOWEC86rEoztz-CQ_4_10"></a><a id="Tc_A2PPbWCvF0OU7GKCl5nwBA_4_11"></a><a id="Tc_uM2IpbxFBEeRcf1i37k-Hw_4_13"></a><a id="Tc_v3uPMpafxkaq0n__EH_MjQ_4_16"></a><a id="Tc_OMVuha_uJESxLUAzA2prKw_4_19"></a><a id="Tc_ps_uDUHhw0Wb_schNJEPog_5_0"></a><a id="Tc_La9Y6yFmoUqzuLaVxNhMjA_5_8"></a><a id="Tc_5nn7hrjt2E2dRbhapaLz9A_5_11"></a><a id="Tc_9U6m3J5D1k2YN7YqNqZRww_5_14"></a><a id="Tc_fz8cWrdzh0Sb28iEVVmjXQ_5_17"></a><a id="Tc_zmM0S-W1QkyN7xs9yDP9lQ_5_20"></a><a id="Tc_H4eqEqFoikGOCBivZuZuuw_6_0"></a><a id="Tc_VttGWTWvQUOJ7VMYYsPeqA_6_2"></a><a id="Tc_pA6j2nr1t0y7xSeHDapqzw_6_5"></a><a id="Tc_-QYFyDewkUq1-nMQBtAdjg_6_11"></a><a id="Tc_P4joHKIKmkWs8mK9MFGGuw_6_17"></a><a id="Tc_aaVTVpH0dUKR5s6uBoH_Wg_7_0"></a><a id="Tc_h8cgfD5Sskq2Key0cj371w_7_2"></a><a id="Tc_8eBl5Plf6EC2piuZJtOHqg_7_5"></a><a id="Tc_C2HoJD9qQU-KHnMjyb5Lfw_7_11"></a><a id="Tc_zKR5Dwus8E-woaOdpemFpQ_7_17"></a><a id="Tc_JZ6U6sBc-kaPM4A_zExyZw_8_0"></a><a id="Tc_ozu4TObltUSTA8SbXU-aaQ_8_2"></a><a id="Tc_gV1-ZC5JCUC9a_KbI9rgng_8_5"></a><a id="Tc_fmtPynu9MEigoH6-u2QASA_8_11"></a><a id="Tc_6NPtKKSzpECTNh5cUORstQ_8_17"></a><a id="Tc_KxhpFtCKv0SplhB8uvy-Xw_9_0"></a><a id="Tc_zwiO-683XUKm2fZFpjmcEg_9_2"></a><a id="Tc_EIlMNhnEWUCrB1iTLAtQ2w_9_5"></a><a id="Tc_S4a9LOmF4EGyEyQkGeO7Ow_9_8"></a><a id="Tc_GsVKNSWKyUWkUpCXmwMzMw_9_11"></a><a id="Tc_rAWV4L0snkC4UPDcDNtBUA_9_17"></a><a id="Tc_0DA2sxCNJEW-6WaYSW_geQ_10_0"></a><a id="Tc_YcvuwBRAJkyr1a1pcRU-Vg_10_2"></a><a id="Tc_yn8iOtw8ak-m1pmz_048sg_10_5"></a><a id="Tc_efsYPAY_DU6HRKGnyNd4pA_10_8"></a><a id="Tc_GayWO2W99UuSPDsOV5-q-g_10_11"></a><a id="Tc_CFiuGDO89Ua4rgCwSbjF5w_10_14"></a><a id="Tc_9EYkqD3uC0CkXq9TL4phhQ_11_0"></a><a id="Tc_3m447Y294USwVioiLZfKuQ_11_4"></a><a id="Tc_1UcVFO-drE6ollSIKeyhTA_11_10"></a><a id="Tc_7AuyBEgdf0-00zrH9oH2AA_11_11"></a><a id="Tc_Q31kFDd1o0SpB1f4bu7t0A_11_13"></a><a id="Tc_Ki0ghVpYq0OIqcsWh6gThw_11_16"></a><a id="Tc_blb4ggHOEkGBZ99VoBxljw_11_19"></a><a id="Tc_gKcTYBfK8kWwAnMbqCXkSg_12_0"></a><a id="Tc_ytnWrMRd7EqiHunfzKwPjA_12_8"></a><a id="Tc_2xsokOKPV0CWJePKItXNfw_12_11"></a><a id="Tc_o6APQvQciE-dYs5HUK4Nxg_12_14"></a><a id="Tc_g87RrW4O2EiEAoIotZfMUg_12_17"></a><a id="Tc_zJTxnjz4PEaX4yrUbM7l4Q_12_20"></a><a id="Tc_bh3gv7Ah8UqdfwhZLr-Mww_13_0"></a><a id="Tc_TXIIwiCpU0yUmWFiLL_Nng_13_17"></a><a id="Tc_8jHbbwVNw06PnaSGXWC83g_14_0"></a><a id="Tc_psR_LRsY8EuSPBb0qRf74w_14_2"></a><a id="Tc_EtV1wxXngEe3Uxg_qHrAbA_14_5"></a><a id="Tc_Wxlp6YPP0ke_oTuuDUXyow_14_17"></a><a id="Tc_N78Q-fl2bkm6imi6ylHiXw_15_0"></a><a id="Tc_hAmCEJQA-EKvnpU29UfB8A_15_2"></a><a id="Tc_LuhMeY8ksUi2w6Le2P2-Iw_15_5"></a><a id="Tc_28LQpEdjI0iRq0B0PzPJxQ_15_11"></a><a id="Tc_IRtXP-eNQUG2ah3X5ka3rw_15_17"></a><a id="Tc_Cb7_H1EPXka3--h-rA1McQ_16_0"></a><a id="Tc_Sqs4aMv84E-eczpbWmxVgQ_16_2"></a><a id="Tc_wngSQYN-VkeL9BjFV3vSVw_16_5"></a><a id="Tc_5kRyts0-O02ucH9MpfSJkA_16_11"></a><a id="Tc_KEnvr9hhx0yqFcRbx6VESw_16_14"></a><a id="Tc_UfrznLULD0yCGt8CluIjUA_16_17"></a><a id="Tc_Q0R4WO3jMUSJFFKLjHR69A_16_20"></a><a id="Tc_1S_lFKinckajIeRyIDoVXA_17_0"></a><a id="Tc_-mPqSboN0k6kPpzvZxqi2w_17_2"></a><a id="Tc_J_roJZDOZkuVPYffp5dQNg_17_5"></a><a id="Tc_bIp4UuP0FEOakIGeVNVOxw_17_11"></a><a id="Tc_6ShJYEGQBUCCDAvtykOfqQ_17_17"></a><a id="Tc_i1CU-UzUFEK_qY_Rc6e9sA_18_0"></a><a id="Tc_oNYJPfPuVkSPEEjpgvzEIw_18_2"></a><a id="Tc_RTbNeRhkdkuMQtTv6AumYw_18_5"></a><a id="Tc_cXssjZ9vPkKiPFNa20GX-w_18_8"></a><a id="Tc_sokH8U3HlU6iYrWVNyQbaA_18_11"></a><a id="Tc_4cMxKDa4YEiKRLFlP89dlQ_18_17"></a><a id="Tc_cqHIRqQhSEmHvisJJfjpGg_19_0"></a><a id="Tc_P0ElOKwey0C70ptpIu4DzA_19_2"></a><a id="Tc_NomaMQTROkGu2Qo1EjzPJw_19_5"></a><a id="Tc_2KveDy7teEK3sUQ-dc7jBw_19_8"></a><a id="Tc_-q2-s8jhP0O2iJN5-9C2HA_19_11"></a><a id="Tc_Hfa3HC38GUWKf4QNFmQvlA_19_14"></a><a id="Tc_HLg9aa9rykKRO-XZyPC6zg_20_0"></a><a id="Tc_VbAc2jIH5USklmWCreWskg_20_2"></a><a id="Tc_38x9M-YWakG8JXoDcroaCw_20_4"></a><a id="Tc_tnyUjUp7YUGtealMiZS_BQ_20_5"></a><a id="Tc_WpRwDOwwO0aMsoXmZQmYqQ_20_10"></a><a id="Tc_LcXHu8QJikWppgMOuiRHmA_20_13"></a><a id="Tc_S5Zk_Dnbs0-W4AzYOuhyVw_20_16"></a><a id="Tc_MwGcEyLRL0-Rd9kkOh7xXQ_20_19"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.03%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Redeemable Convertible&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;&#160;</b></p></td></tr><tr style="height:9.35pt;"><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Deficit) Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2019_0F7kyPmgPE6NFo60sAPzEQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_GFillVLlqkGb9cXS7-aURw_4_2">37,269,149</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2019_0F7kyPmgPE6NFo60sAPzEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_rTn_EyxfxkKJbo5Lqi1XPA_4_5">31,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BuEOalfyI0u2lwqzpEOfWA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_1lFdPEvon02TvajFhUsLDw_4_8">1,004,310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kycqBPxOmUOgzZHFE2RRRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_HptEg1z7bUykp5cAEFui9w_4_14">470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I9FjEp0tz0WGNpk85jBJ1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_qCIF8pKP6EKMUA5KA8aL7w_4_17">15,988</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2019_0F7kyPmgPE6NFo60sAPzEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kCPHZcowykOEFuxIJI8jiA_4_20">15,518</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of Series&#160;A redeemable convertible preferred stock, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_494Nn9bt3E65r2GvytHiBg" decimals="-3" format="ixt:numdotdecimal" name="trda:TemporaryEquityIssuanceCosts" scale="3" id="Narr_QbykmipP6kqCANdL2UTZew">158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_494Nn9bt3E65r2GvytHiBg" decimals="INF" format="ixt:numdotdecimal" name="trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_rdm0XNFiyUO01aCpwfo-Rw_5_2">48,030,736</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_494Nn9bt3E65r2GvytHiBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_5uQmT6uMZUGtbnQDs_WjBA_5_5">49,842</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f79AwiNGhE-sfsUO9KmsTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_O8rwBZ4N9kaw084xCEoLKA_6_8">129,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_603nz09bmES_5kNTHFmsAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_mifG3ffe1kuWgQvEHglUCQ_6_14">214</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_lRiZqeqRWUaIEU3HB4zHWw_6_20">214</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vesting of restricted common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f79AwiNGhE-sfsUO9KmsTg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_Pb5ttRNJ_UOmZXWEmNIkeA_7_8">95,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_603nz09bmES_5kNTHFmsAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_mz2kwJDLmkqlJjWubPakBw_7_14">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="Tc_9VO0ZwC9IUCc4sgP6TpjYQ_7_20">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vesting of early exercised options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f79AwiNGhE-sfsUO9KmsTg" decimals="INF" format="ixt:numdotdecimal" name="trda:StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions" scale="0" id="Tc_u8WIouWPGkGBF3CWWD0BEw_8_8">14,452</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_603nz09bmES_5kNTHFmsAg" decimals="-3" format="ixt:numdotdecimal" name="trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" scale="3" id="Tc_ZWqXl_bc9U2yIAtOX-vxRA_8_14">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" scale="3" id="Tc_VP9P_u5PvEiyl7ZJnK4WWw_8_20">11</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_603nz09bmES_5kNTHFmsAg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_eqo1d9Oxtk-hj8jOVdKEPA_9_14">325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_CeOsvpyBYkSxPxVe7jv9FQ_9_20">325</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_skLgUvkO-UWUx7Bti_R8Vw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fHvhwIxqoUu2RFsQZr-jpg_10_17">26,523</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_osPFz7H2ekGmEze0N9_v7A_10_20">26,523</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_Fpf8-Nb5TUu2Bbdaey3NNw_11_2">85,299,885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_uE1S2Rzx7kq6X0NyquZphQ_11_5">81,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l9HKPBpFZ0iNKAGeJGZG1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_2MOwZM4610ycdArinmL_Zg_11_8">1,244,139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpyy8MnVM0KmlsYrfZMTyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_FM_Or9DqD0uAdd2cklj-Mg_11_14">1,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O7xm61cRg0K4Na8wCgmpSQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_qUM-APeeu0ejcIbweilEJQ_11_17">42,511</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_msaHRz2s4kmrUVuM0-KZdQ_11_20">41,490</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of Series&#160;B redeemable convertible preferred stock, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_u1sl4JaoEU2V5L65kkaVfA" decimals="-3" format="ixt:numdotdecimal" name="trda:TemporaryEquityIssuanceCosts" scale="3" id="Narr_VlV-_46HxUmh2lQ2huKGIw">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_u1sl4JaoEU2V5L65kkaVfA" decimals="INF" format="ixt:numdotdecimal" name="trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_xBX3a_X5uU-GViQrInf2Yw_12_2">53,522,099</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_u1sl4JaoEU2V5L65kkaVfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_tFKNeIJG1EinV64Rb_5XkQ_12_5">115,831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Conversion of redeemable convertible preferred stock upon initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="INF" format="ixt:numdotdecimal" name="trda:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_SqD6zznFDU6Ms5-gvTZcmA_13_2">138,821,984</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="trda:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_jYv6wrvmW0-nXVKvy0bPZA_13_5">197,489</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_E_eMIG0TIkCfgeTMBBaCaQ_13_8">19,185,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_yOhHQeEj4kigEH3D6bKEZA_13_11">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_p9LWBETOxEuwkPY7rihI9g_13_14">197,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_xXd8Y2sNLESXAOR93d_c_Q_13_20">197,489</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock from initial public offering, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Narr_dg4gPfFN5kWL9tnYcniqsw">18,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_pfN-NMr6ZE-tYp6GX4Onqg_14_8">10,436,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_jkWREO21XUyEBh-rGfBGaA_14_11">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc__14Zmhe_EkWTEA4jp5PIOw_14_14">190,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_IjM1ABRnckm5XNAg4kFd_A_14_20">190,691</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_ZG8wMrOxKk2MiItLNHxuew_15_8">223,838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_waVFCSqKJEKgGwE69x9Cmw_15_14">410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_WWBxWEY9C02KFdUDgM-yug_15_20">410</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vesting of restricted common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Tc_dT5dr_hczUaHr62TcvuDJw_16_8">11,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vesting of early exercised options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA" decimals="INF" format="ixt:numdotdecimal" name="trda:StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions" scale="0" id="Tc_hCLETZG9-k2iSWRq2hUSMg_17_8">123,389</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ" decimals="-3" format="ixt:numdotdecimal" name="trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" scale="3" id="Tc_14Rf-MnASkyqgSCQujKJpw_17_14">250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" scale="3" id="Tc_0YMUvnG7N0KhcI4hfYy5Bw_17_20">250</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_zn7nL_PyCUKnU_PRBfvl_g_18_14">2,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_v1pd4OXjfkm5SkBJ_HuxMQ_18_20">2,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kbIUpMM9tU6Bw1ItzOX4kA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_eGJ8Kb9Bl0eHb624-1cGhA_19_17">51,158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_kaAySt4dYEKRLaXX0O537w_19_20">51,158</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:26.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balances at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_78VjKUVPTEe0xf_MNsF1lA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_dAP-m14uZk-Ys9uRlkihiw_20_8">31,224,336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_78VjKUVPTEe0xf_MNsF1lA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UflE2niiV0mHuz3mCthZxg_20_11">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3Evel5BXlU2Nkn6JOeAzkg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0KvClK8zQ0uFKRu3ExHehA_20_14">392,384</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fIyU3F2ce0eWRga502fJBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_PveXJMHlikWDCc3dcvzuXw_20_17">93,669</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YJC9bWRlbkGzTIN8HW0Grg_20_20">298,718</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d674ea83_c66c_409f_89f6_ae5b268d3a70"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ENTRADA THERAPEUTICS, INC.</p><a id="STATEMENTSOFCASHFLOWS_974455"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_f6d19cb3_5944_43b6_9a9f_9c7bc6a3c058"></a><a id="Tc_cQyJ-iiPoEeEuyJmOF07cQ_1_2"></a><a id="Tc_cCSx0mSU_UeCVU9Oh75I-g_2_2"></a><a id="Tc_JxpNwIFOTEmGh9MC_3QkCA_2_5"></a><a id="Tc_qYiP2flnxkK5BQ_OveIqUA_4_0"></a><a id="Tc_6WcGPTFwnUaXPyWWvGG-Bg_5_0"></a><a id="Tc_zi0oqB3u1UajS-_kPaJS2A_5_2"></a><a id="Tc_awmLnUKMNUua1nXBk8QVQg_5_5"></a><a id="Tc_q6EuymZIjkyptXOgqE54_g_6_0"></a><a id="Tc_OCmqWd9m30m813Th_OLBFg_7_0"></a><a id="Tc_m_b9kDZIvUqYkrMr7fNwrw_8_0"></a><a id="Tc_uEosMkQb4kCT7D21YjheGQ_9_0"></a><a id="Tc_yo6osqtvIkOhx2nuas-7_Q_10_0"></a><a id="Tc_sDDevm0ckE-4x6Vdj0edJA_11_0"></a><a id="Tc_6sRITinrwkeMB3K3_tN5Hg_12_0"></a><a id="Tc_2XZR-jb-FkKXTwIuWMN6Ww_13_0"></a><a id="Tc_cb94LXufpkuzF7vk-oc4vQ_14_0"></a><a id="Tc_zCBp8FBE9EKoIJfI0lD9CA_15_0"></a><a id="Tc_9SO2xqHbDUWlIFYSvrhbtg_16_0"></a><a id="Tc_7M2uTK9xwUaFt1i-0LSEkQ_17_0"></a><a id="Tc_dn5dQm_-XUWhkUhBn9Htjg_18_0"></a><a id="Tc_YBoYPwRtfEyJKLoA4T8YbA_19_0"></a><a id="Tc_TyzPEWDdsE6dBe1o0qRehg_20_0"></a><a id="Tc_j5zWL7Tn5ESRZuaODnrF_g_21_0"></a><a id="Tc_uBxK1VmGJUG-zhpy_S0pqA_22_0"></a><a id="Tc_lOYkSggFaEmdcAFHuF_nsA_22_6"></a><a id="Tc_UUiUrn95hUSHcN6Wi0EyfA_23_0"></a><a id="Tc_YN4c3ZEU_Uq0d5O1ARFRRQ_24_0"></a><a id="Tc_vGQERgvVCU24rEvdBaBOtQ_25_0"></a><a id="Tc_velN9kspm0mxmmvDxH8ZIg_26_0"></a><a id="Tc_DYlLHXi2YkWlsDhUAzq7fQ_27_0"></a><a id="Tc_KFw-sx3KoU2rSQ4WpmsSxg_28_0"></a><a id="Tc_tcIyLxV2hk-IdzS_aWIBuA_28_2"></a><a id="Tc_lRp4xiMWhkCJpGqDzmuPHA_28_5"></a><a id="Tc_iBMQUAzLwUiLtWA6zBYOcQ_29_0"></a><a id="Tc_BMWHV774SUO7PWloExFPNg_30_0"></a><a id="Tc_lTFHX6lNa0iGv8GblgGvjg_30_2"></a><a id="Tc_-Q8EcrIDLkmwfVwvt6PkVw_30_5"></a><a id="Tc_KHOUQehCQUODR_7_BUVf3w_31_0"></a><a id="Tc_1Y-KZzY2AUG7NApEPJsaVA_31_2"></a><a id="Tc_KSW0g7vW8k2Q30A2AtxEmg_31_5"></a><a id="Tc_MnloqqWrf0GCMcfIC2Fllw_31_6"></a><a id="Tc_Z8IFDQWO1UO7IHP15oy9PQ_32_0"></a><a id="Tc_1HzQcSCv5EmS7ijG4ItHnQ_32_2"></a><a id="Tc__nhWu-K3o0aMqRgDCD_KUA_32_3"></a><a id="Tc_V3PCX9GqN0u9uSDy_92P_Q_32_5"></a><a id="Tc_OX22eGuezE63niyDKLvzyw_33_0"></a><a id="Tc_5EqqZAJ6xU61SzcGvBNKNQ_33_2"></a><a id="Tc_X_CERUaA-EOZnK2CJ5Clrw_33_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:24.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_VcaIhtuivE-SbT9W2_dEbA_5_3">51,158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_6xhiYGnni0-X47oOu-t0fA_5_6">26,523</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Depreciation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_9QT0M-j5C0OTLEpS4rz6lA_7_3">1,117</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_HRyjSBDpjE61Rk7RrNAn1Q_7_6">326</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss on disposal of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_AoyEwtoBlUKWu0JbTAExqA_8_3">74</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_ri5RDjKiQUS9z9-UvfYcRA_8_6">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock&#8209;based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_GxMNmUKOlUuCQ5L2OWN5jA_9_3">2,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_46PjQdr7PkiPsVY6_RooXQ_9_6">325</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_6fBkrWX9S0OiatLk4Si2mA_11_3">6,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_SyBQ5_Qy6k-BmboJgBaWaw_11_6">311</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="Tc_SOLcWycDF0S9WFDANx1StQ_12_3">331</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="Tc_llS4PifpzkKNuF1lfMwwfQ_12_6">541</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" sign="-" scale="3" id="Tc__coHtoFWI0mGTQTRuOStvA_13_3">715</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_1uyZgUm34EyGmkN7qLkt-w_13_6">631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_xNayNiPhBU-1WGOj_S8klw_14_3">3,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="Tc_AxDgbz5W4UyjTmHSb6iRQQ_14_6">578</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Deferred rent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" scale="3" id="Tc_VlFpcc0-3UWiJy2m4u0QOA_15_3">396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" sign="-" scale="3" id="Tc_OXMfuwm6u0Ctiid3fZGnOA_15_6">75</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Qdv-Is5Ia02zlzeoGtXKkg_16_3">50,862</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_YTazGynRc0mSgPnqtt-wsg_16_6">25,570</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_e9IMfOOAlkmBVJkQBgxnWw_18_3">4,580</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_n-vpwdThu0O8K5NL4H5xcA_18_6">2,318</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_mKAe5LMcOUeUjQrr5zmw6w_19_3">4,580</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_uF8Pfkf4NEWpFM2r6A4Yqw_19_6">2,318</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Tc_RQv2e4isz0KpCYpzWr1EPQ_21_3">115,831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" id="Tc_7GNkFwsgik-NrE_JDnlR9A_21_6">49,842</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Tc_-1hGH5OfwEGlnrBATeA_yg_22_3">190,691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_178T8zj3QUu0yrN1x_52Kg_23_3">410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_d3YUXO-ixUmZl0qFeddqdg_23_6">213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from the early exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="trda:ProceedsFromEarlyExerciseOfStockOptions" scale="3" id="Tc_IfBQW76qH0KGKwR3NeV5-w_24_3">529</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="trda:ProceedsFromEarlyExerciseOfStockOptions" scale="3" id="Tc_h-QMG_jpEk-2nbZMeB896w_24_6">34</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_bovUuF-BcEec8PSVekNCJg_25_3">307,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_rT-gfN7-zUaKo3ymwFrKsA_25_6">50,089</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net increase in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_fGtI6JkRhUa0AEvvAr7t6A_26_3">252,019</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_RIVbtythuk-lUlUHvqZcmA_26_6">22,201</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_JHCeb3rUgUirwR05sgFU-A_27_3">39,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2019_0F7kyPmgPE6NFo60sAPzEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_XbidPCn8WUOcGxuKD6Lrtw_27_6">16,844</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_FsD8G5XhkEy8jaRqXlrvkw_28_3">291,064</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Z2qYOAcqakuqHbQiK9Wi4Q_28_6">39,045</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental cash flow disclosures:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Purchases of property and equipment included in accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_VVch73mVOUyeQehc9LvzCQ_30_3">155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_-Qvct5_Hyker9UIW2vDlKw_30_6">320</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Conversion of preferred stock to common stock upon initial public offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="Tc_NYO9NaquPE2wOXF7bzVTtQ_31_3">197,489</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vesting of restricted stock subject to repurchase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="trda:VestingOfRestrictedStockSubjectToRepurchase" scale="3" id="Tc_m9Oo-hP-GEStIKMQo2LKMQ_32_6">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Vesting of options early exercised subject to repurchase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="trda:VestingOfOptionsEarlyExercisedSubjectToRepurchase" scale="3" id="Tc_uxYrHnJunkiY6VaFQU6p2g_33_3">250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="trda:VestingOfOptionsEarlyExercisedSubjectToRepurchase" scale="3" id="Tc_HGUPQHM2e0Sh5zOcnfkPQQ_33_6">11</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4d41ccec_6f49_4027_a88f_3758aafdfca1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">ENTRADA THERAPEUTICS, INC.</p><a id="NOTES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">For the Years Ended December 31, 2021 and 2020</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb__4AW3E2XGk-WhGPvR98T2A" continuedAt="Tb__4AW3E2XGk-WhGPvR98T2A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Organization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Entrada Therapeutics, Inc. (Entrada or the Company) aims to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>) therapeutics as a new class of medicines and aim to become the world&#8217;s foremost intracellular therapeutics company. The Company was incorporated in Delaware on September 22, 2016 and its principal offices are located in Boston, Massachusetts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Initial Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2021, the Company completed its initial public offering (IPO) in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_LGXl_iZN7E6dEJSRz6h1QQ" decimals="INF" format="ixt:numdotdecimal" name="trda:StockIssuedDuringPeriodAggregateSharesIssued" scale="0" id="Narr_IC1Cca-2kUyvKT6PUk6OQw">10,436,250</ix:nonFraction> shares of its common stock, including <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_dnx581iJhk-tByLmAfE2iA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_76NNAAelyEW95U8-Zz29XQ">1,361,250</ix:nonFraction> shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_1fQTtTn9-E69-ajeccNB9Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_xqpK31IXPkmNoBkEy4-amg">20.00</ix:nonFraction> per share, for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_LGXl_iZN7E6dEJSRz6h1QQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_YxI-AH8L7k-RZLHDDAdAaw">208.7</ix:nonFraction> million. The Company received $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_LGXl_iZN7E6dEJSRz6h1QQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr__QiJGd_gJ0akJGzYa72Gug">190.7</ix:nonFraction> million in net proceeds, after deducting underwriting discounts and offering expenses payable. In connection with the IPO, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock converted into <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_1fQTtTn9-E69-ajeccNB9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_WD_EVj6I3k26vYx7mE8ECw">19,185,183</ix:nonFraction> shares of the Company&#8217;s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">On October 22, 2021, in connection with the Company&#8217;s IPO, the Company effected a <span style="-sec-ix-hidden:Hidden_w1M_9o9Q5kO5Amu-2DsMtA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-7.235890014</span></span> reverse stock split of the Company&#8217;s common stock. All common shares, stock options, and per share information presented in the accompanying consolidated financial statements and notes thereto have been adjusted, where applicable, to reflect the reverse stock split on a retroactive basis for all periods presented, including reclassification of par and additional paid-in capital amounts. The per share par value and authorized number of shares of the Company&#8217;s common stock were not adjusted as a result of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its proprietary, highly versatile and modular EEV platform (EEV Platform), advancing development of its portfolio of programs and general and administrative support for these operations, including raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, technical risks associated with the successful research, development and manufacturing of therapeutic candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accordance with Accounting Standards Codification (ASC) 205-40,&#160;<i style="font-style:italic;">Going Concern</i>, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company has incurred losses since its inception, including losses of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_DuZcIkAsxk2f5m65AU913A">51.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_Al6H2rFOQUGow7gpsZJiiQ">26.5</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_aDyPtmXhcEC90f8JlfCEkg">93.7</ix:nonFraction> million. To date, the Company has funded its operations primarily through the sale of equity securities. The Company expects to continue to generate operating losses and negative operating cash flows for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company expects that its cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_0kCPXl7C1UmlwhzmDSaugQ">291.1</ix:nonFraction> million as of December 31, 2021 will be sufficient to fund its operations and capital expenditure requirements for at least the next twelve months from the date of issuance of these consolidated financial statements. The Company will need additional financing to support its continuing operations and pursue its business strategy and may pursue additional cash resources through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing, or other arrangements. The Company </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__4AW3E2XGk-WhGPvR98T2A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">may be unable to raise additional funds or enter into such other agreements when needed or on favorable terms or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#8217;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_dFmHpR9JOUa9xEodsGtTqQ" continuedAt="Tb_dFmHpR9JOUa9xEodsGtTqQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_lcp2S2Sl5Eu_f5_UOz8RjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The accompanying consolidated financial statements reflect the operations of the Company and have been prepared in conformity with generally accepted accounting principles in the United States of America (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_53IjHMucx0WtHwLUl7yp5w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-style:normal;font-weight:normal;">The accompanying consolidated financial statements include those of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:UseOfEstimates" id="Tb_9dA6pFsADUWjuKAqasrEDg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to accrual and prepayment of research and development expenses and stock-based compensation. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_v1V34wmuWkO8PeBZ9B7tmg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company manages its operations as a single segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for<span style="white-space:pre-wrap;"> the purposes of assessing performance and making operating decisions.  All of the Company&#39;s long-lived assets are located in the United States.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_e3AQ7afShUOsUpYbd2hN-A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value. As of December 31, 2021 and 2020, the Company has <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RestrictedCash" scale="0" id="Narr_MWbPoe3jQ06iq7oqEn8P3g"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RestrictedCash" scale="0" id="Narr_3I81fzgQtEe-w9O5R8pMAQ">no</ix:nonFraction></ix:nonFraction> restricted cash.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_1xe28HucFkKfL0qTnTWeQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_a9wLHozXOky8z-qF5uhy8Q" continuedAt="Tb_a9wLHozXOky8z-qF5uhy8Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f2d4c2c5_4a15_4b48_b29c_2dbf06c187e3"></a><a id="_f2d4c2c5_4a15_4b48_b29c_2dbf06c187e3_2"></a><a id="_f2d4c2c5_4a15_4b48_b29c_2dbf06c187e3_3"></a><a id="_4aa386ef_554d_4d27_9845_44292bf7aa5f"></a><a id="_4aa386ef_554d_4d27_9845_44292bf7aa5f_2"></a><a id="_4aa386ef_554d_4d27_9845_44292bf7aa5f_3"></a><a id="_a41d8098_a8aa_4fc2_a9a2_b499d89fa900"></a><a id="_a41d8098_a8aa_4fc2_a9a2_b499d89fa900_2"></a><a id="_a41d8098_a8aa_4fc2_a9a2_b499d89fa900_3"></a><a id="_1fcd2aff_17bb_4f9d_8b06_130e761f39cd"></a><a id="_1fcd2aff_17bb_4f9d_8b06_130e761f39cd_2"></a><a id="_1fcd2aff_17bb_4f9d_8b06_130e761f39cd_3"></a><a id="_93b43d89_dc00_4e1c_bf74_c4bd728b44cf"></a><a id="_93b43d89_dc00_4e1c_bf74_c4bd728b44cf_2"></a><a id="_93b43d89_dc00_4e1c_bf74_c4bd728b44cf_3"></a><a id="_3120448e_b2e6_47ee_9f8e_ca3abf81db24"></a><a id="_3120448e_b2e6_47ee_9f8e_ca3abf81db24_2"></a><a id="_3120448e_b2e6_47ee_9f8e_ca3abf81db24_3"></a><a id="Tc_pFSzhtpG8UWZZA3p_a-VrA_1_1"></a><a id="Tc_9Exwu6M35ky18_kh_umFDA_2_0"></a><a id="Tc_YYNtGvauSEKqwGpYQ9nNXw_3_0"></a><a id="Tc_AHgWhgT2DUWuHgceOd6Acg_4_0"></a><a id="Tc_dl0QN-qcgUmC5HmI6m2kWQ_5_0"></a><a id="Tc_eic1T4BIRUqDfyHNNK5Q7w_5_1"></a><ix:continuation id="Tb_dFmHpR9JOUa9xEodsGtTqQ_cont1" continuedAt="Tb_dFmHpR9JOUa9xEodsGtTqQ_cont2"><ix:continuation id="Tb_a9wLHozXOky8z-qF5uhy8Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available under the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2021 and 2020. The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_ryQ1qWQRv0iz2w_l9hu6PQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight line method over the estimated useful life of each asset as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="trda:PropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="Tb_sNxURjnkpk26c-jakZg1-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_nypqQlrtZE6lptm3mK1OuA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_dy1WLTJUYkSdKAa0_LILDQ_2_1">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_iZZ8FczNTU2tGeemyaYEYg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_mg0Z-mz-OkGa0q8U3WmWsA_3_1">3 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_iH0SLfAWbk6jaf3g4ibe_g" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_Sm2Ovoy1TEm6PFBcoSwUnA_4_1">5 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in other (expense) income. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are expensed in operations as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_kUqhSU4qj0a2G4JSOMrMyQ" continuedAt="Tb_kUqhSU4qj0a2G4JSOMrMyQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="6" id="Narr_hx60_LUkxEq-JPCt2JvGPw"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="6" id="Narr_M5EWzhqPFku8wmWBDlCUOw">no</ix:nonFraction></ix:nonFraction> impairment losses recognized during the years ended December 31, 2021 and 2020. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dFmHpR9JOUa9xEodsGtTqQ_cont2" continuedAt="Tb_dFmHpR9JOUa9xEodsGtTqQ_cont3"><ix:continuation id="Tb_kUqhSU4qj0a2G4JSOMrMyQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:StockholdersEquityPolicyTextBlock" id="Tb_lVQBJ8SPHEi2KOhvhhKOcw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Redeemable Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company&#8217;s control outside of permanent equity. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:DeferredChargesPolicyTextBlock" id="Tb_6NZfZ-Yd0EK89zf4wojteQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Offering Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">The Company capitalizes incremental legal, professional accounting and other third-party fees that are incurred in the course of preparing for a financing as other non-current assets until the offering is consummated. At the time of the completion of the offering, the costs are reclassified as a reduction of the proceeds of the financing as part of additional paid-in-capital. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="Tb_0KHG-TpSKEeHXVmEF-qI8w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company records liabilities for legal and other contingencies when information available to the Company indicates that it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Legal costs in connection with legal and other contingencies are expensed as costs are incurred.&#160;</span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LitigationReserve" scale="0" id="Narr_HgaX-pjBBUuaFI9GZvSRhQ"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LitigationReserve" scale="0" id="Narr_b1GiE5K2bkStf9yJCxPOvQ">No</ix:nonFraction></ix:nonFraction></span><span style="font-style:normal;font-weight:normal;">&#160;liabilities for legal and other contingencies were accrued as of December&#160;31, 2021 and 2020.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies" id="Tb_rMlQ-3LfLEeIFpvtbwK7nw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations (CROs), business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="trda:RentExpensePolicyTextBlock" id="Tb_Y2rMOvI1FESs7NEVVrEAuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rent Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s real estate operating lease provides for scheduled annual rent increases throughout the lease term. In accordance with ASC Topic 840, <i style="font-style:italic;">Leases</i> (ASC 840), the Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full term of the lease. Tenant improvement allowances, if any, provided by the landlord are recorded as deferred rent and amortized as a reduction to rent expense over the lease term.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_7pgPJVzi5kKrQ-obicHw9g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense as incurred. Research and development costs consist of direct and allocated costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative future use, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="trda:PatentCostsPolicyTextBlock" id="Tb_IoLEUrNpUU2yzz41_dRldg" continuedAt="Tb_IoLEUrNpUU2yzz41_dRldg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dFmHpR9JOUa9xEodsGtTqQ_cont3" continuedAt="Tb_dFmHpR9JOUa9xEodsGtTqQ_cont4"><ix:continuation id="Tb_IoLEUrNpUU2yzz41_dRldg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_Hm5L6kCfu0GfNIbEuDUK_g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s stock-based compensation program allows for grants of stock options and restricted stock awards. Grants are awarded to employees and non-employees, including the Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <i style="font-style:italic;">Compensation-Stock Compensation</i> (ASC 718). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (Black-Scholes) for stock option grants to both employees and non-employees. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s stock-based compensation awards are subject to service-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. <span style="background:#ffffff;">&#160;The Company determines the expected volatility using a blended approach encompassing its historical experience and the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#8217;s product candidates.&#160;</span>The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees and non-employees whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the Company&#8217;s IPO, there was no public market for its common stock, and consequently, the estimated fair value of its common stock was determined by the board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock as well as its board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;<i style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </i>(Practice Aid). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#8217;s common stock at each valuation date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Subsequent to the Company&#8217;s IPO, the fair value of the common stock underlying the stock-based awards is the closing price of the Company&#8217;s common stock on the date of grant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Restricted common stock awards are subject to service based vesting and repurchase rights.  Accordingly, the Company has recorded the proceeds from the issuance of restricted stock as a liability in the consolidated balance sheets. This restricted stock liability is reclassified into stockholders&#8217; (deficit) equity as the restricted stock vests.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_2O1XCuxHtUS_hOH-4pSPYQ" continuedAt="Tb_2O1XCuxHtUS_hOH-4pSPYQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Income taxes are recorded in accordance with FASB ASC Topic 740, <i style="font-style:italic;">Income Taxes</i> (ASC 740), which provides for deferred taxes using an asset and liability approach. The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dFmHpR9JOUa9xEodsGtTqQ_cont4" continuedAt="Tb_dFmHpR9JOUa9xEodsGtTqQ_cont5"><ix:continuation id="Tb_2O1XCuxHtUS_hOH-4pSPYQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by first evaluating the tax position to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_1wHJpZPeC0GBsHyJNyH2vg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. During periods of loss, there is no allocation required under the two-class method since the participating securities do not have a contractual obligation to fund the losses of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.  Given that the Company recorded a net loss for each of the periods presented, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be antidilutive and are, therefore, excluded from the diluted net loss per share calculation.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="trda:EmergingGrowthCompanyStatusPolicyTextBlock" id="Tb_b1Kn3HVaN0uJzM-zFPCKAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company qualifies as an &#8220;emerging growth company&#8221; (EGC), as defined in the Jumpstart Our Business Startups Act (JOBS Act) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards the same time that they become applicable to other public companies that are not EGCs, unless it chooses to early adopt a new or revised accounting standard. As a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#8217; effective dates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_X5JN-br7a0iliscwFQ4Fxw" continuedAt="Tb_X5JN-br7a0iliscwFQ4Fxw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_dFmHpR9JOUa9xEodsGtTqQ_cont5"><ix:continuation id="Tb_X5JN-br7a0iliscwFQ4Fxw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the FASB issued ASU No. 2016-02, <i style="font-style:italic;">Leases</i><span style="white-space:pre-wrap;"> (Topic 842), which supersedes all existing lease guidance.  This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions.  The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments.  Lessees are required to classify leases as either finance or operating leases.  If the lease is effectively a financed-purchase by the lessee, the lease is classified as a financing lease; otherwise the lease is classified as an operating lease.  This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease.  Topic 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction.  If the criteria are not met, the transaction is considered a &#8220;failed sale&#8221; and the transaction must be accounted for as a financing arrangement.  For EGCs, such as the Company, ASU 2016-02, as amended, will be effective for annual reporting periods beginning after December 15, 2021 and interim periods within those fiscal years, with early adoption permitted.  For public entities, ASU No. 2016-02 was effective for annual periods beginning after December 15, 2018, including interim periods within these annual periods. The Company is currently evaluating the full impact that the adoption of ASU 2016-02 is expected to have on its consolidated financial statements; however, the adoption of ASU 2016-02 will require the recognition at the adoption date of both a lease liability, based on the present value of future lease payments, and a corresponding right-to-use asset, which the Company expects to be material. The future lease payment obligation as of December 31, 2021 is disclosed in Note 9, Commitments and Contingencies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses</i> (Topic 326): Measurement of Credit Losses on Financial Instruments. This ASU requires that credit losses for financial instruments measured at amortized cost be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. For EGCs, such as the Company, the new standard will be effective beginning January 1, 2023. For public entities, the standard was effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the potential impact this ASU may have on its financial position and results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2019, the FASB issued ASU&#160;No.&#160;2019-12,<i style="font-style:italic;">&#160;Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes</i>&#160;(ASU&#160;2019-12),&#160;which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends certain aspects of the existing guidance to improve consistent application. For EGCs, such as the Company, ASU&#160;2019-12&#160;is effective beginning January&#160;1, 2022, with early adoption permitted. The Company is currently evaluating the potential impact that this ASU may have on its financial position and results of operations, as well as the timing of its adoption of this standard.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f6a59871_3b5f_44c5_a4b6_44ad3b907516"></a><a id="Tc_xWzNyvAvxUSsWC19JSLHCQ_1_2"></a><a id="Tc_dUzhvQ7af02vKSQyABP5sQ_2_2"></a><a id="Tc_QI0ECUNcW0mL6ejutF3_Dg_3_2"></a><a id="Tc_VeLZXYbZlUy_QK7aU95FFQ_3_5"></a><a id="Tc_9lBG7jdMw0ecDUK8TMc2Ew_3_8"></a><a id="Tc_yi1iOa5Wek-eNre23U05JQ_3_11"></a><a id="Tc_i5iHg5hvs0-HOXtD2xabyg_4_0"></a><a id="Tc__tPVHBMaUkauTaa5_T8u-g_5_0"></a><a id="Tc_r_QacvEeMUG-IZo2A-KnZw_6_0"></a><a id="Tc_f-CugGOBE0aYoVtYs1ESBQ_6_2"></a><a id="Tc_g9NkWErOy0Gqoy85pUEhzQ_6_5"></a><a id="Tc_Jkf-4FlcNE2yL9bVKJejIw_6_6"></a><a id="Tc_OHiUGLB7FEGDjUAcQMQG2g_6_8"></a><a id="Tc_zbDpzFmHrU2Atb2qIIK_jA_6_9"></a><a id="Tc_hWN69AT390SvCaMaDO1mng_6_11"></a><a id="Tc_CapeMJqArkiZa43PddwtRQ_7_0"></a><a id="Tc_FPPFRiobaUSbsIYpVf-9Kg_7_2"></a><a id="Tc_skX5WyeeBki2Z_rlPPb3cg_7_5"></a><a id="Tc_lCEFcwVI70Gp3BgIz7mo_A_7_6"></a><a id="Tc_hZVbxT2B_EiuZ54sBCgZKQ_7_8"></a><a id="Tc_hV2K7nfGu0WYOaU5fPjbZw_7_9"></a><a id="Tc_k1QLp8wukUuB37pG3UNP6w_7_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_Rcddc5JF9UmIkadB8_ujAw" continuedAt="Tb_Rcddc5JF9UmIkadB8_ujAw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Fair Value Measurements</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_2HzYdCe5tU2gj8Bh70wbwg" continuedAt="Tb_2HzYdCe5tU2gj8Bh70wbwg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables present the Company&#8217;s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HJgZfqoHTEiB7zwNlTcURQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_MB-i5iwax0yqf-mNzJlA9Q_6_3">290,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ehK6rCutpEqfLe84L0CqtQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_Z3tzFAO0002JkSFfzAUrdA_6_12">290,814</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BPCLjgwbAkKCfg-NbETCtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_W05MsmUWw0OnJ-kCettqkA_7_3">290,814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P198-NvWk0W9y94TBotMiQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_Us66d1MJR0KRzh0qgjE5kA_7_12">290,814</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_67e19e4c_167a_4a11_aee7_db945a48bfae"></a><a id="Tc_-izptH_Y7UmvPluF0Zos6g_1_2"></a><a id="Tc_F-21k2xhiUyY4eUkHnOf6Q_2_2"></a><a id="Tc_EvcvuSZ8xkKMYeYf5bm2nA_3_2"></a><a id="Tc_M9-sOC5T8EaDrYwXltOXRA_3_5"></a><a id="Tc__91KgHeAUkOPSQY-pCF0TQ_3_8"></a><a id="Tc_M1EqIvuuRUuUIMPUIzrOEQ_3_11"></a><a id="Tc_9NdLDHPEGkm6jRfA9_RDZQ_4_0"></a><a id="Tc_3mff8_4IFUqj4eQ1nrUQ0Q_5_0"></a><a id="Tc_kbkNOLftQUy0Chj7DJRXwQ_6_0"></a><a id="Tc_Bi-pwQVzwUmMgSHZFXuDGg_6_2"></a><a id="Tc_UWWshdgw2USk6BRYmQU0HA_6_5"></a><a id="Tc_XpB_3nJN-kiXNxCJ6PASQA_6_6"></a><a id="Tc_wNw5-XysJ0GlnePvWeLQwQ_6_8"></a><a id="Tc_moSYNvZwXUGDNTNjOOc-TQ_6_9"></a><a id="Tc_MZ7PMwksnE-PLPJeck5kFA_6_11"></a><a id="Tc_W-5lQc8I_0CBneb9q3Llsg_7_0"></a><a id="Tc_u_3b1zuAA0y7DGtTckRDdQ_7_2"></a><a id="Tc_CEShBeE_SEOhUvixOH4yxQ_7_5"></a><a id="Tc_DUXrl0ee40yxlrNHrmkSzg_7_6"></a><a id="Tc_qTvfUpYmDEWpntXoSyvMLA_7_8"></a><a id="Tc_dIGRp-eLvEqBm0POu4H2pQ_7_9"></a><a id="Tc_lsdW2svTTkWZjiOMvRKLmw_7_11"></a><ix:continuation id="Tb_Rcddc5JF9UmIkadB8_ujAw_cont1"><ix:continuation id="Tb_2HzYdCe5tU2gj8Bh70wbwg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-qOWEZ-lG0Wgp-Dc-_n5tA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_9AtN_y00k0a5citVHDRPZg_6_3">38,795</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4PqQOnDumkefao8imFFhKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_506xKTJtPUOOLFPNDEO--g_6_12">38,795</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_L_Yrm18-ZEq_KotDl6_Nmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_SaqkN4aGnEmSPL9aefvhEQ_7_3">38,795</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_voVae7De2EOf0pczy20g7A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_DRh4bI0zAkOL9GnHRNJ63g_7_12">38,795</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Cash and Cash Equivalents</b>&#8212;Cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="Narr_BZSlmw06IEuITN5aOitnKg">291.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="Narr_4EhDDXLbjkufQnxzb6nTHw">39.0</ix:nonFraction> million as of December 31, 2021 and December 31, 2020, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. &#160;&#160;&#160;&#160;&#160;&#160;&#160; </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_4439994e_c12a_44fc_ae1d_e089e899f7f2"></a><a id="Tc_GluH-Ky8gE--mYh02ZB0IQ_1_2"></a><a id="Tc_agZchYqv-U-uFPtYBKsnGQ_1_5"></a><a id="Tc_dcG64wBPtUaoLjD1G_5eaw_2_0"></a><a id="Tc_y5TSjh2vtkiS198tQCU4jQ_2_2"></a><a id="Tc_-DczvdjFHE2exU5cU0S_7g_2_5"></a><a id="Tc_uCLi7ClbcEiAodIXOzhmAQ_3_0"></a><a id="Tc_GMxMMqlUgU-4hPWrtbGrMQ_4_0"></a><a id="Tc_HNHct21CCkG3CQ0yvd-60A_5_0"></a><a id="Tc_hXcnI9IZFUy3OfcHZHaN4g_6_0"></a><a id="Tc_xS-VxK40Xku45b19AJ_NeQ_7_0"></a><a id="Tc_lg0u33Jo5k-H-rTMqXhNOQ_8_0"></a><a id="Tc_s6UOAIsnZkqk6Wzz88GpOQ_8_2"></a><a id="Tc_Flmmczzjok6AYtBjE0pMtg_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_UeqvlguW8EWxQpy-sMzfaQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Property and Equipment, Net</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_Vy7HZexLZkaT3DNNJZJmwA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following at December 31 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QYNTB61VYUat6jQAfNj3sA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_y-8rHVTCiEqjjM3XtBlYew_2_3">5,988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__p-8KrZhskSQeQtAxAXVcg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_XenRoklIb0q5MRWLqMao-A_2_6">2,121</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wcmbqMPhOU6rzqEZYMNIYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_nT_5W3s2Q0ecngjak9_e0g_3_3">96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_QjA51H3Ah0aFo7MeOknVsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_fU8A9wTqD0SNtWN8k05fdQ_3_6">18</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Ue4SlaWOQ0KyF4HIsqdP3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_njm-IEFlQUSyTlBqtyCgNQ_4_3">37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DeQYlMJLU0-AyRtM2oqjfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Gc8ZGMERVU2tqCvS2NjESg_4_6">22</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_fyE8largOkCW__YS3RTN3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ae2mS9FXTEqjviKLFeGrlw_5_3">1,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3wtllMeGF0-uvRoiD-yA9w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_cIZy097rQEuGGuVYpKrCZQ_5_6">1,253</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_klDyXqGEvkekis8UA3gUqw_6_3">7,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_dUixvCtyQ0OYo50ABcr5Fw_6_6">3,414</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_eziH4b09y02DrFVcZoVKUw_7_3">1,416</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_PA--SlK5Fk6dJTCuoVfIwg_7_6">377</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_v0q4n3qksEyWSMySkbDzDw_8_3">6,261</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_nJtHn-Sgd0elclszFzAy9Q_8_6">3,037</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Depreciation expense for the years ended December&#160;31,&#160;2021 and 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_v3E2RPm9EU-bNkLu4DME4g">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="Narr_K-8u2p6MiEK56eDT_DyCMw">0.3</ix:nonFraction> million, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_24ac3992_c59e_458a_9088_d8fe857a1094"></a><a id="Tc_zTH38U3hSECD7Gdm8dxBQg_1_2"></a><a id="Tc_Uow3wh_I6ky28CFqEyXc3g_1_5"></a><a id="Tc_ffflUhQRiky7sj2yj7N63w_2_0"></a><a id="Tc_H9KqA0Ar-UmtgBam1lGJ_Q_2_2"></a><a id="Tc_961eZk3IZEaV8rQvOp-dZw_2_5"></a><a id="Tc_4xLOUpchmkiGp-Y9NPfZHw_3_0"></a><a id="Tc_3GWD9e5HAkSS_oEIoXEp1g_4_0"></a><a id="Tc_GV3fadVn7UGYm9pL941a7g_5_0"></a><a id="Tc_ifEQOpuC_kCZ5yN4Y9Lmdg_6_0"></a><a id="Tc_9kkjm8Rtak2Z6dBNjnvhDw_6_2"></a><a id="Tc_m4HRdO9f7EW1WTo7IMyBVQ_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="trda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" id="Tb_MCa0xMoO4USYoDFp1a_kVw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Accrued Expenses and Other Current Liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_Ma5ns-BZdEuuAB-bBRSuWg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following at December 31 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_Z7yQl9HIlUufZty5xfaQRA_2_3">4,077</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_vbR0K6f4SUSwyzKKWs3m4g_2_6">1,482</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">External research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="trda:AccruedExternalResearchAndDevelopmentExpensesCurrent" scale="3" id="Tc_fIQUa7EgckS-6gK3NTVdKA_3_3">1,032</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="trda:AccruedExternalResearchAndDevelopmentExpensesCurrent" scale="3" id="Tc_szaIvpaePEK7fe28mghE3A_3_6">125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative professional service expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_WM-LkmX9QE-a7Q1tkW50Rw_4_3">419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_tf7SQOv8dU-rGjRk-ynACQ_4_6">35</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_vbSpfJB0xUejA2lmlEcdGQ_5_3">485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_pSn_Oa2APk6JCq1ESrwzOw_5_6">115</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_2b6T9g-bF0GAz4tUNVnZzA_6_3">6,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_QoKZAxIyPEC7mFRniV0gaA_6_6">1,757</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="trda:TemporaryEquityCommonAndPreferredStockTextBlock" id="Tb_Mv54TxLFC0-4T5198ptODA" continuedAt="Tb_Mv54TxLFC0-4T5198ptODA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Redeemable Convertible Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Upon the closing of the IPO in November 2021, the Company&#8217;s Preferred Stock automatically converted into <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_11_30_2021_a0-v3caGu0mm1ZtiJx365w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_irC8lz_pfkK0rGhmXUapZw">19,185,183</ix:nonFraction> shares of common stock. As of December 31, 2021, the Company did not have any shares of redeemable convertible preferred stock <span style="-sec-ix-hidden:Hidden_pW9XlBHI-0ycz6y8QY0knQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorized</span></span>, <span style="-sec-ix-hidden:Hidden_nO6qA4U-90qR30UGTnbjfg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> or <span style="-sec-ix-hidden:Hidden_BSNci6dkMUiwQdU7Toounw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>. Redeemable convertible preferred stock consisted of the following at December 31, 2020 (in thousands, except share amounts):</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9ea7dd63_6b4f_49cb_85d4_9355cc5257d8"></a><a id="Tc_nL_DqXIjzEuGpJ9msvwzoQ_1_2"></a><a id="Tc_CQU7V0OOpEiCvwobMIe0cw_2_4"></a><a id="Tc_wcuxH5CMfUOo4gczJnEXVA_2_12"></a><a id="Tc_wwxCfuRmSkuP4UKDRkps4A_3_2"></a><a id="Tc_xcq15eTrfUavSx4ojv54iQ_3_4"></a><a id="Tc_y43fbyjlUUGZpIxcwb3-0A_3_6"></a><a id="Tc_MQvOpxYkFUiaLT95hr13ag_3_9"></a><a id="Tc_zIp8QSIyL0OoE9Tfoitqug_3_12"></a><a id="Tc_2ayC59IvPkCU4Yp1HybtDg_4_2"></a><a id="Tc_y-mkzM_chked_ixmc5IRZQ_4_4"></a><a id="Tc_vTkXY3SrrkWQeqvedw_Svg_4_6"></a><a id="Tc_nSSyT8wazEaNKJxNp0l2DA_4_9"></a><a id="Tc_XIBMk_6wy0yf1TGWom8Vdg_4_12"></a><a id="Tc_jnkSwtV6FkGOo3UTSUCLTA_5_0"></a><a id="Tc_bTG2ib6HFU-2olyCkdOZ3g_5_6"></a><a id="Tc_134kjzpi9kOrii0ewRZukg_5_9"></a><a id="Tc_thjv6sWgl0yKxWg_FBkwmg_6_0"></a><a id="Tc_CgHyikTsoUaiflLY9xfTKA_7_6"></a><a id="Tc_CCxgcxSHo0ORs7RGHm0kIQ_7_9"></a><ix:continuation id="Tb_Mv54TxLFC0-4T5198ptODA_cont1" continuedAt="Tb_Mv54TxLFC0-4T5198ptODA_cont2"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:TemporaryEquityTableTextBlock" id="Tb_sN7owq16MEqsPUMZwj7JsA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:70.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuable&#160;Upon</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series Seed preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_lTEqb7tLC0WlLxSzSoPt3g_5_2">2,420,746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_MRiCANpNYE-JINtEo3wiNg_5_4">2,420,746</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_YfiOCqf-mUq6Ey2oUFYapQ_5_7">2,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_6VEkxH91K0G-k1JOsVTeSg_5_10">2,100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Tc_1rcMcuMlEki7EG_rL4X-7w_5_12">334,547</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_0p7TG07V3EKfnFPoj_G-_w_6_2">82,879,139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_jr9Z-pYE2Ui0ImGW-h35aw_6_4">82,879,139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_xP13NDczPkeOMcKRtZgV6w_6_7">79,597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_vl2OkmizhUS5q1I3qug0tA_6_10">86,277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Tc_SvGQlNKTu0a-LOOExjTYkw_6_12">11,453,888</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Tc_FrgXnm9LGUSQ4ZPJQWY1UQ_7_2">85,299,885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Tc_Kv04s5Zbw0y3AGuzl-FdXg_7_4">85,299,885</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_G2GA4nHdUEGie7DCFbXOOA_7_7">81,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="Tc_iN6KaSasP0yz8pjaRtBJNQ_7_10">88,377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Tc_tcW_08295EqRnMUg3BXHMg_7_12">11,788,435</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On October 27, 2016, the Company entered into a Series Seed Preferred Stock Purchase Agreement, whereby the Company issued an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_10_27_2016_To_10_27_2016_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_-En8tjRnnUC9eKmjOLrxDg" decimals="INF" format="ixt:numdotdecimal" name="trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_yq1gBerHHk6NARSDeJ6KTQ">691,641</ix:nonFraction> shares of Series Seed redeemable convertible preferred stock (Series Seed Preferred Stock) at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_10_27_2016_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_GsM3bvleAkui8rQ0h-Ql9g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_RYQL_MdKCkGZPz-cDGGL8w">0.8675</ix:nonFraction> per share for aggregate proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_10_27_2016_To_10_27_2016_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_-En8tjRnnUC9eKmjOLrxDg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="Narr_2UVQGNE6_EycJWWZUvz-Ng">0.6</ix:nonFraction> million. On March 3, 2017, the Company entered into a second closing of Series Seed Preferred Stock, whereby the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_3_3_2017_To_3_3_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_3gJUFiFT7E-8naW-uk6dqw" decimals="INF" format="ixt:numdotdecimal" name="trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Gjbpptmfd0O7xRml9cXHKQ">576,368</ix:nonFraction> shares at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_3_3_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_0aluTUFCZU6jYAc_CRSl2A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_3S5GzIX_Ak-S4SLWLw5fvQ">0.8675</ix:nonFraction> per share for aggregate proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_3_3_2017_To_3_3_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_3gJUFiFT7E-8naW-uk6dqw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="Narr_hW8me4TCNE2IWmoW3bElqg">0.5</ix:nonFraction> million. On May 16, 2017, the Company completed the milestone closing of Series Seed Preferred Stock upon the satisfaction of stated milestones pursuant to the Series Seed Preferred Stock Purchase Agreement. In connection with this milestone closing, a total of <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_5_16_2017_To_5_16_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_2d5Zkg5ROU2FOzEjN1-Wlw" decimals="INF" format="ixt:numdotdecimal" name="trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ltodEoCs1E-a9s85NtcUSA">1,152,737</ix:nonFraction> shares of Series Seed Preferred Stock were issued at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_5_16_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_xATBx4mlJkO_FY67Y7xj6A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_fWkk_G0-d025Xuo6kGMbNQ">0.8675</ix:nonFraction>, for aggregate gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_5_16_2017_To_5_16_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_2d5Zkg5ROU2FOzEjN1-Wlw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="Narr_EK-EFd9jn0KiA_KGHasncQ">1.0</ix:nonFraction> million. The Company incurred issuance costs of less than $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_10_27_2016_To_5_16_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_4mA-_qHs2kGfQFglJrYgww" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_nDDGCFzNsEysM1CWxSsQVQ">0.1</ix:nonFraction> million in connection with each of these closings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On December 14, 2018, the Company entered into a Series A Preferred Stock Purchase Agreement, whereby the Company issued an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ" decimals="INF" format="ixt:numdotdecimal" name="trda:TemporaryEquityAggregateSharesIssued" scale="0" id="Narr_rldAWeivg0CMqCw0syw4oA">34,848,403</ix:nonFraction> shares of Series A redeemable convertible preferred stock (Series A Preferred Stock), <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ" decimals="INF" format="ixt:numdotdecimal" name="trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Hv0FltNvYEiuntvcfrP2xg">24,015,368</ix:nonFraction> of which were issued at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tYP56ACKCEObErEOejmqsg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_L3fxLjgwEUOsNSvygl_9OA">1.041</ix:nonFraction> per share for gross cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="Narr_IEiIVUgKmUeQSoDfWCIHUQ">25.0</ix:nonFraction> million, and <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" id="Narr_3kxJD9RT5Uio-Bb0nAsDhQ">10,833,035</ix:nonFraction> of which were issued in satisfaction of principal and interest on convertible notes outstanding held by the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="Narr_u7j1KxhqWka7Vu_rg8FAiQ">9.0</ix:nonFraction> million. Pursuant to the Series A Preferred Stock Purchase Agreement, the Company also agreed to issue up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ" decimals="INF" format="ixt:numdotdecimal" name="trda:SharesIssuableUponAchievementOfCertainSpecifiedMilestones" scale="0" id="Narr_NB3ickUhhEWwE1_705U8-w">24,015,368</ix:nonFraction> shares at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tneHEayNbkCaFY8W_qAw-g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_Me5iNb-9bUu9GdPlMRJAIA">1.041</ix:nonFraction> per share upon the achievement of certain specified milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January 22, 2020, upon waiver of stated milestones in the Series A Preferred Stock Purchase Agreement, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_22_2020_To_1_22_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_xzJvCpIB60egOnueDPk1DQ" decimals="INF" format="ixt:numdotdecimal" name="trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_3OpPw9XXHU20l7AgypZ6BQ">24,015,368</ix:nonFraction> shares of Series A Preferred Stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_1_22_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_epyOIcPzq0SVrlfXNg7yEg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_xCtD-xCR-ES64pyP-ZOYaw">1.041</ix:nonFraction> per share for aggregate proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_22_2020_To_1_22_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_xzJvCpIB60egOnueDPk1DQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="Narr_8s31KXKkB0eQsd8LR6ufUQ">25.0</ix:nonFraction> million. The Company incurred issuance costs of less than $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_22_2020_To_1_22_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_-1_Yd9urDk-m9ncpSMWkLA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_nkNi3Wd7U06jnWK8MctaDA">0.1</ix:nonFraction> million. Pursuant to the Amended and Restated Series A Preferred Stock Purchase Agreement, on August 12, 2020, the Company agreed to issue an additional <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_8_12_2020_To_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_z6226-NgvE6yUlb-QpUJqg" decimals="INF" format="ixt:numdotdecimal" name="trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_yPrCKZnx8Eubc38l5MIaAw">24,015,368</ix:nonFraction> shares of Series A Preferred Stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_7VWTG_vPyUKvAaUWm3BT8w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_B-CgPauC00aOoaWDknJiiw">1.041</ix:nonFraction> per share for aggregate proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_8_12_2020_To_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_z6226-NgvE6yUlb-QpUJqg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="Narr_vTB5IrzZXUes5AveiJfS9g">25.0</ix:nonFraction> million. The Company incurred issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_8_12_2020_To_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_z6226-NgvE6yUlb-QpUJqg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_GjaBLyAYUEO0pOV72SYEXA">0.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 29, 2021, the Company entered into a Series B Preferred Stock Purchase Agreement, whereby the Company issued an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_EV4uTuzkYE6h_aLfr9tQpQ" decimals="INF" format="ixt:numdotdecimal" name="trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_YLw4XARFL028gOLRgIoScg">53,522,099</ix:nonFraction> shares of Series B redeemable convertible preferred stock (Series B Preferred Stock, together with the Series Seed Preferred Stock and Series A Preferred Stock, Preferred Stock) at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_aj5kvebNtEaEwVM3errF3A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_BsKfC-AygUm-o62ze3xTUA">2.172</ix:nonFraction> per share for gross cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_EV4uTuzkYE6h_aLfr9tQpQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="Narr_qFn6JRZS8USDuSTdKeGjgg">116.2</ix:nonFraction> million. The Company incurred issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_EV4uTuzkYE6h_aLfr9tQpQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_zT1VUYQfFkaVAsa08MdTpw">0.4</ix:nonFraction> million. As part of the issuance of Series B Preferred Stock, the liquidation preferences of the Preferred Stock were modified such that, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event, the holders of Preferred Stock then outstanding shall be entitled to be paid out equal to the greater of (i) the applicable original issue price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Preferred Stock been converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company amended the articles of incorporation upon the issuance of the Series B Preferred Stock and the rights and preferences of the outstanding shares of Series Seed Preferred Stock and Series A Preferred Stock were adjusted. The Company considered if the adjustment to the previously issued shares of Preferred Stock represents an extinguishment or a modification to the outstanding mezzanine classified instruments. The adjustments to the outstanding shares of Preferred Stock were qualitatively insignificant. As a result, the adjustments to the rights and preferences of the outstanding shares of Preferred Stock qualified as a modification and no accounting was required as holders of these classes of equity did not receive any incremental value in the transaction.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Upon issuance of each class of redeemable convertible preferred stock, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed on the issuance date of each class of redeemable convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Mv54TxLFC0-4T5198ptODA_cont2" continuedAt="Tb_Mv54TxLFC0-4T5198ptODA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prior to the conversion of the Preferred Stock into shares of common stock upon the completion of the IPO in November 2021, the Preferred Stock had the following rights and preferences:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Each share of Preferred Stock is convertible at the option of the holder at any time after the date of issuance. The number of shares of common stock to be issued in the event of a conversion is determined by dividing the original issue price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_rXp55kz8m0-Oy4jN90htNw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_PJT6xQhb9E-AGqRxnWxMIg">0.8675</ix:nonFraction> for the Series Seed Preferred Stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tneHEayNbkCaFY8W_qAw-g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_oSVoQ_G-SUuDwB8gDLPBYQ">1.041</ix:nonFraction> for the Series A Preferred Stock, and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_WDhCcPxYokqoE__Xm560JA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" id="Narr_O11VYhkoPE6Ae6JM1pNZsg">2.172</ix:nonFraction> for the Series B Preferred Stock by the conversion price then in effect. The conversion price for each of the Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock was initially $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_rXp55kz8m0-Oy4jN90htNw" decimals="4" format="ixt:numdotdecimal" name="trda:TemporaryEquityConversionPrice" scale="0" id="Narr_MBXlMEG0M0y1b6Uzp657bw">0.8675</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tneHEayNbkCaFY8W_qAw-g" decimals="3" format="ixt:numdotdecimal" name="trda:TemporaryEquityConversionPrice" scale="0" id="Narr_cNUsDLmhY0WsaaU80FyZ5Q">1.041</ix:nonFraction>, and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_WDhCcPxYokqoE__Xm560JA" decimals="3" format="ixt:numdotdecimal" name="trda:TemporaryEquityConversionPrice" scale="0" id="Narr_PXIr2gLk6Uy_e7e4z_jngw">2.172</ix:nonFraction> per share, respectively, subject to adjustment under certain circumstances, including but not limited to certain additional issuances of common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Preferred Stock automatically convert at either (i) the closing of a firm-commitment underwritten public offering resulting in at least $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_ydttNEUZL0mEntDbye7NGA" decimals="-6" format="ixt:numdotdecimal" name="trda:ThresholdNetProceedsFromQualifiedPublicOffering" scale="6" id="Narr_uQRgEtmpwUKDfbBKuuylzA">75</ix:nonFraction> million of net proceeds to the Company, upon which all outstanding Preferred Stock shall automatically be converted into common shares, at the then effective Series Seed conversion price, <span style="letter-spacing:-0.1pt;">Series&#160;A conversion price, or Series B conversion price, respectively or (ii)&#160;at the election of the required majority of Preferred Stock holders, upon which all or any portion of the outstanding Preferred Stock shall automatically be converted into common shares, at the then effective Series&#160;Seed conversion price, Series&#160;A conversion price, and or Series B conversion price, respectively</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The holders of Preferred Stock shall be entitled to receive non-cumulative cash dividends, out of any assets legally available therefor, prior and in preference to any declaration or payment of any dividend on shares of common stock (payable other than in common stock or other securities and rights convertible into or entitling the holder thereof to receive, directly or indirectly, additional shares of common stock of the Company) at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_-jrTVd1VsUyOVMX13AXpog">eight</ix:nonFraction> percent of the applicable original issue price per share of Preferred Stock per annum, payable only when, as and if declared by the Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) unless (in addition to the obtaining of any consents required otherwise by the Company&#8217;s restated certificate of incorporation) the holders of Preferred Stock then outstanding shall first receive, or simultaneously receive, in addition to the <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_HUKL6CygQEigBTsPbNDNKA">eight</ix:nonFraction> percent non-cumulative dividend described above, a dividend on each outstanding share of Preferred Stock in an amount at least equal to the dividend payable on each share of such class or series determined as if all shares of such class or series had been converted into common stock. <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:DividendsPreferredStock" scale="3" id="Narr_lFC8sxZ08kurbhBxp3bE0w"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:DividendsPreferredStock" scale="3" id="Narr_EpWLMY7IRU6i0hUE9fCa1Q">No</ix:nonFraction></ix:nonFraction> dividends were declared or paid during the years ended December 31, 2021 or 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Liquidation Preference</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Upon liquidation, dissolution, or winding up of business or a deemed liquidation event, the holders of the Preferred Stock shall be entitled to be paid out the greater of (i) the applicable original issue price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Preferred Stock been converted into common stock. If, upon any such event, the assets available for distribution are insufficient to satisfy the liquidation payment to holders of Preferred Stock in full, the holders of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full<span style="letter-spacing:-0.1pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Voting Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Except as provided by law or by other provisions of the instruments pursuant to which each series of Preferred Stock was issued, holders of the Preferred Stock and common stockholders&#8217; vote together as one class on an &#8220;as-converted basis.&#8221; On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company, each holder of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock is entitled to cast the number of votes equal to the number of whole shares of common stock </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_N2ZR-EEIdkGXcrCOaMK3Gg_1_2"></a><a id="Tc_t5aytTcQfU6QAkiCYxlSSg_1_4"></a><a id="Tc_-vMmpZ2TV0mjR2Od6tA8jA_2_0"></a><a id="Tc_JeMg37yw1kOY623p0CmzqA_3_0"></a><a id="Tc_fbOwB64-UUaz-E-zS6fE0w_3_2"></a><a id="Tc_MMeYJgVnV0iBBnFCqOyO_A_4_0"></a><a id="Tc_p1uGGtZH8EGWAoGYAVAwAQ_4_4"></a><a id="Tc_PrtnjRD5KES2TpIpT1Y-tA_5_0"></a><a id="Tc_Zr9tHtjifESA3iVZZZcL1g_5_4"></a><a id="Tc_8IKpzMSnvUuXnzArPxFFQQ_6_0"></a><a id="Tc_rz50C2da10Wk2HA8fbLVOA_6_2"></a><a id="Tc_ea5mgc_2hk-FRAJOPNYMZg_7_0"></a><a id="Tc_7OXmRcci7kOeA-hVNRNgdQ_7_2"></a><a id="Tc_1k6o7OHJQk6-zPo0yDyp4w_8_0"></a><ix:continuation id="Tb_Mv54TxLFC0-4T5198ptODA_cont3" continuedAt="Tb_Mv54TxLFC0-4T5198ptODA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">into which the shares of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock held by such holder are convertible as of the record date for determining shares entitled to vote on such matter. The holders of the shares of Series A Preferred Stock, exclusively and as a separate class, are entitled to elect <ix:nonFraction unitRef="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tneHEayNbkCaFY8W_qAw-g" decimals="INF" format="ixt-sec:numwordsen" name="trda:NumberOfDirectorsEntitledToBeElected" scale="0" id="Narr_Qetucb4opkuT0Quv34_a9w">three</ix:nonFraction> directors of the Company. The holders of the shares of Series B Preferred Stock, exclusively and as a separate class, are entitled to elect <ix:nonFraction unitRef="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_WDhCcPxYokqoE__Xm560JA" decimals="INF" format="ixt-sec:numwordsen" name="trda:NumberOfDirectorsEntitledToBeElected" scale="0" id="Narr_wn3dn5DzqkSH5FXOzWmS2w">one</ix:nonFraction> director of the Company. The holders of the shares of common stock and Preferred Stock, exclusively and voting together as a single class, are entitled to elect <ix:nonFraction unitRef="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt-sec:numwordsen" name="trda:NumberOfDirectorsEntitledToBeElected" scale="0" id="Narr_We_97RoWlU-qywjwKAC9Hg">three</ix:nonFraction> directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December 31, 2021, the Company&#8217;s certificate of incorporation, as amended and restated effective upon the completion of the IPO, authorized the Company to issue <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_yXuqkcYvjU6Tmu6g5d0jHA">150,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_VkB3yrlLpkOyJ1svwsvKvg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_GcnZLDto0EuxSNKrLPKGOA">0.0001</ix:nonFraction></ix:nonFraction> per share. <span style="letter-spacing:-0.1pt;">The holders of common stock are entitled to </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt-sec:numwordsen" name="trda:NumberOfVotesPerShareOfCommonStock" scale="0" id="Narr_GBw690r3yUKXOAK0WQcIMQ">one</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> vote for each share held on all matters submitted to a vote of the stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. In the event of liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December 31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_XV17NUdTuU-Kzi8g2rmrZw">113,259,306</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_YIRufuI7uUCli1CddMrtpA">0.0001</ix:nonFraction> per share. The holders of common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt-sec:numwordsen" name="trda:NumberOfVotesPerShareOfCommonStock" scale="0" id="Narr_EPvkSgaakU-q_eiJ3U5Vzg">one</ix:nonFraction> vote for each share of common stock. Subject to the payment in full of all preferential dividends to which the holders of the Preferred Stock are entitled, the holders of common stock shall be entitled to receive dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company and all preferential amounts to which the holders of Preferred Stock are entitled with respect to the distribution of assets in liquidation, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Shares Reserved for Future Issuance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reserved the following shares of common stock for future issuance at December 31:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="trda:ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock" id="Tb_rKryZwvgx0OlaMGBVEkVqw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of outstanding stock options</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_BgFK4zqoBECK7m2Ml33zZQ_2_2">3,461,870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JkQZPPgBBUGf-humPcfAMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_wjLl7hBbi0WgHl6kqh-F_Q_2_4">1,625,256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BPELmQx4xEiCTW0PJ5snKg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_JJS-bHAZBUCXB2BN3o7AaA_3_4">11,537</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future awards under the 2021 Plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_5fShMvZuL0CBikfxgEmhJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_MjUMjVV5n0utjwISYd-gBA_4_2">2,843,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future awards under the 2021 ESPP</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_WfsWIAfNmE2sstVPNwOq4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_hXWvDxl6PUaoAcBT24Lqrg_5_2">278,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future awards under the 2016 Plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_trda_StockPlan2016Member_AiSU5Z1vhEGHTV-J1QFVng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_jnI4SChHaUOXkIZksDsuRw_6_4">360,306</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of redeemable convertible preferred stock</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RedeemableConvertiblePreferredStockMember_6iNejRF2DEGk6tYe2YQoHw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_H1Mp89WiIEqZ_gLA140erg_7_4">11,788,435</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of authorized common stock reserved for future issuance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_gMCsO-cpe0m54rO_QsJ5lQ_8_2">6,583,887</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Tc_rFPxzaCV6E6DIdfAPi34Cw_8_4">13,785,534</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Mv54TxLFC0-4T5198ptODA_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December&#160;31, 2021, the Company was authorized to issue&#160;</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_NxKj8krY60qnuGW7lAs9Aw">10,000,000</ix:nonFraction></span><span style="background:#ffffff;">&#160;shares of undesignated preferred stock, </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_NYpYdk_KdEqtXsGSHpiSlA">0.0001</ix:nonFraction></span><span style="background:#ffffff;">&#160;par value,&#160;</span><span style="letter-spacing:-0.1pt;">in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The Company was not authorized to issue any such shares as of December 31, 2020. As of </span><span style="-sec-ix-hidden:Hidden_mKo_OzFuf0iQHjQHrOziTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">December 31, 2021</span></span><span style="letter-spacing:-0.1pt;">, there were </span><span style="-sec-ix-hidden:Hidden_Q1xy7BMWbEaf-hfVggNTxg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">no</span></span><span style="letter-spacing:-0.1pt;"> shares of undesignated preferred stock issued or outstanding.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_f9HoOHR240-S6uW9pv8KJA" continuedAt="Tb_f9HoOHR240-S6uW9pv8KJA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2021 Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In September 2021 the Company&#8217;s board of directors adopted, and in October 2021 the Company&#8217;s stockholders approved, the 2021 Plan, which became effective as of the date immediately prior to the date of the effectiveness of the registration statement for the IPO. The 2021 Plan allows the board of directors to grant </span>incentive stock options or non-qualified stock options, restricted stock, restricted stock units, and other equity awards <span style="letter-spacing:-0.1pt;">to the Company&#8217;s officers, employees, directors, and other key persons. </span><span style="background:#ffffff;">In addition, the 2021 Plan includes a provision that allows for an automatic annual increase of </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_nCvXJPkm-EeVgL-HAKzWCg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_bzNphac1fk6Z8H1uugHQMQ">4</ix:nonFraction>%</span><span style="background:#ffffff;"> in the number of shares of common stock available for issuance under the 2021 Plan.&#160;</span><span style="letter-spacing:-0.1pt;">The 2021 Plan replaced the 2016 Plan and </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_nCvXJPkm-EeVgL-HAKzWCg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_tkZW7H21uUGm-Ax-xpVgZw">no</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> additional awards will be granted under the 2016 Plan following the closing of the IPO. The 2016 Plan will continue to govern the outstanding equity awards granted thereunder. The total number of shares of common stock authorized for issuance under the 2021 Plan as of December 31, 2021 was </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_5fShMvZuL0CBikfxgEmhJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_ZHpOA6y2XkybuicFnFs7_w">3,986,270</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> shares. There were </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_trda_StockPlan2021Member_XN77OWOzXkC7szS4MrVGTQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_CEapZSinn0KK4gGQwaM5fw">no</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> shares of common stock authorized for issuance under the 2021 Plan as of December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December&#160;31, 2021, the Company had issued only stock options under the 2021 Plan. Stock options issued comprise of service-based awards granted to employees. Vesting of stock options is subject to the recipient&#8217;s continued employment or service.</span> The maximum term of options granted under the 2021 Plan is <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_nCvXJPkm-EeVgL-HAKzWCg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_9nfesaqDp0udNrLwyoD8GA">ten years</ix:nonNumeric>, and stock options typically vest over a <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_nCvXJPkm-EeVgL-HAKzWCg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_vLypdG6QBE6kqK4slRu4PQ">four-year</ix:nonNumeric> period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">2021 Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">In September 2021, the Company&#8217;s board of directors adopted, and in October 2021 the Company&#8217;s stockholders approved, the ESPP, which became effective as of the date immediately prior to the date of the effectiveness of the registration statement for the IPO. The ESPP is administered by the person or persons appointed by the Company&#8217;s board of directors for such purpose. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_10_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_eX6Qkp3pp0eD-g-WpjcsYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_OdVurPewv0aeU5HZ20ykLQ">278,762</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> shares of common stock. The number of shares of common stock reserved for issuance under the ESPP will automatically increase on January 1st of each year beginning in 2022 and continuing through and including 2031 by the least of (i) </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_jPFYwfOyHkibNEeOW_EYTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="Narr_ORlra2IR-UOH7Uy_NYQ97A">1</ix:nonFraction>%</span><span style="letter-spacing:-0.1pt;"> of the outstanding number of shares of our common stock of the immediately preceding December 31, (ii) </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_10_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_eX6Qkp3pp0eD-g-WpjcsYA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_TPhWXEs5S06dk4QBYFVfCg">557,524</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> shares or (iii) such number of shares as determined by the ESPP administrator. As of December 31, 2021, no offering periods have commenced under the 2021 ESPP and </span><span style="letter-spacing:-0.1pt;"><ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_q07zOZMvO0O0qAOZXAgC6A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_uP30eIhc2U-ipNo89X_QWw">278,762</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> shares remained available for issuance. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2016 Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The 2016 Plan provides for the Company to grant incentive stock options or non-qualified stock options, restricted stock, restricted stock units, and other equity awards to employees, directors, and consultants of the Company. The 2016 Plan is administered by the board of directors of the Company or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting, and other restrictions are determined at the discretion of the board of directors, or its committee if so delegated. The 2016 Plan allows for early exercise of all stock option grants if authorized by the board of directors at the time of grant. The shares of common stock issued from the early exercise of stock options are restricted and continue to vest over the original service based vesting condition of the original stock option award. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The total number of shares of common stock authorized for issuance under the 2016 Plan as of December 31, 2021 and 2020 was <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2016Member_WSANhifLkU2A9s4mVWiePw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_4qGR83RKZUmJFYUM8cV4YA">2,318,855</ix:nonFraction> shares and <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_trda_StockPlan2016Member_AiSU5Z1vhEGHTV-J1QFVng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_q2k5_EdaqkWdo_cw3RhXjg">1,997,099</ix:nonFraction> shares, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_872c8aa0_2c63_4436_bb89_d550bf87b518"></a><a id="Tc_EKlXLSNoZ0eiDL8u0ESOMg_1_2"></a><a id="Tc_dbIRlNyyXUC57-0vG4_WWA_2_2"></a><a id="Tc_XNyMDFRNdUOP51vmWf0KFg_2_5"></a><a id="Tc_3IE8vHiSKUuKb9NNprnSCA_3_0"></a><a id="Tc_tejpqlgqV0KCKB-xiZnTOA_3_2"></a><a id="Tc__rB_wdCefkqHgTuog6fJrQ_3_5"></a><a id="Tc_sqjyD2pP_0SNVw11PG-52g_4_0"></a><a id="Tc_tsZdC6tU_keA9CHqbjH46Q_5_0"></a><a id="Tc_dPfPn4v26k29hVEmxh-eaQ_5_2"></a><a id="Tc_LVa3alGSIk-8ECdI0hIvpw_5_5"></a><a id="Tc_WgfbMXEIKkSo1dWrcntoTQ_1_2"></a><a id="Tc_Unc9K_OfxESoW4_hXfpMqg_1_4"></a><a id="Tc_djyJu4WOX0yp-5NyhpGNIg_2_2"></a><a id="Tc_QtA9EnhVbkqfCMZ6JAzalg_2_4"></a><a id="Tc_xB3nM6nFCkeHRJKqj1lgdQ_3_0"></a><a id="Tc_W1uq102fyUCcODIKaHsDqw_3_3"></a><a id="Tc_ukGfn9-LX0ufOxvtspvsRg_3_5"></a><a id="Tc_o3VsIYhPEEWI0GNygPmhpQ_4_0"></a><a id="Tc_-1Y0eJPtZkSLZAzpWv15yA_4_3"></a><a id="Tc_RP7pbHA6B0KiQHwG-YQSiw_4_5"></a><a id="Tc_lC6FqAfnZEC65QaADFZtuQ_5_0"></a><a id="Tc_K9aCceySMU6eTp9kwjwkCA_5_2"></a><a id="Tc_wZO1jhlEOEavHclP1IIUGA_5_4"></a><a id="Tc_DheZcbc5ekutN6tvIg09Gg_6_0"></a><a id="Tc_rTJA0LYcQEC2gXV351KwQw_1_4"></a><a id="Tc_puhyk3m4r0OOEyvg5tTD-A_1_7"></a><a id="Tc_m61ZrZCFP0Cj4hHVvx0_0w_2_4"></a><a id="Tc_Rjaj_E8O0UabFd9fyvwOuw_2_7"></a><a id="Tc_5Wl9zpm080izaWmpc04cNA_2_9"></a><a id="Tc_pVzpTbDGM0G7PqeXaqOPKg_3_2"></a><a id="Tc_bdtIVROiCkClFltFyTl3jQ_3_4"></a><a id="Tc_krvpTi7cJ0Kb-8aG6aVpmQ_3_7"></a><a id="Tc_V_kuF4DGwUCkRyUTi-DDxw_3_9"></a><a id="Tc_wBBTVcqizUmn5_nSW5FE4w_4_2"></a><a id="Tc_32pRinDswUCAgC6cgtHZIA_4_4"></a><a id="Tc_uq7p4_uvO0-BdNwTb2NrRw_4_7"></a><a id="Tc_7l3Q_r1vlkWySh_glxKwTA_4_9"></a><a id="Tc_4SKptuiguEiBA2wmbkvT3A_5_7"></a><a id="Tc_IHy8VMyQ8EKrxegEH7-MAg_5_9"></a><a id="Tc_1gJeivCnc0OAwXP2sMX5EA_6_0"></a><a id="Tc_5hldQq-YUEGdbjHGv5dHhA_6_4"></a><a id="Tc_b7yyVshGtUKjN-pfWkIv4g_7_0"></a><a id="Tc_dpqw6S5axUqxOTpkn2gINw_8_0"></a><a id="Tc_W6ULYkdLKES7r3pVPIwTMg_9_0"></a><a id="Tc_dNxNCyhi4EiDFMQOgC687g_10_0"></a><a id="Tc_epC16qNE00qLwPrAa3vUWA_10_4"></a><a id="Tc_gxgUSVMlnUC6yyT_c3oQ0Q_10_9"></a><a id="Tc_gOU_3rw9ekmaqq8aNs67sQ_11_0"></a><a id="Tc_z5FsuEHTQkWvewo_75am_w_11_4"></a><a id="Tc_DfMBzEl5JkOuTgvVAd010A_11_9"></a><a id="Tc_XvZPR_8LokqG32758am0Gg_12_0"></a><a id="Tc_0hkxsph15Uur07C8eToyEQ_13_0"></a><ix:continuation id="Tb_f9HoOHR240-S6uW9pv8KJA_cont1" continuedAt="Tb_f9HoOHR240-S6uW9pv8KJA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For the years ended <span style="letter-spacing:-0.1pt;">December&#160;31, 2021 and 2020, the Company recorded stock-based compensation expense of </span><span style="letter-spacing:-0.1pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_A-wCPtJE_0KfWskR0Y2B3Q">2.5</ix:nonFraction></span><span style="letter-spacing:-0.1pt;">&#160;million and </span><span style="letter-spacing:-0.1pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_Z7Jqff73O0Oz8AS9JZOY-A">0.3</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> million. Stock compensation expense for 2021 and 2020 included less than </span><span style="letter-spacing:-0.1pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_zsGA-ZYjak2Nkhe-ZCUNNg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_VU0nA4yJpEKCFQ9b0Szwwg"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W6iQ9yRAYE2F1wZofX493A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_IgYByknv4kS6lhbDfRTAnQ">0.1</ix:nonFraction></ix:nonFraction></span><span style="letter-spacing:-0.1pt;">&#160;million related to restricted stock in both years and </span><span style="letter-spacing:-0.1pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_6180Mb-bUEeE1MaA_TRpqA">2.5</ix:nonFraction></span><span style="letter-spacing:-0.1pt;">&#160;million and </span><span style="letter-spacing:-0.1pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_0-ko5Z0Ws0K8qxFGP02ZUQ">0.3</ix:nonFraction></span><span style="letter-spacing:-0.1pt;"> million related to stock options in 2021 and 2020, respectively</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb__B0iqFpTIkSkS4HklInlyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense recorded as research and development and general and administrative expenses in the consolidated statements of operations is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_F-9SRQC7hkatUiZQujCAMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_XCokP_zew0uw1F7m2bDQWQ_3_3">878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_l7f8215TfUmkc3xqHhvUwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Rsss8ealskO4QKsabqotBw_3_6">107</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tD1C2qFg_0-xasA5fL3IOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_l0Qgpcze-USYKjFGg6p2Sw_4_3">1,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynIvbasOrkmhLq6FFmJ_CQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_l5w-cnMl9kC1pjavFoFlPQ_4_6">218</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_U-NZUjxmNkmpZA1vy5VviQ_5_3">2,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_6OotLqEIK0yV84-9LAhczg_5_6">325</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Valuation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents, on a weighted-average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted for the years then ended:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_KKLcvaUmk0u5CtFrKGdfLw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_6L91JsRI2UaaV69vuYUDcw_3_2">1.15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_yoOt1yHpJEGBkVTFU3bX5g_3_4">0.53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_4vkMp8vxOkSbcDHPklqB3w_4_2">73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_hA932ozHOEK3YFHMYaATzw_4_4">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_Jo_H5-SuQ0SGeI2ytXMwbw_6_2"> 6.01</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_YA315NJ3Wk-IJLa_FkjanQ_6_4"> 5.99</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Early Exercise of Unvested Stock Options </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding shares until those shares vest according to their respective vesting schedules. Cash received from employee exercises of unvested options is included in current liabilities on the balance sheet. Amounts recorded are reclassified to common stock and additional paid-in capital as the shares vest. Vesting can occur in the year of exercise and thereafter. There were <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Narr_6EN44ylJjU-MsQdDoIK7kg">111,756</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Narr_-nTLC0FySkKCvNiEpL1w4Q">27,869</ix:nonFraction> unvested shares related to early exercises of stock options as of December 31, 2021 and December 31, 2020, respectively. In the years ended December 31, 2021 and 2020, the liability associated with the unvested early exercise of stock options was $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-5" format="ixt:numdotdecimal" name="trda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount" scale="6" id="Narr_Pc1O96LojUeHlwfSkYqGWQ">0.3</ix:nonFraction> million and less than $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-5" format="ixt:numdotdecimal" name="trda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount" scale="6" id="Narr_s0nRZEd8-k-VXPy8CcCDMg">0.1</ix:nonFraction> million, respectively.<span style="white-space:pre-wrap;background:#ffffff;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s stock option activity since December 31, 2020:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_--U7SxNUpkm0wt8_Wy1IKw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (2)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JkQZPPgBBUGf-humPcfAMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_YWRus_FXy0CQx-iMfKU4wA_6_2">1,625,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JkQZPPgBBUGf-humPcfAMQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_p318sVHiFk2WgtBgwqjgTg_6_5">1.88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_pINzMoEC5EO1pSaSweEx2Q_7_2">2,311,485</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_eLGnqjzJ0k2f7pQzTwdHRg_7_5">14.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_j_m9XnMF7U-b2S9e1KuZ1A_8_2">431,687</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_UGQLizPzyEuAyJCMpa-L9g_8_5">2.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_DozPleY3PkeYdwE-iaHlSA_9_2">43,184</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_mi78nER3zUOz7TGAbcu1Og_9_5">3.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_WnF-gEea0061HSwEp4LG4g_10_2">3,461,870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_vLrkKJifWEmyMX5LJCOWUw_10_5">10.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_7UlKvkjzu0qqy1_1EZv3zw_10_7"> 9.12</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_WMfuq-9S3kWiEd5t0K2mAA_10_10">26,730</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2021 (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_ZzD45y8jnEeWP7r40R9CTA_11_2">2,359,876</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_w_ps4l9sbUScnad4j8fKbQ_11_5">5.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_9WGMz-dfpEWustc3dvdj4A_11_7"> 8.79</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_Cj8Bt42RjUSYOmAveACWlg_11_10">26,730</ix:nonFraction></p></td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(1) This represents the number of vested and unvested options exercisable as of December&#160;31,&#160;2021.</p></td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(2) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December&#160;31,&#160;2021.</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_ed4zobHTe0eHJEoiuuxITA_1_4"></a><a id="Tc_L_nmErn21k-qc7ne6V581w_2_4"></a><a id="Tc_H1_ufnUhg0KmUUvs3-_gWg_3_4"></a><a id="Tc_6iKYE_PGPk2x7OqtsuAMqg_4_2"></a><a id="Tc_hiycRsqrOUGz5Q4dxCyi9Q_4_4"></a><a id="Tc_SgJhuWfrqEG-y2QKtzCi2w_5_0"></a><a id="Tc_3Tah7qJhW0uTzSgPG6augQ_5_4"></a><a id="Tc_6xbMknpIn0CTNPs0b9XQkA_6_0"></a><a id="Tc_II7C6j2qM0msqmUw5tWQwg_7_0"></a><a id="Tc_lYY4zlRyn0CLUymVQdC2ow_7_2"></a><a id="Tc_sb_0SIFagECdNCyp6zsTaQ_7_4"></a><a id="Tc_mjkG2kZcx0q4ZS_57Pm03Q_7_5"></a><ix:continuation id="Tb_f9HoOHR240-S6uW9pv8KJA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_jy20Vql5r0GCNeNqamfumQ">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_JzaflrqpdEO3D7ApPiRsZQ">0.1</ix:nonFraction> million, while the company received $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="Narr_wuXq9np3sUmMaQyxiUHQOQ">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="Narr_F2EeAquncECBUdV3_bzZKA">0.2</ix:nonFraction> million in proceeds for the exercise of these options, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_xGPKJlSGp0GiyRDM6J9kNA">9.39</ix:nonFraction> per share and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_2VqcucQY80Ky-gpiHlxWoQ">1.56</ix:nonFraction> per share, respectively. As of December 31, 2021, there was $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_1lqSVRd0xEG1E1QdkrLMKQ">20.9</ix:nonFraction> million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_YSrcERSG_0GSSZxsKJDbXg">3.5</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Awards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company issued restricted stock to its founders and certain officers of the Company. In general, the shares of restricted stock vest over a <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_djIfGJUG3UerKSFCe6I17g" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_-9IVLiEu00-cRufRdNZTfg">four-year</ix:nonNumeric> period, with <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_RWcJH0PTE0iREP0s53rf8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_2Hu71W6wGUC2PDv4wV4SjQ">25</ix:nonFraction>% of the shares vesting after <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_RWcJH0PTE0iREP0s53rf8A" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_uZTWcHdqP0OnMRWXz8G5cQ">one year</ix:nonNumeric>, followed by monthly vesting over the remaining <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_Tt00y1mV6kiK5B4cvFJE-Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_lFiO69cu3U-lN_7uDsoasg">three years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If the holders of the above restricted stock cease to have a business relationship with the Company, the Company may reacquire any unvested shares of restricted stock held by these individuals for the original purchase price or fair value, whichever is lower at the time of repurchase. The amounts received to date for the purchase price of restricted stock are immaterial. The unvested shares of restricted stock are not considered outstanding shares for accounting purposes until the shares vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A summary of unvested restricted stock during the year ended December 31, 2021 is as follows<span style="background:#ffffff;">:</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Tb_OUDHlK2AyU-H23iRr59XOg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BPELmQx4xEiCTW0PJ5snKg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_ywwmdFsBjE-s1Y-DoIfNTw_5_2">11,537</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BPELmQx4xEiCTW0PJ5snKg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_OUVpqs2M0UyA3tANOcja3g_5_5">0.007</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_djIfGJUG3UerKSFCe6I17g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_nXFjv2FZOEO8x8E1n1r2GQ_6_2">11,537</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_djIfGJUG3UerKSFCe6I17g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_4JalRmwmxEG-xlU-o04Ueg_6_5">0.007</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The total fair value of restricted stock vested during each of the years ended December 31, 2021 and 2020 was less than $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_zsGA-ZYjak2Nkhe-ZCUNNg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_VjOh7KC2bkyaLOAjZeVO2w"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W6iQ9yRAYE2F1wZofX493A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="Narr_iWvmqFdtXEGy8Nv28pSqAA">0.1</ix:nonFraction></ix:nonFraction> million.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_XPzFrRoY0k6_LA_vjwg8KA_1_2"></a><a id="Tc_kQ0ZhAl5RUqgNpoSDp2S8w_2_2"></a><a id="Tc_RMzjUjFC10KT73XxQmwuXg_2_5"></a><a id="Tc_hoxv_HG_Eka5OVVcW_CjHA_3_0"></a><a id="Tc_66P3VLFLUE6BKG-xeQ2ptA_3_3"></a><a id="Tc_nGjvmDeIXU6VBEri2HdiFQ_3_6"></a><a id="Tc_ufnc4Zb1o0awk4LsdWtOrQ_4_0"></a><a id="Tc_zimUZUuH-EuLlhoYS3kLAA_5_0"></a><a id="Tc_4wVl55cRLkCCjaBxd88jTg_6_0"></a><a id="Tc_JiW0-Tt8hkO9uLNjWfXqUQ_7_0"></a><a id="Tc_kCfcoVbkP0m6k4ZgIaunmw_8_0"></a><a id="Tc_HJzRsISvck2vECZrWjbR8Q_8_3"></a><a id="Tc_SR2kkOBCI0qqqGJwTrkExA_8_6"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_NHSpwZiKS02sd4jG_Cyuwg" continuedAt="Tb_NHSpwZiKS02sd4jG_Cyuwg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">For the years ended December 31, 2021 and 2020, the Company recorded </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_cOp-lYDXoESNf9bA1vmOeg"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="Narr_kIwLC2X0TEar2WLVbp9oRg">no</ix:nonFraction></ix:nonFraction></span><span style="background:#ffffff;"> income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each period, due to its uncertainty of realizing a benefit from those items. All of the Company&#8217;s operating losses since inception have been generated in the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_tv5LjI4ogUW8KbrQ1W3GkA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_poEvJEWuUEWxjFf6YVDAOg_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_sm7-fnqwYUOtwpQO7JIIcA_3_5">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_n43R4BJjYU2qvQUw8HYhwQ_4_2">6.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_koROORTcyEW1GOH97Tox3Q_4_5">6.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_yWKBbDjhwk6hPqCP0vnhTA_5_2">3.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_gIZjj7QTUE6msdhft-CgEw_5_5">4.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_6wDHlVMf2UCfbvorQF8Eqw_6_2">0.3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc__QxZxaZNj0G-SdjHipMQgA_6_5">0.2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in deferred tax asset valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_m5t_YdVZoUKCkfBznjen3A_7_2">30.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc__kA0J4gM3Ui1xUXH1q2XVg_7_5">31.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_EcmWlvh2TEiknBczU408Mg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-KTlssYZZU-m9cyJXvqw1g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_49df24a4_dc3a_42d8_b1f9_eedad5f00f40"></a><a id="Tc_-fJQw1RT6E2RYl7Wu8SRHQ_1_3"></a><a id="Tc__sgFe18Xu0azLPbGe-bbIQ_2_3"></a><a id="Tc_uZv4-oMJI0eGm88yEMXVMA_2_6"></a><a id="Tc_YCpG3mVuDUmE3ss_-lxYSA_3_0"></a><a id="Tc_UmBKkkS8tEu-FwgDiXZ_Gg_4_0"></a><a id="Tc_hiqNeRxKGk-rajSyscS9lg_4_2"></a><a id="Tc_B6ncqhA7xEGgoQ4chDsd3w_4_5"></a><a id="Tc_WD72Kvsk-kepo9mK7RxMyg_5_0"></a><a id="Tc_RmuVEeyJsE-DCd2orNiDOA_6_0"></a><a id="Tc_VTGwf2FfHkWCMD-DCxyPlA_7_0"></a><a id="Tc_7wyBaQ-Gy0yeoDi50LB4dw_7_3"></a><a id="Tc_NOa4O3NFsE6DhDkBlXd9ow_8_0"></a><a id="Tc_fsjJHtHvjU-4ryNHtoI3jA_9_0"></a><a id="Tc_KmDyHL_5gkypVNKSL3amgg_10_0"></a><a id="Tc_GcEMW4No5E-3j8v85gBvwg_11_0"></a><a id="Tc_X08gujMUbU-2vslww_NACQ_12_0"></a><a id="Tc_iMWuEg80GUyiRppIU0peFA_13_0"></a><a id="Tc_W_mB0HXxpESmE65ZO6ImMQ_13_6"></a><a id="Tc_XAjdpQUJNE-yrPlkz_G00g_14_0"></a><a id="Tc_T84u8bRzskmcDeN7bsdxMA_15_0"></a><a id="Tc_llJrQ6Guh0Gvf2lCydvGeQ_16_0"></a><a id="Tc_NOLITxcmH0Sepfgr8TYJ4A_16_2"></a><a id="Tc_8eGcrVtgQk6huyppcu1MVw_16_5"></a><ix:continuation id="Tb_NHSpwZiKS02sd4jG_Cyuwg_cont1" continuedAt="Tb_NHSpwZiKS02sd4jG_Cyuwg_cont2"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_-mo8-Tak5kGqOSsPQxHnUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Net deferred tax assets as of December 31, 2021 and 2020 consisted of the following (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_Xls-aabUH0uQcfaFEcrd2w_4_3">25,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_rW0YAUqvI0qeNIBM-J1IIw_4_6">11,214</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_hw4FEURNLk6lRg-IFC2FAw_5_3">3,237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_j6ACqt1pvEO0JA9vWPCfkQ_5_6">1,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_GNizQGcowUSH_q46dmPibA_6_3">761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="Tc_II4pukMh90yKac0I1TA3sw_6_6">432</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Salaries and wages</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="3" id="Tc_H-_rJI2q3kSigfGgEghCVA_7_6">313</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_0cfzHwWp-Em87awLe9xifQ_8_3">430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_kVhbgFbzlk64oGdtXhHFHg_8_6">80</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_0TBjDzcJw0uyUR_Et659lw_9_3">137</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="Tc_js7IBJp5iE2Q9pe0-o-DsQ_9_6">76</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_IQY8qhW1PEG2W8BpzhKmMA_10_3">29,689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_t-D2denj6kuwgaMxki5L_Q_10_6">13,351</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_YSo9S8EPZES_92xKbl8GpQ_12_3">261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_N5tlm-al_Ee5NgP_Xb1jBA_12_6">111</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="Tc_EsITb_uyBkKbBmbrAQRJRQ_13_3">485</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_L59OLQeAJUqeclG4_Kjlbw_14_3">746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_SLeqF3n9iku8jf_sgJhdZA_14_6">111</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_8EpiNCDR2k-vHsGsKVR6jQ_15_3">28,943</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_VHMmbkQyvUOrbVhtwl4uZw_15_6">13,240</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_HodcTs_FvES0HiIzmfy6sw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_x7heNc3It0iVSYbvysmtSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December 31, 2021, the Company had federal net operating loss carryforwards of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_a53NGrxD4kSTEvV0srI_NQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_hg2RxSuQGE63rcnTUejPdA">93.1</ix:nonFraction></span><span style="background:#ffffff;"> million, which may be available to offset future taxable income, of which </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-5" format="ixt:numdotdecimal" name="trda:OperatingLossCarryforwardsSubjectToExpiration" scale="6" id="Narr_tM4-CUCiQ0OEttQEew8qRA">3.2</ix:nonFraction></span><span style="background:#ffffff;"> million of the total net operating loss carryforwards expire at various dates beginning in 2036, while the remaining </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-5" format="ixt:numdotdecimal" name="trda:OperatingLossCarryforwardsLimitationOnUseAmount" scale="6" id="Narr_J1HTA6dAgEaMzH8kqdOt4g">89.9</ix:nonFraction></span><span style="background:#ffffff;"> million do not expire but are limited in their usage to an annual deduction equal to 80% of annual taxable income. In addition, as of December 31, 2021, the Company had state net operating loss carryforwards of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_y8-ETpe8yUaoJwpU5roQfA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_9vSIk24VEkyj8Me4mpRs6w">88.0</ix:nonFraction></span><span style="background:#ffffff;"> million, which may be available to offset future taxable income and expire at various dates beginning in 2036. As of December 31, 2021, the Company also had federal and state research and development tax credit carryforwards of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_a53NGrxD4kSTEvV0srI_NQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_g0UP8M9fzUa0K2eyT_xklg">2.3</ix:nonFraction></span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_y8-ETpe8yUaoJwpU5roQfA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_m4IxFUPMwECV1EfexfhTGw">1.2</ix:nonFraction></span><span style="background:#ffffff;"> million, respectively, which may be available to reduce future tax liabilities and expire at various dates beginning in 2039 and 2034, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 and Section 383 of the Internal Revenue Code of 1986 (Code), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income and tax liabilities. In general, an ownership change, as defined by Section 382 of the Code, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 5% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382 of the Code, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards may be subject to an annual limitation, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before their utilization. Further, until a study is completed by the Company and any limitation is known, </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="Narr_3jg2knGjzEWXM7da2-Lh3A">no</ix:nonFraction></span><span style="background:#ffffff;"> amounts are being presented as an uncertain tax position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets, which consist primarily of net operating loss carryforwards and research and development tax credit carryforwards. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception, estimated future taxable income, and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of federal and state net deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2021 and 2020. The Company reevaluates the positive and negative evidence at each reporting period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The valuation allowance increased by </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_O8pVP4l75kOdx-yCEK8aZQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_ZBxkG0FAIE2H2UHzgwrViQ">15.7</ix:nonFraction></span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_zP_saBrSuEeXS1wmFBKk8g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_5HG0plCYekyQlWlh_sNmww">8.2</ix:nonFraction></span><span style="white-space:pre-wrap;background:#ffffff;"> million for the year ending December 31, 2021 and 2020, respectively.  The increase in the valuation allowance for deferred tax assets during the years ended December 31, 2021 and 2020 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards. </span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_NHSpwZiKS02sd4jG_Cyuwg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company assesses the uncertainty in its income tax positions to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more-likely-than-not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. The Company&#8217;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its consolidated statements of operations. As of December 31, 2021 and 2020, the Company had not recorded any reserves for uncertain tax positions or related interest and penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. Due to net operating losses incurred, the Company&#8217;s tax returns from inception to date are subject to examination by the taxing authorities.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7e1aaf79_6a7d_4d50_b6ed_3f605decf9ae"></a><a id="Tc_LxNmJTw5Dkm0RywsxuP3Cw_1_0"></a><a id="Tc_h0iG3iiXL0mUojF_4lEzZw_2_0"></a><a id="Tc_vw66jlLrykKr6TUheAjOrQ_2_2"></a><a id="Tc_KJPpRRPGIEWFFzEysUNzGA_3_0"></a><a id="Tc_vPL-TbhYBkSAshsp94szbQ_4_0"></a><a id="Tc_XsN9tkgb3Ea-A4X3h0yQwQ_4_2"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_mzlXphayhUKUmEwYr7u42w" continuedAt="Tb_mzlXphayhUKUmEwYr7u42w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In March 2019, the Company entered into an operating lease for <ix:nonFraction unitRef="Unit_Standard_sqft_rx7LKou9MUKld2X7S962qQ" contextRef="As_Of_3_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_aI2VmsKba02tMKmJCqhsEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_rMxu9qDoUkSefTBFbR4x6Q">7,981</ix:nonFraction> square feet of office and laboratory space with an end date of April 30, 2021 in Boston, Massachusetts. The Company subsequently terminated the operating lease in December 2020 without penalty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In February 2020, the Company entered into an operating lease for <ix:nonFraction unitRef="Unit_Standard_sqft_rx7LKou9MUKld2X7S962qQ" contextRef="As_Of_2_29_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_jhtKcYUrGUeXiu8kysHe4g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_SJSentwT5UO2m2oIlhaJ-g">26,235</ix:nonFraction> square feet of office and laboratory space in Boston, Massachusetts. Lease payments commenced in April 2020. The lease is subject to fixed rate escalation increases. The Company recognizes rent expense on a straight-line basis over the expected lease term, which is <ix:nonNumeric contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_K6kVW2WPBE-kg0DD1wJujA" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_7wXZPWJv30i0LAcCfXGNVA">5.7</ix:nonNumeric> years. The Company began to record rent expense in April 2020 upon gaining access to and control of the space. Deferred rent is amortized as a reduction in rent expense over the term of the lease. In addition, upon execution of the lease, the Company paid a security deposit of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_G0o0UYvQV06N8dmtQoWrUw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr_qrdIR20SME6nLZwy2BMUpw"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_rM6lo0glkkSHK6fx56dohQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr_2G1DNq1P_UCZuA_trHfMbg">0.5</ix:nonFraction></ix:nonFraction> million, which is recorded as a component of other assets in the accompanying consolidated balance sheets as of December 31, 2021 and 2020. The Company has the option to terminate the lease after November 30, 2023 without penalty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In June 2021, the Company entered into amendments to the operating lease for <ix:nonFraction unitRef="Unit_Standard_sqft_rx7LKou9MUKld2X7S962qQ" contextRef="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_kcauchfWnUmJP3dujL0p2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_JOjiRU5pyEuNkiiQPdxXYQ">8,631</ix:nonFraction> square feet of additional office and laboratory space at its location in Boston, Massachusetts. The term of the amendments begin between July 2021 and March 2022 and run co-terminus with the existing lease. The Company has the same option to terminate the lease after November 30, 2023 without penalty. The Company was required to increase its total security deposit to $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_6_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_-28m7dTNPU20dkA6HHUEeA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="6" id="Narr_OfwlS8udKUWRTrnCr2YdCg">0.8</ix:nonFraction> million as of the commencement date of the amendments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_zmIfsJyrVUWM_pENy-Qn_w">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_St6USnAdUEq13taOJsVuXA">1.9</ix:nonFraction> million of rent expense for the years ended December 31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_PtiJVo-UyEC3BcZjh3ClUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The minimum aggregate future lease commitments at December 31, 2021, are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Years Ending December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_UZVX2WaZqU21OVgZ59OIGQ_2_3">8,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_rOQKKUtcu0Ol3yLDJaah1w_3_3">8,384</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_XaEhBrIQbUSLyAbO6Xp64A_4_3">16,910</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In 2017, the Company entered into an option agreement with a third party, in which the Company obtained an option to license all patents and patent applications specified in the agreement, involving work related to specified invention disclosures, and arising out of that sponsored research agreement entered into between the Company and such third party pursuant to which the Company sponsored certain discovery programs conducted by the third party. In 2018, the Company entered into a definitive license agreement with the third party in which the third party granted the Company an exclusive worldwide, sublicensable license to certain intellectual property under certain patent rights to research, develop, and otherwise commercialize a product generated from the licensed intellectual property. The Company concluded the assets acquired did not meet the accounting definition of a business as inputs, but no processes </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_mzlXphayhUKUmEwYr7u42w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#8220;business,&#8221; the transaction has been accounted for as an asset acquisition under ASC 730. As of the date of the license agreement, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. The Company paid an upfront research fee of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Cy9RrUM470ieiIVBwGRytQ" decimals="-5" format="ixt:numdotdecimal" name="trda:PaymentOfUpfrontResearchFees" scale="6" id="Narr_3dUjvMQprEW-_Qei4sVThQ">0.4</ix:nonFraction> million, paid in <ix:nonFraction unitRef="Unit_Standard_installment_z46z-AyIh0iy55GSvWd0bw" contextRef="As_Of_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_jxCvIM-1WEOJ9WQF7LNJvg" decimals="INF" format="ixt-sec:numwordsen" name="trda:LicenseAgreementNumberOfInstallments" scale="0" id="Narr_0e1mkN9-h0SH7cl-LH9RMg">two</ix:nonFraction> installments of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_6_1_2019_To_6_30_2020_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Hf7j2O4nM06-u1HOfsgByg" decimals="-5" format="ixt:numdotdecimal" name="trda:PaymentOfUpfrontResearchFees" scale="6" id="Narr_GNtNOKOBi0KmQJfPdkiu_Q">0.2</ix:nonFraction> million on June 30, 2019 and June 30, 2020, respectively, which were accrued and recognized as research and development expense in 2018. The Company agreed to pay an annual license maintenance fee for the license of less than $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_-TdaxQCqC0-mYAk7Hd2Eow" decimals="-5" format="ixt:numdotdecimal" name="trda:AnnualLicenseMaintenanceFee" scale="6" id="Narr_7L2-3Q4SIkO6ZGe1YFEK7Q">0.1</ix:nonFraction> million for each contract year, beginning the third year of the contract until the first commercial contract year. The Company also issued a total of <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Cy9RrUM470ieiIVBwGRytQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="Narr_auYfXHTItkyA6wbFAyNLVQ">86,558</ix:nonFraction> shares of common stock pursuant to the 2018 agreement, which were recorded at fair value at the date of issuance of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Cy9RrUM470ieiIVBwGRytQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="6" id="Narr_pK5fVV_up0q2NqhPN0P2Cw">0.2</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Should the Company pursue specified research, development, and commercial activities related to the above technology, the Company would be obligated to make milestone payments up to $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="As_Of_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_jxCvIM-1WEOJ9WQF7LNJvg" decimals="-5" format="ixt:numdotdecimal" name="trda:PotentialMilestonePaymentObligation" scale="6" id="Narr_3dCr9hnazkOH4jyA_WIGFA">2.6</ix:nonFraction> million for each of the first <ix:nonFraction unitRef="Unit_Standard_item_qXeWDqcza0Kv2YWLNzbANQ" contextRef="As_Of_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_jxCvIM-1WEOJ9WQF7LNJvg" decimals="INF" format="ixt-sec:numwordsen" name="trda:LicenseAgreementNumberOfLicensedProducts" scale="0" id="Narr_iBo_VYVTtka50GS7OWXyEg">three</ix:nonFraction> licensed products to achieve each milestone. The triggering of these milestone payments was not considered probable as of the transaction date, and <ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt-sec:numwordsen" name="trda:ExpensesRelatingToMilestoneObligation" scale="3" id="Narr_x-kPjBLizEmh9tWJBR2Iqw"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt-sec:numwordsen" name="trda:ExpensesRelatingToMilestoneObligation" scale="3" id="Narr_bLcnkZ1Z9UiCbm3NXA9Ciw">no</ix:nonFraction></ix:nonFraction> expense has been recorded for these milestones as of December 31, 2021 and 2020. In addition, the third party will receive tiered royalty payments on the applicable licensed program and platform products at a percentage ranging in single-digit royalties of net sales subject to reductions and offsets in certain circumstances, as well as a royalty on sublicensed consideration ranging from low to mid double-digit percentages of non-royalty sublicensing consideration. The Company concluded any milestone or royalty payments under the agreement were not probable as of December 31, 2021 and 2020. For each of the years ended December 31, 2021 and 2020, the Company reimbursed the third-party for patent costs of $<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_FM5MwYyCLk66BYx1-YT-iA" decimals="-5" format="ixt:numdotdecimal" name="trda:PaymentForPatentCosts" scale="6" id="Narr_lnrdW6mnpEOcfC5TY66J9Q"><ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_RYC5_ZIHMEyAEsk0XkA_Hw" decimals="-5" format="ixt:numdotdecimal" name="trda:PaymentForPatentCosts" scale="6" id="Narr_-P0vLC1lc0Wh3-J6fqNXXQ">0.1</ix:nonFraction></ix:nonFraction> million.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_gWEQhYw-MUq8ijlpuLPFUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.17;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">10. Employee Benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has a defined-contribution plan under Section 401(k) of the Code (401(k) Plan). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make, and to date has not made, any contributions to the 401(k) Plan.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_88d8c2b9_1711_472f_befc_27c6602cee53"></a><a id="Tc_5uir5dyftkWC_4Y1yFug4g_1_2"></a><a id="Tc__D0htQLw4keqpQbD9x5xHA_2_2"></a><a id="Tc_vQrftzmnH0SOS5zGzHhuIA_2_5"></a><a id="Tc_e1j7y1OazkO974BJnw1KeQ_3_0"></a><a id="Tc_-IYhcM53rk-L4AvYGPrvhw_4_0"></a><a id="Tc_m6WsiZnsnkGf4YzQcaZHXg_4_2"></a><a id="Tc_a8BetmUcT0yQx52owQAsKg_4_5"></a><a id="Tc_8mAUi4T7YUGfaCBcfG47tw_5_0"></a><a id="Tc_yoccCcbbQEy45VvVR8Nafw_6_0"></a><a id="Tc__mw_zJpQf0eQei5B7yXHKw_7_0"></a><a id="Tc_8thbPF6KskWiErVK1NmnXA_1_2"></a><a id="Tc_9IoDvy8Gk0eBInWVj-Ci0Q_2_2"></a><a id="Tc_GcsqjKhtAkG3tIRAGzUKeg_2_4"></a><a id="Tc_BftvVoZ2F0ahs4au_CHwyA_3_0"></a><a id="Tc_haClWEz3b0WW6mUIIlAl3w_3_2"></a><a id="Tc_Y3K___6GyEC7i4M3cxodCw_4_0"></a><a id="Tc_ctvKql1F2EWF6wPrYXGk8A_4_2"></a><a id="Tc_0juk9-ObKUqzqg4tzXJaFA_5_0"></a><a id="Tc_YgumbA0XJUGfKK9VINsmbA_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:EarningsPerShareTextBlock" id="Tb_9htQ_7pWwEWooaTC_fq_Pw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Net Loss per Share</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_V0VGbZ1g90OR8Y6W5IqaFg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_oDlLv4KsDEqZRRzqulTkLA_4_3">51,158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_I79FtINnEky6c-HRDJPaZQ_4_6">26,523</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted&#8209;average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Nvtu9CBQjUKbTyxNSx0cug_6_3">6,267,776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_EcQG0HBlIEeeOFthY4HFEQ_6_6">1,105,260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_JFF1gzEYxkmqNACNSLO4fA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_dWpeIiIxz0ekYING7kkNBQ_7_3">8.16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KRMqqkYCvkiUV0MKGa8Rag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_g2Zp0_R_nkmOIPxOChuX3A_7_6">24.00</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_Vz2z420ZHUeCPEeNm3BvnQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Redeemable convertible preferred stock (as converted to common stock)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_Yg0eRdnrPE6oZY0L97BMQw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc__0DekTInhUe2N_vslx_8wQ_3_4">11,788,435</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BrM28n-jyUOi_DtOIFHwAg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_xve1ewk8CUWkurqIZfYRMw_4_4">11,537</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested shares from early exercises</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_trda_UnvestedSharesMember_Yg75Vq-JeUiuqL-_773DFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_SCvnGUs3sUKpgs48eHPddw_5_2">111,756</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_trda_UnvestedSharesMember_ONz4dFb4f0-msro3DrkJBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_65XwaZPYEkibIT4OTNMczw_5_4">27,869</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VeWTpBES60mrDvFGp33DJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_2gwnqnHG6EeIYNokHHoPHg_6_2">3,461,870</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_EMioRKOEOUuK6W_DHnQC0w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_DrPeL5CZLkCirmqH413FjQ_6_4">1,625,256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_khm2vh68rkudkTeZZRJl1Q_7_2">3,573,626</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g" contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_G62gDcP0wkudYxJMeDX2XA_7_4">13,453,097</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_KVDvt4KitUutOAzudb1tHg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">For the year ended December&#160;</span><span style="letter-spacing:-0.1pt;white-space:pre-wrap;">31, 2021, subsequent events were evaluated through  the date on which these consolidated financial statements were issued to determine if such events should be reflected in these consolidated financial statements</span><span style="background:#ffffff;">. The Company has concluded that no subsequent events have occurred that require disclosure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_81e90c41_4e04_485b_b832_56dc7fce9922"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_f5382db3_7684_4adc_95ba_58992830275c"></a><a id="Item9AControlsandProcedures_447228"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Item&#160;9A. Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="background:#ffffff;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial and accounting officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. The term &quot;disclosure controls and procedures,&quot; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission (the SEC)&#39;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#39;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="background:#ffffff;">Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2021, our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">This Annual Report does not include a report of management&#8217;s assessment regarding internal control over financial reporting due to a transition period established by the rules of the SEC for newly public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Attestation Report of the Registered Public Accounting Firm</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">This Annual Report does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for &#8220;emerging growth companies.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_befe1b40_7410_435f_9966_28e6d1c5e753"></a><a id="Item9BOtherInformation_773499"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Item 9B. Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="Item9CDisclosureRegardingForeignJurisdic"></a><a id="_6456fd1a_a29e_48ad_bb84_7790287d2b53"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 9C. Disclosure Regarding Foreign Jurisdictions</b><b style="font-weight:bold;"> that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>Not Applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><a id="_9adb6cd8_c86e_42fa_a58a_ef5a33d29c60"></a><a id="PARTIII_735359"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART III</b></p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 10. Directors, Executive Officers and Corporate Governance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item 10 will be included in our definitive proxy statement relating to our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year, and is incorporated herein by reference.</p><a id="_670af4b2_4502_4ca3_9278_44679d3f2695"></a><a id="Item11ExecutiveCompensation_320836"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 11. Executive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item 11 will be included in our definitive proxy statement relating to our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year, and is incorporated herein by reference.</p><a id="_6768c48f_5bc2_47d9_83f0_36ab0adf235c"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item 12 will be included in our definitive proxy statement relating to our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year, and is incorporated herein by reference.</p><a id="_67b4906e_99b5_4480_9595_65878dbfe020"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 13. Certain Relationships and Related Transactions, and Director Independence</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item 13 will be included in our definitive proxy statement relating to our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year, and is incorporated herein by reference.</p><a id="_d282de2c_27be_4e28_83b1_a826f35ef47d"></a><a id="Item14PrincipalAccountingFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 14. Principal Accounting Fees and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The information required by this Item 14 will be included in our definitive proxy statement relating to our 2022 Annual Meeting of Stockholders, which we will file with the SEC within 120 days of the end of the fiscal year, and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_573bc61f_1cac_47ad_ba84_fd9c97823c8b"></a><a id="PARTIV_938268"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART IV</b></p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 15. Exhibits and Financial Statement Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(a)</b></span><b style="font-weight:bold;">Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exhibit</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Number</p></td><td style="vertical-align:bottom;width:2.4%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">Description</p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">3.1</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921132980/tm2131671d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Registrant on November 2, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">3.2</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921132980/tm2131671d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the  Current Report on Form 8-K filed by the Registrant on November 2, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">4.1</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">4.2</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921124689/tm2123090d7_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Investors&#8217; Rights Agreement among the Registrant and certain of its stockholders, effective as of March&#160;29, 2021 (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 filed by the Registrant on October 8, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">4.3*</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="trda-20211231xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities of the Registrant</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.1#</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Stock Option and Incentive Plan and form of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.2#</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.3#</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnification Agreement between the Registrant and each of its directors (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.4#</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnification Agreement between the Registrant and each of its executive officers (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.5#</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.6#</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex10-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Executive Employment Agreement (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.7#</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.8 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.8#</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, by and between the Registrant and Dipal Doshi, effective as of November 2, 2021 (incorporated by reference to Exhibit 10.9 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.9#</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex10-10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, by and between the Registrant and Natarajan Sethuraman, effective as of November 2, 2021 (incorporated by reference to Exhibit 10.10 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.10#</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex10-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, by and between the Registrant and Nathan Dowden, effective as of November 2, 2021 (incorporated by reference to Exhibit 10.11 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.11#</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921129181/tm2123090d10_ex10-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Strategic Advisory Agreement, by and between the Registrant and Peter S. Kim, effective as of November 2, 2021 (incorporated by reference to Exhibit 10.12 to the Registration Statement on Form S-1 filed by the Registrant on October 25, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.12&#8224;</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921124689/tm2123090d7_ex10-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License Agreement, by and between the Registrant and OSIF, dated as of December 14, 2018, as amended on October 8, 2019 and further amended on March&#160;9, 2019 (incorporated by reference to Exhibit 10.13 to the Registration Statement on Form S-1 filed by the Registrant on October 8, 2021).</span></a></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">170</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">10.13</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1689375/000110465921124689/tm2123090d7_ex10-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated as of February 28,2020, by and between the Registrant and MIL 6T, LLC, as amended on March 27, 2020 (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 filed by the Registrant on October 8, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">21.1*</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="trda-20211231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries of the Registrant.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">23.1*</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="trda-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst&#160;&amp; Young LLP, independent registered public accounting firm.</span></a> </p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">24.1*</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a href="#POWEROFATTORNEY"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on signature page).</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">31.1*</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="trda-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">31.2*</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="trda-20211231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">32.1*+</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="trda-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">101.INS</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">Inline XBRL Taxonomy Extension Schema Document.</p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">104</p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4pt 0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:20.15pt;text-indent:-20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>Filed or furnished herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:20.15pt;text-indent:-20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8224;</span></span>Portions of this exhibit (indicated by asterisks) have been omitted in accordance with Item&#160;601(b)(10)&#160;of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:20.15pt;text-indent:-20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">#</span></span>Indicates a management contract or any compensatory plan, contract or arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:20.15pt;text-indent:-20.15pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">+</span></span>The certifications furnished in Exhibit 32.1 hereto are deemed to be furnished with this Annual Report and will not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(b)</b></span><b style="color:#231f20;font-weight:bold;">Financial Statements Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the consolidated financial statements or notes thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_08597d6a_59d3_4b8f_8285_d3ea0997a382"></a><a id="Item16Form10KSummary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 16. Form 10-K Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 2pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">171</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a style="color:#000000;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="#TableofContents"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_07684bca_1d63_4f0d_bcef_466c296c3524"></a><a id="SIGNATURES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 8pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:43.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:6.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:43.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 15, 2022</p></td><td colspan="2" style="vertical-align:top;width:56.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">ENTRADA THERAPEUTICS, INC.</b></p></td></tr><tr style="height:12pt;"><td style="vertical-align:middle;width:43.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:43.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:49.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dipal Doshi</p></td></tr><tr><td style="vertical-align:top;width:43.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dipal Doshi</p></td></tr><tr><td style="vertical-align:top;width:43.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:43.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="POWEROFATTORNEY"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">POWER OF ATTORNEY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:12pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose individual signature appears below hereby authorizes and appoints Dipal Doshi and Kory Wentworth, and each of them, with full power of substitution and re-substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;width:34.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;width:25.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date</p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Dipal Doshi</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dipal Doshi</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Kory Wentworth</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Kory Wentworth</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">Principal Financial and Accounting Officer)</i></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Kush M. Parmar, M.D., Ph.D.</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chairman and Director</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Kush M. Parmar, M.D., Ph.D.</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ John F. Crowley</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">John F. Crowley</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Todd Foley</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Todd Foley</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Peter S. Kim, Ph.D.</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Peter S. Kim, Ph.D.</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Carole Nuechterlein</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Carole Nuechterlein</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ Mary Thistle</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Director</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 15, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:34.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Mary Thistle</p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:41.75pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">172</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>trda-20211231xex4d3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/15/2022 11:37:12 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri Light';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 12pt 78pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 4.3</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">REGISTERED PURSUANT TO SECTION 12 OF THE </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:40.5pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following description of the capital stock of Entrada Therapeutics, Inc., a Delaware corporation (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">we</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">us</u><font style="font-family:'Times New Roman','Times','serif';">,&#8221; and &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">our</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), is a summary of certain provisions of our securities that are registered under Section 12 of the Securities and Exchange Act of 1934, as amended (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">Exchange Act</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Fourth Amended and Restated Certificate of Incorporation (as amended and/or restated from time to time, the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">Certificate of Incorporation</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;) and our Amended and Restated Bylaws (as amended and/or restated from time to time, the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">Bylaws</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;), each of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.3 is a part, and by applicable law. This description also summarizes relevant provisions of the General Corporation Law of the State of Delaware (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';text-decoration:underline;text-decoration-color:#000000;">DGCL</u><font style="font-family:'Times New Roman','Times','serif';">&#8221;). We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable provisions of the DGCL for additional information.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Authorized Capital Stock </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The total amount of our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Common Stock </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.1pt;">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions</font><font style="font-family:'Times New Roman','Times','serif';">. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. Each outstanding share of common stock is fully paid and non-assessable. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Preferred Stock </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our </font><font style="font-family:'Times New Roman','Times','serif';letter-spacing:-0.1pt;">board of directors </font><font style="font-family:'Times New Roman','Times','serif';">will have the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our Company or other corporate action. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">No shares of preferred stock are outstanding as of the date of our Annual Report on Form 10-K with which this Exhibit 4.3 is filed as an exhibit.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Anti-Takeover Effects of Delaware Law and Provisions of our Charter and our Bylaws </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Certain provisions of the DGCL and of our Certificate of Incorporation and Bylaws could have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Board Composition and Filling Vacancies</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our Certificate of Incorporation provides for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our Certificate of Incorporation also provides that </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board of directors, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">No Written Consent of Stockholders </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our Certificate of Incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our Bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Meetings of Stockholders </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our Certificate of Incorporation and Bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our Bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Advance Notice Requirements </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our Bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our Bylaws specify the requirements as to form and content of all stockholders&#8217; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Amendment to Certificate of Incorporation and Bylaws </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Any amendment of our Certificate of Incorporation must first be approved by a majority of our board of directors, and if required by law or our Certificate of Incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class. Our Bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the Bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and special meetings must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Undesignated Preferred Stock </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';white-space:pre-wrap;"> </font><font style="font-family:'Times New Roman','Times','serif';">Our Certificate of Incorporation provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our Certificate of Incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Choice of Forum </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, and employees to us or our stockholders, (3) any action asserting a claim arising pursuant to the DGCL, our Certificate of Incorporation or our Bylaws, (4) any action to interpret, apply, enforce or determine the validity of our Certificate of Incorporation or our Bylaws, or (5) any action asserting a claim that is governed by the internal affairs doctrine; provided, however, that the this provision shall not apply to any causes of action arising under the Securities Act or Exchange Act. In addition, our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to these forum provisions. These forum provisions may impose additional costs on stockholders, may limit our stockholders&#8217; ability to bring a claim in a forum they find favorable, and the designated courts may reach different judgments or results than other courts. In addition, there is uncertainty as to whether the federal forum provision for Securities Act claims will be enforced, which may impose additional costs on us and our stockholders. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Section 203 of the Delaware General Corporation Law </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We are subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 203 defines a business combination to include: </font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Section 203 defines a business combination to include:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">any merger or consolidation involving the corporation and the interested stockholder;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other financial benefits provided by or through the corporation.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Stock Exchange Listing </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Our common stock is listed on the Nasdaq Global Market under the trading symbol &#8220;TRDA.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-bottom:8pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Transfer Agent and Registrar </b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>trda-20211231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/15/2022 11:37:14 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 78pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SUBSIDIARIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Subsidiary</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Jurisdiction of Incorporation</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">Entrada Securities Corporation</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:12pt 0pt 0pt 0pt;">Massachusetts</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>trda-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/15/2022 11:37:16 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><b style="color:#333333;font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><b style="color:#333333;font-family:'Times New Roman','Times','serif';font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';">We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-260563) pertaining to the 2021 Stock Option and Incentive Plan, the 2021 Employee Stock Purchase Plan and the 2016 Stock Incentive Plan of Entrada Therapeutics, Inc. of our report dated March 15, 2022, with respect to the consolidated financial statements of Entrada Therapeutics, Inc. included in this Annual Report (Form 10-K) of Entrada Therapeutics, Inc. for the year ended December 31, 2021.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';">/s/ Ernst &amp; Young LLP</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';">Boston, Massachusetts</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="color:#333333;font-family:'Times New Roman','Times','serif';">March 15, 2022</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>trda-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/15/2022 11:37:19 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:10pt;margin:0pt;">I, Dipal Doshi, certify that:</p><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">I have reviewed this Form 10-K for the Annual Period Ended December 31, 2021 of Entrada Therapeutics, Inc.;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The registrant&#39;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The registrant&#39;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><div style="margin-top:10pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:10pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.93%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:3.14%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:45.96%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:49.93%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 15, 2022</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:0.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.14%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:45.96%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/&#160;Dipal Doshi</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:49.93%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:0.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:middle;width:3.14%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:45.96%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dipal Doshi</b></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:49.93%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:0.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:3.14%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:45.96%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">President and Chief Executive Officer</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Principal Executive Officer)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>trda-20211231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/15/2022 11:37:22 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RULES 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 8pt 0pt;">I, Kory Wentworth, certify that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">I have reviewed this Form 10-K for the Annual Period Ended December 31, 2021 of Entrada Therapeutics, Inc.;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The registrant&#39;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">(Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313);</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:8pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The registrant&#39;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.94%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:45.96%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:49.94%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 15, 2022</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:0.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:45.96%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/&#160;Kory Wentworth</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:49.94%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:0.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:middle;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:45.96%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Kory Wentworth</b></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:49.94%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:0.95%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:45.96%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Financial Officer</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Principal Financial and Accounting Officer)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>trda-20211231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/15/2022 11:37:24 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 78pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:18pt 0pt 0pt 0pt;"><b style="font-weight:bold;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">In connection with the Annual Report on Form 10-K of Entrada Therapeutics, Inc. (the &#8220;Company&#8221;) for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">(1)</p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">(2)</p></td><td style="vertical-align:top;width:89.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 0pt 0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:46.43%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:45.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 15, 2022</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:46.43%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/&#160;Dipal Doshi</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:45.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:middle;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:46.43%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dipal Doshi</b></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:45.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:46.43%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">President and Chief Executive Officer </b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Principal Executive Officer)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:46.43%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:45.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 15, 2022</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:top;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:46.43%;border-bottom:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/&#160;Kory Wentworth</p></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:45.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:middle;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:46.43%;border-top:1px solid #000000;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Kory Wentworth</b></p></td></tr><tr><td style="background-color:#ffffff;vertical-align:bottom;width:45.42%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:5%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#ffffff;vertical-align:bottom;width:3.13%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#ffffff;vertical-align:bottom;width:46.43%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Financial Officer</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Principal Financial and Accounting Officer)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>trda-20211231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %" VH# 2(  A$! Q$!_\0
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M_(H_X6KXE_YZ6O\ WY%'U"KY![>)[I17A?\ PM7Q+_STM?\ OR*/^%J^)?\
MGI:_]^11]0J^0>WB>Z45X7_PM7Q+_P ]+7_OR*/^%J^)?^>EK_WY%'U"KY![
M>)[I17A?_"U?$O\ STM?^_(H_P"%J^)?^>EK_P!^11]0J^0>WB>Z45X7_P +
M5\2_\]+7_OR*]0\$:U>:]X?6\O2AF+D?(N!6=7"U*4>:14:L9.R.DHKS/QWX
MWUCP]KJVEBT(B,8;YX]QS7+_ /"U?$O_ #TM?^_(JH8*I.*DK:B=:*=CW2BO
M"_\ A:OB7_GI:_\ ?D4?\+5\2_\ /2U_[\BJ^H5?(7MXGNE%>%_\+5\2_P#/
M2U_[\BC_ (6KXE_YZ6O_ 'Y%'U"KY![>)[I17A?_  M7Q+_STM?^_(H_X6KX
ME_YZ6O\ WY%'U"KY![>)[I17A?\ PM7Q+_STM?\ OR*/^%J^)?\ GI:_]^11
M]0J^0>WB>Z45X7_PM7Q+_P ]+7_OR*/^%J^)?^>EK_WY%'U"KY![>)[I17A?
M_"U?$O\ STM?^_(H_P"%J^)?^>EK_P!^11]0J^0>WB>Z45X7_P +5\2_\]+7
M_OR*/^%J^)?^>EK_ -^11]0J^0>WB>Z45X7_ ,+5\2_\]+7_ +\BC_A:OB7_
M )Z6O_?D4?4*OD'MXGNE%<)\//%>I^)3>#4&B/E8V[$V]:F^(7B?4?#=K:2:
M>T8:5B&WINK#V$_:>SZE\ZY>8[6BO"_^%J^)?^>EK_WY%'_"U?$O_/2U_P"_
M(K?ZA5\B/;Q/=**\+_X6KXE_YZ6O_?D4?\+5\2_\]+7_ +\BCZA5\@]O$]TH
MKPO_ (6KXE_YZ6O_ 'Y%'_"U?$O_ #TM?^_(H^H5?(/;Q/=**\+_ .%J^)?^
M>EK_ -^11_PM7Q+_ ,]+7_OR*/J%7R#V\3W2BO"_^%J^)?\ GI:_]^11_P +
M5\2_\]+7_OR*/J%7R#V\3W2BO"_^%J^)?^>EK_WY%'_"U?$O_/2U_P"_(H^H
M5?(/;Q/=**\+_P"%J^)?^>EK_P!^11_PM7Q+_P ]+7_OR*/J%7R#V\3W2BO"
M_P#A:OB7_GI:_P#?D4?\+5\2_P#/2U_[\BCZA5\@]O$]THKPO_A:OB7_ )Z6
MO_?D4?\ "U?$O_/2U_[\BCZA5\@]O$]THKPX_$_Q4JAF$ 4]";?@T-\4/%*
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M?O:E_P !JS\8?^/'3_\ ?:O+?^^?UV.G_ER>14445ZAS!1110 4444 %%%%
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M_P#H!ZG_ . DG^%<.7R2@[LVKIMHRJ*U?^$8U_\ Z >I_P#@))_A1_PC&O\
M_0#U/_P$D_PKT.>/<PLS*HK5_P"$8U__ * >I_\ @))_A1_PC&O_ /0#U/\
M\!)/\*.>/<+,RJFM;NXL;A9[6>2&9>CQM@C\:O\ _",:_P#] /4__ 23_"C_
M (1C7_\ H!ZG_P" DG^%+G@^H69!+K6J37*7,NH7+SH,+(TA)'T--?5M0DMA
M;/>SM .D9D./RJS_ ,(QK_\ T ]3_P# 23_"C_A&-?\ ^@'J?_@))_A2O3\A
MVD02ZSJ<WD^;?W+^3S'ND)V?3TILFJZA+>)>27L[W*<K*9"67Z&K/_",:_\
M] /4_P#P$D_PH_X1C7_^@'J?_@))_A1>GY!:16M]5U"UGDGM[V>*67[[I(06
M^M$>I3^9#]I9[F&)S((9'.W)Z]#WJS_PC&O_ /0#U/\ \!)/\*/^$8U__H!Z
MG_X"2?X47I]T%I%?5=3FU?4)+R<*K-@!5SA0.@&:I5J_\(QK_P#T ]3_ / 2
M3_"C_A&-?_Z >I_^ DG^%-2@E9,+-F516K_PC&O_ /0#U/\ \!)/\*/^$8U_
M_H!ZG_X"2?X4^>/<5F95%:O_  C&O_\ 0#U/_P !)/\ "C_A&-?_ .@'J?\
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M[9<_;/M?GR?:=V_S=QW9]<U-;ZKJ%I)+);WL\3R_ZQDD(+?7UJS_ ,(QK_\
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M?_@))_A1SQ[A9F57H=Y>:99>'[:WNIH&,M@FRT%H-^\]'\S''YUR/_",:_\
M] /4_P#P$D_PIS^'?$<FW?HVJMM&%W6LAP/3I6<^2;7O;%1NNAU.K^'M.U/5
M[T6Z7$4T,\,;A638P<?PK@8(QW)IC^#-)2^C5I[L0/;&3!?HP?;@OY? _P"
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MRV""/P]:KR6-S%:)=20LL+ML5CW-'L8">;XQ;Q7W,]4_X6#H/_/2?_OT:/\
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M?V?= S#RCF'[_M4'EOG&QL^F*/8P$\YQ:W2^[_@GK7_"P=!_YZ3_ /?HT?\
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M0TM<Y[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'C/C;_D;]0^J?\ H"U@5O\ C;_D;]0^J?\ H"U@5Z$/A1\'B_\
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M+V]?16V\CHUU[3$.%$B["KY6/ D8 @\9XK,FUB*XTBWM[@/,\=PTA0G V8X
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MLSRR[O)E#QEH^H![BM:TUS3+"U6SCDFFC4$F1X\<D@X STKG?[+U#_GPNO\
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M$$*[GD*[L?05IKX6:5!+!=B6!HP\;K'@MS@C!/!%#A36Z"&*Q\U>,G^!J_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_\ $T?\*TU;_G[LO^^G_P#B:/:P[A_9V*_D9Q=%=I_PK35O^?NR_P"^G_\
MB:/^%::M_P _=E_WT_\ \31[6'</[.Q7\C.+HKM/^%::M_S]V7_?3_\ Q-'_
M  K35O\ G[LO^^G_ /B:/:P[A_9V*_D9Q=%=I_PK35O^?NR_[Z?_ .)H_P"%
M::M_S]V7_?3_ /Q-'M8=P_L[%?R,XNBNT_X5IJW_ #]V7_?3_P#Q-'_"M-6_
MY^[+_OI__B:/:P[A_9V*_D9Q=%=I_P *TU;_ )^[+_OI_P#XFC_A6FK?\_=E
M_P!]/_\ $T>UAW#^SL5_(SBZ*[3_ (5IJW_/W9?]]/\ _$T?\*TU;_G[LO\
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M%HY$A 7!&>>G?C/O1[.F+^T<?W?W+_([;_A9\/\ T"G_ ._P_P */^%GP_\
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M/;PW!GCCA=6=F8'Y /YUKR4^QY_US'O:7Y'1?\+-OO\ GPM_S:C_ (6;??\
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M;YPI&"O;%5)-!U!3(4MV=$SEN!TZ\9S2Y*93Q>8)7YG^!T__  LV^_Y\+?\
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M2I(4",5 .<#YN@/;G\JM)XM5"K_V>#)O1W;SN&*J5X&..M6O^%;ZU_SVLO\
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MK32(8$ (D0RLQD!ZC)Z5(WB2-9HT@TZ..Q1"AMC*S;@>3\W7-:'_  KC6_\
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M?Q7$J[+33?)C.20]PTAW'ODC@>U6?^%<:W_STL_^_C?_ !-'_"N-;_YZ6?\
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MD23?&1,0%&<X( Y_SQ4UQXNGFC(6!D<-E")CM SG!48R?>K?_"N-;_YZ6?\
MW\;_ .)H_P"%<:W_ ,]+/_OXW_Q-.]/N'LLPU]UZ^2*'_"3 .NVR"Q$NTB^;
MRS,,$@XX_(T^+Q2B>0KV&]("IC'G8((]3MYJY_PKC6_^>EG_ -_&_P#B:/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \9\;?\ (WZA]4_] 6L"O8]2\%:5JNH2WMP;CS9<%MC@#@ >GM53_A76
MA_WKK_OZ/\*ZHUHI)'R]?*,1.K*:M9MO?S/)ZLV]]/:Q2QPOM63&XXYX.1BO
M3_\ A76A_P!ZZ_[^C_"C_A76A_WKK_OZ/\*KVT#)9-BT[JWWGGDOB+49Y9Y)
M9$=IL%MR C(7:"!V..]$?B+48H4B61,)LP2@R=C;ER?8UZ'_ ,*ZT/\ O77_
M ']'^%'_  KK0_[UU_W]'^%3[6GV-?[,QU[\WXGG$>MWT22JDH D9F)VC*EN
MI'IFGCQ!J D,GF)N+1M]P=4&%_2O1/\ A76A_P!ZZ_[^C_"C_A76A_WKK_OZ
M/\*?M:8EE>.7VOQ/._\ A(-0^SM#YB;67:24&<;MV,_6E;Q#J#.I+1[%4KY>
MP;"#UR*]#_X5UH?]ZZ_[^C_"C_A76A_WKK_OZ/\ "CVM,?\ 9F._F_$\[B\0
MZA"CHKQX9F;F,<;A@X]*D_X2;4L',D9X(R8QP",$#\A7H'_"NM#_ +UU_P!_
M1_A1_P *ZT/^]=?]_1_A2]K3[ LLQZ^U^)Y==W<M[<-/,09& !(&.@Q6@WB3
M4FL4L]\:QH@C#+& ^T=MW6O0?^%=:'_>NO\ OZ/\*/\ A76A_P!ZZ_[^C_"G
M[:!*RK&Q;::UWU//#XBU$^81(@:0$%P@# $8(!_"F_V_?^:LA:,L%*G,8^<$
M8.[UKT7_ (5UH?\ >NO^_H_PH_X5UH?]ZZ_[^C_"CVM,?]F8[^;\3ST^(]1+
MO)OC#LH7<(P".,<'Z5"^M7DIA,AC=HB"&:,$MC@9]:](_P"%=:'_ 'KK_OZ/
M\*/^%=:'_>NO^_H_PH]K3!Y7CGO+\3R^WO9K9IS$5!F1HWX['K3[+4KG3]WD
M,N&ZJR@C/8_6O3?^%=:'_>NO^_H_PH_X5UH?]ZZ_[^C_  H]M E91C%9IK3S
M/.3KM^R;6E#?(R9*C)#')_6K;^*+MK-8U"K/N8F7 [C''H:[O_A76A_WKK_O
MZ/\ "C_A76A_WKK_ +^C_"E[6F6LMQZVE^)YG=:G<WD"13,K! !NVC<<=,GO
M5.O6/^%=:'_>NO\ OZ/\*/\ A76A_P!ZZ_[^C_"G[:",Y9/BY.[:^\\GJ2W_
M ./F+_?'\Z]4_P"%=:'_ 'KK_OZ/\*5/AYHB.K W65.1^\'^%/V\1+)<3?I]
MY>\6_P#(IWG_ %SKQR&:2WF2:%RDB'*L.QKW35-.75-+FL6D,:R+MW 9(KD/
M^%8VO_02F_[]C_&LZ52,59G?FF!KUZL9TELNYP]]KE]J"HL[IL0[@J(%!/J<
M=30FMWT>HO?K(OG.,-E0588Q@CIVKN/^%8VO_02F_P"_8_QH_P"%8VO_ $$I
MO^_8_P :T]K3.!Y=CV[O?U7^9PSZW?/?F]:1?.*%/NC 4C& .U00WT\%NT$;
M[49PYXYR.G->@?\ "L;7_H)3?]^Q_C1_PK&U_P"@E-_W['^-'M:8GEF.;NU^
M*.+?Q%J#RB0O'OW;\A!R<8R:8==U PK'YV,$?,% 8@= 3Z5V_P#PK&U_Z"4W
M_?L?XT?\*QM?^@E-_P!^Q_C1[2F5_9^8?TU_F<5_PD%^'=T=$+@9*(!T.:7_
M (2+4-DBAXQOSSY8R,]<>E=I_P *QM?^@E-_W['^-'_"L;7_ *"4W_?L?XT>
MTIA_9^8?TU_F<0^O:@[1,90#$P<$*!N8=SZFI'\1ZG(5+S@[9?.&5'WJ[/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 V0%XV19&C8@@.N,K[C((_,5A_V%J/_0WZS_WZL_\ Y'KS
MGQI>747BZ_2.YF104PJN0!\BU@_VA>_\_EQ_W]/^->K3RMS@I<VZ['@5L]C3
MJ2AR;-K?M\CV3^P=1_Z&_6?^_5G_ /(]']@ZC_T-^L_]^K/_ .1Z\;_M"]_Y
M_+C_ +^G_&C^T+W_ )_+C_OZ?\:O^R'_ #_@9_ZPQ_Y]_C_P#V3^P=1_Z&_6
M?^_5G_\ (]']@ZC_ -#?K/\ WZL__D>O&_[0O?\ G\N/^_I_QH_M"]_Y_+C_
M +^G_&C^R'_/^ ?ZPQ_Y]_C_ , ]D_L'4?\ H;]9_P"_5G_\CT?V#J/_ $-^
ML_\ ?JS_ /D>O&_[0O?^?RX_[^G_ !H_M"]_Y_+C_OZ?\:/[(?\ /^ ?ZPQ_
MY]_C_P  ]D_L'4?^AOUG_OU9_P#R/1_8.H_]#?K/_?JS_P#D>O&_[0O?^?RX
M_P"_I_QH_M"]_P"?RX_[^G_&C^R'_/\ @'^L,?\ GW^/_ /9/[!U'_H;]9_[
M]6?_ ,CT?V#J/_0WZS_WZL__ )'KQO\ M"]_Y_+C_OZ?\:/[0O?^?RX_[^G_
M !H_LA_S_@'^L,?^??X_\ ]D_L'4?^AOUG_OU9__ "/1_8.H_P#0WZS_ -^K
M/_Y'KQO^T+W_ )_+C_OZ?\:/[0O?^?RX_P"_I_QH_LA_S_@'^L,?^??X_P#
M/9/[!U'_ *&_6?\ OU9__(]']@ZC_P!#?K/_ 'ZL_P#Y'KQO^T+W_G\N/^_I
M_P :/[0O?^?RX_[^G_&C^R'_ #_@'^L,?^??X_\  /9/[!U'_H;]9_[]6?\
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MBBC^R%_/^'_!#_6&7_/O\?\ @'L_]FW'_0[ZI_WS9?\ QBC^S;C_ *'?5/\
MOFR_^,5XQ11_9"_G_#_@A_K#+_GW^/\ P#V?^S;C_H=]4_[YLO\ XQ1_9MQ_
MT.^J?]\V7_QBO&**/[(7\_X?\$/]89?\^_Q_X![/_9MQ_P!#OJG_ 'S9?_&*
M/[-N/^AWU3_OFR_^,5XQ11_9"_G_  _X(?ZPR_Y]_C_P#V?^S;C_ *'?5/\
MOFR_^,5,NAZ@ZAD\8:RRGH1%9D?^D]>)5U_@_P 8/H\JV=XQ:R8X!/\ RS/K
M]*RK95*$.:#NS?#Y[&I44:D>5/K<[_\ L#4O^ANUK_OU9_\ R/1_8&I?]#=K
M7_?JS_\ D>MJ*5)HEEC8.C#*L#P13Z\D^@3N87]@:E_T-VM?]^K/_P"1Z/[
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M&I?]#=K7_?JS_P#D>C^P-2_Z&[6O^_5G_P#(];M% &%_8&I?]#=K7_?JS_\
MD>C^P-2_Z&[6O^_5G_\ (];M% &%_8&I?]#=K7_?JS_^1Z/[ U+_ *&[6O\
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M *&[6O\ OU9__(];M% &%_8&I?\ 0W:U_P!^K/\ ^1Z/[ U+_H;M:_[]6?\
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M_ V/_P"*H_X2[PU_T,.D_P#@;'_\56S10!C?\)=X:_Z&'2?_  -C_P#BJ/\
MA+O#7_0PZ3_X&Q__ !5;-% &-_PEWAK_ *&'2?\ P-C_ /BJ/^$N\-?]##I/
M_@;'_P#%5LT4 8W_  EWAK_H8=)_\#8__BJ/^$N\-?\ 0PZ3_P"!L?\ \56S
M10!C?\)=X:_Z&'2?_ V/_P"*H_X2[PU_T,.D_P#@;'_\56S10!C?\)=X:_Z&
M'2?_  -C_P#BJ/\ A+O#7_0PZ3_X&Q__ !5;-% &-_PEWAK_ *&'2?\ P-C_
M /BJ/^$N\-?]##I/_@;'_P#%5LT4 8W_  EWAK_H8=)_\#8__BJ/^$N\-?\
M0PZ3_P"!L?\ \56S10!C?\)=X:_Z&'2?_ V/_P"*H_X2[PU_T,.D_P#@;'_\
M56S10!C?\);X:)_Y&'2?_ V/_P"*K7CD26-9(W5T895E.01[&G44 %%%% '
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ME[&EOSA[6I_*9KV\L<IC9#N!QP,T2VTL+E'0Y !..<5KRZQ;S3.^)8]R%05
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,:H_L2C_,_P_P @_M2KV1RG]A:G_P ^C_F/\:/["U/_ )]'_,?XUU?G:_\
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M^U9_RHXW^S;W_GTF_P"^#1_9M[_SZ3?]\&NR\[7_ /GPTS_P-D_^-4>=K_\
MSX:9_P"!LG_QJC^PZ?\ .P_M6?\ *CC?[-O?^?2;_O@T?V;>_P#/I-_WP:[+
MSM?_ .?#3/\ P-D_^-4>=K__ #X:9_X&R?\ QJC^PZ?\[#^U9_RHXW^S;W_G
MTF_[X-']FWO_ #Z3?]\&NR\[7_\ GPTS_P #9/\ XU1YVO\ _/AIG_@;)_\
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MAIG_ (&R?_&J/.U__GPTS_P-D_\ C5 &K165YVO_ //AIG_@;)_\:H\[7_\
MGPTS_P #9/\ XU0!JT5E>=K_ /SX:9_X&R?_ !JCSM?_ .?#3/\ P-D_^-4
M:M%97G:__P ^&F?^!LG_ ,:H\[7_ /GPTS_P-D_^-4 :M%97G:__ ,^&F?\
M@;)_\:H\[7_^?#3/_ V3_P"-4 :M%97G:_\ \^&F?^!LG_QJCSM?_P"?#3/_
M  -D_P#C5 &K165YVO\ _/AIG_@;)_\ &J/.U_\ Y\-,_P# V3_XU0!JT5E>
M=K__ #X:9_X&R?\ QJCSM?\ ^?#3/_ V3_XU0!JT5E>=K_\ SX:9_P"!LG_Q
MJCSM?_Y\-,_\#9/_ (U0!JT5E>=K_P#SX:9_X&R?_&J/.U__ )\-,_\  V3_
M .-4 :M%97G:_P#\^&F?^!LG_P :H\[7_P#GPTS_ ,#9/_C5 &K165YVO_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*(TLG,\1DO"&"MY> N3G&=W3\/QK=_X57)_T%U_\!_\ [*C_ (57)_T%U_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 1E#H5.<$8.#BL[^PK'_ *>?_ N7_P"*KG-<N9TU
MFX5)I%4$8 8@?=%9_P!KN?\ GXE_[[- KG9_V%8_]//_ (%R_P#Q5']A6/\
MT\_^!<O_ ,57&?:[G_GXE_[[-'VNY_Y^)?\ OLT!<[/^PK'_ *>?_ N7_P"*
MH_L*Q_Z>?_ N7_XJN,^UW/\ S\2_]]FC[7<_\_$O_?9H"YV?]A6/_3S_ .!<
MO_Q5']A6/_3S_P"!<O\ \57&?:[G_GXE_P"^S1]KN?\ GXE_[[- 7.S_ +"L
M?^GG_P "Y?\ XJC^PK'_ *>?_ N7_P"*KC/M=S_S\2_]]FC[7<_\_$O_ 'V:
M N=G_85C_P!//_@7+_\ %4?V%8_]//\ X%R__%5QGVNY_P"?B7_OLT?:[G_G
MXE_[[- 7.S_L*Q_Z>?\ P+E_^*H_L*Q_Z>?_  +E_P#BJXS[7<_\_$O_ 'V:
M/M=S_P _$O\ WV: N=G_ &%8_P#3S_X%R_\ Q5']A6/_ $\_^!<O_P 57&?:
M[G_GXE_[[-'VNY_Y^)?^^S0%SL_["L?^GG_P+E_^*H_L*Q_Z>?\ P+E_^*KC
M/M=S_P _$O\ WV:/M=S_ ,_$O_?9H"YV?]A6/_3S_P"!<O\ \51_85C_ -//
M_@7+_P#%5QGVNY_Y^)?^^S1]KN?^?B7_ +[- 7.S_L*Q_P"GG_P+E_\ BJ/[
M"L?^GG_P+E_^*KC/M=S_ ,_$O_?9H^UW/_/Q+_WV: N=G_85C_T\_P#@7+_\
M51_85C_T\_\ @7+_ /%5QGVNY_Y^)?\ OLT?:[G_ )^)?^^S0%SL_P"PK'_I
MY_\  N7_ .*H_L*Q_P"GG_P+E_\ BJXS[7<_\_$O_?9IT=W<F5/](EZC^,T!
M<['^PK'_ *>?_ N7_P"*H_L*Q_Z>?_ N7_XJGZN[)I$S*Q5@O4'FN)^UW/\
MS\2_]]F@9V?]A6/_ $\_^!<O_P 51_85C_T\_P#@7+_\57&?:[G_ )^)?^^S
M1]KN?^?B7_OLT"N=G_85C_T\_P#@7+_\51_85C_T\_\ @7+_ /%5QGVNY_Y^
M)?\ OLT?:[G_ )^)?^^S0%SL_P"PK'_IY_\  N7_ .*H_L*Q_P"GG_P+E_\
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MV%8_]//_ (%R_P#Q5']A6/\ T\_^!<O_ ,57&?:[G_GXE_[[-'VNY_Y^)?\
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M% &;_85C_P!//_@7+_\ %4?V%8_]//\ X%R__%5I44 9O]A6/_3S_P"!<O\
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M**** "BBB@ HHHH **** "NIBM;7]U*T:?ZL1[<=20#G\LURU.\Q_P"^WYT
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MYLF6^\=QY^M-WML";CM!SC/&: -NX@MULXU6-0S(,D0$GZ[LU$VE0><%3SF
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M/:@9J Y )&/:EHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"M+96LLA>2VA=SU9HP2:9_9UE_SYV__?I?\***!!_9UE_S
MYV__ 'Z7_"C^SK+_ )\[?_OTO^%%% !_9UE_SYV__?I?\*/[.LO^?.W_ ._2
M_P"%%% !_9UE_P ^=O\ ]^E_PH_LZR_Y\[?_ +]+_A110 ?V=9?\^=O_ -^E
M_P */[.LO^?.W_[]+_A110 ?V=9?\^=O_P!^E_PH_LZR_P"?.W_[]+_A110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .@\*JINIF*@D*,''2NKHHI#04444#"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>trda-20211231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &0 Y # 2(  A$! Q$!_\0
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M-I'!%G]U:ACYI(_B+= /05L4TLH8*6 )Z#/6AR;''#0A;ENOGN59],LY[::
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M!^8^E2TNAT1J57;G;7:RO?7KHNENW<R8]2NC;>(FU+3O-M8W)9&N<X("@1C
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MXP,KQZ\UA^$-6TO0O%EG<CQ%I>FZ=;^=]JCM=0ED@NPWW=D+C]W@X)RQZ<4
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M=H \6Q1PH+(5_P"!=>:])\(6>H67A+3(=6NIKG43 'N))FW-O;YB,^V<#V%
MS:[U(>E1<$^AIX.1[T@$!R:7KTI&!ZBF/*J#+'G^=,";V-5GF"G Y-,>;S#C
M.T>E9]]J-O8KF5^<<*.IJHP;=D1.:BKMV+Q=G4EC^%9EYJUK:$JTF]Q_"IR:
MYG4?$4UPK!)!##TX/7\>I_"N<DU3EDA!9O[[?T':NV&%ZS/,JX_I37S.LO/$
MLYR(=L2^O4_G6'<:SYAS+.\I^N:P99I9"<DL?<U#ENH'YUTQA&/PHX9U)S^)
MFK)JK9^10/<U7?4IB>9ORJCACRV<?2G;E Z8/M5$)%D74YS^]< ^^*0SR?\
M/Q)_WV:J'+'@FE"$#[U(=BP;F5>DK_\ ?9IT=].&_P!:?YU6"G'6DQM/:BXK
M&DNJ3KUV-]14RZLI&'!0^HYK(8''3'TIF]?NGGV-(=CJK/59D(\FY7/LV/T-
M;MKXCF3"W,88>H%>=J4'/(^AJW#?SQ<"0NOHW-3*$9;HN%6I3^%GJEKJ=K=
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M(1NH <":4<<TW%.)XQC-  #E<FDSGFD)P,=Z:,\T /.#WHSC.>E,S3V^[D4
M(,&@\4T<88BE;IF@8I(S2AL]:BSGZ4H.* 'MZT9P*3(/>@\"@!P/!IR=#3#C
M@]Z"Q4\4 .YQ4%Q;P7<82Y@CF0'(61 P!_&I<Y'%)C+>U B&ZL[6\MS;W=K#
M/ <9CEC#+QTX/%"V=J@@"VT*B 8A 0#RQC'R^G'I4V#CUI5.: (X8(;:/RX(
MDB0$G:BA1D^PJ!-$TI,,NFV08'((@7(/Y5;[@5(0 .>F* *YLK1XYD>U@99C
MNE#1@AR.A/K^-,FT[3[JY%Q<65M+.J%!+)$K,%.<KDC..3Q[U/NSTZ4HX'-
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MG@\<&O7J3G=R.*7&!CUH 0KDYS0%.<"HKBY@L;:2YNIDB@C&7D=L!1]:M1@
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M5-^R/EU'8[>^1SQFL..UN+EIEAAD<PH7D '**.I/TKT(RBUHSQW"2?O+<:'
M4GUIO6E50%R:86YJB3LK-X[;PQISJDHDD,V6AT^*XW8;C<7Y%4(-"T^73HRW
MVG[5+82W8;>NQ2A;Y=N,G.WUXK&@O[ZWC"17MQ%&.B)*RC\@:8;N88*SR\(4
M'SGA3U'T.3Q67(U>S-_:1=KH[$^'[*+3[RT2.9"SVB?;)L%&WL,LG P.?4\5
M7_X1G36NH2\6H6\0N)8'C?YGD"+D.,+D#L>#BN4>]N7@$#3RF$# 0N=H&<]*
M1KRZ>2.5KF8R1C",9#E?H>U3[.2ZE.I#^4Z>7PW:6TUW(]O=3Q1B$Q6]M*&<
MB3/S;MN<#''RCJ,U+%X6TN.\6UFEN97DNI[9)(W4*H10P)&.3S@C(KDA>W8N
M&G%U,)FX:02'<?J>M,2ZGB"[)Y5"$LNUR-I/!(^M/DGW%[2'\IUUMX<TVYC2
M\7[0(&M%F%NTN6R9"A.X(>!C/W>I%<SJELECJES;12.\<4A56=2K$>X/0U%'
M>7,;(\=S,C1C:C*Y!4>@]!4;,6)9LL3R23UJHQ:>K(G*+6B$R74\\BDBE(8J
M>U(#M)]*4$8SCDU1F#'!/I2K(0::>1FHBQ4T#+ZR@\-5>4!'(!X/2F*W?FG.
M0R@^E3LQ#UR5YY%-W,I.*(G !%*Z@\YX_E2!H>S[E$@Z]_I4R2>5LDC."O0U
M#&F[(&,4B,48QO\ A4L5CJ]*U/9.LBG!/45Z%:W"W5NLBD9/7%>-6=PT$H0G
MD5WOAC4\_NV;Y3Q]*RK0YH\QTX2MR2Y7LSN8)-RX)Y%6*SXVV.#5\$$9'2N!
MH]E#NU %)3ATJ1A1110 4444 %(:*6@!HII//%./6FXP:8"AN:AG?:"!U-2=
MZK3MNDQV%-+43V*\\HAB:0]!_.N-\27N2MH&X^_)_05T^H3!2BL<1I\[_E7G
M-Y.;J6:Y<D;V)^@[5T15D<LW>16DS*P7.,_RJ&64(VU 23Q3XI-\+2C@MP!Z
M"H8?FG)_A0?K6J0"2!H8BI4[VY)JI*QR%]*N7$_&:H;SOR,9K2" %4!^3S0[
M@G Z4K+\@(/S'J,TY+4^7OD. >@%4!$I&2>E-=B6ZT\@!L**4!0<G!/I3 :L
M3,NXG [9I&4@=14DMSYG\( J$MD9)IJX#2*OV5DDL;W-TQ2UCZXZL?057MX&
MNKA(8_O,<9]!ZUO*L#-O?/V&S^5>,[G[L?7%>9F6+=)>SCN][;VVT\V]%\WT
M.S!X?VCYY;+[OGY+=_=U$A@NKN-0I-E: 92*/[[CWJ2.*SAN;6,6G,X8[Y>6
M!'J#3)V,@$MRHDB',=W;'E![BI) S:I8JTI?RHVD9R,9!&,U\ZW)IJ]E:3LK
M]$^N[=[7YM;]+'L)15M+NZW\VNG16OMIYF!?7]U=.T<TGR*<;%X6J:@ 'CFG
M2/YDCL!U)-1-E1FOKZ5*-."C!6]#YRK.4Y-R=R4= :4E1P138R#'R>E,)&<U
MJ0.5$W9' ]*=*H497O42G&:E0C;M;OTJ6A$2=R,U-N!CP3C/'-,C #NI.<5(
MH1_4'J*4@%MIMDN#D'O5UE69<CAQT-9+D[_E^_6E V%%3)=26,BR;U9.C X;
MWKT3PU>I'#$%;"GY6'H:\\G^60NOUK<T*\(G:(G[Z[A]:G?0F3:LT>I$;>>_
M2KJN'@7]:R]/G^U6,4C?>QAOK5ZV8<KVZBN22.^,KJY;"G(/8BD([4\$;,TW
M'\7:H*$)^; YII!)YI4."2:5CZT##( I I SZT1KN)S3I#C%(1Y)X\NK-O\
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MD\DT >?>++2UCUSQG']ON([R>&P:.)KIC\IF7<ZQDX^4@ ''RYQWYMZO<?\
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M9J-_- LI2;$*R3)\P^3<0"0#CV J2]U"Y?P_HK77B2WEB_TLQ>;J%Q9)<*'
M1EN<#<Z#(7=D,#GGJ?5[+3-.\/:(;;S +2+?+--=N"69F+.[L>,EB23[U)_:
MVC2[(GO[%RRK(BF9#E6("L!GH20 ?4B@#GKS59;KX17VJ6[7=O.=%EFC>5\3
M*PA)#%EQ\V1G(QZ\5Q^J^19ZMXG=M>FL+V>UL'!GNY=C(S#>2%.53("&0?<#
MGD9Y]@:)65E(!!&,'N*;L0MN:-=V-N<<X]*!G%_#K45O=*O8 SR+:W)02B_-
M["<J#B*8C<RC/1LD$XS7&FYT_2;+4=/_ +3N?,F\03).LVLM;1H@#LHEE.YH
MP^,_+@N5Z\&O9EC1$ 0!5'  & *C:WB)<F)&#XW94?-CIGUH$>2>'[BXUJVT
MC3)=2N39R:[<VS?9;Z8[H5M6E5!*<.RYP03@D8QVI-3U"&VFN?M&OZA!XABU
MR*VBM/MTBDVOGHJ Q[L%&BPQ<CDDY/.*]@*1F3>$0D\YQSG&/Y<5RS>&]'U#
M7I6.LW<IBG2ZFTL7*-&D@8.K,N-X&X!MN[;GM0!P-CJ>I3>)8I;C7+:#5_[6
M,#VCWEPTWE^;CR_LP!3RRG(?&.0V[-=G\.X;2VE\1VD-Y-+.FJS"2*:Z:5HQ
MN.TD,3C<,\_Q8[XKLV@3<) HWXV[L<X]*C5521G5%#MC<0.3CI0!YGI$=SXA
MU73["_U/4_LSPZL\BPWDD9<I?!$R5(/R@\>F .F13?#DEVL?A;4I-3U">ZU7
M2;B2\::Y=U=EC1D(0G:I7)&5 /7.22:]/B:VG#/;F)F1F1C'@[3GY@<=#GJ*
M8UM')$8MH5=I0%0!M!&.*!GDGAW6XH+#0[^PUO4]1OWTR6;68A<M<2*JVY8-
MY;DA'$@0+P-V[^+)-4=-US48[J?^P[X7%Q-H=U,$CU>346>=0A1GW*$63ECM
M3UP1TKV32=.AT;2K/3;;<8K2".W5Y,;V5%"@L0!DX'I5Y(HU7Y8D&,D84<$]
M:!'CFNGPW<>%-5BT;Q'J=^38"XN$%_)-&I5U^>1B24<Y.4R 0#E>!3]3U>#3
M?%:7-MKCZA;PM:+;V\>K2QW.PJG^K1LI=(^<EN2<D;AC->M^3&NX+&H#DEL#
M[WKGUJ18X@BL(D!087"_=^GI0 YOF)]13,T]!@;CWIC#!]J0Q12A<\C@TRGJ
M>E,0*2"21Q3P!VZ49XSC-1$A0QSCO0,KW!.\ '@5EZKJ<EA;#RGVS.<*?YUI
M\L"3UZYKA_$U^6GG8=(UV)]>_P#GVKIH4^:6NQQ8NJZ<+K=EA?B'<02,LUG%
M.JG 97*$_P Z'^)4C*1%I:JP[M/N'Y;17"2'8H)Y_K29Q%QU/)KK^KT[WL><
ML762MS&MJ_BO5=9S#--LA;_EE$-J_CW/XFL5P438/QI8OO%NPX%)))W-;1BH
MZ)&4I2D[R=S:TCQEJVBE8DE^T6Z\>3,<@#V/4?R]J]5TF2'4;&+4S8K;S748
MW!@"Q7L">X[_ (UX0#AL@<U9^VW:QC;=SC_9$IX%8U<.IZK1G50Q3IZ2U1T/
MC;PV=$OOM%LA^PW#?)CI&W=?\/\ ZU<IGYJLM+=3QXGN96CZ[6<FJ[!0>*U@
MFHVD[F-1QE)N*L(QR,4PD(I9SA1W-2' 4LW  S71>"?"7_"3W37^H*PTV!MJ
MH./-;T^GJ?P^DU:JIJY,82G)0CNSG["QU35W9=+T^:X"G!<+\H^IZ#\ZTW\$
M>+D0NVDY YXFC)_(-FMC7?B#J6@>(IM,TZRM8+"S<1+ 8L;@._'3/;'M7K,,
MGFPI(5*[U#;3U&1TKEJSK02D^IW4\%"6CD[GSI<+<V,YM[^UEMI1_#(A4_K3
M<YY'2OH#5]&L-<LFM=0MUE0_=/\ $A]5/8UX;K^A7'AC6FL)F+PM\\$N,;U/
M]>Q%71Q/,[2.>OAY4=6[HJ(/EH)HYQ2-Q769"=>M+Z8'%)32<$"D(Z#3?#,U
M_9173WMI:QSR&. 3N09&'I@'C/%9ES87%M?364D#&>%BKJHW=._':NN\/2N-
M%MXX=0TR:$RDW-EJ6T+%S]Y<\D$?K^-6=+NM)A?6;?29Q"S7:-$1=BW+1#T=
M@<@-DX[BN=U))LZE2BTNAP4$#S,5C1W(YPJY(I!!)(Q2*-Y".2%7/%=]_::W
MG]IKI-[9Z??/J*2LXN J/$%P<,0NX;LL1COWJ"WNGETV^M]-UFVBU(Z@99KC
M>+?SX\=0?3.3C_&CVK["]BNYPL<3M]Q&8YQP,\^E2B&5W\E8W,G(V!3G/TKN
M=0UNT2#Q)-IEZD4TDUOY;1.$:0@8=D[]<\CU]ZLW&H6]QJNO?8-0MHK^XMH/
M(N!,J@X \P!\X!(Q^7M1[5]OZT_S#V,>_P#6O^1Q-[IT^DR6@N&C)NK9+E-A
M)PK9P#D#GBHCME&.XZ&M?QO=I=W^FM'=PW4J:=$DLD3AAO!;=G'0]\>]8D+8
M49IIMQ39A4BHRLAC9:5<\,IZ^HKIM&G" X.'5LD>M<[,/GW#N*MZ?<E)XR3@
M,=IJKF;1ZWI]P+FU1LY8<&M6W?*[?2N/\-W9):)O7 _I_6NJA?:ZG\*X*L;-
MH]K#U.>"9>'2E%)2BL3I%HHHI %%%% !0>E(:0F@!".*0')I_:HR,4Q Q"@D
M]JHDY))JU,<1GWXJB[81C510I.VISOB*[\NR= ?FE.W/M_\ JKBYU\Q @.,\
MGV%;WB6<M.D8Z 9_,_\ UJY^=OFCC'4_RKJ6YRI=2!8S%"4+<GFD0""!1G)8
MY-)>,0^_)]A4<A94C9QVJU=C*]RQW4R"+<VXC@4-AW'/%2,Y2( #K6JV 4%
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M$QDC#>9&"2$;/499N/<TQ'*^#KS7?[7U#3M6EDDCBACFC%U<V\EPA8MG=Y(
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M[;!([AVPVT23 Y8#=_=!.!DG%=PDA! ZBD,60%1[4(WR^M3'ISTJ)TV\CI0
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M*3Z5*"5!!Z5"GRN2>E:F:%G);^51I]X#UJ23@$GUJ)3\X/O0MBA\H [U QZ
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M*1N"%B21UY(R*FL_"5W87D<=OK]W'I$=TUTEBD:J<LQ<H9!R8]Q)V^G&<<4
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MN;201SVUV@5T)4,I^4D$$'/!K);QA;6CF)HK[4+B:_N+2"&VMU#%H^2O+8P
M#\Q(]\5L:?I,EGKNLZ@TJLE^\3*H'*;(PAS^6:Q[/PI/:ZS;7QNHV6'4;R\*
MA3DK,I 7ZC- %<>._M.I^'X;+3;QH=2N)H+CS(0'@:/<K*PW<%6&6Z\ XS4]
MIX[MKW2X-0M-%UF:*[91:*MNNZXRI8E<O@ ;3DL5'IG(ID7A*_M+NPNK:[MC
M);:M>7C+(C$-%<.Y*@@\, _7D9JK=>!+Y_"?A[28[NSF_LN(1S07,;M;W/R;
M06"L#QU&<CF@#27QU8R6-M+!8:C->7$TL"Z?'$OGJ\1Q)NRP0!>,G=CD8SFH
MY_'=A'';F'3]3GN9HVE:T2%4EA56*$N'90/F#  $YP<9'-9FE^ ]3T*"UFTZ
M^T];^TN;EXE-JRV[13["R;%;*X*+@@GISG)I-1\!:AJ%[!JMY<:+JFI^0T$Z
MZGIHE@"^8SIY0SE=N\KR3N'4\"@!=1\<7$DTLNE31M9M:Z;-$7CYS/>-#)G/
M.=HQCL1722>*+""TO;IEF\NTODL),(,^8SH@QSTS(O/UK ;P!,(1%'=VR_Z+
M80GR[985+0733NP1/E4-NP .E.U#P=K$\]_!;:I:)IEWJ4.HM&]NQEW(\;,F
M[=C;^[R#C/;WH MZ9XNG70[:XN+"]U&]N+R\ACAL(5)V13R("2S*JX55ZD9/
M3-3#QY82P:6]K8:C<RZDLQAMXH5WJ875)0V6 !4MZX.#C)QG&O/ -_-I]A;K
M=6%Q';S7DDEK>PR/!)Y\QD5BJLN64';@Y!R>E:'AKP5<:"^BA[NWECTV._C_
M '4/EAQ<3)(N%Z+C:1@>V* +_BWQ%/X?.D"WL9KH7MZMN_EINVJ02<<CYCCC
MZ&D/C2T&J1V4FFZG'!)=?8H[]X56!IN1M&6W]00#MP?6IO$^E7FJ6]B;">"*
MYLKR.Z3SU+(^T,"IP01PQ_*N43X<7YURWOY;O39FM]16\%T]L[74J^9N*,Y<
MA0 <#:.<+T&10!N?\)]8A7DATS59E-RUI!Y<*_Z3,K,&2/+#IL8DG"X!YXI(
M_'^FM92W'V/45N$O38BR:%1,TP0.P +;<!3DL6 XZ],YVKZ-=>'?#>F30/)+
M>:?JL]W'-#:O.B+,TQ.^-3O*[9=I*Y(.#C&:R-,\(7WB?2[K4;X6CWC:S)?6
MZZAIS>1/&84B*M"YW*ORG:3\WR@]\4 ;]W\049]'^PZ;>2-=:D;&[B>(>9;D
M1%]IPV-Q&U@02"NX]JU=)\76FN:@]M9V.H"$-(D=XT(\B1HSM8 AB5Y!QO"Y
MQQFL6'P5?66GV/V9]'M[RVU0:AY=M8""WQY31E $.3PY.XDG/MP%TOP+>V_B
MR+69;NP0Q2R2/-:6K0SW:L& 2;#;"!N!SMR2HZ<T =W&3@U#DAR:F7Y6QZU$
MWWC2&3(=R\TFT=#21\CCM3ASUZB@!@W9VF@@$FGG[P)J)QACZ&@!V#P#Z4W.
M.#4B-N IA7+$9H 9GFG C\*;C!HIB'Y*>X-+M#+D<-30W !Z4H&&XI .!XP>
M#5*[4K+]1FKHR3R,&H+Q,J&':JCN#V.:\1(6M8G R%;!KSN>,PW,B'HK''TK
MU2\A\^SECQDE3BO-]6BVW"28X=<-]17H4'>%NQXV,C:IS=S*? <CMUJ+:"V:
MF>/<<GZ5$@P^*W1S(BW88 ],T.WS$9X-2%,$L.?:H9<\-CK3*/1/A'<J=&U"
MSR/,BN?,(]F4#_V0UW.I7G]GZ;<783>8D+!?4UX?X8UYO"_B%+M@6M)AY<ZC
MKM/<>X//YBO=8)K>^M$FA=)K>5<JRG*L#7DXB$DVD>KE]6+@H/[/Y'+>&/%-
MYJVI/:7446"A=6C4C&/7GI76[$#EPHWD8+8YQ5:TTRQL'=[2UBA9_O%%QFK=
M<F'A4A"U1W9Z5><)SO35D(S!5+,0 !DD]J^<IIUNM3OKI/N33LZ_0DG^M>J_
M$3Q7%I>F2:5:R;M0NEVL%/,2'J3[D<#ZYKR>&,QQA<<]37IX6#OS'AXVHI5%
M!=!W)/M28]:4GBHF?)QGFN\YB?.:3//%)U%)M8'-2,D.2.M,4$DBDR<\FG;_
M )N.@[T@$92!@&NMU+QC#>Z;,(_M<=[/;"W= L8B'&&.[&X@CM^M<D7IH'?'
M-3**=KFD)N*:1U;^)[9]0OKG[/-MN-)-@HXR'( R>>G%68_$VF&Y34)+6[^W
M?83:N%*^7G;@,.<_AV]ZXS-+VR3Q4.FBO:SN=19>(],6+2KB^M[IK[3(PD2P
ME?+E .5W$\KCVSFK>F^-;2"S*WD5W(2TCR6H"/!,6)(^]RG)[9KB0"6Q4I4
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MJD;H\IU.T:UG9<9 Z'U%6-,U6XL8QY3@K_%&W*M72Z]I?FLR 8;^$]JXIU=
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MN;R&RM)9YFPL:,Y ZD $G'J<"O,-.\*1:E<6L>LZ=/>QP^'@B?VA;_,KF5\
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MFEQCWJMI]C!I>EVNGVHVP6L*0QC_ &5  _E5D#. * $!PV32$DGVIS'CWIM
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MN2<FW<]6G34(V0]<   <4O4T=J!TK(U THZ44#I0 4444 %%%% "&DI:3O0
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MH!(/GV4<C'^),5HG%[,CEFMT<2< ?/&1]*A>%'(V-M]<UV4WAV$#Y4E3Z_\
MUZJ'P_'NY9\>V*=B>9=3EQ90@C,@]_>IE,"+M52![#K71?\ "/IN/SOCT_R*
MD7P\F,EFQ_GVI6#F1S)^;A$_$BHFA;N2?H*[1/#D603;22>V&Q5Z+1&48CMT
MA'N!_2C1;L:YGLCB;72)Y2"L6">[=JU8?#\>?G9YY/0#C\Z[&#2(X@#(=Y_2
MKT<,<0^1 *GGBBU1F]]#F;3PY<N0K,EM%W5!R:Z.RL+>S&V).3P6;DFK*QNY
M^49JW!:J#ESGV%92J-G1"E&.Q"D1(&/QJW!" /4]S2E%494_+4BC]T2.O2LG
M*YLD(B[FXZ>M2E@!C-1[MJX'-)G(_&I&*6YI,[1GN>E-/ .3S29SUI@&>:E3
MYJAI\;;7H 5P=QHB.'IQ.2:0?*:!$CY&:B[@U*_.#3&&,>E PC^_4C]:CA'S
M$U(_I2 :AHQM)KRGQWXCU"SO];DT[4K^)M*MT8+%+;PPQ2E-XWA\O,6RORA0
M.V<FI]:\1:G9>*)+^;4I_P"S+=[8/'8S0D0!E0LDT#X=MVXD,K$@$8&0<L1Z
M@O*TE>96_B'5+/QF\EW?W%S9SZA+:0+:SPR6Y^\$A>+ DC=2!EAN!(/8\0Z=
MK^IQ6'AS6HM>EU._U8L+G2SLV#]T[LJ*J[D,;*%)R<\YY- 'J,L\-K;RW%Q*
MD,$2%Y))&"JB@9))/  '>E5E8!E(*D9!!X(KR[^UKFW\&-K0\8R75_?:)<W/
MV.1(W3S1 9,QA0/+"$$$-D'H>:I>)?%.IV\U]J%CJ=]BPE@A $EO#;H^U"R%
M&)DE)W'D #G Z9H ]<21&E9 ZEUQN4'D9Z9JCJ>B6NJ7UA<7+SD64OG)"KXC
M=Q]UF'<J>1[^O%>9ZW>ZAH7B#Q//8ZG/YES?V5N_F2Q(L*2(#N#%"%(X0,V0
M-W.3S4T6MZ]"CZ5=ZM]G@DU*VMFN_MD5Q/:HZ2,P+A H)*(%+ D>9["@#U!+
MB">::**>-Y(&"RHK@F-B P##L<$'GL14HZ\UQG@,*NJ^+%746U$)J,:"Y<J6
M?%O$,$J "1C:3CM7/:AXQU;2M;%G/=L8-'O9'U.1D&7MI)(A#GCLLY)(_P">
M1H ],FOK9)G@>YA65(_-9&D 94SC<1Z9!YHCN8))Y8(YHWEA($J*P+)D9&X=
MLCGFO(M>O-7U'PU>+J%_-$9]%CU%D14!3S+AB$)*GA4*K_P&KNJ0ZAITOC+5
MK+7;U)=+@MIH\",BY=8%.Z7Y?F! Z#:.3[8 /6$.#4=Q=V]E;RW5W/%;V\0W
M22RN$51ZDG@5B>--2N=)\-27%K<"U=YX(7NBH86Z/*J-)@\?*K$\\5P?BE;F
M2/4=!C\17M]912:9<&5FB>2)Y+H(8V;9@@C$@!&05'53@@'H&H-H?BRU?1DU
MB*02Q+-+#97B[Y(&'?:2?+8,!GN#UK8C:-7\B,HOEJ/W:X^5>0..PX/Y5Y[X
M8MKW0+[Q/<6D>IZY,-5%L8=]LC;1;PMYA)"#/(7 .,8XZFJE]>SZ7XA\5ZO+
MJ=]83MI5@5MRL,IB>1Y$"@< E6X!W[07))(Q@ ].;[U2I7CL?B+7+6+Q':1:
MA>));PV4D+7<\%S+ \DQ1LF,;>5 ^4YQU[UI:U<W^G?\)%"?%U]9OHEBLUF9
M7A+7!=6??)E/G&[]V ,8V^IS0!Z>?OBF/(AD,892Z@%E!Y .<''X'\J\DU3Q
M)XBN[Z^\K4#:KIUG;2QO]NAMU)>%7,LBO&Q==Q*X! ^4CJ:Z'PI'._CG7KNY
MOY7FEL[-WM@R&,%E))7"AB%((!ST8YSQ@ [M"=]9]YXBT2RGGCNM8T^"2W :
M=);E%,0/ + GY<Y&,^M>:ZKXB\1OK.LW5M>);#3;W[/%#)?PQ0A1MVB2-D+-
MOSG.[N-N,52N/#TD^IRL=;U(>9XK\D@"# /EYW\QGYATYXQV[T >T1.CH)(V
M#(P!!!R"/6D? (QWKR6X\1^(Y-9U&[@O$@6RU0V<<$E_#'#L#A55HC&7)<<@
M[L_,,<"M;3+VXU(1ZE=^+KBRNKC4)K)M/58V1/G>-8E3;N#@!6WG/<D$&@#T
M/S4D16C960]U.13U^5C[UXO83:M:^#_#EOIVLW4RO#<2RV\-W!#<C#* 4+KM
M9%YRI()+#DC@>J^']2CU?P_IVHQR/*MQ C[Y(PC,<<DJ"0.<\ D>A-(9H.N&
MHZBGR$4T=J8A",&DIS#O3: )%Y^M/SD5 &P<=ZD_BI#&.V6^E-R*5L%NF:4C
M I@.Y"_6A3GBFL<)BFJV&% $A&W(H)P!Z"GMR,U%]X "@09R2:BFB\ULKPU2
M X;%/VX<'M1L!2,10$,,-6/J&C0W)+Q8CDZY'0_45T<A5^"N15.6W9>0<C]:
MTA4:=T95*49JTD>>:GHVR0^<AB?LXZ&L*?3IX06V^8HYRO6O5W19 4= R]P1
M61=^'X9 6M7\I_[I^Z:ZHUD_B/.J8.4=8:GFH <'CIZU$RCJ!79WVA21H3/;
M[O\ IH@_J/ZUS\^E#)\J?'LXK1:['([Q=I(R#-M.#@4\Q^8N2H/O5A]-N0P#
M0JX]4.:#;O%GY'3V(H8TRHZ' &" *@/!X%7SO[X(I%51T09^M*Y5RB(Y)" H
MX]ZM)"4["ILMT15%*%E88X_ 47'<A(V DC'XTQI3_"15M+264\0R,?7;Q4\>
MDS%AOVH/KS^E(+F8D;,=TF,#UJ0022MMACW_ ,JZ&UT9"03&TI[ ]*V[?P]/
M.H#@1)Z#BAV6XXJ4G:*..M],PV;F4$GI&E=9I.B22JI$7E1#ID5O66@6-EAU
MCWR>K5JHF3A1^ K*57L=<,(WK,KV=A!:#**"YZL:OQHSGCIZT^.WQAG_ "%6
M  .@XKGE*YW1@HJR%C4)R!]34G&<BF4H'>H+',>.*: #2MV%(* '=J44F.*4
M=*0PQ2T9Q10 4444 %%%% "'K24II#TI@&*#TI0<BFL* $''- .&YH'6E88H
M =C--)VFA3[TYAFD TC)I,=J<HXYIK<MBF(8_7VH0X//2G  CFF$8]Z )CZT
MP#'/;%+&>-IH89&T&@9$J\$X_.FFW1CG!'TJ8X"[13,X&*!%-X&W97! ['BH
MVA<#.TX]JO\ UYI ,4^85C.*L.H--*C/*_I6F0*6-5)Y4?E3YQ<IE[!UVC\J
M<%VCH!6GM7=]T?E30H'4#\J?.'*9Q#G^$_3%*()#SM/XUI,,8QBDI<P^4IBT
M;'S,/PJ1+>-#TS]:G(S1MI-L=D-"_@*<#S[4O2E'3WI *B\$8XZT/T ''>G1
M]*C/+$T -.<TY2$![YI2*2@!I&YLBD%/H( /% Q@QGFEQC%.HQ0 Y1Q2NN%&
M*1.M28W*<T -4DJ :1P<4AR" *<>10($X&33ASP:;D$4IZBD,S;K0-'OKW[7
M>:38W%SL,?G36Z.^TC!7<1G&">*=-H&C27<%V^DV#7, "PS-;(7C Z!6QD >
MU:'\5*13 STT32H]3.IIIEFNH,.;H0()3_P/&?UHM]&TNTOY;^VTVSAO)O\
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M9&&0P/4$'K56VT'2+.Q-G;:58PVA<2&".W14W@A@VT#&00"#Z@5?QWIQ.5H
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MQ28P#7)#QE/Y2Z@VG*-):7RQ+YH\P#.-VWTSVIO]JZH/'4\/DE[:*W)\L2C
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MX4444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPSB4W)D8R3\]"3T'/IV%=!+HEV^NZM>@Q^5=V?D1C=SNP!S[<5T=%-U&S.&
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=N6I%Q?NJWX*Q-11169Z 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>trda-20211231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &- XD# 2(  A$! Q$!_\0
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MX*;0V2[=L>E3VVK7WVE(K[3FB612R/&V\#'.#Z&LV71[R>QU%1'B0W?G1*W
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M[&[2\5RP\27D217=S':BUE91Y:29D0'H3ZU)-K][+J-S;V26V8./+F?:\O\
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ML3"]C?- (/>N<BUN^AU2VL[P6CFYR$\ALE& SR/2J6CZG=6%GJUW>E'1+E@
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M_P!_31_9,7_/Q=?]_31SU/Y?Q"T>_P"!?HJA_9,7_/Q=?]_31_9,7_/Q=?\
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M8O\ GXNO^_IH_LF+_GXNO^_IHYZG\OXA:/?\"_15#^R8O^?BZ_[^FC^R8O\
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MQ?\ /Q=?]_31_9,7_/Q=?]_31SU/Y?Q"T._X%^BJ']DQ?\_%U_W]-']DQ?\
M/Q=?]_31SU/Y?Q#EAW_ OT50_LF+_GXNO^_IH_LF+_GXNO\ OZ:.:I_+^(<L
M._X%^BJ']DQ?\_%U_P!_31_9,7_/Q=?]_31SU/Y?Q"T>_P"!?HJA_9,7_/Q=
M?]_31_9,7_/Q=?\ ?TT<]3^7\0M'O^!?HJA_9,7_ #\77_?TT?V3%_S\77_?
MTT<]3^7\0M'O^!?HJA_9,7_/Q=?]_31_9,7_ #\77_?TT<]3^7\0M'O^!?HJ
MA_9,7_/Q=?\ ?TT?V3%_S\77_?TT<]3^7\0M'O\ @7Z*H?V3%_S\77_?TT?V
M3%_S\77_ ']-'/4_E_$+1[_@7Z*H?V3%_P _%U_W]-']DQ?\_%U_W]-'/4_E
M_$+1[_@7Z*H?V3%_S\77_?TT?V3%_P _%U_W]-'/4_E_$+1[_@7Z*H?V3%_S
M\77_ ']-']DQ?\_%U_W]-'/4_E_$+1[_ (%^BJ']DQ?\_%U_W]-']DQ?\_%U
M_P!_31S5/Y?Q_P" %H]_P+]%4/[)B_Y^+K_OZ:/[)B_Y^+K_ +^FCGJ?R_B%
MH]_P+]%4/[)B_P"?BZ_[^FC^R8O^?BZ_[^FCFJ?R_C_P M'O^!?HJA_9,7_/
MQ=?]_31_9,7_ #\77_?TT<U3^7\0M'O^!?HJA_9,7_/Q=?\ ?TT?V3%_S\77
M_?TT<]3^7\?^ %H]_P "_15#^R8O^?BZ_P"_IH_LF+_GXNO^_IHYZG\OXA:/
M?\"_15#^R8O^?BZ_[^FC^R8O^?BZ_P"_IHYZG\OXA:/?\"_15#^R8O\ GXNO
M^_IH_LF+_GXNO^_IHYZG\OX_\ +1[_@7Z*H?V3%_S\77_?TT?V5%_P _%U_W
M]-'/4_E_'_@!:'?\"_15#^R8O^?BZ_[^FC^R8O\ GXNO^_IHYZG\OXA:/?\
M OT50_LF+_GXNO\ OZ:/[)B_Y^+K_OZ:.>I_+^(6CW_ T*0U0_LF+_GXNO\
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%<9\E_\ =/\
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MF \V)'VGC<H.*F50H&* '#I1110 4444 %%%% !1110 4444 %%%% !1110
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MIFZC-%@N/HIN31NI#'4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!11FFDXH 7-(329I,T[$W \FLN/47?Q!-II0>7'") V>22>E:E<K;ZA:-X[N
M4692S0+&!ZL#R*I*YC6J<KCKNSJ12TT&ES2-KBT4F:,T"'9I0<4S-+F@=Q^:
M6HZ4&E8=Q]%(#2TAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%)FE-*X#)?\ 5/\ [IK"\(<Z'S_SVDZ_[U:U_P"?]BF%MCSMAV9'&:Y[P/\
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MN68_R^M>2ZWXIU'Q"[L9FM--!PD2G!<?[1[FJ6IZYK6L6T=MJE[$;6-MQV@
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M7%-'6K4D?M47E<T (M2"@)BG8Q0 J@9YJ_\ :))(5B9L1KT4=*SP<5()..M
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M=@8+A4'?%=0.U &*4"E*;D[L<8J*LA13AUI,4\"H*%%.'2D IU(!1U%/'6D
MIPJ1H45(*8!Q3Z3 6BBBD,*:U.I#0)C#333C335$L2F&GTTTQ,8:0U0U/4)+
M>2*VMD5[F7E=Q^5%[L:SI+O4[=MPN8;C'WDV;0?8&L9XJ$)69K##3FKHW3TX
MK)?5WDD9;*U>Y53@OG"Y]O6LR2]FU4F5VD@M^BP@X)]2:>D@AB6./Y$48 !K
MCK8_6T#KI8&VLS4M-22ZE:%XVAG R8V[CVJKXACC.F^<V!)&ZE&[YSTK*NKH
MQ2PSK*B3(V5,G0^HICW%YJ\Z#*SLI^2.)2(U/JQJ'C?:T7!J[9:P?LZJFG9(
MUO#^?)ND_@6;Y?8D FMC%5M.LA8V:P[MSY+.W]YCU-6\"O3P\'"E&,MSS,1)
M3JRDA,4HHI<>U;F #DTN.U+2@4BCEM3\$VNI:[-JZ:C?V=U-&L4GV:3:&5>E
M6;7PI;03V$TMY=W4UDSF.2=\D[A@@UT.!3@*FQ2;.>_X1'3CX9FT F7[)*YD
M8[OFR6W=?K4I\)Z9*VK-*C2+JD4<5PK'C"+M&/0UO 4H'%*Q29R\O@JU9+)X
M+^]MKNSA\A+N-_WCQ_W6SUJ:T\&:;:2:?*KW#RV4KS+)(^YI'88):ND I0*F
MQ0J]*>.M- IPZT#'=J6BBI*"BBB@!#33WIQIIZU+!#33:<1334,T0TTG:G$4
MVI8T(>E--.Q4%W<):VLD\GW$&34,I;Z#S7/:E<_:]0BA0?NK5]TC=BV. /I3
MGN-2<),]P+??\RQ(N<#W-9\(DAC<2N'=G+%@,9S7#7KJUD=M&C9W98FG9VRS
M$GU-1:=IZZE/-)(=L"MC"#!<]^:KRR\=:(9KW3K1?(N52)B66)EW'_\ 57!&
MM!SO4V1UNG)1M#1G71QI%&J(H55& !VI^*R]%U8ZBCQ2J$N(L%@O1AZBM<"O
M7IRC.*E'8\R<7"3C+<0"G"@<THK5(ABBG8I*6J1(FT9Z#\J<%%**7M5HA@%I
M0H/':EI15(EB>6,YP">Q]*>%I12U:)"BBBF 4&BB@!A%-(IY%-IB&$4TC-/-
M--!+&$4TBGFD(IDLC--J0TTB@0PBDQ3S28IDD>VD(J3%(10!AW9-]>S6[RM'
M:P ;PAP9&/;/I6=/9P)DP>9 V,9B<@D>_K5A)/.NKNX'".^T+].,U#.Y(;!Y
MQ7S^*K-MZGT&&I*,4BWX=L08UO6 "X*PH/X1W)]S71 5R-IJ5_::<L,4,(2(
MX,K$X.?;UJ_IGB%IKA;>]1$9_N2*?E)]#7;A<7AXQC33U.+$X6M.3J/8Z$<T
MX"D7! (Z4\"O2//L IPI *=2&*.M.%(*<*!H4#FG#I2 4Z@I!1112&(:8:DI
MAIB&&F$5(::1D4P(^]--/(XIM,1&13:E(IA%,#(UN&0PP7,2EC;2>8RCJ5Q@
MXK+:X65?,1@P;G(KJCQVKBKC;#?WD4?^K68D?4\D5X^:1Y$JG<]/ 2Y_<?0)
M9>#SQ5=%N+E6:"VFE0'&Y5XJ.Y?,# _=)&X^@[UW,"HEO$L0 3:-H'IBO.P6
M$CBVW)[';B<0\.E97N<*D@?/J.H/!'UI5\R.42P2-'.H^5E/7V/K6AKD:?VX
M%B W-%F3'UXJCD@$CKCCZUPUZ;P]=QB]GN==*:K4TVMSK=,NOMNGQ7!7#,/F
M'H>]6\5G>'F0Z+ $(R,AQZ-GFM0#-?:4).5*,GV/EZT5&HTNX@%+BG8HQ6MS
M,,<TM %. I# 4X"@"G 4@ 4X"@"G 4ABTY12 4\"D H%.HHJ1A1110 4AI:*
M &'K333B*2J1(RFFGFJUS=P6B;[B9(U/0L>M#:2NQ*+>B.?UHF#6XY">)H-J
M^Q4\_P ZJ--4.H:C_:.H?:$&V&-3''GJW/)JJTP4$LV%'4U\QB\0G5ER['T.
M'HM4X\VY;:;BH7FR#SS4:V]_+#YR64IBQG/<CV%1P7)1C(J@L#C#CH?I7)4=
M2-G-61T147\+NS7\.K92EGF<27W(99!T'^R*Z-4"C"J%'H!BN#GGD,JW&[$J
M,&4J,5WL1+Q(QX)4$U]#E6(C5IN*5K'B9E1E"2DWN&!1BG8HQ7JGEC<4M+BC
M% !BE I<4H% P I11BE I# 4X4@IU)LI"BE%)3A4E"TX4VG@4F-"T444B@HH
MHH #36IU(:3 8:::<:2H:*0VFFG4AJ2QN.*S]8MGNM,FBC&7QN ]<<UHTTUG
M*-TT5&33NCD3=BX3?DYZ$'JI]*JR25/J^V+6[A4Z,JLWL:S+B0B"7'7::^>Q
M,W&;A<]NC%2BI)"EWE+>5%+*!U,:D@4P2"3G/(XP>U=QID4$6F6RV^!'Y8((
M'7CK7->((8TUM?)4!WCS( /UJ\1@53I>T3)H8OVE3D:,^&:XM;@7%J^V8#&#
MR''H:[?3[I;ZQAN5&!(N<>GM7#9*@D#+ <?6NP\/",:%:>6V1MY_WN]:95.3
M;A?0SS""LI6U-.E'% IU>T>4(*<.M)BG 521(#I3A24X58F%.'-(*<!BJ1#%
M YI:3O2U0@HHHI@%%%% "&FD8I](10(C--(J3%-IB&$4TT\BFF@D:132*>:3
M%,0PBDIY%)B@0S%8MUJ=S)-+#8JBK$</,XR,^@%;N.*Y>*4PQ3V;C;(DS,<]
MP>AKDQ=24(Z'9A*<92NRK#');I()) Y9BW QC-0RO4\S53,4EU<PVT3!7G;:
M&/\ #ZU\[5;G+ECNSW()17,QK3,8O*R0N[<143*&&",BNH/A733#LVR^9_SV
M\P[LUS+0R6\\]LYW-"VTL._O4XK UJ"4INX\-BJ59N,#1T*]EM-1A@WLUO.=
MA0G.UNQ%=H*\YW21O'+"VV2)MZ'WKL-)UN+4\Q%#%<J,LA/7W!KU<IQ:E#V<
MGKT/.S+#-2]I%:&P*4"D%/Q7LGE6"G <TE/ H& I:**104444 %(12T4 1D
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MF_U7FKO)["AQ)#*8;B)X9 ,[7')'J*1E5UVL,@\&OETY4ZB<EJCWM)1T9Z(
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MMW+97JSM"[A=R@=,F@#,\-?\(I+KT TOQ+JMY=+EEAFNI'1ACN",&N5T:_\
M#UXNHRZ_XJU:WOEU&X3RX[N155 Y"@ <=*[_ $S5/$DNI0QW7A2*T@9L/.LZ
MDH/7 KG]"M_%7AR"]LE\+07J/?3SI,9U&5=R1P: +4]R-#N_#.J:?J5U<Z),
MQM9FGE9]V_[K'/OQS6KJ%W=:G\0]/TJUGDCM=/A-W=F-L;V;A$/MU-6+[3[O
MQ-X-GM+^P6QNY%)2$.&".IRIR/>H_ ^BZCIUK=WNM!?[4O9=\P4Y"@#"@?@*
M .M4=Z=2+TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-%% 'GOQ
M0-PB^&&M+>.XN1K41CAD;:KG:W!/:M?2[GQ))?JNH^'=/L[;!W30W8=@?IM%
M6?%/AA?$]M9QF^GLIK.Y6YAFA +*X! Z_6JECX3U:TO8IY_%VHW4:-EH9(T"
MO[' H Y#P9<>(HK34UTSP_87MO\ VA-B6>[$;$[O3::V?%Z7=CI^A^+);1+:
M^TF=3=0PMN402';(,XY R#^%30?#^\L9+G^SO%6I6<,\S3&%(T(#,<G&:Z.V
MT5O[ ETK4;V;4!+&\<DTR@,RM[#CO0!S\&WQ#\2I+D8>QT2 *AZ@SR#.1]%Q
M^==PO2L/PIX8MO"ND"PMYI9\N7>:;EW)]?P 'X5O4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q'Q8W?\*XU3:H8YBP#T
M)\Q:?IUUXK>2U6X\+Z9% 0N^5+T,RC'4#;S6YXFT"'Q-H%UI,\TD,<^,R1_>
M7!!&/RK"A\&ZS"T9_P"$TU1T0CY#%'@@=NE '/:?/KD/CSQ6-*T6SOU,\>]K
MBX\LJ=G0<'-;'B33M5U?P1//=:;!8ZM8RB[MH[>7S &0Y'.!U&1BI[GP)<-K
M5]J>G^)+^P>\*M,D2(02!C/-;FB:1=Z7:S0WNKW.IF1LA[A5!48Q@8H Y2YO
MX_&FM>&[2'YK01#4KH=@1PJG_@6?RKT- .HKG?"_@VQ\+S7TMK++(UW)O_>?
M\LUSD(OMR:Z04 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 UJ\=U0^%X_B;XA?Q-+-"K1P>0RO*@;Y>?N=:
M]D(S436T+G+Q(Q]2H- 'DOB2?PU<?#34X/#TTLULD\33Y:1B,L,\MST':K6E
M7GPWM[^TEM+Z?[6K+Y8,TY&[Z$XKU 6T(4J(D /4!1S2?98!_P L8\_[@H \
MY\:SWGA?Q"=<TZ&20ZM9M8E8U)_TG_EBQQ]2,^U=CX8T9- \.6.F+RT,0\QO
M[SGEB?<DFM@QJV-P!P<C(Z4[&*  # I:** "BBB@ HHHH **** "BBB@ HHH
MH **:.M+F@!:*3-&: %HI,T9H 6BDHH 6BDHH 6BDS1F@!:3:*3=2YH -HHV
MBBC- !M% 4"BB@!:*2C- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
MM%)FC- "T4F:,T +1244 +129HS0 M&*3-&: %HI,T9H 6BDS1F@!:*3-&:
M%HI,T9H 6BDS1F@!:*2B@!:*3-&: %HI** %HI,T4 +1249H 6BDS1F@!:*3
M-&: %HI,T9H 6C%)FDW4 .HI** %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6B
MDS10 M%)FB@!:*2B@!:*3-&: %HI,T9H 6BDHH 6BDHH 6BDS10 M%)1F@!:
M*3-!.* %HI <T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS10 M%)10 M%)FC- "
(T4F:,T ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>trda-20211231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &! WX# 2(  A$! Q$!_\0
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MK82D+YHD!8$G'"]QGC-7;?7YO[0-I?Z>]HS0M-&?,#AE7KG'0C/2LTZ9>_\
M"#Z?9?9G^TQO$7CXR,/D_I6E?6EU)XEL[F&'=&EK,A=ONACC /Y4FHEQE7T;
M;Z=.^_W$=GXBNKI;:X_LF7[#<,%2:.4.R@]"RCH/QXK0UN>>VT6[FME+2I&Q
M7#!<<=<^W6N333;GS[=K#2+S3-1\U3.\<F+;&?F.,X((Z#&>:['4H7N-+NH8
MQEY(F50?4BE))-6+HSJ3IR4M_P"O)&)9:]<0:-I<;V<D]_<QCRHQ*#O 4$NS
M?PBM'3M8:ZO9K&[M&M+R)1)Y9<.K(>-RL.O-85M#J$,>CZB-,N"]E";6>W.
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MINH6%IIEZ+.262U>42VX(WE6)Y'8GVK2TS[;=>)9[^:PFMK=K<1Q^;C<3GN
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M)=-L5K24L8WQD!@>H]Q3Y&0L53=O/]=CI*,50UC4QI.FR71C,C A4C!QN8G
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M_8^G?\^-O_W[%']CZ=_SXV__ '[%%ZO9?B'[OS+/VB#_ )[1_P#?0H^T0?\
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M^Q1>KV7XA[GF6?M$'_/:/_OH4?:(/^>T?_?0JM_8^F_\^5O_ -^Q1_8^F_\
M/E;_ /?L47J]E^(>YYEG[1!_SVC_ .^A1]H@_P">T?\ WT*K?V/IO_/E;_\
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M]Y_^_#4?\+$\/_\ />?_ +\-7C]%']E4>[#^W<3V7]?,]@_X6)X?_P">\_\
MWX:C_A8GA_\ Y[S_ /?AJ\?QGI1BC^RJ/=A_;N)[+^OF>P?\+$\/_P#/>?\
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MYYWG_?H?XT?\+'T3^Y=_]^A_C7E-%'L(!_;6*\ON/5O^%CZ)_P \[S_OT/\
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MB?+[CV2P\:Z'?RB)+HQ2-P!,I3)^O2N@!!&1TKY[KT/X?^(999#I%U(7 7=
MS')&.JUG4H\JNCT,!F[K35.JM7LST*BBBN<]T**** "BBN7\42^(X[JS&BQE
MHB?WFU0>??/04TKNQE6J^RCS6;]#J**9'O\ +7> &P-V.F:?2-2"YO;6S"FY
MN(80QPIDD"Y/MFI@0P!!R#T(KS[PWHNF^*+[7M3UZQM]0NEOY+2-+J,2"")
M,*H;A<YSD=<U9@N8O!UUI>G65XMQHDUS+;R>8_F/:R$;D0$'A0>,'GD4 =S4
M;S1QMM=T4X)P6 X'>O/[7Q7K^M7-E9V#6=J=0DGFAN)(3)LMHR%!V[AN9CSU
M Q5'69M5AUVS?6H+*6[ATV]!\L$Q3*-N"5)R,]UR?K0!ZBK*ZAE(*D9!!SFE
MKSS2=8U_6E2RT-]-T^.QT^WD<26[.LDDB9"* PV( .O)KJ-1O]7M/"DU[#8)
M-JJ6^_[-&Q=3)CD#H2/UH VZ*\CO/%&I:QX1U^!-=L)IHK+S"OV*2VN83GYE
M:)FZ>C _G6Q8ZMXG?58-(M[O3EAM=,ANYIGM6+29XVJ-_'&.>: /1**X:/Q=
MJ+>&/#VI%;?SM0O$AG&PX"ER#M&>#@4NE:IXKUN!-9LY--6PDN'C2RDB;>(@
MQ7?YF[[W&=N,=J .XHKRSPGK&L:;:Z;!-=6]RE_K5Q Y,)5E4,Q.#N/<<>@X
MJ_K/C#7+>_U&SL%LO,BU&VM(#-&Q $@Y+8/.* /1**\PU'QEK5GJL^CR:G:Q
M7-A"K37"Z3/.+F1LD*%0GRUP.I)/I7767B.27P4-?NK.2"1;=I9+=E*D%<Y&
M",@''&>QH WVD1&56906.%!.,GVIU>67MSK\MYX2U?5I[&6VGN/M*P6\+(T&
M8RP7<6.[CJ<#FFZ7\1-4O9+*^5DN(;N<(=.BTRX#11DX#"<C:Q'4]O2@#U6F
MQR)*NY&5ATRIS7G%CXRU:3Q*MCJ-W8V,CW+1?V;=V<D+-&"0K1S$E9&(P<<5
M'H6NZK?BTT?1X]-TV65[J>:;[,61427;A4W#+,3R<^M 'IM%>:0>+?%-R;.Q
MSI<5]-JDUC)+Y+M&J(FX,%W9)]L^U1WGCS5]*M[C3KQK1]1CU%;);R.UD:/:
M5W;S$I+$@9X!H ]/IGFH9#'N7>!DKGG'TKS2+Q[JRV]Q9QB.[NFN(8+.^DL9
MK:)S(<'<CX.5Z\'GVK1\/0ZG!\2]335;FWN9AIL>V:"(Q!EW]U).#^- '>YH
MKS75M4U#1/'NMZD;F.6UM=)646QC.6^; &[=@'/4XZ5J6NL^(=,U/1DUJ>PN
MK?5FV!;:!HVMY"NX $L=Z]L\&@#MJ*XKQEXMN-'U;3])M9TM7ND>62Z>SDNO
M+5>PCCY))/4\"LO_ (3O6+;PW)K=Q;Q26NG7)CO";=X#<PXXDB$A!!Y^Z<]*
M /2<T5Y=?W_B#4;GPEJ,UY:6R75X\J0QPEPL>PE0Q#X8[>ON?:H4^)&J7$CW
MUL4DA%R84TQ-,N&=XPVTMYX&W=WQC% 'J]-=U12S$!1R23@"O-[KQ3XG^RZW
MJL$VFQV6DW1C%N]NS/.@"D@MN^4\^AINMZSKWB'2O$1TZ2QM["RB,)AFB9WG
M8H&;YPPVX!XX- 'I)E01^874)C.[/&/K3E8,H(((/((KC-0_Y) ^!_S"EX_X
M *H:3K'B#2)M%M-0GTZXMKVP+QHD31>0R1@@%RQW#'4X% 'H1( R:ADO;6*-
M'DN(41SM5FD #'T![UYG:>.-1FU.QMI-3L-1AO\ S(I8[6QE1(#M)&R9CMD]
M/>LG0--GU'5O!T<CV4EJEM<2K#<6GF[2'.2,MC/H<<>] 'M-% HH **** "B
MBB@ HHHH **** /-_BE*WF:;%_#B1_QX%>>5Z!\4O^/O3?\ KG)_-:\_KZ;+
M_P#=XGQ&;_[Y/Y?D%%%%=IYH5M>$V5?$]EN( )9>>F2I K%HZ&IJ1YXN/<TI
M3Y)J?8[+3]+*Z?I>GZG;,GG:HQ,,@*LR;,$^N,TL6D:;=+:W,6G@,T%PRVBR
M,1,\;849SGIUQ7'M-*SAVED+CHQ<DC\:3S)!M_>/\IROS'CZ>E<KPT]^8[%C
M*:5N2_\ 2\CKH-'A)NI3H+-<J80+ S,=BM]Y^.?P/3O5BWT71XI_(-HMTLFI
MM:K(9&!1-F>,=2#Q7%"64.7$KASU8,<G\:02.H 61U .1AB,'U^M#PTW]O\
M/_,:QE)6]S\O\CL$T>WN+*")87FF^P7#Q)N))=9,# SUQVJ5O#]I!YNW2S<W
M*06V;;S&!!?.]^#GC\A7+7FJW-Y]F#;(EMH_+C$(V8'4GZFEL-6GL'=A'#/N
M '^D)OQCT.<_A4?5ZUKJ7R^9:Q6'YK./S^1V$7AFP;6+F%K)/LK7+1(5+LR
M(#VX7GG)SGTID&FV=_9Z9YEA'MCLI'3:'_>R!L;3CD_WL#FN,N-0NKJZFN9)
MW\R9][E6*@GZ"H1+* H$L@VG*X8\'U%'U6HUK/7_ ( ?7J*>D-/EW.TCT6Q2
MYN9+73);F5)8%^S.60PAN68#KC/0FL'Q!+);^+;^6%S'(EP65EZ@\=*R1+(&
M9A*X9NI#')^OK368LQ9B6)ZDG)-;4J$HRO*5]+&%;%1G#EA&VM_S/0;?4KV?
M7-"AGN))(I;+S9$)X=MK\GWJE:Z-IEX(+M;)5:2R:9;4,[*SA]N>/F/'.!7&
M>9("")'RHP#N.0/04HED4J1(X*_=(8\?3TK+ZHU\$K?TS;Z_%_'&_K\O\CJK
MW3]+L[._EBT\NXN8X8UG9E,6Y<GOV/3-7SX;L%>S26S56^W)!($WA74KD\M]
M[GN !7"EW((+L03D@L>3ZU9M-1NK.\AN8Y69XF#*)&++D=.,TY8:I;2>HHXR
MCS>]#3_@G7Q^']/EN+9I]/-I,1/BT+L?-"?=/][GVZU6FT&TG%^EG8R_:$2!
MA"58%"6P^T'G;CUZ5R4D\LDWFM(^_.0=QX^GI2>;*'9Q+)N;JV\Y/U-"PU1:
M\_\ 5_44L91>GL_R[6['?OI]K 7M+>P7RX]71"ZEMR*5'.0??'XUFW6D0)9/
M)!I+WID,[2W F(,#*Q 'ITYYY-<D)I1DB:0$G)^<\FD\R3:R^8^UCEAN.#]?
M6E'"SB[\WY_YCGC:<E;D_+_(;1117<>:%%%% !7M_@]VD\):<S')\K'Y$BO$
M*]M\%_\ (HZ?_N'_ -"->5FW\./J>]D'\:7I^IO5Q_Q&=E\-JHZ/.@/ZG^E=
MA7&_$C_D78O^OA?Y&O$I_&CW\?\ [M/T/+****[SX<*5/OK]1244#3U.[\2R
MWA:XB0:QY.$Z(OV;&!GG&<4>)KF^BEN#%_;(1-C#Y5^SC !ZXSBN(-Q.R[6N
M)BOH9&(_G0UQ.RE6GF*G@@R,1^6:R4#T)X[FYK)Z_P#!.OU9;>WL9]1CD2,Z
MSL56Z^6N,R<#W%5+'1[7^SA);V8UAVF,;M&[1B-=N01G&.>YXKF"S%0I9B!T
M!/ ^E*LCH&"NRAN"%8C/UI\K2W,WBHRGS./]=?(ZM=%LO[+4FR/EFS:9K_S#
M\D@/W/3VQ4LNEZ:$=([(12P);2>:LC98N1N!&>*X[>^S9O;9G.W)Q^53VM]-
M:727"XD9"#MERRG'3(SSBCD?<J.*I:+D.N&@6]WJ"LEHTRC4)8YVW$X0#(W'
M-,M=#L7M$/\ 9OFQM:RRM=^8V%D!("]<<5R<UY<3W,L[RN))7+OM)4$GV%6X
M=<NK>Q:UBCMURA0RB/\ >8/7G^O6DXR[FD<50<G>)TD>BVEK:P3RV48EBFM\
MD;RK!L9RQX;KV&!4\VC6$TUY//ISEVN9%=8UD+1J!PP X&>N3Q7"F64J%,LA
M4# 4N<8^E'G2_-^]D^88;YSS]?6CD?<E8RE:W)_7W':V.G06NG2O;6)>-]-=
MVO2QY8Y^7'3^M8GA&\N;?7;:&&9TBE8"11T;@]:Q!+(J[1(X7^Z&('Y4BLR,
M&5BI'0@X(JE#1IF4L4N>$HJW*=G87 U/3]NIQF]\W4EAS(Y!48/3'I3#H6FQ
M:0\AMY)3B;=.BNS1LK$ <?*!ZYKD!(Z\!W SGAB.?7ZT>9)M*^8^UCDC<<'Z
MTN1]&6L9%KWXW=CK'TRR?4EMH-.AVPVBSR,S2,6)4?P@Y/T%6GT&RAEOO)TD
MW;1O!LB+,-H<?-P#FN)$L@?>)) ^,;@QSCZU9CU*ZCLI;59#LE969LG<-O3!
MS0X/N..*I:\T/R_R.M7P_I,<=SM@DN4$\B,Z;W:$ 9 &WC\355-"MOL@O!9[
M[<:=YOF$G:90?KU]JY,2.H8*[@-]X!B,_7UH$L@7:)'"_P!T,<?E1R/N)XND
M_P#EV=U?V-M<SW@EMQ:PE;4!T+!64D9/IQTKG_$%B+3;MTAK%1*R+(9"1*!T
M.#_/I6*99&7:99"N,8+$C%(SN^-[LV!@;F)Q3C%HFMBH5$URV?R_R$HHHJSB
M"MGPFY3Q3IY'>4#\ZQJV/"O_ "-&G?\ 785,_A9OA?X\/5?F>VT445YY]Z%%
M%% !1110 4444 <O?^#5FU.XU#3-9U'2)KK'VD6C(4F(&-Q5U(#8XR,&L?Q%
MX46#PDGAC1]-N;G[7-N>\:49B?()FD8D$M]![5%9^)[T3$7-W>2R'6+FW@AA
M2/$BI'N",3C ]QSFJWA3Q??KI,=WJ$.K:AJ>IW$@MK+]SC:I;.S! 55 P2QZ
MT =9>^$;6X@T[['=7&GW6G)Y=M<VVW<JXP5(8%2#Z$54B^'VF1;6-U>23&*:
M.661P6E,N-S-QUX&,8 ]*U]#UZ'7(9RL$]K<VTGE7%M. 'B?&<'!(((.00<&
MLC4O'*:;)<RMHNIR:=:R"*>^"*J*>,D*S!F SR0* %E\"0*8VT_5M1T]_LJ6
MD[6[)^_C08&[<IPV,_,,'FM=_#UB?#HT-/-BM!$(E,<A5U [ANN>^:Q+_P ?
MP6EUJ$,&CZE>1Z<5-W-"J;(T*[@PRP+<=AS1J?CB-1/%I>G7^H&*U6XFFMD7
M; KKE2=Q&3CG:,G% #QX#M[@73:IJNH:E//:M9K-,45HXCU"[% SP.3DU=TC
MPI!I=T;I[VZNYVM%M&><K\R*203M YYQ4&@ZI<77P]M-3O+F1IWLO-DF15W9
MP>0.F:SK;QVB06MG:Z;JNK79L([QF5(U)C/\3$L%!XZ#\* )H/AW:0RVBMJ^
MIR6=C<BYM+1G3RXFW9QPN6')ZDXJ9? =HEP$&I7_ /98N/M0TW>ODB3.[KMW
M;<\[<XS0WCNUN(+ Z5IU]J5S>0&X6WA55:.,'!+EB .>,9Y-1#X@6\MW:VMI
MH^JW%Q/%YS1B)4,*AMK;]S#&#^?:@!7^']K]G>.'5=1A*WIO;5T9"UM(22VW
M*\@Y/#9I\'@"QB=Y9=0O[B>6[BO)99G4L\D?3H  /84B>/K1Y4F.FWZZ3)/]
MG34V5?*9\[>F[=MSQNQBB^\=)82RRR:+J9TR&<02WY1516SC(4L'*Y/4"@"U
MJGA%;W5)=1LM6O\ 3+FXC$5R;0IB91TR&4X89.&&#6K;:1:6VC)I0#R6JQ>4
M1,Y=F!Z[B>23FL1_&T9U.XM[;2-1N[6UG%O<75NBN(W./X,[R!D9(%,N_'=O
M;7%VT>EZA<Z?92>5=W\*J8XF[\%MS 9Y('% #;;P!;0W5@\VKZG=6VGN3:6L
MSH4C4@C:<*"PP<#)) I]IX%AM)H8TUC5#ID$OFPZ=YJB)&SG&0 Y4'HI.*V-
M8UZST71'U6X9GMU52OE#)?=]T#.!SD=:Y?7_ !OJ5IX9U&Z@T*_M+^V5&59U
M1T*L<;E<,5;'<9R/2@#0_P"$%A:YC$^KZE/I\5Q]IBL971D23.1\VW>0#S@G
M%8VK^&'T9K!M,M-7F$+S,;S3YXQ<1F1MQ4HXVLA/XCBMN[\87%J"D?AW5;EX
M8%FNM@C40@]MS, S<'A<UC_\)M=R^*D_LZSO]3L;C2TNHK:!$4J2W+,6(QQQ
MC/6@";PAX+>ULK2YU+[1#=0W\U['$\PD8;QMQ(W<XY.*U+SP/IUW)>3_ &F[
MBN;BZ2[2>)P'@D48!3C'3L<UC:OXRCNK,7>EWM["\FG7$T<1B0*KH<'?G)#*
M>,=*I:GXSU'3](N9[22[NKV.VLF=&CC\M#(.67D$D\YS[4 =*W@>VN;&ZBU'
M4]1O;JX=)/M<DH5XF3E3&% 5<'T'/>K&B^%5TK5KC59M4OK^^N(5ADDN2F-H
M.1@*H IJ>,;-;?57NK>XM9-,17GBE"[L,N01@X/<?6MRRN?MEE!<^4\7FQJ^
MQ_O+D9P?>@#%U+PA9ZGK,FH37%PJSVQM;FW4KY<T?;.1D$'N"*ATWP9%97]I
M=76JZAJ/V%2MG'=,FV $8S\J@L<<9;)KIZ* ,36_#D6KW-K>17ES8:A:Y$-U
M;%=P4]5(8$,#Z$52C\#61%JMY?7U\L,YN9%N90PGE[%QC&!V48'M7444 <F?
M =FD%M#;:A?6ZVEV;JVV,I\G=]Y!E3\AR>#TS2#P';I,T<.L:I#ICS_:&T^*
M55C+YR<-C>%)Y*AL5UM% '//X/L7TK5M/,UQY6IRM+*V1N4G'W>/:J5_X!M;
MM[I8-5U&RM[V-4O(+=T"S8& V2I*G'4J1FNNHH RYM"MI_#9T-I)1;FW%OO!
M&[:!C/IFJ=]X0T_418K</,R6=NUNJA@-RLFTYXZX]*Z"B@#CX/ ,:R:>UUKF
MIW2Z<?\ 18Y&C547&W!"J-W'&3S5_3/!]CI=QILT,UPS:?%)%$'888.<G/%=
M#10 4444 %%%% !1110 4444 %)2T4 8.M^&;'Q#/&UX9@8%VKY;[>O)_D*R
M_P#A6^B?WKK_ +_?_6KKA_K)/P_E1FMH8BK!<L9-(YJF#P]27-.";.1_X5OH
MGK=?]_O_ *U'_"N-#];O_O\ ?_6KKLTFZJ^MU_YV1_9^%_Y]HY+_ (5OHGK=
M_P#?[_ZU'_"M]$];O_O]_P#6KK=U&ZCZW7_G8?V?A?\ GVON.2_X5QHGK=?]
M_O\ ZU'_  K?1/6[_P"_W_UJZ[=1NH^MU_YV']GX7_GVCD?^%;Z)ZW7_ '^_
M^M1_PK?1/6Z_[_?_ %JZ[-!/I1];K_SL/[/PO_/M'(_\*WT3UNO^_P!_]:C_
M (5OHGK=?]_O_K5UD;[HP><T_-'UNO\ SL/[/PO_ #[1R'_"M]$];O\ [_?_
M %J/^%;Z)_>NO^_W_P!:NNS2YH^MU_YV']GX7_GVON.0_P"%;Z)ZW7_?[_ZU
M'_"M]$];O_O]_P#6KK\TF:/K=?\ G8?V?A?^?:.1_P"%;Z)ZW7_?[_ZU'_"M
M]$];K_O]_P#6KKMU&:/K=?\ G8?V?A?^?:.1_P"%;Z)ZW7_?[_ZU'_"M]$];
MO_O]_P#6KKLY%(7 ') ^M'UNO_.P_L_"_P#/M')?\*WT3UN_^_W_ -:C_A6^
MB>MW_P!_O_K5UGF*3@,*=NH^MU_YV']GX7_GVCD?^%;Z)_>NO^_W_P!:C_A6
M^B>MU_W^_P#K5UVZD)H^MU_YV']GX7_GVON.2_X5QHGK=_\ ?[_ZU'_"M]$]
M;O\ [_?_ %JZW=2DT?6Z_P#.P_L_"_\ /M'(_P#"M]$];K_O]_\ 6H_X5OHG
MK=_]_O\ ZU==FC-'UNO_ #L/[/PO_/M'(_\ "N-#];O_ +_?_6KIM+L8=-TZ
M*RM]_E0Y5=YR>N>OXU8%+'_'_O&HJ5ZE16G*YK2PU&B[TXI#ZH:AIMGJJ&"^
MA$T2D,%)( ///%7ZC_Y:O]!_6LC:45)6>QA_\(9X>_Z!D?\ WTW^-'_"&>'O
M^@9'_P!]-_C6V3BC=5<\NYC]5H?R+[D8?_"&>'O^@;'_ -]-_C1_PAOA[_H&
M1_\ ?3?XUM;J-U'/+N'U6A_(ON,;_A#/#W_0,C_[Z;_&C_A#/#W_ $#(_P#O
MIO\ &MK=S0#1SR[A]5H?R+[C%_X0SP]_T#(_^^F_QH_X0SP]_P! R/\ [Z;_
M !K:W4H:CGEW#ZK0_D7W&)_PAGA[_H&1_P#?3?XT?\(9X>_Z!D?_ 'TW^-;>
M[O2,V*.>7</JM#^1?<8O_"&>'O\ H&Q_]]-_C1_PAGA[_H&1_P#?3?XUM,>0
M1VI'DPN1GG@4<\NX?5:'\B^XQO\ A#/#W_0,C_[Z;_&C_A#/#W_0,C_[Z;_&
MML' &>M&ZCGEW#ZK0_D7W&)_PAGA[_H&1_\ ?3?XT?\ "&>'O^@;'_WTW^-;
M>ZDS1SR[A]5H?R+[C%_X0SP]_P! R/\ [Z;_ !H_X0SP]_T#(_\ OIO\:VMU
M*&S1SR[A]5H?R+[C$_X0SP]_T#(_^^F_QH_X0SP]_P! R/\ [Z;_ !K8:>-/
MO.H^IIOVJ(GAP?I1S2[B^K8?^1?<C(_X0SP]_P! V/\ [Z;_ !H_X0SP]_T#
M8_\ OIO\:VED#=*=NXHYI=Q_5:'\B^XP_P#A#/#W_0,C_P"^F_QI?^$,\/?]
M R/_ +Z;_&MHM1NHYY=P^JT/Y%]QB_\ "&>'O^@9'_WTW^-'_"&>'O\ H&1_
M]]-_C6WNHW4<\NX?5:'\B^XQ/^$,\/?] R/_ +Z;_&I+?PKHEG<)<6]@D<L9
MW*X8Y!_.M?.:7^$_2CFEW&L-13NH+[AT?,:D]<4ZFQ_ZI?I3JDV"BBB@ HHH
MH **** . @\&:G'?V\[/;;(]7N+UL.<^6\>T#IUS5"?X>7ITG1#+:V&H7.G-
M.)+2>5DCE21B>' R&'';%>G44 <QX-\/R:'9W1FL=/LI+F7?Y%D"0B@8 9SR
MY]\"N.UKX?ZYJIU2.:UL+NYN)VD@U*ZO)&,<>0518L84CID?6O6** .+B\+:
M@MKXG1C 'U1$$(#DX(BVG=QZU3MO#?B/0A.FE1Z?<K?V<,4QN)F3R)4CV;AA
M3O4CMP>*] HH YS2]#N[/P)#HLK1&Z2T,!96.PM@]\=*S?#OA34-*OA-<- 5
M&D0V7R,2?,4G/;I7:T4 >=:3X5\0>&OL%]8165Y=):O:W-O+.T:D&0NK*^T]
M,\@BM72?#VM+X@_M36+FVF>33VMY3",;69]P"C'( XR>37844 >4V/PVNK.2
M&Q_L;1)(HKCS/[3E=WD:/=NP8L8W]LYQWJ/5/A[KNI)?1SVVGW-Y)<F6/4[F
M\D9O+W95%CQA"!QD<5ZU10!YIK/@O6-0UJ6YAL=-ANVF5X=8M[AX)XD&,JZ*
M,2$8(!)P:K77PYNH[[4(X=(T:^2\N#,E]>2N'AW8W!HP,/WQR.O->J44 8FL
MZ7<W/AE].L%LFE$2QK'=0[H7 ZJ5[ CCOBN)A\ ZL=*UFWMK>UTJ"[MU2#34
MO))X1*&R7R1\F<8PHKU&B@#S/5?".OZQ?W$^H:?I]Z+BW5($GOY/*L6 (;$8
M7$@)P<\&I=*\->*?#US9W-E;Z;=&/3$LI(I+AD^96R&!VGCVKT>B@#S0_#[5
M$M8T6>VDE:RNDF;<5'G3-NX&/NCI4EWX&U>:RU-(GM/-FM+..$,YP7A'(/'
M/K7H]% 'E^O6 USQQI%FD]NEW-"!K-I#)YFR-"'7)XQR,#(YS7IX&!3%@B25
MI5B02/PSA0"WU/>I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH C'^LD_#^5(:4?ZR3\/Y5 ES!-YOE31R>4Q238X.QAR0
M<=#[4 /W<4FZHH;B"[MTGMIHYH9!E)(W#*P]01P:9)=0QW$=NTT:S2 F.,N
MS@=2!U.,C- %C=0&R:C#@C@@Y]Z8UU!%+'')-$DDI*Q(S@,Y R0H[\<\4 6
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M62\EATB1GW':&VY&?]D?UK;\9-<)X5N_L^[.!OV]=N>:Y'PE<Z=$"K.J7['
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M_5+]*=0 4444 %%%% !1110 44F:7- !11FB@ HHHH **** "BBB@ HHHS0
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MM)U2E'*"LF="'K]W\:>IJ-#G(_&G@<U)1(.M/6F"I%H D%+'_'_O4@ZTL?\
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M>4R ,]?:@#2UCQ)'IGA1M<2%I0T2/%$3M+%\;5/IR17(^,+OQ4GA'4TU>TL
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M91SBGQ3QS%O+)8>N" ?H>]!UBN$.#(%PO=NU."I*C8SL^N.*@RS76V?:N?\
M5J.<XZDT^>&&5B'C4NJ\%L@$9]NU).XVK#E@0IQ"K+ZEL\5S2#9XI"! N'Y
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ML$O+HHA\N%2H.6/1<]@3FIM*\9Z1J][%:P&ZCDG4O;FXMGB6X4=3&6 ##O\
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MC0 \4L?\?^]2"EC_ (_]XT /J/\ Y;/]!_6I*C_Y:O\ 0?UH 1JC]:D;O4=
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M)J*I/W=EH+!471I6EN]62CF/W!IRTR$YRI[T\8S7*=Q,HX%2"HU^[]*D4=*
M'CTI8_X_]XT@ZTL?\?\ O&@!]1_\M7^@_K4E1C_6O]!_6@!#49X-2-UJ-^E
M#&&&Q4;]1]*E:HGYXH A/!YI!3I/O8I "3B@!9%V@#VS4)'R$U-*?G(J/^'%
M,ED;#(JO(N<U9()C_.HRN?RIF4D4Y!\E,88!JPZ?)^-1,ORFJ.=Q(2O H P?
M8BGXXQ2[>E,BQE(9$U/Y6"N6PK'H":Z+[,4M$^U%KF;IC.!G/3L/SK%O;1I8
MO,B'SKU'K4EAK9CDQ>[VP-H('3ZBLI0]Y21="JJ:=.>B>IL"=77,MI)\I 9]
MG3VQU_I6/KUS:2+LA7$RMR=N,>U6Y?$%JC%X59P5P<C;S64$GU>\$\@V(>I
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MPH_X2K1O^?Y?^^&_PK9HIZ!:??\ #_@F-_PE6C?\_P O_?#?X4?\)5HW_/\
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MNPAZ^;( 3\@I\D<A55V.R[N=QV,![XZT^8[%$:R)&0N5W<#%*6M[;BC%*UR
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M]*NEO%9K8Q-YJKU*XYQ0!Y[H]S\/VM(I9;"&S\T 1B68SG9@#EE9@BC<!@D
M9J<7?P[O+Z=I[:-"C_ZV1) LF[)+X].3\S #G@\U7T[4/ -]&MM)<7K1M9HX
M;4+B0A8RP CRS'!RH^7VJ:XM_AU:K,QOUEDC!WQI?.[R*!_J\;OF7C[O3@4
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M?AMI)L7AAO6>5E!C:0H/NDGJ!G'KBN@\%Z)<:'HKPW4\$TLT[3%H  G( P,
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M(Z5+-!R<$U*M11]3]*D7M4LI%A>E2+4:=JD'6D,>.M+'_'_O&DI8_P"/_>-
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M9&!3=O-2D9%)B@!A% '!I^VE XH A(YH*\"I-O-+MH$1J* /E/TJ0+0%XIW
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M7VI=M  *=V/TIO2G=C]* '1_ZI?I3J;'_JE^E.H *.]%'>@#'UG_ )"&C_\
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M\/\ @E3_ (3'P]_T%8/U_P */^$Q\/?]!6#]?\*M_P!A:;_SZK^9H_L+3?\
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M_,T:!:??\/\ @E3_ (3'P]_T%;?\S_A6/X6GBNM<U*X@</%).Q1QT(P*Z/\
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MZ?-*LL4OE)*\2S&-E20J2,@G@]*?+$.:1V/_  MSQ'_SRT__ +\M_P#%4?\
M"W/$?_/+3_\ ORW_ ,57$/:W,=NEP]M,D#_=E:-@K?0XP:<+&\*.XL[DJBAF
M80MA5/0GC@>]')$.:1VO_"W/$?\ SRT__ORW_P 51_PMSQ'_ ,\M/_[\M_\
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MIU]JCFAFMY3%/%)%(O5)$*L/P/-')$.:1W/_  MSQ'_SQT__ +\M_P#%4?\
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MLL;*3] 11R1[!S2.W_X6YXC_ .>6G_\ ?EO_ (JC_A;GB/\ YY:?_P!^6_\
MBJXB>VN+5E6XMYH68942QE"1ZC(YK3L?#MW=V-_=2B2V%I!YX66%AYHSCC./
MSHY8!S2.D_X6YXC_ .>6G_\ ?EO_ (JC_A;GB/\ YY:?_P!^6_\ BJY71]#O
M-;DG6T48@B,LC$'@#L,#D^U32^';M-&LM0B629KIG7R(X6+IMZYQ_A2Y8#O(
MZ3_A;GB/_GEI_P#WY;_XJC_A;GB/_GEI_P#WY;_XJN(AM;FYD,<%O-+(O5(X
MV8CZ@"DCMKB5F6.WF<J<,$C8D'T.!Q3Y(]A<TCN/^%N>(_\ GEI__?EO_BJ/
M^%N>(_\ GEI__?EO_BJXM-/OI/,\NQNG\HXDVP,=A]^./QIL5I=7&WR;6>7<
M<#RXF;)]!@=:.2(<TCMO^%N>(_\ GEI__?EO_BJ/^%N>(_\ GEI__?EO_BJX
MB.VN)9_(BMYGFZ>6D9+?D!FD^SS[Y$\B7?'RZ^6<I]1CC\:.2(<TCN/^%N>(
M_P#GEI__ 'Y;_P"*H_X6YXC_ .>6G_\ ?EO_ (JN1TS1[W5KVWM;:!MUPVU'
M92$]SG%2S:.;:UOI)[CRY[681>287^?G[P;& /KUI<L O(ZG_A;GB/\ YY:?
M_P!^6_\ BJ/^%N>(_P#GEI__ 'Y;_P"*KB6M+J.W6X>VG6!ONRM$P0_0XQ4^
MGV,=\+DR70@\F(R &)GWD=N.GU-/ECV#FD=?_P +<\1_\\M/_P"_+?\ Q5'_
M  MSQ'_SQT__ +\M_P#%5Q4=E>2KNCL[EAMWDK"Q 7UZ=/>DM[2XNB?)@FD5
M2-[)&6">YP.*.6(<TCMO^%N>(_\ GCI__?EO_BJ/^%N>(_\ GCI__?EO_BJY
MC5M N=,UEM,BWWDJHK_N8F)((ST&36=]GN/WG^CS?NO]9^[/R?[W''XT<L0Y
MI'<?\+<\1_\ /'3_ /ORW_Q5'_"W/$?_ #QT_P#[\M_\57#/%+&J-)%(BN,J
M64@,/;/6F4<D>P<TCO/^%N>(_P#GCI__ 'Y;_P"*H_X6YXC_ .>.G_\ ?IO_
M (JN#HHY(]@YF>O^'OBW!=W"6VM6JVI<X%Q$24!_V@>1]>:],1UD171@RL,@
M@Y!%?*E>V?"?6I;_ $&:PF<L]FP"$]=AZ#\*RJ02U1<)7T9X[J=C+I>JW=C,
M")+>5HSGVZ?IBJM>X>/? '_"1,-1TXI'J*KM97.%F4=,GLP['\#7D-YX=UJP
MF,5UI5Y&PX_U)8'Z$9!K6,TT1*+1FT5:_LS4/^?"[_[\/_A1_9FH?\^%W_WX
M?_"JN25:ZS0947P!XK1I%#L;?:I8 GYCT%<[_9FH?\^%W_WX?_"D.EWY(/\
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M4>6S;&SN'0G@=:\M_LJ^!S_9UUGU^SM_A1_95]C']G76/^O=O\*7(A\S/3M
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MRUK1E%U SP:%*A=)%90XQQGH>:\O.EWYZZ==GZV[?X4?V5??] ZZ_P# =O\
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M\_C4<4EU/H?D^']0AMIH-3D>\ N%B.S=PQ)(RM<Q_:OB#G_B50<]?^)/'_\
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MEHH 3\Z/SI:* $_.C\Z6B@!/SH_.EHH 3\Z/SI:* $_.C\Z6B@!/SH_.EHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !VJC#_Q\+_US;_T*BB@#.@_X];/_K]/\S4W_,6M_P#KM)_Z#110 :A]
MZV_Z^Q_*JW_,33_<F_G110!<?_C]C_X%_P"RU'IO_'A!^/\ Z'110 D__(<F
M_P"N(_K4+?\ (5C_ .VW]*** ':S_K;#_>']*U9/N7'^>U%% &?+_P A2T^L
MG\JKV_\ R"YO]R3^=%% $MQ_R#--_P!Z.JD_W;__ *^%_F*** );K_6:M_P"
MKMY]S3?^NJ_RHHH F7_4R_[G]35+4_\ CSD_WA_Z$*** *EU]V__ .N<5:5[
M_P A#3_K_2BB@#.7_D%W/U?^9K0A_P"/0?[O_LIHHH JV'_'YIW_ %[-_.F6
MO_(8NO\ ?7_T*BB@"S<_\C W_7J:9IW_ !X1_3^HHHH 9J__ !Y?\#C_ )BD
M\0?\?MK_ +I_F*** '+_ ,A63_KF/YFGP?\ (7O?^O=?_0C110!-JG^ILO\
MKLE5K;_D(:G_ -LO_9J** 'ZQ]W_ +;QU-%_R,UQ_P!<!_.BB@"-?^0W>_\
M7-/YTD__ "$[?_KG)_.BB@"R_5?]\?S%4V_Y&&?_ *XT44 *GW[W_KH/_0:;
M>_\ (8T_Z"BB@"I<?ZJS_P"N[?\ H5;>F_\ +U_UW;^E%% &A1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>trda-20211231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &! V4# 2(  A$! Q$!_\0
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MMW;M''(LT920X1@W#'T%/:6-)%C9U#M]U2>37'6^G23:9JR17%O(\<JRQ);
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MM889D8-(;=]T;$CMZ'VI<NES>-:2JJD_O^5R;5-3OX=8MM.L(8'>:)I"9F(
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M&<X4$\GZ5P]E:-?1:Y!$T!E1DEC^SCY!(HR,?EBK4%[+KT\^H0 XLK+;&/\
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MI%O\O;*DF0N<[3G%-32(K82<KR3[_C\[?@8S7EMK&NZ6VG$N+42-,X4@(I7
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M!23&<'!(]LUK17<&K>)K:YL#YD4$+"68*0IST7/>NB"* 0% !Z\=:%55&%4
M>PIN1$,-*-DWIIT[?,Y[Q7%+G3KD22QP03$RR1+N*97 ;'M_6L^U$%UJ+SPZ
MI<W[16T@+F,! ".A..M=D0",$9%(J*HPJ@#V%"E96'/"\U3GOOZ]/G;\#DGB
M"^"M+54P1+"< =#NI+W43'K5]%)>KIV"H4)#NDG&T<Y[^E=?M&,8&/2D**Q!
M*J2.Y%'.)X5V7++:WX7[-=SS^W=8M,TV2>.1T34I&<,GS8]2/UK8>YBU36;B
M[L<O;Q6$D<DH4@,QY"^^,5U&Q?[H_*@(JC"J /0"AS)AA'%<O-IIT['"M')!
M!H5U+=36EN+,1F:--WEM@=?3-:_AU(9=2N[J&]N+P,BJ9I$"JWT]:Z,JI7:5
M!'IBE"A1A0 /:ASNBJ>$Y)J5]O7M;O;\##U $^*M/.#@6L_/_?-9*PK_ ,(#
M;+Y8R9 6&.O[PUV6!G.!FC:,8VC'IBDI%2PW,Y.^]_QM_D<_J28\0::0N +:
M89 ]A6'9ZC93>"H=+B0F^D3:L(0Y+$_>^G?-=U)&)$9>Y!&?2JNF:>FFZ?;V
MH(D,*;0Y7!--25B)X:3J-IZ-._SM_D9NGQ%/%-UY@RRV<2[O?G-4-.U*RTG3
MKK3]0RMV)92T90DS[B2"/7((%=;@9SCFD**6R54GU(I<W<OZNUK%ZZ].YQ[P
MW&CZ%I.I/&WG6@*RIWV-GC\.*BNK"XBT&PNW:5&:Z^TW+1KN9-V<-COC(KMB
M 1@C(]Z,#&,<4^<AX);7TM^.FOX(XJ../4;X&TU:ZOYD@DP_E@(F1C!..]1W
MFI64OABVT]8V^UQ-&&AV',9##)/^>]=PJ*GW5"_08H\M,D[%R>IQ3YQ?4W9I
M2WWT_P V-;_CV/\ N?TKD4B"_#ZS4)@Y0XQWW]:[*DVC&,#'IBI4K&]6C[3K
MT:^^W^1R-]J)BUFYBDO5TT!4"L(=SS#'4'],52L0QTB//F$_VP2?,7#=0<D=
MJ[HQHQ!95)'J*7:O]T=<]*?.8/"2<FW+O^/S.?L8IY+W75@E\F1KA=KE<X^4
M5'J5O>0C25N[G[2_]IQD,$VX&UJZ0 #) '-! /4 XI<QJ\.N6U_ZO?8XV=6_
MLG5QM/.H#''NM+J0:T\1RSW&HS6$$T*"*9$!4X'*DXXKL=HY^4<^U(R*PPR@
M_44^<S>$NM_ZU\_,YW09;6SMKV]:[GDAFG4>=-'M#M@#*@#H>.:Z2H9[:.X@
M\EQ\F02!['-35+=]3HI0=./+T_JYP1U&"+P7<:6V_P"W)O1H0AROSYR?;%:"
MZC9:;XJN9+P^6&M8PLA4D#KQ75^6F2=BY/4XJG'IJ)JEQ>EMWG(J;"O Q5\R
M.7ZM4BXV>UNG17\_,Y:7]UI O61HK5]5CN%!7&V/=UQV'>K%]JJ_VU./MR6$
M+11M'*L.YKA2,Y!]LXQ77%05VE01Z8I#&AQE%..G'2ESE?59)6C+M^O9^9Y_
M##)<Z.D(DF5GU/\ UC+AP#WQVK1-O<1^'M4T!4/VJ%"T; <SQDYS[GJ#78;5
M_NCUZ48&<X&?6FYBC@DEOTM\CAE:VOOLD"ZS>W$GF(1;"$ QD>O'&*ZG79G@
MT.[EC@$[*G^K(R#SZ>W7\*OB-%;(50?4"EQFI<KLTIX=PC)7U?\ 75LX&YNQ
M=2Z=MU5KW9<QEDBAVQQC/4\<?2M[3XQ]J\0L4Y:4C..HV5OB-!T11]!2X SP
M.>M-SN33PKC+F;O_ ,,UU;.+L)DTU]%OKP$6@LVAWE21$Y(.3Z9 Q6CH,\-U
MK^KW%NI$,GEE6*XW\'D5T112NTJ"/3%*%"] !]!0Y7'3PS@UKHM=O*QRWB-'
MBURSNY+N6TM1"T9GC3=L;.>?3([U'IDUG#/J.HM>W%[$(51Y7C 5^3@#CD]O
MQKK2H888 CT-($4+M"C'IBCFTL#PS]HYI^?7>UN]OP.-T*!],OF^VP%/M<9-
MJ22?*')\OVJO::E8GP=+IBH6O95=$@"'<[,3AA[=\^U=TZ!U(('3KCI533-.
M33K&*V#"0QYPY7!ZT^=/5F7U24;1B]+/IWL9=E T?BE%E&YX]-12Q]=V#6%"
M5L1>6]]K%S9R^:Y\D1!A(">"..<UWN!G..?6D:-&(+(I([D4E,TGA+K1]^_7
MT:.+N(;:RM-(WW5W8R) PBNW7H"<['':@SBZT-GO"_E1W7[N]MX]O_ \5VC*
MK##*"/<4NU=NW:,>F*.<GZGJ[/2WZ>O_  ?,XZRNYIX-7B%RE] +-C]J6+:2
MV"-I/?BELKB+2[O3+R^REL^F11)*5)". "0?3(KKPBJ,!0!Z 4%%8;2H(]"*
M.<:PLE9\VJ_S]?U.(OMM[;:M>P1M]CGEA5,K@.0PRP'I6[J"8\2:"57@"<<#
MH/+K;VKC&T8],48&0<<CI1S%1PMKZ[V_!W,;Q3\NANYSM61&; Z ,,FH+=XK
MKQ=!<Q$21G304<#CEZZ @$8(!'H: JKT4#MP*2EI8TE1<JG-?M^!Q=W&?[,U
MI=G!U)3C'7E:U=8>.PUS3[^Y4_8XXWC+!<B-CC!/X<5O[1S\HYYZ4%0PP0"/
M0T^8S6&LG9]OP;?ZG)2LNKZEJEWIZE[<Z<8#(%($LF21CUP./QJ&35;6[TW1
MK6!F>6.2(2J%/[L@8.:[-551A0 /0"D$:#HBC\*.9">%D_M;[Z>=]-3DXK^V
MTJ#5+&^BD:XDED95\LMYX;IBHM,0/;^%LKN 1STZ?*:UKG0[Z2:?[/J\D-O,
M26C:$.RYZA6)XK6M+2*SM(;:)<1PH$7/7 IN2L9PP]1RM+1+;[T^_EY',:K:
MS7%[X@BMT)=[:(@#^+')'Y4:AJ=EJ^G6EAIV7NS+$50(08-I!)/I@ BNMP,Y
MQS2"-%.0J@^H%+F-'A7K9[[Z>;>GWG*+J-OIUSK=M<EEGE<M$FTDR KCBH;>
M>.TC\*3W#>7&L4BLS#@$J  :[$HI.2H)]<4%%( *@@= 11S(/JTOYO33S3[F
M=XB!;P[?A02?);@5E"6"]O\ 0)82)8PC?,!P"%%=/C(P:0(HQA0,=,"DI61I
M4HN<N:_;\'<X_5;6>XN/$T=NK;VCM6 4<L!DG'KP*BC:VOKFRB36;R[D$BL(
M1" 8\?WN.*[; R3@9-((T4Y"*#Z@4^<R>#O*]_S[M]_/S,?Q<"WA6_ !)*#@
M?[PK/N;ZTU2XTNTTY3YT$ZNZA"/(5>H/IZ8KJ2 1@@$>]($4$D* 3U('6DI6
M1I4H.<^:^CLMNSN<K8:E9:1!?6>HY6Y,TC;"A)F!/&/7CBJM@&T6?2+K4U9+
M<6DD6X@D0N6##/I\O%=H41CDJI([D4I4,,, 1Z&GS$?59:>]MMIYWUUUV\CD
MK**#6;O7A A$4ZIL8KC<<<,/QJ;PU)+JE]+J$Z$&WB6U0'^\.7/YXKH+F&62
MV=+686\I&%DV!L?AWJ/3-/33+%+9'+D$LSD8+,3DFART%'#R52-]E=OSUT^Z
M[+E%%%0=H4444 %%43:WA8D7[ 9Z;!1]DO?^?]O^^!67M)?R/\/\S3DC_,OQ
M_P B]15'[)>_\_[?]\"C[)>_\_[?]\"CVDOY'^'^8<D?YE^/^1>HJC]DO?\
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M^^!1]DO?^?\ ;_O@4>TE_(_P_P PY(_S+\?\B]15'[)>_P#/^W_? H^R7O\
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M:)W5R'HSCOBA<36WA4202O$_GJ-R,0?TKQG^V-3_ .@A=?\ ?UO\:]B^*_\
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M;K%MX;) SG\:WKCX=I%'-:I=3G488/.?,/[HG&2H;UH=6DM&"C)G'?VQJ?\
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M<#54"J/,_P!7C'7CGI6M!\1[2%X)CIL_F+;?9WC6?$8&.JKCKG%;G_"G=/\
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MZRNOZY/J*0F$2X^0MNQQZUK6_B;2KO1;+3M<TR6Y-CD02PR[#M..#^0KL_\
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M+G?;>:"N .X(%/@URTMEA@DG^TPO<2FYVQE R-M.X#''(S@>E9O_  BNN?\
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MIIX<49VMST- "'@M[4L;;@5H<$YQWIL/\1H <IP<=Q33PY]*"?WA]*:_/.:
M''[QH!^4YI,'YL^E-S\H]J )-P9<&D7 /6FXXR#2B@"8<\T[L*B4X%3"@!PZ
M44"B@ HHHH AE^\/I3*?+]X?2F4Q!1110 4444 9>MW.HVL$$FG0K,QE"R(4
M+$K@],=.<<UBPZMXA@TR?6+F&-[6VMY7>WE5H)'*MG=RI(^4'ZFNBO\ 5+33
M%B:[E\L2OL3@G)QG^0K-;7M.U:WGLX965I;:0@R QC&2AY/0YH&3>%M?C\4>
M&;+6HH&@2Z0L(V;<5PQ'7\*V*YWP/"+;PI! ""(I[E 0^[.)Y!U[_6NBH$%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $L7W34E1Q
M?=/UJ2D,**** "LJ\N);RY^P6K8Q_KI!_"/2K&I79MK?;'S-(=J#WIVGV8L[
M8*>9&^9V]30!+;6T5K"(HEP!^9J+4-2M=,MC/=2!%'0=V/H!2:GJ4&E63W,Y
MX'W5[L?2O.;B>[UV^-S<DX_@0=%'H* +VH^)=1U9S';9MK<\84_,P]S56VT=
MI#N8$D]S6UI^D@ $K6P5M;*,//(D2D@ L<<T 8L&B  96KBZ,@'W:V+:2WN(
M]\$B2("5RIR,BI]@H"YS[:,A'W:IS:)W YKK"@IK1 ]J8',6E_J&DL%R9H!_
M _8>Q[5U-AJ5OJ,6^%L,/O(>JU3GLT<'@5CRVLUC<"XMF*NOIW]C2 ZR6))H
MS'(H93P0:RH9'TFZ%O*Q-K(?W;G^$^AJYIU^E_;[P-LB\.GH:FN[9+NW:&0<
M'H?0^M $U%9VEW#D/9W!_?P<<_Q+V-:- !1110 445YU+XXO]+\1:Q:2PO?J
MVKV^G64"E4\LR0%^6QTRO?/6@#T6BO-U^*<T<4<UWH,D,)GGM&87"M^^B!+
M#NO'6DD^*%]'!/+_ ,(W)MBL%U'FZ7_4=R?]KVH ])HKB!\1K9M.N[U+&4I;
MZA%98+#+;PI#?^/]/:J]M\3 \MK+=:1+;V%RUPB7'FACNA!+?*.V!0!W]%>8
MZQ\2+Y?#TT@T^339[[39KW2[C>LNX( 3N7'RG# X.15__A8DL$4DG]F27-E8
MB".^NQ(JE9'53E4[@9YZ4 =_17!+\1Y)9+:>#1I'TV[U :=;W1F4%I,D9*]0
M.#^5:7A_QM#XAO+&UM[*1))K62XN0Q_X]BDACV-[E@P_X#0!U=%%% !1110
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M>*DT)8E,K8Y9]I(V[B0".<#/2M^N/N-+>/XD0:G%8W!1H@KRJPVD[64D_*>
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MYNV:CL-,\W6(K>-5$C.!(4&0 #E@#W P!GUH3,*D92M9V.^T*R>PT>""1@7
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M4C+1GR2 (PF[ DYRPSP!D5S%GX_U)KW4->\F,3OI<"!,L8%<SNADZ_=XS]*
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MW%*DT:R1L&1NA%%AQE=M=4/HHHH*"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH EB^Z?K4E1Q?=/UJ2D,*S=;8_85C'_ "TD5?Z_TK2K$\17:VKZ
M:K(6\VZ5!@]*:5R9SC"/-+8VE4*H4= ,5QGC>7S+RQM0?NJ9"/J<#^1KM*X3
MQ3EO$B ]HE'ZFD43Z=LM+-[AP=L:EC@9-<1J;3ZI=-(A\HF0R%BVW#'H![@8
MKT6QMUGLVA<L%=<$J<'\ZM6.@Z=82&6"W&\\ MSM'MZ4T[&56G[16O8X'2K'
M4)P$MHI'D4>7YBJ5VCN QP$'/\(R<GUKN="T)-*C,DA5[EP 2HP$']U?;^=;
M%%*Q2C8K:A:PWNGSVUP2(9$*N0 <#OU!'Z5Y_8:;H]KXB1=,UJZM8C#NW*RJ
MKON'!&T \9KT6:9(())I"1&BEF(!/ ]A7-ZEK/G6PW6$$5L_"27YV[OH@^8U
MG42W9Z&$G-)QCL_3]=R'6=.CD\16\UKI]I>W$D!:=+A%(D4<#!(X:E*^&,@W
MFDQZ=..[6_E$'V9?Z&L.WCGMKY;NUU6>/:I58UL)7C4'TR*WK'Q"4GVZE?PR
M0$=[.6-L_B,5":OJ=$X3C%)-NRZ73_*PPWME:+G3_$Q4?\\[G,X_#HWZU1M+
MFZN+VYMKFTM[VUO7!N+B4M"J+@#"ANN.HP:TM4OM*OXUBMM>MK <[VCVAS[9
M/2L7P[#;WLEJ&GM;F1W/F*;=G. ><MT&<=:3WLBH)>S<Y)_-:_>DNW<ZO2C<
MHLEG--'<Q0C]S<B0,SKV##U'3/>K=E^ZU%E[.O\ *GP:=9VCM);6T43L-I*+
MC(I(QC48C]:W2:6IY=22E*Z-6LS2_P!W=WT/82;@/K6G6;:A/[8O"LL;-@;D
M!^9?J*9FVD:5%%% RM?Z=9:I:-:7]K#=6[_>BF0,I_ U4M?#FBV,L4MII5G
M\1<QF*%5V%P%;&.F0J@_05IDA022 !W-9TNK*TABLXFN)/4?='XT 0S>%/#]
MQ;P03Z+8216^1"CVZL(\G)QD<9)-6IK73!IQT^>&V-D4\LV[J"FWTVGC%0?8
MK^ZYN;KRU/\ !%_C4L>C6:'+1F1O5SF@#(M-$\'Z;:3VEIIVG103X,J+$,/@
MY&?6K4T'AN[%P+BVLI1<J%F$D8/F = V>N*UELK51@01_P#?-!L[9NL$?_?-
M &6=#\-7FFPZ<VF:;+90G=% 84*(?4#'!JX-%TH%R-.M<20BW8>4N&B'1",8
MVCTI9-(LI/\ EB%/JIQ4)TVYM^;2[8?[$G(H H:CX,TNYT%])T^WM=.@>02,
ML-I&R.1V9",$?KP.:R+;X964&FKIYO6:U>]%[=1) B+,R[=J@#A%&T<"NF75
M);9@E_ 8_P#IHO*FM*.1)4#HP93T(- #J*** "BBB@ IAYI],[T 59X\'<.G
M>H3W^E76'6JSQ'^'\JQG#JC6,NC*^<?6FY ^M.88%,P2>E9EB-C-"Y!S0>&Q
M4T:D\D8%6DWL2W8%4MC/3'-1RWZVAY/F<?B*==2^3;Y[GI6*S @R/SGH*U4;
M(R<KEJ35YG.8T J$W]ZW1]OTXJB\^6XX^E-$K9Y-.]MQ6OL:,=Y?+*O[PD9[
M\BNC#H!\[8([5R]I.%GC9ONJX)^F:VYK=WDW*V5/((IB*E_->+*##(%B/0CO
M]:I_;+]?^6U:%XGDV6UC\Q8$"L<LS'BF!9&H:B/^6@/UIZZE?CJ4--ALIY1G
M[J^IJ62P=4)5]Q'M0 HU6Z'54/X5(-9F7K"I_&L:1F0XJ(S-GK0!N_VWCE[=
MOP-*?$%OCYXI5_#-8(E:EWN>YH W1XBL5ZF4?5#2'Q%IQ/\ K'_[X-8>Y_6F
MM)(._P"E &^?$.GG_EI)_P!\&GKXAL #\TG(Z[#7-^<_K2K*_J: .D&O:<5
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M_O4G5R:!D;]!2J/D!--8\FGGA!0!"U*N<BDI0>U #\D'BIE/!/>H5.6J0=*
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M%1-)0 YCS3<U&7HWT /S3U?!J(,3VHW8H U+>=V(59"A/&1274B&-QM::8=
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M H KPZ=:0#Y($SZD9-60 !@# KG[WQCIEL2D+/=./^>0^7\S_2LJ7QK>R?\
M'O81H/\ IHQ;^6* .VI" 1@@$>]<"?&NHJV&%KD=1M/^-7;;QG<LH:6SBD7U
MB<C_ !H Z>;3;2<?/ N?51@U5-A=VGS65P67_GG)R*BL_%&G7)"R,UNY[2C
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M=2:Y\>M:=A/N'E,>1T^E1*/5#3- <"@=:0]!0*S&/%%+10 4444 ,D4-&P8
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MIO)B9V"D C<< _H?SJW9QW@O?,E0K#*A+*V"4(/ R/;-42W<Q[+3861I+0Q
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M*D^UJ>]:1C0]44_A0(XQT11^% &<LLDGW$8_05*EK+)S(VT>@Y-7J0D 9)
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M VY$C;6]\@]:ETHM\ZW)562ER2VZ&[;W4%TF^&0,,X/J/PJ:L^#38XH=L,K
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M[AJ"F(*R?$T,UQX<O8;>'SI7C("8!S^8(_2M:JNI MIET 0"8FP3GT]N: .
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M*7EPS0VRJ&103U.1QZ]NM 'KGF)Y?F;ALQG=GC%1"]M"A<7,)4<%O,&*YO\
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MA>_^ DG_ ,335UJV=F58KPLAPP^R2<?^.T :-%9TFM6T43R20WBHBEF)M).
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
&**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>trda-20211231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %8 S8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ K/
MUN^DT[29KJ%5:1,8#=.3BM"L3Q;C_A&KO<<# S^8IQW1E7DXTI-;V8L9\0.$
M8FPVG!/#9Q5NZUG3;)RES>11." 59N0:YZU_X16-H7746\P8(!NI#S],UH64
M,,FNZW(T:,Q5%R1GY=O2K:74Y85962BTVWWOT;\BU>:_:6E_8VQEC*W63OW<
M 8X_,\5:&JV!N_LHNXC/S\F>>.M<K92000^%Y;@HL8$R[GZ9QP,U=M1'#INO
MSFU$[>=+N0=7&.E#BA0Q,V[Z?Y+E3-F#7-+N;K[-!?0R3= JMU^GK3-1UNQL
M1-$UU"+I(V=8F;DD#(%<G)>B8Z2BWEDZ)<1;8;6$CRQGNQZ>GO5J2YL;;3=<
ML]0"B]DFF?:RY:0'E"/;&/IBGR(CZY)Q>R\^FWKO_5CHEUFT@TNTN[^XB@,\
M:OACU) )Q^=7+6[M[Z 3VLR2Q'@,AR*Y)[T6QTI0UI;.-/1A=7*EACNJ@<9X
MS5[P@^\:H?,$F;O=N$>P'*CD+VS4N.ES6EB7*HH/^M+_ -:?,NOKUO::I?6]
M[-%!% (MC,>6+!B?Y5?FU&RM[1;N:ZB2W;[LA;@_3UK*M8(I/%6LR/&K.L$"
M@D9P"&R/QP/RK%CNEM=-TE=ELA$LWEW%R"4B()XP.Y[4^5,3Q$X)MVZV^4K?
MK_P3K;?5M/N[:2X@NXGAC&7<-POU]*++5+'4=WV.ZCFV_>"GD5QBM#>-KOVF
MX,\3P0EI;:';T8\@=P#C-:FAWCRZV(S-:7V8#_I4$>UE / ;MS0X60J>,E*4
M4[:_YM=_\SI+J\MK& SW4R11C^)SBJ%EK45]J-Q'#+$]K'"LBRJ?4G.?RJOK
MKQV^IZ9<W0_T2-VW,1E48C@FL*\:*]N-=DTP;D>*(L47(?!^8@=^GXX-$8IH
M=?$2A.RZ=.KTO]QUMIK&G7\S0VMY%+(O55;FF_VYI8FCA^W0>9(2%7=UP<?S
M%<W;/'=ZCIH75H;AHWW)'!:A2HQR"1T%-6V@/@:9C$A:2X=F..I\TC/Y"CD1
M*Q=1IM):)O[K=F^YU5KJMA>S20VUW%+)']Y5;)%,36M-EO/L:7L+7&<; W.?
M2L?4X-NNV*6J*DC6$ZKM&.@7 K/ENM.F\+0:=;JIU %%2%5_>)*&&3[=\FA1
M14L5.+:=KK\=M%YZG476M:;9.4N;V*-P=I5FY!I]UJEC90)/<W44<4GW&+<-
M]/6LO3K>*36-::6-'<E48D9R-O3Z5B0LD>D:'/\ ;?L=PL#!)I$W1D9^Z<]#
M0HH<L34BKZ=?P=N_^1T=_P"(K&SAM)A/$\=Q(%#A^ .Y_"K<NJV$,Z027<:R
MN0%0GDD]*Y3[5&^F6LT\-M'%%J(W30IB.3U89[9K8MEB/B+5YQ&)"((BN.I&
M"<"AQ2%#$3D]&M;?DW^A?_MW2OM?V7[?!YV=NW=W],U':ZY;7.MWFFAT#VX7
M!W<L>=P_# KCKJ^$NA+&EQ90Q[@PLX8273YN=S'H1W-:D^#J7B"WA*B[GM(3
M N.6PC9Q3Y$9K&3DU:W])Z;^7EZ'26^LZ;=71M8+V&2<?P*W/X>M1:AKEC9>
M;"UU"+I4++$S<DXX%<M"T=S%I]N-5A9UD0QP0V@$D; \_3W-6'N;"WTK6+/4
M OVR220E&7+29^Z1Z]ORI<BN/ZW-QZ+S^6V[U_JQU=A<-=:=;W#@!I(PY Z#
M(JO'JUM%8Q37EY;J7#'>K85L'MFET?\ Y -G_P!<%_E7-Z5%'*/#8D16"K.P
M!&<')YI))W-I5I14+;M?JE^IN7WB*QMM&DU&":.= 0J@-U;/3^M6)-;TV*..
M22]A59 &0EOO G&17-ZHB+;>)P$&!)"V .G3)K3B^S77BF":(1R1_8B8V R/
MO=J?*K$+$5'.VG3\VK_@:-QKNEVEP()[Z&.7^Z6Y'U]*DO-4L=/1'NKJ*)7^
MZ6;[WTKC[J_#0:I$DMG9AY9 UOY)DFD;U.?7K[5:TRYM;*]MKG4758I-.B6"
M20948SN&?7I1R$K&2<K:>O;UU_R.HEU&RALQ>2742VYZ2%N#]*JW.LP'1+G4
M+&6.<1(2,'(R.QKG+]XB=)NK,"RTY7FP\D6Y%8XPV#T!YP:1@LMCKMPE\MUN
MM@KO'#L0D9[]S0H()8N;;BNWZ7NO^&.BAU?_ $ZZCN"D<$,$4I<]MV<Y_*M%
MKB%)(HVD4/+GRP3][ R<5R.H1O(FMJBEF_LZ X'7C)JVVIVFH:WH8M9A+M$A
M8KT'R=/K0XE0Q+7NR[_^W-?@C2L]:B;39+R^EB@1)GCR3@?*Q _&K-OJ^GW5
MM)<07<3Q1\NP/W?K7)I=+;VEME+=6^VSE;BY!*1'<>P[FH3.9WUQS<QW!:Q'
M[R.+8K<GIZ_6GR(S6,E%);Z?I?\ K3YG;6E_:7QE%K.DWE-M?8<X-/6Z@?SM
MLJGR3B3!^Z<9Y_"F6$4<-A;I&BJHB4  =L5S@U"VL)_$%O<R;)I)"\:$<N#&
M "/7I4)7V.N=9TXQ<[:_Y7-^;5]/MXUDFO(D1T\Q2S=5]1^=5=1\0V5GI U"
M*:.9&943#<,20#^0R?PKGK>>SMM0\/S7NT1KIYVLPR%;(P3_ )[T7GE2:+K5
MU"H^Q/=1/&=O!PZ;F'M5\BN<LL7-QE:U[/UVO?\ 0ZFXUO3+2*.2>]A19!E"
M6^\/6HKC5E\W3C:O'-#=RE"X.>,$\?E6+>ZG"NL2M;S6-H#"F+B9"YE7_9[8
MK,M8Y;FPL88;DPROJ4H$H3:5RIY"]N*%!!/%RYG%:^GJO/K_ $SN1>VI$Q$\
M>(#B4[N$^IJ.RU:PU%F6SNXIF3[P4\BN4G#KX9.G+&L=Q97"?:@$W;USGS,?
MQ \$U9L'2[UVS==5BNWC4G$%N%PN.C$=![4N16+6+DY1C;>WX_/IZ?<=3<W,
M%I TUQ*D42]68X%47UVP.F3WT%U%+'$.2&[]@:J>(#'%=Z9<70S9Q3$R$C(4
MX^4GVS6?/);7VJ:A<V(5[<6#)-(H^5WSD?4@=Z2BK7+JXB49.*M^NV_H;6@7
M\VI::+J:6"0N>!"#A1CH<]ZNB\MS!).)D\J+.]L\+CKFJ^BJJZ+9[0!F%3Q]
M*YF34+:UT'6K&63;=%Y@(L?,<YP?I[T<MV#K.E3BY/I^-CJ+G5]/LU!N+N*,
M%0PW-U!Z&D:_CE2TEMKB!HII H8G[P]%]ZR;&*-_$=N[HK,FFIM)&<9/-4+=
M0B6:J,*-:< #MUHY42\1/Y?\,=)-K6FV]RUM+>PI,HRR%N0*LK<P/*L2RJ79
M-X4'DKZUQ5S<6$'AO5;&]"B_,DK,A7YG8DE6'MCO6FEW!I^L6,UW((HGL%17
M;H2,'%-P%#%MOWK6T^5^YOF_M!!+,;B,10L4D8M@*PZ@TVQU*RU)6:SN8Y@O
M#;#TKBV9Y]+EN8VV0#6)9)&>/<%4G@E?8XK5T@K<^(5G74H[N1("KF"WVK@X
MP&8?H*'"R"&+E*:5M[?C\_T.AN[^TL=OVJXCAW D;SC(&,_S%5FU_25BBE;4
M( DIPAW=:J:K%'+XIT,2(&"K<, 1GD!.:I6]K!Y'B4^2F3*ZGY1TV X_,TE%
M6+G6J*;4;::?@F;]WJ5E80K+=7,<4;_=+'[WT]:9)J$4EM;SVMS T<LR(')X
M8$XP/>N>LY[>RO\ 3[G4"%A:P1()7'RJW<9[$BJ[%))#<6RXLY=7MS%@8#'(
MR1[9I\AF\5+R].OJ=3=:SIME<+!<WL,4K=%9N?\ ZU0W&MVUOK5OIK.FZ9"V
M2W0]A^-<PTC6USJL5WJ5O:EYW9HYK8.9$/W<'N,<8JY9+#9:CH*SR$@V;HCS
M)M8G(VC'8XHY$+ZU.3LK+5?G;O\ Y&_%J4,>GM=7=U;B-793(IPO!(QSWJ6V
MU.RN[9KFWNHI(4^\X;A?KZ5Q0$JV&GS^<L-O'>7&Z1X]ZHQ<X)'Y\U:2."Z.
MJS27[7:-;!)GM;?:N<Y!_P!IAS^%#@A1QD]%;I^E^_Z'566K6&HLZV=W%,R?
M>"GD5)=7MM8QA[J=(D)(!<XSQG^0KF-%O&;7+:+SK34 86 N(H]LD2C& W;!
M-:7B"-)+W15=0R_;0<$?[#4G'6QM#$2E2<^M[?EZ]^Y<FUW2[>&*:6^A5)1E
M"3]X>N*F.IV(MH[@W40AD.$D+#!_&N?U*^6VUZX1)+*Q81*#-/&6:0>BCIQ6
M;8)'/IVGQR@2*=7;(9-H/4_=[?2GR*US-XN:FXZ/_ATN_P"GWG96FIV-_$\E
MK=12HGWRK?=^M16^N:7=RB*"^ADD+;0JMR36!K5O))?ZS':H?,>QC)5.K ,<
M_CC(HGO]*O=9T-; *7CF(^1-OEC:?E/I]*.1#>*FG9VW^_6VG],WXM2ACCFD
MNKJW55G>)6!P!CL<]_6I;/4['4$=[2ZCE6,_.5/W?K7)B-)HVCD4,AUV7*D<
M'YJN:K [:WJ<=JN)9-*4X7C)WL/SP,4<J".)G:]M/QV9MPZYI=Q-Y,5] \FX
M(%#<DGT]:37-431]*ENF*;Q\L:L<!F[#^?Y5SES?Z5=2:##9JIGBNHP0J8,8
MP<@^G/;VK<\4*&\.7>0#A01GZBERI-#5>4J4VFKI;KTN%KKEK%8Q27^H6OFR
M8(,>0"#TQ^569]:TVUNA;3WL,<Q_@9N?Q]*SH8(CXLR8TRM@H7CIEN:SH+O3
M+33=3L]1"_:GEEWQLN7ER3MQZ]L4^5,7MYQ5FUUU?E_G_5SI;O5+&Q)%U=11
M$#=ACSBHSKFEAX4-_!NF ,8W?>!K$T6V9=8LQ=H#<1:<@^89*G-5/LT$?@S5
M"D**1=R$$+TQ)@?I1RH'B:MN9)=?P.T=U1&=CA5&2?:LC3];?4-:FM!;/% L
M E1Y!AGRV,X[#@UKI]Q?I6.O_(ZR_P#8.3_T8U2K:G15<DXV>ERYJ]Z^GZ9+
M<QJ&9,8!Z<D"G37\4:RHLB&X2$R^7GD#'4U3\4@GP[=!3AL+@^AR*S=.4Z<N
MHZ?=D/=2Q-.EP1S.N/YCICTII)JYG4K2C5Y>EO\ /\R:SO\ Q!=:;%?QQ63H
MZ;Q%E@Q'IFM.WUNSETF/4995@A8<^8<;3W'UK&T7Q%I=KX=M(GNU:=(0#$H)
M8GTQ5/\ >:9INF"XA@BFEFDF$MR"4@)YP0.]4XW>QA"NXQ4HROIKUL]#J[+4
MK/449[.YCF5>#M/2JUQK=O;ZW!ICN@>5"V2W(/8?C6/X>G,_B6^<W,=P6MT_
M>1Q;%;!/3U^M7-1>*'Q9I[2%$+V\BHS#JV1@?6IY4G8U5>4J2FM-;?C;O^IH
MOK.FQWOV-[V$7&<>66YSZ?6K5Q.EM;R3R'"1J6/T%<9#<Z=%X3FTV=1_:/SJ
M\)7]XTI)P??L<^E=)>VL]QX:EMCS.UMM/NV*'%(=+$2G%O2]KZ?D_,J0:GK#
MF"Y>RA-M,1^Z1B9$4]&-/GU/4IKN[33H(7BM#M<RL07;&2!Z5A,NDK;V;Z:S
M?VSYB#[S&0G(W!_;&>M:<&HVNCW6KP7LHB=YC/&&'^L5E'3UY&*IKLC"-65K
M2EIWOY/K;\"RVMSW@LHM-A0SW,1F8RGY8U'!SCKSQ5S2K^6\6>*YC6.YMY/+
MD"G(/<$?A7/Z<1HUSIMU?9ABELVB+,.$??N /IP:UM"<75YJ5]'DP32@1MCA
M@!C(_&E)*QI1JSE)<SUZKRM?\RRNHD:O=VLNQ(8($EWDXZYSG\JJW^JW37MC
M;Z88'6Z1G#R9Q@8Z8K(UJRN;OQ!>O ?,2""&22V(XG ).TU8O-6L?[9T;4#,
ML=J\,F&;C'3BA11,J\O>BW;7?RYK?@:,.I7]KJ,%IJ<4.VX)6*:$G&X<[2#5
MJXUS2[6Y^S3WT*39P5+=/KZ5E75[!KNJZ=%I[^=';R^=+*H.U0!@#/KS6-=7
MX>QU"));.T#R2;K7R2\SMD\G/KUH4;BEB733Y7==&_3Y?UW.]!# $$$'H12U
M2T<[M&LCG.85Y_"KM9L]",N:*84444%!1110 4A 88(!'H:6B@!GE1_\\U_*
MG8 ).!S2T4!88T2.H5D4@<@$=*=@#. .:6B@+#%AB3.V-!DY.%')H,:,P9D4
ML.A(YI]% K(8T4;@!XU8#H",XIP4#H /I2T4#L)@9)P,GK36B1TVLBLOH1Q3
MZ* L-"*HP%4#&.!2)%''G8BKGKM&*?10*R$95=2K $'J"*1451A5 &,<"G44
M#&)%&A+)&JD]2!C-.VC&,#'IBEHH"PF!G.!D=Z:(HPY<(H<_Q8YI]% 6$P 2
M<=>M-:*-TV,BLOH1Q3Z* L,,4;1["BE/[I'%."@= !2T4!8C$,08L(T!;J=H
MYIWEH7#[%W#@-CD4ZB@5D,$4:N76-0QZD#DT&-&8,R*6'0D<T^B@+(3&!@=*
M JC&% QTXI:*!C2BD$%1SUXZT+&B !550.!@=*=10%AABC+[S&N_INQS0T4;
MJ%9%91T!%/HH%9#2BLNTJ"OH1Q0L:(FQ44+Z <4ZB@=A-H]!SQ35BC3[J*O.
M>!BGT4!88T2.I5D4J>Q'%*(T P$4#&,8IU% K(*8T2,P8HI8="1R*?10,H2Z
M8DNK17S,"(X&A\HKD')!S^E7=B;-FU=N,;<<4ZBBY*A%7MU(S!$=N8D.W[OR
MCBG[5_NCUZ4M% [(3:,DX&3UIJ11QYV(JYZX&*?10.PA4,,, 0>QI%C1%VHB
MJOH!@4ZB@+" 8& *:8HR^\HI;&,XYQ3Z* L)M&<X&>E&U?0=<]*6B@"IJ%@E
M_93VYPC2QF/S-N2N14L5LB6T4+A7$:A02/0=:FHHN3R1OS=1NU<$;1@]1BD2
M)(QA$51Z*,4^B@JPF 2#@9'0T;1SP.>OO2T4 -:-'7:Z*R^A&10$4  *,#H,
M=*=10%AC11NP9XU8CH2,XI6C1R"RJ2.1D=*=10*R&E%*E2HVGJ,<4+&B+M1%
M5?0# IU% [#$BCCSL15SUP,9IQ .,@''2EHH"PQXHY""Z*Q'0D9Q2[%_NCUZ
M4ZB@5B"[MA=VLL(D>)G7 DC.&7W!K,MM%NA>07%_J N1;DF-5A$?S8QN..IQ
M6U133:(E2C)J3$VK_='7/3O45Q +B"2+>R%U*[T.&'T-344BVDU8PX-#NS=6
M\E]J7VF*V??&@A"%F P"Q[XS6V0",$9%+13;;(A3C!6C_F)@9S@9IIBC9P[1
MJ6'0D<BGT4C2PF!G.!GUHVKC&!CTQ2T4 %)@9SCGUI:* $(!&",B@J"<D FE
MHH 8(HP<A%!^E*\:2+M=59?0C-.HH%9#515QM4#'' H:-'(+*I(Y&1TIU% [
M##%&7WE%W_WL<T^BB@!@BC#EPBASU8#FAHHW8%T5B.A(SBGT4"LAKHLB[74,
MOH1FE"A0 H  Z 4M% Q,#.<#/K2&-" "BX'M3J* $"JH^50/H*;Y,>_?Y:;_
M .]CFGT4"LA  !@# I:**!A1110 45GZA<ZA#(@L[-9E(^8EL8/YU3^WZY_T
M"T_[[_\ KUSSQ,82Y6G]S-HT)25TU]Z-RBL/[?KG_0+3_OO_ .O1]OUS_H%I
M_P!]_P#UZCZY#^67_@+_ ,BOJTNZ^]&Y16']OUS_ *!:?]]__7H^WZY_T"T_
M[[_^O1]<A_++_P !?^0?5I=U]Z-RBL/[?KG_ $"T_P"^_P#Z]'V_7/\ H%I_
MWW_]>CZY#^67_@+_ ,@^K2[K[T;E%8?V_7/^@6G_ 'W_ /7H^WZY_P! M/\
MOO\ ^O1]<A_++_P%_P"0?5I=U]Z-RBL/[?KG_0+3_OO_ .O1]OUS_H%I_P!]
M_P#UZ/KD/Y9?^ O_ "#ZM+NOO1N45A_;]<_Z!:?]]_\ UZ/M^N?] M/^^_\
MZ]'UR'\LO_ 7_D'U:7=?>C<HK#^WZY_T"T_[[_\ KT?;]<_Z!:?]]_\ UZ/K
MD/Y9?^ O_(/JTNZ^]&Y16']OUS_H%I_WW_\ 7H^WZY_T"T_[[_\ KT?7(?RR
M_P# 7_D'U:7=?>C<HK#^WZY_T"T_[[_^O1]OUS_H%I_WW_\ 7H^N0_EE_P"
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M]_\ UZ/M^N?] M/^^_\ Z]'UR'\LO_ 7_D'U:7=?>C<HK#^WZY_T"T_[[_\
MKT?;]<_Z!:?]]_\ UZ/KD/Y9?^ O_(/JTNZ^]&Y16']OUS_H%I_WW_\ 7H^W
MZY_T"T_[[_\ KT?7(?RR_P# 7_D'U:7=?>C<HK#^WZY_T"T_[[_^O1]OUS_H
M%I_WW_\ 7H^N0_EE_P" O_(/JTNZ^]&Y16']OUS_ *!:?]]__7H^WZY_T"T_
M[[_^O1]<A_++_P !?^0?5I=U]Z-RBL/[?KG_ $"T_P"^_P#Z]'V_7/\ H%I_
MWW_]>CZY#^67_@+_ ,@^K2[K[T;E%8?V_7/^@6G_ 'W_ /7H^WZY_P! M/\
MOO\ ^O1]<A_++_P%_P"0?5I=U]Z-RBL/[?KG_0+3_OO_ .O1]OUS_H%I_P!]
M_P#UZ/KD/Y9?^ O_ "#ZM+NOO1N45A_;]<_Z!:?]]_\ UZ/M^N?] M/^^_\
MZ]'UR'\LO_ 7_D'U:7=?>C<HK#^WZY_T"T_[[_\ KT?;]<_Z!:?]]_\ UZ/K
MD/Y9?^ O_(/JTNZ^]&Y16']OUS_H%I_WW_\ 7H^WZY_T"T_[[_\ KT?7(?RR
M_P# 7_D'U:7=?>C<HK#^WZY_T"T_[[_^O1]OUS_H%I_WW_\ 7H^N0_EE_P"
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M]_\ UZ/M^N?] M/^^_\ Z]'UR'\LO_ 7_D'U:7=?>C<HK#^WZY_T"T_[[_\
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MZ2?$&I$G_EZE_P#0C6?7?!6BD?#8JK*K6E*7<****HYPHHHH **** "BBB@
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M=C'KTKHO^%<:M_SWM?\ OH_X4?\ "N-6_P">]K_WT?\ "ES4RWAL<]XO^O\
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MZBNQ_P"%<:M_SWM?^^C_ (4?\*XU;_GO:_\ ?1_PH]I'N']GXK^1G'45V/\
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M^YF!16__ ,(7KW_/BW_?0H_X0O7O^?%O^^A1[>E_,OO#ZK7_ )']S,"BM_\
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MAZQ?]]4?\(KJ'K%_WU7-+!8J3<G!W9O'$T(JRDC$HK;_ .$5U#UB_P"^J/\
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M]_R!YO\ >3_T,5QXK^!/T?Y'90_BQ]4:5%%%;F04444 %%%% !1110 4444
M%%%% !12$TTF@5QV:,BF$TFZG8+DF12YJ+-*&H"Y)13<TH-(8M%%% !1110
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M44 %-)I33&- F(33":"?>HV:J(;'%J-U0EJ3=3L3S$^ZE#57#4\-18$R<&I
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MZU*13&%6B&0M56]M8[VTFM9AF.5"C?0U<84PCVJTS)H\*USPKJ&B7#^9$S0
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M&G1?I-_(5NU@ZI_R-.B_2;^0K>JZGPQ]/U84OCGZ_H@HHHK(W"BBB@ HHHH
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MY8*R%4E*;YI.[("M-V>U3E:3;5W,N4AV^U."U)MIP6BX[# O%2 4H6G 4AI
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MVQIG_01M/^_R_P"-']L:9_T$;3_O\O\ C19A[6'=%VBJ7]L:9_T$;3_O\O\
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M%7Z*+L/94_Y5]Q0_L/2O^@=;?]^A1_8>E?\ 0.MO^_0J_11=A[*G_*ON,_\
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MB",!>_O6#K4&D^'M0DO_ +'I\ETL!+)';(#'@ #'N:UISIQ^)7(F[*]RC/\
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M444 %%%% !16?>W+VE_:N[8MI,QOGH&/W3_2M"BPD[NP4444#"BBB@ HHHH
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M,JE)35CRCPMX=U"VU9+_ %&RN%@7;^[9#EG"\<'GC'7I7IFFQRQ6$23*%*@
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M'XFKMS81W&]@[Q.Z[69#C(]_6K8  P!@452&,B3RXD3.=J@9]:?110 4444
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M3LCT<5BZ>&ASRZ['IU%>!&YG)),\A)ZDN:3[1/\ \]I/^^C6OU?S/*_MU?\
M/O\ '_@'OU%> _:)_P#GM)_WT:/M$_\ SVD_[Z-'U?S#^W5_S[_'_@'OU%>
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MJ_F1_;J_Y]_C_P  ]^HKP'[1/_SVD_[Z-'VB?_GM)_WT:/J_F']NK_GW^/\
MP#WZBO!([RZB</'<S(XZ,KD$5Z#X-\7S7UPNFZC)OE8?NI3U;'8^]3*BXJYT
M8;-Z=::A)<K>QW5%5M0OH=-L)KR<XCB7<??T'XGBO(-8\4:EJ\[%[AXH,_+#
M&Q"@>_K4PIN9TXS'T\*DGJWT/:**\!^T3?\ /:3_ +Z-'VB?_GM)_P!]&M/J
M_F>=_;J_Y]_C_P  ]^HKP'[1/_SVD_[Z-'VB?_GM)_WT:/J_F']NK_GW^/\
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M5_,X_P"W5_S[_'_@'OU%> _:)_\ GM)_WT:/M$__ #VD_P"^C1]7\P_MU?\
M/O\ '_@'OU%> _:)_P#GM)_WT:N6&MZEIDPDM;N5><E2Q*M]10Z#[CCGL6_>
MAIZGN5%8_AS78]>TP7 4),AVRH.Q_P #6=XQ\3-HENEO:X^US+D$_P "],UB
MHMOE/6GBJ4:/MF_=.IHKP.YN[B\F,MS/)-(?XG8DU#6WL/,\=YZKZ4_Q_P"
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M.Z_Y]IO^^#2Y5W+C6:5N4O:W;65M<0BQ<,K19<!]P#;B.OT /XUEU-]CNO\
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M=P,CU%7[#4;74XGDM79A&^QPR,A5L X((!Z$'Z$4 6Z*** $V+G[H_*C8O\
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MT-(^S+Y4;M.S &681*,#/)(- 6-38O\ ='Y4;%_NC\JQXO%&F/I\5Y)(\(D
M_=LA+*2%.W SD_.O3UHB\4Z4\@B><QR%F&&C<!<,Z_,2 %/R-P?0T!8V=B_W
M1^5 50<A1^55-.U6SU:%Y;.7S%1MC94J0< \@@'H0?H:N4!8**** "F[%_NC
M\J=10 W8O]T?E1L7^Z/RK#7Q5:-?7=J(VW6\R0[MPP^2%)'L"<'/I3AXOT0G
M NVSG&/)?@?WNGW?]KI[T!8VMB_W1^5+L7^Z/RK&C\4Z2TGE/<A' ))V,5 !
M8<MC&?E/'M5VPU:QU.$2VDX<%BN&!5LC!Q@X/0@_B* L7 H'( 'X4M%% !0>
M115/5-2ATFQ-Y<'$0EBC8DX"[W5,GV&[/X4 6MB_W1^5+L7^Z/RK(L_$^F7K
M7 CN%*PRB+<IW!LE0""/]IP*;%XKT:5MJW3=,[FA<+CGN1CG:V/7!]* L;.Q
M?[H_*DV+_='Y5CIXKT:1HU6Z;=(Q7!A<%2-N=W'R_?7KC[PIK>*+.+7+G3)H
MYXS#M7S3$Y#L5WD# Q@+R3F@+&UL7^Z/RI0H'0 5@#QEI#720H\[ QR2%Q;O
MA-A0%3QG)\Q2![CU&9CXITDPAXKI78IO"E6!V^IXX';/KQUH VJ*HZ=K%CJI
ME%G*7,9^;<C+^(R!D<'D<5>H 3&1@TFQ?[H_*G44 -V+_='Y4;%_NC\JYZ/Q
M2T^J36$%BLDB2R1(/M R63J6&,J/?GM5=_&3Q6MA--IR1_;(7N%0W0R$79TX
MY8[^GMUH"QU.Q?[H_*EV+_='Y5S][XKBM(;Q_LDB_9G@3,[")6\UL YYP >I
MQVK3TC4H]7TV*\C0JKY&-P8<''!'4>] 6+H4#H *6BB@ I" >HS2T4 )L7^Z
M/RI-B_W1^5.K N/$\<&NS::T<*B$*9'>X"M@KNRJ8R<#WH"QN[%_NC\J78O]
MT?E7-W/BTVD#S3Z>T2F,2Q%[A!E2P'S=U^\#T(QGGM3)/&(BGCC>TB;="DS>
M5=*Q(9F4!!@;S\G3CJ* L=-L7^Z/RI0 .@ ^E+10 4444 (0#U&:-B_W1^5+
M6%+XHMH=3O+&2"17MI8XPY("R;E1CM_W=ZY^HH W-B_W1^5)L7^Z/RK%/B_1
M 2/M;;@Q!7R7R,<YQC[N#UZ4EUXMTNWD5!))*3,(CLB8]=W*\?.,KCY<\T!8
MV]B_W1^5+L7^Z/RK*/B;2 Q!O!@1F7=L;;@+NQG&,[><=<=J9I_B?3M0EDB1
MWCD6?R%21&5F.,]",CH?I@T!8V  .@ I:** "D(!Z@&DDD6*)Y'.$0%F/H!7
M/2>*_LZ127>FS017 W6[-(IW#(^\!]TX.<<\9YSQ0!T.Q?[H_*EV+_='Y5C_
M /"4Z2K;)+G:P0L?W;%>%#$!L8) (X'/(H'BK1VE6/[4P9ASF%P%/. QQ\I^
M5N#@\4!8U]B_W1^5+L7^Z/RK-?Q!IJ2+']H+.<<*C' (&"<#@<CD\<U6A\6:
M0\8,MQY+^3YS(RD[1C.,@8)]AS0%C;V+_='Y4  =!BL$^+]+^UB'?*JA2SRR
MQ,BJ &)!)'!&PY!Q3K?Q=I4T[Q/))"XG\A1)$RECM0Y((RHRX'..: -VBBB@
M HHJG>Z@EA+:B53Y<\AC,G9#M+#/L=N/J0.] %RBL%?%^DI$K7,K6[,AD"LC
M'Y0">H&,E1NQUQ4R^)M,WJDDQC9FP T;_+S@;LCY23P >_% &Q164WB/2EGA
M@^TDR3;=@6-CPP!!.!P.1R:U: "BBB@ HHHH **** "BBB@!DL:S0O$_*NI4
M_0UCZIX:M=2M$@R4VQK#NY)"!@V!SU^4<UMT4 8T?A?38KHW 68MYGF(ID)6
M,^8LAVCL"R*3]*6/PSI\-U!<1^<IA?S%02G:6P0&([G#$5L44 9,WAW3Y_MF
MY) ;O'FE7(Z-N&/3FJ0\$:,MN(%6<1YW%1*<$Y)Y'3^(UT=% '/IX,T:.V:W
M6.;RVC$;9E/("%!^2DBMFWM(K:2X>($-<2"23)SE@JK_ "45/10 4444 1W$
M"7-O)!)G9(I5MIP<&LQ?#.DQSB6&U6$A-FV+Y5^ZRYP.^&(S]/2M>B@#!_X1
M'3!+YL;7,<@965DF(*D*R\>G#-^=.'A+2APJS*H4!5$IPA&W#CT;Y5Y]JW**
M ,.U\,VMIJL%ZCNWD)(%\PEF+.VYF)/6MRBB@ HHHH 1F51EF 'N:J3?8]4M
M9[=I%DCR4D"M@@@\BL_Q+I5QJ\5A# L)$=T9)/.7<H7RI%Y&1GEEK-C\%&&"
M58[I?-DAFC>0H?WFYXV7=SR!Y9'T8T :FHZ'97MO<JKJLMPDHW,=P&]=K'&1
MV%-@T?1XGAM%?,L:(RC?R0J-&#^3-^-<]?\ @>^^R73VMU#YSVD\0B6,@9>-
MU55R?E7+#\JT;?P;Y=PMR\L F62-T\J(A8MLJNP3G@$ C\30!9?PCHIMUA!E
M2)?E*K.0&YS\WKBI)= T.9)+"09VJ692_*AVSG\Q6;9^"1!&!>O'=1)$4,4:
M;3(=FW?R?OGJ3Z^E0Q>#M1GTK-W?1F_N51[HNFX%@3QP<< JO_ : .MLK:UT
MZSCM+<JL40X!(R,\Y/YU:!!&1R*X1/ -XD+1C54.Z&-'8QDF1E"@[B3T.T\>
M]=?I=D=.TNVLS(9##&$+'OB@"Y1110 C,JC+$ >I-5Y[6VNIX)Y0KM#DID\<
MCFH-7TQ-6M8K>0KY:SQRNK#(8*P.TCWQ7/-X.O?)-O'J4:P#)4>6V0=I4#.[
M[N"!CTH U)=%T>\U62X:5VG5TE9!,0@8E2&QTR?+'Y5(WA[2?WX=,B60R2!I
M."2TC'\,RO\ G6'>^")[R-P+R"#>03%#$5C& PX&>,;LCTJ6]\%S7=Q<R?;(
ML2,64M&2S=.'.?F QP,4 ;.G6NE^'K*:.!_*A60;V<_Q$+CGOP5K6#*V=I!Q
MP<&N+D\$W4D:"2^@E;<A/F0DA=J0KE1GAOW)Y]&-:WAGP[)H)NS+=FX:?;S@
MC[I;D_[1W<GV% &_1110 4C,%&6( ]32UC>)K6YN]-C%K;K<O',LA@;!60#/
M!!(!'.<9'(% $4.@:%*X,$:>9;28=T;#,^0_SG^(Y(//K45GX/T2S$IA$A\Q
M/+<M+GC&/ZUD:5X0OK-=,BEE*@8DNRA^7A$"IUR<.N<^U3VO@JY@-J3>P 0-
M&2L<1"R[1C+?-R6ZD]R!0!J/H&B(/LD@_P"/C+;&D/S8W$_^A-5C3-.T?3,6
MMJ(#+"!+EBI=0^0#GL#M(_"L"#PA>S6<IEN?*E+R1PI*-_EP#B-#@\X&2>OW
MC58?#R?R=HOX-Y15=A#C=MDE8#KT E Q_L"@#OZ*BMH?L]K%#N+>6@7<>IP*
MEH *ANK6*\A6*8$JLB2C!Q\R.'7]5%344 9%QX;T^YO#=/YRR-*LK[)" Q4J
M1D=QE%.*:WAC3&MOLYCD";$3B0@X4,!S_P #:MFB@#"M/".DV4<B11R8D)+9
M<\Y*$_\ HM/R]ZN3:)93W4MRZOYLN=Q#D=4V?RK1HH YQ/!&C11&-%N%!+DD
M2D9W>7G/_?I/RI\/@W1X$54CF&V,P@^:?N$Y*_3//UKH** *=EIEK8.6@5@2
M@0Y;/ )(_F:N444 %1SSQ6T+S3R+'$@RSL< "I*J:G9'4-/DME?8S%65B,@,
MK!AD>F0* (-*DTQH9IK&12KS,TA.0P=CD@@\CJ#CT(J.VMM)@BM[B*2-DL89
M+=&+[@J@KO'U!C'Y5E:UX:U/6[(QS:A:QS&0MF. A5&W:,<YSGG)K.N? %S*
MJQPWUO#&LDCC9 0?F=F/?K\V#[ 4 =)J%EI=Q"]S<7#1+<M"1*DNTED;,>WW
MR?QS5W3K6WL[58;9F922Y+MEB6YR<^M<H_@R:\%Y',Z!$DB%D)T#A "KR, #
M_&P^H %;.B:#-I5VTLDT,H*%0XC(D;.WACGD#;P/>@#=HHHH **** "LV31;
M=[^6\\ZY5IL>;&LI"/@8Y7Z5I44 8B^%=-%PL[">1T&V/?*3L&0<#VRH_*M,
M64 OWO=F9WC6(L?[JEB,?BQJQ10 4444 %%%% !67=^'M.O7D>>)BSW*W18.
M01(J*@(]!M0#%:E% '/VO@W1[.2:2*.4O,A1RTA.0:>_A'3&?>&N58-NC*S$
M>7UX7T!R<UNT4 8;>$]*8D%)=FPIY?F';DJ4W8_O;21GWI+7PQ:VFL1:@LDC
MM$KX\QBS,[8RQ)Z\# ^I]:W:* "BBB@!&4,I5@"",$'O6*?"VG,NV0W$B*-L
M:O,2(QG.%].@_*MNB@#EQX,A.I/+)=2&RVMY=NI(VLRA2<YZ\=0 >:OIX8TU
M87C*2OYC*[L\A+,RDD$GURQK9HH PX/"FGV[J\<EV'& S>>V7 QA6]1P.*8/
M!NC!Y'$+AGB\LD/R/0@]0>!S6_10!A-X2TJ3_6K-)D,'WRD[]P8$MZG#&D7P
MAI0NDNG$\UPDOF^9+(68G"CDG_<7\JWJ* "BBB@!OF)@G>N!U.>E4-8M]/O]
M+FMM0E5;8[2[>9M*X((.>W(%<K#X)O9M):*:ZBMY9!%NC1"5;8S'Y^?F)W8R
M/[HI8_ ]Q*+I+B2W"$L(V>,NTGW<;SGE05R!V- &I=^'?#]UJ%M=3%A+(3'
M@<J"1&PP!_N!ORJY+X<TN:<W+;\%][@2G8Y#;AN'?!Y%8<W@6XE>,B_A0J),
M2K$?,0M#)'A#GA1Y@;'J*T8/#$T&@Q6 GAD=+CSBLB%HG&"-I7/3G./4"@!W
M_"(Z,%C5WF8Q%6!><DX7  SZ<"N@\V/GYUXZ\]*XV3P-<3ZHMS-?0F#$8:(1
M'YPK1G!YY'R'C_:JO'X4U&XUF]D>"VAMQ(YC,J!EG!E+ , W( ( R!C '/6@
M#O ZEMH89QG&:6N9TGPO/IFL17OVU9$6W2&0,AWN5C5,YST^7./>NFH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LOQ%+=0>'KV6R,@N5C_=F,#=G/;/&:** ,&+3O
M$'VU;T37"LODHJ2.A+Q^>=XDQQD1DGCVZU76+Q@L4#[KEF5UWQL\?S-@;N1T
M3.<=\=J** (;2T\2:I;07+7%[&5C=U=VC#>9M.-HQ]T\=>:T9[?Q/-?NJ37$
M43,F65H]@3"9VC&=V=^<\>E%% %54\0WD\LT;O,EE-+! ^0IE 5_WG(&3\RI
MZ90U';1^-0T+2&4Y#KM=DP/F8@MCO@KT]*** .D\,IJL>ED:O([W!<D>9MW
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F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>trda-20211231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !_ V@# 2(  A$! Q$!_\0
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M%NE4GLX*_P ZF.,P\](S7WE2PU:.\6:5%(K*ZAE((/0@TM=)@%%%% !1110
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MBB@ HHHH ***AFNH+<9FF1/J: )J*S)-?L$/#L_^ZIJ,>([(GI*/^ __ %Z
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M1110 5DWVMQP/Y-LOG39QQT!_K4&HZA-=7'V"QR6)P[C]1GT]ZO:=I<-@@.
M\Q'+D?R]* ,Y=+U#42)+Z<QH>0@Z_ET%7X=#L(@,Q>8?5SFJVI>)+6R9H81]
MHG'55/RK]36%+K&K7A.)O)4_PQ#'Z]: .O6RM%&!;1?]\"FOIME)]ZVB_!<5
MQOD7<G+W$S'WD-31B_@YCNIE]MY(_(T ;T_AZV?YH'>)NW.15;S]3T<CSQY]
MOTW9SC\>WXU%;Z[>P$"YC69/4#:W^%;MK>6U_$3$P8=&5AR/J* "SOH+Z/?"
MV2/O*>HJS6#?:9)92?;=/)7;RR#L/;V]JTM-U"/4+?<,"1>'7T/^% %RBBB@
M HHJCJNIQ:9:F1_FD;A$]3_A45*D:<7.3LD5"$IR48[LDOM1MM.A\R=\9^ZH
MZM]!7/\ VS6-=8BS7[-;=-^<9_'O^%.T[2)M4F_M#5"6#<I&>,C^@]JW;N]M
M-,MP\SK&@X50.3[ 5P1C6Q?O2;C#MU?KV.QNGA](KFEWZ+T,NV\*VJ?-<RR3
MOWYVC_&M*/2-/A^Y9P_BN?YUSMUXGO+ABME$L*=F<;F/]!5(MJ-R<RW<[9_V
MR!^0KIIX2A37NP1SSQ-6?Q29V;:=9.,&T@(_ZYBJ<_AS3)U($'EGUC.*YI+>
MZ0Y6XF!]1(:N0ZCJEJ1^^,JC^&09_7K5SP]*:M**?R)C6J1^&3)GT34M+8RZ
M9=-(HY,9X)_#H:MZ=XC2:3[-?)]GN <9/"D_T-3V.N0W+".=?(E/ R?E/T-2
MZIH]OJ<1W ),!\L@'/X^HKD>%G0][#/_ +=>WR['2L1"K[M=?-;_ /!-&BN9
MTO4KC3;O^S-2.!TCD)Z>G/I735U8?$1KQNM&MUV9A6HNE*SU71]PHHHK<Q"D
M) !)( '4F@D $DX ZDUSUS<SZU=&UM25ME^^_K[G_"@">[UMGE^SZ?'YLAXW
MXR/P'>HX]$NKMO,U"Y;)_A!SC^@K5M+*WT^'$8 ./F<]3]:R-0\4PPL8K)/M
M$@X+DX0?XT :46C6$0_U 8^KG-6!9VH&!;1?]\"N-DU+5KPG=<M&I_AB^4?X
MTP6]TQRT\Q/J7- '82:78R?>MH_J!C^54)_#L>=]K,\3CH"<C\^M8T;ZC;G,
M=W-]&;</UK1M?$$\9"WL09>[H,'\J 'IJ-_ID@COT,D1Z..OY]ZV[>YBNHA)
M"X93Z=J:CVU_;94I+$W45B7-K/HD_P!JM"6MR?F0]O8_XT =%14%I=17ENLT
M1X/4=P?0U/0 4444 %8NO>)[#0(OW[>9<$92!#\Q]SZ#WJIXL\4+H=NMO; 2
M:A,/W:8SL']XC^0[UG^'/!Q\T:MKI-Q>R'>(Y.0A]6]3[=!6D8I+FD<%;$SE
M/V&'^+J^B_X/D9ZIXJ\8?.7_ +.TYN@Y7</YM^@K8L/AYH]J-UR9;M^Y=MJ_
MD*WM0U:TTQ!YSY<_=C3EC^%<Y<>(]1NV(MU6W3M@;F_,T.H]EH$,OI)\U7WY
M=W_EL;\/A[1K<8CTRU ]X@?YTZ70=(G4K)IEH0?^F(%<H5OISF2ZG8GU<U)'
M#=QG*7,ZGV<U',^YU^QIVMRK[C0OO .AW:GRH7M7[&)^/R.16&^C>)_"I,NE
MW1O;-3DPD9./]W_XDUL0:MJ=L1O<3IZ..?S%;EAJ]O>X0YBF_P">;=_H>]6J
MDMGJ<M3+Z,GS07++NM#*\/>,K+6R+>4?9K[IY3'AC_LG^G6NEKE_$W@^WU=6
MN[/;;Z@O(=>!(??W]ZJ^$_$\\UPVBZQF/4(CM1GX,F.Q_P!K^=#BFN:)-+$5
M*4U1Q'7:71^3[,[*BBBLST HHIDLJ01-+(P5%&230 LDB11F21@J#DDUASZQ
M<WDI@TV(GUD(_P XJ("XU^Y)),=FA_S]3_*MI5M=,M2<I#"O5B?YT 9<6@/,
MWF7UPSN>H4_U-:$>D6$0XMD)]6Y_G6'>>*W=BFGPY'_/60?R'^-9KW.J79S+
M=RX]$.T?I0!VGV.UQC[-%_WP*ADTBPESFW0$]UX_E7(K;7.<^?-GUWFK45UJ
M=M]RZ=@.TGS#]: -270&A;S+&X9''0,?ZBD@UBXLY1!J49'I(!_G/X4ZT\0@
MD)>Q^6?^>B\C\1VK5F@@O8-LBK(C#((_F#0!+'(DL:R1L&1N01WIU<Y_I&@7
M(!)DLW/^?H?YUT$4J31+)&P9&&010 ^BBB@ HHKC?%?B>>*X71=&S)J$I"NR
M<F//8>_\JJ,7)V1CB*\*$.>?_#^1=\0^,K+12;>$?:KWIY2GA3_M'^G6L!-&
M\3^*B)=4NC96;'(A P<?[O\ B:W/#7@^WTA1=WFVXU!OF+MR(S[>_O6CJ7B&
MUL&,29GG'\"'@?4]JOF4=(_><2PU7$^]B'9?RK]7U,ZQ\ Z':*/-A>Z?N9FX
M_(8%:\6@Z1 NV/3+0#_KBIKFI=:U:\)VR"!#_#$/ZGFH?)NY.7N9V/O(:ASD
M]V=D,+1IJT8)?(ZF?P[HUP,2:9:D>T0'\JQ;_P"'FCW0W6QEM'[%&W+^1_QJ
MM&M]!S'=3K_P,FKUOKE_;D"X19T]<;6_PH4Y+9BJ82A45I07W&$R>*O!_P X
M?^T=.7J#E@H]^Z_J*ZO0?$]AK\7[AO+N%&7@<_,/<>H]ZT+2_M[^,F%\D?>1
MA@C\*Y3Q'X/;S3JVA9M[V,[S''P']U]#[=#5WC/26C.1T:V$]ZBW*/\ *]_D
M_P!#M:*YKPGXH77+=K>Y CU"$?O$QC>/[P'\QVKI:SDG%V9W4:T*T%.#T844
M44C4*AN;N&SB,DSA1V'<_2F7U['8VYEDY/15[L:Q[.QFU:87E\3Y7\"=,C^@
M_G0 &^U'57*62&&'H7/^/^%3P>'8@=]S*\K]\' _QK1N;JUTVVWRNL4:C"@=
M_8"N;NO%%U.Q6QA$2=GD&6/X=!0!T4>F6,7W;:/\1G^=2&RM2,&VB_[X%<6T
MFHW)S+=S'/8-@?D*5+:Z4Y$\P/J'- '52Z+82@CR A]4.*H/HMU9MYFGW+?[
MA./_ *QK/AO]4M<8G,BC^&0;OUZUL66O13L([E?(D)P#G*G\>U #+37"LOD:
MA&8I!QNQ@?B.U;0((!!R#WJK>V$%_%ME7G^%QU%9%M<SZ-="TNSNMV^X_I[C
MV]J .AHH!! (.0>]% !1110 4452U6[^PZ9/.#\P7"_4\"IG-0BY2V14(N4E
M%=3"U&237-973X6(MX3F1AZCJ?Z"M^::UTC3]S82&)< #OZ >YK.\,6?D:>;
MEN9)SNR?3M_C6/X@O&O]4^RH?W-N<<=V[_ETKCP5-N+KS^*6OHNB.G%32?LH
M[1_/JRG<W-SK-UYL_" _)&.BC_'WK0M=/  R*?8V@ '%;,404=*[CD*L=FH'
M2IQ;+Z59"@4M %-K53VJK-8@CI6MBF,@- &987DFG2"*0EK8GI_<]Q[5MW=K
M#?VC0R ,CC@CMZ$5F7%N&!XJ?2)SL:V<\IRGTI2BI)Q>S&FXNZ,W0KF73[^3
M2+H]R8C_ (>QZUTU<YXHMFC$&HP\21, 2/T_7^=;MI<+=6D4Z])%#5PX-NG*
M6'E]G5>C_P CJQ*4XQK+KOZ_\$FK,UJ_-I:^7&?WTO"XZ@=S6G7/PC^TO$+R
M'F*#I^'3]<FN\Y"_I&GBRM@SC]\XRY]/:L;7]<>25K"Q<@#B61>N?[H_K6MK
M^H'3]-8QG]]*=B>WJ?PKE=/M,X)Y/O0 ZST_@<5LP6*J.E3V]N% XJZJ "@"
MJMJH'2G&V7TJUBB@#/DLU(Z52,$MK,)H&*.._K[&MPC-0RQ CI0!9L+U;V#=
MC;(O#KZ'_"LB^B;1]12]@7]PYPZCI[BEC8V5XLH^[T<>HK9O+=;RSDB./G7Y
M3Z'L: )HY%EC61#E6&0:=6-X>N&:WDMG^]"W ]C_ /7K9H ;(ZQ1M(YPJ@DD
M]A7+6,+>(-7DO;A3]EB.$0]#Z#^IJ[XINS%8);)]^=L8'H/\BM+3;1;#3HH.
M 57+GU/>O.JKZQB%2?PQU?F^B_4[:;]C1]HOBEHO3J,U74XM*M#*PW2-Q&G]
MX_X5QF+C4KDW%RY=S^0'H/:I;ZZ;5]5>7GRE^2,>P[_C5\>1I]C->7!VP01M
M+(P&<*HR3CZ"O1.(=;6  '%:"6BCM7.P_$+PR=.FOFN+N*WAV9::RECWESA0
MFX#<3Z#MS6KI?BS1M7O)+6QN'E>.1HF;RR$#*,L-W3@4 :7V9?2F/:J>U"ZM
M8/);K%<QS"X9UC>%@ZY49;+ X'%*=4TW[.+@ZA:>0Q($OGIM)'49SCB@"E<6
M((/%6=,U"2"1;6Y;*'A'/;V-)'JNFW6IR:;!>P2WD42S/$C@D(WW3^/^'K27
M5L&4\4 7-;TM=2LSM \]!F-OZ?C4'AW4FN[5K>8GSX.#GJ1Z_P!*NZ9<&>UV
MN<R1_*Q]?0UAWX_LCQ-#=+@0W'WQ]>#_ $->=B5["K'$1V>DO3H_D=M!^UIN
MB]]U_E\SJ:**:[!$9VZ*,FO1.(Q]<NG=DT^#F27&['IZ5H6-G'86@C7&1R['
MN?6LK14-Y?7&H2#OA?8G_P"M3?%.H-#;)91$AY_O$=E_^O0!EZSK,FJ3-;6S
M%;13@D?\M/\ ZU,L]/''%9USJ.GZ!:Q7&H2.JROY<:1Q-([MC.%502> 36[I
M>M:5?013VUTK026WVI9B-J"/=M))/0@@@@]* +<5DJ@<596U7TIG]JZ8L0D.
MI60C/ 8W"8/3OGW'YBJ.H>+=&TRY6VNKAUG>X6VCC6,LSN5W?*!U&",GI0!H
MFV7'2H);-2.E2V^JV-U';,ES&K72;X8Y&"NX]E)S2_VEISQR2"_M"D;;'83I
MA6]"<\'VH SX_/TZ?S8#Q_$IZ,*Z*":*^M=X 9&&&4]O4&L"35M*EOK>Q2_M
MGN;F)I88TD#%T!P2,=1_]?TJS82&TO=A/[N4X(]#V- $*;M#U;82?LLW3V__
M %5T=9^LVHNM.? ^>/YU_K^E&BW7VG3D+'+I\A_#I^E &A5/5=1BTG3)[V;[
MD2YQW8]A^)JY7!>.YY=2U;3= MR<R.'DQ[\#\ADU4(\TK'-C*[HT7);[+U>P
MG@[2I=7OY?$NIC?([DP*>F?[P]AT%=/KNLC3(1'#AKJ0?(#_  C^\:NJMOI.
MF!4 2"WCP /0"N(5I-1OI+J7[TC9QZ#L*)RYG<,+AU0IJ/7J^[$@MI;F8S3,
MSR.<LS=36S;V  '%,FFM=(TNXU"\8QVMM&997"EB%'4X')INA^+="USSEL[M
MD>#89$NHF@8!CA3AP,@G@$=ZDZ332T4#I4GV9?2AM0L8Y%C:]ME=F*!3,H)8
M'! &>H/&*JW7B/1[.*&674+<Q37 MEDCD#J)""0&(.%X!Y- $SVBGM5&>QYR
MHP1R"*MG6],^VFT^UQ[Q:B\W[AY?D[MN[?\ =Z^]6E,5Q$LL3I)&XRKHP8,/
M4$=: $TO47D/V:Y/[T?=;^]_]>L3QQH#75L-7L@4OK7YB4X+*/ZCK5ZX@*L'
M3AE.01VK;M9Q=6JN0,D88>_>JC)Q=T8XBA&O3=.74S/"^N+KNC1W!($Z?),H
M[,._T/6MJO/=&'_"->/[C3,[;2\&8P>G/*_U%>A4ZD4GIL8X*M*I2M/XHNS]
M4%<_J<LFI:BFGPG"(<N??O\ E_.MF]N!:V<LQ_A7CZ]JS?#]L5MWNGYDE/!/
MI_\ KJ#L+[-;:58%F(CAB7_/XFN+O+VYUJZWR96%3^[B[+[_ %J]XDO6O-06
MQ0_NH3E_=O\ ZU+86@ '% #;73P ,BM..S4#I5F*$*.E3A0* *PMEQTIK6JD
M=*N48H RIK($'BF65U+IDH1LM;D\K_=]Q6LR U4N( P/% &I+%#>6Q1L/&XX
M/]16+IDTFFZ@^G3GY&.4/O\ _7JUI$Y0M:N>GS)].XIGB"V+6Z72<21'DCT_
M_70!LT5!97 NK.*8?Q+S]>]3T 8OBC7%T+1I+A2#._R0J?[Q[_AUK)\$: ;2
MV.K7H+7UT-P+\E5//YGJ:S=8'_"2_$"WTSEK2SYD';CEOZ"NQUF__LW3'D3'
MF'Y(Q[G_  K5^[&W<\VDOK&)E5?PPT7KU9E>(-<=9&L+)\/TED'5?8>]8]G8
M9P2.M-L+4N=S9))R2>]=';6X4#BLCTB""Q  XJVMJH'2K*H *?B@"J;9?2H9
M+-2.E:%(0#0!AO;26\HFA8HZ]"*W=.OA>PG< LR??7^HJ"2($=*H_-9W2SIV
M/S#U% &'XQTJ72+^+Q)I@V.CCSU'3/J?8]#79:5J,.K:9!>P_<E7./[I[C\#
M4MQ!#?V4D$H#PS(5(]017$^!)Y=-U74M N&YB<O'GV.#^8P:U^*'FCS;?5L4
MK?#4_"7_  3O:0D*"2< <DTM9>O7)@T\QJ3NE.WCT[UD>D4(E;7-4:1\_98N
M@]?;\:U]1U"'2[,S2?[J(/XCV%&EVHM+"-,8<C<_U-<CJMV=5U9B#F&(E(QV
M/J?QH KN]SJMUY]RVYC]T=E'H*U;73P .*DLK0*HXK6CB"CI0!6CM%':I?LR
M^E60,4M %-K53VJG/8@@\5L8IC(#0!0TV_DM)%MKALPGA6/\/M]*U;^R2^MF
MB; ;JK>AK+NK<,#Q5_2K@RVYB<Y>/CZCM0!4T2[=6>PGXDBSMSZ>E;58&M1F
MSO[?4(QCG#>Y'_UJW48.BNO(89% #J*** "N<\6R'[-;0 _ZR3./I_\ KKHZ
MYGQ&&;5M.7!*[N?^^A7%F-WAY)=;+\3JP5E63?2_Y&ZQ6PTTD#Y8(NGT%<1I
M\9ED,C<LQW$^YKL-;R-%N\=?+-<UI:<"NQ))61S-W=V;=M$%45E>-?$,WA;P
MS)JEO%!)(LT40$Y8(-[;<G:">/85I6>IZ=<.\=O?VDLD0)D2.=&* =20#Q^-
M1:UH]IXGT=;62YG2!Y(YXY[.4*P93N5E;!'6F(Y+0?B6U_8[KK3OM%R^H"Q@
M7322LK&/S,XEVLH R.?2MA?'VELTQ-O>K"L<[P3M&H2Y\DXD"'/4'UP#R1Q1
M9>#-'TQX]2DO[VXF@NOMKWMY=!V9EC,8WL0!M52?2HV\!^'K]+N,37,T#"6-
M84N0R6K2$.YC 'RL3@\Y]A@T 0)\2M-NM*2ZL;*]N+F1KA%M412R^2N78D-C
M:,KR"<YXKI- U%]8\.Z;J<D:QO=VL<[(A)"EE!P,]JQ'\ :2L)S>:DDIFEE:
MY^T 2$RJ$D4G;C:V!QC@],5OZ/:VEAI%K86$OFVUI&+=&WASA/EP2.XQS0!:
M=<BJD?[B_B<="=I^AJZ1Q5.<892.S#^= %[58!<:7<QGO&2/J.15#PM-YNCA
M2?\ 5N5_#K_6MF1=T3+Z@BN.TR;5M+BDCBTZ1P[;OF1N*\W$S5'$PJM.UFG9
M7.ZA'VE"4$];IG8N"48*<''!]*H:3IS:?'*'=7=VSN7TK)?6=:9&!TH@$')V
M-4?AK4;Z206Q1IK=>KD_ZO\ 'O\ 2J68TW4C32>ODR7@IJ#FVM/,B\2R_:-7
MB@'W84R1[G_ZV*HW>MV'A^;34U"1((;V9H1/+(J)$0A;+$]CC%6M2!;Q%<Y]
M5'Z"FOI6E>(KJQDEF@NO[,N&D: %)5+%"NUQSCKGUR*] XR*P\?Z-<6XN9)!
M!:^5+*)2X?<J3>3E0H.[<Q&,>HI9OB-X?AO(HC/*8&2=I+CR7Q$T10.K+MW#
M&\$G&!@YJAJ'PZBCTQQI<DC744;K;1LRQ*C-<"<$$*<%6& ,8QUIND^ )I+.
M]FUF]E%[>K>Q2>6ROA+@IDE@H!8;!T '- &]XG\32^';"&^AT>YU*W<@.]O*
MBB/<5"9W'G<6&,56A\=Z;&)8]5233;J.7RFMF_?2!O+$C9$8/ 4@D]*UM2T.
M'4]#729))$B7R?G4#=^[96'Y[16%JW@.QUFXU%AJ5Q%)=70N91&D;&-O+" +
MD$J< $$8(S0!IR>,M BFO(GU 9LU9IV$3E5VXW#=C!(W+D YYIU]XMT+3VG2
MZOPCP3&&11&[%6"!SP > I!)Z 'DUCWWP^T^XN[VZN=4O4CN[<V[+E%^\%4%
MFP#(00"-V>35>?X<:=J\4LL^LW-Y<O=O-)=%(F^8HL;IM VCA!VR"* .NF5)
M8@Z$,K ,K Y!!Z&M#3W+V29.2ORG\*IB!+>VCAB7;'&@1!CH , ?D*L:9_J'
M'HYH CMM->WU6:Z611')GY .>?\ Z]:58.JZW=V>I+:6UNDI9 0.<DG/I]*@
M_MK6_P#H%'_OAJXI8^C&3CK=>3.J.#J.*EIKYHN7^E3WNM6MR60V\6,KGGKG
M_"K&N7!MM&N74X8KL'U/%<U)J^J)JXE\AHYG 4P8.''TK7\1O))H<321^6[2
MIN3.<=>]1@JU*I.;@FG?6_\ 7X%8JE4A&"DU:VG]?J8FF0#"\5JZGI[ZAX?U
M"QA95EN;62%"QX!92!GVYJMIRX3\*\V\->+O$4&CWNM7FHR7GD6,DT<$]];-
M&[A@!^[0"5>/7IWKT#C->Q^'FK1Z(^G36.D6Y,MI)YD=[//YGE2*S9$F0N5#
M?=]<=*O77P\O+@7<<4]K;+/<:DXDC!RJW"A8^ !TP<CTZ5*WC761?OH[P:7'
MJ OGMO/9G$ 1;<3=,YW<[>N.,^U9NC?$+5?[%LIITM;@06]FUXTKD3W+7#E0
M8@./E]QSSTH NWG@74]3L4A:'2-+;%PK?8-W\=L(@Q.!DY'. ,+ZFDTSX>7$
M#V#W45H1%=///$\[3JW^C&)2-R 9S@XQT ZD4R/XD:E'%J:WMA:174.PVT>7
MV;7F\H.T@)5XQD$LI'<8[U'?_$36K5KN"*STR2>PCO'N)-TGER_9]A_=X.1D
M/@YS@@]: -?P;X0O_#>HQS7/V.5#I-O9N\;'>LD1;IE>5(8<Y'3I78R*"*\[
MO?B'J]I:W,)M-/;4HK@HB*7*/&+<3D\D8(!P22!W /2MSPCKUUKU[J<TS$0F
M"RFA@R"(O-@WL >_)H Z*P/E7Y7M(I'XBH?%<(DTI9<?-'(.?8\5.@Q?0D?W
MJFUV%Y]&N$C1G<@851DGD5S8R'/AYQ\F;X:7+6B_,L:?-Y^G6\O=HU)^N*=>
MPO<6<L*.$9QMR:YJSU'6;*TCMTTQF6,8!9&R:9J.K:K-9.DU@8$X)D 8;>>.
M:Y8YC"-)-IW2[,Z'@IRJ635K]T=)IMG]ALEA)!;)+$=":Y+4W-WK]PQ.5C/E
MK^'_ -?-;WA^_O;VV/VF(E%^[,>-_P"'?ZUSL +7\Y;J96_F:[J-:-:"J1V9
MR5:;IS<'T(/$6@7VKV%H-/2S>6WG\W9<O)%G@C*2Q_,C#/4=>AKGM1\%:U:Z
M$;B^NH[Z6#3XX66.-Y3(RW0F"$ ;G3;\I;!)ZX->F6RX45;Z"M3,\DTGP7>:
MXE_?3V%G:Q32ZD(898F4 SHBHZJR@@94\D ]P*U['P#J$&JVEW</92"&\BN'
M.2256S$!QD==XS].>M4'UK7;CXFWUE_;%Q%IT&HQPB(7MM&H0JA(\MQYCY)_
MA/.<"KEO\1-1E@UC-OIADL+J*Q5DE8QO))*4$I/:(#'ON!&: ':-X%U729+'
M='H]WLM[6-Y;D,S6K0AQF(8YSNR.1@YSFJ&G?#;5XMPO&T]Q)+8O*!(S"3R)
M69R5V@#<#PH&!T]ZM7?Q!UN/SX8+33&GLX;Z2XD9I#')]F*_ZO!S\P;'.<$'
MK7H=E<_;+"VN@NWSXDEVYSC<H./UH XO0?!=[HVOVM\4L7AC>^5E4X:-)IA(
MA7Y>H&01QC/%=7=1\9'4<BM"J\X^4T :,+B:W1SSN7FJ6EZ=)IYF#2*R.<J
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MGUJN5\O-T%=7L=)1114C"L+Q&NTVLP_A8C^1_I6[6?K5O]HTR0 99/G'X?\
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MK)_L.[A_X][]@/0Y%']G:ST^W\?[Y_PH VUCCB'RJJCZ8JG=:Q9VH(\P2/\
MW4YJA_8-S*?](OF8>@R?YU=MM%LK8AO+\QAW?G]* ,XG4-<; 'D6O\_\:V;.
MRAL8?+B7G^)CU:K(&!@=** "BBB@ HHHH 9-#'<1-%*@=&&"#7,S:7?Z+.US
MICM)">6B/)Q[CO\ 7K74T5S5\-"M9O22V:W1M1KRI:+5/=/8P['Q-:3X2Y!M
MY>AW?=S]>WXUK@P7*;@4D4]Q@BJ]YI-E?<S0#?\ WUX;\ZR'\*F-BUI?21^Q
M_P 16"EC*6C2FNZT?^1MRX:IJFXO[T;AL;8G/DK^'%.6U@3[L2C\*Y_^Q]=3
MA-3R/=S_ (4?V#JTW^OU0X] S'_"G];K=*+_  %]7I]:B_$W+G4+2S7,\\:8
M[9Y_*L*X\076H2&VTF!\G@R$<C_#\:L6WA2TC;=<223M[\"MN"WAMHQ'#&L:
M#LHQ2<,57TD^1>6K^_8:EAZ6L5S/ST7W&1I.@+:/]INV\ZZ/.3R%/]3[UMT4
M5UT:,*,>6"T.>K5E5ES284445J9A1110!EZEHZ7;>="WE7 YR.C?7_&JD.KW
M-@X@U&)CC@2#K_\ 7K?IDL,<R%)45U/9AF@"*"]MKI?W4R-G^'//Y4YK2W<Y
M:%"?I6;/X=M9#NA=XF]N14/]CZC%_J;\X]R10!K"RMATA6I/W4"Y.Q%]>E8O
M]FZPW#7^!_OG_"E7P\TAS<WCO[#_ .O0!8N]>MH 5A_?2=MO3\ZIQV-[JTHF
MOF,4(Y5!Q^0[?6M:UTRTM#F*(;O[S<FK= #(88X(ECB4*B] *?110 4444 %
M9FO>'].\2:8]AJ=N)86Y!Z,C=F4]C6G10!XB^F>,OA3<O-I9;5M!+%FC*D[1
MZLHY0^XX/>NT\._%CPUKJ(DUS_9UT1S%=$!<^S]#^E=UUKD=>^&GA?Q S2SV
M M[ANLUJ?+8_4#@_B*OF3W ZA3;7<8=3%,C=&&&!_&F_8;7/^I6O)W^#.IZ>
MQ;0O%5Q;CLKADQ^*'^E-_P"$&^)R'8GC %/4W#__ !-'*NX'KJP01\K&H]\5
MA:YXY\.>'HV^W:G#YJC_ %$1WR'VVC^M>?\ _"JO%NI'_B;^,9&1OO*CR/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>trda-20211231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %" VH# 2(  A$! Q$!_\0
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MZU_[]?\ UZU^H5?(GV\3W*BO#?\ A:OB/^]:_P#?K_Z]'_"U?$?]ZU_[]?\
MUZ/J%7R#V\3W*BO#?^%J^(_[UK_WZ_\ KT?\+5\1_P!ZU_[]?_7H^H5?(/;Q
M/<J*\-_X6KXC_O6O_?K_ .O1_P +5\1_WK7_ +]?_7H^H5?(/;Q/<J*\-_X6
MKXC_ +UK_P!^O_KT?\+5\1_WK7_OU_\ 7H^H5?(/;Q/<J*\-_P"%J^(_[UK_
M -^O_KT?\+5\1_WK7_OU_P#7H^H5?(/;Q/<J*\-_X6KXC_O6O_?K_P"O1_PM
M7Q'_ 'K7_OU_]>CZA5\@]O$]RHKPW_A:OB/^]:_]^O\ Z]'_  M7Q'_>M?\
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M$?\ >M?^_7_UZ/\ A:OB/^]:_P#?K_Z]'U"KY![>)[E17AO_  M7Q'_>M?\
MOU_]>C_A:OB/^]:_]^O_ *]'U"KY![>)[E17AO\ PM7Q'_>M?^_7_P!>C_A:
MOB/^]:_]^O\ Z]'U"KY![>)[E17AO_"U?$?]ZU_[]?\ UZ/^%J^(_P"]:_\
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M_<B_FU:'QB_Y!&G_ /7<_P#H)KRY?[[_ %V.E?P3Q^BBBO4.8**** "BBB@
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M 'Y;_"C^Q]3_ .@?=?\ ?EO\*TYEW)LRE15W^Q]3_P"@?=?]^6_PH_L?4_\
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M /T!K_\ \!V_PKT.>/<PLS)HK6_X1;7_ /H#7_\ X#M_A1_PBVO_ /0&O_\
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M?_Z U_\ ^ [?X4?\(MK_ /T!K_\ \!V_PIJ4$K)H+-F316M_PBVO_P#0&O\
M_P !V_PH_P"$6U__ * U_P#^ [?X4^>/<5F9-%:W_"+:_P#] :__ / =O\*/
M^$6U_P#Z U__ . [?X4<\>X69DU[G\*O^1-7_KL_\Z\B_P"$6U__ * U_P#^
M [?X5[)\-K*ZL/"BPW=O+!+YKG9(A4XSZ&N+'2BZ6CZFU%/F.!^+?_(W1?\
M7HG_ *$U<'7I?Q/T75-0\41S6>GW-Q$+95+Q1,PSEN,@5Q7_  BVO_\ 0&O_
M /P';_"ML/.*I1N^A%1/F9DT5K?\(MK_ /T!K_\ \!V_PH_X1;7_ /H#7_\
MX#M_A6_/'N19F33D=HY%=&*NI#*1U!'>M3_A%M?_ .@-?_\ @.W^%'_"+:__
M - :_P#_  ';_"CGAW"S,]KJX:[^UM,YN-_F>;GYMV<Y^M36^KZC:3S3V]]/
M%+,2971\%R?6K7_"+:__ - :_P#_  ';_"C_ (1;7_\ H#7_ /X#M_A2YJ;Z
MH=I%6/5M1AMI;>.^N%AE),B!SAL]<T?VKJ'/^F3<[,_-_<^Y^7:K7_"+:_\
M] :__P# =O\ "C_A%M?_ .@-?_\ @.W^%+FI]T%I%4:MJ(;<+V8'S&ESN_C;
M@M]30-7U(6@M!?7 MP<B,2' .<U:_P"$6U__ * U_P#^ [?X4?\ "+:__P!
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M /0&O_\ P';_  H_X1;7_P#H#7__ (#M_A6G/'N39F316M_PBVO_ /0&O_\
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MK_\ T!K_ /\  =O\*OGCW)LS)HK6_P"$6U__ * U_P#^ [?X4?\ "+:__P!
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M>-U-:?\ 'Y#_ +X_G1["(+/,1?9?C_F>[7M]!86$E[,3Y* ,2!DX/_ZZY_\
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M!-<Z8E\9%C5YEB12.N3C=]*.2F)8S'M\O,[[G1?\++O?^?&'_OHT?\++O?\
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MV;B_Y&<317;?\*TU'_G[MOUH_P"%::C_ ,_=M^M'M8=P_LW%_P C.)HKMO\
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M+D9Y&1D9XXYYH5.F7+'9A'=_@G^1VO\ PLY?^@:?^_G_ -:C_A9R_P#0-/\
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MF7'_ #X1?]]&N271-2=866T<B8A4P1R3T[\9QWIEMI5S<ZH-/^1)LG<68%4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \9\:?\ (W7_ /O+_P"@+6!7
MH_B#P/?ZKKES>PS0K'*00&)SPH']*S/^%;ZG_P _$'YG_"NV-2*BM3X[$X#$
MRK3E&#LV_P SBZ*[3_A6^I_\_$'YG_"C_A6^I_\ /Q!^9_PJO:0[F']G8K^1
MF1IGB:?3([:..$,D(=64MPX;_"GCQ7<+;01K"H>)D^;=PP1MP&,?UK4_X5OJ
M?_/Q!^9_PH_X5OJ?_/Q!^9_PJ.:F="H9@ERJ+M\C*G\2B2UEMXK(1I(DJ\R9
M.9&#$]/:EB\4O$R2"T7S?D$K;S\X08&!VK4_X5OJ?_/Q!^9_PH_X5OJ?_/Q!
M^9_PHYJ?<?L<PO?E?W(QU\1R)"$6W7(@6($MZ2;\_P!*F?Q3F=9([1HOWTLS
M;9>2SXSVZ<=*TO\ A6^I_P#/Q!^9_P */^%;ZG_S\0?F?\*.:GW$J&8+[+_
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MH[7Q&MC;S6UM9*MO-M#HTA;<H!!!)]<U>_X5[KGI;_\ ?S_ZU'_"O=<]+?\
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M+TP]GC]?=>OD53XH/G%ELE59'>29=Y.YF7!(]*(O% 00(]D'C@,;1CS,$,G
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M()7:,Z>*Q=27+&;OZFA_PL'7/^>D7_?L4?\ "P=<_P">D7_?L5'<^$I3<RK
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MW7AR:R@BFN;B*.-F59"0?W>X9'U_"BU/L)U,>MY/[S0_X6#KG_/2+_OV*/\
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MH6D63R9%&?DDVE@OOG!&?6I/^$/O%,?FS11B1%.3GAF_A^M'[L2>.?VI??\
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MSU/$&HHCJ)5PY8_<'&X8./2G'Q)J;1NC3*0X93E!T88(%>@?\*YT;_GK=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &.R[2OF!3CKD9%9_V*?_H,W'Y1_P#Q->6^-+JXC\6WZI/*JAEP
M Y ^XM8'VZ[_ .?F;_OLUZU/*W."ES;KL?/UL]5.I*')LVM^WR/<?L4__09N
M/RC_ /B:/L4__09N/RC_ /B:\.^W7?\ S\S?]]FC[==_\_,W_?9J_P"R'_/^
M!G_K"O\ GW^/_ /<?L4__09N/RC_ /B:/L4__09N/RC_ /B:\.^W7?\ S\S?
M]]FC[==_\_,W_?9H_LA_S_@'^L*_Y]_C_P  ]Q^Q3_\ 09N/RC_^)H^Q3_\
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M./\ PH\AO^@[+^<?^%>&^=)_?;\Z/.D_YZ-^=']D+^?\/^"'^L+_ .??X_\
M /<O(;_H.R_G'_A1Y#?]!V7\X_\ "O#?.D_YZ-^='G2?\]&_.C^R%_/^'_!#
M_6%_\^_Q_P" >Y>0W_0=E_./_"CR&_Z#LOYQ_P"%>&^=)_?;\Z/.D_YZ-^='
M]D+^?\/^"'^L+_Y]_C_P#W+R&_Z#LOYQ_P"%'D-_T'9?SC_PKPWSI/[[?G1Y
MTG_/1OSH_LA?S_A_P0_UA?\ S[_'_@'N7D-_T'9?SC_PH\AO^@[+^<?^%>&^
M=)_ST;\Z/.D_OM^=']D+^?\ #_@A_K"_^??X_P# /<O(;_H.R_G'_A1Y#?\
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M_<L_^_0_PH\SPY_<L_\ OT/\*=_PD&D_Y04?\)!I/^4%']HT?^?B^\/J,_\
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M^_0_PH\SPY_<L_\ OT/\*=_PD&D_Y04?\)!I/^4%']HT?^?B^\/J,_\ GW^
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M !H_X2;3/^>$G_?"_P"-']JT?^?OXA_9DO\ GU^"&^1X5_YY6G_?-'D>%?\
MGE:?]\T[_A)M,_YX2?\ ?"_XT?\ "3:9_P \)/\ OA?\:/[5H_\ /W\0_LR7
M_/K\$-\CPK_SRM/^^:/(\*_\\K3_ +YIW_"3:9_SPD_[X7_&C_A)M,_YX2?]
M\+_C1_:M'_G[^(?V9+_GU^"&^1X5_P">5I_WS1Y'A7_GE:?]\T[_ (2;3/\
MGA)_WPO^-*/$NF$X\B0?\ 7_ !H_M6C_ ,_?Q#^S)?\ /K\$,\CPK_SRM/\
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M&[XVJ2"<9QQFMA-5@(3<TBOM3=(HR25/(_&HY-2@DB&TR0X+9B4#:V6R"?\
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M*FO?VE^9J4445] >.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QVLZ3?7.
MK3RQ6[,C$8([\"J']A:E_P ^KUW[;MIVXW8XSTJAOUC_ )X6/_?Y_P#XBO(J
M9/2G-S<GJ[]#T89E4A%126AQ_P#86I?\^KT?V%J7_/J]=AOUC_GA8_\ ?Y__
M (BC?K'_ #PL?^_S_P#Q%1_8E'^9_A_D5_:E7LCC_P"PM2_Y]7H_L+4O^?5Z
M[#?K'_/"Q_[_ #__ !%&_6/^>%C_ -_G_P#B*/[$H_S/\/\ (/[4J]D<?_86
MI?\ /J]']A:E_P ^KUV&_6/^>%C_ -_G_P#B*-^L?\\+'_O\_P#\11_8E'^9
M_A_D']J5>R./_L+4O^?5Z/["U+_GU>NPWZQ_SPL?^_S_ /Q%&_6/^>%C_P!_
MG_\ B*/[$H_S/\/\@_M2KV1Q_P#86I?\^KT?V%J7_/J]=AOUC_GA8_\ ?Y__
M (BC?K'_ #PL?^_S_P#Q%']B4?YG^'^0?VI5[(X_^PM2_P"?5Z/["U+_ )]7
MKL-^L?\ /"Q_[_/_ /$4;]8_YX6/_?Y__B*/[$H_S/\ #_(/[4J]D<?_ &%J
M7_/J]']A:E_SZO78;]8_YX6/_?Y__B*-^L?\\+'_ +_/_P#$4?V)1_F?X?Y!
M_:E7LCC_ .PM2_Y]7H_L+4O^?5Z[#?K'_/"Q_P"_S_\ Q%&_6/\ GA8_]_G_
M /B*/[$H_P S_#_(/[4J]D<?_86I?\^KT?V%J7_/J]=AOUC_ )X6/_?Y_P#X
MBC?K'_/"Q_[_ #__ !%']B4?YG^'^0?VI5[(X_\ L+4O^?5Z/["U+_GU>NPW
MZQ_SPL?^_P __P 11OUC_GA8_P#?Y_\ XBC^Q*/\S_#_ "#^U*O9''_V%J7_
M #ZO1_86I?\ /J]=AOUC_GA8_P#?Y_\ XBC?K'_/"Q_[_/\ _$4?V)1_F?X?
MY!_:E7LCC_["U+_GU>GPZ)J*S(QM7P"*ZW?K'_/"Q_[_ #__ !%&_6/^>%C_
M -_G_P#B*:R2C_,_P_R!YI5[(75(I)-&FC1&9RH 4#)ZBN)_LJ__ .?.?_OV
M?\*[7?K'_/"Q_P"_S_\ Q%&_6/\ GA8_]_G_ /B*Z,7ET,3)2E)JRL8X?&RH
M1<4KW.*_LF__ .?.?_OV?\*/[)O_ /GSG_[]G_"NUWZQ_P \+'_O\_\ \11O
MUC_GA8_]_G_^(KE_L2G_ #LZ/[5G_*CBO[)O_P#GSG_[]G_"C^R;_P#Y\Y_^
M_9_PKM=^L?\ /"Q_[_/_ /$4;]8_YX6/_?Y__B*/[$I_SL/[5G_*CBO[)O\
M_GSG_P"_9_PH_LF__P"?.?\ []G_  KM=^L?\\+'_O\ /_\ $4;]8_YX6/\
MW^?_ .(H_L2G_.P_M6?\J.*_LF__ .?.?_OV?\*/[)O_ /GSG_[]G_"NUWZQ
M_P \+'_O\_\ \11OUC_GA8_]_G_^(H_L2G_.P_M6?\J.*_LF_P#^?.?_ +]G
M_"C^R;__ )\Y_P#OV?\ "NUWZQ_SPL?^_P __P 11OUC_GA8_P#?Y_\ XBC^
MQ*?\[#^U9_RHXK^R;_\ Y\Y_^_9_PH_LF_\ ^?.?_OV?\*[7?K'_ #PL?^_S
M_P#Q%&_6/^>%C_W^?_XBC^Q*?\[#^U9_RHXK^R;_ /Y\Y_\ OV?\*/[)O_\
MGSG_ ._9_P *[7?K'_/"Q_[_ #__ !%&_6/^>%C_ -_G_P#B*/[$I_SL/[5G
M_*CBO[)O_P#GSG_[]G_"C^R;_P#Y\Y_^_9_PKM=^L?\ /"Q_[_/_ /$4;]8_
MYX6/_?Y__B*/[$I_SL/[5G_*CBO[)O\ _GSG_P"_9_PH_LF__P"?.?\ []G_
M  KM=^L?\\+'_O\ /_\ $4;]8_YX6/\ W^?_ .(H_L2G_.P_M6?\J.*_LF__
M .?.?_OV?\*4:3J!./L<_P#W[-=IOUC_ )X6/_?Y_P#XBC?K'_/"Q_[_ #__
M !%']B4_YV+^U9_RHK:)HB6$8FF :X8?]\ULUG[]8_YX6/\ W^?_ .(HWZQ_
MSPL?^_S_ /Q%>M1HPHP4(+0\^K5E5ES2W-"BL_?K'_/"Q_[_ #__ !%&_6/^
M>%C_ -_G_P#B*U,S0HK/WZQ_SPL?^_S_ /Q%&_6/^>%C_P!_G_\ B* -"BL_
M?K'_ #PL?^_S_P#Q%&_6/^>%C_W^?_XB@#0HK/WZQ_SPL?\ O\__ ,11OUC_
M )X6/_?Y_P#XB@#0HK/WZQ_SPL?^_P __P 11OUC_GA8_P#?Y_\ XB@#0HK/
MWZQ_SPL?^_S_ /Q%&_6/^>%C_P!_G_\ B* -"BL_?K'_ #PL?^_S_P#Q%&_6
M/^>%C_W^?_XB@#0HK/WZQ_SPL?\ O\__ ,11OUC_ )X6/_?Y_P#XB@#0HK/W
MZQ_SPL?^_P __P 11OUC_GA8_P#?Y_\ XB@#0HK/WZQ_SPL?^_S_ /Q%&_6/
M^>%C_P!_G_\ B* -"BL_?K'_ #PL?^_S_P#Q%&_6/^>%C_W^?_XB@#0HK/WZ
MQ_SPL?\ O\__ ,11OUC_ )X6/_?Y_P#XB@#0HK/WZQ_SPL?^_P __P 11OUC
M_GA8_P#?Y_\ XB@#0HK/WZQ_SPL?^_S_ /Q%&_6/^>%C_P!_G_\ B* -"BL_
M?K'_ #PL?^_S_P#Q%&_6/^>%C_W^?_XB@#0HK/WZQ_SPL?\ O\__ ,11OUC_
M )X6/_?Y_P#XB@#0HK/WZQ_SPL?^_P __P 11OUC_GA8_P#?Y_\ XB@#0HK/
MWZQ_SPL?^_S_ /Q%&_6/^>%C_P!_G_\ B* -"BL_?K'_ #PL?^_S_P#Q%&_6
M/^>%C_W^?_XB@#0HK/WZQ_SPL?\ O\__ ,11OUC_ )X6/_?Y_P#XB@#0HK/W
MZQ_SPL?^_P __P 11OUC_GA8_P#?Y_\ XB@#0HK/WZQ_SPL?^_S_ /Q%&_6/
M^>%C_P!_G_\ B* -"BL_?K'_ #PL?^_S_P#Q%&_6/^>%C_W^?_XB@#0HK/WZ
MQ_SPL?\ O\__ ,11OUC_ )X6/_?Y_P#XB@#0HK/WZQ_SPL?^_P __P 11OUC
M_GA8_P#?Y_\ XB@#0HK/WZQ_SPL?^_S_ /Q%&_6/^>%C_P!_G_\ B* -"BL_
M?K'_ #PL?^_S_P#Q%&_6/^>%C_W^?_XB@#0HK/WZQ_SPL?\ O\__ ,11OUC_
M )X6/_?Y_P#XB@#0HK/WZQ_SPL?^_P __P 15Y-^Q=X ?'(4Y&: '4444 <!
MX@\>WFD:Y<V$5I"Z1$ ,Q.3E0?ZUF_\ "S]0_P"?&#_OHUB>-_\ D<-0_P!Y
M?_0%KGZ]&%&#BFT1=G=_\+/U#_GQ@_[Z-'_"S]0_Y\8/^^C7"457L:?8+L[O
M_A9^H?\ /C!_WT:/^%GZA_SXP?\ ?1KA**/8T^P79W?_  L_4/\ GQ@_[Z-'
M_"S]0_Y\8/\ OHUPE%'L:?8+L[O_ (6?J'_/C!_WT:/^%GZA_P ^,'_?1KA*
MZ!?#T$GA]=0CN99)3&9&$<89$.?N-@[@?<C%)TJ2W079M_\ "S]0_P"?&#_O
MHT?\+/U#_GQ@_P"^C6#;>%[MYU2X9$3:=_EN&:-MNX!AV)%3Q^$I'U(PO,(K
M?Y@K.PWN53<<#OVJ>2CV#4U_^%GZA_SXP?\ ?1H_X6?J'_/C!_WT:Y31;2SU
M"^CMKN:>(RD+&8E#?,3WSVJU-H)EN2NG.TD(F-ONGPK;QG/ [<4W3I)V:"[.
MA_X6?J'_ #XP?]]&C_A9^H?\^,'_ 'T:Y]/"NHNBOOM%#!#AI@" QPN?J>*A
M_P"$=U'R6=HXU92_[HR#>P0X8@=P#1[.B%V=-_PL_4/^?&#_ +Z-'_"S]0_Y
M\8/^^C7.R>&+^(3EWM0(,"0^;PI(R 3CKBL:FJ5)[(+L[O\ X6?J'_/C!_WT
M:/\ A9^H?\^,'_?1KA**?L:?8+L[O_A9^H?\^,'_ 'T:/^%GZA_SXP?]]&N$
MHH]C3[!=G=_\+/U#_GQ@_P"^C1_PL_4/^?&#_OHUPE%'L:?8+L[O_A9^H?\
M/C!_WT:?#\3+^6>.,V4 #,!G<:X&IK3_ (_(?]\?SH]C3[!=GN6MZC+I_A^X
MOX0IEC16 ;IR1_C7G?\ PLK5_P#GE!_WS7<^*O\ D2[S_KBO\Q7C=A9MJ&H0
M6B,$:9PH8]JPP\(N+<D-G5_\+*U?_GE!_P!\T?\ "RM7_P">4'_?-<WJ&E-9
MM;^4SRB=2RC9AASCG&14DF@7<4\<+RVJNQ((\X$H0,X8=<_G6WLZ785V=!_P
MLK5_^>4'_?-'_"RM7_YY0?\ ?-91\)WHA(,D7VH77V?R-W^SNW9^G/TJ)/"^
MI.[+FW4#9M9I<!]WW=O'.<4N2EV0:FU_PLK5_P#GE!_WS1_PLK5_^>4'_?-9
M)\+7;I$8VC0LJ[_.D"@,Q( 'XBJNF:4ESJ-S;7KR0K;1222>6 6^3J!GBGR4
MNP:G0?\ "RM7_P">4'_?-'_"RM7_ .>4'_?-9,GAF2X$$^F3>;:31[Q)/\A4
MYQ@XSSFH%\-ZB8G=EAC9%=C&\@#E5."0/2ER4NP:F[_PLK5_^>4'_?-'_"RM
M7_YY0?\ ?-8@\,7YOWL5DM6N4 W1B7)R><=.N*?;>&;F6REFD95E$:O% K N
MV6P,CL*?)2[!J;'_  LK5_\ GE!_WS1_PLK5_P#GE!_WS6(_AC4(S(9#;K'&
MGF-(9/E !P><=<U#HFEKJM\T4LQA@CC+R2JN=HZ#CW)%')2M>P79T/\ PLK5
M_P#GE!_WS1_PLK5_^>4'_?-8:>&M0D>=5\D&*9H</)M+,HS@#Z5H6WA$2O C
MW@)E$9/EX^3=GKGZ4G&DN@:ES_A96K_\\H/^^:/^%E:O_P \H/\ OFL(^'+W
M?P]OY'E^;]H,H\O;NV]?7=QBI[+PM=2SLEXZ6P7>H!<;F*C)P.XZ<T<E+L&I
MK?\ "RM7_P">4'_?-*OQ+U8,"T,!&>1MKF+W2+O3XC)<!%7S/+&&SN.,Y'M@
MU1JE2IO9!=GO&AZY:Z[8K<6[88<21D\H:U*\$T;6;K1+];JU?&/O(>C#T->T
M:'K=KKNGK<VYP1Q(AZH?2N.M1<'=;%)FG1116 PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#Q/QO_ ,CAJ'^\O_H"US]>M:UX!BUC5Y[]KYXS,0=H
M3., #^E9_P#PJZ'_ *"3_P#? KT(5X**39-F>:T5Z5_PJZ'_ *"3_P#? H_X
M5=#_ -!)_P#O@57UBGW%9GFM%>E?\*NA_P"@D_\ WP*/^%70_P#02?\ [X%'
MUBGW"S/-:*]*_P"%70_]!)_^^!1_PJZ'_H)/_P!\"CZQ3[A9GFM:\7B*YAM%
MA2VM?.6'R%NO+_>B/TSG!^N*[/\ X5=#_P!!)_\ O@4?\*NA_P"@D_\ WP*3
MK4GNPLSD1XJO5;<L-NK-S*P4YE.W;D\^GI3QXMO/.\U[:V=U+&,L&_=[EVMC
MGN/6NK_X5=#_ -!)_P#O@4?\*NA_Z"3_ /? J?:T1V9YW9W+V5Y#<QA2\+AU
M#="1ZUHV7B*YLFD8002;YS.-X/R.<\C!]^]=G_PJZ'_H)/\ ]\"C_A5T/_02
M?_O@53K4GNQ69QQ\279'^JAZ1#H?^6;;E[_G2OXGO7#DPV_FGS LNT[HUD;<
MRCG&,D]>>:[#_A5T/_02?_O@4?\ "KH?^@D__? I>UHCLSD(?$]W!?W%ZD,/
MG3G).6 '&,8!P1['-8K,68L<9)R<5Z3_ ,*NA_Z"3_\ ? H_X5=#_P!!)_\
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M;D\^E$'BN\@$16WMRZ;/F(;YMN<9YQWKIO\ A5TO_013_O@T?\*NE_Z"*?\
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M10!G?V'IW_/O_P"/&C^P]._Y]_\ QXUHT4 9W]AZ=_S[_P#CQH_L/3O^??\
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M_N^PH&:JG*@D8)'3TI:**0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH JRV=K+*SR6T+L>K,@)-,_L^R_P"?2W_[]C_"BB@0
M?V?9?\^EO_W['^%']GV7_/I;_P#?L?X444 ']GV7_/I;_P#?L?X4?V?9?\^E
MO_W['^%%% !_9]E_SZ6__?L?X4?V?9?\^EO_ -^Q_A110 ?V?9?\^EO_ -^Q
M_A1_9]E_SZ6__?L?X444 ']GV7_/I;_]^Q_A1_9]E_SZ6_\ W['^%%% !_9]
ME_SZ6_\ W['^%']GV7_/I;_]^Q_A110 ?V?9?\^EO_W['^%']GV7_/I;_P#?
ML?X444 ']GV7_/I;_P#?L?X4?V?9?\^EO_W['^%%% !_9]E_SZ6__?L?X4?V
M?9?\^EO_ -^Q_A110 ?V?9?\^EO_ -^Q_A1_9]E_SZ6__?L?X444 ']GV7_/
MI;_]^Q_A1_9]E_SZ6_\ W['^%%% !_9]E_SZ6_\ W['^% L+,$$6D ([B,44
M4 -UCC2)_H/YBN#HHI@PHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &_X653=RDJ
M"0O!QTKK***0T%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>trda-20211231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %W V8# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$'^]L0#/UI_V>$Q+$88_+7&U-HP,=,"ES6-)89SNY6NT^G>W^1!JW_(&OO\
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M/[9KO_/C'^='VS7?^?&/\Z/KD?Y9?<P^K2[K[T;E%8?VS7?^?&/\Z/MFN_\
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MWHW**P_MFN_\^,?YT?;-=_Y\8_SH^N1_EE]S#ZM+NOO1N45A_;-=_P"?&/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 445'/+Y$$DI1G"*6*J,D_2@&[:E'1"6LY223^_DZ_
M6M*N<\)ZO!J4%S'#'*-DK,6=<#YCD#KUKHZJ2LS##34Z47%A1114FX4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113)9%BB9V.
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MLRV)A8\Q''X=1_7\JXRMGPS<^1JFPG"R*1^(Y_Q_.@#NZ*** "BBB@ HHHH
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M$&M+J607'SJ-P"DXYYXZ\>E01^.Y7,%\VDR+HD]V+1+SS1NW%MH8IU"EN,T
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M>;912$Y+(K'\0#5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN9[C38QIZ-$1:VQ5IP5V[V8G.[OZ5/I_@*Y6'2[;4+N"2WL([NWVQ(098YE
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M_P"-:4\TP^!TK-Z]D-8.KB=::V/+:*]2_L/PS_T 5_\  N7_ .*H_L3PS_T
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M\.K:A:ZK'=SW?D+Y!M@6"JZ'"G/ !!;%>JT4 9=E>R0W=KI%WNEO/L0F>X5
MJ.5(5L#L<D''O7+>-/"&LZM?7>JV&IQC982016DD ?DJ=VTYX9NF:[ORT\PR
M;%WD;2V.<>E.H \ZMK&XTS1_#3:_H*ZN;6V>-I8H TELS 8'EDX((&"?4"M/
MPIYWA_2UCN[*6"/4=2D:VMP!_HT;\JK#/'0G Z9KLJ:T:.RLR@E3E21T- &!
MXMB22TLY)]%75K:"Y626'&YT !PZKT8@GH>Q-4O!UC+%JNNZE'8/I^G7TL1M
MK5U"$%5(=]HX7<<?]\UUU% '->"+&ZT_1KF*[A:*1KZ>0*W=2Y(-<IXPMM;O
M-:UZUBM=06&XM8X[/[!$@6Y^0[A+(>1AB1CTKU"B@#S_ ,+Z+>V^J+/<V3HH
MT"VM=S@?ZQ5PRUE^';'4O#$^G7U[H]W=1R:2+/9"@=X9%D9MI&> P8<^U>J4
M4 <K\.]/N],\!6%G=VAM+E#.3 Q^YF9V X[8(KG/[,-W/IEC8^%VTO4+74EN
M;BZ2,",(&)<B3.6WCC'O7IM% 'FVLIJ6O7EK&_A^XMO$%I>KY=\G^H2%9"=X
M;/(*=1C.37I-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% $5R,V[\9X(_I7FK<,1[UZ:XRAKSB]C,-]/&?X9"/UKP<\CI"7J>OE4M9+
MT(****^?/8"BBB@ HHHH [W09!)I,!'90#^'']*TZYKPI=!H9+<GE&W#Z'_Z
MX_6NEK[3!5%4P\)>7Y'S&*AR5I+S"BBBNHYPHHHH **** "BBB@ HHHH ***
M* *VH2^18S2YQM0M^0KS2NV\4W/DZ:8@?FE(7\.I_D/SKB: "BBMO2M.2.$:
MA>1%XMP$<>/OGU/M0!B45L3Z:ESXBFM8\0Q EB0.%&/2J$]E)!:Q7)*F.5F"
M>IQWQ0!6HHI5!9@!R2<4 >B:.A32K<$?\LU_EG^M7ZAMHQ%;H@.0HV_EQ_2I
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN:RR"#@C!%% !5S28?/U6V3&0'#'Z#D_RJG70^$[7S+N6X(X0;!]3R?T'ZT
M=DH(0 ]0*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBLS^W;'_A(!HJL[7GE-*VU
M#L0#'!;IGY@<>GX4 :=4M4M1=V$L1[KQ]>WZXK*/C/2VBO)+=;BX%K<?9V\I
M1\S[2QVDD @ 'GV[UJV>HP:B\Z6X=DA*JTA'REBN[ ]P",_7ZXF<5.+B]F.,
MG%J2Z'GK*58J1@@X(I*U_$-E]EU R*/DEY_'O617Q%:DZ51TWT/JJ515(*:Z
MES3+HVEX'V"0,"I0]#FM+4ESI;-=00PSK(!%Y8 ROX5@TI9FZDGZFKIXAQIN
MF]29T5*:FBS<7K7%G;P.@W0Y DSR1Z55HHK&4W-WD:QBHJR"GQ2/#*LD;%74
MY!%,HJ4VM4-J^C.XT?68[Z((Y"S*.5_J*V.U<!&?[*MQ<'_C[E'[M?[BG^(^
M_I6MI7B=2!%>X5NTG8_7TK[/ SJSH*57<^8Q4:<:K5/8ZFBHXYHY5#(P(/(P
M>M25UG.%%%% !1110 44UI%098@8YKG]4\30P!HK4B63ID?='X]Z -#5=6AT
MZ DD%S]U0>37!W5U+>7#32G+-^GM39[B6ZF:69RSMW-1T %2P7,]L28)GC)Z
M[6QFHJ* +L6HE+*XMI$\P3,&+EN0?ZUI1:G;RZF;ICY<5O!MAC;J2!BL"B@#
MK(8;1(+<-&ACD3?-(T6[.?\ :[8K*?3+2.PBN)KEHGF+%%VYRHZ5F+<3I$8E
ME<1GJH/!J2[O);PQF3'[M B@#  % %>N^\/6?V334W##O\S?4_Y%<?H]D;W4
M(TQ\BG<Q]J]$10B!1VH =1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD^IJQ!;16T8CB0*HZ "I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV%O:KB*)4_W1BK(  P.* ,ZPT:TL /+0%_[QY)_&M$  8%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4F!Z444 +@4444 &!28&<XHHH 6BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>trda-20211231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %N Y # 2(  A$! Q$!_\0
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M45#VO[KX;:]K]/F7Z***@[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"O?6BWUE-:NQ595*DKU%/MH!;6T4"DE8U"@GJ<5+11<GE7-S=0HHHH*"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[7;?\_$7_?8H^UVW_/Q%_P!]BCGCW#EEV)J*A^UVW_/Q%_WV*/M=M_S\1?\
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M.R#GEW*_]GV?_/I!_P!^U_PI/[/LO^?2#_OVO^%6:*/90[(.>7<K_P!GV?\
MSZ0?]^U_PH_L^R_Y](/^_8_PJQ11[*'9!SR[E;^S[+_GTM_^_8_PI?[/L_\
MGT@_[]K_ (58HH]E#L@YY=RO_9]E_P ^D'_?L?X4?V?9?\^D'_?L?X58HH]E
M#L@YY=RO_9]E_P ^D'_?L?X4?V?9_P#/I!_W[7_"K%%'LH=D'/+N5_[/L_\
MGT@_[]K_ (4?V?9_\^D'_?M?\*L44>RAV0<\NY7_ +/L_P#GT@_[]K_A1_9]
MG_SZ0?\ ?M?\*L44>RAV0<\NY7_L^S_Y](/^_:_X4?V?9?\ /I!_W['^%6**
M/90[(.>7<K?V?9?\^D'_ '[7_"C^S[+_ )](/^_:_P"%6:*/90[(.>7<K_V?
M9_\ /I!_W[7_  H_L^R_Y](/^_8_PJQ11[*'9!SR[E?^S[/_ )](/^_:_P"%
M']GV?_/I!_W[7_"K%%'LH=D'/+N5_P"S[+_GT@_[]C_"C^S[/_GT@_[]K_A5
MBBCV4.R#GEW*W]GV?_/I!_W[7_"C^S[+_GT@_P"_:_X59HH]E#L@YY=RO_9]
MG_SZ0?\ ?M?\*/[/L_\ GT@_[]K_ (58HH]E#L@YY=RO_9]G_P ^D'_?M?\
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M  H_L^S_ .?2#_OVO^%6**/90[(.>7<K_P!GV7_/I!_W['^%)_9]G_SZ0?\
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M\C5O3/ $NEZA)+'=1O!_9?V% P.[=G)8^U=Y11S,##\):+-X>\-V>F3R)+)
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &N('@_6M/\
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MGAP?.B&)%Z@?Q#TJS16EB!D4@EC#KWI]5D'E73(/NN-P'O5FF 4444 %%%%
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MW)%=6^ZP/T-.J%K=#RHV-ZKQ1%(V[RY/OCH?6D,FHHHH&%%%% !1110!4?\
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MJ:]EV*5>+BO9Z?F6*6L,Z]/=*&TO2;JZ0\"67$"?7Y_F(^@-#1>))^1<:=:
M]A&\I'XDJ/TKIL9FY16&NEZVW^L\0,#_ -,[2,?SS0^F:O&I8>(I!@9)>UC(
M_D* +,\JVNKQM_#*N&^N>#6F*XI3K$KS.VHVEP#\HWV;CCURIXJ[9:]J<;"W
MN-+%QMZRVLZG(_W7VFN>G.-W9JS-IP=MMCJ**QHO$^E22^2\[6]Q_P \+B-H
MG/T# 9_#-6@9;[GF* _FU;-V=C*P]9D>Y+EU"J, D]:MJP894@CV-1);0QC
MC7ZD9I&MU'S1_(_MT--$D]%112[\JPPZ]14M PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH BG8K'A?O,<"ECB6-0H ^M-?YKE!V
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MP[CN#[U/65=V+V\QO;'Y9!S)&.D@_P :NVEW%>6ZRQG@]1W!]#3IU'?DGO\
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MC<6J+A( R>E4US<76XCY%'%2NC8S-(-@[*,9IJ.RNS"%RIQB@'J6J*A\Z3M
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M_8H.RD#TW'%6:*5D U$6-=J*%'H*=113 **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *@GR[)$/XN3]*GJ"7Y9XW/3E?SH0F3 8  %+110
M,***:S*HRQ 'O0 ZJL\@,R( 3@Y( HEG=E_=J0#P"1R?I4D$/E)SRQZFGL3N
M1R.Q9&,3A5.3FK((8 CH:7%5R3;$G&8R>GI1N/8L45&LT;]''TJ2D,:\:N,,
MH-1Q'8?*8]/N^XJ:LLK<7.I.5X@C7 )Z$^HIH3T-2BJWF2PK^]7<O]Y:<UT@
M7C))Z#%%@N5Y;D_VM!!C@J23[U?JCLD7;*\:Y#9)SS5T'(R*&"%HHHI#(+C@
M(WHU3U#<_P"I)]Q4HZ"F+J+113)7V1D]^U(97M;J.6>>)22R-SZ4D]B)I&<,
M%)]O;%/M+..V#LH.^0[F)]:LTQ)::F=_9AP,R+QC@+@?SZT_^S\.K*Z@ARV=
MN35ZBBX604444AA1110 5',Y2(D=>@J2HK@$Q9'\)!H$]AT4?EH!W[GUI]-5
M@RAAT-.H&%%%% !4%S($B*]VX%(]QU$8#8ZL>@I((F9O.E.6/3/:F)N^B$=F
M:'8L4G3Z5-"ZL@VC&."/2I*K3K(A\Z$98#YD_O#_ !I-V0):EFBJ,.JVDN 9
M1&W]V3Y:NJRL,J01Z@U,9QE\+N7*,H[H&4,,, 1[U  +>7@8B;]#5BL[4C<2
MRP6]N#\S;I#V 'K5(AFC155%GA'&'7T[BGB[C*Y.1]13L%RMK%R;>RRHR68#
M\,U?7[HJFRO<;F,0*,N!NJS"VZ)?4#!^M#$MR2BBBD4,E&Z)AZBD@.8$)]*>
M>E16QS;I^/\ .GT%U)J**"<#-(93ENHXM2BA;.^1<#%7*IQVT<MW]L8$N/E3
MTQ5RFQ(*I7K,)8QYDJ+@\QC.3V[5=HK.<>96+C+E=S)%Y>;"FQ?,10S,5/?M
M@=^M*ES>F0C:.6& T9&!C/KZUIJB*254 DY) ZTZL51EUDS1U8](F2;ZZ&T,
M$&XXSY;<<$XQGGI1Y][\SE/E; *;3D<=1Z5JE02"0"1TI<4>PEUDP]K'I$S[
M6>[>91(BB,G;]TY'RYSG/K6A116T(.*LW<SG)2=TK$-RQV!%ZN<5(B!$"@<"
MHKCC8_96YJ8<BK(%HHHH&%%(S!5))  [FJ,]ZY0F!>.GF-T_#UJ922W&E<9J
MDZCRH,%BS@D*,G J*^FFGB0+93^6K!F#8Y'YU9L;,Q9FF):9^I/:KV*Q]G*:
M;;M<U4U&R2O8B@FCGA5X_ND?E4M9TZ26$CW,*[H6YDC';W%2P:G:3@;9T4G^
M%C@_K51JI/EGHR73;]Z.J+E136\-PNV:))!Z,N:D!!&0012UJTFK,A-IW1E6
MA&FW1LWX@<[H6/0>JUJUA:BLNIW@MH C1Q<L23@'ZCO3XY-3TR'-PJW4*]60
M_,H_K7)&?L7RVO'NNGD=#C[76_O=N_F;58>LSJ;VSM\\AP[#^56/[?LO)\S=
M(">BE#DUG20ZA-%-=/:H-S"0;G^8*.@QBIK8B$H\L/>[VU'2HS3O+3U.D'2L
MK4%_XGFE/Z&4?F!6C;RK/;I*IX89K-U%LZYI2>IE/Y 5W1:>J.5JSLS7JAK*
M!M,E;'S)AE]B#5\=*J:I_P @RX_W*RKJ]*2\F:4G:I'U+$3;X4;U4&GU!9-N
MLH6]4%3U<'>*9$E9M!6=;W,;:O<Q#.[ ^G%7II%AB:1CPHR:IZ?9K&6NF!\Z
M;EL]JF5G-+YE*ZBV7Z***T("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *;(@D0J>].HH KB4P_+-T[/V-3>8A&=PQ]:=@$
M<BH_(BSGRU_*F+489PQVQ#>WKV%)Y8 \R=MQ'..PJ<  8 P*BFQNCS]W=S0
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M-:-<V%HJ,>=K5FU>HY/E3T04445UG.5=2&=.F'JN*?9Q>1:11YSM4#-1ZAS
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MW/,07^\P%-^UQO(T<1$CKU"GI3EC=G#RD<=%':G85R8=****0PHHHH ****
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M'ND*W,[,OH@VU8M;6*SA$4*X7KSWJ>BJ22V$W<****8@HHHH **** "BBB@
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M[PAOGZ8/3(KIM(L!IFF0V8</Y8.2 0,DD\9)..?6D[ 7J***0!1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M''5.M.F\500Z7;7HMWD:=VC6)&Y!7.03Z\=*7R HS-XK(GDCN'4[KHQQB!"
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MJ02+)]H1$(R\6=JKP3@/C(/XU,;_ ,3+$D?V:8RR>4PE$2$(NYMX;ISC;_\
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M.#WK4HH H'1].PVZQMCNC$;$Q@ED'8GN*J3MH M]DHL'CB G5#L..<!@/<\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>trda-20211231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %@ Y # 2(  A$! Q$!_\0
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M^\?SHW-_>/YTTL!U('U-+3$+N;^\?SHW-_>/YTE% "[F_O'\Z-S?WC^=)10
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MB_NY;NZE:6>5MSNW4FKHT9PFW(F<TU9$-%%%=1F%%%% !1110 4444 %%%%
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M,,0WZ ?G67XTOEO/!GB)8^(;748[6,#H BH#C\<UQ*>-M:CUN/5EDA%TEO\
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M^2=>,/\ KFO_ *":X6NZ\)_\DZ\8?]<U_P#036&)^#YK\RZ>YPIZT4'K16Y
M4444 %%%% !1110 4444 %;GA_PK>^(H;N:UGM88[7;YK7$A4#.<<X]JPZ[_
M ,"):2^$?%:7\LD5H8XQ*\:[F5<-R!WK&O-PA>/D7!)NS,+6?!>J:-I9U-WM
M;JS5MKRVLN\(?>C6O!FIZ%H]OJET]N]O,5 \MB2NX9&<BM&^UOP_I/@S4=#T
M*2\NI+]LS2W$>P(!CH..>/2NWU6V?7M/E\. CS)M)MKF#)Z,K8/]*YG7J1LY
M;7_ T4(O8\VNO!NIV?A>/7YF@%K(J.$W'S,,<#C&._K4FE>"-2U/34U&6>SL
M+.0XCEO)=GF?0>E=MXPNDF\(>([6(G[/87-O:H/0*J$_J36!\4 WGZ&8_P#D
M'_85\C'W,]\=LXVTZ=>I.RV;?_!%*$5J<UKWAK4?#DL2WJ1M%,,Q3PMNCD'L
M?6LBN[N P^"]K]JSG^T/]%W==F3T]L;JR/!5M--JL\T>FV=X+> NSWLFV&#_
M &VX.?I]:VA5?(Y2Z$..J2.;7YB O))P .YJWJ6F7>D7AL[Z+RK@(KM'D$J&
M&1G'>O0]8:S7P_HVN)%I%W>1:D(6EM+<K#(#G*D'KCC\165\5+TS>*VL_(@4
M6Z*WFHN)'W*.&/?':E"NYS22[_@-PLKW,#0_"^H:]#/<0-;P6D! DN+F38@/
MIGUIU[X2UBRUNVTEH%DN+H P-$^4D7U#>@[YZ5+X;TG5/$2RZ9%=O!I*$37;
MNW[J,#^(CH6XX^GM7;^'];L-5^(>FV>G9.GZ;8R6]L[=9" ,M],#BIJ59PD[
M:V_ <8II'#ZWX/U+0[(7DTEK<6XD\IY+:7>(W_NMZ&N?KN]&Y^&_C#S^GVE<
M9_YZ9'ZYQ6?\.K6WO?&EM!<PQS1-%+E)%# _+Z&JC5:A)RUM_D)Q5TEU.4R/
M449![UZ7I]_I]]X6U^ZGT'3,:1,#:1K%@#D@;CG+>ISUIMWIUCXBA\%WD]G;
MVTNHS-%=?9D\M75><8'KC]:7UG6SC_5KC]GV9YKD>H_.M"PTF;4++4+M)$2*
MQB$DA?/S9. HQW)KTO2;NRU'XB76@S:!IHM+,2+#MMP&3: ,MZ@Y[^U<<0-/
M^'\V/E?5-4V_]LXO_LC1[=RT2L]/Q%R):F1KNAW7A[4197CQ-*8UDS$Q(P<X
MZ@>E9N1ZBO;O$NF6D4VHZS%#;ZAJT6GIY5I, PBC!.9-O<]?RQWKC+*:#0?A
MY%KL=C9W5_?WC1O+=1!UC4%N .@SCVZ_2IIXIRBG;7;YCE3LSA**[7QS#:+H
MWAJYM=/ALC<VK2/'$N.3M/U/4XS7%5TTY\\>8B2L[!1115DA1110 4#K10.M
M '=:[_R27PQ_UW?_ -GKA:[K7?\ DDOAC_KN_P#[/7"UAA_A?J_S+GN@HHHK
M<@**** "NCT7P9?ZWI+:E#=6,%LLIB)N92GS#'MCO7.5Z-H4FEQ_":Y;6()Y
MK/\ M'E(&"MGY<<GWK&O.4(IQ[EP2;U.9U;PE<Z3;Q3/J&FW DF6$+;S[V!;
MH2,=*TY_AMJ=M*8I]4TB*0<E7N=I_(BLJ_G\-2W%B-"L[R"47"^8;B0,"N1T
MP?6NS\>7'A*/Q7.NKV%_->>5'N>&4*I&..":PE4JII=[]%_F6HQU9QTOA"^2
MTU6YCN;.=-,(\\0R%B00#E>,$8/Z&JFC>'[O6X[Z6W>&.*RB\V:25B !SQP#
MSP:Z+P)J-A%XQNM/A1TTK5$>W6.0Y(&,KD^OWA^-6=5LY/!OP]N--D^6]U2\
M=#ZF&,X!_$ ?]]53JS4N3J[6_42@K7.!B4RR(B\%R%&?4UV;_#+6$N/LYO\
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MG=0_Z"]K_P!^6_QH^MT?Y@]E/L>;45Z3_P *=U#_ *"]K_WY;_&C_A3NH?\
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MI8QA9[ER!M+CGIR.N.:Y/_A5GB;_ )YVG_@1_P#6I/\ A5GB;_GG9_\ ?_\
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M3Z5(D=S;1+/Y;I')D*_0&B'NRNU=(-T="_Q&\9 L!XEU, GI]H)Q3&^(WC(
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MMOF"624EHCY;G*GMR!7@SHR.5=2K#J#VKV3X4_\ )*/B#_U[?^TGISES.]K
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M;"WF8/)S5+D<;2O<AIW-)_'/BH<#Q+J_'?[8_P#C31XY\6Y_Y&75_P#P,?\
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MCCA"%1\S9R6-"DN7T'K<@8DGFFYI<'I1MK,"2-R%('(/:K5_=K<O&R6R0%%
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MS,<,9AN$D9ADY!'IFMO9J4.?;]2;V=C.MI3;W"2!5;'\+#(.>*FEL98(89I
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MS,< #O6WH/AX:INN;N;[-I\1P\N.6/\ =4=S5N[O-,TBX:/2H&#%=IFD<2,
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MUQ3O!Q=M;DJ-1/EE%IHR)?\ 7O\ [Q_G5D747]FFV$"B4N"9>^/2J\O^N?\
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M)[W&U)O78F#POK:3-'Y4#2AMI/ &:7Q 8!JTHMU"J  VWH3W(JD8G8?+\V.
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ML!VY-=KX=235O">J6\Q,S0E6AW'E, D_@<5Q;R;U4;1E1CCO7<> -L-IJCR
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MY\_= )X]:W+7S]+LIVME3[01@RA=Y"'KCT/UJOIVN*)3#J$*R6DB&-_+4*R
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MJYV"[>SO%N8-H;.=O4>X/M70R_;&F-G=D364P"/<P?,K'^%SVR,X/MFI=?\
M"UGI\-JEO=JMX(-]Q',X&&[X_P *Z*=12AR6LBZ]";J>UI_Y:G-%[9+U+@QG
M[.YRZ+U4^E:,UA;WUJAL98Y)3)@+N )4]B#TQ56*"RBLYC<7.Z5U(1(^1GWK
M(*$'Y3S4\S<>5=#!M4FW-)\RVOL:]E;_ &2[5+Y2+=R49NJYQU!%.UB[@NX+
M);2V$,5M#Y1QR6;<26/UID U673BN?\ 14!P'P!TYQ5;SX3 SAO+FQC:!\KB
MMO9MQ5U:VOJ82E&.BO9D$;!6RRAQ@\9KI_!TD5S<7.F721RQRPL\*2KE1*HS
MGVXS^E<LC+(2H0^83\N#Q6G;?:=*F%T8W$1S&SC@D$8(%1.+G3=E>P4)QA55
MWHR*]GV74B01I"H.W"CK[\UK^&]8N+?5[2WG(DC,@6/>,^620 1^E<_=-&;E
MVBE9USD,XP3]14VGB)M0@,TPC0.I9SS@ U,HQE!]S6%62K63TO\ +_(RY?\
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MNH1!.8U=7 'WEZ5&DKQJP5R-PP<5"M&7O*Y2=G<1C2"B@'FH O0Z3<36,EX
MHB3/+-C./2J)P.!5HW\[6*V>_P#<*<A<=_>JM:3Y-.42OU"@=,Y&1T&.M6KE
MK5H(!#$Z2!/WA)X8^U55.#G&:B2L[7 FM[RYME?R)63<,-M[BH>222<FG*C.
MK%5) &3CL*6$*94#\*6 )]J=V[*X#5QG#$@>M.6)I"VQ"<#)P,X%;.LZ9%')
MOL%5H5C#/ALX]ZJ6NIM:6$]M'&H>4X,G<#TK5TN2?+-B4KJZ,UD*]J=!(T4H
M=0"1V(XJ6XN7N7WOC<!C@8JN.E8NU]!V-=-?O$B2.$1Q@$_=7KFJWVV6-)5
M59'?+.!S]!Z"HK"V:[O(H%X+L!GTJUKEA_9VIR09XP&Y]ZT7M/9W^SL0E!/E
M** .6+MC S]35FSD22Z1;F1TA;AF0XQZ53HJ(RY7<MHW;>]329IHK>2*:+=P
MS+R>*9JJ75W9Q7\\L91CA8U_@!__ %5B%JMZ?;B[N$A:4(&/5CP*T==\K4MO
MR'&GSR2BM1C6DL<0E=2B'E=W!/O3$V#=O!/!QCUK0U6..)8XXGDD6/Y&=CE=
MWHOM66.3CI[USIW5RY1=.3B[-H 2#Q4\U]<W$*0RRL\:?=![5&DIC.5QGU(I
MI.<<"K4FDTF9[C1R<5*!&A82 DXXP>E18YH/7-(8$#-7=+@%QJ$<+;</D?-T
MZ56(41C(.X\CTQ38Y'B<,C%6'<&FK7U$]46(;@VKR;8T<-QAUSC_  J(+$R.
M6)#YX4#BF^6Q 9LA2?O4U5)!/I1>XK"=*FMUC9P)"0O?%+(D<>],AWSPRGC%
M0CZXI(I/J2XB$K;LE<'&#CGM7L'PI_Y)1\0?^O;_ -I/7E&H6MO:M&L,_FED
M#,0. 37L/PU:T/PE\<_9496%G^]W=V\IJMTW&]WL3>^IXG#AI45CA<CFM'7H
M$MM0\J,G 4'GWJ'2X6:X2=%\SRF#&/U INJWAOM0DG*;,\;?0"FG#V;_ )KE
MM3279E>*%YIDB1?G8X /'-36MA<74[0PH&D .03Z574/)( N68_G6MH%W;V.
MH-)=%E^7:"!T.><TZ2A*24B)-I71G0I&EQMN,JBD[@.O':BZ>"6Y=X8S%$?N
MKG.*N:W+8R7>;($@Y+MG@D^E9E%3W;P6H1UU"I(.9E^<)R/F/0>])'%)*6\M
M"VT%CCL*9BLK,8Z0 2, P8 ]1WI .>G%-JPDK-!]G &TN&Z<YZ=: )[VVM+>
M*+R;H32$9<*O"_C4T.K1Q:.^GBV7]X^YY2>3Z"H[[2+NR&Z6([,9W Y%4DA>
M0J%4_,VT<=ZVDY0GHK$N*:U!Y2R8X Z\"A'*-N'TJ6\M)+"Z:"0J67&<'(YJ
M6YNH9[6")82CQ+@L,?,:R<>5M/<J_8KQS/$X='9&7H5XJ,DLV22236QIGV*Q
ME#:@H=G V#A@O^]6=.8I;ES""B,W 8]*MQM!2O\ (2E=CEBMTM)&F#^:P'E>
MG7DU'#")0_SJFU2PR<9]J9)*TA&]B2HQ]!4EJB2W,:22"-"P#.>PJ&[I(;T+
M=C;S+9W5V+=9(PA0.S8V'CD#N?\ &H[:"75+B*T@1/,/W03C/'J?I4UCJK::
M\T:*LT#G[KCKZ&JCEKF6:9$5<9=@#C&3V_.M7[.,59Z]419W;&^00)<NBF/L
M6Z\XX]:EAM;G4/.D#>8Z+O;<WS$>OO5/M4D4SQ',;%2002#U'I6<6K^]L7J3
M17 @DW0H 1T8\D59U:>=WCCE>4X16*.?NDBH[.U*@7EPC"VC89('WCV J:\O
M5U;6?/F*QI(Z@D\ +[_A2BET9O)N-/WNIE5K>>NGZ;+:M&AGF"R*XP=@]#[_
M .-5=5BM8M1E2QE\VW!^5\=>.:C3RS%*7R9",(,]_4U<;PDTF<_Q68P7,PG\
MX2,LF<[@<&G"5[BY224F4E@6#'DCTJ+:!FIOL\D-RL:E2_!&#GKS4Z\OD5:[
M.BD\/6MW+<W%K,(X.L:]=N><&L/3KTZ;?B4H)  489Z@]:CEU&Y?S$:0@,<L
M!P"159-NX%\X[XIQGRI66JZF<8-73=T.GD4S,T0*J22!GI5G39TBN LVT0R8
M64D9^7.:ANDA$H$#EDV@Y(QS4(&.U"DXRN6UT.AN]?B6UFL[&W6.)N V.2,<
MUD36Q2Y,4)\T$ J5'4$9JNR%",]2,UT=OJ=TEE!-;6("P1;)9".&QQUK6+=>
M7ONR78SMR?"96JVRVERB*",QH2IZ@XYJ":RG@MH;ATQ'-G8<]:EU&66\D^W.
MBJLK;1M/<"DGU&2XLK>U<#9#G![FE/DYI?@6KV0[3=)N-18F/:L:G#,3T_"F
MW6G/:R2JSQG8P7AN3GOBI=/MQ>:FEO;RR1QMU8GD<<]*AU")[6Z:U9MPB8X)
M'7/>BT?9*7+\[AK<]3OT@?\ 9T\-_:)"D8U*0\#)/,O KS%I3)-Y=JK1H3M5
M0>6^OK7JDNFW&J?L]^&K>W"[O[2D8LQP%&9>2:X?3M':RUZ.W:XM9;N-\I"K
M;@Y SC/2N65EJSNP]*=1)16C>Y0UBW6PO?LB#]\@'FL#GYB <?A2^'VW>(+!
M9G/EK,"<GH,\TP6]^=6^>"62[=L[2I)8D^G>I;^T;2MT=PV-0D;YXU/^J7N#
MC^(^G:HG;X.K-;VJ>U:LD]O0L7NC06.HWIGE+VT4G[MHS_K5)."I/6K<>K6B
M^$]1MK>V:W<R*JNIRTBD]&/MCITK4_LBUUCP/I,IDD%_&)44XRK -PA]#CI]
M:I:[I5OIW@O3748N9KAQ)ANNU1U';&:YI->["IO?\NOX';[-PA*I!6C9Z];L
MX[&3C K>'AB>UTZWU'4,P6<RDHW!)/88[$]JH:78R7MZB11&380[CK\H(S6G
MXJUTZE>M;0NK6<,A\M@N"QP!D_EBNJ;E*2C%^IPTJ<(4W5J*_;S,^T2R=)XQ
M,V7MSPZXR^>@K%==C$'J*N6H+7<0]^GX52)R<UHE9LXISYGM8U]+GCDTZ\L9
M,[F4RQ^[*/\ #-,@C:_CCMHT)N%SL /WAC/YBJ%K.;:Y28 ':<D>H[C\JVH[
M.&QF>62Z,;1OF'8,EAP1^AIN[T[!AHI5''HR2PU&XTA3%(""Z[D((W+D9'-9
M5Q.;J7S2H#$?,!W/K6M?_P!F7M_)/!<[68CY"A )QSCTJ?3K>UU!HQ';[?)*
MK(Q/!ZDC]*NE13YI7U7XFU:*C4TVE97_ "N)X3MF@UJWO)D"Q)DHSL$#-C@9
M/6IK_P ,232.;<L;C)9XF3:H.?N@]":SKN:X34TMKN=GBAE#+D\ >WIQ76V@
MFU+P_P")9GN&26XEC\J('C.<CZ96N-S:?-:][?U_F>C"C3E'V>ONWNOZV\CC
M1HMR"RRO!%(N/W<DJJQS[5K26T/A^TN[:X5WNYX-K,$!2//(YSUKG9HWCE=)
M 0ZG# ]<UT.C63W>A:I.9'"* LJ[<@+U#9[8(Q^-54BVE=Z&%!1<W&"L]>I@
MW-J;5H\2QR"1 X,9SU['T-:DQFTOPW%:ERCW[^<Z8P0@X7/U.35;29[9=1MQ
MJ$?F6P)!7.,9[_AZ5J^(;*>ZUL,['RA:I*&)Z1A>G_UJJ:VYG_P2:,=)2IK7
M;[]SGH'"2EP,[1TJYX?(7Q'8EG"*)@0QZ#N,TZ)(!H]U-D*YD41YY;CFI[.V
M-U;?:[=#OC<;W0<HW;/L?Y\5O*2BES;,RI4I2DK=-?4HZS;26.MWMNX *3-T
MZ$$Y!'MBF6FJ2VB,A1)8V!_=R#*@GN/>M/Q/:RI<V,DP*R36RLV>N>A%<^5*
MG'IVJ(R4H^Z[H56,J55O9FQ8745Q'/8,J0Q7 7+9X5USM;]<'V-4;NPN;.0I
M/"RGUQP1Z@]ZCMH&>3)& %SFK']IW,+JJRLT<;$HK-N _"ER.*YH]1NI&<4J
MFC[_ / )M&U2?2;H30R*H<;)%8;@R^A'ZU8US9<36^IVL+01W:EM@/"2*<-@
M^G0_C6>;\277FS6T39/S*HV@_ETK;@UU&T.YM\1QR0N)+52-W!X8?D,U$W-6
MLO4VI>SE%PE+3IH:'BFVEUZQA\103O/BW1;N)_O0L %) _ND]_>N.0@G:?IG
MTKI='U*2]M6TY9&@FGWK+(%W+)&>2".V".M5M1\-/&OVBPGBNHF)PL9^8?AW
MJX)0C:"LD*K2=2U2.I)X4U(6.JB$RE(;N)H)0Q^7)& 3]*SY?M6@:O/;9!:%
MVC96&58?3W%9VUHY"KJ58'D'BNAUN[L=3L[>^C?_ $XILN$8\<# (_+]:P<>
M6I>UU+<NG-RI63LXZH=+<:/K(/GQ/87K,N9"VZ,CIWY%5)K:RTK42L=Y#=@Q
ME<QMD D8ZU<\20+;V&D742+LNK!%)Q@Y4X/]*Y?! S^570DG&\=KBQ-3EG[R
MO+N:%K/)]EEM#&'BN"2@]''<?A1::DFGRI-;VP^T(P97E.X*1[5+8Z?<WMU(
M]@R[[>,3[=W?T'OQ6?=*?.,A!PYW=,<]_P!:JT9-KN<RKM:)^]'\NA;N=8O]
M1U1;^XE,ER&!! QC'0 #M6MXIN=-O+FSNM.@$7FJ&D &,-GD?@<_ABF:9:Z?
M/H4DA/\ ID;,6 ;'R\8_6J<%LKF.&8X1GW1R _=.>_M23C&7N]-#L5&I[+5W
MY]3 D&ZX<>K'^=3&RF6;R]H))(!SP<>AJ*3_ %[G_:/\Z>US*T,<+,2D>=H]
M,]:V5CR"(C!YJS%;;[623S$#+SM)YQ58\FBB+2W&3>4T:13.@:-R<#/7'6FE
M=\WR+P3P/2B)'GD2)!EF. ,T^=1#*%7<&0 -D_Q?X53VOT$:.HV,.F621R'?
M>2_,<=$7_&L>GR3/,Q:1BS'J2:91.2D_=5D$4TM0%6[58)M0A5LI"\@!R<X&
M>:ETS2_M^YVN(X40X)8\U<O+33+&SE19Q<71QL(/"UK3HRY>=[$N2O8J:Y:B
MTU26-0!'UC /1:SJ629Y7+R,6;IDG)HB4O*JY S6,VG)M;%+1:EM+AXK;[/N
MQ'(,L /7I5-N":M1W$*^8TT0DD/ &> ,8_PJN'5N&7CU'6DXI*XD.CG>/=M;
M[R[3]*CP:>4C[2#'N*U$DTRUT\H%-Q<2 !F(P$'M[TTG);["<K;(R""*3 K3
MO;:V2RBN+8NR2$@ANJ$=C6<JD]!4CC+F5T7-)U#^SKT3&,.,;3GL#W%/UV]7
M4-5EG1BR'&&/4\53B@DE;:B%CWP.E7)K!%@+M<('0[67WJ^:;2AT):BI\W4S
MJ<(V?A1FIE\I""Q# =@>M2SS^0IAB&TGESW/M]*SN6WV*WV:00B<H?+)VANV
M::IQ3A,XC,>X[#R5SQ3[H0*R"!F<;06+#'/>K:35T!?U"[L9]+LHH$D6XB3$
MIQ\K'U_E655NTTZYO8WDB7Y$^\Q. *JNNQV7(.#C(Z4.+2NUN3"*C[J'202Q
MQI(Z,J/]TD<&H\>]6KF_FNK>"&0C;"I5<55SS1+EO[I2#!JP,Q"*7RCQSEAP
MW-09P1BK?VJXN+:*U8YB5MJ9'3/O1%1>X,K.6FF9@HRQ)PHXI@XJY=6D^F7/
MENP#XS\ISP:2RM1,_F2[A;H0)&'8&FH2YN45U:Y$BRS%88]SDMPH]:8RO&61
MAM/<'M5N^>"+4':P9A$I^5L\_45#'#+>W!6/=)(06/J?6AQ2?*M6"?4AQL?#
M#/MFG.Z,HPN&[TAB8+O(.,XS[TP\5!0I.:]E^%/_ "2CX@_]>W_M)Z\8'6O9
M_A5_R2CX@_\ 7M_[2>@1X]!</ &V<%AC-(JM,X5%9G)[<YJ,=*LV=S):74<\
M7WT.1FG%*^I3;:L0 M&^1D,/TJUIL<5QJ4,=R^(V;YB3C]:@N)C<7$DS  NQ
M8@=*CY'.*::C*^Z)W1<U&&-+V8VRG[.K;5/4?G5/&3[5H?VK(VEK8%$\L')8
M#G&<XJI')&B2ADW%EPI]/>JJ\K=X]1*]M1Z/<VL1*[XTF7&<?>%:5C#;/H5R
MURP0"0&-E^\3CI]*K7NJS7]M!;LBJD0 X').*J3PR6Y57X)&['UJ^>,)>[JK
M!RRDKC9D1" DF_CDXZ&F+U%)R35RV\NSN ]U!Y@VY"$X!/;-8Q2;LV5K8>=4
MNFMC;NP=", L,D>O/X4RYOVE$<<*"&&([D13G![G/K5VUA@O[?4)W2.$KM92
M,X3GG K(V@[CD#'3WK2K&249-W[$Z-^A)-YTN9I2Q9QNW-_%3(O+W$R;L =%
M[T--)(B([LRH,*">%'M3*R;;W&6W%HUF)$9DG#X*'D$>N:K_ "B,X.2>?I3*
M,G&.U*P)6$J=(9&MWG"_NT8*3Z$]/Y5$0N[Y3D?E4RRSP121#_5R@%E(SG'0
MT [VT$BA$OF$R(FQ"_S'&['8>]1QJ9) B LS'  [FDR:T-(O8=,NTO&B\V6)
MLQH?NYQU-/8+.SL0:A9M87;6TA!DCP&VG(SUJLH/:I+F9KFY>9@ SL6./>DP
MWE[QG:#C/O3E:^@*]M30M[LFPDM[D[X I**#RK=C5*2=6MHHA"BE"29!U;/K
M0T3FV,H3**V&?W/05 .OK3D]$K ]=S=L+?1_[+\^\G/FEB"JGE?H*6>[T/R"
M(;%_-VM\S.<=./\ &L>V6%WQ.Y1,'D#/-,;!D(7.W/'K3G:45T,_9^]=MC2V
M3CM4T22[3<*IVQ,"6QP#GBIVTR<*[*%<)&)&VG.![U,-1C70S8B/YS)N9L=O
M\:J-/?GTT-&^QG29E9Y"1N)W'\33/:M'3(+:1Y);HXA1>F?O$]!5)U&YB@.W
M)Q4<MDF/0MZ3;PW-ZL<Y.S!.!U8^E2PPVTDMU;R(T<S,$A#?PG.,&J5I<?9;
MA)@@<H<@'U[&FBXE%Q]H!/F;MVX\\^M:1FHI:$M.Y8U6SCL-3GMHI?.2-MH?
M&,_A6V]ZITBVTVR3?++$ Q'\.>O]:YIW>1V=R2S')/J:V]/U>TT[3V6*%OM3
M*07/K_A6M"45*6MDR9+17U*FL626$D5NA8D+EV/0MWQ696Q?ZG%?:5:PN";F
M-L,YZ8K*DB9,Y'3J:RK\G/[FQ47IJ/M)1#<QR,,JK D>HS4VIE'U*8QDLC.6
M4GN#4-I$+BZCB9MH=@"?2KVKVL-E?K%#*9=JC))S^%2E+V;[7'U/3K^ZN+']
MG+P_Y,AC+ZC(K$=QF4_TKRE)I(YEE1B'5@P8=<UZKJD4][^SMX=\J(NPU)R0
MHS@9E%>?1:#=QJEQ?0RV]H>3(4YV^P[UDG?0ZH0J2CI>WX&A!XJU2'2;K,R&
M28B-)3CS$!Y;'H*YIF9W+,22W)).2:Z#Q!!:7)COM*M'AMBHC:,G.& ZCZCG
MZYIEEI,-A]EO];!2T<ED@4_O)0/;LN>]9^[!WDK2?WG1456K)1;NEUZ>I1M1
M>,+>$SR00L^4))"Y]176#[+KWA34-K$RV)$J[AR2<!FXX^;'YUC^(-9L]5BM
M7@$D1MT*K$0,9)[8Z#&*/"NNR:.+P1PB19D =6/R%1G(([^U15AS:KH=5&:A
M/V-[IKUZ?@1Z1/9H9T^VR6QDB$>]DS@$_-T]:H:OI,VG7!Y66)AN61&##'X=
M*KW2>1.Y3*JQR@(_A-%O=2P-* YVRH5<+T;TS^-7&#OS1.6K5BX^RJ*S75?Y
M#+,A;CS2/EC1G.?8<5G]:TKIA!:A>!).H+#T'_UZS:TZW/.:U8JX+8/3O6FT
M?VB]C22X1-X4;WZ#C SCZ5E]ZNVKKY08YW1GMW4_X?UJF_=MU'&W,FRW.O\
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MPES(EZZ,\%O!%+)&\#%GE&YTQ]UB>@JKM(ZCI7T*/V;[56#+XCG!'0_9A_\
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MC')\1SG_ +=A_P#%5-U:P'SVS)A@J]3D>PJ//-?0_P#PS;9_]#%-_P" P_\
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M##_XJD!\_FX+JH=054$ #BM"SLK<:9+?7C';G9&@."S5[A_PS;9_]#%-_P"
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M26<6X^;/XUI*-U8Y*511ES/_ (<^?]QW$JQ*J>.>U/F>)D5EW"7/.>E>[?\
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M=U^ 65EKT5Y&]YJEO- ,[XU@VD\>N:Q]*T>TU?6=?-^KSI'>E8XV<A5RHR0
M>M:D'AZ_AN(I'U^]D5&#%&5<,!V-:&G:4FG7-_.DC.;R?SF!'W3@# _*ERWW
M(5)R<>:.B?5WZ'#VL\\VBZ;I+W$H@FU:2U=]QW>4I)"Y]^E:NH:-9:7XF\/O
M9(84>X=6B#$J2$/S8/?M6H/"EK_9,M@TTIW7+723+PT;DYR/I38O#,AU.TO[
MS4Y[J>U8E-R@+@C&,#^=3RLQ6'FDDU=Z:]K&;H&DVGB&RN=1U16N+B:XD0$N
M1Y2JV %QTK'F07VAV"79-PUMK'V-)68Y>/=W_P ?:NJD\,O'<7#Z?J=Q917+
M%Y(D4,NX]2N>F:?/X6M'T.'3+>22!8)%FCE7E@X.=QSU-'(["EAIN/+;6SOY
M_P!>9D_V-9WOCJZM9D8VL%A%B$,0&Y(&>YQ6?<7,VAV'BFUL)'2*":%8!N)\
MKS, XS]:Z^QT;[)J;ZA)<R33R6R0.64#.TYW?4YJ,^';66;5FG+2QZEM\Q#Q
MMVC Q_.GR/H7+#2M>*LVW^*=CE+BPGMK2&72]$O;:^A966Y>8'?SR'^;G(S5
MZ=F_M+Q@W*M]AC/!Z'RVK2'A22588+S5KJYLX6#+ P W8Z!B.2*N2:!%)<:K
M-YS@ZC"L3@ ?( I&1^=+E9*P\^BM]W9KIZG/7#VDFG^'X+K[7=,;17%C "?-
M^4?,QST%1Z4#;>)=0MX;*6PMY-.,GV9WW<@XW8R<5NS>&!FPEM;V6VNK. 6Z
MRJH.],="#2VWAE8-2>_>]GFN)8&AE9P/F!Z8],>E'*[A["IS)VVM]UOO'>#/
M^1.TO_K@/YFJ>E83Q]KJR_ZUX86BSW3'./QK<TC3DTG2;:P1V=($V!F')JKJ
MV@1:G/#=)/+:WD(Q'/"><>A]156=EY&[I35.%MXV_*Q:U&]L;*.%[UD"O*J1
M[ES\YZ8KBU9M5UW5I;S2;G4E@N#;Q(K@)$H'ID<GKFNBMO#)_M"*]U&_GOY8
M.85D 5$/K@=33KGPZQU&:^T^_FL99P/."*&5R.^#T-)ILBK"K4LVM$]M.WW'
M+7*7L/AS[/=1RQQ1ZM +=97#.(RP.TD'L:Z+3?\ D?-;_P"O>#^M2'PI;?V4
MED)YBWVE;J29N6D<'/-:%OI20:U>:D)&+W,:(4(X&W/^-"BQ4\/.,HM^7Z_Y
MFC1116AWA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %)BEHH 3%&*6BE8!,"C%+118!,4 8%+13 Y/Q
MC_R$/#7_ &$T_D:V=?DAC\/Z@\Y B%O)NS_NFH?$&@C74M1]JDMGMIO.CDC
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-G)6K>TA&[NU?_@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>trda-20211231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ', B@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_0QZY_W]3_XFC_AG_2/^ACUS_OZG_P 30!Z[17D7_#/^D?\ 0QZY_P!_4_\
MB:/^&?\ 2/\ H8]<_P"_J?\ Q- 'KM%>1?\ #/\ I'_0QZY_W]3_ .)H_P"&
M?](_Z&/7/^_J?_$T >NT5X[<? 328;:64>(M;)1"P!E3L/\ =K3^ MW<WGPX
MS<SR3&.]D1#(Q;:N%.!GMDG\Z /3Z*** "BBB@ HHHH **** "BBB@ HHHH
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MR'.?+']TUI54U3_D$WO_ %P?_P!!- 'G'P _Y)I_V^R_R6O4J\M^ '_)-/\
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M*_\ M2"@#UVBBB@ HHHH **** "BBB@ HHHH @OO^0?<_P#7)OY&O,?V?/\
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MS_UR;^1KS']GS_DF\G_80E_]!2O3K[_D'W/_ %R;^1KS']GS_DF\G_80E_\
M04H ]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .7\4^#FU^:*^L-9O]&U6%-D=U:R$JRYSM>/.'&2?
M3ZUS2>#/B3</Y%[\1]MH/XK?3XUE(^H (^N379^+/$">%O"U_K3PF<6L>Y8@
M<;V)  SV&2.:\X_X65XOT:/4+O7M-TJ2"SELFFCLW8&*"<.."Q^9P0GMU^H
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M_L_#?R_BSJ_^$WD_Y\4_[^?_ %JJW/B6.\FBEETV)FB.>7SN'/!X]3G\*YX
MGI3@,!L^E3+,<3-6E*Z]%_D..!P\7>,?Q?\ F=3_ ,)M)_SXI_W\_P#K4?\
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M%M^8,<]@0,UX;!;:+<6=Q!JOQ%TVYFU2]@DU/[/$S&:*$8C1!MZYQZ=!UQR
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M[4^4"BBB@ HHHH @OO\ D'W/_7)OY&O,?V?/^2;R?]A"7_T%*].OO^0?<_\
M7)OY&O,?V?/^2;R?]A"7_P!!2@#U6BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YWQUH-SXF\%:IH]G(
MD=Q<18C+G"D@@X)[ XQ^->3ZE\./$$%]:OH_A73+>:]2T=[F*1!_9DT+?.5_
MO!EQG&<GU.,^H?$B:>#X=ZW+;WYL95MR1<+NRO(R!M!()'&1TS7D&C'X-R+8
MN_B#6!?-L)25K@GS..#M3;U]#B@#Z)HHHH ***:[K&C.[*J*,LS'  H =15&
MPUG2M5BDET[4K.\CB.)&MYUD"'W*DXI;'6-+U02G3]2L[L0G;(;>=9-A]#@G
M% %VJFJ?\@F]_P"N#_\ H)I+'5M-U3S?[/U"TN_*;;)]GF638?0X)P:75/\
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MC^SY_P DWD_["$O_ *"E 'JM%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!R7B*?Q3+J\UEH,FC/$+$R>
M3>$F3S2Q"D@?P<?F*XVZE^)>CHEWJW_"%6MH'4.[*P)R>B^I]!6I\2;>TLM4
ML_$.G>(]/TOQ/8PGR;>]O$C2[AR<QLK,.#S@^OX$<9X+OO#OCS4%\0^.O%%K
M-J%O,5M](N)EMX(#G@H"W[S/'Y<YXH ]^HHHH *H:U9Z=?Z/<V^K!38,A,X>
M0HNT<G)!'%7ZS]:T33_$.ERZ;JD+36DI!>-97CS@Y'*D'J/6@#S/5[=]1T[7
M_$^GV0T_2O[+:SMMJ^6UTF03*0,84 ?+GGG/2IO'=M#HKM_8L,< ?1)XY#",
M?NE*8/'IZ^]=O9>#-$L%F6*&[DCFB,,D=S?SSHR'J-LCL/TI=,\':)I(G\BV
MEE,\7D.;JXDG(B_YYC>QVK["@#GHK6VTKQQX=32H(XDETF5)%B& Z*%*9QUY
M[^]<]JGCGXD^3>P_\(#_ */M=/-WG[O(W=?3FO1M%\*:1H$SS6$$HE9!&'FN
M))BD8Y"*78[5]A@5?U3_ )!-[_UP?_T$T ><? #_ ))I_P!OLO\ ):]2KRWX
M ?\ )-/^WV7^2UZE0 4U_P#5M]#3J:_^K;Z&@#PJ\_X_9_\ KHW\Z@J>\_X_
M9_\ KHW\Z@H$%%%% !1110 5?T7_ )#EE_UV7^=4*OZ+_P ARR_Z[+_.@#V^
MBBB@85C^)_\ D 7'U7^=;%8_B?\ Y %Q]5_G7/B_]WGZ/\C?#?QH>J/.Z***
M^&/K@HHHH **** "NC\&?\AB;_KW/_H2USE='X,_Y#$W_7N?_0EKLR__ 'J'
MJ<N-_P!WGZ'<T445]J?*!1110 4444 07W_(/N?^N3?R->8_L^?\DWD_["$O
M_H*5Z=??\@^Y_P"N3?R->8_L^?\ )-Y/^PA+_P"@I0!ZK1110 4444 %%%%
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M4_Y!-[_UP?\ ]!- 'G'P _Y)I_V^R_R6O4J\M^ '_)-/^WV7^2UZE0 4U_\
M5M]#3J:_^K;Z&@#PJ\_X_9_^NC?SJ"I[S_C]G_ZZ-_.H*!!1110 4444 %7]
M%_Y#EE_UV7^=4*OZ+_R'++_KLO\ .@#V^BBB@85C^)_^0!<?5?YUL5C^)_\
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M_G6I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>=^(]1U74?BUH?AFVU*33["*V&I3&/@W15R!%GT^7)'H3[5'\2[_ %GPSJ>C
M>)-.U9UMA<1V<^EL/W=P')R1_M8_SUST?BSP3IWBS[-/-/=V.HVA)MK^RE\N
M:+/4 ]P?3^58^D_"^WM]8MM4US7M6U^YM&WVJWTV8X6_O!?[WO\ I0!WM%%%
M !1110 4444 %5-4_P"03>_]<'_]!-6ZJ:I_R";W_K@__H)H \X^ '_)-/\
MM]E_DM>I5Y;\ /\ DFG_ &^R_P EKU*@ IK_ .K;Z&G4U_\ 5M]#0!X5>?\
M'[/_ -=&_G4%3WG_ !^S_P#71OYU!0(**** "BBB@ J_HO\ R'++_KLO\ZH5
M?T7_ )#EE_UV7^= 'M]%%% PK'\3_P#( N/JO\ZV*Q_$_P#R +CZK_.N?%_[
MO/T?Y&^&_C0]4>=T445\,?7!1110 4444 %='X,_Y#$W_7N?_0EKG*Z/P9_R
M&)O^O<_^A+79E_\ O4/4Y<;_ +O/T.YHHHK[4^4"BBB@ HHHH @OO^0?<_\
M7)OY&O$O@KXV\->'_ KV6K:Q;6ER;V201R$YVE5P>GL:]MOO^0?<_P#7)OY&
MO$O@KX)\->(/ KWNK:/;7=R+V2,22 YVA5P.ON: /1?^%I>!_P#H9;'_ +Z/
M^%'_  M+P/\ ]#+8_P#?1_PH_P"%6^!_^A:L?^^3_C1_PJWP/_T+5C_WR?\
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M>\_X_9_^NC?SJ"@04444 %%%% !5_1?^0Y9?]=E_G5"K^B_\ARR_Z[+_ #H
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M !1110 4444 %5-4_P"03>_]<'_]!-6ZJ:I_R";W_K@__H)H \X^ '_)-/\
MM]E_DM>I5Y;\ /\ DFG_ &^R_P EKU*@ IK_ .K;Z&G4U_\ 5M]#0!X5>?\
M'[/_ -=&_G4%3WG_ !^S_P#71OYU!0(**** "BBB@ J_HO\ R'++_KLO\ZH5
M?T7_ )#EE_UV7^= 'M]%%% PK'\3_P#( N/JO\ZV*Q_$_P#R +CZK_.N?%_[
MO/T?Y&^&_C0]4>=T445\,?7!1110 4444 %='X,_Y#$W_7N?_0EKG*Z/P9_R
M&)O^O<_^A+79E_\ O4/4Y<;_ +O/T.YHHHK[4^4"N ^)FM:CI$>GG3[R2W,A
M??L/7&,5W]>8_%[_ %6E_P"])_2KA\1R8Z3C0DU_6IQ?_":^)/\ H,7/YC_"
MC_A-?$G_ $&+G\Q_A6#171RKL?/>VJ?S/[S6N/$NKW4L<MS>&:2,Y1Y$5BOT
M)'%2KXNU])Y)EU6X$D@ 9LC) SC^9_.L2BBR#VL]^9_>;W_":^)/^@Q<_F/\
M*/\ A-?$G_08N?S'^%8-%'*NP>VJ?S/[S>_X37Q)_P!!BY_,?X5ZO\/=1O-4
M\,?:;ZX>>;SW7>_7 QQ7A5>V?"[_ )$\?]?#_P!*SJ)*)WY=4G*M:3;T.THH
MHK ]T***S;G5&@G:,1 [>^Z@#2HK(_MEO^> _P"^JB;5IR20 !Z4 ;E!('6N
M=2_N4D+^:QSV)X_*DN+R6Y #G@=A0!T=%<_%J,\,80'('3-6!K+@#,()]=U
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M[6\^KZ(T;=0%4?\ M.LJ]-U*4H+=IFE&:A4C)]&6**Q/^$$^+7_01T;\Q_\
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MZ"NB_D/_ (W1_P (W\9O^@KHOY#_ .-T =]17 _\(W\9O^@KHOY#_P"-T?\
M"-_&;_H*Z+^0_P#C= '?5U2?<7Z5XO\ \(W\9O\ H*Z+^2__ !NK8T[XX  #
M6-#X_P!A?_C= 'KU%>1?V?\ '#_H,Z'_ -\+_P#&Z/[/^.'_ $&=#_[X7_XW
M0!Z[17D7]G_'#_H,Z'_WPO\ \;KTGP\FKQZ%:IKTL,NIA/W[PC"%O;@?RH U
M**** "BBB@ HHHH **** "BBB@ HHHH **** "CK110!7M;&SLO,^R6L%OYC
M;G\J,)N/J<=35BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M",>'-0A+QZ@FXF-\9VL/>N#?Q,=<^%=MX*TO1M6FU>XMH[5M]FR1QX()8N>
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M+!1GI0!TFE>.M4UK0==2WT=(/$^C';<:9+)O5CR1M=>NX!L>X].:H:)\5_\
MA*]6T+3- L4EN;F(SZIYS,!8HIPPZ?,V>!]5]>,G0]0O-'D\9_$.YTJ\BCU%
MHX]-LI82)IMH*J60<@$X_ $^E9OA'2-?^''B2QUO64-Q;>)05U$0P<V5PS%D
MW8'"_,0<<#YO09 /=**** "BBB@ HHHH *\QD^*=U!\6G\(S:= MB)TMQ=[S
MNWO&&48Z=3BO3J^</'&DZD?&?C'6+2SG>:PNK.YMR(V.\A54[>.<9/Y4 =[H
M/Q7NM;^(E[X=338%LH#.J7(D)9S$#GCIU%5M/^)'C:_T&7Q##X4L+C2H6?S/
M*O"LNU3\Q"D=:Y3X?:'?:?XRT.XN+699+G2KF>=C&0 [E^"?7&*O>$?&2:-\
M/+CP\-&UBXU>1IEBABL7*L7/'S>E '<ZS\21I^B:'XEM;1;CP]?.%NIN1);
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**\M\2:]XIN/B>?#>CZ_:Z5;"S%QOGM4E&>XY_QK N/B5XGM_!6OL]_8RZEI
M5^EJNH6\0,<JGJ=IXH ]CLM'T_3KJ[NK2TCAGO)/-N'4<R-ZFKU>*0^-_$VG
MZQHD</B[1?% OYECFL;.%!+$IQELH3C'OZ56U+Q]XKOO%FL6-KXFTK0);";R
M[73;Z!1]J ]97&!GV(_K0![I15#1I[ZZT:TFU*!(+UX@9HXW#JK=\$$@BK]
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M<B!U/L1D5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM(V!)9EMB%W$;C\N\G@ C=G )^Z>M0VFL^*M/U;6;S7+=?[$M8))U>*#!<1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH @OO^/"Y_P"N3?R->4^'+/Q%XA\%:-HCZ3%!IHE69M2%RI#1K(6P(_O;
MLC'I[UZXRAE*L 5(P0>AJ.VMH+.W2WM8(X(4&$CB0*JCV X% &'J/@W3;N[>
M^LWN-*U%^6NM/D\IG/\ MK]U_P#@0-8UW8^)O#_B"?4M*TY=;6]M4BF)GC@=
M)4SAR&P"#GD#\J[JB@#F/#>DW^B:%9:9/;).\YDDO9HY0%B9R6. >3R<<5S'
M]@^*FT=/!YTN ::ESG^U/M*[?(W[]OE_?W=O3WKTZB@#B=7_ .$J3^TM+M=
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5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>trda-20211231x10k018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "\ WX# 2(  A$! Q$!_\0
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M]<#JT?C&'1H(H9M?GN$O=26.6,.'>43 6K2!0!Y)7>>FS&.V*]8L/^0=;?\
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M5A%?*,+<6H'H+=O_ (NE\N__ .?FV_\  =O_ (NK5%4+E*N+]?\ EI;/_P
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M?:ROF0@*.0N%&=@Z9^;T:O+_  L\;?%35]ZR"],EP'D0VHC>,/A1\L8D8@;
M<N<'KCI0!ZA1110 4444 %<?\4O^2<:M_P!L?_1R5V%<?\4O^2<:M_VQ_P#1
MR4 =A1110 4R4.8G$1"R%3M)Z ]J?379EC9E0NP!(4'&3Z4GL!GZ7'?I9 7$
MT;/N./DSQ^8]ZN[;C_GI%_W[/_Q50Z=,\]F'>%HN2 &(.1Z\4Z>]BAD\H;I9
MR,B&,9;'J>P'N<"HIT^6*6I=2I>3EH2;9_\ GI'_ -^S_P#%54EO)!*88&6X
MF'!2.,X7_>.["_3KZ T_R+FZR;F3RH^T,+')_P!Y^OY8_&K444<$8CBC6-!T
M51@"KY49\TGL<[8V-ZVNSM<7Y5MFYXX9V8 ,S84!AT&#V&,\=:V?[,LV(,L/
MG$=#.QDQ]-V<59$4:N7"*&/5@.:?41IQCI^>I3DWO^&@BJJ#"J !V Q2T45H
M(JW7_'S8_P#7<_\ HMZM57GMO/FAD\Z1/*;<%7;@G!'.0>Q-6*!+=G'_ !)_
MY%JU_P"PK8_^E"5V%<?\2?\ D6K7_L*V/_I0E=@3B@844T2(VW#J=XRN#U'J
M/SIU 'GOCF^OK'Q':K97NEVWVB",/]MC#.Y67<NP[&V$$G#/E,D8&<D=]!!#
M:P)!;Q1PPQC:D<:A54>@ X%>=?$47(UJU^R2S9EMPDUK%;73_;%WMB-FB&S'
M)P&(^\<G!KTF@ HHHH **** "BBB@ J,P0F.2,Q1E),[U*C#YZY'?-244 %1
M3V\%R@6>&.558,!(H8 CH>>]2T4 -9%<8=0P!!P1GD'(/YTZBB@!J(L:!$4*
MJC 4#  IU%% 'E'C:WM=:UFYUC,JV>E30:?=7#6BRM;L)!(9;=O,!0C<JNVT
M\8P#M->AZMK]CHQ1+A;N6:092&TM);B0CUVQJ2![G KBO&%]X+T7Q;"=5TFX
MGO9UCN96BE(B8@L$+Q%PLC?NS_"Q&T>J@Z7Q*C:XTFRC*E(8KM9GDD=EB?"L
M/+;RV$G.<_*#]WF@#J-*UBSUFW:6T,PV-M>.>!X9$/H4<!A^57ZXCX9:.^EZ
M#._]LC4HKB163;Y@6(A0K#$A+ Y'?'8]Z[>@ HKG;[QKH^GWFI6DKS-+IUNL
M\X2(D?,VU44_Q,20,#U%58/B'HL]W96P2\66Y<1N'AQ]F<RM"%EY^4F1&4=>
M10!'X[_X_O!W_8P1?^B9J["N&\9ZC976J>$8;>\MYI5U^(LD<JLPQ#,#D ^M
M=S0 4444 %%%% !5>[NA:Q A&DE<[8XEZNWI_B>PIUQ<I;("V69CM1%^\[>@
M_P \ $G@5%:6TB.UQ<L'N7X^7[L:_P!U?;U/<_@ $M]$+;6IC=IYB'N9  [C
MH!_=7V'_ ->FQ>;_ &G.[6\BQF-%5R5P2I;T.?XAVJY10'*%%%%!04444 %<
MO\2/^2:^(_\ L'S?^@FNHKE_B1_R37Q'_P!@^;_T$T 0Z8_C1M$N1>6^C1O]
M@;[$;.>1W,VWY-P=  /QKSM)/&[^'+5?)\2).LMQY3>9,SM<%(3%ORJN(0WG
M [\KGH=NT#VJP_Y!UM_UR3^0JQ0 5RGCK7K30;'3Y+VRM)X9[ORFDO"!%" C
M.3D@_,0I51QDD#-=77$?$L23Z/:VT-[J%HS3@O+I_FM,BX/(6-USR/XB0#S@
MF@#4\%^()?$6CS32Z<EBUM<-:^5$Y=/E53\I*KTW;3Q]Y6KHZYOP/&8_#P#2
M:E)(7R\E^\K,Y*J<KYK,P7&.,D!MWO724 %%%% !1110 4444 %%%% '$^.+
M>/6I1IT-O'=W6GVYOWMKFP^UP.C;D4;-Z9D.'*<_PMZUK66LZ3H_A#2+F2_>
M6S>UA6WF,;-)<#8"I"*"Q8CG &:R_'(T"VN-.N-5COA-=2K9B2SO6MLQLPR)
M&#IN0%LXY/)P,9-3:TT.I_#N :7:2I9W5M"\*)A1%%A656 =6"X 7Y"2,\=*
M -O2?$&F:WO%C.Y=.6BF@>&0#UV.H;'OBM.N%^'NBBR-W?QW7R3_ "O:H;C;
M&P/&/..[@<YP,[CV KNJ "BL;4_%&EZ1JMOIUY)(D\\4DX(C)1$169BS=!PK
M<=>*R8OB1H4B6Y*W:-+)L='B : 9B&^3GY5_?Q<\_?'H< "?$G_D6K7_ +"M
MC_Z4)785PWQ&U&RDT2VM4O+=K@:M9 Q+*I<$7"9XSFNYH **** "BBB@ HHH
MH **** "BBB@ HHHH *Y+XDF<>"9C;",W'VVQ\H2DA2WVN'&2.0,]<5UM<O\
M0?\ D4S_ -A"P_\ 2N&@"OJ,GC0^#];,\.G1:F(#]C_LR621B<'=]] =WIC/
M-<KI1\6'6M##)K2VXD 0RM.8VC\^;S3+OY&8O**"7+#( ).:]:HH *X?QIK=
MCIVM:?:S:)IU]>31YM6O, LYD10J$JW W%V/\*KG![=Q7G7Q&CU.34]/-C>:
MO:K'&SDZ?;74PD.?N-Y(PF?[V2?:@#M-!U-M:T&RU)H# US$)#'G(&?0X&1W
M!P,@BM&JFF1+#IT,2274BQ@J'NRQE;!(RQ;D_6K= !1110 4444 %%%% $5S
M-]GM9I]CR>6C/L099L#.![UY_P"&KNSN/$^EW,4JSG4;2:\%O!J/GQV4K$,Y
M";1@-OQN/1B0 ,UZ+7$:!JUPWC74M-7PW%91B20O<QVCQ[U!PCM(5"N6ZX!/
MWO8T 2:Y\0K;0M7:QN+*- G):XU.TMV<?WD224$C@\G;TKKK6X2[M(;E 0DL
M:R*#C.",]N*\R\97=C:>,8SJ]Z\43" R06J[VD19&,1(:%MOS9SLD&['2O1-
M&BL[?0M/AT^3S+&.VC2W?.=T84!3GOD8H M3PBXMY86>1!(A0M&Y5AD8R".0
M?<5Y/I_@GQ%;7^@L+4QBT&%G:=&-KBXG=\_,2?,1XQQG./FQBO7** /$!X \
M4_V)%;KIVQ@0HA^T1G9<_9HX_MF=V/\ 6*[==_.<9)KJ?BEIVK?\(IJUW_;L
MGV'="?L/V:/&/,08WXW=>:]&KC_BE_R3C5O^V/\ Z.2@#L**** "JNI7$UII
M5Y<V\?FS0P/)''@G<P4D# YY-6J:Q(1BJ[F X&<9H$]CEO"-[JNN:.9+Z,V*
M1S-&$2-E=Q@'.6Z#DCCGCJ,5TT%O#;1[(8PBYR<=2?4GJ3[FHM/26.T5)HPC
MJ3P&SGG-6J;>I%*'+%7U84444C0**** "BBB@ HHHH XOXH)))X2A2*4Q2-J
M=D%D"@[#]H3!P>#BI=9\.Z[>>$-6TY];?4+JY11$6@CAP 063@8.X9'S<<^F
M:3XD_P#(M6O_ &%;'_TH2NPH \JT3P1KMIKNB75Q:VR+;^6QE0HIMD5KHM'M
M7 RXGCSL 7*MV"UZK110!Q?BW5M?L]<MK+3"\5O<0#$ZQ(ZQMOS(S;CU"#Y!
MT9FYZ8KI-#FO;C0=/FU)46^>W1IU3& Y ST)'7T)^M>7?$>Z\/:GXMM(;I+2
M[GM$"!9)(D,<FX_>#Q.7'S#Y<[>>F>:]8L($MM/@@CM(K..- JV\( 2,#H!@
M 8^@H LT444 %%%% !1110 4444 %%%% !1110 4444 >6?$YR-?L&CN1;SQ
MB 0S27B(D+M(YR4,;-RL;?,".%[8S6Q\5FMU\/Z;YP0R_P!I1^1YHA,7F;)/
M]9YI"[<;N^<XK'^(0,WBB+[/IMC<R"U16GFG(RH>3?"5$J\DE "1PK2=1D5W
M.O\ A[^W4C U&YLWC.1Y:12H?JDJ,N>3R #[T 8OPT\-VN@^'3/;REVOBLC@
M/$R*5&SY3%\IZ9XSZ=J[2LW1-(_L:R^S_;;F[).2\P1<>RJBJJCV K2H Y_6
M?"5GKEU=SW$\\;7-FMH?+(&P+)YBN,@_,&QUR..E9D'PWT^"]L[LZC?R2PRB
M:YW&/%W(L[3JSX7C$CL<+@=J[.B@#SWQ9X>T32]:\)WFGZ/I]I=2Z_&LD]O;
M)&[@Q3$@L!DY(!^HKT*N/\=_\?W@[_L8(O\ T3-784 %%%% #78HA8(SD?PK
MC)_,@55&H1_8%NVBE57 *1D N^>@ !/)IFM7EQI^C75W:0>?<1)N2+:3N/I@
M<UD^#I[K4M'AO]0A:*91Y4494J$0 #(!YR?6G;2YE*?OJ"W-FVMG,@N[H#[2
M5P%!R(E/\(_J>^/0 "Y112-$K!1110,**** "BBB@ KE_B1_R37Q'_V#YO\
MT$UU%<O\2/\ DFOB/_L'S?\ H)H Z"P_Y!UM_P!<D_D*L5RNBS^,$TR634;#
M1G"6>ZUCL[F0O+(!\JL70!0>F<\5YU.WC\Z<ZW,>OK=B\NFC: M@SE83""$)
M @!\WK\G3.: /;Z\O^*UG;W&H:,3H$=Q>-,%M[V6WM9DD.R4F!UED1BH&Y^H
M7.._%>H5PGQ4%E)X>MHK][,0/<C*W=\ELC$*<<O%(&/M@?6@#5^'HMA\/M#%
MF9#;BU7890H8_4*2!],FNFKF_ 3+-X,TV[3[0L=S"DB0S2!_)7:%"J0BC&%S
MTZDXXQ724 %%%% !1110 4444 %%%% '#?$X0MHULMP&:(2,[*+J.'[JYS\\
M;[L>PZGWQ3];*R?"*,WLT5R6L;8M*"KQRO\ )AF+[5,9;!)./E)Z4WXC$-'I
M2QVEK<3K=*R//+M%NV?ED8!T)0$%B.02@&,X(TK729=5\#Z1:K</IKBS@)2%
M$E080?(5D#AE_7@<]Z ,3X8Z%!:6UUJRQZ?#<7#&.6/3DA6$XP01Y3,!@8P"
M21EC_%@>@UC:!H<VC1.LVI279<Y"_9XH8T]PL:CD^I)K9H R-9\.VFN7%I)=
MM)MMUF38IP'66,QL#WZ$]*YZ+X8:6@@+7]_)(LFZ>1C'FX3,)"-A< ?Z/$,K
M@X!YYKN** //?B'X>T2WTZWU2'1]/CU!M7LF:[2V02DFX3)+@9Y[\UZ%7'_$
MG_D6K7_L*V/_ *4)784 %%%% !1110 4444 %%%% !1110 4444 %<O\0?\
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M_P"$DN/[/W0G^S?LL.S'F(,;]N_KSUH ]+HHHH **** "BBB@ HHHH ****
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M8_\ HY* .PHHHH **** "BBB@ HHHH **** "BBB@ HHHH X_P")/_(M6O\
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MH^&_.M/#X0:XGV39<S$L_E2[?,S'P-N<XR<XKI/.^(__ #X^%/\ P,N/_C5
M'845Q_G?$?\ Y\?"G_@9<?\ QJCSOB/_ ,^/A3_P,N/_ (U0!V%%<9+=?$:&
M&25K#PJ512QQ>7&< ?\ 7*J>B:Y\0->T.RU:UT[PREO>0K-&LMW.&"L,C($9
M&?QH [^BN/\ .^(__/CX4_\  RX_^-4>=\1_^?'PI_X&7'_QJ@#L**X_SOB/
M_P ^/A3_ ,#+C_XU6;:>(/']YKVI:/'IOAH7&GQPR2LUW/L82[MNT^7G^ YR
M!VZT >A45Q_G?$?_ )\?"G_@9<?_ !JCSOB/_P ^/A3_ ,#+C_XU0!V%%<?Y
MWQ'_ .?'PI_X&7'_ ,:K-U?Q#X_T7[!]ITWPT_VV\CLX_+NYSAWS@G,8XX]_
MI0!Z%7+_ !(_Y)KXC_[!\W_H)JOYWQ'_ .?'PI_X&7'_ ,:K.U_3OB)K_A^_
MTB6V\+Q1WD#0M(MY<$J&&,C]U0!W-A_R#K;_ *Y)_(58KE+(>-8])O8;Z#1H
MY([)ULVL9Y'8S!<+D.BC%0?#G^U/[)O?[0_M3R?M"?9O[4W^?CR8_,SO^;;Y
MOF8SVZ<8H [*BBB@ HHHH **** "BBB@ HHHH **** /,_&^M:+;^-(-+\0:
MC+#8R6]OF Z@UO$RN;G>[*N"V#%&#DX^8<>O:^%+F.\\':'=16T=K'-I\$B0
M1?=B!C4A1[#.!]*Q-?LO%:^*X;_18H+BQ$<'F0RZ@\&6C-QN7 1@0WFQG/\
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MC-JZK\X& 3E3G&21Z'GTHTSPMIVDZS>:I;>=Y]T6)5WRL>]R[[!VW.=QZ\T
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M&&-(XHU"(B* JJ.  !T H ?1110 4444 %%%% !1110 4444 %%%% !1110
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I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>trda-20211231x10k019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %  X\# 2(  A$! Q$!_\0
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M1#@X![<5T-<;\,=,N-/\(B2[C:*:\N);HHP(*AV) (/0XKLJ "BBB@ HHHH
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M&X;<9&WCY3GKQ9\->,=:;2K^X/F^)I([:RN46T2-&#3AB\8VX&$V@\\X;G-
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M$?&K>)[_ %*QGT:ZTNZL-GFQ7+*3\P)'3Z5UE !1110 4444 %%%% !1110
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MHEL([%MSGR(K 6:CYCR(@QQGKG//6@#I**** /.=:\5ZO9?$-;*"YSIT4MO
M\ 6/YGDCD;&"/,))"893M'.0<'%;PUXUUQ]/N;EED\22&PL[WR+1(XV@DF+A
MX>.,+M!^;YNN:]'>PLY+R.\>T@:ZC!5)VC!=0>H#=12VUE:V?F?9;:&#S'+R
M>5&%WL>I..I]Z /,_ ^J76K_ !:\17=YI5SI<QTZW4VUP07 #'GCCFO4Z\_T
M;_DMWB3_ +!EM_,UZ!0 4QS(#\B(P_VF(_H:YKQ1=W-O=0"&XEC!0DA'(SS[
M5@?VG?\ _/[<_P#?UO\ &O)Q&:PHU'3<7H>C1R^56"FGN=^)9S(R>5'D '_6
M'OG_ &?:I4+G.]57_=;/]!7G7]I7V2?MEQD]_-;_ !I?[3O_ /G]N?\ OZW^
M-8+.8+>+_ U>5RZ-?B>CT5S_ (6N9[B"X,\TDI#+@NQ;'7UKH*]?#UE6IJHE
M:YYU:DZ4W!] HHHK8R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "N4\?O?0Z#'-93WT*1S*9VL)8TF\OOM\SY2?8U
MU=<)\2T>[TF.%--ENC!,DQW:=]KB8>A3>H/XT )\/%U\FXGU"^OKJPE7=#]M
MFADD0YX&8^ <9R,GM7>5S'@%9$\+1"2PBL29&/DQ:>+-<<<^6&;'USS73T 8
MGBK0CX@T.6RC\D3DJ8Y)5SL((SCC(XKE]9^'E]JVJ7S'4+:.PGDDN8QY;&02
ML@3!YQM& ?6O0Z* ."_X5M;ZQI#P>)+AI+F2[:[8V$C1(&*A<#N1@=ZI_""P
MATNV\0V-OO,,&I,B;VW-@#N>]>DUY_\ #+_CX\4_]A5_Y4 >@5PVJ:G?1:G<
M)'=2JJO@ ,<"NYKSS6/^0M<_[]>/G$Y1I1<7;4]++(QE4=U?03^U]1_Y_9O^
M^S1_:^H_\_LW_?9JE17SWMZO\S^\]KV5/^5?<7?[7U'_ )_9_P#OLUW]NQ:V
MB8G)* D_A7F=>F6O_'I#_P!<U_E7MY-.<I3YG?8\K-(1BH\JMN2T'IQUI"0H
M))P!R:HG6M-'!O(_SKVYU(0^)I'E1A*7PJY/*;B.,MYD1Q_TS/\ \53PL^>9
M(\?]<S_C5&?6=.:%@+N,GZ^]2?VUIO\ S^1_G6*K4;_&OO\ ^":^RJ6^%_<7
MZ*I)J^GR.J)=1LS'  /6KM;0G&?PNYE*$H_$K$4\\5K"TTS;8UZG!/\ *J'_
M  D6E?\ /U_Y#;_"G:]_R!KC_=K@*\K,,PJX:HH02VZ_\.>A@\'3KP<I-[G<
MR^(-+;9BZZ."?W;?X5)_PD6E?\_7_D-O\*X*BN#^V:^]E^/^9V?V71[O\/\
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M]D9#.T3. 1CS"20O*G Y!!J71O%^M16=Y((+GQ&Z1V\JI;B)74R*2R_* ,#
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MD#@&1&X"]0.H/H#4GPTT@:=H3S)?WTJRR.&M[B^ANDB<.VXAXD4%B22<YYH
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M!^M 'I%>>:Q_R%KG_?KT.O/-8_Y"US_OUXN=?PH^OZ'J95_$EZ%&BBBOG#W
MKTRU_P"/2'_KFO\ *O,Z],M?^/2'_KFO\J]S)/BG\CR,UVC\Q9_^/>3_ '3_
M "KS1_OM]:]+G_X]Y/\ =/\ *O-'^^WUJL[WA\_T#*MI?(;1117@GKEK3?\
MD)6_^^*]'KSC3?\ D)6_^^*]'KZ+)/X<_4\3-?CCZ&;KW_(&N/\ =K@*[_7O
M^0-<?[M<!7)G7\:/H=&5_P )^H4445Y!Z9N^%/\ D*-_US-=I7%^%/\ D*-_
MUS-=I7U.4?[M\V?/9E_'^1DZ[J,^FV\<D 0EFP=PS7//XFOI,;D@./\ 9/\
MC6MXN_X\H/\ ?-<?7GYEB:T,0XQDTM#MP%"G.BI26IK?\)#=[MVR'IC&#C^=
M/3Q-?1YVI ,_[)_QK&HKSUC*ZVDSM>&HO>)W.@:G/J44K3A 48 ;1BMBN;\(
M?\>]Q_O#^5=)7U& G*>'C*3NSY_%QC"M*,59!11178<P4444 %%%% !1110
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M"N>I@</4DYSC=OU-H8NM3CRQEI\CR*#4_&MSXBNM!B\+6IU"VA6>6/\ M!0
MA. <XP:U/L/Q'_Z%"S_\&<==?K&I^'/"?B;4M:GL[UM2>RB,CQ?,)8S($544
ML!N#%?3J.:Z+1]?L]<>Z%FLI6W,8:1@ K%T#C'/]UES]:C^S,+_)^+_S*^OX
MC^;\C@M(N_B1I2RA?!5E)YA'754&,9]O>M+_ (2+XE?]")8_^#=/\*] HKKI
MTXTHJ$%9(YYSE4ES2W/*M6G^)&JR1LW@NRCV C U5#G]*SOL/Q'_ .A0L_\
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MFT@O(+J5KD$@PJI"@$ D[F&>HX7)/I6A!QJ>/_'<GB.705\$V9U&*V%TT?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*9,YBA>0 $JI."<9Q3ZS==GTZVTQI]4O$M+:)U<RO<B ;@?E!8D#DX&">: .
M1\ ^--0\3WYBO=0T>3_1?.-K9VEQ'+$V5&&>0E6 R0<=3@CBO0*\K^&%S;W>
ML/<07%F1+9%Q"GB22_F0%D.'B;A<="W8\=Z]4H **** . U__DM/@_\ Z\[W
M_P!!%=_7 :__ ,EI\'_]>=[_ .@BN_H *BFMHKC;YJ;L=.2*9<WMI9A3=74,
M ;[OFR!<_3-0?VYI/_04LO\ P(3_ !H)<H[-D8L;?^T2GEG;Y6<;CUS]:O0V
M\5N"(EVYZ\DUF#6M*_M,M_:=GM\K&?/7'7ZU9_MS2?\ H*67_@0G^-/4B,H=
MT7Z*@MKVUO QM;F&<+U,4@;'UQ4](T3OL%%%% PHHHH **** "BBB@ HHHH
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M3&3M,>/E!Z\&NDTYO';Z.A\--I+6GVF<1-KIN#*8=Y\O!')&W'WN: )_@_\
M\B=/_P!A"Y_]&&N_KSSX,>=_P@[_ &C9YWVZXW^7G;N\PYQGG%>AT %5FOH5
M8@I<<>EO(?\ V6K-% G?H4UU*W=0RBX93R"+:0@_^.U;!R >>?456TW_ )!E
MM_US7^56J!1NU=A11104%%(P#*58 @C!![UG7VG6*V4C+9VX/'(B7U^E FVE
M<TJ*JII]DA5EL[<,,$$1+D'\JM4 K]0HHHH&%%%% !1110 4444 %%%% !11
M10 4444 %5[V".XLY8Y8(YUVY$<B!U)'3@]:L5%<D+;2DLR@(3E>HX[>] 'D
MO@.]U/3]?B$NC:]-]HB$%^TEK:A+:X+KRIC*LL0&_(()X7CBO7Z\H^%4-A+?
M0WEI?^'MXTWRS;Z;)BYN 60^==(3D2*1C^+!=OF.17J] ''?$9/.\/&&-;];
ME@YMI;6&:54D"G&Y8B#DY(4G(#8/;!Y[0X_$7_"1[U@O(]5/VDW'VTRM;^68
MD\A68?(V&Q]SGA_>O4J* /(H?^$L_P"%R>%_^$J_L7S/LMWY']E^;C&P9W>9
MWZ8Q[UZ[7 :__P EI\'_ /7G>_\ H(KOZ /,_B]_Q[Z5_O2?R6O+*]3^+W_'
MOI7^])_):\LKII_"?.X__>)?+\@HHHJSC/5_A%_QXZI_UTC_ )-7I%>;_"+_
M (\=4_ZZ1_R:O2*YJGQ,^CP/^[Q_KJ%02WEK ^R:YAC;&=KR ']:GHJ#J=^A
M4&IZ><XOK8XZ_OE_QJQ%-'.F^*1)$_O(P(J"T_UUY_UW_P#9%JU0*-WN%%%%
M!056>TWN6^T3KGLKX JS10)JYG6=N\MOO>ZN"=[C[_8,0/Y5?1=B!=Q..[')
M-5]/_P"/3_MI)_Z&U6J;%%:(****104444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &?K?]I'29QI(M#=E<*;N1DC [DLH)'Y5YC\-8K5/$SH&\/37
ML4;B6>ROKJ2:0YP2%E4(PSU(->L7>S['/YA(3RVW$#) QS7D?A>PO;O7=.23
M5]=M;?RW?3'D>UD62('YAM5-R<>O;C(Z4 >Q4444 %<!?_\ )<-(_P"P7-_,
M5W]<!?\ _)<-(_[!<W\Q0!W]%%% !55/^0E+_P!<Q5JJJ?\ (2E_ZYB@3Z%J
MBBB@84444 02WMK ^R6YAC?KM>0 _K4?]IZ>2<7UL<?]-5_QJW56U_U]U_O_
M -*9+O<GBFBG3?%(DB=-R,"*?112*"BBO+?$WQ"UK2/$-W8VR6IAB?"[XR3_
M #JHQ<MC&M7A1CS3/4JJV'_'N?\ ?;^=>0_\+4\0_P!RR_[]'_XJHXOB?K\*
M;52SQDGF(_\ Q55[*1R_VC1OU/;**\7_ .%J>(?[EE_WZ/\ \57K&B7DNH:)
M9WDX42S1!VVC S4R@X[F]#%4ZS:@:%%%>":IXIUZ+5;N./5[Q465@JB4X S1
M&/,&)Q,:"3:O<]XF_P!3)_NG^51V?_'G%_NU\_GQ9X@((.LWN#_TV-"^*]?1
M0JZQ>@#H!,:OV3.3^TX7ORL^AZ*^>XO%GB S(#K-Z06'_+8U[_;,6M868Y)1
M22?I4RARG5AL5&O>RM8EHHHJ#J"BBB@ HHHH **** "BBB@ K@_BA%?3:(B[
MM+_LL.IFCO%G=I7SP@6+)8'T]O:N\KD_B&(V\-QHQN%F>ZC6W:"Z%N5E.<$R
M$':.O;/;O0!%\-5ME\+_ .BVVG6R^<VZ&QBEC5&[AEE^8-78UPGPYTY8H+RZ
M:^U.2Y$[PW,-QJ NHO,!Y96"C.?4\]J[N@ HHHH X#X/_P#(G3_]A"Y_]&&N
M_K@/@_\ \B=/_P!A"Y_]&&N_H **XVY^)F@VMS+;R)>;XV*MB(8R/^!5%_PM
M3P]_<O?^_0_^*JN278Y_K5%?:1UNF_\ (,MO^N:_RJU7!6?Q.T""SAB=+S<B
M '$0_P#BJF_X6IX>_N7O_?H?_%4<DNPHXJC9>\CMZ*:K!U##H1FG5)TA5;4/
M^/&7Z#^8JS5;4/\ CQE^@_F*!2V98'W1]*6D'W1]*6@84444 %%%% !1110
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M>_\ CG^-/DEV(CC*%E[QZ#15:PO$U"PM[R-65)D#J&Z@$=ZLU!U)W5T%%%%
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M6CC_ +*B=("!_=#=?K76USO@V+6(=&9=9NS=R^:QBG+JQ>,]#E1C'I[8KHJ
M/&6B\2)?:L)(K^5Y)";QHXKA2D0N%X5MQ63,9;&P @#'>MRR@\>G2$'AB738
M+/[3.8EUI9_-$/F'R\#!8#;C[W->E44 >=_!<3#P,PN"AF^VW&\I]W=YASCV
MKT2N ^#_ /R)T_\ V$+G_P!&&N_H ^;M:_Y#=]_UW?\ G5&KVM?\AN^_Z[O_
M #JC78MCY.?Q,****"3Z;A_U$?\ NC^50:H[1Z1>NC%76!RK*<$':>14\/\
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M%#X6M_"_QD\+QP:CJEZ)[6[)-_=&8KA!]W(XZUZ[7 :__P EI\'_ /7G>_\
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MLA_Z\T_]">N&K>'PH\3%_P >7J%%%%4<Y[A\-?\ D38/^NK_ ,ZZ^N0^&O\
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M:TF#7=(N--NGD2&=0K-$0&&"#QD$=O2LZ#PAIT&N2:GYD\@9Y9%M9"IAC>0
M2.!MW98#G)(Y. ,FN@HH \XU:QM++XT>$1:VL$ :TO"PBC"Y^0=<5Z/7 :__
M ,EI\'_]>=[_ .@BN_H \S^+W_'OI7^])_):\LKU/XO?\>^E?[TG\EKRRNFG
M\)\[C_\ >)?+\@HHHJSC/5_A%_QXZI_UTC_DU>D5YO\ "+_CQU3_ *Z1_P F
MKTBN:I\3/H\#_N\?ZZGC/Q6_Y&R'_KS3_P!">N&KN?BM_P C9#_UYI_Z$]<-
M6\/A1XF+_CR]0HHHJCG/</AK_P B;!_UU?\ G77UR'PU_P"1-@_ZZO\ SKKZ
MY9?$SZ?#?P8^B/G_ ,;?\CEJ?_74?^@BL"M_QM_R.6I_]=1_Z"*P*Z8[(^<K
M?Q)>K"BBBF9GT5X:_P"19TS_ *]D_E6K65X:_P"19TS_ *]D_E6K7(]SZNG\
M"] HHHI%A1110 4444 %%%% !1110 4444 %%%% !1110!G:WJ+:5I4MXK6B
MF/!/VN;RD(]-V#@^G%<KH'B+4]7\6J9+U8-/FC9H;20J?, '6-ECP^#DDB4\
M=5%=E?Z?:ZG:M;7<7F1$@XW%2".A!!!!]Q2V=E;Z?:16MK$(X(AA%!)QWZGF
M@"Q7!?$?5(K*33;==3O;2\G<B'RKAH84Z9DDVC+8[+T)/2N]HH \MT?4?$4F
MLW*V%S)=ZGLG\Z&]DD%NN,>4=O1 ?]GKFJ^E2^)9?C-II\2V^FP7 TZ;RQ8.
M[*5]]W>O6JX"_P#^2X:1_P!@N;^8H [^O+/B[_Q\:;_NM_.O4Z\L^+O_ !\:
M;_NM_.KI_$<>/_@2/,Z***Z3YT*]>^$W_($O?^NX_E7D->O?";_D"7O_ %W'
M\JBI\)VY?_'7S/0:\7^*7_(U+_UP6O:*\7^*7_(U+_UP6LJ7Q'I9E_ ^9Q%%
M%%=!X 5[G\./^1-MO]]_YUX97N?PX_Y$VV_WW_G6=7X3T,L_C/T.LKP+QU_R
M.6H_]=/Z5[[7@7CK_D<M1_ZZ?TJ*6YV9G_"7J<[1116YX85]$>%?^16TW_K@
MM?.]?1'A7_D5M-_ZX+6578]/*_CEZ&O7S;K'_(9O?^NS?SKZ2KYMUC_D,WO_
M %V;^=*ENS;-/AB4J***V/&'P_Z^/_>'\Z^EK7_CS@_ZYK_*OFF'_7Q_[P_G
M7TM:_P#'G!_US7^58UNAZV5?:^1-1116)[ 4444 %%%% !1110 4444 %<?X
MRU^ZTN:*TLKJ,2W,6SR6ADW*7.U76500AW' ##!/<=:["J\]C9W4T4UQ:P2R
MPG,3R1AF0^JD]/PH P?!,%Y;Z1+'?S7SW E.Y+Q) 8^!PI>20L.^0Y'/&.@Z
M:BB@#Q_4=*N+_P 0:S-9:!J%HFX!P;=R=0C\Y&E+2-][*@A4],COBMK3M'\9
M)HZ)X?O+31[0W,[Q6M]:%F2(N3&N!]W"XX[5Z-10!YY\&!*O@=Q.RO*+ZX#L
MHP"?,.<5Z'7 ?!__ )$Z?_L(7/\ Z,-=_0!\W:U_R&[[_KN_\ZHU>UK_ )#=
M]_UW?^=4:[%L?)S^)A11102?3</^HC_W1_*J^K_\@6__ .O>3_T$U8A_U$?^
MZ/Y57U?_ ) M_P#]>\G_ *":Y%N?62^%GS:?O'ZTE*?O'ZTE=9\F%:WA?_D:
M=+_Z^4_G636MX7_Y&G2_^OE/YTGL73^->I]$USWCG_D2]3_ZYC_T(5T-<]XY
M_P"1+U/_ *YC_P!"%<L=T?35OX4O1G@-%%%=9\L%=A\,_P#D<HO^N+_RKCZ[
M#X9_\CE%_P!<7_E2G\+-\-_&CZGM]<+\6/\ D5+?_K]3_P! >NZKA?BQ_P B
MI;_]?J?^@/7-#XD>]B_X$O0\:HHHKJ/F@KT7X1_\A74?^N"_^A5YU7HOPC_Y
M"NH_]<%_]"J:GPLZL%_'B>M4445RGT@5%<VT%Y;O;W4$<\+C#QRH&5OJ#P:E
MHH 9%%'!$D4,:QQH JH@P% Z #L*?110 445YY;>*-8/BJ>-93=JUQ>P+I:B
M-=@A161@V-P+$C)8D?., =P"37_^2T^#_P#KSO?_ $$5W]>.ZCJ/C6^\<:+X
MA'P^O$33H9XC";Z(E_, &<]L8]*Z+_A-_&7_ $36^_\ !C#0!3^+W_'OI7^]
M)_):\LKM_&5UXV\51VBIX O+?R"Q.Z^B;.<?3TKD_P#A%_'7_0FW7_@5%_C6
M\)Q4;,\7&86M4K.48Z%2BF)I_BJ36I='3PM<'4(H1.\'VF/(C)P&SG'6KW_"
M+^.O^A-NO_ J+_&J]I'N<WU'$?R_D>F?"+_CQU3_ *Z1_P FKTBO&/!MYXV\
M+0743^ +RX\]E;*WT2XQGZ^M=/\ \)OXR_Z)K??^#&&L)N\KH]O"PE"C&,MS
MF?BM_P C9#_UYI_Z$]<-74^+H?&_B;5TOD\"7=N%A6+8;R)NA)SG(]:P?^$7
M\=?]";=?^!47^-;1G%*QY6(PE:=64HQT?H5**BT^R\4:I=WMK9>%[B:>QD$5
MR@N(QY;'D Y/MVK0_P"$7\=?]";=?^!47^-/VD>YC]1Q'\OY'LOPU_Y$V#_K
MJ_\ .NOKR;PQK?C3P]HD>GO\/+V<JS-O%_"N<^U;/_";^,O^B:WW_@QAKGD[
ML]ZA%QI1B]TCS_QM_P CEJ?_ %U'_H(K K;UW2O'&L:W=:@O@B[B$[;MANXC
MC@#KGVK.;PSXY52S>#KH #)/VJ+_ !K=3C8\2K@J\IR:CU\BK14>D6/BG7K
M7NF>%KBYMBQ02+<1@9'!')%7_P#A%_'7_0FW7_@5%_C3]I'N1]1Q'\OY'O\
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M+=Q"01FQ#%<]L[N:U/\ A2GB/_H;[7_P7_\ V5'M8D_V96[K^OD>TP_ZB/\
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M?+.L26<A\]".98]ROM_[[C0_0&E\(>&7\,V=[#)<+.T]R71E7&V)55(T_P"
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>L^H364;(]_<M=3Y;.7/7'H.^/4GUK3H **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>trda-20211231x10k020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &9 K@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JWO\
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M7<5P_P '_P#DE&@?]<G_ /1CUW% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55O?\
MEW_Z[K_6K55;W_EW_P"NZ_UK.K\#+I_$BU1116A 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <SXB\?^&O"NH1V.LZBMM<21"94*DY0D@'CW4_E7
M%>-_BKX-U7P/K=A9ZNDMS<6<D<2!&&YBI '2MKQCI/B*77?[0LM$T;6;$1*@
M@NEVS+C)(5N_))Y]:PX_$WA*Q<1>)O \NB2#[TDMH)(A_P #48H [7X;_P#)
M-?#G_8/A_P#017451T:ZTZ\T>UGTAXGT]D_<-$,+M'''Y5>H **** "BBB@
MHHHH *Y_QW_R3SQ+_P!@JZ_]%-705S_CO_DGGB7_ +!5U_Z*:@#'^#__ "2C
M0/\ KD__ *,>NXKA_@__ ,DHT#_KD_\ Z,>NXH **** "BBB@ HHHH ****
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MH/\ T$HOR/\ A7 ?\+.M_P#GTB_\ I/_ (FC_A9UO_SZ1?\ @%)_\30!W_\
MPEN@_P#02B_(_P"%7=/U>PU7S/L-RDWEXW[<\9SCK]#7F?\ PLZW_P"?2+_P
M"D_^)JY8?$22Y\S[);0C;C=F!X_7'4#/>BP'IM%>??\ "=:A_P \(/R-'_"=
M:A_SP@_(T[ >@T5Y]_PG6H?\\(/R-=?H.H2ZII,5W,JJ[%@0O3@XI :5%%%
M!1110 4444 %%%% 'GWQ/OO&]II[#PI:)) 8&,TJD^<C9XV =3BN8-W\8-1\
M/+:MHVF_OK8()I&_>C*XW')X;O\ 6N[U_P ,ZQJ.JWM[:^*+O3[:6P-ND$9(
M6*3=GSAR.<<5YX?#UXI(/QOP1P0;Y?\ XY0!ZSX6TVXTCPKIEA>%#=0VZB<Q
M_=,F,L1^)-:]9OA^)H/#VGQ-J7]I,D"@WN[=Y_'W\Y.<]>M:5 !1110 4444
M %%%% !7/^._^2>>)?\ L%77_HIJZ"N?\=_\D\\2_P#8*NO_ $4U &/\'_\
MDE&@?]<G_P#1CUW%</\ !_\ Y)1H'_7)_P#T8]=Q0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %5;W_ )=_^NZ_UJU56]_Y=_\ KNO]:SJ_ RZ?Q(M4445H0%%%% !1
M110 4444 %%%% !1110 4444 %%%% 'F?C'_ )&6?_=3_P!!%8-;WC'_ )&6
M?_=3_P!!%8-4(**** "BBB@ HHHH **** "BBB@ HHHH *],\'?\BW!_O/\
M^A&O,Z],\'?\BW!_O/\ ^A&DP-ZBBBD,**** "BBB@ HHHH Y/XFJ&^&NO@W
M+VX^RG,B#)'(X^AZ'V->'Z5K/P772+1;[0[_ .V"%1/G<V7Q\QSOYYS_ /6K
MV7QEK'CNPU6*#PQX9M-4L&@#2333JA$FY@5P77C 4].]<K=^-/B7H]K+J.K?
M#ZQ%A;J9)S#<(65!R3P['@>QH ]*\+R:;+X6TN31XVBTUK9#;(_58\?*#R>U
M:]9V@:Q:>(-!L=6L<BVNHA(@88*YZ@^X.1^%:- !1110 4444 %%%% !7/\
MCO\ Y)YXE_[!5U_Z*:N@KG_'?_)//$O_ &"KK_T4U &/\'_^24:!_P!<G_\
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M3:SXVNM:LH;N8ZF^G@3H&*6Z1IM"Y^Z#N8\=3S0!Z+7/^._^2>>)?^P5=?\
MHIJY'PUXHUO3?@YHFI6>C7.OWH9K;R8Y"KM&DDB*Y.UL_*B]N_6L'Q/\1O%]
M]X3UFTNOAIJ-I;SV,\4MR]PQ6%60@N1Y0R #GJ.E ':?!_\ Y)1H'_7)_P#T
M8]=Q7#_!_P#Y)1H'_7)__1CUW% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55O?^7?
M_KNO]:M55O?^7?\ Z[K_ %K.K\#+I_$BU1116A 4444 %%%% !1110 4444
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M !W_ ,D\\2_]@JZ_]%-0!C_!_P#Y)1H'_7)__1CUW%</\'_^24:!_P!<G_\
M1CUW% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH_LZW'0.!_OG_&K5%%D%V5?[/@_V_P#OLT?V?!_M_P#?9JU119!=E7^SX/\
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M QYC@<MCWJ]45M<PWEK#=6TBRP3()(Y%.0RD9!'X5+0 4444 %%%% !1110
M5S_CO_DGGB7_ +!5U_Z*:N@KG_'?_)//$O\ V"KK_P!%-0!C_!__ ))1H'_7
M)_\ T8]=Q7#_  ?_ .24:!_UR?\ ]&/7<4 %%%% !1110 4444 %%%% !56;
M_D)6O^Y)_P"RU:JK-_R$K7_<D_\ 9:3&BU1113$%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5>ZC:3R=HSME5C]*L44FDU9C3L[
MH****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH \S\8_P#(RS_[J?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPJVGMX3TIM*AFAT\VJ?9XYL[U3' ;)/./>MBLSP\=1;PYIK:NBIJ36Z&Y50
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M"@!]%%% !1110 4444 %%%% !1110!YGXQ_Y&6?_ '4_]!%8-;WC'_D99_\
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M /,_&/\ R,L_^ZG_ *"*P:WO&/\ R,L_^ZG_ *"*P:H04444 %%%% !1110
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M5/RDNQ_D175_\+B\"_\ 0<B_[Y- '=45PO\ PN+P+_T'(O\ ODT?\+B\"_\
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MH W?^$8T#_H!Z9_X"1_X4?\ ",:!_P! /3/_  $C_P *PO\ A:?@[_H,1_\
M?)H_X6GX._Z#$?\ WR: .DM=$TJQG$]IIEE;R@8\R&!4;'U J]7&_P#"T_!W
M_08C_P"^31_PM/P=_P!!B/\ [Y- '945QO\ PM/P=_T&(_\ ODT?\+3\'?\
M08C_ .^30!Z-I'W9?J*TJ\WT[XM^"8%D$FM1C)&/E-7O^%Q>!?\ H.1?]\FD
M,[JBN%_X7%X%_P"@Y%_WR:/^%Q>!?^@Y%_WR: .ZHKA?^%Q>!?\ H.1?]\FC
M_A<7@7_H.1?]\F@#NJH:Y_R -2_Z]9?_ $ URG_"XO O_0<B_P"^35/5?BYX
M)N-'OH(M:C:22WD11M/)*D"FB9_"SR6BLG_A)-*_Y^U_*C_A)-*_Y^U_*NKF
M7<^7]A5_E?W&M163_P ))I7_ #]K^5'_  DFE?\ /VOY4<R[A["K_*_N-:BL
MG_A)-*_Y^U_*C_A)-*_Y^U_*CF7</85?Y7]QK53M?^/Z_P#^NB_^@+57_A)-
M*_Y^U_*JUOX@TQ+N[=KD!7=2IQU^4#^E)R7<N-"K9^Z_N\T;]%9/_"2:5_S]
MK^5'_"2:5_S]K^5/F7<CV%7^5_<:U%9/_"2:5_S]K^5'_"2:5_S]K^5',NX>
MPJ_RO[C6HK)_X232O^?M?RH_X232O^?M?RHYEW#V%7^5_<=5X:_Y&K1_^OV'
M_P!#%?1E?+.A^+-%M/$&FW,UXJQ1744CM@\*'!)_*O;/^%Q>!?\ H.1?]\FL
M:K3>A[&6PE"$N96.ZHKA?^%Q>!?^@Y%_WR:/^%Q>!?\ H.1?]\FLCTCNJ*X7
M_A<7@7_H.1?]\FC_ (7%X%_Z#D7_ 'R: .ZHKA?^%Q>!?^@Y%_WR:/\ A<7@
M7_H.1?\ ?)H S?&/_(RS_P"ZG_H(K!JIXF^(OA>^UR:XM]31XF50& /8"LC_
M (3GP[_T$$_(TQ'145SO_"<^'?\ H()^1H_X3GP[_P!!!/R-,#HJ*YW_ (3G
MP[_T$$_(T?\ "<^'?^@@GY&@#HJ*YW_A.?#O_003\C1_PG/AW_H()^1H Z*B
MN=_X3GP[_P!!!/R-'_"<^'?^@@GY&@#HJ*YW_A.?#O\ T$$_(T?\)SX=_P"@
M@GY&@#HJ*YW_ (3GP[_T$$_(T?\ "<^'?^@@GY&@#HJ],\'?\BW!_O/_ .A&
MO$?^$Y\._P#003\C7=^&?BMX,L=#A@N-9C2168E2I[DTF!ZC17"_\+B\"_\
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M_P */^$+\,_] '3_ /P'7_"MVB@#"_X0OPS_ - '3_\ P'7_  H_X0OPS_T
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M_H Z?_X#K_A1_P (7X9_Z .G_P#@.O\ A6[10!A?\(7X9_Z .G_^ Z_X4?\
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M.O\ A1_PA?AG_H Z?_X#K_A6[10!A?\ "%^&?^@#I_\ X#K_ (4?\(7X9_Z
M.G_^ Z_X5NT4 87_  A?AG_H Z?_ . Z_P"%'_"%^&?^@#I__@.O^%;M% &%
M_P (7X9_Z .G_P#@.O\ A1_PA?AG_H Z?_X#K_A6[10!A?\ "%^&?^@#I_\
MX#K_ (4?\(7X9_Z .G_^ Z_X5NT4 87_  A?AG_H Z?_ . Z_P"%'_"%^&?^
M@#I__@.O^%;M% &%_P (7X9_Z .G_P#@.O\ A1_PA?AG_H Z?_X#K_A6[10!
MBQ>$/#D$R31:)8)(C!D98%!4CD$45M44 %%%% !1110 4444 %%%% !1110
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M7_#6HI?*R:/I[VCILYE=]Y9\]N7)K(TSX7^*='TF[TBP\6QV^GW4KR2*EO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,'L;FV<"6%N<G)!SNR=P((.:M>'O"T&A7%Y>R7MUJ&I7FWS[R[8%V51\J@*
M%49/ '>MZB@#*M= M;3Q+J&NI),;F^ABAD1B-@$><8&,Y^8YY-:M%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>trda-20211231x10k021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $$ Y # 2(  A$! Q$!_\0
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MLUEI]U&[2SHI(^=@< G'&,?AUKTO4K)-2TN[L)&*QW,+PL1U 92#_.O'-/\
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M*** "BBB@ HHKR'XY^&M+FTFV\2/"QU2&>WM4EWG C\PG&WIU8\T >O4444
M%%%% !1110 4444 %%%% !1110 445D>(O$=AX8TY+[4/-$+2I%F.-G(R>2<
M#H!DGV!H UZ*16WH& (!&<$8-+0 5#=VL-]9SVERF^">-HI$R1N5A@C(Y'!J
M:B@"GI6EV6B:7;Z;IT/DV=NFR*/<6VCTR22?Q-7*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ***\C^/WA[3;OP5+KTT+'4+(QQ02!R JM(
M 1CH>M 'KE%%% !1110 4444 %%%% !6?K>B:=XCT>?2=6M_M%C/M\R+>R;M
MK!ARI!'(!X-:%% #8T6*-8T&%4!5'H!3J** "L?Q%KZ^'K."X:RN;OS9UA"V
MX!(SR2<GH%#-Z?+R1UK8HH Y'6/AIX5U_4IM1OM.D%Q<A?M/E7,D0FQTWJK
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M 'T?\*/^%J>!O^AFL?\ OH_X5V%% ''_ /"U/ W_ $,UC_WT?\*/^%J>!O\
MH9K'_OH_X5V%% ''_P#"U/ W_0S6/_?1_P */^%J>!O^AFL?^^C_ (5V%% '
M'_\ "U/ W_0S6/\ WT?\*/\ A:G@;_H9K'_OH_X5V%% ''_\+4\#?]#-8_\
M?1_PH_X6IX&_Z&:Q_P"^C_A7844 <?\ \+4\#?\ 0S6/_?1_PH_X6IX&_P"A
MFL?^^C_A785Q_P 5/^27>(?^O0_S% '84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5Y;\<=2L$\)0Z:U[;+?O>6\JVIE42LF\C<$SDC(/
M..U>I5Y7\<=)T]_"T.K/90-J,=W;PI<E!YBIO)V@]<9)_.@#U2BBB@ HHHH
M**** "BBJ]\2-/N2#@B)L$?0T 6**\K\ >!- UOP'HVI:C%?37EQ;AY9/[3N
M5W')YPL@ _ 5TG_"K_"?_/I??^#6[_\ CM '845Q_P#PJ_PG_P ^E]_X-;O_
M ..T?\*O\)_\^E]_X-;O_P".T =A2$ ]1FN0_P"%7^$_^?2^_P#!K=__ !VC
M_A5_A/\ Y]+[_P &MW_\=H ["BN/_P"%7^$_^?2^_P#!K=__ !VC_A5_A/\
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M1_\ @VE_QH_X5;I/_09\1_\ @VE_QKN** .'_P"%6Z3_ -!GQ'_X-I?\:/\
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M'_)*-?\ ^N2?^C$KN*X?XP?\DHU__KDG_HQ* .XHHHH **** "BBB@ HHHH
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M_(FZK_UP/\Q6]6#XT_Y$W5?^N!_F*<=T9UOX<O1GS]11176?*A1110 4444
M%;W@O_D<M*_Z[C^1K!K>\%_\CEI7_7<?R-*6S-*/\2/JCZ!HHHKD/J@HHHH
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MI&VV(YP6 />O/ZOZ'_R']-_Z^HO_ $(4.$>Q4,56<E[S/I"BBBN4^D"BBB@
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M*M7LH0YN;V]O6^R1YC8!=K &1LD<#IG/:MSQ[%I6H^*=(TNYO=?BNY87D?\
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M344459(4444 %<YX\_Y$G4_]Q?\ T-:Z.N<\>?\ (DZG_N+_ .AK3CNC*O\
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M1_'Z+6F\%2RV]S:KHZF,74+H3*[^8-I4] !QFO7*\W^.O_)*-2_ZZP?^C%H
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MJ]5 TB1E7.%!]P,D<@<],U6^']Y8W&K72VOQ N/$CB#)MY0H$8W#Y^!^'XT
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M71USGCS_ )$G4_\ <7_T-:<=T95_X4O1G@=%%%=9\L%%%% !1110 5T?@/\
MY';3/]]O_0&KG*Z/P'_R.VF?[[?^@-2ELS6A_%CZK\SWRBBBN0^I"BBB@ HH
MHH X#Q7\,AXFUBZNH]<N;"SU%84U2TBB5A=+$24PQY0C.._TK5TWPE-:^-;G
MQ#=ZAYR+;"RT^T2,(EK#D$C_ &B2.OI^E/XH:K=:1X;M);?6?['AEU"&&ZO0
M@9XX6W9*#N<A?PS6?X!O+"XUV=+7XAW/B-Q;,3:2A<(-R_O.!VZ?\"H ]&HH
MHH ***S-=UZP\.:<+[47D6$R)$HBB:1F=CA5"J"22: -.O(_C]IE[-X*EU&/
M5IHK. QI+8J@*3$R##$YX(KN'\=Z!%J6G:?-=2Q76H)&\,<EO(I7S"0@?(^0
ML00 V#D5S?QU_P"24:E_UU@_]&+0!Z11110 4444 %(5# JP!!Z@TM% $7V:
MW_YX1_\ ? JAK%O"NFN5AC!WQ\A1_?6M2J&L_P#(+?\ WX__ $-:PQ$8^REI
MT?Y&U&3]I'7JBU]FM_\ GA'_ -\"@6\*L"L,8(Z$**EHK7ECV,N9]PHHHJA!
M1110 5@^-/\ D3=5_P"N!_F*WJP?&G_(FZK_ -<#_,4X[HSK?PY>C/GZBBBN
ML^5"BBB@ HHHH *WO!?_ ".6E?\ 7<?R-8-;W@O_ )'+2O\ KN/Y&E+9FE'^
M)'U1] T445R'U04444 <WX^U631? ^IW\4$$TD:(JK<+NC4LZKN8=U7=N/TK
MC=%@O?#'C/0K>77],UY-6,BE8K"&&6W(C9_-C,?\!QM.>,'BNY\97$MIX/U.
M>*6PB9(<YU$9MV&1E7]F&5_&O)OACK&EZCXYM4T;PYIGAQ3;&:X68LUQ>!E;
MB L.(P0&..H7TS0![M1110 5@^--%G\0^$[W3+9+>26;81'<.Z(^UU8J60AA
MG;C(_6MZB@#QM_A?XE_LM+6.YL-M[:2V-U&\\CBRA>X$JB)B,R;5ROS8YQVJ
M_P#$[X?:;<:'XB\1MJ.K"Z%J\WD+=8@RJ8 V8Z<<BO5:Y#XGWUI:_#O78KBZ
M@ADGL9DA220*9&V]%!ZGD=* +_@3_DGGAK_L%6O_ **6N@KG_ G_ "3SPU_V
M"K7_ -%+704 %%%% !1110 5P_Q@_P"24:__ -<D_P#1B5W%</\ &#_DE&O_
M /7)/_1B4 =Q1110 4444 %%%% !5#7/^0!J7_7K+_Z":OU0US_D :E_UZR_
M^@FFMR9_"SYOHHHKK/DPHHHH **** "K^A_\A_3?^OJ+_P!"%4*OZ'_R']-_
MZ^HO_0A0]BH?$CZ0HHHKC/K HHHH **** "BBB@#B_B1?3VVEZ98P2V=J^HW
MZ6OVZ\A66.URCMOVMP6.W:,\<UF>"Q=:)XVN_#D^IV.L(=/%XMY#:1PRPGS
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M0!O>!/\ DGGAK_L%6O\ Z*6N@KG_  )_R3SPU_V"K7_T4M=!0 4444 %%%%
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M^1)U/_<7_P!#6NCKG/'G_(DZG_N+_P"AK3CNC*O_  I>C/ Z***ZSY8****
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M )"]I_UU7^=4JNZ1_P A>T_ZZK_.M*'\6/JC.K_#EZ'H=%%%?<GR@5@^-/\
MD3=5_P"N!_F*WJP?&G_(FZK_ -<#_,4X[HSK?PY>C/GZBBBNL^5"BBB@ HHH
MH *WO!?_ ".6E?\ 7<?R-8-;W@O_ )'+2O\ KN/Y&E+9FE'^)'U1] T445R'
MU04444 %%%% !1110 4444 %<O\ $C_DFOB/_L'S?^@FNHK@?B]J6IV7@74(
M+#16O[>YM9DNIQ.(_LJ;?OD$'=U/ QTH WO G_)//#7_ &"K7_T4M=!7/^!/
M^2>>&O\ L%6O_HI:Z"@ HHHH **** "N'^,'_)*-?_ZY)_Z,2NXK*\2:!:^*
M/#UYHM[)-';72A7: @. &#<$@CJ/2@#5HHHH **** "BBB@ JAKG_( U+_KU
ME_\ 035^J&N?\@#4O^O67_T$TUN3/X6?-]%%%=9\F%%%% !1110 5?T/_D/Z
M;_U]1?\ H0JA5_0_^0_IO_7U%_Z$*'L5#XD?2%%%%<9]8%%%% !1110 4444
M %%%% !1110 4444 %>;_&__ ))^G_80M_\ T*O2*\A^.>I:FFDVVFIHS/I;
MSV\KZGYX 23S"/+\O&3P <Y[T >O4444 %4-:_Y UU_N5?JAK7_(&NO]RL<1
M_!GZ/\C2C_$CZH\^HHHKX@^K"BBB@ HHHH *OZ+_ ,AFU_WZH5?T7_D,VO\
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M;\#UNBO-_M'QD_Y\O!OYW'_Q5'VCXR?\^7@W\[C_ .*KH,3TBJ&N?\@#4O\
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MXC?W?#__ '^D_P */:Q#^SJ_D8=='X#_ .1VTS_?;_T!J@_X5?\ $;^[X?\
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MX-_.X_\ BJJ:I;_%[5M,N+">T\(K%.FQC&TX8#VR336Y%2+E!I=4>9T5N?\
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M 2%!"Y(Y[4 =]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKI31ZQ;NNK.T=B5R1,ZD KTX(+ 8..M6X_$VBRZU?:0NH1?;["(3741R/*3
M.XL1C&&'?O7D_BOP)<:9_9-M:337U^D6IZHUUY6W==AH)5PJ\)DH  />LU=
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH KSV-O<W-K<S1[I;5V>%MQ&TE2I.!UX8CFK%%% !1110 4R&&.WA2
M*) D:#"J.PHHH BOK&WU*QFLKN/S+>="DB;B-P/;(YJQ110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>trda-20211231x10k022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $$ XD# 2(  A$! Q$!_\0
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M%MJ5G(LD$Z;E9>GH?US5ZLWP_)=RZ%9F^LGLKD1[7@=U8KC@<@D<@9_&M*@
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M2DFD=;J)8?+;(!CC&.<8R3S0!V'B#XHZ-ID]O::;<6]_>OJ$-G)$'(VAVPS
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 -DC26-HY$5T8896&01[BB...
M&-8XD5(U&%51@ >PIU% !1110!'/;PW4#P7$,<T+C#1R*&5A[@]:BLM.L=-B
M,5C9V]K&3DI!$J GUP!5FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
M);>!;AKA88Q,X"M(%&X@= 3UQ4M%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&50"Y]3ZU+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKIZR)]6OXI+E$T2YE$4\<<;*ZXE1@-SCG@+SD'GCC.10!G[_ !Q_<T'\I?\
M&C?XX_N:#^4O^-:$6K7[W,<3:)<HC7+PM(77"H!Q)U^Z3QCK6O0!S&_QQ_<T
M'\I?\:-_CC^YH/Y2_P"-=/10!R#ZQXGTW5=,@U.'2FM[RX$!-OYFY>,YY.*Z
M^N8\5_\ (5\-_P#81'_H)KIZ "BBB@ HHHH **** "BBB@ KC[NQ33+K6)SI
MUQ>QRM!)&A+2;Y,ODGJ<#(_"NPHH \\@TJ:..14L[B2:XV-;2^5L6W;<2_!Y
M4?SK1U:X\2Z+=65Q+JUK<6EQ?1P& 6FU@KD_Q9[5V5<QXW_X]-(_["MO_,T
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MPE_T!(/^^G_QH_X5UX2_Z D'_?3_ .-=110!R_\ PKKPE_T!(/\ OI_\:/\
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M,8?\:/[=\3_]";+_ .#&'_&NGHH YC^W?$__ $)LO_@QA_QH_MWQ/_T)LO\
MX,8?\:Z>B@#F/[=\3_\ 0FR_^#&'_&C^W?$__0FR_P#@QA_QKIZ* .7M_$^I
MKK5CI^I^'I;$7A=8Y3=1R#*C)!"\UU%9FH:0+_5M+OS,4-@[L$VYW[EV]<\5
MIT %%%% !1110 4444 <-\20K6^DI;PZD^K-=-]B;3V571MC;LEN-NW/%5_
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MZXC_ -"%=/7,?$3_ )$#6/\ KB/_ $(4 =..@HH'044 %%%% !1110 4444
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MW^^W\JNG\2.3'?P)'E5%%%=)\X%%%% !71> _P#D=M,_ZZ-_Z U<[71> _\
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M%%% !1110 5S'A#_ (_?$W_87D_] 2NGKF/"'_'[XF_["\G_ * E '3T444
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MR*T0C^TMYI4[E*YQC P,5)XPU/5IHK6VG\/SV]J-1A NFN(F4@-P=H8MS]*
M/0**** "BBB@ KF/B)_R(&L?]<1_Z$*Z>N8^(G_(@:Q_UQ'_ *$* .G'044#
MH** "BBB@ HHHH **** "N8\%_=US_L+W7_H9KIZYCP7]W7/^PO=?^AF@#IZ
M*** "BBB@ KSKXM_\@FP_P"NY_\ 037HM>=?%O\ Y!-A_P!=S_Z":NG\2.7&
M_P "1Y+11172?-A1110 5N^#/^1PTS_KK_0UA5N^#/\ D<-,_P"NO]#2EL:4
M?XD?5'T%1117(?5!1110 5Y[XW\4:CI?B2VTZ'Q%I.A6SVIF\Z]A\TRMNQM
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MC9K:%FB):,F,$H3U(]*Y_P =?\@:S_Z_X/\ T*NGKF/'7_(&L_\ K_@_]"H
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M#K;:I'J5D9C<22',PY0QA0O7L>:9H-JFCZE>S-J]A)!<.6">=DC)SG)/OTH
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M@>L('_CPKIZCN+>&Z@>"XB26)QAD=<@_44 8X\&^&\?\@2Q_[]"C_A#?#?\
MT!+'_OT*W** ,/\ X0WPW_T!+'_OT*/^$-\-_P#0$L?^_0K<HH P_P#A#?#?
M_0$L?^_0H_X0WPW_ - 2Q_[]"MRB@##_ .$-\-_] 2Q_[]"C_A#?#?\ T!+'
M_OT*W** ,/\ X0WPW_T!+'_OT*S_  /;PVC:[;V\:Q0QZG*J(HP%'' KK*CB
MMX8#(88DC,C%W*KC<Q[GWH DHHHH **** "O.OBW_P @FP_Z[G_T$UZ+7G7Q
M;_Y!-A_UW/\ Z":NG\2.7&_P)'DM%%%=)\V%%%% !6[X,_Y'#3/^NO\ 0UA5
MN^#/^1PTS_KK_0TI;&E'^)'U1]!4445R'U04444 %%%% !5'5=*MM8M!;71F
M$>X/^ZE9#D=.0:O44 9!\.6#21.YN7,8 .ZX<B0 Y&_GYL>]9OC9%%KI!"@'
M^U;?G'N:ZFN7\;_\>FD?]A6W_F: .HHHHH **** "N8^(:E_ .KJJEB8AP!G
M/S"NGI" 1@@$>AH A^QVO_/M#_W[%'V.U_Y]H?\ OV*GHH @^QVO_/M#_P!^
MQ1]CM?\ GVA_[]BIZ* (/L=K_P ^T/\ W[%'V.U_Y]H?^_8J>B@"#[':_P#/
MM#_W[%'V.U_Y]H?^_8J>JU_?V^F6<EW<F00Q_>\N)Y&_!5!)_ 4 .^QVO_/M
M#_W[%<]X*C\J+6E";%_M>ZP,8X\PTO\ PL#P_P#W]2_\%%W_ /&JCC^(OAF1
MY$BGOF:-L2*NE71*G&<']WP>: .KHKG+?QSH5U<Q6\3ZAYDKA%W:7=*,DX&2
M8P /<\5T= !1110 5YK\7?\ CTT[_?;^5>E5YK\7?^/33O\ ?;^573^)')CO
MX$CRJBBBND^<"BBB@ KHO ?_ ".VF?\ 71O_ $!JYVNB\!_\CMIG_71O_0&I
M2V9K0_BQ]4>^T445R'U(4444 %%%% !6=J^L0:-;QR2Q3SO*XCCA@3<[M[#(
M'3GK6C61KVE7.I1VLME/%#=VLOF1F5"R'(*D$ @]": )'O[?4?#LMY;L3%+;
MNR[A@C@\$=B#Q5/P4P_X0S2>1_Q[BJ\?@31I;&VAU&!KJ:*,HT@FDC#9))^5
M6 QDFD3X=^%HT")IKJHX"K=3 #_Q^@#I]R^H_.C<OJ/SKFO^%?\ AG_H'R?^
M!<W_ ,71_P *_P##/_0/D_\  N;_ .+H Z7<OJ/SHW+ZC\ZYK_A7_AG_ *!\
MG_@7-_\ %T?\*_\ #/\ T#Y/_ N;_P"+H Z7<OJ/SHW+ZC\ZYK_A7_AG_H'R
M?^!<W_Q=8VG> -+/B/6A<Z?<?808?LFZZFVXV#?@[N?FH [[<OJ/SHW+ZC\Z
MYK_A7_AG_H'R?^!<W_Q='_"O_#/_ $#Y/_ N;_XN@#I=R^H_.C<OJ/SKFO\
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MZ 5[R+?3VSB&V..N%7BLC1]!BL=5UJXFBM62]N5FA4*"0HC53GCU!JO[-?\
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M4]237T$;6Q ),%N ."=B\4X6=FP!%M 0>X04.JVK%0RV$9*7-L8__"=^$?\
MH:-&_P# Z+_XJC_A._"/_0T:-_X'1?\ Q5;/V&T_Y]8/^_8H^PVG_/K!_P!^
MQ61Z1CKXY\).P5?$^C%B< "^CY/_ 'U6_4'V*T!_X]8?^_8J>@ HHHH ****
M "BBB@ HHHH **** /+(;CQ5J7CC45TZXOC;V>L)$Y,D0MDMPJLZ%2-Y;G@C
MU%<_X=\5ZZ;_ $Z6?5[A4NA>K(UQ+'+&2B.4(C0;T *Y)/7'O7M\=O#"TC11
M1HTK;Y"J@%VZ9/J>!56WT32K6X,]OIEE#,<YDCMU5CGKR!F@#@?AQKFHW6M2
MZ?J.IW%Y(]@MT,O'+$QW8+JZ %<Y'R,,]_6O3*JVFFV%@TC6=E;6S2'+F&)4
MW?7 YJU0 4444 %%%% !7#_$2]U*WFT*VT^2^4W5TR2)9.BR. N< N,"NXJ.
M2"&5XWDBC=XSE&902I]1Z4 >.ZCKOB[P]>::NI7LI<6+"6'Y6)9W=8V8@8R"
M%!QQS4FD:WJMXFFZ=K'B.XT^$P3RO>KL5I95D*A26!&  #C'->MS65K</OFM
MH97P!N>,,< Y'7WYJ*;2M.N(1#/86LL2L6"/"K*&/4X(ZT 97@C4KW5_"-C>
M7YW7#J09-NWS "0&Q[C!_&NAI$18T"(H55&  , "EH **** "N-^)>H7NF^%
MXY;"YDMYGO((B\;JAVLX!&Y@0..YKLJ@NK.UOH#!>6T-Q$3DQS('4_@: /(=
M2U36(9]$LHM6O,3FX:;_ (F,&X[0NT>9LVX]L9J]?:]K.F73Z)%J$TMQJT5N
M=/E=U=D);;* P&#C@YKT0^'-#,2Q'1M.,:DD(;5, GJ<8JRNF6"& I8VRFW&
M(2(E'E#_ &>./PH \\\7:WJL^IZ3INFQZW"3))%((E6%YRJ<,K2#!&1DU@WN
MO^+]$U 6VH7\K3M9) T:A3MF?[C9 QGU[<5[.\$,DL<KQ1M)'G8[*"5SUP>U
M,DL;2:3S);6!W)!W-&"<CIS[4 >3V.NZE>VFG6VJ^))]-1-*^T"Y78&N9@S
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MR&P:]'%O ,XACYZ_**<L,2J56- IZ@*,4 >?:W=:M8> 5M#'?O?21)(]TK$
M,S@E-W4=<51U.S\2:-9Q2FZN(P;T3Q6ZW#3%8U7+*S'J#R<5ZB5### $>AH*
MANH!^HH \FLM1U5XS)JE[>6^GW6H![F3>084:/<J _PKGTKM/!=S-<6=^//E
MN+&.Z9+.>4Y9X_KW&<@&NDV+@C:,'J,=:4    8 ["@!:*** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "F10Q01B.&-(T'14& *** 'T
M444 %%%% !3&AB>1)'C1GC)*,1DJ2,'![<444 /HHHH **** "BBB@!CPQ2,
MC21HS(=R%ADJ?4>E/HHH **** "BBB@ HHHH *9%#%!&(X8TC0$D*@P.3D\?
66BB@!]%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>trda-20211231x10k023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #* ZL# 2(  A$! Q$!_\0
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M^'(IK*XDGN=/2S>*PN"P !* DEE X)Z^U>GT4 >2VGPLUF#0_P"SY+W37?\
MX2%-7+QHT:E /F4)@[3GH.F.]=1XA\,:O=^-]#\1:3<6(-BDD,T5V'^9'QDK
MM_BQGKQ7944 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M66DK((.#G>=YZ^P&*]#HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M='.._O0!O45AV'A^:RFLI&UO4;@6PD#+-(")MQS\_'\/;%;E !1110 4444
M%%%% !1110 4444 %%%% !113)3((7,2JT@4[0QP">V3SB@!]%>4S>._$$6E
MQ32SV$=S$]]),HB)6;R)E01)D@\ACSUX'%7]#\>W\CZE<7\#WD$=NUTEM8V^
MZ:'$[Q>7C/S$A0><<YH ]'HKD_"GQ T_Q;J5YI]OIVJ65S:(LDD=_;B(X8\<
M;B:ZR@ HHHH **** "BBB@ HHHH **QM0\-VNHW5S<275]&\]O\ 9V$-P4"K
MG.5 Z-[U!-X1LY_.WWVI#S1$#MNF&WR^F/3/?UH Z"BD    [4M !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R_B_\ X_/#W_85
MB_K74#H*Y?Q?_P ?GA[_ +"L7]:Z@=!0 4444 %%%0W?%G-_N'^5 $U%>?>$
M/!/AG4?"NGW=YH=C/<2QEI)9(@S,=QY)K;_X5YX0_P"A<TW_ +\"@"]J'A]-
M0N;B8ZAJ$/G0^25AG*JG.=RCLWO4+^&$>1W_ +5U0%I(Y,"Y.!L[#V/?UJO_
M ,*\\(?]"YIO_?@4?\*\\(?]"YIO_?@4 =-17,_\*\\(?]"YIO\ WX%'_"O/
M"'_0N:;_ -^!0!KZOI46L6L=O+(\:QSQS@IC)*,& Y[<5?KA]>^'6B-I$O\
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M%]]<Z9X-UJ^LY3%<V]E++%( #M8*2#@\'GUK:KG?'O\ R3[Q#_V#I_\ T T
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M?_'G-_N-_*IJAN_^/.;_ '&_E0!A> _^1)TK_KC_ .S&NCKG/ ?_ ").E?\
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MMZQ>WVY .U3(JJPY^\4R>YZ5UGARR:PT*UA>$P2% SP^<TJQL1RJEB3C/;)
MKG=7T"^C\7MK4&E0ZA&\7E^6UVD?\)4[@T9)7!Z!L=]N>:ZC1H[F'38X[JUM
M;1EX2"U<ND:=AD@9_  4 <7\2?$&I:+>Z1'8:@]HLGF.X79\Y4H ,,#YG#']
MVN&;L>*A\.^)M;N-4U8(9M7FCBED>P#1QFWE6=D2,,0-N8P#AB>F>]>CLBOC
M<H.TY&1T-*%522% +<D@=: /+/ UY>WWQ:\43ZAIDFFW+6=N&MI)DD*^AW)Q
MS7JE><^'O^2U^*_^O*V_E7HU !1110!'/_J)/]TUSW@#_D1-(_ZX?U-=#/\
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MNQ\HW9\P9/ R#Q0!L^(O^2F>#_\ MZ_]%&NVKR^71]3TOXG>%3J'B&[U8/\
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MYXT1L;SQA !0!Z11110 5S-Y_P E&TS_ +!\_P#Z$M=-7,WG_)1M,_[!\_\
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MU6)Z,=K8'?% &3XB_P"2F>#_ /MZ_P#11KMJXGQ%_P E,\'?]O7_ **-=M0
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MM-IGA_2;R2562XN;FSAED3&-O^LZC&[ ]<=LUU^DQ30Z/917$,,,Z0(LD4(
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M^PK%_6NH'04 %%%% !4-W_QYS?[C?RJ:H;O_ (\YO]QOY4 87@/_ )$G2O\
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M-+'4%CS:Q6<L3ON'#%E(&.O8T ;M%%% !1110!S_ (X_Y$G5O^N!_F*W+?\
MX]XO]P?RK#\<?\B3JW_7 _S%;EO_ ,>\7^X/Y4 24444 %9'BK_D5M3_ .O=
MOY5KUD>*O^16U/\ Z]V_E36YG5_AR]#YSHHHKL/D I\/^NC_ -X4RGP_ZZ/_
M 'A0"W/IBQ_Y!]M_UR7^0JQ5>Q_Y!]M_UR7^0JQ7$?91V04444#"BBB@ KSG
MXG#1EFL6U;4$L]\$\,1N+ 7<;[MN0BY&V;@;6^O6O1J\T\3Z[<VWB6YMYM.:
M>-'DB5SI;SC[.UIN"[@I!!GP"/P/% 'H.F1K%I5I&GG;5A11Y_\ K,!1][_:
M]?>G7-_9V<D$=U=00/._EPK+(%,C?W5!/)]A4&AF0Z!IQFB$4OV6+?&$V!&V
M#(V]L>G:N8\<Z1?ZO?:9';:)'>6H;_2[A98TF6,,K"-"Y& S*I8CG"X')R #
MKX+ZTNY)X[>ZAF>!_+F6.0,8V]& Z'V-<#X5_P"2S>/?^N=A_P"BJ3P[X/UV
MRDU,&X7293 +:.\MMDK3L)Y)3*5(QRK[<-SRWL33^']I=V/Q4\<6]]J,FHW"
M1V6^YEC5&?,9(RJ@ 8&!QZ4 >I4444 %<[X]_P"2?>(?^P=/_P"@&NBK&\6:
M?<:KX0UC3[1 ]S<V<L42E@H+,I &3TH UX_]6OT%.IJ A%!Z@52UC4'TRP^T
M1P"9S-%"J%]@R\BIDG!Z;L].U %^BL(Z_<G0A?Q:<\LPN'MY(8V+A2LA1FX7
M<RC:3PN<=JU-.O8]1TZWO(F1DF0."C;E_ X'\A0!9/0US'@C_CRU;_L,7O\
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MDL6)QYG]XD_4U-#J^KVPQ!X$OHA@+A+JT' Z#_6=JZO(]:,CUH YG_A(=?\
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M[5L_\*UD^S[_ .U'^T_=V<^3MSG..N[W_2LB3Q3XFMX-6:4!H9I;A4C*R>9
MRVJ2 *X(^7=D8P#R>>U6[OQ;K-R+NW$R0RP7D*+:PP2B=4$T8W-(<J0ZD]AP
M>^#0!H_\*V\N:,Q:O=;2=TCL?G0_],S_  CTSG'O5C_A7+_]#MXP_P#!DO\
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M-;MI;$QPR,WV:3S%\R(B%9"C)@@]3SG\*GN?B#<R7(C@AMXEBOUA=%N%EF9
M^UMT> 8R>W)SF@"S_P (]XS%V,>)%+E"!=&$%4SV\K.&QZYYI_\ PCGCW_H?
MK;_P11__ !RM'P5XN/C#2Y;W^SY+,(X4!GWA@1GK@<CH1CBNFH XN'P]XY29
M&F\<6\\8.6B&C)&7'IN#G'UQ5:]\&^(=1DBE3Q$MDJ9#1-:BXW>^XL,5WM8/
MC+4KO2/">H7UBP6YBBS&=@;!^AX/XUA5PU.K)2FKVZ=#:G7G3BU'2_WG,>(=
M+U?2?#][?FZ686<1D","PFP.F ?EJ]8:!J\EI;M]N&V2,2;ER@7(SMVY-<[J
M?C+Q9X;FM'U-2;=O.=DE@C69X_D5"P0E5(=CT/2H;+QSX@?2_.O]6LK6^M80
MRVK6P)U!][*57G(QM"_+SDYKF_LS#VV?WFWUZM?_ (!V*Z'KB[7%Z0V[&WS2
M=OO[_2H'\.^.V=BOCRV52<A?[#C.!Z9\SFNSC8O&K,I4D E3V]J=6^'PL*%^
M5O7NS*M7E5MS6T.(_P"$<\>_]#]:_P#@BC_^.5S%Q\&M8NKF6XF\91F25B[$
M:2HR2<GCS*]"\8:E<Z1X1U34+-U2X@@9XV8 @$?7C\ZX"X\8Z[$--B76K?,[
M2F23S[,\*%P-^=G<\=:ZDVMCEG2A4^-7*Y^"FJ $_P#"8I_X*E_^.5C^&_A=
MJVOZ;)=OXG6V*7$L.PZ:&SL8KG[XZXS7H-MXEU4:V=+EWSM;C[9+)# ',ML4
M^4*%X+%\CCM61/XE\6RS:Q>V?FK86K2K_I%M&J1 1@K@[MY?<1D$8Q3YY=S+
MZK0_D7W&=_PI/5/^AQ3_ ,%2_P#QRNAT[P7XSTFQCLK/QW;I!'G:IT1&(YSU
M\RN=M/B+XBN;F1))K>VMT@CAFGDM\B&42*LLQZ?* P..E=_X/U>YU2WODGNX
MK^.UN3%%?0QA%G7 .<#(R"<9'%)R;W+A1ITW>$4C,_X1SQ[_ -#];?\ @BC_
M /CE=!H%AK-A;2)K.M1ZI*S921+-;?:/3 8YK7HI&H4444 %%%% !1110!Y[
MIWA;7X/$>JW4,D>GO-'*J7YVS^:S,I0F/(SM (P<>U1Q^ _&$6N3ZRGCJ 7L
MT*P._P#8J8**<@8\SU/6O1J* .(_X1SQ[_T/UM_X(H__ (Y4<WA_QNJ()?%$
M=^=X(,=JMIL]SACN^E=W6;K\M];Z+<SZ<5%S$OF*&7<& Y(_$4 <M_PC_C3[
M4P_X23!V_P#'SY0(;V\OH/3/XUA7:^,[7Q!8Z+_:$A6]BFDP),X*8.=^.,^F
M:NR?$NZMWLY1ITMS!JKN]GC"&.)<#/(^9B23@XX%.L/B!J#PV\=[:;9@RN7B
M=6\Y"6'3'RGY>@S]: +K:!XT\V'_ (J'=GHX4 0<="/^6GU-+'X?\;&:94\3
M);-Q_I#VRSB3Z1D@+^=95S\4+F&*'4!:VTEO]GDD>WM;D39/R[=SA?D(W<C'
M%=[X?U8ZYH=KJ+6S6QF7)B9MV.<=>XH YO\ X1SQ[_T/UM_X(H__ (Y4-UX1
M\;7L)AN/'ELT9.<#0XQ_[4KO:*4HJ2Y9*Z&FXNZ. M/!.LVD?EW.L1:@[G_6
M_9A!Y8_W03FLO6="UK0C9%M5MKP7=TEL!]A*>5N/WN'YQZ5U'CC4]6T^'38M
M(>59[FY\LB&&.1R-I/ <A?UKB-6\=>+](GFL[C[.MVUO&J!8@1'+RS$GD?<'
M3IFN)9=AKM\N_P#6AU?7:]DN;8Z>+P7J]L&:75(+W/ 5;;R=OOG<<U6_X0+Q
M/'>?:+7QC!;X;<B'24?9[9+C-1:/XOU6[U:Q\S4;662XNOL\NDK !+"FW/FY
MSN]\D8QTKTFJA@,/"?.HDRQE:4>5R.(_X1SQ[_T/UM_X(H__ (Y4-WX1\;WU
MI+:W'CRV:&52K@:&@)!]_,KO:Y'Q]K=_HNGV+:?<QV[SW2Q/(YC&%(]9/E'X
MUV'*U=69Q?\ PI/5/^AQ3_P5+_\ '*I:M\(=5TS2;J]7Q6LQ@C+B,:6HW8[?
M?-;T/BC6[GQ%%8KK5ND1@B(/FVGSLV[)ZY?D#[E:^D>+-3NXKNXN+>8QVB_9
M9%AMBQ-R,[F/HH 'M\U5SR[F'U6A_(ON.0LO@WJMW8V]P?%R(98U?;_9:G;D
M9Q]^IU^"FJJP8>,4R#D?\2I?_CE2-XL\:6NCQ:C(<P32(5:>WB4L,G<J!&.5
MVCJ<&C3O'NM:GYGVK5K32+=YI&BN9H%("!=R1\D#)'///I1SR[A]5H?R+[CI
M8_#'CN*-8T\?6P50% _L*/H/^VE._P"$<\>_]#];?^"*/_XY71^'-0GU3P]9
M7MRBK--'N;:I4'GJ >0#U_&M2I.@I:5;WUKIT4.I7ZWUVH^>X6 0A_\ @()Q
M^=7:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ J-X(9$9'B1D8Y92H(/UJ2B@",V\+=8HS]5'TH^SP[R_E)N8@D[1
MDD=#4E% #(XHX5*QQJ@))(4 9/K3Z** "FNBNI5U#*>H(R*=10 QX8Y#EXT8
MXQRH--^SP[D/DQY0DJ=H^4GT]*EHH **** &NB2(4=0RL,%6&0:K_P!F6&P)
M]BM]@.0OE+C/Y5:HH :L:*<JB@@;>!V]*3RH]K+L7#<L,=?K3Z* (_L\(SB*
M/D$'Y1SFG1QI$@2-%1%X"J, 4ZB@ HHHH **** "BBB@ HHHH **** "@\C!
MHHH C:"%@@:)"$.5!4?*?;TH%O"""(HP1T.T<5)10!"+6W"E1!%@YXV#OUJ1
M$6- B*%4#  & *=10 4444 -9%8@LH)4Y&1TIK00N26B1B>Y4&I** (U@B63
MS%C0/C;N"C./3-2444 %1S6\-PFR>))%Z[74,/UJ2B@"L-/L@R,+2#<GW3Y2
MY7Z<<5.$4 @* "<GCK3J* &&&(J%,:;1T&T8%--K;LA0P1%202I08R.E2T4
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>trda-20211231x10k024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $4 ZX# 2(  A$! Q$!_\0
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MHH=&N3'/),C/ ER()+B/O&K]B:X#3-1O-,\/>*+&PEUK2=3ALC.+'5G,HB4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBJ-MK.FW=VUK;WL$LZYS&K@G
M@X/Y&@"]152?5+"VO([2>[ACN)<;(V;!;/2K= !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-M!,T<(>0W*%5*,6PZD'<!G@KWKLX;^)S)YDD*8<A?WJG</7VK!_X5QX2_Z
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MJF?#4;?!D"9)"32JN23@!R .: .NHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!C2QHRJSJK-T!
M/6FFX@"LQF3"G#'<.#6?J?A^QU:^L[RZ$AEM&W1[7(&?<=ZSG\"Z-):W5NPN
M#'<S">3]\V2P/\O\* .C$L9D\L.N_&=N><4^LBW\-V%KK7]K1B7[3Y0AYD)7
M:!Z5KT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIK3_ .$BT3_H,Z?_ .!2?XT :5%9O_"1:)_T&=/_ / I/\:/^$BT3_H,Z?\
M^!2?XT :$G^J?_=-<I\-_P#D3X_^OB;_ -#-;3>(-$92O]LZ?R,?\?2?XU%X
M9TVTTG14MK*[%W!O=UE!!!W'/4<=Z -BBBB@ HHHH **** "BBB@ HHHH *J
M:G>26%B]Q#:2W<@("PQ8RQ)QW[5;K'\3V.J:EH%Q9Z/>)9W<H"B=@3M7/.,=
M\9H P9?B38)%: 6Q%S/<RVS123*@1HQEB6/!'3\ZNMXWM$UJ/3FM9=IECMY)
MPP*)*XRJ^_UK-'@S4(O#4&D6@TJ%%22.3? TF0P^^&)SNSDGUJ.V^'D]IJ-L
M$OT?3XY[>YD#H3*SQ)M'.<8. : .W;4+)'*-=P*X."ID /\ .K ((R#D5P'C
M_P *:#%X5UG58]+MUOUB,@N N'#9'.?6NVT[G3+3_KBG_H(H LT444 %%%%
M!1110 4444 %>>ZIH5EXB^*]S:ZCYSP0Z+!(B),R ,9I03P?2O0JR(]#">+Y
M]>\XEI;&.S\K' VN[[L_\#Q^% &/_P *S\,_\\+G_P "G_QH_P"%9^&?^>%S
M_P"!3_XUU]% '(?\*S\,_P#/"Y_\"G_QH_X5GX9_YX7/_@4_^-;7_"06?_"1
MC0\2?:S%YOW?EV_7\_R-:M '(?\ "L_#/_/"Y_\  I_\:/\ A6?AG_GA<_\
M@4_^-=?10!R'_"L_#/\ SPN?_ I_\:/^%9^&?^>%S_X%/_C77T4 <A_PK/PS
M_P \+G_P*?\ QH_X5GX9_P">%S_X%/\ XUU]% '(?\*S\,_\\+G_ ,"G_P :
MR_$?P]\/V/AC5KNWBNDF@LY9(V^U/PP0D'KZBO0ZQO%__(EZY_V#Y_\ T6U
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MTV.:&>35HHW/G,05*N2,$^PKTN@ HHHH **** "BBB@ HHHH **** "BBB@
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M1_PA?AG_ * =C_WY%;M% &%_PA?AG_H!V/\ WY%'_"%^&?\ H!V/_?D5NT4
M87_"%^&?^@'8_P#?D4?\(7X9_P"@'8_]^16[10!A?\(7X9_Z =C_ -^11_PA
M?AG_ * =C_WY%;M% &!)X+\,B-C_ &'8]#_RQ%9_PT18_!D*(H55GE  [#>:
MZYQN1AZC%8OA/1IM!T)+&=T>02R/E>F&8D?SH VZ*** "BBB@ HHHH ****
M"J]W?V>GQK)>W<%LC':&FD" GTR:L5RWCN+29-)M_P"U]1^PQK.#'(8%E!?:
M>"I5ATSVH >/%4-UXTT_2+"[M+JVFM)II6AD#E64H%'!X^\?RKIJ\^\#/ILF
MKRK87NAWGEQ$L]M9F"X4$]QT*_0"O0: "BBB@#F?B'_R3_6O^O<_S%;NG?\
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M_!9+_A1_PL?2?^@?KG_@LE_PKL** ./_ .%CZ3_T#]<_\%DO^%'_  L?2?\
MH'ZY_P""R7_"NPHH X__ (6/I/\ T#]<_P#!9+_A1_PL?2?^@?KG_@LE_P *
M["B@#C_^%CZ3_P! _7/_  62_P"%'_"Q])_Z!^N?^"R7_"NPHH X_P#X6/I/
M_0/US_P62_X4?\+'TG_H'ZY_X+)?\*["B@#C_P#A8^D_] _7/_!9+_A3[?XB
M:-/?6MHUOJD$EU*L,37%C)&I=C@#)&*ZVN0\>?ZSPW_V&K7_ -#H Z^BBB@
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M^P?/_P"BVK9K&\7_ /(EZY_V#Y__ $6U #_"_P#R*NE?]>L?_H(K6K)\+_\
M(JZ5_P!>L?\ Z"*UJ "BBB@ HHHH **** "BBB@ KA?B,VEWEBMC<:M%9WD"
M-=*KP&92H&#N4?7CD<UW5>;^,K+0I/%D3ZEXC&E>=$@GAGC"QW"JVX 2-@#G
MJ,T :'PQCMAHEU-%>FXN))@)U-L;?RV"@ ;#R.._>NXKAO!VHZ+!J5];0:_;
M:OJ5_.9Y#9+NCC & ,KD# ]3S6AXX-]'H\D^FZA-!<V\;RK#%*B&3 SDY!)
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M /D'W/\ UR;^58'P[_Y$+2O]Q_\ T-J .GHHHH **** "BBB@ HHHH ****
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MDA@7Z&M=ONGZ5\]ZYIMO%-=W8N"2T[X7'?<:TIP4GJ<6-Q,Z"3@KGM)\5>'
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MOG:M&9HG.U85A,K2'T"@'-;-<A\05L)=*MK>[L]2N9YIPEL-.D6.97(ZAF(
M&/6@#7\/:EI.I6LG]DQ"%(F"O'Y/EE21D<8]#5G4]$TO61&-2L+>Z$9RGFH&
MV^N*Q/ FGIIVE31C3-3LG,@WMJ4Z2RR\8!RC$8 XQQ754 9K^'](?4(;]M-M
M3=0J%CE\L;E X&/I3K+0]+TV[GNK+3[>"XG_ -9)'& S<YY/UK0HH Y#Q[][
MPW_V&8?_ $!ZZ^N0\>_>\-_]AF'_ - >NOH K7__ !XR_2N=KHK_ /X\9?I7
M.T 4M8_Y M]_UP?_ -!-7:I:Q_R!;[_K@_\ Z":NT *OWA]:ZKM7*K]X?6NJ
M[4 %%%% %>__ .0?<_\ 7)OY5@?#O_D0M*_W'_\ 0VK?O_\ D'W/_7)OY5@?
M#O\ Y$+2O]Q__0VH Z>BBB@ HHHH **** "BBB@ HHHH *Y#QY_K/#?_ &&K
M7_T.NOKD/'G^L\-_]AJU_P#0Z .OHHHH **** "BBB@ HHHH **** "BBB@#
MR'Q)JMYH?BN^@O\ 7?"MG!+&LEO'=::[N 2V2=IZ],DD@^@[^A>$M5L=4T"W
M^QZK;ZFT"+%-/ @0%P!GY!]W/7%<?XUO#8>*9O[/U9H[NZL5AN;;^QY;[9%N
M;:Z[/NDY;@Y!Q71>"= 72+22Z6[EN$NHH%C\Z$QNJ1QA1O!YW'DGIV':@#JJ
M#T-%!Z&@#D/AU_R ]1_["UY_Z--=?7(?#K_D!ZC_ -A:\_\ 1IKKZ .?U+_C
M]?Z"LN6YGCEVI922K_>5U _4UJ:E_P ?K_054'!H 6YNI5M49+*5V;JH*C;^
M)-0P2R2J3) T)'9F!S^1JW)-O3;BH: -G1_]3)_O5I5FZ/\ ZF3_ 'JTJ "B
MBB@#C;_7_$T_BJ]T?0K'29%M(8Y))+Z>1"=^<8VJWI3O/^(W_0/\+_\ @;<?
M_&JV[70XK7Q%?ZPLSM)>11QM&0,*$SR/SK5H X_S_B-_T#_"_P#X&W'_ ,:H
M\_XC?] _PO\ ^!MQ_P#&J["B@#C_ #_B-_T#_"__ (&W'_QJCS_B-_T#_"__
M (&W'_QJNPHH \_UKQ#X[\/Z7+J5]IGAUK:$C>(+N8O@G' ,8'?UKT"LKQ%H
M<?B+1+C2YIGA2;&70 D8.>_TK5H **** $;[I^E?-6KRN=4O(RQ*"XD('H=Q
MKZ5;[I^E?,^K?\AF]_Z[O_Z$:Z</NSQ<Y^&'S,\)=2/MC5&)Z  DT@MKVV0"
M2-5]"RD58AE:"9)4.&4Y%7-4U ZA.K $(HP![]ZZ=;GB)KE?<SUW;1NQGVKW
M_P"'W_(F67_ OYUX#7OWP^_Y$RR_X%_.L<1\)Z64?QGZ'3T445QGT84444 %
M%%% !7/^-)K,>&+VRO9GA2]@D@#K;//MRC$DJG/0'TSTZFN@KE/'NJ76BZ3;
M:C9ZI:6<\$X80W;A([L;6S%N/0D<@^H% &1X&UJ>\U);)]?6_2.#B/\ L*6S
M/&!G>WR_ABNSUK3H=6TBYLKCS3%(AW+'(R%O;*\X-<)\/?%5SXPU+^T[S7K1
M&:-Q%H=L.8AG&YV/+'Z#'->E4 >2?V1):^#/#C-;:[!J-E!.+5;.VWK'(2P
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M:)Z&@#B_AC*;CPS=S-%)"TFIW;F.0 ,F9"<''&1TKM*Y#X=?\@/4?^PM>?\
MHTUU] '/ZE_Q^O\ 054JWJ7_ !^O]!52@ HHHH V='_U,G^]6E6;H_\ J9/]
MZM*@ J"YN?LZJ1!-+GM$N<5S/C6ZDM1:E)WB#$\JY7-5]'\9:99:>D-Y<RM,
M"23M+?K0!1U?4+XZO+Y<MW$I;B,L5(_#-=O:7IG*H;6YC^7.Z1,"O,]6UFRN
M]9>:*1BDAW E&[?A762^.-$>S>(3R;BFT?NFZXI@=7N!Z$4M>:^$[B*;Q'"(
MVR<,?T->E4@"FR2)$A=V"J.22:=468KJ%AD.ARIP:3?1;C2[E-=<T\)NN+N"
M DG"RR!21Z\T]=:TMSA-1M6^DJ_XU!J-O:VVG31*A43#80#U_.G2"ZN;F&Y@
M"^4!D#=U]:P]JXKEEK+R-O9J3YEHO,TZ*@>ZCCN(X6/S/TJ>MU)/8Q::W$;[
MI^E?,^K?\AF]_P"N[_\ H1KZ8;[I^E?,^K?\AF]_Z[O_ .A&NK#;L\/.?AA\
MRG11176>"%>_?#[_ )$RR_X%_.O :]^^'W_(F67_  +^=<^(^$];*/XS]#IZ
M***XSZ,**** "BBB@ JKJ,ME;V$UUJ B^S6Z&61I%!"@#)/Y5:K*\326</A?
M5)-0@>>S2UD,\2?>=-IR![XH S_#_B;0-8O!!I\+07#([JLEL8F95(!Z@?WE
MX]Q72UYOX!T26RUAKR;2]23S(6,=Q>W\4VP-M) 5>03M7)/I7=ZMJ<.CZ9-?
M3I(Z1#.R)"S,>P % %VBN(D^(D8T?3+V+399);VWENC!O ,<49PQ)/?IQ[U+
M%\0;2XU2""&TE:REDAA-UN "R2KN48ZXP1D^] %SXA_\D_UK_KW/\Q6[IW_(
M,M/^N*?^@BN<^(=W;'P)K40N(O,\@C9O&<Y':NCT[_D&6G_7%/\ T$4 6:**
M* "BBB@ HHHH *\G\>_\C1+_ -<T_E7K%>3^/?\ D:)?^N:?RH YBJZ?\A"?
M_KE'_-ZL5*VFS0S2W#,NTHHP.O!;_&@"*O0/AITU'_@'_LU>?UZ!\-.FH_\
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M)LY9+&X)%]+!+&L@C_NKO8#GUJEX.\.N]V-6U"/5HKR*5G87_E@RNPQNPF0
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M 'JTJS='_P!3)_O5I4 <)\2O^/>P_P!]OY"O-Y7= -D32?[I Q^9KTCXE?\
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MOA]_R)EE_P "_G7@->_?#[_D3++_ (%_.N?$?">ME'\9^AT]%%%<9]&%%%%
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M>B?#3IJ/_ /_ &:O/Z] ^&G34?\ @'_LU '?U@>*_P#CQA_ZZ?T-;]8'BO\
MX\8?^NG]#7)C_P#=IG5@OX\3F+9$:4;R HYYJEJ*JE_;!2"OF$C'TJ>I8[)+
ME?,?JARG/>OEX:^ZD?13TU;'O<AX!%Y8 '0YJSH?_(8M_P#>K.(P<5HZ'_R&
M+?\ WJNA)NM"_=$UDE2E;LSNZ***^P/E0K&\7_\ (EZY_P!@^?\ ]%M6S6-X
MO_Y$O7/^P?/_ .BVH ?X7_Y%72O^O6/_ -!%:U9/A?\ Y%72O^O6/_T$5K4
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M/_J9/]ZM*LW1_P#4R?[U:5 '"?$K_CWL/]]OY"O.Z]$^)7_'O8?[[?R%>=T
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MLA0Y_!JEET?2YG:273;.21N69H%))]SBKU!Z&@#COANBQZ!?HBA475;P*JC
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MU('/_"4WO_@+!_\ $5<_L37/^ALN_P#P#M__ (B@#H.U>&:K_P AB]_Z[O\
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M2N-22^T]=/0L03"6/F[1W7[V[Z#-=??7GC5+V9+'1])EM0V(WEO&5F'N-O%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNC\J"B'&54XZ<4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>trda-20211231x10k025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k025.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $, YH# 2(  A$! Q$!_\0
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M=1OU$L4;G,4*+QR><%F/Y5S5%'LU9(.;4[74->BN+WQ!*;T/#Y*VELF[AUR
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M]J;+@.[,>LC@#C^E<M15..M[D\VAUNKW0/AA[74+[3[FZ69&LQ9,#A?XR^T
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M_P"%2>'O[]U_W\H_X5)X>_OW7_?RN?\ ^%[V6X Z'-[_ +\<?^.TO_"]K/\
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MNO\ OY1_PJ3P]_?NO^_E8!^.EJH);0Y0!ZW _P#B:8OQXM6'_(!E_P# D?\
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MX.!7)?\ "I/#W]^Z_P"_E=-K>NKHWAR76#;F58XP_E!L$Y[9Q[UYW'\<899
MB:!*2?\ IY'_ ,34?6_9>[S6*JU*,7^\-[_A4GA[^_=?]_*/^%2>'O[]U_W\
MK*O/C-%:QB1=#EEC[NMP,#Z_+Q52#XZ03R*B:!+ECC_CY'_Q-']H_P!\QCB,
M+*/,FK'0?\*D\/?W[K_OY1_PJ3P]_?NO^_E8-S\=+."=XET660*<;A< 9_\
M':2#XZ6LTPC_ +#E7.>?M _^)I?VCI?G*]MAK<WZ,W_^%2>'O[]U_P!_*/\
MA4GA[^_=?]_*PKCXXV\&T_V%,5==P)N /_9:@_X7U:_] &7_ ,"1_P#$TUF#
M:NI@JN&:NCI/^%2>'O[]U_W\H_X5)X>_OW7_ '\K+7XR1R&%HM#D>*49\P7
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M=V0.A[@U4%E<'I"Y_P" U?$\T&GVK1.R@A@<'OFK45XUY;+ 93',OW3G ?\
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M9S*'@<%L=U(&<C\JA-]9PD/!;N74Y'F-D5G9WY4M5U#EE?D2U6S.DT^VEL?
M.N1SQE3]L@ ST/7I7.,0$  Y[UMVEW/<?#?6VFE=R+V C)SC.:YU(@T6Z1F8
ML."#TKJ:E9<SMH=52+Y8N>]AEVP=50')'/TJH8P(RS'#9Z8[5;2-%&3D-]:?
M<.KV[;@,XP,"B$HQ5MPC+EM%$>FW#QR,!C!7!SW%69T&&>,@9/*#M]*SK=MA
MVX(-7LL>QQ14E*]GT)J1M.Z*9S3E/8]*DD7VIJJ :5]"[W0T *@XI0<=.*#]
MWVI.?I0&XN"23R0.II2-H-"DC(SP>M+(X?''(&,^M:6@XMWU_/\ K_,7404K
M#(R*C4_-BI%;S6* A% SDU,*<IR2B-D#DLVVEC&UN?2GQ(A8[\X/?WJ2$@$@
M\''YTY*T$[_YC<K(C'"Y-!8U*R*_/0]141 /S \=ZA-/82:8Z/YB,\XIY7<0
M,4R(X)]^14F>M)W3LR9;C?+&UE.3]3T]Z6>/:=I'(H'0_2EDY/OBAR;LNPKN
MY7 J51R/SIN*G"_NDP 22<_2GHW9E28SEJ>[,( IZ4!.:1Y%QY9Z]:CJ1NR-
M&*N*D<C&,<TP(2P]*<V5[=:I)-ZL;W(1]ZO3?B,,_#OP.!U-N?\ T!*\S'WJ
M]-^(O_)// __ %[G_P! 2MJ?PR_KJ=5/X9>GZGF @<J7X"@XS37./D'0?J:?
MDKTJ,J=N[WI64OA1DO,3'O2=_:EHZ@U)0YJ0&G##+SQ2 <TA$ML0K$' SWJZ
M=L9#/GV7N:JV: W'/)4$J/4TY]S.2V<D]ZSE\1A-7D+=1I) TJ%@RXRK'/Y5
M &4@8Z^E3W#>5 J@X=^?H*JP$+*,CBJBO=*@O=+4<2CF0Y/IV%2B3:,#CV%-
M)"]34"RM(Q5%P,=:BS:NR+.6I<W9')J"25$_BR:C^S[@296#5']EV*Q+9IQC
M&^K'&,>Y!*-TS8<L/4U9@M)3 TY)6)3@DGK5>/!)8C//%7#?RS0QVH($0Y(
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M#$+>$;1G,ASR3Z?A3[Z(RV%M<=>"A]:J_O7>S+O^\4I;/0C:XL[H*LEN89.
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M:A%P0@4J#CO3#([=3@>U3RL7(R:2<*"J]:C 3RLGEL]*B/7CI4B!3&<EB_\
M"!TK2,>Q7*DAI.<X&/:E*\Y+ Y].U+A2I)^7 X I\3)LVE?FW9S[5HDK.[!N
MQ82&)D#=158A2Y*C*CM4MQL7! ZCD5"'QG;QGO4TZEJ?+;K<B"=KB8RQQT_E
M4]H +J'']]?YTP#BI[./==1,3P)%_'FLW+6Y5SZ5^(7_ "2V[_ZX1_TKYWTU
M 9)2[;(@AWMV]OUQ7T;X[B$WPTND+J@,$>6;H.E?-MY<1(GV>V),0/S,>K'_
M  J\5+]XE:Y6/]Z:@NJ"+$=P%:+#KR.>/:IY%=4:>ZSB3A5SRW_UJJ_Z^W7!
M/F0CCW7_ .M4U[*9Q&XY4H/PQ7&[W2^\XFFY(C5K9I 65T/]X'/YYHDB"[F=
M5V8)21>AJ!5>3"J"3T  ZU<0R6%N4<!99#G:PR5'T[$U;;ON5+39ZC5ADF*L
MH(3MO8 '\Z=<6TUI:E98RC%P1GN,=:ANV#2I(HP'0'CL>]7K3;>:?Y$S8$9^
M^3T!Z?D?YU,G)V?0SDW%*70RP[(P8<>XJVQ7RTE!P'.&'HU175M);2>6WW>H
M(Z&IX@BZ:_FJ2'D&,'GBJ]UV=RY--*2(26$@'4&I#>2QS%&(=0<889IHS;A,
MG?$>$9>Q]/K4L=H @N;ES%&>1N^\_P!!_6H=K7:T);CU+4,5S,Q>/[/%&O66
M10H'L/4U&83<S _;!<1Q_-)&%*Y'MZU0N;U[AL E(EX1,\ 4MC*Z7\)7JS!3
M[@\4G"5N;8GV4DG+8<MZYERRJR'@ICC%3:A"&43Q'<A !]1]:+BQ$;[XB6@<
MG8Q]C@CZBI+622-957 (&5)[&ES+240<EI.!1AM)I<%8R$_O-P*OPPP6SY2=
M);D E0OW0?ZFJ<DEY<2 3/*Y]"34EM;2_;(\@K@Y)QTJI-M.[*G=KWF5&F9M
MX)R6.235K3]T33RJ<,L3=/RJ:73S^]/ )/R#ID9_2IK:RD6SGA15,LNT;L\8
MSTS2E5CRZ"G5@X61DGGFM*QN'2TD4D;4;.2,\54GMI(&*.A5AP015K3T+6=Z
M>F(\\T5&G&XZKC*%_0H.T#LSNLK,?5JN6\,*6#7R*5\MPA4MDDGI^'6LT YP
M3P:T;]39V-O9'[Q_?/[$C 'Y5;;C*/*];EU%M%/?\BL]_/)*"&V\]%&*N7]S
M#-=N+E2"H #)WX[UF6\;27"*.N>M6KJ)[J8O A<=&VCH:<HKFNPE""FNA&]\
M%79:Q^2.[9RQ_&H[-LW:EB><Y-)+:3Q %H74'U%+#&8OWTH(0=!ZFG:/*[&E
MH<KY>I'# ;BZ6%,_,V/H/6ME;&!E#>8W(S52SN888+GR(S]IE4JK-_"O<#W-
M(MQ/M'R#I34'4=G-1MWO^B9E4YY/32Q8^T6^H(L5VH67HLZCG_@0[U VG06\
MY2ZO$7'4("33HK"83)O 52?O;ABJ-[)YMY,^#@L<9K**O*T7H*G&\N6$M"U-
M)IL+@012S^\AVC]*/[7>3"301- .D8&-OT-9PQWI*U5-=3?V,>NIOVL%K);R
MW$4Y1=I1D89*YK/?2YDA,J,DJ*,G8V2/PJ32$:1YXP#AX\>V>U7H;5K.7S9Y
M%A5#R,Y)]JRE44)67_#G*YNE-I,PXHFE?:HR?Y5<O"D-K!;1'(_UC-ZDU*=3
M$1(M[>)5/7<,DBK 2UE@CFN8B(2,+Y1Y![CGM5SDK*3W[&DZDKIR6AB<U:LK
MIK60Y&^)QAT/1A6FEEI;EGC:=E1=[(2,D#K4)U6TC)\G2[<#L7)8TI2YE;EO
M]P.K[1.*BW^ DNF2N6EM$::'KP.5SV-3:+;RKJ22.A6.,,9"PQQ@\4^&^DOX
MF\@+#<(=^V,D;QCL/44MO>7-P=UPY>"($LS'&.,=?6L'*IRN+_X)SRE4<'"7
M_!*$%]/;$A'RA.2C#*G\*GU>8RV=JT0"6[ DH!P'[U%]FB<GR;J%_0,=I_6K
ML>G/-I\MO(R1ON#1[V !/?FKE.$6FRY2IQDIF KLC!E8JP.01U%:4=W;WP"7
MJ[)>@G7O_O#O4%QI-[;#<]NQ3LZ?,/S%-ATZ[EE5%MY06Z90@5K)PDKW^9T2
M=.:YK_,U+>S2"WGC\U#+* J9. 1FJRAK5WANHG$,@PP]/0CWJ'4V4WFV,\1J
M$S[CK4<&HW, VA]Z?W'&X5FH2:OW,HTYN/-O<+RRDM2K$AXGY1QT84RTNY+2
M;S(\=,,IZ,/0UH?;[2]M5MKE/L^PEHWCY )ZY'I56XTN>%/-3$T)Z/$<C\?2
MK4TURST+C.ZY*N_YDT^G1W$)N;%MRGEHSU7VK*(*D@@@CJ*T+,S6LC,RLJLI
M7:1]XGH /K5R.SD:.6>ZMDEFC7)C5_F/.,L!Z4U+D6KN)5'3TD[KIW*>G6V_
MS+B5Q'"BD;CW)["K5K90SVK;IU:&,@>9C#+GV]*S[J]DN=JD*D:_=C08 JWH
MLH9Y[1CC[1&57/\ >'(J)J7*Y,553Y7.]O\ (EDT"=E,EK)'/$.K!L8^N:KM
MHM\N#Y!(/3!!J2"YEMI3C[IX=3W]C5R:UG\KSK1I&MR-QP>1[4N><5JT9^UJ
MP=FT8DUM-;OMFB=#_M#%:%Q:W%[I\-W@,X4H1GEE7OCO4MM?S!ECE43Q[O\
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M ( E>:=^!Q7I/Q&_Y)UX)_Z]S_Z E=-->[+^NIWT?@DO+]3S.*/>?7'6KLG
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M]"7RT&<C//!IDBJH&.E2$'@4V0GTXKFO=DINY 1QD#BEC81L'(SCH*=@C,8
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M \X]JC@."1ZT 27,W3)-$D,D3 ,*V2TLS=62Y7N2Y&#49.33MA53D\TSO4I
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M@!&!R%]/6C)P44@IU.?:NETXQO:[YMOEU^;^[7<BVMRNPPYJPA=8SCY=PYJ
MG+'TJ9I"T3;1@8'>N7E<MBY:V(O,8;><A>E,W%C[9S1MX% &*IMMW9=D3B<8
M''(%.MW+7D))_C'\Z@J:V/\ I4 X_P!8O\ZE)$I)'U!XZ*+\-+EG)"B",\?A
M7SDU_#,S+<VZNIR5*G:P/UKZ)^( +?"^[ _Y]X_Z5\RMU-7B4G-7[%XVG&51
M-]C8A$0L9O*5@KX(9SDG!Y%93_?-:,1?^S@$*O&J[PH/.[O^E51!YS(RD!6/
M<]*XJ>EV>?3?*Y-EJS5(+&:Z<;B/D13T)-0H;:Z&R14A<])$&!^(_P *6^;:
MJ6R A(N/]YNYJIG:*(QO[W<<(\R<KZLLS6,EC(XF'W0"N.A]Q6>SDL3ZUKPW
M N;;R9\D1J2I[X[BLJ2(HY';L:UBV[MFE*3=U/<E1V:S9,]'!_2M>QNI3IDD
M4?WE9=S'& HJC:Z;/-9M( %4D<MP,"I+B);?35\N82%GPY4<5G6@KJ+ZV9E5
MY)OE7<BU%6^U/,HS&YRK+TIVFS7$EPD2R/M&20#V%0V[RRV\ULI)5AN"^XJW
M':W=C =D;B:4;3@?=7_Z]$K*/+U'*RAR.U^A=2(W-CN=51K8$KM48.>Q(K&M
M5EM;OS\[57)_WO:M!1>V>F2QQLOEO_K0I!(K+B1IFPS$(.35T^>$>9/3I^MB
M:*TEJK#[2W^T2G>2(ER6;VJ^D-M?L+=$$4@^X<]?:DF?R=.BC4!1(2<8["J*
M2LDP=3@J<@BI^)W*?-4O).W8;<VCVLC1N.0<57!.:W[I4N;:*Y52QD?;*/[K
M8ZBJ*Z=EPR2(Z9R<'I353^;0JG73C[VX\7-L\D,5Q"S%5"F16P?RJI<W(D<I
M$NR%3PH[^Y]33Y83%NGDX9R=B_UJM%&TL@506)["B,8K4J$(KWC1L)A.C64S
MXC8$H2/NM_\ 7IQ>UA'D1J9'8X9^GY4V**"RD5I'\R3^XA^[]33KN."T<3H^
M\O\ ,BX_G63LY:=3%\KGI>S_ #*5S,R.T* (HX.WC/UI+$$W:?SHG;[3$)<
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M D$$$4]G8228. 6(-*?-R<;S6L>62U;N.Y#+/+.VZ61G/N:N:)&'U6 M@*K
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MCFIV5=H<'ENHIF!DG ('2LFK%IDEM-*FY8P!N')/I2"%V'##Z4L9+9/M4H!
MSGFG[:22B]E?3S?_  R,V[/085(Z@ ^U"GGFGDC;GO43<GBL^9R=V"U).,#D
M GM2!2<TW;E"&SQT-,A$[_.&P/>E8+:$X1E887.> /6E).T#MVIQ263&93D#
MKMZ4;6VE6(..A]:GFNK$7(@>:]&^(V3\/?!?_7N?_0$KSC!#<UZ/\1<_\*\\
M%?\ 7N?_ $!*Z*7PR_KJ==#X9^GZGEX'>IUB+<%MM.152,'&2><TN<GK63EV
M,'*^Q6D0QN5)SCO30*EN#F4^PQ40ZU:V-$]!VXD<DX'2D-+3XXC(W!  ZD]J
M5[";2(ZFA08WGGTI9;8+&71PP'7CFEAYB^E)NZT)<KK0CN%'RL!@GL*C'"U)
M)(2ZLG1>E1')^IJE;E\RH[:C23N JRKN$ P.*B5"C@GO^E2<#DFD[!*S$CD&
M/GR"3R:62:-48 Y)I3%E0['([ =OK2/$KCGCZ4FDGJ3[MR""0PMO&"1V-1SR
MA^,9;.<T;3'+M;%-F51)^[)9?4BNJ"?*Y7T_S\OD;I+FN*DNT^U3;T()W#VJ
MJ 1Q1G*X.....]2X7U8W%,ED^0]03[5(JJ8@W4Y^8^E5\E4*@@[@,TZ*5HVZ
M @=CTJU&"6MW_GT!Q=M!Z NC_, 5Q@>M#+PP<89>*B#@2AF4$9S@<4^28.H1
M<\\MGJ36W+1=*][-?CO_ ,!;]&#3N,*MLP1POM2$ #TJ=<[<-TZ\TR.$.>>E
M<]25Y:O8?-W&_?VJHQQZ]Z9@C@U*8&,RQJ1SSDTR0;,+OW'O6_LI2H^V2TOO
M_P  ::Z$ZG@#C & *6 8OH0!_&O\Z!R >G%%N^;V(C_GHO\ .N5RE*5V[D1W
M/I[QNS+\-KHJ0&^SH!GUXKYL@LW\\-, %#9()ZU]'^/7$?PRN7;H(8S_ "KY
MLG5]X<$NC=&%7B_C^1KCD_:*W5%NXBE99.0SOP #5I;9+NV2,$K<JO1^ V/2
MJ5G!(UTAVMA?F/'I4\?VB:1W?(C;)W/P!^-<?-%1<>O<\N=UHGL9DR%92K=1
MP:2.-G=54$DGM5_R!.[-,I1U.&8,,,?7FGQ9LIT:)"(R<-*Q!Q^72J<VE;J;
M>UTLMQ;J[,$RP'!5%"MQGFJUY$CHMQ",*QP1V!J"X5Q,V_[Q/)J6U8E9(6SL
M9<\=CVHL_BOK^8E#D2DAEN^(9%925)7./K4IM9%FW(<(#D29P!3HF^RQRNI^
M=6VC([XZU!]ND/R28D3NIJ^:3E:6R*]YMN(_5)GDE5<@H!E<=\]ZI1QF215'
M4G%:K) MFCMB5/X>#E?8T6YASOMX!YHYRS\*/6G)>S?+;\4UK_6HHU.6%DMA
MFK.(S%:(?DA7]3UK.7K5_5;>3[1Y^/W<HRK Y'TS4-G;2W%RD<2%V)Z 5$7&
M,-RJ4HQI)W)]6^6:&(?\LX(U^AQG^M9ZCFMS4M*N;J[FGM]LJ,WRA9 6 ]QF
MHH]$N(%9[H+&BC)^<$X^@-13JPY4KZF=.O3C32<M2*-#;:=+*<AY\1H/]GJ3
M48F,FE21D\QRAQ^/%+J4A:ZP#\BJ F.F,4P@1Z:P(.Z1P!]!3MI=[MCBKI2>
M[?\ 7X$UE=).I@NE,BX+*V?F!'O4CO#>6$WE1['BP0H.<KT_.JEDBI'/.YP$
M0A?=CQ4NER>5-+)C)2)FQZXHFKOFOM84X)-RCT*<>4WR^@P/J:LQ"*>R<SLW
M[LC:WMZ5))?Q764DM452VX^5\O-,N3;)";./<KA@V\GAO8TY:NW]6+;D[)JS
M*-Q.)7 0;448 J9XQ.J@']Z!G'J*9]AE#[7VK[EA43N1<%E.-IP/PK7XMC96
M?PO8V+1$TZQ$\T8>24X6-NF!W-'DVNJA@JB"Y_AY^5O;VJK=,SQ1.2<%:KPL
MP88X.:QC&_O/<YU3;O._O#GTR=&VR&-&[AF&14D=AM)?SHFV<E5/-&L C5;G
M/7?DU%8<WL>>F<U5YN'-<TYINGSWZ$;$L/0[LFFE)L\2G'^]39G*N67H2: <
MBMHRE'5,V2=AB]*LV]Y);@I@/&WWD;I_]:FM&\'$D;*?1ABH"<FE92"RFM=C
MH;B[M[328S9AEGNERS$\HO3'XG]*P=Q)JW<D&RLUYW!#GZ;CBHK:V>XD"*..
MK$] /4U":LY/^K:&-&,:<6WW8R&>6"3?&Q!_G6M:&UN+:XN&LX6GA&XJ20K
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MHVRPVK&1]_ZCTJ(J,Y+6VO6_X_\ #$WC9.&ZZ&+TIM;XM;744*PP>3=')PC
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MFJW&X>YIS=14O435RREL^[Y_D ZEN *AGD5\)'G8O0GJ3ZTPN7C(:0\'@&D
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MCC)ZU2N9?/N6?MT ]J= S1L2#M/2M5&\5S?,U</W:74L._V+(&#.1C'79_\
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M@\VY+2G9'&HRQ[_3WI0R2J4AB,4 ^\S').>Y_"G7[/<W\@!) 8A5':J^H/\
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MC!]%YK0L;=QYB/ #"IQO+87'6E.:DK+U^XFM6CRZ&2&9&X_/TK7M=6,Q6._
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6+'K5:38)7 C3@GM5IWO;H7"HDK'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>trda-20211231x10k026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $$ X # 2(  A$! Q$!_\0
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M *X)_6N(KM_BK_R.C_\ 7!/ZUQ%>[0_A1]#S:GQL****V("BBK^DZ9_:MQ-
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M<<$^]<[115QC9$MW"BBBJ$% ZBB@=10!T7CO_D<K_P#[9_\ HM:YVNB\=_\
M(Y7_ /VS_P#1:USM9TO@CZ(J?Q,****T)"BBB@ K5\-74%EXBL[BYD$<*.=S
MGMP16512:NK G9W.C\VQT?3M4BAOX[RZU!! /*4[(TWAB23U/ &*FU./3[70
MUL]-U6UDC&)9QAM\[^G3@#L*Y:BHY.MRN8Z/2M;M[>[GOEM[>RG@LY5M_(#?
M/*P"CJ3R 2:N6.MVT$OA^&2\8V]D'N9LD\S') /J>GYUR%%#II@IM'9Z??Z9
M)!H,UQJ2VZ63RRW$ !WO,7+!N.Q&T9]J6PUNSMM/O[=KPB[U!99UG XMI,'
M'NPR"1ZUQ=%)TDQ\[-!=5\M;0P65O!-;LKB:,'>Q'KDXKI[GQ!I-IK.DRV9,
MEH+PW]TH7I(W&/?:,_G7$44Y4TQ*31VL>KV]IJ-D/M6G&T%Z+AS;J^[O\QW=
M.M4M/U>W2Q=+BY)D.LPW0W$GY &W-^HKEZ*7LD'.SJ[BZL=4L9;==22S>*_E
MN-SAL2*QX(QW%2Z;K=A:'0Q)*K^3:W,$K,I(C9W8J3WZ$'CUKCZ*/9*U@YWN
M;FO7GF6UI9I+8O#"695M V%SUR6K#HHJXJRL2W=A1115 %%%% !5S2?^0Q9?
M]=T_]"%4ZN:3_P ABR_Z[I_Z$*3V!;G5_%7_ )'1_P#K@G]:XBNW^*O_ ".C
M_P#7!/ZUQ%94/X4?0NI\;"BBBMB HHHH *Z*T^Q7OA2.QFU&&TFBO&E(E!.5
M*@<8KG:*F4;C3L=:D^BZKK,7VJZ$=CI]JD4(F!'VAE]<= 3U]JSK_4!%K$]S
M/]AU1IE!SAMB>@4<8P.*PZ*E4TAN1U]EK=I;W7AR'[3LM+"-KF8+G'GDLV/?
M^$4:1KMJAT^2_N"\KW\EU.S@ML.W"$_CS^%<A12=*+#G9UC2V":2FGOK(EEN
M+_[3=SKN(4*O&W/4DG\Z3Q!XBM=0N+*\AACFC$;*]G.#A7SC><8R6&#FN4HH
M5)7N'.[6.F@\0):>'72WBM5NFO\ SEB:+>(UV8!7/3FC3O$1L],^T23F2_&J
MI=,K=738P;/USC\:YFBG[.(<[.TN-7TFWGNK'3YB-.2RF6)B/OR2'/Z# _"J
M-Y_9NO&SO9-3BM)$MXX;B&53D%!C*XZY%<S125-+9@YWW-W5==M[O4;R6.P@
MFCD 2)Y@=ZJJ[01@]>,U<>+3[3PV;>QU>U\^XC#W;,&#MCD1+QP/7U-<M13]
MFK)(.8ZS3+Z"ST>:"[U6"XT^6W8?8ECQ)YA'R\XXPW.<UR8Z<]:**J,;-L3=
MPHHHJA!1110 4#J**!U% '6?$7_D;'_ZX1?^@"N3KK/B+_R-C_\ 7"+_ - %
M<G6=+^''T*G\3"BBBM"0K?TIK2X\-7^GSWT-K+)<Q2H90<%5# ]/J*P**F2N
MAIV.I#Z+?W>FZ;/?;-.L(6WSLI!F8G) ] >F:K:M?HFKK=,=/U",Q^7' @;R
MX4'"J.AXKGZ*E4TGN/F.HM]4M/L>BV)F$%NU\;J]2/(5/F&T>^%!_.IH_$-M
M<2W=S?3-(UWJ<<DB-DXA4D_ETKD:*7LD'.SLKJZL?L6K0G64FN=4NX][@-LC
MA!+9^O2HM<U^SO+*P^S8E6U<QR03C_7@#"R-C&>./:N2HH5)7N'.SK=%U>/^
MS=5CAN[72;B>6%HQL)3:H;<!D'U%/TO4!;:?JEJFMVT%W+=)(+ADRLBA3G''
MJ1VKCZ*'23N"FSI='N[./4]0L=4O%DLKL9DN$'REU.X,!^8_&J5SK23:Q>7D
MEE;W*S-\BS X11P,8([8K'HJN17N+F=K'33^(WM=%TJ#3V@6XBBD623R@9(B
M6/"L>G%3Z=K5E#9Z':W$N82EU;WRXY5)&!!]^F?PKDJ*3I1L/G9UMWKMH;74
M8;>3]W%);I9H1]Y(SR?Q//XTZ=]'G\2-X@_M1! \WVEK;8?-#=2GIU[UR%%+
MV26S#G9J7.J1WS3J]E:H]Q,7-P0V] 6SZX_2M36H]/ATJ*QTW5;:2TC8/( &
M\R>0\%CQT'85R]%5R;6%S'5W=_"OAFZL;O5(-0R$^Q)%'M:)@>6)P/X<C!S7
M*444XQY0;N%%%%4(**** /I'5?!^B:U>F[O[,2SE0I;<1P*I?\*Y\+_] X?]
M]G_&N*M_%'B&:X2..^D8L0%! _G3M0\:ZM]I:.UN2@0;=^=P<^H';O7']0Q"
M?*I_BSZ!Y:^:VAV?_"N?"_\ T#A_WV?\:/\ A7/A?_H'#_OL_P"->?+XTU_=
MM^WR'GJ<?X4R?QOKXG*IJ+X7C 4<GO\ K3^H8G^?\6/^RWY'HG_"N?"__0.'
M_?9_QH_X5SX7_P"@</\ OL_XUP%MXX\0KE7OBV]2/F0$CCJ/>JO_  FOB(;L
M:H[!3MR ,''OCFE]1Q/\_P"+%_9KO9V/2?\ A7/A?_H'#_OL_P"-'_"N?"__
M $#A_P!]G_&O/G\7>)7TTSQ7TKK&^)&4#Y01QGCZU57QUX@\H@ZC+O)Y)4#:
M/;CK26"Q#^W^+)67WVL>E_\ "N?"_P#T#A_WV?\ &C_A7/A?_H'#_OL_XUYJ
MGC7Q*V7_ +2D\L'&<#KZ=*D7QKXA^^VHS$#L%&/84_J.)_G_ !97]FOR/1O^
M%<^%_P#H'#_OL_XT?\*Y\+_] X?]]G_&O.%\9^)#DG4GP/0"KEGXUUO[5%#+
MJ.Z.0[68KDC/ Q]#S0\#B4K\_P"+%++6E?0[O_A7/A?_ *!P_P"^S_C1_P *
MY\+_ /0.'_?9_P :\_N/%?B6QN+FWN=4(8-B,X&<]Q4<?C/Q%(V%U"5B&P0H
M'^%"P.(?V_Q8++KZZ'HG_"N?"_\ T#A_WV?\:/\ A7/A?_H'#_OL_P"-<%=>
M+_$$4H U%U;'SJ,$*?RZTP>-=?$; 7[DD8' SG\J:P.):OS_ (L:RUM7T/0/
M^%<^%_\ H'#_ +[/^-'_  KGPO\ ] X?]]G_ !KSW_A,_$'3^T)<\\X%21>,
MM;9),ZJQ9?0 \]AP*'@,2OM_BP>6V5W8[[_A7/A?_H'#_OL_XT?\*Y\+_P#0
M.'_?9_QKBY?$?B.$1M+J.Q77<.020>G&*DD\3ZM%IHNCK#O*)"GDA<$\9]/I
M4O!8C^?\R'@+)6L[G8?\*Y\+_P#0.'_?9_QH_P"%<^%_^@</^^S_ (UP,'CC
M78Y8Y&O&D"G+1R84,.XR/YU9;Q+KCQ->6VK3O99Y#*OFQG^XP]??I3>"Q*=G
M/\64\N:=G8[7_A7/A?\ Z!P_[[/^-'_"N?"__0.'_?9_QKSYO&FO[R5O9!GM
MD8'Z5(?&NMQJS'4'+= N ?QJOJ&)_G_%C_LQ^1WO_"N?"_\ T#A_WV?\:/\
MA7/A?_H'#_OL_P"->;0>-O$4AWMJSLJMCY5 !Q^'/7]*N3>/-:VJBWI# <D*
M.:/[.Q7\_P"++_LJ7D=[_P *Y\+_ /0.'_?9_P :/^%<^%_^@</^^S7 -XTU
MU613J,@R,DX%=)X.U_4M2UE(+R]E=0I.T@8;@]>/\XJ:N!Q-.#FY[>;(J98Z
M<7)VT.COO WA_4KR2[NK$/-)C<V\C.  /T JO_PKGPO_ - X?]]G_&N)U7QC
MK$&N7$$5U*L"R.JE7&0 Q'*XYQQ59O&VO!F+W\NWC:T2*P/7 (/3.#D^U3'!
MXBVD_P 65_9;:OH=_P#\*Y\+_P#0.'_?9_QH_P"%<^%_^@</^^S_ (U6MSJ,
M_A^WN[K6YX[IUX\I0J[B> 01GCIVK"U7Q7K%G?R6!O4#0@QLR@<G&2??J,=.
MG2L84ZTW:,_S.2GAHU).,;:'3?\ "N?"_P#T#A_WV?\ &C_A7/A?_H'#_OL_
MXUQ3^+->YVWDS*>CQJK9'J*E/B+Q#'$)7O9_*=1L. &//H1UX//O6GU6O_/^
M+-WEZ78[#_A7/A?_ *!P_P"^S_C1_P *Y\+_ /0.'_?9_P :X-_&.NQH2U_*
M<+G@#BFMXTUY1N^WNA P=PX^O2J^J8C^?\65_9C\COO^%<^%_P#H'#_OL_XT
M?\*Y\+_] X?]]G_&N;TWQ=?WEO# +]&O/)?=$<C>3DJW'/('&.F.>M%KK.M3
M2/)+J5Z$C(\R-(X\JN"=V>X[<#O6#IUDVG/\SF>&BFT[*QTG_"N?"_\ T#A_
MWV?\:/\ A7/A?_H'#_OL_P"-<,WB_7G9B-1=7/S;<# 'H*UM(UCQ#J%CJ2K>
MO+<I #!L7!!S\WXXZ<5K+#8B,>9S_%FU3 >SCS2L='_PKGPO_P! X?\ ?9_Q
MH_X5SX7_ .@</^^S_C7+:3K7BB>^59I)WA&1)_#@<C//0CKBJEQXZU*9A9V,
MLD4<;<W,[%I)!R.@&!S]>G2E]7Q#ERJ=_F2L%>7+%)G:?\*Y\+_] X?]]G_&
MC_A7/A?_ *!P_P"^S_C7'Q^+M8M[6Y,U\T\I?RD3HJC^_O Y'I]>:BMO%FO7
MH6WBU".WS\S7$N<* #G)/ 'X<\4?5L1K[^WFQ_4-]%H=K_PKGPO_ - X?]]G
M_&C_ (5SX7_Z!P_[[/\ C6'H'BZ2ZN?L?]KI=W3,2@9'5& 'W5;: 3[UE3^+
M-;M4"SWDD<N0,28 R3G'3M_(4H4*\I.//MZDPP:G-Q26AV/_  KGPO\ ] X?
M]]G_ !H_X5SX7_Z!P_[[/^-<=!XDUR5C"=1F+$D[E(&..@X_QJO=^+/$-PWF
M27<EF\F"8H",1^B\YYQU/<^E:?4\3>W/^+-/[.=[:'<_\*Y\+_\ 0.'_ 'V?
M\:/^%<^%_P#H'#_OL_XUS6B:YK-Y<@W.KK#;R(T8,KJ#NXY7/<<_G78:X-1E
ML6_LZ\^SS*,ACTX]:PG"K"?(Y_BSFJT84JBA*VI4_P"%<^%_^@</^^S_ (T?
M\*Y\+_\ 0.'_ 'V?\:\^N/%OBFVF$4UX5^?9O0A\G(&..!QGG-#>.-<$;DZ@
MX*\YRHX_+_&NB.#Q$MI_BSLCE;ELU_7R/0?^%<^%_P#H'#_OL_XT?\*Y\+_]
M X?]]G_&O/H_%OB-+=)3J<S%LDJX4%0>5[>@_6K-KXG\32I(SWKY"Y"@@\>O
M2FL%B+7Y_P 6']F:7NOZ^1W'_"N?"_\ T#A_WV?\:=%\/?#4,R2QZ> Z,&4[
MSP17'IKWB*2T-P^HRP0 <3L@(9NRJ,<D_I4WAWQ7K%_X@LK:6>=H9'P^]-H(
M^M2\)72;]I>WFQ/+M&TUI_78[75?!^B:U>F[O[,2SE0I;<1P*I?\*Y\+_P#0
M.'_?9_QK)O\ Q!>Q^)KNQAO7#*W"L?DC&>X&"<_6N9N?&.O-J$R+J$D:F1BN
M%& G;J.E94\/7EHIVT[LSA@O:/IW.\_X5SX7_P"@</\ OL_XT?\ "N?"_P#T
M#A_WV?\ &O-I?&OB01%5U&82,.,H.*EM_&NO33>6=5=0P*Y !YQQCCKFM7A,
M0E?G_%FLLL:5]#T3_A7/A?\ Z!P_[[/^-'_"N?"__0.'_?9_QK@-.\6>)%<S
M7.HRS+LW$,@4'CK@>]1_\)QKGV8Q&_?S?,+"0'D@_P )'H/:E]5Q/\_XLE9;
M)[)'H?\ PKGPO_T#A_WV?\:/^%<^%_\ H'#_ +[/^-><)XWU]6)EU5E4#G.V
MEM_'.O3O<A=6)*+E5\O[P]CZ^U#PN(7V_P 6.66-*^AZ-_PKGPO_ - X?]]G
M_&C_ (5SX7_Z!P_[[/\ C7.^&/$^LWL0,\[3!YQ']WD#C)[<#J:Y+3?%WC-=
M>FTV^O)U+R-Y6^/:%4$\9QS]:R]E7YG'GV\V<DJ,8S<';0]/_P"%<^%_^@</
M^^S_ (T?\*Y\+_\ 0.'_ 'V?\:Y.;Q7K/]@ QW,ZW<,I68N@#?>(P!Z=.:Q?
M^$T\184?VA(-S9W<9&.V,5<,/7FKJ?XLWH8'VT>:-CT;_A7/A?\ Z!P_[[/^
M-'_"N?"__0.'_?9_QKS^#QKKPRKW[DNA4$J/E/8U _C?72WR:C<J%&"'502?
MRZ57U3$7MS_BS1Y8U+ET/1_^%<^%_P#H'#_OL_XT?\*Y\+_] X?]]G_&O-O^
M$W\2R;A'>RLV<87 Q[=.M6?^$R\0+@-?2@CAE;&13^IXC^?\64LK;['H'_"N
M?"__ $#A_P!]G_&C_A7/A?\ Z!P_[[/^->;W/C+Q1"^_^T'*< *,?B<X_2NB
MTCQ!KUUHC3-=2O-YI&?+&=N.V2 ,'GO4SPU>*NY_BS*K@%3CS.QTW_"N?"__
M $#A_P!]G_&C_A7/A?\ Z!P_[[/^-<CIMYXJBU3.I:U/);1$8V1A0X]^.GTJ
M+Q%XIU^.<RP7LMK9M(8T(4 \8Y[YR<X]JE4*SERJ?XLSCA82FH1:9V?_  KG
MPO\ ] X?]]G_ !H_X5SX7_Z!P_[[/^-<SIOBC4Y[*!X]1:2-G*N[KN<GH !@
M;1ZYS6%X@\=Z]!KDT$%\T21JJ;$ (SC)//?G]*<<-B&[<_XLN& <Y\J2/0_^
M%<^%_P#H'#_OL_XT?\*Y\+_] X?]]G_&O,H_''B,M@ZG)CZ#_"N[\-:QJVKZ
M>D\=X&C:)DD>=<,) 2 5QQC/7CFE5H5Z2NY_BR,3A%AX\TK&E_PKGPO_ - X
M?]]G_&C_ (5SX7_Z!P_[[/\ C7-:]XQU/2-1L7BNFGMS;.&3R]HDFSA6+>G4
M[<=!UYINC>.-3UJ26QFEC@NF0^1)"C8R/[V2<5,:.(E'FYM/4BGAN>G[11T.
MG_X5SX7_ .@</^^S_C1_PKGPO_T#A_WV:\_N/%OB6VF,4FHDE3ABNTC-&E^,
MO$5SK5G UY*\;SHK@J,%2P!K?ZGB+7Y_Q9UK++QYDT>E:CX*T'5;LW-Y9>9*
M5"[MY' &!57_ (5SX7_Z!P_[[/\ C6%XQU_6-/\ $!BL;MT@51NCXXR <CCG
MZ5S3>.=<+(IU"9=S=0@R/7(I4\%B)04E.R?FR(Y>YI2TU/0O^%<^%_\ H'#_
M +[/^-'_  KGPO\ ] X?]]G_ !KSQO&'B38&_M-@#SP!_A4X\8:Y)I\KC59%
MGB((PHPZG@]NHX_6J>!Q*^W^+*_LUVOH=Y_PKGPO_P! X?\ ?9_QH_X5SX7_
M .@</^^S_C7F\?C?Q$4W&_D&..0.3^5/_P"$V\0 9.HN<].E'U'$_P _XL'E
MC6]CT7_A7/A?_H'#_OL_XT?\*Y\+_P#0.'_?9_QKS*;QKXE+E9-1FB*\ +@$
M^_2KG_"7>(IX(IUUM5FD)7R %'3H?Q_G4O!XA?;_ !9/]G^AZ#_PKGPO_P!
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MG" Y !'7)]?:J-U%;37LXV",I,Y7:3CN*AL8Y[BYA6-&!CN5*JQQN 8?Y_\
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MI;D\GM6GHEO)-J*K" 60;\L,@'M^N*S"6 (ZGKZ5TGAJS>6SO)GD6-&!3?\
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M5[&\+;74,"?;!S^E55#HX"ERV,8]:'OJ*2=VGM8TC(L@V;0<\'-36P6*W1
M,9SGKG-2)(+B-XC'&)Q@Q2#J<'E3ZY'\JI,K$LRRNKYP??\  U<7<(MMZHUK
M.V%U=+"6(,A('IG'%4[I-CF!^';(QCTJ)781+(^,H2.O_CU6V<7-DEVN&(/E
MGV&.*=]0N^;R9"T,EZPA0.97<?='4=P/<U);6<S7RE8FS#ND96XPJ@DYIML6
M:ZC\MB#G[W;I5MGN+-+EH;B2,3Q-'* <Y!(Z9Z42O9V%-M74>IG-NW;F/49W
M>OX4H;"E6P/Z4I"H.?P!]:;&-V H)/H*1<6R_HLUO;:E$]VCR0X8.J\%E(Q5
MK6;9-/F:PMF(ME59-QX,FX AF^F<8[5!;%+1IIIHQ*\:913]W=GC/M[51NKB
M34;PWEY(TDP(RV<!N,8P.,#_  K)QO.Z,)1;J\R&H5=&8!2!U"L,U'YRF9@!
MRN 5]*,*#]T ?PX'&*<F!*7/!/!/J!TK0WL6(4\V8!-H YW-P!]2:GOH+>*Y
ME_T@3,QR&3E.>>O>J>X*YV<\Y -0*R[/O-RS$;^IR34N[9$DW*]]"R(4,AD"
M!F(QGIQ0"@C0Y*[<\D\TQ7Q"5/!/7UQ42MO=F)W=AD\8H#EU-SP]%+J&IK'&
M2L,2^=(QY "^WZ?C5+7]02_U66X8E5=]J+CDX]OUJQHVKOI-SF-4/G#9(",Y
M3T'IS2:JO]CZJ-1:W!C\LEH7Y C?GCZ'CZ5C)M3N_D<SO&LY2[:?J94>^49Q
MNC)*E?X2,X.?UJQ'\TJIGY5X'LH_^L*9'YJVC&8KNED,VW(^4-R!4:.R2(\?
M)# GGCKR#^%:]+]3HZ7ZDDUS)=RF>64EB.[?I3EGMTC*P[_M"_?=@ !Z%?6H
M;B!X"Q6)DC?+1J1V[<TV)2!ET'F #;N],YQBCT%I96)8T9F+ Y<]?_KU<\CS
MK*2)GC06^)Q([8#] 5QCWX_&BYU&2X$2&**-(Q@") N?<U'/^YMH@<XE^;..
MN"1BEN)MRMT(6C6(+NS*7Y558<?7O4L,T:QN@A'7*N."!Z'].?>H7 92R\D#
M[OJ*(Y1'<!&C5B8R0V>ASCI5%/3<D4LYR0S&I%1-P\SIW('(J$N3NR<9/..]
M212I&V3$),CHXX!]ZLT>VA#-/ER6.!_"N<XYZ"K5G>S1ONWMM'.*@C:UCD9I
MT60!?N=SGI].:<9"Y+,@5@,<= */(':2Y;:&WK&J17<-A##& 8TW3,R[=SMC
M/ )P  /6J"KO'RAB^<J%_B]JK2QX6,JV2PW$5,I=<9&S/.3Z#THA%1C9$4Z<
M:<.6(Z.5F<%V)(R,'M[5V_@>X5-9AMY8UDD<%D?.6C&#_.N1%Q%*$+P R*#D
MAL%_2NG\"V8_X2"WNXY 48."K<,#@\&L<4TZ$D^S,<3*+IM2T.<DN%F\1:GI
M$]M$\$US(_V@'#1N"QX&/3 ]ZKW6G3Z;I5TB2/<))+&)"X"@*6!4[>O&,=A\
MU7K_ %BVT76+OS(4DEEN)&*Q1#=M+,%R1T.1FKEC+%>:3)J-M;L9+V,6LTCL
M2UN 6PS>HW;1^5<;J.-K+30YIXGEFE%::'+@0W$X!0F-#S+G&T>P_B/M3?LT
MHEQ-,FTG!D"G>?\ :P>,^U2PH%<LL33E<;XB<X'MZ43(!+)*D0,1(V*'W,H_
M'\:Z^IZ37O7(I%>W<LS9P?E4,/S Q2H0+=3\B*V65>^,@$_4E:?&\+W"$W$
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M8'; %9-S.'NI#N!(;:>...*FBO<CZ(UH1?+%WW2&^;B)PRI(SD,/,!.T#O\
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MA0ZK 1\J''F)VQ[\5R^H\QB4G:R??5A@@^A%:TWI;JCIH27P]46DN0N,*/\
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M2OR.FYC_ $K-2VDDW22 )#G;N[$XS^?2M+7HYGUR_2%D8&XD'S$C'S>]5FA
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M^>:Z_P [0H;&VTFQDWVGFD2QO'P21T4D?,X(W<G^E75JVLK7-,1B>512C=G
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MK=@I4)#Y>Y.I(8G)]>"*ABD1PV6;  R.GOUJ>V7?#*G#;?GX],X_D:CDB4C
M7.3DYJHKH7%*UD2O.#\NX;3P%]*6$!EE BW+L);(X'OBJKP[,R2MCC)QUI]A
M<W-N9#'';O$Y.!<Q[R%/4=01FB3=M!SO:RU%,:-$/,&_:,#(Z#VIJ,+>#:,*
M) J28'7!X-3S7%K-D);3P2#[X1PR?AGG\#GZTLHMEA22(R.2^-DJ@<>O!.?I
M2WZ"NGK89=0R6A*RE=P4-Y:D%B#T.*(G^R$3J["1<'(ZK446F7]UK,VI_:1-
M*5VK&1_!Z>^.PI'E5FV$CK1!MWY@A*4DU+<62,S/YC3-O)W;P>OO6E;S)>:6
MS31GS89/+:1> 0168MM(B,7D=4(4QJ..#WJS9RA)/)9W%NY^=%/7WQZU3VNA
MMMQ370KSHD<++%*'B1.#TX^E/CM8GRP P1@[>,TZ> AU/(&<!O2G%GCG7[I5
M, J0/F]\]?UJD4W?S*\IN9-7L]'^T!(I\-O=<MSD?EQG\:W;SP[::9X=NT<^
M=Y=I( 6ZJ^#\P_PK U;3)-2>"\L]B3V[!N68\#V[_P ZU1?ZIJ:-$U[;JCJ4
ME1X"NT$8S@GGBLVI.35M#EG"<FULAZ/YB.>  Y (!&?IGFH^<8VG'KCI4K11
MB0N=P?:%!' XZ9%-R"%&T*=O/.<UUV9U13V9<O<BX/[Q9595*R>HQQ5!F=YB
MI)"H!T_B8]OH*M2Q^;9P_P!Y6*G '3J*@CM</(ZLQ_B?<>IZ8 J%HK$[*Q'(
M#(P5/F92#G/ I&=HY=LJM@C*E3G-3XV'9C!';&*CDB FCF[X*#Z]:9;5BPET
M+B,!O,5D7:NY??I4 *B<NH^9?ER1T]:/)D8DD>6IZCO^?:K\TLVJR[6=&G5<
MC@+D#^M2]->AFUR^AERLRNI52Y)Y&<<>M78K2YET]96MI'@#E7*H20>V<53E
M+K*ZF([U (XP,9]:>A(8$.XPV[ 8U+3>PI1<DN5D<MR(E*.CJC<9,9P1VZCZ
MU):VZ7+J&E^SQ %@9,@<?XU)=W+-=-)<2"1BV=[GKFFB4$%58-Z#-%FUJ/E=
MM7J1HQ1Q@@KDG+=Q5DRPR(?-!4[,9SP3VSFHMF%(!4XZ8[>U-,9V9SDX_*G8
MNUQ\X\N4D]"<*W!!^A%1.T;!6D )5@5'O[5/:1N+E0\@-L?]9'CJ/7_Z]/EM
M[;S)!#([1DD(K#YL#O2OT8G)?"Q+9S<6YM@6W[MT:^I[CZUG2M(ZR+'D.I^4
M$8!/I5F,F)PPQE3D9[5)=1L/WP?:C_,H[D9Z46LQ.-GIU(WC,>2Z'( ^7/K4
M4:38#D '<>!V'89JQ+)N0S%68*I.U3C\JC<ND!DBE!P,@]./>F%VMR;S&G5?
M,X:,<'^\/3\*;(AMP(_O#&02.:85D"*X<9P","M"^G%W!;2/&@G52&* *NT=
M./7K2U3MT"[32MH9Y"A,#@_RIR#?+Y>"P; &*4I^\.&VLRXR><#K0BN%9D)
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MB9<[E:W<Y8YC/VKERVTU3\CS'[-=0Z-/:&UF69Y0I4H1@^U0RVX@N_+E&QP
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MACG'H0"3Q7#Q330@*DC =2,@BMZ$+IW.W"4N>,KFHT9U>]@B@9%E*;0';;N
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M4G?[PK59SI/FU2ZF=XNU>^&N:GIUP^^V64,@V\@8!&#7/R(ZN ^T[QN5@?O
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M@*T45,C.>[^1!:,1SZ40*)-,BD;EFB!/Y445?4UE\2*!C62&)B.1*N,?6K:
M%AGN2#113*8VX427"JPR!C%6YY&#QJ#C:.,<4451:V1+=C[3!;3.<,P*-M&
M<=#]>:S6 C8H@"K[=Z**4-C.CM]_YDUI(RNSAB#L)HN)I#D[B"\6#C_>HHJP
'FES_ ''_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>trda-20211231x10k027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %O X # 2(  A$! Q$!_\0
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M'DG$[R%B?4L:QJ]&7P1X/969?&EJ57J1+%@?^/4X>!?"10N/&5MM'?S(L?\
MH5:+&8>*LG^9+IRZGF]%>D#P+X28D#QC;$@X.)(N/_'J3_A!_"!!/_"9VN!P
M3YL7'_CU6\;16[_ 7LY'G%%>CGP/X0"!SXSM0IZ-YL6#_P"/4_\ X0+PIMW?
M\)A;[<9SOCQC\Z7UZ@NH>S9YK6KX8_Y&G2O^ON+_ -"%=D/ _A @D>,[4@'!
M/FQ=?^^JNZ1X-\+VVL6<]MXLMYYHIU9(EDC)=@0=O!J9XVBXM7&J<DSU:O./
MC#_R ]/_ .OD_P#H)KT>N3\=Z7I.JZ=:QZOK$6F1)-N225U4,V#Q\Q%>7AYJ
M%12EL=51-Q:1X#17H?\ PAW@K_H>++_O]%_\51_PAW@K_H>++_O]%_\ %5Z_
MUVCW_ Y?8S['GE%>A_\ "'>"O^AXLO\ O]%_\51_PAW@K_H>++_O]%_\52^N
MT>X>QGV,'3/$UC;: ND:AHJ7\*3&92;AH\$_2K5OXYV:\FI3Z5#)'!#Y-K;I
M(56 >H.#S[UJ?\(=X*_Z'BR_[_1?_%4?\(=X+_Z'BR_[_1?_ !59NOAG>_ZE
M<E0Y?4]>@N+Q;O2K*73+CDRRQW;NTF?4FK,'BYX[?2H9;4S"QN&N7+RDF=SZ
MG'%;_P#PAW@K_H>++_O]%_\ %4#P;X+)P/&]GG_KM%_\53^L8=V7^8>SJ;F
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M_H>++_O]%_\ %4?\(=X*_P"AXLO^_P!%_P#%5/M\-_5Q\E0YV7Q2TEGJ=O\
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ME"^.M$C\ME/V^#$O3< P'XY%8EL%F,L^T,957(/0,#@_CG!_&MOPHXD\<Z*
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M7S 2 C"'G=5?$K6+:36I]VT444SM"BBB@ HHHH **** "BBB@ HHHH ****
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MO3,Y)W$U>J>KN]B'34M67UN58Y=P :^I?@>P?X<0D'(^TR\_B*^2R=R\G&.
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M'2GB()O).Z+' SU-.9TR) FTMV'2GDD1*TEN%3J!D\FJNFNQHWV/N:BBB@[
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M0>N*=EO*_EV)<;O0T()6C:3S,>6R9W8Z'%9ZN)2 F1\W2K*()HHXY'9=RD
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M<Q@BU&)EAD=]NQ5#<'M^=3W3M&&AV/%;QA41.S.W<^M<T:;;\E;^D0_LKR&
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MR%VCDW%#T5?YU!-%]G(.Q#N/WN_TI\S3:;W".]K@7W.BD;CP5QQFGV,^-T;
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M4D\"@0$(<*H]3GYJZJX^"7CB4%%2SYQN<W0[#'3%-MO@?XWA;YEM".W^E_\
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MX5K!I.[Z"/+223D]:4<\=Z]0_P"%!>-_^>%C_P"!0_PI5^ ?CA3_ *FQ_P#
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M'[BPX_Z>A_A2GX">-\G$%CM/;[6/\*N+BK/F_K^MQGEF<9%/0$G)[<BO3?\
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M0BX8Y'KG-4(]5USF676;\*!PJW#G)_/BDJ#:O<2RR35^8^BZ*^;)M?UML?\
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M;X)CETJ807$<MV9#(CC^->@Q63JQC\1A+$0AI,Y.V=8I KC"Y^\HJS-+(&1
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MJ&0GD9)^F*Z\/LSV\J^"1+,%B\J.68K;8^\A)'/]:IW *S".W?SH.TC#)_\
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M) Y8C^5=!V/NR>*,>?(\\ABF7YN1N#?E6_H5YI5O/&]V9'!;#JW0'TI;#7=
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MI$BLAY)90Q/U]* \SN9 0$ R%XP/I4V71&=DM4K$EO\ :)& 0@J1]T+BG/\
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M\6?ZU@V<4$\ N)9$6+."B-EP/I03$-ZP3[]_ .,$ ^M8^RC=^9R_5X<TO/\
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M4DFKD$=UJM_$C0A%E<(=BXS]*.O,Q6L^=@J1K;M<7,12)5V)L Y;M38KO[-
M]MY,;-+C$A[5L:SI3FX5)IHQ9H/+C96 W8XY [UE2K:@FV_ULO W*W %$9*2
MN*$E)7.X^&$:Q^() &)86QR"?<5ZY7D?PK5HM<NT"C88B<D<]1^E>N5QU_C/
M#S#^,SQ7X@Q%?%=U*K<X3@?2LI-+N+S3I+X'<L!"E<\"K?Q#FD3QG>*K[1M3
MWSQ6#_:\]E*(UF"*Z .N.#GU'K71%/D5CVJ,9>QA;LB![:1MQX(Z'FHTTU_+
MN9,[H]N6!/1JT+P2")#Y493.TRJ.O?D5G!\RR8/EE1U'>KN;IW6AERVKDJ6
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M_C30X[L; LR#]VH)(^8,U131RK\KM+@G<I!Y6I&CQSMW-D8STQ_6IHH[HAY
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MA;&96;>[KER ?ES26E3W5<%=5?<5]+>ASGV1F.Z"W++'P[+R%-7([;5DD?\
ML^:X1$^;]T^% '7/K5!;V61! &E2-V+NJ]#GDU(6A+"*&>95=>593R?2MW?J
M=33>C.R>XCC\(2SW5O$VJ>=LCG#=SSG^=<Q%:SJJW$,'FON(+$?*.E6;#P]<
M31RS+<I'#"F7:8X^;'W0/7WJ)[F]EA6VMMZP@;2RGCDY)_2LXJUTF802BVHN
M_<>=/MWDBM]Y,V[YY8^5+'&/PJ-X(;:\GW@%$D.R<#KVJ!I9;+54BC6.1X6
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M\$M<TU;!=._L\0!4W,S.&<$RG('!;)% 'K.E?$;0-:OTL[,7YE=2R^992(I
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M4[1\JDC%2IL#?O 0P'S<=:8-=1&B4!69R6)^9::426 +N 4=Z==R(;L>5\P
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M7GM45[+*\N/G8,,$YZ5&D;A\[223VII&B3"6*,#:J@.#@MG.?2HFBFAG</\
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M);<H0$CC'I5BU$UQ=) KQG)VD%L<>]*VA/*TG<7 66::%?.2-L;7YP.U.O\
M5#J#D^5&A;&[8, X[?2IM7T^*#49(X+E74#YE7C!QS]:RXN"J+'D9XSU-.-G
MJ."C)*0V17CE' "L,  =JDL[:.\Q%(1&Q! )[FK$L3+M4!0 .<FH0;N&%+K
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M@M4-NZG)_BY]C3OS: WSOE:/H2BBBN$^8"BBB@ HHHH **** "BBB@ HHHH
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M:I71S;I.J()$CVLP[@>WK[TMK+Y,4GF0ADE(1F5B/TJS1]S.A1$^:9)W520
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AMH8%N@)X2Z'YC@XJ2Y<K<K-&C+&_W1D9/UJNH[:V/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>trda-20211231x10k028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Q YD# 2(  A$! Q$!_\0
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M(]CDNS3_ .$BUS_H,ZC_ .!3_P"-'_"1:Y_T&=1_\"G_ ,:S**.2/8+LT_\
MA(M<_P"@SJ/_ (%/_C1_PD6N?]!G4?\ P*?_ !K,HHY(]@NS3_X2+7/^@SJ/
M_@4_^-'_  D6N?\ 09U'_P "G_QK,KT&?PAIESK_ (;6RA=+#4K<32*9"3P,
MMS]*SFZ<-U_2*2D]CD?^$BUS_H,ZC_X%/_C1_P )%KG_ $&=1_\  I_\:[5_
M!>E/X^LK*!6;2+FU^TC$AY4 _P 77KBN<O["P/AEK^UTRYCW7S)'=&0&/R\G
M"8SG.,<XJ8U*<K67],;C)=3-_P"$BUS_ *#.H_\ @4_^-'_"1:Y_T&=1_P#
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M'_P*?_&O8/A9>75]X6GEN[F:XD%VZAYI"YQM3C)^M>&5[9\(O^11G_Z_7_\
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MMJ5B^FZG=6,C*SV\K1%EZ$@XS3BJ4I.*CMY W)*]S8_X3SQ1_P!!B?\ )?\
M"C_A//%'_08G_)?\*YVBK]E3_E7W$\TNY]54445\X>@%%%% !7@/Q*_Y'[4?
MI%_Z+6O?J\!^)7_(_:C](O\ T6M=^7_Q7Z?Y&%?X3DZ***]@Y HHHH ****
M"O6O#6H0#X;-J$A'VG2XIX8F[C?C'\Q7DM%95J2J)(N$N5GK.B:C ?AK)JCM
M_IEC:S62G/9BN/Z5S\I'_"GK49Y_M(_R:N&HJ%ATG>_6_P#P!N=SV:[NH(/B
M?-&\Z0RW&F>3;R,<!9#TY_"L6'2]0T?X:^(+34G59C*KB'S [*"1\QP>,X_2
MO,Z*E8:R2OV_ ?M/(*[7XB,5OM#93@C2X2".W+5Q5*I 8$C(!Y'K6\H7DI=B
M$[)H]5UB^MSX-NO$T3@7>JVD=E(!_?!(<_B!^E2:KI>IZI8>$?[.F4>1"LCK
MYH4H/E^?!/('M_6N$USQ*NJ:;9Z99Z>EA86I++$LAD+,>Y8_YYIFO>(CKEGI
M=N;40_8(/)W>9NW].>@QT]ZY8T)JWJ_DK61HYK4]%@U+2]3UWQ7;6J1W4UTL
M8CB6X\G[0%7#A7'OGZUS7CZX2+2](TMK2&VGMU+>2MV9Y(E/\+$J,?F:X.BM
M(891DI7V_P K$NI=6"BBBNDS"BBB@ HHHH *]D^#W_(OW_\ U]?^R"O&Z]D^
M#W_(OW__ %]?^R"N3'?P6:T?C/1J^>?'W_(\ZK_UU'_H(KZ&KYY\??\ (\ZK
M_P!=1_Z"*XLN_B/T-L1\*.;HHHKV#D"N[^&UM)>IX@M(MOFSZ>T:;C@9.0/Y
MUPE%14ASQ<2HNSN>GZ#HLO@"'4-6UJXMD=K<Q6\$<FYI&/I3_"7A&[L=#37+
M>VM[K5IQNMDG?"0*>CGU:O+:*QE0D[^]J]]/PW*4TNAUS?V;I>N:C#XQLKB^
MOF=7W6\V "1D\Y'J*TW:.P^'\[::LENNLZ@4A4M\XA'&"?J"/QKSZBK=&]M>
MWIIY"YSV)CYOQ!TS3_,/V30[$2N,\;]G_P!=:QH5NO$'@.^72'1KR?47EO4\
MP(QC.2,YQQT_(UYM16:PUK:[6*]IY'K6M:5J5_>^'-)BN@K:;:K/<WA;Y8^@
MW9[_ '3CUJM\1-1?5/#UK>:3<B32Y9FCN/+7:7E' +>HXX_#VKRZBB.&LXN^
MWD#J737<U]<TW5-&-M8ZC,2OEB6*(2EE0'VZ UUOPY-OK.FZIX:O&_=RA9X\
M^Q&[^GZUYW16LZ;G#E;U[DJ5G<]+7Q!92?%Y9[B1$M+<M:Q,QPJD J#[#.:L
MZ^RZ1X4U>&XTN*T^VS?*)=2,[S-G/F("O3\17E=%9_5E=.^UOP'[31GI/B&X
ME&N^"8A*PC6WMF"@\ E@"?R%:49 ^('BWISITG\EKR2BCZMI:_3];A[34]%6
MTN?$/@31+;074W-E,QN(EE",C$\.<G]:FT 7":]XF2[U*+4+A=+D5[B,Y!.!
MQG'..E>:44W0T:O^'G<.?J>NZ1]FU7PMX?6RL!?/9OB4+?&W-L^?OL #D=3_
M /KK@/&5[%J/BN^N85A"LP!,+[T8@ $@X&<D>E8-%.G04).5Q2G=6"BBBMR
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M3/\ KTB_] %>;F/PQ.C#[LB\3_\ (IZS_P!>,_\ Z+:OFJOI7Q/_ ,BGK/\
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M^_<7^%/DU3X81[=UWXD&Y0P^2+I^5>5B.UE8-&70 Y9#SQ[&H+B0R3,V,#.
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MW]:A))/-/Z]B/YAW\CU]]7^%R$!KWQ'DC(_=Q\_^.TC:S\+5./MOB,_1(O\
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MU\76G_@)/_\ $5YIN^;(.*=N)Z]*7]IXCNON%\CTG'A@#/\ PEUIC_KTG_\
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M;L>WGPUX+!P?B#IV?HO_ ,70/#7@LG ^(.G9/LG_ ,77B0N%;/F0HWN,@U+
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M3\2)>>/LL7\J^HJ^7OCK_P E)E_Z]8OY5O/8Z:GPGF)!H]C3C]*9WK,Q%)
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M$EB23DGG-2DWML2DVW;8MXD"$%X@SCCCG%?5'P?4K\,-(!Z@2?\ HQJ^5+L
MB%U/#1C].*^J_@^<_"_2/I)_Z,:M:/<VP^]SN:^6_CQ_R4J7_KUB_E7U)7RW
M\=\?\+)E_P"O6+^5;3V-Y['F@4[=W0>M*K =1N^M(<D#GBD Z\UD8#OE/3BF
M]>!UI*<<<^O:@8#@<'KUI?E([@TW-% A02.G%!8YZTA.>M% [!FC.*" #@'-
M)0 O!-.90I.#D>M-!&,8_&B@0E+28I_RDC&1ZYH&-[T4$]J,T )2CCK2JNY@
M!UI&P"<<B@ )X&/QH!(H.,#!Y]*2@!0"3@4E .#FE'7- "<T[M[TG:E H$+W
MK[ ^%W_),]!_Z]O_ &8U\@$XXKZ_^%W_ "3+0/\ KV_]F-5#<TI;G75\B?%
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MTL86)BRL&8@@8[4@8V?9+,P4\@XR>]0_,C=P13S PYRN/K4[9,825E;CY?\
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MO1;FU"W/K<^[*ANHX9K.:*XQY#QLLF3CY2.>?I4U07L"75A<6\C;(Y8F1F]
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M]8OY5M/8WJ;'F=&?84N .#UIM9&(N?84$Y[4E YZT %* 2"1VHVC/!XHY H
M2C-!HH&%+24H!QD4"$[&E5L=1D4=#2=Z %.#3@!CKS3** %Q1TI1TSZ4W/-
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MH($@PI_B.1G&?2H%E&X;D4_A5)7U948WU:)C!^\SO0*><DXJ2^/VNX:6$!E
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MZGK2@KY0,  ;HP[U 87SR /J:>H2&498DCT'2BRMH%E;0!&Y_@/Y5-Y3K;,
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M*OJ.OEOX[_\ )2I?^O6+^5;3V-ZFQYG0?TI*4#)QD#ZUD8B'ZT9(Y%!ZTG-
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M]*PN<S9"R-&W.13FS(@('3@U([!EP65B3V%1A54C?G:>E.XT[B.=K@JV>*<
M'7<%RW<4[;N&%567VZU&RX  !Y[4!>X_<5^\J+QCIS21NN?+QE2>],\ESU&/
MKQ3_ "50!G?@\C;SFC0'8>SP*Q'E,2/5J<C*[82%0V"1WZ4+Y-Q)@AE8^AZT
MGV@1 K$FP]"QZU/EU(\EN5G=G;+$D^].224_*K-]!S4\,GF3(DJJRE@#D<TD
MLDL;M'NVA21A>*J_2Q=];6&E9'CPX8MGC-+&4M^2H>3T["GI(RP^8WS8?&3V
MJ"1=KD=NHI+702UT9U%G=Q?\(G>097#3(WE@D'G(/X<5SK;A(2(TC]>:UH)K
M"UT>/?.WFSMB2-5SM5>GZUD.(I"2C%3Z/_C7/1C:4FNK.7#QY93:3LW_ ,#]
M!P1%8-(Z[6ZCUIK$1  (""<@GFAHI%@.]2 #E34<;JR^6^<?PGTKH\SIM?4E
MD*# >/(Q]X'FFB#S2?*;<O?/! IS1ET9@=R]01VJ-,QQNY[C:*2VT!;:#F4.
MK;#G:>GM4()7H2/I2PN4E![9YI[S2*Y7(X/I5:K0K5:"Q2%F"-\RD\@\TDTC
M;C&,! >@[TL<I:4;@N.Y P:>S1%/-,1))Q@-Q2V>PGH]AEO&&DW.<(O+&K']
MH#_G@M0B198VC5 C=5"]Z@VGTHY5)ZB<5)^\?==%%%=AZ 4444 %?+?QA/\
MQ<S6HSA X@^8GKB)*^I*^5/C2"/BEJA/0I"1_P!^DK*LKI&-=7BEYG#0Q-]K
M1#P0<U+?7,CE82QV(. 34<$[C:N1P<C(YQW%)=@FZ;WQ7/:\]3DM>:N;&A:C
MH]AI\W]HZ VHR-)@2"]>':N.F%'/UK7TW5/"]]J,%I!X*VR3N(P6U>4 9XYX
MZ5RTMQ]DC6" !7'+OU)/I3;6ZE><(Y+*XVM@<XI\TK-V&IRLW8[BY'A&UCNF
M?PAN^S$!RFJ38)SC X[&B\MO#]C8K?2>"$-L7";EUJ0D$C(X'L*XAXK=3@W:
M\]@I/YTJA((WD1Q(I4C(XQ1[3L/VKMI^7_ .D?Q5X6S@>#'('3_B;2_X5RUX
MZ7'^D1IY:,Q CW9V\Y SWXJ,)'*<1DJW96/!_&EMDW2&W?(W'KZ&FVM^PVTM
M5T$M_G22$D O@C/J*3[-+E5\MMS=!BI6G6-MMNJJ@XR1DM[U+ SS1NI)! X;
MM4MM:DN37O="-8;6%O\ 2)2S?W8^?UH:6"1@BQ%5S@<]*AEMY8?]8A /0]J?
M9INE+G[L8W&AI6YK@TK<U[C[M&6X90I"KPN!QBI(=R6,^]?D?:,GV-1?:Y]^
M5D8#L/2K%V[2Z9%(WWFD(/O@5+OHF0[Z192VP-P'96]2.*3[/(LBC'7D$=*B
MS5FT?YV0G 92![&M'=(U=TK@WV=F)<.2>I7I2>2N=T,@;'9N#3ELYG<+Y97_
M &F& *>YMX_ECCWD?QD]?H*F_1$WZ)W(Q!$!ODDVJ>@ R34T<<#Q210LQ<X8
M;QC..U,EC#Q)(F>/E(/K3[2)HI5ED 51_>[FDWI>Y,G[M[CDM(H@'NI-O^P!
MR:7[=#@PK (XFX+9YJI*LFYF;)YZYS38XRY))PHZFCE3UDQ\B:O)W&RQ-$Y4
MG(Z@CH1ZTD;E3ZCN/6K#SP;500EE7H2U1(8WD4;=N3USFK3=M4:)NVJ!H6X*
M@D$9QW%?6'P?!7X7Z0",'$G_ *,:OE">9_-95.T*<<5]7_!]BWPOT@L23B3D
M_P#71JTI7OJ:T;WU.YKY;^.__)2I?^O6+^5?4E?+GQV4GXDRGC_CVB_E6D]C
M6IL>8T4I&#@TE9F)LZ+J6B6,,JZKH']INS H_P!M>#8,=,*.:V+;6?"-S=0V
MZ>" K2R+&"VKS  DXYXZ<UQX&>E(1VIW&I'H-V?#-HUT&\$HWV8X8KJ\V"<X
M('R^XZ]:;='0+/3O[0F\!1BVW*NY=;D)R1D# YZ5P(]R:!QU&:?,5S'6#7_"
M!Z>!_P#RKS?X5RUPT;W$CPQ>5$S$I'NW;1V&>^/6F' Z4F:3=R;MB=Z=WI *
M<*0F*HR<"ED&TX%(&QTI<$@,2*1(RC%+Q1GY<>],8Y5!5B<Y':F9S3UZ\<48
M^E*XAF*<!2[:4#)Q1<+@.M.S3&PIX;/THW$CGH*06'-@8'<U&WK2$Y/6C)(I
MI#2L)GFCK1BG 4RFQ*^POA=_R3+0/^O;_P!F-?(21%VQ@U]?_#-=GPWT)1VM
MO_9C50>MATVN:QUE?(_Q02,_$C726P?M'(_X"*^N*^0_B@?^+EZ]_P!?'_LH
MHJ[#K+1'),@_AZ?2D$9Q3@:<>.]8W9SW9K:5)X62RQK%IK,MUN/S6EQ$B;>W
M#(3G\:UM/MO!&IWT5G:Z9XD:>4X0&^@&>,]3'7('DY[^M*KR1.)%9E8=&4X(
MJU(T4CLI+'P5%;R3C3O$31HZH2M] <ELXQ^[Y'!IUYIGA/3H5FO-"\5P1.Y1
M6DNX "PZC_5UQINI2C(TLA5CN(+'!/K3Q=22$":221!R%=R0/<9H<O('/R.B
M:;P$5P-/\29'K>0?_&ZY)NO'3M5MC$R_+P3TJ KR14J5R5._08&(.:F,X>/#
M=?6HRO'6F$$463!I,>,]J4TT$@T\9ZKC% ,9@9.130#BI@.>/RI=HZDT7%S!
M"3;W,<CQ!@K!BC=&'I4MU/')=RRP0>3#(<K'G.T>F:@P=OK2]  <U+2O<EI7
MY@5\ @ X/;--);.1U-..#T%%,9"RMGFF\U8S4;KD9 Z529:D148-+2XXSG\*
MHJXT'%2;D]*92GITH$/ !^E?8OPZ_P"2>:%_UZ)7QNJ[N^*^R/AV,?#S0A_T
MZ)50W-*6YT]?)_Q@#-\3=6P<@%.!V^1:^L*^3_B]A/B;J\@)W;HQC_MFM.KL
M.ML<7$B,\4<KA5)P21TS4DL?D7DMOO5D QN4\$>M5P0T>YOF(..M*"94*J,,
M.P[BN9IW.1IW-K1QX;6W<:O;ZK//ORC6-Q&B!,#J&4G.<UKK)X*U*ZM[(67B
M1Y,B*$&\@')/ SY?K7%("LB]CFGE7:ZQ'G>6^7!QS5WUU-+ZZG<MH_A6&.5U
MT?Q,R)C>Z7UN0,^_E\U5#>"X[+[0=-\3K SA/,^UP8W<\9\OV-<Q'=S1,Y25
MO.[OG.[M40D:5/)8G:3D>F?7%-R3Z#<DUL=-(? K*QBLO$;MCY2;R#K[CRZY
MJ6-EMERI'SDCUQ4#(RG&#4ULKK*&(;:.3[U,GH1)NUR $@Y!JRR&Y42(I+C[
MX]?<4PSR>P_X"*:9'8Y+&BS>H6;U%CC?S0,$$'TZ4^Z1O.9_O*S$AAWJ:,EX
M=D\I16(VD]:K@RQ$A2?3CD&I3;9*;;%DPMG&N3EF+'^E*@61DC926P "#39=
MSLI;D]Z?DAW*GYL8 '6CH'04O%)(R. J@X5QV^OM49A97,>TE\X '.:B*E3@
M@@^AJR,%$+N4=> ?44_AV&UR[#5.RV<D]6  /ZTTA0%EYY[43C#;0,(.GO[T
M+S;N/[I!H\P\Q5=4"E5R,_,#_*GRB.3#;BD?.U>I%0Q@[&.W(R*<6!C<-]X'
MCZ46U!K47="GW8RQ]7/]!22Q^8%DC4\CD#L:CP3C ZU8V@1&$$[P-Q]/I0]
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MM_T+VF_^ R_X4<@_9L^+B00!T/K29K[2_P"$(\+?]"]IG_@,O^%'_"#^%?\
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M/^$>M\?[[_\ Q5'LV+V+/D0"EQ7UU_PJGP/_ -"];_\ ?;__ !5'_"JO _\
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MX55X(_Z%ZW_[[?\ ^*H/PJ\#GKX>M_\ OM__ (JFH,:I2/D(''49I.]?7O\
MPJCP-_T+MO\ ]]O_ /%4?\*H\#?]"[;_ /?;_P#Q5'(Q^S9\A]*^Q_AU_P D
M[T'_ *]$JI_PJCP-_P!"[;_]]O\ _%5U5A86NF6$-C90B&V@4)'&I.%'IS51
MC8J$'$L5\G_&$?\ %R=6 '\:$_\ ?M:^L*YK4_A_X5UG49=0U#1X;BZEQOD9
MW!; P.A]!1.+DM!U(N2T/CJ(KM96/!Z5/Y;*@$0)+#DCK]*^LO\ A57@?.?^
M$>M\_P"^_P#\51_PJKP.#G_A'K?_ +^/_P#%5FZ39BZ,GU/DY3("!(N5'7<.
ME-2X,$PD4?.IR">QKZT'PL\$C_F7[?\ [[?_ .*H;X5^"&Z^'[<_\#?_ .*I
M>Q?47L'U/D?S$W%@I!/O4D>XC<L? [DX%?60^%/@<'/_  CUO_WV_P#\53F^
M%O@E_O:!;G_@;_\ Q5-TF-T&?*,L<I^:'&ST!'6JS^<OWMX^M?6__"K/!.W;
M_P (_;XSG&]__BJ5?A=X*7IH$ _[:/\ _%4E1DA*A)=CY&69NC?,O<&G.6C)
M"J /45];?\*L\$[MW_"/VV?]]_\ XJD_X55X(SG_ (1^WY_Z:/\ _%4_9,?L
M&?(;$DY))^M.C+@Y!_"OKK_A57@<_P#,O6__ 'V__P 52CX5^"%Z>'[<?\#?
M_P"*I^S=BO9.Q\C[R<Y'3VJ)68-D$Y]:^OO^%6^"=V[_ (1^WS_OO_\ %4A^
M%G@@]?#UM_WT_P#\525-B5%GRB+Z:8<A#(!]_:-Q_&J;[R<N&_&OKM/A=X)0
M$+X?MQGK\[__ !5*/A=X*'30(/Q=S_[-25%K8E4'':Q\B),R K@,IZ@U-$T:
MJS@-Z8]#ZU]9'X5>!R<_\(];?]]O_P#%4[_A5W@G;M_X1^WV^F]__BJ;I-C=
M!L^3!O<J,Y(.<CN*2%PTK#8AR"1D5]:+\+?!*9V^'[<9_P!M_P#XJD7X5^"$
M;*^'[<'_ 'W_ /BJ7L6+V$M3Y-BN93,@+_+G&, 5#N,<Y/=6KZW'PJ\#@Y'A
MZW_[[?\ ^*H/PJ\#L23X>MR3_MO_ /%4_8V&J%F?*6Z",2("P$J#GLO>FPQ>
M5*7;!"J2".AKZP/PK\$-C/A^W.!C[[__ !5*OPM\$KTT"W'_  -__BJGV,K;
MD_5Y6M<^1,/(Y;!))["G?9Y/[AKZZ/PP\%L,?V!;@>@=Q_[-3/\ A57@?_H7
M[?\ [[?_ .*JO9R*]E([&BBD) !). .IK<Z1:*YV7QYX7AE:-]9M]RG!VY8?
MF!BMC3M2L]6LDO+"=9[=R0KJ#@X.#UJ5.,G9,WJ86O2CSU(-+NTT6J^;OCWK
M6HV/CZVM;;4+FVA;3HVQ%*5 ;S).>/H*^D:^7/VB_P#DHUI_V#(O_1DE-JYE
M&3B[HX%O$.MVJG?K5\TC#@"Y<X'KUID/B37!!._]L7Q(  S<-W/UK.E@+.KE
MU5"HY8^@]*5&MDC>(LYW_P >.!^%1?0ZN2T^R5[?=I_PYJ6?B76G$D<NK7Q7
M:6'^D/D8_&H)/%.N/A5U:^51T N'_P :J+;M#!+(K!]PP"OIGDU2IQLVVB*O
M-"$8-?\ #>ILV_B/7FE &KWY&#G_ $A^GYT/KOB%!G^U[\KZK<L1_.LY_P!U
M;(@X:3YF^G84^T9D@N&!P G'US0V]T.-.+M3EOOZ:7-0Z[K_ -A!_M;4 P8G
M'VA\X_.G6WB;6HK661]7O6)P%!N&_P :PHFE\P>66+'H!5YK=Y%D0L/.*!O+
M';%3+31FM%<SYX+5*WX?GY%D^+M?9OGU>\88QCSV'\C4YUW6U7YM:O(D<9 :
MY?/\ZP$7]ZJMQS@U9U('[:R@'   IO=)$0;=.52>MFE]]_F7GUSQ$C '5K\[
MNA6Y8@_K2W/B77%=8QK-]\@P2+ANO?O6=:ET9MY=8L9:F[8)6)#E&/\ >'%.
M[OJ2X1Y/=T;[FM'XIU\VDG_$XOLJ1@^>V0#^-5?^$EUW_H,W_P#X$/\ XU6C
MB>(MO&8V7!*G.?2FFWA7[URH/H%)Q0FDPG3G*,;].^GYFM!XHUZ2.1!K%[O"
MY4^>V?<=:J?\)+KO_08O_P#P(?\ QJ"W6%)U:.;<XZ!E(!-++,EL[)'$F_NQ
M^;'TI)V=DBY4^:FI3E:VG?\ +J7[7Q!KSE@VJZ@8RIR?M#\?K0?$>K0XW:OJ
M,C$9Q]I< ?K6.]Q+(/FD8CT[4]3Y\>QB=Z_=..H]*;3W9"E!KE@M>E_Z_P S
M5E\2ZU+;!X]5ODV'# 7+]^_6F0>(=?\ ,5_[7OMH/):Y;'\ZI0#[/O\ GC9F
M7 4<\^]59'=V^<G/IZ4+JD$[+EG+?MZ&T=?U@.[_ -MW[1@\!;A\_P Z8?%F
MN#_5ZI>(/^N[$_J:R(G\N0$C(Z$>HJ66U<2 1J75N5([BC2^I*<I1O37K8WG
MUS7W@AG36K[! #@7#?XU1E\3:]YA!UB_&#C'VAN/UJM;PW4:D,&6+J1ZU$1'
M<3D896/?KS4Q=GW.BO'GBK)IOH^OH7X?%/B!?D75[Y@?X3.QS^M?5_PCN+BZ
M^&>DS74DDDS"3<TC%B?WC=2:^0XP4MV6-0'?J6.#CVKZV^# *_"K1@P(.).O
M_71JM:LYJB<8)/\ X8[VOF#XYZOJEE\2)8K74;J"+[+$=D4S*,X] :^GZ^5_
MCY(B_$F4>4"_V6+YB?;TILRBD]W8X%?$&O,/^0Q?*/5KE_\ &G-X@UN-<G7+
M[/;;<N?ZUBL23S1@GI19E<T5T-<^(]=?++K-^?7_ $AO\:C_ .$EUW_H,W__
M ($/_C6: 0-V<4A.302S3_X277?^@S?_ /@0_P#C2CQ+KPY_MB__ / A_P#&
MLP;<=\TA)[TQ&K_PD6O;,_VS?X/_ $\M_C2?\))KO_08O_\ P(?_ !K+H))Z
MT!H:S>)=<V*!J]_GN?M+\_K3/^$EUW_H,W__ ($/_C6:&(&,\>E)C/2@'J:?
M_"2Z[_T&;_\ \"'_ ,:>/$>NE,_VQ?\ 7_GX?_&LH)\V._M3D^\!G@<FDQI:
MZFFWB+7D"YUB_P GG_CX;_&C_A)=<? &L7X/_7P_/ZUE.Q=BQ[TZ(98\XPI(
MHZ#5G*R-(>(M>)Q_;&H?^!#_ .-#>)M<)XUB_P #_IX;_&LZ.0@-GD8J*@'9
M+0U1XFUSOK%__P"!#_XTY_$>NQO@:U?GW^T/_C613W;<%XZ"@2V--O%&NM][
M6+_/K]H;_&C_ (2/70H/]L:AS_T\/_C633E?"E3T/Z4!>^YJ?\)-K>,?VOJ&
M?^OE_P#&C_A)-<!YUF__  N7_P :RB,&C)QBF(U?^$FUW&/[7OO_  (?_&G_
M /"1:\JC.LWO/;[2V?YUD(<-GVXS3:0T]-36_P"$CU[/_(8O_P#P)?\ QKZ\
M^&$\MS\--!FGE>65[;+.[$ECN/4FOBVOL[X5'/PN\/G_ *=?_9C3$=C7RA\2
M]9U6U^(VMQ6^JWB(+CB-)&"J,#WXKZOKXX^*+N/BEXA ;:HN.3Z#:*F2;6AM
M0E&,M5<P[CQ-KO;6;['0XG8<_G3(O$NN,I0ZQ?XZ@_:&X_6LSS(P,!"?J:3S
MAG_5K^M%M+ Y)RYKFBWB+7E/.L7^/^OA_P#&EC\3:X&YUB_/UN'_ ,:H'#KN
M#;1CO3"IP&. #1>Y+A9W1J+XAUQCG^V=0Q_U\/\ XU+_ ,)%KKKM.L7RD]#]
MH;_&L20'=D=#3XV8J0<[?7TH94&D[-&D/$.O[\?VO?GZ7+_XU,_B'77A5CJ]
M^K@X/^D-S^M8F6C;()'H:=YH)R1SZBAIBBXI-,U$\2:Z,@ZQ?\@];A_\:B_X
M277?^@S?_P#@0_\ C561$PI\P L...*KLI4X-"=Q5(..AI?\)+KO_09O_P#P
M(?\ QH_X277?^@Q?_P#@0_\ C67FEXQ[U1D:X\0ZZP++J^H;1US</_C3&\2:
MX.FLW_\ X$/_ (UEY(&,\4,Q;&3G'%(IM6-/_A)==_Z#-_\ ^!#_ .-'_"2Z
M[_T&;_\ \"'_ ,:RZ*9)J?\ "2Z[_P!!F_\ _ A_\:7_ (277,?\AG4,_P#7
MP_\ C6510!J?\)+KO_09O_\ P(?_ !I1XFUT?\QB_P#_  (?_&LJB@#7'B36
MF'.M:@#_ -?#X_G33XDUT'_D,W__ ($O_C66,=Z3% S4_P"$EUW_ *#%_P#^
M!#_XT?\ "2Z[_P!!F_\ _ A_\:SE;C:2,>XII !X.: L:?\ PDNN_P#09O\
M_P "'_QK[8\..TGA?27=BSM90EF8Y).P<FOA8"/'.X5]T>&O^15T?'3[%#_Z
M * :L:E?%WB37->'BO58TU6^2-;N4#%PP55W'WK[1[5\/^)F5_$&I^:6 6\F
MZ=_G-3)V-:48R33()?$^MM*2NL7^.W^D/_C5I?%&LQQQRS:I?%STQ</R/7&:
MPP8 ?NN?J:FGD@=]L@?*_+N4]?PJ7KH;4W;FG=7_  N:/_"0ZG(3C7M1C_WY
MW/\ (T]=>UJ"-Y_[<O)0O"[;A^I]>:Q_)A;&R<9]'&*GCM]MO(K.-KXP^> 1
M2;\RZ<&W?E7JGUZ=;%Q/%&MR)Y3ZS? ]5;[0W'UYZ4]-9\0B4;]7OU0<EOM+
M8Q^=98L\!G,BLBC)V\TGVU]_ 'EXV[.Q%.[?PD*,8V==>G_!\C6'B[7&E8-J
MUYL)XS,WR_K43^*?$22D'6;X$<?Z]L?SK-:%95\RW!(_B3N/_K5*\";4\^7R
MWQ@C&31[J!JK-;^=^GWEY/$OB&X<#^V;X <D^>P _6I)/%&I2.6.KZF#_LW#
M8/ZUF3KM@ @8&'^(CJ3[U4 )( ZTTKZDSDZ?NO5_?]QT,GB;6(D1UU:^((PJ
MM.WXYYI!XGUN2TD\O5KU74@L!.W*_G6<Z0M!M=F!A !VC.<T"..UB65DD990
M1R<<5%U;S.IQES-Z<MM?+IZ[Z%Z'7=:N(_DUG4%<=<W+X_G4\_B+Q%!$C)J]
M[@* P\]C@_G6-' '/[F<;#R0>#^51-<N+AI4/4]#Z4[-O0S4HTZ?O*S>ET_Q
M-6+Q5KLDP\W6K[!!7/GMQG\:6/7]>C:4MJ]^2H( ^T/R3^-9L9@D9B8L-C.,
M\4X>;'$9L8=FQD]A3;Z$1C=7;ON[ED>(M?)XU?4#_P!O#_XU,/$6N-#Y0UF^
M\P-G'VEN?;K6;$\TLFQ7)SU]*;/($F98@%4'TZT[MNQFHQC'FZ;?\,:::WXA
M8_-K%^BCJS7+C^M2W'B36A#$L6K:@01U\]^?UK+5LP>;* Q'W>.OUI8KJ7[-
M*5;#*0<@=JEM[FL8TTG'NK]WW\B]'K?B.1AC5=0 ]3<.!_.K5SXAU?8V-<O>
M7&&$[$#CIP:YYYI)3\[LWU-3I"PCC1@1O<'&.U-I[MDTI0LXPC?S?]?J;'_"
M2:Q:0G&L7[RN.-T[<#UZU'9^)-<DND#:O?$$G=FX;I^=8UPY>=V(QSC'I4U@
MP%P%/1P5_.AJT6^I4)J5>,5I%/\ 7]32N_$VNQ3-&FL7P3 QB=N1^=5?^$EU
MW_H,W_\ X$/_ (U%/;/+<JB<HJA=YZ<4[^SX?^?@?F/\:2G%)7"IAJM2I)Q6
ME_ZL?=U4=:"'0M0$GF[#;2;O)&7QM/W??TJ]5?4+M;#3KJ\==RV\3RD#N%!/
M]*TELSEI7YXVWN>/>']9T/3M*AM-0\$RW,T>0UP;-7:3G@G<,_AFO4O#-U9W
MNA0SV&G-I]NS-MMVB$97DY^4<<]:XF+Q!\0+JZMXX8-*0W=L;F"-L_,@QQG/
MWN1^==CX2OK[4O#L-UJ3QM=L[B01K@(0Q&W'J,8KDPSL[?I8^ASF+E3=1I7;
MUM-RWOTM9;/\C<KY@_:(=4^(EI\F6_LR/DGI^\DKZ?KY=_:+!_X6+:''']F1
M_P#HR2NP^;3:U1Y5*B%$D,F-P^Z>2*6&&%W&9?\ @)')J.8?)&P.05Q]*BJ4
MG;<VE-*=W&Y.]Q-YF=S*1P .,5/+(B1(9(T:9AEN.W;--B7SWC,BG.X#(XW5
M!<.9)W9A@D]/2ILF[&KE*$'*][[7_/U+FV*=%=E)0 DD'!7V_P *8MW!L,)M
M\1,><'GZU#:RA2\3MB.1=I]O2HWAD2384.?84N57LRG7ERJ<%KL]%_5G_6QH
M'RK"/S8E+F0?(S53MVEEO$(8[V/)JQ^Y\N&*Y8@H#P.V?6G/<6Z21^2B9 P&
M&>#4K2^EV;S2;B^91BK:=;]?Z8M]<^3<[$1"4_B902:<SR262RP1CS,X8@9.
M/:FZ@L E5IM_F,N3LQBHKC"V\+V[MY:Y!/0@THI-1L:59SA4JW>G9;K5?IN-
M@,\DWER[V5^&SGCWJJZ-&Y5A@@XI[7,SC#2N1Z9JR'BDL]]P-S*VU2#R:TUC
MJ<-H55RIZK6[_(JPS/"X93^'8U-+:N3OC4X89VGJ*=%+:I(#Y3#GJ3G'X5!,
M)$ER[$D\AL]?>GN^PK1C3U?,O+I]_<E4BS4,5#3$9&>BC_&D^T+-A9T'LR#!
M'^-.4I<6Y,ORNAQO Z@^M#^5:. BB5\ [F''Y5/77<T=TDXM*'];KN+)':V[
MM&_F2./3@41-"S,L2LCLI +'/-* M_N(&VXQG Z-_A5<03;\;&4CN>,4+56;
MU"3<9*4(IQ>UE^N]R,@@\]:D5UD&V3KV;T^M6EG!+*T,<@;C<!S388X0S%7#
MR*"0N.,_UJG+N1&CJN65T_Z^?R(5MU 9I) %7^[R34Z.K6SQV[.'ZX/5AWQ4
M"W+Y82?.K<$'^E/$#I<(8VXR"&Z8^M)KN53:7\->3[Z_U_F0*[JX*DA@>*O>
M=Y=ZK.BJIP7XQSBHKFYE6X<+A #CA1582,6R23GKDT6YE=DJHJ,N6+;L_P B
M_JD+-()T&488)%?6'P8)/PIT;/7$G_HQJ^4YKP648MXLLP'):OJWX-.TGPKT
M=G.21)_Z,:E2O:SV-,>J?M'*+]Y[KHGUU.\KY3^/K%?B=+C'_'K%V]C7U97R
ME\?L?\+.E_Z]8OY&M3@1YAD'@_G3>_6@8]*./6@8,?3H*2BCM0(*<.1C'-(J
M[CC(%.<KD;1C'7GK0-+2XRE/0'%)10(4$^E+R1C'/K3B28P00,<' INX\9YI
M%-6$Y%&2#GO2Y[CBDXIB'_(PR%(P.<&FA]IX IR!<G+<$4W"@]<BD4[[CPR%
M3\N#WP>M1=*=NP?E&*<).&!&<B@&T]QNWC)(%*!P0",4REIDW#%(!FE'N:7@
M*><D]J L"@9PQP*3=@@X'%)10%QQVGGG- Y7: ,YSFFTN< 8I!<"I'4$5]F_
M"G_DEOA[_KU_]F-?&A9F4[F)QZFOLOX4_P#)+?#W_7K_ .S&F#MT.QKX[^*2
M ?$[Q <APUS@C/(^45]B5\<?%/"_%/7SO _TGH?]T4I&E)I2U.,,0+85U/Z4
MTQ,.N/S%#@;B5Z4R@EVOL6,B.,KG..?8FH&8L>3FGDE H'!QS0'0GYTX]5XI
M(J3OI>PJ_P"K)/.#BA0RG=&?RIP4>62I+*>#QT--7,; GIWQ0.UK7%SA""GS
M$T&- P5FVG'Y4PLP;/.*5E#+N7\:+"O?H68O)">7)\Z'G*L,@TR?8(]H).#\
MN1C JK3@Q'&>*.76Y;KWCRV&T4_:&7<,=>13<\8Q5&#5A****!!1WHHH #UH
MHHH **** % )H[T8-)0 N,]*2BG9'0C\:!AD@>U?=/AG_D5='_Z\8?\ T 5\
M,,B[05=3[=#7W/X9_P"14T?_ *\8?_0!2&TUN:G:OB/Q1 )/$6J*&^=;R7(]
M,L:^W.U?$WB>^7_A)M6A>'"F[E!8<'[QJ)WTL=.%]G:2J.QS;*R,588(J>6%
MI$69%)W#YA[U-(D!B4L[, .H'/L*JR3,T@9<J%X4#L*:;>PI0C3NI:W$6&1C
M@*?QJ:[!C"0@?(HSN'\1-(Y-R"Z9W@?,OK[BHXYFC4HP#(>JM_GBC5ZB]R*<
M>CZC[1L-(3RNPY'K2!K9A\R.I_V3D?K4L&)(94B0!R!CGK47V5E_UKI&/<Y/
MZ4KJ[N5RS4(\JNOP^]D]J8GD$4:, >2Q//%1M:3N[,5XR<L6&*&N$BA,<"D$
M\,YZGZ4^W3RX7,[E8I%P!C)/OBEJM35<E2U-ZVZK1+^N_GU 2QVD96,K+(W#
M''R@4^V:*4/(T2JR<Y7C]*KFT+<Q2HX^N#^1J;8;:REW8WN0.#GBD[=-QTW4
M4KR7NI/T^_U(8'#2.CG DX)]#ZU',90Y21F)7C!-(D;RMM123[5;EE6WQ$R+
M(Z#EF'2K>CT.>"YJ?O.R77]/U([5=BO(P/*[5'KGO0+4*K.TJ[0.<#-$TIDM
MU; !+$-C]*9;G=',GJN?RI:[EKDNJ=KZ?U^A8A=8(7DBYP."1SFKD5S!<63B
M;EPO/J:SK=E^SRK(2%)'(&<5/:0HDP)F1LY"@=_K43BM;[G7AJTTXJ-N5JS7
M_ &K_H\,LD:MO.!EAT!JB 6;'))J3SI$F+@_-GGWJRGEN&G"!-O7'K[5?PZL
MXW:M:,7:W3]2*Z95"1*>%'/UHM066= ,YC)_+FG.+65BYE=2>2"M.MY1YRQ0
M JK'YF/4_P"%'V;%I)UN9M6>FFOE_5QMK#@F:48C3GGN:=:RNTTTI/(0G\:C
MNIV9_+W91#@4MF,B=1U,9Q2:;3;"$HQJ1A#I?YO^MAQGBN0!.-C_ //11U^H
MJ6WM%5Q*)ED1#D[,YJC'&\KA$4DGM4]Q*(T%O$WRJ?F8?Q&FUTB%.JFO:U5>
MW7JW_6X^[D>-C"I*@G<WN35/\:OW,D8>-98=_P"[7Y@V#TJ#SK?_ )]1_P!]
MFB+LMA8B"E4=YK\?\C[VJ.=8FMY%G"F$J0^[IMQSG\*DJKJ=O'=Z5>6TLHBC
MF@>-Y"<;05()_"K>QR02<E=V. DTWP]J7@@WFGW^HPVFE2S-%<1']Z!U95R>
M0>,9Q76^$(M.A\,62Z5,\UH5++))]YB222??.:XK3+WQEH>D1Z):^'H;N.,%
M(KN-\QNIZ-Z5VG@_19M \,6FGW#*TR M)MZ!F)) ^F:Y:&LD[=-=#W\SO&A*
M,JEUSWBN9.ZUNW;5:]^[T-VOF+]H67;\1;2-ANC;38LC_MI)R*^G:^8OVA9(
MD^(MH7C+-_9L6#NX_P!9)74]CPJ3M+>QY7BVBD:W<N1N^]Z&BY^SQ<B$[VY
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M4C"Y&,>]5O-D_OG\ZG<FXM@_5X^&]QVJK3BN^YG6E9I1TCT/O^J6L[/[#O\
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MC/&*!B4444" @@X(YIP( .<TVEXH&)1UHH[T""BEQUHSV[4 )12L,8/K2=*
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M@CI@U1F 89R5!]J#M(R,CUS3<4Y1P3@G YI#NWH(%)&>*2ER<8[4E,D****
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M^*^!\4?$!!Y^T_\ LHK[+KXU^*Q/_"T?$ P"/M/_ +**9*.1,CJ@5AUZ&HG
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M);AE8'"@#L%IKEEER&)/4&F[O0B#C#WEK_7XDGGQ#[MNN?<DT?:3)A9$5EZ
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M^E232;76$* @QWSG-2[[&D/9+]XOZ?I_P2$S+VA0'\34R22 !W**O;*\_A3
MZI*5>,#!QD#I39(F!W.ZX/(.<YIZ$)R6J?Z?>2-"EPS/$X'/(;C&:1F2V)5$
M#2#J[#I]!2(B$,D<A9B.!C%39+Q*/W?GCJ3R<4O(U2O[R5G]_P!WF0%9KCYW
M)Q_>8X I=\,'W!YC_P!XC@?A3I(9&.9)H_Q?-(+9 "S3*RCKLY-%T1RS3NEK
MW?\ 7^8Y6CDMWDF3<RL ,'&<U&;DK_JD6,>W7\Z#<8&Q$41_W3SGZTA>!O\
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M *]8OY&K.8\P+D@ @<=*0X/2C%*"5.1UH'>^XVBMK1=%M-5BFDN==T_3F1@
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MTB/VB6IUO_#-^GE-A\07&,Y&(%_QJ,_LU:>>GB*Y'_;!?\:Y,_'CQI_?T_\
M\!O_ *](?CSXU_O:?_X#?_7H4T#K)[G7+^S98H<KXCN0?^O=?\:>_P"S=IT@
MYU^X#>HMU_QKCA\>O&F?O:?_ . W_P!>G#X\>-",[]/_ / ?_P"O1S(:K65C
MJQ^S78#IXCN?_ =?\:</V;;#&#XBN#_V[K_C7)?\+W\:_P![3_\ P&_^O1_P
MOCQITW:?_P" W_UZ.=$JJCJQ^S78 \>([G_P'7_&E/[->GG_ )F&Y!_Z]U_Q
MKE%^.WC5@2'T_CM]GY_G33\>?&@_BT__ ,!O_KT<Z'[2R.L_X9JL/^ACN?\
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MGKQ1ABU_HX=A@E9)/Y;*GB^,_BZ"T>XO7L.>(XUA&2?SJ*P^-OB^[U"*W=K
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M&LK.,G)*US12YXJ%[E2VA@@BEFN1O=.$C'(S[U]+? Z=[CX>+)(03]JD'
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ML-W?GVK(ENKAKU[EG83ERS-T.:D6SNF*@02@DC'RD58NWLYKAQ-))YJ@!I5
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MODHHEJ1QE\=>U?6GPR);X;:$2<DV_P#[,:ND[OR-E#D^+<ZROD7XG@M\2M>
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MM:VN^:Q-^5<MP\J*[.;<+')_SS+<'Z&K 18;#9?Y7)_<@8+CWQZ55GB5T%Q
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M?[0S6;36Q2E%;JQ4:!P021SZ&G"/8 2.M3[@1R!0&7?N,:M[=JKF9G>_4C#
M8X%?87P]_P"2?:'C_GT6OCUV4,<  >E?8'P[_P"2>:%_UZ)6E+<TI+4Z>OD+
MQ[(A^(&MP@8S>/R>><^E?7M?(GQ -K%\0]:RKF3[4QSG@&G6V1L]#DW\DR8
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#C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>trda-20211231x10k029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k029.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $! WX# 2(  A$! Q$!_\0
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M$8_B)Q6]IFIVNKZ=#?6<GF03+N5L8]B"/7- %RBC.:* "BBB@ HHHH ****
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M_P A7QE_V%G_ *UZ17F_PM_Y"OC+_L+/_6O2* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,KQ+_R*^J?]>LG_H)KG_A)_P DMT+_ *XM_P"AM70>)?\
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M:--MDE\N-_,7Y_<"I+CQ0MOJ(MGL9_)\P1-/T <]!CO3TAFN?%TDTL3""V@
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M!2#QUH W_$O_ "*^J?\ 7K)_Z":Y_P"$G_)+="_ZXM_Z&U;6O74-SX0OYHY
M4ELG=#Z@ID5B_"3_ ))=H7_7%O\ T-J .UHHHH **** "BBB@ HHHH ****
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M5/\ KUD_]!-<_P#"3_DEVA?]<6_]#:@#M:*** "BBB@ HHHH **** "BBB@
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M\#Q!5@G9@0B$#IM/3VKT^@ HHHH **** /-_A;_R%?&/_86?^M>D5YQ\+?\
MD*^,O^PL_P#6O1Z "BBB@ HHHH **** "BBB@#C?B=_R)DW_ %UC_P#0A7B%
M>X?$[_D3)O\ KK'_ .A"O#ZZ*7PG@9G_ !EZ?YBT4E+6AYPE:WAG_D:-*_Z^
MH_\ T(5DUK>&/^1ITK_KZC_]"%#V-*7QQ]4?1=%%%<9]8%%%% !1110 4444
M %%%% !1110 4444 %%%% '%?$>YL;/1Q//.1=!2(8/M9@\U=REP"#UP./\
MZ]97PLOH-3^W7EJ6C@<*$@FO&GE4 GE@3A<^E6OB2VH1W&D36ME+=0Q^<Q2*
M(/NFV@1JV>BDYS]!47PVL;W3;_5+69Y98D2+S)98PO\ I!!,BJ0.5'% 'HM%
M%% !1110!E>)?^17U3_KUD_]!-<_\)/^26Z%_P!<6_\ 0VKH/$O_ "*^J?\
M7K)_Z":Y_P"$G_)+="_ZXM_Z&U ':T444 %%%% !1110 4444 %075[;62![
MF>.%2< NV 34]>?_ !:_Y%^S_P"OD?\ H+4XJ[L95ZGLZ;FNAU_]O:3_ -!&
MV_[^"C^WM)_Z"-M_W\%?-^*,5M[)=SRO[5E_*?0UEKFEJ)]VH6PS*Q'[P5:_
MM[2?^@C;?]_!7S?11[)=Q+-))6Y3Z236]+D=42_MV9C@ 2#)-7Z^=/# _P"*
MITK_ *^H_P#T(5]%UG./*>AA,2Z\6VK6"BBBH.L**** "BBB@ HHHH ****
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M+O.8VQA"=N/Q&#6YI/CC5K3PEIES+H6J:U/*TT;RVB*3A'*JS=.H% !\+?\
MD*^,O^PL_P#6O1Z\O^#UR][-XJN9+>6V>74V<PRC#(3G@^]>H4 %%%% !111
M0 4444 %%%% '&_$[_D3)O\ KK'_ .A"O$:]N^)W_(F3?]=8_P#T(5XC712^
M$\#,_P",O3_,*2BBM#SA:U?#'_(TZ7_U]1_^A"LFM;PQ_P C3I7_ %]1_P#H
M0H>QI2^./J?1=%%%<9]8%%%% !1110 4444 %%%% !1110 4444 %%%% '->
M-;J>/0IK;3YBNJ2KNMHTF1';:PR?FXVC/S>U9/@4ZW%JE_;Z[/!)<"*.2,6D
MB>3L/<(.0<YY/7M3_'N@ZYJM[8W.BV]I,8[6YMI5N)C'@2A0", YQ@TG@C0M
M>T[4IKK6K>S@Q906D:V\QDW>7GDY QUH [FBBB@!"<<GI2"12,A@1TSFL+QK
M#]I\&ZK!Y[P"6 HTL<1E*@\$[1R>,UY!/ !IL$$MG$VDP1WT=M/;6ABCN+CR
ME\J38O1]V0#ZCCF@#VGQ+_R*^J?]>LG_ *":Y_X2?\DNT+_KBW_H;5F>*)/'
M,?AI$L;?3)+7^S%^V/=2,)1)L^?&*T_A)_R2[0O^N+?^AM0!VM%%% !1110
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M ))QKW_7JW]* .CLO^/"W_ZY+_(5/4%E_P >%O\ ]<E_D*GH **** "BBB@
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M/6M&#3[6VE$L4$:R[ AD ^8J.@)[T 6J*** #K2;1TQ2T4 97B7_ )%?5/\
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M ?0/@C_D2]*_ZX#^9K?K \$?\B7I7_7 ?S-;]<CW/K*/\./H@HHHI&@4444
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M[#XY/,!.QEQ_>&*?115KS(84444P"BBB@ HHHH **** "BBB@ HHHH ****
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M%O\ T-J .UHHHH **** "BBB@ HHHH *\_\ BU_R+]G_ -?0_P#06KT"O/\
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M=GE>6;0M.>5V+.[6R$L3U).* (K/Q/H*V5NIUBQ!$:@CSU]/K4__  E&@?\
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MFN\G\.Z3<PW,4UE&Z7,HFE!'WG'1OKP*2/PWI$6I?VBEE&+K'^L[],9^N.]
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M%5NH!]:O5C^%=(FT+PU8Z9<3^=);Q!"^.OTK8H **** "BBB@ HHHH ****
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MUFX^+%K<:A8W<$+VT\4,9^XL8*X8^YYS^%>F&-"NTJ"OICBC8NX-M&X< XH
MK:KG^R+W;G/D/C'^Z:\$TW1]7TNR$D4)MKFYTJ1[9[=G)G;N&R>& KZ&(R,'
MI3/*C^7Y%^7IQTH \N\"7VJ0:5/#8:6MU;M.!+<>88P,H-Q ;J0<CCTKD8_!
M^J1>!K[7PZ0@V$X,<)D,LY8X&\'CC&>*^@$C1%PBA1Z 8I/*39LV+M_NXXH
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M ./.#_<'\JGHHH **** #M1110 4444 %%%% !1110 4444 %%%% !2]J**
M$HHHH CN/^/:7_</\J>GW!]*** %K-L?^/Z^_P!ZBB@"'3/O/_UV-;-%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>trda-20211231x10k030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k030.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $. V<# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#.379U0SJ_\ =LO^^G_PI/\ B<?]./\ X_0!H450QJW]^R_[Y?\ QI=NJ_\
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MX5;MO&-SJ&IZ?;Q6:VT<DZQS"64&3)B9\!<=.G.?PH [*BBB@ HHHH ****
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MFQSQSIHDBS1+MCD%D R =@<9 K:K,U;59=/DM8;>Q>\FN&8*BR*F,#).6XH
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M-<81 %4<-V %+8?"KP7IEV+JTT2..8(Z;O-<_*ZE6'+=U8C\: &?\+9\$_\
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MSVQWS715'O7^\*7>NWJ* 'T5'O7^\*564G@B@!]%,R/6C(]: 'T444 %%%%
M!1110 4444 %<AJ$&N/XG^UVEA<?+^YCF,D7DB,CEBN\,3G!QMKKZ* //V\+
MZNL<9N(1=3I<O*CQM&R9;'S.LH/'^[R*[.5=1\O$+VH.S W*W7'UJ[10!#:B
MX6UC%VT;S@?.T8(4GV!J:BB@ I,4M% !1110 5QOC71_%VJSVW_"+ZU;:;Y:
MGS_.3=OSTQP?>NRIB_Z]_P#=']: /++3PG\5([R%[CQAI\D*N#(@B.67/(^[
M4NH^#/B/<:E<S6GC6V@MGD9HHC;Y**3P.E>HT4 >:6GA;XCV.F7RGQ597=Y*
MJBW,D)58SGDGCTK/_P"$?^,?_0PZ)_WPW_Q%>MT4 >::IX4^(M\UM):^+;2S
M*P*LR"#<"XZD<=*?H/A3Q[IVKPW.L>+;>^L4/[R!(-I;\<5Z13)O]4: 'T44
M4 %%%% !1110!'%G:?\ >;^9I_--B^X?]YOYFGT %!SVHHH 3GVI>:** (I=
MVZ/:1G/>EQ-_>7\J5_\ 61_4_P J?0!&5E.,,H_"@"4'EE(^E244 1XF]4_*
MFNLY4;'0'OD5-10!6"7>>98_^^:LT44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &7JNB1ZI<6\_P!MO+26 ,JO:R!20V,@Y!_NBJ7_  BMN=5@N"0L
M%M;-!"JEO,RW5F;/)Y.._)KH:* .:M_ ^DVUNL,;W( D:1SY@!<DJ3D 8_@7
MH!T]S2ZIX.L[^*],<TZ/.DA1&D)BBE=2K2!?[Q#'OW/K7244 8,7A+3H_,9G
MN99I8WCEEDEW,X8IG)]MB@>PJ2V\+Z=:3++%YNY95F&7_B!<C_T-OTK:HH X
M[XA^!4\>Z-#I\MX;3R9A*LBKN[$8QQZUYI_PS7!_T,4O_@./\:]Z9E4?,P'U
M--\V/_GHOYB@#R+PQ\"K?P]J$UR=9DN!) \.TPA<;AC/6LH_LVV!)/\ ;]SS
M_P!,5KW-70]'4_0TF]?[P_.@#Q&W_9QL(+F*;^WKEMCAL>4O.#4_B?X"_P#"
M0>(+G4DUHP";'R&'=C QUS7M =<_>'YT%U!Y8?G0!X!_PS8W_0P_^2__ ->O
M5_ 7A0>#/#XTC[3]HV-N,FW&<^U=/O3^\OYTU"#+)@CM_*@"2E'2DI1TH 2E
M'6DH'6@ /6B@]:* %-)2FDH Q_$FD-KFF?8EN9+<LX/F1G!&.:Y'_A6,W_0>
MOO\ ONO0V^_']3_*GT <-I/P_ETW48[EM9NY@N?D=N#D5(WP]C9V;^T[P9.?
M]::[8=:2@#B1\/(@0?[3O?\ OZU:USX62=U8WEPN%"\2$=*Z"@D9ZT <S_PA
M\?\ S_77_?TU6UCP,-4TJ*R74KF()(7WJYR?;-=?D>M&1B@#S#_A4/\ U'K_
M /[^5JZ#\/AX?O)+HZI=7(=/+V2-D#)'-=UD5'-_JC_O+_,4 4/[%A_YZ2?]
M]&E71H5<-YDG!S]XUI4#K0!D7&CSRW#R+>RJ&.0H/2HO[#N/^?\ F_.MP]:*
M ,UM*+V\4;SNQ3/S$]:C_L5?^>S_ )UKGH*2@#/ATL11R*)6.\8ZTW^RO^FS
M_G6ED 'FDW+_ 'A^= &>NF^6=_FL<<X-61:J0#D]*F9E*'D=/6A2-HY'2@"'
M[*OJ:);7>1\Q&!BI\CU%*6 ZD?G0!3^P_P"V:E2VVQE=Q.3FIMR_WA^=+N&W
MJ/SH @^S#U-.2 *V<FI-R_WA^=*&'J* (/L_^T:/L_\ M&I?,3^^OYT>8G]]
M?SH D' HHHH **** (;J<6UI+.59A&A;"J23@=@*X)M>UUM$O(=/M=0NY\B;
MSE15>%'!)4"0KDJP*\9P".#BO0Z* .4T>;4&\0732F>3S(\B*1I56'@8!R-G
M)SRN?QJ[:WWB Z)=3W6EQ&^5V$,$$X.\9X.7"#]>?:MZB@#@;+5/%$B:,D^F
M:E'']HQ<S-Y.7^<C# .2% ] ?K4VLZ]XABU&\MK6Q:1(9$:#R86&\9Y#.6Y^
M@4#WKN** .*/B36$U&"!(8CY@#LC6LI9\G! ^;"8]\CBNGNKZY@+B+2[JXVC
M(:-H@#^;@_I5ORD\WS=B^9C;NQSCTS3Z (+.:6XM(Y9K=[>1ERT3L"5/ID'%
M3T44 %%%% !1110 56EE:*=ML+R94?=[=:LTT+B1F]0!_.@" 74A('V64>_%
M#7$P8@6KD ]<CFK-% %87$I5B;608Z#(YIOVN7_GTE_2K=% %9YYQC;;,P(S
M]X#%5-1U"XM--N;DV3L(HR^U2"6QS@5J4UUWH5]: /'/^%XW7_0F:U_WZ/\
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M6OI#;[4N.* /D_\ X4Y\1/\ GD/_  ,_^O70^#_A=XXTK5+F:^3;$]G-$O\
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M_P!"OI7_ (#+_A1_PEU__P!"5XC_ .^;7_X_1_PEU_\ ]"5XC_[YM?\ X_0
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MQ7 4.K*<$':2.H]:TZ .7_X5OX*_Z%?2O_ 9?\*/^%;^"O\ H5]*_P# 9?\
M"NHHH Y?_A6_@K_H5]*_\!E_PH_X5OX*_P"A7TK_ ,!E_P *ZBB@#C_ 5A::
M8_B:RL;>.VMHM981Q1+M51Y$!X'U-=A7+^$/^0AXK_[#3?\ I/!744 %%%%
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MVN7M98KN+RY$D4 L"N3C&X#ZYH W**** "BBB@ HHHH **** "BBB@ HHHH
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M#KO:\^^#LR7'@^[GCSLDU.Y==PP<%@1D'I7H- !1110 4444 %%%% !1110
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MVE[:RB;,TK+MRK+PRNN#AO4\9XYR"PG.*W98TE]+TO4[Z)-3CFGU:Y%\B <
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M ':45R8@U!O%*RB*^#&<-YID80?9]OW=N<;LX[9ZUUE !1110 4444 %%%%
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MDLOB.([32K18$ODG'F71=I P^\%,V1M"L<E>I  (YH ]A=UC1G=@J*,LS'
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M 6/[(\1?]#1_Y(1_XT?V1XB_Z&C_ ,D(_P#&J_\ PG5A_P! CQ'_ .".Z_\
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MY9G]WP!ZUZ)10!Q.E^-]#LH)4N]?N[YVE9U>33I4**>B\1\X]:O?\+#\,?\
M/]/_ . ,_P#\17444 <O_P +#\,?\_T__@#/_P#$4?\ "P_#'_/]/_X S_\
MQ%=110!RY^(GA@<F^G_\ 9__ (BMW3=3L]8T^&_L)A-:S#*2 $9'T.#4]P";
M:4 9)0\?A7.?#Z":V\%6$5Q%)%(H;*2*5(^8]C0!T]%%% !1110 4C?=/TI:
M1ONGZ4 <E\+_ /DG.D_27_T:]==7(_"__DG.D_27_P!&O774 %%%% !1110
M5R_P^_Y%"W_ZZS?^C&KJ*Y?X??\ (H6__76;_P!&-0!U%%%% !1110 4444
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M +"UU_Z'7>UXO\./B3X0T70+RWU'6XH)9-1N)E5HW.49LJ>%[UV'_"X/ /\
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M)) ZJOE2<DJ0!]VL)OWCW,'&4</9K74\C/6BLK_A)-'S_P ?J?\ ?+?X4?\
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M=WU.-)V+A!&IY7 PBA1@=!3O^$$\'_\ 0J:'_P""Z'_XFN@HH Y__A!/!_\
MT*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B:Z"B@#GF\#>#D0LWA;0E51DDZ
M?" !_P!\U7@\*> KET2WT#PW*TD?G(L=G Q9/[PP.5Y'/2NDNH3<6DT(.#)&
MR GMD8KS@_"^_AT](;/7IX9A8):L[R.X)5U8@9/RH0I&!0!?\7?#/0=4T"2W
MTO1M#T^Y$B2?:/L<<>%4Y895<\BM"#POX :*!1HGAF1I-JH1:0'S"1QCCG-8
M#_#G7G>PSXBREJ@&"7)/)R,YZ8/H/I3+?X4RQ7BR27D#1_NRY4R(Y*J1@$'I
MR#0!U_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UAV'A?6
M+?7M/AEN)WTZ"%'NI6ER)YDR$VC=NP ><@ X'6N\H Y__A!/!_\ T*FA_P#@
MNA_^)JM?>%/ 6EVK76H:!X;M+=2 9;BS@C0?4D 5U-8OBC2+K6=,B@LY88YX
MKF.=3,"5.PYP<<T 9$6B_#6?[+Y.F>$Y/M>[[/L@MCYVT9;9Q\V.^.E<YXS\
M._#_ %;PA/9Z5-X/TV\O@!9WG[B,$K(-VUE&3T*\>N*LW_PSO]1G>]DU*VBO
M9#/)NAB8)$\C)R@)S]U6&3U+9J6W^'NIZ;;K!I]WIWEFWN[9EGB=E5)I2X(
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>trda-20211231x10k031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k031.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Z W@# 2(  A$! Q$!_\0
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M]N+2]9EMW&27*YW< 9&W!SD<=\5'<>/_  K:VL-S+K=L(9HC-&RY;?&&*E@
M.0"#S[5Y_)X4UCP1;:#<VRF]O+&6^3,%E-<Q&.8A@2JY=6';J#@@L.\GACX<
MZP?"UO\ :C#:SR^%KG23!-G?'+-*75FP.  >>_M0!Z5I'B?1->N;FWTK4H+N
M6VP95C.< ]"#_$#CJ,BM:N/\.>$;O1O$*:C-/ \2Z-:Z=M3.=\6<MTZ'/%=A
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !117FFH>,/$=E'XR$XM(I["6RBLTC'F+")V"[F) W$!@Q[<8
MZ<D ]+HKQ^^\<>)H;>[LXK^%;G2QJ<LMTUJI%VMKL*IMZ+N#X)'IQ5V'QYK3
MZ\+MBG]FM>R6 T_R1O!2S%QYF_KDMQCICWH ]3HKQ^Q\<>)IK>TLY;^%KG5!
MIDL5TMJH%HMUO+)MZ-M"8!/KS72:5X[O4\(Z5?WFAZMJUU<-/%*VE6JN 8I3
M'N8%AMW8R ,]Z .\HKGO"WB^V\5&_2'3M1L)K"58IX;^)8W#%=PX#'MZUT-
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%96AZ_:Z^NH-:QS
M(+&^FL9?-4#,D9PQ&"?E],X/M0!JT444 %%%% !1110 4444 <Q=>+9+7QQ:
M^'WTN>.VE@FE-](0%8QJC$(!DL ' )XYX&<&N;M_BK<-823W&@B.:XMH+K3(
MEN@WVA)IO*0.=O[L[BI/7@^HKMKW0K>_U_3=6E=_,L(IXDCXV.)0@;=_WP/S
M-<S;_"O2(+&YM6U#4I0\4<%K))*N^RCCD\Q%B.WL^#ELYP!0!GW'Q2OH[>:.
M+P_'+J.GQW<VIP?;-J0QV[*'*-M^<G<"!@>]:5M\0VNO$<-M%I@.C2WPTU+\
MS8?[08/. \K;]W'&<]:9/\*],GLUB_M75([B03I>W22()+U)V#2I)\N,$J,8
M P!6A#X TR#Q(FK17%VD*3B[73PR_9Q<"/RA+C&<[/?&>: $E^)_@F":2&7Q
M'9))&Q5E+'((.".E=6CK(BNARK#(([BN+^*5I;+\,O$,BV\0?[*3N"#/4=ZZ
MZP_Y!UM_UR3^0H L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!4@U*RN=0N["&X1[NT"&XB'6,."5S]0#^56ZX?PU_R5?QU_URTW_T7)7<
M4 %%%% !1110 4444 %%%% !1110!FZ[KVG>&])FU/5+A8+:(=_O.W95'=CC
M@"LB^\?Z)IZ6#S_:MEW;1WC,D.X6\+D*LDN/NC+8XST/85L:[I[:KH.H6,?E
M^=/;2Q1-)T5F0J">#CKVKAM8^'>JW]I:VT%W9*D^BP:/J!D+Y18WW%XL#YB<
MN,-M['/:@#I/^$\T,:O<Z?)+-%]G\Y6N7B(A9H5W2HK=V4<GCL<9Q5>'XBZ+
M-I[W*PWZS"6&%+-K<B>5I1NBVKG!#*"0<C[ISC%8=S\-K^^U*\@N+VV329)M
M0N873<9]]W$T;*RD;0%WN003GC@4R'P#K^5U2:XTW^U[>YLI((4>3R'6VCDC
MPS[=P+"5SPIQ@#GK0!W^CZM::[I-OJ5B[/;SKE2RE2""000>A!!!'J*O5Q%E
M\,]%N?#&EZ9XCLX=2GLC-('#.JJ\TADD"X(.,D 9[ 5E?#/2K'1/&?CK3=-M
MUM[."YM1'$I)"@Q$]3SU)H ],HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HKC_BI_R2[Q#_UZ'^8KJ+#_ )!UM_UR3^0H L4444 %%%%
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ME2U#OL^Q_827.S.S;YW?^]0![317S[I>HNVBJ1J%ZVBLVD_VW-)/+^[F8O\
M:07)RO(3?@X''3-=[X;G\9R^ M#DT3^S)F(GWOK$DP8PB4B J5!)S'C);VH
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M,\QCO0!TU%>=^!-?\1:CK$4.LZC;W<-Q8S7"+%:"$QM'<>5UW'.0">W6O1*
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M(*L2$/R8!)Y!QCI0!W=8^OZ%_;G]E_Z3Y'V'4(KW[F[?LS\O48SGKS]*V**
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M_/M;D[E [<Y) !J(>/9#XKCTW^SD_LYKR/3FNQ/EQ</!YP 0#!3'R[MW7VH
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M=R,X4;CA,G:,IT*\]<BNP^'MO]F\#:=%E>/-/R61M%&97.!$0"H&<<CGKWH
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M\CA8@C$A=[R'YO7CTH [JBBB@ HHHH *\_\ !'_)1_B#_P!?=K_Z)KT"O/\
MP1_R4?X@_P#7W:_^B: /0**** "BBB@!DLJ00O+(P5$4LQ/8#DUD^&8G.E&^
MF4K/J$C73@]0&^XOX(%'X4WQ*QN+6WTE#\^HS"%L=1$/FD/_ 'R"/Q%;2J%4
M    8 ':GT,]Y^G]?UZ@3@9- 96^ZP/T-5[^XCM[.1I K94A8V_C./NX[YK$
MT'[5<VLBHL=I&'.Z2.+YGR2<#/'&<?E7-.ORU%32NV=<*/-3<V[6-VXNX+4
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M!*P20;7V*Q'!9@<<%10!K>%['1])COM/TW4VO[E;DRWKS78GG$K #]YZ'"@
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M1NS^'3ZU/#)>7<$9A_T> J,22?/(PQP<=!^.:KWMB$2-I(9+R=I%9Y-H.%#
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M".1@CB@#T&BBB@ HHHH *\_\$?\ )1_B#_U]VO\ Z)KT"O/_  1_R4?X@_\
M7W:_^B: /0***Y?29;Z_O)X6EN(HESN)8D@9'RY/0^_UK"K7]G*,;7;-J='G
MC*5[)&W<7A+M;6J^;<8P<'"Q^['M].M<B-+,FKVVFR.LI>X,DW&<1Q88DY_O
M,4'YUV$J1V&F3^1&JK'&S >I [GK^-<%\.=:GUC6]4DN$0'RU9,9)09Y4$\D
M'W)Z4OJ\ISC5EK;\/\S*IB80C[!77-^-M[]CTBBBBN@04444 %%%% !1110
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M4=3U6VTJ!7G+-)(=L4,8W22M_=5>Y_EWH$VDKLLW%S#:6\EQ<2I%#&-SNYP
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MXO4GW)R3]:EAM;>W),$$41/!*(!G\JFHJ3=12T"BBB@84444 %%%% !1110
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MK&JV%MJ$MX(@%N8580A%V_*3Z\$_2N@T[3;+2+"*QTZUBM;2+.R&%0JKDDG
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M^S.,&0Q[<;_;.<UM?V+\1?\ H;]*_P#!3_\ 9T =Q17#_P!B_$7_ *&_2O\
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MH6D^E7-U8QV%K;ZA'I\T;,9)&N91(/-4C"A<8X)KL_"6CZK976LZKK8M$O\
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M7::W'X8\1VLVG3/>R6T+:E<103QR,XN?WT;9)$K&+>V] /E..F*^@J* ./\
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MNR\16C23*EC!I[W$$37<ENT]P)5!6(H?FEVXV@Y&">#S@TW4+J7XFH#=W/\
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M3AEE4MR2=K[ESVK>L_ F@VV@II$EJT\/^CF5GE<-*\"(D;$@\8$:\#CCIR:
M,.+X@ZCJ-AH3:;IEJ+S7;J>.S2XN"%CAB#%FE*@D/A?NC.">O&*K6/CC4-4N
M/"6JF'['!?:C=:;=6:R^8I(#;&S@<AH^OHQK9\0> ;34;#R=+6VM9#?-?MYX
MF=3*PPS*4E1HR>ORL ><CFH= ^'::)!X<MVOA-%H\ES<$"+:)9I<@$#)VJH9
M\#GM0!W%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD\ZWFACC0HY# G:%V8(=P1MZ,>AYH 4^(K6V2%=262RN)"P,3J7V@,%WEE!
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M5SJ%T!<G_2U4(!< .7 /R_*,LWW<<,?8@ T]-US3M7DD2RN#(T8#-F-ER"2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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H X6VL-9T^$65T2^=0@>"7Y,RO]H+RLNWYN8@6;=T)8#BBNZHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>trda-20211231x10k032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k032.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %> :P# 2(  A$! Q$!_\0
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M^O.+_P! %:- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M53ARF>#Q;KMIJUC0HHHK,[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@#I@5\Z>/M=\4Z=K.J>%M0\1WFH6L3K')YC$+)PK#(^N/RKZ]KY/^+=O9_\
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M:PQPP1*%CCC4*J@=  . *EHH *^4OBWI./&NOWWV;_EJI\S[?%_=4?ZK&_\
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M,/SK3!##(.12+4E+86BBB@84444 %%%% !1110 4444 %%%% !1110 4444
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MWX::S>66BV5O<QI&4ECA 9<R*.#]#0!NZ)\0?"4&@Z=%+KUFLB6L2LI?D$*
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M74)-/,L9!NHB T0ZD@GIQFO'Q)?Z3X<\:ZQH<]\FA+8I!927$C$S2\*\Z9Y
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M(<$@Y&X $>U 'OF:*\_^',LUOK7BW1//FFLM-OU6U,KERBNN2@)[ C]:] H
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MHH PK;PGIMOJFO7^UY'UM8TNT<Y4JB%  .V0QS6=X9^'FF>%]3^W6]W?W3I
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M*W*** "BBB@ HHHH *Y_Q1X2M/%$=JTMW>65U:.7M[NSE\N6,D8.#[BN@HH
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MBG6-+U.822_9[6^ 1V9(V=2CJF[D+OB) _VC6@OA'1EG$PMF\P:@=3!\UO\
MCX*E2W7T)XZ>U.TK2+BU\0:UJMT\9:]>)(%C).R&-, '('S%F<\<<B@#:HHH
HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>trda-20211231x10k033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k033.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &9 X # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \?\
MA+_R4?XC?]A-_P#T;)7L%>/_  E_Y*/\1O\ L)O_ .C9*]@H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'_A+_ ,E'^(W_ &$W
M_P#1LE>P5X_\)?\ DH_Q&_[";_\ HV2O8* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH :[H@R[*H]2<4N1C.1CUKQ+XGOIQ^)NGP^,YKJ+
MPLU@QMS%O\LS@\YVCD__ &-<J?&=VGPDGL(+R\^R?VX+!)\GSA:E=^!WSC ^
ME 'TLLB."4=6QZ'-.KQSX6KH=CXQOK*PMM:T:Y:V#G2M0^[(N1^]&><_XUW/
MCVV\17>AFWT"[ALPP<W5P_WTC"D_)_M'I0!U*LKKE6##U!S2UYS\#LCX6:>"
M<GSI^?7]ZU>C4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 45R_C[Q6_@_PO)J4-N+BY:1(8(V. 78
MX&?:N>T+QEXET_Q3'H'BZULS->6;7=G+9$X.T$LA![\4 >DT5XD/BGXJ328?
M%+V^F'19=0-D+(,?M Y(_/C./QKVQ6W(&P1D9P>"* %HKS,?$Z2^^*MGX9TZ
M!'TUC)'+=$'YY$!+!#Z \&O3* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***RKSQ-H6G736UYJ]E
M;SIC='+,JL,^Q- 'FGPE_P"2C_$;_L)O_P"C9*]@KQOX/3Q7/Q ^(4\$BR0R
MZBSHZ'(93+(00?2O9* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHI&SM.W&['&?6@#BO&FB^+KW4[.]\.ZA9F"-"DMA?1!HBW.) <9R,^O:L5
M_A1+)X!?2VU!/[;:^_M,783Y/M SCC^[@XKL3#XKW'%[I.,\9MY/_BJ/(\6?
M\_ND_P#@/)_\53L9>T?\K.9\-^$/$S>+I?%/B>\LFOX[0VMM%:*0@S_$<UT^
MD6FNR>%Y;77Y[:74Y$D0R0+M3!!"\50BO/%4NM7&FBYTH-#"LI?R'P=Q(Q][
MVJ]Y'BS_ )_=)_\  >3_ .*HL)5K[194^'7AJZ\(^#;;1[V2.2>*25RT?3#.
M6'\ZZJL.*'Q0)D,UYI9CR-P6!P2/;YJW*&:1ES=+!1112*"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#DOB7
M!97'@6_6_P!-N;^W4!FBM3B1<'[Z_3K7D_@O3UUKX@6>K:!?:OJD&G6$OF7N
MHYP)"I"0KGT)Y^IKVC5O%FFZ->?9+I;DR;0W[N N,'W%41\0-#'2.^'TM6I\
MK,G7I1=G)'@4<-@+&!X;:]'Q(_M3>T8B/]_D[<;=N._K7N/B#6;[6K+5_"NA
M2O;>)([2-C,ZE8E#$!MK^NTMCT.*M-\0]!3#.MXN3@$VS#FG?\+!T3.?+OL_
M]>K4^5]B?K-'^9'D$>A^,- ^('@[3C:Z5'-;0R+;>2&*%/XRY_O'DU]%5RG_
M  L'1,Y\N^S_ ->K5T.FZA#JEA%>VX<12YV^8I5N"1R#]*336Y<*L)NT7<M4
M444C0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "N)U_X4>$?$VL3:KJEA++=S8WNMPZ@X&!P#CH*[:B@#Q7X
M*6%OI7C3QWIUHA2VM;XP1*220BR2 #)Z\"O:J\?^$O\ R4?XC?\ 83?_ -&R
M5[!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !117G^N_%6TTG6;_3K31-3U/^S0&OY[5%V0 C/<\G\J /0**XC6/B?I&G
M:3I%W96MYJ=QK";[*TMDS(X'4GTQG'UK6\(^+['Q?I\UQ;0SVUQ;2&&YM;A=
MLD+^A']: .AHKB_%7Q%M?#FL1Z/:Z5?ZOJ;1>>]O9("8X_[S&MSPSXDL/%FA
MPZKIS/Y,A*LD@P\;#JK#U% &Q1110 4444 %%%% !1110 445A^)/%%EX8A@
MEO8KB19F*KY*@D$#ODBFE?8F<XP7-)Z&Y17!?\+9T+_GSU'_ +]I_P#%T?\
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M4%[=Q6%C/>3DB*"-I'(&3@#)J>LCQ3_R*>K_ /7G+_Z"::W)F[1;1A_\+/\
M#G_/2X_[]&C_ (6?X<_YZ7'_ 'Z->)45O[*)X/\ :=?R/;#\3/#3'):8GWA-
M)_PLOPSZS?\ ?@UXI11[*(?VE6\CU#Q/XWT/5;.SBM3)NBO(YFS%CY1G/\ZV
M_P#A9?AGUF_[\&O%**?LT2LPJJ3EIJ>U_P#"R_#/K-_WX-.'Q.\-@8$DX'M"
M:\2HI>RB5_:=;R/;?^%G^'/^>EQ_WZ-7]'\<:-KFHI8V;S&9P2 T9 X&37@=
M==\-/^1VM?\ KG)_Z":4J:2N:T<PK3J1B[:L]RHHHK ]L**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'_A+_
M ,E'^(W_ &$W_P#1LE>P5X_\)?\ DH_Q&_[";_\ HV2O8* "BBB@ HHHH **
M*1L[3MZXXH 6BOF'5?$.H1WNHK+XBU./QDFJ>5:VT=P!:["W )SL QZUZ#K,
M.J^-?B3+X:EUF[TZVT[3DFD^Q2%"\S=\CJ!Z4 >NT5P7P@U^_P!?\#[M2F,]
MW974EF\S=7VX()_!@/PKE/BWJWB^&]M?*']G:%%J,$*2Q2D2W;-R>AX48(]_
M>@#VBBBB@ HHHH **** "BBB@ HHHH **,@=Z3(]10 M?/FN6LFN>*_B#/9Z
MP- 2TC$<]OGF^VJ?F;)X!QCCU%?061ZBN<UKP'X6\0Z@M_JND6UQ=* /,;(+
M =,X/- 'ECI%>:!X UW2M0T[0-;BMWAM+:]#^3,F<,,X./7G^]6M\)IY[;6_
M'.K:OJ=I-"UU"LE[&=D#2*'W[2>,?,O->CZQX4T'7M,AT[4M-MY[2#'E1D8$
M>!CY<=*6+PMH,/A]]!CTVW32W&'ME&%;Z]S0!YYXJA>#XCQ:UX9\3Z/::K=:
M?MF@U MLDA&"'5@"#T''M]:N? V&X7PMJ<\TWGQSZE,T<P7:)>>7 [ GFNMU
M;P+X8URVM(-1TFWFCM$"0 Y!11_#D'.*V[*SM--LXK.RAC@MXEVI'&,!10!8
MHI,CU%&1ZB@!:*** "BBB@ HHHH *\W^+W_(/TO_ *ZO_(5Z17F_Q>_Y!^E_
M]=7_ )"KI_$CDQW^[R_KJ>3T445TGS04444 %%%% !1110 5[!\)O^0#>?\
M7?\ I7C]>P?";_D WG_7?^E15^$[LN_CKYGH%%%%<Q]$%%%% !1110 4444
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M385DFAU&&XD#,%PBYR?UI=+\3>*=8L$O;/1K1H') )G(.0<'M[5<_M/QG_T
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MO_(5Z17F_P 7O^0?I?\ UU?^0JZ?Q(Y,=_N\OZZGD]%%%=)\T%%%% !1110
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M8V7Q>T6.VA&V.,HK;!V SV'I0![!X<T;3[57UB+1UT_4M1C1[M2Q9E('"<]
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M4/A1\QC/X\O4****HY@HHHH **** "BBB@#WWP'_ ,B9IW^X?YFNCKG/ ?\
MR)FG?[A_F:Z.N26[/JZ'\*/H@HHHI&H4444 %>;_ !>_Y!^E_P#75_Y"O2*\
MW^+W_(/TO_KJ_P#(5=/XD<F._P!WE_74\GHHHKI/F@HHHH **** "BBB@ KV
M#X3?\@&\_P"N_P#2O'Z]@^$W_(!O/^N_]*BK\)W9=_'7S/0****YCZ(****
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M2%6)_$BKE% 'COPAC2+XA_$2.-%1$U)U55&  )9, "O8J\?^$O\ R4?XC?\
M83?_ -&R5[!0 4444 %>!>/?^1WU/_?7_P! 6O?:\"\>_P#([ZG_ +Z_^@+6
MM+<\S-/X2]?T9SE%%%;GA!1110 4444 %%%% !7TKI?_ "";+_K@G_H(KYJK
MZ5TO_D$V7_7!/_0165;H>ME7Q2^1;HHHK ]H**** "BBB@#QKXK?\C1#_P!>
MR_S:N$KN_BM_R-$/_7LO\VKA*ZH?"CYC&?QY>H44451S!1110 4444 %%%%
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M?R3_ !H_X6WI'_/A>_DG^->/T4>SB/\ M&OW_ ]@_P"%MZ1_SX7OY)_C2?\
M"V](_P"?"]_)/\:\@HH]G$/[1K]_P/?/#7C.R\3W$\-K;7$30J&)EQ@\X[$U
MTE>3?"/_ )">H_\ 7$?^A5ZS6$TD[(]G"595:2G+<****DZ0HHHH *R/%/\
MR*>K_P#7G+_Z":UZR/%/_(IZO_UYR_\ H)IK<BK\#]#YVHHHKK/D@HHHH **
M** "BBB@ KKOAI_R.UK_ -<Y/_037(UUWPT_Y':U_P"N<G_H)I2^%F^&_C0]
M4>Y4445R'U(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 4-;C\W0-1CS(-]K*N8AEN5/W??TKY]MM7TFW\ _V*_PSOI=2$'DFZ:P)
M+OC'F;MNX'/.,U[CXAMM8-Q#>V.LK86-M#*US&8@^\[3M;)!(VGFO/[BR\<6
MVC#6)OBG8IIS+O6X-I%M(]CMY/M0!T'PR\4'4=-MM";2=6M7T^S0-<7T!02D
M87@GOWKT"LSP]</=^'=.N)+O[8\ENC&XV;?-)'WL=LUIT %%%% 'C_PE_P"2
MC_$;_L)O_P"C9*]@KQ_X2_\ )1_B-_V$W_\ 1LE>P4 %%%% !7@7CW_D=]3_
M -]?_0%KWVO O'O_ ".^I_[Z_P#H"UK2W/,S3^$O7]&<Y1116YX04444 %%%
M% !1110 5]*Z7_R";+_K@G_H(KYJKZ5TO_D$V7_7!/\ T$5E6Z'K95\4OD6Z
M***P/:"BBB@ HHHH \:^*W_(T0_]>R_S:N$KN_BM_P C1#_U[+_-JX2NJ'PH
M^8QG\>7J%%%%4<P4444 %%%% !1110![[X#_ .1,T[_</\S71USG@/\ Y$S3
MO]P_S-='7)+=GU=#^%'T04444C4**** "O-_B]_R#]+_ .NK_P A7I%>;_%[
M_D'Z7_UU?^0JZ?Q(Y,=_N\OZZGD]%%%=)\T%%%% !1110 4444 %>P?";_D
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M*[OXK?\ (T0_]>R_S:N$KJA\*/F,9_'EZA1115',%%%% !1110 4444 >^^
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M8[_=Y?UU/)Z***Z3YH**** "BBB@ HHHH *]@^$W_(!O/^N_]*\?KV#X3?\
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MFNCKDENSZNA_"CZ(****1J%%%% !7F_Q>_Y!^E_]=7_D*](KS?XO?\@_2_\
MKJ_\A5T_B1R8[_=Y?UU/)Z***Z3YH**** "BBB@ HHHH *]@^$W_ " ;S_KO
M_2O'Z]@^$W_(!O/^N_\ 2HJ_"=V7?QU\ST"BBBN8^B"BBB@ HHHH Y#XF?\
M(E7'_76/_P!"KPZO<?B9_P B5<?]=8__ $*O#JZ*7PG@9G_&7H%%%%:'G!11
M10 4444 %%%% 'H_PC_Y">H_]<1_Z%7K->3?"/\ Y">H_P#7$?\ H5>LUS5/
MB/H\O_W=?,****@[0HHHH *R/%/_ "*>K_\ 7G+_ .@FM>LCQ3_R*>K_ /7G
M+_Z"::W(J_ _0^=J***ZSY(**** "BBB@ HHHH *Z[X:?\CM:_\ 7.3_ -!-
M<C77?#3_ )':U_ZYR?\ H)I2^%F^&_C0]4>Y4445R'U(4444 %%%% !1110
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MT=<YX#_Y$S3O]P_S-='7)+=GU=#^%'T04444C4**** "O-_B]_R#]+_ZZO\
MR%>D5YO\7O\ D'Z7_P!=7_D*NG\2.3'?[O+^NIY/11172?-!1110 4444 %%
M%% !7L'PF_Y -Y_UW_I7C]>P?";_ ) -Y_UW_I45?A.[+OXZ^9Z!1117,?1!
M1110 4444 <A\3/^1*N/^NL?_H5>'5[C\3/^1*N/^NL?_H5>'5T4OA/ S/\
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ME>/U[!\)O^0#>?\ 7?\ I45?A.[+OXZ^9Z!1117,?1!1110 4444 <A\3/\
MD2KC_KK'_P"A5X=7N/Q,_P"1*N/^NL?_ *%7AU=%+X3P,S_C+T"BBBM#S@HH
MHH **** "BBB@#T?X1_\A/4?^N(_]"KUFO)OA'_R$]1_ZXC_ -"KUFN:I\1]
M'E_^[KYA1114':%%%% !61XI_P"13U?_ *\Y?_036O61XI_Y%/5_^O.7_P!!
M--;D5?@?H?.U%%%=9\D%%%% !1110 4444 %==\-/^1VM?\ KG)_Z":Y&NN^
M&G_([6O_ %SD_P#032E\+-\-_&AZH]RHHHKD/J0HHHH **** "BBB@ HHHH
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M5_\ KSE_]!-:]9'BG_D4]7_Z\Y?_ $$TUN15^!^A\[4445UGR04444 %%%%
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MI_Y%/5_^O.7_ -!-:]9'BG_D4]7_ .O.7_T$TUN15^!^A\[4445UGR04444
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M6_Y&B'_KV7^;5PE=W\5O^1HA_P"O9?YM7"5U0^%'S&,_CR]0HHHJCF"BBB@
MHHHH **** /?? ?_ ")FG?[A_F:Z.N<\!_\ (F:=_N'^9KHZY);L^KH?PH^B
M"BBBD:A1110 5YO\7O\ D'Z7_P!=7_D*](KS?XO?\@_2_P#KJ_\ (5=/XD<F
M._W>7]=3R>BBBND^:"BBB@ HHHH **** "O8/A-_R ;S_KO_ $KQ^O8/A-_R
M ;S_ *[_ -*BK\)W9=_'7S/0****YCZ(**** "BBB@#D/B9_R)5Q_P!=8_\
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M4445L>.%%%% !1110 4444 :?AW_ )&?2?\ K]A_]#%?1M?.7AW_ )&?2?\
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M@#Q_X2_\E'^(W_83?_T;)7L%>/\ PE_Y*/\ $;_L)O\ ^C9*]@H **** "O
MO'O_ ".^I_[Z_P#H"U[[7@7CW_D=]3_WU_\ 0%K6EN>9FG\)>OZ,YRBBBMSP
M@HHHH **** "BBB@ KZ5TO\ Y!-E_P!<$_\ 017S57TKI?\ R";+_K@G_H(K
M*MT/6RKXI?(MT445@>T%%%% !1110!XU\5O^1HA_Z]E_FU<)7=_%;_D:(?\
MKV7^;5PE=4/A1\QC/X\O4****HY@HHHH **** "BBB@#WWP'_P B9IW^X?YF
MNCKG/ ?_ ")FG?[A_F:Z.N26[/JZ'\*/H@HHHI&H4444 %>;_%[_ )!^E_\
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M@#WWP'_R)FG?[A_F:Z.N<\!_\B9IW^X?YFNCKDENSZNA_"CZ(****1J%%%%
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MXT/5'N5%%%<A]2%%%% !1110 5\OU]05\OUM1ZGCYM]CY_H%%%%;'CA1110
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M$"N[_P"%5>!_^A<LO^^*/^%5>!_^A<LO^^*:=G<SK4E5@X/J?/O_  D.E?\
M/['1_P )#I7_ #^QU]!?\*J\#_\ 0N67_?%'_"JO _\ T+EE_P!\5I[5G!_9
M=+NSY]_X2'2O^?V.C_A(=*_Y_8Z^@O\ A57@?_H7++_OBC_A57@?_H7++_OB
MCVK#^RZ7=GS[_P )#I7_ #^QT?\ "0Z5_P _L==OI/@GPW/\=-7T632;=M.A
MLA)';E?E5OEY_6O2_P#A57@?_H7++_OBCVK#^RZ7=GS[_P )#I7_ #^QT?\
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M;_H8K3\S1_PMCP-_T,5I^9IW_"JO _\ T+EE_P!\4?\ "JO _P#T+EE_WQ0
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M*\_+SZ8KJ** .>U/P-X9UG55U/4-&M[B\7'[QL_-CIN .&_$&NA  &!THHH
MS+#P]I&F:G>:E96$,%Y>MNN)D'S2'.>?QJC)X%\,2Z]_;;Z-;'42_F&;!Y?^
M\5SM)]\9KH:* ,EO#.C.VJ,VGQ$ZJH2^Y/[\ $ 'GT8]/6JU_P""?#>IQV"7
M>E0R+8#;:_,RF,>F01D>QK?HH R8_#&BQ:7=Z9'I\2V5XS/<0@G$C,<L3SWJ
MIJ7@7PQK%M96]_H\$T5E&(;<$LIC0  +D$$C '!KH:* ,MO#FCO/I\QT^'?I
MR&.TP,"%2 " !QC 'Y53TWP/X9T?5VU73]'MX+UL_O5R=N>NT$X7/L!7044
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>trda-20211231x10k034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k034.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $N Z4# 2(  A$! Q$!_\0
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M- %^BLEO$-F.@E;Z+4?_  D=M_SQE_2@#:HK&'B.U[QRC\!4JZ_8MU,B_5:
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M@M)[*6Y <(98F3&5;&0>N>.M44\)6&IV^C7&D7=T(K^Z:U<72+N0J"2PV]L
M\4*M2?\ 7]=@Y)'-?VOJ7_01N_\ O^W^-']KZE_T$+O_ +_-_C7:0:;H@\+^
M*(M*>XGEB,46ZZC0'=YF-R$= 3D>O%&J?#I+#3+UTEN_M-G!YS2R!!!,0,LJ
M8.X$>_6E[:G>S5OZ7^8<DNAQ?]KZE_T$+O\ [_-_C1_:^I?]!&[_ ._[?XUV
M2>"M%DU*TTI;^^%_>6(NHCL3RT.TMANYS@]*H:A:Z/%\.-,N(X)UO);B0>9A
M/F<==QZ[<=/UIJK!M)+?^OT#ED<Y_:^I#KJ-W_W_ &_QH_M?4O\ H(W?_?\
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MNI_WB35ZFF1!U84 1+96J?=MXA_P$4[[/#_SQC_[Y%+YT?\ >I//C]3^5.S
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M]X@TSQ&MII*Z9?:7:ZE:QRF:%9RRF-R.<$=0?2GV/B@6UI<6-SI-G=:?+/\
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M=1L]2ECM7M+8S >:OSDCY2#_ '/5NU/GHQ7H*TFRE=^*8]0LU6^T6QN;Y8!
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MJU6!?6<FF7/VZS_U>?G3L/\ ZU:]G>1WMN)8S[$=P: +%%%% !1110 4444
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MRNDMUWS&&=6\M>N6P>!P>:\TU^37] ^$%SH5_I@MXH[*"PBNTN/-:4L55_D
MRH"[N_:LSQ ]MJ1GO?"MG)'86VDMI+7:V[1"XEG>.-4 (!;:,L3CC- 'KI\4
MZ"-/M;\ZO9_9+N3RK>;SAME?)&U3W.0::OB[PZVK'2AK=A]O$AB^S>>N_?\
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MG:00V#]*S]1UF34?LH>)$%M D"[>X7N?>J!R5Q4D-N&!9B !VHY8H3;-J_\
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M5+E.>3K\WNI6.@TK5K36;/[59.7BW%,D8Y%7JJV&FV>EVWV:QMH[>'<6V1C
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M)]_-2P,PWXZXJ%\MN[$52W$1[LFACW- &VGYR![4VQC O&34B1N^0B%MH+'
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M\Q:^BN)/,E2[5) S9SD_+SV ST &*S?ANH3P'IRJ %!E  & !YKT =71110
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M1T% ''R-XY35(+43Z.T4D4DC3BUEVH5*@*?FZG<3_P !-6OL_C7_ *"&B?\
M@++_ /%T[49K^'QQHT8O"+&>&X!MU3&655.XGOUX%=)0!S/V?QK_ -!#1/\
MP%E_^+JIO\<_VL+/SM(\DP&7[1]EEV[MV-GW^N.:[&N1B,\GC<"RU*ZN%C=S
M?*S#R(E*_)$HQ]_.T^N,YZB@"Q]G\:_]!#1/_ 67_P"+H^S^-?\ H(:)_P"
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M2_VL3QD-N'RX V\@\<C&,&@#2\SQ?_S[:+_X$R__ !NCS/%__/MHO_@3+_\
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M/.98ALY]:?;*5B+M]XFGF-5(VXV^U/+ *0 3QZ57,K;BL^Q.KA(&8]2.!4<
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MH JQZ;8PBT$=I"@LU*6^U /*!&"%]..*F2"*.665(U624@NP'+$# S^%244
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MDD$J#\S9/)/TK3\,:&OASP[::4)C.80Q:4C!=F8LQQ]2:UZ* "BBB@ HHHH
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M&:+4ENR5'!4+@CZU1A\-ZB+I[=(D,\4(GD7S "BGU]#22Z%J9OUL?)S*T7G
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MJW."(A]YN[?2A))$-N3LMQ_AK1 =DTJ 11_=']XUV0!) '6F1QK&BHBA5 P
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MP)-$V,JXR#WJQ10)I-69#;6L%G D%M$D42#"JHP *FHHH&E;1!1110 4444
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MVGTN*,M'+&^YB!C!)SZFK>L7>DZ?JNGV]Q:0([RG8"B?O,J5&/Q85T%M;01
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M*TBV5L\-[YJ1F%,SGRI%V#_OK=_P&MC^Q],_Z!UI_P!^%_PHN2HI-M+<K?\
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M7NGVZ0RGRDWMM !)'\_K6[_8^F?] ZT_[\+_ (4 7%8,H92"",@BEI
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M(O"]Q-8WD%S>M;M<Q10,;4C[B(5/WAWR?TJ2#PM=6UO%!#XDU18HD"(O[K@
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MPG)S[GM7(_9O'7C'_7/_ &98MVY3(_F:Z30?ASHVD%9KA3>W0Y+S#Y0?9?\
M&M?94Z?\1W?9?YD<TI?"CER/%OQ"?!!T[22?<!A_-OY5W7AWPAI?AN+_ $6+
MS+@C#3R#+'Z>@K>"A0 H  X %+45*\I+ECHNQ48):O5A1116!84444 %%%%
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M72[NUUQ'DTV6UD@AGCO+E^EV[R!D8'^+@,<]LXKNJ** "BBB@ HHHH ****
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MHZC[#8PQL/X]N6_,UJ45G.O4G\3*4(K9!1116104444 %%%% !1110 4444
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6HK(]0**** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>trda-20211231x10k035.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k035.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %. X$# 2(  A$! Q$!_\0
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MIZ;HR>(H;V*:9FD,>GB!HPJDY!QR2,C%$I0C*W+I:_\ 6@)-J]SE/^$JU_\
MZ#%[_P!_C1_PE6O_ /08O?\ O\:W;3PWI'B&%9=(^UV7E7T=I*+EQ)O5SPXX
M&&XY6F6<&@MXJTVTTV'4;>XCU(0N\LBNKJ#C=T^5LCI@BGS4]?=V\@M+N8O_
M  E6O_\ 08O?^_QH_P"$JU__ *#%[_W^-5-63R]:OT!)"W,HR>IPYJG6JA!J
M]B;ON:__  E6O_\ 08O?^_QH_P"$JU__ *#%[_W^-9%%'LX=A<S[FO\ \)5K
M_P#T&+W_ +_&C_A*M?\ ^@Q>_P#?XUD44>SAV#F?<U_^$JU__H,7O_?XT?\
M"5:__P!!B]_[_&LBBCV<.P<S[FO_ ,)5K_\ T&+W_O\ &C_A*M?_ .@Q>_\
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MVUWI]L0U['"NH) (_)+G&PXX(^M27>@:+,NLV^GK>Q7.CD&22>0,MPH;:W
MV'/3UI\T%I*.H6?1F)_PE6O_ /08O?\ O\:/^$JU_P#Z#%[_ -_C773>&/#<
M?BC4])%O?"/3[-[F23[3DL0JL !CC&3UZU!IWA;0;O2K74+J3[)#J#OY7FZ@
MD9MD4X!^8?O3GD]*GVM*U^7\$/EEW.8_X2K7_P#H,7O_ '^-'_"5:]_T&+W_
M +_&M6;1]"T?3;%M4%[=37RRNDUG(H2-5)5< _?SU//2M[38-,EM/!*06DD$
M]Q/+^^609R,AB>/FSQC/0<4Y3II74?ZU_P A)2?4XS_A*M?_ .@Q>_\ ?XT?
M\)5K_P#T&+W_ +_&MM=$T:TAT^75$O;B75KF1(S;R!! HDV9(Q\S9YQ4[^&=
M%TBQ:34UNKJ9-6:P'D2B,,N 0QX.,9S^E'/2_E_ +2[G._\ "5:__P!!B]_[
M_&C_ (2K7_\ H,7O_?XU/>>'UC\;OH$$Q"&[$"2OU )')_ UJ3Z)H,L6K&SA
MOD?1I%\_SI@1<IOVMC ^0^G6J<J:MIOY"M+N8G_"5:]_T&+W_O\ &C_A*M?_
M .@Q>_\ ?XUM?$NZB;7Q800F&*TA4*H(V_,H/  &/QS7::GIUGJ,^E7)AB5-
M'V377R@9B,/F GVW)C\:S=2"C&3CN4HMMJ^QYC_PE6O_ /08O?\ O\:/^$JU
M[_H,7O\ W^->H7-Q!;ZMXAO3<0V"K8V;B=K<2B+<3_#WSG%5[;R+SQ)X8U!&
MMK^)XKI7O4A$7G,%8[3'CC&.M1[>-K\G]6OV*Y'W/-_^$JU__H,7O_?XT?\
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MM&/\H?5WW/G+(]1^=&1ZC\Z^C?[ T;_H$V/_ (#K_A1_8&C?] FQ_P# =?\
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MV)(9_P!V.47D >G4U/!XY\0VUBMI%J.$1-B.8U,B+Z!R,BO;/[ T;_H$V/\
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M?_ =?\*GZ[2_D'[&7<^=I[AKFYEN)6!DE=G<CC))R?U-1Y'J/SKZ-_L#1O\
MH$V/_@.O^%']@:-_T";'_P !U_PJ_P"T8_RB^KON?.61ZC\Z,CU'YU]&_P!@
M:-_T";'_ ,!U_P */[ T;_H$V/\ X#K_ (4?VC'^4/J[[GSED>H_.C(]1^=?
M1O\ 8&C?] FQ_P# =?\ "C^P-&_Z!-C_ . Z_P"%']HQ_E#ZN^Y\Y9'J/SHR
M/4?G7T;_ &!HW_0)L?\ P'7_  H_L#1O^@38_P#@.O\ A1_:,?Y0^KON?.61
MZC\Z,CU'YU]&_P!@:-_T";'_ ,!U_P */[ T;_H$V/\ X#K_ (4?VC'^4/J[
M[GSED>H_.C(]1^=?1O\ 8&C?] FQ_P# =?\ "C^P-&_Z!-C_ . Z_P"%']HQ
M_E#ZN^Y\Y9'J/SHR/4?G7T;_ &!HW_0)L?\ P'7_  H_L#1O^@38_P#@.O\
MA1_:,?Y0^KON?.61ZC\Z,CU'YU]&_P!@:-_T";'_ ,!U_P */[ T;_H$V/\
MX#K_ (4?VC'^4/J[[GG/P>(.O7_/_+K_ .SBO9*S=.TVPLIG>TLK>!F7!:*(
M*2/3BM*O/Q%559\R1O3CRQL%%%%8EA7D?QC_ ./W2O\ KE)_-:]<KR/XQ_\
M'[I7_7*3^:UUX+^,C*M\#/,:***]PX@HHHH **** "M[3O&6LZ7I\5A;2V_V
M>(DHLENCD9.3R16#14RC&2M)7&FUL=#;>-M<M&N3%+; 7$OG2*;9""V ,@8X
MX JJ_B;5'UR'6/-B2]A&U'CA55QSU4<'J:R**7LX+H/F?<FOKR;4;V:\NW$D
M\SEW8@#)/\JFOM4NM2%J+F17%M MO%M4#"+T!QUZ]:W/ B0G6+R2:WAG$-A/
M*J3('7<H!&0:THH(_&GAR2==.L;/4H+R&".2UC\M)!(<88>V<UG*HHRLUHOU
M&HMHYVR\3ZMIZV"VMPJ"P,AM_P!V#C?][/K^-1/XAU1X;:/[45^S3O<1.@ 9
M9&.6.?K6U-X:T=AJ*V>HW;R:4Z_:_-B55>/=M=H\>ASPW6K\_P .72SU*2*Y
MD>>&X"6D>!^_C^3Y_P G'3BDZE%/7\OZ[CY9F!J?C'7=7LFM+N\!@<@R+'$J
M>9_O$#FLJROKK3KR.[LYWAN(SE'0\BNQNO".@V4,L\VI7[PIJ7]GCRHT)9MH
MR>>F"3^ I;+P%:S7VIVLEY<3RV=UY BM1&)-F ?,(8\CGH.:2JTHQT5EZ XR
M;.>U3Q7K.L)$EY=_)$_F(D2",!_[V%ZGWHOO%6L:C;-;W%RFQV5I3'"J-,5Z
M%R!EL>];<.CZ3%X2U7SHKHWD6HI;"9HU5EY^48/*C^\.M3MX(TZ3Q)>Z3:W=
M])]@B,MRS+&"_3:J9P,\\EN*.>DNFWEZ!:3ZG-OXFU634K[4&FC^TWL)@G;R
MAAD( ( [< <TEAXDU/3K(6<$L+0*Q9%F@27RR>I7<#MS6Y/X-M;763;/-?S0
M-:"Y1+>-'E!S@H[9V+CUSBI+KP9IMA/K375_=_9M.A@G4QQH7=9/X2.F>V0<
M4_:4;6M^'R#EF85CXJU?3K1+:WN(_+C+-$9(4=HBWWMA(RN?:BU\4ZM9V]I#
M%-$5LY3+ SPJS(QSG#'G!R>*W;_P;ID":C';:A=R7%M8K?H)(E"&,X^4X.=W
MN.*S_"5G9FWU?5KRU6\&FVXECMG/RNQ. 6]0*.:DXN27X?UW"TD[7*5CXJU?
M3X3%;W$93S6E3S(4?RG.<LA(^4\]JK/K5_)9):23;XDNC=C<H+&4]6)ZGZ5U
M>H:?>>(-"LKEM#TRUEGN(HX[NSD5!MD. KQC)ZGK1J?@&WLO*\N[N/EO([:7
MS?+S(&8*7C"DD8)Z-S252E?568<LNAQ]YJ=W?:I)J4TO^ER.)#(@VX8=",=.
ME7=0\4:OJ=JUM<W">7(P:7RX50S,.A<@98_6MJ^\'V'EZC'IE[=275A?1VD@
MN$548R-M!!'/!ZY]*7Q%X(BT;2[FZBNIFDM9%203>6!,#P6C"DD8/9N::J4F
MTON#EEJ<OJFIW6L7TE[?.KSR *S*H4$ 8' ]A5Z7Q3J\JWBM<KB\@2WF C W
M(HP /3@GFMWP9)I,>F7(G_LZ'4GF BFU. R0LF.5!Z YI][X9LGU'7;G4(GT
MV"RABG6*Q994<.<90G'!/3TS0ZD%+E:V_P" '*[73,:'QMKEO=37"7$!DFCC
MB?? K JF=HP?K22^--=FU"VO7NX_-M5=85$*A$###?*.,D5N6N@6-C;:M/ W
MVNTN=!DN[5IXP)(SN Y[!AZBFZCX:M2\]]>W$B65EI]K(XMH461VDR%4#@=N
M6-3S4;[?A_7H.T[;G+P:[J-OH\FDQW ^Q22"4Q,H.&!!R#VY K4NO'FO7L,T
M4\MJRRJ4<_9$R01CKBI[?3-.ET77Y-/NWGMH3;!'EME#_,^",GE<>W6K&K>$
M-+M'UNUL[^\DO-+A6=A+&HC=3C*Y'.1GKTJG*DWJOP]/\T*TK:,Y?^T[LZ.-
M*WK]C$WGA-HSOQC.>O3M4^F>(-2TBWE@LY46*5@Y62)7 8=&&X<,/6NE;P9I
M4=Y>Z8^HWG]HV5BUU*!$OE,P4-M4]>,C.>N>*X<<@&KBX5$TD2TXFK?>(M2U
M&*\CN98RMY,D\X6(+N=1@'CIP*G'B[61?7%V9XF>YC2.9'@5HW"C"Y0C&1ZU
MAT57LX;6%S,OZMK-]K=TESJ$JRS)&(PP0+\HZ=/K5"BBJ225D#=PHHHIB"BB
MB@ HHHH **** /IVBBBOF#T@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!!1U;<-O/'/KFFZMXAEUB-O/T_3X[AV#RW,4&V61O4G/&>^.M>Q_\*S\*_\
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MTKZ(_9Y_Y$&__P"PF_\ Z+CKGG'E=CHA/G5T>MT445)84444 %%%% !1110
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M%%% !1110 4444 %%%% !1110!+!]\_2K%5X/OGZ58H **** "BBB@ HHHH
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MOXAT.TU:UCE2WND\R,2J VW) ) )ZXS^-<#J%EKUU\%[IM:TW[5X@^SRB%!
M&F4N2BL0HP)-C<D>]>@:'8KI>@Z=8*NT6UM'"!_NJ!_2@"_1110 4444 %%%
M% !1110!2HHHH *!R<44J_?7ZB@#E?\ A8OA47K6CZH(Y%E,+,\,BH'!VD%R
MNWKQUK;CUC3YM9FTA+E#?PQ+-)#SD(W1O0BO.[7Q1H,'@/5M&N;R&XOY)K^$
M:<GSRR.\LFU0@YYR/YU50W'AG5CK5WN,VCVNG0WHZED>!D<>^'"'\* /3K76
M+"]N;ZWM[I'DL'$=R.@B;&<$GCI4NGZA::K8Q7UC.L]M+GRY4Z-@D$C\0:XG
MP;H41N_$&F:I$+GS&LI+I9.DDC1[VSZC<>GM6[X$4+X-LE4  /.  , #SY*
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MV_V:X9 25ZJ3W%05J:T )(3GYMIW<=\UEURU8J,VD=M*3E!-A11169H%%%%
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MEFMY,4 $+1>8&&X9.S(W$#) R,D"MFN6\?Z;;7GAJ:[EL'O)K,;XHUDE7&2
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M0(OK5H2V98?NYZ]*[VN7O/\ DJ.C_P#8&O/_ $;#744 %%%% !1110 4444
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MXM/U2PL'M[B1KO?B2-,JFT9^8]LUG6OC2SNO[/VV5\OVTRA-T.,;.N>>,]J
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MEV@CN&B4RH!@*V.1^=6**39K"FXR<F[A1112- HHHH I4444 %%%% !1110
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M@65[.:^T\0D?+F3<RJ%ZXQD9_2LCQY'<OXP61?#T5Z4M@+9S8O,)I,%E#N"
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M1_\ L#7G_HV&NHKA+.?6IOB?IO\ ;-C9VC#2+ORA;7)F##S8<YRJX[>M=W0
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M.FW6I_8(;C=,1E2$.QCM#$!L8)"L#@'.#6;J_P#R/WAO_KWO?Y14 =-1110
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MRIY<K)Z'%,KSVK.QZ"=]0KZ7_9Y_Y$&__P"PF_\ Z+CKYHKZ7_9Y_P"1!O\
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MZ/\ ]@:\_P#1L-=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** *5%%% !1110 4444 %%%%
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M(Y3(8C% &KKGBBRT509)4^5U$A;(55S\WS=-P'.#U K=4AE# @@\@BN1\-Z
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M+)79XG,I5E67Y\1N,AT+9!4], C'(KO[.SAL+2.VMTVQ1C !))]223U)/.:
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MC110 4444 %%%% !1110 4444 2P??/TJQ5>#[Y^E6* "BBB@ HHHH ****
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M=H9) Z](B!QQ_%P,\=CCJ:R]6T&UU:2&9Y)K>XBRJSV[['*'[R$_W3^G48-
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MBOI?]GG_ )$&_P#^PF__ *+CH ];HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )8/OGZ58JO!]\_2K%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!2HHHH **** "BBB@ HHHH **** "O#/VD/^/3PW_UTN?Y1
MU[G7AG[1X)M/#F!_'<_RCH \ HIVQO[I_*C8W]T_E0 V@$CH:=L;^Z?RHV-_
M=/Y4 ;5GX@>RA:-$;)0#(;C-95Y<?:KEIM@7=V%-BB#%O,)4 <<=33-C?W3^
M5;U*]2<%&3T,84:<).45J-K1TJ^2V,D4N1'(.OH:H;&_NG\J-C?W3^59TYN$
MN9%S@IQY6=3;Q-$I&[<I;[V.,4ZX^]F-AM%95GJ.V)8IU;"\!@*MF[MRG#@<
M],5ZL*U.4=&>7*C44[M%N7[+<V"+AFD!(DW ;?;;[]:Y:YA\BY>+.0IX-;4]
M\J)E&4_[*BL20R2R,[ Y8YKCQ,H-))W9U82$HWOL1T4[8W]T_E1L;^Z?RKC.
MT;13MC?W3^5&QO[I_*@!M%.V-_=/Y4;&_NG\J $ +$ #)-6AIMT4W;./K4^D
M*OVLAUY*D+D=ZUA<2PD(8LC/!Q771H1E'FDSEK5IQERQ1SKVL\?WHF&/:OI+
M]GD$> K_ #_T$W_]%QUX\9UD5?,"\#:3C&:]S^"K1-X.O#$!M^WOG'KY:56(
MPL:<>:,KDT,3*I+EE&QZ11117$=@#J*X,^(-6&F6<MK=K<W%Q&DDBF-?W3><
MB[>.FY2PYY!&:[RFA$7.$49ZX4"@#EK+7M0OG%Q$R+:RZI%'&'C^;[.Z C\2
M><GL:LW^I74?BR&Q$S1VIM8Y3M:-<L9&4YW\D8 X%=#M'H/RI&1&(+(K$="5
M!H Y#3M<OY-)?4)IF<POYDT>8R#$)"'VJ/F&%YY]*MW>KZ@-!AN8TF26YN(B
MC+&/EBDE "\_Q;"#SZUT@C0$D(@)ZD*.:7 ]!^5 '"W&NZ]87]]97#KO:U_T
M,M&"5D+2%2^.,[$)('''O6M8ZK>3:A;!YPQEN7A>UV %(PA(DSUY(!]/F%=(
M5!Z@?E1M4-N"C=C&<<T <_JWB&YT^ZEB2T1T65(E<MCDQF0D^@XP/<UCS>-+
MQ%N8DMT$V7V%_P" E79 <=<;.<5W!56!#*"#U!&:0HA.2BD^NT4 <D_B^XA#
M1_8_-EW%@P;Y3&'*%^G0-M_ U=O-9N'\+Q7\>+662YBB9LA@JF<1LP[=,D9Z
M9KH=BXQM7&,8Q1M4KM*KM],<?E0!P[>)M3AUN6V\P36BI+%#+Y8_>R%E$;9'
MH25..#BMS1[Z_N+RVCNI(VCDTV.?Y4P3(6PQ/U["MP(H  50!TXZ48 ["@#F
MIO%$PNC:P6T;2AW0[G.%VM(.<#N(\_C5"S\87\L%S,]I$RJ6D502"J%T50?I
MOR3Z"NTV+DG:N3U..M&Q>?E7GKP.: .*NO&MUY4D4-K''.$8!F;<H;:[ \=5
MPGZU,_C&Y?S(DM(XB0^R:63"(5W_ 'NX)V#'KFNN\M./D3@8'RCIZ4>6F"-B
M8/4;1S0!6L)I;G3(969#,\*L2.@8J#S^)K-%KXE\@ ZC8^;]G92?(./-+<-U
MZ <8K=  Z #Z44 <UJ&J:MHLL;7<ME-%<L4B',>PK$SMD\YR5P/K4=_KFJ)*
MH^RFTMY&A"2LA<A'=0SEONJ5#'@UTDUM!/)#)+$KM"Q>,L,[2002/P)%2$ @
M@@$'J#WH Y2YUN]&D6$GVE('D$YDG* YV!C'QT&_ /\ *J=OXBU.XDMEGG%J
MMQO-P2@_T,JS!5Y_O!1U_K7;%%(P44CT(%!1#G**=W7*CGZT 86@:GJ%_=8O
M5C17TZVN1&J$%7??OSG_ '1QVK?HP,YQS10!+!]\_2K%5X/OGZ58H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** *5%%% !1110 4444 %%%% !1110 56O-.L=0""]L[>Y"9V^=$'VYZ
MXSTZ59HH S/^$;T/_H#:?_X#)_A1_P (WH?_ $!M/_\  9/\*TZ* ,S_ (1O
M0_\ H#:?_P" R?X4?\(WH?\ T!M/_P# 9/\ "M.B@#,_X1O0_P#H#:?_ . R
M?X4?\(WH?_0&T_\ \!D_PK3HH S/^$;T/_H#:?\ ^ R?X4?\(WH?_0&T_P#\
M!D_PK3HH S/^$;T/_H#:?_X#)_A1_P (WH?_ $!M/_\  9/\*TZ* ,O_ (1O
M0_\ H#:?_P" R?X4O_"-Z'_T!M/_ / 9/\*TZ* ,S_A&]#_Z VG_ /@,G^%'
M_"-Z'_T!M/\ _ 9/\*TZ* ,S_A&]#_Z VG_^ R?X4?\ "-Z'_P! ;3__  &3
M_"M.B@#,_P"$;T/_ * VG_\ @,G^%'_"-Z'_ - ;3_\ P&3_  K3HH S!X<T
M13D:/IX([BV3_"GG0M(/72K'_P !U_PK0HIW:%9&?_8.C_\ 0*L?_ =?\*LV
MMG:V49CM+:&",G<5B0*"?7 J>BB[862"BBBD,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** )8/OGZ58JO!]\_
M2K% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>trda-20211231x10k036.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k036.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3 YL# 2(  A$! Q$!_\0
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M(:8M'&O7>QYZ^@]*IW'@^^%QIZV,]OJ$&H.4M[B!CL+#J#GE<<G\*%['JE^
M>^'_  G/B;_H,W/YC_"C_A.?$W_09N?S'^%3MX4%I=V;Q:CINI1F]2UFCCD8
M;7) VD=2O;(K(U^U%EXAU"U$440BG9!'$247'8$\X^M.*I2=DE]PFY+=E_\
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MO\*/^%.ZE_T$[3_OEO\ "CZW1_F#V4^QYM17I/\ PIW4O^@G:?\ ?+?X4?\
M"G=2_P"@G:?]\M_A1];H_P P>RGV/-J*])_X4[J7_03M/^^6_P */^%.ZE_T
M$[3_ +Y;_"CZW1_F#V4^QR/A+6+?0?$UKJ-TLC0Q!]PC +<J1W^M7=,\26K:
M7J.CZTDUQ8SEI;=U&Y[>7/!&3T_SWKH?^%.ZE_T$[3_OEO\ "C_A3NI?]!.T
M_P"^6_PK.5;#R=W+^D4H5%T*]EX\M1IEBEU/J<$]E!Y'DVFP1SX&%8L>5/K6
M;;^(]'N](T^#6(;TW.FS/)";<J1,&;<0Q/3GN*VO^%.ZE_T$[3_OEO\ "C_A
M3NI?]!.T_P"^6_PJ.?#+:0[5.QGR^+-'OKOQ)#>1WB6.K/'(DD2J9$* #D$X
MYQZT\^-].CU;3I(;2Y-A%IIT^XC8C?M)ZJ>A/3TJ[_PIW4O^@G:?]\M_A1_P
MIW4O^@G:?]\M_A1SX;^;^K6"U3L8EEK7AS0]9TBYTJTNY%M9&:XN9\"212"-
MH4''&?QHE\2:=:Z9JEKIWVIFGU&*\MWF0#&TAB&P?4''M6W_ ,*=U+_H)VG_
M 'RW^%'_  IW4O\ H)VG_?+?X4_:X=N[E_6XN6IV*4OBW0H]2O-?M+6]_MBZ
MA,?DR;?)C9E"LV1R>!TK.'B:R%SX4DV38TE5%Q\H^;#9^7GG]*WO^%.ZE_T$
M[3_OEO\ "C_A3NI?]!.T_P"^6_PH53#+[7];#Y:G8X'5[I+_ %:^NX@PCGF>
M10W4 DD9KL%\9Z<-3BN3%<[$T0Z>1M&?,XYZ_=XJ]_PIW4O^@G:?]\M_A1_P
MIW4O^@G:?]\M_A52K8>22<MA*%1=#DKC6+>7P38:,JR?:8+J29V(&TJP.,'U
MYIVGZW!9^$M5TLB47-U/%+$ZCA=F.ISP>*ZO_A3NI?\ 03M/^^6_PH_X4[J7
M_03M/^^6_P *?M\/:W-UO^HN2?8IWOQ BO;?P_-+;.;[3[L3W.  LN%*Y!]2
M*@OO$NA)IFOV^FI?F;59$FWSJH5&#;MN >@YY[UI_P#"G=2_Z"=I_P!\M_A1
M_P *=U+_ *"=I_WRW^%9J>&6TOZO<JU3L9.K>(/#>LM-JMY8WDNJRVPB,#$"
M$2 8$FX'/X5:MO'=I;7^FR)%<^3'I*Z?<,H4.K#G>F>#@CO5S_A3NI?]!.T_
M[Y;_  H_X4[J7_03M/\ OEO\*.?#6LY!:IO8I'QCI?\ ;6F23G4-1M+57WR7
M83=YC# =8_NC%3/XWTXMI >;4KHV%^;AYKA$W.A4C@ X&,\"I_\ A3NI?]!.
MT_[Y;_"C_A3NI?\ 03M/^^6_PHYL-_,%JG8\_P!1N%O-3N[E-VV:9Y!NZX+$
M\UJ6^MP0^"KK1P)A=2WB3JZ\+M P1G.<UUG_  IW4O\ H)VG_?+?X4?\*=U+
M_H)VG_?+?X5J\10:2YMB?9S['*>&]<M]-DOK?4HIIK*_@\B8QM^\4=F&>N/2
MM>+QC9:,^CVVC07$ME83O/(]SA7F9@0>!P.":U/^%.ZE_P!!.T_[Y;_"C_A3
MNI?]!.T_[Y;_  J)5<-)W<AJ-1;(PI=3\+6=W;7.FVE]).+Y+EYKC ,2!LE%
M .#]36)K]_%JGB#4+^!76*XG:1 XP0#ZUW'_  IW4O\ H)VG_?+?X4?\*=U+
M_H)VG_?+?X4XUZ$7?F$X3?0\VHKTG_A3NI?]!.T_[Y;_  H_X4[J7_03M/\
MOEO\*T^MT?YA>RGV/-J*])_X4[J7_03M/^^6_P */^%.ZE_T$[3_ +Y;_"CZ
MW1_F#V4^QYM17I/_  IW4O\ H)VG_?+?X4?\*=U+_H)VG_?+?X4?6Z/\P>RG
MV/-J*])_X4[J7_03M/\ OEO\*/\ A3NI?]!.T_[Y;_"CZW1_F#V4^QYM6AH7
M_(PZ9_U]Q?\ H8KN?^%.ZE_T$[3_ +Y;_"K.G?";4++4[2Z;4;5EAF20@*V2
M P/]*F6*HM/WAJE.^QZQ1117A':%%%% !7RQ-_KI/]X_SKZGKR!_@_J3.S?V
MG:<DG[K5WX&K"GS<[ML85HN5K'FE%>D_\*=U+_H)VG_?+?X4?\*=U+_H)VG_
M 'RW^%>A];H_S&'LI]CS:BO2?^%.ZE_T$[3_ +Y;_"C_ (4[J7_03M/^^6_P
MH^MT?Y@]E/L>;45Z3_PIW4O^@G:?]\M_A1_PIW4O^@G:?]\M_A1];H_S![*?
M8X_0+S2+=KJ#6;-Y8+B/:L\./-@8=&7-=/!X@TZ5M T'3)+ZZCCU*.=KB]^\
M#G 51V'-6?\ A3NI?]!.T_[Y;_"@?![4P01JEJ".A"M64ZN'D[N12C-="#7M
M9T;2=2\3BS6\;4[_ ,RU=) OE1Y/S,#U.?2H/^$RTW^U&N=EQY9T/^S\;!GS
M/7KT]ZOGX/ZFQ);5+4D]20Q)I/\ A3NI?]!.T_[Y;_"I4\/:SD.U3L8XUOPY
MJ>GZ6VM07K7.G6WV;R(0/+G4?=RV<K3]-\5Z=:0>&D>*9?[-NIYIE5<@*Y.
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M.T_[Y;_"J^MT?YA>RGV/-J*])_X4[J7_ $$[3_OEO\*/^%.ZE_T$[3_OEO\
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M_BJ2JX5=?S'RU3DH_%UW-I^K0ZG+/>3WMLMO'*Q'[L!BW/MS3UN%OOAV;=6
MN-+OA,!GGRY!C(^C?TKJO^%-2_\ 0;3_ ,!C_P#%4?\ "FY?^@VG_@,?_BJ?
MM\/T=M;[,7)4ZHPSXPT6]O+?5M4T2:?5X%4%DF BF91PS+5'2_%%M$-7MM5T
M_P ZQU-Q))';,(S$P.1M[8_PKJO^%-2_]!M/_ 8__%4?\*:E_P"@VG_@,?\
MXJE[;#6M?\Q\E3L<O?\ BR*-=)M]#M9+2VTR4SQ^>^]WD)Y+8[=1CWJ_%XO\
M/PZH=:30[M-3+>842ZQ 9/[V/UQ6S_PIJ7_H-I_X#'_XJC_A34O_ $&T_P#
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M'\ZL>!%N;:^\3:=-J%Y>QV6HK%"]W+YCA3#&V,_5C0!V=%%% !1110 4444
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M .0OISU^M9/Q"N[JUTB$I=7-I9LTGVFXMN'3$;&,9 .U2X4$_0=Z .PHKC?
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MN2UGXE>%M"NM/@O-33=?$>68P7 4\;F(Z#GK76@Y&10 4444 %%%% !1110
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MT23"7"H'VY&X@8#'J21CFICRRC>+NQSDJ;]_0ZJBBBI+"BBB@ HHHH ****
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MO/2N0\'_ /(R^-/^PLG_ *314 =?1110 4PQ1GJBGZ@4^B@!B0Q1G*1HI]E
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MCUB&UO=3U^-O";SQS.L]Q/<2R2A@1D("IP,]-O%>QW*226LT<3*LC(P5F7<
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MA6(PR2$HNWN.>O7\ZW* "BDR/6C(XYZT +1110 4444 %%%% !1110 4444
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M(/<&EH **.E%  >E<AX/_P"1E\:?]A9/_2:*NN[5R/@__D9?&G_863_TFBH
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M,0X//KS^9JJ5+VE]4K*^IC7K>RY?=;N[:'56'A[3--U6[U*TM5BNKL 3.O\
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MKG?%WA#3-%&@W=J]\THURQ7]]>22+@RC^%B17J%<=\1/^/#0?^P]8?\ HT4
M=C1110 4444 ><_$C_D:O __ &$)?_11K6[5D_$C_D:O _\ V$)?_11K6[4P
M//\ XP_\B9;_ /81@_D]>X=J\/\ C#_R)EO_ -A&#^3U[AVI ?//C+_D<=5_
MZ^6KB=.N-6DUBZCNXMMJN=AQ@=>,'OQ7:^,O^1QU;_KY:L.NM+1'R=2:C.:M
M>]_EJ>C?"+_D,:A_U[K_ .A5Z[7D7PB_Y#&H?]>Z_P#H5>NUA5^(]W+?]W7S
M"BBBLSO"BBB@#&\1ZM-IEI;1VMH+N[O;@6T,1?8I)5F)+=@%5C^%>;-H?AE=
M7;9X1B.B0ZB-/:[%W('6<D+N"9^Z';;G.<YKT[7=#@UZQ2WFFG@>*030SV[[
M9(G&0"#]"1]":S(O!%G%_940N[MK+3G\Y;9F!$T^XMYLAQECN)/IF@#<TS3+
M31]/BL;&+RK:+.Q-Q;&22>22>I-6Z** //\ XCW'_$PT*RNK^:QTR?[4\\L4
MQB.](MT8+#WR<=\5GZAK5W=?#3PU]MO7AFNY+!-3E239(D,A^9B1RN[ Y]S7
MH]]IUEJ< @O[2"YB#!@DT8< CH<&HY=(TZ<3B6QMG%PBQS!H@1(J_=!]0,\4
M <9X4UG5H?""M:6%SK2)?W4$$@G0,8$D8(Q9R-W QGVI?!5[>R7OC&ZDTR6*
M[.J(3:&1"P/D1#[P.WISUKNH+:"TMDM[:%(88UVI'&H55'H *Y7P?_R,GC3_
M +"R?^DT5 $NOZ_J>FR78M+99/*3<@*$Y.,]JYN#X@^(+UEMH-$9;@)EV*G;
MQG)QU_N_K7IU&*6&7LG)S]Z[NK]/(G$1=6W(^72VG?N9^GW%_);V0O;,QS20
MEIR&&(W&/EZ\YR>GI4D-U=.MH7L9(S+N\T%U/DX!QG!YS[>M7**IN[N-*RL5
M!<W.R,_89,M.8V&]?E0$X?KT.!QUYI/M5SLD/V&3*SB-1O7YDR/GZ].2<=>*
MN44AE.:ZND6Z*6$DAB*B(!U'G9 R1D\8R>OI3IKBXC-SY=F\GE1!XL,H\UN?
ME&3P>!UXYJU10!6\^?SMGV1]GD[]^Y<;_P"YUZ^_2DCN+AWME>S=!+$7E8LI
M\IN/E//)Y/(XXJU10!4AN;F1;4R64D9E+"4%U/E8!QG!YS@=/6LGQ#K6IZ;X
M>FO;73&:Y24H(V(;"Y(#\=B,<>]=#131,TY1:3L<=IVI:_?);:I)H)#&$PF/
MSU4L&93O )X'!X/-;\0?3K.>"STUA';X\F-'4>;GDXR>,$GKZ5I447Z!&-K7
MU:ZGGGQ%O_$UM<11:2)4LIH3$[+$'W.V>G.1@>U8^B>#O$&E31VB!W@D E:9
MU5#G'*XR<<G'O7K=%-RO!TVM&K/^O(S]E+VG/S/1IKY?Y]3'T6.^L[.UM[F%
MFWAW=MP_<],(>>3R>1Z5I6LLLULDDT#02'.8V()7GU'%345G""A%16R.B4G*
M3D^H44451(4444 %%%% !1110 4444 %%%%  3CK7F=Q?WL7B6272+6#Q!<+
M.59YK(1-;C."HN,8XZ8Z\5WNL0-/IDH2V>YD0K)'"DOEEV4A@-V1CD=^*\KD
MMKRZ2:XG\*2P7LDCL1+KIC16WGDKYF0._ ^E 'L0S@9&#2TU/N+]!TIU !11
M10 5QR_\ECD_[ "?^E#5V-<<O_)8Y/\ L )_Z4-0!V-%%% !1110 4444 %%
M%% !1110 54U.[M+'3IKJ^9!;1+N<N,C\JMU'<6\-U;R03QK)%(NUT89!%-6
MOJ!R=AJNE^)8=/NM-@A5A<.C))$,HWE28S[=ZA\$V'B.TU'4GUE8A"7(3"@$
MMZKC^#'^>M:UEX3M=,CBBT^XFMHHI#(JJ%/S$$$DD9/!-;L2-'$J,YD8#!9N
MIK1SBN916C[[DI-V;,+Q=J5UI>FQ7%K?VUH?,VL9H#+N&#P ".>]<?<ZGXF3
M9K,.KZ;/&+)V7;9.,CS$!!&[@YQ]*[_6M$M-=LQ;7:MM5@RLIP0:S[?P?96L
M:QPW5XL:QM'LWJ058@L,%>Y IQ]DH)N][Z]K&$EB'4DE91MH^MRGX%US4M=M
M+R749(6,<BJ@BB* #'/))S76U#:VEO90^5;0I%'G.U%P,^M35%1QE-N"LC2C
M&<::51W?<****@U"BBB@ HHI"0!DG H 6BD#!AD$$>U+0!\\?M+?\?\ X>_Z
MY3_^A)7@]>]_M(1-/JWAN),;GCG49]=R5X/+$\$ACD4JPZ@T[.U^@KJ]AE%%
M%(85H:->P:???:)XS(JJ<(/XC[^U48UWR*F0-Q R>U6=1L'TZZ\AV5SM#!EZ
M8-:T^>'[R/0RJ<D_W4NI6D?S)7?&-S$XJ2&ZGMQ((I&42*5?'<5#16:DT[HT
M<4U9A5E+^ZC0HDS!2,8]JK44*3CLP<5+='0Z8FE#0KN>:<&^VL-C#GVQZUSU
M%/BC\V58PP4L<98\5K.I[11BE:WXF4*?LW*3=[_@,HJQ>6-Q83>5<Q%&(R,]
M"/457K)Q<79FL9*2NM@HHI0I8X )/M2&+&YCD5QU4@BK]]/;74*W&]FNI"?,
M0C 4YZBLZBKC4<8N/1D2@G)2ZH**N:=>16<Y,]LEQ"W#(W!_ TMC=P6FH>?)
M:+-%SB)SP*:A%VO+?\!.<E>T=OQ/8/V;/^1GUG_KR7_T,5])5\_? '4+:^\4
MZN8+&.VQ9+G8>OSBOH&E.*C*T7<<).4;R5F,FD\J%Y-C/M4MM49)P.@'K7'Z
MAX^B4PII5E)>3MO$L#*R21L,84KC.3DXSQQUKK[B(SVTL2R-$SH5#IU7(QD>
MXKE=/\"6\<4RZM=R:DS[/+D?*O$5!^96R6!.><'' XJ"SJXG:2%'9"C,H)4]
M0?2GTU$$<:H"2%  R<FG4 %<=\1/^/#0?^P]8?\ HT5V&1G&>:X_XB?\>&@_
M]AZP_P#1HH [&BBB@ HHHH \Y^)'_(U>!_\ L(2_^BC6MVK)^)'_ "-7@?\
M["$O_HHUK=J8'G_QA_Y$RW_[",'\GKW#M7A_QA_Y$RW_ .PC!_)Z]P[4@/GC
MQE_R..K?]?+5AUN>,O\ D<=6_P"OEJPZ[(['R%;^)+U9Z-\(O^0QJ'_7NO\
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M+0 45'<7$-I \]Q*D42#+.YP /<TV*[MY[0744\;VY7<)%8%2/7- $U<<O\
MR6.3_L )_P"E#5U-G?6NH0>?9W$4\6<;XV##/U%<LO\ R6.3_L )_P"E#4 =
MC1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C:EXL
MT/2-2BT^^U&&"ZEP0C'H"< GTR?6MFO*?&.DZS-?>,H+70[F\76+6VBMKB/;
MM0HISG)R,$YH ]%M-=T^^U6ZTVUN!-<6J@S;!E4)/ )Z9]JYGQ @U?Q]8:'J
M%S-#I?V![I8XY3%]IE#A=I8$$A5YP#WK0\'S1PVYTR+0+G2DAC5_W^W,A/!)
M()).>I-9WCW3=7U*2T2VTJSOK! 6=GW>="^>J;2#C'H<T )ID*:%\0X](TJ>
M:33[G3Y+BXMGF:06SJZA&!8DC=EAC/\ #7<UYWX",-KJMQ9PRZ;'*4W3VXCD
M6Z)'0MYG) YKT2@#YY_:48IJ7AQE."(IR#_P)*\2U'4)-2N!/*B*X4*=HQG'
M>O;/VEO^0AX>_P"N4_\ Z$E>#U2G)1<>C)<(N2DUJA[QO&%+#&X9'TIE6KNX
MBGBM@B%6CCVN3W-5:)I)V01;:U"G/(\A!=BQ P,G/%-HJ;E!16EHB027_ESP
MF8.I4(HR23W'O52\M9+2Y:*1"A'(!ZX[5HZ;Y%/H9JHN=PZA/<":*!!&J>6N
MTD?Q'/6H***AMMW9:22L@HHHI#+<^H2W-C!;2_-Y).QSUP>U5*MZ:;?[8JW(
M'EN"N3_"2.#59UV2,OH2*TG>24V[]/N,X<L6X)6Z_>-JQ;WCVR?NE59,Y$F.
M1QC%5Z*B,G%W1<HJ2LP))))ZFBBBD,***F,*?8Q,)!OW[2G<<=::3>PFTCV?
M]FS_ )&?6?\ KR7_ -#%?25?-O[-G_(SZS_UY+_Z&*^DJ0PHHHH **** /.=
M'NY?[:TRX6YFEU"XOK^.^@\PG]VGF;1MZ+@K& ?]KWJMXHU?7]=MM-CA\':K
M&;74K:\;>4Y6-]Q YZFO2([*UBNI+J.VA2XD&'E5 &8>YZFI\#TH XJ7QGK@
MAD,7@G5_,VG;N*8SCC/S5Y[I?Q1^)&L074UEX2BE2U)64[67:1VYZGBO=\"F
M'9&I)*J,]>G- 'A.F?%7XBZMI-QJ=EX5AGM+<L))%#<%>H [XKI_!_Q(\2:U
MH8O+SP??3,TC!)+4 (5&/[Q!SG-=[X>T2/P_I9L8YFF4W$T^YEQS)(TA'X;L
M5J!54    =@* /)?%5WXAU[6?#U[!X0U2--,NGFD5RF6!3;@<T^]\4ZIIWV8
M7?A/5(OM,ZV\.2GS2-G"]?8UZQ@>E9&N:#'KATPR3-%]@OX[U=JYWE,_*?8Y
MH \C\<V?B?Q3H,5A;>$]1BD2ZCG+2%,87=D<'WKT'_A,M9_Z$K6?SC_^*KL<
M"EP/2@#Y_P!=T7Q3JVN7M_'X6OT2>4NJL5R ?QK%M]%\1W5Y>6D/AZ\>>S94
MG0%?D+*& Z^A!KZ:P*RM/T2/3]:UC4EF9VU*6*1D*X";(UCP/7.W-:>TD<,L
MNH2;;6_F>6>"4\2>%[ZYGN?"6I2K+$$ C*9!SGN:[VQ\5ZK=7T%O+X2U6VCD
M<*TTA3:@/<X/2NKP/2C%0VV[LZJ5*-*/)#8****1H%%%% !1110 4444 8'B
M7Q,/#_V***QGO[R\=EAMX,;F"*68\\8 'ZU7U+QOI]CX&C\51H\UK-'$\2 A
M6;S&  YX')Y^E4M8\&Z@]W:ZEI.K,U_;7$LJ?V@=\:K(A1E&T @#((^E+#X4
MU.P\*6V@V4VGO%916ZP&ZA,@D9.7WKV!/0CD4 ;NAZTNL:)!J,D:VXFW;5,J
MN, D?>4X-87A&>%?$GC(F5 #JJ$98<_Z-%2Z3\/]/3P^NGZU%'=N;N:\*PL\
M4<;R,250*1A1G %2CX8^#E+%=& +'+$7$HR??YN: .H^U0?\]H_^^Q1]J@_Y
M[1_]]BN8_P"%:>$?^@3_ .3,O_Q=5=/^%?ABTMC'<6CW;F61Q(\\JD*S$JO#
M]%!"_A0!V/VJ#_GM'_WV*/M4'_/:/_OL5S'_  K3PC_T"?\ R9E_^+J.X^&'
MA26VECCTUHG="JR+<2DH2."/G[4 =7]J@_Y[1_\ ?8H^U0?\]H_^^Q7(V7PM
M\+6UA;P3V+W,T42H\[W$H,K  %B V 2>?QJ?_A6GA'_H$_\ DS+_ /%T =/]
MJ@_Y[1_]]BC[5!_SVC_[[%<9J?PI\,WMBT%K;264I9")HYY&( 8$C!;N 1^-
M7/\ A6GA'_H$_P#DS+_\70!T_P!J@_Y[1_\ ?8H^U0?\]H_^^Q7,?\*T\(_]
M G_R9E_^+JI=?"KPQ/=V<T5K)!'!(S2Q+/*1."I 4G?Q@D-QZ4 =E]J@_P">
MT?\ WV*/M4'_ #VC_P"^Q7,?\*T\(_\ 0)_\F9?_ (NC_A6GA'_H$_\ DS+_
M /%T =/]J@_Y[1_]]BC[5!_SVC_[[%<:?A3X9_M@7GV:3[,+<Q&T\^3:7W ^
M9G=G..,>]6_^%:>$?^@3_P"3,O\ \70!T_VJ#_GM'_WV*/M4'_/:/_OL5S'_
M  K3PC_T"?\ R9E_^+JG:_"GPS!>WLTMM)/%.ZM%"T\@$ "@$ AN<D9Y]: .
MS^U0?\]H_P#OL4]'21=R,&'J#FN5_P"%:>$?^@3_ .3,O_Q=;ND:+I^A61M-
M-M_(@+E]F]F^8XR<L2>PH OT444 %%%% !1110 4444 %%%% !1110!A>+KV
M[LM!/V&807,\\-LDQ7=Y?F2*A;'<@$UQ]OIVK:EXDO\ 1WU&W(T]XVDUAK=/
MM;I(F5C4XP"/FRWH1Q7?ZOI%GKFG/87\;/;NRL0K%3E2""".1R!7/)\,_#4<
MK2I!=B1R"S"\ERV.F?FYH ZY1M4#.<#O2T@&  .@I: .1^(UM)<>&H"+=[BV
MAU"UFNX40N7@652XVCJ,#I[5RL45P_PQU_2K&VN(9M0;4+C3K81,I%N9"0H'
M\.0>%]Z]8HH \X\(VMZ\/B>Y\.0)IUK=7,!T];JW9$!6&-93LX/)!'U%2#PQ
MXX'B(ZY_;.C_ &HV@M"/LS[=@<OTSUR:]#HH YJTM_$D<!&K75M<2%_D-G&R
M #WS5@IJ'SY\SWK3O-0M;&&>6XF5!!$9I!GD(,\X_"JFD:];:N\\<:2Q30MM
M:.5<'H#D>O49]#Q0!E7MKXQDE5M,U#3H+?:/DNH&=\]^0:K?8?B#_P!!C0__
M  %D_P :[.L_4-9M-/@\QW,C&40K''\S%R,[<>N.?I0!R.G)\2;N"1[B\T>U
M99GC"/;.2RJQ ;KT(Y_&KGV'X@_]!C0__ 63_&NETK5+;6-/CO+4MY;C[KKA
ME^HJ[0!Q%S;?$6&UEECU/199$1F6-;5P7(' '/>FV=O\1KBQMYYM1T6"62-7
M>%K9R8R1DJ>>W2MS6?%-GHDYANU:-CY91GX60,X0X/JNX$CTK7MKJ"\A\VVF
M26/.-R'(H Y/[#\0?^@QH?\ X"R?XU4U*/XD6=BT]M>:/=RAD A2V<$@L 3R
M>P)/X5WM<_/XNT^VU5-/N2;>4S-&WG';@!2P8>JG'!H S/L/Q!_Z"^A_^ LG
M^-+]A^(/_08T/_P%D_QKKXI8YHEDB=71AE64Y!%.8[5) )('0=Z .#NX_B1;
MW%G'%>:/.D\I21UMG A7:3N//3( _&K7V'X@_P#07T/_ ,!9/\:O6?C73+K5
M?L#N+>00>8XG.UD?>5*$'H1C]172@@C(Z4 <;]A^(/\ T&-#_P# 63_&J>SX
MD_VP+3[9H_V;R#+]J^S/MW[L;,9SG'-=M>W/V*RFN?)DF\I2QCB&6;'H.YK+
MTGQ7I>KW5Q!;W,6Z.143YQF3**V0/^!8^H- &3]A^(/_ $&-#_\  63_ !K8
MT&#Q%"T_]NWEC<*0OD_98F3:><YR>>U;5% !1110 5B:EK&J6=ZT-KX?N;R(
M $31RQJ#[8)!XK;K'U?Q-I.BNL5Y= 7##*P1@O(WT4<T 8NA1ZGJ'C>\URYT
MU[*T?3HK5 \J/N=9'8GY2>S"LOXD:KJEC?V,%IKMKI]K)&S20E7,TF#RV55M
MJ 8YK5^'NI-?Z+']DL)XM("LUM<W# /.6=B?E'0#/>F:Q8ZW;>.SK-AI27]M
M)I8LV4SJA5O,+'[W;&* &>#]"O;2]74I(-&DAN(<B[MY9)IG!P5^=Q]T_6NW
MKB?AZFMZ9H=AHFH:8D<=E"87N4N4<;U/W< Y'7]*[:@#YX_:6_Y"'A[_ *Y3
M_P#H25X/7O'[2W_(0\/?]<I__0DKP>@">>SGMH8)94VI.NY#ZBH*EEN9ITB2
M60LL2[4!_A%154N6_N[$QYK>]N%%:5CI/GW 6\E^R1E"X>0=0/2J=VL"74BV
MSL\(/R,PP2*;IM1YWL+G7.X=47;>\CTR6TN;1B;A5+.?0G(Q5?4K]]2NOM$@
M <J <=\=ZJ454JTG'DZ=B51BI<_7N%%%* 3T%9&HE%%% !1110 4444 %%%%
M !3WC:-5+ C<,BF5/!')>2K#N);!"@_RJHJ^G43=M7L>S?LV?\C/K/\ UY+_
M .ABOI*OF[]FX%?%&M C!%FH/_?8KZ1J1A1110 4444 %%%% #)98X8VDE=4
M1>2S' %<?J@U#7=5N$M)D63298Y8["7A+O(R&9O0_P /HR\UH^*K&_O[&:VC
MMXKO3YH&CN+;[LOLR$\$CT/I61X1T>6:6RUA9KNT> 2VUU9S(</CCY<\JN0&
M YQD@4 =;I>H+J>GQW2PRPELJ\4R[71@<$$>Q%7**JWNI6>G+NN[F.$%6<;V
MQD*,G'TH 34KX:=I\MV899EB )2(98C/.!WQUQ[5QLGCJ:379([9H6LHF1MN
MW+31,HVLC9Y8L2H4=-ISBH+[7&U/4M/C2.2^MHI'/EQMY9N#CIC(PZ$9VGJ#
MD=*Z/P_H,5LC7UW9QQWDTC2^60I$!+'[O]TD;=V#@D9H Z&B@D 9/ KB/$'C
M>6VFMQHD<=V$D<W"NK#S(UX<Q,!ABIY..U %W4M7.IZOI^F:?J:VUM<I,S7<
M)5BSQE08E)X#?,2?9:N>'[N]^UZCI=]<"[>R=-ER%VET=<@,!QN&#GV(-<;H
MFB)JNL7$UO9&"QGE2[DB?/E2!\Y>)UX#A@2"#RK8/2O1K#3;33(#%:1"-6;<
MQR26;U)/)- %JBBB@ HHHH **** "BBB@ HHHH **** "B@G S7+:EXMLU$+
MZ=<"XD.-L>,1N2>$+]%?@X!QS0!%XF\7-I0N;5(WBF4H4E"B3=&<;V4 \LO=
M3VYZ5?\ ">JW6I:>XNRLLD#!#<1CY)"1NX]2 0"1QD&N<T'1YM6L[..6VC2T
MCE>2XN@V);AU!521]Y) ?O?0CD&NZGGMM-LGFF9(;>)<L<8510!8)P*X37/&
MT\;PVUDHM;AGDBD,Z;@CC'E@G. C#<=V<84CK2^)O$2W%K>VFGW3.LD15W4$
M>4%X+H1]]0>&V\@<BKFCZ*+^Y@O+K38K.U@A5+>!'5P^2Q8G'!0Y4@'N,\4
M=!H]\=2TN&Z*X+9&<8#8)&X?[)QD>Q%7))$BC9Y&"HHR6)P *4 *    . !7
MGVI:[<^(I_LUN$BTNY$D%NTZYCO958J\3D<ID X[]^U !<>,;[^V[>*S47=H
M]V"&_P!251D8*C;NQ;&UNAZ5WEK+)/:QR30-!(PRT3$$J?3(XKF/#FCZA%J
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M2-)[ZE(****0!1110 4444 %%%9FJZS'IKQ0)#)=7DV3';Q8W$#JQSP /4T
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MRVH?[3*55LDQE1P>#R:S+;P??6=S/!"%-BUW'<(6DRV8_+"$_@&/_ 17>44
M<YHFDW5G>6[2P)$+>V:&216!-RQ92'/Y$\\Y8U5ET?69]2?=-*ML\Y,Q$^/,
M3?E0H_APG!]:ZVB@#A-(TG7+/4H8+B=Q]HD\Z[(;(VHJ;2#ZLRE3[5W=%% !
M1110 52EU& WYTR*<"]:%I H7=L'0%O3D\>N#576]?LM%:VANI6A>[+I%)Y9
M9%8+G+$=!7+Z+8RW%H=;TB4?V[&YCU"-Y=T=V0<[2>PP04(Z CWH L:I%KOV
MS3Y+W34NVAD$3SV@RLT,GRR(Z'E>,-W'RUOZ-X:T_0R#:>:0D?E1"1]WE)G)
M5?;//.3P*UU)*@L,''(]*S=0E&H07^EV-^MMJ AX8#+1;A\K8H ?<W37<-Q;
MZ5>6POHL9#_,%YZ,!SZUR-UIESJ^OFUU?1YHX+^'RKF2!]T8>/YHI0PY4_>7
MGVJEX>T[5CK5PT2V6E:G8V_V8VQB:19HV(8S%\@MN9>#R1SW->DQAA&N\@O@
M;B.F: *.EZ1;Z4DOE,\DLS!Y97QN<@!1G  P   *?J]G+J.D75G#.UO)/&46
M53@IGN/>KM% '*P:9J4EU)!.YAOH8PD.K)$&,T&<[&'9L]?S%=#I]C#ING6]
MC;@B&"-8TR>< 8JS10!B^(M(?5K94-T\,$:2,RJ[)EMOR'*\_*><5R^AZ$^L
MQ:A'+J+R6<CQI/+ FV.\^12QP?NMG@L.OUKT*D "C   ]!0 M<1XSCO8-9L+
MP,ZV+;8C<@,RV;Y8EV0$;@WRKD\#'O7;T$9'- '$^%="DN+*SNKBXF6W@N7E
MAM@N(RP9E61<\JI!R%[9]*[:BB@#S;Q;INHK/?RW!(26;=!=/+F+R=G,#1=R
M2".!GYLYXKJ= T62W%K?W5S<R2BU$<4,Y!,"MM9E+=6(*@9/I6^0#U ..>:6
M@ HHHH **** "BBB@ KS;XH-IEUI%]8)I$ESJK& K*ED7)42*3\^/[H/>O2:
M* .>\.WNAW4\XTG33:2*H,C&R,&X9X&<#-<SXVTRTOM?U,G73I\AT!DO$-OO
M'V7>V6!SP<YKT>N"\8>%=;U75[^YTMK/RK[1FTR3SW8%,LQW# Y^]0!%I6G&
MS\8^'VOM;:]F&FSBQ1+78OE?NMQ)R>?NUZ%7#Z1X?\0'Q+H^H:H+&.#3+&6T
M402,S.7V<G(&/N?K7<4 ?/'[2W_(0\/?]<I__0DKP>O>/VEO^0AX>_ZY3_\
MH25X..O- !16M?7&ER:1;16MNR7:-^\<]QC_ !I--T4Z@F]KNWA!' =\$UI*
MG:7+%W]"*<G-7:MZF513YD$<SH&#!6(##O3*S+"BKBZ9='36U Q$6P8+O/<U
MJ&WMH_#S3! KR';ENHQS^O%;PP\I7OII<PG7C&UM=;'/T445@;A3TD9%=5QA
MQ@\4RBFG;8&KE^PTUKZWNYO,5%MH]YSW]J@MK&XNSB",N?:H4D= P1V4,,,
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MW8YR*[Y8T1G944,YRQ P6/3GUH JZ;IMOI=H+>W!Y.YW8Y:1CU9CW)JY110
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MO0@#M7:4  # & ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_OR'[S8[9//XT 1Z1IC:;:D37#W-U(Q>:=^K,>N!V7T%:-%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT43+'<N$1CN1XI2(^G7<@_,4 >2?\,Y^)/\ H):?^;?X4?\ #.?B3_H):?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT5<G)VC&308HR5)1<KRIQT^E/HH 8(HU)(102=Q('4^M/HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>trda-20211231x10k037.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k037.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Q YH# 2(  A$! Q$!_\0
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MRDQC'W1T]*XF/Q9XRDU6XTU?!=E]H@@BG<?VV,;9&D5>?)]8F_2K7]N>.?\
MH2K#_P '@_\ C- '5B"%00(D . 0%'..E.\N/=NV+NSG..<UR7]N>.?^A*L/
M_!X/_C-']N>.?^A*L/\ P>#_ .,T =8T,;1O&478^=PQUSUJMI^F6VF6-M:0
M*3';1B.)G^9@HZ#-<Y_;GCG_ *$JP_\ !X/_ (S1_;GCG_H2K#_P>#_XS0!U
MP50Q8* 3U..M-\F/_GFG?^$=^M<G_;GCG_H2K#_P>#_XS1_;GCG_ *$JP_\
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MUY(S7._VYXY_Z$JP_P#!X/\ XS1_;GCG_H2K#_P>#_XS2-#J6M+9_O6\3?5
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MZY#^W/'/_0E6'_@\'_QFNAT74#J^A:?J30^2UW;1SF+=NV;U#;<X&<9QG H
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MT'<U>TSP]9:=IL-B46YBM[AYX//16,3,S,-O'&-Q /7%9'_"7:W_ -")K?\
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M/:@Q1M&\9C4H^0RXX.>N:Y/^W/'/_0E6'_@\'_QFC^W/'/\ T)5A_P"#P?\
MQF@#?TW1+'2["WLX(0T=NH2-I &8 =.<=JO!%4L54 L<D@=:Y+^W/'/_ $)5
MA_X/!_\ &:/[<\<_]"58?^#P?_&: .K\B+ 'E)@ @#:.,]:JZ?I-IIDUY+;J
M1)=S>=*3W.T* /0  8%<]_;GCG_H2K#_ ,'@_P#C-']N>.?^A*L/_!X/_C-
M'7T5F>']3N=7T=+N\LELKGS9H9;=9O-"-'(T9P^!G[N>G>M.@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .?L_^2A:S_V"K#_T;=UT%<_9_P#)
M0M9_[!5A_P"C;NN@H **** "BBB@ HHHH *P_"?_ "![C_L)ZA_Z5S5N5A^$
M_P#D#W'_ &$]0_\ 2N:@ \&?\B+X>_[!EM_Z*6MRL/P9_P B+X>_[!EM_P"B
MEK<H **** "BBB@ HHHH R/%'_(LW_\ UR_J*UZR/%'_ "+-_P#]<OZBM>@#
M(T#[FH_]?\W\ZUZR- ^YJ/\ U_S?SK7H **** "BBB@"CJVEVVL:=):7,,<B
MG#IYBY"N.5;Z@X-86F>";&.X%SJEK:W=Q$3]GD*Y,0.0V#VR,5U=%8SH4YS5
M22U7ZFL*\X0<(O1_H9UAH.E:9>W%Y96$$%S<*JS2HN&D"C R>^*AM_\ D<-0
M_P"O"U_]&3UKUD6__(X:A_UX6O\ Z,GK5))61FVV[L- ^YJ/_7_-_.M>LC0/
MN:C_ -?\W\ZUZ8@HHHH **** "BBB@ K%\'_ /(DZ#_V#K?_ -%K6U6+X/\
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MO'6]<M$=QR$'E_-\N.I')/I5KPWI<VB^';'3KBX,\T$05G+$C/7 )_A&<#V
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M&3UU',:]%%% !1137D2( R.J!F"C<<9)Z#ZT .HHHH **** ,?PS_P @J?\
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M73+5['2[6UDD\QX8E1G]2!BK5%% !1110!C^&?\ D%3_ /80OO\ TJEI=/\
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M:T->_P"1=U/_ *])?_0#6?XD_P"2>:O_ -@F;_T4: .@HHHH **** "BBB@
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M@J?_ +"%[_Z52UL5C^&?^05/_P!A"]_]*I:V* "BBB@ HHHH **** "BBB@
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MB@ HHHH *Q?!_P#R).@_]@ZW_P#1:UM5B^#_ /D2=!_[!UO_ .BUH ?X;_Y
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M0\&?\B+X>_[!EM_Z*6MRL/P9_P B+X>_[!EM_P"BEK<H **** "BBB@ HHI
M01D$$>U &3XH_P"19O\ _KE_45KUD>*/^19O_P#KE_45KT 9&@?<U'_K_F_G
M6O61H'W-1_Z_YOYUKT %%%% !1110 4444 %9%O_ ,CAJ'_7A:_^C)ZUZR+?
M_D<-0_Z\+7_T9/0 :!]S4?\ K_F_G6O61H'W-1_Z_P";^=:] !1110 4444
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M?\B+X>_[!EM_Z*6KVI:QIVCQQR:C>16R2,%0R-C)S_\ 7_#K7(^$-/\ %+>
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MPC8_^E45&M?\A7P[_P!A!_\ TEGH V:*** "BBN#\2:UXLT[Q)##9V\<MHS
MPI#$S>8#V=B.&X/0],4 =Y17FEI:_$"/Q,]R4MO-?_6!YY#9[?13C=QDXXZ^
M@S7I= !1110!D?\ ,X#_ *\/_:E$'_(WWW_7A;?^C)Z/^9P'_7A_[4K.GURT
MT_Q[)9S)=-)<V=NB-%:R2(I\R;[S*"%'(Y/]* .F=UC1G=@J*,LQ. !ZU2TK
M6]-UN)Y=-O([E8SM?8>5.2.0>>QQZUR&M?$_P2+;4],U34I[4B,PRQ2VLL<C
M*X*Y0%<GCG(]C7,^$/'7P\\(JUO'XF>Y:_*.7:V=5C&6 #<?*<'G/UXIZ6,V
MY\Z26G4]DHKFX_'&DRZ=-?)#JABB=4(_LR?>V[."J[,L.#R.*F3Q=ILEY96J
MPZEOO%5HV.GS!5W= [;<(?8XQ2-#>HKG/^$VTO[)<7(MM6,=O*L3 :9/N8G.
M"J[,L/E/(X''J*G'BO3_ +99VQAU%7NH1.C&PFV*I!(#MMPK<?=.#T]: -RB
MN<3QMI3Z=-?"WU81Q2+&R'3)Q(2<X(39DC@\C@58B\5:?/J%M91PZB9;B+S5
M8V$P11@G#,5PK8'0G/0=Z '^&?\ D%3_ /80OO\ TJEI=/\ ^1BUG_MA_P"@
M&J_@R[COO#OVN)95CFO;QU66,HP!N9>JD @^QJQI_P#R,6L_]L/_ $ T :]%
M%% !7)>-O%-]X;%H+.UC<3;MTLP)48QP,$'/.>?UYQUM-9%<8=0P]QF@".SF
M:YLH)W38TD:N4_NDC.*FHHH **** ,?PS_R"I_\ L(7O_I5+6Q6/X9_Y!4__
M &$+W_TJEK8H **** "BBB@ HHHH *ANWE2SG>!=TRQL47U;' _.IJP?$=UX
MDM1')H5KI4T*HS3M?3O'MQTQM4YXS0!Y'H4^ASZQ'J.JZU)NO/#D[:G<RW1$
MD4XFCRHY^0J1A5'H*]6\ 7=_?^ M%NM39VNY;96=Y/O./X6/N1@_C7GT%IK_
M (BL1XI_X5_X4N)74S0M)*WFSJ,X897'/4;B#SSBO3/">KR:_P"%M.U658%>
MYB#E;<L47V&X \?3K0!LT444 %%%% ',ZGX3EO?$$>JV^H_9BCK-Y?D;\RJC
MHK9+#C:[9&.H!SQ@PZ=X+93K:Z]=VVK1:L^90;5HGV G;&3YC JHX  '<\YK
MK** .,\+^'=)\,^-=<LM&L8[.V?3K&5HXR<%S)= GD^BC\J[.N?L_P#DH6L_
M]@JP_P#1MW704 %%%% !1110!G:UHL&N6B6T]S>P*CB0-9W3P,3@C!9""1ST
M^E8?_"O--_Z"_B/_ ,'5Q_\ %UUM% &?HVCPZ)9M:P7%[.C.7W7ER\[Y( QN
M<DXXZ?6J?A/_ ) ]Q_V$]0_]*YJW*P_"?_('N/\ L)ZA_P"E<U !X,_Y$7P]
M_P!@RV_]%+6T\:2J%D17 (8!AGD'(/X$ UB^#/\ D1?#W_8,MO\ T4M;E !1
M110 4444 (RJZ%'4,K#!!&0145M:P6<7E6\21)G.%&.?6IJ*7*KWZCN[6,CQ
M1_R+-_\ ]<OZBM>LCQ1_R+-__P!<OZBM>F(R- ^YJ/\ U_S?SK7K(T#[FH_]
M?\W\ZUZ "H;RT@U"RN+*ZB$MM<1M%+&W1T88(/U!-344 <,GPKT$W<WGJ9M/
M90(K-A@1D8Q\V<G!'']:O:#X!TS0]0%^7DN;F)V-N\G'E @KT'4X8@GWX KJ
MZ* "BBB@ K(M_P#D<-0_Z\+7_P!&3UKUD6__ ".&H?\ 7A:_^C)Z #0/N:C_
M -?\W\ZUZR- ^YJ/_7_-_.M26:*WB:6:1(XU&6=S@#\: 'T4R*6.>)9(I%DC
M;HRG(/XT^@ HHHH *,@]ZP==\9:'X;NH[;5+F>*61/,41V<TP*Y(ZHA Z'BN
M'\/>/_#MEJ5W-=:K=.&^4XTZZ)<YSN(\KCO6-2I*,XQ4;I]>QK"G&4)2<K6_
M$]6K%\'_ /(DZ#_V#K?_ -%K6E8WL&HV,%[:LS03H)(V9&0E2,C*L 1]"*S?
M!_\ R).@_P#8.M__ $6M;&0_PW_R!S_U]77_ */DK7K(\-_\@<_]?5U_Z/DK
M7H **** "BBB@ HHHH R/%'_ "+&H?\ 7(UKUD>*/^18U#_KD:UZ ,CPW_R!
MV_Z^[K_T?)6O61X;_P"0.W_7W=?^CY*UZ "BBB@ HHHH **** ,_7O\ D7=3
M_P"O27_T UG^)/\ DGFK_P#8)F_]%&M#7O\ D7=3_P"O27_T UG^)/\ DGFK
M_P#8)F_]%&@#H**** "BBB@ HHHH **** ,;Q/\ \@F#_L(V/_I5%1K7_(5\
M._\ 80?_ -)9Z/$__()@_P"PC8_^E45&M?\ (5\._P#80?\ ])9Z -FBBB@
MHHHH **** "BBB@#(_YG ?\ 7A_[4H@_Y&^^_P"O"V_]&3T?\S@/^O#_ -J4
M0?\ (WWW_7A;?^C)Z +VHR7,6F74EE&LMVD+M#&W1G .T'D=3CO7)?#G5M=U
M:QO7UH2X20"%Y(=F>6W ' S@C'MC%=M13OI8S<&YJ5]N@4444C0***AN+RVM
M IN;F&$-]TR.%S],T 345R$.H./%<D[ZG:?8^>?M*[=N. !NZ\?YS756]S;W
M<9DMIXID!P6C<, ?3(K*C5=1.\6K.VOYFM6FH6L[W5S,\,_\@J?_ +"%]_Z5
M2TNG_P#(Q:S_ -L/_0#2>&?^05/_ -A"^_\ 2J6ET_\ Y&+6?^V'_H!K4R->
MBJ>JZG;:-I=QJ-V6$$"[FVC)/8 #U)(%9GA3Q99^++*6>VBDADA;;)%)SC/0
M@]"#@_E3MU)<XJ7+?4WZ***104444 %%%% &/X9_Y!4__80O?_2J6MBL?PS_
M ,@J?_L(7O\ Z52UL4 %%%% !1110 4444 %,FC2:"2*4 QNI5@>X(YI]5[Z
M/SM/N8L.=\3+A/O'(/3WH \?&MZ;HEN^A6'Q3L[?3(MT2(]H)9X$R?D67...
M@)!Q7IWA*+2+?PKIT.A3B?3(X@L$N[.\#J2?4G-<9X0UO6O#OA>RTB;P!JZO
M:IY>ZV\C;)@_?.7&&/4]>2>37H>FW<M_I\-S-93V4D@R;>?;O3GH=I(_(T 6
MJ*** "BBB@"H^IV,>HQZ>]S&MW(NY(B>6')_H?R/I1:ZG97UQ<06US'++;MM
ME53RAY'\P1^!KE]6T#5'\70ZI:0QSPI/%<G?+LY2*2/9T/7S <^QIFB>%-2M
M)=1CENY+,/&T,-U;LID.Z>27>-P(!PX'(/.: )9M>TK2/B==VFH7T-O<7^G6
M$5K'(<&5O.NAA??++^=6F^(GA(3O -;MGECD\IU3+;&R1S@<=*I+X!NTOI;U
M?&GB$7,L:1/)FWRR(6*C_5=B[_G574_AC_:[PO?^)]6O#$W!N5B.$_B"[47!
M/')S]*:M?4BHYJ/N+4SK[XP:=%XC2*TEMY]%0JD]X#T)QD@YZ+G^?I751?$+
MPC/87-]%K]D]K;,BS2A^$+YV@_7:?RKF?#G@NYOK%+IO%6L1RV=S=65NR);$
MQQ13R0J QB)&509Y[FM[_A#=3_Z'GQ%^=M_\:H=N@J<9*_,[FG#XN\/W%[96
M<6K6S7%]!]HMHPW,L6&.X>V$;\C54_$#PD-/DO\ ^W[+[)',+=IM_P HD()"
MY]<*3^%8>N^'=8TO3XKB'QMK[,]Y:VY#_9\;99XXV/$74!R1[XK3_P"$-U/_
M *'GQ%^=M_\ &J1H:,7C'P[-J5IIT>KVK7EY&DMO"&^:1&7<I'L1S7*6?C_2
M9=;N]1;Q#;-I$#B.27S#Y2[@=@QTR=I_(UM?\(;J?_0\^(OSMO\ XU6;#X=U
MB3Q+?::?&VOB&WL[>=6'V?<6D>92#^ZZ8B7'U-95:7M'%W:L[FM.KR*2M>ZL
M=*_B_P /1ZHFF/J]J+YX?/6#?\VS87W8[?*"WTJOX(NH+[PV;NUE66WGO[Z6
M*1>CJUU*01[$&JG_  ANI_\ 0\^(OSMO_C5;FAZ2NB:5'8K<SW16221IYRN^
M1I'9V)V@#JQZ 5J9%3P9_P B+X>_[!EM_P"BEK<KCH?AQIMM!'!!K/B2*&-0
MB1IK,ZJB@8  #< #M5/6/ JV]E&]EK7BEY3=6R,%UBX;]VTR+(<;NR%CGMC/
M:@#O:*Y+_A7UE_T'?$__ (.[C_XJC_A7UE_T'?$__@[N/_BJ .MHK@XO JMK
M]Y ^M>*19I:P/$_]L7 !D9I0XW;N<!8^.V1ZU?\ ^%?67_0=\3_^#NX_^*H
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MY)'WSQTH RM)U'7([_7H;?0%FM(9IY(+@WJJ;B7@B,)CY<GC<3CO7)>/M?\
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M^(%ENK6*=U3[/@,R!B!F+IS0!TGB?_D$P?\ 81L?_2J*C6O^0KX=_P"P@_\
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MJ-CXEU4K;0F.:QDG/E7*A-HR%VC=DEB2#DX'  Q9_P"$-U/_ *'GQ%^=M_\
M&J/^$-U/_H>?$7YVW_QJHG!3BXOJ5"3A)270S4\/>(A8R%[MY(I)$:.S/WHO
ME()W%NAX^4 8.2<]M?3_  K=C4X=7U'7=5>Z52#:PW3):XVE0#'D@L <DYY8
M9K+B\-:O)KUW8GQOX@\J&V@F5A]GR2[2@@_NNG[L?F:O_P#"&ZG_ -#SXB_.
MV_\ C58T,+&C+FBWLE]QM6Q,JJLTMV_O+G@JT%AX:%H)[B<0WMXGFW$ADD?%
MS+RS'J?>NAK,\/Z2^AZ.EA)>RWKK+-*UQ,H#N9)&D^;'&?FQD 9QT'2M.NDY
MPHHHH **** "BBB@ K$U[PVNO20L=7U:P\H$8L+@1A\_WN#FMNJ]^2-.N2 Y
M(B; 0X8\'H?6@#E/^%=I_P!#7XH_\#Q_\174:98#3-.ALQ<W-R(ACSKE]\C<
MY^8X&:\C\/\ A2QU;P*NLW/CO6X9Y(C+(ZZH0ELW/R,#SE>AR<G%6?AUJ-];
M:EX=@.L:A>QZQITMQ<VM]/YS6[(5VR*3RJMDX% 'KU%%% !1110 4444 %<[
MXE\32:$]LL.GS7"/(IN;@*?*M8MP#.Y /KT'N3P":V-1FN[>PFELK5;JX092
M$R;-_J 2",XZ9XSW'6O+_#&L>(;KQ?,'B6]*R?9M2AE003K"<F.4I]UMN2I(
M]#U&#0!ZPCI+&LD;!T8 JRG((/<4.Z11M)(P5%!9F8X  [FJVG:;::39BTLH
MC%;JS,L>XL%W$D@9/ R> .!VJCXCN-1LK..\L!#,(G_?6<A"FY4\;58]'].Q
M/% $>A>+-.\0W$T-FERAC02HT\1031$D"1#W4D'FMVO.?"WA;2M0U>\U>'2[
MFUL#,LEH;C?#.K@?,$VL&$6<C8W&<X&#7H%S<QVL)DD=%[+O<*&;L,GN: *F
MLZQ#HUK'+)!/<232B&&"W4,\CG/ R0.@)R2.E+I&L6NMV9N+7S$*.8Y89D*2
M1..JLIZ'_$&O)KOQ?J6K^)$M=0MK^SC=U46813-97,9SOB<##Y!W;3G< 1CI
MN]0T/0WTN>^O+F^>\O+YT:60QB-<*NU0%'3CJ>M &S1110 A( ))P!U-<[H_
MBAM3UZ\T^>QEL450UF;D%7NE!(9U4] ".G7&#C!%9GQ$U76M,TPR6$#"T4!Y
MIUC$P91]^.1",A2IX8'J,';UIG@ZUN=8T.&'6[2&:WLY4FTN_@G)\V/&5(((
M92/ND'J.#GG(!W-9VM:U::%8?:[OS&W.L<44*;Y)78X5$7N36C7#>)[V:&2Z
MTC6-.EU6UO07T_[$-LR/D80X.4()!$O0=\'J =9I.J6^LZ;%?6RR+')D;)5V
MNC D%6'8@@BKM<UX3\)6OAVUC<1*MX8_+D>)F57&<@L@.TOZL!DG/K5+QUXE
MDTVU-AIQM[F\=2;FU6Y\NY6 @@R1@=QU^@- &GJWBZRT>_>UEM;Z80QK+<S6
M\!=+9&) +XY[$\ X R:W(I8YX4FA=9(G4,CJ<A@>A!KRGP-%K>MQ"8W=Y!<P
M0?9AJ;HKBXB'*K*C'#, VY77/5@2>_IFCZ9%HVCVFFP.[QVT8C5G/)QW- %V
MBBB@ KF=<\:66CZY8Z2 ))YY56>0DB.U1NAD8 A2V,*#C)K6UFYO[337FT^Q
M-[,I&85E".5[E<C!8=@<9]:\H\)'6]<UR022PZG'$[:?K%O?1^3.8#EHW88P
MQ&<=,]1R,$ 'L]%5=.L8],T^"RADE>*%=B-,Y=L=@2>3CI6/XI\0RZ#I<&JV
MP@N;5)E2>$-^\E4G;B+G!<'^'OTXH S;/XB65UKL=I+'#;6$[2QP7,URJNSQ
MG#9C/*@G@9Y..E=FK*ZAE(*D9!!X-<1HUIH7B3Q'=:[IUC)]FDB$5Q)+;J(;
MQO96^;<G0M@9R1SBNMOK^QT:P:YO)XK6UB &YN .P _P% %?7]870M(EOC"T
M[*RHD2L%WLS!5&3P!DCFJ>C^(+JZU6;2-6T[[#J,<0G0)+YL4T9.-R-@<@\$
M$#''K7DGB?5M1\4:_:B2WX#/%;R6<C36]U:2,!N>/@\' 8KDCG."%->J>%?"
MZZ.B7MU+>S:B\ B875V;@0+G.Q"0/ESW/)XR: .FHHHH *YRZ\4_9?%<&DRV
M<T-FXV-?SHR1-,1E8T)&"2._3/ )/%6?%&J76DZ---:0N9F1E2<1>9' V#M:
M10=Q7. < XKD/!&IWGB.WN=/U:P^U:3?1M/%<*_FQ*V[]Y%NSN7#<@'D<X)
M!H ])J"\O+;3[*:\O)DAMH$,DDCG"JHZDU)%$L$*1)G8BA5W,6.!QR3R?J:P
M=>U9])N0VJ6\,GAZ>/RYIBN?L[>L@/!C/3/8]>#D %CP_P")K+Q''<-:Q74+
MP,H>*ZA,;X8;E;![$'(K9KA_"/A'2()!K%I!*L+R&:S:0/%.JG(VN0W[Q,8V
MAAP,>E=+KVJOH^DS7<-M]KN57]S:B4(TS?W5)ZG&>* %UC7M.T&&*74)G02M
MLC6.%Y78XR<*@)( Y)QQ5NRO;;4;.*[LYTGMY5W)(AR"*\DT'Q'J/B7Q$L*W
M,S7$4SW5A<2VXWVZ.,-%*B\-'U4LIX*KGK7I?A[2)](M+E+F>.6:XN7N&$2;
M(T+8^51D\<9^I- &O1110 5@0>)K#4O$MUX?6(OY,1WR2KA)&XW(F1\^ 1G'
M R!4OBC5+K2=&FFM(7,S(RI,(O,C@;!VM(H.XKG . <5Q'A"XNO%2&VU.TE:
MSD)O;+4;:7<+>8-\Z*_WE(.?E;L2/F7% 'J-07M[;:=9RWEY/'!;PJ6DDD.
MH%3@8 &<^]<IXBU'3I'N]%\3VZVVF7$>^WO3)A&(&2-W&R12,CU['(Q0!MZ3
MJNFZ[:KJ&G2":/)CWF,HZG/*D, P[<$>E:%<7X)\,MIH?4?[2O9Q<,T@=KF1
MENU8 B22)Q\C]OEQG ^E;_B+7(?#NC2ZE<6]S-#&5#_9X][("<;B,CY1U- $
M]WK6EZ?=Q6MYJ-K;W$W^KBEF56?MP":N(B1KMC557).%&!SR:\>T'5M3\1ZK
MJ$<D.EZC>2Q?99TG1D@N$4L48,%8QMAN58<CI@@UZGH5C<Z9H-C8W=Q]HN((
M5C>7GYB!COS^= &A1110 5SL'BDR^+)-(FL9K2VVE8+FY4H+F48W+&#U !ZG
MKSC(!-1^-]>OM"T22:P@)FVEEGDCWPH5(.U\$%=PR W0'J16)X-GF\2:3-IF
MM:<TU@H6XLKSS"Z2(3D;9 =P93T/#=.XR0#T&J6K:K9Z)ID^H7\OE6\*Y8X)
M)]  .22> !U-7 ,  =JY;Q#JT.GS7%KXEM(GT"ZCQ'<JA8*V.8Y%'.3_  D=
M3QP<9 -?0];MM>L7N;>*XA,<C12PW,>R2-QU##Z$'\:TZY#P=X2L-)BCOXX9
M%F;<8GDWQS&-N<3@-AW']XC/3O6IXHUY_#^DO=06;WLX(/V:*15D*?Q,H;[V
MT<XH DUGQ-I.@20QZC<M&\P+*J0O(0HQEB$!VJ,C+' YK3AGBN8$G@D26*10
MR.AR&!Z$&O)?".J:MK^KJ1>M-J-DCQQW\MO\DUNY#!)T&,'@%77C(8?7TKP]
MI+Z+HT5E),LSJSNS(FQ068MA1V49P!0!J4444 (S!5+'. ,\#)_*N>\-^)GU
MR[O[>ZL9-/FA<&"WN%*RR0D#$A!'0G(XSC&#@UA?$3Q)=:="MBL9M;>9A'+<
M3DQI(K# ,<J$E&5L9R/?!&:UO#?FZ_IUE?:YIDUKJVG2M&'<[2QQC<I4X9&!
M!QR,_04 =365KFOVF@P0O/'//-._EP6ULF^65L9(5?8<D]!6K7 ^(KRUU"WN
M/#WB>UN$O9),:?-8(=TX)P&B/\+*#\P)QCU!H [33K^WU73K>_M6+07""1"1
M@X/J.QJU6'X;\-6GAZU(@BCCGD51-Y!9(F(X!6,L53WP!6/X^\3W6BV0M;*.
M8-<*4>^MRCM9.?N,T9Y*D\9_+)P* -NZ\5:-9:N-+N+PQW)*J<Q/Y:LWW5:3
M&U6/8$@ULUY5X>75/&NC:D\<\-L]]&(+]9[4O$[A=GF)R-KC&"IR,@$<<GT^
MU@-K9P6YD:0Q1JF]_O-@8R?>@":BB@YP<=>U &=K=WJ%IIKMI5BM[?-\L432
MA%S_ 'F)_A'?&347AW5UUC2(I7=?MD8\N[BV[&BE'WE*Y)'/3GD8/(-><:WK
M7BMO&$<$<445\G[ZQLKC"J[*,2)',  ZNO(W<YSG:0,^IVD$1/VXV:6]W<1I
MYW W\#A6(ZXR: +5<OJ/C>ST_P 0C2VMY&1)(HKBY+JB1/)]P88@M[D<"M[4
M8[R6PE2PG2"Z(_=R2)N4'W'H>E<5']G\::O9FYT1[?4=.W?:KHHLD YVF(,>
M)589/'W>.AXH [Y'61 Z,&4C((.0:221(8GDD8*B*68GL!UJ&"WM-,LA%;Q0
MVMK"I(1%"(@ZG@< 5Y'XL\8ZG<ZY;7&F3![*WF)M9[&;SH;M"N)(Y8^[+R>,
MD#\P >B:-XPL-:NH[=;>]M'GC\ZU^UP^6+F/^\AR<]C@X.#G%=!7&:!X8N/)
MTJ:XN+FVM+)VF@TV3:_DM@KM$HY:, G:#S@C/3%=G0 445!>?:OL<OV+R?M.
MW]V)L["??'.* ,/Q/K>IZ>B+H]B+QXV62\92':"'(R1'N#,Q&[ 'H?H=RSO+
M?4+.*[M)EFMY5W(ZG@BO+/#L?B;_ (3>0,TT=U;R[IX-0&?,M)&)(291APC9
M*@]!CID@>J6]K;VB,EM!'"C.798U"@L3DGCN30!([K'&SN<*H))]JY?P]X[L
M/$.H-:QPR6X>+S[5YG7]_'N*[MH.5.1T8 XJ]XFDN+?3XKZSU*.SFMY0469@
M(;@GY1&_USP1R#BL+P[X?BU'5K[6;WP_'IT%PZM]BNHXY',Z]9AC.SGC@_-C
M/% '<UEZ[K*Z-9QR+;M<SS3)!#"K!=SL>,D\ <'D^E.UC7=.T*!)+^Y\KS6*
MQJ$9V8XR<*H).!R?05Y!?)XCU7Q?$MS;1W$EW'Y;2VLC"WN8 =T4NW)*X) W
MKRIY/'W@#UW1M9&K)<1R6LMG>6K^7<6TI!9"1D$$<,I'((K4K(T308]':XG:
M[NKN[N=GFS7,@9L*,*HP ,#)[<Y)-:] !115/5+U].T^2Y2VGN-N,K @=@/[
MVW(R!UP.?04 9.O>*#HFIV-L;*8VTC@W5\Z,(+9"< EL8R3QZ#J<"NA!#*&4
M@@\@CO7EW@OQ'K.J:S)%?6T=_8WC-!=RVV6BAF48R4;YD#J!P<CIT.17I5C8
MV^FV45G:(4@B&U$+%MH],GG'\J )V944LQ"J!DD] *P=#\8:7XAO9K6Q^T91
M/-CDDB*I<1[BN^,_Q+D8S_2IM>U*^TGR;U+5;G35R+Q4!,L:GI(H_B [CKCD
M=,5S&@^%?#NJZK<:UIL.[3GDW0N%>)ED4@[H9%8'RB2?E^Z3DC@T >@52U35
M;/1;%KR^E,<*D+\J,[,Q. JJH)8D]@*EO[M;&REN&V91255Y @=NRY/ R>*\
M?7Q;J'B'Q#]BN5NX4N)8Y8+9XE\[3KB+ .S'$B]RI^;:Q/;% 'K>EZM8ZS9B
M[T^<30DE3\I5E8=0RD J?8@&KM8>A:/>V%]J%]?W,$L]Z8]RV\1C0; 1G!).
MXYY^@]*W* "BBB@ HHHH **** "BBB@ J.XF2VMY9Y,A(T+MCT R:DJG>W-K
MMDLY+R"&>2!W59&7.P<%]IZJ,C/;F@#R1=*;Q1.GB*U^$^ES171\Z*6XU-8C
M,I.0[QA-N6'/.>O4UZ?HM@N%U:\T:UL-8GB$=QY3"0JJ]%W@#(P!Q7F.EF71
M=/CL++XU:$EM%D1H\5J^P>@)DZ#T[5ZGX>E>;0;2235X-7=E.;Z!55)N3R I
M(]N/2@#3HHHH **** "BBB@ IOEH)3+L7S"-I;'./3-.JO?M=I8S-81Q2707
M,:2L0K'T)'3ZT <_XF\;6'AK4K2RO0(UN$+M.\JH%7./E!YD;)^ZH)QS7+>$
M]0UC6]2-A=_8_$&F64R2B\N"J2*228Y$ &&P!SD*0P(R<5=\.3ZIKCWMM=6]
MS%8M=2+&WVD?;--D'4,2,[6.2I&>".H/'::?IUAH&F^3!B*",%GEE?)/)8LS
M'KR2<GUH ODA022 !R2>U><_$&"QU^QN6,\45YI,OE"VOT#0S&50%(4\%B#\
MC=B"/6I]6\5RW.K:>$MEN/#^H1&*/S J1W#DD-YK2 ;%"@LH ^?M5_P]X=TU
MM4AU_1-1N6TR2%H?LDJ%HWPWRLA?Y@ 0<=1@\8% &SI&D64<5C??9YEO$M$@
M,EP?WK* ,"3!P6'//.,G'6MBBB@ HHHH ",C!IJ(D482-%1%& JC  ]A3JX[
MX@+JXTMI+)$DLP%\QU#>;:,&!$Z[3EPHZK[?44 <YKGCBT\1V$L.GWUQ8:I9
M7'G6UO!=@2W(3<&C<+D*Q ;"/DY X[5UOA&QU%[>/5M<73Y]2FMHU2[MXBLA
MB(W;&R!T)[8SZ"FZ=X?DU#[+>ZS)YEQ X<?992MO=$<I,R=F]LD?7BMS4]6L
MM'@CEO)2@ED6*-54N[NQP J@$D_04 &H:G;Z>JK)+%]IE#"W@>4(T[@9VKGJ
M:X."PM=:\56&LZ.)I+:2:.^O[5@4 EVM&KAR.67!#1Y[>V#&NKO#J=[HOBVT
M^VO=2AXHR/,^T%FVQBV0# 55&6).0>3CBNVT#P[:>'(+F"REN6AGG:?9/+O\
MMFZA3UQGGDGDF@#1MK2WLH?)M8(H(LEMD:!1DG).!ZDDU-110 4444 %(%4,
M6"@,>IQR:6L_6H]2DTR3^R)H8[U2&03)N20 Y*'T##C(Z9H S=>\8:;H5U#;
M70+B2(S22;T5(HMP7>Q9@,9(&!D^U<9X,\*+_;EW=Z)JLEOH"R+/9BT >"Y#
ML2=V[(W+@KP 0,9)IOA?PS>ZK'-).+:U7SYBUJ]J#)I,^[($/F!@R,.3V.<C
M'2O1=$TB'0=,%I'-)+\[RRS2D;I'8EF8X  R2>@H T'>.&)G=E2- 68G@ =S
M7G_BC4[+Q";>WLMT\X5;S1KZPD67=,"4? /RG:&&03T)Z8I_BSQ;<0IIE_IC
M2RZ*9RDUQ;$+OF#;41F;A(BV<N,],=ZLZ9H/AKQ!J<6N64#07EC<YDELF9()
MI@N&QP%D R06 YP1F@#3\)Z"-.\/:=!J%A"M_:L[LY82GS6)WR*Q&1NR3VZX
MKHZ** "BBB@ JI8Z98Z8)Q8VD-L)Y3-*(D"[W.,L<=^!5NL?Q+<W]II$DUC9
M->*JMY\,4A28I@Y,9_O#KC\N: ,OQ!XDMY#J&B6VH'3;\)Y4-]*R)&)RH98P
M6/S,01P >#6?X2N-8\2K!-KMBCV]I,_DS&;9*LJ_(RRQ+\K8)8 ^V=HS6=IW
MAF?QAI$,FK&V$SPJ#JMI'#*US"01Y3%UW+(O0L .?3H/1P(+*V))2*&-<LS'
M  '4DG^9H E9E498@#IR:\O\916'B:[MIK6=3JD<LED=.N8PTP",'=X03\DH
M4!@_0@CU%:&IZ^UWXC^Q:I;V\WAV[MP]NS,GV>6(#<\S.>=RX&$'USZ:_AGP
MY:6.HR:WI^H74UE?6Z>7;W*$E/1@S /TXPW;'H* -VQTVSLY)KBWMQ%)<'S)
M3W+$#)(Z G SCKBKM%% !1110 54L=,L=,$XL;2&V$\IFE$2!=[G&6.._ JW
M7-^--8N=&T62:*&Z$;*5-U;!6:W?^ E6XVD\$]L\X'( (O$FO7/V;4++097_
M +5LE69R;5I8P!ABA/"[BIR%R#R*I>'Y8_'%M9:EK>A@^2ADM9BVZVG4D8D6
M,G(/R@@,,@'K6;=^&)_&-MYMWI]MINLKM%U-+&\T;93 EMV#JN[&,$@D8P>G
M/?6UM:Z3IR01!(;:!.^%"@=2>WO0!-<3I;6TL\F?+B0NV!DX R>*\XO["XD^
M(.DZM%?O<6&HD2+(C,[I#LQY/E [3$Q927(.#C/4&K%OK\/B2ZU"TU>6;3'L
MI"R2Q.8?L8)VH'D8[9&?[P !7&.N:W?"7AB;0(95O;BVO)%=UM;A(=CI"QW;
M#[;LG X_E0!I:/X=TS01+_9]LD7F8!.,D*,[4!Z[1DX';.!6I110 4444 (0
M&!! (/4&J]AI]GI=J+6PM8K:W5F81Q(%4$G)X'N35FN;\:WNH6.ASS6EI)<6
M_EL)FMY2DT1_A=?4 ]>^.QZ4 9FO>*8]1L[[3](U!['4HI2EM([1I]JDC;YX
MXPV2QX*GY>M.\'SW_B6*RUG5[2-DBC9K&Z24J9%8XS)""0CX [G&2.*I6/A.
M3Q"MO>ZHEK;W(,;W%W811,NH@897#E=Z'(&<8]J[JXN;33+*2XN)8;:UA4L[
MN0J(.YH F9P@R>O8=R?05YAK5M9>(_$>EZMILZ7%Q(4:>T= ;JVCADPS0Y_U
M9#_*X[C.*MWFMI<Z_J-AXJMXAI:I]HM]^T1)"H^65'^^\C,<87&WCN1GH_#'
MAJ/0[B^NK>_N;BVOBDJ1W*#?$<<_-@$YXZ\\<Y- &Q8:99:8DB65NL"2.9&5
M>FXG)P.W))P.,DU;HHH **** (+RRM=1LY;2]MXKBVE7;)%*H96'H0:,6^GV
M/RJL5O;Q\*HX55'8?05/7$>.-0UJSN;**T2.".6XC6WOFE*Q1OSN2X7!RK#@
M>Y'(.#0!F^)O%UU<V-OJ>AZA)9SV>9;C3I1$9)H' V2F,G(4$J>J\$]*ZSP_
M97>Z;4]6L(;;5IPB3&"X:6-E4';LSC:/F;CZ\FL?1_!=H^I6NL360TXQ%V_L
MV**$1B4@HSEU&YU()(!/?IV'67E[#9(GF2Q)+*WEP)(X7S)#T4>YH ;J-_'I
MFGSWDJ22) AD9(AEBHZD#OBO.]-\/:=-\09[FVFCU.QG61KEXPKR*\R ^7.Y
MY:+: 57L<>U.T_4[77BUIXIBEAU6*Y^SQRH=DT4S\^7$J9<QA<'>W##)/'3M
M?#&A-X<T9-.:]>\$;L4EDC"ML)^53CK@8&?04 :5I:0V-K';6ZE8HU"J"Q8X
M QR3R?QJ:BB@ HHHH :T:.RLZ*S(<J2,[3ZBL;Q1XCA\+Z2M]/%Y@:58EW2K
M$@)[L[<*..I]AWK;/2O.7B\2_P#"9M%,EEN-N Z,&\K4XPV,CJ(I$!'&#G/I
MT *":OJ>L>+DN/"FLB>SU%=TL=VS2V\#(GS1[,9&X;2""!]X\\5Z5I=A!IFF
M6]E;6T%M%$@ B@&$4]\>V<U6T?0K;1S<212W,\]P09);F4R.0.%7/H!P*Q_%
M.JW%Y:WNEZ%/*]_;;'NTMAB01$G<D;GY1*0. >>^* )=?UC1+V%]'O)$N+*Z
M9[.Y>&4'R9-N0C <@M@X]\#O5/P9H12VNYM2B^V"YGCN;>YGC"ET50(\Q$#R
MW4#'OU[X&=8V^A?$.UVSV\D6H11(TUW9,RF$[LI&TA'S2+@$@@X/I7H:KM15
MR3@8R>IH 6BBB@ HHHH *Y;Q/XIN-&NM/CM;$7=M<,PED59)"<$ H@C5LOU.
M#@?*>:Z&^MY;JQG@@NI+65T(2>, M&>Q /!K@_#N@ZU_:VJQ:I*42YE/VVVB
MB:*W="OR2V[J<AR5^8$YYZ#@D I^"M"NAJEX^DZE-#X?2;S8+>> NK,9&,B%
M7/[MT8,ORX[$YKTRXG2VMY)Y Y2-2S!$+' ] .2?854M[;3?#ND%(ECM+&W5
MI&). HY9F)/4YR237!ZWK6H7,UGXGL+B1-*CC :.:-MUFK,?]):%?F<,G0-C
M:.<=< $^J:I9^+G>RMUN#<[P=,U'36RRQN-KLQ)& IR'4]MO<BNUT:R:PT:Q
MM)(8(I((5B*0$E%P,?*2,XXK,TC2M,U&[M_$XT=['4'5]I;Y'96XRZ@XR0 >
M>1714 %%%% !1110!5@TRQM;ZYO;>TABNKK;Y\J( TFW.-Q[XR:RM:\3Z?IM
MZ=-N9VM6>'>]XS*D5N&W!"S,0,DJ<#GI6GJDE]#822:=!%<7*X(AD?8'&>0#
MV..F>,UYYH^F7GBRT/VV&)0LDGV2]DCBGN;$!N8)A(IR?0@<>O<@$WAJ?Q#K
M<DVCZW$FH6-I,B3W)G$4N]?G5@$XDC8;2/N_>QSBO1_DCC_A5%'T %4])TNV
MT72K:PML^5;Q+&'?&Y@HQDFN2\0^)+HZO81VT4%YH-UNMR\;(T=Q.25,<KMP
MB 9/ )8C'L0"#QXVG:Y$]F;FWAU*PG6."TU&,/#=/*N$^3^+.6"M_"RGT-=-
MX>T:TLK&SN?LLL=Y]ECAD>?_ %AVC W8."PY&?3CI63H7AS29-8M=?T+4)OL
M,:20?9BI:)AG&8RW( ()&"5ZXZUV5 !1110 4444 %%%% !1110 4444 %5[
MH6\4<EU/&A\J-LL5!(3J1].*L53NKZ"*Y^QRQ3.7@>4[869-JX!!(&,G/ ZG
MF@#D-/9]9\&-KECX2TI;B;][:6LVT>;#D$$L%P&9<D#IR,XYKH_"NK6>N>%]
M/U.PMQ;6UQ$'6$ #RSW7CC@YKRX/HMO"]E8ZKX[LM*<M_H,.G3;%!))56,99
M1ST!KU3PTNGIX<L(]*MIK:Q2()##-$T;JHXY5N0?K0!JT444 %%%% !1110
M45SVK>-]!T35%TZ]NG$_R&4QQ,ZP!CA3(P&$!/3.*Z'K0 U8XUD>144.^-S
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M#W/\C5W2=:M-:CN7M&++;S&%CD$$@ @@@D$$,"#Z&@#0HHHH **** "BBB@
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M1H);^ZUD2Q3.4W&W\H#.2>!NSQU]J]>HH \]\,V4UOXA\/6LEA]@EL-#=+B
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MUKV!(HXV=D15+G<Q48W'ID^M/H \VU7P1)?ZUJ>H/H\$T\VKVDT4SA"QMT5
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M5'_"*^(?^A]U;_P$M?\ XU76T4 <E_PBOB'_ *'W5O\ P$M?_C5'_"*^(?\
MH?=6_P# 2U_^-5UM% '%76DZ_HQM;U_&.HWD8O+:)[>6VMU619)D0@E8P1PQ
MZ&M_Q++<Q:#.;.Y:UN&:.-)T56,>Z15) 8$$X)ZBF^)O^05!_P!A"Q_]*HJ7
MQ+_R!&_Z[P?^CDH R?\ A%?$/_0^ZM_X"6O_ ,:H_P"$5\0_]#[JW_@):_\
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M/#NE:AXVU+5+FT#7UO'%%%<*[*Z*4.0""/4T 9^J^'O%UGID]SI_C+4[RZB
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M8H2"N<8STK5HJ)TX3MS*]M2X5)0ORNU] K(T7_C^US_K_P#_ &C%6O61HO\
MQ_:Y_P!?_P#[1BJR T#[FH_]?\W\ZUZR- ^YJ/\ U_S?SK7H **** "BBB@
MHHHH *XL_P#)$_\ N7/_ &VKM*XL_P#)$_\ N7/_ &VH [2BBB@ HHHH ***
M* "BBB@#'\3?\@J#_L(6/_I5%2^)?^0(W_7>#_T<E)XF_P"05!_V$+'_ -*H
MJ7Q+_P @1O\ KO!_Z.2@#7HHHH **** "BBB@ HHHH P=?\ ^0UX6_["C_\
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M-NZWZP+/_DH6L_\ 8*L/_1MW6_0 4444 %%%% !1110 5D:+_P ?VN?]?_\
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MAECB<NJM]IER Q R/? JQHW_ "$-=_Z_Q_Z(AK4R,;^W?'7_ $)-C_X/!_\
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MK:K%\'?\B1H'_8-M_P#T6M #]'_Y"FO_ /7^G_I-!6O61H__ "%-?_Z_T_\
M2:"M>@ HHHH **** "LJSUZWO-6GT^.-PT><.>AQU^G-:M48-)L[?4)+V*+;
M-(#D@\<]>*QJJJY1Y'I?7T-:;IVESK6VGJ7JP_"7_(&N/^PGJ'_I7-6Y6'X2
M_P"0-<?]A/4/_2N:MC(99_\ )0M9_P"P58?^C;NM^L"S_P"2A:S_ -@JP_\
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M,@))VG(&3TK'GG[7DY?=MOY]C7DA[+FYM;[?J0^)O^05!_V$+'_TJBI?$O\
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M*LDUZ*** "BBB@ HHHH **** ,;PQ_R"I_\ L(7W_I5+3M/_ .1BUG_MA_Z
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M!7))XP>,'K5OQ@-5:301HLEFE]_:)V->(SQ8^S3YR%(/3/>K&O\ _(:\+?\
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M10!S=B-4'C>X_M![-H3IZ>0+=&5@<C?NR2#\V<8QQC.35W3_ /D8=9_[8?\
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MQ_V$]0_]*YJ &6?_ "4+6?\ L%6'_HV[K?K L_\ DH6L_P#8*L/_ $;=UOT
M%%%% !1110 4444 %9&B_P#']KG_ %__ /M&*M>LC1?^/[7/^O\ _P#:,5 !
MH'W-1_Z_YOYTOB3P_;>)M'?3KEWC4L'21.J,._OW'XTF@?<U'_K_ )OYUKT"
ME%25F97AS0+;PWH\>G6KO(JLSM(_5F)Z_P A^%:M%% 1BHJR"BBB@9SOB30;
MC4I$NK2YN/-5!$UN;@K"RYSNV=-V<<]<<53A\$AK>-KC4;MIV;=+YLIE"C ^
M1,_=48X XR37745RU,'2J3<YJ]_T.F&*J4XJ,':Q!9VJV5E#:K)+(L2! \S[
MG;'<GN:Y(_\ )$_^Y<_]MJ[2N+/_ "1/_N7/_;:NHYCM**** "BBF2S101-+
M-(D<:C+.[  #U)- #Z*I7NL:=IOD?;+R*'SV"1[F^\?\/?H*N]: "BBB@#'\
M3?\ (*@_["%C_P"E45+XE_Y C?\ 7>#_ -')2>)O^05!_P!A"Q_]*HJ7Q+_R
M!&_Z[P?^CDH UZ*** "BBB@ HHHH **** ,'7_\ D->%O^PH_P#Z1W-3:U_R
M%?#O_80?_P!)9ZAU_P#Y#7A;_L*/_P"D=S4VM?\ (5\._P#80?\ ])9Z -BB
MBB@ HHHH **** "BBB@#(_YG#_MP_P#:E&G_ /(PZS_VP_\ 0*/^9P_[</\
MVI1I_P#R,.L_]L/_ $"@#7HHHH *Y?QAX4E\3BR\J[2 V[,&W(3E6VY(YZC;
MT[^HKI)Y'BMY9(XFFD5"RQJ0"Y X )X&>G-<M_PE'B3_ *$'4_\ P-M/_CE
M'46T"VMI#;J2RQ(J GJ0!BI:P='UO6-0O3#?>%KW3(=A;SYKF"1<^F$<G].U
M;U !1110!C>&/^05/_V$+[_TJEIVG_\ (Q:S_P!L/_0#3?#'_(*G_P"PA??^
ME4M.T_\ Y&+6?^V'_H!H UZ*** "BBB@ HHHH **** ,?PS_ ,@J?_L(7W_I
M5+2Z-_R$-=_Z_P ?^B(:3PS_ ,@J?_L(7W_I5+2Z-_R$-=_Z_P ?^B(: ->B
MBB@ KB?&%_XIM=8M(]&AE:V*@YBBWAFSR&X^4=._X^G77]A:ZI836-[ L]K.
MI22)^C*>QKR#QA\/='L_$.FQZ/X6MGA=0-@A)CDD+'Y6.?0>HP.>* /9Z*Q-
M#\'^'O#<\L^C:3;V4LJ[':($%AG.*VZ "BBB@#(\+_\ (LZ?_P!<OZUKUD>%
M_P#D6=/_ .N7]:UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#GM8\1
MR:9J\-I';I)$!"9F9B& EE\M=O;@\G/:DD\2-:>)YM,O1:I;I:27C2I(28(T
M*C,N0 N[+$?[IZU;U;PW9:Q<)/</<(ZJ%/DR;-P#;ESW^5N1CO3=-\-VVEZG
M>W\-S=227I!G69E8,0 !SMW< 8 SCDT 8WA[Q#H^N>/]9?2M3M;Q?[+LAF"0
M-RLMSNZ>F],_[PKLJYVQBCC^(6L[$5?^)58?=&/^6MW714 %%%% !1110 44
M44 %8O@[_D2- _[!MO\ ^BUK:K%\'?\ (D:!_P!@VW_]%K0 _1_^0IK_ /U_
MI_Z305KUD:/_ ,A37_\ K_3_ -)H*UZ "BBH;NY2SLY[J19&2&-I&6)"[$ 9
M(51R3QP!R: )'D2/;O=5W$*-QQDGM3J\;\>^*[+5[O3/L\.JV_E[]QGTZ>(C
ME?F *C./;FO1=!\46>LS?8X+;54ECAWM)>:?- K8('WG4 GGIG/7TH WZ***
M "L/PE_R!KC_ +">H?\ I7-6Y6'X2_Y UQ_V$]0_]*YJ &6?_)0M9_[!5A_Z
M-NZWZP+/_DH6L_\ 8*L/_1MW6_0 4444 %%%% !1110 5D:+_P ?VN?]?_\
M[1BK7K(T7_C^US_K_P#_ &C%0 :!]S4?^O\ F_G6O61H'W-1_P"O^;^=:] !
M1110 4444 %%%% !7%G_ )(G_P!RY_[;5VE<6?\ DB?_ '+G_MM0!VE%%% !
M7-^,?#,WB.QB6WO9898<[8C(5ADR5Y< ')&./3)]:Z2B@#SK_A6,T]I;"YUR
MZ>5  T3MYD,0[B($ K_4UV^CZ;_8^E06'VRZO/*S^_NGWR-EB>3@<#.!Z  5
M>HH **** ,?Q-_R"H/\ L(6/_I5%2^)?^0(W_7>#_P!')2>)O^05!_V$+'_T
MJBI?$O\ R!&_Z[P?^CDH UZ*** "BBB@ HHHH **** ,'7_^0UX6_P"PH_\
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M ($)_C1_;FD_]!2R_P# A/\ &@"_15#^W-)_Z"EE_P"!"?XT?VYI/_04LO\
MP(3_ !H OT50_MS2?^@I9?\ @0G^-']N:3_T%++_ ,"$_P : +]%4/[<TG_H
M*67_ ($)_C1_;FD_]!2R_P# A/\ &@"MXF_Y!4'_ &$+'_TJBI?$O_($;_KO
M!_Z.2J7B#5=.N=/MX8+^UEE;4++"),K$_P"DQ'H#5SQ0ZQZ#([L%19H"S,<
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MW<32S+<0S1-$3M'[T()3E<'+;!].<5T=% '$?\*A\#ABW]CR[B,$_;[C./\
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MZ]/83V-KIUI%>W5Y*\:"2X\J,;%RP+;6^;T&/7TJYHNK+K%DTWD/;S12-#/
MY!:*1>JY'!Z@@]P10!0_X03P?_T*FA_^"Z'_ .)K6@TVRMM)CTN.VC^P1P"W
M6!AN7RPNT*0<Y&..:M44 <__ ,()X/\ ^A4T/_P70_\ Q-9^H_#[PW+?:2]M
MX6T40Q7;/<A;&)08_)E4 C;\PWLG'J >U=1?7D&GV4UW<RI%#$NYGD.%4>I/
M85S.AWNKZ5JLEGXEG2:34IO,L[F#/D+\O^H (^4@ D$_>Y/!XH O?\()X/\
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M+S17:_ZJX7.2$'\)7.-ISP,Y/8 L?\()X/\ ^A4T/_P70_\ Q-'_  @G@_\
MZ%30_P#P70__ !-=!7'>._%FH^&8K7[!9Q.9MQ\Z='=&8?=A4)\WF.>%[?7I
M0!)I?P_\,PV\RW?A;16<W,S)NL8F^0R,4_AZ;<<=JN_\()X/_P"A4T/_ ,%T
M/_Q-7-"UZR\061GM'.^,A)X75E>%\9*LK $'\*TG=(UW.ZJN0,L<<GI0!R'B
M#X?>'+GPWJD&F^%M%6^ELY4MF2RB1A(4(4AMO!SCGM6C_P ()X/_ .A4T/\
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M;'\73(KH=/O[?4["&]M6+0RKN4D$$>H(/0@\$4 9'_"">#_^A4T/_P %T/\
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MOJ:7D?DW"N!F.0@#:Y(PNX8R/7;D^J4F%7+<#U- #8HHK>)8H8TCC4854
M^E8/B6ZO]*:WU:TN!)%$?*ET]V51<!B,>63_ ,M,]!G!SCWK-\1^*(K?56T>
M\M0VF7%M^]F02O+('!'[I8T;('&22,9%9OP]T?4X[7$NJ"\T>"4"TCN(S+YB
M!04F21CD9R#CD#D#% &YH.C6UY+-K4^E-8F]?S393!6!88VS,I'R2X'.#Z9Y
MK1\1Z]::#IK23WUM:W$H*6QG#,I?'&0O.!U)["M.XN(K2VDN)FVQ1*7=L$X
MZ]*\]UVXLO&#/:0&9-0239I]]IY+AH95(+.1C"<,K ]"!CG% '-Z0=>UGQ;<
M6M]92JEX4DNTBG8PPS*!B6)^3&2 &4_=89')Z>J:'X?CT1KN8WMW?7=VRM-<
MW3*7;:,*,*JJ !Z"K.DV8L],M(FM8+>6.!(FC@8LJ!1C:&(!(';(J]0 4444
M 5K];Q[*5;"2&.ZQ^[:="R9]" 0?UKS'POHWB:V\9/ODN;4VDA,D=T6FAN+:
M0DD1R]<JW0'T' RV?5Z* $X SP!7.^)[A5T5-9L]52V:R;S8Y,EX90>"CJN2
MP;IQR#TJGK?BB\M[ZT.F6K7^G,&$C6L!N'ED5MIB&&"H1R26/;%8/@/P]MU2
M[U+2[F[L=',@,%H$41R#<V])%)(WHP*[EQP!R: .LT.UO+V\;6]6TR"PO2OE
M11Q2EG\O_IH0=K<Y(XX!]<U;\0:]9Z!8K+<M*99F\JWA@B,LLKD=$0<L<9/T
M%:DDBQ(6;/ Z#DGV [FO/M7U^P\37%SH1M7NS,J-:)&WV>X@D!P^=^"C*"'&
M.JYZ\T <AIMEX@U?Q-!<[K743=V^R:Z,?EQWMOD[3)&<#(Y1@/F4[3CCGUS2
M?#FFZ-/+<6D4OGRHL;233O*0@Z*"Y.%&3P*DT'3&T?0[33F,+?9H_+#0Q^6I
M Z'&3@XZ^^:TJ "BBB@#&\466HZCHD]IIYB)E1HY49VC9E((^1P?D8=02"*Y
M+X;:=K5O-<W5W+<QPOF&[M+V(B43I@!PX^5U*X^;KT!)QFO1J9--';PO-,ZI
M%&I9W8X"@=2: "66.")I)9$CC7JSG 'XUS/B.>[TG4[/5--G>XFN/]';3&?Y
M;H %@4)X1P,\G (X/8UC^*-?>274]/U73;BX\/2VV/,M;7S/W90,9C(6"X'(
MV@$\9J[X"\/:CI%FTEYJ$K(SN%M J^1C.%DC')0,.=H('S'@4 ;NA:8UG%+=
MW%M#;7UX?,N8K=V,0?GH"<;L8!( R167XT\2QZ592:?;7LMMJ<T1DCGBMC.M
MLH('F2#&%3/&3Z^U=%?WT6G6CW,RRNB8)6&,R-C.,A1R<9KSJXFB\>W"62VL
M4MY:W#L-1MY!Y2P?>3>F=SJQ 1D/1E)XP* ,SPEH&L7NOW\&HZ?'!922^==Q
MI(5C6X[O%@[D8YW!E)!#$'D#'J>EZ39Z-:M;V:.JO(9':21G9W/5F9B23TJX
M@(10V-V!G P*=0 4444 >?\ Q'L=?EMTN[..:XL[9@YCL&*W"J05<%3E900<
MX([="#70^#K+4=/\/0VVHW276PDV\@C:-O)/*AU/1ADCZ 5OU5OKZ.S15+Q_
M:)=RP1,X4RN 3M'OQ0!,\\,<J1/*BR29V(6 +8ZX'>N+<ZI%JU]X=L4MM6LI
M2'E^VLQ^Q))DE'S_ *Q2 =H!R.,\8-<OX@N;GQ396=K?Z=<1ZXDK-8SFS,,9
M8IF2%2S[RP4,0V%!*@@UZAHVG3:7IZVL^HW%^R])[D+YA&.A( W?4\T 6+*S
MAT^RBM+<.(8EVH'<N0/3))->;>-_$#Z[+)I&C3_:($$L-Y:R6I,5X /G6*7O
M)'UVCWZXQ7:>)?$$>B6#E9$CN'1O)DF1O)WCHKN.%)Z#)K"\/6%MJ_B8>*M.
MLA:V[Q[&\W#K,64%GC4']VX8!6/5L'/2@"AX-\)R:KH"MXBA9P8Q%#)%=.KR
MP_W69&&^,CD!N1DCM7HT4201)%$@2-%"JJC  '04^B@ HHHH \S^(FFZW-=V
M]TR3S:<KF%VT\%G2)\ ^9"<B0 @'(YQGH<$=SX?M=0LM"M;;5;F.ZO(EV-.B
MD;P#\I(/.<8S[UIUG:OJ+6-G,ML(YM0,#R6]L6P92HZ =3VZ4 7'D@>0VS2K
MYCH3Y8?#;>F1W_&N*M8M0NI[CPPT4.KZ/#-Y<U[=2'?$F ?*;H6D&1M<?CR.
M>;U59O%U_IJ-;WEMKT((6Z^R&V\ZW+KO:'+EU9"5.3C//!!Q7JFG6LME9)!/
M>27<BYS-*JAF],[0!G'?% $T,26ULD2LVR-0H+N6. .Y/)^IKR7QKKD_BI9[
M;2)#<Z4D1\ZWGM60/M<8N8)!RP1P <9QUP>M=SXJ\4IH5N!&5^T?+(HF1A',
MH;YXU?[OF;0< GKBJ/A/2(#K5[X@L;/['97@*1Q2$/O7(821X.(U8DDKW(!X
MH K^&O"3:CH\-QXEMG-XVW>HN&_>JOW1+L;;+C'#$9(QGO7=T44 %!&01110
M!YEJOPRFO?$7FR3FYL+F,QRW!E,=W;X^:-@_\>T\#/.",YP"/2;>)H+:*)I7
ME9$"F1\;FP.IQWJ2N8\4ZQ?1026>AL7U*$I)/$B*91 <Y:,.0K'.!R<#GOQ0
M!J7%QH^L?;='EFMKN1%VW-H'!=<C(!&<CJ#7/>'= U.ZCMYM;N+A["W^:RL+
MI5,T?S95IG!.YU  &"..N37-6&F'QWXECU":$V1MP%OGLKU&<R!/W3K-&.#@
MD,H(Z+G(%>I/)#861DN)PD,$>7FF8#  Y+&@"/5-2M]'TNZU&Z+""VC,C[%+
M' ] *\<UBUUOQ9JLMW:K=.J749%I<E7:PE*@JR219PCJ1SSM)Y ^\.V\1^-_
M[(O+?S[:2*S,ABD%PJ^5<(XPDB2#(P"1D'!P2<<5L>$M &@Z=(B+%"ER_P!H
M:UA^:.&1A\P1L LN>F>G;C H ?I'ABSL7AO;J"WN-64'?>"((SD\%B!QN(QD
MC&?;I6[110 53U-+V2PD73V@6X/03AMK#N,J01D=^WH:N44 >5^!-$UZQ\22
MF66[MQ9DV]S!>@R">$@F-HYAP^TYZ\CGIG ]39E1"S$*JC))X %+TKC=<\37
M46H0+:V$NHZ-/;Y8VEOYS3DEE90VY40* "=QYSQTH N^)Y7@M;76]/U$130,
M%2,L6ANPY \M@,\DXPPY!]LU8T.RGFN)-:U#3DT_4+@;##'*6(CXVB3!VLXY
MY'3.,URWP]\.S6C27UGJ$\6D.R-:6ZHHBGA*Y4LISMD!.TE<9V<YS7H-Q.MM
M;R3,KL$4MLC7<S8&< =S[4 9/B;Q!;:%8A9'N/M5R&2W2U@,TN0I)8(.H4<G
MZ5Y?HFF>(-3\4F2XAM[E+V%#?7"#;!>Q@?)*R9X) 'S)@JRC( //1:KJUKXR
MGN-"%HUT[RHUG<6TOD2VR$8D+[B&5DYRN/F# =S7?:9:O8Z7:VK^46AB6,F%
M-B<#'"]A[4 0:3H5AHQG:T27S)ROF233/*[;1A1N8DX Z"M*BB@ JGJ:7LEA
M(NGM MP>@G#%6'<94@C([]O0U<HH \K\":)KUCXDE,LMW;BS)M[F"]!D$\)!
M,;1S#A]ISUY'/3.!ZFS*B%F(50,DG@ 4O2N-USQ-=1:A MK82ZCHT]OEC:6_
MG-.265E#;E1 H )W'G/% %WQ/(\%I:ZWI^HB*:!@J1EBT-V'('EL!GDG&&'(
M/MFK&AV4\UQ)K6HZ<EAJ%P-AACE+$1\;1)@[6<<\CIG&:Y;X>^'9K5Y+ZSU"
M>+2'9&M+=4413PE<J64YVR G:2N,[.<YKT&XG6VMY)F5V"*6V(NYFP,X [GV
MH R?$WB"VT*Q"R-<&ZN0R6Z6L!FER%)+!!U"CD_2O+M$TSQ!J?BDR7$-O<I>
MPH;ZX0;8+V,#Y)63/!( &Y,%649 !YZ/5=6M?&4]QH0M&NG>5&L[BVE\B6V0
M\2%]Q#*R<Y7'S!@.YKOM,M7L=+M;5_*+0Q+&3"FQ.!CA><#VH @TK0K#1C.U
MHDOF3E?,DFF>5VVC"C<Q)P!T%:5%% !63XCM+^^T::VT]HM\BE)$D9D+H000
MKJ?D;G(.#TZ5K44 >:_#G2=>MKRXGO9[E(<-;7MI?1G>TBXVR*X)#@J<9Y]"
M3@8]'CCCAB6.-%CC0855& !Z 4YF"*68@*!DDG@"N%\2>)[>34=1\/ZE;/%I
MDEML:X197E?>N=Z*B$!%SRQ8<B@#4\3S76DWMEJMA=%IW86QTYV.R\SD@+_<
M<8)#=,9!XY#_  ]X=%KYE]>VEO!<W,GGM9Q /%;R9/S*2,[R"-Q! )&0!63\
M/+'78+$F_P!0:2RCD>.*VG5I& 7A729CN*MRP!S@, #Q79WM[;Z?9R7=U)Y<
M$8R[D$[1Z\4 9/BGQ#!H>G,HOK2VU"=2MH+H,R%^Q8+R%]3P!ZUYGX;M]7UK
MQ'>VES:7,4,DWVN0><2;&XZ,T+D$J><A6&UE;@D=>@UEK7QLS6MKYT&K(SP)
M<6IW12VK#</,<?\ +*0#;D<ALXZ&O0K2!8;>,>3%%)Y:JRQ\@8'0' ) [4 4
MM$T2/189Q]KN;R>XE,T]Q<E=\C8 Z* H   P .E:E%% !1110 4444 %%%%
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MG0'&X[5///KS530?!MQH6L2M#J'_ !*M[2I"%/FRLPQB5R?G5!]T?GG%=?0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#:7D93N).<C<N/UK9\1ZGKAT;2=-TRYMUUW4 &,\'SQJB+O=UR.0<!1D?QT
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M6\4>]T4C,@R^T)R!R0<]J .[HKEI?'>GK86DUO9:A=7EU+)#'I\4(^T!X_\
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MZXVM7)EN]$EE65F #2)]Z(X&!EE( ]2#0!V-%9.A+J,7AFU;5)FEU P^9,Q
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M+B2XL1:^3:0NBQX8'C<22..YZFNYHH .HP:QK_PY93>']1TNS@BM1=HV2BX
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M+# R$H\817<DG+<#.,#COFMR;PE-/::7;M<QJ+32YK"1@#R71%W#V&TUU=%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>trda-20211231x10k038.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k038.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '6 ?X# 2(  A$! Q$!_\0
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MP+7_ )[7?_?]J -2BLO^P+7_ )[7?_?]J/[ M?\ GM=_]_VH U**R_[ M?\
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M$%Q<Q$(TS2*I1=F"R C@DDC'IFGP:$JSZ+=)91P2VBLLFYP[HI4C ;OR><4
M=#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 9M__ ,A?2O\ KI)_Z+:M*LV__P"0
MOI7_ %TD_P#1;5I4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5G0?\C%>_P#7M#_Z%)6C6=!_R,5[_P!>T/\ Z%)0!HT444 %%%% !6?KG_("
MO?\ KBW\JT*S]<_Y 5[_ -<6_E0!>3[B_04ZFI]Q?H*=0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!ES7U^^HSVUG;PNL*H6:1R,EL_X4>=K?_/K:?\ ?T_X4MG_ ,AW4O\
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M)(U!(Z\%LUJUEZ%_J+O_ *^Y/YT ._M"_P#^@-<_]_HO_BJ/[0O_ /H#7/\
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M$=K#%/+N"%I%7Y4W#(SWZ?E6U6E.E&FK1./&8^OC)*5=W:T"BBBM#C"BBB@
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M/KX98G%/E,G['_O?]]4?8_\ >_[ZK6^ROZ4?97]*7M_,K^S%_*9/V/\ WO\
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M/[S_ )BD.G@'N?<XJ_Y2?\]6_*JL[SQ2;84WKC.33C.3>C'&I)O1D/\ 9_\
ML_RH_L__ &?Y4[S[O_GB*//N_P#GB*N\^Y=Y]QO]G_[/\J/[/_V?Y4[S[O\
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M?WV_[ZJ?J3_F.+^PY_S_ (,[;<OK1N7UKB?M%U_?;_OJC[1=?WV_[ZH^I/\
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M]ZC*_P!ZI]H^Q]7]3A_,_P /\BAY,_\ S[I_WT*/)G_Y]T_[Z%7\K_>HRO\
M>H]H^P?4X?S/\/\ (H>3/_S[I_WT*H7D,OG\KL.!P#6]E?[U4[I2TV5 (QUJ
MZ=1W.7&8*+IZ-[^7Z(Q?*D]3^='E2>I_.M3RV_NBCRV_NBM_:GE?4%YF7Y4G
MJ?SH\J3U/YUJ>6W]T4>6W]T4>U#Z@O,R_*D]3^=>P?L\HR^+=5+$_P#'CZ_]
M-%KS/RV_NBO6/@(I7Q3J>0!_H7_LZU=.I>21S8S!\E"4M=#W^BBBNP^<"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBHN^QT\E/N1[&]*-C>E2><GJ*/.3U%%WV#DI]R/8WI7J?P*4CQ/J61_RY_\
MLZUYAYR>HKU+X&R*_B;40"/^//\ ]G6MJ#?M$>=FL8+!U+/H>[4445ZI\"%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?+6O7TZ^(=34!\"[E'7_;-9_\ :%QZ/_WU6KKI7_A(-2_<@_Z5+S_P,UGY
M7_G@*^:ER\ST/F)<O,_=(O[0N/1_^^J/[0N/1_\ OJI<K_SP%&5_YX"E[O\
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M**] ^1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7C+"S21] T445Z)\8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYT>:?^>I_.NKV,NYV?5*G\QL>1;?\]$_(T>1;?\ /1/R-8_FG_GJ?SH\T_\
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M+ 67_LZUK1C)5%=G#F6(HRPLU&.MCZ HHHKTCXH**** "BBB@ HHHH ****
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M-E_<7\Z/L-E_<7\ZRO/D_P">Y_.CSY/^>Y_.CV4_Y@]E/^9FC<6EFD#LBKN
MXYK+^3T%.:9V4@REAZ9ZU%G_ &*TA%I:NYW86\(M/4?\GH*/D]!3,_[%&?\
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MI27OHXLPG?#31] T445Z!\B%%%% !1110 4444 %%%% !1110 4444 %%%%
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M/[R_G7JWP(DC?Q1J00@G[%V/^VM>V?V'I'_0*L?_  '3_"IK;3K&S<O:V=O
MS#!:*)5)'IP*N&&49*5S#$YU*O2E2<$KEFBBBND\0**** "BBB@ HHHH ***
M* "BBB@ HHHH *\H@U3Q%8>./%R:-X.37(FO8B\K:A%;^6WDI\N'!)]<UZO7
M"WW@36FU_4]3TCQE<Z6FH2++)!'9QR#<$"YRW/1: *?BB]U>\^%VL3:KX=32
M+L8"6JW:3[QD8.Y0 ,GBGZ=KWC1S:1R_#.*.!MBM/_;,!VKQEMNW)XYQ6@?!
MFKWGAO4](U;Q7<:@UX%$=P]I&A@QZ!>#VZ^E5$\$^,$557XD7H51@#^S8.E
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MDJDI@=3DCB@#;KRSXMZ1XCFT2^O(/$PCTLM"!IO]GHQSN49\W.[KST]JUO\
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M '>T5P7_  L/5_\ HGOB3_OW'_\ %4?\+#U?_HGOB3_OW'_\50!IV7_"?_\
M"0G[</#7]B>:V/(,_P!I\OG;U^7=TSVZUU5<%_PL/5_^B>^)/^_<?_Q5'_"P
M]7_Z)[XD_P"_<?\ \50!WM%<GHGC'4=6U2.SN/!^M:=&X)-S=(@1<#O@UUE
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !17/>.1?CP;J4VF7$L%Y;Q^?&T3$$[#N(X]0",>]
M<UXTU74]:TO0--\/7\UI>:G&]X9[=R&6*./=U'8LR+^- 'HU%>?WVO7>NZ-X
M2BL;B:WN-5EC>X:%BC*B+F09'N"*Q_$'A&^LO$6BVT/C?Q6(M2N9$E']H#Y
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MX&(_B'ZUV-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>trda-20211231x10k039.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k039.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %M L8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[,ZZ56%6*G!W3"BN,N_B+9VE[/;-87+-#(T9(9<$@XJ#_A9MC_T#KK_OI?\
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M==1V(^7D'UJ#_A:5U_T!(_\ P*_^QK14IOH<4LRPL7RRE9^C_P CTJBO-?\
MA:5U_P! 2/\ \"O_ +&C_A:5U_T!(_\ P*_^QH]E/L3_ &IA/Y_P9Z517!:5
M\2H;J_CM]1L1912':LPFWJ&[!N!@>]=Z"",@Y!J91<=SJHXBE7CS4W<**;(S
M+&S(F]@,A<XR?2N,N/B-;VMQ)!/I=W'+&=K*Q7(/YT1BY;"K8FE0M[1VN=K1
M7"_\+-L?^@==?]]+_C1_PLVQ_P"@==?]]+_C5>RGV.?^T\)_/^9W5%<+_P +
M-L?^@==?]]+_ (T?\+-L?^@==?\ ?2_XT>RGV#^T\)_/^9W5%<+_ ,+-L?\
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MG/3ZUU]%%9RDY.[/2P]"-"FJ<-D>5:GX(UVYU6\GBMXC'+.[J3*!D$DBJO\
MP@/B#_GVB_[_ "UZ_16GMY'G2R7#R;;;^_\ X!Y!_P (#X@_Y]HO^_RT?\(#
MX@_Y]HO^_P M>OT4>WD+^P\-W?WK_(\CB^'^O/*BO##&A.&<R@[1ZXKTO1=%
MM-#L%M;5?=Y#]YSZFM&BIG4E+1G5A<OHX9N4-_,1B0I(&2!P/6O./$.A>*M?
MOO-EMHT@0D10B<84>ON:](I&944LS!5'4DX J8SY=4:XG"QQ,>23:7D>0_\
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M=6U^F@4445N8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!6O_P#CT;_>3_T(59JM?_\ 'HW^\G_H0JS0 4454NM2M+)U2>8*[#(4 DX^
M@H MT5%;W,-U")8)%D0]"*?)(D,32.<(@+$^@H =14,=W#+*(T?+F,2 8_A/
M0U*[K&C.QPJC)/M0 M%,BE2>))8SN1QN4^HI] !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ<G"6Z.RE4C5@IQV84445!H%%%% !1110 4444 %%%% !1110 4444 %%%%
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M-<3>W"W=]/<) D"2.66*,85 >@%9PJ.4G%JUC6I24(J2=[D%=C\,/^1XMO\
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M/^1XMO\ KC+_ .@UQU=C\,/^1XMO^N,O_H-9XO\ @3]&:X/_ 'B'JB/XE?\
M(\WO^['_ .@BN2KK?B5_R/-[_NQ_^@BN2HPO\"'HA8O^//U9T?@NX@M];E\V
M:.":6UDCMIY.D<I'RG)Z?6M2Y6]T_P *:K!K]['/)<%/L<33B9Q(&^9@03@8
M_.N(HP!T%$Z'-/FOV_ (8CEARV[_ (A116GH6A7OB'4DLK),L>7<_=C7U-;2
MDHKFEL8QBY-1BM0T+0KWQ#J265E'DGEW/W8U]37H^KZQIWP[T;^QM&VRZI(,
MRRD9*G^\WOZ"DU?5]-^'>C?V-HP675)5S+*>2I_O-[^@KRF::6XG>::1I)9&
M+.[')8^IKS4I8V5WI37XGH2E'!QY8ZS>[[>2\S6\/W#S>)89YM4>SN'9F%VW
M.)"#C=GL3P?K75:AJ-_8>'-4769[,37D8@M[6TV#<<Y:1MOL.]>>48 Z"NN>
M'C*2?16Z=CFIXAPBX^O7N%*JL[JB*69C@ #))H56=@J*69C@ #))KU_P7X+M
M_#MF==UW8MRJ[U5_NVX]3_M?RJ<5BHT(]Y/9!AL-*O*RVZL9X0\(6GA>P/B#
M7RB7"+O5'Z0#^K5Q'C'Q?<>)[\A2T=A$W[F+U_VF]_Y5)XT\93^)[WRXMT6G
M1']U&3]\_P!YO?V[5RM987"R3]M6UD_P-L3B(J/L*/PK\0KI7D0_#6.+>OF?
MVJQVYYQY?7%<U179.'-;R=SCA/DOYJQVMY8OXKT[1;FTN+96MK9;6Z$DRH8B
MI^]@GICFLCQCJ,&J>)KB:U?S+>-4AC<?Q!5QFL' /845$*/+*]]KV^9K4K\\
M;6WM?Y'K/P<_X]-7_P"ND?\ (UZ=7F/P<_X]-7_ZZ1_R->G5\[F'^\R^7Y'T
M>7_[M'^NH4445QG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %8?B>TNKRSLDM WFK>Q/N"[M@!Y8CTK<HJH2Y9*2)G%3BXLP(/#LBZA#
M?SW8DN1<&>0B/:&^38% SP *@M_"*VU\KI/$+9)VN%46Z^;DDG:7ZE<G/K73
M45?MY]S/V%/L8=GX>^R'2C]HW?8()(ON_?WXY]L8K)'@>1;46ZW\;*;46Y:6
MW#E.6Y3)PI.[GZ5V5%-8BHMG_7],'AZ;W7]?TCFI?"TKB79?!"R6Y4^7G;)#
MT/7D'N*EMO#LR7XO+B]$LINQ<MMCVCB,IM'/OFN@HI>WG:UP]A3O>QS4?A-8
MK]9$GB%L+@W&W[.OFDDYVE_[N3GUJ[KFBOJQA*S1!4#*T4\(D1L]\<$,.QSW
MK8HH]M.ZE?5#]C"SC;1G+CP@4XCU!QB&!5=DRPDA.5;.>1R<BJ^I:!J'VRTN
MUN#->R7L;R2K%A(D1& ^7/3)YY[UV%%4L1-.[)>&IM61F:?I M;:[2YF^T2W
MCL\[[=H.1C '8 #%9H\+W$FGC3Y]4=K6*+RX%2,*5((*LW/S$8'I72T5"JS3
MO<IT8-6:.=D\-W%U(]W<ZANOLQ&*5(L+'L)(^7/.<G//>F1^&KM+A[TZBIOS
M<^>L@A^09385VYZ8'KFNEHI^WF+V$.QA:?X=^Q7T5XUT99OWS2DKC>\A4DCT
M V@8J]HVG?V3I4%EYGF>5N^?&,Y8G^M7Z*F524E9O^OZ94:<8NZ7]?T@HHHJ
M#0**** "BBB@ HHHH *\HU'X4:C>ZI=W2ZC:JL\SR!2K9 9B<?K7J]%;T,14
MH-N#W,*^'IUTE46QX_\ \*?U/_H)VG_?+4?\*?U/_H)VG_?+5[!171_:6([_
M ('-_9F&[?B>/_\ "G]3_P"@G:?]\M1_PI_4_P#H)VG_ 'RU>P44?VEB._X!
M_9F&[?B>/_\ "G]3_P"@G:?]\M1_PI_4_P#H)VG_ 'RU>P44?VEB._X!_9F&
M[?B<;X3\&W7A[1M3LIKJ&5[P?*R @+\I'.?K7(CX/ZF !_:=I_WRU>P45G''
M5HR<D]6:2P-"45%K1;'C_P#PI_4_^@G:?]\M1_PI_4_^@G:?]\M7L%%:?VEB
M._X&?]F8;M^)X_\ \*?U/_H)VG_?+5<TOX1O%J$4FI7T,UJIRT<08%_;)[5Z
MI12>8XAJUQK+<,G?E&0PQV\*0PHL<: *JJ, #TI]%%<)WA1110!A>*?"UGXG
MTXP3@1W"#,,X'*'^H]J\\_X4_J?_ $$[3_OEJ]@HKJHXRM1CRP>ARUL%1K2Y
MIK4\?_X4_J?_ $$[3_OEJ/\ A3^I_P#03M/^^6KV"BM?[2Q'?\#'^S,-V_$\
M?_X4_J?_ $$[3_OEJW/"7P[O?#OB"+49KZWEC1'4HBL#R,=Z]$J))2UQ)'CA
M0IS]<_X5,\?7G%QD]'Y%PR^A"2E%:H\^\5?#F^\0>(;C4H;ZWBCE"@(ZL2,#
M':L7_A3^I_\ 03M/^^6KV"BB&85X144]%Y!/+\/.3E):L\?_ .%/ZG_T$[3_
M +Y:C_A3^I_]!.T_[Y:O8**K^TL1W_ C^S,-V_$\?_X4_J6?^0G:?]\M7;0^
M'KGPWX;-CX;A@:^DX>XG;;D_WCQS["NJHK*KC*U56F]#6G@J-*[@K,\3F^%_
MB>XG>::6UDED.YW:<DL?7I3/^%4^(_6S_P"_Q_PKV^BK688A*R?X(P>5X=]_
MO/$/^%4^(_6S_P"_Q_PH_P"%4^(_6S_[_'_"O;Z*?]HXC^;\$']E8?S^\X+P
M3\/5T.7^T-4\N:^!_=JO*1#U]S_*K?C+PQK?B=DMX=0MK>P3GRB&R[>K8_E7
M945@L14]I[6]V=*PE)4O9):'C_\ PI_4_P#H)VG_ 'RU'_"G]3_Z"=I_WRU>
MP45T?VEB._X&']F8;M^)X_\ \*?U/_H)VG_?+4?\*?U/_H)VG_?+5[!11_:6
M([_@']F8;M^)X_\ \*?U/_H)VG_?+4?\*?U/_H)VG_?+5[!11_:6([_@']F8
M;M^)R7@;PE<^%(;V.XN8IS<,C Q@C& 1SGZUUM%%<=2I*I)SENSLI4XTH*$=
MD%%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !5>+_ (_I_P#<3^M6*KQ?\?T_^XG]: +%%5KV^AT^ 37!(3<%R!GK2W%Y
M#;11R.25D=44J,Y)Z4 6**** "BBB@ HHHH **** "BD)"J2>@&:JV&HV^I0
MM+;DE5;:=PP<T 6Z*JV>H07SSI Q)A?8Q(XS[5:H **AN+F.V\KS,_O)!&N!
MW-.AG6;?M##8Y0[AC)'I[4 244V21(HVD=@J*,DGL*$=7174Y5AD'VH =114
M*7,;W4EN,^9&H9N.,'I_*@":BJ=WJ4-G.D+I*\CJ6"QH6X%+::C!>.\:;UE0
M9,<BE6QZX- %NBBB@ HHHH **** "BBB@ HHJ"&ZCGEFC3.Z%MK9'?&: )Z*
MB\]?M/D;6W;-^=O&,XZ^M2T %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5XO^/Z?_<3^
MM6*KQ?\ ']/_ +B?UH IZXJO;6R,,JUS&"#W&:RKLO9F#3)22JW,;V['NF>G
MU%=+-!%<!1*FX*P<>Q'0TRXM(+HQF:,.8VWH3V- &,$^V0W]U-=312Q2.J;9
M,",+TX[_ (T0"34;VU$\LJJ]D)'1'*Y;/M6I-I=E<3&66W5G/WN3AOJ.AJ<6
M\0G$X0"0)L!_V?2@#GE>XDM(H!,TA2YE3RS+L:55Z#=[4LMW)'I;PP/<+(+E
M8I%D8;HP>P;^1]ZVGTRS>(QM "I<R=3D,>I![4Y-/M4MGMU@7RG^\IYW?6@#
M$;[3;+=A4FBB-J[%9)P[!AT(YS4Z1O:3Z7*)YF:?Y9=[DAODST[=*T8]+LHE
MD5(!^\78Y)))'ID]JF-K"WDY0?N3F/G[O&/Y4 <_;R/#+;SW#SLKRX%S'-N2
M3)X!7L*1GNKM[V4I<>9'*R1LDP18\=,@G^=;::58I,)EMU#AMPY. ?4#I1/I
M=E<RF26 ,S?>Y(W?4#K0!)"\DFGH\H'F&/+8.1G%<[I\W]G6N]>#<VH9!ZR
MX_J*ZD(H38  N,8'I5;^SK0I AA4K =T0Y^4T <\/-TVWU*.W)#"2&,L.HR!
MDU90W5G,S11S(GD.66:</D@9! SFMO[';YG)B4^?_K,\[N,4RWTVTM9#)%"
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M6\S>>P)R47[N?KD5T-4+&SECN;B[N1&)YL+B/H%'2K] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57
MB_X_I_\ <3^M6*P;'4;V;Q!<6LELBA!\[ GH,XQ]<T ;U%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !114?GQ;]GF)N]-PS18+V)**;YB>9LWKOZ[<\T>8GF;
M-Z[^NW/-%A70ZBHQ-$7V"1"WIN&:>SJB[G8*/4G%%@NA:**:KHS,JL"5Z@'I
M0,=31&BR-(% =@ S=SCI0DB29V.K8ZX.<4Z@ HHHH **:716"E@&;H">33J
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H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>trda-20211231x10k040.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k040.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'W QH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNJ/>7)61BK(68@)\O)Y'7%7/%W@'6-<\72ZG$=*O;.6R-M'#J9D86;G@R1H
M58GWQSWH UKCXD:<=+T*YTZRO+^ZUS)LK.(*LC!?O%BQ"J!W.:H2_%JQ@TW6
M[V?1M1A_LBYAMIX9 @D+2'' !QQCUY[5S=SX?G\&:9X'GN=9T:SUK2?.MU2\
MG9+:Y1_O#S-N5(!'4=ZS--\/:KXWLO'45K=:?-+=ZK:NEU$S"V?R_F8(V"2
M,#/>@#M[CXJ+;7.J6C^&-7%WIT(NIH28OEM\9\PG?@<$?+R?R-=OI.IV^LZ1
M9ZG:%C;W<*S1[A@[6&1D>M<5J/@?4[OQ!XNOXY;41:OI*65N&=MRN$P2WR\#
MZ9^E=1X3TJ?0O"6DZ5=-&T]I:QPR-&25+*,'!(''X4 ;-%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %74KU=.TN[OG4LEM"\S =2%4G^E>6Z%X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;3DMWEXDE+%Y''H68DX]JN:9H&G:/<:C/9PE)-0N#<W)9RV]R,$\]/H*TZ*
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M +!L7_H,% 'K5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M +!L7_H,% 'K5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCCD(5?*95=P'P-W#'J<XKT2@ HHHH X/XP61N_AQJLGVJXB6WB,ACB<*LIR
M _&2O.<=ZK^/;^SE\/:=927,+VT-]8MJT._[EJS<F0#D(2![5Z$Z+(A1U#*>
MH89!IIAB)8F-#O&UOE'(]#0!YSX9FU^W\",WA:UM+E/[5N19I=RLD8L_,?84
M/ITV]L5SW@"35IOCWXF?6X+>#43IL?FQVSET'^IQ@GVQ^->U*JHH50 H&  ,
M "O)O#O_ "<IXN_[!L7_ *#!0!ZU5/5;F2STNXN(L;XTR,C(JY6;X@_Y 5Y_
MUS/\Q0!R/_"7ZI_TQ_[X_P#KTR7Q9J<L31[XUW#&Y4P1].:P^]%4!>L-7O-.
MF:2"4Y;[ROR#^%:/_"8:I_TQ_P"^/_KU@44 =KX>U^]U+4C!/Y>SRRWRK@Y&
M*ZJN \'?\AL_]<6_I7?U+ *B^T0_\]4_[Z%2UYI*!YTG'\1_G7!CL8\-RV5[
MG9A,*L0WK:QUL^AZ9/>FX,^ S;FC#C!-7_,MS=NA>/880N-PQC)XK@,#THP,
M]*\B.8Q@VXTTK[Z_\ ].6 E)6E.]CK+70+&VOEN#=AT1MRQDC@^YSS6\+B$D
M 2H2?]H5YK@>E3V/_(1M>/\ ELG\Q5X?,8TO=ITTKON16P$IKFG.]O(]'HHH
MKZ,\,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#!\0Z'=ZLZ/:7D%NWV6>U?SH3)E9=N2,,N"-OOUIG
MA[3Y;._NOM.HVEU<);6]N8[>,H8U3>5+ LQR=Q].E0^,H;J:VM5MKF\C <EX
MK>"9UE (.':+YT'7IUR>#67\+[J#^R;O3$TI[.XL)MEQ)Y9V3.<GAV 9BHP#
MN&1Q0!W=%%% !5/5=.MM6TR>QO(S);RC#H'*[@#G!((...G>KE% 'E^@VUY'
M\%K?PZ+6ZBU2]TV]B@C,3+M;Y\!CC"9W#&<9[4>#;/5)I?$%]I%BVE&6PL[:
MV%];-&IGBC8,2G7 R%R.N/:O4** /!]5@\3P?&7P0/$UWIUS*7D\DV,;( N#
MG=N]\5[N.@KR;QY_R6SP!]9J]9'04 +7FK>(]7W'_37Z_P!U?\*]*KR%OO'Z
MTT!I_P#"1ZO_ ,_K_P#?*_X4W_A(-5$AD^V/N( )P.@_#WK-HI@:G_"1ZO\
M\_K_ /?*_P"%6],U[5)]5M(I+MF1Y55A@<@GZ5@5=T?_ )#5C_UW3^8I >I4
M444@.#U__D.W7U7_ -!%9M:6O_\ (=NOJO\ Z"*S:^,Q/\:?J_S/J\/_  8>
MB_(****Q-@/0UZ-8?\@^V_ZY+_(5YR>AKT:P_P"0?;?]<E_D*]G)OCGZ(\G-
M?AB6****^@/$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KG_&#S?V*MO;7EU:SW,Z0QFU16D<G.5&X@+D Y;(P <'-=!63XALOM
M5BDXN9+=[*3[4KQQB0Y56!&T]>": ,#P5?\ FRBRL?GT^")A)Y=@($@EW8,9
M;>=T@.=V,^YR>>UKD/!D.HP0Q"3[1]@DC::/SO(ZR-O_ .69S_$?:NOH ***
M* "BBB@ KR7P[_R<IXN_[!L7_H,%>M5Y+X=_Y.4\7?\ 8-B_]!@H ]:K-\0?
M\@*\_P"N9_F*TJS?$'_("O/^N9_F* /,N]%'>BJ **** .@\'?\ (;/_ %Q;
M^E=_7 >#O^0V?^N+?TKOZ3 *\TE_UTG^^?YUZ77FDO\ KI/]\_SKPLZVA\_T
M/7RG>7R&4F[FEI,"O!=^A[0M3V/_ "$;7_KLG\Q4%3V/_(1M?^NR?S%7#XEZ
MD5/@9Z/1117VY\B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!R?CBYN([:UMXM0^RQ2EWN$2"1Y)(E
M+89#E%&?F8<\@#!-3>#KV*:UGL[7[&UG9[8XGL876'/.0K'AB.,D9Y/)S2>,
M+27[-_:,=VD BMI;5U:V:9G$Q0#: R_-E0!VY[5/X26]M]-6RNH#%%:QQQ0C
M[*(?E QT$CYZ#TH Z"BBB@ HHHH **** /)?'G_);/ 'UFKUD=!7DWCS_DMG
M@#ZS5ZR.@H 6O(6^\?K7KU>0M]X_6F@$HHHI@%7='_Y#5C_UW3^8JE5W1_\
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M1[05/8_\A&U_Z[)_,5!4]C_R$;7_ *[)_,54/B7J14^!GH]%%%?;GR(4444
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MY&1D=JDKD]!\$QZ'XCOM76]DF^U[OW+;ML7/R[<L?X< YSR.,#BNLH ****
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M,?\ OM^=6;1L[LL2WN:J'*W8\J>95.5Z(^CO^$U\.?\ 07M?^^Z/^$U\.?\
M07M?^^Z^;KEB)?E=NG.#4/F/_?;\Z4N5.PUF55K9'U9I^I6>J6WVBQN$GBW%
M=Z'(R.U6JXCX5?\ (G+_ -?#_P EKMZ35G8]:A-U*:F^H4444C4**** "BBB
M@ HHHH **** "BBB@ HHHH *S]<L%U31+RS8L/-A905D*'.#CD$'%:%5M0\C
M^S;K[2C/!Y3^8J@DE=IR!CVS0!R'@UK.:\A A5[NWM=AE_M0W.W.T-M4L< E
M1R!V%=Q7#>&+BW.K:>+B6=V:Q8Z=YEQ%($ARF0=BC#']WUST.#Z]S0 4444
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M 57OF*:?<LOE;A$Q'G'"9P?O>WK[58K'\17<L%G!;0I$7OIQ:[I<E5#*Q8D
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M_P"B<I_X-XO\*0$^O_\ (=NOJO\ Z"*S:S;^Z^(=]?2W)\!*F_'R_P!IQ'&
M!_2JV/B%_P!"*O\ X,XJ^9KY?B95924=&WU7<^@HXZA&G&+EJDNC-NBN3O\
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M$S3PFTETM;(1 G>'$F[/3&,>]<W]E8?S^\Z/[2K^7W'FO_"72_\ 0L>(O_
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MI;N[G73IJG!0CLC@;;XI07-U# /"_B6,RNJ;WL,*N3C).>!7?48HI%A1110
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M2\BM$\RQLK^-4:V++C]YCEW ) )Z<UV] !1110 444R::*WB:6:18XUY+,<
M?C0 ^O/3X_U8Z:?$T>C12>%@[ RK/FY\H-M,VS&-N0?ESG'/M7*>/_'LMX\\
M%M/J>A7>B7ZR>84S'<QG@-QU&#N /# $#GIL^&O"$^N:5.EQ>WNG:5<RE[K2
MX-K6UP6PQ>"7[PA?.=H]2.* /4HY%EC61&#(P#*1W!IU(JJB!5 "@8 '0"EH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$."PZ9SBN@\;:EHOB3P1<2-J,MK]GU 01KY1<O<QO@1O%C+J3SMQR,&G>#M
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M3-O,J?-%(5/S(ZG(_P"!#!XKT+1- T_P_:O#8QN#(P>2660R22$  ;F/)P
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M6"RM(K6UA2&"% D<:#"JHX  J:@ HHHH **** "BBB@ HHHH **** "BBB@
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M)Z=X#TP:.MI=0SI [B9;3S^+8$?- KK@F/)/RYQ^%=;'&D,2QQHJ1H JJHP
M!T %.HH **** "JE_J=EI<*2WUS%;QO(L2M(V 68X _$U;KRWQAXATK6KJ*%
M+2:XAB:2*-Y%(M]0P2L]LI_O@+N4_P!Y!@]: +OC'Q&UZEO#::C>6.C_ &BX
MM;W4+.$O)!/$0$7V4L&!..<8XSFKW@W5F\8Z0]KXBTR)K[3I8F?S(P4=BH>.
M0 _=;!!*GE3Q5;P/X M=$DFOUO)[F&>0SVDAGE5WBD4?+,I.UB,\'&?6NTTS
M2K'1[-;/3K6*VMP2VR-<#)ZD^I]Z +E%%% !1110!'//%;023S.J11J6=F.
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M))H Z,:=9C4CJ0MHA>F+R3.%^<IG.TGTS5JBB@ HHHH *:[K&C.[!54$DDX
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MS82N.?4[@<>E2:WK=MH-DMU=K*8VD6/]VF[!)P* -*BN;NO&NFV@U(RPW?\
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MVG/3M3[71H=;O;?6]6LXGEBVRV"G>&@0J#AU)VEPV><<<5T= !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH J:EIEIJUJ+6^A$T'F))L;H2
MK!AGU&0..]8VB>$+;19+FW607&E&59K.RGC#BS?G=L8_PY.0.W-=)10 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]:W>V+S(%D0&1<Y#J1CZ9QGZ5C#PU._A^?3I4M'\V?SS")&5,AE.W( ..,\
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MJ:G932:K8_9)DDVA<$9&,]_3IGO6WD>M&1ZT +129'K1D>M "T4F1ZT9'K0
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M<:-9@/32;_\ \"C_ /%TAUNW'72K_P#\"C_\71H*\^R^_P#X!V=%<7_;EO\
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M32KW=C'RW&T?D&HT'>5MOZ^XZ^BN,_MNW_Z!5_\ ^!1_^+H_MNW_ .@5?_\
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MN@F0II]A).\^) 0!ZT :3$ ]:3<*Q-:O9[2]CCC4L'Z'TK&D\47$,K1O;O\
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M5;11RAB*'\17@#_!S7Y]8FB1%6WWG:Y]*^C/[4L/^?V#_OX*7^U+#_G\M_\
MOX* /G*#X/\ B"#7;>%XPUN) 6D'89KW7Q1X837O!W]B!L%$ 1CZBMC^U+#_
M )_+?_OX*3^T[#_G]@_[^"@#Q$_ BY^S _:QYF*L>%?@]J.E>*+6]NI5:WA;
M=QWKV?\ M2P_Y_8/^_@H_M2P_P"?V#_OX* *'BK3;C5M+,%H^R0&N&?PCKXM
M]JRGCWKT?^U+#_G]@_[^"E_M2P_Y_8/^_@H P_!6EW^F6,BZC(6=CQFLGQ.N
MNQZWNL49H6':NQ_M2P_Y_;?_ +^"C^T]/[WEO_WV* //+B]\26D?F-"["NU\
M,3W=UHBS7BE96Z U=;4=.88:ZMB/=Q2C4M/486[MP/02"@#DI]2U*.\G0;L!
MN*S+O6?$,#JT8)4FN\-WI+,6-Q;$GOO%->XTA\;KBVX_VQ0 Z.:X?0EFQBX,
M><>]<K%K&N!R'48!KK?[2T_;M^V6^WICS!4/GZ3_ ,_-O_WV* ,R#7;D2Q1R
MI]\X-;>H736=F9E7<?2J++I#3I+]KM\J<@>8*M37VG3Q[&O+?'_704 9*^)I
M!]^'%6K#7Q>7HMO*()YS1(FCR#!N[?\ [^"DM(]*M+KSEO;?.,#]X* -6YG^
MS(&VD_2H1?Y7.PT-J.GN,->6Y_[:"F_;=-_Y^[?_ +^"@":WN?/8C:1BK7AG
M_CVOO^OV7^8J@NH:<G2\MQ_VT%7O"S*]G>.A#(U[*58=",B@#=HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#\6<:#(W998B?8!Q6Y00"
M,&@#SPZA8DY^T)2?;['/-Q'7H6Q?[H_*C8O]T?E0!P/]IV(7'VE*KBZTY22)
MX^:]&V+_ '1^5&Q?[H_*@#SO[9I^X'SXZ>^HV+H5-PA%>@[%_NC\J-B_W1^5
M 'FXGTX#_71U(EY8(V1.@KT38O\ ='Y4;%_NC\J //9+^PD&&N$(I/MNGCCS
MXZ]#V+_='Y4;%_NC\J //EU"Q7I<(*:]]8.V3<(:]#V+_='Y4;%_NC\J /-W
MGTU_O2QFI8[ZQC0*MP@ KT/8O]T?E1L7^Z/RH \Y-UIY<L9H\FHG?2Y""SQ'
M'/2O2]B_W1^5&Q?[H_*@#SW^T+'9L^T)C&,5 +C3_P#GLE>D[%_NC\J-B_W1
M^5 'FHN+ 2!A/'Q4S:A9D?\ 'PE>B;%_NC\J-B_W1^5 'G/V^R_Y[I2"]L@>
M)TS7H^Q?[H_*C8O]T?E0!YI-<6$Q4M,A([U$_P#9CJ07B.?:O4-B_P!T?E1L
M7^Z/RH \VM;FPMH?+2:-1Z"J$UMI,LK.S1'<>:]8V+_='Y4;%_NC\J /&+G0
M]"F&-L0'?%;22:?'IOV-94$>W;MKTW8O]T?E1L7^Z/RH \*7PGX>RY:.-BQR
M2:HIX"\.KJ<5TIV;&W8!.*^@]B_W1^5&Q?[H_*@#S::[LGMA$LZ8 P!5!I+<
M)M$PKUC8O]T?E1L7^Z/RH \NLY;. AC,N?>ND\-SQ7.M[H7#JEF58CL?,SBN
MMV+_ '1^5*% Z "@!:*** "BBJ>K7ITW2;J]"!S!&7VDX!Q[T 7**Q[WQ':V
M5Z+=TD=0@9Y4P57(; ZY.=IZ#ZUFP>-[:\@MY+6TG;S)-C[\#ROGV\\\_AGW
MQ0!U5%<U'XPA9$)LKEBZ(8V4*%D=@AVC)X_UB\G ZU)<>+K.WL+:\:"<Q30F
M=L 9C0$ D\\\GH,T =#17/#Q7&65/[/NM^2)1\A$1SA02&P<DCIGKS45IXRA
MN(X&>PN8S(5#9VD)D)D]>0"X''- '35%+;03D&6&.0CH74''YU7TB^;4M)M;
MUHQ&TT8<H#G&?>N?\0RRG7/*^U7$426BN%BDV_,7(R?PH Z3^S[/_GT@_P"_
M:_X4?V?9_P#/I!_W[7_"O/VNF#8%_>_]_P TL5R\C[?M]]_W_- '?_V?9_\
M/I!_W[7_  H_L^S_ .?2#_OVO^%<@L)90?MU_P#]_P T>2?^?Z__ ._YH Z_
M^S[/_GT@_P"_:_X4?V?9_P#/I!_W[7_"N1$!_P"?Z_\ ^_YI#"1_R_7_ /W_
M #0!U_\ 9]G_ ,^D'_?M?\*/[/L_^?2#_OVO^%<?Y)_Y_P"__P"_YI1"?^?Z
M_P#^_P": .O_ +/L_P#GT@_[]K_A1_9]G_SZ0?\ ?M?\*X\Q$'_C^O\ _O\
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M_P */[/L_P#GT@_[]K_A7'^6?^?Z_P#^_P":;L/_ #_7_P#W_- '9?V?9_\
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M* (-(UE-7>Y\N)D2(H 6ZG<@;D=B,X_"F^(KN>RT>26VD\N7?&@;&<;F /\
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MZ"LO_?I/\*B7%#2JO4T 3"YU4_\ ,5E_[])_A6AHUW>G5OLUS=M<1O;>:-R
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M]0:Z?2/BAXALK?9<6CS@#AMIKV!_"5Y(,-H@/U9/\:D3PI<*FTZ#G_@2?XT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBRM=#\+_ !*LM(M=5\0K)-FWD@N"TL%T63(.\], ]1WKT_7M!T[Q)I,NFZI
M)K:3!QG!4CHP/8BN=T7X::3I&JP:E+>ZIJ5Q;'-L;^Z,H@XQ\H^E '#?V9KA
M\4/\,UO)AI)G&J?:_./FBRW?ZG.<Y\SC/I4'BS2-07Q/K%U>+KESIT>U+&YT
M>YW"P"IR'C!SP>3GK7K?_"-6?_"8_P#"3;YOMOV'[#LR-FS?OSC&<Y]ZP-9^
M%VCZOJ]UJ27NJ:?)>'-U'8W)C2<],L/4B@#F_&MUK6I_"6+4-)UU'TU--\VY
MO!&4GN6!   _@R<[N_:O3]().B6))))MX\DGD_**SKKPCI=QX-?PM&CP::UO
M]G B;YE7ZGO6S;6ZVMK#;H24B144GK@#% 'S+H^G:QK&D.^D:;XEDUEKQQ!J
M271%HA$IZY]!P:]?MO%>O3^--9TD1V(T_18X);N=RWF.K1[F"@<9R#BNH\->
M'+3PMHXTRR>5X1+)+F4@MEV+'H/4TVQ\,6-CX@UC6$:5Y]56-9T<@H BE1@8
M]#S0!QEC\0==-KHVO7^GV<>A:Q=);0I%(S3P[R0C/Q@@D<@=,UBV7Q!\1:-I
M_BS4]7:UO%M-6.G6T488;9<J!V_U8&3_ 'B:[:P^&VCV%W:.MQ?36=E,9[2P
MFF#002=F48SQDXR3C-$_PVT:Y?6!+->&WU6?[3+ )0%CGR#YJ'&0V1ZT <-J
MWQ%N]0\">)!J.G0W#V MY$DC\Z&*=7E4$<[7!4_G6QJWCSQ);ZAXLBTZRTYK
M7P_%%.S3NX9U:/>5 '?KS6_<_#;3+W0M4TR\OM1N6U,Q_:+J:8&0B,@J!QM
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>trda-20211231x10k041.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k041.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #' V # 2(  A$! Q$!_\0
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MO=3SQZ=- @P8GW8; ^@)%5]:L8-$\0*-#LXX[C3M)FFDDC3YW8\+N/4],\T
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M>,9=)MK==-AT807$<48\E[PEM@VC@L 5S]10!Z!HVOV>L:##K*'R+68%E,S
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M*-[2UEFGG51YC@*$&YNIR3W]*Z3Q+J6GZ;I8_M6$R6-S(MO,2!L0.<9;)X%
M&0GC'5+;[+<ZMX;>RTVY=46Y6[65H]WW2Z #&<CH3BMNRUM+W6=2L%BVI8;
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MG;+IWC72[5;?1[5K&UEGF_LT'=L"\*[$#.>O(]ZZWP%"5\+QW3_?O9I+D_\
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M?---9Z79V\DV1(\4"J6'H<#I6C10!1N-&TR[T]=/N-/M9;-<;8&B4HN.F!C
MI\>EZ?%IW]GI8VRV6-OV<1+Y>/3;C%6Z* *&FZ)I>C*ZZ;IUK:"0Y?R(@F[Z
MXZU?HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP8\V5(\]-[ 9J2O*M1&@7?Q \0?\)E)']GM;>$V,=RY"",@[W Z9W8&: /5
M0P!!!!Z$4M>,^#?%MW87&GZ>+Q&T6634/LTT[9+1Q[?+PQ/3EORJ"]^)6M2>
M%M.NK>]5=0-C+>2HD"[6"R,JDEF'&!T&30![8S*BEF( '4D]*4$$ @Y!KQ/Q
M'XJU?7/#NO+-J=OI\,&EP2+;&/YKHRIN8J<Y'/ Q7KF@DGP[IA/)^R1?^@"@
M#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY9EE!!VX!YZ5O1W>K6GQ;&FRZI)/IUUI\ERELT8 A965< ]3U)_&@#MZ***
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M:= $1MX&0HT,94MN(*C&?7ZUQGQ#_P"/_P %_P#8PP?^@25W%</\0_\ C_\
M!G_8PP?^@24 =Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%</XXG:+4+$L$93N18Y)64.2,YX/;% '<451?4+6PTN&YN
MIDBA**-W)&2. /6K%K=P7MN)[>3?&W1L$?SH FHI&94&68*/4G%([K&A9V"J
M.I)P!0!Q_P 4O^1"O/\ KK#_ .C%KK+7_CS@_P"N:_RKD?B=(DOP_O'C=77S
M8N5.1_K%KKK7_CS@_P"N:_RH FHHHH **** "BLZ77=*@F>*6_MTD0X96?!!
MJU:WEO>Q>;:S)+'G&Y#D9HL2I1;LF3T444%!1110 4444 %%%% !1110 444
M4 <%XN6,>)H%:2*"26!!#*R\K)O;YEQ]X@;>#[>IJ_\ $%I&T6*V5;A5FD8-
M-%TC^1@-PSD\D8QW ]*F\0:);ZM>R/\ VREH[0"!D*HS+AB0R[N5;YNH]O2D
M\6)<Q:1IP#O<W:72[?+ 5Y&V/]T=,XR?H#0!I^&=Q\/6K.S,S[WRQ!ZNQ_ <
M\#L.*U=Z[]FX;L9VYYQ65X9\K_A'K7R5*+\^Y2V2'WG=D^N[.?>N:2W;3_C!
M+=37D\D,NB32MYC?)$!-%PH[8&: .Y:2-75&=0S?=!/)^E<3=?\ ):M._P"P
M+-_Z,2N3\:7,=WK.LW*RR/>265C)H#(6^8L[%BF.,YVY]JZ!3J!^.D7VQ81
M-)E^S&,G<4WIG=[YS0!Z(>E<3=Z9J4,>J7-^R21,OR$X)^\,8].*Z;6=2_LG
M3GN_+\S:0-N<=3BN/U'QD;^PEMOLFSS!C.[I3 Z*VUNW'B%]*BL_+[%U4#)
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M:UF"(7$ !<CYSD@_D*[Z)2D**QR54 U3V1A3DW5FFNP^BBBI-PHHHH ****
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M&P_Y!UK_ -<4_D*&!8HHHI#"BBB@ HHHH **** "BBB@#GO''_(FZE_UR->
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M6G0O%!Y&UY&D.Z//)ZUZ7X%U^\\0Z3+<WNSS$DVC8N!BOG]M1LE4LUW  /\
MIH*]0^&GC'PWIVA3Q7FN6$#F;(62=02,5511MH<^ J5G52DW8]9HK'TWQ7H&
MLW7V73=8LKN?!;RX9@S8'? K8K ]L**** "N7U7PG)J&N'44NH -RN(Y;<.
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MW/\ >P/F_&BB@"7^RM.Q:C[!:XM#FV_<K^YXQ\G'R\>E7*** "BBB@ HHHH
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M/-I5WI9TU#9W<YN)X_,?YY"<YSG(Y]#6Y%$D,211KM1%"JH[ <"BB@!]%%%
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520V\*"..-!A44#  '8 5+110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>trda-20211231x10k042.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k042.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $' @<# 2(  A$! Q$!_\0
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M1A#OD948CJVQ2%R?I5B31=+FD$DNFV<D@ 4.\"L< 8 R13T N"1&<HKJ67J
M>13JS;C0-)N[L74VGP-<A@WG!,/D=#D<]J:--O8-2^TVVJ3&"1RTMK< 2+C_
M &#P5^F2/:@#4HK+L=;CN;AK2YMY[*\4%C%.O#*.K*X^5A]#]0*U*0!1110
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M8W'&,GU. /RI.5RZ-"5-W;]?T'T445)TA17$W>NWB>)=;$=PPL[&S8A.,&3
MQ].2?RK;\)3WEUX;MKB^F:6:7<VYL9QD@?H/UJW!I7.6EBX5*CIQ7?\ !V-N
MBBO"]?\ ^1CU3_K[E_\ 0S3IT^=F6/QWU2*ERWOYV/=**^>J*U^K^9YG]O\
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M8LDNW6[N]KW# #)!V]1C'<_E7;4Y1L9T:ZJMI+:WXJX4445)N%%%% !1110
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M_E(HV(CE<D%N>G;)..@Z5-_:T?G[/L\_E;MGGX79NQG;US[9QC/>JVHZ MX
MMO/]G4[Q(,,=V\Y;HP[D\-N7VJZ-+M!<B?8^\<X\UMN<8SMSMSCOC-'ND)5[
MV]/^"0V^M1S@%K6YAW>64\P+\P<X!&&/ZX/M3Y=556V16MQ<29<%(@N0%.">
M6'&?Q]JDDTRTDA$31G:$5!M=E("G*X(.00>_6HSHUB84B"2J%+$,D\BL=QRV
M6#9.3R<FCW1VK6M=?U\BBWB:VMH4:[PKR22A1N6/"(Y7)WL.>G R>O%2R:^A
MLY;B"TG=/*>2"0[0DVT=OFR/7D#('%63H]EY21)')$J%BODS/&1N.2,J0<9[
M=*!HUB/-_=R$2*R%6F<@!OO;03A<^HQ3O$CDQ'=?U\BK/KC1?:T2UFEFA!8H
MJ+^[&Q6RQW<\MVYZX!QDOC\0V3ZDM@6 F)"D[T^\1G&W=N[]<8]ZFDT2PEW;
MXY<M]YA/("PVA<$ALD84<'TJ4:=;K="X7SE<=EG<(>,<H#M/XBE>)7+7ONK7
M_ MTA( ))P!U-+67XCN_L7AS4)\X(A95/H6^4?J122N[&U2:A!R?0\WDN2_A
MK6M1.=VI7RQ+ZX!+G^8%=CIOB_PW8Z9:VHU'_4Q*A_<2=0,?W:Y>"T$L?A32
M2 ?-=KN5?[RELC_QU37H7]@:-_T";#_P&3_"MZCCLSQ,#"NVY4VM$EK?K[SV
M?=F?_P )SX<_Z"/_ ) D_P#B:\GU>>.ZUJ_N(6W12W$CHV",J6)!YKVC^P-&
M_P"@38?^ R?X5XUK<:1:]J,<:*D:74JJJC 4!C@ 55'EN[&&<*OR1]JUOT3_
M %90KH!)#)H=Q+-8P06HB6*V;8#*\P(R=^ Q'WB<\#('I7/UIWNL"^A2.33K
M16CC$4;H9044>@W[?T[FMFKGC49**E=F95S2)X[76K"XF;;%%<1N[8)PH8$G
MBJ=7]$C277M.CD17C>ZB5E89# L,@BF]B*5^>-NYZ1J_C+0+K1;^WAO]TLMO
M(B+Y,@RQ4@#E:\HKV;6]$TF+0=1DCTNR21+65E9;= 5(4X(.*\9K&C:SL>KG
M"K<\?:M;=+_J:.D7"Q7 B;[%&)&&9[J#S0@'8#!'/T_$<U'J\20:Q>11PF%$
MF8+&3G:,]*;:7JVJ.DEG;7*L0V)E;*D>A4@]^F<>U0W%Q+=W,EQ,VZ61BS-Z
MDUK;6YYCFO9*/7^OZ_/H%O<36EQ'<6\C1RQG<KJ>0:]/T?X@:9/8*=4E^S72
M\,!&S*WN, X^E>=Z/H]WK=^MK:IDGEW/W47U->M:?X5T;3[%(&L;>X91EYIX
ME9F/<Y(X'M659PV9ZV40Q5W*DTH^>QP'C&;0-1F_M#2KQ3<L<31>4ZA_]H$C
M&?7U_GRE='XMU33;N\^RZ596L-M">98H54R-]0/N_P ZYRM(*T3SL;)2KR:M
M\MC>GLH+7PS(&C!O5N(C*Y'*!E<A/;@ GW..U8-:4FOZI-I\ME->SRQ2LK,9
M)68X&>.3T.>1["LVG%/J9UI0DUR=CV3_ (3GPY_T$?\ R!)_\37C=>Z?V!HW
M_0)L/_ 9/\*\+K*ARZV/5SE5O<]JUUVOY=V:NA"W%Q<RSRVT?EP,8S<J&3>2
M /EP=V,DXP>E5=3BFBO6\_R2S*KJT,81&4@$$  8R,=A[TRTNA:LY>V@N$==
MI2921USD$$$'Z$4EW=R7MP9I J\!55>BJ!@ 9[ "M;:W/*<X^R4>I"K,CJZ,
M593D$'!!KTGP_P"/;.6P,&N2>7,@V^9Y982CW !Y]>U>?6-C<ZE>1VEI$9)I
M#@ =O<^@KU.P\-:+X=T5Y=2BMKAE&^::>,-SZ*"/_KFLZKC:S/0RJ.(YG.DT
MH];['G?B*+2%U RZ-="6WER3'L93$?3D#(]*T(;/9H]I%;IISS7%M),\<Z9E
MDY8?*V/EVA<CD9.>M9&MZC#J6HO+;6<%I;CY8XXHU7CU..II;?69[>U6(0PN
MZ(\<4[ [XU;.0.<=SU!QDXJK.R.55::JS;V?;UZ?U^!4LXH)KN..YN!;PD_/
M*5+;1] ,FO2D\7>'-#T7[/I4AG:-<)$(W4NWJQ('XUYE#*8)TE548HP.V10R
MGZ@\$5ZIHL/AWQ1H[[=,LX9MNV9(XE5XSZ@@9QZ&IJVT;V.O*I3O*-)I2?>]
M_E_PQYCJ.HW.JWLEW=R%Y7/X >@'85IF[*>&V>>"T:2X?R8"+6-655P6;<%R
M3R!G/K4?B+P[<^'[WRY,O;N<Q3 <,/0^A]JSIKR2>UMK=@H2W#!<#DY.23_G
MM5Z-*QPR=2E.:J7YOU_X8T?#L.C->^=K5X(H(SD1"-V,A]RH.!7=:MX^TJTT
MTKI,@GN,;8U\IE5!ZG(' ]!7GVBZE#IE^LMS907=NW$D<L:MQZKD<&O4&T+P
M]XAT;?9VMM&DHRDT$2HR'\!^8-95;<R<CT\M=65&4*#BI?._WWM^&AY%<7$U
MW<27%Q(TDLAW,['DFHU&6 P3ST'>K^L:/=Z)?M:W28(Y1Q]UU]16>"000<$5
MNK-:'BSC*,FI[]3J-?@@2QN1'!:@PW*HH@15>W4J?DD(^^>.N6Y!Y[5R]:5]
MK4]] \306\1E<23/$I#2L!@%LD^I/&!DFLVE%-+4UQ,XSG>/]?U_6AZOI'C+
M0+71;"WFO]LL5O&CKY,APP4 CA:N_P#"<^'/^@C_ .0)/_B:=HFB:3+H.G22
M:79/(]K$S,UNA+$J,DG%7O[ T;_H$V'_ (#)_A7&^2_4^MI+&<D;..RZ/_,S
M_P#A.?#G_01_\@2?_$USWBK7=/\ $:Z=I>FW)F\VZ7S,1LN.PZ@?WC^5=C_8
M&C?] FP_\!D_PKEFL;1_B9:V]I:P016<'F2+%&%!;!()Q_O+50Y;W70QQ:Q+
M@H5'&TFEHG?\R; O_B>JJ/W>G6O [ X_^S_2NTKC/!/^G:KKFK'D33[(S[9)
M_D5KLZBIO;L=. UINI_,V_QLOP04445!VA1110 4444 %%%% !0>AHHH Y^V
M&I_9;9A)-#Y4%OF!8%"L2<."-N1@=AC%1/+J#74LH-VT\<4_R&VPD9R-H1MN
M&R!ZM^'2NEHJN;R.;ZN[)<S,.:^NIE>2/[;!;><%\Q+0F0+L[(RDXW<9*G^M
M1VG]HSDKYEQ;B2YYF%LB.R"$88@J1R1W'MQT'044<WD/V+;NY/\ KYG,OJ-]
M&T2RW-PDRB%=B6X*/N8!BYV_*>N!E>V >E6-3NM4AUB-( PML+C",RL<G=NV
MQ-[?Q+6O)9VLUQ'<26T+SQ_<D:,%E^AZBIZ?,NQ*H3LUS'/FZU+$VY[M8LCR
MW6V!?R]WS-C:?G'0#'3G!.0%W:I/!^[N;N-5CE=)#;J'D((V!E*\9YX !..U
M;]%+F\BO8/\ F?X_YF'JT]\)K=(1,R21D21QQG&2.I.PC\-RGZ]*JF?4H+,2
MR(R3PVD^3Y0(1ALV!6(&1C\R#GIQTU-=%D0HZAE88*L,@BA2\A2H-MOF9SSW
MMXB1K]JOQ \^WSC:#SB-A) 39TR!SM]?K4BMJ4A)Q)%(\5NIE6!=W,C!CR#S
MMP2#P,]*W2BLRLR@E3E21T/3BG4<WD"H2OK)_C_F<S>WU]:1.DMY<JT22LDB
M6ZLTA#';O&W"KC'/RCW%7M?TF;7="^Q)<"%W*LS,N0<<X_/%:-Q9VMV4-S;0
MS&,Y0R1AMI]1GI4]'-LT'L+J49N\6K=3GK?PT8/$=MJ9N%:*WM1!%%MP5PN.
MOXG\ZZ&BBDVWN:TZ4*::@MW<*\HU?P;K]UK5_<0V&Z*6XD=&\Z,94L2#RU>K
MT54)N&QAB\%3Q45&;>G8\;_X0;Q'_P! [_R/'_\ %4?\(-XC_P"@=_Y'C_\
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M9YYQQZ\FI_M"G_,CB_U;A_>_#_(\S_X0;Q'_ - [_P CQ_\ Q5'_  @WB/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!F:YK=KH6G/=W+@8!V*3]X_X5Y1)\
M4M<,KF/8$+':"J]/^^:W_&>FIK7BI[2XN+G9#;+(EM;[3)*<@':&X.T$M@<G
MM7)VOAK2KJVLG6ZU!7FDN%DW1H ! NY\#J"1C /3O7#6G4<K1T/K<KPF"A04
MZZYF]=MM&_R3.Q\'?$-M3NVL]694D<_NWX _0#C^7TZ>C5XE#X.M#9/J$-]>
M1IY:SP2E4Q"IA\T&4_7Y>/45ZUX=D>7P[8.Y)8PC)-:X><WI,\[.,-AH257#
MZ)Z-=C3HHHKI/#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-_'T=
M_IFIC6(;.VN[9D0%9D+;&0A@P(((((SUY'T->>Q^)]02:"8B%WBGGG.Y.)#,
M,2!N>A'ICK7T+<VT5W;O!.@>-Q@@UY;JG@+2[3Q-I6FAI"-3:<AP2OE>6H;H
M#SG..V/TKBKTI7YHL^KRC,<.Z?L:\=4G]R3O^%_4Y%[_ %+Q/Y>DQV\*QF5&
MC2)#B(*@C51DG@#\2:]WT>TDL='M;:7'F1Q@-CUK)\-^#+#PVSR0DRRL>'8?
M=_4_Y_'/25K0I.&LMSSLVS&GB6J5!6A'\6%%%%=!XH4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 444A(4$GH.30 M%91\1Z;F,(US,9(4G7R+.:7Y&SM)VJ<9P>OI2MXATU8[
M9UEFE%RC/$(+:25B%(!R%4D8) .<8/%7[.?9D>UAW1J45G2:W9Q6T4[BZ"S.
M41/L<OF,0"3\FW=T!YQBK\;B6)9%#!6 (#*5/X@\CZ&I<6MT-2B]F.HHK);Q
M+I:LVZ2X")(8FF-I,(E8-M.9-NT 'C.<4XQE+97"4XQ^)V-:BJL.I6=Q=7=K
M%.&GM"OGI@Y3<,CZY'I4<FL:?#I\%_)<A;6?;Y<A4_-NZ<8R..>>@SGI1R2V
ML'/'>Y>HHHJ2@HHHH **** "BBB@ HHKY_\ $7B+6X/$VK11:SJ$<:7DRHB7
M3@* Y  &>!75A<*\0VD[6.3%XN.&2;5[GT!17S;_ ,)/K_\ T'-3_P# N3_&
MC_A)]?\ ^@YJ?_@7)_C7;_9$_P"9'#_;$/Y6?25%?-O_  D^O_\ 0<U/_P "
MY/\ &M+P[XBUN?Q-I44NLZA)&]Y"KH]TY# N 01GD4I95.*;YD5'-X2DERO4
M^@**S?$4LD'AG5I8I&CD2SF9'0X*D(2"#V-?/_\ PD^O_P#0<U/_ ,"Y/\:Y
ML+@I8A-IVL=.+QT<,TFKW/I*BOFW_A)]?_Z#FI_^!<G^-6;#QGX@L+Z*Y&JW
M<^PY,4\[.CCN"":Z7E%2VDD<JSBG?6+/HFBL;PWXDLO$VFBZM6VR+@30D_-&
MWI[CT/>MFO+G"4).,E9H]:$XSBI1=TPKDO$'_)0O!W_;[_Z*%>6>(O$6MP>)
MM6BBUG4(XTO)E1$NG 4!R  ,\"LL^)-=+*QUK42R]";I\C]:]%Y/.I%/F71_
MJ<-'/88>HVX-Z26_>+C^MSZ4HKYM'B?7P0?[<U+C_IZ?_&O7? WCF+Q# MC?
M,L>IQK]!,!W'OZC\1[1B,NJ48\][H6&S*G6GR6LSM:*\V^(FF:[8[]9TG5=1
M6U_Y>(([EP(O]I1G[OJ.WTZ>;?\ "3Z__P!!S4__  +D_P :=#+W6ASQDA5\
MQ5"?).#/I*BOFW_A)]?_ .@YJ?\ X%R?XT?\)/K_ /T'-3_\"Y/\:V_LB?\
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M%K$LY$NH3*/.E'0#^ZOM_/\ *O,S6-+E3?Q=/^">IE,JW,TOAZ_\ \5\3_\
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M^Y^/_ //_L;^_P#A_P $^6*U?#'_ "-FC?\ 7]!_Z&*^DJ*4LVYHM<GX_P#
M*CD_+)/GV\O^"97B?_D4]9_Z\9__ $ U\VU]3T5RX3&_5XM<M[^9U8S _69)
M\UK>7_!/EBI[*RN=1O(K2TA:6>5MJ(O4FOJ"BNMYP[:0_'_@'(LF5]9_A_P3
MEO!G@RV\+V?F2;9=1E7][-CA1_=7V_G^0'4T45Y%2I*I)RD]3V*=.-**A!62
M/FWQ/_R-FL_]?T__ *&:RJ^IZ*]:.;<L4N3\?^ >1+)^:3?/OY?\$^6*];\
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M"R34+&6VDX#CAL?=/8U+;P):V\<$0PD:A14M% !1110 4444 %%%% !1110
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M;EW^S"V#M)N8 -N#;B,[L\Y_2FWGA>UO5N5>ZNT6Z5!.J,H$C+T8_+P>!G&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>trda-20211231x10k043.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k043.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "\ WT# 2(  A$! Q$!_\0
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MTZ]\.Z*-%-WIL,=TT21N_P#I++*/[Q:,CIZ$4_W'\GX"]_N5!\3?%1!(FB(
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M--964T2P(JD!HP3S7JU>"_$S_D=KG_<3^5=F"A&=2TE?0RK-J.@[_A:'B?\
MY^(/^_(H_P"%H>)_^?B#_OR*XVBO5^KTOY4<OM)=SLO^%H>)_P#GX@_[\BC_
M (6AXG_Y^(/^_(KC:*/J]+^5![27<[+_ (6AXG_Y^(/^_(H_X6AXG_Y^(/\
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M_*@]I+N=E_PM#Q/_ ,_$'_?D5Z;X UV^\0:$]W?NKRB4J"J[1BO *]M^$O\
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M5_O0?^@FNNH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3+ZM*5/Y;35>UN[NZB$HMH54LR\SG/!(_N^U %ZBBB@ HHHH **** "BBB@
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M?7>I:]<>';::Y=;C"M%-'&$4A=WR-@G![[T=2>..: .PTC5Y-31A/IE[83(
M6CN57]&4D&M.L?PQI_\ 9>AQ6OE3Q%"<I,4)!]M@"@>@ 'TK8H **** .1\.
M?\CUXJ_WH/\ T$UUU<CX<_Y'KQ5_O0?^@FNNH 1G5%+.P51R23@"JO\ :NG?
M\_\ :_\ ?Y?\:MU3O%7S[7@??]/:@":&\MKDD07$,I'41N&Q^534@ '0 4M
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MTC_L,6O_ *$:W4\4:+)K"Z2FH1->NH98P>N1D<],XYQ6%\2O^01I'_88M?\
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MPCF968F>0N"OW=KEMRX[8(QVK4T[3;32;);2RA\J%23C<6)).223DDD]R<T
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M\J /";S_ (_)O]\_SJ&IKS_C\F_WS_.H: "O3OAW_P @:;_KH:\QKT[X=_\
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M7UQWK/\ B5_R"-(_[#%K_P"A&@#M*\S^(W_(9M_^N/\ 4UZ97F?Q&_Y#-O\
M]<?ZF@#C**** .N^'G_(P2?]<3_,5ZC7EWP\_P"1@D_ZXG^8KU&@ HHJ!KN)
M<9+#)Q]TT";L3T4Q)5D.%W?BI%/H&%'2BH;NU2]LYK:0N$E0HQ1BI /H1R*
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MDJ<7HF6J***104444 %%%% !1110!A2^+M'ACNW>:0+:2B*;]TWRL<<=/?\
MG5RUURPO=2DT^"5FN(T$C*4(PIZ=:LFPLR&!M(,,<M^[')R3D\>I)_&G1VEM
M%+YL=O$DF,;U0 X],_@/RH FHHHH *Q9O%>D0->K)<%398\_Y#\F>F:VJ@-C
M:,7+6L!+_>)C'S?6@"G;>(-.N[Y+*&5FG>,2A2A'RGO6G4*6EM'()$MXE<#
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M6!_WB)Z]7SYXY_Y'/4_^NIKZ#KY\\<_\CGJ?_74UE1W/4S7^%'U.>HHHKH/
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M'I,EFES8V)-W.((]EX3\Q]?DZ4 4J].^'?\ R!IO^NAKCO\ A!/%O_/GIO\
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MO89)1,+9@$V8XQNYSFM_:Q/#_LW$=OQ.:KZ#\#?\B7IG_7+^IKSO_A3>M_\
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M^N6-<Y] :=%%% !1110 4444 %%%% !1110 C*KJ590RG@@C(-"J%4*H  X
M':EHH *R)?$FF03ZA#+*R/81B6<,AX4]QZUKUQ7B[P9=Z[K-G=V5S%!"0([Y
M6)S)$#G QWH Z>VUBQNH(9$N$4S1^:D;D*Y7&<[3S6)=ZEX>U_3X=3>Y9X]/
MD-P%1L."N1RO7%8-U\/M2D\4SWT5S#]DEG296:1@\05<;  .G_ A]*@?X;WX
MTU(('LDF-O<12,"1N+G*Y..10!Z$FJV+1QM]IC5I(_,6-F <KC/W>M0:?X@T
MS4K*&[AND6.=BL?FG86(.. :Y"R\$ZK97DA,>F7:3"(^?<EB\&U-I5 !TSTY
M'TK&D^%^MF&%!>6K9B\I@9641?/NW+\N2<?[OUH ],UC6;#0=-EO]1N%@MXQ
MDL>_L!W-9\_C#2X9[&!1<S37L/GPI#"6)3ID^E3:[HIU7PO<:8!%),T'EQO,
M,@-C&>]<UJ_@W4K[3+2SA@TPRI:);_;6=UF@(()*8'S#VXH Z74VT;4XXX+R
M^A4P2K-M\Y5967U_.KSZG81!-][;*' 9-TJC<.Q'/->?P?#:[6]CGG:RFQJ3
MW+LV2SQE,8/'7/;I61+X(UM-8M-/6RMKA5T22V-Q+N\F-FE)&UMI^8 YQQ0!
MZ=:^(--N]0N[&.X GM9%CD#_ "@L1D $]>/2K&IZG!I5H;F=977(4+#&78D^
M@%>=Z3\-M6TKQ3%K/VZ"Y\IXU\J1FVN@0*S8QPX(XKT#68[^;3VCT^*TE=B
M\5T6573N,KR#[X- &5/X\T&"S@NC/*T<T;382)F,<:G#.X_A /4FK.M)H>N6
M2V5[?0B,2), LZJV5(8?TKC?^%?:[!IYBM[JR>2?3[C3Y$D9@L"2L2"AQEMH
M)&#C/'-2#X:SKJ'G9M)(UU&"<,^2QACB5"IXZDCITH []]4T^-$=[ZV5'7<K
M&50&'3(YY%01Z]ITFIW&G_:%6>!49]W"G?\ =P>ASBO,;;P3K6G:[IEH=/L[
MY([*^!>;?]G3S)@R+NVG#!3TQV./6KUE\,]6L=<L-4_M"&X:RAMHQ%,QV2[
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M/&^JQFU'F&V0P?,A<C.XY^;]*EN?ATY%U)'>1!I+B"==L/($:8*]>] &_?\
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M?BK_ *&Z/_P6+_\ %UU%% %>QAN8+...[NA<SJ/FE$>S=^&3BK%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 86I:7K]S>M+8^(DLX"!B$V*
MR8_X$6%5/[#\5?\ 0W1_^"Q?_BZZBB@#E_[#\5?]#='_ ."Q?_BZ/[#\5?\
M0W1_^"Q?_BZZBB@#E_[#\5?]#='_ ."Q?_BZ/[#\5?\ 0W1_^"Q?_BZZBN;\
M>ZA=Z5X,O[RQDECN(PNQH@"XRP' /&>>] $?]A^*O^ANC_\ !8O_ ,71_8?B
MK_H;H_\ P6+_ /%UQ.I:YKNG^#+F^CF\40W!G@C4ZE#;JY#'GR@G!/UJVVI:
M_:>';O5(I/$Z/:212O'J\5N@DC!^<+Y?;!YSZ4 =7_8?BK_H;H__  6+_P#%
MT?V'XJ_Z&Z/_ ,%B_P#Q=5/"_B&Y\17VL:M!=1MI,0$5J"X\MBJY9R<9'/!^
ME<AX<\<^(M;\826D>HZ)<)F=X[6"])#;3M5<[,XX+>I!S0!W7]A^*O\ H;H_
M_!8O_P 71_8?BK_H;H__  6+_P#%U0\->*GM?#MQ?>*]1MXI%OY;?S "$!#'
M"CC/05R%MXB\4W^N7HTRYUJYGAUEH%A6T4V8MPW.Z0KP0/\ :H [[^P_%7_0
MW1_^"Q?_ (NC^P_%7_0W1_\ @L7_ .+KSI_'OB"W;Q!ITE\WVRZN#'I+F+.S
M;*R2@8Z[5 ;GUK7\.ZQX@\77-OI_]NRZ=]GTR*Y>6&-&>:1\\MN!&T8Z#K0!
MUW]A^*O^ANC_ /!8O_Q=']A^*O\ H;H__!8O_P 74G@'7+KQ'X+L-3OO+-S)
MYD<C1C"N4D9-P^NW/XUTE '+_P!A^*O^ANC_ /!8O_Q=']A^*O\ H;H__!8O
M_P 77444 <O_ &'XJ_Z&Z/\ \%B__%U)!HWB:.='E\5)+&&!9/[.5=P],[^*
MZ2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q=6TW6[N[$FG:\MC"
M$ ,1LQ+D^N2P_*MJB@#E_P"P_%7_ $-T?_@L7_XNC^P_%7_0W1_^"Q?_ (NN
MHHH Y?\ L/Q5_P!#='_X+%_^+H_L/Q5_T-T?_@L7_P"+KJ** .7_ +#\5?\
M0W1_^"Q?_BZ/[#\5?]#='_X+%_\ BZM>-;^YTSP7J][9R-'<PVSO&Z@$@@=L
MUP4&MZY!X/U/4VF\4QW$=CYB/J4-NL18@<Q[.3[9H [/^P_%7_0W1_\ @L7_
M .+H_L/Q5_T-T?\ X+%_^+KD[.]\13>'K^\@G\4174-LLR'58;=8G(P2$\O)
M/&>O:MSPIXFNO%6O3W=O,1I5M:1J5Q@/.PR>?;I0!H?V'XJ_Z&Z/_P %B_\
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MW%GN\E@>!N&#5VB@#(U;PSI>MW<5S?P&62**2%?FXVN,-Q5*/P'X=2UN;8V
M>"XA2&2-F."J?=QZ$>M=)10!BZ)X5TK0)99K..9KB4!7GN)FE<J.B[F)X]JV
MJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ JCK&DVNN:7-IUZ'-O, &V,5/!SP1TZ5>HH Y)OAWHTEE+9
MS7&J3PR%3MFOI'VE3D%<G@_2K^F^$M/TV"Z@6>^N8KI/+D2\NGF&/8,3CK6]
M10!FZ+H.G>']*33-.@$5JF<(><YZY]:KZ/X3T70IA+864<<@C$8? )P"3U]>
M36U10!3T[2[72HY8[5"JRRM,V3G+,<FF:7HUGHXNA9H4^U7#7$N6SEVZFK]%
M '/'P5HAN[:Y-LQEMI+B6,[^C3#$GY_I4-Q\/_#]S;VL7D3Q&VB\A)()WC=H
M_P"XQ4C</K73T4 5K"PM-+L(;&Q@2"V@4)'&@X459HHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J:IIMMK&F7&
MGWBEK>X0QR!3@D'WK @^'^CP6EQ:FXU.:WGA,+13WTDBA?8$X%=510!S^D>#
M]/T:5G@N=1E#(8S'<WCRIC_=8XJWH7AW3/#=E)::7;^3#)(TK#.<L>M:M% &
M%8>#]#T[4CJ%O9(+DEFWL >6.2:O6.CV>G7E[=6R%9;R023$G.2!BK]% %&S
MTFTL;V[NX$*S7;!I23G)%9DW@C0KB[DNIK0O*]S]J)+?\M,8S^5=#10!S$W@
M'0)K."W\B:+[.6,4L,[1R+N.2-RD'!]*VM*TFQT33X['3K=8+=,D*"3DGJ23
=R2?6KM% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>trda-20211231x10k044.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k044.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $N JH# 2(  A$! Q$!_\0
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MCX-T^RU/P[#9S65TUVB^9!+,_P"_)!._(&0G';VI.K20^61Q7]L:G_T$;O\
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MQ21S)YD,\+;HY5]5-4I4V[+<34DKD/\ :^I_]!&[_P"_[?XT?VQJ?_01N_\
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MQ/I>EV\^H6:W@)ECOX0LD6!G ;[K$XQQ[51M]<T2+6IKA]+O7M&BV0DWS&>
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M$BFW,"5"D8QT'8_45E:?XCO=-U^76(/+,TK.9(W&4<.<E3[5*HU->F_7K?\
MR'SQ-Y[/0M=\+ZQJ&GZ2=-ETTJT;B9G$JGLV>AX[>M<56_J?BJ:]TK^R[2PM
M--L6D\R2&U!_>-ZL3V]JP*WI1DD[_P"9G)I[!1116I(4444 %%%% !1110!W
M/PI_Y'#_ +=I/Z5[C7AWPI_Y'#_MVD_I7N->+C_XOR.RA\)\W?\ ")>(O^@)
MJ'_@.W^%'_")>(O^@)J'_@.W^%?2-%:?VC/^5$_5UW/F[_A$O$7_ $!-0_\
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MH# ^!7TA11_:,_Y4'U==SYN_X1+Q%_T!-0_\!V_PH_X1+Q%_T!-0_P# =O\
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M[>_]!:W_ ._3?XT?\*=O?^@M;_\ ?IO\:]>HH^NUNX>Q@>0_\*=O?^@M;_\
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MI=WJ:OI)L;21HI[@QH$1UQD$XZ\C\Z (_P#A9?@K_H9]+_\  @4?\++\%?\
M0SZ7_P"! J)->\#S:!<ZW;RZ7/86W$DD,*L0W9=N,Y/88YK7TZRT74]-M;^#
M3;80W,*3('MT!VL 1D8Z\T 9O_"R_!7_ $,^E_\ @0*/^%E^"O\ H9]+_P#
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MB[\Z)F+'SY-R_+A!$P8>7M;YN!R:N>,? ]IXPT0:?<W5PICC*Q%I&9 _&'=
M1O88XSZFNJHH S=#T2U\/Z:NGV33_9D8F-)96D\L?W5+$D*.P[5I444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VN7.GZ?I%UJ6IQ
M+);6<33/F,.0 ,G />M&L#Q:+JXT>XTZ#3;R\CO+>:.1K2=(GC^3@ MW8\ ]
MN] &?X:\11ZKJ0BC\&ZQI(,1<7-W9QQ)CCY<AB<GT]JZB]MS=V-Q;A@IEC9
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M &JTH7S _.=G;&,8Y)K*^%5O:1/J$EM:^'(/,B@?&D><'*L&92XDZ CICWH
M]*HHHH *\T^('_)3_AU_U]7/_H*5Z77FGQ _Y*?\.O\ KZN?_04H ]*'04M(
M.@I: "BBB@ HHHH \]^)G^NTW_=D_FM<%7>_$S_7:;_NR?S6N"H *LZ?_P A
M*V_ZZK_,56JSI_\ R$K;_KJO\Q0![L**!10 45!<3RPE1':RS9ZE"HQ^9%54
MU.6225%TVZ+1D*WS1\$@'^]Z&BQ+DD:-%,B=I(U9HVC8]48C(_(D4^@H****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YSQU?:39^$-1CUC
M5!IUO=6\D F!^?+*>$'5FQG@<FNCK$\76INO"FIJFEV^ISI;N\%I<1"19) I
MVC:>O- 'G/PZL],M?%T"IXCT*^G6WN3;6VBP[55&:,OYA!.T @;5]68U[#7D
MOPVN9#XF,5C<'4+1K-C>ROHB6!M9@R[8P55=V<M\O.-H.:]:H **** .%U__
M )*[X/\ ^O.__P#04KNJX77_ /DKO@__ *\[_P#]!2NZH *\-UC_ )#=_P#]
M?,G_ *$:]RKPW6/^0W?_ /7S)_Z$: *5%%% !1WHH[T >R>$?^16L/\ KF?_
M $(UMUB>$?\ D5K#_KF?_0C6W0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 45PD/Q-LYO'S^%187(N  G)3(?<<D_-MV[=K<$MSC&:[N
M@ HHHH **** "BBB@ HHHH **** .$^)VKZ;8Z3:6>H6VJL;FZB,%QI\19H)
M%=2'!P1N!P0I'S=!5/X86]G#<Z@+8:[<,D$,7VS5K?R,J"Y$2)@<+N))_P!J
MM_Q^VHKX5E73+B2&=YHD(AF6*:1"XW)$S<"0C(7WZ<UE_#JWU:*;4WF@UJVT
M=_+^QP:U,)+A7&[S".250_+@$GG)H [RBO/OB^-73P;-=:?J?V.U@*M<I&I\
MR;,B!5#@_*O))[G@=,UH?$K4+BQ\#79M+AX97D@B>2-]KI&\J*Q!ZC@D9]Z
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M3RL793R%3YC@<\5U5<MXL\/:MJVHZ/J.C:C;65YITDK*UQ 958.FPC ([9H
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M^-59KJWDE+)K:Q*?X%>(@?F":=B7-(C7PKH::M_::Z9;"YV@ ^6-H(<N'"]
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MO&?6NC\)>%(M U75KZQ^QP:9?>5]EM+)2L:JJG]XV>-[;NW& *Y3XG06<7B
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MB8'>-6"O@E1W*\=<$'%=S0 FT9!P,B@  8 P*6B@#A=?_P"2N^#_ /KSO_\
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M_B.3^!KT^@ HHHH X77_ /DKO@__ *\[_P#]!2NZKA=?_P"2N^#_ /KSO_\
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M&]@M%,JH#Y;2LBLP!X_B)'X5TWB'PIIGB7R#?"X22$.B2V\[1/L<8="5/*L
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M\"KUS%&*VP^ HT)\\-S*MBZM:/+/8\Q?XS63(RCPCXLY&/\ D'C_ .*KC_\
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MUG3[E%M]K-#<HX!W'C@UPG]J:?\ \_UM_P!_17T'_P *R\$_]"QIG_?@4?\
M"LO!/_0L:9_WX%:QJM*QYM;+859N;EN?/G]JZ?\ \_UM_P!_11_:FG_\_P!;
M?]_17LGC?X:>'5\%ZL=&\+VAU'[.?L_V>#,F[C&W'>MFS^&?@TV4!F\,:<)/
M+7?N@YS@9S3]L^QG_9,/YF>!?VII_P#S_6W_ ']%>H?"WQ7X>T[3K];W7=-M
MF:52HFND0D;>V379_P#"LO!/_0L:9_WX%'_"LO!/_0L:9_WX%3*HY*QMA\OC
M1J*:E<M_\)YX0_Z&C1O_  .C_P ::_COPB48?\)1HW0_\OT?^-5O^%9>"?\
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M3AI;>;E7"D[67D.I7@,I%>SZ'H5MH5M,D,L]Q-<2F:XN;E]\LSX RQX'
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M],E5(9=P[8(/%>2ZEK&I^*/$EO//IUU:7-S&VE7FFW#F6S=Q\RQL1S&7YPV
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M*A_@R0=P PQP< BNUHHH **** "BBB@#CO&GB.71[JWLY]*N+K1;FUF.I7,
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M "BBB@ HHHH **** "BBB@ HHHH @O+&TU"V:VO;:&Y@;[T4T8=3^!XJ8 *
M   . !2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% $$5E:P7,]S%;0QSW&WSI40!I,# W'J<#IFIZ*
M* "BBB@ J 6=L+TWHMXOM1C\HS;!OV9SMW=<9YQ4]% !1110 4444 026=M+
M=0W4EO$]Q"&$4K("T>[@[3U&>^*GHHH **** "H+BSM;MH6N;>*8PR"6(R(&
AV..C+GH>3S4]% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>trda-20211231x10k045.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 trda-20211231x10k045.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %] U8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMH8-EU!;N ^[: .XR <]ZBM]&N_*U]$L#;+>VZ"!&<-R PPQSP>0?QHM'?\
MK<S<ZUE!7VMM_=]._G\B/4+G4+Z30;6>QD:.969XQ<A?.*ID9(Z8ZUMMJ\B3
MRV>G:=)=BT 61O,"A3CH,]3BJL-O>W%[X>G>SDA%JLJS!R,K^[V@\'N:>GV[
M1M0OS'ITUY%=2>;&T+*-K8QM;)&/K0[/0J'/%N5WJUK;6W*O+N22^)HOLUE+
M:VLL[W99$BR%8,.JGT[TKZ]=?:OL<>E2278@69H_-4!02<@M[8_6J5CHU[;2
MZ9)-&#)]HEN+C8<K&7!X%:D-K,OBBZNS&1"]JB*_J0Q)%)J*-(2KRMS-K5=/
M*_YE%/%3RV2WT>ESFS#;992Z@H<X.!_$ >]7]?NI[;P]>7-J"9%A+*P;&WC[
MWX=:R[;3+Q/!$EBT!%R3)B/(SS(2/TK7U.TENO#]S:1 >=);LB@G'.W%#Y;Z
M#@ZTJ;YF[N-]NKN4H=;GBLK"%K*2:_N(@RPB0<J ,NS=A5W3M4^VSS6TUN]M
M=0X+Q,P;@]"".HK(BBU""73M473I6>&V-K/;;EWA>#N7G!Y'3-7M+@NI]7N]
M4N;=K9)8UBCB<@O@9.3@D#KTH:5@I5*G,EK]W2V][;W_ .&+%_JIM;J.SM[9
MKFZD4OL#A0JCN2>E5O\ A(/]!N9OL4GG6CA;F#<-R \[ACJ,<U6UK2V;6H]1
M-E)>P&'RI(XGPZX.00"1GKZU';6M]:Z?>O::4MO-=NJ1H7W,JXQND.<=SP*$
MHV%*K6YVNFO3RTZ=_/Y&@FN"\EN(]/@-PD,.]I@X5=Q&0@]_Y51TK79H/#L5
MS?0R/-)+Y4*APS3,3P!Z=_RJ71M,NM$GETY5,UA*GF)-QE)/X@?8]16:VD7U
MSH5O;/8N)K"Z\WRV< 3KSG:0>.#WIVCL9N=>REKS6>EM+W7Z;=_P-VWUEVNF
MM;RR:UG\LRHOF!PZCK@CO5*+Q3)):VUZVES)8S,JF<R+\I)Q]WKC/>H[#3R]
M^T\6D/:1)"RA[A\R,Q&,* Q 'UI6TR[_ .$)M;$0'[2@CW1Y&1A@31:)7/7:
MNGLF]M[6MT7GT1?GUJ47T]K9V$EU]G ,[JX4+D9P,]3CM4?A&1YO#-I(Y8L3
M)DL>?OM4(6_TC5;^2&PENXKQEDC:)E&Q]N"&R1QWS5OPU:W%GH%O!=1^7,I<
MLN<XR['^M)VY="Z3G*O>5]I=-%JK?@0MX@E?SY;/39KFU@8J\P=5R1UV@]<5
M9MM:AN]1@M84+)-:_:5DSVW8QBLNV74M'LKC3(],EN<NYMYHW4(0Q)^;)R,9
M]#3(--O=#NM.N$M9+Q(K,VTHA(W*=P;(!(R.U%D2JU9--W\]-M>FFOXE^Z\1
MQ6D5_*]NY6SG2%L-RV['(_/I6AI]S<74!DN;-K1MV C.&)'KQ7,R:;J5S8ZF
MTMD8Y;F\BE6/<#\H*YY^@KL:4DDM#6A*I.3<MO3S?Z6,>?7)?M5Q#96$EV+8
M[9G$BJ <9P,]361K5_)JS:0MM;22V=RY8@3^67(!RA],8I)=(>RU'4&?29KY
M+F8S0R0R 8+=58$C SWYJ[%I=S"NAJ+:./[/*[RK$?ECR#ZGGDU2Y5JCFDZU
M2\9;>G]Y>7;U*6F._P#;VH7=]:/''9@ ,;C<(5"=,#KD=ZTAXC=(HKJXTV:&
MPE8*MPSJ<9. 67J :!I4UPVO0R*8TO/EC<]QLQG\ZHW46JZGHT6B/ILD#'8D
MURSJ8PJD'*X.23CIBC1L:]K2BU&_5[;N^ST_KOH:#:]</J=S96FER7#6[!7?
MS JC(R.M9^D^(+J+1EEN[=Y9IKEXXLRCYSN/!/\ "!C%:VEVDUOJFK2R1E4F
MF5HV_O *!6-!9WT.DO8SZ/\ :8XKEV=69<R(6)#(<]1GO0N78<W634KO[73S
MTZ=CH=/OYKMYH[BRDMI(\=6#*P/<,.M4Y+Z&WUR_/E2&6&T61CYGRL,G@#L?
M>H/#]G<V]]<R+!<VNGLBB."YD#-OSR0 3@=NM+=6%U)K.J3+"3'-8K%&V1\S
M9/'ZTK*[-.>HZ<7;6[Z>OE^B"/Q-(R6EQ+IDT5E<NJ+.9%."W3*]<9[UT%<]
M=Z?=2>&M/M4A)FBD@+ID<!6!-=#4RMT-J#J7:F[Z+_@A1114G0%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %,26.1W1)$9D.& 8$J??TK+U"_O#JL.F6
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MW;=;?\LRHS@\GK4*:SK,FD-JRK:BWB+;HB#N=5;!(/:GR,S^N4[75^OX6O\
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M^A1S+N%F/HIGG1?\]4_[Z%'G1?\ /5/^^A1S+N%F/HIGG1?\]4_[Z%'G1?\
M/5/^^A1S+N%F/HIGG1?\]4_[Z%'G1?\ /5/^^A1S+N%F/HIGG1?\]4_[Z%'G
M1?\ /5/^^A1S+N%F/HIGG1?\]4_[Z%'G1?\ /5/^^A1S+N%F/HIGG1?\]4_[
MZ%'G1?\ /5/^^A1S+N%F/HIGG1?\]4_[Z%'G1?\ /5/^^A1S+N%F/HIGG1?\
M]4_[Z%'G1?\ /5/^^A1S+N%F/HIGG1?\]4_[Z%'G1?\ /5/^^A1S+N%F/HIG
MG1?\]4_[Z%'G1?\ /5/^^A1S+N%F/HIGG1?\]4_[Z%'G1?\ /5/^^A1S+N%F
M9FH6%W_:D.IV#1F9(C"\<I(5T)SP1T.:S_\ A';NZM]1^V3Q+<7,R31-&"1&
MRXQUZ]*Z/SHO^>J?]]"CSHO^>J?]]"J52W4YY86,FVT_Z5C(M;35'O()+@6<
M$46=P@7)E./<<"F'06/B;^T/,'V4XE,/_34#;N_*MKSHO^>J?]]"CSHO^>J?
M]]"CVB[C^K1:2=W9W,>]TJY35VU*R6WD,L8CFAG'#8Z,#S@\XJ*31KZXMK03
MSPF6.^2Y947:JJ,_*..?QK=\Z+_GJG_?0H\Z+_GJG_?0H]IYB>%BV]]3'-AJ
M5C>WDNG&WDCNV\PK,2"CXQD8ZCCI65<Z;<Z9<:)#;RH]V9YI7=P0KN5RW3I7
M6^=%_P ]4_[Z%-+V[,K,T99?NDD<4*HB9X126E_\M4W8P+G0KW4(=1GN7A2Z
MN8!!&B$E44'/)[G-:,6FRIKJ7Q9?+%F(,=\[LYK0\Z+_ )ZI_P!]"CSHO^>J
M?]]"CVGF7'"Q3O;7_A_\SFK_ $P6=E?3W%PD3/J NH)=N1&> -WZ@_6H89+N
M_P#%VF/+<VLWV>*5W6VY5 5V@D^I)Z>U=2\D#J5=XV4]02"#4<$=E; B!8(@
M>H3 S3]JK&4L&^9<NBT?W.Y!>6,EQJVG7:LH2V,A8'J=RX&*IW^@MJ%UJ+/+
MLCNK=(U*_>5E).?SQ6SYT7_/5/\ OH4>=%_SU3_OH5*J6ZFTL/&5[K?7\+?D
M8DFG:IJ4EK'J+6RV\#K(_DY)E8=.O09YI;K06G\1Q7Z2*MN=KSQ]WD0$*?R/
MZ5M>=%_SU3_OH4>=%_SU3_OH4_:>9/U6+^*[UO\ <9.HZ5.^K0ZI:"%Y5A,$
MD4_W63.1@]CFH+C1K^[T>Z@GE@$T\L;JD: )&JNK8SC)Z'K6[YT7_/5/^^A1
MYT7_ #U3_OH4>T\QRPL9-WOK^NA5UBS?4-'N[2-@KS1%%+= 369!%XE@MXH5
M_LXK&@4$[NPQ6[YT7_/5/^^A1YT7_/5/^^A24TE8<\/S2YKM/R,.]T_5WU*S
MU"V:U\^.W,<JOG;N.,X]JMV1US[4OVT67D8.[RMV[VZUH^=%_P ]4_[Z%'G1
M?\]4_P"^A1[16$L/:7,FS#U#0)+S6DN$E1;.4QF[B(R9#&25_#D?E6M/I]E=
M2"2XL[>9P,!I(E8C\2*F\Z+_ )ZI_P!]"CSHO^>J?]]"CG\RHX>,6W;<QKO2
MKR2_U%X6A\B]MC$=Q.Y6VD _3FEGT>:70=-L0Z>9:M 7/8[,9Q^5;'G1?\]4
M_P"^A1YT7_/5/^^A3]IYD_58ZZ;_ *ZF&^DWMG?WDU@EI+%=/YA2<8,;D8)!
MQR#UQ4L>D72WFD3RW"2M:+-YK;0NXN !@#TK7\Z+_GJG_?0H\Z+_ )ZI_P!]
M"CVGF"PL4^O]._YF'/I-VFNW&H0Q6EQYZ(JF?.82H[<'@UEWFFWFFZ=I]N)H
MC<-JHD1\';EMQY'IFNP\Z+_GJG_?0IK/;OMW-&VTY&2.#ZTU51G/!1E>U[O]
M7=F/_8]SJ-W+<ZF8TW6[VR1P,3A6^\23WJ&VTG58K>VLMUDD4.U3<*F7=!T&
M", D=370>=%_SU3_ +Z%'G1?\]4_[Z%+VA?U2-[ZW_,Q'TW4[;5;^XL9+<Q7
MNS<9,@Q%5VY&.M0IH5]!IFEQQ20O<V4QD)?(5P<Y_G70^=%_SU3_ +Z%'G1?
M\]4_[Z%'M ^J1N]_^'=_S,-_#\EQ9:M;S2JIO)Q,C+SM(VD9_%:LV\&KS7L$
MM[+#%%"IRD#$B5B,9.>WM6GYT7_/5/\ OH4>=%_SU3_OH4>T7<:PT4[J_P#3
MO^9G:GI]Q-=VU]9/&MS;Y&V3[KJ>H)[50OM&U/4[68W5Q%YCR(R6X),053G!
M]<]ZZ#SHO^>J?]]"CSHO^>J?]]"A5$@GAHSO>^O_  QA1Z3?/JUE>R):016R
MN@@A!X#+@G.!Z#BI(]&G7PO-I9=/-=7 ;MR2?ZUL^=%_SU3_ +Z%'G1?\]4_
M[Z%'M/,2PL5??6_XV_R1B_V;J%C?-=6!@D\Z)(Y8Y21AE& P(_E4%OX?O([.
MVCEFB:6/4/M;L,@$9S@5T/G1?\]4_P"^A1YT7_/5/^^A1[3S#ZI"_7_AS$.F
M:G9SWJ:?);_9[N0RYDSNB=OO$>OK55/#MW!!I)Q;7+V4;(T4WW23_$..HKI?
M.B_YZI_WT*/.B_YZI_WT*/:>8G@X/O\ Y:W_ #.=7P_>2+K/GRP!M1B11Y8(
M$94$8]Q@BI'TB_9K&]'V4WMO$8)(V!*2)VY['C-;WG1?\]4_[Z%'G1?\]4_[
MZ%'M?,/J<//^G?\ ,R$L-6-K=-]J@M[F4J8EBC!2,#L3C)SW_2HK/2+DZVFH
MW$%I;,D90BVZRD]V.!6YYT7_ #U3_OH4>=%_SU3_ +Z%'M$5]5C=-WT'T4SS
MHO\ GJG_ 'T*/.B_YZI_WT*GF7<WLQ]%,\Z+_GJG_?0H\Z+_ )ZI_P!]"CF7
M<+,?13/.B_YZI_WT*/.B_P">J?\ ?0HYEW"S'T4SSHO^>J?]]"CSHO\ GJG_
M 'T*.9=PLQ]%,\Z+_GJG_?0H\Z+_ )ZI_P!]"CF7<+,?13/.B_YZI_WT*/.B
M_P">J?\ ?0HYEW"S'T4SSHO^>J?]]"CSHO\ GJG_ 'T*.9=PLQ]%,\Z+_GJG
M_?0H\Z+_ )ZI_P!]"CF7<+,?13/.B_YZI_WT*/.B_P">J?\ ?0HYEW"S'T4S
MSHO^>J?]]"CSHO\ GJG_ 'T*.9=PLQ]%,\Z+_GJG_?0H\Z+_ )ZI_P!]"CF7
M<+,?13/.B_YZI_WT*/.B_P">J?\ ?0HYEW"S'T4SSHO^>J?]]"CSHO\ GJG_
M 'T*.9=PLQ]%,$L9/$BGZ&BBZ"S.,F\9>!XII(Y)D#HQ5A]FD/(Z_P -,_X3
M;P)_SW3_ ,!9/_B:\8U/_D*WG_7=_P#T(U5KU5E.&:O;\O\ (YOKE;O^9[C_
M ,)MX$_Y[I_X"R?_ !-'_";>!/\ GNG_ ("R?_$UX=11_9.&[?E_D'URMW_,
M]Q_X3;P)_P ]T_\  63_ .)H_P"$V\"?\]T_\!9/_B:\.HH_LG#=OR_R#ZY6
M[_F>X_\ ";>!/^>Z?^ LG_Q-'_";>!/^>Z?^ LG_ ,37AU%']DX;M^7^0?7*
MW?\ ,]Q_X3;P)_SW3_P%D_\ B:/^$V\"?\]T_P# 63_XFO#J*/[)PW;\O\@^
MN5N_YGN/_";>!/\ GNG_ ("R?_$T?\)MX$_Y[I_X"R?_ !->'5TVA>$HM=M?
M,CUJSBF5&D>!U8LBKU)J997A(*\E^"_R&L76>B9Z7_PFW@3_ )[I_P" LG_Q
M-'_";>!/^>Z?^ LG_P 37CVH:8MK>FWL[I-04(&,MNIQ]*I+#*^=D3M@XX4G
MFFLJPK5[?E_D'UNMW/;O^$V\"?\ /=/_  %D_P#B:/\ A-O G_/=/_ 63_XF
MO$E@E896)R,[<A3U]*189&W;8W.W[V%Z?6G_ &3A>WY?Y"^N5N_YGMW_  FW
M@3_GNG_@+)_\31_PFW@3_GNG_@+)_P#$UXZ=&O1HHU8Q@6C2>4&SR3]/2J%)
M95A7LOR_R']<K=_S/<?^$V\"?\]T_P# 63_XFC_A-O G_/=/_ 63_P")KPZB
MG_9.&[?E_D+ZY6[_ )GN/_";>!/^>Z?^ LG_ ,31_P )MX$_Y[I_X"R?_$UX
M=11_9.&[?E_D'URMW_,]Q_X3;P)_SW3_ ,!9/_B:/^$V\"?\]T_\!9/_ (FO
M#J*/[)PW;\O\@^N5N_YGN/\ PFW@3_GNG_@+)_\ $T?\)MX$_P">Z?\ @+)_
M\37AU%']DX;M^7^0?7*W?\SW'_A-O G_ #W3_P !9/\ XFC_ (3;P+_SW3_P
M%D_^)KPZ@=11_9.&[?E_D'URMW_,^E;^#2-,L9;V[MXHX(1N=MA.!]!S7-_\
M)MX$_P">Z?\ @+)_\36QXY_Y$K5?^N/_ +,*^=JY<)E]"M%N4?R_R-:N)JP=
MDSW'_A-O G_/=/\ P%D_^)H_X3;P)_SW3_P%D_\ B:\.HKJ_LG#=OR_R,OKE
M;O\ F>X_\)MX$_Y[I_X"R?\ Q-'_  FW@3_GNG_@+)_\37AU%']DX;M^7^0?
M7*W?\SW'_A-O G_/=/\ P%D_^)H_X3;P)_SW3_P%D_\ B:\QTGPI_:>BOJLV
MJ6ME LODYGS@MC/44Z[\%WUE+>K+<6[);V@O$EB;<LT9. 5-9_V=@[V_R_R*
M^M5][GIG_";>!/\ GNG_ ("R?_$T?\)MX$_Y[I_X"R?_ !->)>1-Y0D\I_+)
MP&VG!_&MR'P=JDFJZ?I\BI%+>Q><A8DA$YR6QWP.GN*J65X2.Z_+_(2Q=9[/
M\SU'_A-O G_/=/\ P%D_^)H_X3;P)_SW3_P%D_\ B:\;OM/^RW\UM;R_:UB/
M,D<; 'UX(S55(99#\D;MSCA2>?2FLJPK5[?E_D'URMW/;O\ A-O G_/=/_ 6
M3_XFC_A-O G_ #W3_P !9/\ XFO$O(F(SY3XQG.T]*:T;H%+(RAAD$C&:?\
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MX=175_9.&[?E_D9?7*W?\SW'_A-O G_/=/\ P%D_^)H_X3;P)_SW3_P%D_\
MB:\.HH_LG#=OR_R#ZY6[_F>X_P#";>!/^>Z?^ LG_P 31_PFW@3_ )[I_P"
MLG_Q->'44?V3ANWY?Y!]<K=_S/<?^$V\"?\ /=/_  %D_P#B:/\ A-O G_/=
M/_ 63_XFO#J*/[)PW;\O\@^N5N_YGN/_  FW@3_GNG_@+)_\31_PFW@3_GNG
M_@+)_P#$UX=11_9.&[?E_D'URMW_ #/<?^$V\"?\]T_\!9/_ (FC_A-O G_/
M=/\ P%D_^)KPZBC^R<-V_+_(/KE;O^9[C_PFW@3_ )[I_P" LG_Q-'_";>!/
M^>Z?^ LG_P 37AU%']DX;M^7^0?7*W?\SW'_ (3;P)_SW3_P%D_^)H_X3;P)
M_P ]T_\  63_ .)KPZBC^R<-V_+_ "#ZY6[_ )GN/_";>!/^>Z?^ LG_ ,31
M_P )MX$_Y[I_X"R?_$UX=11_9.&[?E_D'URMW_,]Q_X3;P)_SW3_ ,!9/_B:
M/^$V\"?\]T_\!9/_ (FO#J*/[)PW;\O\@^N5N_YGN/\ PFW@3_GNG_@+)_\
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MRQ^_G^M<]J^JOJ?@<&[NEFN4U5PBDC<L>P=!V7/X52_X0'Q3_P! >;_OI?\
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M(#XI_P"@/-_WTO\ C1_P@/BG_H#S?]]+_C1[:G_,OO#DEV.<HKH_^$!\4_\
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M>SI?SK\!\TNQSE%='_P@/BG_ * \W_?2_P"-'_" ^*?^@/-_WTO^-=7MJ?\
M,OO,N278YRBNC_X0'Q3_ - >;_OI?\:/^$!\4_\ 0'F_[Z7_ !H]M3_F7WAR
M2['.45T?_" ^*?\ H#S?]]+_ (T?\(#XI_Z \W_?2_XT>VI_S+[PY)=CG**Z
M/_A ?%/_ $!YO^^E_P :/^$!\4_] >;_ +Z7_&CVU/\ F7WAR2['.45T?_"
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M?3(].MV5L%U.+A\ EY".(ER1D*.6YY/%*2A'H7AZN*K2LJC2]69/_">^(?\
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M112$@#).!0 M%,$JL,J01Z@U6DU6QA;;+=PH<XP7%.S%=%RH)9&1\ \5,"&
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MVOZ=%/;PBY21[F-Y8MCKAE7&>2<=_P"?I5I-0M'DCB^T1+-(@=8BXW8^@/\
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M+_\ Y\KG_OTW^%*,4G<TKXB=2"@HOST*M%6O[,O_ /GRN?\ OTW^%']F7_\
MSY7/_?IO\*NZ.+V<^Q5[U[77CW]F7_\ SY7/_?IO\*]CV/\ W&_*L*SV/;R>
M,ESW7;]1M%.V/_<;\J-C_P!QORK ]JPPJI.2H)^E*  , <4[8_\ <;\J-C_W
M&_*F%A@  P !1L7^Z/RI^Q_[C?E1L?\ N-^5 6&D9&#0  , 8IVQ_P"XWY4;
M'_N-^5(+#:*=L?\ N-^5&Q_[C?E0%AM%.\M_[C?E4J6LKG[NT>IH&DV0@%B
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MZ?RH 2BEVM_=/Y4;6_NG\J $HI=K?W3^5&UO[I_*@!**7:W]T_E1M;^Z?RH
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MU-&X^IHL [>__/%OS'^-&]_^>+?F/\:;N/J:-Q]318!V]_\ GBWYC_&C>_\
MSQ;\Q_C3=Q]31N/J:+ .WO\ \\6_,?XT;W_YXM^8_P :5"23DTDGWJ #>_\
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M/\:-[_\ /%OS'^-,R?6C)]:+ /WO_P \6_,?XT;W_P">+?F/\:9D^M&3ZT6
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MM;N2V9H3!*T4:*'0DMC & 02<$>IJ1/#,<3PO'=2*\4JR E0<@1^61^*DT:
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MZ[!9F;_:S_\ 0+U#_OVO_P 51_:S_P#0+U#_ +]K_P#%5I44778+,S?[6?\
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M]*+@<A_;^JK;2O9BPABMX9YY$:W=M^V9EP"'&W(&<\\GI4\7B/4)=30>=8)
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M9#_[/W3791VL$,+10PQQ(V<B-0HY[\57L-)L]/M%MXH8R  &8H,O]>.:+H#
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MM7CTO#QK%&58#OD]_>N_TZ\34-.M[N/[LT8;Z9K*M&.DH[ BU1116 PHHHH
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M?\][#_OR_P#\51LUK_GO8?\ ?E__ (JM$D 9)XHHY@L9VS6O^>]A_P!^7_\
MBJ-FM?\ />P_[\O_ /%5HT9!Z&CF"QG;-:_Y[V'_ 'Y?_P"*HV:U_P ][#_O
MR_\ \56B"#T.:*.8+&=LUK_GO8?]^7_^*HV:U_SWL/\ OR__ ,56C11S!8SM
MFM?\][#_ +\O_P#%4;-:_P">]A_WY?\ ^*K1HHY@L9VS6O\ GO8?]^7_ /BJ
M-FM?\][#_OR__P 56C11S!8SMFM?\][#_OR__P 51LUK_GO8?]^7_P#BJT:*
M.8+&<$UG(S/88[XA?_XJM&BBDW<=A\?4T2?>_"B/J:)/O?A4]0(WW;&V$!L<
M9Z9K/V:U_P ][#_OR_\ \56C2$@#)( ]ZI.P6,_9K7_/>P_[\O\ _%4;-:_Y
M[V'_ 'Y?_P"*K0# @$$<TM/F%8SMFM?\][#_ +\O_P#%4;-:_P">]A_WY?\
M^*K1HHY@L9VS6O\ GO8?]^7_ /BJ-FM?\][#_OR__P 56CWQ11S!8SMFM?\
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M\,^'8_#EA/;I,LKW%P]PY2(1H"V/E503M4   9-;5)[@%%%%( HHHH ****
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MCF78+&=YVL_\^%A_X&O_ /&J/.UG_GPL/_ U_P#XU6C11S+L%C/$VLY&;"P
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MT-',NP6,[SM9_P"?"P_\#7_^-4>=K/\ SX6'_@:__P :K1HHYEV"QG>=K/\
MSX6'_@:__P :H\[6?^?"P_\  U__ (U6C11S+L%C.\[6?^?"P_\  U__ (U1
MYVL_\^%A_P"!K_\ QJM'I1UHYEV"QG>=K/\ SX6'_@:__P :H\[6?^?"P_\
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M< UVVNZJ]QX"GU33KZ.S:6V66*XD^['G'7 //..G6MZ.UMX4=(H(D60DNJH
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MCP[%I'AU]'CG>2-_-_>, #^\8D_ENK2^U'_GWG_[Y_\ KT?:C_S[S_\ ?/\
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M;!61> Z\<,1P?455F\-O)?VTBW]XJ1Q2*\OF_O&+%3W&,<=@*V/M1_Y]Y_\
MOG_Z]'VH_P#/O/\ ]\__ %Z/:+N/D9ES>$]-E$>P2P^4$$>QA\H1=H !!'2D
MC\*6$"Q+#-=Q!"V[9-_K 9#)ACC)^8G\ZU?M1_Y]Y_\ OG_Z]'VH_P#/O/\
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H?>BP7&T4[;[T;?>BP7&T4[;[T;?>BP7!/O?A13D7!ZT5I'8A[G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>48
<FILENAME>trda-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2022 11:35:50 AM-->
<!--Modified on: 3/15/2022 11:35:50 AM-->
<xsd:schema targetNamespace="http://www.entradatx.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:trda="http://www.entradatx.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.entradatx.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40301 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40401 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails" id="DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails">
        <link:definition>40802 - Disclosure - Income Taxes - Reconciliation of U.S. federal statutory income tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesNetDeferredTaxAssetsDetails">
        <link:definition>40803 - Disclosure - Income Taxes - Net deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails" id="DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails">
        <link:definition>40902 - Disclosure - Commitments and Contingencies - Minimum aggregate future lease commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity" id="StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" id="StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical">
        <link:definition>00305 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails" id="DisclosureNatureOfBusinessDetails">
        <link:definition>40101 - Disclosure - Nature of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Estimated useful life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails" id="DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails">
        <link:definition>40601 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails" id="DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>40602 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails" id="DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails">
        <link:definition>40603 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Conversion Right and Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails" id="DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails">
        <link:definition>40604 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Voting Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails" id="DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails">
        <link:definition>40605 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Common Stock and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails" id="DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails">
        <link:definition>40606 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails" id="DisclosureStockBasedCompensationDetails">
        <link:definition>40701 - Disclosure - Stock Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails" id="DisclosureStockBasedCompensationCompensationExpenseDetails">
        <link:definition>40702 - Disclosure - Stock Based Compensation - Compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" id="DisclosureStockBasedCompensationStockOptionValuationDetails">
        <link:definition>40703 - Disclosure - Stock Based Compensation - Stock Option Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>40705 - Disclosure - Stock Based Compensation - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails" id="DisclosureStockBasedCompensationRestrictedStockAwardsDetails">
        <link:definition>40706 - Disclosure - Stock Based Compensation - Restricted Stock Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" id="DisclosureIncomeTaxesOperatingLossCarryforwardsDetails">
        <link:definition>40804 - Disclosure - Income Taxes - Operating loss carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>40901 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" id="DisclosureCommitmentsAndContingenciesLicenseAgreementDetails">
        <link:definition>40903 - Disclosure - Commitments and Contingencies - License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntidilutiveSecuritiesDetails">
        <link:definition>41102 - Disclosure - Net Loss per Share - Antidilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>10101 - Disclosure - Nature of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10301 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10401 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>10501 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStock" id="DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStock">
        <link:definition>10601 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10701 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10801 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10901 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>11001 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11101 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11201 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30403 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockTables" id="DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockTables">
        <link:definition>30603 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30703 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30803 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30903 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31103 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationEarlyExerciseOfUnvestedStockOptionsDetails" id="DisclosureStockBasedCompensationEarlyExerciseOfUnvestedStockOptionsDetails">
        <link:definition>40704 - Disclosure - Stock Based Compensation - Early Exercise of Unvested Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>40801 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>41101 - Disclosure - Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="trda-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="trda-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="trda-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="trda-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.entradatx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" id="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TemporaryEquityIssuanceCosts" id="trda_TemporaryEquityIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProceedsFromEarlyExerciseOfStockOptions" id="trda_ProceedsFromEarlyExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SeriesaRedeemableConvertiblePreferredStockMember" id="trda_SeriesaRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesBRedeemableConvertiblePreferredStockMember" id="trda_SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VestingOfRestrictedStockSubjectToRepurchase" id="trda_VestingOfRestrictedStockSubjectToRepurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="VestingOfOptionsEarlyExercisedSubjectToRepurchase" id="trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedExpensesAndOtherCurrentLiabilitiesAbstract" id="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" id="trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedExternalResearchAndDevelopmentExpensesCurrent" id="trda_AccruedExternalResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="UnvestedSharesMember" id="trda_UnvestedSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockPlan2016Member" id="trda_StockPlan2016Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount" id="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" id="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OfficeAndLaboratorySpaceInBostonMassachusettsMember" id="trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LicenseAgreementWithThirdPartyMember" id="trda_LicenseAgreementWithThirdPartyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeriesSeedRedeemableConvertiblePreferredStockMember" id="trda_SeriesSeedRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TemporaryEquityAggregateSharesIssued" id="trda_TemporaryEquityAggregateSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SharesIssuableUponAchievementOfCertainSpecifiedMilestones" id="trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TemporaryEquityConversionPrice" id="trda_TemporaryEquityConversionPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfDirectorsEntitledToBeElected" id="trda_NumberOfDirectorsEntitledToBeElected" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfVotesPerShareOfCommonStock" id="trda_NumberOfVotesPerShareOfCommonStock" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodAggregateSharesIssued" id="trda_StockIssuedDuringPeriodAggregateSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LicenseAgreementNumberOfInstallments" id="trda_LicenseAgreementNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PaymentOfUpfrontResearchFees" id="trda_PaymentOfUpfrontResearchFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseAgreementNumberOfLicensedProducts" id="trda_LicenseAgreementNumberOfLicensedProducts" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="InterestAndOtherIncomeExpenseNet" id="trda_InterestAndOtherIncomeExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EmployeeStockPurchasePlan2021Member" id="trda_EmployeeStockPurchasePlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions" id="trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" id="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ThresholdNetProceedsFromQualifiedPublicOffering" id="trda_ThresholdNetProceedsFromQualifiedPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RentExpensePolicyTextBlock" id="trda_RentExpensePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PatentCostsPolicyTextBlock" id="trda_PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OperatingLossCarryforwardsSubjectToExpiration" id="trda_OperatingLossCarryforwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLossCarryforwardsLimitationOnUseAmount" id="trda_OperatingLossCarryforwardsLimitationOnUseAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PaymentForPatentCosts" id="trda_PaymentForPatentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AnnualLicenseMaintenanceFee" id="trda_AnnualLicenseMaintenanceFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PotentialMilestonePaymentObligation" id="trda_PotentialMilestonePaymentObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" id="trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" id="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember" id="trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockPlan2021Member" id="trda_StockPlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExpensesRelatingToMilestoneObligation" id="trda_ExpensesRelatingToMilestoneObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock" id="trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EmergingGrowthCompanyStatusPolicyTextBlock" id="trda_EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TemporaryEquityCommonAndPreferredStockTextBlock" id="trda_TemporaryEquityCommonAndPreferredStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>49
<FILENAME>trda-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2022 11:35:50 AM-->
<!--Modified on: 3/15/2022 11:35:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.entradatx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails" roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails" roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.entradatx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637829409493855738" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_637829409493855738" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637829409493865505" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637829409493865505" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637829409493865505" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637829409493865505" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637829409493865505" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637829409493865505" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637829409493865505" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637829409493865505" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637829409493865505" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637829409493865505" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637829409493865505" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_637829409493865505" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637829409493875508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637829409493865505" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637829409493875508" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637829409493875508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637829409493865505" xlink:to="us-gaap_AdditionalPaidInCapital_637829409493875508" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637829409493875508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637829409493865505" xlink:to="us-gaap_CommonStockValue_637829409493875508" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637829409493875508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637829409493875508" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637829409493875508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_637829409493875508" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637829409493875508" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637829409493875508" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637829409493885333" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637829409493875508" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637829409493885333" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637829409493885333" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637829409493875508" xlink:to="us-gaap_LiabilitiesCurrent_637829409493885333" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637829409493885333" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637829409493885333" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637829409493885333" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637829409493885333" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637829409493885333" xlink:to="us-gaap_AccountsPayableCurrent_637829409493885333" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637829409493895336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637829409493895336" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_InterestAndOtherIncomeExpenseNet" xlink:label="trda_InterestAndOtherIncomeExpenseNet_637829409493895336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_637829409493895336" xlink:to="trda_InterestAndOtherIncomeExpenseNet_637829409493895336" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637829409493895336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637829409493895336" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637829409493895336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637829409493895336" xlink:to="us-gaap_OperatingExpenses_637829409493895336" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637829409493895336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637829409493895336" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637829409493895336" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637829409493895336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637829409493895336" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637829409493895336" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409493905336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409493905336" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637829409493905336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409493905336" xlink:to="us-gaap_Depreciation_637829409493905336" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637829409493905336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409493905336" xlink:to="us-gaap_ProfitLoss_637829409493905336" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637829409493905336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409493905336" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637829409493905336" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637829409493905336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409493905336" xlink:to="us-gaap_ShareBasedCompensation_637829409493905336" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637829409493905336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409493905336" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637829409493905336" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637829409493905336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409493905336" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637829409493905336" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637829409493905336" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409493905336" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637829409493905336" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637829409493915329" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409493905336" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637829409493915329" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_637829409493915329" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409493905336" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_637829409493915329" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637829409493915329" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637829409493915329" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637829409493915329" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637829409493915329" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637829409493915329" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637829409493915329" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637829409493915329" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637829409493915329" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637829409493915329" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637829409493915329" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637829409493915329" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637829409493915329" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637829409493915329" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637829409493925327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637829409493915329" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637829409493925327" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ProceedsFromEarlyExerciseOfStockOptions" xlink:label="trda_ProceedsFromEarlyExerciseOfStockOptions_637829409493925327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637829409493915329" xlink:to="trda_ProceedsFromEarlyExerciseOfStockOptions_637829409493925327" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637829409493925327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637829409493925327" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637829409493925327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637829409493925327" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637829409493925327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_1" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637829409493925327" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637829409493935327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637829409493935327" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:label="trda_AccruedExternalResearchAndDevelopmentExpensesCurrent_637829409493935327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="trda_AccruedExternalResearchAndDevelopmentExpensesCurrent_637829409493935327" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637829409493935327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637829409493935327" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637829409493935327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637829409493935327" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes - Reconciliation of U.S. federal statutory income tax rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637829409493935327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637829409493935327" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637829409493935327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637829409493935327" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637829409493935327" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637829409493935327" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637829409493945274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637829409493945274" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637829409493945274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637829409493945274" order="5" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes - Net deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637829409493945274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637829409493945274" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_637829409493945274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_637829409493945274" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637829409493945274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_637829409493945274" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637829409493945274" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637829409493945274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_637829409493945274" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637829409493945274" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637829409493945274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_637829409493945274" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637829409493955328" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637829409493945274" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637829409493955328" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637829409493955328" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637829409493945274" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637829409493955328" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637829409493955328" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637829409493945274" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637829409493955328" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_637829409493955328" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637829409493945274" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_637829409493955328" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637829409493955328" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637829409493945274" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637829409493955328" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637829409493955328" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637829409493945274" xlink:to="us-gaap_DeferredTaxAssetsOther_637829409493955328" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Commitments and Contingencies - Minimum aggregate future lease commitments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637829409493965325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637829409493965325" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637829409493965325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637829409493965325" order="2" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>50
<FILENAME>trda-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2022 11:35:50 AM-->
<!--Modified on: 3/15/2022 11:35:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails" roleURI="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationCompensationExpenseDetails" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationStockOptionValuationDetails" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationRestrictedStockAwardsDetails" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.entradatx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="trda-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://www.entradatx.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:label="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions" xlink:label="trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:to="trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityIssuanceCosts" xlink:label="trda_TemporaryEquityIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="trda_TemporaryEquityIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of the Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockIssuedDuringPeriodAggregateSharesIssued" xlink:label="trda_StockIssuedDuringPeriodAggregateSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="trda_StockIssuedDuringPeriodAggregateSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Estimated useful life (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesSeedRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesSeedRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityAggregateSharesIssued" xlink:label="trda_TemporaryEquityAggregateSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="trda_TemporaryEquityAggregateSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones" xlink:label="trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Conversion Right and Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesSeedRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesSeedRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityConversionPrice" xlink:label="trda_TemporaryEquityConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="trda_TemporaryEquityConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ThresholdNetProceedsFromQualifiedPublicOffering" xlink:label="trda_ThresholdNetProceedsFromQualifiedPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="trda_ThresholdNetProceedsFromQualifiedPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DividendsPreferredStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Voting Rights (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="trda_SeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_NumberOfDirectorsEntitledToBeElected" xlink:label="trda_NumberOfDirectorsEntitledToBeElected" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="trda_NumberOfDirectorsEntitledToBeElected" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40606 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Shares Reserved for Future Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockPlan2021Member" xlink:label="trda_StockPlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="trda_StockPlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_EmployeeStockPurchasePlan2021Member" xlink:label="trda_EmployeeStockPurchasePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="trda_EmployeeStockPurchasePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockPlan2016Member" xlink:label="trda_StockPlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="trda_StockPlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockPlan2016Member" xlink:label="trda_StockPlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="trda_StockPlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockPlan2021Member" xlink:label="trda_StockPlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="trda_StockPlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_EmployeeStockPurchasePlan2021Member" xlink:label="trda_EmployeeStockPurchasePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="trda_EmployeeStockPurchasePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stock Based Compensation - Compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stock Based Compensation - Stock Option Valuation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Stock Based Compensation - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Stock Based Compensation - Restricted Stock Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes - Operating loss carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="trda_OperatingLossCarryforwardsSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="trda_OperatingLossCarryforwardsSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_OperatingLossCarryforwardsLimitationOnUseAmount" xlink:label="trda_OperatingLossCarryforwardsLimitationOnUseAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="trda_OperatingLossCarryforwardsLimitationOnUseAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember" xlink:label="trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember" xlink:label="trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Commitments and Contingencies - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_LicenseAgreementWithThirdPartyMember" xlink:label="trda_LicenseAgreementWithThirdPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="trda_LicenseAgreementWithThirdPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PaymentOfUpfrontResearchFees" xlink:label="trda_PaymentOfUpfrontResearchFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="trda_PaymentOfUpfrontResearchFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_LicenseAgreementNumberOfInstallments" xlink:label="trda_LicenseAgreementNumberOfInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="trda_LicenseAgreementNumberOfInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AnnualLicenseMaintenanceFee" xlink:label="trda_AnnualLicenseMaintenanceFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="trda_AnnualLicenseMaintenanceFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PotentialMilestonePaymentObligation" xlink:label="trda_PotentialMilestonePaymentObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="trda_PotentialMilestonePaymentObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_LicenseAgreementNumberOfLicensedProducts" xlink:label="trda_LicenseAgreementNumberOfLicensedProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="trda_LicenseAgreementNumberOfLicensedProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ExpensesRelatingToMilestoneObligation" xlink:label="trda_ExpensesRelatingToMilestoneObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="trda_ExpensesRelatingToMilestoneObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PaymentForPatentCosts" xlink:label="trda_PaymentForPatentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="trda_PaymentForPatentCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Net Loss per Share - Antidilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_UnvestedSharesMember" xlink:label="trda_UnvestedSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="trda_UnvestedSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>51
<FILENAME>trda-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2022 11:35:50 AM-->
<!--Modified on: 3/15/2022 11:35:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Redeemable Convertible Preferred Stock and Stockholders' (Deficit) Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 9)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable convertible preferred stock, par value $0.0001 (Note 6)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' (deficit) equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value $0.0001; 150,000,000 and 113,259,306 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 31,336,092 and 1,283,545 shares issued as of December 31, 2021 and December 31, 2020, respectively; 31,224,336 and 1,244,139 shares outstanding as of December 31, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable convertible preferred stock, par value per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares, authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Authorized (shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares, issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares, outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (expense) income:</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_InterestAndOtherIncomeExpenseNet" xlink:label="trda_InterestAndOtherIncomeExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_InterestAndOtherIncomeExpenseNet" xlink:to="trda_InterestAndOtherIncomeExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_InterestAndOtherIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net interest and other income (expense) during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_InterestAndOtherIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest And Other Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_InterestAndOtherIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and other (expense) income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other (expense) income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share attributable to common stockholders, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of type or class of series A redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="trda_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of type or class of series B redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock outstanding</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of shares issued upon conversion of convertible securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During the Period Value Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock upon initial public offering</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued upon conversion of convertible securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During the Period Shares Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock upon initial public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of redeemable convertible preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of redeemable convertible preferred stock, net of issuance costs (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balances (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balances (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock upon initial public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock to common stock upon initial public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of redeemable convertible preferred stock upon initial public offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock from initial public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock from initial public offering, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:label="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:to="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock shares issued from early exercised stock options during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Vesting Of Early Exercised Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of early exercised options</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions" xlink:label="trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions" xlink:to="trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock shares issued from early exercised stock options during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Vesting Of Early Exercised Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of early exercised options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityIssuanceCosts" xlink:label="trda_TemporaryEquityIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_TemporaryEquityIssuanceCosts" xlink:to="trda_TemporaryEquityIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_TemporaryEquityIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of issuance cost associated with the issuance of temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_TemporaryEquityIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_TemporaryEquityIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable, Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issue of redeemable convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ProceedsFromEarlyExerciseOfStockOptions" xlink:label="trda_ProceedsFromEarlyExerciseOfStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_ProceedsFromEarlyExerciseOfStockOptions" xlink:to="trda_ProceedsFromEarlyExerciseOfStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_ProceedsFromEarlyExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from early exercise of stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_ProceedsFromEarlyExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From The Early Exercise Of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_ProceedsFromEarlyExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the early exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental cash flow disclosures:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment included in accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_VestingOfRestrictedStockSubjectToRepurchase" xlink:label="trda_VestingOfRestrictedStockSubjectToRepurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_VestingOfRestrictedStockSubjectToRepurchase" xlink:to="trda_VestingOfRestrictedStockSubjectToRepurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_VestingOfRestrictedStockSubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of vesting of restricted stock subject to repurchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_VestingOfRestrictedStockSubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Of Restricted Stock Subject To Repurchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_VestingOfRestrictedStockSubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of restricted stock subject to repurchase</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase" xlink:label="trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase" xlink:to="trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of vesting of options that were early exercised subject to repurchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Of Options Early Exercised Subject To Repurchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of options early exercised subject to repurchase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:to="trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityCommonAndPreferredStockTextBlock" xlink:label="trda_TemporaryEquityCommonAndPreferredStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_TemporaryEquityCommonAndPreferredStockTextBlock" xlink:to="trda_TemporaryEquityCommonAndPreferredStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_TemporaryEquityCommonAndPreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for temporary equity, common stock and preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_TemporaryEquityCommonAndPreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Common And Preferred Stock Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_TemporaryEquityCommonAndPreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement Benefits [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentrations of Credit Risk and Off-Balance Sheet Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guarantees, Indemnifications and Warranties Policies [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indemnification Agreements</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_RentExpensePolicyTextBlock" xlink:label="trda_RentExpensePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_RentExpensePolicyTextBlock" xlink:to="trda_RentExpensePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_RentExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for rent expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_RentExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent Expense [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_RentExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PatentCostsPolicyTextBlock" xlink:label="trda_PatentCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_PatentCostsPolicyTextBlock" xlink:to="trda_PatentCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="trda_EmergingGrowthCompanyStatusPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="trda_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for emerging growth company status.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company Status [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_EmergingGrowthCompanyStatusPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Emerging Growth Company Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of property plant and equipment useful life.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of estimated useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value hierarchy for assets and liabilities measured at fair value on recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property and equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock" xlink:label="trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock" xlink:to="trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of shares reserved for future issuance under share based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Shares Reserved For Future Issuance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of the stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of unvested restricted stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of U.S. federal statutory income tax rate to effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of minimum aggregate future lease commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities excluded from computation of net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockIssuedDuringPeriodAggregateSharesIssued" xlink:label="trda_StockIssuedDuringPeriodAggregateSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_StockIssuedDuringPeriodAggregateSharesIssued" xlink:to="trda_StockIssuedDuringPeriodAggregateSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_StockIssuedDuringPeriodAggregateSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate number of shares issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_StockIssuedDuringPeriodAggregateSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Aggregate Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_StockIssuedDuringPeriodAggregateSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate shares issued and sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issuable upon conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable convertible preferred stock, shares issued upon conversion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets transferred from Level 1 to Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets transferred from Level 2 to Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities transferred from Level 1 to Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities transferred from Level 2 to Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of assets into (out of) level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of liabilities into (out of) level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve" xlink:label="us-gaap_LitigationReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserve" xlink:to="us-gaap_LitigationReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Litigation Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities for legal and other contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee compensation and benefits</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:label="trda_AccruedExternalResearchAndDevelopmentExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:to="trda_AccruedExternalResearchAndDevelopmentExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_AccruedExternalResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount of current portion of  accrued external research and development expenses as at the end of the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_AccruedExternalResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued External Research and Development Expenses Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_AccruedExternalResearchAndDevelopmentExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">External research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative professional service expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesSeedRedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:to="trda_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents Series Seed redeemable convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_SeriesSeedRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Seed redeemable convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation Preference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Redemption Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price (in dollars Per share}</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityAggregateSharesIssued" xlink:label="trda_TemporaryEquityAggregateSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_TemporaryEquityAggregateSharesIssued" xlink:to="trda_TemporaryEquityAggregateSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_TemporaryEquityAggregateSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of aggregate stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_TemporaryEquityAggregateSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Aggregate Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_TemporaryEquityAggregateSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued in satisfaction of principal and interest on convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes outstanding</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones" xlink:label="trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones" xlink:to="trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number od shares issuable upon achievement of certain specified milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issuable Upon Achievement of Certain Specified Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable upon achievement of certain specified milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityConversionPrice" xlink:label="trda_TemporaryEquityConversionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_TemporaryEquityConversionPrice" xlink:to="trda_TemporaryEquityConversionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_TemporaryEquityConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The price per share of the conversion feature embedded in temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_TemporaryEquityConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_TemporaryEquityConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, convertible, conversion price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ThresholdNetProceedsFromQualifiedPublicOffering" xlink:label="trda_ThresholdNetProceedsFromQualifiedPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_ThresholdNetProceedsFromQualifiedPublicOffering" xlink:to="trda_ThresholdNetProceedsFromQualifiedPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_ThresholdNetProceedsFromQualifiedPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of net proceeds from qualified public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_ThresholdNetProceedsFromQualifiedPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Net Proceeds From Qualified Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_ThresholdNetProceedsFromQualifiedPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold net proceeds from qualified public offering.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends preferred stock</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_NumberOfDirectorsEntitledToBeElected" xlink:label="trda_NumberOfDirectorsEntitledToBeElected" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_NumberOfDirectorsEntitledToBeElected" xlink:to="trda_NumberOfDirectorsEntitledToBeElected_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_NumberOfDirectorsEntitledToBeElected_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of directors entitled to be elected.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_NumberOfDirectorsEntitledToBeElected_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Directors Entitled to be Elected</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_NumberOfDirectorsEntitledToBeElected_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of directors entitled to be elected</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_NumberOfVotesPerShareOfCommonStock" xlink:label="trda_NumberOfVotesPerShareOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_NumberOfVotesPerShareOfCommonStock" xlink:to="trda_NumberOfVotesPerShareOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_NumberOfVotesPerShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_NumberOfVotesPerShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Votes Per Share of Common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_NumberOfVotesPerShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shares of authorized common stock reserved for future issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockPlan2021Member" xlink:label="trda_StockPlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_StockPlan2021Member" xlink:to="trda_StockPlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_StockPlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents 2021 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_StockPlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Plan</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_EmployeeStockPurchasePlan2021Member" xlink:label="trda_EmployeeStockPurchasePlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_EmployeeStockPurchasePlan2021Member" xlink:to="trda_EmployeeStockPurchasePlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_EmployeeStockPurchasePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents 2021 employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_EmployeeStockPurchasePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockPlan2016Member" xlink:label="trda_StockPlan2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_StockPlan2016Member" xlink:to="trda_StockPlan2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_StockPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents 2016 Stock Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_StockPlan2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016 Stock Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional number of shares granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum term of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares remaining available for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock authorized for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares annual increase as percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumptions used to determine the fair value of stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility (as percentage)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options Early Exercised, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested shares related to early exercises of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount" xlink:label="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount" xlink:to="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liability related to early exercises of non-vested stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options Early Exercised, Nonvested, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested early exercises of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Outstanding at end period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price Outstanding at beginning period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Contractual Term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Contractual Term, Outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Contractual Term, Exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of stock options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant-date fair value of stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost, weighted-average period for recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares vesting after one year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares vesting after three year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested balance, at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested balance, at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted- Average Grant -Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted- Average Grant -Date Fair Value Unvested balance, at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted- Average Grant -Date Fair Value Unvested balance, at beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total fair value of restricted stock vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal and state research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nondeductible items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in deferred tax asset valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Salaries and wages</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="trda_OperatingLossCarryforwardsSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="trda_OperatingLossCarryforwardsSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_OperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating loss carryforwards subject to expiration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_OperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Subject To Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_OperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards subject to expiration</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_OperatingLossCarryforwardsLimitationOnUseAmount" xlink:label="trda_OperatingLossCarryforwardsLimitationOnUseAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_OperatingLossCarryforwardsLimitationOnUseAmount" xlink:to="trda_OperatingLossCarryforwardsLimitationOnUseAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_OperatingLossCarryforwardsLimitationOnUseAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating loss carryforwards limitation on the use to reduce future taxable income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_OperatingLossCarryforwardsLimitationOnUseAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards, Limitation on Use, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_OperatingLossCarryforwardsLimitationOnUseAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards limited in usage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember" xlink:label="trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember" xlink:to="trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents office and laboratory space in Boston, Massachusetts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and laboratory space in Boston, Massachusetts</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember" xlink:label="trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember" xlink:to="trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents additional office and laboratory space in Boston, Massachusetts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional office and laboratory space in Boston, Massachusetts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of Real Estate Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Area of office and laboratory space</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_LicenseAgreementWithThirdPartyMember" xlink:label="trda_LicenseAgreementWithThirdPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_LicenseAgreementWithThirdPartyMember" xlink:to="trda_LicenseAgreementWithThirdPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_LicenseAgreementWithThirdPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents license agreement with a third-party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_LicenseAgreementWithThirdPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement with a third-party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PaymentOfUpfrontResearchFees" xlink:label="trda_PaymentOfUpfrontResearchFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_PaymentOfUpfrontResearchFees" xlink:to="trda_PaymentOfUpfrontResearchFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_PaymentOfUpfrontResearchFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash outflow for upfront research fees payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_PaymentOfUpfrontResearchFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Upfront Research Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_PaymentOfUpfrontResearchFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront research fees</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_LicenseAgreementNumberOfInstallments" xlink:label="trda_LicenseAgreementNumberOfInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_LicenseAgreementNumberOfInstallments" xlink:to="trda_LicenseAgreementNumberOfInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_LicenseAgreementNumberOfInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of installments for payment of upfront research fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_LicenseAgreementNumberOfInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Number of Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_LicenseAgreementNumberOfInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of installments</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AnnualLicenseMaintenanceFee" xlink:label="trda_AnnualLicenseMaintenanceFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_AnnualLicenseMaintenanceFee" xlink:to="trda_AnnualLicenseMaintenanceFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_AnnualLicenseMaintenanceFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of annual license maintenance fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_AnnualLicenseMaintenanceFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual License Maintenance Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_AnnualLicenseMaintenanceFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual license maintenance fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Purchase of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of assets purchased (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Purchase of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of assets purchased</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PotentialMilestonePaymentObligation" xlink:label="trda_PotentialMilestonePaymentObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_PotentialMilestonePaymentObligation" xlink:to="trda_PotentialMilestonePaymentObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_PotentialMilestonePaymentObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents potential milestone payment obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_PotentialMilestonePaymentObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential milestone payment obligation</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_LicenseAgreementNumberOfLicensedProducts" xlink:label="trda_LicenseAgreementNumberOfLicensedProducts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_LicenseAgreementNumberOfLicensedProducts" xlink:to="trda_LicenseAgreementNumberOfLicensedProducts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_LicenseAgreementNumberOfLicensedProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of licensed products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_LicenseAgreementNumberOfLicensedProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Number of Licensed Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_LicenseAgreementNumberOfLicensedProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of licensed products</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ExpensesRelatingToMilestoneObligation" xlink:label="trda_ExpensesRelatingToMilestoneObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_ExpensesRelatingToMilestoneObligation" xlink:to="trda_ExpensesRelatingToMilestoneObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_ExpensesRelatingToMilestoneObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses recognized relating to milestone obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_ExpensesRelatingToMilestoneObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses Relating to Milestone Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_ExpensesRelatingToMilestoneObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense relating to milestone obligation</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PaymentForPatentCosts" xlink:label="trda_PaymentForPatentCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_PaymentForPatentCosts" xlink:to="trda_PaymentForPatentCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_PaymentForPatentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_PaymentForPatentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment For Patent Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="trda_PaymentForPatentCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, Basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, Diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted common stock</label>
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_UnvestedSharesMember" xlink:label="trda_UnvestedSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="trda_UnvestedSharesMember" xlink:to="trda_UnvestedSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="trda_UnvestedSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents unvested shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="trda_UnvestedSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested shares from early exercises</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from common stock</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>52
<FILENAME>trda-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/15/2022 11:35:50 AM-->
<!--Modified on: 3/15/2022 11:35:50 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.entradatx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.entradatx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.entradatx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity" roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureNatureOfBusiness" roleURI="http://www.entradatx.com/role/DisclosureNatureOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.entradatx.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStock" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureEmployeeBenefitPlan" roleURI="http://www.entradatx.com/role/DisclosureEmployeeBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureNetLossPerShare" roleURI="http://www.entradatx.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureSubsequentEvents" roleURI="http://www.entradatx.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.entradatx.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockTables" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.entradatx.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureNatureOfBusinessDetails" roleURI="http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails" roleURI="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails" roleURI="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationDetails" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationCompensationExpenseDetails" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationStockOptionValuationDetails" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationEarlyExerciseOfUnvestedStockOptionsDetails" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationEarlyExerciseOfUnvestedStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureStockBasedCompensationRestrictedStockAwardsDetails" roleURI="http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails" roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" roleURI="http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails" roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" roleURI="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.entradatx.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="trda-20211231.xsd#DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" roleURI="http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.entradatx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_637829409494605711" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentAnnualReport_637829409494605711" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637829409494605711" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_637829409494605711" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_637829409494605711" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_637829409494605711" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637829409494605711" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637829409494605711" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637829409494605711" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637829409494605711" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637829409494605711" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637829409494605711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637829409494605711" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637829409494615850" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_637829409494615850" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637829409494615850" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_637829409494615850" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637829409494615850" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637829409494615850" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637829409494615850" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637829409494615850" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637829409494615850" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637829409494615850" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637829409494615850" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637829409494615850" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637829409494615850" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_637829409494615850" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637829409494615850" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_637829409494615850" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637829409494625750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637829409494625750" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637829409494625750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_637829409494625750" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637829409494625750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637829409494625750" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637829409494625750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_637829409494625750" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637829409494625750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityPublicFloat_637829409494625750" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637829409494625750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_637829409494625750" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637829409494625750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_637829409494625750" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637829409494635891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_637829409494635891" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637829409494635891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637829409494635891" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637829409494635891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorName_637829409494635891" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637829409494635891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorFirmId_637829409494635891" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637829409494635891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AuditorLocation_637829409494635891" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637829409494635891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637829409494635891" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637829409494635891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637829409494635891" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637829409494645803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637829409494645803" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637829409494645803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637829409494645803" order="36" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637829409494645803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_637829409494645803" order="37" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637829409494645803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_637829409494645803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637829409494645803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637829409494645803" xlink:to="us-gaap_AssetsCurrentAbstract_637829409494645803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637829409494645803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637829409494645803" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637829409494645803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637829409494645803" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637829409494655653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637829409494645803" xlink:to="us-gaap_AssetsCurrent_637829409494655653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637829409494645803" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637829409494655653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637829409494645803" xlink:to="us-gaap_OtherAssetsNoncurrent_637829409494655653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637829409494645803" xlink:to="us-gaap_Assets_637829409494655653" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637829409494655653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637829409494655653" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637829409494655653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637829409494655653" xlink:to="us-gaap_AccountsPayableCurrent_637829409494655653" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637829409494655653" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637829409494655653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637829409494655653" xlink:to="us-gaap_LiabilitiesCurrent_637829409494655653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637829409494655653" xlink:to="us-gaap_DeferredRentCreditNoncurrent_637829409494655653" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637829409494655653" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637829409494655653" xlink:to="us-gaap_Liabilities_637829409494655653" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637829409494665709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637829409494655653" xlink:to="us-gaap_CommitmentsAndContingencies_637829409494665709" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637829409494665709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637829409494655653" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637829409494665709" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637829409494665709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637829409494655653" xlink:to="us-gaap_StockholdersEquityAbstract_637829409494665709" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637829409494665709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637829409494665709" xlink:to="us-gaap_CommonStockValue_637829409494665709" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637829409494665709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637829409494665709" xlink:to="us-gaap_AdditionalPaidInCapital_637829409494665709" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637829409494665709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637829409494665709" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637829409494665709" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637829409494665709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637829409494665709" xlink:to="us-gaap_StockholdersEquity_637829409494665709" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637829409494665709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637829409494655653" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637829409494665709" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637829409494675695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637829409494675695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637829409494675695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637829409494675695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637829409494675695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesAuthorized_637829409494675695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637829409494675695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesIssued_637829409494675695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637829409494675695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_1" xlink:to="us-gaap_CommonStockSharesOutstanding_637829409494675695" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637829409494675695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_637829409494675695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637829409494675695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637829409494675695" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637829409494675695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637829409494675695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637829409494675695" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637829409494675695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637829409494685793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637829409494675695" xlink:to="us-gaap_OperatingExpenses_637829409494685793" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637829409494685793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_637829409494685793" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_637829409494685793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_637829409494685793" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_InterestAndOtherIncomeExpenseNet" xlink:label="trda_InterestAndOtherIncomeExpenseNet_637829409494685793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_637829409494685793" xlink:to="trda_InterestAndOtherIncomeExpenseNet_637829409494685793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_637829409494685793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract_637829409494685793" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_637829409494685793" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637829409494685793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_637829409494685793" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637829409494685793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic_637829409494685793" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637829409494685793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_637829409494685793" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637829409494685793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637829409494685793" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637829409494685793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637829409494685793" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637829409494695834" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637829409494695834" xlink:to="us-gaap_StatementEquityComponentsAxis_637829409494695834" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637829409494695834" xlink:to="us-gaap_CommonStockMember_637829409494695834" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637829409494695834" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637829409494695834" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637829409494695834" xlink:to="us-gaap_RetainedEarningsMember_637829409494695834" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637829409494695834" xlink:to="us-gaap_EquityComponentDomain_637829409494695834" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637829409494695834" xlink:to="us-gaap_StatementClassOfStockAxis_637829409494695834" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637829409494695834" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409494695834" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637829409494695834" xlink:to="trda_SeriesBRedeemableConvertiblePreferredStockMember_637829409494695834" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637829409494695834" xlink:to="us-gaap_ClassOfStockDomain_637829409494695834" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637829409494695834" xlink:to="us-gaap_StatementLineItems_637829409494695834" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637829409494695834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637829409494695834" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637829409494695834" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637829409494705700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637829409494695834" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637829409494705700" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637829409494705700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637829409494695834" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637829409494705700" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637829409494705700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637829409494695834" xlink:to="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637829409494705700" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637829409494705700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637829409494705700" xlink:to="trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637829409494705700" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637829409494705700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637829409494695834" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637829409494705700" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637829409494705700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637829409494705700" xlink:to="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637829409494705700" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6378294094947057001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637829409494695834" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6378294094947057001" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_6378294094947057001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637829409494695834" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_6378294094947057001" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637829409494695834" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637829409494715728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" xlink:to="us-gaap_StockholdersEquity_637829409494715728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637829409494715728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" xlink:to="us-gaap_SharesOutstanding_637829409494715728" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637829409494715728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637829409494715728" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637829409494715728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637829409494715728" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637829409494715728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637829409494715728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637829409494715728" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637829409494715728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637829409494715728" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637829409494715728" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637829409494726073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637829409494726073" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637829409494726073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637829409494726073" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637829409494726073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637829409494726073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637829409494726073" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637829409494726073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_637829409494726073" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_637829409494726073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:label="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_637829409494726073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" xlink:to="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_637829409494726073" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions" xlink:label="trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions_637829409494726073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_637829409494726073" xlink:to="trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions_637829409494726073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637829409494726073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637829409494726073" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637829409494735883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" xlink:to="us-gaap_NetIncomeLoss_637829409494735883" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637829409494735883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" xlink:to="us-gaap_StockholdersEquity_637829409494735883" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637829409494735883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637829409494705700" xlink:to="us-gaap_SharesOutstanding_637829409494735883" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637829409494735883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_1" xlink:to="us-gaap_StatementTable_637829409494735883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637829409494735883" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637829409494735883" xlink:to="us-gaap_StatementClassOfStockAxis_637829409494735883" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637829409494735883" xlink:to="us-gaap_ClassOfStockDomain_637829409494745986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409494745986" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409494745986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409494745986" xlink:to="trda_SeriesBRedeemableConvertiblePreferredStockMember_637829409494745986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637829409494735883" xlink:to="us-gaap_StatementLineItems_637829409494745986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityIssuanceCosts" xlink:label="trda_TemporaryEquityIssuanceCosts_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637829409494745986" xlink:to="trda_TemporaryEquityIssuanceCosts_637829409494745986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637829409494745986" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_637829409494745986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637829409494745986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637829409494745986" xlink:to="us-gaap_ProfitLoss_637829409494745986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637829409494745986" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637829409494745986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637829409494745986" xlink:to="us-gaap_Depreciation_637829409494745986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637829409494745986" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637829409494745986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637829409494745986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637829409494745986" xlink:to="us-gaap_ShareBasedCompensation_637829409494745986" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637829409494755736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637829409494745986" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637829409494755736" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637829409494755736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637829409494755736" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637829409494755736" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637829409494755736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637829409494755736" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637829409494755736" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637829409494755736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637829409494755736" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_637829409494755736" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637829409494755736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637829409494755736" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637829409494755736" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_637829409494755736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637829409494755736" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_637829409494755736" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409494755736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637829409494755736" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637829409494755736" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637829409494755736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637829409494755736" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637829409494755736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637829409494755736" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637829409494755736" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637829409494755736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637829409494755736" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637829409494755736" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637829409494755736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637829409494755736" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637829409494765744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637829409494755736" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637829409494765744" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637829409494895828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637829409494755736" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637829409494895828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637829409494895828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637829409494755736" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637829409494895828" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ProceedsFromEarlyExerciseOfStockOptions" xlink:label="trda_ProceedsFromEarlyExerciseOfStockOptions_637829409494895828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637829409494755736" xlink:to="trda_ProceedsFromEarlyExerciseOfStockOptions_637829409494895828" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637829409494895828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637829409494755736" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637829409494895828" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637829409494895828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637829409494895828" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637829409494895828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637829409494895828" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378294094948958281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378294094948958281" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_637829409494895828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_637829409494895828" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637829409494905812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_637829409494895828" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_637829409494905812" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637829409494905812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_637829409494895828" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637829409494905812" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_VestingOfRestrictedStockSubjectToRepurchase" xlink:label="trda_VestingOfRestrictedStockSubjectToRepurchase_637829409494905812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_637829409494895828" xlink:to="trda_VestingOfRestrictedStockSubjectToRepurchase_637829409494905812" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase" xlink:label="trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase_637829409494905812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_637829409494895828" xlink:to="trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase_637829409494905812" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of the Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637829409494905812" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637829409494905812" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637829409494915828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637829409494915828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10301 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637829409494915828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637829409494915828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10401 - Disclosure - Property and Equipment, Net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637829409494915828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637829409494915828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10501 - Disclosure - Accrued Expenses and Other Current Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_637829409494925851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_637829409494925851" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStock" xlink:type="extended" xlink:title="10601 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityCommonAndPreferredStockTextBlock" xlink:label="trda_TemporaryEquityCommonAndPreferredStockTextBlock_637829409494925851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="trda_TemporaryEquityCommonAndPreferredStockTextBlock_637829409494925851" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10701 - Disclosure - Stock Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637829409494925851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637829409494925851" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10801 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637829409494925851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637829409494925851" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10901 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637829409494935869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637829409494935869" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureEmployeeBenefitPlan" xlink:type="extended" xlink:title="11001 - Disclosure - Employee Benefit Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637829409494935869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_637829409494935869" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11101 - Disclosure - Net Loss per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637829409494935869" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_637829409494935869" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11201 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637829409494945795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637829409494945795" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637829409494945795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637829409494945795" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_637829409494945795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ConsolidationPolicyTextBlock_637829409494945795" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637829409494945795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_UseOfEstimates_637829409494945795" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_637829409494945795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_637829409494945795" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637829409494945795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637829409494945795" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637829409494945795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637829409494945795" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637829409494945795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637829409494945795" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637829409494945795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637829409494945795" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637829409494945795" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637829409494945795" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_637829409494955939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_637829409494955939" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_637829409494955939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_637829409494955939" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_637829409494955939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_637829409494955939" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies" xlink:label="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_637829409494955939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies_637829409494955939" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_RentExpensePolicyTextBlock" xlink:label="trda_RentExpensePolicyTextBlock_637829409494955939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="trda_RentExpensePolicyTextBlock_637829409494955939" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637829409494955939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637829409494955939" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PatentCostsPolicyTextBlock" xlink:label="trda_PatentCostsPolicyTextBlock_637829409494955939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="trda_PatentCostsPolicyTextBlock_637829409494955939" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_637829409494955939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_637829409494955939" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637829409494955939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637829409494955939" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637829409494965815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637829409494965815" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="trda_EmergingGrowthCompanyStatusPolicyTextBlock_637829409494965815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="trda_EmergingGrowthCompanyStatusPolicyTextBlock_637829409494965815" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637829409494965815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637829409494965815" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_4" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_637829409494965815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_4" xlink:to="trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_637829409494965815" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637829409494965815" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_637829409494965815" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30403 - Disclosure - Property and Equipment, Net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637829409494975713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637829409494975713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637829409494975713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_1" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_637829409494975713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockTables" xlink:type="extended" xlink:title="30603 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock_637829409494975713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_1" xlink:to="us-gaap_TemporaryEquityTableTextBlock_637829409494975713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock" xlink:label="trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock_637829409494985803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_1" xlink:to="trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock_637829409494985803" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stock Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637829409494985803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637829409494985803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637829409494985803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637829409494985803" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637829409494985803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637829409494985803" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_637829409494985803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_637829409494985803" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637829409494985803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637829409494985803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637829409494985803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637829409494985803" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637829409494995662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637829409494995662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31103 - Disclosure - Net Loss per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637829409494995662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637829409494995662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637829409494995662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637829409494995662" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of the Business (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637829409494995662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637829409494995662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637829409494995662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637829409494995662" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637829409494995662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637829409494995662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637829409494995662" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637829409494995662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637829409494995662" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637829409494995662" xlink:to="us-gaap_IPOMember_637829409494995662" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637829409494995662" xlink:to="us-gaap_OverAllotmentOptionMember_637829409495005720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_637829409494995662" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockIssuedDuringPeriodAggregateSharesIssued" xlink:label="trda_StockIssuedDuringPeriodAggregateSharesIssued_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" xlink:to="trda_StockIssuedDuringPeriodAggregateSharesIssued_637829409495005720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637829409495005720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" xlink:to="us-gaap_SharesIssuedPricePerShare_637829409495005720" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637829409495005720" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637829409495005720" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637829409495005720" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_637829409495005720" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" xlink:to="us-gaap_NetIncomeLoss_637829409495005720" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637829409495005720" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637829409495005720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_637829409495005720" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637829409495005720" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Estimated useful life (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637829409495015908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_3" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637829409495015908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637829409495015908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637829409495015908" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637829409495015908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495015908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637829409495015908" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495015908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637829409495015908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495015908" xlink:to="us-gaap_EquipmentMember_637829409495015908" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637829409495015908" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495015908" xlink:to="us-gaap_ComputerEquipmentMember_637829409495015908" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637829409495025420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495015908" xlink:to="us-gaap_FurnitureAndFixturesMember_637829409495025420" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637829409495025420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637829409495015908" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637829409495025420" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637829409495025420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637829409495025420" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637829409495025420" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637829409495025420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_637829409495025420" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_637829409495025420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_637829409495025420" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_637829409495025420" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_637829409495025420" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_637829409495035989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_637829409495035989" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_637829409495035989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_637829409495035989" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_637829409495035989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_637829409495035989" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_637829409495035989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_AssetImpairmentCharges_637829409495035989" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserve" xlink:label="us-gaap_LitigationReserve_637829409495035989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_LitigationReserve_637829409495035989" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_637829409495035989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_RestrictedCash_637829409495035989" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637829409495035989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637829409495035989" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637829409495035989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637829409495035989" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637829409495035989" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637829409495035989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637829409495035989" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637829409495035989" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_637829409495035989" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637829409495035989" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_637829409495035989" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637829409495045793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637829409495035989" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637829409495045793" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637829409495045793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637829409495045793" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637829409495045793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_637829409495045793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637829409495045793" xlink:to="us-gaap_FairValueInputsLevel1Member_637829409495045793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_637829409495045793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637829409495035989" xlink:to="us-gaap_CashAndCashEquivalentsAxis_637829409495045793" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637829409495045793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_637829409495045793" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637829409495045793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_637829409495045793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637829409495045793" xlink:to="us-gaap_MoneyMarketFundsMember_637829409495045793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637829409495045793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637829409495035989" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637829409495045793" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_637829409495045793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637829409495045793" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_637829409495045793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637829409495045793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637829409495045793" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_637829409495045793" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_637829409495045793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_637829409495045793" xlink:to="us-gaap_AssetsFairValueDisclosure_637829409495045793" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Property and Equipment, Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_2" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637829409495055708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637829409495055708" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637829409495055708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637829409495055708" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495055708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495055708" xlink:to="us-gaap_EquipmentMember_637829409495055708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495055708" xlink:to="us-gaap_FurnitureAndFixturesMember_637829409495055708" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495055708" xlink:to="us-gaap_ComputerEquipmentMember_637829409495055708" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495055708" xlink:to="us-gaap_LeaseholdImprovementsMember_637829409495055708" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637829409495055708" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637829409495055708" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637829409495055708" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637829409495055708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637829409495055708" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637829409495055708" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637829409495055708" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637829409495055708" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637829409495055708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637829409495055708" xlink:to="us-gaap_Depreciation_637829409495055708" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:label="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637829409495065868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_2" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637829409495065868" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AccruedExternalResearchAndDevelopmentExpensesCurrent" xlink:label="trda_AccruedExternalResearchAndDevelopmentExpensesCurrent_637829409495065868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_2" xlink:to="trda_AccruedExternalResearchAndDevelopmentExpensesCurrent_637829409495065868" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637829409495065868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_2" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637829409495065868" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637829409495065868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_2" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637829409495065868" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637829409495065868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract_2" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637829409495065868" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637829409495065868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_3" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637829409495065868" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637829409495065868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495065868" xlink:to="us-gaap_StatementClassOfStockAxis_637829409495065868" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637829409495065868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637829409495065868" xlink:to="us-gaap_ClassOfStockDomain_637829409495065868" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesSeedRedeemableConvertiblePreferredStockMember_637829409495065868" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409495065868" xlink:to="trda_SeriesSeedRedeemableConvertiblePreferredStockMember_637829409495065868" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409495075693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409495065868" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409495075693" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637829409495075693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495065868" xlink:to="us-gaap_TemporaryEquityLineItems_637829409495075693" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637829409495075693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495075693" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637829409495075693" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637829409495075693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495075693" xlink:to="us-gaap_TemporaryEquitySharesIssued_637829409495075693" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637829409495075693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495075693" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637829409495075693" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637829409495075693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495075693" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637829409495075693" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_637829409495075693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495075693" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_637829409495075693" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637829409495075693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495075693" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637829409495075693" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637829409495075693" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_2" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637829409495075693" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637829409495085821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495075693" xlink:to="us-gaap_StatementClassOfStockAxis_637829409495085821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637829409495085821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637829409495085821" xlink:to="us-gaap_ClassOfStockDomain_637829409495085821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesSeedRedeemableConvertiblePreferredStockMember_637829409495085821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409495085821" xlink:to="trda_SeriesSeedRedeemableConvertiblePreferredStockMember_637829409495085821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409495085821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409495085821" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409495085821" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember_637829409495085821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409495085821" xlink:to="trda_SeriesBRedeemableConvertiblePreferredStockMember_637829409495085821" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637829409495085821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495075693" xlink:to="srt_RangeAxis_637829409495085821" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637829409495085821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637829409495085821" xlink:to="srt_RangeMember_637829409495085821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637829409495085821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637829409495085821" xlink:to="srt_MaximumMember_637829409495085821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637829409495085821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495075693" xlink:to="us-gaap_TemporaryEquityLineItems_637829409495085821" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637829409495085821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495085821" xlink:to="trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637829409495085821" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_637829409495095682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495085821" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_637829409495095682" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637829409495095682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495085821" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637829409495095682" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityAggregateSharesIssued" xlink:label="trda_TemporaryEquityAggregateSharesIssued_637829409495095682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495085821" xlink:to="trda_TemporaryEquityAggregateSharesIssued_637829409495095682" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637829409495095682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495085821" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637829409495095682" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637829409495095682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495085821" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_637829409495095682" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_637829409495095682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495085821" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_637829409495095682" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones" xlink:label="trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones_637829409495095682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495085821" xlink:to="trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones_637829409495095682" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Conversion Right and Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637829409495095682" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_4" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637829409495095682" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495095682" xlink:to="us-gaap_StatementClassOfStockAxis_637829409495105790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637829409495105790" xlink:to="us-gaap_ClassOfStockDomain_637829409495105790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesSeedRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesSeedRedeemableConvertiblePreferredStockMember_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409495105790" xlink:to="trda_SeriesSeedRedeemableConvertiblePreferredStockMember_637829409495105790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409495105790" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409495105790" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409495105790" xlink:to="trda_SeriesBRedeemableConvertiblePreferredStockMember_637829409495105790" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495095682" xlink:to="srt_RangeAxis_637829409495105790" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637829409495105790" xlink:to="srt_RangeMember_637829409495105790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637829409495105790" xlink:to="srt_MinimumMember_637829409495105790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495095682" xlink:to="us-gaap_TemporaryEquityLineItems_637829409495105790" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495105790" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_637829409495105790" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_TemporaryEquityConversionPrice" xlink:label="trda_TemporaryEquityConversionPrice_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495105790" xlink:to="trda_TemporaryEquityConversionPrice_637829409495105790" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ThresholdNetProceedsFromQualifiedPublicOffering" xlink:label="trda_ThresholdNetProceedsFromQualifiedPublicOffering_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495105790" xlink:to="trda_ThresholdNetProceedsFromQualifiedPublicOffering_637829409495105790" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_637829409495105790" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495105790" xlink:to="us-gaap_PreferredStockDividendRatePercentage_637829409495105790" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock_637829409495115703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495105790" xlink:to="us-gaap_DividendsPreferredStock_637829409495115703" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails" xlink:type="extended" xlink:title="40604 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Voting Rights (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637829409495115703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_5" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637829409495115703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637829409495115703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495115703" xlink:to="us-gaap_StatementClassOfStockAxis_637829409495115703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637829409495115703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637829409495115703" xlink:to="us-gaap_ClassOfStockDomain_637829409495115703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesaRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409495115703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409495115703" xlink:to="trda_SeriesaRedeemableConvertiblePreferredStockMember_637829409495115703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="trda_SeriesBRedeemableConvertiblePreferredStockMember_637829409495115703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637829409495115703" xlink:to="trda_SeriesBRedeemableConvertiblePreferredStockMember_637829409495115703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637829409495115703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495115703" xlink:to="us-gaap_TemporaryEquityLineItems_637829409495115703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_NumberOfDirectorsEntitledToBeElected" xlink:label="trda_NumberOfDirectorsEntitledToBeElected_637829409495115703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495115703" xlink:to="trda_NumberOfDirectorsEntitledToBeElected_637829409495115703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails" xlink:type="extended" xlink:title="40605 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Common Stock and Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637829409495125437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_6" xlink:to="us-gaap_CommonStockSharesAuthorized_637829409495125437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637829409495125437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_6" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637829409495125437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_NumberOfVotesPerShareOfCommonStock" xlink:label="trda_NumberOfVotesPerShareOfCommonStock_637829409495125437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_6" xlink:to="trda_NumberOfVotesPerShareOfCommonStock_637829409495125437" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637829409495125437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_6" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637829409495125437" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637829409495125437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_6" xlink:to="us-gaap_PreferredStockSharesAuthorized_637829409495125437" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637829409495125437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_6" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637829409495125437" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637829409495125437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_6" xlink:to="us-gaap_PreferredStockSharesIssued_637829409495125437" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637829409495125437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_6" xlink:to="us-gaap_PreferredStockSharesOutstanding_637829409495125437" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40606 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Shares Reserved for Future Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_7" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637829409495135629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495135629" xlink:to="us-gaap_AwardTypeAxis_637829409495135629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637829409495135629" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495135629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495135629" xlink:to="us-gaap_EmployeeStockOptionMember_637829409495135629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495135629" xlink:to="us-gaap_RestrictedStockMember_637829409495135629" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495135629" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_637829409495135629" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495135629" xlink:to="us-gaap_PlanNameAxis_637829409495135629" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637829409495135629" xlink:to="us-gaap_PlanNameDomain_637829409495135629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockPlan2021Member" xlink:label="trda_StockPlan2021Member_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637829409495135629" xlink:to="trda_StockPlan2021Member_637829409495135629" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_EmployeeStockPurchasePlan2021Member" xlink:label="trda_EmployeeStockPurchasePlan2021Member_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637829409495135629" xlink:to="trda_EmployeeStockPurchasePlan2021Member_637829409495135629" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockPlan2016Member" xlink:label="trda_StockPlan2016Member_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637829409495135629" xlink:to="trda_StockPlan2016Member_637829409495135629" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637829409495135629" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637829409495135629" xlink:to="us-gaap_TemporaryEquityLineItems_637829409495135629" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637829409495145431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637829409495135629" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637829409495145431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495145431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495145431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637829409495145431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495145431" xlink:to="us-gaap_PlanNameAxis_637829409495145431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637829409495145431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637829409495145431" xlink:to="us-gaap_PlanNameDomain_637829409495145431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockPlan2016Member" xlink:label="trda_StockPlan2016Member_637829409495145431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637829409495145431" xlink:to="trda_StockPlan2016Member_637829409495145431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_StockPlan2021Member" xlink:label="trda_StockPlan2021Member_637829409495145431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637829409495145431" xlink:to="trda_StockPlan2021Member_637829409495145431" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_EmployeeStockPurchasePlan2021Member" xlink:label="trda_EmployeeStockPurchasePlan2021Member_637829409495145431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637829409495145431" xlink:to="trda_EmployeeStockPurchasePlan2021Member_637829409495145431" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637829409495145431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495145431" xlink:to="us-gaap_AwardTypeAxis_637829409495145431" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495145431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637829409495145431" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495145431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_637829409495145431" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495145431" xlink:to="us-gaap_EmployeeStockMember_637829409495145431" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495155325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495145431" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495155325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637829409495155325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495155325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_637829409495155325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637829409495155325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495155325" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637829409495155325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637829409495155325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495155325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637829409495155325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637829409495155325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495155325" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637829409495155325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637829409495155325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495155325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_637829409495155325" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637829409495155325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495155325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637829409495155325" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_637829409495155325" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495155325" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_637829409495155325" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Stock Based Compensation - Compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495165319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495165319" xlink:to="us-gaap_IncomeStatementLocationAxis_637829409495165319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637829409495165319" xlink:to="us-gaap_IncomeStatementLocationDomain_637829409495165319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637829409495165319" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637829409495165319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637829409495165319" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637829409495165319" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495165319" xlink:to="us-gaap_AwardTypeAxis_637829409495165319" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637829409495165319" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495165319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495165319" xlink:to="us-gaap_EmployeeStockOptionMember_637829409495165319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495165319" xlink:to="us-gaap_RestrictedStockMember_637829409495165319" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495165319" xlink:to="srt_RangeAxis_637829409495165319" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637829409495165319" xlink:to="srt_RangeMember_637829409495165319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637829409495165319" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637829409495165319" xlink:to="srt_MaximumMember_637829409495165319" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495175326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495165319" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495175326" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637829409495175326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495175326" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637829409495175326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stock Based Compensation - Stock Option Valuation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495175326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495175326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637829409495175326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495175326" xlink:to="us-gaap_AwardTypeAxis_637829409495175326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495175326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637829409495175326" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495175326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637829409495175326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495175326" xlink:to="us-gaap_EmployeeStockOptionMember_637829409495175326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495175326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495175326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495175326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637829409495175326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495175326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637829409495175326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637829409495175326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637829409495175326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637829409495175326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637829409495175326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637829409495175326" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637829409495175326" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637829409495185334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637829409495175326" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637829409495185334" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationEarlyExerciseOfUnvestedStockOptionsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Stock Based Compensation - Early Exercise of Unvested Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637829409495185334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637829409495185334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount" xlink:label="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount_637829409495185334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5" xlink:to="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount_637829409495185334" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Stock Based Compensation - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495185334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495185334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637829409495185334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495185334" xlink:to="us-gaap_AwardTypeAxis_637829409495185334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495185334" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637829409495185334" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495185334" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637829409495195328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495185334" xlink:to="us-gaap_EmployeeStockOptionMember_637829409495195328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495195328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495185334" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495195328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637829409495195328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637829409495195328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637829409495195328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637829409495195328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637829409495195328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637829409495195328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637829409495195328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637829409495195328" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637829409495195328" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637829409495195328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637829409495195328" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378294094951953281" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378294094951953281" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637829409495195328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637829409495195328" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637829409495195328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637829409495195328" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637829409495195328" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637829409495195328" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637829409495205316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637829409495205316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637829409495205316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637829409495205316" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637829409495205316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637829409495205316" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637829409495205316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637829409495205316" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637829409495205316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637829409495205316" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637829409495205316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637829409495205316" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637829409495205316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637829409495205316" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637829409495205316" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637829409495205316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637829409495205316" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637829409495205316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_637829409495205316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495195328" xlink:to="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_637829409495205316" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637829409495215331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_637829409495205316" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637829409495215331" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637829409495215331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_637829409495205316" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637829409495215331" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637829409495215331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637829409495215331" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637829409495215331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495195328" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637829409495215331" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637829409495215331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495195328" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637829409495215331" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637829409495215331" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495195328" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637829409495215331" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637829409495225515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495195328" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637829409495225515" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails" xlink:type="extended" xlink:title="40706 - Disclosure - Stock Based Compensation - Restricted Stock Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495225515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495225515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637829409495225515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495225515" xlink:to="us-gaap_AwardTypeAxis_637829409495225515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495225515" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637829409495225515" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495225515" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_637829409495235365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637829409495225515" xlink:to="us-gaap_RestrictedStockMember_637829409495235365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_637829409495235365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495225515" xlink:to="us-gaap_VestingAxis_637829409495235365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_637829409495235365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_637829409495235365" xlink:to="us-gaap_VestingDomain_637829409495235365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637829409495235365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637829409495235365" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_637829409495235365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637829409495235365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_637829409495235365" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_637829409495235365" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637829409495235365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495225515" xlink:to="srt_RangeAxis_637829409495235365" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637829409495235365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637829409495235365" xlink:to="srt_RangeMember_637829409495235365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637829409495235365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637829409495235365" xlink:to="srt_MaximumMember_637829409495235365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495235365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637829409495225515" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495235365" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637829409495235365" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495235365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637829409495235365" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637829409495245336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495235365" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637829409495245336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637829409495245336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495235365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637829409495245336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637829409495245336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637829409495245336" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637829409495245336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637829409495245336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637829409495245336" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_637829409495245336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6378294094952453361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_637829409495245336" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6378294094952453361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637829409495245336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495235365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637829409495245336" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637829409495245336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637829409495245336" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637829409495245336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637829409495245336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637829409495245336" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_637829409495245336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378294094952453361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_637829409495245336" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378294094952453361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637829409495255317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637829409495235365" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637829409495255317" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637829409495255317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637829409495255317" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_637829409495255317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637829409495255317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_637829409495255317" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_637829409495255317" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637829409495255317" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_2" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637829409495255317" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes - Reconciliation of U.S. federal statutory income tax rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637829409495265312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_3" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637829409495265312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637829409495265312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637829409495265312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637829409495265312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637829409495265312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637829409495265312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637829409495265312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637829409495265312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637829409495265312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_637829409495265312" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637829409495265312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637829409495265312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_637829409495265312" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637829409495265312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637829409495265312" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_637829409495265312" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637829409495265312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_637829409495265312" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637829409495265312" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes - Net deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637829409495265312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637829409495265312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637829409495265312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637829409495265312" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637829409495265312" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637829409495265312" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637829409495265312" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_637829409495265312" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637829409495275339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637829409495265312" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_637829409495275339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_637829409495275339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637829409495265312" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_637829409495275339" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637829409495275339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637829409495265312" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_637829409495275339" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_637829409495275339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637829409495265312" xlink:to="us-gaap_DeferredTaxAssetsOther_637829409495275339" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637829409495275339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637829409495265312" xlink:to="us-gaap_DeferredTaxAssetsGross_637829409495275339" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637829409495275339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637829409495275339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637829409495275339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637829409495275339" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637829409495275339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637829409495275339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637829409495275339" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_637829409495275339" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_637829409495275339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_637829409495275339" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_637829409495275339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637829409495275339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637829409495275339" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637829409495275339" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_4" xlink:to="us-gaap_DeferredTaxAssetsNet_637829409495275339" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - Income Taxes - Operating loss carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_637829409495285314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_5" xlink:to="us-gaap_OperatingLossCarryforwardsTable_637829409495285314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_637829409495285314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637829409495285314" xlink:to="us-gaap_IncomeTaxAuthorityAxis_637829409495285314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_637829409495285314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_637829409495285314" xlink:to="us-gaap_IncomeTaxAuthorityDomain_637829409495285314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_637829409495285314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637829409495285314" xlink:to="us-gaap_DomesticCountryMember_637829409495285314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_637829409495285314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_637829409495285314" xlink:to="us-gaap_StateAndLocalJurisdictionMember_637829409495285314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_637829409495285314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637829409495285314" xlink:to="us-gaap_TaxCreditCarryforwardAxis_637829409495285314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_637829409495285314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_637829409495285314" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_637829409495285314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_637829409495285314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_637829409495285314" xlink:to="us-gaap_ResearchMember_637829409495285314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_637829409495285314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_637829409495285314" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_637829409495285314" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637829409495295322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637829409495285314" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637829409495295322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637829409495295322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637829409495285314" xlink:to="us-gaap_OperatingLossCarryforwards_637829409495295322" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="trda_OperatingLossCarryforwardsSubjectToExpiration_637829409495295322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637829409495285314" xlink:to="trda_OperatingLossCarryforwardsSubjectToExpiration_637829409495295322" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_OperatingLossCarryforwardsLimitationOnUseAmount" xlink:label="trda_OperatingLossCarryforwardsLimitationOnUseAmount_637829409495295322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637829409495285314" xlink:to="trda_OperatingLossCarryforwardsLimitationOnUseAmount_637829409495295322" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_637829409495295322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637829409495285314" xlink:to="us-gaap_TaxCreditCarryforwardAmount_637829409495295322" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_637829409495295322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637829409495285314" xlink:to="us-gaap_UnrecognizedTaxBenefits_637829409495295322" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637829409495295322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_637829409495285314" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637829409495295322" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" xlink:to="us-gaap_LesseeLeaseDescriptionTable_637829409495305314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637829409495305314" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637829409495305314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637829409495305314" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495305314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember" xlink:label="trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495305314" xlink:to="trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_637829409495305314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember" xlink:label="trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637829409495305314" xlink:to="trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_637829409495305314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637829409495305314" xlink:to="us-gaap_BalanceSheetLocationAxis_637829409495305314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_637829409495305314" xlink:to="us-gaap_BalanceSheetLocationDomain_637829409495305314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_637829409495305314" xlink:to="us-gaap_OtherNoncurrentAssetsMember_637829409495305314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_637829409495305314" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_637829409495305314" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637829409495305314" xlink:to="us-gaap_AreaOfRealEstateProperty_637829409495305314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637829409495305314" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_637829409495305314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637829409495305314" xlink:to="us-gaap_SecurityDeposit_637829409495305314" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_637829409495305314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_637829409495305314" xlink:to="us-gaap_OperatingLeaseExpense_637829409495305314" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Commitments and Contingencies - Minimum aggregate future lease commitments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637829409495315311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637829409495315311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637829409495315311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637829409495315311" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637829409495315311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637829409495315311" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Commitments and Contingencies - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637829409495315311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637829409495315311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637829409495315311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637829409495315311" xlink:to="us-gaap_TypeOfArrangementAxis_637829409495315311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637829409495315311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637829409495315311" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637829409495315311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_LicenseAgreementWithThirdPartyMember" xlink:label="trda_LicenseAgreementWithThirdPartyMember_637829409495315311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637829409495315311" xlink:to="trda_LicenseAgreementWithThirdPartyMember_637829409495315311" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637829409495325333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637829409495315311" xlink:to="srt_RangeAxis_637829409495325333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637829409495325333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637829409495325333" xlink:to="srt_RangeMember_637829409495325333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637829409495325333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637829409495325333" xlink:to="srt_MaximumMember_637829409495325333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637829409495315311" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637829409495325333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637829409495325333" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PaymentOfUpfrontResearchFees" xlink:label="trda_PaymentOfUpfrontResearchFees_637829409495325333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" xlink:to="trda_PaymentOfUpfrontResearchFees_637829409495325333" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_LicenseAgreementNumberOfInstallments" xlink:label="trda_LicenseAgreementNumberOfInstallments_637829409495325333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" xlink:to="trda_LicenseAgreementNumberOfInstallments_637829409495325333" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_AnnualLicenseMaintenanceFee" xlink:label="trda_AnnualLicenseMaintenanceFee_637829409495325333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" xlink:to="trda_AnnualLicenseMaintenanceFee_637829409495325333" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_637829409495325333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_637829409495325333" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_637829409495325333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_637829409495325333" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PotentialMilestonePaymentObligation" xlink:label="trda_PotentialMilestonePaymentObligation_637829409495325333" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" xlink:to="trda_PotentialMilestonePaymentObligation_637829409495325333" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_LicenseAgreementNumberOfLicensedProducts" xlink:label="trda_LicenseAgreementNumberOfLicensedProducts_637829409495335322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" xlink:to="trda_LicenseAgreementNumberOfLicensedProducts_637829409495335322" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_ExpensesRelatingToMilestoneObligation" xlink:label="trda_ExpensesRelatingToMilestoneObligation_637829409495335322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" xlink:to="trda_ExpensesRelatingToMilestoneObligation_637829409495335322" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_PaymentForPatentCosts" xlink:label="trda_PaymentForPatentCosts_637829409495335322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637829409495325333" xlink:to="trda_PaymentForPatentCosts_637829409495335322" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Net Loss per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_637829409495335322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_EarningsPerShareBasicAbstract_637829409495335322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637829409495335322" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_637829409495335322" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637829409495335322" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637829409495345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_637829409495335322" xlink:to="us-gaap_NetIncomeLoss_637829409495345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_637829409495345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_637829409495335322" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_637829409495345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637829409495345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_637829409495345309" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637829409495345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637829409495345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_637829409495335322" xlink:to="us-gaap_EarningsPerShareBasic_637829409495345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract_637829409495345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_EarningsPerShareDilutedAbstract_637829409495345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_637829409495345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637829409495345309" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_637829409495345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_6378294094953453091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_637829409495345309" xlink:to="us-gaap_NetIncomeLoss_6378294094953453091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637829409495345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637829409495345309" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637829409495345309" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637829409495345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637829409495345309" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637829409495345309" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637829409495345309" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract_637829409495345309" xlink:to="us-gaap_EarningsPerShareDiluted_637829409495345309" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Net Loss per Share - Antidilutive securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637829409495355310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637829409495355310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637829409495355310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637829409495355310" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637829409495355310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637829409495355310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637829409495355310" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637829409495355310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_637829409495355310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637829409495355310" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_637829409495355310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_637829409495355310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637829409495355310" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_637829409495355310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="trda-20211231.xsd#trda_UnvestedSharesMember" xlink:label="trda_UnvestedSharesMember_637829409495355310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637829409495355310" xlink:to="trda_UnvestedSharesMember_637829409495355310" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637829409495355310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637829409495355310" xlink:to="us-gaap_EmployeeStockOptionMember_637829409495355310" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637829409495355310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637829409495355310" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637829409495355310" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637829409495355310" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637829409495355310" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637829409495355310" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700082205032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Nov. 05, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ENTRADA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3983399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6 Tide Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">520-9158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 474.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TRDA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,251,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001689375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700084545832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 291,064<span></span>
</td>
<td class="nump">$ 39,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,636<span></span>
</td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">298,700<span></span>
</td>
<td class="nump">39,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,261<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">541<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">305,833<span></span>
</td>
<td class="nump">43,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,013<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,719<span></span>
</td>
<td class="nump">3,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,115<span></span>
</td>
<td class="nump">3,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock, par value $0.0001 (Note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' (deficit) equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001; 150,000,000 and 113,259,306 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 31,336,092 and 1,283,545 shares issued as of December 31, 2021 and December 31, 2020, respectively; 31,224,336 and 1,244,139 shares outstanding as of December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">392,384<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(93,669)<span></span>
</td>
<td class="num">(42,511)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' (deficit) equity</a></td>
<td class="nump">298,718<span></span>
</td>
<td class="num">(41,490)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity</a></td>
<td class="nump">$ 305,833<span></span>
</td>
<td class="nump">$ 43,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700083903416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares, authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">113,259,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">31,336,092<span></span>
</td>
<td class="nump">1,283,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">31,224,336<span></span>
</td>
<td class="nump">1,244,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700083799160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 35,926<span></span>
</td>
<td class="nump">$ 21,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,201<span></span>
</td>
<td class="nump">5,565<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">51,127<span></span>
</td>
<td class="nump">26,667<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(51,127)<span></span>
</td>
<td class="num">(26,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_InterestAndOtherIncomeExpenseNet', window );">Interest and other (expense) income, net</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (51,158)<span></span>
</td>
<td class="num">$ (26,523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (8.16)<span></span>
</td>
<td class="num">$ (24.00)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (8.16)<span></span>
</td>
<td class="num">$ (24.00)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">6,267,776<span></span>
</td>
<td class="nump">1,105,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">6,267,776<span></span>
</td>
<td class="nump">1,105,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_InterestAndOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net interest and other income (expense) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_InterestAndOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700079228472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series A Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning Balances at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,816<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,269,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of redeemable convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,030,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balances at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,658<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,879,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,299,885<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="num">$ (15,988)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,518)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balances (in shares) at Dec. 31, 2019</a></td>
<td class="nump">1,004,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">129,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="nump">95,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised options (in shares)</a></td>
<td class="nump">14,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,523)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="num">(42,511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,490)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2020</a></td>
<td class="nump">1,244,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (197,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,821,984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of redeemable convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,522,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock upon initial public offering</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">197,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock upon initial public offering (in shares)</a></td>
<td class="nump">19,185,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">190,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs (in shares)</a></td>
<td class="nump">10,436,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">223,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="nump">11,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised options (in shares)</a></td>
<td class="nump">123,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,158)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2021</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 392,384<span></span>
</td>
<td class="num">$ (93,669)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298,718<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balances (in shares) at Dec. 31, 2021</a></td>
<td class="nump">31,224,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock shares issued from early exercised stock options during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock shares issued from early exercised stock options during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued upon conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of shares issued upon conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700087277432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Net of issuance costs</a></td>
<td class="nump">$ 18,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_TemporaryEquityIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance cost associated with the issuance of temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_TemporaryEquityIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700079156088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (51,158)<span></span>
</td>
<td class="num">$ (26,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="nump">2,526<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(6,733)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(331)<span></span>
</td>
<td class="num">(541)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(715)<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,962<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent</a></td>
<td class="nump">396<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(50,862)<span></span>
</td>
<td class="num">(25,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,580)<span></span>
</td>
<td class="num">(2,318)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4,580)<span></span>
</td>
<td class="num">(2,318)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">115,831<span></span>
</td>
<td class="nump">49,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock upon initial public offering, net of issuance costs</a></td>
<td class="nump">190,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">410<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_ProceedsFromEarlyExerciseOfStockOptions', window );">Proceeds from the early exercise of stock options</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">307,461<span></span>
</td>
<td class="nump">50,089<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">252,019<span></span>
</td>
<td class="nump">22,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">39,045<span></span>
</td>
<td class="nump">16,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">291,064<span></span>
</td>
<td class="nump">39,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock upon initial public offering</a></td>
<td class="nump">197,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_VestingOfRestrictedStockSubjectToRepurchase', window );">Vesting of restricted stock subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase', window );">Vesting of options early exercised subject to repurchase</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_ProceedsFromEarlyExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from early exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_ProceedsFromEarlyExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of vesting of options that were early exercised subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_VestingOfRestrictedStockSubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of vesting of restricted stock subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_VestingOfRestrictedStockSubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088199912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Organization</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Entrada Therapeutics, Inc. (Entrada or the Company) aims to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>) therapeutics as a new class of medicines and aim to become the world&#8217;s foremost intracellular therapeutics company. The Company was incorporated in Delaware on September 22, 2016 and its principal offices are located in Boston, Massachusetts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Initial Public Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">In November 2021, the Company completed its initial public offering (IPO) in which the Company issued and sold 10,436,250 shares of its common stock, including 1,361,250 shares pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $20.00 per share, for aggregate gross proceeds of $208.7 million. The Company received $190.7 million in net proceeds, after deducting underwriting discounts and offering expenses payable. In connection with the IPO, all outstanding shares of the Company&#8217;s redeemable convertible preferred stock converted into 19,185,183 shares of the Company&#8217;s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;">On October 22, 2021, in connection with the Company&#8217;s IPO, the Company effected a <span style="-sec-ix-hidden:Hidden_w1M_9o9Q5kO5Amu-2DsMtA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-7.235890014</span></span> reverse stock split of the Company&#8217;s common stock. All common shares, stock options, and per share information presented in the accompanying consolidated financial statements and notes thereto have been adjusted, where applicable, to reflect the reverse stock split on a retroactive basis for all periods presented, including reclassification of par and additional paid-in capital amounts. The per share par value and authorized number of shares of the Company&#8217;s common stock were not adjusted as a result of the reverse stock split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its proprietary, highly versatile and modular EEV platform (EEV Platform), advancing development of its portfolio of programs and general and administrative support for these operations, including raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, technical risks associated with the successful research, development and manufacturing of therapeutic candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accordance with Accounting Standards Codification (ASC) 205-40,&#160;<i style="font-style:italic;">Going Concern</i>, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company has incurred losses since its inception, including losses of $51.2 million and $26.5 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the Company had an accumulated deficit of $93.7 million. To date, the Company has funded its operations primarily through the sale of equity securities. The Company expects to continue to generate operating losses and negative operating cash flows for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company expects that its cash and cash equivalents of $291.1 million as of December 31, 2021 will be sufficient to fund its operations and capital expenditure requirements for at least the next twelve months from the date of issuance of these consolidated financial statements. The Company will need additional financing to support its continuing operations and pursue its business strategy and may pursue additional cash resources through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing, or other arrangements. The Company </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">may be unable to raise additional funds or enter into such other agreements when needed or on favorable terms or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#8217;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700087435400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The accompanying consolidated financial statements reflect the operations of the Company and have been prepared in conformity with generally accepted accounting principles in the United States of America (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="font-style:normal;font-weight:normal;">The accompanying consolidated financial statements include those of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to accrual and prepayment of research and development expenses and stock-based compensation. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company manages its operations as a single segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for<span style="white-space:pre-wrap;"> the purposes of assessing performance and making operating decisions.  All of the Company's long-lived assets are located in the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value. As of December 31, 2021 and 2020, the Company has no restricted cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available under the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2021 and 2020. The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight line method over the estimated useful life of each asset as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in other (expense) income. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are expensed in operations as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no impairment losses recognized during the years ended December 31, 2021 and 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Redeemable Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company&#8217;s control outside of permanent equity. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Offering Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">The Company capitalizes incremental legal, professional accounting and other third-party fees that are incurred in the course of preparing for a financing as other non-current assets until the offering is consummated. At the time of the completion of the offering, the costs are reclassified as a reduction of the proceeds of the financing as part of additional paid-in-capital. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company records liabilities for legal and other contingencies when information available to the Company indicates that it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Legal costs in connection with legal and other contingencies are expensed as costs are incurred.&#160;</span><span style="font-style:normal;font-weight:normal;">No</span><span style="font-style:normal;font-weight:normal;">&#160;liabilities for legal and other contingencies were accrued as of December&#160;31, 2021 and 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations (CROs), business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rent Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s real estate operating lease provides for scheduled annual rent increases throughout the lease term. In accordance with ASC Topic 840, <i style="font-style:italic;">Leases</i> (ASC 840), the Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full term of the lease. Tenant improvement allowances, if any, provided by the landlord are recorded as deferred rent and amortized as a reduction to rent expense over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense as incurred. Research and development costs consist of direct and allocated costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative future use, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s stock-based compensation program allows for grants of stock options and restricted stock awards. Grants are awarded to employees and non-employees, including the Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <i style="font-style:italic;">Compensation-Stock Compensation</i> (ASC 718). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (Black-Scholes) for stock option grants to both employees and non-employees. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s stock-based compensation awards are subject to service-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. <span style="background:#ffffff;">&#160;The Company determines the expected volatility using a blended approach encompassing its historical experience and the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#8217;s product candidates.&#160;</span>The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees and non-employees whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the Company&#8217;s IPO, there was no public market for its common stock, and consequently, the estimated fair value of its common stock was determined by the board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock as well as its board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;<i style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </i>(Practice Aid). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#8217;s common stock at each valuation date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Subsequent to the Company&#8217;s IPO, the fair value of the common stock underlying the stock-based awards is the closing price of the Company&#8217;s common stock on the date of grant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Restricted common stock awards are subject to service based vesting and repurchase rights.  Accordingly, the Company has recorded the proceeds from the issuance of restricted stock as a liability in the consolidated balance sheets. This restricted stock liability is reclassified into stockholders&#8217; (deficit) equity as the restricted stock vests.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Income taxes are recorded in accordance with FASB ASC Topic 740, <i style="font-style:italic;">Income Taxes</i> (ASC 740), which provides for deferred taxes using an asset and liability approach. The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by first evaluating the tax position to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. During periods of loss, there is no allocation required under the two-class method since the participating securities do not have a contractual obligation to fund the losses of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.  Given that the Company recorded a net loss for each of the periods presented, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be antidilutive and are, therefore, excluded from the diluted net loss per share calculation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company qualifies as an &#8220;emerging growth company&#8221; (EGC), as defined in the Jumpstart Our Business Startups Act (JOBS Act) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards the same time that they become applicable to other public companies that are not EGCs, unless it chooses to early adopt a new or revised accounting standard. As a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#8217; effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the FASB issued ASU No. 2016-02, <i style="font-style:italic;">Leases</i><span style="white-space:pre-wrap;"> (Topic 842), which supersedes all existing lease guidance.  This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions.  The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments.  Lessees are required to classify leases as either finance or operating leases.  If the lease is effectively a financed-purchase by the lessee, the lease is classified as a financing lease; otherwise the lease is classified as an operating lease.  This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease.  Topic 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction.  If the criteria are not met, the transaction is considered a &#8220;failed sale&#8221; and the transaction must be accounted for as a financing arrangement.  For EGCs, such as the Company, ASU 2016-02, as amended, will be effective for annual reporting periods beginning after December 15, 2021 and interim periods within those fiscal years, with early adoption permitted.  For public entities, ASU No. 2016-02 was effective for annual periods beginning after December 15, 2018, including interim periods within these annual periods. The Company is currently evaluating the full impact that the adoption of ASU 2016-02 is expected to have on its consolidated financial statements; however, the adoption of ASU 2016-02 will require the recognition at the adoption date of both a lease liability, based on the present value of future lease payments, and a corresponding right-to-use asset, which the Company expects to be material. The future lease payment obligation as of December 31, 2021 is disclosed in Note 9, Commitments and Contingencies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses</i> (Topic 326): Measurement of Credit Losses on Financial Instruments. This ASU requires that credit losses for financial instruments measured at amortized cost be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. For EGCs, such as the Company, the new standard will be effective beginning January 1, 2023. For public entities, the standard was effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the potential impact this ASU may have on its financial position and results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2019, the FASB issued ASU&#160;No.&#160;2019-12,<i style="font-style:italic;">&#160;Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes</i>&#160;(ASU&#160;2019-12),&#160;which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends certain aspects of the existing guidance to improve consistent application. For EGCs, such as the Company, ASU&#160;2019-12&#160;is effective beginning January&#160;1, 2022, with early adoption permitted. The Company is currently evaluating the potential impact that this ASU may have on its financial position and results of operations, as well as the timing of its adoption of this standard.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088187496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables present the Company&#8217;s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 290,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 290,814</p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 290,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 290,814</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 38,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 38,795</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 38,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 38,795</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Cash and Cash Equivalents</b>&#8212;Cash and cash equivalents of $291.1 million and $39.0 million as of December 31, 2021 and December 31, 2020, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. &#160;&#160;&#160;&#160;&#160;&#160;&#160; </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088273048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following at December 31 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,121</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,253</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,414</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,416)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (377)</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,037</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Depreciation expense for the years ended December&#160;31,&#160;2021 and 2020 was $1.1&#160;million and $0.3 million, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088153944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following at December 31 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,482</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">External research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 125</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative professional service expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 115</p></td></tr><tr><td style="vertical-align:bottom;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,757</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088227784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityCommonAndPreferredStockTextBlock', window );">Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Redeemable Convertible Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Upon the closing of the IPO in November 2021, the Company&#8217;s Preferred Stock automatically converted into 19,185,183 shares of common stock. As of December 31, 2021, the Company did not have any shares of redeemable convertible preferred stock <span style="-sec-ix-hidden:Hidden_pW9XlBHI-0ycz6y8QY0knQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorized</span></span>, <span style="-sec-ix-hidden:Hidden_nO6qA4U-90qR30UGTnbjfg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> or <span style="-sec-ix-hidden:Hidden_BSNci6dkMUiwQdU7Toounw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>. Redeemable convertible preferred stock consisted of the following at December 31, 2020 (in thousands, except share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:70.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuable&#160;Upon</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series Seed preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,420,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,420,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 334,547</p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,879,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,879,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 79,597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 86,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,453,888</p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 85,299,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 85,299,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 81,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 88,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,788,435</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On October 27, 2016, the Company entered into a Series Seed Preferred Stock Purchase Agreement, whereby the Company issued an aggregate of 691,641 shares of Series Seed redeemable convertible preferred stock (Series Seed Preferred Stock) at a purchase price of $0.8675 per share for aggregate proceeds of $0.6 million. On March 3, 2017, the Company entered into a second closing of Series Seed Preferred Stock, whereby the Company issued 576,368 shares at a purchase price of $0.8675 per share for aggregate proceeds of $0.5 million. On May 16, 2017, the Company completed the milestone closing of Series Seed Preferred Stock upon the satisfaction of stated milestones pursuant to the Series Seed Preferred Stock Purchase Agreement. In connection with this milestone closing, a total of 1,152,737 shares of Series Seed Preferred Stock were issued at a purchase price of $0.8675, for aggregate gross proceeds of $1.0 million. The Company incurred issuance costs of less than $0.1 million in connection with each of these closings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On December 14, 2018, the Company entered into a Series A Preferred Stock Purchase Agreement, whereby the Company issued an aggregate of 34,848,403 shares of Series A redeemable convertible preferred stock (Series A Preferred Stock), 24,015,368 of which were issued at a purchase price of $1.041 per share for gross cash proceeds of $25.0 million, and 10,833,035 of which were issued in satisfaction of principal and interest on convertible notes outstanding held by the Company of $9.0 million. Pursuant to the Series A Preferred Stock Purchase Agreement, the Company also agreed to issue up to an additional 24,015,368 shares at a price of $1.041 per share upon the achievement of certain specified milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January 22, 2020, upon waiver of stated milestones in the Series A Preferred Stock Purchase Agreement, the Company issued 24,015,368 shares of Series A Preferred Stock at a purchase price of $1.041 per share for aggregate proceeds of $25.0 million. The Company incurred issuance costs of less than $0.1 million. Pursuant to the Amended and Restated Series A Preferred Stock Purchase Agreement, on August 12, 2020, the Company agreed to issue an additional 24,015,368 shares of Series A Preferred Stock at a purchase price of $1.041 per share for aggregate proceeds of $25.0 million. The Company incurred issuance costs of $0.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 29, 2021, the Company entered into a Series B Preferred Stock Purchase Agreement, whereby the Company issued an aggregate of 53,522,099 shares of Series B redeemable convertible preferred stock (Series B Preferred Stock, together with the Series Seed Preferred Stock and Series A Preferred Stock, Preferred Stock) at a price of $2.172 per share for gross cash proceeds of $116.2 million. The Company incurred issuance costs of $0.4 million. As part of the issuance of Series B Preferred Stock, the liquidation preferences of the Preferred Stock were modified such that, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event, the holders of Preferred Stock then outstanding shall be entitled to be paid out equal to the greater of (i) the applicable original issue price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Preferred Stock been converted into common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company amended the articles of incorporation upon the issuance of the Series B Preferred Stock and the rights and preferences of the outstanding shares of Series Seed Preferred Stock and Series A Preferred Stock were adjusted. The Company considered if the adjustment to the previously issued shares of Preferred Stock represents an extinguishment or a modification to the outstanding mezzanine classified instruments. The adjustments to the outstanding shares of Preferred Stock were qualitatively insignificant. As a result, the adjustments to the rights and preferences of the outstanding shares of Preferred Stock qualified as a modification and no accounting was required as holders of these classes of equity did not receive any incremental value in the transaction.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Upon issuance of each class of redeemable convertible preferred stock, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed on the issuance date of each class of redeemable convertible preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prior to the conversion of the Preferred Stock into shares of common stock upon the completion of the IPO in November 2021, the Preferred Stock had the following rights and preferences:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Conversion Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Each share of Preferred Stock is convertible at the option of the holder at any time after the date of issuance. The number of shares of common stock to be issued in the event of a conversion is determined by dividing the original issue price of $0.8675 for the Series Seed Preferred Stock, $1.041 for the Series A Preferred Stock, and $2.172 for the Series B Preferred Stock by the conversion price then in effect. The conversion price for each of the Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock was initially $0.8675, $1.041, and $2.172 per share, respectively, subject to adjustment under certain circumstances, including but not limited to certain additional issuances of common shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Preferred Stock automatically convert at either (i) the closing of a firm-commitment underwritten public offering resulting in at least $75 million of net proceeds to the Company, upon which all outstanding Preferred Stock shall automatically be converted into common shares, at the then effective Series Seed conversion price, <span style="letter-spacing:-0.1pt;">Series&#160;A conversion price, or Series B conversion price, respectively or (ii)&#160;at the election of the required majority of Preferred Stock holders, upon which all or any portion of the outstanding Preferred Stock shall automatically be converted into common shares, at the then effective Series&#160;Seed conversion price, Series&#160;A conversion price, and or Series B conversion price, respectively</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The holders of Preferred Stock shall be entitled to receive non-cumulative cash dividends, out of any assets legally available therefor, prior and in preference to any declaration or payment of any dividend on shares of common stock (payable other than in common stock or other securities and rights convertible into or entitling the holder thereof to receive, directly or indirectly, additional shares of common stock of the Company) at a rate of eight percent of the applicable original issue price per share of Preferred Stock per annum, payable only when, as and if declared by the Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) unless (in addition to the obtaining of any consents required otherwise by the Company&#8217;s restated certificate of incorporation) the holders of Preferred Stock then outstanding shall first receive, or simultaneously receive, in addition to the eight percent non-cumulative dividend described above, a dividend on each outstanding share of Preferred Stock in an amount at least equal to the dividend payable on each share of such class or series determined as if all shares of such class or series had been converted into common stock. No dividends were declared or paid during the years ended December 31, 2021 or 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Liquidation Preference</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;">Upon liquidation, dissolution, or winding up of business or a deemed liquidation event, the holders of the Preferred Stock shall be entitled to be paid out the greater of (i) the applicable original issue price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Preferred Stock been converted into common stock. If, upon any such event, the assets available for distribution are insufficient to satisfy the liquidation payment to holders of Preferred Stock in full, the holders of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full<span style="letter-spacing:-0.1pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Voting Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Except as provided by law or by other provisions of the instruments pursuant to which each series of Preferred Stock was issued, holders of the Preferred Stock and common stockholders&#8217; vote together as one class on an &#8220;as-converted basis.&#8221; On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company, each holder of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock is entitled to cast the number of votes equal to the number of whole shares of common stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">into which the shares of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock held by such holder are convertible as of the record date for determining shares entitled to vote on such matter. The holders of the shares of Series A Preferred Stock, exclusively and as a separate class, are entitled to elect three directors of the Company. The holders of the shares of Series B Preferred Stock, exclusively and as a separate class, are entitled to elect one director of the Company. The holders of the shares of common stock and Preferred Stock, exclusively and voting together as a single class, are entitled to elect three directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December 31, 2021, the Company&#8217;s certificate of incorporation, as amended and restated effective upon the completion of the IPO, authorized the Company to issue 150,000,000 shares of common stock, par value $0.0001 per share. <span style="letter-spacing:-0.1pt;">The holders of common stock are entitled to </span><span style="letter-spacing:-0.1pt;">one</span><span style="letter-spacing:-0.1pt;"> vote for each share held on all matters submitted to a vote of the stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. In the event of liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of December 31, 2020, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 113,259,306 shares of common stock, par value $0.0001 per share. The holders of common stock are entitled to one vote for each share of common stock. Subject to the payment in full of all preferential dividends to which the holders of the Preferred Stock are entitled, the holders of common stock shall be entitled to receive dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company and all preferential amounts to which the holders of Preferred Stock are entitled with respect to the distribution of assets in liquidation, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution<span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;background:#ffffff;">Shares Reserved for Future Issuance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reserved the following shares of common stock for future issuance at December 31:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of outstanding stock options</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3,461,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">1,625,256</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">11,537</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future awards under the 2021 Plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2,843,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future awards under the 2021 ESPP</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">278,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future awards under the 2016 Plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">360,306</p></td></tr><tr><td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of redeemable convertible preferred stock</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">11,788,435</p></td></tr><tr><td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of authorized common stock reserved for future issuance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">6,583,887</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">13,785,534</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December&#160;31, 2021, the Company was authorized to issue&#160;</span><span style="background:#ffffff;">10,000,000</span><span style="background:#ffffff;">&#160;shares of undesignated preferred stock, </span><span style="background:#ffffff;">$0.0001</span><span style="background:#ffffff;">&#160;par value,&#160;</span><span style="letter-spacing:-0.1pt;">in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The Company was not authorized to issue any such shares as of December 31, 2020. As of </span><span style="-sec-ix-hidden:Hidden_mKo_OzFuf0iQHjQHrOziTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">December 31, 2021</span></span><span style="letter-spacing:-0.1pt;">, there were </span><span style="-sec-ix-hidden:Hidden_Q1xy7BMWbEaf-hfVggNTxg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">no</span></span><span style="letter-spacing:-0.1pt;"> shares of undesignated preferred stock issued or outstanding.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_TemporaryEquityCommonAndPreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for temporary equity, common stock and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_TemporaryEquityCommonAndPreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088247608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2021 Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:-0.1pt;">In September 2021 the Company&#8217;s board of directors adopted, and in October 2021 the Company&#8217;s stockholders approved, the 2021 Plan, which became effective as of the date immediately prior to the date of the effectiveness of the registration statement for the IPO. The 2021 Plan allows the board of directors to grant </span>incentive stock options or non-qualified stock options, restricted stock, restricted stock units, and other equity awards <span style="letter-spacing:-0.1pt;">to the Company&#8217;s officers, employees, directors, and other key persons. </span><span style="background:#ffffff;">In addition, the 2021 Plan includes a provision that allows for an automatic annual increase of </span><span style="background:#ffffff;">4%</span><span style="background:#ffffff;"> in the number of shares of common stock available for issuance under the 2021 Plan.&#160;</span><span style="letter-spacing:-0.1pt;">The 2021 Plan replaced the 2016 Plan and </span><span style="letter-spacing:-0.1pt;">no</span><span style="letter-spacing:-0.1pt;"> additional awards will be granted under the 2016 Plan following the closing of the IPO. The 2016 Plan will continue to govern the outstanding equity awards granted thereunder. The total number of shares of common stock authorized for issuance under the 2021 Plan as of December 31, 2021 was </span><span style="letter-spacing:-0.1pt;">3,986,270</span><span style="letter-spacing:-0.1pt;"> shares. There were </span><span style="letter-spacing:-0.1pt;">no</span><span style="letter-spacing:-0.1pt;"> shares of common stock authorized for issuance under the 2021 Plan as of December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December&#160;31, 2021, the Company had issued only stock options under the 2021 Plan. Stock options issued comprise of service-based awards granted to employees. Vesting of stock options is subject to the recipient&#8217;s continued employment or service.</span> The maximum term of options granted under the 2021 Plan is ten years, and stock options typically vest over a four-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">2021 Employee Stock Purchase Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">In September 2021, the Company&#8217;s board of directors adopted, and in October 2021 the Company&#8217;s stockholders approved, the ESPP, which became effective as of the date immediately prior to the date of the effectiveness of the registration statement for the IPO. The ESPP is administered by the person or persons appointed by the Company&#8217;s board of directors for such purpose. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of </span><span style="letter-spacing:-0.1pt;">278,762</span><span style="letter-spacing:-0.1pt;"> shares of common stock. The number of shares of common stock reserved for issuance under the ESPP will automatically increase on January 1st of each year beginning in 2022 and continuing through and including 2031 by the least of (i) </span><span style="letter-spacing:-0.1pt;">1%</span><span style="letter-spacing:-0.1pt;"> of the outstanding number of shares of our common stock of the immediately preceding December 31, (ii) </span><span style="letter-spacing:-0.1pt;">557,524</span><span style="letter-spacing:-0.1pt;"> shares or (iii) such number of shares as determined by the ESPP administrator. As of December 31, 2021, no offering periods have commenced under the 2021 ESPP and </span><span style="letter-spacing:-0.1pt;">278,762</span><span style="letter-spacing:-0.1pt;"> shares remained available for issuance. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2016 Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The 2016 Plan provides for the Company to grant incentive stock options or non-qualified stock options, restricted stock, restricted stock units, and other equity awards to employees, directors, and consultants of the Company. The 2016 Plan is administered by the board of directors of the Company or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting, and other restrictions are determined at the discretion of the board of directors, or its committee if so delegated. The 2016 Plan allows for early exercise of all stock option grants if authorized by the board of directors at the time of grant. The shares of common stock issued from the early exercise of stock options are restricted and continue to vest over the original service based vesting condition of the original stock option award. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The total number of shares of common stock authorized for issuance under the 2016 Plan as of December 31, 2021 and 2020 was 2,318,855 shares and 1,997,099 shares, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For the years ended <span style="letter-spacing:-0.1pt;">December&#160;31, 2021 and 2020, the Company recorded stock-based compensation expense of </span><span style="letter-spacing:-0.1pt;">$2.5</span><span style="letter-spacing:-0.1pt;">&#160;million and </span><span style="letter-spacing:-0.1pt;">$0.3</span><span style="letter-spacing:-0.1pt;"> million. Stock compensation expense for 2021 and 2020 included less than </span><span style="letter-spacing:-0.1pt;">$0.1</span><span style="letter-spacing:-0.1pt;">&#160;million related to restricted stock in both years and </span><span style="letter-spacing:-0.1pt;">$2.5</span><span style="letter-spacing:-0.1pt;">&#160;million and </span><span style="letter-spacing:-0.1pt;">$0.3</span><span style="letter-spacing:-0.1pt;"> million related to stock options in 2021 and 2020, respectively</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense recorded as research and development and general and administrative expenses in the consolidated statements of operations is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 107</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 218</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 325</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Valuation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table presents, on a weighted-average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted for the years then ended:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Early Exercise of Unvested Stock Options </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding shares until those shares vest according to their respective vesting schedules. Cash received from employee exercises of unvested options is included in current liabilities on the balance sheet. Amounts recorded are reclassified to common stock and additional paid-in capital as the shares vest. Vesting can occur in the year of exercise and thereafter. There were 111,756 and 27,869 unvested shares related to early exercises of stock options as of December 31, 2021 and December 31, 2020, respectively. In the years ended December 31, 2021 and 2020, the liability associated with the unvested early exercise of stock options was $0.3 million and less than $0.1 million, respectively.<span style="white-space:pre-wrap;background:#ffffff;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s stock option activity since December 31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (2)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,625,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,311,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (431,687)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,461,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26,730</p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2021 (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,359,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26,730</p></td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(1) This represents the number of vested and unvested options exercisable as of December&#160;31,&#160;2021.</p></td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(2) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December&#160;31,&#160;2021.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $2.8 million and $0.1 million, while the company received $0.9 million and $0.2 million in proceeds for the exercise of these options, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2021 and 2020 was $9.39 per share and $1.56 per share, respectively. As of December 31, 2021, there was $20.9 million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of 3.5 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Awards</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company issued restricted stock to its founders and certain officers of the Company. In general, the shares of restricted stock vest over a four-year period, with 25% of the shares vesting after one year, followed by monthly vesting over the remaining three years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If the holders of the above restricted stock cease to have a business relationship with the Company, the Company may reacquire any unvested shares of restricted stock held by these individuals for the original purchase price or fair value, whichever is lower at the time of repurchase. The amounts received to date for the purchase price of restricted stock are immaterial. The unvested shares of restricted stock are not considered outstanding shares for accounting purposes until the shares vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A summary of unvested restricted stock during the year ended December 31, 2021 is as follows<span style="background:#ffffff;">:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.007</p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.007</p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The total fair value of restricted stock vested during each of the years ended December 31, 2021 and 2020 was less than $0.1 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088266264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">For the years ended December 31, 2021 and 2020, the Company recorded </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;"> income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each period, due to its uncertainty of realizing a benefit from those items. All of the Company&#8217;s operating losses since inception have been generated in the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in deferred tax asset valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (30.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_EcmWlvh2TEiknBczU408Mg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-KTlssYZZU-m9cyJXvqw1g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Net deferred tax assets as of December 31, 2021 and 2020 consisted of the following (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,214</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,236</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 432</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Salaries and wages</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 313</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 76</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,689</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,351</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (111)</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (485)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (746)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (111)</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,943)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,240)</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_HodcTs_FvES0HiIzmfy6sw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_x7heNc3It0iVSYbvysmtSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">As of December 31, 2021, the Company had federal net operating loss carryforwards of </span><span style="background:#ffffff;">$93.1</span><span style="background:#ffffff;"> million, which may be available to offset future taxable income, of which </span><span style="background:#ffffff;">$3.2</span><span style="background:#ffffff;"> million of the total net operating loss carryforwards expire at various dates beginning in 2036, while the remaining </span><span style="background:#ffffff;">$89.9</span><span style="background:#ffffff;"> million do not expire but are limited in their usage to an annual deduction equal to 80% of annual taxable income. In addition, as of December 31, 2021, the Company had state net operating loss carryforwards of </span><span style="background:#ffffff;">$88.0</span><span style="background:#ffffff;"> million, which may be available to offset future taxable income and expire at various dates beginning in 2036. As of December 31, 2021, the Company also had federal and state research and development tax credit carryforwards of </span><span style="background:#ffffff;">$2.3</span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$1.2</span><span style="background:#ffffff;"> million, respectively, which may be available to reduce future tax liabilities and expire at various dates beginning in 2039 and 2034, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 and Section 383 of the Internal Revenue Code of 1986 (Code), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income and tax liabilities. In general, an ownership change, as defined by Section 382 of the Code, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 5% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382 of the Code, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards may be subject to an annual limitation, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before their utilization. Further, until a study is completed by the Company and any limitation is known, </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;"> amounts are being presented as an uncertain tax position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets, which consist primarily of net operating loss carryforwards and research and development tax credit carryforwards. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception, estimated future taxable income, and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of federal and state net deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2021 and 2020. The Company reevaluates the positive and negative evidence at each reporting period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The valuation allowance increased by </span><span style="background:#ffffff;">$15.7</span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$8.2</span><span style="white-space:pre-wrap;background:#ffffff;"> million for the year ending December 31, 2021 and 2020, respectively.  The increase in the valuation allowance for deferred tax assets during the years ended December 31, 2021 and 2020 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company assesses the uncertainty in its income tax positions to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more-likely-than-not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. The Company&#8217;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its consolidated statements of operations. As of December 31, 2021 and 2020, the Company had not recorded any reserves for uncertain tax positions or related interest and penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. Due to net operating losses incurred, the Company&#8217;s tax returns from inception to date are subject to examination by the taxing authorities.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088210440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In March 2019, the Company entered into an operating lease for 7,981 square feet of office and laboratory space with an end date of April 30, 2021 in Boston, Massachusetts. The Company subsequently terminated the operating lease in December 2020 without penalty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In February 2020, the Company entered into an operating lease for 26,235 square feet of office and laboratory space in Boston, Massachusetts. Lease payments commenced in April 2020. The lease is subject to fixed rate escalation increases. The Company recognizes rent expense on a straight-line basis over the expected lease term, which is 5.7 years. The Company began to record rent expense in April 2020 upon gaining access to and control of the space. Deferred rent is amortized as a reduction in rent expense over the term of the lease. In addition, upon execution of the lease, the Company paid a security deposit of approximately $0.5 million, which is recorded as a component of other assets in the accompanying consolidated balance sheets as of December 31, 2021 and 2020. The Company has the option to terminate the lease after November 30, 2023 without penalty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In June 2021, the Company entered into amendments to the operating lease for 8,631 square feet of additional office and laboratory space at its location in Boston, Massachusetts. The term of the amendments begin between July 2021 and March 2022 and run co-terminus with the existing lease. The Company has the same option to terminate the lease after November 30, 2023 without penalty. The Company was required to increase its total security deposit to $0.8 million as of the commencement date of the amendments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company recorded $6.0 million and $1.9 million of rent expense for the years ended December 31, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The minimum aggregate future lease commitments at December 31, 2021, are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Years Ending December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,526</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,384</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,910</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In 2017, the Company entered into an option agreement with a third party, in which the Company obtained an option to license all patents and patent applications specified in the agreement, involving work related to specified invention disclosures, and arising out of that sponsored research agreement entered into between the Company and such third party pursuant to which the Company sponsored certain discovery programs conducted by the third party. In 2018, the Company entered into a definitive license agreement with the third party in which the third party granted the Company an exclusive worldwide, sublicensable license to certain intellectual property under certain patent rights to research, develop, and otherwise commercialize a product generated from the licensed intellectual property. The Company concluded the assets acquired did not meet the accounting definition of a business as inputs, but no processes </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#8220;business,&#8221; the transaction has been accounted for as an asset acquisition under ASC 730. As of the date of the license agreement, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. The Company paid an upfront research fee of $0.4 million, paid in two installments of $0.2 million on June 30, 2019 and June 30, 2020, respectively, which were accrued and recognized as research and development expense in 2018. The Company agreed to pay an annual license maintenance fee for the license of less than $0.1 million for each contract year, beginning the third year of the contract until the first commercial contract year. The Company also issued a total of 86,558 shares of common stock pursuant to the 2018 agreement, which were recorded at fair value at the date of issuance of $0.2 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Should the Company pursue specified research, development, and commercial activities related to the above technology, the Company would be obligated to make milestone payments up to $2.6 million for each of the first three licensed products to achieve each milestone. The triggering of these milestone payments was not considered probable as of the transaction date, and no expense has been recorded for these milestones as of December 31, 2021 and 2020. In addition, the third party will receive tiered royalty payments on the applicable licensed program and platform products at a percentage ranging in single-digit royalties of net sales subject to reductions and offsets in certain circumstances, as well as a royalty on sublicensed consideration ranging from low to mid double-digit percentages of non-royalty sublicensing consideration. The Company concluded any milestone or royalty payments under the agreement were not probable as of December 31, 2021 and 2020. For each of the years ended December 31, 2021 and 2020, the Company reimbursed the third-party for patent costs of $0.1 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088266264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.17;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">10. Employee Benefit Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has a defined-contribution plan under Section 401(k) of the Code (401(k) Plan). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make, and to date has not made, any contributions to the 401(k) Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700087443848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51,158)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26,523)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted&#8209;average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,267,776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,105,260</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_JFF1gzEYxkmqNACNSLO4fA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KRMqqkYCvkiUV0MKGa8Rag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24.00)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Redeemable convertible preferred stock (as converted to common stock)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,788,435</p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,537</p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested shares from early exercises</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 111,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27,869</p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,461,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,625,256</p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,573,626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,453,097</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088266264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">For the year ended December&#160;</span><span style="letter-spacing:-0.1pt;white-space:pre-wrap;">31, 2021, subsequent events were evaluated through  the date on which these consolidated financial statements were issued to determine if such events should be reflected in these consolidated financial statements</span><span style="background:#ffffff;">. The Company has concluded that no subsequent events have occurred that require disclosure.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700087208664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis Of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The accompanying consolidated financial statements reflect the operations of the Company and have been prepared in conformity with generally accepted accounting principles in the United States of America (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="font-style:normal;font-weight:normal;">The accompanying consolidated financial statements include those of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the Company&#8217;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to accrual and prepayment of research and development expenses and stock-based compensation. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company manages its operations as a single segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for<span style="white-space:pre-wrap;"> the purposes of assessing performance and making operating decisions.  All of the Company's long-lived assets are located in the United States.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value. As of December 31, 2021 and 2020, the Company has no restricted cash.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk and Off-Balance Sheet Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available under the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#8212;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2021 and 2020. The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight line method over the estimated useful life of each asset as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in other (expense) income. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are expensed in operations as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no impairment losses recognized during the years ended December 31, 2021 and 2020. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Redeemable Convertible Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company&#8217;s control outside of permanent equity. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Deferred Offering Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">The Company capitalizes incremental legal, professional accounting and other third-party fees that are incurred in the course of preparing for a financing as other non-current assets until the offering is consummated. At the time of the completion of the offering, the costs are reclassified as a reduction of the proceeds of the financing as part of additional paid-in-capital. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company records liabilities for legal and other contingencies when information available to the Company indicates that it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Legal costs in connection with legal and other contingencies are expensed as costs are incurred.&#160;</span><span style="font-style:normal;font-weight:normal;">No</span><span style="font-style:normal;font-weight:normal;">&#160;liabilities for legal and other contingencies were accrued as of December&#160;31, 2021 and 2020.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies', window );">Indemnification Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations (CROs), business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_RentExpensePolicyTextBlock', window );">Rent Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rent Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s real estate operating lease provides for scheduled annual rent increases throughout the lease term. In accordance with ASC Topic 840, <i style="font-style:italic;">Leases</i> (ASC 840), the Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full term of the lease. Tenant improvement allowances, if any, provided by the landlord are recorded as deferred rent and amortized as a reduction to rent expense over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are charged to expense as incurred. Research and development costs consist of direct and allocated costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative future use, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s stock-based compensation program allows for grants of stock options and restricted stock awards. Grants are awarded to employees and non-employees, including the Company&#8217;s board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <i style="font-style:italic;">Compensation-Stock Compensation</i> (ASC 718). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (Black-Scholes) for stock option grants to both employees and non-employees. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s stock-based compensation awards are subject to service-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. <span style="background:#ffffff;">&#160;The Company determines the expected volatility using a blended approach encompassing its historical experience and the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#8217;s product candidates.&#160;</span>The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees and non-employees whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the Company&#8217;s IPO, there was no public market for its common stock, and consequently, the estimated fair value of its common stock was determined by the board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock as well as its board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;<i style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </i>(Practice Aid). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#8217;s common stock at each valuation date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Subsequent to the Company&#8217;s IPO, the fair value of the common stock underlying the stock-based awards is the closing price of the Company&#8217;s common stock on the date of grant.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Restricted common stock awards are subject to service based vesting and repurchase rights.  Accordingly, the Company has recorded the proceeds from the issuance of restricted stock as a liability in the consolidated balance sheets. This restricted stock liability is reclassified into stockholders&#8217; (deficit) equity as the restricted stock vests.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Income taxes are recorded in accordance with FASB ASC Topic 740, <i style="font-style:italic;">Income Taxes</i> (ASC 740), which provides for deferred taxes using an asset and liability approach. The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by first evaluating the tax position to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. During periods of loss, there is no allocation required under the two-class method since the participating securities do not have a contractual obligation to fund the losses of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.  Given that the Company recorded a net loss for each of the periods presented, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be antidilutive and are, therefore, excluded from the diluted net loss per share calculation.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Emerging Growth Company Status </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company qualifies as an &#8220;emerging growth company&#8221; (EGC), as defined in the Jumpstart Our Business Startups Act (JOBS Act) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards the same time that they become applicable to other public companies that are not EGCs, unless it chooses to early adopt a new or revised accounting standard. As a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#8217; effective dates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#8220;opt out&#8221; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company either (i) irrevocably elects to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the FASB issued ASU No. 2016-02, <i style="font-style:italic;">Leases</i><span style="white-space:pre-wrap;"> (Topic 842), which supersedes all existing lease guidance.  This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions.  The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments.  Lessees are required to classify leases as either finance or operating leases.  If the lease is effectively a financed-purchase by the lessee, the lease is classified as a financing lease; otherwise the lease is classified as an operating lease.  This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease.  Topic 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction.  If the criteria are not met, the transaction is considered a &#8220;failed sale&#8221; and the transaction must be accounted for as a financing arrangement.  For EGCs, such as the Company, ASU 2016-02, as amended, will be effective for annual reporting periods beginning after December 15, 2021 and interim periods within those fiscal years, with early adoption permitted.  For public entities, ASU No. 2016-02 was effective for annual periods beginning after December 15, 2018, including interim periods within these annual periods. The Company is currently evaluating the full impact that the adoption of ASU 2016-02 is expected to have on its consolidated financial statements; however, the adoption of ASU 2016-02 will require the recognition at the adoption date of both a lease liability, based on the present value of future lease payments, and a corresponding right-to-use asset, which the Company expects to be material. The future lease payment obligation as of December 31, 2021 is disclosed in Note 9, Commitments and Contingencies. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses</i> (Topic 326): Measurement of Credit Losses on Financial Instruments. This ASU requires that credit losses for financial instruments measured at amortized cost be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. For EGCs, such as the Company, the new standard will be effective beginning January 1, 2023. For public entities, the standard was effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the potential impact this ASU may have on its financial position and results of operations upon adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2019, the FASB issued ASU&#160;No.&#160;2019-12,<i style="font-style:italic;">&#160;Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes</i>&#160;(ASU&#160;2019-12),&#160;which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends certain aspects of the existing guidance to improve consistent application. For EGCs, such as the Company, ASU&#160;2019-12&#160;is effective beginning January&#160;1, 2022, with early adoption permitted. The Company is currently evaluating the potential impact that this ASU may have on its financial position and results of operations, as well as the timing of its adoption of this standard.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for emerging growth company status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_RentExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for rent expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_RentExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088199912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Summary of estimated useful life</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5 years</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property plant and equipment useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088192680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of fair value hierarchy for assets and liabilities measured at fair value on recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables present the Company&#8217;s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 290,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 290,814</p></td></tr><tr><td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 290,814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 290,814</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 38,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 38,795</p></td></tr><tr><td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 38,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 38,795</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700087441000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and equipment, Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment, net consisted of the following at December 31 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,121</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 18</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 22</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,253</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,414</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,416)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (377)</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,037</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088218552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following at December 31 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,482</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">External research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 125</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative professional service expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 35</p></td></tr><tr><td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 115</p></td></tr><tr><td style="vertical-align:bottom;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,757</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700168513784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:70.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#160;and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liquidation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuable&#160;Upon</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Authorized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preference</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Conversion</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series Seed preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,420,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,420,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,061</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 334,547</p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Series A preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,879,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 82,879,139</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 79,597</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 86,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,453,888</p></td></tr><tr><td style="vertical-align:bottom;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 85,299,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 85,299,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 81,658</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 88,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,788,435</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of shares reserved for future issuance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of outstanding stock options</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">3,461,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">1,625,256</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">11,537</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future awards under the 2021 Plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">2,843,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future awards under the 2021 ESPP</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">278,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future awards under the 2016 Plan</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">360,306</p></td></tr><tr><td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of redeemable convertible preferred stock</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">11,788,435</p></td></tr><tr><td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total shares of authorized common stock reserved for future issuance</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">6,583,887</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;">13,785,534</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of shares reserved for future issuance under share based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700086959448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense recorded as research and development and general and administrative expenses in the consolidated statements of operations is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 107</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 218</p></td></tr><tr><td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 2,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 325</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 5.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value (2)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,625,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,311,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (431,687)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (43,184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,461,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26,730</p></td></tr><tr><td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of December&#160;31,&#160;2021 (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,359,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26,730</p></td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(1) This represents the number of vested and unvested options exercisable as of December&#160;31,&#160;2021.</p></td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(2) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December&#160;31,&#160;2021.</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of unvested restricted stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,537</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.007</p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 0.007</p></td></tr><tr><td style="vertical-align:bottom;width:77.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088172200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of U.S. federal statutory income tax rate to effective income tax rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Federal statutory income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">State income taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Federal and state research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in deferred tax asset valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (30.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_EcmWlvh2TEiknBczU408Mg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-KTlssYZZU-m9cyJXvqw1g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of net deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Net deferred tax assets as of December 31, 2021 and 2020 consisted of the following (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 25,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,214</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development tax credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,236</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 432</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Salaries and wages</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 313</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 80</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 76</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 29,689</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,351</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (261)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (111)</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (485)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (746)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (111)</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,943)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (13,240)</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_HodcTs_FvES0HiIzmfy6sw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_x7heNc3It0iVSYbvysmtSA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088150408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum aggregate future lease commitments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The minimum aggregate future lease commitments at December 31, 2021, are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Years Ending December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,526</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,384</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,910</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088266264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share attributable to common stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51,158)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (26,523)</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted&#8209;average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,267,776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,105,260</p></td></tr><tr><td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_JFF1gzEYxkmqNACNSLO4fA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8.16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KRMqqkYCvkiUV0MKGa8Rag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24.00)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Redeemable convertible preferred stock (as converted to common stock)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,788,435</p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11,537</p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested shares from early exercises</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 111,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 27,869</p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,461,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 1,625,256</p></td></tr><tr><td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 3,573,626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 13,453,097</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700082321848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 22, 2021</div></th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Redeemable convertible preferred stock, shares issued upon conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,185,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,788,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.1382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,158<span></span>
</td>
<td class="nump">$ 26,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,669<span></span>
</td>
<td class="nump">42,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 291,064<span></span>
</td>
<td class="nump">$ 39,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_StockIssuedDuringPeriodAggregateSharesIssued', window );">Aggregate shares issued and sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,436,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Redeemable convertible preferred stock, shares issued upon conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,185,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,361,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_StockIssuedDuringPeriodAggregateSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of shares issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_StockIssuedDuringPeriodAggregateSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700083796648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated useful life (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700081902792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Assets transferred from Level 1 to Level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Assets transferred from Level 2 to Level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Liabilities transferred from Level 1 to Level 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Liabilities transferred from Level 2 to Level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfer of assets into (out of) level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Transfer of liabilities into (out of) level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Accrued liabilities for legal and other contingencies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700084580440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 291,100<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">290,814<span></span>
</td>
<td class="nump">38,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">290,814<span></span>
</td>
<td class="nump">38,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">290,814<span></span>
</td>
<td class="nump">38,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 290,814<span></span>
</td>
<td class="nump">$ 38,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700082292184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 7,677<span></span>
</td>
<td class="nump">$ 3,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(1,416)<span></span>
</td>
<td class="num">(377)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">6,261<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">5,988<span></span>
</td>
<td class="nump">2,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 1,556<span></span>
</td>
<td class="nump">$ 1,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700082038040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">$ 4,077<span></span>
</td>
<td class="nump">$ 1,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_AccruedExternalResearchAndDevelopmentExpensesCurrent', window );">External research and development expenses</a></td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">General and administrative professional service expenses</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 6,013<span></span>
</td>
<td class="nump">$ 1,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_AccruedExternalResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of current portion of  accrued external research and development expenses as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_AccruedExternalResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700083581160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,299,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,299,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,299,885<span></span>
</td>
<td class="nump">37,269,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,658<span></span>
</td>
<td class="nump">$ 31,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,185,183<span></span>
</td>
<td class="nump">11,788,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesSeedRedeemableConvertiblePreferredStockMember', window );">Series Seed redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,420,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,420,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,420,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred Stock Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,879,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,879,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,879,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issuable upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,453,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesSeedRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesSeedRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700078554264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>Jan. 22, 2020</div></th>
<th class="th"><div>Dec. 14, 2018</div></th>
<th class="th"><div>May 16, 2017</div></th>
<th class="th"><div>Mar. 03, 2017</div></th>
<th class="th"><div>Oct. 27, 2016</div></th>
<th class="th"><div>May 16, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issue of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,831<span></span>
</td>
<td class="nump">$ 49,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesSeedRedeemableConvertiblePreferredStockMember', window );">Series Seed redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152,737<span></span>
</td>
<td class="nump">576,368<span></span>
</td>
<td class="nump">691,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Purchase price (in dollars Per share}</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8675<span></span>
</td>
<td class="nump">$ 0.8675<span></span>
</td>
<td class="nump">$ 0.8675<span></span>
</td>
<td class="nump">$ 0.8675<span></span>
</td>
<td class="nump">$ 0.8675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issue of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesSeedRedeemableConvertiblePreferredStockMember', window );">Series Seed redeemable convertible preferred stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,015,368<span></span>
</td>
<td class="nump">24,015,368<span></span>
</td>
<td class="nump">24,015,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,030,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Purchase price (in dollars Per share}</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.041<span></span>
</td>
<td class="nump">$ 1.041<span></span>
</td>
<td class="nump">$ 1.041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issue of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityAggregateSharesIssued', window );">Aggregate shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,848,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued in satisfaction of principal and interest on convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,833,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Convertible notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones', window );">Shares issuable upon achievement of certain specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,015,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">53,522,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,522,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Purchase price (in dollars Per share}</a></td>
<td class="nump">$ 2.172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issue of redeemable convertible preferred stock</a></td>
<td class="nump">$ 116,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number od shares issuable upon achievement of certain specified milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_TemporaryEquityAggregateSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of aggregate stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_TemporaryEquityAggregateSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesSeedRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesSeedRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700083426104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Conversion Right and Dividends (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th"><div>Aug. 12, 2020</div></th>
<th class="th"><div>Jan. 22, 2020</div></th>
<th class="th"><div>Dec. 14, 2018</div></th>
<th class="th"><div>May 16, 2017</div></th>
<th class="th"><div>Mar. 03, 2017</div></th>
<th class="th"><div>Oct. 27, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_ThresholdNetProceedsFromQualifiedPublicOffering', window );">Threshold net proceeds from qualified public offering.</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesSeedRedeemableConvertiblePreferredStockMember', window );">Series Seed redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Purchase price (in dollars Per share}</a></td>
<td class="nump">$ 0.8675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8675<span></span>
</td>
<td class="nump">$ 0.8675<span></span>
</td>
<td class="nump">$ 0.8675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityConversionPrice', window );">Preferred stock, convertible, conversion price (in dollars per share)</a></td>
<td class="nump">0.8675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Purchase price (in dollars Per share}</a></td>
<td class="nump">1.041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.041<span></span>
</td>
<td class="nump">$ 1.041<span></span>
</td>
<td class="nump">$ 1.041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityConversionPrice', window );">Preferred stock, convertible, conversion price (in dollars per share)</a></td>
<td class="nump">1.041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Purchase price (in dollars Per share}</a></td>
<td class="nump">2.172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_TemporaryEquityConversionPrice', window );">Preferred stock, convertible, conversion price (in dollars per share)</a></td>
<td class="nump">$ 2.172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_TemporaryEquityConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_TemporaryEquityConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_ThresholdNetProceedsFromQualifiedPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of net proceeds from qualified public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_ThresholdNetProceedsFromQualifiedPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesSeedRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesSeedRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700083724632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Voting Rights (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_NumberOfDirectorsEntitledToBeElected', window );">Number of directors entitled to be elected</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_NumberOfDirectorsEntitledToBeElected', window );">Number of directors entitled to be elected</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_NumberOfDirectorsEntitledToBeElected', window );">Number of directors entitled to be elected</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_NumberOfDirectorsEntitledToBeElected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of directors entitled to be elected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_NumberOfDirectorsEntitledToBeElected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesaRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trda_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088359304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Common Stock and Preferred Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Authorized (shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">113,259,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_NumberOfVotesPerShareOfCommonStock', window );">Number of votes | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future awards</a></td>
<td class="nump">6,583,887<span></span>
</td>
<td class="nump">13,785,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_NumberOfVotesPerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of votes per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_NumberOfVotesPerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700081930312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Shares Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">6,583,887<span></span>
</td>
<td class="nump">13,785,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=trda_StockPlan2021Member', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">2,843,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=trda_EmployeeStockPurchasePlan2021Member', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">278,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=trda_StockPlan2016Member', window );">2016 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="nump">3,461,870<span></span>
</td>
<td class="nump">1,625,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of authorized common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,788,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=trda_StockPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=trda_StockPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=trda_EmployeeStockPurchasePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=trda_EmployeeStockPurchasePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=trda_StockPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=trda_StockPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700078544792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,583,887<span></span>
</td>
<td class="nump">13,785,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=trda_StockPlan2016Member', window );">2016 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,318,855<span></span>
</td>
<td class="nump">1,997,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=trda_StockPlan2021Member', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Additional number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,843,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,986,270<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Shares annual increase as percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=trda_EmployeeStockPurchasePlan2021Member', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Future awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=trda_EmployeeStockPurchasePlan2021Member', window );">2021 Employee Stock Purchase Plan | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for future issuance</a></td>
<td class="nump">557,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock authorized for issuance</a></td>
<td class="nump">278,762<span></span>
</td>
<td class="nump">278,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Shares annual increase as percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=trda_StockPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=trda_StockPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=trda_StockPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=trda_StockPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=trda_EmployeeStockPurchasePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=trda_EmployeeStockPurchasePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700079235960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,526<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,648<span></span>
</td>
<td class="nump">$ 218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700083733384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Stock Option Valuation (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to determine the fair value of stock options granted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as percentage)</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">0.53%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as percentage)</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700168222792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock Based Compensation - Early Exercise of Unvested Stock Options (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Unvested shares related to early exercises of stock options</a></td>
<td class="nump">111,756<span></span>
</td>
<td class="nump">27,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount', window );">Unvested early exercises of stock options</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability related to early exercises of non-vested stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700083387816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Stock option activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">111,756<span></span>
</td>
<td class="nump">27,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 410<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">1,625,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,311,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(431,687)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(43,184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end period (in shares)</a></td>
<td class="nump">3,461,870<span></span>
</td>
<td class="nump">1,625,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,359,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding at beginning period (in dollars per share)</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted (in dollars per share)</a></td>
<td class="nump">14.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised (in dollars per share)</a></td>
<td class="nump">2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited (in dollars per share)</a></td>
<td class="nump">3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at end period (in dollars per share)</a></td>
<td class="nump">10.38<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable</a></td>
<td class="nump">$ 5.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Term, Outstanding (in years)</a></td>
<td class="text">9 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Term, Exercisable (in dollars per share)</a></td>
<td class="text">8 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding</a></td>
<td class="nump">$ 26,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">26,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of stock options granted</a></td>
<td class="nump">$ 9.39<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 20,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, weighted-average period for recognition</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700083567176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Restricted Stock Awards (Details) - Restricted Stock Awards - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, at beginning of period (in shares)</a></td>
<td class="nump">11,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(11,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant -Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant -Date Fair Value Unvested balance, at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 0.007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">$ 0.007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant -Date Fair Value Unvested balance, at end of period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of restricted stock vested</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Shares vesting after one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Shares vesting after three year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700088207640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700083558280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of U.S. federal statutory income tax rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal and state research and development tax credits</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nondeductible items</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="num">(30.70%)<span></span>
</td>
<td class="num">(31.00%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700084580488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Net deferred tax assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 25,124<span></span>
</td>
<td class="nump">$ 11,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">3,237<span></span>
</td>
<td class="nump">1,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Salaries and wages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">29,689<span></span>
</td>
<td class="nump">13,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(261)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Total deferred tax liabilities</a></td>
<td class="num">(746)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(28,943)<span></span>
</td>
<td class="num">(13,240)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700078530904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Operating loss carryforwards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_OperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards subject to expiration</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_OperatingLossCarryforwardsLimitationOnUseAmount', window );">Net operating loss carryforwards limited in usage</a></td>
<td class="nump">89,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and development tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">93,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_OperatingLossCarryforwardsLimitationOnUseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforwards limitation on the use to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_OperatingLossCarryforwardsLimitationOnUseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700078448040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember', window );">Office and laboratory space in Boston, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office and laboratory space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,235<span></span>
</td>
<td class="nump">7,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember', window );">Office and laboratory space in Boston, Massachusetts | Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember', window );">Additional office and laboratory space in Boston, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office and laboratory space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember', window );">Additional office and laboratory space in Boston, Massachusetts | Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700087204248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Minimum aggregate future lease commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 8,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">8,384<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future lease payments</a></td>
<td class="nump">$ 16,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700079169096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - License Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>installment </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 35,926<span></span>
</td>
<td class="nump">$ 21,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_ExpensesRelatingToMilestoneObligation', window );">Expense relating to milestone obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=trda_LicenseAgreementWithThirdPartyMember', window );">License agreement with a third-party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_PaymentOfUpfrontResearchFees', window );">Upfront research fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_LicenseAgreementNumberOfInstallments', window );">Number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Value of assets purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Value of assets purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_PotentialMilestonePaymentObligation', window );">Potential milestone payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_LicenseAgreementNumberOfLicensedProducts', window );">Number of licensed products | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_PaymentForPatentCosts', window );">Patent costs</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=trda_LicenseAgreementWithThirdPartyMember', window );">License agreement with a third-party | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trda_AnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_AnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of annual license maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_AnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_ExpensesRelatingToMilestoneObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses recognized relating to milestone obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_ExpensesRelatingToMilestoneObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_LicenseAgreementNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of installments for payment of upfront research fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_LicenseAgreementNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_LicenseAgreementNumberOfLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of licensed products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_LicenseAgreementNumberOfLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_PaymentForPatentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_PaymentForPatentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_PaymentOfUpfrontResearchFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for upfront research fees payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_PaymentOfUpfrontResearchFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trda_PotentialMilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents potential milestone payment obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trda_PotentialMilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=trda_LicenseAgreementWithThirdPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=trda_LicenseAgreementWithThirdPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700083372648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (51,158)<span></span>
</td>
<td class="num">$ (26,523)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">6,267,776<span></span>
</td>
<td class="nump">1,105,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (8.16)<span></span>
</td>
<td class="num">$ (24.00)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (51,158)<span></span>
</td>
<td class="num">$ (26,523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">6,267,776<span></span>
</td>
<td class="nump">1,105,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (8.16)<span></span>
</td>
<td class="num">$ (24.00)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140700084600456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Antidilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from common stock</a></td>
<td class="nump">3,573,626<span></span>
</td>
<td class="nump">13,453,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,788,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=trda_UnvestedSharesMember', window );">Unvested shares from early exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from common stock</a></td>
<td class="nump">111,756<span></span>
</td>
<td class="nump">27,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from common stock</a></td>
<td class="nump">3,461,870<span></span>
</td>
<td class="nump">1,625,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=trda_UnvestedSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=trda_UnvestedSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>trda-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:trda="http://www.entradatx.com/20211231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="trda-20211231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_O8pVP4l75kOdx-yCEK8aZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_zP_saBrSuEeXS1wmFBKk8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_aj5kvebNtEaEwVM3errF3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-29</instant>
        </period>
    </context>
    <context id="As_Of_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_7VWTG_vPyUKvAaUWm3BT8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-12</instant>
        </period>
    </context>
    <context id="As_Of_1_22_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_epyOIcPzq0SVrlfXNg7yEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-22</instant>
        </period>
    </context>
    <context id="As_Of_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tYP56ACKCEObErEOejmqsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-14</instant>
        </period>
    </context>
    <context id="As_Of_5_16_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_xATBx4mlJkO_FY67Y7xj6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-16</instant>
        </period>
    </context>
    <context id="As_Of_3_3_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_0aluTUFCZU6jYAc_CRSl2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-03</instant>
        </period>
    </context>
    <context id="As_Of_10_27_2016_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_GsM3bvleAkui8rQ0h-Ql9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-27</instant>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_dnx581iJhk-tByLmAfE2iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="Duration_10_22_2021_To_10_22_2021_uQZsCRIxnUqAluL0h4RX7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
        </entity>
        <period>
            <startDate>2021-10-22</startDate>
            <endDate>2021-10-22</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fIyU3F2ce0eWRga502fJBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3Evel5BXlU2Nkn6JOeAzkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O7xm61cRg0K4Na8wCgmpSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpyy8MnVM0KmlsYrfZMTyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I9FjEp0tz0WGNpk85jBJ1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kycqBPxOmUOgzZHFE2RRRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_78VjKUVPTEe0xf_MNsF1lA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l9HKPBpFZ0iNKAGeJGZG1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BuEOalfyI0u2lwqzpEOfWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_jPFYwfOyHkibNEeOW_EYTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_q07zOZMvO0O0qAOZXAgC6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2016Member_WSANhifLkU2A9s4mVWiePw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:StockPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_eX6Qkp3pp0eD-g-WpjcsYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_trda_StockPlan2021Member_XN77OWOzXkC7szS4MrVGTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:StockPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_Tt00y1mV6kiK5B4cvFJE-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_RWcJH0PTE0iREP0s53rf8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_djIfGJUG3UerKSFCe6I17g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_nCvXJPkm-EeVgL-HAKzWCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:StockPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_rM6lo0glkkSHK6fx56dohQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:OfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_-28m7dTNPU20dkA6HHUEeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_G0o0UYvQV06N8dmtQoWrUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:OfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_iH0SLfAWbk6jaf3g4ibe_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_nypqQlrtZE6lptm3mK1OuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_iZZ8FczNTU2tGeemyaYEYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_fyE8largOkCW__YS3RTN3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wcmbqMPhOU6rzqEZYMNIYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QYNTB61VYUat6jQAfNj3sA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Ue4SlaWOQ0KyF4HIsqdP3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3wtllMeGF0-uvRoiD-yA9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_QjA51H3Ah0aFo7MeOknVsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__p-8KrZhskSQeQtAxAXVcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DeQYlMJLU0-AyRtM2oqjfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_22_2020_To_1_22_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_-1_Yd9urDk-m9ncpSMWkLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-22</startDate>
            <endDate>2020-01-22</endDate>
        </period>
    </context>
    <context id="Duration_10_27_2016_To_5_16_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_4mA-_qHs2kGfQFglJrYgww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-27</startDate>
            <endDate>2017-05-16</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_y8-ETpe8yUaoJwpU5roQfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_a53NGrxD4kSTEvV0srI_NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kbIUpMM9tU6Bw1ItzOX4kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_skLgUvkO-UWUx7Bti_R8Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_K6kVW2WPBE-kg0DD1wJujA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:OfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_1fQTtTn9-E69-ajeccNB9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2021_a0-v3caGu0mm1ZtiJx365w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_5fShMvZuL0CBikfxgEmhJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:StockPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_WfsWIAfNmE2sstVPNwOq4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:EmployeeStockPurchasePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BPELmQx4xEiCTW0PJ5snKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RedeemableConvertiblePreferredStockMember_6iNejRF2DEGk6tYe2YQoHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JkQZPPgBBUGf-humPcfAMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_trda_StockPlan2016Member_AiSU5Z1vhEGHTV-J1QFVng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trda:StockPlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_0F7kyPmgPE6NFo60sAPzEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HJgZfqoHTEiB7zwNlTcURQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ehK6rCutpEqfLe84L0CqtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-qOWEZ-lG0Wgp-Dc-_n5tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4PqQOnDumkefao8imFFhKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BPCLjgwbAkKCfg-NbETCtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P198-NvWk0W9y94TBotMiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_L_Yrm18-ZEq_KotDl6_Nmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_voVae7De2EOf0pczy20g7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_kcauchfWnUmJP3dujL0p2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_29_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_jhtKcYUrGUeXiu8kysHe4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:OfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_aI2VmsKba02tMKmJCqhsEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trda:OfficeAndLaboratorySpaceInBostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VeWTpBES60mrDvFGp33DJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_trda_UnvestedSharesMember_Yg75Vq-JeUiuqL-_773DFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">trda:UnvestedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BrM28n-jyUOi_DtOIFHwAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_Yg0eRdnrPE6oZY0L97BMQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_EMioRKOEOUuK6W_DHnQC0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_trda_UnvestedSharesMember_ONz4dFb4f0-msro3DrkJBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">trda:UnvestedSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W6iQ9yRAYE2F1wZofX493A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_F-9SRQC7hkatUiZQujCAMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tD1C2qFg_0-xasA5fL3IOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_zsGA-ZYjak2Nkhe-ZCUNNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_l7f8215TfUmkc3xqHhvUwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynIvbasOrkmhLq6FFmJ_CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_ydttNEUZL0mEntDbye7NGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_29_2021_To_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_EV4uTuzkYE6h_aLfr9tQpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-29</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="Duration_8_12_2020_To_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_z6226-NgvE6yUlb-QpUJqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-12</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="Duration_1_22_2020_To_1_22_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_xzJvCpIB60egOnueDPk1DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-22</startDate>
            <endDate>2020-01-22</endDate>
        </period>
    </context>
    <context id="Duration_5_16_2017_To_5_16_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_2d5Zkg5ROU2FOzEjN1-Wlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-16</startDate>
            <endDate>2017-05-16</endDate>
        </period>
    </context>
    <context id="Duration_3_3_2017_To_3_3_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_3gJUFiFT7E-8naW-uk6dqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-03</startDate>
            <endDate>2017-03-03</endDate>
        </period>
    </context>
    <context id="Duration_10_27_2016_To_10_27_2016_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_-En8tjRnnUC9eKmjOLrxDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-27</startDate>
            <endDate>2016-10-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_u1sl4JaoEU2V5L65kkaVfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_494Nn9bt3E65r2GvytHiBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_rXp55kz8m0-Oy4jN90htNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesSeedRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_603nz09bmES_5kNTHFmsAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f79AwiNGhE-sfsUO9KmsTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_LGXl_iZN7E6dEJSRz6h1QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-14</startDate>
            <endDate>2018-12-14</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2019_To_6_30_2020_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Hf7j2O4nM06-u1HOfsgByg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Cy9RrUM470ieiIVBwGRytQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_RYC5_ZIHMEyAEsk0XkA_Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_FM5MwYyCLk66BYx1-YT-iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_WDhCcPxYokqoE__Xm560JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tneHEayNbkCaFY8W_qAw-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trda:SeriesaRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_jxCvIM-1WEOJ9WQF7LNJvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_-TdaxQCqC0-mYAk7Hd2Eow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">trda:LicenseAgreementWithThirdPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_5_2021_klmSXHbwckOZOadD2UgSvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
        </entity>
        <period>
            <instant>2021-11-05</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2022_1msmRA4SCkq2Cr9ERvHZHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689375</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_installment_z46z-AyIh0iy55GSvWd0bw">
        <measure>trda:installment</measure>
    </unit>
    <unit id="Unit_Standard_item_qXeWDqcza0Kv2YWLNzbANQ">
        <measure>trda:item</measure>
    </unit>
    <unit id="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw">
        <measure>trda:Vote</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_sqft_rx7LKou9MUKld2X7S962qQ">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">
        <measure>pure</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      id="Hidden_Of58JJxZ4keNwMsnoEV_Hw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      id="Hidden_UbgNrvtLyUiiH7YvL8dZzg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      id="Hidden_2ziGg0HHdkeDmqmrnAviXg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="2"
      id="Hidden_drr4vLhnZUCSHDjSts1PsA"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">-8.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="2"
      id="Hidden_NTFV33O3hk6TxzH7NJ9c5g"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">-24.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="0"
      id="Hidden_3VJWT4ngp0aczaFLk0nApg"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">6267776</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="0"
      id="Hidden_saaCB_HxK0Gfhe0kWokcQA"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1105260</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="0"
      id="Hidden_NJwUPpejpEG2GASt6Z9RoA"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">6267776</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="0"
      id="Hidden_x-mNzE4UUkGBx0e3FnoP8A"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1105260</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="2"
      id="Hidden_JFF1gzEYxkmqNACNSLO4fA"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">-8.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="2"
      id="Hidden_KRMqqkYCvkiUV0MKGa8Rag"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">-24.00</us-gaap:EarningsPerShareDiluted>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_fV_WLEBahE6doBQcQvAU4Q_2_1">0001689375</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_ag9IyKqV4UWAyY1Fzexp2g_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_gVLyzqVObEWjzwPXAFxHaA_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_5i7nXnmtfE-rsTyJ45mPAQ_6_1">false</dei:AmendmentFlag>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Hidden_EcmWlvh2TEiknBczU408Mg"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      id="Hidden_-KTlssYZZU-m9cyJXvqw1g"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_22_2021_To_10_22_2021_uQZsCRIxnUqAluL0h4RX7Q"
      decimals="INF"
      id="Hidden_w1M_9o9Q5kO5Amu-2DsMtA"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.1382</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      id="Hidden_HodcTs_FvES0HiIzmfy6sw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      id="Hidden_x7heNc3It0iVSYbvysmtSA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Hidden_BSNci6dkMUiwQdU7Toounw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Hidden_nO6qA4U-90qR30UGTnbjfg"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Hidden_pW9XlBHI-0ycz6y8QY0knQ"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Hidden_mKo_OzFuf0iQHjQHrOziTg"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Hidden_Q1xy7BMWbEaf-hfVggNTxg"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Hidden_MKSePaSzEkGUhAEuj95QSg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Hidden_rEQdZS50-kOSKfpodxCC5Q"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Hidden_55OB18X63USdH30lIVVNWA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Hidden_Ga0buu0SgUSrUdG99nJxqA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Hidden_s0CI3ABO1UOwyiaMjM21WQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Hidden_STNba99TEE2P8TlOmIf09w"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Hidden_bdDNugQjEkeWGJ5RRTmMeQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Hidden_rAODftV1WkevOqiQBf1HaA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Hidden_Lf1kOd_TBEa3WfZ4jJXYSA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Hidden_hbAR-Fm85kGGPUqDJIMHMA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Hidden_Y9_kSFxPbUCICwx3C4cQwQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Hidden_t79w48C3NUGADeWiFga7Hg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g"
      decimals="INF"
      id="Hidden_ym4vD8Ib1EeCt_yPBK0BDg"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">2420746</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA"
      decimals="INF"
      id="Hidden_UU486mV8PEqPdC425qxydw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">82879139</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Hidden_YSRag8nKMEqb6M9fhWc-MQ"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">85299885</us-gaap:TemporaryEquitySharesIssued>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Hidden_wvP2J5Tt3UeeM1ma9KGLpQ">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_rRhc2Fb5Wkug2-7VSQS25g">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_ly_3_2Vksk-8YgkE_ZmbJA_2_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_YYUW0mnnD0mzTGCdIEli8w">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_qEJUA_NscEqEZBG3jwGeXQ">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_00HvY3o5ekOJRpDj5FoRUA_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_uTH8Kq4rLEumernYnRcYKw">001-40969</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_H-fgWQLDdE-1NEv4gQQgWA">ENTRADA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_JFpL1Nh-v0efRi4eFho9DQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_Boba7Qt4XUWQ6MyQ0st28w_1_1">81-3983399</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_sj5YdNvbo0uggZ_YZy0L8Q">6 Tide Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_x8W7MSvSWkCZn5x_i8frXQ">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_hmEu1AtUrUygGx7_YnuNgg">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_Y2mOe8DDgEekdaDV1LRP6Q_5_1">02210</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_CdpeunhQk06Uk8bxLXk8qw">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr__smCWVeYsk2eR0Ded3vizA">520-9158</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_c8_doWk920mjZt7HtDkhvQ_2_0">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_-THN0Cw5yUi6O97WNaBsvw_2_1">TRDA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_iYXBnQI7-U6qkoQOGIFwEQ_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_iyiCx97i-0KfESIZ6YqNLw">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_KbhZqXnkQEGJ7ROxGEusdA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_HNBcD1ki4EeuKr_9SdE2aQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_08HRlrpklE-rZiT5NYQ_rw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_r6uOWJsA_k-8YRh-oNmqpw_3_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_8c0bfDPseU-xABtZo3nhUg_3_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tc_DE8fbUnACUShackwPnMepA_3_5">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_Xlhmul0PnESaHNvcAh8RIg">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_kirHdxZPD06GfVKLmsnyjQ">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_11_5_2021_klmSXHbwckOZOadD2UgSvg"
      decimals="-5"
      id="Narr_wyLTzTYyLkS9iwCVWLnsMQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">474900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_28_2022_1msmRA4SCkq2Cr9ERvHZHg"
      decimals="INF"
      id="Narr_GCpR3Z5lh0yj7ELrkzPGfQ"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">31251484</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_tbEqwkb3lkyqlp02qtfLzw">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_Lv8dU-Y-DUGoMsp1kYAvew">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Narr_LpEzv___dkupwQf_GyWMMA">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_YC2pk23Fv0iKCbYbJ7elqA_5_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">291064000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_UIPHQUjK60OjBzx-uWcCOg_5_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">39045000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_EsQgL5nUhUevoJHTLXUz4Q_6_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">7636000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_4mmrfxMBVkaXc6yUBgLWaA_6_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">904000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_5M2igIMuoU-fB0P6NybYgw_7_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">298700000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_ya9RYTkEw0av-gTTNUuFnA_7_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">39949000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_L8Abny57Gku5uSiajhIA0g_8_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">6261000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_MB_aIoESdkeV9xBHr5AGmA_8_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">3037000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_rxoaCSCLaES4vAnYBcXW-w_9_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">872000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_jhUWWACy3kiYVvBPWlue7Q_9_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">541000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_SO-H6JTrM0efa5uIyxVhhA_10_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">305833000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_6199Rfy_WE-Z51pCIbECVA_10_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">43527000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_ALXDIFZ0IUaTfNsXdDxANw_13_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">706000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_FF_OHbZ5WUmyvLz38zps3A_13_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1602000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_q0841-UhLkiuvY02Q6EE3g_14_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">6013000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_Mffc3he5q0utINORykHpxg_14_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1757000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_CTZHcaWEgkyjpEPK0IHxfg_15_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">6719000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_zxV0OwVbtU214g3tgrOKMA_15_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">3359000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_2R2cqCDVT0Kd7A1uljZOZA_16_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">396000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_hLN8BPcw0U6BJBrIJ3dK5Q_17_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">7115000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_qCRdj9Mvo0KL153YS8ayOw_17_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">3359000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Narr_4PfnsgxMWE-tqu7rbK2tVg"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_8SEVFFQNVE6OQN4D6upzCA"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_SoPBMUgqRk6zuv3-LFnoMA_19_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">81658000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Narr_YmXsJ5RW90WerYJq-cMlYA"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_5RFZUWklcEydCxN1Ypbv9g"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_L6SXid1S1keb3sbW_ZGThw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Narr_XSZ0wMm520-prCHmnRDnqg"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">113259306</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_KPEF6e4dvkOVMcMHWZTzNA"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">31336092</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Narr_jNV0Pkgpa0-ISKTNjiZnFA"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1283545</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_Wyo0DBolakimCrBHHERCrw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">31224336</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Narr_7Jx3Oy7HOUqpv0fONkwtuQ"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1244139</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_3r1csMLn-kqu65RfqubVDg_21_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_bDaD1oYc00uMnJKjdrPeMQ_22_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">392384000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_pl-W08GCGUuausQcDQrJ9A_22_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1021000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_6mDDCMjj30-yT65MPGd5eg_23_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-93669000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_oNzr4ZCcKUSh3eWHU-WVQw_23_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-42511000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_6UvE1dqSYEOL0J-CSwjgMQ_24_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">298718000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_vZUb_DGtm0yAJSzQxnxO4w_24_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-41490000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_xgbn072hD0Km8U4L5SY1vA_25_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">305833000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_l76Q5-RG-k2Vr7WxcxtlNw_25_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">43527000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_han1bwOp60uxwW5PrzbpRw_5_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">35926000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_W9MG9ZQMxEyn0me046d4bQ_5_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">21102000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_kQs25rFTDECxdO7IpPKKVQ_6_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">15201000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_mnkhJm5hU0mJf_oqsoUyiw_6_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">5565000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_2GPgEdefQEeufSr4IJKV4A_7_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">51127000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_XMRwH0hzK0moCsM3qGcgrA_7_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">26667000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_wIoDSfGpF0WE46rs4kCp9Q_8_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-51127000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_MiMnto8M7E2I4K2dcawsrQ_8_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-26667000</us-gaap:OperatingIncomeLoss>
    <trda:InterestAndOtherIncomeExpenseNet
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc__QqRdg5Z1kKDHhePTk7OBQ_10_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-31000</trda:InterestAndOtherIncomeExpenseNet>
    <trda:InterestAndOtherIncomeExpenseNet
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_AoJtjM3VkEOgZL_NYj6PPA_10_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">144000</trda:InterestAndOtherIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_7lJiIpi5l0-HnFNBaFsvjg_11_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-31000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_c92t7GJM7EqMgULBouxDUQ_11_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">144000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_2ScpIb7YVkagsltX9-ZzjA_12_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-51158000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_2V47968seE2qa1DGEBooEg_12_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-26523000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="2"
      id="Tc_myq2k-5tUE6NtDsXfrpyAw_13_3"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">-8.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="2"
      id="Tc_Qso2n8BkU0CREUYRXv_Wrw_13_6"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">-24.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="0"
      id="Tc_Tb4i8xRddUq3iVulW38P0Q_14_3"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">6267776</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="0"
      id="Tc_Kor8OCWzIUeqWZJS_upwSA_14_6"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1105260</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2019_0F7kyPmgPE6NFo60sAPzEQ"
      decimals="INF"
      id="Tc_GFillVLlqkGb9cXS7-aURw_4_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">37269149</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_0F7kyPmgPE6NFo60sAPzEQ"
      decimals="-3"
      id="Tc_rTn_EyxfxkKJbo5Lqi1XPA_4_5"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">31816000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BuEOalfyI0u2lwqzpEOfWA"
      decimals="INF"
      id="Tc_1lFdPEvon02TvajFhUsLDw_4_8"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1004310</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kycqBPxOmUOgzZHFE2RRRg"
      decimals="-3"
      id="Tc_HptEg1z7bUykp5cAEFui9w_4_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">470000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_I9FjEp0tz0WGNpk85jBJ1A"
      decimals="-3"
      id="Tc_qCIF8pKP6EKMUA5KA8aL7w_4_17"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-15988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_0F7kyPmgPE6NFo60sAPzEQ"
      decimals="-3"
      id="Tc_kCPHZcowykOEFuxIJI8jiA_4_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-15518000</us-gaap:StockholdersEquity>
    <trda:TemporaryEquityIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_494Nn9bt3E65r2GvytHiBg"
      decimals="-3"
      id="Narr_QbykmipP6kqCANdL2UTZew"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">158000</trda:TemporaryEquityIssuanceCosts>
    <trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_494Nn9bt3E65r2GvytHiBg"
      decimals="INF"
      id="Tc_rdm0XNFiyUO01aCpwfo-Rw_5_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">48030736</trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_494Nn9bt3E65r2GvytHiBg"
      decimals="-3"
      id="Tc_5uQmT6uMZUGtbnQDs_WjBA_5_5"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">49842000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f79AwiNGhE-sfsUO9KmsTg"
      decimals="INF"
      id="Tc_O8rwBZ4N9kaw084xCEoLKA_6_8"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">129607</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_603nz09bmES_5kNTHFmsAg"
      decimals="-3"
      id="Tc_mifG3ffe1kuWgQvEHglUCQ_6_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">214000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_lRiZqeqRWUaIEU3HB4zHWw_6_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">214000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f79AwiNGhE-sfsUO9KmsTg"
      decimals="INF"
      id="Tc_Pb5ttRNJ_UOmZXWEmNIkeA_7_8"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">95770</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_603nz09bmES_5kNTHFmsAg"
      decimals="-3"
      id="Tc_mz2kwJDLmkqlJjWubPakBw_7_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_9VO0ZwC9IUCc4sgP6TpjYQ_7_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <trda:StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_f79AwiNGhE-sfsUO9KmsTg"
      decimals="INF"
      id="Tc_u8WIouWPGkGBF3CWWD0BEw_8_8"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">14452</trda:StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions>
    <trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_603nz09bmES_5kNTHFmsAg"
      decimals="-3"
      id="Tc_ZWqXl_bc9U2yIAtOX-vxRA_8_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">11000</trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
    <trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_VP9P_u5PvEiyl7ZJnK4WWw_8_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">11000</trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_603nz09bmES_5kNTHFmsAg"
      decimals="-3"
      id="Tc_eqo1d9Oxtk-hj8jOVdKEPA_9_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">325000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_CeOsvpyBYkSxPxVe7jv9FQ_9_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">325000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_skLgUvkO-UWUx7Bti_R8Vw"
      decimals="-3"
      id="Tc_fHvhwIxqoUu2RFsQZr-jpg_10_17"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-26523000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_osPFz7H2ekGmEze0N9_v7A_10_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-26523000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Tc_Fpf8-Nb5TUu2Bbdaey3NNw_11_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">85299885</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_uE1S2Rzx7kq6X0NyquZphQ_11_5"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">81658000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l9HKPBpFZ0iNKAGeJGZG1Q"
      decimals="INF"
      id="Tc_2MOwZM4610ycdArinmL_Zg_11_8"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1244139</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bpyy8MnVM0KmlsYrfZMTyQ"
      decimals="-3"
      id="Tc_FM_Or9DqD0uAdd2cklj-Mg_11_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1021000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_O7xm61cRg0K4Na8wCgmpSQ"
      decimals="-3"
      id="Tc_qUM-APeeu0ejcIbweilEJQ_11_17"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-42511000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_msaHRz2s4kmrUVuM0-KZdQ_11_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-41490000</us-gaap:StockholdersEquity>
    <trda:TemporaryEquityIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_u1sl4JaoEU2V5L65kkaVfA"
      decimals="-3"
      id="Narr_VlV-_46HxUmh2lQ2huKGIw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">420000</trda:TemporaryEquityIssuanceCosts>
    <trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_u1sl4JaoEU2V5L65kkaVfA"
      decimals="INF"
      id="Tc_xBX3a_X5uU-GViQrInf2Yw_12_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">53522099</trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_u1sl4JaoEU2V5L65kkaVfA"
      decimals="-3"
      id="Tc_tFKNeIJG1EinV64Rb_5XkQ_12_5"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">115831000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <trda:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="INF"
      id="Tc_SqD6zznFDU6Ms5-gvTZcmA_13_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">138821984</trda:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <trda:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_jYv6wrvmW0-nXVKvy0bPZA_13_5"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">197489000</trda:TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA"
      decimals="INF"
      id="Tc_E_eMIG0TIkCfgeTMBBaCaQ_13_8"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">19185183</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA"
      decimals="-3"
      id="Tc_yOhHQeEj4kigEH3D6bKEZA_13_11"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ"
      decimals="-3"
      id="Tc_p9LWBETOxEuwkPY7rihI9g_13_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">197487000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_xXd8Y2sNLESXAOR93d_c_Q_13_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">197489000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Narr_dg4gPfFN5kWL9tnYcniqsw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">18034000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA"
      decimals="INF"
      id="Tc_pfN-NMr6ZE-tYp6GX4Onqg_14_8"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">10436250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA"
      decimals="-3"
      id="Tc_jkWREO21XUyEBh-rGfBGaA_14_11"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ"
      decimals="-3"
      id="Tc__14Zmhe_EkWTEA4jp5PIOw_14_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">190690000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_IjM1ABRnckm5XNAg4kFd_A_14_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">190691000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA"
      decimals="INF"
      id="Tc_ZG8wMrOxKk2MiItLNHxuew_15_8"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">223838</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ"
      decimals="-3"
      id="Tc_waVFCSqKJEKgGwE69x9Cmw_15_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">410000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_WWBxWEY9C02KFdUDgM-yug_15_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">410000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA"
      decimals="INF"
      id="Tc_dT5dr_hczUaHr62TcvuDJw_16_8"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">11537</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <trda:StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AGDoX7a9ikGXxaDuqdClmA"
      decimals="INF"
      id="Tc_hCLETZG9-k2iSWRq2hUSMg_17_8"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">123389</trda:StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions>
    <trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ"
      decimals="-3"
      id="Tc_14Rf-MnASkyqgSCQujKJpw_17_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">250000</trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
    <trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_0YMUvnG7N0KhcI4hfYy5Bw_17_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">250000</trda:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_V8BJyXdBTU-NgrIKg8jaDQ"
      decimals="-3"
      id="Tc_zn7nL_PyCUKnU_PRBfvl_g_18_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2526000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_v1pd4OXjfkm5SkBJ_HuxMQ_18_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2526000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_kbIUpMM9tU6Bw1ItzOX4kA"
      decimals="-3"
      id="Tc_eGJ8Kb9Bl0eHb624-1cGhA_19_17"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-51158000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_kaAySt4dYEKRLaXX0O537w_19_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-51158000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_78VjKUVPTEe0xf_MNsF1lA"
      decimals="INF"
      id="Tc_dAP-m14uZk-Ys9uRlkihiw_20_8"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">31224336</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_78VjKUVPTEe0xf_MNsF1lA"
      decimals="-3"
      id="Tc_UflE2niiV0mHuz3mCthZxg_20_11"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3Evel5BXlU2Nkn6JOeAzkg"
      decimals="-3"
      id="Tc_0KvClK8zQ0uFKRu3ExHehA_20_14"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">392384000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fIyU3F2ce0eWRga502fJBw"
      decimals="-3"
      id="Tc_PveXJMHlikWDCc3dcvzuXw_20_17"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-93669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_YJC9bWRlbkGzTIN8HW0Grg_20_20"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">298718000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_VcaIhtuivE-SbT9W2_dEbA_5_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-51158000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_6xhiYGnni0-X47oOu-t0fA_5_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-26523000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_9QT0M-j5C0OTLEpS4rz6lA_7_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1117000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_HRyjSBDpjE61Rk7RrNAn1Q_7_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">326000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_AoyEwtoBlUKWu0JbTAExqA_8_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-74000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_ri5RDjKiQUS9z9-UvfYcRA_8_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-20000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_GxMNmUKOlUuCQ5L2OWN5jA_9_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2526000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_46PjQdr7PkiPsVY6_RooXQ_9_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">325000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_6fBkrWX9S0OiatLk4Si2mA_11_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">6733000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_SyBQ5_Qy6k-BmboJgBaWaw_11_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">311000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_SOLcWycDF0S9WFDANx1StQ_12_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">331000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_llS4PifpzkKNuF1lfMwwfQ_12_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">541000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc__coHtoFWI0mGTQTRuOStvA_13_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-715000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_1uyZgUm34EyGmkN7qLkt-w_13_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">631000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_xNayNiPhBU-1WGOj_S8klw_14_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">3962000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_AxDgbz5W4UyjTmHSb6iRQQ_14_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">578000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_VlFpcc0-3UWiJy2m4u0QOA_15_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">396000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_OXMfuwm6u0Ctiid3fZGnOA_15_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-75000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_Qdv-Is5Ia02zlzeoGtXKkg_16_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-50862000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_YTazGynRc0mSgPnqtt-wsg_16_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-25570000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_e9IMfOOAlkmBVJkQBgxnWw_18_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">4580000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_n-vpwdThu0O8K5NL4H5xcA_18_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2318000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_mKAe5LMcOUeUjQrr5zmw6w_19_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-4580000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_uF8Pfkf4NEWpFM2r6A4Yqw_19_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-2318000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_RQv2e4isz0KpCYpzWr1EPQ_21_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">115831000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_7GNkFwsgik-NrE_JDnlR9A_21_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">49842000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_-1hGH5OfwEGlnrBATeA_yg_22_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">190691000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_178T8zj3QUu0yrN1x_52Kg_23_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">410000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_d3YUXO-ixUmZl0qFeddqdg_23_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">213000</us-gaap:ProceedsFromStockOptionsExercised>
    <trda:ProceedsFromEarlyExerciseOfStockOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_IfBQW76qH0KGKwR3NeV5-w_24_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">529000</trda:ProceedsFromEarlyExerciseOfStockOptions>
    <trda:ProceedsFromEarlyExerciseOfStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_h-QMG_jpEk-2nbZMeB896w_24_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">34000</trda:ProceedsFromEarlyExerciseOfStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_bovUuF-BcEec8PSVekNCJg_25_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">307461000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_rT-gfN7-zUaKo3ymwFrKsA_25_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">50089000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_fGtI6JkRhUa0AEvvAr7t6A_26_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">252019000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_RIVbtythuk-lUlUHvqZcmA_26_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">22201000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_JHCeb3rUgUirwR05sgFU-A_27_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">39045000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_0F7kyPmgPE6NFo60sAPzEQ"
      decimals="-3"
      id="Tc_XbidPCn8WUOcGxuKD6Lrtw_27_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">16844000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_FsD8G5XhkEy8jaRqXlrvkw_28_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">291064000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_Z2qYOAcqakuqHbQiK9Wi4Q_28_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">39045000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_VVch73mVOUyeQehc9LvzCQ_30_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">155000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_-Qvct5_Hyker9UIW2vDlKw_30_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">320000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_NYO9NaquPE2wOXF7bzVTtQ_31_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">197489000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <trda:VestingOfRestrictedStockSubjectToRepurchase
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_m9Oo-hP-GEStIKMQo2LKMQ_32_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1000</trda:VestingOfRestrictedStockSubjectToRepurchase>
    <trda:VestingOfOptionsEarlyExercisedSubjectToRepurchase
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_uxYrHnJunkiY6VaFQU6p2g_33_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">250000</trda:VestingOfOptionsEarlyExercisedSubjectToRepurchase>
    <trda:VestingOfOptionsEarlyExercisedSubjectToRepurchase
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_HGUPQHM2e0Sh5zOcnfkPQQ_33_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">11000</trda:VestingOfOptionsEarlyExercisedSubjectToRepurchase>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb__4AW3E2XGk-WhGPvR98T2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"&gt;1. Nature of the Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Organization&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Entrada Therapeutics, Inc. (Entrada or the Company) aims to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;) therapeutics as a new class of medicines and aim to become the world&#x2019;s foremost intracellular therapeutics company. The Company was incorporated in Delaware on September 22, 2016 and its principal offices are located in Boston, Massachusetts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;In November 2021, the Company completed its initial public offering (IPO) in which the Company issued and sold 10,436,250 shares of its common stock, including 1,361,250 shares pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $20.00 per share, for aggregate gross proceeds of $208.7 million. The Company received $190.7 million in net proceeds, after deducting underwriting discounts and offering expenses payable. In connection with the IPO, all outstanding shares of the Company&#x2019;s redeemable convertible preferred stock converted into 19,185,183 shares of the Company&#x2019;s common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;On October 22, 2021, in connection with the Company&#x2019;s IPO, the Company effected a &lt;span style="-sec-ix-hidden:Hidden_w1M_9o9Q5kO5Amu-2DsMtA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1-for-7.235890014&lt;/span&gt;&lt;/span&gt; reverse stock split of the Company&#x2019;s common stock. All common shares, stock options, and per share information presented in the accompanying consolidated financial statements and notes thereto have been adjusted, where applicable, to reflect the reverse stock split on a retroactive basis for all periods presented, including reclassification of par and additional paid-in capital amounts. The per share par value and authorized number of shares of the Company&#x2019;s common stock were not adjusted as a result of the reverse stock split.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its proprietary, highly versatile and modular EEV platform (EEV Platform), advancing development of its portfolio of programs and general and administrative support for these operations, including raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, technical risks associated with the successful research, development and manufacturing of therapeutic candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations. Therapeutic candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts will require significant amounts of additional capital, adequate personnel and infrastructure. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In accordance with Accounting Standards Codification (ASC) 205-40,&#160;&lt;i style="font-style:italic;"&gt;Going Concern&lt;/i&gt;, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The Company has incurred losses since its inception, including losses of $51.2 million and $26.5 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the Company had an accumulated deficit of $93.7 million. To date, the Company has funded its operations primarily through the sale of equity securities. The Company expects to continue to generate operating losses and negative operating cash flows for the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company expects that its cash and cash equivalents of $291.1 million as of December 31, 2021 will be sufficient to fund its operations and capital expenditure requirements for at least the next twelve months from the date of issuance of these consolidated financial statements. The Company will need additional financing to support its continuing operations and pursue its business strategy and may pursue additional cash resources through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing, or other arrangements. The Company &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;may be unable to raise additional funds or enter into such other agreements when needed or on favorable terms or at all. The inability to raise capital as and when needed would have a negative impact on the Company&#x2019;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <trda:StockIssuedDuringPeriodAggregateSharesIssued
      contextRef="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_LGXl_iZN7E6dEJSRz6h1QQ"
      decimals="INF"
      id="Narr_IC1Cca-2kUyvKT6PUk6OQw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">10436250</trda:StockIssuedDuringPeriodAggregateSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_dnx581iJhk-tByLmAfE2iA"
      decimals="INF"
      id="Narr_76NNAAelyEW95U8-Zz29XQ"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1361250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_1fQTtTn9-E69-ajeccNB9Q"
      decimals="2"
      id="Narr_xqpK31IXPkmNoBkEy4-amg"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">20.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_LGXl_iZN7E6dEJSRz6h1QQ"
      decimals="-5"
      id="Narr_YxI-AH8L7k-RZLHDDAdAaw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">208700000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_LGXl_iZN7E6dEJSRz6h1QQ"
      decimals="-5"
      id="Narr__QiJGd_gJ0akJGzYa72Gug"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">190700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_1fQTtTn9-E69-ajeccNB9Q"
      decimals="INF"
      id="Narr_WD_EVj6I3k26vYx7mE8ECw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">19185183</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-5"
      id="Narr_DuZcIkAsxk2f5m65AU913A"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-51200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-5"
      id="Narr_Al6H2rFOQUGow7gpsZJiiQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-26500000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-5"
      id="Narr_aDyPtmXhcEC90f8JlfCEkg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-93700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-5"
      id="Narr_0kCPXl7C1UmlwhzmDSaugQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">291100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_dFmHpR9JOUa9xEodsGtTqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The accompanying consolidated financial statements reflect the operations of the Company and have been prepared in conformity with generally accepted accounting principles in the United States of America (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The accompanying consolidated financial statements include those of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to accrual and prepayment of research and development expenses and stock-based compensation. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company manages its operations as a single segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for&lt;span style="white-space:pre-wrap;"&gt; the purposes of assessing performance and making operating decisions.  All of the Company's long-lived assets are located in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value. As of December 31, 2021 and 2020, the Company has no restricted cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available under the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2021 and 2020. The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight line method over the estimated useful life of each asset as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in other (expense) income. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are expensed in operations as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no impairment losses recognized during the years ended December 31, 2021 and 2020. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Redeemable Convertible Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company&#x2019;s control outside of permanent equity. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Deferred Offering Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;"&gt;The Company capitalizes incremental legal, professional accounting and other third-party fees that are incurred in the course of preparing for a financing as other non-current assets until the offering is consummated. At the time of the completion of the offering, the costs are reclassified as a reduction of the proceeds of the financing as part of additional paid-in-capital. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The Company records liabilities for legal and other contingencies when information available to the Company indicates that it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Legal costs in connection with legal and other contingencies are expensed as costs are incurred.&#160;&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;No&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;&#160;liabilities for legal and other contingencies were accrued as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Indemnification Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations (CROs), business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Rent Expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s real estate operating lease provides for scheduled annual rent increases throughout the lease term. In accordance with ASC Topic 840, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (ASC 840), the Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full term of the lease. Tenant improvement allowances, if any, provided by the landlord are recorded as deferred rent and amortized as a reduction to rent expense over the lease term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are charged to expense as incurred. Research and development costs consist of direct and allocated costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative future use, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s stock-based compensation program allows for grants of stock options and restricted stock awards. Grants are awarded to employees and non-employees, including the Company&#x2019;s board of directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;i style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/i&gt; (ASC 718). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (Black-Scholes) for stock option grants to both employees and non-employees. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s stock-based compensation awards are subject to service-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. &lt;span style="background:#ffffff;"&gt;&#160;The Company determines the expected volatility using a blended approach encompassing its historical experience and the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#x2019;s product candidates.&#160;&lt;/span&gt;The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees and non-employees whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the Company&#x2019;s IPO, there was no public market for its common stock, and consequently, the estimated fair value of its common stock was determined by the board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock as well as its board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide,&#160;&lt;i style="font-style:italic;"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation &lt;/i&gt;(Practice Aid). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#x2019;s common stock at each valuation date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Subsequent to the Company&#x2019;s IPO, the fair value of the common stock underlying the stock-based awards is the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Restricted common stock awards are subject to service based vesting and repurchase rights.  Accordingly, the Company has recorded the proceeds from the issuance of restricted stock as a liability in the consolidated balance sheets. This restricted stock liability is reclassified into stockholders&#x2019; (deficit) equity as the restricted stock vests.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Income taxes are recorded in accordance with FASB ASC Topic 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (ASC 740), which provides for deferred taxes using an asset and liability approach. The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by first evaluating the tax position to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. During periods of loss, there is no allocation required under the two-class method since the participating securities do not have a contractual obligation to fund the losses of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.  Given that the Company recorded a net loss for each of the periods presented, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be antidilutive and are, therefore, excluded from the diluted net loss per share calculation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Emerging Growth Company Status &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company qualifies as an &#x201c;emerging growth company&#x201d; (EGC), as defined in the Jumpstart Our Business Startups Act (JOBS Act) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards the same time that they become applicable to other public companies that are not EGCs, unless it chooses to early adopt a new or revised accounting standard. As a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#x2019; effective dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt; (Topic 842), which supersedes all existing lease guidance.  This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions.  The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments.  Lessees are required to classify leases as either finance or operating leases.  If the lease is effectively a financed-purchase by the lessee, the lease is classified as a financing lease; otherwise the lease is classified as an operating lease.  This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease.  Topic 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction.  If the criteria are not met, the transaction is considered a &#x201c;failed sale&#x201d; and the transaction must be accounted for as a financing arrangement.  For EGCs, such as the Company, ASU 2016-02, as amended, will be effective for annual reporting periods beginning after December 15, 2021 and interim periods within those fiscal years, with early adoption permitted.  For public entities, ASU No. 2016-02 was effective for annual periods beginning after December 15, 2018, including interim periods within these annual periods. The Company is currently evaluating the full impact that the adoption of ASU 2016-02 is expected to have on its consolidated financial statements; however, the adoption of ASU 2016-02 will require the recognition at the adoption date of both a lease liability, based on the present value of future lease payments, and a corresponding right-to-use asset, which the Company expects to be material. The future lease payment obligation as of December 31, 2021 is disclosed in Note 9, Commitments and Contingencies. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/i&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. This ASU requires that credit losses for financial instruments measured at amortized cost be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. For EGCs, such as the Company, the new standard will be effective beginning January 1, 2023. For public entities, the standard was effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the potential impact this ASU may have on its financial position and results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In December 2019, the FASB issued ASU&#160;No.&#160;2019-12,&lt;i style="font-style:italic;"&gt;&#160;Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes&lt;/i&gt;&#160;(ASU&#160;2019-12),&#160;which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends certain aspects of the existing guidance to improve consistent application. For EGCs, such as the Company, ASU&#160;2019-12&#160;is effective beginning January&#160;1, 2022, with early adoption permitted. The Company is currently evaluating the potential impact that this ASU may have on its financial position and results of operations, as well as the timing of its adoption of this standard.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_lcp2S2Sl5Eu_f5_UOz8RjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The accompanying consolidated financial statements reflect the operations of the Company and have been prepared in conformity with generally accepted accounting principles in the United States of America (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_53IjHMucx0WtHwLUl7yp5w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="display:inline-block;text-indent:0pt;width:36pt;"/&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The accompanying consolidated financial statements include those of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_9dA6pFsADUWjuKAqasrEDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to accrual and prepayment of research and development expenses and stock-based compensation. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_v1V34wmuWkO8PeBZ9B7tmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company manages its operations as a single segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for&lt;span style="white-space:pre-wrap;"&gt; the purposes of assessing performance and making operating decisions.  All of the Company's long-lived assets are located in the United States.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_e3AQ7afShUOsUpYbd2hN-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value. As of December 31, 2021 and 2020, the Company has no restricted cash.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="0"
      id="Narr_MWbPoe3jQ06iq7oqEn8P3g"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="0"
      id="Narr_3I81fzgQtEe-w9O5R8pMAQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:RestrictedCash>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_1xe28HucFkKfL0qTnTWeQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_a9wLHozXOky8z-qF5uhy8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (ASC 820), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available under the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#x2014;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2021 and 2020. The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term nature.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_ryQ1qWQRv0iz2w_l9hu6PQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight line method over the estimated useful life of each asset as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Costs for capital assets not yet placed into service are capitalized as construction-in-progress and depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in other (expense) income. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are expensed in operations as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <trda:PropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_sNxURjnkpk26c-jakZg1-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;3 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:31.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;5 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:31.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:68.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</trda:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_nypqQlrtZE6lptm3mK1OuA"
      id="Tc_dy1WLTJUYkSdKAa0_LILDQ_2_1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_iZZ8FczNTU2tGeemyaYEYg"
      id="Tc_mg0Z-mz-OkGa0q8U3WmWsA_3_1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_iH0SLfAWbk6jaf3g4ibe_g"
      id="Tc_Sm2Ovoy1TEm6PFBcoSwUnA_4_1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_kUqhSU4qj0a2G4JSOMrMyQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no impairment losses recognized during the years ended December 31, 2021 and 2020. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-5"
      id="Narr_hx60_LUkxEq-JPCt2JvGPw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-5"
      id="Narr_M5EWzhqPFku8wmWBDlCUOw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_lVQBJ8SPHEi2KOhvhhKOcw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Redeemable Convertible Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded redeemable convertible preferred stock at fair value upon issuance, net of any issuance costs. The Company classified stock that was redeemable in circumstances outside of the Company&#x2019;s control outside of permanent equity. No accretion was recognized as the contingent events that could give rise to redemption were not deemed probable.&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_6NZfZ-Yd0EK89zf4wojteQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Deferred Offering Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;"&gt;The Company capitalizes incremental legal, professional accounting and other third-party fees that are incurred in the course of preparing for a financing as other non-current assets until the offering is consummated. At the time of the completion of the offering, the costs are reclassified as a reduction of the proceeds of the financing as part of additional paid-in-capital. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_0KHG-TpSKEeHXVmEF-qI8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The Company records liabilities for legal and other contingencies when information available to the Company indicates that it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Legal costs in connection with legal and other contingencies are expensed as costs are incurred.&#160;&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;No&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;&#160;liabilities for legal and other contingencies were accrued as of December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:LitigationReserve
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="0"
      id="Narr_HgaX-pjBBUuaFI9GZvSRhQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="0"
      id="Narr_b1GiE5K2bkStf9yJCxPOvQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:LitigationReserve>
    <us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_rMlQ-3LfLEeIFpvtbwK7nw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Indemnification Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations (CROs), business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.&lt;/p&gt;</us-gaap:GuaranteesIndemnificationsAndWarrantiesPolicies>
    <trda:RentExpensePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_Y2rMOvI1FESs7NEVVrEAuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Rent Expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s real estate operating lease provides for scheduled annual rent increases throughout the lease term. In accordance with ASC Topic 840, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (ASC 840), the Company recognizes the effects of the scheduled rent increases on a straight-line basis over the full term of the lease. Tenant improvement allowances, if any, provided by the landlord are recorded as deferred rent and amortized as a reduction to rent expense over the lease term.&lt;/p&gt;</trda:RentExpensePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_7pgPJVzi5kKrQ-obicHw9g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are charged to expense as incurred. Research and development costs consist of direct and allocated costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative future use, laboratory supplies, depreciation, manufacturing expenses, preclinical expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <trda:PatentCostsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_IoLEUrNpUU2yzz41_dRldg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/p&gt;</trda:PatentCostsPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_Hm5L6kCfu0GfNIbEuDUK_g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s stock-based compensation program allows for grants of stock options and restricted stock awards. Grants are awarded to employees and non-employees, including the Company&#x2019;s board of directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;i style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/i&gt; (ASC 718). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (Black-Scholes) for stock option grants to both employees and non-employees. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s stock-based compensation awards are subject to service-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Black-Scholes requires inputs based on certain subjective assumptions, including (i) the expected stock price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) expected dividends. &lt;span style="background:#ffffff;"&gt;&#160;The Company determines the expected volatility using a blended approach encompassing its historical experience and the historical volatility of a peer group of comparable publicly traded companies with product candidates in similar stages of development to the Company&#x2019;s product candidates.&#160;&lt;/span&gt;The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, Share-Based Payment, to calculate the expected term for options granted to employees and non-employees whereby, the expected term equals the arithmetic average of the vesting term and the original contractual term of the options due to its lack of sufficient historical data. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the Company&#x2019;s IPO, there was no public market for its common stock, and consequently, the estimated fair value of its common stock was determined by the board of directors as of the date of each option grant, with input from management, considering third-party valuations of its common stock as well as its board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent third-party valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide,&#160;&lt;i style="font-style:italic;"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation &lt;/i&gt;(Practice Aid). The Practice Aid identifies various available methods for allocating the enterprise value across classes of series of capital stock in determining the fair value of the Company&#x2019;s common stock at each valuation date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Subsequent to the Company&#x2019;s IPO, the fair value of the common stock underlying the stock-based awards is the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Restricted common stock awards are subject to service based vesting and repurchase rights.  Accordingly, the Company has recorded the proceeds from the issuance of restricted stock as a liability in the consolidated balance sheets. This restricted stock liability is reclassified into stockholders&#x2019; (deficit) equity as the restricted stock vests.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_2O1XCuxHtUS_hOH-4pSPYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Income taxes are recorded in accordance with FASB ASC Topic 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (ASC 740), which provides for deferred taxes using an asset and liability approach. The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined on the basis of the differences between the consolidated &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by first evaluating the tax position to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_1wHJpZPeC0GBsHyJNyH2vg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. During periods of loss, there is no allocation required under the two-class method since the participating securities do not have a contractual obligation to fund the losses of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.  Given that the Company recorded a net loss for each of the periods presented, there is no difference between basic and diluted net loss per share since the effect of common stock equivalents would be antidilutive and are, therefore, excluded from the diluted net loss per share calculation.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <trda:EmergingGrowthCompanyStatusPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_b1Kn3HVaN0uJzM-zFPCKAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Emerging Growth Company Status &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company qualifies as an &#x201c;emerging growth company&#x201d; (EGC), as defined in the Jumpstart Our Business Startups Act (JOBS Act) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section 107 of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards the same time that they become applicable to other public companies that are not EGCs, unless it chooses to early adopt a new or revised accounting standard. As a result of this election, the consolidated financial statements may not be comparable to companies that comply with public company FASB standards&#x2019; effective dates.&lt;/p&gt;</trda:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_X5JN-br7a0iliscwFQ4Fxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that the Company adopts as of the specified effective date. The Company qualifies as an &#x201c;emerging growth company&#x201d; as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to &#x201c;opt out&#x201d; of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Company either (i) irrevocably elects to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its consolidated financial statements and disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt; (Topic 842), which supersedes all existing lease guidance.  This guidance offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions.  The new standard requires lessees to recognize an operating lease with a term greater than one year on their balance sheets as a right-of-use asset and corresponding lease liability, measured at the present value of the lease payments.  Lessees are required to classify leases as either finance or operating leases.  If the lease is effectively a financed-purchase by the lessee, the lease is classified as a financing lease; otherwise the lease is classified as an operating lease.  This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease.  Topic 842 provides accounting guidance for transactions that meet specific criteria for a leaseback transaction.  If the criteria are not met, the transaction is considered a &#x201c;failed sale&#x201d; and the transaction must be accounted for as a financing arrangement.  For EGCs, such as the Company, ASU 2016-02, as amended, will be effective for annual reporting periods beginning after December 15, 2021 and interim periods within those fiscal years, with early adoption permitted.  For public entities, ASU No. 2016-02 was effective for annual periods beginning after December 15, 2018, including interim periods within these annual periods. The Company is currently evaluating the full impact that the adoption of ASU 2016-02 is expected to have on its consolidated financial statements; however, the adoption of ASU 2016-02 will require the recognition at the adoption date of both a lease liability, based on the present value of future lease payments, and a corresponding right-to-use asset, which the Company expects to be material. The future lease payment obligation as of December 31, 2021 is disclosed in Note 9, Commitments and Contingencies. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/i&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. This ASU requires that credit losses for financial instruments measured at amortized cost be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. For EGCs, such as the Company, the new standard will be effective beginning January 1, 2023. For public entities, the standard was effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the potential impact this ASU may have on its financial position and results of operations upon adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In December 2019, the FASB issued ASU&#160;No.&#160;2019-12,&lt;i style="font-style:italic;"&gt;&#160;Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes&lt;/i&gt;&#160;(ASU&#160;2019-12),&#160;which is intended to simplify the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends certain aspects of the existing guidance to improve consistent application. For EGCs, such as the Company, ASU&#160;2019-12&#160;is effective beginning January&#160;1, 2022, with early adoption permitted. The Company is currently evaluating the potential impact that this ASU may have on its financial position and results of operations, as well as the timing of its adoption of this standard.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_Rcddc5JF9UmIkadB8_ujAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables present the Company&#x2019;s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 290,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 290,814&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 290,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 290,814&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 38,795&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 38,795&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 38,795&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 38,795&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/b&gt;&#x2014;Cash and cash equivalents of $291.1 million and $39.0 million as of December 31, 2021 and December 31, 2020, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets. &#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_2HzYdCe5tU2gj8Bh70wbwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables present the Company&#x2019;s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 290,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 290,814&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 290,814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 290,814&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:39.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 38,795&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 38,795&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 38,795&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 38,795&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_HJgZfqoHTEiB7zwNlTcURQ"
      decimals="-3"
      id="Tc_MB-i5iwax0yqf-mNzJlA9Q_6_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">290814000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ehK6rCutpEqfLe84L0CqtQ"
      decimals="-3"
      id="Tc_Z3tzFAO0002JkSFfzAUrdA_6_12"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">290814000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_BPCLjgwbAkKCfg-NbETCtg"
      decimals="-3"
      id="Tc_W05MsmUWw0OnJ-kCettqkA_7_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">290814000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_P198-NvWk0W9y94TBotMiQ"
      decimals="-3"
      id="Tc_Us66d1MJR0KRzh0qgjE5kA_7_12"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">290814000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_-qOWEZ-lG0Wgp-Dc-_n5tA"
      decimals="-3"
      id="Tc_9AtN_y00k0a5citVHDRPZg_6_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">38795000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_4PqQOnDumkefao8imFFhKw"
      decimals="-3"
      id="Tc_506xKTJtPUOOLFPNDEO--g_6_12"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">38795000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_L_Yrm18-ZEq_KotDl6_Nmw"
      decimals="-3"
      id="Tc_SaqkN4aGnEmSPL9aefvhEQ_7_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">38795000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_voVae7De2EOf0pczy20g7A"
      decimals="-3"
      id="Tc_DRh4bI0zAkOL9GnHRNJ63g_7_12"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">38795000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-5"
      id="Narr_BZSlmw06IEuITN5aOitnKg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">291100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-5"
      id="Narr_4EhDDXLbjkufQnxzb6nTHw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">39000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_UeqvlguW8EWxQpy-sMzfaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Property and Equipment, Net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consisted of the following at December 31 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,253&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,416)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (377)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,261&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,037&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Depreciation expense for the years ended December&#160;31,&#160;2021 and 2020 was $1.1&#160;million and $0.3 million, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_Vy7HZexLZkaT3DNNJZJmwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment, net consisted of the following at December 31 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5,988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,253&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 7,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,414&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,416)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (377)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,261&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,037&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_QYNTB61VYUat6jQAfNj3sA"
      decimals="-3"
      id="Tc_y-8rHVTCiEqjjM3XtBlYew_2_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">5988000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember__p-8KrZhskSQeQtAxAXVcg"
      decimals="-3"
      id="Tc_XenRoklIb0q5MRWLqMao-A_2_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2121000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_wcmbqMPhOU6rzqEZYMNIYg"
      decimals="-3"
      id="Tc_nT_5W3s2Q0ecngjak9_e0g_3_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">96000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_QjA51H3Ah0aFo7MeOknVsg"
      decimals="-3"
      id="Tc_fU8A9wTqD0SNtWN8k05fdQ_3_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">18000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_Ue4SlaWOQ0KyF4HIsqdP3Q"
      decimals="-3"
      id="Tc_njm-IEFlQUSyTlBqtyCgNQ_4_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_DeQYlMJLU0-AyRtM2oqjfg"
      decimals="-3"
      id="Tc_Gc8ZGMERVU2tqCvS2NjESg_4_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">22000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_fyE8largOkCW__YS3RTN3g"
      decimals="-3"
      id="Tc_ae2mS9FXTEqjviKLFeGrlw_5_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1556000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_3wtllMeGF0-uvRoiD-yA9w"
      decimals="-3"
      id="Tc_cIZy097rQEuGGuVYpKrCZQ_5_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1253000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_klDyXqGEvkekis8UA3gUqw_6_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">7677000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_dUixvCtyQ0OYo50ABcr5Fw_6_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">3414000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_eziH4b09y02DrFVcZoVKUw_7_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1416000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_PA--SlK5Fk6dJTCuoVfIwg_7_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">377000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_v0q4n3qksEyWSMySkbDzDw_8_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">6261000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_nJtHn-Sgd0elclszFzAy9Q_8_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">3037000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-5"
      id="Narr_v3E2RPm9EU-bNkLu4DME4g"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-5"
      id="Narr_K-8u2p6MiEK56eDT_DyCMw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">300000</us-gaap:Depreciation>
    <trda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_MCa0xMoO4USYoDFp1a_kVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Accrued Expenses and Other Current Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses and other current liabilities consisted of the following at December 31 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,482&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:82.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;External research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative professional service expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,757&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</trda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_Ma5ns-BZdEuuAB-bBRSuWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses and other current liabilities consisted of the following at December 31 (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee compensation and benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4,077&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,482&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:82.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;External research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 125&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative professional service expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,757&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_Z7yQl9HIlUufZty5xfaQRA_2_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">4077000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_vbR0K6f4SUSwyzKKWs3m4g_2_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1482000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <trda:AccruedExternalResearchAndDevelopmentExpensesCurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_fIQUa7EgckS-6gK3NTVdKA_3_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1032000</trda:AccruedExternalResearchAndDevelopmentExpensesCurrent>
    <trda:AccruedExternalResearchAndDevelopmentExpensesCurrent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_szaIvpaePEK7fe28mghE3A_3_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">125000</trda:AccruedExternalResearchAndDevelopmentExpensesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_WM-LkmX9QE-a7Q1tkW50Rw_4_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">419000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_tf7SQOv8dU-rGjRk-ynACQ_4_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">35000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_vbSpfJB0xUejA2lmlEcdGQ_5_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">485000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_pSn_Oa2APk6JCq1ESrwzOw_5_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">115000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_2b6T9g-bF0GAz4tUNVnZzA_6_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">6013000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_QoKZAxIyPEC7mFRniV0gaA_6_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1757000</us-gaap:AccruedLiabilitiesCurrent>
    <trda:TemporaryEquityCommonAndPreferredStockTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_Mv54TxLFC0-4T5198ptODA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Upon the closing of the IPO in November 2021, the Company&#x2019;s Preferred Stock automatically converted into 19,185,183 shares of common stock. As of December 31, 2021, the Company did not have any shares of redeemable convertible preferred stock &lt;span style="-sec-ix-hidden:Hidden_pW9XlBHI-0ycz6y8QY0knQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;authorized&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:Hidden_nO6qA4U-90qR30UGTnbjfg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; or &lt;span style="-sec-ix-hidden:Hidden_BSNci6dkMUiwQdU7Toounw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;. Redeemable convertible preferred stock consisted of the following at December 31, 2020 (in thousands, except share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:70.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preferred&#160;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common&#160;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preferred&#160;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuable&#160;Upon&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Conversion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series Seed preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,420,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,420,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 334,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,879,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,879,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 79,597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 86,277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,453,888&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 85,299,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 85,299,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 81,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 88,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,788,435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On October 27, 2016, the Company entered into a Series Seed Preferred Stock Purchase Agreement, whereby the Company issued an aggregate of 691,641 shares of Series Seed redeemable convertible preferred stock (Series Seed Preferred Stock) at a purchase price of $0.8675 per share for aggregate proceeds of $0.6 million. On March 3, 2017, the Company entered into a second closing of Series Seed Preferred Stock, whereby the Company issued 576,368 shares at a purchase price of $0.8675 per share for aggregate proceeds of $0.5 million. On May 16, 2017, the Company completed the milestone closing of Series Seed Preferred Stock upon the satisfaction of stated milestones pursuant to the Series Seed Preferred Stock Purchase Agreement. In connection with this milestone closing, a total of 1,152,737 shares of Series Seed Preferred Stock were issued at a purchase price of $0.8675, for aggregate gross proceeds of $1.0 million. The Company incurred issuance costs of less than $0.1 million in connection with each of these closings.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On December 14, 2018, the Company entered into a Series A Preferred Stock Purchase Agreement, whereby the Company issued an aggregate of 34,848,403 shares of Series A redeemable convertible preferred stock (Series A Preferred Stock), 24,015,368 of which were issued at a purchase price of $1.041 per share for gross cash proceeds of $25.0 million, and 10,833,035 of which were issued in satisfaction of principal and interest on convertible notes outstanding held by the Company of $9.0 million. Pursuant to the Series A Preferred Stock Purchase Agreement, the Company also agreed to issue up to an additional 24,015,368 shares at a price of $1.041 per share upon the achievement of certain specified milestones.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On January 22, 2020, upon waiver of stated milestones in the Series A Preferred Stock Purchase Agreement, the Company issued 24,015,368 shares of Series A Preferred Stock at a purchase price of $1.041 per share for aggregate proceeds of $25.0 million. The Company incurred issuance costs of less than $0.1 million. Pursuant to the Amended and Restated Series A Preferred Stock Purchase Agreement, on August 12, 2020, the Company agreed to issue an additional 24,015,368 shares of Series A Preferred Stock at a purchase price of $1.041 per share for aggregate proceeds of $25.0 million. The Company incurred issuance costs of $0.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On March 29, 2021, the Company entered into a Series B Preferred Stock Purchase Agreement, whereby the Company issued an aggregate of 53,522,099 shares of Series B redeemable convertible preferred stock (Series B Preferred Stock, together with the Series Seed Preferred Stock and Series A Preferred Stock, Preferred Stock) at a price of $2.172 per share for gross cash proceeds of $116.2 million. The Company incurred issuance costs of $0.4 million. As part of the issuance of Series B Preferred Stock, the liquidation preferences of the Preferred Stock were modified such that, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event, the holders of Preferred Stock then outstanding shall be entitled to be paid out equal to the greater of (i) the applicable original issue price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Preferred Stock been converted into common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company amended the articles of incorporation upon the issuance of the Series B Preferred Stock and the rights and preferences of the outstanding shares of Series Seed Preferred Stock and Series A Preferred Stock were adjusted. The Company considered if the adjustment to the previously issued shares of Preferred Stock represents an extinguishment or a modification to the outstanding mezzanine classified instruments. The adjustments to the outstanding shares of Preferred Stock were qualitatively insignificant. As a result, the adjustments to the rights and preferences of the outstanding shares of Preferred Stock qualified as a modification and no accounting was required as holders of these classes of equity did not receive any incremental value in the transaction.&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Upon issuance of each class of redeemable convertible preferred stock, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed on the issuance date of each class of redeemable convertible preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Prior to the conversion of the Preferred Stock into shares of common stock upon the completion of the IPO in November 2021, the Preferred Stock had the following rights and preferences:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Conversion Rights&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Each share of Preferred Stock is convertible at the option of the holder at any time after the date of issuance. The number of shares of common stock to be issued in the event of a conversion is determined by dividing the original issue price of $0.8675 for the Series Seed Preferred Stock, $1.041 for the Series A Preferred Stock, and $2.172 for the Series B Preferred Stock by the conversion price then in effect. The conversion price for each of the Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock was initially $0.8675, $1.041, and $2.172 per share, respectively, subject to adjustment under certain circumstances, including but not limited to certain additional issuances of common shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Preferred Stock automatically convert at either (i) the closing of a firm-commitment underwritten public offering resulting in at least $75 million of net proceeds to the Company, upon which all outstanding Preferred Stock shall automatically be converted into common shares, at the then effective Series Seed conversion price, &lt;span style="letter-spacing:-0.1pt;"&gt;Series&#160;A conversion price, or Series B conversion price, respectively or (ii)&#160;at the election of the required majority of Preferred Stock holders, upon which all or any portion of the outstanding Preferred Stock shall automatically be converted into common shares, at the then effective Series&#160;Seed conversion price, Series&#160;A conversion price, and or Series B conversion price, respectively&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Dividends&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The holders of Preferred Stock shall be entitled to receive non-cumulative cash dividends, out of any assets legally available therefor, prior and in preference to any declaration or payment of any dividend on shares of common stock (payable other than in common stock or other securities and rights convertible into or entitling the holder thereof to receive, directly or indirectly, additional shares of common stock of the Company) at a rate of eight percent of the applicable original issue price per share of Preferred Stock per annum, payable only when, as and if declared by the Company&#x2019;s board of directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock payable in shares of common stock) unless (in addition to the obtaining of any consents required otherwise by the Company&#x2019;s restated certificate of incorporation) the holders of Preferred Stock then outstanding shall first receive, or simultaneously receive, in addition to the eight percent non-cumulative dividend described above, a dividend on each outstanding share of Preferred Stock in an amount at least equal to the dividend payable on each share of such class or series determined as if all shares of such class or series had been converted into common stock. No dividends were declared or paid during the years ended December 31, 2021 or 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Liquidation Preference&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"&gt;Upon liquidation, dissolution, or winding up of business or a deemed liquidation event, the holders of the Preferred Stock shall be entitled to be paid out the greater of (i) the applicable original issue price, plus any dividends declared but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Preferred Stock been converted into common stock. If, upon any such event, the assets available for distribution are insufficient to satisfy the liquidation payment to holders of Preferred Stock in full, the holders of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full&lt;span style="letter-spacing:-0.1pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:11.5pt;text-indent:20pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Voting Rights&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Except as provided by law or by other provisions of the instruments pursuant to which each series of Preferred Stock was issued, holders of the Preferred Stock and common stockholders&#x2019; vote together as one class on an &#x201c;as-converted basis.&#x201d; On any matter presented to the stockholders of the Company for their action or consideration at any meeting of stockholders of the Company, each holder of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock is entitled to cast the number of votes equal to the number of whole shares of common stock &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;into which the shares of Series Seed Preferred Stock, Series A Preferred Stock, and Series B Preferred Stock held by such holder are convertible as of the record date for determining shares entitled to vote on such matter. The holders of the shares of Series A Preferred Stock, exclusively and as a separate class, are entitled to elect three directors of the Company. The holders of the shares of Series B Preferred Stock, exclusively and as a separate class, are entitled to elect one director of the Company. The holders of the shares of common stock and Preferred Stock, exclusively and voting together as a single class, are entitled to elect three directors of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2021, the Company&#x2019;s certificate of incorporation, as amended and restated effective upon the completion of the IPO, authorized the Company to issue 150,000,000 shares of common stock, par value $0.0001 per share. &lt;span style="letter-spacing:-0.1pt;"&gt;The holders of common stock are entitled to &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;one&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; vote for each share held on all matters submitted to a vote of the stockholders. The holders of common stock do not have any cumulative voting rights. Holders of common stock are entitled to receive ratably any dividends declared by the board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. In the event of liquidation, dissolution or winding up, holders of common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2020, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 113,259,306 shares of common stock, par value $0.0001 per share. The holders of common stock are entitled to one vote for each share of common stock. Subject to the payment in full of all preferential dividends to which the holders of the Preferred Stock are entitled, the holders of common stock shall be entitled to receive dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution, or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company and all preferential amounts to which the holders of Preferred Stock are entitled with respect to the distribution of assets in liquidation, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution&lt;span style="background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;background:#ffffff;"&gt;Shares Reserved for Future Issuance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has reserved the following shares of common stock for future issuance at December 31:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise of outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3,461,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;1,625,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;11,537&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future awards under the 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2,843,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future awards under the 2021 ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;278,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future awards under the 2016 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;360,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Conversion of redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;11,788,435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total shares of authorized common stock reserved for future issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;6,583,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;13,785,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;As of December&#160;31, 2021, the Company was authorized to issue&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;10,000,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;shares of undesignated preferred stock, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.0001&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;par value,&#160;&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The Company was not authorized to issue any such shares as of December 31, 2020. As of &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_mKo_OzFuf0iQHjQHrOziTg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"&gt;December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;, there were &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_Q1xy7BMWbEaf-hfVggNTxg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; shares of undesignated preferred stock issued or outstanding.&lt;/span&gt;&lt;/p&gt;</trda:TemporaryEquityCommonAndPreferredStockTextBlock>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_11_30_2021_a0-v3caGu0mm1ZtiJx365w"
      decimals="INF"
      id="Narr_irC8lz_pfkK0rGhmXUapZw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">19185183</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_sN7owq16MEqsPUMZwj7JsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:70.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preferred&#160;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common&#160;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preferred&#160;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issued&#160;and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuable&#160;Upon&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Authorized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Preference&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Conversion&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series Seed preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,420,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,420,746&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,061&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 334,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Series A preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,879,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 82,879,139&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 79,597&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 86,277&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,453,888&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 85,299,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 85,299,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 81,658&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 88,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,788,435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g"
      decimals="INF"
      id="Tc_lTEqb7tLC0WlLxSzSoPt3g_5_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">2420746</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g"
      decimals="INF"
      id="Tc_MRiCANpNYE-JINtEo3wiNg_5_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">2420746</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g"
      decimals="-3"
      id="Tc_YfiOCqf-mUq6Ey2oUFYapQ_5_7"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2061000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g"
      decimals="-3"
      id="Tc_6VEkxH91K0G-k1JOsVTeSg_5_10"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2100000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_JUzvOsYHvEedX4Eqk0iK0g"
      decimals="INF"
      id="Tc_1rcMcuMlEki7EG_rL4X-7w_5_12"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">334547</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA"
      decimals="INF"
      id="Tc_0p7TG07V3EKfnFPoj_G-_w_6_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">82879139</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA"
      decimals="INF"
      id="Tc_jr9Z-pYE2Ui0ImGW-h35aw_6_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">82879139</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA"
      decimals="-3"
      id="Tc_xP13NDczPkeOMcKRtZgV6w_6_7"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">79597000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA"
      decimals="-3"
      id="Tc_vl2OkmizhUS5q1I3qug0tA_6_10"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">86277000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_byB_0VKiTUiog8s9tpi0GA"
      decimals="INF"
      id="Tc_SvGQlNKTu0a-LOOExjTYkw_6_12"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">11453888</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Tc_FrgXnm9LGUSQ4ZPJQWY1UQ_7_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">85299885</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Tc_Kv04s5Zbw0y3AGuzl-FdXg_7_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">85299885</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_G2GA4nHdUEGie7DCFbXOOA_7_7"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">81658000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_iN6KaSasP0yz8pjaRtBJNQ_7_10"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">88377000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Tc_tcW_08295EqRnMUg3BXHMg_7_12"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">11788435</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_27_2016_To_10_27_2016_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_-En8tjRnnUC9eKmjOLrxDg"
      decimals="INF"
      id="Narr_yq1gBerHHk6NARSDeJ6KTQ"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">691641</trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_10_27_2016_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_GsM3bvleAkui8rQ0h-Ql9g"
      decimals="4"
      id="Narr_RYQL_MdKCkGZPz-cDGGL8w"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.8675</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_10_27_2016_To_10_27_2016_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_-En8tjRnnUC9eKmjOLrxDg"
      decimals="-5"
      id="Narr_2UVQGNE6_EycJWWZUvz-Ng"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">600000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_3_2017_To_3_3_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_3gJUFiFT7E-8naW-uk6dqw"
      decimals="INF"
      id="Narr_Gjbpptmfd0O7xRml9cXHKQ"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">576368</trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_3_3_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_0aluTUFCZU6jYAc_CRSl2A"
      decimals="4"
      id="Narr_3S5GzIX_Ak-S4SLWLw5fvQ"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.8675</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_3_3_2017_To_3_3_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_3gJUFiFT7E-8naW-uk6dqw"
      decimals="-5"
      id="Narr_hW8me4TCNE2IWmoW3bElqg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">500000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_16_2017_To_5_16_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_2d5Zkg5ROU2FOzEjN1-Wlw"
      decimals="INF"
      id="Narr_ltodEoCs1E-a9s85NtcUSA"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1152737</trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_5_16_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_xATBx4mlJkO_FY67Y7xj6A"
      decimals="4"
      id="Narr_fWkk_G0-d025Xuo6kGMbNQ"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.8675</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_5_16_2017_To_5_16_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_2d5Zkg5ROU2FOzEjN1-Wlw"
      decimals="-5"
      id="Narr_EK-EFd9jn0KiA_KGHasncQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1000000.0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_10_27_2016_To_5_16_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_4mA-_qHs2kGfQFglJrYgww"
      decimals="-5"
      id="Narr_nDDGCFzNsEysM1CWxSsQVQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <trda:TemporaryEquityAggregateSharesIssued
      contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ"
      decimals="INF"
      id="Narr_rldAWeivg0CMqCw0syw4oA"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">34848403</trda:TemporaryEquityAggregateSharesIssued>
    <trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ"
      decimals="INF"
      id="Narr_Hv0FltNvYEiuntvcfrP2xg"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">24015368</trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tYP56ACKCEObErEOejmqsg"
      decimals="3"
      id="Narr_L3fxLjgwEUOsNSvygl_9OA"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">1.041</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ"
      decimals="-5"
      id="Narr_IEiIVUgKmUeQSoDfWCIHUQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">25000000.0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ"
      decimals="INF"
      id="Narr_3kxJD9RT5Uio-Bb0nAsDhQ"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">10833035</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ"
      decimals="-5"
      id="Narr_u7j1KxhqWka7Vu_rg8FAiQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">9000000.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <trda:SharesIssuableUponAchievementOfCertainSpecifiedMilestones
      contextRef="Duration_12_14_2018_To_12_14_2018_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_cMUkAnBbNkSU7sbAXSUHbQ"
      decimals="INF"
      id="Narr_NB3ickUhhEWwE1_705U8-w"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">24015368</trda:SharesIssuableUponAchievementOfCertainSpecifiedMilestones>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tneHEayNbkCaFY8W_qAw-g"
      decimals="3"
      id="Narr_Me5iNb-9bUu9GdPlMRJAIA"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">1.041</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_22_2020_To_1_22_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_xzJvCpIB60egOnueDPk1DQ"
      decimals="INF"
      id="Narr_3OpPw9XXHU20l7AgypZ6BQ"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">24015368</trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_1_22_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_epyOIcPzq0SVrlfXNg7yEg"
      decimals="3"
      id="Narr_xCtD-xCR-ES64pyP-ZOYaw"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">1.041</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_1_22_2020_To_1_22_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_xzJvCpIB60egOnueDPk1DQ"
      decimals="-5"
      id="Narr_8s31KXKkB0eQsd8LR6ufUQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">25000000.0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_22_2020_To_1_22_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_-1_Yd9urDk-m9ncpSMWkLA"
      decimals="-5"
      id="Narr_nkNi3Wd7U06jnWK8MctaDA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_12_2020_To_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_z6226-NgvE6yUlb-QpUJqg"
      decimals="INF"
      id="Narr_yPrCKZnx8Eubc38l5MIaAw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">24015368</trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_7VWTG_vPyUKvAaUWm3BT8w"
      decimals="3"
      id="Narr_B-CgPauC00aOoaWDknJiiw"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">1.041</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_8_12_2020_To_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_z6226-NgvE6yUlb-QpUJqg"
      decimals="-5"
      id="Narr_vTB5IrzZXUes5AveiJfS9g"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">25000000.0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_8_12_2020_To_8_12_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_z6226-NgvE6yUlb-QpUJqg"
      decimals="-5"
      id="Narr_GjaBLyAYUEO0pOV72SYEXA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_EV4uTuzkYE6h_aLfr9tQpQ"
      decimals="INF"
      id="Narr_YLw4XARFL028gOLRgIoScg"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">53522099</trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_aj5kvebNtEaEwVM3errF3A"
      decimals="3"
      id="Narr_BsKfC-AygUm-o62ze3xTUA"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">2.172</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_EV4uTuzkYE6h_aLfr9tQpQ"
      decimals="-5"
      id="Narr_qFn6JRZS8USDuSTdKeGjgg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">116200000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_3_29_2021_To_3_29_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_EV4uTuzkYE6h_aLfr9tQpQ"
      decimals="-5"
      id="Narr_zT1VUYQfFkaVAsa08MdTpw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_rXp55kz8m0-Oy4jN90htNw"
      decimals="4"
      id="Narr_PJT6xQhb9E-AGqRxnWxMIg"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.8675</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tneHEayNbkCaFY8W_qAw-g"
      decimals="3"
      id="Narr_oSVoQ_G-SUuDwB8gDLPBYQ"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">1.041</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_WDhCcPxYokqoE__Xm560JA"
      decimals="3"
      id="Narr_O11VYhkoPE6Ae6JM1pNZsg"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">2.172</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <trda:TemporaryEquityConversionPrice
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_rXp55kz8m0-Oy4jN90htNw"
      decimals="4"
      id="Narr_MBXlMEG0M0y1b6Uzp657bw"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.8675</trda:TemporaryEquityConversionPrice>
    <trda:TemporaryEquityConversionPrice
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tneHEayNbkCaFY8W_qAw-g"
      decimals="3"
      id="Narr_cNUsDLmhY0WsaaU80FyZ5Q"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">1.041</trda:TemporaryEquityConversionPrice>
    <trda:TemporaryEquityConversionPrice
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_WDhCcPxYokqoE__Xm560JA"
      decimals="3"
      id="Narr_PXIr2gLk6Uy_e7e4z_jngw"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">2.172</trda:TemporaryEquityConversionPrice>
    <trda:ThresholdNetProceedsFromQualifiedPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_ydttNEUZL0mEntDbye7NGA"
      decimals="-6"
      id="Narr_uQRgEtmpwUKDfbBKuuylzA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">75000000</trda:ThresholdNetProceedsFromQualifiedPublicOffering>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="2"
      id="Narr_-jrTVd1VsUyOVMX13AXpog"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="2"
      id="Narr_HUKL6CygQEigBTsPbNDNKA"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Narr_lFC8sxZ08kurbhBxp3bE0w"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Narr_EpWLMY7IRU6i0hUE9fCa1Q"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:DividendsPreferredStock>
    <trda:NumberOfDirectorsEntitledToBeElected
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_tneHEayNbkCaFY8W_qAw-g"
      decimals="INF"
      id="Narr_Qetucb4opkuT0Quv34_a9w"
      unitRef="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw">3</trda:NumberOfDirectorsEntitledToBeElected>
    <trda:NumberOfDirectorsEntitledToBeElected
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_trda_SeriesBRedeemableConvertiblePreferredStockMember_WDhCcPxYokqoE__Xm560JA"
      decimals="INF"
      id="Narr_wn3dn5DzqkSH5FXOzWmS2w"
      unitRef="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw">1</trda:NumberOfDirectorsEntitledToBeElected>
    <trda:NumberOfDirectorsEntitledToBeElected
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_We_97RoWlU-qywjwKAC9Hg"
      unitRef="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw">3</trda:NumberOfDirectorsEntitledToBeElected>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_yXuqkcYvjU6Tmu6g5d0jHA"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Narr_VkB3yrlLpkOyJ1svwsvKvg"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_GcnZLDto0EuxSNKrLPKGOA"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <trda:NumberOfVotesPerShareOfCommonStock
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_GBw690r3yUKXOAK0WQcIMQ"
      unitRef="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw">1</trda:NumberOfVotesPerShareOfCommonStock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Narr_XV17NUdTuU-Kzi8g2rmrZw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">113259306</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Narr_YIRufuI7uUCli1CddMrtpA"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <trda:NumberOfVotesPerShareOfCommonStock
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_EPvkSgaakU-q_eiJ3U5Vzg"
      unitRef="Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw">1</trda:NumberOfVotesPerShareOfCommonStock>
    <trda:ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_rKryZwvgx0OlaMGBVEkVqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise of outstanding stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;3,461,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;1,625,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;11,537&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future awards under the 2021 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;2,843,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future awards under the 2021 ESPP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;278,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future awards under the 2016 Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;360,306&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Conversion of redeemable convertible preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;11,788,435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total shares of authorized common stock reserved for future issuance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;6,583,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;13,785,534&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</trda:ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw"
      decimals="INF"
      id="Tc_BgFK4zqoBECK7m2Ml33zZQ_2_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">3461870</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JkQZPPgBBUGf-humPcfAMQ"
      decimals="INF"
      id="Tc_wjLl7hBbi0WgHl6kqh-F_Q_2_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1625256</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BPELmQx4xEiCTW0PJ5snKg"
      decimals="INF"
      id="Tc_JJS-bHAZBUCXB2BN3o7AaA_3_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">11537</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_5fShMvZuL0CBikfxgEmhJw"
      decimals="INF"
      id="Tc_MjUMjVV5n0utjwISYd-gBA_4_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">2843255</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_WfsWIAfNmE2sstVPNwOq4Q"
      decimals="INF"
      id="Tc_hXWvDxl6PUaoAcBT24Lqrg_5_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">278762</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_trda_StockPlan2016Member_AiSU5Z1vhEGHTV-J1QFVng"
      decimals="INF"
      id="Tc_jnI4SChHaUOXkIZksDsuRw_6_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">360306</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RedeemableConvertiblePreferredStockMember_6iNejRF2DEGk6tYe2YQoHw"
      decimals="INF"
      id="Tc_H1Mp89WiIEqZ_gLA140erg_7_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">11788435</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Tc_gMCsO-cpe0m54rO_QsJ5lQ_8_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">6583887</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Tc_rFPxzaCV6E6DIdfAPi34Cw_8_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">13785534</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_NxKj8krY60qnuGW7lAs9Aw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_NYpYdk_KdEqtXsGSHpiSlA"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_f9HoOHR240-S6uW9pv8KJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2021 Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;In September 2021 the Company&#x2019;s board of directors adopted, and in October 2021 the Company&#x2019;s stockholders approved, the 2021 Plan, which became effective as of the date immediately prior to the date of the effectiveness of the registration statement for the IPO. The 2021 Plan allows the board of directors to grant &lt;/span&gt;incentive stock options or non-qualified stock options, restricted stock, restricted stock units, and other equity awards &lt;span style="letter-spacing:-0.1pt;"&gt;to the Company&#x2019;s officers, employees, directors, and other key persons. &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;In addition, the 2021 Plan includes a provision that allows for an automatic annual increase of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;4%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; in the number of shares of common stock available for issuance under the 2021 Plan.&#160;&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;The 2021 Plan replaced the 2016 Plan and &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;no&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; additional awards will be granted under the 2016 Plan following the closing of the IPO. The 2016 Plan will continue to govern the outstanding equity awards granted thereunder. The total number of shares of common stock authorized for issuance under the 2021 Plan as of December 31, 2021 was &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;3,986,270&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; shares. There were &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;no&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; shares of common stock authorized for issuance under the 2021 Plan as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;As of December&#160;31, 2021, the Company had issued only stock options under the 2021 Plan. Stock options issued comprise of service-based awards granted to employees. Vesting of stock options is subject to the recipient&#x2019;s continued employment or service.&lt;/span&gt; The maximum term of options granted under the 2021 Plan is ten years, and stock options typically vest over a four-year period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;In September 2021, the Company&#x2019;s board of directors adopted, and in October 2021 the Company&#x2019;s stockholders approved, the ESPP, which became effective as of the date immediately prior to the date of the effectiveness of the registration statement for the IPO. The ESPP is administered by the person or persons appointed by the Company&#x2019;s board of directors for such purpose. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;278,762&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; shares of common stock. The number of shares of common stock reserved for issuance under the ESPP will automatically increase on January 1st of each year beginning in 2022 and continuing through and including 2031 by the least of (i) &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;1%&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; of the outstanding number of shares of our common stock of the immediately preceding December 31, (ii) &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;557,524&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; shares or (iii) such number of shares as determined by the ESPP administrator. As of December 31, 2021, no offering periods have commenced under the 2021 ESPP and &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;278,762&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; shares remained available for issuance. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2016 Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The 2016 Plan provides for the Company to grant incentive stock options or non-qualified stock options, restricted stock, restricted stock units, and other equity awards to employees, directors, and consultants of the Company. The 2016 Plan is administered by the board of directors of the Company or, at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting, and other restrictions are determined at the discretion of the board of directors, or its committee if so delegated. The 2016 Plan allows for early exercise of all stock option grants if authorized by the board of directors at the time of grant. The shares of common stock issued from the early exercise of stock options are restricted and continue to vest over the original service based vesting condition of the original stock option award. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The total number of shares of common stock authorized for issuance under the 2016 Plan as of December 31, 2021 and 2020 was 2,318,855 shares and 1,997,099 shares, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;For the years ended &lt;span style="letter-spacing:-0.1pt;"&gt;December&#160;31, 2021 and 2020, the Company recorded stock-based compensation expense of &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;$2.5&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;million and &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;$0.3&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; million. Stock compensation expense for 2021 and 2020 included less than &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;$0.1&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;million related to restricted stock in both years and &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;$2.5&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;million and &lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;$0.3&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; million related to stock options in 2021 and 2020, respectively&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense recorded as research and development and general and administrative expenses in the consolidated statements of operations is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 325&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Option Valuation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents, on a weighted-average basis, the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted for the years then ended:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Early Exercise of Unvested Stock Options &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding shares until those shares vest according to their respective vesting schedules. Cash received from employee exercises of unvested options is included in current liabilities on the balance sheet. Amounts recorded are reclassified to common stock and additional paid-in capital as the shares vest. Vesting can occur in the year of exercise and thereafter. There were 111,756 and 27,869 unvested shares related to early exercises of stock options as of December 31, 2021 and December 31, 2020, respectively. In the years ended December 31, 2021 and 2020, the liability associated with the unvested early exercise of stock options was $0.3 million and less than $0.1 million, respectively.&lt;span style="white-space:pre-wrap;background:#ffffff;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the Company&#x2019;s stock option activity since December 31, 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,625,256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,311,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (431,687)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,461,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26,730&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2021 (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,359,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26,730&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(1) This represents the number of vested and unvested options exercisable as of December&#160;31,&#160;2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(2) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December&#160;31,&#160;2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The aggregate intrinsic value of stock options exercised during the years ended December 31, 2021 and 2020 was $2.8 million and $0.1 million, while the company received $0.9 million and $0.2 million in proceeds for the exercise of these options, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2021 and 2020 was $9.39 per share and $1.56 per share, respectively. As of December 31, 2021, there was $20.9 million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of 3.5 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Stock Awards&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company issued restricted stock to its founders and certain officers of the Company. In general, the shares of restricted stock vest over a four-year period, with 25% of the shares vesting after one year, followed by monthly vesting over the remaining three years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;If the holders of the above restricted stock cease to have a business relationship with the Company, the Company may reacquire any unvested shares of restricted stock held by these individuals for the original purchase price or fair value, whichever is lower at the time of repurchase. The amounts received to date for the purchase price of restricted stock are immaterial. The unvested shares of restricted stock are not considered outstanding shares for accounting purposes until the shares vest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A summary of unvested restricted stock during the year ended December 31, 2021 is as follows&lt;span style="background:#ffffff;"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.007&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.007&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The total fair value of restricted stock vested during each of the years ended December 31, 2021 and 2020 was less than $0.1 million.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_nCvXJPkm-EeVgL-HAKzWCg"
      decimals="2"
      id="Narr_bzNphac1fk6Z8H1uugHQMQ"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_nCvXJPkm-EeVgL-HAKzWCg"
      decimals="INF"
      id="Narr_tkZW7H21uUGm-Ax-xpVgZw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_5fShMvZuL0CBikfxgEmhJw"
      decimals="INF"
      id="Narr_ZHpOA6y2XkybuicFnFs7_w"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">3986270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_trda_StockPlan2021Member_XN77OWOzXkC7szS4MrVGTQ"
      decimals="INF"
      id="Narr_CEapZSinn0KK4gGQwaM5fw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_nCvXJPkm-EeVgL-HAKzWCg"
      id="Narr_9nfesaqDp0udNrLwyoD8GA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2021Member_nCvXJPkm-EeVgL-HAKzWCg"
      id="Narr_vLypdG6QBE6kqK4slRu4PQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_10_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_eX6Qkp3pp0eD-g-WpjcsYA"
      decimals="INF"
      id="Narr_OdVurPewv0aeU5HZ20ykLQ"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">278762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="Duration_10_1_2021_To_10_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_jPFYwfOyHkibNEeOW_EYTw"
      decimals="2"
      id="Narr_ORlra2IR-UOH7Uy_NYQ97A"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_10_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_eX6Qkp3pp0eD-g-WpjcsYA"
      decimals="INF"
      id="Narr_TPhWXEs5S06dk4QBYFVfCg"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">557524</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_trda_EmployeeStockPurchasePlan2021Member_q07zOZMvO0O0qAOZXAgC6A"
      decimals="INF"
      id="Narr_uP30eIhc2U-ipNo89X_QWw"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">278762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2016Member_WSANhifLkU2A9s4mVWiePw"
      decimals="INF"
      id="Narr_4qGR83RKZUmJFYUM8cV4YA"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">2318855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_trda_StockPlan2016Member_AiSU5Z1vhEGHTV-J1QFVng"
      decimals="INF"
      id="Narr_q2k5_EdaqkWdo_cw3RhXjg"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1997099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-5"
      id="Narr_A-wCPtJE_0KfWskR0Y2B3Q"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-5"
      id="Narr_Z7Jqff73O0Oz8AS9JZOY-A"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_zsGA-ZYjak2Nkhe-ZCUNNg"
      decimals="-5"
      id="Narr_VU0nA4yJpEKCFQ9b0Szwwg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W6iQ9yRAYE2F1wZofX493A"
      decimals="-5"
      id="Narr_IgYByknv4kS6lhbDfRTAnQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="-5"
      id="Narr_6180Mb-bUEeE1MaA_TRpqA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow"
      decimals="-5"
      id="Narr_0-ko5Z0Ws0K8qxFGP02ZUQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb__B0iqFpTIkSkS4HklInlyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense recorded as research and development and general and administrative expenses in the consolidated statements of operations is as follows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 2,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 325&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_F-9SRQC7hkatUiZQujCAMA"
      decimals="-3"
      id="Tc_XCokP_zew0uw1F7m2bDQWQ_3_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">878000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_l7f8215TfUmkc3xqHhvUwA"
      decimals="-3"
      id="Tc_Rsss8ealskO4QKsabqotBw_3_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">107000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_tD1C2qFg_0-xasA5fL3IOw"
      decimals="-3"
      id="Tc_l0Qgpcze-USYKjFGg6p2Sw_4_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1648000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynIvbasOrkmhLq6FFmJ_CQ"
      decimals="-3"
      id="Tc_l5w-cnMl9kC1pjavFoFlPQ_4_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">218000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_U-NZUjxmNkmpZA1vy5VviQ_5_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2526000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_6OotLqEIK0yV84-9LAhczg_5_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">325000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_KKLcvaUmk0u5CtFrKGdfLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 5.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="4"
      id="Tc_6L91JsRI2UaaV69vuYUDcw_3_2"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.0115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow"
      decimals="4"
      id="Tc_yoOt1yHpJEGBkVTFU3bX5g_3_4"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.0053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="2"
      id="Tc_4vkMp8vxOkSbcDHPklqB3w_4_2"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow"
      decimals="2"
      id="Tc_hA932ozHOEK3YFHMYaATzw_4_4"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      id="Tc_Jo_H5-SuQ0SGeI2ytXMwbw_6_2">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow"
      id="Tc_YA315NJ3Wk-IJLa_FkjanQ_6_4">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="INF"
      id="Narr_6EN44ylJjU-MsQdDoIK7kg"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">111756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="INF"
      id="Narr_-nTLC0FySkKCvNiEpL1w4Q"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">27869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <trda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-5"
      id="Narr_Pc1O96LojUeHlwfSkYqGWQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">300000</trda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount>
    <trda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-5"
      id="Narr_s0nRZEd8-k-VXPy8CcCDMg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</trda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_--U7SxNUpkm0wt8_Wy1IKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value (2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,625,256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1.88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,311,485&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 14.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (431,687)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (43,184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 3,461,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26,730&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of December&#160;31,&#160;2021 (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,359,876&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 26,730&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(1) This represents the number of vested and unvested options exercisable as of December&#160;31,&#160;2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(2) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December&#160;31,&#160;2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JkQZPPgBBUGf-humPcfAMQ"
      decimals="INF"
      id="Tc_YWRus_FXy0CQx-iMfKU4wA_6_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1625256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_JkQZPPgBBUGf-humPcfAMQ"
      decimals="2"
      id="Tc_p318sVHiFk2WgtBgwqjgTg_6_5"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="INF"
      id="Tc_pINzMoEC5EO1pSaSweEx2Q_7_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">2311485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="2"
      id="Tc_eLGnqjzJ0k2f7pQzTwdHRg_7_5"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">14.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="INF"
      id="Tc_j_m9XnMF7U-b2S9e1KuZ1A_8_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">431687</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="2"
      id="Tc_UGQLizPzyEuAyJCMpa-L9g_8_5"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">2.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="INF"
      id="Tc_DozPleY3PkeYdwE-iaHlSA_9_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">43184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="2"
      id="Tc_mi78nER3zUOz7TGAbcu1Og_9_5"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">3.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw"
      decimals="INF"
      id="Tc_WnF-gEea0061HSwEp4LG4g_10_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">3461870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw"
      decimals="2"
      id="Tc_vLrkKJifWEmyMX5LJCOWUw_10_5"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">10.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      id="Tc_7UlKvkjzu0qqy1_1EZv3zw_10_7">P9Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw"
      decimals="-3"
      id="Tc_WMfuq-9S3kWiEd5t0K2mAA_10_10"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">26730000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw"
      decimals="INF"
      id="Tc_ZzD45y8jnEeWP7r40R9CTA_11_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">2359876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw"
      decimals="2"
      id="Tc_w_ps4l9sbUScnad4j8fKbQ_11_5"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">5.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      id="Tc_9WGMz-dfpEWustc3dvdj4A_11_7">P8Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw"
      decimals="-3"
      id="Tc_Cj8Bt42RjUSYOmAveACWlg_11_10"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">26730000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="-5"
      id="Narr_jy20Vql5r0GCNeNqamfumQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow"
      decimals="-5"
      id="Narr_JzaflrqpdEO3D7ApPiRsZQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="-5"
      id="Narr_wuXq9np3sUmMaQyxiUHQOQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow"
      decimals="-5"
      id="Narr_F2EeAquncECBUdV3_bzZKA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      decimals="2"
      id="Narr_xGPKJlSGp0GiyRDM6J9kNA"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">9.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9E1E939BHka8LXNDWcDgow"
      decimals="2"
      id="Narr_2VqcucQY80Ky-gpiHlxWoQ"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw"
      decimals="-4"
      id="Narr_1lqSVRd0xEG1E1QdkrLMKQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">20900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww"
      id="Narr_YSrcERSG_0GSSZxsKJDbXg">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_djIfGJUG3UerKSFCe6I17g"
      id="Narr_-9IVLiEu00-cRufRdNZTfg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_RWcJH0PTE0iREP0s53rf8A"
      decimals="2"
      id="Narr_2Hu71W6wGUC2PDv4wV4SjQ"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_RWcJH0PTE0iREP0s53rf8A"
      id="Narr_uZTWcHdqP0OnMRWXz8G5cQ">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_Tt00y1mV6kiK5B4cvFJE-Q"
      id="Narr_lFiO69cu3U-lN_7uDsoasg">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_OUDHlK2AyU-H23iRr59XOg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested as of December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,537&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.007&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 0.007&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BPELmQx4xEiCTW0PJ5snKg"
      decimals="INF"
      id="Tc_ywwmdFsBjE-s1Y-DoIfNTw_5_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">11537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_BPELmQx4xEiCTW0PJ5snKg"
      decimals="3"
      id="Tc_OUVpqs2M0UyA3tANOcja3g_5_5"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_djIfGJUG3UerKSFCe6I17g"
      decimals="INF"
      id="Tc_nXFjv2FZOEO8x8E1n1r2GQ_6_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">11537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_djIfGJUG3UerKSFCe6I17g"
      decimals="3"
      id="Tc_4JalRmwmxEG-xlU-o04Ueg_6_5"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_zsGA-ZYjak2Nkhe-ZCUNNg"
      decimals="-5"
      id="Narr_VjOh7KC2bkyaLOAjZeVO2w"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_W6iQ9yRAYE2F1wZofX493A"
      decimals="-5"
      id="Narr_iWvmqFdtXEGy8Nv28pSqAA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_NHSpwZiKS02sd4jG_Cyuwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;For the years ended December 31, 2021 and 2020, the Company recorded &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;no&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; income tax benefits for the net operating losses incurred or for the research and development tax credits generated in each period, due to its uncertainty of realizing a benefit from those items. All of the Company&#x2019;s operating losses since inception have been generated in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal and state research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Non-deductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in deferred tax asset valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (30.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_EcmWlvh2TEiknBczU408Mg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-KTlssYZZU-m9cyJXvqw1g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Net deferred tax assets as of December 31, 2021 and 2020 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 25,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,214&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 432&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Salaries and wages&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 29,689&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,351&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (111)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (485)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (746)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (111)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,943)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,240)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_HodcTs_FvES0HiIzmfy6sw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_x7heNc3It0iVSYbvysmtSA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;As of December 31, 2021, the Company had federal net operating loss carryforwards of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$93.1&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, which may be available to offset future taxable income, of which &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$3.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million of the total net operating loss carryforwards expire at various dates beginning in 2036, while the remaining &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$89.9&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million do not expire but are limited in their usage to an annual deduction equal to 80% of annual taxable income. In addition, as of December 31, 2021, the Company had state net operating loss carryforwards of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$88.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, which may be available to offset future taxable income and expire at various dates beginning in 2036. As of December 31, 2021, the Company also had federal and state research and development tax credit carryforwards of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2.3&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million, respectively, which may be available to reduce future tax liabilities and expire at various dates beginning in 2039 and 2034, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 and Section 383 of the Internal Revenue Code of 1986 (Code), and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income and tax liabilities. In general, an ownership change, as defined by Section 382 of the Code, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 5% over a three-year period. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382 of the Code, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards may be subject to an annual limitation, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before their utilization. Further, until a study is completed by the Company and any limitation is known, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;no&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; amounts are being presented as an uncertain tax position.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets, which consist primarily of net operating loss carryforwards and research and development tax credit carryforwards. Management has considered the Company&#x2019;s history of cumulative net losses incurred since inception, estimated future taxable income, and prudent and feasible tax planning strategies and has concluded that it is more likely than not that the Company will not realize the benefits of federal and state net deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2021 and 2020. The Company reevaluates the positive and negative evidence at each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The valuation allowance increased by &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$15.7&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million and &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$8.2&lt;/span&gt;&lt;span style="white-space:pre-wrap;background:#ffffff;"&gt; million for the year ending December 31, 2021 and 2020, respectively.  The increase in the valuation allowance for deferred tax assets during the years ended December 31, 2021 and 2020 related primarily to the increases in net operating loss carryforwards and research and development tax credit carryforwards. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company assesses the uncertainty in its income tax positions to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more-likely-than-not threshold, the tax amount recognized in the consolidated financial statements is reduced by the largest benefit that has a greater than 50% likelihood of being realized upon the ultimate settlement with the relevant taxing authority. The Company&#x2019;s policy is to recognize interest and penalties accrued on any uncertain tax positions as a component of income tax expense, if any, in its consolidated statements of operations. As of December 31, 2021 and 2020, the Company had not recorded any reserves for uncertain tax positions or related interest and penalties.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. Due to net operating losses incurred, the Company&#x2019;s tax returns from inception to date are subject to examination by the taxing authorities.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-5"
      id="Narr_cOp-lYDXoESNf9bA1vmOeg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-5"
      id="Narr_kIwLC2X0TEar2WLVbp9oRg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_tv5LjI4ogUW8KbrQ1W3GkA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State income taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal and state research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Non-deductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Change in deferred tax asset valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (30.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_EcmWlvh2TEiknBczU408Mg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_-KTlssYZZU-m9cyJXvqw1g;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="3"
      id="Tc_poEvJEWuUEWxjFf6YVDAOg_3_2"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="3"
      id="Tc_sm7-fnqwYUOtwpQO7JIIcA_3_5"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="3"
      id="Tc_n43R4BJjYU2qvQUw8HYhwQ_4_2"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.061</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="3"
      id="Tc_koROORTcyEW1GOH97Tox3Q_4_5"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="3"
      id="Tc_yWKBbDjhwk6hPqCP0vnhTA_5_2"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.039</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="3"
      id="Tc_gIZjj7QTUE6msdhft-CgEw_5_5"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="3"
      id="Tc_6wDHlVMf2UCfbvorQF8Eqw_6_2"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="3"
      id="Tc__QxZxaZNj0G-SdjHipMQgA_6_5"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="3"
      id="Tc_m5t_YdVZoUKCkfBznjen3A_7_2"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">-0.307</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="3"
      id="Tc__kA0J4gM3Ui1xUXH1q2XVg_7_5"
      unitRef="Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w">-0.310</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_-mo8-Tak5kGqOSsPQxHnUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Net deferred tax assets as of December 31, 2021 and 2020 consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:20.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 25,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,214&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Research and development tax credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 432&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Salaries and wages&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 313&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 137&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 29,689&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,351&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (261)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (111)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (485)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (746)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (111)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,943)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (13,240)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_HodcTs_FvES0HiIzmfy6sw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_x7heNc3It0iVSYbvysmtSA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_Xls-aabUH0uQcfaFEcrd2w_4_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">25124000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_rW0YAUqvI0qeNIBM-J1IIw_4_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">11214000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_hw4FEURNLk6lRg-IFC2FAw_5_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">3237000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_j6ACqt1pvEO0JA9vWPCfkQ_5_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1236000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_GNizQGcowUSH_q46dmPibA_6_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">761000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_II4pukMh90yKac0I1TA3sw_6_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">432000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_H-_rJI2q3kSigfGgEghCVA_7_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">313000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_0cfzHwWp-Em87awLe9xifQ_8_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">430000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_kVhbgFbzlk64oGdtXhHFHg_8_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">80000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_0TBjDzcJw0uyUR_Et659lw_9_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">137000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_js7IBJp5iE2Q9pe0-o-DsQ_9_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">76000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_IQY8qhW1PEG2W8BpzhKmMA_10_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">29689000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_t-D2denj6kuwgaMxki5L_Q_10_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">13351000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_YSo9S8EPZES_92xKbl8GpQ_12_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">261000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_N5tlm-al_Ee5NgP_Xb1jBA_12_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">111000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_EsITb_uyBkKbBmbrAQRJRQ_13_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">485000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_L59OLQeAJUqeclG4_Kjlbw_14_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">746000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_SLeqF3n9iku8jf_sgJhdZA_14_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">111000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_8EpiNCDR2k-vHsGsKVR6jQ_15_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">28943000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A"
      decimals="-3"
      id="Tc_VHMmbkQyvUOrbVhtwl4uZw_15_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">13240000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_a53NGrxD4kSTEvV0srI_NQ"
      decimals="-5"
      id="Narr_hg2RxSuQGE63rcnTUejPdA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">93100000</us-gaap:OperatingLossCarryforwards>
    <trda:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-5"
      id="Narr_tM4-CUCiQ0OEttQEew8qRA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">3200000</trda:OperatingLossCarryforwardsSubjectToExpiration>
    <trda:OperatingLossCarryforwardsLimitationOnUseAmount
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-5"
      id="Narr_J1HTA6dAgEaMzH8kqdOt4g"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">89900000</trda:OperatingLossCarryforwardsLimitationOnUseAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_y8-ETpe8yUaoJwpU5roQfA"
      decimals="-5"
      id="Narr_9vSIk24VEkyj8Me4mpRs6w"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">88000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_a53NGrxD4kSTEvV0srI_NQ"
      decimals="-5"
      id="Narr_g0UP8M9fzUa0K2eyT_xklg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_y8-ETpe8yUaoJwpU5roQfA"
      decimals="-5"
      id="Narr_m4IxFUPMwECV1EfexfhTGw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Narr_3jg2knGjzEWXM7da2-Lh3A"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_O8pVP4l75kOdx-yCEK8aZQ"
      decimals="-5"
      id="Narr_ZBxkG0FAIE2H2UHzgwrViQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">15700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_zP_saBrSuEeXS1wmFBKk8g"
      decimals="-5"
      id="Narr_5HG0plCYekyQlWlh_sNmww"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">8200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_mzlXphayhUKUmEwYr7u42w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Lease Obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In March 2019, the Company entered into an operating lease for 7,981 square feet of office and laboratory space with an end date of April 30, 2021 in Boston, Massachusetts. The Company subsequently terminated the operating lease in December 2020 without penalty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In February 2020, the Company entered into an operating lease for 26,235 square feet of office and laboratory space in Boston, Massachusetts. Lease payments commenced in April 2020. The lease is subject to fixed rate escalation increases. The Company recognizes rent expense on a straight-line basis over the expected lease term, which is 5.7 years. The Company began to record rent expense in April 2020 upon gaining access to and control of the space. Deferred rent is amortized as a reduction in rent expense over the term of the lease. In addition, upon execution of the lease, the Company paid a security deposit of approximately $0.5 million, which is recorded as a component of other assets in the accompanying consolidated balance sheets as of December 31, 2021 and 2020. The Company has the option to terminate the lease after November 30, 2023 without penalty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In June 2021, the Company entered into amendments to the operating lease for 8,631 square feet of additional office and laboratory space at its location in Boston, Massachusetts. The term of the amendments begin between July 2021 and March 2022 and run co-terminus with the existing lease. The Company has the same option to terminate the lease after November 30, 2023 without penalty. The Company was required to increase its total security deposit to $0.8 million as of the commencement date of the amendments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company recorded $6.0 million and $1.9 million of rent expense for the years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The minimum aggregate future lease commitments at December 31, 2021, are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ending December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,384&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In 2017, the Company entered into an option agreement with a third party, in which the Company obtained an option to license all patents and patent applications specified in the agreement, involving work related to specified invention disclosures, and arising out of that sponsored research agreement entered into between the Company and such third party pursuant to which the Company sponsored certain discovery programs conducted by the third party. In 2018, the Company entered into a definitive license agreement with the third party in which the third party granted the Company an exclusive worldwide, sublicensable license to certain intellectual property under certain patent rights to research, develop, and otherwise commercialize a product generated from the licensed intellectual property. The Company concluded the assets acquired did not meet the accounting definition of a business as inputs, but no processes &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;or outputs were acquired with the licenses. As the inputs that were acquired along with the licenses do not constitute a &#x201c;business,&#x201d; the transaction has been accounted for as an asset acquisition under ASC 730. As of the date of the license agreement, the assets acquired had no alternative future use and the assets had not reached a stage of technological feasibility. The Company paid an upfront research fee of $0.4 million, paid in two installments of $0.2 million on June 30, 2019 and June 30, 2020, respectively, which were accrued and recognized as research and development expense in 2018. The Company agreed to pay an annual license maintenance fee for the license of less than $0.1 million for each contract year, beginning the third year of the contract until the first commercial contract year. The Company also issued a total of 86,558 shares of common stock pursuant to the 2018 agreement, which were recorded at fair value at the date of issuance of $0.2 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Should the Company pursue specified research, development, and commercial activities related to the above technology, the Company would be obligated to make milestone payments up to $2.6 million for each of the first three licensed products to achieve each milestone. The triggering of these milestone payments was not considered probable as of the transaction date, and no expense has been recorded for these milestones as of December 31, 2021 and 2020. In addition, the third party will receive tiered royalty payments on the applicable licensed program and platform products at a percentage ranging in single-digit royalties of net sales subject to reductions and offsets in certain circumstances, as well as a royalty on sublicensed consideration ranging from low to mid double-digit percentages of non-royalty sublicensing consideration. The Company concluded any milestone or royalty payments under the agreement were not probable as of December 31, 2021 and 2020. For each of the years ended December 31, 2021 and 2020, the Company reimbursed the third-party for patent costs of $0.1 million.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_3_31_2019_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_aI2VmsKba02tMKmJCqhsEg"
      decimals="INF"
      id="Narr_rMxu9qDoUkSefTBFbR4x6Q"
      unitRef="Unit_Standard_sqft_rx7LKou9MUKld2X7S962qQ">7981</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_2_29_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_jhtKcYUrGUeXiu8kysHe4g"
      decimals="INF"
      id="Narr_SJSentwT5UO2m2oIlhaJ-g"
      unitRef="Unit_Standard_sqft_rx7LKou9MUKld2X7S962qQ">26235</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_K6kVW2WPBE-kg0DD1wJujA"
      id="Narr_7wXZPWJv30i0LAcCfXGNVA">P5Y8M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2020_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_G0o0UYvQV06N8dmtQoWrUw"
      decimals="-5"
      id="Narr_qrdIR20SME6nLZwy2BMUpw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">500000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember_rM6lo0glkkSHK6fx56dohQ"
      decimals="-5"
      id="Narr_2G1DNq1P_UCZuA_trHfMbg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">500000</us-gaap:SecurityDeposit>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_kcauchfWnUmJP3dujL0p2w"
      decimals="INF"
      id="Narr_JOjiRU5pyEuNkiiQPdxXYQ"
      unitRef="Unit_Standard_sqft_rx7LKou9MUKld2X7S962qQ">8631</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_6_30_2021_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember_-28m7dTNPU20dkA6HHUEeA"
      decimals="-5"
      id="Narr_OfwlS8udKUWRTrnCr2YdCg"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">800000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-5"
      id="Narr_zmIfsJyrVUWM_pENy-Qn_w"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">6000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-5"
      id="Narr_St6USnAdUEq13taOJsVuXA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">1900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_PtiJVo-UyEC3BcZjh3ClUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The minimum aggregate future lease commitments at December 31, 2021, are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years Ending December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,526&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,384&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_UZVX2WaZqU21OVgZ59OIGQ_2_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">8526000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_rOQKKUtcu0Ol3yLDJaah1w_3_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">8384000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w"
      decimals="-3"
      id="Tc_XaEhBrIQbUSLyAbO6Xp64A_4_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">16910000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <trda:PaymentOfUpfrontResearchFees
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Cy9RrUM470ieiIVBwGRytQ"
      decimals="-5"
      id="Narr_3dUjvMQprEW-_Qei4sVThQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">400000</trda:PaymentOfUpfrontResearchFees>
    <trda:LicenseAgreementNumberOfInstallments
      contextRef="As_Of_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_jxCvIM-1WEOJ9WQF7LNJvg"
      decimals="INF"
      id="Narr_0e1mkN9-h0SH7cl-LH9RMg"
      unitRef="Unit_Standard_installment_z46z-AyIh0iy55GSvWd0bw">2</trda:LicenseAgreementNumberOfInstallments>
    <trda:PaymentOfUpfrontResearchFees
      contextRef="Duration_6_1_2019_To_6_30_2020_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Hf7j2O4nM06-u1HOfsgByg"
      decimals="-5"
      id="Narr_GNtNOKOBi0KmQJfPdkiu_Q"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">200000</trda:PaymentOfUpfrontResearchFees>
    <trda:AnnualLicenseMaintenanceFee
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_-TdaxQCqC0-mYAk7Hd2Eow"
      decimals="-5"
      id="Narr_7L2-3Q4SIkO6ZGe1YFEK7Q"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</trda:AnnualLicenseMaintenanceFee>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Cy9RrUM470ieiIVBwGRytQ"
      decimals="INF"
      id="Narr_auYfXHTItkyA6wbFAyNLVQ"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">86558</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_Cy9RrUM470ieiIVBwGRytQ"
      decimals="-5"
      id="Narr_pK5fVV_up0q2NqhPN0P2Cw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">200000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <trda:PotentialMilestonePaymentObligation
      contextRef="As_Of_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_jxCvIM-1WEOJ9WQF7LNJvg"
      decimals="-5"
      id="Narr_3dCr9hnazkOH4jyA_WIGFA"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">2600000</trda:PotentialMilestonePaymentObligation>
    <trda:LicenseAgreementNumberOfLicensedProducts
      contextRef="As_Of_12_31_2018_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_jxCvIM-1WEOJ9WQF7LNJvg"
      decimals="INF"
      id="Narr_iBo_VYVTtka50GS7OWXyEg"
      unitRef="Unit_Standard_item_qXeWDqcza0Kv2YWLNzbANQ">3</trda:LicenseAgreementNumberOfLicensedProducts>
    <trda:ExpensesRelatingToMilestoneObligation
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Narr_x-kPjBLizEmh9tWJBR2Iqw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</trda:ExpensesRelatingToMilestoneObligation>
    <trda:ExpensesRelatingToMilestoneObligation
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Narr_bLcnkZ1Z9UiCbm3NXA9Ciw"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">0</trda:ExpensesRelatingToMilestoneObligation>
    <trda:PaymentForPatentCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_FM5MwYyCLk66BYx1-YT-iA"
      decimals="-5"
      id="Narr_lnrdW6mnpEOcfC5TY66J9Q"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</trda:PaymentForPatentCosts>
    <trda:PaymentForPatentCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_trda_LicenseAgreementWithThirdPartyMember_RYC5_ZIHMEyAEsk0XkA_Hw"
      decimals="-5"
      id="Narr_-P0vLC1lc0Wh3-J6fqNXXQ"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">100000</trda:PaymentForPatentCosts>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_gWEQhYw-MUq8ijlpuLPFUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.17;text-indent:0pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10. Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company has a defined-contribution plan under Section 401(k) of the Code (401(k) Plan). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. As currently established, the Company is not required to make, and to date has not made, any contributions to the 401(k) Plan.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_9htQ_7pWwEWooaTC_fq_Pw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (51,158)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (26,523)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted&#x2011;average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,267,776&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,105,260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_JFF1gzEYxkmqNACNSLO4fA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8.16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KRMqqkYCvkiUV0MKGa8Rag;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24.00)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Common Stock Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Redeemable convertible preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,788,435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,537&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested shares from early exercises&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 111,756&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,461,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,625,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,573,626&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,453,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_V0VGbZ1g90OR8Y6W5IqaFg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (51,158)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (26,523)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted&#x2011;average common shares outstanding, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6,267,776&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,105,260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_JFF1gzEYxkmqNACNSLO4fA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8.16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KRMqqkYCvkiUV0MKGa8Rag;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24.00)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="-3"
      id="Tc_oDlLv4KsDEqZRRzqulTkLA_4_3"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-51158000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="-3"
      id="Tc_I79FtINnEky6c-HRDJPaZQ_4_6"
      unitRef="Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ">-26523000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="0"
      id="Tc_Nvtu9CBQjUKbTyxNSx0cug_6_3"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">6267776</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="0"
      id="Tc_EcQG0HBlIEeeOFthY4HFEQ_6_6"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1105260</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="2"
      id="Tc_dWpeIiIxz0ekYING7kkNBQ_7_3"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">-8.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="2"
      id="Tc_g2Zp0_R_nkmOIPxOChuX3A_7_6"
      unitRef="Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw">-24.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_Vz2z420ZHUeCPEeNm3BvnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Redeemable convertible preferred stock (as converted to common stock)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,788,435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 11,537&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested shares from early exercises&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 111,756&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 27,869&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,461,870&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 1,625,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 3,573,626&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"&gt; 13,453,097&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_Yg0eRdnrPE6oZY0L97BMQw"
      decimals="INF"
      id="Tc__0DekTInhUe2N_vslx_8wQ_3_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">11788435</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_BrM28n-jyUOi_DtOIFHwAg"
      decimals="INF"
      id="Tc_xve1ewk8CUWkurqIZfYRMw_4_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">11537</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_trda_UnvestedSharesMember_Yg75Vq-JeUiuqL-_773DFg"
      decimals="INF"
      id="Tc_SCvnGUs3sUKpgs48eHPddw_5_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">111756</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_trda_UnvestedSharesMember_ONz4dFb4f0-msro3DrkJBw"
      decimals="INF"
      id="Tc_65XwaZPYEkibIT4OTNMczw_5_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">27869</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_VeWTpBES60mrDvFGp33DJw"
      decimals="INF"
      id="Tc_2gwnqnHG6EeIYNokHHoPHg_6_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">3461870</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_EMioRKOEOUuK6W_DHnQC0w"
      decimals="INF"
      id="Tc_DrPeL5CZLkCirmqH413FjQ_6_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">1625256</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      decimals="INF"
      id="Tc_khm2vh68rkudkTeZZRJl1Q_7_2"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">3573626</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_Xt0P0x66OUij_brNb3BJPw"
      decimals="INF"
      id="Tc_G62gDcP0wkudYxJMeDX2XA_7_4"
      unitRef="Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g">13453097</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ"
      id="Tb_KVDvt4KitUutOAzudb1tHg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;For the year ended December&#160;&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;white-space:pre-wrap;"&gt;31, 2021, subsequent events were evaluated through  the date on which these consolidated financial statements were issued to determine if such events should be reflected in these consolidated financial statements&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;. The Company has concluded that no subsequent events have occurred that require disclosure.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>110
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  J/F]4Z*WB!SD&  "F&@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;*59;7/B-A#^?/T5&N:FTYL)8,N&P#7)#('08R[A*'!WDW;Z0=@"/+$E*LDA
M^?==F1>3&[-VVR_@MWWT>'?U[$J^VDKUI-><&_*2Q$)?U];&;#XVFSI8\X3I
MAMQP 7>64B7,P*E:-?5&<19F1DG<I([3;B8L$K6;J^S:1-U<R=3$D> 3172:
M)$R]WO)8;J]K;NUP81JMUL9>:-Y<;=B*S[CYNIDH.&L>4<(HX4)'4A#%E]>U
MGOMQX#O6('OB6\2W^N28V%=92/ED3T;A=<VQC'C, V,A&/P]\SZ/8XL$//[>
M@]:.8UK#T^,#^C![>7B9!=.\+^/O46C6U[5.C81\R=+83.7V$]^_4,OB!3+6
MV2_9[IYMM6LD2+61R=X8&"21V/VSE[TC3@Q\>L: [@WH#P:N?\; VQMX50W\
MO8&?>6;W*ID?!LRPFRLEMT39IP'-'F3.S*SA]2-AXSXS"NY&8&=N!C)((8R&
M,!&2.V$B\TI&8I=/-BYU\G4V(+^\_T#>DTB0ARB.X;*^:AH8W$(T@_U M[N!
MZ)F!7$H>I#!K#:.$/'P+T 361^KT0/V6HH@#'C2(YUX0ZE"W@% ?-Q_R18/0
M3F9."\P'N/E8/C>(TRH:_<W;>,= >!F>]Q\#\6=OH8V":?(7,IA_',S/!O/+
M!IN_;GA1+'%SUZE_1EBTCBQ:U5CTA$A93*9\(Y4IHH/C&)5RA$[[2*==C<Z$
MJTC:((0$YE2A?TJ0]IGYT[MW)=EQ>>1V63%@BH'F9AEQWETXUI+%&O-7Y\BI
M@^+LDW08Q9R,TV3!51$7',-QW+KO=-M=A$_WR*=;A<^4KR([4\!98Y841J\$
M9SR?]@8],O]T-^U-[K[.1_W9!1F-^PV$I.OD@NM4H3D2@500P&QV7Y"9@4PC
M4I&^3(51K_ ?%G(O01_<821/JH);A>2<O9!1"'D7+:-@IT/G(UT"V7'K7K?C
M>5TLUB[-&=(J#'MAJ+C6%X<#<@_/D2^BV'<X9)O,HY!#*!144XQDKNFN]Z](
M]NT9!'DNMZ*0( YW*Z$?$!BSO "XN(2_9;9/OR^*3)1\CD10[#X<\J&',<N+
M@HNK^8\^F\!+0W'X(]J<GQ,X(M1WU\&XY17"Q84]BU\/^NOS5'" 3NL2(Y*7
M Q?7\'L9@$\F:RDP[2T!:5&GWG5;'8Q17@S<2M7@.W3P]2<!^4UFG&G@%Y*1
MUND9@CCF6&+4\KK@5BH,WV0,T@J+FZQDJ>(>%D=""=&\!-!*):"?*F5K^JZ0
M1V*53<.TD%@)XB/7&+-<]VDEW1\)P]5N269;(':@6L@,1RQAENL]K:3W6>A(
M']1J)=5K(1\<9RQ%G04!+#RA]$)R9H 8PUSL:26QGR4LCLEMJN&V+HXECE/2
MSM)<XVDEC;]+N%K9[/H-$,P:I"O9,%'L.QRPC%FN\;22QM^]G/:SN[:[D!:.
M5M;0TES?*2[/H_YP2GII&!DHTCUC.)2>C-LP9JM"9CA>*;-<\"FNU8?D6H.^
MHA'\?[T_S?6>5M+[2;J(HP#\(UF1.@SV**T,Q6Y"/=_XEWX#>L#GHN%S3:>X
M$L\C \L.N20N_67Q 6I-D"K@4^@2' F<F4"$9T8&3Q=DPQ1Y9G'*R7NGX<#R
MA&Q ;_2:*<QM7B[]'B[4D.]AIO2OR4+&173+ *8#K,_R<JGW<&$^N QF8;!F
M8L7/+I=*@,:]V:#W.\8I%WFODLB_#<G,.E^3+ZF!V2BL]XHV>_;([9-$\US:
M<OV.7YQKWLG.#"[(!T$XZY^2NJ"$-N1GEFQ^)8^PNEN1^_L)YJY<X#U<CP_$
MAI%*R&A0R U'\"E&)-=S#U?@ Q';EEJ]+&2"0^S6-A?D@6G-@G6JN3%8Y^#E
MHN[A(GQ(*NA?%#3-(Q'R%_*9%VI%"905A':GZUVV,&:YJ'NX&A\:P&&D;3O_
MR$%\L%VG$KAZW:5U#]V,S.7=P^7]N.%TRFT(%PL[FA*PLBW27/4]7*M_9+7?
MJ3O/"X<;/F)[J;FF^[@D]X!2N*-UIDTH 3A;E9LG&_NVB\L^D&@2V#VBW1[_
M\>KQ(TPO^_30S!_??<%Y8+8)U"3F2S!U&I<P'=7NH\CNQ,A-]IE@(8V127:X
MYBSDRCX ]Y=2FL.)'>#X:>KF'U!+ P04    "  J/F]4@F8S%?L$  !#$@
M&    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U8VV[;.!#]%<(HL"W@Q+Q(
MLI4Z!E(GBQ;HMD&<[CXS,AT3E425I'+IU^]0MF5'HA1ONP^)*6DN9T:<.4--
M'Y7^;M9"6/24I;DY'ZRM+<Y&(Y.L1<;-J2I$#D]62F?<PJ6^'YE""[ZLE+)T
M1#&.1AF7^6 VK>Y=Z]E4E3:5N;C6R)19QO7S!Y&JQ_,!&>QNW,C[M74W1K-I
MP>_%0MAOQ;6&JU%M92DSD1NI<J3%ZGQP0<[FE#J%2N)O*1[-P1JY4.Z4^NXN
M/BW/!]@A$JE(K#/!X>=!S$6:.DN X\?6Z*#VZ10/USOK?U;!0S!WW(BY2O^1
M2[L^'TP&:"E6O$SMC7K\*+8!A<Y>HE)3_4>/6UD\0$EIK,JVRH @D_GFES]M
M$W&@0((.!;I5H,<JL*T"JP+=(*O"NN26SZ9:/2+MI,&:6U2YJ;0A&IF[U[BP
M&IY*T+.S^=<OBZ^?/UU>W%Y=H@\7GR^^S*_0XN/5U>T"G:!OBTOT]LT[] ;)
M'-VN56EXOC33D07/3G^4;+U\V'BA'5XN17**&!DBBBGQJ,^/5\<OU4<0;QTT
MK8.FE3W6%72IM<@MXL8(:\YZ+++:(JLL!ET6N5DCR U*W$+\*.4#3\&%-U<;
M4^/*E"NSAQF-"8Z"Z>CA,"=M,1;C(*RE7@ -:J!!+]!K+0HNET@\02,PPE2@
ME5T+#;OM,"L^X!O3T0&B<<2B!NRV$*#V@PYKT&$OZ%ME>7H$OK#EFL:3,<8-
MA&TQ%L=![,<8U1BC5Q(+K57;YRJA;@,4T.SL$.7"^J!&+0P1C4@#:%N(83;V
MXQS7.,>].+]6[SI7^<GK^1RW_$_&M(&Q+1,&Q ]Q4D.<'/&ZNV%-/&D))XPU
MD+7% A;2CO3%-;;XJ-:12GXG4VFEZ.T?!._[,.X-^B))5 D- Q7\F=^EPMMD
M<;L <;/^/$(DPM0?-CG@"?(:/EV*WL9QD!,O>M+>\Y@TWYI'BHS#CK=&]AV?
MT/_00EY#2MM(QR1N(FU+,19VM!&R9Q+23R678B4 Y1+I7?] :E4C+Y1VXX\7
M-?/TM:@#SIXO2#]A;!+W6L(\S$!(V$Q86ZHG87MR(/WL,%=9)JWKMIM-F:C<
MROQ>Y F@16^_*"M0_,X+N]>PFZ#/3,$3<3Z $=D(_2 &,^0=7W[?T,O@]ZQ#
M^FGG1BP%#/;0,%S<#\! TJW!S787P029?!]"5]$(1I)2H#?X%&-,MHF)?(F9
MDS;S3$@43CI>U9Y[R+BW>RX<F+5*ET*;/]!;&+=E(NV[BB_M<V\CW9,'Z6</
MMQW@?- 5]WM$0CR$E?NK]@LA;$C#>,APA,R::]?;2KM66OZ$_''CR@\F4)'=
M0:_;#;&59O,N'D+1FD)41Y/T^;V[SU@TQ#'=>!K2"1N&0;CS(XTI_P<?E ;.
MS\Y'$ P)BW<^X.QF+#R!DO@=1][Z\3!QL^9[7]8O5,:>J$G<3UC+I72M$KJ7
MFWA/X 23\$)"-_.&$GN:)V63YE#ND2/5F<97&'3/_O15]B^S,N46=L.V*GPH
M:9O;3V(614UJ\LD%-"1=./=3 .V? C9L8'K+V N\S>IN-">3)O"VW$E @AAW
M #\X\1W#_P<TYG;W,:VSJHU?")BV3V^^(=4CYYM21P<G?/=YY2^N[V5N4"I6
MH(=/QT! >O/%8G-A55$=^N^4M2JKEFO! ;\3@.<K!=U_>^&^(]3?C6;_ E!+
M P04    "  J/F]4B7$7ZJ "  "+!P  &    'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;*U5:T_;,!3]*U:T#R"QYIT":B.5M!-(#"K*ML]N<MM8.'9F.RWL
MU\].0E9*>&KYD/AQS_$YU_'U:,O%G<P!%+HO*)-C*U>J/+5MF>908#G@)3 ]
ML^*BP$IWQ=J6I0"<U:""VI[C1':!";/B43TV%_&(5XH2!G.!9%446#R< >7;
ML>5:CP,W9)TK,V#'HQ*O80'J1SD7NF=W+!DI@$G"&1*P&EL3]S09FO@ZX">!
MK=QI(^-DR?F=Z5QD8\LQ@H!"J@P#UI\-)$"I(=(R?K><5K>D >ZV']F_U=ZU
MER66D'#ZBV0J'UO'%LI@A2NJ;OCV'%H_H>%+.97U&VW;6,=":245+UJP5E 0
MUGSQ?9N''8 ;O #P6H#W7H#? OS::*.LMC7%"L<CP;=(F&C-9AIU;FJT=D.8
MV<6%$GJ6:)R*D^NKQ?7EQ71R.YNBL\GEY"J9H<7Y;':[0 =S+("I'!1),3U$
M7]$79".9ZU$YLI5>W7#8:;O26;.2]\)*4T@'R'>/D.=X;@\\>3_<>0JWM>?.
MN-<9]VH^_^/&7V'W.W:_9@]>8+^!#/1Q6U) *6<;$(J8MCYH*Q ",J0W-KT[
M0B46:(-II:= -*E%!X2AC%.*A?PW>MB7\$;#<:W!'-=-[ P<Q]'9W>PF]LVP
M)Q:#SF+PJL6$%X4^A__%2/ ^(V^&/3$2=D;"#QAI?N\CA"N5<T'^0-8GN&&,
M=I2XH=,\>YI[(EW?"T]\)^J7'76RHT_()E)6_9*C9T)\U_<CY\3;4_P\T/6.
M_3 (^_4..[W#3^C5%XM4F&6$K?M$#WM$>UZ@=>^)?A[H>D'@^B=[HNV=4FFN
MJ>]8K F3B,)*(YW!4.^7:$I_TU&\K*OGDBM=B^MFKF]+$"9 SZ\X5X\=4Y"[
M^S?^"U!+ P04    "  J/F]4Y'[[U,@#  #2#   &    'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;+67VV[B.A2&7\5"<]%*;1,[)$ %2"UT]JXT+55A]EP;
MLB!1DYBQ#73>?J\X(:3DH/9B;LAIK=_?[^-B>!#R304 FKS'4:)&G4#K[:UE
MJ54 ,5<W8@L)?ED+&7.-CW)CJ:T$[IND.+*8;7M6S,.D,QZ:=R]R/!0['84)
MO$BB=G',Y9][B,1AU*&=XXO7<!/H](4U'F[Y!N:@?VY?)#Y9A8H?QI"H4"1$
MPGK4N:.W$^JF"2;BOQ .JG1/4BM+(=[2AT=_U+%3(HA@I5,)CI<]3""*4B7D
M^)V+=HHVT\3R_5']NS&/9I9<P41$OT)?!Z-.OT-\6/-=I%_%X5_(#1G E8B4
M^26'/-;ND-5.:1'GR4@0ATEVY>]Y1Y02J->0P/($=I[0;4AP\@3'&,W(C*TI
MUWP\E.) 9!J-:NF-Z1N3C6[")!W&N9;X-<0\/9[,GN>S'X_3N\7#E,P7>'EZ
M>%[,R>P[F;T\O-XM'C& 7).?\RFY^'9)OI$P(8M [!1/?#6T-#*D2M8J;^\^
M:X\UM$<9>1*)#A1Y2'SP/PI8"%\X8$<']ZQ5<0JK&^+0*\)L1FN )I]/MUMP
MG*)#':/G-.C-MB"Y#I,-@7=<:PK4;8MJMU#M&M5N@^HK*.!R%1#L=9RE>UQ^
M6UQ,NFX ,J6>44I7\7[LN /F#:U]N5>J48Q2FQ51'S#= M-MQ?P'$G0?&4KN
MXW0-E4Y[8P]UH)F65T*@+K/I&6@URG4]MY[3*SB]5LZ%T$@I*D-51^E5VZ>4
M]<XHJU',\[Q>/6:OP.RU8OX02I&U%/$1522UB+U*X]=UC#5A+9#] K+?/N%U
M ))<Y%UXB?O#2L30-ND'A?*@U?YCHD&"TF8ZB=IFKD@"M8M@4/7JG,^L:@SM
M=NL[@]JG_=3^S-3Z&FVNV8Y;$]3,6]K_:2OO,Y8*$<ZS6BQ:V232B>7VS\EJ
MXICG,J<!CIW@V*?@"$Y_H@(N@7"M9;C<:;Z,@&A!L%]C+ ?PH%R]!2+R0:JK
M]& /5^0"CRI?1!&7)8'+6J,9QJ!LH']#S_?,/.RCSZ81.!T8U/DK)OTPVFGP
MOV+3^9Q-YPLV3R<8;3_"?IF*"OQKOL>]; .%J117$2PQE<:%CMMQ>?RRK_5N
MNI7UX#&OU^M5_%0#\:ASF6<W>#H==[3]O/N*I_)PM;FJGG<-KFJ.SUI75JDZ
MC$%N3-&L$'67Z*S,*MX6A?F=*4?/WM^G!;NI.D\R6;7_Q.4F3!2)8(V2]DT/
MV6160&</6FQ-#;H4&BM:<QO@GPZ0:0!^7PNACP]I \7?F/'_4$L#!!0    (
M "H^;U24,X3ZFP8  &$A   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
MS5IM3]M($/XKJZA2B]0TWEV_5H!$$D.CH\ E:4^GTWTP]H98M;VI[4#[[V_M
M&+_M2X!KN/M"[&1F]MF9V7EF;(X?:/HM6Q.2@Q]QE&0G@W6>;SZ.1IF_)K&7
M?: ;DK!?5C2-O9S=IG>C;),2+RB5XFB$-,T<Q5Z8#$Z/R^]NTM-CNLVC,"$W
M*<BV<>RE/\<DH@\G SAX_&(>WJWSXHO1Z?'&NR,+DG_9W*3L;E1;"<*8)%E(
M$Y"2U<G@#'Z\T$N%4N)K2!ZRUC4HMG)+Z;?B9A:<#+0"$8F(GQ<F//9Q3R8D
MB@I+#,?WRNB@7K-0;%\_6C\O-\\V<^ME9$*C/\(@7Y\,[ $(R,K;1OF</GPB
MU8:,PIY/HZS\"QXJ66T _&V6T[A29@CB,-E]>C\J1[04()8HH$H!]120)5'
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MPI=]N2P(=!SX!9QO/09J=\,&AM]KKG\'4$L#!!0    ( "H^;U1D1D6N,!T
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M1?4H0,+ZTEL-Q(0N7)&SVMW1" NGU>02#%>'QA$K8D5#.M-E5WH1'!I"!.[
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M[H<_1K?CEQ&3S(UNRQ\WUI UQ0/T^\H1A_0/'!#?3OW3_P!02P,$%     @
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MU^0:#R:C '3+O:U@5>WY;J4LL:=?EO1<H78&I%\K90^""] ]@,O?4$L#!!0
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M;0OZZJ"R +K/I32]80,,W['U7U!+ P04    "  J/F]4CZS&'E@0   $/@
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MC-_"REM>"W2]U160O8@#9PR1G>F83T\0^(SQ&EBH')F5D@EA?C*=;%;K):M
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M;3K=710&IR.4=_M-V],K5Z$@:1A2$RN.,UK H'L;43D^Y 6DW,@W<F4!=!_
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M-@L@>Z*\:I#FIC5#&H/3H9MPXF\B4^QHIQJ*K-[JV"DYYY(5I/+1FD>"E*X
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M1B3*KN*>%\5%')!(0(LTE[:MPJ&+T.!O-UL#IP.? 7_AH9UFQH']*CL\4CA
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MCIF)L)[K]U(K6&$8V'6\<&-C4 H;]*H<AR6N#[2FTIUN=Z;QIB"143%:1_C
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MK&=43:=(G!0F:1-_<SKC0M048/TLXHO.IE%!GU-$XD\)(O%XL/I7)BP^'T-
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MV\H]?JA]@/,71/9X\ +]<[KX#5!+ P04    "  J/F]4Z)O;10,#  #J"0
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M(-G>[_16)&%GID<;)4NO.O._A?;:F^$%FR+YKS=%=W][[V#WF:O8.#W>$B_
M6G=+Q"OW;XEV&EX9#C)3::JOXE;:/F2.Z_O[IWG]"CH7=BJUXW-PPJ[)SMYN
M!+9^6=03,K-PFX\-\=L@_!;\&$/K#5@_,8:6$Q^@?=X-?P!02P,$%     @
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MO@>Z'7JM8E75#)JELC2V&K&@_P1J!Z#S7"F[59R#[L\S^P-02P,$%     @
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M/@#M[PQ?W""- ,Y/A-!UQVS0O.'/_P502P,$%     @ *CYO5(*<%=#^ P
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MM\UQ, =E&?!_)J79'>P%S:@_^Q]02P,$%     @ *CYO5.2N"TE? @  C04
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M[2W;"+0G\]A1+H^(BQWOJN?-7N!-,[@DJL;"1U5B^90@)I&#TFRO=)4=9;S
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M025B.7K*F9)7\!#&GQ)>2I+'<F8J8*+MF5'C]:;V:@]XO8_4!-GV%;(M&_?
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M#?71*LJ>J)PHOK5MQ88KW:388:[[2!#&0+]/.5>'B0E0=Z;3OU!+ P04
M"  J/F]44IZK2:H"  !B"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6RE5EUOFS 4_2L6ZD,K;05#OJ@2I#91M4FK5#5M]^R2FV#5X-0V22OUQ\\V
MA)"%T&QY 1ON.?>>@[GV<,W%JTP %'I/629'3J+4\LIU99Q 2N0E7T*FW\RY
M2(G24[%PY5( F5E0RES?\WIN2FCF1$/[[%Y$0YXK1C.X%TCF:4K$QPTPOAXY
MV-D\>*"+1)D';C1<D@5,03TM[X6>N17+C*:02<HS)& ^<J[QU1AW#<!&/%-8
MR]H8&2DOG+^:R<_9R/%,1< @5H:"Z-L*QL"88=)UO)6D3I73 .OC#?NM%:_%
MO! )8\Y^TYE*1L[ 03.8DYRI![[^ :4@6V#,F;17M"YBNZ&#XEPJGI9@74%*
ML^).WDLC:@#<.0#P2X!_+" H 8$56E1F94V((M%0\#42)EJSF8'UQJ*U&IJ9
MSSA50K^E&J>B6T(%>B8L!W0'1.8"]#=2$IU/0!'*Y 7ZCIZF$W1^=H'.$,W0
M8\)S2;*9'+I*YS<L;ESFNBER^0=R32"^1 '^AGS/QPWP\?%P;Q?N:M65=+^2
M[EN^X #?M92@Y%4+4U Q!9:I<X!I3&2"X"VG*\*,>TW6% Q]RV#^K57DAQA[
M6LBJ;L%^6!!ZM:B=^CI5?9W6^AX@SH6@V:)%:[?BZI[H6J]BZK56]<@584U6
M%;#>CE7> '?^LFH_+!CTPVZS5?VJJ/YQ5J%/=,<S^- _FWC5[72>[ZWYG02#
M*L'@1/_"BBD\>=6%QUFY']9B)?:VO<4[VLQ?L *&<(MN7.M9^$0/\;8)8/__
M5F&)^]*[AK@V\[8]!;<WE0;S_G5-XFV#P)U3'=TV"-P]>5V6%/TOS=V/:S+7
MK6V YO1Q1\2"9A(QF&N<=]G7-*+8T(N)XDN[)[YPI7=8.TST(0B$"=#OYYRK
MS<1LL]6Q*OH#4$L#!!0    ( "H^;U0VH'H_=0,   \-   9    >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;+U746^;,!#^*Q;:PR9U!9N$)%42J4TV;5([
M16N[/4Q[<.$2K %FMFG:?S_;)$ (8=.D]B78YNZ[[S[;EV.ZY>*7C $4>DJ3
M3,Z<6*G\PG5E&$-*Y3G/(=-OUERD5.FIV+@R%T CZY0F+O&\P$TIRYSYU*ZM
MQ'S*"Y6P#%8"R2)-J7B^@H1O9PYV]@M?V2969L&=3W.Z@5M0]_E*Z)E;H40L
MA4PRGB$!ZYESB2\6>&(<K,4W!EO9&".3R@/GO\SD<S1S/,,($@B5@:#Z\0@+
M2!*#I'G\WH$Z54SCV!SOT3_:Y'4R#U3"@B??6:3BF3-V4 1K6B3J*]]^@EU"
M0X,7\D3:7[0M;0/?06$A%4]WSII!RK+R29]V0C0<<'#"@>P<2-MA<,+!WSGX
M-M&2F4UK216=3P7?(F&L-9H96&VLM\Z&968;;Y70;YGV4_.5T"="J&=$LPA]
M^%VP7.^1.D-?] EZNP1%62+?H??H_G:)WKYYA]X@EJ&[F!=2.\BIJS0'@^2&
MNWA793QR(AXFZ(9G*I;H0Q9!= C@:O)5!F2?P17I15Q">(Y\?(:(1W 'H<6_
MNWL]=/Q*4-_B^7\1] RM$IJI0UW1CVMMCCXK2.7/GF"#*MC !AN<"';'%4U0
M7H7,JY"P#]FU127HR(*:>_XX'P6CT=1];,IV;.0/\* R.N [K/@.>_E>@Y07
MZ#(,B[1(J()(WSA=?4)&S9WNHEKB!0T6[_$ !RVN'59^(Z$#KD'%->CENNI3
M]0QET"EM<,0D( %NT3TV\CW_!-U117?42W?9$!+!DR[S$KH(CHYB8XS;>W]L
MY).@F]^XXC?NWWKZP 557#R?.IL'L),*=O+RUPU[=;7T7N+"[5";@@XGXW%+
M]0XK@@GNUATW*CSNY?RQ$!E3A0#+<\V>S%CVR4%J:/(*ZM>E%?LOHKY_I.ND
M74$Z;/#XA/)U=<;]Y7G!T[Q0(/[IQ..ZB.+A*ZA>UT'<7PC_5_6.*M>N,QTV
MA)Q0O2Z$N+\27H-NZV*>1(BEFO4C&(:]Y[VN87C\"LK7M0U/7D3YR=%?-QX.
MCTY\AQ49^BWUW49KF8+8V(Y;HI 7F2I[M&JUZNHO;2_;6K\RW;YM66N8\E/A
MAHH-RR1*8*TAO?.1/OVB[+[+B>*Y;6 ?N-+ML!W&^HL%A#'0[]><J_W$!*B^
M@>9_ %!+ P04    "  J/F]4\T^=A;,"  !G!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6RME6UOFS 0Q[^*A?JBE;;R'+J*(+5)]R!M6M6'[;4#
M1[!J;&:;)/WVLPU%-"317NQ-L/'][WYW\1WIEHL760$HM*LIDW.G4JJY=EV9
M5U!C><D;8/JDY*+&2F_%VI6- %Q844W=P/-F;HT)<[+4OKL76<I;10F#>X%D
M6]=8O-X"Y=NYXSMO+Q[(NE+FA9NE#5[#(ZCGYE[HG3MX*4@-3!+.D(!R[MSX
MUXO$V%N#7P2V<K1&)I,5YR]F\ZV8.YX! @JY,AZP?FQ@ 90:1QKC3^_3&4(:
MX7C]YOVSS5WGLL(2%IS^)H6JYLZ5@PHH<4O5 ]]^A3Z?V/C+.97V%VU[6\]!
M>2L5KWNQ)J@)ZYYXU]=A)/"C(X*@%P3_*@A[06@3[<AL6DNL<)8*OD7"6&MO
M9F%K8]4Z&\+,O_BHA#XE6J>RFSP7+13H;J?OA02),"O03U6!0(M6"& *?2=X
M12A11)^>+T%A0N4%^HB>'Y?H_.P"G2'"T%/%6ZFU,G65QC+.W;Q'N.T0@B,(
M2\@O4>A_0($7^ ?DBW^7>^_EKB[&4)%@J$A@_87_I2(G H9#P- &C(X$O*L;
MRE\!4,YK$Q)W]UM'70&#DJB#->U\)M:G:=5-%GE)DKJ;<>6F1GYT%0Q&[W"C
M 3<ZC;M3(!BFNH<E8)%7%K6 C9X(36W* WWE#F%WOF=C(B\,]K /& 7Q8>IX
MH(Y/4G_1I10:VK#B0C<2D4I@,T)0(W@)THPE?2Y!;$@.)W.()WB1_VDOA:E-
M>"2#V9#![&0&]@H>PIE-<:[B/9RIC>\?X4D&GN0DSQ-7IIY]M\"X6[CMEKSO
M%GJL6SK\9')'9YX?[O%/C?PD3O82<$=CT'R"?F"Q)DPB"J66>9>)_E-$-]:[
MC>*-G8PKKO2<M<M*?PE!& -]7G*NWC9FV [?UNPO4$L#!!0    ( "H^;U0Z
M5$Y#YP,  &T1   9    >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;,68:X^;
M.!2&_XJ%^J&5N@,V$*!*(DV3KK92=S6:]/+9 TYB#>#4-DF[OWYMPP )ES#5
MK/IEALMY#^_QL1]#YB?&'\6>$ E^9&DN%M9>RL,[VQ;QGF18W+ #R=6=+>,9
MENJ4[VQQX 0G1I2E-G*<F9UAFEO+N;EVQY=S5LB4YN2. U%D&>8_WY.4G186
MM)XNW-/=7NH+]G)^P#NR(?++X8ZK,[O.DM",Y(*R''"R75BW\-T'Y&F!B?A*
MR4FTCH$NY8&Q1WWR,5E8CG9$4A)+G0*K?T>R(FFJ,RD?WZND5OU,+6P?/V7_
MTQ2OBGG @JQ8^HTF<K^P0@LD9(N+5-ZSTU^D*LC7^6*6"O,7G*I8QP)Q(23+
M*K%RD-&\_(]_5 /1$D!O0( J 9HJ<"N!.U7@50)OJL"O!*9TNZS=#-P:2[R<
M<W8"7$>K;/K C+Y1J_&BN9XH&\G57:IT<GE/$J*FWD-*P(KE1\(EU<=WJEV$
M<Y* C63QXUMU,\M47\T9P'ER&0'^ --2@==K(C%-Q1LE^;)9@]>OWH!7@.;@
M\YX50J46<UNJRK0_.ZZJ>%]6@0:J6)/X!KCP+4 .@CWRU;C\'W94<F=0OI[^
M=*='_F&R'$;G<EMULVXIJEN*3#[W?V[IB!6WMN(:*]Z E<O>WQ9RSSC]ER1]
M/2YSS4PN#;CC4HWFL=V';D3HHR@*0[\.///IU3Z]9_G\*$31[]&[ZK$;,>[1
MKSWZ$ST*XU%17TC5-IKO^HSZ5XUV(SI&R^G;#70#-(N@%_57-*LKFHU6M,*<
M_U3VP5><%J1OW97ZH&T1SOSPPE\WRH4JKM]<4)L+1LU]HM\+FF"SFY5#3_*X
MUV30-1FZ0=#_^+!^?#@^-N7B+%M-U70TZ[DXJ&NQ6=1ZI^XC7=AI%HQ@Z,/0
MO6A_3R ,PM!S!^9I5#N/1IUO"*=$@ U1,Y4W*(I;*#J<3^41T$"GV<><WTT]
MV-I4X<MQ;UTE:[<"><@)O($I#)N= **7X=JZ2C3=0[,%P*E[P!1NK6&7\>-&
M&L;#<<A?QTV5H+V4D3.# P]NP W'R3T=)56B,P/0<08,-)R%5T#[BS!95WG/
MT.]ZOC< -]C %8[3M8+$[<27QK%%V1 5AK^=$ TDX3@EGTF(J+M7HS"(H#NP
M!:.&F\AY(414B9YAHN$EFLK+28Q 76!><=)Z=QXGYG5(5 G::S2(_&A@2:"&
MDVB<D],I424Z>^.8H:$W#M0 $ET!Y*]B G7?>2'T?#<,PPM/=NM+5?\0\3?F
M.YH+D)*MDCHW@0(@+[_MRQ/)#N;C]8%)]2EL#O<$)X3K '5_RYA\.M'?P_4O
M+,O_ %!+ P04    "  J/F]4I@_<OTP%   >&@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6S%65MOVS84_BN$T8<6Z&R2NKI(#,1VVB1%L:!9MV=&
MHFVBDNB1=)("VW\?*;&ZV+JA31<$B'7YOG/E.8>2SAZY^"IWE"KPE":9/)_L
ME-J_F\UDM*,ID5.^IYF^L^$B)4J?BNU,[@4E<4Y*DQF&T)^EA&63Q5E^[58L
MSOA!)2RCMP+(0YH2\6U)$_YX/D&3[Q<^L^U.F0NSQ=F>;.D=55_VMT*?S4HI
M,4MI)AG/@*";\\D%>O?1@8:0(_YD]%'6CH%QY9[SK^;D.CZ?0&,136BDC BB
M?Q[HBB:)D:3M^-L*G90Z#;%^_%WZ^]QY[<P]D73%D[]8K';GDW "8KHAAT1]
MYH]7U#KD&7D13V3^'SQ:+)R Z" 53RU96Y"RK/@E3S80-0)R.PC8$O!8@F,)
MSEB":PGN6()G"=XQP>D@^);@C]406$(PEA!:0CC6I+DES,=J0/![YN!H2IGL
M8M$5JR1?8FNBR.),\$<@#%[+,P?Y.LWY>F6QS)34G1+Z+M,\M?A,8ZJ+]#ZA
M8,6S!RH4,\>W>F%3(6@,[A2/OK[5-]-45T!^!D@6'R/ ;V"<* V\B&-FZHDD
MX#HKNH*IKM=KJ@A+Y!L-^7*W!J]?O0&OP S('1%4 I:!+QE3\JV^J(__V/&#
MU(;(LYG2<3#>S"+K\[+P&7?X_(F(*<#SMP!#C%KHJW[ZQ6$[!0CG=-A"7_?3
M;TBFM7?3+_OI:QII[:ZAH["%_G[(]V\ ^3D[:&%_&!$YZ'32K_KIOT=*NQ[D
M=+^%?OU3MM^,")R#.K/^<3S]*&TS77-EX>&R\' NS_G%A==CBE.:XN2FN!VF
MW H>41I+L!$\!4S* P5\HP=F:6%4LW!?ZI>G^HM$%.J"7)V9Z0\+A+S0T5%_
MJ ?\%.;.0Q>7J(8S;NF,V^O,'15,=XL[[= />=!0ZI5*O9=.IE^:XO?[;[NE
MR6+<UA\*NM],#@Z<H)F=#Z<X+_ =/VS"KDYA_ASY+FK/8E!Z$?0OR8.(=GJG
MI'/%(@I>ZX8?\R0A0H);*HJ1\&^;=X78L&8.G(9^X!TY-PYV-0YV/0YV,PAK
MA"HL0Q7^K]7[/CRM7@CA40!/0=XQYNH4X]<P#6?GI;/S9ZYN\ _X1)Y8>DA[
MB@O!:KL$7[K246WOAGJC<:V33;+(^"]5VT;HV@HX2F9[#E UNA >DX6+D5N^
M/E^K&86<%P]\-6/0P) 9:+(KRZ^W1>Q"Y)WTS_5HY.5HY,<6I!M"!P:.WY'Z
M:M A[Y<TYI65BU!]*4ZABX[C,0YW.1)W,XQK1J*:LZA_T#YWWUU9??5:Q=Y)
MYUV/@UT.PIIN5X,9]4_FB^U6T"U1M'PNZRJ"2RNIO@P=-]1_T.FPHIIYJ'_H
M#7:^%6H=8QUZJ_&#!N9/W6?S&"KULZO<D.+]D$Z_+HLL8GO]:&MZ#\L4U7@%
M],WZ:LBXHFU67UKUC=T9#!T'.AV[!%Q-+@Q[35\=ZP?\H*329K)LVV:+E5>/
MX+QS >%J:.'^H54+85XEAWW^9FW'Z --::9,%"-M*#'1W=.(;9@.=<H2'4>>
MM8?-JNQMC4US:X]ISSKK1FTW<#7U\(M//5Q-/=P_]0:+;FT%C"HZ7,T<W#]S
M; J6/[_=P%5WQ_Z+![[JN;B_YPYM-Y;XM--ZCH<QG,^/QN$89-/*JB?C@0>1
M']P:+*W<QHC&4Q3@8]L'<4W+JZZ.^[OZ<X_RI=77? /BXZY2<*HF[O0W\<$2
M7#JG7=L]T3NKO3 V7TX^$;%EF00)W6@6G :Z($7Q,:(X47R?OT.^YTKQ-#_<
M41)380#Z_H;KB6)/S&OI\I/0XC]02P,$%     @ *CYO5,$$[\8\!   HQ(
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M3Y#>?HGWMI2C?]#=PVIEVT'VQDKP^\@\Z0V6V&VQ71,<]$E/6QI]4GMWNB[
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M-,Z!UPNM:6>X#?K7<OX'4$L#!!0    ( "H^;U0CKPTW-@(  &P%   9
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MT;$#1X79Q(H.L=XCJ\<'&HX!AE< N0CV %H.-W<M<'!#/2[]88._OW?9,^6
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M[2;@\[E2]NW&+5#WDJ/_ 5!+ P04    "  J/F]4<3E1S1,"  #I!   &0
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MWR)4SL'NUU*:H^$.&%^WXB]02P,$%     @ *CYO5(!,ZD$; P  TPD  !D
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MWQJF0*DATF[\KCF=QJ0![H]W[ ]6N]:RQ!*FG/X@B<I&SK6#$DAQ2=6<;[Y
MK>?2\,6<2ON+-O5>WT%Q*17/:[#V(">L^L?;.@Y[@*!_!!#6@/ ]H'<$$-6
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M>3J.+E3IQHPC/[=QRVT\R.T?78#TT1EW=T=G!W5CLI[],VGI3 ;I/ M-N<\
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M30/*&N#S3$IS&-@%FJ^DR;]02P,$%     @ *CYO5/^70B4; @  XP0  !D
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M\(BT!F9^)83>=^P"5<TX^0M02P,$%     @ *CYO5).;>=P- P  UPH  !D
M  !X;"]W;W)K<VAE971S+W-H965T-38N>&ULO5;?;YLP$/Y7+)XV:2L8 B15
M$JE)-VW2.E6-NCT3N 2K!C/;)-U_O[,AY'?4AZPO8)N[[[[[#HX;KH5\43F
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M_.LW^>TUK779'/)9][G$Y!-02P$"% ,4    "  J/F]4!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M "H^;U06?EJ>[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( "H^;U297)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ *CYO5.BM
MX@<Y!@  IAH  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( "H^;U2"9C,5^P0  $,2   8
M  " @7T.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  J
M/F]4B7$7ZJ "  "+!P  &               @(&N$P  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ *CYO5.1^^]3( P  T@P  !@
M         ("!A!8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( "H^;U24,X3ZFP8  &$A   8              " @8(:  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  J/F]45. =9[ "  "W!@
M&               @(%3(0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ *CYO5)IE0F$,!@  Z!<  !@              ("!.20  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( "H^;U3>7M6RK0<
M +L1   8              " @7LJ  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    "  J/F]49$9%KC =  "I6@  &               @(%>
M,@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ *CYO5.](
M"P_[ @  T D  !D              ("!Q$\  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    "  J/F]4'*$;&>\"   ,!P  &0
M    @('V4@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M "H^;U2N?%8VL@(  -,&   9              " @1Q6  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ *CYO5(^LQAY8$   !#X  !D
M             ("!!5D  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    "  J/F]4>RW-V9<,  #"*   &0              @(&4:0  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( "H^;U3S=+4KRPH
M #,A   9              " @6)V  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ *CYO5/<>?LLV"0  B!@  !D              ("!
M9($  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  J/F]4
M7)RWT*P"  #T!0  &0              @('1B@  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( "H^;U1N&)M3U ,  (8)   9
M      " @;2-  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ *CYO5&RU3*%S @  IP4  !D              ("!OY$  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  J/F]4U<PZ1Z<>  #-90
M&0              @(%IE   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( "H^;U0KS+A%5P(  %H%   9              " @4>S  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ *CYO5.B;VT4#
M P  Z@D  !D              ("!U;4  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    "  J/F]4Y9BW"L8"  "%!@  &0
M@($/N0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( "H^
M;U3Q+]^0Q (  *X&   9              " @0R\  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ *CYO5)WUS5N, P  50H  !D
M         ("!![\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    "  J/F]4;4*1D" %  #/#P  &0              @('*P@  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( "H^;U2"G!70_@,  /8+
M   9              " @2'(  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ *CYO5.2N"TE? @  C04  !D              ("!5LP
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  J/F]4PS1H
MM8$#   Q"0  &0              @('LS@  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( "H^;U1V;'QD[P,  ,4-   9
M  " @:32  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M*CYO5 W33%1] @  FP<  !D              ("!RM8  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    "  J/F]4:%9EG0L#  "E"@  &0
M            @(%^V0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( "H^;U12GJM)J@(  &()   9              " @<#<  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ *CYO5#:@>C]U P
M#PT  !D              ("!H=\  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    "  J/F]4\T^=A;,"  !G!P  &0              @(%-
MXP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( "H^;U0Z
M5$Y#YP,  &T1   9              " @3?F  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ *CYO5*8/W+],!0  'AH  !D
M     ("!5>H  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "H^;U1MTYR1#00  (L0   9              "
M@4#]  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ *CYO
M5 5O(0<E P  Y@L  !D              ("!A $! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    "  J/F]4Y&$\FZ0"   Y!P  &0
M        @('@! $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( "H^;U0CKPTW-@(  &P%   9              " @;L' 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ *CYO5(^B*M0K!0  )A8
M !D              ("!* H! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    "  J/F]4*JTC ,(#  !7#@  &0              @(&*#P$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( "H^;U1Q.5'-
M$P(  .D$   9              " @8,3 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ *CYO5(!,ZD$; P  TPD  !D
M ("!S14! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  J
M/F]4/_#N7(0#  #H"P  &0              @($?&0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( "H^;U3.1NJH9P,  /,+   9
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M970U-2YX;6Q02P$"% ,4    "  J/F]4DYMYW T#  #7"@  &0
M    @('B+0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M "H^;U3UXVB20P,  /@4   -              "  28Q 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ *CYO5)>*NQS     $P(   L              ( !
ME#0! %]R96QS+RYR96QS4$L! A0#%     @ *CYO5!7<X(2=!   F24   \
M             ( !?34! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "H^
M;U0,/Y#\Y0$  '\A   :              "  4<Z 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( "H^;U2/X;=ITP$  #8A   3
M          "  60\ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !  $
*=Q$  &@^ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>117</ContextCount>
  <ElementCount>364</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockTables</Role>
      <ShortName>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Nature of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails</Role>
      <ShortName>Nature of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureNatureOfBusiness</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Estimated useful life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated useful life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Conversion Right and Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Conversion Right and Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40604 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Voting Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Voting Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40605 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Common Stock and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Common Stock and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40606 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stock Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails</Role>
      <ShortName>Stock Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Stock Based Compensation - Compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails</Role>
      <ShortName>Stock Based Compensation - Compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Stock Based Compensation - Stock Option Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails</Role>
      <ShortName>Stock Based Compensation - Stock Option Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Stock Based Compensation - Early Exercise of Unvested Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureStockBasedCompensationEarlyExerciseOfUnvestedStockOptionsDetails</Role>
      <ShortName>Stock Based Compensation - Early Exercise of Unvested Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40705 - Disclosure - Stock Based Compensation - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock Based Compensation - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40706 - Disclosure - Stock Based Compensation - Restricted Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails</Role>
      <ShortName>Stock Based Compensation - Restricted Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Income Taxes - Reconciliation of U.S. federal statutory income tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of U.S. federal statutory income tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Income Taxes - Net deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Net deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40804 - Disclosure - Income Taxes - Operating loss carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Operating loss carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Commitments and Contingencies - Minimum aggregate future lease commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Minimum aggregate future lease commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Commitments and Contingencies - License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails</Role>
      <ShortName>Commitments and Contingencies - License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.entradatx.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="trda-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Net Loss per Share - Antidilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss per Share - Antidilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="trda-20211231x10k.htm">trda-20211231x10k.htm</File>
    <File>trda-20211231.xsd</File>
    <File>trda-20211231_cal.xml</File>
    <File>trda-20211231_def.xml</File>
    <File>trda-20211231_lab.xml</File>
    <File>trda-20211231_pre.xml</File>
    <File>trda-20211231xex21d1.htm</File>
    <File>trda-20211231xex23d1.htm</File>
    <File>trda-20211231xex31d1.htm</File>
    <File>trda-20211231xex31d2.htm</File>
    <File>trda-20211231xex32d1.htm</File>
    <File>trda-20211231xex4d3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>trda-20211231x10k006.jpg</File>
    <File>trda-20211231x10k007.jpg</File>
    <File>trda-20211231x10k008.jpg</File>
    <File>trda-20211231x10k009.jpg</File>
    <File>trda-20211231x10k010.jpg</File>
    <File>trda-20211231x10k011.jpg</File>
    <File>trda-20211231x10k012.jpg</File>
    <File>trda-20211231x10k013.jpg</File>
    <File>trda-20211231x10k014.jpg</File>
    <File>trda-20211231x10k015.jpg</File>
    <File>trda-20211231x10k016.jpg</File>
    <File>trda-20211231x10k017.jpg</File>
    <File>trda-20211231x10k018.jpg</File>
    <File>trda-20211231x10k019.jpg</File>
    <File>trda-20211231x10k020.jpg</File>
    <File>trda-20211231x10k021.jpg</File>
    <File>trda-20211231x10k022.jpg</File>
    <File>trda-20211231x10k023.jpg</File>
    <File>trda-20211231x10k024.jpg</File>
    <File>trda-20211231x10k025.jpg</File>
    <File>trda-20211231x10k026.jpg</File>
    <File>trda-20211231x10k027.jpg</File>
    <File>trda-20211231x10k028.jpg</File>
    <File>trda-20211231x10k029.jpg</File>
    <File>trda-20211231x10k030.jpg</File>
    <File>trda-20211231x10k031.jpg</File>
    <File>trda-20211231x10k032.jpg</File>
    <File>trda-20211231x10k033.jpg</File>
    <File>trda-20211231x10k034.jpg</File>
    <File>trda-20211231x10k035.jpg</File>
    <File>trda-20211231x10k036.jpg</File>
    <File>trda-20211231x10k037.jpg</File>
    <File>trda-20211231x10k038.jpg</File>
    <File>trda-20211231x10k039.jpg</File>
    <File>trda-20211231x10k040.jpg</File>
    <File>trda-20211231x10k041.jpg</File>
    <File>trda-20211231x10k042.jpg</File>
    <File>trda-20211231x10k043.jpg</File>
    <File>trda-20211231x10k044.jpg</File>
    <File>trda-20211231x10k045.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="465">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>116
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "trda-20211231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 117,
   "dts": {
    "calculationLink": {
     "local": [
      "trda-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "trda-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "trda-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "trda-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "trda-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "trda-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 420,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 36,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 41
   },
   "keyCustom": 35,
   "keyStandard": 329,
   "memberCustom": 10,
   "memberStandard": 27,
   "nsprefix": "trda",
   "nsuri": "http://www.entradatx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Fair Value Measurements",
     "role": "http://www.entradatx.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Property and Equipment, Net",
     "role": "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "trda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "trda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "trda:TemporaryEquityCommonAndPreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock",
     "role": "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "trda:TemporaryEquityCommonAndPreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Stock Based Compensation",
     "role": "http://www.entradatx.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Income Taxes",
     "role": "http://www.entradatx.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Commitments and Contingencies",
     "role": "http://www.entradatx.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Employee Benefit Plan",
     "role": "http://www.entradatx.com/role/DisclosureEmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Net Loss per Share",
     "role": "http://www.entradatx.com/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Subsequent Events",
     "role": "http://www.entradatx.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "trda:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "trda:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.entradatx.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "trda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "trda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock (Tables)",
     "role": "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockTables",
     "shortName": "Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Stock Based Compensation (Tables)",
     "role": "http://www.entradatx.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.entradatx.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.entradatx.com/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.entradatx.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_A9_82EYsGUyAdwdKWf3-Vw",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Nature of the Business (Details)",
     "role": "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails",
     "shortName": "Nature of the Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_11_1_2021_To_11_30_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_LGXl_iZN7E6dEJSRz6h1QQ",
      "decimals": "INF",
      "lang": null,
      "name": "trda:StockIssuedDuringPeriodAggregateSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "trda:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_nypqQlrtZE6lptm3mK1OuA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Estimated useful life (Details)",
     "role": "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails",
     "shortName": "Summary of Significant Accounting Policies - Estimated useful life (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "trda:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_nypqQlrtZE6lptm3mK1OuA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "trda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "trda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock (Details)",
     "role": "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails",
     "shortName": "Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_cYC4Ln7I7UuO7joYqLLj9A",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_5_16_2017_To_5_16_2017_us-gaap_StatementClassOfStockAxis_trda_SeriesSeedRedeemableConvertiblePreferredStockMember_2d5Zkg5ROU2FOzEjN1-Wlw",
      "decimals": "INF",
      "lang": null,
      "name": "trda:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Conversion Right and Dividends (Details)",
     "role": "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails",
     "shortName": "Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Conversion Right and Dividends (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "trda:NumberOfDirectorsEntitledToBeElected",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40604 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Voting Rights (Details)",
     "role": "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails",
     "shortName": "Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Voting Rights (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "trda:NumberOfDirectorsEntitledToBeElected",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40605 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Common Stock and Preferred Stock (Details)",
     "role": "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails",
     "shortName": "Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Common Stock and Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "INF",
      "lang": null,
      "name": "trda:NumberOfVotesPerShareOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_zpzaX_MWaEmLm5IOpbP7fw",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "trda:ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40606 - Disclosure - Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Shares Reserved for Future Issuance (Details)",
     "role": "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
     "shortName": "Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock - Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "trda:ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ITETWdme0EqNs4fieGHHPw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "trda:ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Stock Based Compensation (Details)",
     "role": "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails",
     "shortName": "Stock Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_PlanNameAxis_trda_StockPlan2016Member_WSANhifLkU2A9s4mVWiePw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Stock Based Compensation - Compensation expense (Details)",
     "role": "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails",
     "shortName": "Stock Based Compensation - Compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Stock Based Compensation - Stock Option Valuation (Details)",
     "role": "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails",
     "shortName": "Stock Based Compensation - Stock Option Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - Stock Based Compensation - Early Exercise of Unvested Stock Options (Details)",
     "role": "http://www.entradatx.com/role/DisclosureStockBasedCompensationEarlyExerciseOfUnvestedStockOptionsDetails",
     "shortName": "Stock Based Compensation - Early Exercise of Unvested Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-5",
      "lang": null,
      "name": "trda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40705 - Disclosure - Stock Based Compensation - Stock option activity (Details)",
     "role": "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock Based Compensation - Stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Hr56gTTFvEyoKjsvmNyTww",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_djIfGJUG3UerKSFCe6I17g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40706 - Disclosure - Stock Based Compensation - Restricted Stock Awards (Details)",
     "role": "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails",
     "shortName": "Stock Based Compensation - Restricted Stock Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_djIfGJUG3UerKSFCe6I17g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Income Taxes (Details)",
     "role": "http://www.entradatx.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Income Taxes - Reconciliation of U.S. federal statutory income tax rate (Details)",
     "role": "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of U.S. federal statutory income tax rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_YmqBoIu3ekW7hKvS2hQx7w",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_0F7kyPmgPE6NFo60sAPzEQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY",
     "role": "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_trda_SeriesaRedeemableConvertiblePreferredStockMember_494Nn9bt3E65r2GvytHiBg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Income Taxes - Net deferred tax assets (Details)",
     "role": "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Net deferred tax assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40804 - Disclosure - Income Taxes - Operating loss carryforwards (Details)",
     "role": "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails",
     "shortName": "Income Taxes - Operating loss carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-5",
      "lang": null,
      "name": "trda:OperatingLossCarryforwardsSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Commitments and Contingencies - Minimum aggregate future lease commitments (Details)",
     "role": "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails",
     "shortName": "Commitments and Contingencies - Minimum aggregate future lease commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_qJEeTOrXCk61-9jbZbHr3w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - Commitments and Contingencies - License Agreement (Details)",
     "role": "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails",
     "shortName": "Commitments and Contingencies - License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "trda:ExpensesRelatingToMilestoneObligation",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "lang": null,
      "name": "trda:ExpensesRelatingToMilestoneObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Net Loss per Share (Details)",
     "role": "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails",
     "shortName": "Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Net Loss per Share - Antidilutive securities (Details)",
     "role": "http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
     "shortName": "Net Loss per Share - Antidilutive securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_F0HXL2bWUUS2yJ-_YQFk6g",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)",
     "role": "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_skOiL5HBskWVcZKI3jYapQ",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of the Business",
     "role": "http://www.entradatx.com/role/DisclosureNatureOfBusiness",
     "shortName": "Nature of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trda-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_PWox2JXyQEuIIciJPaMCAQ",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 39,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.entradatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r159",
      "r168",
      "r196",
      "r197",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r349",
      "r350",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r159",
      "r168",
      "r196",
      "r197",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r349",
      "r350",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r159",
      "r168",
      "r177",
      "r196",
      "r197",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r349",
      "r350",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r159",
      "r168",
      "r177",
      "r196",
      "r197",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r349",
      "r350",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trda_AccruedExpensesAndOtherCurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesAbstract",
     "nsuri": "http://www.entradatx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "trda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accrued expenses and other current liabilities.",
        "label": "Accrued Expenses and Other Current Liabilities [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "trda_AccruedExternalResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of current portion of  accrued external research and development expenses as at the end of the reporting period.",
        "label": "Accrued External Research and Development Expenses Current",
        "terseLabel": "External research and development expenses"
       }
      }
     },
     "localname": "AccruedExternalResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents additional office and laboratory space in Boston, Massachusetts.",
        "label": "Additional office and laboratory space in Boston, Massachusetts"
       }
      }
     },
     "localname": "AdditionalOfficeAndLaboratorySpaceInBostonMassachusettsMember",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trda_AnnualLicenseMaintenanceFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of annual license maintenance fee.",
        "label": "Annual License Maintenance Fee",
        "terseLabel": "Annual license maintenance fee"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFee",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for emerging growth company status.",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "trda_EmployeeStockPurchasePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents 2021 employee stock purchase plan.",
        "label": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlan2021Member",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trda_ExpensesRelatingToMilestoneObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses recognized relating to milestone obligation.",
        "label": "Expenses Relating to Milestone Obligation",
        "terseLabel": "Expense relating to milestone obligation"
       }
      }
     },
     "localname": "ExpensesRelatingToMilestoneObligation",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_InterestAndOtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net interest and other income (expense) during the period.",
        "label": "Interest And Other Income (Expense), Net",
        "terseLabel": "Interest and other (expense) income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeExpenseNet",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_LicenseAgreementNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of installments for payment of upfront research fees.",
        "label": "License Agreement, Number of Installments",
        "terseLabel": "Number of installments"
       }
      }
     },
     "localname": "LicenseAgreementNumberOfInstallments",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "trda_LicenseAgreementNumberOfLicensedProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of licensed products.",
        "label": "License Agreement, Number of Licensed Products",
        "terseLabel": "Number of licensed products"
       }
      }
     },
     "localname": "LicenseAgreementNumberOfLicensedProducts",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "trda_LicenseAgreementWithThirdPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents license agreement with a third-party.",
        "label": "License agreement with a third-party"
       }
      }
     },
     "localname": "LicenseAgreementWithThirdPartyMember",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trda_NumberOfDirectorsEntitledToBeElected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of directors entitled to be elected.",
        "label": "Number of Directors Entitled to be Elected",
        "terseLabel": "Number of directors entitled to be elected"
       }
      }
     },
     "localname": "NumberOfDirectorsEntitledToBeElected",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "trda_NumberOfVotesPerShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes per share of common stock.",
        "label": "Number of Votes Per Share of Common stock",
        "terseLabel": "Number of votes"
       }
      }
     },
     "localname": "NumberOfVotesPerShareOfCommonStock",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "trda_OfficeAndLaboratorySpaceInBostonMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents office and laboratory space in Boston, Massachusetts.",
        "label": "Office and laboratory space in Boston, Massachusetts"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceInBostonMassachusettsMember",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trda_OperatingLossCarryforwardsLimitationOnUseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforwards limitation on the use to reduce future taxable income.",
        "label": "Operating Loss Carryforwards, Limitation on Use, Amount",
        "terseLabel": "Net operating loss carryforwards limited in usage"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationOnUseAmount",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforwards subject to expiration.",
        "label": "Operating Loss Carryforwards, Subject To Expiration",
        "terseLabel": "Net operating loss carryforwards subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for patent costs.",
        "label": "Patent Costs [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "trda_PaymentForPatentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for patent costs.",
        "label": "Payment For Patent Costs",
        "terseLabel": "Patent costs"
       }
      }
     },
     "localname": "PaymentForPatentCosts",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_PaymentOfUpfrontResearchFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for upfront research fees payment.",
        "label": "Payment of Upfront Research Fees",
        "terseLabel": "Upfront research fees"
       }
      }
     },
     "localname": "PaymentOfUpfrontResearchFees",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_PotentialMilestonePaymentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents potential milestone payment obligation.",
        "label": "Potential milestone payment obligation"
       }
      }
     },
     "localname": "PotentialMilestonePaymentObligation",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_ProceedsFromEarlyExerciseOfStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from early exercise of stock options.",
        "label": "Proceeds From The Early Exercise Of Stock Options",
        "terseLabel": "Proceeds from the early exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromEarlyExerciseOfStockOptions",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_PropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of property plant and equipment useful life.",
        "label": "Property Plant And Equipment Useful Life [Table Text Block]",
        "terseLabel": "Summary of estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "trda_RentExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for rent expense.",
        "label": "Rent Expense [Policy Text Block]",
        "terseLabel": "Rent Expense"
       }
      }
     },
     "localname": "RentExpensePolicyTextBlock",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "trda_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of series B redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "trda_SeriesSeedRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Series Seed redeemable convertible preferred stock.",
        "label": "Series Seed redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesSeedRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trda_SeriesaRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of series A redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesaRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability related to early exercises of non-vested stock options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Early Exercised, Nonvested, Amount",
        "terseLabel": "Unvested early exercises of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedNonvestedAmount",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationEarlyExerciseOfUnvestedStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "trda_ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of shares reserved for future issuance under share based compensation.",
        "label": "Share-based Payment Arrangement, Shares Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Schedule of shares reserved for future issuance"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementSharesReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "trda_SharesIssuableUponAchievementOfCertainSpecifiedMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number od shares issuable upon achievement of certain specified milestones.",
        "label": "Shares Issuable Upon Achievement of Certain Specified Milestones",
        "terseLabel": "Shares issuable upon achievement of certain specified milestones"
       }
      }
     },
     "localname": "SharesIssuableUponAchievementOfCertainSpecifiedMilestones",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "trda_StockIssuedDuringPeriodAggregateSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of shares issued during the period.",
        "label": "Stock Issued During Period, Aggregate Shares Issued",
        "terseLabel": "Aggregate shares issued and sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAggregateSharesIssued",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "trda_StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock shares issued from early exercised stock options during the current period.",
        "label": "Stock Issued During Period Shares Vesting Of Early Exercised Stock Options",
        "terseLabel": "Vesting of early exercised options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVestingOfEarlyExercisedStockOptions",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "trda_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock shares issued from early exercised stock options during the current period.",
        "label": "Stock Issued During Period Value Vesting Of Early Exercised Stock Options",
        "terseLabel": "Vesting of early exercised options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_StockPlan2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents 2016 Stock Plan.",
        "label": "2016 Stock Plan"
       }
      }
     },
     "localname": "StockPlan2016Member",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trda_StockPlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents 2021 plan.",
        "label": "2021 Plan"
       }
      }
     },
     "localname": "StockPlan2021Member",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trda_TemporaryEquityAggregateSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of aggregate stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Aggregate Shares Issued",
        "terseLabel": "Aggregate shares issued"
       }
      }
     },
     "localname": "TemporaryEquityAggregateSharesIssued",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "trda_TemporaryEquityCommonAndPreferredStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for temporary equity, common stock and preferred stock.",
        "label": "Temporary Equity Common And Preferred Stock Text Block",
        "terseLabel": "Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityCommonAndPreferredStockTextBlock",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "trda_TemporaryEquityConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in temporary equity.",
        "label": "Temporary Equity, Conversion price",
        "terseLabel": "Preferred stock, convertible, conversion price (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityConversionPrice",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "trda_TemporaryEquityIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of issuance cost associated with the issuance of temporary equity.",
        "label": "Temporary Equity, Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityIssuanceCosts",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued upon conversion of convertible securities.",
        "label": "Temporary Equity, Stock Issued During the Period Shares Conversion of Convertible Securities",
        "negatedLabel": "Conversion of redeemable convertible preferred stock upon initial public offering (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "trda_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of redeemable convertible preferred stock, net of issuance costs (in shares)",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "trda_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of shares issued upon conversion of convertible securities.",
        "label": "Temporary Equity, Stock Issued During the Period Value Conversion of Convertible Securities",
        "negatedLabel": "Conversion of redeemable convertible preferred stock upon initial public offering"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_ThresholdNetProceedsFromQualifiedPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold amount of net proceeds from qualified public offering.",
        "label": "Threshold Net Proceeds From Qualified Public Offering",
        "terseLabel": "Threshold net proceeds from qualified public offering."
       }
      }
     },
     "localname": "ThresholdNetProceedsFromQualifiedPublicOffering",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_UnvestedSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents unvested shares.",
        "label": "Unvested shares from early exercises"
       }
      }
     },
     "localname": "UnvestedSharesMember",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trda_VestingOfOptionsEarlyExercisedSubjectToRepurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of vesting of options that were early exercised subject to repurchase.",
        "label": "Vesting Of Options Early Exercised Subject To Repurchase",
        "terseLabel": "Vesting of options early exercised subject to repurchase"
       }
      }
     },
     "localname": "VestingOfOptionsEarlyExercisedSubjectToRepurchase",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trda_VestingOfRestrictedStockSubjectToRepurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of vesting of restricted stock subject to repurchase.",
        "label": "Vesting Of Restricted Stock Subject To Repurchase",
        "terseLabel": "Vesting of restricted stock subject to repurchase"
       }
      }
     },
     "localname": "VestingOfRestrictedStockSubjectToRepurchase",
     "nsuri": "http://www.entradatx.com/20211231",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r315"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities and Other Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r32"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "General and administrative professional service expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28",
      "r136"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18",
      "r235",
      "r315"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r232",
      "r233",
      "r234",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r199",
      "r201",
      "r238",
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r172",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Net of issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r201",
      "r228",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from common stock"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of office and laboratory space"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r58",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r69",
      "r114",
      "r122",
      "r126",
      "r130",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r276",
      "r281",
      "r299",
      "r313",
      "r315",
      "r331",
      "r340"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r39",
      "r69",
      "r130",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r276",
      "r281",
      "r299",
      "r313",
      "r315"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r202",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis Of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r25",
      "r60"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r55",
      "r60",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r55",
      "r300"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r68",
      "r69",
      "r88",
      "r89",
      "r90",
      "r92",
      "r94",
      "r102",
      "r103",
      "r104",
      "r130",
      "r148",
      "r152",
      "r153",
      "r154",
      "r157",
      "r158",
      "r166",
      "r167",
      "r169",
      "r170",
      "r299",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r145",
      "r333",
      "r345"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r146",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Total shares of authorized common stock reserved for future issuance",
        "verboseLabel": "Future awards"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share (in dollars per share)",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails",
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares, authorized",
        "verboseLabel": "Common Stock Authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails",
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r315"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.0001; 150,000,000 and 113,259,306 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 31,336,092 and 1,283,545 shares issued as of December 31, 2021 and December 31, 2020, respectively; 31,224,336 and 1,244,139 shares outstanding as of December 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r107",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r15",
      "r16",
      "r171",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Common stock issuable upon conversion",
        "verboseLabel": "Redeemable convertible preferred stock, shares issued upon conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Convertible notes outstanding"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Shares issued in satisfaction of principal and interest on convertible notes"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r13",
      "r307",
      "r312"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r259",
      "r261",
      "r262"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "terseLabel": "Salaries and wages"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesNetDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r58",
      "r134"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r175",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "terseLabel": "Dividends preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r47",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r86",
      "r88",
      "r92",
      "r93",
      "r94",
      "r98",
      "r99",
      "r289",
      "r290",
      "r335",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Net loss per share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r47",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r88",
      "r92",
      "r93",
      "r94",
      "r98",
      "r99",
      "r289",
      "r290",
      "r335",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Net loss per share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r70",
      "r248",
      "r268"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r248",
      "r268"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r248",
      "r268"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Nondeductible items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r248",
      "r268"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r248",
      "r268"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Federal and state research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesReconciliationOfUsFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost, weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r43",
      "r44",
      "r45",
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r101",
      "r131",
      "r172",
      "r175",
      "r232",
      "r233",
      "r234",
      "r264",
      "r265",
      "r288",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r351",
      "r352",
      "r353",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Assets transferred from Level 1 to Level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Assets transferred from Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r160",
      "r162",
      "r163",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r192",
      "r292",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r291",
      "r292",
      "r294",
      "r295",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r160",
      "r178",
      "r180",
      "r185",
      "r192",
      "r292",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount",
        "terseLabel": "Liabilities transferred from Level 1 to Level 2"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount",
        "terseLabel": "Liabilities transferred from Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net",
        "terseLabel": "Transfer of assets into (out of) level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "terseLabel": "Transfer of liabilities into (out of) level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r160",
      "r162",
      "r163",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r192",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r296",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.",
        "label": "Guarantees, Indemnifications and Warranties Policies [Policy Text Block]",
        "terseLabel": "Indemnification Agreements"
       }
      }
     },
     "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r138",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r249",
      "r252",
      "r258",
      "r266",
      "r269",
      "r271",
      "r272",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r71",
      "r84",
      "r85",
      "r113",
      "r247",
      "r267",
      "r270",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax benefits"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesDetails",
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r42",
      "r243",
      "r244",
      "r252",
      "r253",
      "r257",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) In Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of minimum aggregate future lease commitments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesMinimumAggregateFutureLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r69",
      "r123",
      "r130",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r277",
      "r281",
      "r282",
      "r299",
      "r313",
      "r314"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r69",
      "r130",
      "r299",
      "r315",
      "r332",
      "r343"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders' (Deficit) Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r69",
      "r130",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r277",
      "r281",
      "r282",
      "r299",
      "r313",
      "r314",
      "r315"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r34",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Accrued liabilities for legal and other contingencies"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r55",
      "r56",
      "r59"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r40",
      "r41",
      "r45",
      "r46",
      "r59",
      "r69",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r84",
      "r85",
      "r91",
      "r114",
      "r121",
      "r124",
      "r125",
      "r127",
      "r130",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r290",
      "r299",
      "r334",
      "r346"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of unvested restricted stock"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r114",
      "r121",
      "r124",
      "r125",
      "r127"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Nature of the Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r32"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other non-current assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r177",
      "r179",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureEmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r202",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Dividend rate (as a percent)"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockCommonStockAndPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Gross proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock upon initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs",
        "verboseLabel": "Proceeds from issue of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r231"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r40",
      "r41",
      "r45",
      "r54",
      "r69",
      "r76",
      "r84",
      "r85",
      "r114",
      "r121",
      "r124",
      "r125",
      "r127",
      "r130",
      "r148",
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r275",
      "r279",
      "r280",
      "r283",
      "r284",
      "r290",
      "r299",
      "r336"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r28",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r27",
      "r135"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r137",
      "r315",
      "r337",
      "r344"
     ],
     "calculation": {
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r26",
      "r137",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable convertible preferred stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r241",
      "r328",
      "r363"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r65",
      "r330",
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock Awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Unvested restricted common stock"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r175",
      "r235",
      "r315",
      "r342",
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r131",
      "r232",
      "r233",
      "r234",
      "r264",
      "r265",
      "r288",
      "r351",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Accrued Expenses and Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from computation of net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of net deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share attributable to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of U.S. federal statutory income tax rate to effective income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r201",
      "r227",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value hierarchy for assets and liabilities measured at fair value on recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r28",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r202",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r209",
      "r217",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of the stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional information"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested balance, at end of period (in shares)",
        "periodStartLabel": "Unvested balance, at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted- Average Grant -Date Fair Value Unvested balance, at end of period (in dollars per share)",
        "periodStartLabel": "Weighted- Average Grant -Date Fair Value Unvested balance, at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant -Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of restricted stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions used to determine the fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (as percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (as percentage)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Stock authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Contractual Term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Early Exercised, Nonvested, Number of Shares",
        "terseLabel": "Unvested shares related to early exercises of stock options",
        "verboseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationEarlyExerciseOfUnvestedStockOptionsDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r211",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at end period (in dollars per share)",
        "periodStartLabel": "Weighted-Average Exercise Price Outstanding at beginning period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Shares annual increase as percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Additional number of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r200",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Shares vesting after one year"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Shares vesting after three year"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Maximum term of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r223",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Contractual Term, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Contractual Term, Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Stock price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r66",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r68",
      "r69",
      "r88",
      "r89",
      "r90",
      "r92",
      "r94",
      "r102",
      "r103",
      "r104",
      "r130",
      "r148",
      "r152",
      "r153",
      "r154",
      "r157",
      "r158",
      "r166",
      "r167",
      "r169",
      "r170",
      "r172",
      "r299",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r37",
      "r43",
      "r44",
      "r45",
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r101",
      "r131",
      "r172",
      "r175",
      "r232",
      "r233",
      "r234",
      "r264",
      "r265",
      "r288",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r351",
      "r352",
      "r353",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r101",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r36",
      "r161",
      "r172",
      "r173",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock upon initial public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r172",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock from initial public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Value of assets purchased (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r172",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r172",
      "r175",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r37",
      "r172",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock upon initial public offering",
        "verboseLabel": "Conversion of preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r172",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Value of assets purchased"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r16",
      "r17",
      "r172",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r172",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r20",
      "r21",
      "r69",
      "r129",
      "r130",
      "r299",
      "r315"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders' (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' (deficit) equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNatureOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r9",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r148",
      "r152",
      "r153",
      "r154",
      "r157",
      "r158"
     ],
     "calculation": {
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "terseLabel": "Redeemable convertible preferred stock, par value $0.0001 (Note 6)",
        "verboseLabel": "Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails",
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheets",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Redeemable Convertible Preferred Stock, Common Stock and Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockSharesReservedForFutureIssuanceDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockVotingRightsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Liquidation Preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r9",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Redeemable convertible preferred stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "auth_ref": [
      "r9",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Redemption Price Per Share",
        "terseLabel": "Purchase price (in dollars Per share}"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockConversionRightAndDividendsDetails",
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Preferred Stock Authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Preferred Stock Issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)",
        "terseLabel": "Preferred stock outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockRedeemableConvertiblePreferredStockDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r9",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureRedeemableConvertiblePreferredStockCommonStockAndPreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r242",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain tax position"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r105",
      "r106",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureStockBasedCompensationRestrictedStockAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r87",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r86",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails",
      "http://www.entradatx.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.entradatx.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r364": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r365": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r366": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r367": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r368": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r369": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r371": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r372": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r373": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r374": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>117
<FILENAME>0001558370-22-003614-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-003614-xbrl.zip
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M)9]5\343KS),5<UX:ME*KG*D[[S)R'UIS@H407 H)MBN_]-_ 5!+ P04
M"  K/F]4WIUM*00,  !<G@  %0   '1R9&$M,C R,3$R,S%?8V%L+GAM;.U=
M6W/B.!9^WZK]#UKF9;=J";>0#JGNF2*$]*2*A%2@=V>?IA1;$-48BY%,2/;7
M[Y&PP8YOLJ$; ?O2'4 Z.M_YCHZ.+I8___(V<] KX8(R]TNE<5:O(.):S*;N
M]$ME(:I86)16?OGYKW_Y_+=J];?KIP&RF;68$==#%B?8(S9:4N\%C=E\CEUT
M3SBGCH.N.;6G!*'.V<799?V\>=:ZN&S44;7J2[K& FHR%RF1S;/&^I>>+Y6Y
M5ZA5:[1KS7JSB1J-JU;[JEU'W?MUR7M0<T+SBSK4_>-*_O,,C2( [(JK-T&_
M5%X\;WY5JRV7R[-EZXSQ*0BH-VJ_W0]&U@N9X2IUA8==BU00E+\2ZLL!L["G
MK!6J_O;,G4! J[9N*[6$_%0-BE7E5]5&L]IJG+T)N^*K*'_6:"0H_A8K[V-J
M=#J=FOIU710$T0S1:]A@/80^<^:0)S)!2L:5]SXG7RJ"SN:.;%M]]\+)Y$O%
MXS8&+,U&H[E"\M/( RJEK_28*YA#;<GL-7:D\-$+(9ZH("G]V]-=1!VHP3$4
M?CNSV*PF2]1T1"ET6B:K?1=DZR_%<#*<$Z[\9$N(:3)-PMK#XN768<L=0@V)
M_(%(;ZBP'"86G-QBRO^%G06Y)UA^5FK=$ ]31Q^EKKB]('SD#-S)>^^Z=O_/
M!9U+E1Z(5QYCGL"]H.Q:%E\0N_\V)ZX@ G0;>B^$]Q:<@WH#BI^I0SU*MN"V
M>!-[L<0=#.LS,L9O1#P1B[D6:*6"R7#R3=P2&T*+(WO@PF/\?5WX";ID>=/L
MH,U]VTIY\ 2R&F+#YZX09)LXH"MX+ZA[;#:CG@I-X,00F3W( B$;!->]IRZ=
M+6;=Z923*=!SN_"@P@""6;A6>;OLKNG"EK.P8RT<Y94#^,VWEM1O)RE)B _R
MYA'7)O;Z6^K)1B#EK$-FC-;BX._>\&$T'-S==,?]&W3='70?>GTT^K7?'X\*
M0%0  :+#K(@BCDQA&8]ZAA0G0)Z2-<'B60F$*< 4X[G,K!LUXG@B^$8Y4;7>
M\)/6G_RO?U\Y<B#:P<_$41.)R(^U?6BFHO)*@P<(1:OPG*)H8MG?+UJ?+IN=
M\WKGO-.Z;+<_M2Y#4$)^U.515)A;03OP9\RUHNSY)6IB,9LI:54*;A'4GW V
MB]O3;XR5 < XA&&8^E700H!>;"[;Q$X%+0F=OGCJE[WP%>03C]"AO ])10IM
M656BX"_:[7K;6/8*X_!);!I'X@IC+[.S1<H<$DWYBON\M(SC1<ZOY$@+_TGG
M>L6.&GN]'N;\'<9>-5E)X4NKKJD\9K$59[@\5(/#*IEC&DQ7@MF*3C_5J'D<
MK)<%:FP4#DU" <W(8]8?+\P!987T:N\]A?#\:GM!HZU_O*!Y_JE+3=@_-7$9
M&X*>Y&3-)78?<Q>"J.A:UF(F#4]LF!)3BZ9%H/R*44-\ D/L.T?7)"O.<DFP
MQK+>M6VZTN41@NN=V\-SZDG%DI/"Y-)'Q&\1A,:.+'()AKG*!IDIXX=B1T2C
M%C1CYP%C,ILSCOG["G.0UW9G; $S3\_C]'GAX6>'C-DCSL@-"\LQSP/*C,2[
M@6UT[TY9ELWHZ"DUCH/QH@"-[?DA\/GI_W%PEP?(Y^K<.*Z"C:(GN=D _U,O
M=P4[JTH4_&6[U6J9PV8B,W$N"^,S-B\.8<]>?XD7/ 8B-5$9.T;ZV__:+*:6
M-YK,+!T3IC:%,!K;,P&&S./$(WZ7.5PNKPF%CXM478#ZG?5S[</^^W?9E$\]
M1*>S.]_,WIT?C>&_^_[#>(2&MVCXV'_JCN^@@.'[] _$6QU&&3"1E@!^*+._
M77L8VMF*-G>ZTLA?F\_:OD^M%'79#KCLQ9[[9"(9L>W\8H!V'U7C9X?D-[_?
MN1[A1'C!/DE$M?A>O58=\R@JP<"&QO*8C1T;AU$[9$21A)+FT9O? S51&)NG
MK@$$!U7SZ K*F4>6+A<9+&:"R^UTU7V1^)6X\LPLA)"N/:,N%9Z$\YHS'.;4
M,IC@3)KB])8!:FR$?2*"@-'D^9,;\DH<IDZ 93.=6>=X>"X.T^092?A9%YT)
MR7F1"4FO._H5W0Z&_S9]0B*M\.&<%=#L<6J!N?QS6-$O0B4?":?,AN& RW/A
M-V3U/WQV%K9R+^L%NU,BGRSH3R;$2IO$_V@E]A)8(->1FC]R]DK!OZ[?OPD"
M:J\[8]>"F)FU,: O(-(7.W4#0LY^W"P<O+:TGK'CU0V9<V*MGN])W938%#'/
M-;8D)FF/(@>NL5R"#2;4RYC4;0J< (\Y8(V=\GW%U)5:#]T1Q*_A)/)8P?J9
M@K1)@U;E$V!_"T/D;O[O;2(Y>L&<J$L8>FPFT^:LL)U<^ 2H+P#<V+,#\6S%
M/]X>[* G'G-/\81RPD[ 4W9H&-^3VN8%C3C(8%7</WA1T'<2:Y^DL^A;PO>.
MBT/PC@\[QF..[;2%*[W*)^D;VH;P7>/3 0Q!\0,B06!<6R[_?.*V8J-&;+1;
MS<Y)>-.V)O+][/( _"P8?<LX4T+=D_0873OX;M$QSBU2;'3GOA*QS7IG@@#S
M',38]4Y=ZQF[N@+CL=K &;.N!2;;7( 5N[4A;0U-6X!Y;K4EJ0EK;-L9P]PM
M^Q1+W5(7N]86T2=!@'EN8FSTT;6>L8_O ""+$%O<@KWOA%C(2Z>&DR=B$S)3
MQW,9=$7N4?CSD?LCN'I*)GU!OYP\\YQN2\H3U_]W:!N3-WUB,.]<,!1V'A?/
M#K6&T,LX&+" "R76/U&7T;>%N3E/");R\*%23?3?"+>HV!Q6R7"-Q'I1,S3!
M#)^.V27T;;#[ 2CE&'=8O3[FSGN@UW 2UC;I-+=FU2/F>&LSZ&\?[?Q\FO8M
MQ?EGT\[KK7H#5=%&)'R04I$2B\)RT=]]R?\P_&#::C%^;9L-MI18EU'>H*O>
M]/%HUS>O?^=2EW_7FRY._:SN.W;@W"NX=;KP>;P+!W(1=FVTEOQ/!+(/IAOO
M^CK1/3Z4NKD&:G.^#/YVB.I<KMV=,9B-_%=]7W11:E?BS0L&>6S&(\)WM86Y
M*U:I.+[RS .!&96.P1M*(-SC4P=;O9] 9YAHQX<)OR44-*6&"]48\EM#H>8.
M9N38V0T/>^K/_=G<8>^$/!$5RK1QY-:+^GS+@%Z=2U6X0Y?#]\.>JU[W6X]P
M:"#SF:<4)DO+.5!F=XO7V%4X'Z$\EDZ$4$K=$LVHE%+I0 G? IRQ.SNK\Z$%
MQYSL2@?.;@EP1JRG[>+U1SJIV&6]^3$56TE#JFWX&&T>L0GZ=C8Z0Y.5#D@$
M2B"ZJN?A-\1!CX/)T58;P/251,RXNIYQ0=UI_-:?C\E. 0'[R>(2%8P2V_4R
MO:H0]$*2S0LPQ1TBDAI^)Y.8.^G70:P>.8<\2KX"U0D%MRW\*DWD*3I4(5OD
M)J=&>Q)\N;JT4P3I^18^%!=VBMZC:05S'TG4 ?G 9 *TL-19F^RK4,J*BUKM
MO-W\='[TOJ-MA]RTVFCOZ:GS@IL3[>OW;LH-OA6GCL.6_AN_RSI5@59.T=>V
M-4^!QR-_S-0N^T6N>O.W5L[\36ZTVGXC:G*&53,',SV+&2A]TS6YZ%ZO72\>
M)PZR[V>1E'3U>LF>:^#D)T"T[M6A5:9\3TVI=?@$%P%F[GPDA#J$H^BYB()2
MS"6_"*F9?;^T&8P] )\&+OPVR+3%#JVZI^85^>"-W6.+Q<JLPR_)A<UEN_ (
MGX['V&VT&(;-\^V 1;VI:\+X$G-;F]5T"5'3M-NMYK[?CU2 0@W^"R(_A B_
M K9>-8N REF4+"CEV)VC!/H#"ON,V4OJR#NE[UP/NU.Y1)9YSU$1$<?N&D6A
M'\YH G]\N-HK?$4<X+TF+IE03P2GS#3NV=MM(\?N6[LWCK%W^)7'GGR#88\)
M[>6W'33U?T\L9Z+<I6YC_%&=T-).HV7A8_>)=)"Y-_C]B/V+C-?8WE.7SA:S
M[G3*R11[Y';A086!O'LC5*O8#D<G?D(M)$L])Q#1 7[WU4 XT --E"+(D9H@
M*U3]4'9!!@1<@VSF4A)(L%[R'ER <Y/Z$G7]ZOMYCZFF>O^!:<%XR;8$Z4N)
M]K +Z&'M?;]?L2#)D7>A[@"\L7-O77 /$$7&2^*\DGL("2^I;Z<N*>XT/4;+
M"ML]KO:YMJ+)C[ __P]02P,$%     @ *SYO5,@YHVY')0  /; " !4   !T
M<F1A+3(P,C$Q,C,Q7V1E9BYX;6SM/=MRX[B5[UNU_\!U'C:IBMMV]W1GNFLF
M6[(M3[PK6X[M[B1/4S0)6<A0A *0;BM?OP"I"TD1(,#KH<R7;EG"Y=R!<P'P
MT_^\+CSK!5&&B?_ST=F[TR,+^0YQL?_\\U'(CFWF8'ST/W_^S__XZ;^.C_]^
M?C^Q7.*$"^0'ED.1'2#7^HZ#N?5(EDO;MVX0I=CSK'.*W6=D69_??7KWX^D/
M[]]]^/3CV:EU?+P>Z=QFO"?QK6C(]^_.MK]<K$<E_A?KP\G9QY/WI^_?6V=G
M7SY\_/+QU!K=;%O><#!GN+BIA_W?OHA_GOBD%D?89U]>&?[Y:!X$RR\G)]^_
M?W_W_<,[0I_Y *=G)W^_F3PX<[2PC['/ MMWT)'%VW]AT9<3XMA!1*U$]]<G
MZFT&^'"RG4O:0OQUO&EV++XZ/GM__.'LW2MSC]8@BI\U)MDT%[^ZP;9#LO''
MD_C'9%.L&#J!=MQ^#Y0UN<X^?_Y\$OUZQ EM63]1XJ%[-+.B[[X$JR7Z^8CA
MQ=(38T7?S2F:_7P44-?F:+\_.WL?(_V[AX!S78C5!?$9\; KA&#[)9O.[I&+
M./F?/,1;<(D-,/]XQT?C$B=:$N>WD1__/R>>RT7Z$LVP@X/QOT(<K(XL =O7
M^^L4'GQH:O.I7M\Y9'$B6IPT#TA$5"W.GD"GZIU-^3AS%&#']L"0. -5B_2^
MQ,SQ" LINK4#_N]T=AXR["/& 0QL[#%M&FF,U E>#^%B8=/5=/: GWUN?AW;
M#T:.0T(_X&O&'>>F@Q$;LP O!%>_,C0+O0F>H?($J#YE)Y2ZLC']9GLAND&V
M^#N2[?)44 _7"89WE"RY<JZX+@K%6PJ0;E%0'L>B 3O!4L,879#%@O@;NY3^
M3:-[>8*U"-N!TG[DNEALYVSOVI\1NHCV=I 9H@:XCUR*.PD/Y!X_SP/^^R5^
MP2[RW0KFL@68^DCK;T2LF1%.W1$W%X@^4O-ASG>:[!XQ1%^0>T7H52CV:M>,
MA<)_ZHS NG!ULX,4$$;^/T=AB7Q6T>06C <(Q^3G\:OX6&57;#P%($I$WTZ7
MXJ/8TS8B <HY8-)BY 1\E0E6#9)B;PI E. &*Z#8"38[G>\VK;(%*#-))]2X
M]CGTZ-%^16S*_1];K(X3PMB%3>F*[_$JTL%L^$XH(!8S'$0N+5_,^)HG8$2^
M\.O+XZTS*#1L)]@1-GOT3%'DX3>"O722;B)E*!#2>(=HM&T9<4!=[(7<3*$'
MY(24>SM5I,!L>&,*1$ANR%#"1-F^R]5/<"AD 5F,7C&[) L;\Z5J9H=>P$R,
MJO9@:4XE4;&IL\%F_3&)T)88V ].7+PX6;<YL3TO?^PD\!*J;M(3(@_R,<(I
M&JT&J/AG+NC<Z!^[$1EJ!'%_Z#K@C88Z7J#%$Z)U IL>MP9(YQPHZH1/Z'A+
MB!KAS1V]7GF(%:(9@=B,K0]Q9"C8PGZ'0DJ6XK]H_!/NP<VVT'_'+J+'/E^U
MR?>RXN%1NAU/3'B\_H/C<?;C\=G9\?O8JF3G2J+"\<-^%(.:\#_74XI!&K%[
M,7[H-4"^B]SMMS@0\WW^_/GTU#JV=B/S/S:#6WQT*Q[>$N-;\036=H8(IPU6
M'G%2,WHBSTOH/DG91L)F-GN*B!JRXV?;7HKT\]D)XB-OOHDL]?'IV3JS^[OU
MU[]N<UUQODIL3XD?K=0<S,V,GOV$O"@)7]SGU[,,8;1[G71&A Q$ERD+G4$^
MMZT4:6GK-+([.1[1--I<*39#SRA9F#.!:  3,CX36<:QW$W/M3I6,64Q+7;(
M?=$$WGHD5B'0A'*[\/-1IX*S2Q][-F/36>S':6A.MGVQUN3UZ [Q)#1*==EO
M*$4UOVE]BJ*@.2F"HCL-V8<ZJ1WYT$)0C6V2^'R52!-?4?2OD+M^*X62:/24
MRI!F7P!DR0-/J4D:/8O)HNY;6=?,6$>, 6Q=#;402BJD)B+ -'3[\2\844ZN
M^6J"7I"GIZ2*SCIZ6M = 'V292[[T!HKK70,(_55CE*G(NNQMT"7E=!VJ=5*
M[(H46XD5!!6_L-E<.+;\/[&/?K&] M=.WD&^;5-VZ0[W778E'\+\;V]2 :\,
M=:H,*:5?U4$KZ[H6STE] +>N[BH$DRI>%3$(&K^I6[SS1&EJHGCQ?/7()U>H
MOD9/J0QK]@5(%@&><@77Z&E.EG3?RAILQCIB#&#K&JN%4%)U-1&!H*'Y:;_Q
MJ^.%+G*O.&-%L"L,HA*!Z6QL4Q_[S]NLX?DJ?P"%9C<XHU3T&YX3&OMN[87:
MC!1U,R1DNF-E ]*.A! SK%JW.HU2(6FM=+"'8*J$-150J78-B2;R=3#3J'N,
MU$M^JE$A5G4NY/G4)*I)VU^<4T"F5N$]X"!(<5QTM@VH;T[-*H1:T4,J#05]
MP*&OU !E'U,2U*@?>HPA!B"UKCU*%)+*5 @Z!-V*:E8+',M4&_D^)]NJPZQN
MM)IGJW5'E-K^<QSW.U_MVMS9*_%=!/\."=_56FJ:F$J>2VYHLNK;3XF$D.9A
M;W^3F<8UJ?%-X0C!4'Q#3%3]*LQ$HH54@C-M.D='J=NI-D4HU:A-^80DBBE;
M5X(4B$D5V ,-@NR>VYXXJ_8P1TAG]RAK+A4!50=86"OE7=[!"/,:-4&#$T07
MF-9U1 Y\4F'40$/0'K$L36>)54RA.KEMI=(C;=WA?CBQ6/.U^):(NN7--X_\
M$[,=P2)UGM%P%/F>VGR<RCI7Q$)2";S6M5""3BJ:9XY& WK):) 04_Y75D3Y
M5[_>"[!R]"_UVYXX[?W: ="Y^I+Y50YX#?(M(Q')G:8U.<V )>0R!QP(Z\!#
M^,2B.KA@_+).S*DJI?-;RWU;>7M0**NC ;+V)FC763I=R 2B"4K[]=,RT%,.
MMPID*#J#76S3U8/M(8WS!;+V2@&2]N@0\1TP(I8QG2764;4*%7:4DT*K:RU*
M5<0C8@I5)_HEP2*E85K00U"U[=4$HS"8$XH#U1&%_,8%B9&\YI#PU<@([3<W
MP+GV/)""_GLIH'Q .LK^[ .^G_C)!QB"IG#(+BAR<9"\M4/EU,O:RQU[50]@
MB!>F> IZF1&AYL2+#FN($4CM.^AR%))*I0%Z5T[Y-L7["R+/U%[.Q5W!$B==
MVC;7]U6V;AE)])P%)%=KE&WSD52UKN3NZQ";: #1:C!  ?0F.* $%L(*,R'^
M<X#HXA(]%<4)\II*3:JL,1Q,E2M)?F-M;&M<-PJH3G2 :'VER <ZN4C(@>U\
M;7APD&]33(K6A60[]9J0;=DR8NO9O_ILB9SH\0SY>B!KFX^@JG4]ZX&$R$0#
M@&[6@C3 VW5 !6A6XG\ZR9!LPO^,?RE]"T\+#UPD>"JYN.?T]$-T<<]V7O[Y
M8GK[,)U<7XX>QY?6PR/_[V9\^_A@3:^L^_'E>'PS.I^,1:MOX_O':_'Y[GY\
M-;Z_CYI/+_[/&MVN/_UE.KD<WS_\M_7[R_'5]<7UXQ^L\5^_7C_^XTC_AK>M
MT'9QM<FC(+\LVI9I=-(II'5=893 0\M":*MO[F5B.T7+C1;FLB$5(%2CDC$X
MG7"H\OU*C7%D_^X\37:H9*WPSB487$E<VZVL1LAIUQ0WTI<#JEFA%*K4C3[[
M\$,@_^[UA#L;N]?^A;W$@>VI"T/4?5IER_N*;"G !0*+[L5=K#YR-R>]"BX'
MR&_<*E,^5&2*# D(W*CMLK5.UG>)NABL[_MH0.!*A9O@X*WJ,LE27Q!7D1'[
M%RF+;WY]0!0C9FNX0+EFJ>08$%9VN4@)/I1$K#D6G=? (I,Q(*SRVBPR00R"
M.=N=M^/+X#7_6+BZ)!HVQ)GH#G)-"[8'=NY2LEYLLL&HZ![I+P[Q _0:C+VH
MZ<]'+$X7['[W"$.NX'+8E<M_[8L7?\6#,O'_U_XCXGL;:M-5O-6Y)YYW%2?Y
MY 4-!D- T#D]'IOAM:0XJC"(! N"_F6 C;*UXJ300KRQ.0H"BI_"0$CO(XG?
M5I5EW<W'@;#TE1'L5(;>'&WH(A"_(#8- _$2M'@-7(_C.=T@*''-#,[!LCY^
M2G8]61#$$B[><T/N94C%,[A\X2=N="WB[NW"Z2RQ_._N/,G;$=4[/@3WNRS3
M&R '$.F(Y;9!\=">H$NKWY@Z&0J/-K' KQ4*XMVB[]$OTC+%4D.U*CX_M+.F
MZ&$.RI+(F%ME( C[P2KR7<H(-,+@QKR^9.:_O.-7, J$'419WZ\ -7 LWH=7
M&G[9;PA!84O*:#I*LX\:/$9I>F6]<</,V=2DZU6G.M7DF]4T)@1K6I>20G##
MFI64<GY:78-",.BU^6-U$:4OHJ/E=/7:RZK5:$#>>)=RO4P[0U?V7/_*%,F^
ML#;"./IM&L''QJ^(.I@AF5=58IQ6&?ZQ$Z668-X7*8C%MP8Q4 X$7?&5^&L;
M@9Z+0D2)W0,Y<8644(E?*&%E5G?%6*T*Q*=.#(,"^[Y(1"S6-8E$X6#0C40A
M';0-12NB(2MH4V"XOIHU>O?"6VU-6-*NY=:W51VR5<[_J79K4 \1NN)\+)+U
MLMY@S,Z3LS4I1)$@&) $W/(P<O\9LB ZL/E()(<Z(OR>LC>;WR.N. P'Z '1
M%^R@F!;WR"'/,:\C,DL6DN:G;57X?FQL&](\H<")Y"T*XDN4)O*-2*9-J\S^
MW!BS,U@5<^:GDUZ=Z(Z+%N<H$)>6'*78HSC>_;&#X]W6[U.P_N%H..X]' .K
MXYCW< QL. 8V' ,;CH%!**,8CH$-Q\#*' /3J_@4?K)XW.2"L$"GL#/3'H*"
MJ!FB@00XWTK+G=Q%.50\K&=(" 5%>GI7#<_6?;E+S(2.AQ3=V@'_=SH[#QG'
MCW&7++"QM\-1Y7_]<'IV>L9]KMUH_(]X0(O,+.X?69MAN0\5#PS>6=I>?CZE
ML=;>H&!..!=?$ L02MQZ?K[:;[QIIG2U:IVBFS6TKL<+0#EJ#; ^^XJ&A @0
MK'^#[S+ <0.+Y-;L>088C+N^FRIO+TK\#L'WTY>SU/F''1(0:#[E?L[(\TBT
MY,<)'"4/%.U![&5+\42!% 0>Y2I[H=-7T*E#!U +G?P%IXX%#8PK*4FTCIZ?
M*7KFF_4XXQHW,,A=2_J#4$]MUI= $)P;>G@ER3+7TERC>UN+G!"Y.QHGG*/O
M9&R4MX=P8* $Y^0(@6/6'24.0BZ[XCAO(A77@M*V=Q<^>=B9SF:(R@\&&O2'
M4"ANSDP#!,$Q-X&C2.1C3IEU18B#\ MRIWYB[U?L\>F, :'HMX3&FB$)CM'2
M9$S2%'U=$G]W,$V6URTS$H3:3G.FET(5'.OW:XMN21 ?=GA8>CC8 7\O1/I,
MM9<R&@9"75W)7941GN XWM.R.'->&5?!=7RO^,AQPD7HB5JY=;6;A#LZ'=L-
MWYW6Q3,=U, Q\L)F\Y'OBO^$37CAN(JW((+-O8NJ F;-ONVRL[:PDB9V'28U
M'\+%0@2R9@_XV<=<PFP_X$(G+LH4/C/A.W2,V)@%>"&$\"M#L]";X!DRRWZ^
MW\]^KF<6Z<_$W-9N<FLS.V^\!4"0AT-@>1R$_F1*G3ER0R$RW!U:\DW3ZLX3
M=/9=(17+PH)3[>Y=^<#Y0)VO-@_,R;W?XIZ LIZ&;,SXP<6H0C#F<M16!0\S
M:O4$DMTTD%DM+B91A,#%+6#*5-M>*PA)3P,!S#XQE<(% AO$.:(P0%2/'=+6
M$!(K)=DBQ0D">ZY"OLL6-5@<GRO\*CZI7S=2=8"0)BG))!5:$/@D16MO\ZV[
M)$T@I*GUT4J%8+1W(;U]V$**V,[],&5XLB=H<UJ432E&KT-O\LK&-/)I;Y M
M_HZJ?,T\Q0_[GJ(8U8J&M9+C]L;]VU)EQ!CB[K_O3K#]A+WH*KLU1NY49$M"
M*E)AO,$M\>GFSW.;8:;R#VL<OYME> /_^2K!WRN*_A4BWUDI'$BMGG <R-H%
M(;6(Z] "PFJ>9R2V8"H]3*V>0#Q, Z'.Y:(*1:A<9%O)5>^BM;I"\$4-1+6(
MB?L(@N+B^6K[\2\844ZM^6J"7I"G9WV5G>&\,]J6 5:2 Q3?DQ*Z#[6Q-5:,
M <\N:TA\H5;+\07%YFM_&08L0N],SS;G]8!JD@LE-Y>->1A"8)HD:2BWPZH.
M'=A>26RJ4=NK(@$$GNZN,\R'-/_;@I?6JPP)Q!H7RWJZ.J(*RA#DX(;X:'5C
MT]]0<!7ZKIK#LL80S' = IUDK0Q7"$RKPW(51:IKGJ.[H'8CQ,I=OZNO([T-
MD,>H;RFQBY:.GKA:VHZL<DZC'X3@>.,RI$&'GE39Y>!@M$O,[0]A@=$6\>)M
M8"Z.X/@K1=A4EV'H<"G^*7#J,*NUR;HE$VZW*##+:_VPG]?:C&O9OFMM1_ZC
MQ<?N36YK*&TT3$0/I8WPRDB&TL:AM'$H;7PKM7/U%CA"KYWK8PEJO=6-H$M0
M)^**>W&@\GJQI.0E3F<H6:3L >'&AY)L4N(%@55#%>I0A1HAIGK9JZ@3Z)5.
MR?$BS. %5))G9Y<4.3BZE()_]E!$=]\=+0@-\+^C[Z7XR>(OM0T/>FU5QU%K
MHP$XZ9'">HMD$J'N GII+J?Y$5[@.)>41 FGTDT@W*Q4CC-I/#H,D6H\;,"W
MX0OB;]XV2O^FT=TLVOII/]JZF\-*3&)M9[&B:?YHQ7#&?T61V4P+[:%Z$\/-
MW+U_ODH^:*&*WNIT'%Y'JBM&J\^FX<6D5B.N@%],>D#(K>%%'L-A(,1:M1_E
M,<1M>-VJDZ>36GO=JIDUM2A$)&_>76"H"(6D5=-9FWH;",H@%]]O. J#.=]M
M_WOOXFSM7A#TKP*/]Q$"YPGF0IQ[V[E6#PAQFLH, WN7>2ZTTS!@ 7?"Y#<H
M%W>#$'BIS+841M!YM[G>;K005[F-@H#BIS 0J\ CB=\#UF.FSC@0@C<5N*N#
M(G1V3S#_SUU'>,6&#/F.9LA TA7"-=@5F"K!"AP?AWNOC;C<T(W7/0[*[IYO
MO/9GA"[6V1^S2.W[[B.UQ]8.$RN!RA#"'4*X0PAW".$.(=PAA#N$</L2PE6R
MZ+P&%IF, 2%HI,TB$\0:6'H8#1++#O\KN^3PKWZ]M_WGO),WF=_@7#IDMNAG
MT.B4RKEZL/=KQTMXKDRD*-FUQ-[8KW@1+J34S/S>Y=(K8?V&G!E((>P^AT0;
M@$2;9,7-1K++O%9:92 (VR,=YE;!$5Q0,8.'V%$LEG$HM/@Q4]W.$'95%=16
MBA<X;N:]WSF=:6P3)0RN,%[?\G@54*U/#/0LL_:#X'K]^I*3,T )GF+:J^B$
MW'KIWPC8!6&!]&R2LDO?<FYJ;,#QZQ(])5['7.L^<J]]QC=< I&DO,F>&34=
MI&\9-E/\^L?E.,]?FK_;[A">CZV5LUO,&E_[=C(D5F&1KQTY<XSB$\?3V04'
MC-/@88D</,/(O<$>8@'Q\SV3"H-!>%56>Y6L@&=_,^")UXSQ\UP<R[K$+]A%
MOFOXJ,FGTP\-)KEW8%H1G%&S+:1##GO(80\Y["&'/>2PAQSVD,,><MA##GO(
M80\Y["&';9C#YE11YK#3OT/.8:<AA;#[''+8 '+80_JSM:.C+:0_]?)>N\A)
M!(A&QFNO!X2]4=E<UQXRS=.?_\K$)8^W*$CF1_\:VEX4.+P+GSSL3&=\L[9_
MYK/<$'W)&Y?##EP*)'-MTSH,>6\'0L\=;JWM9_GKW3I=^Y)=-L,*'!^W 62M
MN@YIZ[ZEE:6(]#>-\8T$W%1$J0'CO,4/#>8M8KCBG,60IAC2%$.:8DA3=)JF
M..C0=]4$Q1#Z!I^=Z#CT/<2]^ACWDJC;;2CD9#J[Q!0YO!,;^]&VT'TDYX@#
M(IY^S5,QO7X0U$K;)]=#J;_^05S;=8\8HB_(O2+T*A3/V&PJ:DU=AD\-N@PQ
MJ-8&5FM&J!5#:VW '1R)SAR)T7>;NN*5%X7SD&G3=X<A@PZ$5372D7,NU:YX
M^8@C;\=4I2(G%I7,GZ]V;=9E]!$>.V2XB?!L_]9>J-_%:V8J((Y*KC2GG,5&
ML(<@0N/%TB,KA"+9GT:PJ%_;D[>'X.,TJ1&IA_KD9(# 5;YJ!A2+W8K<32IH
M"V'?UA8W)22 P<ER3G")_A#RF^UQO%?N\P8AU3/$J29]K2?+QP82"]2O!\/<
MW^2)3QZU&XV["GZ+B<1/BKA=7C,(.PNY39'#W00=4SN/NY Z<VX)B^FJU0W"
MFE] 9RT\&I;?LT]:\KMK!F%EU9??'=P0[.X0.080.:[OA>I-:/+"7N+ ]@H"
MDK*<I_DX$$R;V0W4QBAV&):.X-S;MIN%D_^T_Y!?' N.QK62 _<F\+M[.[F\
M8Z.*#]<X_N#7F 61:V?MX/Z\$?<']O:QLOM3T_:Q[VYD.?=F<"/;<7>:=R/?
M5*)5%K]O<HT<\K%#/O; \['ZF5A(6X5.<K"0;'8A 63X%P6WZABXNS!8?61)
MF8+ZUIC>QM5*4S9YR>*U']\[7;?LY<\!82_>D$#62RAPIP4C,)^*\7O*XC=^
M76(:/Y58*&CUC _!$6E0R.HA$DP!*T.QZ)]OB 7;._1EMZ_6.P6$8^? ;%DN
MG<!)VEO)1TF.MC<C,XUDKOIB@C8'2&*41R\V]L3>DN/\"^\K>PR[N>D@G,D'
M9IH*:7:PTA@&<X[8O_=.<S4X#X1KZ6'+7X)8AR-XN^M.IK-I&+# ]EV^$X@C
M-?'+8G7+H-:4$.[2!R:.6G0#5UJ2_,Q=&O[1\/#BG_8?(Y=6FQRG_T3Q?$,1
MRH$4H5S[7.S0]K**B9A*@"U/N"E[O)$2%24-("Q>$@"56;6"/D#28QH"J\$I
M2%DOX1MR:LS%NQOH!7ED*2!=&_:BTVO%/2%DQ;3$,7,HK1@S",S[!?F(VAZ'
M<^0N.'E9( *,+TB'?9I](60+C!FHB1L$%@Y5)D.5R5!E\D:K3(93_\.I?T@+
M[>&=^N_Y2R&RS'83Z^[PH,CA/2@21Q'E#XJD?X?\H$@:4@@V?Z@U;#/(/M0:
M_CKRHM&1FT^"M7,K\R$U._=B&U)*A'0I "[CDMCS?K.]L-0!W[VG<14IE_BG
M>$)K.^.0=#F0I$L_(DY=)%:&B-,0<1HB3D/$J0\1I\'[&+R/?@C<E8VIV$6B
M$6-A_"(AXQIX@X(Y<8E'GE>C)Y&@<VJOT369^7#]GE;(=S@%E'E8WV/VVQ5%
MZ)IK*44L$._*M2&L^?/V8A6NSQHT)LOYU#UL2191#I%W^48\/HPGWHEM299E
M,_?:\ *29AE]8<ISF0.4*JP?$5THCQPV-&&OS[G6(+T-D15R#';D!/B%PV8:
M@OUH'(*-<;;L]81#!':(P X16'#;KR$".T1@APCL$($=(K!#!!:FP,6ZPQ)G
M3.^)YUT1*GZL6P@+)NNUN]],G+6 8C =^'H0C4_D-R^"FWEZL7Q64N.&)')#
MP(,3QNCF$;:Y].T72ECMR[)JIEZ;P]8%,I>$\$12[%?CRP0O0[J]ABO"C"4V
MLVS\RIUOS.2WPI08J-<!27.!*D$A>/)2D5R</C.$Q;U>K*F;1%4S]?H.OM9-
M6"X)#TXDU^HF'*Y&MW@Y\_3Z>K_6Q3&'@ <GC EJ_@WAYWF W-$+HO8SVJP*
M=Q0[2%!ZUI9/K U(K]?SMOQE;6J^5=GN5J /SN\V-",=2'T?15T:N,WU_IH0
M]SHA.##/ODF1KY/LAR?V&P0[E7Q#('J]:X$E_(:4/SSYS_&8N]  8S .+"[2
MI0X8T[Y_6J#OIW>PS]>>_<""+QWN\[5)?G"B/G)='".PJY9E31T1TYNSUZ:\
MT2!, >%@"F>9HO5"XW"/!#/Y]Q?$C[ /;4]4L[]7B6S;D!Q"'$;+/M1R4*$*
MI0].\N4+DHP*M9_'J0+)(81C6I?\4I2N3_)E#]%7).,UAQC[##OQ(:3\G46C
M,_5ZFYR[GVB47#!M:3TN1AKGYO,TV?FZW!&TH,T-I5ZR5(0IH?58_C2N+2SJ
M>Q-VN79W(:,-D1&FD%:/D>R"@H\DL+U6+*K>U,,;D-7H!TYB[RAQ$'+9%2>Q
M226O1K_#?:]1 WEPC*XJW\J4=?3CI1V@[4T(K1PYT(!B>*6Q-E*"$^GM<5I$
M7["#\@ER2_P7Q 1F G<66>7D[Q>$!;<D^ <*[I%#GGW%F[8-SM>JF'YN4TP;
M)-K;$<A81Z\(77\EVLG\EK:!:-??/CT(V960$MPE09EG;6(,3:\)^F1P3=!N
MPG6K>,KAHJ#ZQQ\N"AHN"FJJT&VX*&BX*"C"K&_/R'5\05![S\@9<_(;!PW[
MSPJ[G6KQ1IYT3>$,B$U*8YMI \1*Y@A8#J4A&3>)/$4"PV6*R]W45S]9;30"
M!$.8*UX:2UD^1OU@XB.?KRH;4V- J-RI@9$IG(:73K/+T?#2:1X[AI=.AY=.
MP1K]X:;+1A)5PTV7Y2D;_;->K..HL;)>J;8I(.Q1@.5-<^D$+@=5NMXJB=Z]
M2 8SCJ3#?[6?E=G\^N?J]5GK8MFKGV PA; ,]<;_"CD>US[CMCI:$*;!'-''
MN>VOJQ:VV;8&+_PM"<1PIJXN2KY%>6[F5CGS^2%$F;HQ'RU+_.'=3E>(^[<(
M\::N]#2>OM=[W!Z(>I;>;TC2M\0OK*L$L8\Q@_+P#ON!)?6@,BW4EM<*VAO9
M/Y6Q:] T[4VI5WHQAJ=CQO"]D=T;7$4SYM@;TK96KWRJ"LUPJ+-VDKXA44^;
M@>CX Y15) O,8>_-REVFTP$;P"G'<)"P)[LB8Q'O]/1A8X>UKGW^)7JT7Q&;
M+OEV2V0%)X2Q"YO2U?H*3\-C6C^>_I ]IA7/8D73\#^W,UF\!;.<Y%R].9\E
M)Y?JU%5AKTZLUE8*1F$PCT1149PO:PSG=)4F:Y+:+4,*PIJR#YNR)E_>'$AY
MOEK:U%R!5+3/81%E%,X%";F)72GKNB5M(6PCB\0KR1 )&A"X\1#8@3@:->%S
M>/\;4LQ<[ B(U/7V1;T@[(),.%2($ 1><50N*.(;L*1Q5BPYBO9P3H>56'44
M>(%E4^$!W,)>0):A0B$LY!3 ([*(4V->=#8VU0C"$J0I:)GSK2DT(-!?;@'V
M0HO:;L$$0C6_ 6))'A5:Q-X6X6]7Y/&K\.W1.?(Y3V3A>&EK")N+DKR5X@0N
M)"='T%@98124UZZ-+=Q++I_\(7SZ)W*"1\(%"=,H2I;A2YD!(%10&_*I#)H=
M\FV"%SB(P)CZ7QD:+81+:,8YR1 0BL+JY9T$47"F,G]+G,=9K1X0LL$EC:42
M+W!\^^K3;3J!0[Y>BV7KF[0UA&MV2_)+BA,X7HG,99S%\CSRW?8==(EFB-((
M[A%C*+B8B^S6M:]4//-A(-Q?6Y*[YLAVF%*[( MN[:.DX\AWQ1LP'%_D.Q@9
M)M(^GYYE$VF)L2W;%W<>)D;O3>IL@CC+T 3Q^2\1<RB.6*-*FRE[='7;.9?E
M8"5NX@HXGT7">1EGI LN)=3J"2>9IL&LS(7FQ=A!L,-20 68R@"G5D\@04X#
M,=7B8A+%1OR-V0P[4?["?B)4=%L]+&V'6_9SP@+BW]B,V<Z<3QT$+#?.67X8
M")%0 ZG<^1UED&V">;N:FIK86'% ".&U,@RMB#8$ZWIN>V*;]C!'*!"IR(CV
M\C51WAQ.?L]P(92C!)4_RD5/U0'(6E<D<T7<@93*B\H5;XGOA-S+X89#^#CY
MAE*K!X2EK5CD4M%J%3H0.)1O#HH2?86]NDOR:2*49)+2)/8VN3>BR)[.[I'M
MC9FHIMDLX1*6RIM#V'^4X*H<(7#!M!B[751)H"F>VIW.-F_O*O50W1%"KJ^T
M4JI1 \?(!\0-O2AL0TO"I(GTO580TGPE6+2'!SA^I,5GG>,OS)>GVD)(XY7@
MC00;F 'E"?<..7BC9XJB]=0TP/S!+,!\;*TGM+8S]B;HO+L[]()X7NQ.XQ>4
MO#*44U?L."4_B[NJN;,=G1[2>UBGOHFZR0;S&::S!&"J"MW\MG#"V,VQ/Y4V
MSB<#!(N^CZF=CYS2RS0>!4AL0"G+Z<VO(8)-!%*S9OUO.)@_SC%U[VR^#Y?'
M2_7Z00@&E)3&;8A4#]/A*0'-V&:SUG%X4V!X4V!X4T!_J:Y!!XOBD/5.T5W0
ML@E2Y;\X4)]A[&U@='/FAF-\B5Z01Z)$ICHX4- '0HBT:1DJ($'C-=SK>S&F
MLZ]+CK@?;."Y0BAK'C3:0XB*-L4Q#?0;YU9V9QM?[CR=B;M,N$&,T-39^^?W
M@Q P;91[>F1HG(LCWP]M;PW,#:=-@'R1_>1"E%OHHFH.(9#:*,^4V(,+C4?O
MJ5XS%B+W,J3;%URB"X'87<@MA<U$K"'*6,MBA&9C0#A(T?A.RXPD?1&+Z**R
M:E(A&0+":8V.A$)"D>9W4H1;I@#;W@WVD*B_0YO-PI.'GZ5G%[6Z03B>T>R^
M2H<*G6VOUM^[=Y2XH6.VQ=KOVRHS/P/:9NV3HG&.KATI=H^\*&_[2+8"IE9+
MS8[MQJY..V"F)B':<E2O"+VSA:T0MR6J/-1LPW8YU7)$2H5XA\4)MZ*8DXDW
MY**=VHA;>!=[H<!N7>5B>N[M[.ST?;8L@<]BB6FL):)6-!'_,CF7Q;:3]; B
M(9]JXU?'"SF!KKA\B4M$P_41\MG8ICY7TRW1]:H1ZIFDF]QU-=#/5_D#*.H9
M&IT18E5$G2*8RJ<W24@(?E\^?(6WI!5W U(YT8+N%<L+O)O67+[O%3)_(6Y\
MI@'F'^_H^E!ZY+467,*FW1]$M8:FC*>S'MHHPN H"RAV@C5H7SFEV?W#UZ*K
M]%1](.2VRG%.B583._^OZVO3XVB?O, IOQV$E)0)H16H0%"%[4WW@OOQ=?E*
M-5"TAY!N*J,""I0@<*CBFKSG7]:[^9U * RIFT3Y12'U[)I[6Q!2$7WE!4<U
MC0UW$:Y'%FLB4ZD(TD\G,>/6090__S]02P,$%     @ *SYO5 0#17ZJ8
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M1SL<IXHXV9D][Q:G81)<QL$%F30H-&^W6X#O=:K6=KY&(^#>URWK:/?C9,G
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M44X94=*NRL?5REV1OW0E2LE; O;('O7:M>-:S8#Z8Y^THRO'B?[(2#MQ1IZ
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MRFH?PR9QZ'L<D^AJ?#B\2PYD_4%W.OA0PU]I0X=]$HN;$Z2!N.V151+,O*$
MRG@=XS7#,BX0NJ@KU'&QBD>7SQMF%7<G:MGF+CP#S[A-*^EMOW&W#6,B@1>A
M_>$Q"GW2FS1Q,:SP07/"<46?P?('EH'&'#BR:%(_C:%EJ++&Y0FJZXRG-+;,
M9;W!@TNQ5ESXZ#*7>:T/+T"NGPX8PS_B+^P;V<&#(2F@8XT- ZDVLG3H+&AS
M:Y ZTV(<9[WBLV=:\O@+;^"HGJ$32U$R=&M('ZQ8,57:/"R[^DF6&U7>LS +
MEF'-*$) D6:\<8QFKU!0QNHLU5X$U;/1F  ('\]9FD>X#4G,>!G**S3"_(2I
MF*^ZKC3OQEY'YVTJ:"[?17>%S0[M9 V9)]_T5U2$=6B_>W%M""KWX;B$ATGZ
M0Q\5H(/82+.HDR"4) !/DDTUL9P*(3+])W#I$+KY#PM,>-#*<%A22H/]<]UR
M)@ B9>&;R5%PG90P:]ZLO3-\6S2APY:MLWHK!"'#H=,33XV]K_DW]W5WQ4[\
ML'CJ!1A$,[;MU2HG;OVP?=H!PNPTWAK190X1!J?N=B@N;Y"8Z^!29QMN<</$
M/TY]IYL4]QWSGLBYKO%![M)/;N<Y@%S P>S\)[&-Z1!U1QE,6#R,G6.69 @9
MBSFA-3."]NQFP:AA_70'\*'AW*90'70Y7E].>2@Z%B07,,5BWVU848;L\BM.
M_3"3OD5G0F>9,-IO&MUI6">1Y8&KABX33L]XDX(SJEB#PMP)+22%)+:\PP4?
MEJW.+R1R > A#L=J"Y"C)K1,S-$PCO8T[D101T>947.:,_HY8/7E<9RQM#^T
M3E-"D1<W>7Q%8KM;[Y7]>4T3%58E(*TJ1,IHB@,7W=7SZPXL65%R?_?;@?:&
MX+R J>$=SO(T]/.BS!5S^M_2)#/9C5/16B9<ZYE(=YHH);0\T-;49\+I8LV\
MF#D6>,T$  5,$]OJ=T*9VH<=&%0V$5$*'O1PK+:$/?W$E@D^FD;2GB^>$/SH
M*C3EMN!R &AJ:_4CT-B)D*QDKP)P"Z$VVTLOC5ZKJ: X/VQ9T1))H&!CTV!U
M?=]Q]*#?!+.EGG%@L7HLU:JB6:: ;55CRKQ:@ 2MY8=P,\P_I"E=U3JY(>;:
MCG(X+TK>E BVV2(F1KW]V-R6='!KS+7M!'!O.]N(+<AA@,X',+N(/H3F B%]
ML,GZ,%V;X$)!?;A^%NK.G"2LSV=)!:X7I]G+ _;YK->/[$#V+]?!?QVRG 9U
M]I!('DYD9F,;^.(^_QV]*9^%.;['Z4OH8V[B.^PG3S&CPH91R6IJ!K9 !Y:Y
M#=]\T'-:GH W.V93W;@:Y^WU^:K[L*P^3UNAZEKP-DG1>9+E2)#$S<X(>-/R
MT8@;U1?83U</ISS3HC^03MF;=GN@V*6MJJR(3:,Q],FLENS&)5;(!-.K"O V
MLMZ0EV6)'[)'6[^$^7/UA$]Y2MHN5N.V)HUENQR5!:O.A\^[TJ9GF$Q.JB_'
M)C"IX5I87D^N53AGB210*+1IL,%3- F]I4^_^M0RGEK5S.E%UM8#[JA^P+U9
M@] M]("PW$=P-U>*5[,VVW,O>[Z*DB_9^C'+4\_/I>=VRB[ X45'X<YGU3K:
M X8'+;&-+WYN/MYO;JXOU@^7%^C^@?SSX?+CPSW:7*'S]?V_HZN;S9_O'3HU
M"3*J]&V:O(0!#MZ_?B(+E>MXL\>I1S>1UGX>OK [L#VN;D0(> "8&T<,B^%4
M  ?+"&7&C .4)RJ9TL3>-Y0O&3V_1Q5K5/-&GTON1P7)YADX'9B)F6A+P8L?
M-2257;R*V:\.D8;88AOF-_(LL$8#X,APK(P8\?6W@".Y0\@Q$7H=^\D.HS>4
MX/=LJS ZL))EMTG*,_/S/ T?#SDK>T!FPA^)E?E+P1%M=AV3H,)9[B9>+1LC
MZL@4<[60ICN:L1]&F C&?R2JYD-B9]B?B!7P\)_2P-(%N24^@"%I4G4M+> K
ML= 1ZM&OES9168+)T\KD<8&M]*_TLT^M?> &!C?AN<![(GG8M<4O:0(<];H4
M$M%*_!XPRG2*:>JJ(C$W$3R9.@A_I:>5V&$(_>:%,86@37SO17BS)2!$@CQ_
MO27JY?1$9$]!0F(8[<[ PVZ8$<2 U.L).%0'*F#J]91-.883O[\(LWV2L;UN
MN@%=,D6,*ZK8NKHD/)-1* MJC8!9PXMX9<["%%X<L//?3D/,7?/]?3NU0[;1
M*VL,' #42AZ5@#]J"3C >P2V41Z@,Y.);C[0N>-E]Q WS\@]E?*2C", X_GQ
M.Q;5,J(X3>S9;AA$ 'A8#S>&^G$366_ X6^@A.4G3>I%><'0^8I\1IN</U-$
MS%J+YRS#9-U-1_@H]![#R/E"^M@BMRG>>V%P4=3++5!\'0>;_!FG:Z:!MGDU
MB2T.388828TL.I06A3*#%+*,. 7O<NK! HVQ19ROJV6%(RN5YB@F)QQX$F:/
M\@Z4UVD7M],6*B"=1'(1!R*.K/?B($9IAI[92E?718&(6@/;\Q06$34W<& Q
MC36XVG$2GP$&@[7OTUSZC*PTZ>'V0^H%LJMGVIT7!P4J(ZB1H*OGHH! J8!E
M'"AYH8+9"C%V4)8JDYBBTGG/J4(+_O1 P+)>*I43I&K9)GPWQ)##R"X1, P,
MUPLE V@N#61,5+,//U0*)+ 2%C#U9HKP/2!HFM. I:44ZYI(;B2GD%8N^$QP
MJ[OOXL!)80(U G5T7!3,J.2WB277,2I9H3OKAZGF*#&%_I6BJ=O#4OVD=(FY
M!A$ 'O/#C6%VIP-P]!LH,>,=CFD0(<F]2(4(,]ND-X$1'EQ<QR^\OM#8JV%J
M0LN$#PWC:,"(@LKRX$1'F8E@I6(-*>/:@9G:5\/"RBXP,J6+%!UZQ]S_VR%,
M<2.EC2S3^E(]!Q$ CBS#C=&X>J;=&S"2&"AA?/Q8L&*U&3BS*N%SQ3,^5VSI
M[CSM<TZC$/&?/;II 3'G4Q] 1R,P?+08;@RS^0=@M#!08L;Y!JAES%0V:2QC
MNF87\.#B*HR]V+>PC%$36B9\:!A' T845)8')SK*3 0K%>L%+&.F-%-[&;.M
M[ )D&9,F/L9!=D6$*TMA;;9W.,!X1\^MSQ."C&D>DH^W:;$GS)+U93.^$?2
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M182_>24 #*&.##'FG'/%@5B08X5J$?F7-"&K_;=&A^+)W([[-V*!]E(#1%5
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M#78#.H"19)0ZQI>_*Z8H25')EL[-*>,SQAEQUO PQKG%.JSD\G""%H]Y3J*
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M0\>.@8;H3JQ6]X6,%4-5F/*Q')<I'5+UW[\^$.:*K#N]GL##8(#Z6D]$U=T
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M6],888YWT%'H_)F>PEW'%WB+4X*;I-$ZRW">T4,TOCZ.HN0+33T?8>QA7$X
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M^R0V=5>1+DNS*2F[J1PPG9H^3G./C"=TUWJ?9*'CHEK'=R#:*=CEZUW*L<:
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M;.^=A>NM(SY^,G#[WV;WN0&APIXY-X/WGRQW_067^,+76$0A%]N^U*7N.4!
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M4#5&[)]#.T1F&G@&5NC5]/Z+-2_,@0W:DJ/^H\7V ?V8D(T'(>FN8H:UX#T
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MS7DTJV^0';YTO2W5U[LKU2=1L >>2J"SO?CSVK3M3*K!<@GD2O5) NR!IT>
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M=IIZ2].!?T8\_$B!A?'LS)\R_)TN$L<L3@R69L=B;$0DM=V)\5-K[!^P>$$
MNK;)\1>RNU%.7TG%5]9@:H5S;;W^W*B&>P[7:]/;3A?/<.G !;1P &A\/PS;
MF8AQ5L9@9^B]TZ+>2]K'BB_3@_'1A9'I0V5=6&0**P<3I4(W6S::A%FZB*]R
M?IX,NO<<L:66VV=5)[*=37ZCJN#.A%ZTI?P*3/SW.NNL9LS\87'FX^:,J#UC
MKT&5I_F."1^TL"8ZO4HG4[UL2*P93JVCW,3FD5-V:HM3I\&,3J]U9&]T/(*
M<TZ?%>=TVJ!A.G-CU^3?C+A1E><U\88+8W)SU.LJVK%\7/S;"Y$FE)O_W/+<
MBV^L1[$&.B&Y<Y]DK=E=N+^)<XR4W"]G:(E144LD71AI'Y&VB'HQDFZ,?#^-
M* Z"JY";?H)BJ-J(%#\G=[^DN5^QE?QD.!U=CCJ*+J@GPIV#4Q('-% ''%=5
M;MSUVG72=QG+;PXQE,1Y44E\=&QD>C9VS1M1^W\SXM[COR)%LE="<;MC[ZV.
MC!ZFVQT<]9IX7B7F=D',5'4BV(0RND181*0'6"I1K('NB*@DYDUEJ(2+$E]A
M-,>C!HV]%E6>XA\TX!/X['/R-K[?'KV+\O'@?'KWGC'_ZS;:3>IOWD%?9P?-
MVJ?4;%4Y?2,'+[F\X0UP2 /]%*<Z?C'?N3<SET6E%#=BI*VHK(AV]');&=0:
M7:4^VQ\12S_0JB@W^3EDM)?&3(PV#:8M-J=@G+H<V51H<X!/88 C< YY59S&
MF4:C7<1^LRK/:PI#N&>Z8!O=!"KSC)&E#<0:R<^AX>CR_*KC=UZKR#H7JER?
M?@UTR&2]L=TM -?  0L88(<OG^X8G!1U1]J8D;1F),TIKC-V9F!T<R: \0&L
MB,;@;Z&;,Q TO'APD??N"9FYWFZ4B:P$-$?5YE34(:*RSYV2R.2#!KKD$40/
MU3T!+]I#<>J1LAA0$!BX)6,#/"-M2V4E,C$]!ZT>.](9&H-<O!/UL#\<UOPG
MEE=N@K/DDIW-8E1I,%V?PU<?_!&B,I,W_@BF06GL8MJ2L6M*Y>FZ3SGS*BBI
M>$>76O/#848DDLKG@7TVNK@:=7TM@RZ7_-55$:JTF*X\ <A"@<@(8">GU0.1
MC;^DG_ZJ^(27&)/\O:N[[->F#_WI8F]DV_B_+!W 5UDYA4 70U$IU"!3R\O'
MN2L=?$BA5>D]/H2)TS)5_#><@V[B!W!M!L0[YOE"O9<\!SEJ7>"592R")?9&
MS,#&]407#:ZZO4=&=2JUS-*89!#:S[#&MW;PU.T]8*I3J>6+26A-M:*-2Q1(
M ?U_W2 Z8( _D4T,4HW^@T.0-EEO'"D%B;(+<B(+#W?]WL.E'J5:9N$BWCWA
MPPYO]=Y#IQ:A"7(NM4+._7J#IE.4_LZ[A?[&]4U[NGAP\>.8;V >/PO,AZ(J
M3?4>4=*(3M!UI16ZHJ#KE6LCTOPXG)US%\6JEV?A:'0U[/C43'@'58G"U.%V
MHA5*TL=3;U:FMP2<VH9>J??XJ$!>"HZZ[EA;%5Q0HLUX_;*\#?0>+S5)3;&C
ME]/VU]#TD*$'<$+5.5C'YW)1TCG$H]]-#_]8<OZWAR+!5GH/)1GTIGA2Q#%,
MN)\XPR?A\35=ND)AE.ZMR*O0E8I6+Q?N#,D(\1<[*6_!&[#=:%N88PM!/7#4
M["T^ZM*88D41[RWI^2XS0-1$%]DXU "Y=&_%7(6N5+1Z>6%)%QRY[4V>VKW%
MB0PZ4]SHY8#=7:7C=)41BO<>&4*$I5#0RZ.Z'Q/-APA&K3S_SD>7@Y[Y2:O0
ME^)#$9\HP7J8K(&W1*3]ZKD_@A56C::SQ0E_0QYK@K]V;R$@@\XTIDPOQ^<C
M^)%AHN<ZZ*,59S(5.?H5;::W2))*< HI_>/;7W B++[H]N')Z<FP3G1[W-<A
MQ;:?R7M$NOQL^IL/%J'] !<@8BY]<RK:2)]TP5EQSRJ%7 TNNI2FUQ::]\/B
MO"<DV>[+))><;?M[9X?HU@K,0QM,%[OAQ6$%"/"9;)*)B.93M"7'K\>A&11=
M[: JC4;Z4$ZGL,1:<CS?.#\T4#J$#.!":N>LJ'8H><#[HGH:2PC>F1(BCJQR
M;"%A>ER,+O"IH=+IO\MU1D5*-5 $_!F/153#J*@:Q))_-ZXME,H"KH!]DHQY
M7^#\Q@>K 6541741T6R-2N1KH#]JY@D7TBKG1:TB*UMX7ZR3QM*&=Z:"]D;&
MI76H=911-$*\+^H6<2+5NM-/6&$+^8;'."IM&?DGHM]\'+'BO8'YG>O=A?AU
M5/S"M>E8'#XT:8WG^7LYNCSI%XA:X$8[N0(Z2%0OM"9=E/C<">GJ^[+&*)BW
M7@$#.4WV^8PF#+3 Q]S*956TH\% _(+L#%CNTH%_(FH PG5,(K\]+;D_Y11:
M?4#0S/$VN*?6<BL=\,75XX?IQ59[\OP[]JW&C$2KQCK^3G#7**.3 X-V8RS3
M,OE/&=^R,LGR;6P%\(UW#U*_X8/%K00V:9F\Z!%[,'S$:626!QZT@L1)$MOJ
M0NBLTM1!X%$:8]K)AM36.SA">Y[+XIXG^QI.7_8Y4I_%46&'LE@ C-\/N<[0
M-,&&K6-!&W[L;04V(<)-*J=$&#*C;B+D4*_Y/B&][H[84Q9G(8@XH=9T EM]
MPC5PR%&NP@NM4%?%%8KZT%-?EJS67WSJ;%E[ &@2@.D&X-1RSO(!():GTV'[
MU0Q"C]<4KM!2?GI=C<[/3[O5*\(R*VH:66S0X,QZ[^$6$<TR&!0U2_'YEKZH
M$TGON*A@^^X-#8=R6OC*.[3# "^J8F:O2&O**0N:F*CF;FVJ-;=TQTCMSC$S
MT);@&0<-1Y;9Y-VR0Z0J[I 0L)<B#)(C!=%WAN1WI TT&V6(!G;S(UZ_$9^N
M0Q\Z:*&_!8$);;XU[>RD[$FRJ$%\;2Q8 2-MUOA+TK#J"]O46YH._#-B:NX1
MA#@ ;<?PZ>(..B:RHTP;7V@%/"?94MKN;LD,7WTTE?#-0R\.)?D*@I4[OX_=
MHN#9C'SU46#$ME@X+18M!B0])K$+Y328-.F7J+NF^29I>4Z2#'8,WPPWQN^0
ME ".6%XY8#4N?1K@>)BC WH^R'PTU^CCBV<Z/IJ0B));=VU"AP0C9D6%\<0C
MW!)P5"-9 Y3</TV_@O4K\ A@V/VNGLRKR:PH?#J)&LAX^@8\'/X5^=3B\ .J
MS(GELPP:G9R,+G">$RTP($:RI$V4<K8%VI*!>V2^"1D8NTKJH4,1*X/.H2[!
M1+JV@$>-H^/!_#;$E\7C,-'Q<NF!);+OX_B1N$#IS02!^@JCAEN$'SB00[Z>
MKL5RKL3,> 0_HI^(FH>KLEY8DD"[GE&NF>GSY$$+I)Y/$G9(Y36%BQ"Y6L:6
M/GFN!<#<Q[[R])+7O0,#:-I/X:L-K>D"T89F$@$QW/7U1% ]\K5\.3/#3>P(
MA7.0O ((+(#?3YHZF9T'VZ_";D-/9-5G@:[/;)9G$\CJ\F^;R F/"OIDC%5H
M24^DR6*$I#<\41>OKD*(*S[K]>@&\17AYXT-@P^NS+#H!S2S7* 9/;$FA0M:
MOO?Y"((X2AB'C)%N[V3+Z D0-HEUW^R\BJ7O1/Z%N3+RG^$("@?,TQB5L66%
MZS"ZT'0+%M""I+@#=D4]D5*1[KJ/<BH*G_+7V,?!C>EY6\2>*-\ER1+BJ:LG
MB*J3WM*[G0KD&I_X 5QCL']D8!:+(SLMQI$)Y!__;.P&@#F-1F#8: B]B3F3
MF9A\V)4-O(NX)&?$I$5^<5;/3[3!Z.KD4MG,Y4-Z9&H%0C4X/B=2?;U]09U3
M K(X:BJ'CEK2+O4E5F*!SKC!A%,CL#AJ*H>;JH(6@ R#>@T@LR.5&I^S5ZH_
M4& (L @%'DHU$'M\GP-X?.(GE-88!B(4:Q";=1>BS3^^DH*8=@??\2>?B@AR
MA3R+3D=G76]PY8%"D&A)!]U*&A0/C+@]=D7E<-*6&4KG@ ;*A./I*5'4?-14
M#C85Y2P & ;Q&F0,X'.@B7K+3NN\UG> 7K&N?.Y[[T@]@#=@#U[<Z-_3*#H#
MP=@?K_&X2>:(0!/*:1"Z2$K,D+K$:AGL6\:5TX0K@^HH(C6A)8J$B-4RTG?'
ME4QNL%H*B;<=??!4BV(M@X.)K*FJGWC;R;-X.+JZO-($5$(4:QD?7/:N[>\P
M6'USW%?\Z@C>JMX[FS#P\QDU\\]Q1LI_Q\-'P(2>W-[T 6@+?-$R$%D. W>9
M]EJ#<FF/1S@+\D92K+-:D(YF\_UZ@WB)^7>S,KTE\9IA>>'> TF +"W#D!^0
MJ;),ID;T!AA!_(5RO9<\'T5UHX^5%/K'FP<X$)(89YPMU'MQ<Y!3-U18 0=U
MV;HHZ(\>%J,W<:M&U*R1;;<WSN<=5SZH8KF?:56^GW9M@Y9EAD\D,Y]^&#FH
MP*/K>#F;AQ:W*:U]Y;0%2YQ,MZ-D7F@0F;-CT/4VHQ3N//!'"!QK2XG]Y*BI
M+H :@0,%?H(\T@E89813@T,Y:JH++$%!\^V)>:C7%#+^;B[2 \0XJJH+&D%1
M\X&&BWR=4'.]W7W\!P0>DL-J&WGM^18Q2N4\Z\Y&%U<=OTS4X3HFRB8-(LQ*
M9U>1#\*+&K$-=?$F+G].927$"IVT5NS?CD\7^9:X8@UU\5)9Q!38<-*O 4@(
M]YS)RQFY@KH0:6D)$V2-!M'T>5]ID?;R;ZDZJ$Z3RB%0$!$L9[0$;FB@LKZZ
M#MA^-;U_@> N=.9T.)475@XHTN5<A)( )S0 B0S=_\"X$B2U#^4@V=D&L#%N
M2HJ:ZQ+6,6]*#BE8ER18];2$'QT.A!@/82YI>?F@?,$I88W0-J&DOG+ JP8"
MWMT +P>T!!61M:):2UO0B%$LZ\**&YAV1W$HZ1W1[/701Q"(1:*<%2-1TG:C
MI]MW+?\M>GNY+]$HQ/NSC,6>6:^SN)1.TH6-1A?*IO&@AY;4HE>#35R+6<,4
M $DM:1?!4Y4%.N-&?M8P!7!35= "D&%0KP%D)&0-4QD*# $6H<!#J09B;RQ-
ME%9@$"1:@WB,!K+):84($8HU..=\ &@/B%^GN%]O//<M#C:@0H)20V-8B%*M
M@4>^M81R"@"EK1T*G0,:+"]$RG_UR(^\T"LI!Y:*TA6 "9EN/;WGV7=,$"%6
M?%,=?;9!)%=G/EZ[7@#_C+XGLHWD;)?4O+Y ;)1#=;6:HL_/$)E 3F=!JZ(O
MN(2IEI58BG[XTS)<LO.* (]L$7WAP*2RG110C9[](7WJA6 ^>=\ QP<XQ&,:
MK(!W$WI>Q+%=N(?8:>"H>!J8]&2D746G@E%G1M*;D>FN^0-"_,1]- 4&I\D$
MB!Z]YV8(X0"P6B.=G09.UAO;W0(P ]&:FAE:,EB2%Y95+S]ASD>7YQVIA>H"
M*?'(5J):+4N8A7O4#1H<3K."+V\@3MWB*QANI$%3_I5CHW([6F%%+A>TS(>:
M< <MU O@^Q%!=X"E<>B5M()0#9*U3'4:,2]A!O<*1:^D)5XJD*QE%E-1J!P6
M2BH!I'9^T [C&V=@#L :.\7C%\P#B#X^I<./GJ:]<==KUXD^(K;F?^.H+K8Y
M.B]NCC[Z,#*=&+M>C*B;OQGQ..._H@W47@GNIGH3@/D"UAO7,[UM_"(]]VT+
M9KW.WFO=&]GU]L8V?3]Y(YD6>LFNJ(R^$I)"4455I%2#8)AG))[HR#9+,27(
MDEA>=2CPRK0(#C&2-<!$EDYJY&2QH'(H$!->2= +'XE=2IW@8'D&'C*UG@&8
M<Q@4I7$M59M1#@2<0MSSJ<BB7%ELF!* P=]&GC<7H_.N[V_5045-LC4(9]E;
M7A\8D4^DXLJA0IK9($1Q VY7%5#QO#)Q+MTP6*$-^)\?6U,Z./9KJ8X1NFB9
MR. B5ZTSG2;1<N_[H1A2XAH'@1(*J5J>W)0R81H&?F Z<^@L16"2J7806&'1
MJ^71S1XG;DS/V^),(=&[:N,@\.!K&.!5_,5],BDN>N%V-(=4109(.NY!!O:K
MJR[*'B#Z9YX$@&*Z@&-Q.E5+JVJ.)7Z:M7PLCKAAS"[QWS:N$Q?TR6&1%5K2
M#5JR6-#.&VX]/W8<S^<PYLN]LW"]=1(*+W8667C0OOVSR,_&!R5&AI3C(65G
M<:&M'5*JI_+*I5#_D%*NYT##0\K+T>7I0"DH\,JT\B%E0K(&F)!V2*D "L2$
M)WY(J8#4%3^D5  $G$*4?4BI.C:Z/*3L.2IJDMWE(245$M<2(,'?AE:0J$FV
M>FE=?"_(V SHKWU[ 7WU?68ZR[+,@;G?E)-S;=N039YZ<0C\\BR=X7N_*B-3
MMBA*Q*;H<EU#<%_-=[@.UT31Y7Y73WB4<>7%QZ9#/0&J$0&D@]ZM1'$#I[%2
M3*[]HV7,A-BK?AOB1Q>>D%WASF-O^R/X$?VT#X'J#:D.#KI,]TPP>1R0I#T4
M/U;%MNIZ$Q\30@L@]D2\X=,OA,IY=EZ-SB]/>PDH"51K&3#TY+D6 '/_#C$9
M3R#3L<!TP;'K(:"J<GNZ 4TN(R2M=M(4&-_B-UXNO2C7%B52D;N>+@"I1["6
M]\&?S&V4!36Q&=/I<N/Z 3'1(Z6*+DBI3*N684"WX#7X"$I)U">8WSM^X(68
M/]FY,R# 1JP1W8 D@?IVXGY4@U8<Q5D95$GU@X,3C>X$2!=J (ET?K*;#]AD
MPV%Q8\1.$"?MGBYN$+TF=)XWP((+".9?H0W\P'7*-_25&],%-PUP(4'1Y>&&
M(7Y,P!E<KG ^S5OX!N? F0NFA#P_&388:?@Q3",:9U1L-])C(.'W,S5\2,T%
M$JJGM\JEP/09\5*JP9%%,X&$@Y/1Q=6)4E#@E6D1'&(D:X )68&$*J! 3'A%
MX7.2J&RP6.>!A"J @%.(^W:L),J5Q4:'@81]1T5-LH^!A/I!HB;9!Q-(J(*<
M:]N&;/(.*I"P2YFR15$B-D67ZSJ!A-"A!Q)F?U=/>)1QY<7'ID,] 2H12*B%
MWJU$<>>!A#T-!E,0,71!,W$B0K5:^<7XPG$^?/ 1?1R!.'LU=)%_55+5B@ D
M"1W]ZN/WA1]!D U"^\_0M*,CM:?PU8;6=(%&7,P(5J4)O6 A@78M,X7E]ZKI
MT=W,#+"BM+"$EZ35A:>J+B"J3;.6$7Z[DUZN(&)"Z3R[!J.+$[42DXA"1(3,
M=D+Z5 YT^,T-D+Z-@@>$(QO.&HQLB,<51S4< QF"[R,U]C^-!3(HJ'C*I5 [
MD&%/]_399=)0((-Z4."5:>5 !GTP(2V000$4B E//)!! :DK>UBM@/@YQ2?U
ML%IU2'1Y6-US2-0D6[W#336.6!1 A31K08CBSE]K(2B*QQ!C>+JXA1ZP4"5_
MXD2;QOF+>PTF-OJN_+HJ3SW514^7V)Y:J$QP.\<D*KLM:+^)NC%&C5[08!0Y
M>C;..TN OX,0YP-1E!KY:7HZ.AM>**67ROE>LF,1)+&1%#!=P^')]*9>M/>;
M_V;:(>N4GZ.FAO 0(E62J5(')@QCY3<W 'Y*PW21(91FJI!K]5WB=<C4)?8G
M0^>-N8&!:<<Z<8:$Y[V!^9WKW84!8F&:.X*M(/C:Z3MXY!+>R.M-"ASV<UH=
M]$JZ0*4"E0T<WBJ "D'C@Z^RGBBI8H+(3+&B %HX'BLE5] 3%4P*&\B1H@P2
MV(^2,FKIC D6F0VD/5'?D\:PR$2=:><-.M/BH1KI6(V%ZQGQ:(UTN$=_VO<+
M-0YWFHL4&H[.3Z]45TH7,B*%$DHUB H9_S"]^0OJAA(=E"NCNLAY95<$ 9M,
M#>0=J>IKI%SG2*]O@.,GHO+PO<,H[>;U]J-,DHHSXLP'>]!*99O.H[D&U#BB
M)KI2#GULT)2$GK7%& WP.EEO;'<+0#2;IQ$!I5$LS/+*(:<U%!0!*,8D#5"$
M+-/ @_C8GAP'12U[1$\5!FD0&54UJDZX_A%ALIBF7O(8<0]2PC6*49XMHAQV
MI-GD3"HU4#%<QK3B9C!33F31*FJ_DH*MH_,--'3\$R6>NEA,69EQJ68AJA24
M6\[D?0H]:X56+;8<.:II(->J5*J8N>\#HH-SKOF9%M- CKQ4:6 A-7)C00&A
M2[.<A"@^!H9)#0P[&YT-^_ 0)1D]<A@@UPYH^R9$1'UA RQV[GIQ,M@_=XT/
M3:-VC6S#O3DA_: FBCC=$3 #-H[XB=[IBM#RFG$,^(SCTWJ-?C_MZCC%6H%Y
M:*-!5W>7T(Y@I;6OG(*J+_"2@Y5&N:6!'[R67TD!T#0K8!'WDWZ8J.Q^4@ 7
M3#F)N9\4$&[#VUN%9$81@.CVMA=RJ^4V[+O<J%0IZ$YJRVW82[E6I5(#]U/-
ML#D%Q-VV*<7FA@9'>5I%URD 4C9H2C:!;3%& ]L_I\'YX^H47<%:DWP1=+SL
MT0 S3"Z3F,PZHZG?<)[EH]'P='18BVQ#+-3 8*O,F>RMQ7OG"7C0)5WHE-J'
M>EAN!EL20<S-1K5>,Y&)\%<VVU[WV39YWT O*LQ&MXSV#QS9C;%0K>=:NM;;
MT7]^ S[.5A\S;2!;;9=T<>#8;I*+6KXRHTC RB$!50ZK&LE]U#T>*TLAS4B6
M) AZ,Z&-]RV(F;^BNJ2HCZ:Z.UQTM\K1=E[IZ>D48*4/D][/$?3-LK*!1%4]
M1OO'LV[3129_3^P -=_QL\2R@<_1Y7$.M,;5!K)UJ1'AF_V,-M[HHV"RI8N3
M4^Z@W\_Y/T'<WS$6N$9HZ+ K5=K/6.#ST7#0\:67^@)O+18XX98&YWCW#M*(
M8/>2U@/N"O.%'-!"J:$<I)H5?Q%NHKS1%T#4J!5J'>5 )"I4;EA0Z-4 &-B3
MAIB\&COS6_ &;'>#:4],*5;N'5;-OH"$(N(B3*K2K0%8?@4.\$P;43Z>KZ$#
M\9H>P#?  Q>NNEH"ICKE&D19U@R^50 ";5LG;&YH  NM@F\5 "D;-%T$W^JS
M\C64VE(!Y+2& D8@+I-)&J!(<FK+PT8//X/46R]]+\B@!OVUCQCTU?<9YF&)
MV93[33U$M&0NL;F@7B0TO]A+5</>K\J(GBV*$K'U2M-S"2XY@".*+O>[>L*C
MC"LO/C8=Z@E0WYLS%Z/AZ?EAJ/R&62@I3+!3;XL=M0[FY2Q*/$XD-PQ79?70
MUPP:2APSU?FCP5OSY?$7F:T;?CVP4M:UH4  1OQ3W*&QZ_$8@E'C1/[L&((A
MLBHIH/'J"[RU$ RY^J_'!QD*P*99$0L=9.@#"ZT.,A0 *1LT71QDZ(/7A@XR
M%$!.:RBH?)"A#XJ.WA%UE]UFO2,*':*TA]H[$WIXLPG&OA^N(\I]I"N^@F#E
MSEW;76X96[06>E8/]VWY9;IBKKZ9260Q<P;]?]UY -P[B$C@!S.T/6UCAI3U
MJ\_\J G;AB<0-^^/TX?%2NQ1QO$-O[DV:L9&A+4U@<I[/DZA=J:0 /?US2/T
MRF;FJP@S7X"WIF85:J3#O- N1\/AV7'*=,+T=E(2=7 $-S$]>SMY!YX%?;3)
M_.:\H54W"8J+?1&^Z(G<F<")7-2]D?9ON LC'4'NL,X_GM'5.+(9]<V<F:;3
M,H(%]E[$Z3MD&R^D?I33N_4!(-'H$.*:6G8ZZ<V.NJS(*M'YHYNHL/':#0L)
ML9KO4&OT=L2^=BSE;D-PQE8 W]" 1-?[D7 $3LP^PTPZ/"[N-6;'^3$ 1^3@
MH__JL'P[U"BW-#ASK!F HP!LFA6Q4 "./K#0*@!' 9"R0=-% (X^>&TH .=J
M-#R]5-RU* L%E0-P$B9I@*+>!."H@,N6E]V&6'C( 3C)KC^3\G3FVO:=Z^$?
M&_(IEG>F'KJ;09M\;Z, /]5R.:H'_D9]Z85^](&\.!(;G084]DJ: 9OHC9;G
MP/0";>9!],2!G[X9]JOG^M)M&7)/Q[D@<R[P,EC/*!>\5XD?P+L-O=V#2A'#
M_.SI_>Z8@P1SX8:.*,ZA6 [_Z@:87,4@=< 2^Y#5@6E-T2!9+ #$;S3Y33W)
M2>[I"'29ZIJ7P743:6@Z$U0RX%5__5OE:<#)7TD/;L4F_,0ISH/3GLX#18+"
MCJM!&^R5]!"7-F\O%B7W.X#+%8Y=0C2:2Y :F4\>M "6ZJ(M+R?G0/2911UZ
M0.OP6L_=<#N\[786Z3-UY"*ZLZEV]+WR'H"6>NR:F&GR1I 3[NG):#CHZW7%
MSF=;PT(YS!6-Q=24;YU.-Z%!'&=<:S.NOES:N1#9MTE7XN/L8MH)#N,X\5J;
M>#(D(RG3=,^FGG8[N.-$4VP'MS>_CJYWBL^V@SG&V?MQCG7@PJ\ZQ^HZ]O5:
MP\;S.8SY\'%%D'5[M-$^]9E+;3OKQ=FJ[X;JE<W&5V'=-P/X@@_Z_L9U(J:&
MIHW3]YS*3M)4?23ZS)[*H"9,+ 7DH.\E@1K,):_H).9*SXE6?23'Z=; =),E
M![5\] VE ;I'C(".#ZTXOURYX=9@3_K, %YSK6UF'EUO]"4YS\KFG6WY_O(B
M&XR&PXX"5=N&9:/^,PX>'XTI^M*99V$+-M->A\>)T163U;)[%%DP"J?/+VY@
MVJVL'3Q=*S-;>N?UJLQ=24<N:DV3)\^U )C[=TB8(C<RF?4.%Z#56',\;! -
MNHM^O#4#L,N6WLHE>>8H#A?Y*C ZF4<76LVC7?(OX+U!"Y3S^2-%,&:I'RUK
MV=]QSLY'-_@G"&; <I<._).HW1OK[W#G1KLL36;!Y7$6\+ PUC=WKI=\A<N1
M-L#M#B(OW-/1:# ZSI>V^)Q,HBOM\JG/$,\\:*5/J,3,$\VH?BZ04?VCPZ14
MW.4QIWJ-%-L7QYSJ KDL5="=]05>8G(WRBT-TLC6RZFN FR:%7$14FQN: "+
MZJQ4+Z>Z"B!E@T;F115!QFB USV3C9I/O;1LGC'#T?"\:[76EO2+P.-GD ;(
M^0T1"YTE9?G+E% /)2TO?BQ>:)"B/"&1NF;ERB@'"I:0B&*ET*/!3"?,D&@*
MH%F"9M+4 =250Z %54%!$3&W!<)-[T& Y@7U5Q<VF38.!#@LBAL(NI&!']\+
M,MA!?^WC!GWU?8:7W!*#(O>;<G)NRY1@<T'2-2J):H-?[*6*8.]7943/%D6)
MV'JE[[D$]]5\A^MP311=[G?UA$<95UY\;#K4$V![,34/[;Z+=4@JOV$6-G"C
MHU_0C?Z3V&GQ^2TU/EU2%^K!N1EX2<0Q+Q>/ES%(7)OAH#<?\<["X%I28QIE
M]Y47U=EH.-3K;AX#\*VP\WC9(LN^R1\A&OB]XP=>&*W"TV %O)>5Z20AH;L(
MGUESKR%6&L2!SY5N^:QO'I)F^=K,8Q2B_>LS=>0ANI-I1A''(6<(K\S8WR*N
M-O4&F&#WQUG6[2SCD$9=6U"W5\0T6,CZ>IVEGW.,2QZ2C$6-4J7R\Y5Y!T^)
M;9G(*/59%A7<M]46Q#%W44.,5WARZC,C6YPH:D[OXU:RF=V#>M-;<'S'.:[X
M')<AS^/1QG'Q/H@M<*]F=EU9'K?/PBQO]8V$>J/)RWPT&@XN>CI]U=D.BS-<
MR]1R;1DK4=8/52SA_&#TF5T-@+X[\Y9#2%H&J&F:1NPXKQCSJETYM+,-;#1M
MTKV#O@0OYCL03(MT>3+83XL4MV5$C?4FX=&. 1^D,.Q72HWO75GXNS%-WC&,
MP35PP (R*<B75D[7,#A=G/XBA$E:]] 6\]558?IB7>58T(91B]/%-_\.( I-
M^QGU$2+@;7>%9V@O+#K;3ZFS'2<^RW9ON OCVT_//QF+> R&GP["@'&]P'PW
M/#2. U44PZX,H\4"6 %\ SDPX$>#H!-"9SG=('%%RW'R4UZN#(HEM9Z?K^=H
MOIZJJXB&I79(@XR0>[-/ 5N]E%=[# FHRDP(CD(M*P?%)I'%B^/Z'-1ST\G!
M+,PCG,WI 8W#SJS>-1!,:O((7;FLT_+0CX=+Z,L;1!T,D(WI R3O50VT%AL[
MXE06T[2\+,3#GT<7[UI"5.S5!LG>KP9&RYH[HE0>V[2,?>3AT,T*>TGOG=N$
M3%1H[/L@\+%[/A:+;;L_3,>J U^!7HZH;IR;6IYX\HNIMJ?@"-$ZC)+UV!8^
M(^G>Q_D(@L(T%'5D#AF.3-2',4\ZB;R49M3-@?HISSI2,/@\SG6B8\)%0>0,
M>KCJ*J=6&%(H:H;J9&KI?2FP(-&,SO+!]?T;T_.VBSA0D;0F";2@''JJ@Z$(
MK+I\. QX[?;D.88P/"2"K1P6S"KP0DN?7($QO[KN_ >T[;$SOT?R=I9X@QW_
MQ(LS2A-YQEZ,AL,KC4$FR@@M?6IE4R_]+G'<Y**[G'D22>&G 5;9GP5T7?5.
M#@NE\EFEI<^M.M_*(P-QY)]T-).[.F):!L.T=+ 5;7 <+<N]<<&%#PM=9)*U
M?&^^:-=X:&_&;0WBPH>%#S+)LMY1I[M(U?"?/4#S%=HP@,Q;>OP-*(<C69XT
M7EIUWX1F^/#DN1O@!5O\&%V EFQ\J6.#;W.P-0]/*\I!J28RJ'JI,D/J^M<4
M3:9'8@W8F#"U&#E6.'+=PT47FPV:)FA,&;);$C)L>00LK46H=3@X$F% 74=9
M'D$O2EE3U>-UA*-&%("3L/U4E4BYD%$7+6Q-DRVJ(1X8.J.V4U*-Z!3R,:EH
MC,H9(T9EUY.!2OB&E>WK0 -51AU-=K+0H^>T")0P:N4GR^5H.#A35P64YIRI
M0J &3];M^#0.@U6DARBOD9<75D[V5419!(0 L5KB@/H(.:FX<E@0D"(/!"A4
M:@ "1!U^+LNZ<4-D06RI#TN7ENV!^"D2++$+N8G40/JYNX7_-_2@/X<6)H/^
MP#B]EFZ(J$*N)'=[E]@HC72C6 K$\LKA08ZQ($:OKH!X--> :C8P:BD'#C&Q
M<L*"0:\&*TD: 4M=./*%^B%ZANB* . @4@-YDW7H ^-A<XZ:RB%#SHI1E7))
MX;U*[#7EY7Z[&@U/.[YI4%6@E&TG!\5M)8531J,(*Q*-@2)(M%RSLP9( F]N
M1I(?G"9RQ]]0R'D.7_\;6,&+BV8$],IB^,4;T! 7DIB@U@T28; \P#6,!3=U
MOOE@O,;.&S&XE#9Q>(#A9X.6ES7*=W]E<.*HH2%ZJE(MZ?Z#,OD@OSG>+NTV
MXD5Z*X2 $4)IC?$A0K&6=Q^*T47[ 2=ISAZJ=A%M1F-(26&%K'L4'6;#OW'7
M:(F.7B<8._,XR<X2.!84S8Y_5<R.GVG;,)VYD6N]-T$[- [QAO$(M=%92OT'
M@' /'@#B]"WP+0]NXDR,Y* >2HW<A!F>=.]U$Y9!46F(DJN!9Y9X3^-Z^X(Z
MIYS@<=14#B.B BY"I"K5.D,%$TX]U>.HJ1Q4J@I: #(,ZKN$#,FGLEA *XIN
M,%]=#U?;/F],"UE1UZX?N,Y7T_=-:X7&&P1^Z>%>U6;Z@P^&5/=]*Y)8H2!8
M/EZ_D@2;6@WJ"B#Y3-$@^.3:M/&6[WD%0( #L2*QDDT94G'E,%/??A$B55,D
M4&T5<@7ET" D2SXH*&J.R#HTQAE5'EW'"CW,V_@F%S4&B5*C%W#@6D>J$JL!
M(LH5Z@,C*(E12SEDU%\VJE#<P"EQ)Q@9>\"<+F; M"?XS3^0&FX$<)"*]P05
M=)D6D2%$KI9Y=&,^?AQ=8(:^ &\]76 G),5KS*ZH*68J$JYE5J)G@)9;?,D$
M;%R?&..X5TI37/!0J5;LD?1H1LQ!^G-/I64U!00_K>W$%W5U5/L5.G =KL?+
MI1=E!KD+ U0A8DJFENB!;N$!9/J![F<C&89AIN,P%M% #!N/Q+ RU8^GOZ23
MQZ[>22Y;=-,D2-LG<QM#* 2/"#$O/X#]!KXB2E;T/9!X<_G9.T#_&_3IW+CT
M;62IO#@8&[F,0_\$IO?RPZV)N:250X8:C05:VM&\C*D)K4/&% U,M>WQ#A->
M45CX "UL<HZ1O0-P 5$3J_ T&\O$2CHT=CT>+2DBF+MZR>W96H%Y: /LKK#M
M^+ 5OH&QY^&(TG3TV)%.^/D%??+-*"L$-:>6_(YZKK[*O0;M<$F#TPX<63!=
M9"BG)>@H*ZL<?%J2?1%T_.S1 #=%=IKE'*2>I0JVHAS6^$5>=DI2GW8%0[SV
MS:/?8;!Z64%O_F1Z07EZ,.YZRLE?A@SW@K<J\T$]I>)[04:AH+_VE0GZZOL,
MLZMDT<G]EB?X=#0<#@]LD6&S0[W(+'[YEZJ%O5^5P0!;%"5BH]#0TXG[U7S'
MGG^BZ'*_JR<\RKCRXF/3H9X *^S4:VNQ!T:$E,PNE(%3YYN.QKFJ2\A6FE4-
M\>46O ';C0+KZ>?JU#K*8;!Q*!31)\X@U7)/$78QB8M[NOBV04QV@I30.U!X
MG8E9_I"!4HTY:IU&<6YT'T-L($P7]XX?F+8=,91GHUM6[^ A4YE):L6"D:[!
M.4YHV@F-7TWH!,#!<?IH0I1><B,7/WB@B/)&RZ13SX%K_>O>]T,POPT]Z"R?
M !K3/'IBVG\*D:HU?>RGC&YOD Z61-HX9-C)8YB6;WH3V(*3[X!Z4"QMXHA$
M"?Q2*X$6R21WD6H/H&E_A3; EY=!:E>^VG!)S._)4>V0,52+1Y*28=EMF^C)
M]_,GSYV'EIB9OE\WSYAA]PG35#'5N1B5(.A2:<V3OBD\ W84#??B[N8)7?=P
M53QX %7G4H*>*Z71DZC2.]=[,K&:O7']<HU36O#@T<'/E=2U>-+C"S^/^)Z^
M[R,#+MI'",66#@;%?(RH/0,W:&R 9T1-]B9X=&)Z#M(&.UXPXD1)Q3M+K;@_
MH&O3AY8@$;DZRJD"&LN+NQ1QVK2\]H)F9/Q6!YZ6XS<T$_%IWXN+HUY=)]K*
MK5P;$>[S *9B:\I#B3W:(L!D\D)_Z/$ *L^:L]'PI.-'VF6*F &@4MI5.[V4
M!(S? 5RN C ?HX&92Y#NX&)7YC0,_,!TYFAZ\FBD2FTI!S09^D@>)]0Z#^T"
M=#+ IAS(Y &D)OB:U'5J@:YT7HL8X\J!2(:FXJ=4K>/UAD!Q"^T03QVQO=I>
M+>6!(K9;XZ%.RV6*W^3D@TWE]I0'%,]XZ^S:!""HUZ(E8]_6\44IN5(6W[K)
MNQ_5U[V;I&V;YMI("ANT7 <)G$G87&"0&,Q(K2B',BGXX(:=$%NT7/H(LUK,
M)%<.17)TE0BU[>S;VCP:'3L!G&.*X1M(DH2*/F W&!3S'98<F'XVLGT9_JZS
M@SM*[2I/X<?MNG*I3]XM.T0"OD.S#%F4FS!Y@'BQ3PE?9AT9G>1GX6@TQ&$)
M*ND<>OZO%IBAP:W9FKRYWI8W0$G!TV"/RB&V!0P6@=\V@[6=!8_FFOX"(*N:
M<GAL&QJ\X&2P3 .$S< <@#6>Q3>N@[9( 40?G]+A1]XC:IHI[OH]P1Q#XD7@
MU&. %@A"U@ZT@H38;PX,_-GS-P9J*'7T18HHT5WF'2*$7']#&/=WCA-RSK&R
M<KH)5HQ027Z"+J?Z9+VQW2T $7ZG$0'4:4XLKQL2JA$LZ<*T>@8JM^'VP$AL
M)*MYY?#6QPT8G9L-G,ST$='CM1LZ).^?E+:5PW*CL)*.8@H3VSGF*?7D__U+
MC)?$E?WO_Q]02P,$%     @ *SYO5#AB.C)FHP0 " @D !4   !T<F1A+3(P
M,C$Q,C,Q>#$P:RYH=&WLO6ESXKRV,/K]K;K_P;?W/6=W5X6T;>8\PUL,)B$)
M0QA"R!=*V (</! /#/GU5TNRC2&0H0.)Z6;7.4\'D&5I:<U:P]__=ZYKW!1;
MMFH:__Q7..7_RV%#-A75&/[SWW:K%,O\]__^^W\X\C_Z'X[[^_^-Q3CU+M^X
MYA13=G5L.)QL8>1@A9NISNB,:YF3"3*X"K8L5=.XO*4J0^P]DCU-G6;XA'@:
M3V4$GHO%_@U/FT<VF<4TSKS1PJFP/J3@O0H&Q7\*R9\B+XJ<()S%DV=BBLM5
MUA]@,UVK?0M9"W^G9V1J?KF0U.:'FMB:JC+F+LT^5RZ><4EY,$#I>#J63O+I
M6$+)Q&/]?I:/B8.4DLIBF5=2*#03^>?OD4/ 2T!LV&>N'1LB-/GGV\AQ)F<_
M?PZ0W3\UK>%/[P?8B1#CA5A<^.8]HJG&.!@_F\U.YWU+H\^(/!__"3_W"<C\
MX7-;71D]B_MCA9]WE>NF/,(ZBJF&[2!#7CY%YE2<X,'P*Y(_V8_^4'7NQ&PL
MK[R$?#X=FM.?JD&6@P%N/QT+&?; M'3D$%B3B81DC,^$]F5;SG,PD"\W@$"=
M;P. $ ^]TQ]NX<%6@*5^DE_]@:YC;1V8_4E^#8-'?>$0UL&I8'45ECZ R ]T
M?X^)8&^VF1"%]$N3LQ'> YL.5\AFLS_G@&;^K(ZEH)61A$(MI"!G?BJ;.EV"
M("X!/'^&9"LSPZ]+_/H%]"(XLWF#KR&,&!-3*SBJ;L31%,-1]=N_?X\P4O[]
M6\<.XF33<,B^__GFX+GSDX$''H[A1U>=_O/-^SWF+"9DI3___=M1'0W_^_=/
M_U\V5]]4%O_^K:A3SG86&O[GFXZLH6K$''-R%N<GSE_DK3_)SRMC%-6>:&AQ
M9I@&A@'J_ QFPQ;[4U44;- _R8"2A638,^<:JM, Y&V3/WI- D(%64JOW2SV
M['%-O4Y>Y.UQYU:^ORK''[IH<D- 8Y\9JD:V:+ED#W1'<S9'SN[5!CU![,6%
M'IQW[_%2PJV:=5<8IX18]J%_W[^PXK-OG(%TLF"/ 9T53%U7'>#H=LY0"F1"
M(@6(-%"Q_8U3E7^^7="UD[F3F<O+^7UBC*NSBFV8TFWO8@:@6-W4IVZ2[\G=
M0N+:2)?3;;>6?C"[C]?7#]G<KVZRW1]6K:ESO6BKZD6Z.[W.*/=/PP/:I&DT
M'5,>WR(-)@WM3'Q2SX?\Q84RQD7]4;>,W%2]>__.BNI453#;UPA9V.[ELKV,
M*'7M\_8BI\R4J\X@'KLE6&:K0^.?;['5G15=BU)[3^AY2-HRPRA;[YAS\?)N
M<2.YY;*L7M91I9 CL%*PK.I((ZQ(7-^UA"R#'*9=QU835E14-9?H"BN;5RPK
M,;T>&??M0O.B^-!T;*%NY[[]FSD54E\+ 'X% 'SOSN'K_#R5JK75AU[?JO;C
M^<OZ[,, J+9*M_%X+3X:IUKSIXMT]3(K)\GIBXE3GO]5Y/;V7^(O[J[%?J?=
M;HJ+RUBO>U,:IX:[/G=^?=L=K Y'9)\YHMVA(:ZZ>A];M8&W>PH)N^8Z()=
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MN+R;/LZ$?<%@\Z[YGB@NSW[YR;VYMPN-\MQH/^8T]YH?)1IWZ15Q5:Z6UL%
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M/DGC\_8H)[D/V>1-\RL ]GY+^FL 9DDWRGTSR<?&M>;58&(J\T(A^1'&\5:
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MU)<?]U9S.H\T:&#2'&'L7)LR8WPKD8K."%M5TX!Z,F2+K-3(NKEFF60IS@(
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MEQ]\^GU3-<#\VV_1I-N$VW*?QETI->JAZX&5=6XFD14);ZL&^/;M[Q.%XJ&
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MY<3;&%<$'66OSJ\G-V]U.&Y(=J!/$!PEE*FMI#]X7SWS44:$M[X_R,4>06:
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MICHT<IY@'?FH>9]\3]Y'Z/:08DJ"&&'>+R<>A@TER1!TPHY.+M<W7<=/V(?
ME".91I%,$X=*IIE 1@0)HS;!QZ8[F6CT$[(6'R#3S %1*9ES*3"7T*#DN0(/
MVNSM2(>1I,-#C0S+%FAZM T(J! !@(869O@'&=4Y6N7K W28/2PZ]( !):Z
M^E;@P5+,&40<\)Q!MG9N608-'EC2\5*6'@DVB@2;.M08Z6P.4CDM4P-Q2>-
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MB('W E)Y33J\-_MH2&U$PIOM#;U4J&/2T*"D!@4AO/.4ZQ)$9LA!WTK.7L;
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M[KLDW?X(^X)L=O\-9;%E#;&<35JP$T["#S7U5N'52($ES$Q+4T"4"NF_J$V
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ME-Y&"1ZEI8,WAIBNEC:';DW",K/H8(;1(<&@.PD&#W:%-=T 22N&6C]F[J'
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MBPASC8M%8394YEY@[/%4J\?9-*1;*Z;@JC!#AZ-N)H\[W-,:Z9XXLC)C$Z6
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M/$+$HB=7-B])&K(PE&2"3S&T%]W")V0",]=LLG9(#5\,#G62C4,!F@S!#2X
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M.;L<&U+2&TZ%]U+ZB>ONMV":C,J@IA#_K=*8;V#[TPP!J8RO-6F,7(JP)">
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M?-:@-K8'N[D:W31\ .>UK !.80XUM(^:C4WVCXW1&7/'A0M]:C8$6 -VA$T
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M0%&B).Z(JVQSDD+*7/01;?Y\I=!R(? TNV*8ALB4WA=8.:F!L*<AFG=,I7L
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M3BU$;&NF4P\13,.J_?5CV:?G3P=;:VYV*KFYU,)6MIGB P*P$0%X<D  #@C
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M, D,77578<5%.0MF_%K5K/5.P.->Q3H.'3);?46A.>*<V%#K@<06&6LL8;;
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M$1KO3I)_&8LH8(T9,8%#RF^%1V&MFC#X)4K"\Z=#MQZB=;92(:J60" AK,N
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MT*8>3G6%LK8E?T7R*:G/@^D*TMS./IWN/-O#QF3) ATT)_F.LU<^2T_[P+7
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MF V/?""8P@Z9,XLF_U7_<?@-%)#B2S"!0X,]H$D3<&26K:IE^^NT^))/+/!
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M9_^G!7BBO>PX)3RL%:@CL;QA\+$W755Z"[B7<?0(Z4/\P-U%RI*S!](7C0^
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M S MC2&:$<^07\].D:\T14',0?VW@7:0'5-,26W(\*".*M6\:+HT));=*GX
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M+9IYAW\6C0QUN&F?4%K .8*M[=40.O^&SMT0@A8D(?3T,<4*N2<>L,ER_U^
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MPFOW:7]-M8=!2"BY [5_L.?9V@<X%T<#I?@"0@P)2<,Q >,A2(:F$^AR^A&
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M(R*AIRR=&VK3U2.5$WLF1Q;:\ N2I]=>Q?*U/C@SSZV[3L5'NC,!'R>D9O#
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M B::%!>LD;EX7+Q*81*HA0:.U;!BB!,X@";E&;MOU8!4Z3+,'B8L*/Z$XEG
M7:=*YUBE\\%4Z9PJG5.E\Y-4.@F/[U;%:)1@'7XV]P6?'*!,&RJ)B;]%J<1L
M+(F3H<.V%VFEV+:A<'DGO_5'U;/WWG69^RGS7MAZM]NV?_[F&T=_6.Q.W28_
M=?15^L]G(\]\^^KUB]ES$10>?:C/EC .W/4/.JD)27?[6S]EINM;+UX_O>V/
MMWW%O-#T)'ZI!L;F54Z<^CC<K8(AGX5-O@5)%^6,EL52/9M$4J=>03,U)U[9
M*,:V\@^.]*M<!BLOH(A X<D'O9_I&B6TUR]TY+<P^U3"9T[\@LEM 3(% (_
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MR5OZ^\M&Y,3R)L>9A"K?9IL+_:9H52?V]IS:[Z7(+L26#$F*E'$2!UJO>40
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MYA/+VJV\F1<[>'USM[ND^_EM>H*]*#EN/[?Z<W*]VQG\*)T)S:QC%TL_GU)
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M*SXP.(^<CR:G$@QNOO<!6KZ#Z(Z.#HU5%]V:C$U7%&W,B>3GYY2QVUEV=7K
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MJH6+#0Q!=DL$9@3!Q=#0D:49(]Y]J^G.))$HC/?)-.:M6$7>U>V:0!,Z^0Q
M-XP&9G-6-:E@VZ&$+"CWFE16L$O7_['\DV'BMX=<M-L'G*\PD.%L,08^/%?W
M'$H5B!P=*5)'2,ZDD;/H=/8RFCI%\DLS$NZ=')887=S24>FCA@8WJ7V+Z+3H
M.6BH@Q[L?3.$&F*XSS;&3@P\84W$D@07.FZOHD_$A-/-]9_ <1$RV?\._Q5&
MIARP=B<JS@HST1,_(LA%T9!M&0C01#]I GI< ?3X=@)Z3$"/">CQZ5$,8XZ%
M*KKU7"O3Y-60XXZ2,!_$ 9Q)AF_( Q8.5VW- J"U9FP>'VW13ELOXXOUTG[5
MS"9A)4]%_U0]Q(C31H+[2C)V50B#LN3HSJ+V'6-C11TV8EZ%S! Q'?][432+
M_8;2> NA +H4RB&I)1RK$8=>&2=L,B0.)5S6=(I&W7<!%X10 I5S/CV#8Y]O
M=7.U^ZU*&PT61^&IVKI99@NC0UD%CN/2?)5([L9!?^:U]KM CY)$GLE^B?/$
M5%&6F$P(29%NMZ&KI(. ,8_%5Z6ZH]@<RX(K\T0)M.6HEKAE6JX($\88KXYL
M"K,R\:+ NA7YGTP%8RC-!5X:#5V&\2.C&LB1V]<$G5^7=2&D>P<ST<_.C,1
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M]XW>1R3%X[YAL.)]U$M*NX'35Y:P_)(A8D*. 0[?WBU/9R^1"?(S A8W_]_
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MSMX1Q4">-&?K)_E[(&Z?T4S.+M?T/VZVSB]HH>UXSJE07.];OZJ86HJBN1U
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MB "WFIDQT%- 08HCW#;28 BW)))'T;=HL1@X,1U2K"L[6J^F1L\5B"<"SF1
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M/>:X&,VB*?T\[8";M0/$-4Z6N97=CBCQV;;>AN SH'V(7"1O_>E?Y]#HH/@
MJ9*Z05#2^)<Z;8II4]SH30'WI,PIC(7H9QX40%K#[T6BX/"'EI22*>;(2Y)+
MY7^(F1GQCR[SADZ:"28P;8X;MCGFJ79@6KZ\%.D^C?1)&5.2E&XZ"J;5?A-7
M>^!W,^P#1Y@6C8B*U5).MXWY/MI,8\"A$FTWDEUJZBX:Z"ZZ/W473=U%4W?1
M=&[^D<Y-J5D.%ELIG%HV^64V"W"*92:U05OAM8YDA(FF 56%/H@DXA)7%.<T
MD &A$-,4[8>9\U??<VT(58)B)X0H,R[XGQ]NS'$[[;9IMPW$9+3ZU<&D'1 R
M%\1+SAYE%L#9FHA@Q 81!9GTW[03IIUP W>"G_@)Y3RAG&_8TB5%]J9 =^DR
MWQ Q-=H]";.VW3/>:D(T7Q78C<$@S',."/;.ZW(Y^EZ>,P8'B7T29-X#@Z1N
MIA%F]T=M8%3JZX8(Z(4ADW43I,GY#2]<L<455'O@,(1[_-I *"\C7+:L%T#;
M>I><IY1ZD*, =@0[>U?F'*C$,-?H=U%*-R<OQD<*"EEI8PHO!1Q+C_,H^-OJ
MZ9V^.Q4,2N?][07<IFK)#$$3D&W1DPUL TAS#+SZG6/)%W M^/EUN\$2+"#D
M]<8=Q\*B2*L1>GF8M7X_EYD/FA16'M9T#WM5T&LN5H<PT:>SIZ6?G?UY )DA
M]T4UWSK*B;;*%-'AT5=HEF!#O6NZ+/+SJJ:.)F0]^9'HR4F?PCS9"!2)$!MT
M+M'%UZ[<Q@'WEPAM1R&,->YM%I[#F-Z>4BK"5 *3LO*._V5VA7BJ>5JXV>./
M[*>TZC'@"OFM8W6"ZTW=\%,(ZE@40.+;->0#B N.#S+S;P!X:JY^FC4#;*Y.
M>T*V.(I$3I";3*>P,S _O^[R"S_7F,W>4U+KI[YDV,1M@S;0JVZK$@]L1\<A
MF;PG%K3V]E4<AV84L Z_,A.<O(_1[<!5[6:_#;TV?8%X_QES&-+N)%Z)DBAE
M^PACZ6*AJ]35>4UKY]F/__/J^<G98_\V_>-M_)L!*C@6&.F(D,81?Z]7;[_S
M]K"D\X%8+_AE$8I4='[P.1_QKE8$[_0+!6;]7V&XZ[K=%MQ4T?J1+AB1S+DE
M@MECK[!MR;W96^3,&+?ROT7AAN&A6JYA3D6T!@B'1T76!E.Q<7GK%XZ&V(R+
MS#>UW2_YG*@7#3,I-[KTIZV1]A.9H]#KL*D;TA<S9M,"=)&.TXD>.I#&,,J$
M=4!_"UY5FV]< @_*VR-G#W.1A$?T=FUV"1\(4W19M-2;%8WUV-[=H,6DW5%S
MB+@& S/3?^C__(]'=\\>/AD[9[_B;<P4+]YZTF(V3@/*\142J?XLK(;\"KR%
MA%L]?>&7C/)EOP2'8^PY>_[Z>1:Z8_QH&G)DS3%L;T/;9H,E)DB:P0'[\^(O
M]:5#XTIT66BIDUTH2W]$QJ8F;BT04#XL5-&::_'0!CU-<^OHZJ3XZ'#SSGU=
MU<*!I7T2+X/>K+IT[<+%66ZOH3?QJU;E==;'&WD%QD)C.AH&PO.F,=V&.;KB
MV&-FBZ;=8.%]3_#K*>/Q;W(?8!<4>15LM3TP]'<@JRHNI'[#AZS27:F)&J;8
MVE<(#VB-9W*V>F/0E*-]!N(3NV5H\ZR\N\B-<OL*OF.5?%>9L+)967S@MI\7
M+_YG[/((*L0 4L@4'$R ;E6<1AA4FOV$#IRV]$W;TG294+OM'?L9>CG#1H2S
MT9 _X8,+[R03G%;*4AQFRB_K*O:V<0,2Q1T4*Z[JQ;ZEGGYIU8+/#@S[0% Z
M[:9I-]VLW21MW7K();[BM)JGU7RS5K-;><O,63P?3%"J!L3!!:2'TM11)[J?
MUOJTUF_86D=6BYO:D6G@+GPB)&C\$_M5/:WI:4W?K#5M<NS@")*T$1>%_%..
ML(E,"WU:Z#=KH;>4<99%;@)1J8)QT9ES2TG69EKHTT*_60O=QY*_%!OU47KV
M?4@V#LJ(PHE#_"\W+KDR]:@-]*A]._6H33UJ4X_:=/K]D4X_0SJGC!^@C2L
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MYS[8YH/(HO'R^5/!8;9H"_'ST'DO?A6?-_DF41_YCK(^NW6#7K'W>%6'V7.
M62+SQLN\W<W>-Z148?Z4!:T&- CHX&CU+1:N9%KY*%I@!@**^-C)!UP!<7Y_
M94C_%X1!+<+2TX5W3:LPTF21);3QIK]+H^&DN6MX%Z.WZUC/#T(1!!ZZ2W+6
M_YG7,\HK;F/_BH$/<N.((P3NEAME+S 8^2(-6A'"TJY"FAG*31N_, X39H$@
MZN11)"$NP=V>"W2 UH&TAIL]AXP8M:'NFW:O2H;8N!5+L\0"J5^_:PA[^#>=
M*+%PDCV8"R/1FSY5;PI.9\_C^^)E($VH]N5=M3!,#\7@^NA+(L"D9VI0C%Y3
M_\LB*F.-\]?#S/_;=Z#_U%[5Y<NVG?HV.J3ZJ<11AX$_J.*0)^(:5;P2BEJ@
M[5/%!MO\+#M8.M,S.6U5$!2D3E(P#<N\OR[$H1C1R-;%%=2%T"**+KR"<\1Y
M%7LZ07/#BEWJ2?#360]']; YJ_?//34YJL(1ZVM0[9?\YX$%&E9<IFL11(V\
M0&E)#JS@K^ST^;OC(X)LJS!I09-HM*7"OX7U?I/W('TB5&XN=W"[H%2S')2J
M(2>@;=&6N0Y*$[(QH!UE5LZ+']Z_/7EPY^SD_GW3M\X+HO:!8EWM%Z6K=]+@
MKT/WXW+5OPX;LK.PKW M4GP+J=N87PG5F?:H]%D;,NT+.9G#J[6WXS-<VTRD
MFR1J8)7D,^(9YP7IYO($)L.-6N];TCM#C]>:]-RH944Z^:C VS$,9@;-?C*S
M9II91X8.1UJ(43>L\5*6)T'W#!X WI><Z#Q?5HRJ $,PB-U:59KR3[$L_"ET
MN7:5J(M<7_<%W@7L 1XNK#YJZ&OI7C EA.7 )/A)W=(^]^]YCQQ"*])%VO3G
MOT&-/>@8XD.X<=HB9TTKA]G']4W&S;=V.GD#>CI[:PZ\ 2]#X[(+1P)>L[4_
M/:0]R= 0!  +GY.T4='-C;9H,VKB6ZC(K4>KW\)/1;X@<"*UW/LI^ZD"A3]?
MTGX/MIY[ Z\ZD\*Q4(_R;"!L\K>E]O(LGC%K[T#UPTL3F@9U*EY]@1C0O_QP
M%L@VXBL>UY1+N4%X<>?2F.P(AC\\_%,*<-"N=:("O.E<L3XF?HJZO&[1[(N=
M2N4A](O BWZZGD6;6,0K.HO)6;>MJ5HJYR/\N++0:_I]6&R$;(+W(GD4"Z9?
M6 CQP?4\LM3ULF=K>?C*SKJ@(MA=A+Q2BF;FO5WJ_O4KG_6IJ$%^6\8()KZ2
M7E1^.OL[1(_8Q?'O>L G#VD)R'XV@;K []B:VHXS;IZBC[';TMG=1UU&>N5U
M5<*4^8."#')08DI?J]]-S;D?VL (,1(71!L';\7+;C]F2X[:H(\PHD.D /2,
M< S8+76ETF^+W\EOT2812-]2?<[.G_24J_*FJ2_)6+.WO)];6IX@0TOS<>RA
MA2>B^[P-:8![#T>MMK>(^%E>L*;=C+%'0)K#73]1J5+OG2I"RWH(@^XTS[UA
M%1J/E.DL%G?;KU\713P[-.E@7.7#@7RW U("?M_ AZ!$5@$UTE8RTY=1/'1$
MOE)%)0E\U*H"AS8!MNOZ$AYCO2F8/8AT]0X^V )_CC!TP$TC^TQ<[(Z2:7OF
M ^ 3*GD]W,[/!$\D^\N&(%TH*YU'#*I#;'-,9I22")1A<4)]4TEG@!R1'&*;
MC*,^ $?HJ\);:3;@2V=D@C]W%'S$^%Z;PP+^5O0%H3$$%X^FX(JMSS;*;Y:Z
M(EL%) =M%#\LDE6^&(@^B:6!/<)]Z^*Y.'(/Y@5JQ=/UJZ7U"\2;%E:_.V@$
M,!P >+>43E2(A57_V#?@K+$O84(E#J 2'TRHQ F5^ =!)?ZNN<C1?F-*UFVX
M2S.&_YVXEM/X<$;F?A07+)ZH4K8AN],B'4#_#;&#?-=;5"1\$("0%;X$CV)%
MYQF<0!9\OH!HJ,T_P\L@[B*./87R6N*:X%-0D$LL LF)S@=_I+U39V^_K2MK
MIY%LR*9XZ B'4,M(@A&/7.0PQ4O,NGQR^EY+B@C"R]051NR*4K*D:2T&' (3
MHE^IZ)ZW'UA9W8@V<\J+Q<[](C<OLEYE3,1"OZL<!H)'Y/R=Z5[NZL-=H4;_
M:F4R;?Y!-FU<^J"S8&P *12P/SP\I;0N03^).6#%H%"WV^0?G"0[%@7Z3%ES
MR#*?CJ=?\HWCJE?DBN\_$_CQJ-C<^P.H_Z@L&8IDB9YD]^-??;WFQ^-TK(:J
M/WJG\G+4HB#;4U :5^,W5/!;"L=1H?2/>$(UC/T&+&S( 9#5,]>A=2'I-V^V
ME!]W:3@=E<.6M9\#!S'_* LG< _WE<./+/JOR_)1AF\(<]#1GL_"]B&ZJ<6'
M_!S_;/V6\UXGMH_W+$\^.+?EE[:$X]WR%WSX6@M)#@CZ,F17&MQ$U,&R5.FD
MEW26X['#RX=4_W[N@^/_Q]Z[-L=M)%G#?P41&[MA1X <21Y[QN/]0DNRK=V1
MI;!D^]WW&[H;W82%!GIP(=7^]4^=O%1EX=*D)-LCTHC8'8MD-RY5655Y.7E.
M*PDDV8["$5]4D$M1 ,:-A,(W6;!)I0J.Y,>*LEBONDQY,E?'V^=8<17]! \&
MHPU&5TX5%@'_XH#HN.LD)<%J]"=>K'=+I,3W3T1RG&R1=^/,K[(.8=2\@/34
M5PM&T-!@89 [<(FY;1MGE?-?CLZ#0OZE+.MKG37-BFC&83(;[LSW"GSA;E):
ML#IR4H1S+>3>4#[G>' WY1SR6ZT,4-4IM+G.!M=7=4EGN?'IND!.'?&!5E,(
M).>@Z2 H8ZLI!] 7::\BJE>/P"#SN<Q:^V)43FYRBU!"YCT,LLS&"%<5L$Y#
MV(+;)([143Y3C*:CC&8*X#3BIGR2@T)6,O)N0Q*F!\QQ+JW![,U.XI5\46R,
M8ILQGPHYP&37NS7C@A#DX+[/"UJ_U[!XYCA63N4Z$&<#&^QB6ER0'*J)=2$(
MC=,YEO%"'JV9Z85ROTZ#E^ 2#GY@867B1V?DG#5-#B>FD*2T:1]3J):9/K=0
M^A9HRKTS0)*K$IB'62+.P=Z0K\V)84$$2[F]+,](Y8?K2Y,U><GEMVYEMEOV
MQW6'>-?:6,H^.SDFIXX3E&II[5"T!CN2/'31!$5Q)-Q#>91>;@HD,,% 07OD
M*N<JH_N.K,J0A$4&Z#PQR#J<XCGCMJ*;U"8Y33'$:3QJ(J31>SGC:2#H>Q$M
MN\=E36F'FK-4'<-WJ$N^^XQEIDC.07<:\OPQ DP!8U;-=&)&ZG$5^X9ADUWM
MX!=:PS*I!E'!S/9U\$-*41\8ULTGL*KW;#]ZGWFF)?&;'87FN%U8@9?^E@]D
M7R$*T&'5K&A)<\/@Z84;D80A>?$'*0).KM ^<-(=\M";A;-H635W>M5X8"M\
MR/VJV/7(GC?66YH11M'/J$NRSW/.")4X.2E=@)75=GRH^P3W.LXNWMX_W#GO
MM! J&3UME@6W++B[M>!P22PQ!E]Z -,\$% J6*$80LO&=UW--]90*O](>187
MVO7X#=/3$T>\5S$3M<!IEWI97\OZNF/K:\H-Q/G$T+=A'$[I)EXN7"_)R-6C
M !55#/,%(1^6T)3J?7W5-:R]1@(MEZ0<56VR9D-I5ZK2M0'/B7Y+GSR03%?F
M2R=13F=9>,O"NUL+CS./)B%\0PBE!UMH@K;I24;QS25!VXG<GQ8 LF[Z6[X?
MV2_H4,<*NC!]1V^;X ?;T+:LQV4]WJWU>(M\2-TW(;GMLR#A8+Q=5O;.+(T%
M+#L!EOW; I9=P+)_$K#L<C8N9^,-02(=CAXQ2D<A#(.3-'0HSBC(GJCDFJ8K
M:OR:JMN.P59NG+[GO.C7_S2X5?LA@R:8QG[,@ 7RLLTI9#4 P.%H4'>U3]7N
M/0O,.Q=M[XQ[L.P.R^YP"\_9+;2L\0@QX!^]2J%'0;M5]1?IB 3 GPH?#%@[
MN5LL2V59*G=KJ?BC1I(Y.X(8;KA#G 0U#<J3<SK4;F[;Q*DS4OO5B>#JFEN%
MB-:.+R,+BJ/6$3N/IW"@%5:-T<Z]L\9E;2UKZTZMK<EC".UJ1-H(#W+M)>OS
MN*- \<P$S)O"4-M:AIY(1;,Y0UGQ:*Z5-T)%Z85TWRW'2Z!1=R5:Q%'BU3 )
MP <NB^7X6Y;H75NBMA5!^T>'*S8^[+A90>B'P'<)( TTP:AY3IK[POH*5#"W
M0J%1O%I4)L2,P#+NXLL26UC+[](*NZF<G]F$R :<J+4[\O8U5I/T^0K4F!NC
M*+%(QQ4UKG72LQJG7Q:F\]^?$!).A?/;#X+#'[3II8/6K(W;^UKN5^/)#=@+
MYTRDB2';UD847'%74U<=,Y)25HN;TN(L%M.>"5\.VBOW;CNE.C2W\UT5;IB
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MSM>7E6=2U1?,11!IDA\M$@^8><M:O;_Q:]:KM@9OXSUL.G)GNF]]-CPI;GK
M_@P.N\+=I0#7QT$L8$(2(S73N1ET3_K)C<R(A3/R#J>('6NE2@!P'1WW;6#6
M)9 N&YN?]?/DYTOPWBH)L:>SV697-6^OP\K(T:/E9^TZ'9$:TS#E&^))WGB_
M1W[+G#2*EX*)^KV82CI\F&QE+[L]]2$C&\,>[#D$3*\J*D=4US]/7BB%\N0=
M(CKEE#A[JVALACH,XR%82<NQLZQGWS_AQP.!G])'3W4(SKXQ/R_HCK,&U(9N
MHZ@W6-6FKSW:O0K*7N1EV1-2VG*7>/2:6/.VIWJ;6B>-F"'CF^G8)F]B?H+F
M=T$E$[ZLK\GCH6&#CX#G&')&>H6&:?)(RLN2?>5XDZ*COM_P\&&,U46B:PIS
MS"PM IN.ECW[2AF1:]_U/3:N\\2SIZYR)B$AYIC3-=9J6EJ$<LTG%IQR8)CO
MBD-G'%,2K=GJ_L'7]>,9,9[ZZQ7.S8(> B?FD$?C%F#5F]@P.71Q6=<;21O0
M?HCWB$X-S[)/M[UG)T'D'V.@G)?KCUE>D"._%^6$OA6_'[Z8M^1?A:LH.Q0;
M<-ULKEANQYS<<,JQ_L6/TU%G24,Z>FA[RIHN&9\Z7MXS4Z^ 9:P%9A+P=#"Q
M<%)\DQ4E;H9*?X=NZ,[')LYS% \H\BU"@HCI@=6?C%8_FJB)3,O:_BG&7N/>
MJL<JGHW'SY9''AY]/87H#AP4OSVJ@Y)&Y+?OZ &EF#2>+#Z/\K=%>]KC\NS<
MD1N)((5D(Q1>'[Z11@#\'(]:\9%)RQ,W[^C4ES8:8@8)/JL2M0A_G>_QA]N9
M-T0ZH%UR_F3Q@R0L;][MB*WQZZ,DR-ONMKL1;^ D144D7%12<PML?Z"_TX;I
M6WOL459;QYP:\_E^Y5'WJ[G-*IK&R SI[7Q\=)K.['TWKP6T.0':_/L"VEQ
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M44H88BCW'0\B=1THAR/:8NH")\6A>OWFTCF-P#QJ/7O8&2182-YA5$@G5X5
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MD3&BWJ]M?N;V27BQU#/L\0B\"4FZV"V#/,/?<=;;&\G23)!>-R!G_@@L@+K
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M; P)!S(13E?6-:KP^9<V?0E*Y^"I/NBW[J:!OCF(Q[N;%*V6*WQO,G5^J<^
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MD0%POEF2=1T3TR\FOYC\W3+YF#MRX)HS)V'A'E3:-2)>+P^47DJ]RR*XTXN
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M47,&D*0[0IJ@&;64P9]<V0POI*T7DX@D>[4A"FME$9FOO&UJ]S]SL$=S-X.
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MFX?3L?<:+R%F/=3M!^8MZ71%WPNYC4AI7&9M]%A\L@I8<O(1 QH'#[> )FX
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MI(>\T8SHL-_>+&E2HYV4$M$F6>-XE%E?K2\MG,(L9+\1\$.U==F'C<$\3'3
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MGX@+DY@R;+,1PAUW_&KMS3TSU9YK+Q0WZ[P* '*6.DB^(JV8 :M%=X_X-(8
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M?FO)IGI0.R \T(::3.&U'%R7ZZVW!#1+RU?$CCU03/0_=MU9&(0F/]3M,\M
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M_@P&VW4]7O-GPV6)U185)>I023$O7#K$Q" R9QR4\-0V%1H)^!AXM%W8627
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M)X?ED>ILUC3IH05.$]]A07JBU1=W"4T\FB*'OPK64?+Z%N)R7NP047:(##@
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M,HH+5[[JR;&+P&>DP.88H%*1S[A#-3V&+N@51&XHQPC7^*\/J-1&=2?"OMP
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MG_M=B%.O";#)#%U6OU(5>1*JI3E< D#P/"G[\#T7<'H>E^<98^'AP=]O:D8
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M<&T^_:@#(8G#\I'6C]F!*2-!PVYB\M@3L1AA)=2F.&=2*7S4L;SHD"4*]L&
M:;6#>E[-  &R_S3)U2OFK:4JO?BYN.N3>2V./,F? 6LQ]MGX!SVC'A(56'G"
M@=CG2E30 -YJ(4?9L\])I)SH()OP9O^?XXZ':@ZML(,CS.K:JWX_A:RN/X1D
M);+FB$I.V#F8G4H',FF0?R1+1Q^>]O:?^186%!]O7R[[#;Y=XW?T#!3N/;4=
M@8F+\,NQO]$MA?N@)S\H2N9P#9(A$#++?N]0A,4:HJ#FCPGO]?#WD)\,P: :
M#36?=SXZU!@*/K1I7@E].!!WV9,XW6MB.>=ILI1EA[L(?/.8.)9[3SQX2)5
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M<"TTD,36*E5E:8E<J"E_1ZC]GEEW8_/37"]>!!!!P8_#OX<;V8I\.IVZ:?8
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M6G%AC) >#G1K9R&,4V?M@_-1>ZQ'#=-++2<U=K!BB-<DO9_W98,_1*[B<38
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MCHLX18?WHL-<9?Y-YDFT_-$=+33FFX"T=_A.?M-^5%%IRO@SX=>O0ZI.0&H
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M#4^E+-S^.#;*?B!U.$ZV1?Q1A4+I-.H =T)PB=(I1("M:/2O</?4V,8*$#Z
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MOW!MQ.N%RYI3(TQ'Y)<9G48$DCVXV@(40W=H;"6FMI&ID/*FLE*EE#P&C8-
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M;[\"*S9Y?;':W"")0.X9?H !.CC:L0$;]B/$(+2L%7W?7$)K83][)O2*Y4,
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M4W?PA(4+X^)&VN(P&+U?;;?4M+99]4WMA8UB552)U:*W4B<R,F7!"NLAI!/
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M^_TL^-U#@S6EULA=2-?U7C]!'PU-++G9__._/OW3GS_]++^O]$/ON&FSV.0
M?TQ>B0?!O@WNF 91&BDOC\F$O\%TAWT^ EF(!\.N9W"7F']%GI"(C8GT!DY4
M !J>=_O/2B?@G2_G_(S1J_\#;=H_8)>?3]SYQ,F)H_ 1DT'6? /+$#,%#>/!
MSE^"(YLE$IZ,V+,?)>72\^DXGXZG=SH69:M,94LE8/;G4W ^!>_A*7!165&
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M^%D*/P*[]5+UQ8O?Y0:F=5%*^"F'ZIQY<JFM5+:_5 Y<YPCH#VUV]=\C&\Q
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M2HJ8M=ZD>RQ:!LQ47:$E2C=*Q((F0CB">IYQ9VG7&])^,%F?E/-:Z&7@L_K
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M<N;<K(XI=-(&4[F>J;/4OJUZ:*[J:<W(B[.9@VT:9V4G%M.AK83WMS5U^E#
M2 T(]2B]4.X5MNR=)P+04RNLJF)62I!76"5JLIYE$!U2@J769.RY#+W1)')'
M?PERA-Z[E0RPL"&I8/2$L&M;+VP,-FEB-F*O%43"?L>:(_+YV$^UN.XG+X9N
M5Z4I8YW((DTH\P@MM08I9&AA'[P//")+"M0N/99QYU2A$^2M5"=8&W3;+!ZX
MA1R<XD?Z6-3>9I5+3IM4^;A/L"*6EQ.C'AS2_=FB"UK*0M\M2<T4VT:=>4DB
M0',/V@&H$!:_JMD#MCKIBPMR/D\(M=KV/4JWKK6A*2-PF>0M70PKZ3E*Q5@I
M3(<G^P8@M Z78TB![$VE9^*Q!\FX4![CMW([($:BJZ+:,FF8EM,.9R<Y5R[%
M9.8=1RM+FQL0'0<O6"_VB55R;PWC@,$:O"9/Z"*;HP+!U/@S5J9G33EY_U\_
MC#=PUK=WUTMU'V8),#'%K4-%Q("%*&1_M5G*(H$V,T@R:@8Z.>RB<OI>F'24
M:%NNHQI7D ,/KH7 (R;%6OYL@G_3'](O$/78<!U9C<@/K#\H$V8=5O\-7[%A
MZU-OZ3>:]61G.VNX'0 S1+8T*D:R)5E57(_E$Q9\G%1:OF2WNCMCUY2?PX&!
M2U=YAWJ+S+P:XRF*/9N#N\6Q GVL/(Y@<%PNQM\I#:IX=6:+&R<  ,3Q2E4]
M</-<^%^=:=@.<\3*-B7U/\)*Z )]:PQ6*&P)VIJ""3AT^1P5NXW.]4V%!SV*
M! %U1AW<"5I82U[D+8VW#%6"U^LDF>/1Q*@X3I9LAN6;:S&'>I_HI1<4Q6D2
M!02GM<\":2V/. RWVAL=@:XX[=C6:I:XP84#<PC?G(6_CSH/Q4;VCL6L;PM$
M/UU2(CH7$Y5Q9%R,CBR$3CD-2[Q#Y7I@SL9O%T[++%\]9%% B*QK@<A'# CX
MAZZF! 2M%4OH$=.\1>-*.E +P:3CB*Z6%$VYA*2+ZW9EM')3FL-9-^A.TE;#
M$Z6B/>[SA\@\"IPFWV+G4";<4TD5L[N >-E@^A83)+GXT&#UN:R'A^L?3(F4
M&?V6Z7FH>!CQ''*O9(TPYBIJUFILV;4$(QFTF*QOP4535T@&^L!$[<>J3&P<
MG(\?^:S7*@9RH9U3A,59V,T:YSN6SH3<U%8%*^M:WVH'47;=%QV&0P_DTKM:
M(9C0T(Q>\K<4AJE6I$9$QLUK<\7EX?+#4X9$>DMT'DJBK>]AS]$\^=1M9G)I
M#:J2-;=%]\:\-D_T/Y[>@O;6V#7N^%,OK$E20D'I/+DNV^;)-/M@4C^FJ7%9
MEI*F@O^76JQ,^AI)%H9EF]3_\+-&W8F.DR##>)_ZZ)Q@'B,VIXSUF.+,%.25
MP?[C;R>'1R=/N^,*O_25@YK+3I9880J)[N4]7OWZ''G!%WGF. T> )W5*X,Z
MXO>7M7_^-*+QM$^$O_IZ+!X2W+L?4.I^(#$=CLQP9+PC(]$9122U"49-S*+1
M#59(*T7,9%+W!O2<G:@%SHNM4,,9&<[(/3LCU$F@"&J$Z8E1#F3JZ-P<,46<
M5GU#BG:XW(6^4#A:T/"KPSD9SLG].B>8F""\CDB*ISQ4CBE1\-4V=+?$ME*D
M)RU_Z5:>(V\>$C_V?J'+D$/--PXLRL<($0!45_Z-63)8)64*EN$.9W X@_?L
M#"Z>"XIM3H3=-R0W8K+I",MQD,NU4_H+_R6$B7CVGOWR>C@/PWFX9^?!5_J3
M?B*USG6DB?TEKG_'X[=$L9ZSU/_CX>P,9^=^G1T-'*/[[X%R.,83/ OG57F%
MYXEPZZ4J4$_5$!D;I/_>2C]%QI2:6J3<]A1PF4.#C.J-)&7NCX@/)?M])?N[
M0\G^4++_C93L#Y?<<,G1,$*\-7P!EJ,@5#VU%E+8H(XJ5U**MV);WX!%=F]N
MPN$<#.>@&R8H*Z&F#$)H'FUX@%(CM#*#Q \2?[\D/I!N*=)K&Q,$B_%60))/
MQWR.W29,G\.?>>6V?M,,MX\,AV(X%/?K4/CL*4BUTF9-@',@!Z(,*NN]?J5!
MX@>)OU\2W\%RLX"%%57JUL@CWE+OJZ0^M%8YYJY.(6]'@F>I5R:*P1E<*ZEK
MV;BR-)7!.PAO#1MPJ7N$B)NX(C/)K^OA^A@.TWT[3(1(:2857!M:L9(:;+'
M)#M(_GMS[?II!_$>Q/M^B?="$7#;EQ&G&BK/CJ)^O5JQB)9U]L4,[Q4A4!F<
MEA#M5ZX1;3;$^X5/V'!'#(?HOAVBFY+JB),YXV)(:A1WF%[2SQ('18_P99,3
MT2-19(2VUV!8#8?F(1R:;@\M&EJ$8*)^BVMJ=27"XVNOL9G[=>EKE8(=ML-)
M&$["/3L)%C[3,B/)<;BQ[QL;=,MJD/A!XN^7Q'NF$;/35^U$'>H+D^3-Q00A
MIN;)-=E#-5@X9C9H]D'.[YF<,Q_*:JR-I&'Z3+5@D)>D0'1"\@0$OD1^F*.3
M8'O9&?AF.!7#J;A?IP)E=^H \V?&,!"*YR4SC/6?2LTJ -L.J8CB16V1,36$
MXU&]]F B+16%3P@ZG);AM-ROT^)':%'8$<UITCB4? 'ZP<X_CBK!=3' ,@S"
M?B^%G8F1^V#:*#412[Z:4/ULHD)H #U<Q$'P!\&_7X(/6CUSU"<2$4)8Y'2K
MG$ZI@!7$>ZN=>S1=@Y0/4GZ_I%P(RY))HP0_1=*T54*4R@FXO((LSU##' F*
M0-BK<P.&C5&JHX2)0LN"V7:>O?[/J^=;.R<1S)$X>X>#,1R,^W4P!.XU,I.R
M*$&"XVA>8@GJ! &H+)8H8RUWD@5/\<^#P"\1^.U!WC=1WH6QX5+;#2Q8LE*C
M,%@R1D_'YKJTS'.,F'Q?I+V_^W9G5^2'&CXW$\_X-ZIZ1&;%@(Y/XG#)N+QD
MGFX!DJ1/DFA,*,@5YG8L>S9_+:"H)Z#5U-23*ALO 2*>]@(1*_FE$.NE58+D
M+A-&&!.0)#4OBK6PE>\E*/RKJ5\!5%;^!<'50$J40894?1%PUDL5.!5[9U.F
M+-#OZ2(BF5!6YX:3#[V_9DQJ_%C=<D<;6@E3"ZY][$@+O$1()Z_!VYH2DJ]Y
M8-#@/@I]A^LB"' 0-<D8@]S3O&6P=N*M-F[]&0"9B_@IYGV3&-A]E8K_51M%
ML.$4AB=B669P+U@6RLK8LZ_/OKHHN=J_)AHM[""KUQ>@5?(S*U.D)EK*]!F(
ME(\RWY$[DF\*$%F8=(6/)@:F(/?@HJHU:SN>YJ+X,L^[4 :HR$9KR*Q_?A<7
MMO:6EBEY;2L%?*&56Y)'[8XUKV5)E+G<[UKEU\0*Y;$^7&9U)I0<DG!W]8>"
M<Z)$4/AY6RE'TR2AMO#. @AYG7=\B?7J\\[N@%_2AU^R-^"7#/@EWPA^R7VQ
MOGXO:O9B/;8/==O]&C[+UJ@(''HW8GF'^8NN^%I)H%?2/3,%C=/ #\Q .JV)
M5 =N4[[/3!I'YWDYQB6H#"P!S7_AREK.;2/4/7C?X2]!WU?M/"RL3&HTGBXI
MYG(-8HJ>9PE_J\R$"2?3UA8.&'C>)>&L+HLW^MX-/95, R2M@%O:I,)+I^/1
M25W";2Y46;'>GS1"8L&<$10%\\=.3/@%*VX,84:O1[(Q_K0MF F1$L:5K:?
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MJ.J#1Z)JY!/*Z>B9LLRLA18YBBQ<O)YT4+H&UJ&@" >^@<((!CE5'6XU,=7
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M704'B'A+'>1DIWLQC)EI+LH4U;0  ZANE:IW#BSAB\Y+Q)1 F--1]%KDHJE
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M/[6P3]/T1_BTN ^^(.ZOHE'SG'R0VJ\@)HJ46I0CW&V"BD&5B#&7(:K&\=)
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M_7<+QR-Y2 8#D:>+?>9AA7#T@@; 78OPRIR>?W?B@GZM]JPQA!5G(.70B>)
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M3@Z/3IYVQQ5^Z:O+%$<@"I-O60]0+H>@""Q!-$Q#X5C^%D.^ZKU#!<7"=1W
M*<K#Z&K#2.]EEH(3AP6EY\DY.XA+"U"F;<%^EFO1Q*7[ 3?]!Y*206*_08GU
MC1>VFS+J2"PD)BV&N/%L) ZZ]9?BBHFTS,=AIX8%U%5$N9/!X&_)>656."@:
MOD<C$/PCC+?'-N!;*L8RQED'41]$W8DZQ?VP487H@6Q%,V==*(ZF_D"8:5#Z
M3]2Z6/.A&&3>$:@;D%^-1]MR27&5[;<:[&9<R"[ID*KDRK8\$C&R#?@MY]#S
M/!J*4>,]0$3&X;&YIO3#<!J&T]!_&GP>QA9Q;[JZVLKE($.##"W*D'0 2_1O
MEJ3&PKB""MIB%<3A/]*X[G[WT19$7=KG:-N[I%^[335>3!0FB6T3F.W&NA2N
M<$NIMWV#Y'5[$->[%5>7.,:2"KR_,Z^5@]*>7#W#91VYTN7V^7"5[>VBWWF=
M<<PPZ%*282YQS?M\M%QN^R-(I QM].HNLK'JG"Z=G;9.V;5!U-QB"T$MBE3X
M9[E1R*H EQUXSU[O>5FF@H-276;2V#WVFET[60IGLJVQZ)2#8284WCAJ'LJ<
M #"!BOZ5ZW#Y5_(-^A7#A;!.X_$F5#5%??N<R^?:))D!D6^:"I.GV'2D%;Q9
M@\0)11GE97$N[5^4!J9%P2?PP[7 =_D+*BP:H/7^?3ZM2NQ&T05F-6TS,YYB
M]B?5SHE& )9X;A/B]C=4 47)9*HG-EQW.#5FW:?+EF$A3ID&Z.[74KN@XO*+
MZODU)Y!,)E6+:\KH!TB-S549J5>9"FO'!WI2GA=8PA.O&)&[:G!S;(U%*F)H
M.52IIHJN(7M?^6(A)=Q9[2B4KR7_?LN @Q]7:YSX7LT6==Y:%!!9%#A$,-:Y
M!2D.:6)6:3<Y_U0N 6)BH1NX2JF<;L'_3W4","+?H:(2UDO$1L@C'XB##P()
MP)Q*^)8&'D9KX#>\M@#<,97*48/K<LB(E9DH$G[2$80DT=18@16$*[@*S!:%
MV?=82SSC6I5N)$;R3^2/!BL?NJQ4:]W;C>QNF,C-^&,F3!11R@Q%$[577><L
M2MU%CM4K+5=EP8D"2]#A'-CCVNE-QU#.>REONWEL8H(6)+X45-H:7V_)?W+'
M@!1%(=%0DTV]2IT @D/SV7YS:FEOI:7]IP$U\ 9B;KN:![5I;,F7FBM+VIJ7
ME#)0O;!G3#FS*#"K;"NH5B7KV[#;8V$#E+R9=]TI"W@D#A64YJ0JL?P(&R3G
MN0FVCEJ-,3 8V\JL&AM_F3. D(;@;5R>*1:!DRJ/\MEW6+P#ZP.C4)42B<F:
MMAS+'BBOA&-(1-*@H:9;.LQW6W^S#,-A <&A=QH"? -K2\4[6$ANJIX#+N1Z
M)=MS> ]E-SX\]G8NE5)+@M^S!:8P8=X[K^:<AJW77QB]"Q25ML[<K#7)2-.W
M=L"*EJEYO>:6G4!M:NKTS=\D*WJ1%R;A=B?1U)[=O#!)0<"[89*=^HC.I!=?
MRRJ90'\:(]@'PA>/;(L@JFG5(OS/K\\?;U&?$1T'-Y/5)55DK8-WH:@.TKFR
M8'$UU/CU'GQ:'F""2Q!+PUTL"#>U*_W5/6#G1*QOV#XXQE@\SF !C C2L+MP
M\_9( >G*] E['UZ-V/J)%[@ N_T9^+2,/O'.Q>WT,8;Q;0O#-]3%+*^+.1CJ
M8H:ZF*$N9D@4?%3D=7=[M'-P3X*O%)&:@ ?H;E9&'!,81,78ZEH3VFC3FUJ]
MH;:S>_6"(>'L" DQQ%T+SXOJKF/<4ZO-!!U\"X\R),D&V5^4?1\7ATQ>0CHU
M106[SG:38"FBZ2B.2%<T.<(BU,X4_W5?F6/Y"\9[!_$;Q&]!_!0^9(ITO:I/
M!7>I8!11T(Z46J& ;\5M+> [P7I@TPF2X7C-KQA)NF*(*OBYNB#]%2\W^&F#
MO [R&LCKU04W3Z]P:.L+D#YI=I?N7%B.R;663/7=Z0R3JD!CZ.%N2=TM8\[D
M-D9!:2S, <[+N5!D#U(Z2&DHI=2*Z[!.+["-EW,Y5*[RWERO0 /4.O%!J@:I
M6B5507NG2%#<A_Z+(.P.5E=Z1.L;PH+:R6I+"S!1,_% 88358="#@\2N*[&6
M_$-D4B#F>FOZ)='FTEU*7>X*J[$<U;$1]5WK#B8US)L13.@-#=<*]3L(]2#4
M@5#[V+N2R%@&RTZ (%BPY7"CU8!-<H%VIQ2?WP[OH),'A3K(WDJ%ZE2H10Q*
M?4>&O2 LJLA!1OEW<>@4J7MSDS6@?%EJ/PRB.8CF>G<])NM=@3\%D7QU%T)^
MA,P"+JB_1"X1>3"Y+#DB95&("#E\$-!!0 ,!Q2(*3,<P&9%6CA.G8*W:,V90
M?Z9<2;$:,*A:01C;<M*2W TW]"!E?6I060UB>SO3/Q1W4,+K!@'1B @._&A;
M!EYA>U1M)A63<34>^*?GT)L/DQQ4W25JVB%\/DCGITAGX('3OU/S5\O4(EA/
M?ZX!RVPV;JN:LSB">^9:A^>P<Z #AV:Z0=!Z\HKKPJ+>MX:V4X6XE)00R-1$
M^+NE4)/KU GQ>9R;>H%8NP<][,823\&D]R!,<XNUZ9IMZ1KA?&ZW'K/GI5K
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M[=NS>_$&VNV&(.1*61ZHB_VK!4PF-,/ _1*K*GC"0OCN?/DM^SD!O!WO[I,
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M!^"I5<MQ#+-/D?T3<<SN1/M;? KL0CU.V ;"R O%7>P6F2P'(-U"!_X-#02
M]1HW:.($?OJV@3D+-@S@5E$P=S_6@QT#"QG=,GJ2-X0#?P?UL'[ M!6(DV;?
MG@3QFK=B/%[K S&V (K5[+ $\1W0PZO<@T#+R\.PL#C]"V+64]0;#H1/5 "
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M J=\!.T<',.C#23W2T]\%.> >#D$&N8*B A<,'6WQ48XQZH'H!0,.D@3W.P
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MFG9BR$RM03318*L2)U&'*_.3T/.D4Z\/QTQUUJ9;\;7:Z"\EWK]254?-BLB
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M1.&;J(HXHT[Y]4HCSBOV3E=*A"E6>Z6$[E2L2_RXU,BDIF;L#RLEW@BPGQ:
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MC,L3-*K5#,A6( D4S)<=U&?IH/,#NI[__+M[%V'NBWOG]VB6A33;T^WN!-P
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MTI^*\!I2N$8*UPCJD\*U+U&X=M^!FM\5C=E1D8[%:YHRGO+/I=B &Z=Z$E;
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MRW!QIH8O%9X! ZW]?L/0,!V%GQVN9U@BOD0#J]_.#49])TDN0E"M,2:&Q#K
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M$B]5YK7%3>ZRU1=R3V5-,JIF;]G9#8D/'G?2D'B/7XB_B'2M^1PLTIA0>8[
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MKQO_AD06XHMD<7&>N#S_\;R;C[]"! V"7AKY;Y3 O@?@%[Z%T3J-=/6,0A$
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M$D%'$5$1#$,>RWC@6C:GLAHAFGPD#L^94Q09XSU&5K#)R-2V!D1&2!0L \&
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M_;5\1O[-OUQ^<XZ/4$$'2"AW\:GJKH*UX&CU5D,8^:PP\G=UYQE%/;/<@X:
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M6&FSREI."V\,M#A.9W@CGH<L#NP6*AHC8M\L^F.:OR(TS]L+6^%@O;P@Z@8
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M?]2P.&2A;\Y"5PIH_T2@A(3R47/HT63G+CW6K9WV\JS'/Y X3H!SJ]JQ5T,
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MZ5U:H-.C%,D,S +KT,):J/0G%-9;GQ5U-T%]P:Q1XY4BTK(MI8P6/L-:2OH
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M_RJB!>0A_!1\1P1VD"J^4\!&;. )H6^: %WFQ$,^^)()42/L'VA"AH;GMR)
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MF58SX[K<89/FF'[NL,5QZS*V".T#+1AT/ZNU#$6@^Z*TFN+9VC*[QDUG'=.
MZ4'%HJE8*AK#J7?8'O1'@X,GA/'O:(C;Z]N9Q16>5ZSZ:L!(MFJM^(G1)#?
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MR)*XDJ2GCCY,9%KO$FY!K_X8O7=P^ZZ.05%W&B6^N5WBG9ZA3)[KTZ3#W$,
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M- ,J3E? ^1=[06X+6#"G5C$T7^ "U%O!1+^>X;DC(GU'&<5K9I'+LIPPMTV
M^4-Q#@C"!(2)!+K[;G<=NJ+T"!]L<"5IMJGLC/67J<P0P6H3BCMHT0-P@R/8
MDCESKSPA^[JB@W<!Z+TA>-Z%N-URJH1J?8 X=\6,M,N?,-W][W=IGGO(RQM$
ML(!L+0&M(:U$>"@ @JF*-@6+D( @Y< Y3%OQ1,J9=WT&?<<[09M I^/,8[C
M!ZO O>)Y* +@<]9@D0'DD62X7PC(.3_U&T#+?9.(3#H@<^!#+/ U7@0GC7CJ
MVT"Z$DBJ%:< 2>6);<O@5--5*D\'#!I@(=)K^7%COGQ4>0'S.PXX'^7B(SS
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M_>Q!_@WY 5-^KPN"PC'0RS+CG':ZA+0$K'Q(Q-P4*)I K:Q[K<MMI(6]V#D
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M"+[0V#K;M,K,"*],^J;<Q@=DAH+I/D_GFFJ^'Z(N/@&I*2A8_<&;W&OC S_
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MH[!A\A_S0*9$(*)64#"9$C1.3H3?_:K"@_0<K JGO1V_4 F.86RRLZFSNKS
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M-%/G3^G;S0UTBRFT2:C;?JAMXR>CA03P@XR;+/@()@W:<#!?:.#\3 .G!&A
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M7+5^48ECS?:Z 0%8P=7A1X854/H"JC5'^AMU88^(X!7"3G]'@.J.H L):"_
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MX&LYV1+O;^Z:_;19 1(8YOM+ZMHBQ6E,RQQYQ#798*8M0@SB<&:?((G [@;
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M#I-AZ^][_['Q_14WJ=[#_:\X9P:=^TXBVA9--M!!F8\*B:_4(W*MMLDA@(0
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MQF[58(S$I%5''WV)($Y5UF5+@\=A$&<HMTD8I0D=L6_JB$V:$84*$"K =U2
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MU%<O!8(%&CR!F9,(G_$TS\=[*N7]7)F#%[4ABAN,_= K9S&,]J\&*8,K,9@
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M(@E D,$5[&GPPW36,U.EHJ^@V:B>L&';-OYINSW0+U ^E4Z+/1X^H-AZKW1
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M;G4U=Z!G'AU_RG\QNC#=6D5RG](3.F[JB&,/:"E@RZYC^E\PM*;?[/@4Y!2
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MN?;_9Z)U]'_G-(/4M+#<Q]#L#GS <S90<)EPAI3^4TI/*@^#]"Z9UB1P#=B
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M+$M?4 19D"]7Z19I14B2H<F0?0,I*"P;^&HUZ ,[\;MH;8!*HCJ2PM#HXIL
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M=]_TDS.GP^Z7#UU<>K/RX+587JBXJVI_OY*'<V$.P&@DVV:+VQ/P82I\V:B
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MS-EUG(J"I4@5/8:25^%B92H4>/.Q=RP+XS.UAA9*G[:<7:\]C>"V^S;+1(Y
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M:L'CQX$@H7TLTL'VX4C4%N1))=B/YA,'JHM!,R-DR'M]\@&P*K\;.;O2C#X
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M Y>.-#=X$6G0OC8YP[5;OYF5]V,HS7VA663A$8YJAYIX.0@TEP71I+8G*P;
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MO$&36BOB\L@X,USC_LJ 3=R@^0'\*3W%@<XE O;Z[(*]6'TG)X[E:F7N,S(
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MW@EXW'425'<N"7;\/'#C:9".V-C\T-CV^DL<2@@T'X4<DS*V59/;^JN@RHI
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MBUOK7\V.*2^+6.KD=@HU?&$5?4DSQE1G,6Y]YP;KO9'S9P5CS_A)*AUV85(
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M)0.^3&SK2$I!)H6=5A)L].X'X 9DNR9LO&!MPOMTU1Q0:,Y%"L%,G6Z,7?_
M)T]Y7[[ETQYB7C)6L+K2@40\ 2"(:7/IJ_9@$"Z4^$_T3\GB986/VM4Q0PK
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MWTPT06\.>WB> %L@'6,9^YJBDMF!RV7?*TCOS/%9OVNU["?4,((:S]T!3P5
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MRL@P6=,I"<._4ZZ+*FVV:F%IN-&>Q9IY^_W1X8GXU@:T.%J\R'$[SDYQOUJ
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M<N6!8A7'0QB6,=P5,5TO+;J4RM6N=IJF[^>K2Y/%+<IPVEX^TDELYH9(C+7
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M19!)Z3WFFHH2Y[0T5V-DV62/TDT1E4]WH$7 PT7:^?T>4V!=R[,I7( VK@=
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MN5U^MY&6XXK^\KD_)5(E4::Y[&,IKG<IOV,Q&UNT*9I4(@:Z0"KNS,FWG40
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M6_A!L_6F( L%MZ>?;X6 #MYQ$&+G=[R!MRPQN]URYA0E7!E<S)$6JZZ,^O\
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M1"&5>*6RA^V70CP0H^9VST%5T;S!M /US6O!9M%;1VJ'$MT=TK#^&/\ ^O\
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M4UL+RW)]*UO$ZH/$VHLN!B8DX]:PY&R/:O4B^9)GSTXVDT(SM(^T"G,=HQP
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M].0I::7+8P[OM2;B@:0G=M^\5 &,9.:]<O=8TZQ6<W-W&GV?R_.&<F/>=J9
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MA,EU//(I(I2&*GM2 [2?2E!&,XY-49@QP3Z4JR$&FGD9J(L5- R^LH/#57E
M1R >#TIBMWYISD,H/I4[,0]<E>>13=S*3BB)P 12NH/.>/Y4@:'L^Y1(.O?Z
M5,DGE;)(S@KT-0QINR!C%(C%&,;_ (5+%8ZO2M3V3K(IP3U%>A6MPMU;K(I&
M3UQ7C5G<-!*$)Y%=[X8U//[MF^4\?2LJT.:/,=.$K<DN5[,[F"3<N">15BL^
M-MC@U?!!&1TK@:/90[M0!24X=*D84444 %%%% !2&BEH :*:3SQ3CUIN,&F
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METJ_U6]M_#L'B"2VGN)+R16CB^RI)'&TV[<J&1CR6]!GFO4EBC$:JL:!5.5
M7@'VK/UG08M8MDC^U75G(DGFK-:.%<-@J<@@JP()&&!'Y"@#S#^W8!X<EA&L
M7MU8RZ_-!!<W.JM;1M"L88))<D%E3TV\MZ\FH='UA;NTLK;6M9E@\/KJ-Y$]
MQ'J$H3<J1-#&;ABKE,-(021NPOM7J6FZ/8Z%I4D!E>6,N\]Q/=L&:1CRSN<
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MZI5:W $18U8C.5KE>YUH;P#COBF#KFE_Y:#-&,N1VH <IRIHI%/..U*PP>*
M#I0AZYI&/3FG 8&: &FG$8%)TI3]T4 -!S0!SS2B@T ./THW<=*;G% YH&&.
MXIXY%1C*DTJ$YZTA#F7(SWIHQWXIV=P/K1@,O/44#&=#UXH:@J5^AHY':F(<
M#TIW7-19IR-S2 3IR.?6D7@[E[=14NT<GUJ G:Q% R;KG%1E3&012A@.G0U)
MD;<GD4 1A@#QWZBG@JW3K36CSRM-4XZ]: %V@Y!Z]J"K,IIY^[FF#*G((YH
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MKN:YNKHZEJD4$2,B(ZPM)L5\CH HQ@CD<YK2N/ TNH)>2:GK<]Y>31Q01SM
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MD1TD)=B9#E.02. !ZD[<_A[Q)JWE-J^K61$-W:3I!:V[)'^ZF61F)8EMS!<
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M<-30W !Z4H&&XI .!XP>#5*[4K+]1FKHR3R,&H+Q,J&':JCN#V.:\1(6M8G
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M_K_2N;S@YR<^M=%+".2YGIZZO\=C*I7MHO\ @?\ !.J?5M,TIF?3+-IKH_\
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M3.WFE3!4 =J1QS06<_JGB+4(]>?2-'TF._N8;=+F<S78MU579@H7Y6+'Y&[
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M,A@3(DMCY?U'A9+;<U83Q$X!+RJR40KH2*;QB+:2)^MM3(QK4[KY?*C+V,8
M +GF'="ST+TZ7G(F(4U=6/U_G[W_#_"DBH:JMX"VN](R 4,$\V!D<BU;Z9'R
MHZBO6R5%><5@&^)P!!J4O'D66NZ;>3M)7VUE9-23SYYXLGQK1:OQ8YZMAW;)
M"\!O[#^*GKPH;J:KNC/@*Q5W$_>TSSEV6N/0\.C=Q0:=T/-))C33[XS "BX@
M=F6+9,768TS)^R&=$3J)&E_.TJ+B,@;)\>4Y5[:T.2#H+.'P!FA1_&F=H"%
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M?PG*0$^?W5N$Q,D.8F#4-F#$JV"F3@[#!3L94'$0PZ&1NR&=W72Y-YY4/>I
MY"$U6ILP]GO]CT.TD"BAHT(5&UG;DZSM*F$EEO'!DJYF^?(TND;"  L.M<55
ME?-GP)W8!(N,1KH$AWSQPY>$+C8FMEQZ6L[]'4B-HCY<W)Q?<RT*,'ODQ5:6
MQ1'$VV3==J0BBI ZP>BVD(7L4Z&U7PZZ:EXL1'+V(J45]'418DSR+PO!%9>U
MY=R<JYO$Y([@/I+\+=&C*6&8@'.#IRE12DT:$>? V D9#J2;8[^X:P.>*;XQ
MSM1,APYR='(-LJCL>/MW#C;T,*N+6#-"%CIE*I:]BY2>H"SO@$:.]2513][/
M7^#2/]#_%:=H<:3GJ:?&"4ER'? -O6Y*W]=]HYEG?_E^;;*Q:KP\5:X$@H=-
M860<7""&;_>F"&@BZSLBABU=8>77';OH>[L9QIIF:O7,QW[(9S]=DG _'XNI
M:L.P_ZDP.B6T^Q>E?%R4O_EZU5@QJ0^7*$6!F+4H)$5!%(#BJV-E1B+/*BN%
M$LHVW@.M=7@AAOV]BLO4>X Q3$PM[<JOB4[#I7*'(XRC2B'R2QWZ5)HR7*E"
MG/CN?UI4;)C_UJ<!*#AAMHO/L8<39S,PN>P"A'J/<@!W \FDNI+')BYM4KO6
M9;8)D"+#X\P%(J)/0H2:3Z/HW71>5!Y97JP^E&^=>MDG7NT1X=O8>%,6%5/[
MQAO+1CW9[/*_2J*P-@=1-04E)Y($W%(G5 A;ZCXGEIH<;UB'JBC"EFO?E@D&
M[LN/Z+@X/S+3%R&QHU%:_RK$5E>*8LJQ*0(+I"!_8&4+M3!' /37]Z& ![2+
MZ_B&O#%8C[O9=>:,--#*AT+WQC+\C0:X%(/1B&&J(GIBY=[#NC/0>FNQ%6*@
MWS*55G*2U5E)"@V6]VECBOP[ "P;+,9C=V*9O>F7I:N=.&$) E@I[[A09J/D
MT+6%*NR%"A7[?*-6C.EML+1TI&@0VN^,->V<OZ/"-.7\&024#2 4DTDF@%/C
MV8KZK @F0*][0:X]3CHF=>_FF:^&KLQE*H7";"[I:/<6D$1*GP+-) _Y$]2:
M 6+?L##E7+R<K)PXYE>OC%8&!!38:W&T?5.\":)W5!0/%"[G,@E;X.?7O6G\
MBGZ&MXM6QC-B4['6BUX94\7H[LO?42!+X)AN&,@P9CM;?8_>C=YM1[7XOAR*
M.A",DZ3MH14*=T@:9A/(#@T@X8LJP1UH5,),W[Y(0::X3_%OQD#V"UMHIK.9
M?XD:^Y11_&"7F.Z#D- ?]J0'?C2'/4AV7XD-EOB"V[CF9>HC QKXIYT^^/Q(
M"A,-[Q4<$CRV+;T[??X:Y:]7-5ZQH:\*TPDQ<OTU9NY#^04=!9#N"+?11$2?
MPAV,K>K4I5GJ?1I(N\AA?D518AB^_1^ETI*@JY?&XPBCW+*C<0Y[DD^J+HM=
M(#L]@6>O%WKU J*O!MW1YHT&V::XBTCS!?[9:GF.KTL(Q"O';I*4X,#',M$H
M2^X(S6,X*Y0D+&>71ZJQSE3M*Z:HVHNZSAI)6&V^M0.[T_VAPUQFN/$X;:>]
MB1=N*R)V6D)9.Q6ZG,CC@6E'6T_Z?L;DQ/H2#W&?%7WZ[P@:>6KR6XN\JV"L
M,[0-@P<P[30[!"Q28Z$6JN1,ZIZQAS^ #?C%M#<IRWMB:E?Y&#O@5'TBH+L8
M;0]<V6@<Q,B\'$35:+%)X?\\T2,T>;[CR*U=*RI&_YQ7[=$E[P-FNY:'QT#8
M.PCB+LAR/XCSO)"DG,8K+DSAQXB#0R0/%0-1 >*\ZAA:KZBB=A<\R%H_X2(U
MS&/F.2L$83B?8A'H%'%G,@Q3GT_]X>ZM<>"YW]'$.=8+Y&QM:&^=8VQP$-/E
M__*TSA>MY;BYB>1P(#:*2 JXE>"CE[%9-L#V$,*_>]+_MQB[I%)E^"C1G_'L
MV>C!TRF .^Z$N?IQ-8XG6+W]S-+4M214"4M^T[<N\H[Y+@C["!;G*EKE B_^
M1(?ZQV64%0TA[Q*-\L<,2>%)1'$Y9$0&Z%E&@]I7 N&Z4"E$(RJHD1 B -B3
M>U5(Q"0-B5AUIZW&Z/8Y9I?2P6=A[7Y:"!?:SAE&B[%M)E9'_.$P4I@'=\AR
M-C(A\Q ,'X+LJE!>%CMA7X>IB1 Q*.%(3CEGCT2'(RF-P6=Q3 H4H._43U!M
MH\">TY.CT=NLE='*6,M,<I4PG"$@]9+589&UG9$#V_KRCV+G13"=[ORL9KD]
MVD)J?HH1&KNKTW,W@).3'%_%,2 *I(J0-)Q_@;P=_2MK+S:0B+JI--NC^%:Q
M7XB"D@"&XC$?(WEZP?"3?_*NG+\#RJ(DRM^@4U.E& 6L_GZ"-80=Y E7GBD\
M&"NJ6$BBP_N<BF$7NE0J;1@(GVO%U/?#'*^L=]WO:2. 8PF1 +-@5H2^39V;
MGF[4$AV-:>3 IEJ=,5HA>FKFG?4:>@81]%R.:0(99@-]B\1>#9?5'_'!*=R/
MLZ1:+_0Z34T96@,\W'<K@VJ4J=S?>FRQZ_YSH;:LY$:*&0N$A9*/"FP.$6+O
M@+%V,A,2-,2A&7#O;4U'$+::</#F%W!8#$7&3DQ:?E&"\(9R__=]=84C4CV#
MDL,4Q<HOIMK293).!C:$_/H>B?[@&L/R;$&-1_0Q'3\*Y]\"U6/WGA\-,8I"
M#ZI(>TAYP<*^LSLM0R3O !I= $+A=ML>6_YT:$P#(1_:")66IDM>C!4SQ?$'
M\N$$ED($Q;5PZD(4SU+\K.TT]Q*N00Z20?S_)W1%UC"PE(BQ!)N'S:21Q]BA
M Z2&@0@1^R$+Z1',<$L3P/RR</';?9(2!/G1DF%;UP2ALA:.&'/BUX!RZ; I
M16=  NB'Q7HPHWA3+_>4O>:0-\SF6W(3*?*7JC[!EZ.R->(#Q !6B^ .&5Y!
MXD(9@9 6*V?)4^]R&!&"B*I8Y7_Y)T>26RU+ES?FUS$FL'R*[5DW&SZ#3]-'
MXTGK@(@E\Y<'3(+5V:2XD  "]0J8?M+Z'#*'/58@Z)H](/2&=SO('"H].?NX
MD(IA05Q2^D=<,ZO)WO^/!'HRQX[TK(1A7MQT<ZJ]I_3G-_@\;/&Y+A8Y-5])
MUD^(%@E-$I(H%$?3M^53["H X %PCP;N(D>3A1FNQ-$^1DJM,!@;'\-LR*=T
MB%NU&!^P1Z[9OB7+@E>C$#_F)HFIJ1@,(B?7) \%0"AEX!$W+6<C14D=I? A
MY26\_">2TQ=U@8L^)4NKQJ?<3[-&Q=TS7'HN)$-HV_G\(<4*7D@K1_R8;H /
M&!/VX3L(A;I#DI3S/U^T2[00Q( JK&+*QZ R@]K"_MR?\&AJ+]@DKS8MTTT=
M2D].9TTK@DZ,[P C%W+T!H6W&[C4Q_DW%09XWN++MUCR%DW&1$AU9M2HZ[A]
M\"2DW"TQBW)SUM%?Z.?::M?$4"Q$161X#]A@6,S+R-V4PB,K. B:'0;"Y3+&
METZY\0W '$H:)XB2Z>O@,[QO\G\DI[0A)*0E'1K*=.<SYF-E6E#$%00N<_S]
MLJ&#@%)JDWQCGMK-#%^:D?^MK%CNFY6#;6+H.*)B\"822>\I@$H22<ZE^*A%
MQ761-*"ZQC54Z$]2E4^Y,)NE?Z_E)FGG^ 0'0"M5Y5<;C\^][O53TA-V-X/#
M]#O >=>U$RRLA2<S4]24,R/&,^%0)D7^JQH=YR_F3P.74, .2@N!]S^MGHA@
MFAQF2'Q1.J'\*H'EMZ3>.T1*J.Z*U S[J4I^<[H%YD\7FE 1=^UU5+,5R:'_
M"MXQTM?A_\*D(2"4S<C/*WTK0A#F=</ 7$CD#]=6/[<)E[J$K5CG50SR<B.+
M[>*?W';#^3'*CGZV!ZY(X6U9*36AH_=%USV( 0RW7.Y'.Y#$4%"IQ?#\Y&=H
M8(:1.1,CE)T'=B[H17=BB2KX.E*IX\A>/G&F& SRR@HA_C[EQ?OH+#]E$;>H
M7;S/1]-K"!AO_0NT*VW^IYMNY7I?CHL,1DHN1BC4E**MQA0?V'@'V 0D;)RM
M?TV_+V#QG\B>7%N:Y%T1K*+V*B'G V@4R,Q YNCF.('C+'7FPYDN].@SC,+?
MHD8J)!KM_7]OF#>/YIZ17&>^.G+W0-:'24YT5PJ!.+/KP<PJ12!-6[3R\3(#
MA2!*_C6^]FP]"J['D9] !W9;B!:I0]8<:E_[QT^Y<19D5P4+=90RK)_<Y#$@
ME]TAPD!<&U^+WU:\6; 9GC+IN&[NAP1D-5,VK7%Y#5R@]A<X'6TS@#" Y5@(
M&+EOKXY MK^?YMQ6BI"J*$<YU^MXD9D#V YET;:H4Y3DT\O+,;[*$;F:R4.6
MX2+N)"4-.9(B!@+6BW/4VXKQW_(>"E'P"C)A112OE>IM)/BS,8#8_-6Y?O8>
MQ<0>/F91\!Q&U YCCE2%,R8PCA3Q\Q7;'?GS'+;]1O_(0U5:ZPYPUNS/-2D?
M(.R63_5 N;YS-&,934R>6"*KIA-ASE(+L]/RDBN@,NU4.M0OK^KQ^[Q^EE4.
M[_E*Y(EZ3^1WZO ,1JHS##W#A64)OYMRV/RPBR'KS+G99=J&=&QJOQ?5S1CO
M[3=E<8HV.JKO6D]ZM@ZK09@"HZD-.76.?]Y*L7GC*<E;=SS:0^X(OHD*N+R.
M]#[8GGSAE%L#%L$D!:E4;>Y/"=$I'%VO'GTU'@YDOLH8OP.$6PC#;'_P.B4E
M:B7^U3V$NBWBWS:9AB=NJ1^WS"T(VMK]S,?_^)LKN?*-0%CVFBH-5\SV>64(
M<A[WG).NS>F6IRV46\Y0;\CF++% U:N]12"H#K@O97#K+4'<+WI@-O3D8F$!
M ;327.2%9].N)'^G.;,((D<  =; XAH!XD&)_S$ A%+ _[YF\Q]H2L28"V_+
M:% 4M29HP2QH^R&QB8K&EFXJJZ"^1DF,([4I$J88.PS2F.L9MA,ACN^C,5+0
M8$%ZW^\A(BN?Y4L5U-N%V]\!/JHRKCGW/[?%/IT1235=?:^+"D/F[ 4CB^1T
M_==D35,:HVG^*:,-/9IG_4A]W5J\YB.L(\]\XYBQ7R.&]9+N36+-]-.XK81*
M&+;"#C"]=&87U[P4#!Z>['7G/2:,5!MFBH(:9(*\6L?W+Z-0*J8HY'9!W^<]
M_!S0')ER1DMSMF@3_(+ ?+([+G<7FMYIRS)5!JNVAEIKAJC+_G>K*V1_(<I!
MX'FJ<.!>RK &#PQ_MM;Q@]'*9-MOW\TWJG3=O);ZR L*+Q6%^Y.R6#V(Z196
MER],>:0ZY1CYKKIF5^?WB!25N+ 91H$J6X6.5;1.@5\PG+V%RUTMXYE5RJ+F
M7%/Y#_4EFI8&?3WR<TK[8&S[N'^D2Y?0/YG(+QQ_'G19N AOE >S(S:R+*^=
M08K")J1;)Q(V/SF<6L:>W\B>O3B/A=<+2O"),LDL W4(E+@I6RDJ$VJVE8R"
ML,1+K41=,\6-Z4.E@CZ+.*,=$"@^:Q1[CZDHWI.8SMA](W<M(KQ>LD@0MD:Y
MJ7X'-!A+A+](>7*4Q+"-=H[0L-TXK H-V[\#%/%UXV):*UOR+&9>^70-);*G
MO6W/ Z3EC;(O<(_RNZ\'&YT0V"["P+;--=NY'^3KJ$./ E?0^:=_I6.A?/;]
MW@R$LI48P*/2(B)2;C#7D@IA)D17'RX2:G7=IHC$?9'W$.RW7B$I8N$?J]$M
M9=6(\8-4]3B9+/^5KC*6S_D@-L?-MYU*[T"&1]/[KP0#J^MJH48@YE:_3GQR
ML5 P(&Z%S,Q)96GP6Q3#QN;%FL1(3<^>Q">TQ9F&VK!EOOFN@A6SK*GDLBE'
MI@3IY!'!X2,P:QH>5P9G#9_'7L^CUGE/;=PY5,Q-=88"]WJ3KH>ULC0KT1AK
MKM'.UU[8UO:3>X]5TA:%E$AB(87;L.*>QR?HT3H]T0.NFC7Y@FVH/+7!YU\(
M+"/4KMA'&C@NI8^.$ULMR;AVC6PJ;O:U]YL[&!^=A7$EGN]$8Z45+&Q95(QD
M L$9?G=/OOE6X*ZR8_Z;52G7;F,$G@LD16S_5TQIJVT3)O4.PH4'H?0VR9'Q
MGJ/D"3??+[AJXMV<-.T=1!_96+Q?(%EN(\2]X@7A4B7C@O/N(_8EK1WQQ&C4
M'<TD4%/>2#'NLX2P([5D6X:$JG,3CJ#)M7< V^NP@<>V">/8+4S-FU!=TIZ%
M1JT- 1Z:A@P(114-%5G,DT]=#K(]6M0TK5HUYD7]UJQ'! "CFO,^OT$7@BQL
MOW^@AR[0-\40X_)'%^K1)^P>U'))H&=+<98U<>O8"ID*M,C8U?AO//GBF7IG
MRM=W\K<0?;,R)4;\CE:@B8RD4'[2[IBZ5S,_1"JS6AFCGWZW W7C7F.,Y8=:
M!4&4//@F1C/PK\<Y?J?V3F(K9NIUMH?I0J,DW9=@?Y%2/D@!?[P#IJA=>BDW
M%@IHV[!)^ C7Z@*J;^<O*K_&",LMNH_<IL_%__U'EU\D6>USVTORRFK ]T'_
MTV9]BDD+;ZB%"F0?8'D3AQ59XQQKY;J!Q1@LQ92/.?J)LK\5(.<T!"6]\P@B
M!A'QW\_F>D2HF\J/A2H*4,T"73_]H8O/W5-AZ_XZN/PZU!G(-FW903CN_8'7
M'K.^&>^H@QCRG^WR/$9LSY]O7YLWWRC3\J]W)N8*#HDUYFP'^=D4+:H1A6I(
MD)JLM:;S@G]&]5*^!OQ;E*'7+""QU23.8@-96F+QIN\ 5W%IP9S5"QUK#C<W
M+V>'-I]B@7+>.DXA-PGXIV9PDT([B<-/.O'2)K/N'3]"SW?I:WGP6<Q1*GHW
M]>C$2GHNJSF*"2_VGP9C3D4:N]J&9Z"U)K>)I";KQ@:K:IBKZ$E-W!=] /B>
M!!97VN+8FK&VFCJV+G"FVM3XE3"FA$;3/(U/]3[N4(+%=W2Y/UPN(P\$=@1_
MO#$L%+J0^*F:1Z^#O/9,V2H'OZ3G)YSRR>FF67,L!9N74&:7H8O,\!-$TH9R
M88'6?&<$#*6)6?ZYR6/C(]QHP6V::5O7R'L34-!\> '"#2+@;RE;H [*H^#'
MP0&+RU@ "YO[N>M@61D^4)3.[HU\/W)>,7S80DCR-AB9F8XQ+D0R)((%2@.8
M52M%P ');VK>XH<W!C/# 7[OYZBJ0>67!KDP<CYCN)<=[#.66"QI 48+D2X2
M#64G0<,7&L/ (6 "2^]+:XGH3)AD)"51C-EV00X("$C;>0 !)A#_PI-^9K$1
MLX%K/5-#ET'G78@0_<L;;>*F/U?G)%-Z%U]E-#9*D==_D$KU]:OMQMNRD@K/
MPHX!_!A(]?</0KBGVTD4DOTVHW_QPMM&69U2Q8HYP:YT*3/\E#:G4E-,)SD1
MSR+C06B'=D'X*8J?X#ZVL.OEL4S8;^<GXA+GI#WE7T * JN*;ZVM('8YGA7
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M:QB @__O1:/_ />^_'\ 4$L#!!0    ( "L^;U3W?=7VD'L  &*'   8
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MCE4<^F:\ *@X&]NO6$U&2) CMH<(J2;B @DNPM[K08+D,"AWG7"?PS?25>'
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MT,+J:,:F5&KY$^FE^C,-8RO6;_F9P=W];2<G(M[UV/NY"(98]ML\9T[&8WS
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M-9KOJ59S)4@@ M?5^V8;;J7!,%NBE_,?V73A+'P3$&0["3?56>*?N,.(MN7
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MT_@KYF8K_9S(4PCILNM>@C'*ME%_M)M85,!W%_!,]?,XA90GUKENM('^S;T
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M>1<;JSC.*L[\H%,910_<C-NR07,T(8V2,3KL/]>9NL+8K>MWB:%&//X<7T'
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MO*GJEHG4^*QHWYUN0.8"PYN?)S=$H8TEM88Y(8>(\&/BA<BW'_HZ,+4G!?S
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M?5 FJA_;1UB"\JBA&2H$.R?-$1)8, $J&&:&3&-:Q:9!@*F;A;SXPV1%&PE
MP V,4)EKQR@@LEWY/'!;U#7(CW[#0'+S _4]0&NV[(GK^Q+-^(@VULO^7@)7
M_FUR^PWAB;N7E4].[E:R30R7'=Q%3HUM1U95XV7CBEY;S"LD$G[ *E;AU$5L
MHG]**&5)D5P%^SS*QH^R$M>"OGYC+3Q147,B1AU&LTF\??PJ2<SP0MB<33M%
M2&8:17CD97W.E=XG)/E&_4GZH/OGCZTCO^($&6*F\5<Z)+NNX*T7H7M5Q>K,
M(GK]<@R14QA&XJ6%S.Y:4/(TAMQ'B>0QPL56U8*,CS(?QLD[8& LN6$DN9<
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M9JE';(QM:;*S)R(FK^9UM%@Z7@Q*/:N[3JLKV'EN2%U*?)O_9,O???09C[M
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MIYL/2WA3]!SLCNP@)<=D><!D$1[?JRZBB"O;E!M&-*^TW!&!TR)CEP((3N\
MVO>@L9PN6WCNZ;KH9^,Y*7JA##J_9C2X^NN&GV;R)B?X:E?I=B/ZB4VIYP-9
M:>Q[5B'FO'NM&5H?Y@8B/KJ)WE[6^3KJ#7+MBK=^,L1,[<X\(SS6YB"XKBY\
M;_![C]V&XECK* [U"$1LJ+!?18,9=%8//]&H%>NXNCC=3'VV(V%=$G?T^K#\
M+? [J,= ;.V]NK9EQO#K%WP<;WWY-O>CMM_[4%V->/"-B4A/)",-H^-JL(E$
MH:J QJ^A>L9M18)&!NP@0"&$3-/(D!T&**1)R%77 H4@#3%M4,&\^ XT<4/M
M?EKGW]TKF8>5H,AL?7!7#ZN:B8RRJJX_=UV=>N![?YO>9?7MGFI,,W%KVKTQ
M<O&.OZP+]21KCU^1JMG3#YT&\+599?G2U+$Y;9;G9;;+)M\_NC<>'9;VBS\=
MTTZ>TA+]+<+Y/1L"6^>,Y(N]EP!\ D#$UMVSNO^CX%5=M8RH#&]3<J[?%$M;
M?TQS'+QD@7E1P2UCDE%CPZAY55E8:&.M6T2ZM"B)QTDODZ$(J]R]4J% 6[I9
MN!3+QRVC4@KGD)L:=8=OI7QX^:48[:,UOGOQ(AUS09F^?,1+CG!@LC*HNBF+
MH-\:3OSR;<Z!.-9"<["[ZU[ _-ESL$O;H!03WBV8E\HQUAA"KR^F",&_TLI/
M(9[=("&6:OAZT;>OL_JLW0)?,5,LY@66M;L%-3<F]4679XGC>BMW!5XD-3P)
MLZ&GE*=)!Z;?W3EYZ+4X_[Z&W.F4M]S1H7FEWV7V92UH-^N],'Q("/RV6)W-
MG*8WFJ2S#F1:* 79()7:&2T?:6H=J_S$=US*-^=_,F[+G2_VGH\/0]&$=K0+
M!OVB^)A!]%V%5#_/-HP]\@I\'5! CNVF:04MEH%IW'_<[_4IR$,E_GW?=0E,
MF,N %9;ID@Y@720L %;3%X C@5,I8*YU??"FR2W?*P@$[\^@+A89VH*/84.>
M4\G#4X>7<Q^<EIC/\OB(Q@)^&V<M0MR3E-OJO^V+:#6V'<MD7TYDGM&9G\VH
M?"*9,4$7L#&NZ<(JZ^L45?CL>35CD+YZ(>P'SA"<R/Y!V.&RA/7Q2LEG<7;G
M2,2LPNB+M\E::2D6[WWO_ &8NFO4L.T8.WHW>1C5@)_9L,& \#>YIAH =MQ)
M:>LM,P64$J1(]\T'"W$-CKS:M@K;C'QYG*;#8(8U[Z)H%WF&(!L>-<;-G)>)
MTH%BM-(U A@&,H 0E.V8<R093#6L%PXU,HFR]W>XVR90>5 840"L_;<-VD?.
M>2',ZF"4/W#*GE1'$X; ([K_=&"XWXM$$^!J^MRO:+F3@/O:*,>$+0PWIIL+
M2/;:1_]P<WQ'6!,!N-W!QL)\-%SPS/ 9N6/[ROW)'GN/*QP7M7:\^^7EV]27
M=VK$"=%$Z4:N#_[=+RZ$JETV@JA8$Z,AHB<^7<SCAR%70S_D7%R?R?:TN<;4
M-P4W/T)[= (EPM]\'^CZOCH]7K&>Q04KOSEW>)WE8@GU$A)$YS./]//K 1.(
M"UWS" .#_,DU3?!WT*U+Y K&;15:^YOD&7\EF3F_3!Y"XY[C_.AN(?V[$.,B
M$"702,N>U0X'BDR+9+5CXL(F).A=/B7H*\6":KHTU&4+N-/4):1D&APEVCT9
M4V3Q_M'Y..LG"U53\TZ/)9DE7#V$BY5\RH46G\L=)VA>E#WE#3+D-8]#:R8(
M90X;DHD%(P^N.'W?[S97;V@T<Q;%)I/U+-L**:8.TC+,\KJJA+7Z2@CQM>A>
M(Y.-R0FP;]F\R2A?-Y/5ZRIP;7?=TG:5)I%ZN&B#X5(0S'PPUDB$$>Q9],O2
M\+'##RCK$NR\X2:G'-@RZ8ZM4*S6I=B&Q1_6,NLMRK[,K5FK-J!B(@'A6480
M^SA=V.UN3MNYPO&ZU:K[F9]__-J'2SP\7+WYS]!$"IFC=[S+.E)!<:EE3*PQ
M8@MDNB@?P6Z$IT0ON(;,@#R^S3@DA\8=&$(25$ AF98]X1V$S) \GH92 26D
M\4]8;60*"F#W0Q^\ !)*X %AL^"U0S,WHSXN.,88JO:6T6'*N_+FWJP>YCT9
M7XS/X@^#GS(I_0$H%!%,%"+SS_.+@G*I)AV,V?PW9G["2_2 C$,1[/HO>L2O
M95IZ; ;1<[PU61QJ=,$NY/I7,2@1$6[!(BH>ECKV/9XS<79&[1Y&T:B<#_*=
ML:_7K9/9M;X.6;)?-PJ^VBQSIE '2?'/T [J<XKWNK.)6ALCCQ:*X BQ;[B[
M&C]0?[M22,))2-)F\V&+5F^HR8W':LGV/&;I*+/*A:<F3E= <@U/C/[2(: P
M10Y8TY /!-B_H[&&O+K?1F.D ;J/D0#.:X&(Z2 :D#J?O,D[47ECV'>(P]^
M ]3?^%P*?;@W%Z;M[^L-3)$S1A8-(T9B*AL6J@_?/FLB\*,D4WN^*R.'G GZ
MSP1GP2:.A*:[-WS$;KPT"+@6@#LHKM(VWCBU']]F4I JD:LL_1QU.=3:>PJQ
M6BF-3(\8=HTVR</$%\Q!YDP@ ]3&K(F4$EJ\JTJQ$H'F2*SZ):A3U?1WS>70
MR^Q^/ZPGWG#%R-3^-*'VV^>D."SI>F*J8#LJY6Q_7F"@$7WRM*&VX=;-BKHG
MDF%]R#5$/6$[Y7?/[61F1C'D^I:UK$[H_<]DO>/-# R7>R)@RW4:<\%S.U G
MXR376R/#$J%5R;7@=4T@C7>@YCO.0OJ:M$(RDP1.!>,(/GG3J AY3RU0FSWN
M6C<%&FIP4*M*\^^11I=A&/ML+75R'C!>2,^8A$& !$-NM#,O#(@'K20!NR10
M.O[ M!PU28MZ:.9@DBX=*J]4DT$Z.OHWF57#0J-?@42W<GI,%>]@KW+[&B+I
M%N11[.NGC!E.PE6EDOVNB5=XZ2W?NDM&$Z5:#:5-I8&IYA+3#]MM?::8_P 8
MREYLF:V*66P/>UQ1]Y0LDV9N*8UOKK]N)!7)S,/=%#9O ^ZL?O[QV=G1/OWF
MA-1(OYO2T1=?L&C-AYT=8U3;>,X[[+:2K%#RTT4*3=76%()1)-WF^'YFQ)4O
MXYOJ/J$MJUX)+1X=TXY1];G'Y9W:XPO$_>MJ3 /153<F9E@//3*@[Y0SLEH9
M%*4Z9<1A3+D?2'P$/#.O\C>C<6?#&[?E/ $YYR7\6ZR NBB0C 6 @C%Q 3LD
MAR1I_U)+51F$>58@P=/-#UJ"7#=%L@2,[:__]M2]J31AQ^:_WG!\)IS4$&(E
MH<:5:/9KR<W3QK6^\&,NML;H&I\&HV96>.Q8=Q^>-^)9[,/47#/CC#\ Z*^S
M>1,/;>'\KY_][[H%J7-*Q6L\P)6Y5I1-]-6W2/9FA$S*GQG"H[L]<FY5-SS2
M,#]V7$F+K6C;4 @COF1:5!_/+6XZ8] _56A2E%I9$WWWZ]EP8_!A4N6PRIAY
M 1-?9MGR0>);/Z9Q*3*^/553R1M5YG;;^)AIT35&L$(']ZKC1OM$G2;GQ&-4
M_^B!OP@&D9YBEA%37#)*?3+>([SQ<\,4],@(U[@_.96 ,T=3('4H[[F5"3+-
M>="19U 7B(I):UTJ)-.A% -9 T@*BO2+!!BW82C &_$D7GOU/^/^C$E\=AD;
MWH/^[BK.N AI;&@RE"\!1EWY94*S$X/\W?MZ.[\E<67@G@*(?B6:32KKY)!I
M]>FC$B'$UQ\.S61"R/35#0?IFW=Y.#K0$91#C>GGYNCF_DU!)*]4FBNWGR.%
MHK6'9A'&R=RF5(J!ZJ/-7>.BC)2BXYIW7L_R +(Q#3WRW>Y-%<GGS?Y+UZN7
M9\/:7WA"K%I&V^POIM&"R)]Y,;WK2::6G%%F\E>E8G4EVAULZ^QB(P*$0!P^
M5VG6B*['W%[[P/*@?9NZ&,59F.R^]C'*(P@15_]J1VRA1N/K2I856\0.:GLK
M1]>9D3GU<I@STT=M P0ZB+8:UC/ KCEJL*,>1#=,T^G<K8 "Z$'P"]$05AHC
M=4%@^:.\%)0UA)G, -,MRI7;D:D%@NO\93^)OU'*F!U==7X*.GY)0S!!R]D5
MA,W4?O2(8'(H_.G#^K[U(M\MSL QO%#9>=XWB\_/>SGL%U62;Q@F_]RVAJZ8
M3RZ( 3H^\V*MWD?^NDV8*LD*(%9;VDYIV6=-03I#^IK# E'&=D7%PC+AIU;8
MD2MGFO!?T)H2 Y>&ZK5<2(9]&>_-5/,ZE'UMLZ1& &B) 0O7\'MB)@0-+/P#
ML%2\,V(J\>UN3+LV\*RO\Q*KMUJ%D9@VP]<'S1CV$JM.:25H_C3M+XC&8[<G
MF@'#596?/NU#IR[/\@2]ATD.>?WFC_[M'_CV/<5,GX3/.9$CM-GC3,;4U*0V
M82BZS/!K@^M0/,BY6Y#I0%;I_E]L"]SD!-9 4"2@"]RX#^K 72-9O$?_^J$*
MG9T^#H0QOL$,:RC$VX=J0.PSU/G(;VNC@O@%R=**%2*3W8KX'6VJ7D4D&%PN
M8X/(,NERS.#?.?#!GIOP"3;W>H9Z\KKQ2C/,/9QF_GU*Y/"*-V3JLI!2G7['
M\7JJU/J&AZMXWU35H&H%OGBB9R*IT&QOO?(0G)BL;)!TP?CY,8][J)OBG8TC
MDC#WBIB!W,3N-C7S;FZ6F))Q+GD7/'WVO)+W=+QVGR8YN7#D2PI]IL V70E:
MM7%"I"O8C]'J?,;T)F5!Q(L.%)[R*04O1;<OU#;*I6#;^5A;.FC]#JY,:D:D
M>,CD8U12;)=&!IOM)IX$HJAUW)D.-;\ @+])S/3/1MK_*"0Z%.5<[L,N8+C3
M4?8\)$#X6^>)-!"?DQ%_Y9B)7SX')4>NT#WNQ?LQ6O\YCGTJ([*'(D[-*MP(
MA:K)-5.J@MXR*,5]1HM\G] EOGU^D^&3LB[=ITQO5I7WY^E/C=+ Y;Y:G>,U
M>QK"J70A!:]3P;X*PHM"9M85=@T%W6(@=^&&Q=NZ*'<.HDO>XC4&N+5QY;J&
MLG/#%90[L&%(GN8^IRVL#?)*5^<[\%_"@O\I7,":1Q27L0F0ZWK@?NE#=JEO
M1J_RT3)/VZ=.E@UKW37D0F&<J>>.HI5OUA $.@_H=I2[N.U/O+@,[XK6Q [%
MAG#_D$1YF8JSJ-'Z\F2LMOS0VB K65_?2IG5NMPQWA^!$+EL.,R;S\S1V5CV
M7HF'4>*4C]"1QJ(JQU!4P9IB98NQ3E162)N2@(NF39GM;#4K9P<BAPEL$[ZO
M+)N>1E&A5VR&1 8E'%T[1P+,L,)K/\_ 'PX:'0^5E+S]QG%^,?G 32/43F,W
MB0X%W<QY\W8@&%)=."*$!@JZGV-/PF\0//-?%.?-#Z'YZ[7^ZR<5?Y%)/&TO
M\-U/4*TH,"T-NY"YI8TR8T[#]+8J NTQ3U4J\_D++H/J%)/O6DI.3$XH--TL
MQ?L'/U7?6KG55[X2;<[WG$D(OY*H +/?,(X3$H1!X; Z7?+,H4R2R\A?89]:
M(#YO0UKA92NVGTE)S:R4@@4%Y$6JI+DA];D P/RY$-#D$(03*@@T_=^^)X5
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M   8    =')D82TR,#(Q,3(S,7@Q,&LP,#DN:G!GY+AE5%QKMBY<!!(@6"!
M<(([! L.P2VXNTM12' +$"! \ #!+;@[1:%AHX5;H84%UR*XR\?>I[MW]QVG
M3_<YW[WWQ_>]-=88-6J]<Z[GF<]<<\ZW'F8??@)>*,C(RP"0G@  2(\?P,,\
M0!* ]NP9ZK.G:*BHJ.CH:,\Q\;$P,3 PB?%>XN"3DU!2D).0D;VF96=X3<U*
M0T;&R,?$^H:3AX>'DD% A)]+F)V;A^MW)TCHZ.B8&)A$6%A$7%1D5%S_[?7P
M&P 7#2D0V1\9B1KP!!<)&1?IH1M ^8CS*=(?"_"7A?0$&>7I,U0T].<8CQO
M+P!/D)"1GZ @/WV*@O)XU^_Q/@ %]RD>%:?XLY=J9JC4SOA<@7$Y:#02-1T$
MZN.'M-SF+D'HSPE?$1&3T-$S,#(Q\_"^Y>,7$)24DI:1E9-7T-#4TM;1U=.W
ML+2RMK$%VKFZN7MX>GG[!'\."0W[$AX1G_ M,2DY)34M-R^_H+"HN*2TMJX>
MW !I;&KN[.KNZ87V]0],P":GIF=FY^ KJVOK&YM;VSN[1\<GIV?G%Y=7U[_S
M0@(@(_UU_:>\<!]Y/4%!049!_9T7TA//WS?@HCREXGR&)ZZ&:N;\DIHK$ U?
M(BZGI@.=AEO]D,#<9?PY(2W/"MW1[]3^8/;O$0OZ'S'[&[$_><$!F,A(C^(A
MXP+$ !?7C+F?GEO&E=?P.&26/\\@^P \547%"EC)Y%KN%E3* /('_53<Y,C:
M$M+$'?$J(XE"S[&#DPGZM<*P8(C/<O+6+ LU/P.8IR<K&)*[X;S=SMR2:.E#
MSN,NWS$G=M_6#:^*D*SRI^:&C9R0N1D6/@,9.U1Z5P;%\M':7R4O?A]TPF6\
M^>@375*7-L#)&MG*S^@:A+8'*^ 4EG;)MDF[4$B:'EF9PK-@KE%?]O2);<GN
M+;739YO.*]F3>Y'O^9:S![_B0C%(62S1IB<_?W5Z\2,?CP[2S&C\JO:;[^0*
M7Y?YE!D5J)@389#3LU/$MCN\4B;!2[SCA=A]$.@S[%4'HD ?C%B+3,!+#0A@
MO*H95?CE3K1DQ+7+.%G7REZ*ZB)>Z:DPZ;3/$ZDH+RSD/XK)'-5EC8Z\IT!*
M$![AK@%2=%<Z8[X,X>D+"UM)TE;BX$@Z(;+RL'01."TY_2),?YU!H]P(9 _5
M>S7R=2O&2]BM!&S=EK8E-6D^46G2[TVBZ SQL?K /<)\5EGCSCOD_"/8[TF=
M:=_-VZJFCB(_--78!H>"";CHH#DE5HM>?S$0KX9^Q/R(4(">X2KY>%VC]:W^
M.>C.K)_%G5/NF1<N R"VI+_TGK9Z$FO5&.A,F.:E/V)/YJ"]8?@ :':]FA&W
M I)'1Q'68,H^1S'Y3E3BI'C!5X#N>BR2=XVXH$DZPM?FHV"K"=-(D;5SH&7@
M)NI%=)$%B>RR4-;H769-S$NT>O^,%\!:4.1,Q$<Z;E#^X*H/N;8P]FH>\:X@
M!$G5Q^EE2C*:=R&CMNO/A4XL31$[_(QX[?-EC#V ^>.T/'&Y4**\HG3EG0_9
M4GB)HLU*M+ TB'>Q^UCN2\0'T1O+.@I C\']8JNKGPU]QIA)%VK&%WK,RJ*H
M4*C%+@N5/2\_CP@]NL,OK%IYII:@N?,!<7.='%2*[R3IBA.;L8;-:>1<!HIZ
MY5&V5GY#PRUE+G(,8@5ODS8_9&H-/O6//#S]M6F]L+C+]X-PW#QK:B-FTVMJ
M80%@0Y9!J;1<R)(3K)FTD,DG/T%B9AU1&RO,W"LW\INR)\D(N+X]06H,8:*2
MQ63O1(T7AOQ41\ L&);6@MLZ=B8B]0"P,32:7QS<ZC[_B4<*(#"5@RK7+V8%
MY1<1YL_/L<P;M0G%#ZX6AV8#79]FP$2Z>Y?[^K#C,3=45CFOQY:HV@R*[0-J
M\F_<JE,_5HEX%&/%&,#:5"'C9VC)2DFV8A^OTQ='OKA08^(0GZ^"[P?%;NG1
M/3?XOK*^][=QF.^ ;FC8IO5J;91YS!<MJ9D0&,F#A(]LZ][4LT+>#>29D4L\
M 'QC?'6DG3XD:]<8RF;&?W<?S2&N])_NW.')]*$/[$Y^.3+.<=&ABD104R!-
M2\*;P<4DK[Y(\.V<2IJ);FSZ<ZG)LB?LC&OKB&!7TMD3.YI[[ITN3RRCC&F;
M0@Y93+N^=SLXV0B<2IV8[_LLE=+_E;5XAXEQQHP(>ZJWNY4GUF9R@'MITP>Z
M>),%[!:%V]G?B-:(*PR41 ^-=XYYZR-*"GC8E45UKOPU?G64ULH*VTTES#@(
M>E\'I)2M7BE])HG<>5GQ.9\CC?9I( ,9AW,6MX[#V55[/5;!?=9YU%C]>/8;
M?BOC)J@$]T2=<JKO P!---OJW.;FO1.NUV5?U_I]8H$?T)TAW/[ +,P-".)Z
MY=1,M :XUTP+=T[T(W4J4KZYZ_;PIVYN-@#%[J?Z=WWH4+?=P![ D1@0Q(%&
MC$UO9<U+MZ3-*2K$U1B^,72>$5T$)2B]W1J%@+"H3]Y/?ISB;G4QGR>^BN$.
M0MOFS +53.;X1K/O$O4:RZ5J4JHSR=-.1>8))A31L3T JFC-]4 S+VSAADXV
MM!<7G+',G(Q"OZDJU@6@59 +Z8+*YLH=$203QW1XWE9=951K+M5[PV8&DL62
M%+'%T5P_V[[13_NZ?EHW_;@W@M97P29*6O;K17^9$I"NG,EI72K^I]#Z>@WR
M]\()ZD2%Y(B6'5@!A-VNN4774!_>X7 >61:_I$_\A!W03YOVZ3)X_]I]>/@N
MZGSBW2KWJZ43HKO%L#P;GE'<^?1 ^SJ@I&H=RE60V%E-UE!K;&^-Q3A8H'ZP
M!L63"=.UAS<1O)Z>O2[P.B,#>?:EA%I#7IEVN1TO><!*FY@)"^G7/0B3MY-3
M";#"FEUYUE"!]FE-9D5,:-VID<[^V]+:WE'RW@(>>J/EW7X+B.C<:D%FE?L\
M0B2@SI&-JB%%A2>9B"RPLQ)]5&2GX9JM!QIZAB&09UODFVH5)B*^F.BTH3Q8
M(CQE6$7:8CRR%)HYW?:TX*ZG]<O'%E" *-"U\Z1SK4EXRO96^D/HD@&"6=%
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MS^=,NGOZFJ<6/E^C';>!FP15+Y6EKF/E:9,0\GLA;S]PN-!W'-.'[7WMJE4
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M32N';]:!K A+O&WL6"E!PLXMQ.8RV]VG(M[X+F^NA_":8..&^\T_JIQ+E^>
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MS6QT)@W6/NEN>V!CX+7O4+%*R0JIQ=W,:F=$#3RP7;>X'G*\">AZ ,2U2;M
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M!.1&* #,LNAH>;Z@[>NJ^^7B7"$H[TZ9T7E:B"V!M/4AF3&*^"AI3N>BF0\
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M,8V#4_TL^;PF]W#>J?O ./R8B.J/R@'J\((T5KQ.C.7OZN(VZV2R2 SQ$\@
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M03QOWC:;%&6,[HI%T7H<^,*$@S?KS0RAP:V\%6.PGY[6GGKT[QI<I-@G&N/
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M+C]BNZU>!ZMM";:S:1XIHGX+S[UQ/2Q3MR8/!GN*/XU:(F0-1K'F7 'P?(=
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M>7(=#;/^_#KN:G=KKLN>D(Z;Z:B21]7A]]=7R>MXA%%29>KX+F%#1#8EHOD
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M-D9"A%A_EMN0U#;QA!EC5A^*&X:L807-4@%U]N_.D$E5OR AECN3,.=I16K
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M#EH+MA2BWG[]6';/\$1=;VD4M4091(4<P@PH^=S?.(2#%)*V>5+6F5,X(UH
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M;)COU#<R!W1;#O<+.8+"*2*F7A;RI"@V>1T^A)^*\#2#-U4\&@S/FY.%3VF
M#N*4&M?6N!KZD @[*?IVL=]1ZZ0H'H'RC<H(?XC:/!QF+:-VH>;>Y\+YML/S
M+/1E8+XI8WJ^[?KK0B/&@U%4,1T?4N8'>+7VXT13LDO$SQ3&SCZD?&@TQ+;)
MGQ9YI._EH(3WSIT &)WPN&>E9T-@EL\)ZE%2@C\@Z08/2,+6A*?I> ^(S&I9
MZ0X:&DBD9WFGM?CZB&1'OA=P(3;(6K1KIM6%.'ZHK[[3O'XL8_':X4Y^M[?D
M&5A#[=W*W:?T,P08$.!(3V9>Z_9B5XWE!Z6"KMET0J<$/N\++&8TG_1'2,V
MDS/TU8@E93A:XC.&X0_^YS*F*7W!IT[3 HIG>3J7)Z]K]"G<B[^NENQ/@LI8
MNP@=3.BX2"'ZWZ==,MH_!PRL?E:<9.(@E 1)U,5C2_#0/F1^*R":GGU<Q),>
MN]S8F%)05E*6AS5#-R.1JPNI*:H=JY?JMA\:?^O#TY=!O)EP(H9FISTGPUC?
M\+JZUE4J& 8\Z^51J2/A&/E44YE.:]KTJD!WGEZ21(-80KD:S8=W Z?-3+;X
MTOV;PG1I$.->OQN1HBPV:Z;+=T&B"J#4<U/OX?:URCE!6,+4A=BG>";]T8.F
M$#+36)>OLY^F*C;F??@%I2<LSXJ1#RRI3O0]?-ZI^'$]]^]^?L[AU-"" &8#
M$U"\Z$BJ3G:=-PDIU73"AY[$V,W7+W^6!FBR0O_C7]AO&Y>3^1AG,5ZDO=$%
M#]@&/<'U^/FDFJ9'*$#P^./)?-NN9I&?T7U#_]-"R;P5PJ(QMABV[QX+HHI2
MMQ+3$)ZS B-M-,,:*UQ[69R%@U=+;_A>KBAU"UQ,9MLT7DYV;YBQ!68[/1.(
M"^+*(<88_5@JE<XV0U[I(<_M+Q*MLC*@W[)Q!A'K1-X+;3\R,\P.W*U$FQC5
MO6;])E6D5&>HW(IK@>AS@7>U$1?CF>A[9Y$O11&MU^=HE8\$'GQLX,(XT<1H
M$T:<.PX#%O3NW&:2!Y$L=[\"<-7QW:?+#<6-$_$W:1_%S#$5=_FB,EF>P\V>
MYX0*\_&>+QJM\'>ZC9 S?*CX3"KM4(D\7H7(S6>E)/O6$4N*7>&U4?+K<*&O
MIEP/,L?VF9A4Y,G%HQKZS=D:\1=3KR/,)5<#5],@1!]\;+]VY;[!H)X==7^L
MT[@@VE>*:=;R)"B!DRR5F72W!09H3^7" !+/$UVK9>7SC& 9(D_1UQF1FJ>I
MM^T"\1,?)IEMW(GPO6*+<2JCUF_&U_(RFI/MIIYLQ91)1[NI6"A%9(0#?+_%
MN5'484#DW8H01@$,6*NZ0SHKI/O];18S.(+LLT+"9HE[Y*=(@B!S*Y+MY:/P
M$ E"1J2< GD!L+]\?%JT:M!"4,N%6!R=.O9:"O--T],=U1RB&MTHP]!"NA6*
M^4*B,3%G//B=-_Q2A3FZ<!<%/^3FZ<((\.3Q3]F/Q@1.QX;'?!8CQI%%=DB.
M-Y#%'YO,2/=XD$SQ7NBK).H:74@]=.5^KN\V>0;)K8G/H_*W<8X*VTAO(*8S
MND9/)9;2RZ(,' 35/;@&11][*7R#V^MD4WN'(T2$H OLJ62%?*BH2U<-.T8M
MM;^:H+^3.Y&OO[H-$L=3X/=.>PMYF-VPV:LF9R-#0%F=B M)@]348;I%2L=H
M)"!/F@Z14DPQ<&A%.]0A)T6+#[-$^RL%.\K*SG9K**2>')>MS1?2WE,%*3@_
MG]R.:OR,JCE*0]-XF9H(7?W:D][P324NK@%/HW[#14'U'B<A0'C0:Y\HN!':
M,B$GJR>#0"-@[;I/Y[FM>SK\;KS^:R&/%/9X=JY(#>MYYJ-GF?DP &/I#3:T
M:TL(_;?-M^\M/W?B_NXW;Q'IFG!!DV/R[)@21+'EKAHJ#_;"C*Y354-I@.P_
MNOP2Q8Y[CS.410P;T%<,I<F$QW[[>P_$/T?ZV>7A@]X?-IJ'PG@-1D^J/XDO
M9V[@GQ8>_><DA7]*5B"$T/Q>RH< ;%_HV+YV2*XT<S2L^Y![96\IE&\<%F;D
MBE'/WR( ;-C2C2KN8<GO\!<5WWF]Y:^0?13WPPO$@>9/P6$6F8@#CQ%[ GD[
MZ)J5';9?,/M6,%>=/H:."C]LLB=U]+5N]4<\Q(S(N$AS,^*B?;'W\ ]1"HLT
M[QK?--1U,;2\O&G/U88G,T.-=P/_F,-:Z2_I)P7,WU(WC.;QRL0<^=\M722>
M#BWI['T+Y.6FU&F,1F5:\8WBG4IV\9=.'CVX4>JS2_LZFZ]B<X"R58V!\\,"
MM ,N<%6<,T30VY>6$&%;F"Y^(I]Q43Y3B,<#'?#4S:[2$E@_2S*MK(O.<<4?
MYC;%HZ;@YU6!NJ'&U9'5=8?U;76R"C2-!5^I0'$>3Y0X1['+%:=BE;@5&_HA
MK]<[V"B/5RD.5P H6@#Z+9KR2Z:EBJJ$;:<9;&F=R-$DCG$"J\0T]W?1605H
M^[:Q$?,UZ]#G1PA#H=8K8Z>;"[N?OJAN&@G.VPC1:V(3:[@ZFN"5J)A)R!J=
M"R^YY$[>JC+ETZ45=8+.J;E(-T:;&3_#JU\CAI-\R,W]O-B[P!Z^;:'%C32=
M3I55*.ALG%FNHD, 2C@ 27-'SA+8C9%Q]Z:?'H5-T<Z^R?950@GW.AC-41SU
M(>&G-80*7H0_WY$A/8(!369P9[]E O],;IAL^97<H)C^6'+._-66$)I!8(?X
MG<1HKGG(U;(/&1\)&(%'OCE4Z!%7)D*TDP]_E4+T\5-E:2\[.L&E#E8-0K30
M,O(-#B,_P]MMUH;;PB0I[%72%RR!<,7H&=0KBJRW>04;MF3TK9EHI&]I+U>P
M&]V4R3N5\)\J7ZG3)[15;#XJ_;#;P?AT3ZS49"MLT92?%V.PPL:*0+VI.VBP
M60(B90#YN-JQ?]XZC4PLD%49Q[]&J8-2E.RPD>66\L#1L;\VQB,'T3.-OV+J
M&B30; \FWPVP9:VCMF;9 ZT=(12QN*BFXGSMGADP?IBAUO2TFY-L6ZAUI:Z9
M7JIZ2F0;Y.__WM&F;MMB*U1-+M)W+'*P3%PR+"+UO"3-;MOJ5;MF_$3QPP14
M4Y<>P$=HQ5];(&@E_.UPWUVY2;UX;:#92H,?O?.+.95XE@0$Q/U+#LO15"M"
MDDQT.A$7DK.V;1+N5,_2T79Y4&/(O@)?;(!0><&+*R3J==*7=9J94-X)JO(Q
MZ- #>LI:V[G9*AJFT0(35!(>PR_>Z+0$.6XRI,DYVZ$6@[L"9+(OFAY3)8^V
M(;2D\6K3V&ZP*+Y'@>OD+[80.8K=OB[!U?N11>\>GRY)=2-I0DXU[4PEH)WA
M)D91HAGG6)"0MTN#=[8COPO^( ]]^J=R^BU/X*<NF?>AT]L&)5O*O%C=0:FR
M4OJQ>FVKXKU$.^*]<>5]$ @#4'1,H2($$G>>WKOA*AZ"[O9,G[Q,ZYM<T+YH
M2]G#@9"H&004'IP3NYDVL[ZDFOO0<AAOMG!RVW+1[AU ^I>RY8BX+_CB5G#Q
MX\*_[2$C5'T#)3U\8W,I76US!=6[66IIB[R4=OBC7&M.6-A14U(5ST A<HE4
MBF@VS"@  X)NG[)!L=*>0;T3H9<VA]GW9<+?RZ46,I>?#-Q2]G=7JV7]WNRS
M$N=*X2EDQG;E\3\J=FYY<IKB&+E[I#TH$Q?K((_W_J0]ADN0=@5"@)"_< @#
M_*R\VU2S8,#0\3V<> S%]FY3SO;^O8*3!@-0D80(?1,VRX=Z&8U>^ RNZW(K
M5J_>J"22O!K=*PNOCI[+F.UBMT[871:Z>DX#S]U*>:/\^X2Q#FY?:+ZZA0$O
M[PX7EB3^6M%TJE.8GQ9SM'D>@Z_ P[79>OQ8]M]\+W^6:\VR_Q_ID9^IZ7EO
MZ"ZI7OW;Z6NQ*_U!%$(H%H3P;T3YLPQ)IOF_I0OM)FZ&=SOT43@,> 2ZOPCV
MP0"/5Y>*?U\%#6";_8_]JE'E6Y9@P,.?AUP5B\. C#48\(7PEN;OJ_0FH>S_
M)QWS_W:'[B[ADT5!^X:F7&573(.>XG3)%/72EO;.=8EQQ(C==U*?O&<Q8#9(
M5B@M[E_?GA?_[?4>T<F_)1A:?\RK$P)KY1*#?,@I-CI$VC%VE$D:SCM$J1]'
M"Z$^FR_0J6,1J*%[E]M,]U3V4;CU8XF(EC2I6;>W*6$F$'PIG-!#<W(!)?ZB
M$;V$3S-1>35OVB3]B52,W29B6CC$^WIPP$GLS.@9F@^6'F$O"NSQXDD[XP2?
M^TE'(5,WVT_G^V<UOF1*WT%[O_K-:^O:34VFCDF0YQT^]1C16+B4\#Q#<IR!
MJJ;9TEL!QI$5EM<75!R;<%@TMQC2<190YHQ51=88EK@Z .I2NOS*L1O-=DN)
M(:*>>V.37B)$7NVA4;D5F"!&<G'IL+:Q9+!JF^USJ:MKAKT7?&9IW^OADFH7
ME@?[\5].(>,3F?TF"NH9<Q5?!98A76T8YIVEY/8@-Z8N6;07//))YC?EI^?9
M?$>C47;RH[X#]FPU6.+OVO*)B%18SG#(T^V5^E[OC.&0C]UCN(BXP-_@-<%?
M<P AO\RD! Q@U-H4A !D.XKI\60%R3Z8QPVG>22DA_D1:MB=.]<*#QD$O+BS
M& )SO!H^>2WQ;\(%Q4IZ%II3U?O1JE(F4SIMEBP^/7UX(O3Q:#XI,NZ.UJ,[
MZ"/?MUZ,C'M[,#5VE/M"XQV^5"L?R7QU_S2Y\97D>8$.LG($_X",+7:L<"TM
M7RW%@8J\]0=<4^=H%4 C9.,0NR&#HT3&;ZVY=T;'EYZ.>5=H@+P1V>VJ$I#O
MICV6(%/5B>AK3.LRA#N(J+Z*Z'A2$H*/&C_7VD%KX6Y-TT&O[9.$ILB$9GU;
M3NRS _7<&@*C#=UTCZ>>;8+?V-WE,0@(AS<\BM_FG2C/>#4*,8O&"K5Y&[.5
M4,1*CH340%5*[HL, $A"2-(NQ+(HS#G*R%\9HZ1L'D\TE<L3R*"%JJ[81K6>
MDU=9W5(OS?"Z!UM5\PO@63^U[(ZBP4)OO9[,YU[.I7CB R;(9K[4$W9_4>-)
MT)&IQHK<3V'VEEF.7S)?:JD9128XWY.D)S= E<(>N1?A)I/4>J*(Z\V8]_L[
M,&[8^+!#<.Q;<$)H!O4#ELBH-4%R*1QY\4//P,0RV>(N]E%M2<I68S'4IK4O
MVWYSO.MUYBK\LN31SW>4T?T^Z=9P91IV/4B[I=Z2)1H+$OU;OH7W;_D6$:?W
MAI'E+.,*V0P&G)W!@$J"*6($(PO!8\P1&+"S P.,.$IY4"R#]SO^D%(<>=6&
MP#'IS_4-83UHMFP\+T':=G1KRA.@'Z?%N4T@"\.GKD7-TBNI"DCIFQ>"&-.C
MM,;E@4,#@/B+CX-.^N@:&GXTLXB/ )/\9][H!R_SP7O9(I'0VM=1#"F5,BMC
ML2?,\.D8''IRXWSPG@0S4K9N(S7)7%8BRR*XK*W(Q_WO[++7S@M+&:'$FB7]
M-I,:%$@>8(_]8QK2[:/&=5V! SD$@*K89I%1MPTAXLZ*PL18PR"\03OF!T,^
M:H+@*_CT&A-/F:6Y[4\-]2'37$HOG)]2X.A]A@.,[K@I^(MH+ 6(/WJ,?PD.
M\4T0>DG*E(^O!APW="$URSH:'AYO4Z!-U98\1WW>,6,LH%#4GEY/<9*)/B,7
M,ZC#,W=Z@E_%$DG==]/H_A:BJL-#K^ZPX[(;6E.9>1Q:NZA6,>0-T<Q\4&C^
MN3DBQ/A\0'S):N^B"!^/Z$$7?'Y#<4U2Z6;"-#2=H;3/5<!<LA5PMN+^.F0H
MA%$[>3I3GRY91CX=,5)A,A-([';WF)/86SK=-()?9"XT'O\$<9(Q[9.\:"I)
M?)NY+MPAU%]?]T:KN:[B9?V!F'?*^K2,%37 0G34Q6$!Q7Q,JAJ(NE+<PZQ?
MZ?J!R"PLA\0)>+!*PI6)7NO]U&SX352:^-R:QU[$*_0N)"3?K>1*1T]VM#21
ML:![+##U<AYZH/MEXEM^.S\=M2NI6EK2QR3\]Z[/3S>('(@FXBX-\HRG91I6
MWY9\^+A"J+)!C$1I=#LG"SCKF.5E[8KI"8<Z M@_*-6S7(F6%'"IAU$<Q>P)
M^JP8K&=4APLIRLE]6*M;<,RNVQIJ&K\JX(5DFX4HC_B\8^7B"_6 THPPKJ?3
M.M([6CA@O!QDSCSD/CO?T4:/7%QXK,=0#DZGB%X+=K59:R?RIJ;S4LIDX:;P
MIJIN6=( )X%D-0U\##^PB'S7=4976^=+EY/,1.\<TQT]H A?;G[OZA.GIA_6
MZOQU \=N>GO^^ ECR9$\_B*?')[7VWIN+T(P5<=2X%DZ2,$0C(+Q66H;T78G
M=)/O69:VF1M]NR/?4QGV/18SX%$W/#R /N_GPT/W*]6TY$Y->\Q!,D96?(]Q
M4GPZI5)*4'@ 4&LY$H_-V[;=NG#&(-K'A@&%=A_J%ZWUF1OX[,S[=I)5%*[*
M"C6"H38I0[I.9P>#].F3IV5HV@MIAJ"&@*;-AT_8,$4VHOHBH&>Q&.V>),(X
MO>;'Z8A;3\B5>M76B- 163(T@5-4K8*75F\;:N.-_531(_+)?#?%9%78N\G&
MV&?<G[RK1#52=R8NDD/"A_<QO_OM:(:N2W>HN*P6] OA%<HN?>3AQ6U8<MV=
MQZMC[!&,90D#,6PEAG\1.@MJ_L.=?@R\G@,_@W!W#<AN1;H!!L3RS:+4WE[F
M(*[6 B-N>R'D(#_>Y6RN#GZOP^LQH3[#^>2G%!00,E+G+;FS3T& FZU*L*$D
MWOGR)\5CS\=RKN'-A;XN7&?%;WJRZHEE68(&E X^#+"XAJS#U><M-9+4[X2&
M\=GIYP0O!:H4PV?D\4QH!ST!-FG?N73PVM"?YL+OCS5PXB&2)%K#7:,X+:1F
M0+@3 R\ZGA$'6BWGJ'8/U7 T"Q+$AW8\,N%2U8Y5^@%&DT_>EC_'?+GL>N\!
ME.=?&,Z.<Q:T,0\R'V/M\K,->\$_R%,\?CG%P5#-PQ(C!E_ /B[((G!Z,D61
M*\-.E/I4"2)&JGQ:^*Q&AA;W6:YD#8%3(9*F* G/Z"_S*OW7Z%6QY\_HU<O?
MHU< !^%9X6/Q.S& PVT,>37#S?L-07A]!R!&K2R9U@7!(JHHXBG-QPW/T=E6
M[CP6LW@JW4/R"A-)./T43DL]2"?J]33C7!@"JP[3DBG6-9,P@H2NN*SK1C#$
M5(]00V=0;+X>H1IL>I?X96[*EFFD]P=]'?<0DJ_.>OSRJZ9 F311J<\C>U@<
M4?*>[,)X)!_INHC=)]\G=Z;@E*BQFH-";+B_*55O8XGNVOL+D<AD;Z*6+/3D
M!Z2/'NQ.B:K7QR"V2VT@1GKM(G431TIO\9$5W05I!8ER#KV<MFJ7<-BK:8H#
M/3HVW$]]FGJHCK)O-%X".E1O/BO_/%,O9*)SX^FTP=7!NJ V6KJ<!*E!I?4(
MF".+,.)]-KYX2!O38ZPA6X4LB>6-;H['.)00_L[C1R!K5V;A[OY>&22@(^W;
M*TP67J. ]L);,?ZX.'WT47O_+>6^ WN4:[NXEW8'Y:9O[>Z"ZCAH3Q[FTT P
MB0QC'G,2LB8,8.^MLQ%5]*R7! "+#JBOM7-BW1[&O9W6C%L+% D^'PN.Y;8\
M[:K+U81?%XC[HNDYEVWAB+>CT D5/L[C(L82'0GZ="HXF!PJ6S.>,",E\/Z;
MOA=7YCG[N:XM=((CB.NT""?(ZLI>3M#A1CD24/037KR;%GN^ZS_MVYNAK5CM
MPXKQX'WWKC<=XO,=>>T]]C%Y.950,0S--'<5>(C<ESBT*.6@.?:.G7_EMQ)O
M9C<#ACO_8(Z[)[U7R;+O=?(4M-M"VP'[QY.Y#W\(:N#V_G3G7'YC?>@\S@YE
MZ1.)99>2E(PG+N;[DUJNCGML1J&J%>YX7(+A]J2$+:L)YMX'8C#@4^C54T'Y
M7A^!2@'<2_NOLN8CQ%IV]>/9E$1PL]$CWLJ@O)$F>(ZZ'X,-9A0K<(XTG<PS
MS9X6JPPCR<#UR0UIZX)I?=AE OD%V>LQ8B7^@^HPHPVD3&(>E @=^*7;VO*9
M-*=Q!LJ/W\T5UZ1FAOB\D<NB3\3-X/<)^;W;<3G?37\MW;+ IGF"-$.Q*4@P
M43EN68/7G_ JX4+1WV]8NA3NM)OC$.25$>_)<</CW9WB#0/TO&\8 ;>.?4@^
M.!?A[@Y2"@,:-_HK]J^-3E0%E^@.#^Z0JEMNT2)O+3I:P/+-F8<\,G?TK?9"
MI"8N"3?B4[MO:X(ZIG5RWBH<%R9SXQJ3MK:[< WINI9:7EJT/]4E_-""!V8S
MD6>)8Z=?)_(3O=UXAW<EO$F_9OESO>Y0S 4TY%7%%1WNI-IX5ZKP)-O(:[#_
M6 3719E8[1%UT-[>V_>706^B.GU?I=3[6J*9^H=>.@MN8)_J8_0CK0F--@JL
MDU -JQM9N(%)IFQA0#A8E%T-LZ2\.T9\A6ZSU8]?&.=(6WSHAI]S]W&$"\Y9
MOL\Y#&A[E&VU=:[:82A7QFO>)4Z!L6L%&:!/\Q:O3,MLG"AYGN36Q=A+@=&:
M.N'*)[\T%1Y[XRV#CS<T0P$#"*YL5O1NX^[D?4<$3PE.9B>[6,Z27=R_HMI8
M!WW3M)<AY.4;< H;:G0"^C#K&:,CEJM6#LL"[]DK:4BJCZES9M7''WX]S.:*
M:"6!V&*M_^=W$"B(?/F6!5,/'VQH:46X_/KJ*UX7*Q&&MOY-Z&X3;Z&+M_#(
M\['(D-.^2'K!IE<LU,IC<)_5.I*RV>$N5+RHAHVC#2.UQG2^+ZE:KU!F&"2/
M,P"4J7!ZCUV4,W#!.H(KVP(+>R@W?CM0OG488-L2#YC6A?()E*C6S#$S<SV?
MZXJ^GB2I<<TR5ZM-G-1E&F,H8_2GZS8)55 -1)Y6M]_T3O/P+"*]3-%U@ &Z
M=RW3' I&J2C =;H\VJ6Y5D+2K45^C'KM$B79;'ICM\W'ZW?,7$5J)#@CLLM2
MI&$.&@D2)#:I!F0J3' SC6CSMVK]^<]_,NO6V:%W(+8/GXV^(19]</_(XJ)^
MC/-JW9=W_/0CV4>"08;A"A;7!BA 3U.DX. 7@J&K#AYVL)'ZL/''10PWX*9R
M3'OTY<:QY9D,?9)M6M0L1:V SV2 1]4AU=R>%XTK5L )UKS0C.1S(K?0ZX\*
M:5]YM_WJ80"&=W=/L?=4NS>93H ME 0&1,>"8$!9(%0DF>Q6<O=>WL4"_A)X
M?Q+Y:S\K:O2W_\EF<$&9.0:CJ>YC1+=M/G@K:Y2JSC?K^98!71"16PZ ^>RA
MDH.A/#Q[F]=;\"<6SI&7\[?@=C]9\0T(JWKV)32^]S)OZ-LS#.MICYB>/ 3R
M[=%!6X3^H+LDO"=AWLAT\A#Y0I=2+7XO3_(AD:9QD]!Y[E47DU .53NAFUVV
M"UF+]B+U/H<$08NZ9S/.'&6I>6(KU'08YL4Q(^M5TYL\+1$!89@R^4.$S,E;
M67%#]O2OE?LP_'"P2>S>2:Y,9F3WP0#DVCJ#?$JJ8\*0]$'4\"\*>JFN 9@/
M!(Z(3'.,IK*8&G*E$+Z%%&M4@V;EVM:D.Z 7?"I8.],,G(<#3!#]:.G<+*=Z
MH5*XKW3V0]0UK!KV]ZXNFG+P5_CY8F^S[XR[H$A/RSIEILU/K*47))FFE*J5
M< 9G10U$V9(;))FC>ST;TW&1*0+CBX^^=F&7L@=W]PQPP(!1?!5[+-*?+XT%
MV60>7*DZ1)?B[)FPMMOVO$"<Z\50Y><Q/"GIV_,ZG]\K*:DF3/HF8?8.68EE
M!CY_1>43+2_Y"Q!F)!N/ZC;&9.32-<I:8,5RDFJM&7+J44/+MY&[PN5O;])0
MJ(:RO<]5[L(:RYJQ*A1VH>L..UT<SV\RPNT$#V,M.!=36A[/ CP?+T@WS;6\
M2<!OYG7&U3C+H--&7JG0N#24-)P[#MJWFV=.9V,G/#D[RA&=5;N.J/SB;(QI
M_?8T7+SR%-L\H</P:R6:%N*.8GFE(;'12B^ILJ3CS:5)?@^?_QD6^/#;0;<)
M?SGHUFIL2XG 8(,=F,3K$%]P2(Z^#@VYU(, 0C# K?)6+$^JY-)9<<S (4*K
MV#E$]\W>PS"CE510\5F.8@P-_""C%\E\5];LUI[ATHX25)G^1TU;526FL DU
MG=NBSSMW@BKPHHYF+SVU5AKK\3)V?<A2<TCR\Y@H^]8^YBY*WT;J7.=OQYY;
M*WYR9O!#3$T81:1/) IKYCY\16@;+"1@-T7%;?L$S)Q2QH:A=(T*D&[SM 0P
M@K9E/+D3Y=S-1KF2*!E&K>\V!5+<34LM)F8@4E.V9YD2O$N"&$.?-.;NBE3<
M/S3T#U(X.1(!W)98+JN+3I!C+O9%+KW.,-M+9<J Q$]G.40-A1AS>5D7["AM
MWIC88;Z^2G /'?C\-:Z_-!MDTU@4LI&MO973:$&?"%B[_/ MIXIEU&%]$[A;
MB=RX6BZDP)]4]*B8.(?6<G PFDJ,]&C8:+X:]/A(:'O; ']:#+*[J^V</I^7
MDG1D:#'3QL)XBRB($O3FL#8VC]EE[_T8NL<6U D&P%V"XD:QD3$1G;D4[^3+
M<_:&'28D2O:V8,##XL*OS@5;O0FO.GOMA%GI]BG&W4$O;\FF[%;G7"*@(A*\
M+E"3SR^J9SRF!.S3^BYX5?H#I@0,?3>9N0K?YUJI?B@624V;SV?RP(!#@E+S
M1/,+7(\)+J&FLZ5X8VX_R? @715S%$'.>MM=;[)M)V?^1M_N,0>M(]F2V:D$
MU?2K#U;8GK%ZH:L8B_4B@A\Y;-Z,\TDGVFIMNZE8AKTS]:V''S^!XHR\)(]W
M8=>V_=1[@,]QTK(NS<7!<SH@NJ70A3;<R"JI@[=AX91C_<,5?!<N@=\])*KD
M_>A:@>4>_A3KY?Y^1GP!D-V,[9R)YODS8B_X,V(?6-,EK$$P=/N>W?OZ&@;\
M>&P1X9="SEN%]$US;C*6,0Y4WD6AS:W<]#0,[10GFC3,1D7>UM8"J*I+-"KY
MY(N"C.#+Y[REXS@1D'M<-#<CRE/8C96IC[&BD!>9USG88V!>LE/3'>!EL.FR
M"I)CM=Y*&]]1#&.DT4E=,?]"&X/PN:8\\'4<8@1_AJ,D%_?<D,U@K0-JFN;Z
M(W2(=;DTGJ4JW@JILF9O:!$ P+4^2,0>UW1NP*'O5%Q3D!DJW&CY'8=)_,)A
MZ%^:+N=@ &65\KT\"=ZAJ74[FG(IQ^-']N;<(4A96$^]>H2%EL!5!AKVX,_?
MJC4_R>++,4HH?:/+BF<VM_U#T=_\#H/*+$>^*4P@*TFWI1@,>E7QE$@:(Q-G
M_7/G1TMJ+CSM<0/;X;+<DMXT 56'?6.U,>^JC-N0.AAP=@$#*J?Z\[XDWZ7"
M@%79EGM3TW*7T!C6+SBM?& F*.6=ZX+@#@/V:"^J27-:1IL>^) 2F:@A-\NJ
M-U3$?'\\MW6M4Y*H%AP=8:_3N.5D\KBR$,PR67^$ERLMQ?8Y ,4^9^V5]107
M,OZ3XQ4.PG)32C69(A?'23:^)W4)/*FVVF.TROZ3M;D@G&?L<F[5U'*#,A+E
M].6++!V>98<G4*GSH'MS_D'O*7K->5?[T!7U-.F=&Z.EH?UZ1KCWL0K'RRSO
M38Z-FDT]@ONY%YCKO88!PQ9#XP]:20)]GF+'[_%(!+)+W9+DT>!*H5B#@S>X
MRNCJ1YETKU5JZV(DVZ/PU4(7VTVP=WH5->TN&(5[K9^H673W=^#\D,A1U]IZ
M4YE_#9I-Y\;IJI]>=9^2I3LJ]M(-F,@IG-'Z4EQ1O"1_1<A>=GT="0-$<"X>
M3]VZ#D!7O.DNW=LRCCG!>F=GI-#W]/N$99<G*7>=4-6*D,.$0AA YCYTO0\#
MKI] 'A-*U;?4)"U6@4-3/;*IJ8=!7G^]7_;ZTJ!$2WV^Z*OE$)>2$6\YMMN=
M120IR*& ^ZM.MK2B4GQ2S[;7LPQY?ZR<K$T:DT@;>4O'TL2E*=]J&("IJ:-C
MCN\47HOL'-_54-JH><084!>LN:) B]7M(RZ'5QEYH 8/N:P=Y6U,"4>4:=1*
MTD+;%)(@J3\KH\,+,V&*K JUM1Y*R?]4H\F2;'U;N^7=\W&>;03B0(JEK:[1
M;QS"+,PO[JXFJ"3+GHC55,4K19%:Q=)#E5WF%&>,8L[J#+:VYTP9/I/W(3U6
M>@IMSH&JGNEX%!["0Z5%O*>J,WJ_%$,>_A]&(<;D?CLSC'T8WGV,-+]%VMZ9
M/?S[S?!#TSC$+-M89<.U6W/^:F NAU%<+;E< GNN&N[IRV[: #M[$,HIR?A<
M_.M4I. F5.?BRT]GP9!J^OKT2:Z'FJEV%6&%AO'?);2A<2V'OKIUH8(U C]L
M;-!BV*L8"(\[LK\+B??>D\<2\QW0X0;(QQ[EHG8 KM.7U!K0KQ]DG_&\MK(@
MPNQ@ .V6L8K?M+C<J0GN^OO'/#;*]SM+>Z4R6J*OQ=U=-RXCSZ#$]VB#->H1
M7^!7KB%MM1*KS#(J7Q*PQ>&@A8[T0*(BUH^.<_'8?C#.A5 ]H1"OG+O1;=/9
M@+-:HM,DS8N&>$/MV(B-33K4.YWLJ&EUB8VYIQ&((O?NA+#%4NL):K,J=()[
MPX#[WKLC7=/LI*7OWDB3H.Z3U8$B6FQ/?RG78+>0IR):G!VXX_72*"9P\F7*
ML*7*=?;FF/@NDHDE8L<2X0:-']U3T=:G\VTE@E,8HM05]=@YCI(76$XIV#,K
M)C<4MJ=5<?8.FN5@;&6I,LY1G6FZ.8.J4C$#YX7"('P04GIGHFE?<O>F%&:1
M1WY$=:Z <(> U-[>IP6&4+B54M<B)(TZ.B<Q^E+;J)Q0<U9W,ND<BD8FNI49
M#J+)=]KAB9ABK!=8SVTV%$6+-;M56,R^KP(K.!X&XZQ1$@4Y8Q$K2N_/QW--
M<S7 N= NRZBKCR^K^%9RM1(D0N?2*%B?W)+G=KX#2W[MRJ6:<38N*"B6$.'5
MBJM7$%>Y4%9#4J"K#T&U[B0<5PT@IN5U(&A17$X07($!+J._[8N(_BW/W/#.
MX@[I+!,QO7JL73GYX]PF7"G7'6V:@I<JA0-V*_I"82:RME$RY^+;M%!7;#CT
M:7N,>/!7L.3*82:R;6QR%!H">R-XR4N^TX?B1^MY)J,T4I\D$KFOND\^7LF<
M\1G7WA.'^H>QC59,DM\,IY)'M8*-&MP=+;NS*>'NS!6:E,EEDC384D9NZ1'B
M6YN;;6K-'Y_@&ZW2P@ CTHW;8FOQ[RGE4D/"\R7Q7>R=5W!<E.CU>Z+.V+2=
M*".LI923J,S5-?XV)M';8;&7?KQ7&@XS%L'C"#JQ^CZN_!:Y ';WJKN*EI/V
MDQ_C3\ZP]ZFE6JK[I3CZ"DK16,T2/\YB\QCX7@P@J4X8)_;5#><BDX)C7!^@
MN4W>+"G@DDDT=*A$/&P"4\8EBEF2KP8L?RAM<]BX78B.F!9HM']'V3C95!!?
M63%#Q75!E8(1:&,5S&QQT:"]AT5C/-3",8[3.V8KP891+.KLW9S:IFOA)OWJ
M/,=V5HL&!D2F>+>D_]"<K*V7N42K=4[Y>J9XG&$[72T]\6R4[.3;Y+>9GM0,
M!OU7XTI.9K9A6\W$4TE.S*_-\=9\5E<@<GZ985SP_<_K"@JG/N58-9"?Q,KQ
M8XPF-RDWDN;^/)K6XJ^9Y\Y9$:=PD24PH%OTWOB6E=U%3?0-R W)'W?,M7W3
MV]\?XI#7@ %1@?=J74_OABQ_.UDE^7UY#\Y45'=)T(5!)9[^Q7*([C1>3X]>
MO#F88:1R34=R)PH</2?,X#YJ]H-5?+&=R+$4[/$,2]Q0JVNFGOD%ZZS#PXV,
MOGQL&' INHS9Z[<D*@@$2\#;4GJU9!8V-3[9HX<!U,LV<WHS&J^-TU55'J*=
MK9X6J&F,S=HZ8W)3()1[TPU6'D)RJXM.<.K;XLE62#EM_;P^WIG#@'/<)!^!
M#EQ>V]%P\31G2 Q76;@29<NC,WP*_>Y.<CP2Y'GZ5>NSLZ'.C]G^2P+9V-(X
MV-\ XL C/0I5PN(S#G8DE0D*JF9<F:"XYT0HQXVN84]+/DS(.D^K!5O.OWC*
MC/3%HK>?IE=6CFYM,+$V=W?R@O-;*4NLMLV'O#EF(M!\\;(6C:& %-K\1-OV
MLR%/[NAP8Y_VH8QTZ8ZQS,/35%/ZRGC/5S?<]U_V'Q$<CUXWM3&]OP,?U48&
MT-$,=^'KG_$:^@48\#-Z<_<"&K^(#3=Z*>VRV&CBX7"@H\Q3/7,4G3J5,J/-
M7_UIJF)+!\LE^C7%A:OY\9&+AK3'T;8C>[&BPGH=[0]SMV\V^?41LP6J7QF'
MU>+EON:]Y4W^/MXD_&*NW!=QXB#B+!!Q17/QW7P;TYU<B1?CY'O:!GNMWC;G
MLAHHB7>/P# ,V!FQ6!Y[ L]QGO$G['"FMN^WM;!?C_P+])C8%/PK] CQY''9
M!1V=!W]?<EV%8G._J*><[QP*/).YLMX[[6R.9O@!-4+RXZ?_ 2DMR:S#S,T1
M9V9FF54;XCQIKMYB,$7+)_\L>"G'P?(TZ[V2.!QINRZG84+?$\JMS2\K8+6R
MW=%<Y?C\RT<K].M6;HZ^211#<TBY]OB%INDR2>E@]:J*'NIF,5T(BG0\!WJG
M(]4&-96EBS)4?( >^N7>EQL.\&QWA $DL=[U"[U?2 [S;\.3U>X\?R)0E)O
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MR+=!F2(U&[^,4;X.R#HNV>-+W6@A4BM6Q4?X>[7>B+)RRP\#**@@]S+V^#:
M7?0R^KNB&/:'OQ[_1/Z;G\A$)TT#YZ,8ZHD-]"N]S<GRH>C *Z3)1#X2O[_Q
M@$\Q-"84"#!$D=J6=_.B/56 9Y'ZV1)I16C^\S8*YZ\:]E\?E/G;6/AABC]S
MCIOE[S_RC[#IS^YP2HI":!UX^2-"3Y83L:__^)Q([/K[IOL;]TUP'[-_77-F
M?O6E0I 2 ]BPWV;\O'Z\_QS$MV'*FW]>_5O9[SM7_!80^YDQWXRM@/@LN)2\
M.D.F/NU<E'A0IYOR9:_;<B+T*0:&]S (8^J6'CQB)%+"BJ&9Z<#/E9IB?#O
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M$4;"EL$!2E@B"L&Y:>DZ!<@RQJ11@(O6NU-->1P&]/]\\PZ$,O9?4$L#!!0
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MS[SL8X8A1%;24K;X+=HI .]5QB_A%J2S;/\ O3*(^(/$/+"=!'&,-TH_)HE
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M?3B,L<?]N_R8*8:K2I][][1G?;VJ6YO4H[DB;SELQ"-@ PT\GAY@'XGTIV:
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MW[]J, X(E*D]UY+[6ES82Q)#Q+PS1.UA[E1NLNIXG6Z<PN[AYTQ.[<#SY1?
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MY\\ %IVR^S6+EYV8]P491C4.GFZ !>OVIR'A5YCY' M<!7R&1#A/I*&'O,^
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MJEQST:-A4B6&K>ASE.R.-Z5+?29-J7'0A(!PM6:93"OJI!-<XV1M!-I74X]
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MD"*R^4THMY*&O.CZ72Z.H$T*T!^WT;ZW0M6T4_RN&UO1M>_#%*I2/5%RE)F
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M#M\$?2NE]D (>1!K,Q7YBRQD7EV84EWZG24I@_LA;=+F.D3IV&3?E9KSZS,
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M@<\4/3$=YBXS2/-+"W#/"4]^B&)VR*T(4W;BF^JP]$<)+JKD*?UKX_0W?2T
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M9QQK^89VCGRNXS1D_'$5*G.2UO29]A5P .%:Y0L'O9DAN&GFU4C.5\#="LI
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M8#($5:[%2F?F/?&IP)0B",0FQTPG _ (HG+Q&U;0]**9NXZ?P?BE1NF@^%<
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M5A:"T_1-=:K6B'[#WCW5XMK*P5\GK?PP(O3LT[N:^&OQVLB4L<(NG<7:DM)
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MP<\W,5%PG3WW5(/X??8I[_;,8C8:L&V>X ?$;[\/H,"Z' MCI8" @0"([EG
MES2"UYP;(Y:,2\RE+T^'0=7KJ0?75,ZWT0"XP?[G5M)%&V3WN  SL_OH=&@G
M!_'FV3+R\B#J'%/L]A\AW5#/;=  /S3@<$VREG@Q#G49#6B'%RC6G??7@DV1
M" ,TX+T>= :*])&<*8;V<8&V$:@&.H.@O2XTX!)T@4XKSN,XPQ76?.Z/J9[O
M5Z !C6C V8'?KW1_L)4LXE[?EEDD"_I5[,I?*%WING@NKJ !;_WT#/]KA5?.
M%D"QQB?7T #ZLXIZ> -UM!;=Q&'OV94<Y#$:,)KQ*]UA.Y03L7,3)75HXV7L
M(\Q:^"M*LK]2K;]%Z4)G>2Y>K@UL-1XX0G2@3J.@%?+4XQDTP"C\5ZK1VQ>8
M"N>C\2GN<-:4W\ID>@GJ%XA^I2J6/K5$ YXA]HC_ ^Q_@/T/L/\!]C_ _@?8
M_]\!"_FK(;F.CFGEU;[!;\A%WEK&U^'/"?*\H7B;G6R+3WQJPP/]J&UOLEBZ
M;,;K[KQ^'') Q=&)F#-=!TU58_BQH@$!085H@.<,ZJ3@B$\$#:ARGH:ZK%5H
MQT _-8] ZYW0@*<0-. :L2YJ$X'<E2U]"[6?^X#Z-FP-9_^%-@-%?JL<.0$]
MGP\WIT=];?9&MN7W&VG^0GC!*6%U7H4&'+?<:I5"E@?NGX=KIG\H^$EWHN/3
M>^R J<]@$B$OSZT(EX]O%8"]M7_2T>V4'*9N3: !,T!?2MRC+]2]6Q):L#WX
M3T+03[N.^(@WDX13)WV*R!:-?Q+^8M2&!=V$B!.HYE#OGP#)&&L'_5\'1^7)
MFT*<+N;:6XD<OK(G 0X>[,VYG[GB:TCS.OTEHY/9&!6\BZDR:YV<U*O2(^0L
M":[2[UW=5M1->0T!FZW[LPZZ\T3.*QUC6TC3<9V<:3X@35R$U3-DR:F'"TQ%
M5(*]AQ W+*:?%HEZH@$5%X.@N<>3:$"?&,_YQJCV$"]MV,V$.6CBCE4FQ B#
MU#6A9=3S?NC,X_ 3W6K0 5$PZEP #2A?/[J0/M>^=C'S4H(!M@_]^1[T4P\F
MSM^[&Q]_S3B71#A]!E4Z(WI.^ =8X<(8<!/=,$FP@M@NQX WD7J&"\9L 0F@
M_[#[/Y^=H&O7O&%]C?X$2ZB*=FBU^4[F#MD @O5;@JE^M?#LEST8W-+/(7>\
MJ">SBU.I/^Z43EJ+(R([.7XZP7:%-1TFC<\>FY:O;U,:&%_6MI5^*-BK-#\1
MZ#1U'X;8I$GX!@]+D]KK67/O_Z29#R=+&X48.%TP>R'VO_!TAI\H;$.7DXQC
M,/K:S=4C:B;.A1 17_]N!=WXB>/V%O'&.$K6$NR"V(F91@-Z11#LH#F.!C0@
MQ<5? _J# ZC<[I0VAJP5#?BD[8L&W)N_R$4#7A4?H[Q;3B%(>. 6:A;5 U_P
MU-"F1@/P#+<O]H/W,E"D]3.GRS<798\:J>O/7_Y'B?]))79/JE:$MV^'QO6Y
MZ)\YECOD7<[U5,!YY#"Z<UBT8KZB%<=IE"WH[)'';<-%2,6:7J]LWO74KTC>
M*Y]63)CAVE-' '(94P%HT^E1K;)\IHI@01EE8;:M4*O1IV3I$3MC^64%>FIQ
MSNDP]C#,+U; [R/O=G7"D@KW58N8W>3<K##)%QG%RTU"PEIG'B,%3D[+C[9*
M/N><UU[I/3W(2ZK5_!(B2.P N3_73C\;0J6P,=,\@@;L)"M:>E#[Q6IX#V&]
M#+EQ1C-L4U@1U$\_M+G)I,)^:!I!$+]_$SYKZ]V?T:1DM&D#;89V+Z57U23#
MFK$C[QHN,) ^.-N=F(Z831")E(6!PY0A\7*$!Q+K_=SS536[A@N0PI(//F[\
M JYD4Y]F72;&<\D'H27WQ&F1A5&G:1&>C5/O:Y<G!XY29,H^,GOT5*(!.'%K
MSD/:QI+/<U;0@/$X89>&(:W!0LA#.D<O@H6(3379N0:Q;VJER=AYYBZVHW=(
MOUJ.BQH,'KWN6A-T<N"96+9#+C-4#7Z0=)5F!-<_WGE5O/WH;$")H&KO77;H
MMPB?@CQL?YQZ05^.<#QQG8D.!\HA$MUK6TW?WOJ_R\OI<[ <]@BN+QK%L^]/
M9RK?G%0(TPWEL9GLG]57C)AQ4D9(!ET!>T:L^%P?.9+X_/AFU;YY4"_UP_@F
M+1==(Y:!^<'L:FLN(^P8_G!^'U)0W;""33W%T"?EZVX.UB80,)D5ZX];.3_'
MI540L4=.3774H^0N"IF5-ZCMG#G#'F^>9Q3AP#O$.N_H!AIL:]8YY,XNL@OS
M3>.$E0B@-^RP'O9;UAIXYRR\IMNFVK59CESR2K#B84SN_KRGY$/W>95"?W47
MBN=I?@B AGJW^(IZ"%(9('47K,BRV"^2KV/46+DE]Q<] !!#E9?NZY@<V;S!
M!3.2!]Y.?_,NI/J>A?IA@Y!J5>SF>^GLBGUL72VUKRPAYKN%MQC8<UA.H<W)
MBG@L\IJ-*)7!RC!EV,K6!T:)#UXU#561OH(S3.S*LXT5;Y]H3(XI>1'EV*[B
M.T51GCY93=6#ZN383:;FCS04G=)LDM4T4M3Y3G"XQPKIUSP]B+:R-CH]TQA)
MN1&Y-C"^"M],"UN2"9,X[3"1:_L&<VP0+(".'KPJ&=8O"S_,.<U(3J_>OL?A
M8F/NX7)4[VU18<(2@,<9OZH<_DF;&)^X<J+H6\LR<QJ++S?_P>IXN)/R: VJ
M0.]H472-(SWXD[I@-'^/GX,3TXH1:U;[)&AZA2/%DKU%F8^(B%"#7<9K\;%;
MEIBGJU9-- 2L^^ZOKFN8,_0TO*$E78-,T+K&OASB@R+;^!@(>-FTH-WKL4UU
M+Y0[U)*1IOS^*]2##T\'$I3Y#572.CCD\]1]N2">&37Q#IL+\:@U-O,3C9A$
M^&ZZP;?SC%/8KIW2IZ3LNCM^A*S[2N!#*Q)O#^;-P5ZV+MZ+H"PI,-G.0%34
MDF_YV@!$2PH,5/OMUB!8WNEFJAM0M_7HVNF@?+7%G8WB]I6BB<1S7XZ1\K!/
M4^]#-AU68YV>#D6M[NBUY.>W%I*19'#R:;.4%B/RC2[*&N#06D3?\MF74:W&
M&1\T@#\EO6IYD+!E@7>)]:W^&]J(NX V]35;/($ H?Y>!^<[NLQ[0PY-O0T/
M2V(T-ZK8S.@W/2W[]096=I_?<Y[BC+M.T)[H,EA,*,E%>N><-7*#<?*]A6'M
M0O^APF@E@FSU-&C$9OSXHMN6?7^UZ%:J8)=(MYLWV&5T.@?5XE3U^M[L=>EE
M\8ACL$*SIA\H!PT@4(<K>?#E%B52<UB.<'Y2I.WFL[H=EX.;FZETFYE'H.R4
M=9]/AHQ_YH!,$0]2 %]WK/=@GJ=/3CU$G%(<:*6O+(ER^P_?A;%2<-RE[)#@
MU2IT?X*3<[F+/G9:8X:R;>9(0!I72XE##PU8=NIF?I,#G.JFXM#?L'6?2*5O
M8W@S3-;YM$TRJ*2@RD>SJ*%[5U[ [=';TB=?1=3#AE6;OBAQ8W90?V0 YR.&
M1!2B2-D5-EK=?V_,E$^E3+?57.E5B&?'IJ)3FE/5?DY\%+?JE0=C;? LA:81
MSS+JSP.&CWS8]EH9XOON.N10!TD_*GY<N-$SV)CV_0'1]Z$2:/7",E:(?<WU
M:C;D@8/X>]LS_OZ*\U(_<^"W B+9M&WPXQ.=J,R(,3D7L%\C>4:>#+]OQ=.B
M)ZR:T=HRWC*8\H@1!W.*&*NA 2N/<[5-4-<1(X=<REOC.EJ\OGRF';BWPZL;
M>"XX0O51ON.8*EWV@F-(':9E?^(]6WHC*MIDW/Y;;G$;BJRU" V0V(1N9Z P
MW4G-,&*Y 8X\@'Y*K0AWA9;O&K=_$8-M0.<,;&?VIT=19Z YV5]9LAY%;-%]
M/8$O6-&"/4$[Q8).I]MVF&*,;B?C3YQ]Y8Z)-RZT]_C#TNOI3K2IJB^.,8=!
M8_@)IIG!_Z:%.=:/$,?]F/\E,GV#COPY3BG;-,^3C9;6E2M*;C.^&!7'-GGQ
M^9 E1>5D%/P7"M ONBF.2QVRF92Z*+%*/'K]5,7OVM=V4AQ?N03@8S5Y+8KE
M%)?Q?$*]61NEG"OA'?QX^R_K/7G7!^IX_BN%#(:ZGMB[3?.<H0&!_*DMHW"7
MH^<.UBS65+AO95S77#J6X<!8?\X/%9655>=<2?WCRYW[9AWJ2<NBZWK&_XP'
M_!'"_)W1T6.)ZC=.IBEK\K'4F74.@V Q1RV),''5:98AHB+R]&R!)W%=8<R/
M9/*0?1(<YO_L*D$^?WAX96%W02K0<%+/+\:AB/YESPWL0*X:T]XBO/G$?C\O
M-R:A@:(QB "I[+L)ZX_?! O^"Q1E!7G/"?RVK9#0YGB.^<2Y/'E/\VH.)G]U
M_7>8]E*]I$5KV"/OT!3_GFHS >#U7(!G_G(1IMWZ1:/P7Q%5S5*R93/='0@.
M#BX76>,HQ=3O+@707E_C<TP)$$#W*TCYF' R1Z;"4#(N0]KF_Y6*%>'.J-X6
M*./_ \.,<=D:J-4\(B+)@VSLGU6$;#).@O[[P6YI#$ #VOOID&ZVAW7[".(G
MGMOW=PWSI^X]LGS3/B:_"CM06"H<C.D_$%4257__3= *NG?O?!XZ-=@(1W)\
M61^4I!^;M!6FLJPL]+<H6KJ.>*3-C 9<-<)4MY)<&+7QCTHT3:E(U##56(JR
MN4SFKIISL*_[GLP5,L2?EH'FKHTBEEL0VVF&1M-Q^SP?YLZ*H M0M[NLF#@Y
M>7"X?;KK=+X"^1.-1 //DO$3/RW$'JCV'1"#[L5MG^.+DVKD 2NF>.8Q0@-2
MR3&0!-SZP5"RP/B4;K(;GP.*NM[@BWJJCSK#1-Y-.+0W&#KS(-Q)\31NFDX3
M?A&^]?B?E9.MSKKHVB;.'T7)'M_=&<DQ-R?*N++?&3'5O(@3ZBJK1WO H1^L
M'RQ>WV$1-D<;J_%QG$CEF^P_Z&6V".[H2H4*N+/. X$2*1/670[SUQCS[4;I
M/GSUQ9-K-'(+.Q3\DO5>/DTZ6W_*4(J4\ LY3;SQ<)B=^-^9D#TD4'&T;RC
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M]1>S?XHJ.(!XWNI,W8/7I/U4ZJ<D[97TC?\-"&O6O ^<$I(FE4%,@0'^,<Q
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M?KWVAOCWDG+.7<3)7)/]"\">:R+O?V[, _+HS=QZ#&B[NZ,&9!;0=6NJ) 4
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MR$PWDC5.TV?XZ<V3QZ7%YFA+1,FDL&9;UJ/TFV]? %<S= BHE I!N_-[^R^
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M$K/:?S:I6^2/F&)QIQK+\&#O/!4,01?\K.H#50<4%;1W=!QYNI?L3T7QMG%
ME2>-,PUN1TEP6V.GOASA5=FE2(.W4]$K]H[U5$+S1%;E>B/\K%_R2F(,O(LN
M4X0AKB \8<;A'@!\9(&QG9#4Q&:UXNR@?(Q_+V(1EJZ3+CS 6S1*W% _H5N
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M85<H.6]@H&KR.W $3GVCZ2+W.B_4@,WF\30^<4D4FZDW'\Z+]_^2O%E'*_G
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MN$-P=_?@[FZ'R7N_^>[4G9H?,].[^E>O6GL]W;WZZ=Y5^VWQ[2^ *2,A+0'
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MRNLMA3^G>9$XIQ/S08&Z_G>^XDF8_[$?]D]_=GD@!SZO^EQ )4^#@VHY\LN
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M_MN:.J4 &[S7"[JJHB7I>TC>"QY._R.>H^/]1[;[F-FI7P]\X".3NW6IERC
M3F'SV.PQQRV\U2GV>]NK@B3E!*E/I]S2.(AT(TK<KG+]CW!SE*F"(G?C@]HI
M9+?^Y6MO5ZB$&G%T2<Z[\2>4@_ON)<ISNB/ZL1\;%G&:TG=K HDK(^0G@NWM
MY;)RLY2S3/>H2'BA^F)0;!C'"-J<=Q'TX/+2OB*M5+*]V*:OMZ!-)>4"B[YQ
M^2$<1!E')?!)W+-2PTSN-8VWV5G)T8:(SANPPA7E$E:K7ZOMO)%A=GG^H%)W
M2F&C;'>*IIB$-BSA/@@-6FZT/;?A'+&_YN\/"E;D$_JC#F>DC7<NW=33J'Z\
M>&*;1295:>%VT([::H>\7#SFQ!C?Z>L:?0FAO8D2(FLVP]AJAKJ,K[EG76U&
M+'W]76SJT!Q]@R/5D._HQ+1ZFGTW2!93F>8N@[W0"N<T\5'-#SMUJ2'3>/O]
M]#O0<4J9TX/3MTPI3 ^S>8Z(O;CU0W2UK1\^7T,JQ4J.D@I\'X;S'XP)7CWG
M)C!D+*<C_"B,M I\"=C-IKB8F");3&:D\N,)_F;WY)9[NH5-6PB->6>;-2$0
M"-"!)F?O^'=X&"DSO<,58&EV06+*1VF"'<58J^^^(8R0$T.%\II)<9T%3SC>
M@$:]#>8!F5[1JE9=[_DWX$*.D"%U^I8ABOO\F4.9EX0R)BLKXTE=3E?#^ZM5
M_[%$HVYJL"5S0L6M+IG]/\9SPBR@ J3)86;3D( /\L"1G-,"#\>QNL3\;&*#
M?@>T8_^%]IU7NTV6?NWAY6,-*<\VY07)$>^-;'G#-1=*TA 4TRGZ@$%M>GA#
M(13+'UW(3%!AOH8+ [L'!;\B_O0#.DK\S_^0BY+Y/!;&+4QT><9<@)GE>_@Z
M_?L_E=QRLFIM-"XC$L4/AH^2#S/P[3/$==<?CW0F$0RHDXUHUANBC]Z#$A6S
M>ZKW?2HF/H+],Z(G($823U'-HVY./@2-&/-U-MXB L9,)R+)K3E=+R4PAR4;
MAW&(YY-#6 ?;5?OK#:=GABUATB@A*H?+:=$V?C:)=(QRLVJ?QRJ>J-X R[K/
MD*''F+L[T+8P"0X.?.&L>M(QIV30K!O"Y.S_HFXUYO8M+[1W+!N-J?82RG @
MMGNAH/4R]]H^E-P52/OO#Y8?,=:*.'[[N4?O?)GW"Q4@]IXJMRI8U1MT"]O9
M^71KIW(ZJ18;(9LF"6_];1=D$/K0TO$+BA&;5;I5A>^]^Z\8UNT=\.GV/#8>
M,!CV;.Y%6_+HI-IN-+LN=\9 3L74ZF8P/2:20:Z<N]&;.KL#8;=$#11K:FM?
M?MC:C4X>"28%H';$><_Y/+KY[59W8H3663F$W8PH"FXA/,X43CJ'SU:DF>0B
M0%,"='*U#\>-6S+#;YV4)=%6S>B<^+/-N(@GFA=.+)97R\\X6=I@<]=*KW*]
MU$\,?4&4L1IV^>[9W04CA6M$*UQ\K+'QT?=^#_':F);+F=5$J_)98+Z7/EL-
MR[O[)K&4HG\$8+-QX#57%K=TY#@[<C!T+>(XTC(Y?'$?65%?P[1+9MIQN,NV
M&?U,\^12F=3L]]%=:$-=K;5VQ:Z$Y=-"P*?[^_NRCH^7 M<ZW+\J3 5%*>L)
M'MB-JM\ J\?)K;2]<,YJ'#HYI5Z795VR^)/QX0C:B@EAVKQ4QE(X.<9('&SC
M>&$4JG!L4VE\>G1IKE"A:B</NB"YL&Q-Q#> M\2_:>%,FFK -/3E5>$*4JBM
MRSZ;4<!:I4;S./E>1PMV=-WDMN=+5J["+5<N::P!YM82TJVM7Z;!NCMD+<+B
M8L=O0A/ABFQ;L\JI3#=CQ(U9$/.4K!!PS3:J[Q<:^U=BZ0DX?R$YI3O#W>N!
M$AT9;)PR'J_-%CS*E70M73<<#Q?1I[U[;G/0I)W?![>-$(5(DL"2'=&1SS,S
M[F):*L4>DI/M@X+Y9WK)8Y*K'\V@GBR4ER3E:N;D[4'6$364J(&@%$X81D>J
MZHK8W\:V(B2'<^-^!>9XY!^,:YV@OJ&/"R+8I9RR5-8$^,98PAC_JZW8]E;?
M\MAJTL63&$W[6<!0XV@T87#^4I:/1V-L%%:%C+F?_0**=>L58J^9DF[\Z5-V
M7YQ0' PZ)3N<__U1XA(4$9:LVL*M9NWX"1:![.P-"(=,H/V+EY22FT?#MJ)=
M2JLCI= Z]#:_U#UDOBM2.G6?[$]HP*U@V6."<_2Z R.7CD)[F*O^<*?Z['CU
M!7JH>?Y8\%EV<VK32PB\55_.(2;SXLV(,.@X(FVO<+[>JMMUD%SLA0WCR*/$
M.[V9SRMU\7G0DGCGWLR8M<ZB7 +)&USDAWZP /O!(JG ZRO"587V&Q":)CBY
M9FU2Y]M'Y B5?+&LL_)!8%N3[[Q@M[SM:/:S%6X2SQ1TJ._L#N9C2BDSH%55
M2\!;-6!W+^_ZEP]^IR1\GD%)R(+/54<,Y9/>"@95?<\A5V?8)G^=KC$<C@2/
M1:>AZU!V ^_8^]@0Q!>&A$NRH)4Q_H;@=*_%\6MB;X1[?;'3R;EUCFDMCM@I
MR,_[DD;:-X!A8^<-$*O/:ZY">LAU&7%M;'XG*(KUW-O/$WT.\S)@>6C%1X-G
MZJ8$09Y4"9H*QE:2FJ4G2F^RWF+_MBEIL/I*E[Q0O;B2:KQS\_VLO_KDQ'2N
M""^Y]U'_3R8[* ?J#!"=2GYW3)(R",UU@H(V5;HV%P,VG!B&7R_L0?UUMK80
MYQ6;JY8^PDA:DE?_2MOC/CR5:FW\K])+.P1&#\[8,%.211I]]S;Y+Q)^F5+6
M$*FNAE_0!YR^NK2HH=%&)^([M(!'9-6&%I58@3]/H9PP<[)YBS*(5^_(5'G+
M,/+6-!M3BU<;GW]NOP$55D)$K\H+^!F#_WB-J%.OOMJD2OP+XIGZ8$P&;$;I
MBY<B+!-7=\TCX4]3.@2BZH '\%P=(CFF(X9GN9<!_(NVB9Y?\("2)NX"Q\&"
MZ/3)6:-=$S1K>V79GY^0%@X3D0^A_7^WM,ISMM">(@5>$*L.R^P%O1D78K.L
ML2K%[F><V>Y9XWB=>76%X+#&GWL2I/FET,#&O;0%J9E[[@_XR0 ZU-\K;?RB
M+SNV.#UI3WK\)%M^8UL#2MYF]:IR4N+G9.LPX'K^Z%PI@,.]=3RQE=3Q*X_?
M047ZF?:4;**<;G5U]9A'S_J%'$1EE!=]>0]!T14 V.GNN/UA^JS[,)6F6\&B
M%:Z6"#(9VBR%FLCP3("*U7?!LHIY<G B),*(G!,FU<"#.I,\0E1K,2M[]9YT
MKM'-"NTU7XP<%<Q+V9B+D^I@BT]*[T/A5 W)N,HHGD[(*\C0&[5H:LWG$6U.
M5NB,EVH1' K[E^;5Q[I<3EFT#>:]A)$"TA\!J5>0_KYV0S**BP7V\;0XF@XO
M]^&PAH=/IGK^&T!9_B%AFW"D$MIY(5W.H=7)G=2A8W8_?=%TA."DY3+1#:IK
M$[TB-0PJWIRY':J\CNDLL-@:7N2(WN =R5:P[%^X'8A3^UWM"&QIXE7ZM8 @
M5E9/ 3,W\VS9&S*N-(VE+PR),Z<<@1Y"-\"Q("B@S[K+L(Q?]>YN4WBKL@R@
M?5>V7$)"U[_D0S]/FX/ZR#@+3I3J8JKH-L?/!T,[^AL1Q\08A<$),*;=MW8_
MUJ)J6- [0E\8*)ZHIVZQVP/\[/?1\XN;"J.B$K>&A<XE2?,:[)CFK\:EP$(N
MCPJY)^;OS'<TC30Q=S6,"5V,W#TWT]9ES9XG&V$7_TW?QZ;^1)052G5@^S(D
MJCN<$8WN=?*YG?8FE3L-,!:&V &HM+R#KI5-XW.-S^,*/FG02\3TC UNCWP$
M.LSWD6R5];:C\F/\8.D7MKG'CE^W7RPZC22762*T6.3SN73EF>@GAWN<HWHM
M7K>A./V&V\K-/'C,NA,["#EWI7:5Z>IS>GK>A8^4I#V=V^H#L<6+8Q[VKEUP
M-HR1[^W+V.6% ML_AKG4^P,.6DCF^?5.OU]$+X9FBCJL?C5!-I>2TH8U[I-Y
M%=/]5Q5R3L<L#WT9I^J]AIBL;4G5P1+AZ2.?8&E'T-9XL6$*[TQNB@3+LF:9
M(3^NM"O4V4:9">9Y@H,J54UJ_OQUD'&1XSG9^GN$FR7V :[#TX;*A6"<-P=9
M'9<\J$]SA@N)/-;&5IO675*P/8K*LS+=I72HJ,L+KC'V:ZV U-^8J'N%;2AI
M7;):5\*E,!Y7.Y,+ T<=AN![([O#AUE2DMFTLSG('LU$4%!6@><;(--:I$-P
MZMH\&OM2X>.#9K 1?1+]4<RY"7/5Y_+V[[\2J.?ZV0NYNE?2K*"='Q2[(O*L
M9?MKPP6JSU&:%V'U^ZN9;02[U11OI(_CX5J\0E#JY_X33T^UX*@,5]Q KGY)
MYH'FVPH(#MKN;7\N^7GP'<T; )&[E,^97/F<\#4T^QQKR>_I!B:YXIC=,IZK
MOA:G3B50\J7N#3A68;RY',#)="HY?(*O4"?\"2YG>'0H<. $GT9N?A>A\9>S
M/?2<3_2!4UG191#YW+B<9,B=$^TZ+2V(2!Z((0,TXL25$']/K->7,;NK3*E&
M0B\TIA1XSX,4--/A,[!'#\[=6B/ZUJQM51ZJN;YIDQ]EQ#B^Z^:=XX)/25,(
MF*>;#,@$:G-1%LK:E2VN25H/.1'63]N%\.$S--TI.\F^%A8+.$JQG")+K)#\
M/ RV$W7JNLM!?7AYY??CAAVXI#OH;J&ECGA:<(>)#2%0L%.T>B>G+9/TM-['
M<IJUMT>=A#\MW#=)_(%MUN_VE7[L9\CTO0&H->%OM-CB)!Q=J]A<PP??$1X%
MNS?@N[-+=L7R+PC?A9 [U 7:64C(M+#LO,/H>'A%UE-\*$R(H_!]UG#:>>C<
M]#F6V6$MVN AK5D'#[R?K#Q7M_9N-6-P<V>@$_:*@$LQFK/"R8BAA5,GZ9E%
M_7<6^G3AW/GN)7,1S^#9-V1/L^>>16><F>.6P9E/6#TA+3'>_F\ (O2RO*SA
M23X%!Y!BVOX#.XF\A5,P:U?0DGPNM320<T*;T9S9@Q*J2E=R>_1<3=Z0M&?$
M.3I!F5'+HZ+-?0? ]+%;0)RCF+<5VXQ(('6FFCITAM@NO,1IMJ%;:R@ZUTGC
MI[%_%XUE2]+>PX"Q-_\,TOA+>L87S,B*PQ9*_[L@N?4H^#L:RW=+NBDY*NR!
M&L28[SV#^NDA"V$W7KRY2;JBJWU<?QHT*6/XPQ&IWI-ONB/$"W\4S,N:D_ B
M=<R'<T0L-].>$5JV$5H@O;1DX3DCU8]OM3U] ]RJVK54<'IE&>7C)+;I#[J"
M,!0EM0 Y%B4/C*5*A7/)-;MSO]OCCP.$L+K::'J#V!WUC^'R*+30?(A>DW\Y
M@CR!O A)N>V\@XMEI? 0OL'Y>AF[@YL$;P16E=Q,L@I']]/6<0NG&UP OW<\
M[4E/Y^0MI.QZ#=^OFVO[.8KCBPW+>R.$8H&J6YP#U2-QFJ)^7OKI4IF9A[R3
M5T5U4.D(=6%)4392]Z>1;-\W(/D:DKX28&7&./"@'EUE.7;Q6JWMUN)KG'"A
M4/P&5.:<L-1J6ZC!IX1MAOM-;%G]:FMOGJ]L'$H,5CC;.NEX [3:MV3GVV9Q
M^S#.<OG\7/]=*^5%+0 !&UCY#P4RR'_A@BW4C,#,+Y3'1@8JF)))Z""6!<[E
M"8;^[$4U<*1T2>K*AW$_K>N;!:KN??JLV&&_,Y.C8F##E#(JKFMC6PO8\H)F
MU9A3.=-L<YZ<]W>,$H3>@%?/^@)YQ?KRK&QVGR\19F%,O[0+IQVH).,$0:_.
M,+7B(B;VS!5;*7X?KF_/52;?LT1P]4W663!C!WUYB2F%7IX_N%1DPYF_GUX\
M6LBIOYU<1;GZK@!*/;+BT2"[B'L1;ISALY(5,B9IVNW,J1S0[(2.S9!^'4CQ
ME1IH?@.0YYZK&YW&"CJJPQ/5+WK$C^=2]<@72(RM4&AZ;I)$YGQ"VXV6%LW@
MP'4K*,K[3L9QCM+GNB3U38J\%=%2@2B8P!8$4A8P75$&T#WD(!?]8S^"_S!?
MKI0P)TS(W;3V,'5P!/\-1:/S\:87TNJ[T6P?OY(2JC"LZ9*7>3=9?E<0ZRTV
M3.@V";TN!93E@T6047ZTH.2WIVRCR0630DO6HV5CO-^O0^J\T,,S$*SRJ@C:
M:T*,#&P/.P[E+):.0@!-LMR<"].[S>;PD8%LHZ#'2,*%K= T@14?;6S(Q>S+
MYS< [MP""1F)!G"48S(Y7J!&$^@O.$LXW9YI-_841TRL'U,J\'Y-8@Y:6+F$
M^$@JALK6<DA#C\BAE(M*A<N_9!%G\!UY0+,+E&5KF>IJAN@&80F1KD+%ESG(
M9_?\D(5LQY64UZDER1R(]K_TX"UEA+PKV:K/#Z,]%,;)KU-:+GQF?_H>PR8K
MC+T\IV!9+!A&?JF-7\0.*XS-N?+(1*5M%3)*$VST(K0A,]=9(WML&OZ;J*PQ
MMZ*UW/[/I?I->1!3<_BXGI!0?CV@.L6\IGE"LR55VRB4E5BO03AK.@[=4(PT
MRN!I)GNU7)- CS@>-(@51O_/ %3IU%=#5JLMC/$TQ!']G[1OX=_SEB"HM^&S
MESG;AS[A]*6L;>XD:[/T'G5IJLG==.[85FNC<<8(:5 <WN#T6ERF&K/S, XX
M".VUHME1BK<.Z#,N<!46OVO](*U)/+:VENXZ!:^DJ<=UB;J.>S&:5MBF*$TQ
MABTLKT&^ON+H&NA^AU-H5GJX@'ZYLK$L2R6<^H%O*@)F-@:#+$H<8GZ713,U
M/R^;.HT0Q[>=-:Y802"_:V*--9\"EA5Y2%JX^U)9=UZGTY'#^$.7,ZZF.GIT
M_//R,#"X/]V -["LS=F[LE[!0'P.=TKXL_E*G@K1:99,!W:(6,GD[QC9-_=;
M.I9S6^K X],J+P]GDM0D#OSU7IAZU6R9J#:$S>.;UD@Y)T[4SU$&LC%#EM.8
M9T: =X4\!M\=/B?,.V^9&=NZ@I;JFO:FYMA*+!LE[)I'AF1#,2/SX2ND<??*
M>.%9?8V+L_32(<+^>]?J\<&?,84)Q*AW%9(7[^-^9ZQ;2M.E:6KMGP)2W\H^
MB-/8<C<@X/^]Z;,[N&M((A2'!/_LL*DO,%PC<G?Z^6@O=<8V!FBY#);%0K>@
M-"1(R[XAE;%]*AD&">!14":@-_<#CU!WU*S-.+IDYSL&BMS>P:;T&Z"VZX?>
M.=]@K#O%_A3( )ZAGJMK*@ S\4NBKW08VS*,]8XI]7:7R\];+.F<Y9)9B"HJ
M:!>Y,B-)(-L[=-V4$<IG+'L[AKJXN8[OWE0DS[L422#(_)M+7+DD-R$23]+P
MU1)I:Y[-H*,W@/1?EU.8,N-"*4=3%?_Y;U'.WO+,Z*_>FM=\]0B8>X-OL6=^
M3XME/)YKH:%[,RJ*L>0A=Z8_%1@CPK$0M1D5C"*_0Z1P+W'&?51] ].>U!*W
M&,H)/J>A5)V,A,3FP']6[D,^=1CGWU^@:(>-C.@9>.+J:VJ.$X&O2F3,4]Z\
MIY?;V14-:G7"BO2,T.R@=/<E&LSC&/YAG%G0=*6/Q2D.6\Z\UD/418./SU=&
M&-I3DC]#;.$HM: D<6Q#Q-Y;,F9/ X=9#*_Q ]6(Q*)%P9\Z;OS.QO1.R<NS
ML5IZMZ;CP]\BZ1\YN$0(P@B<,.U;?A]E-U<0[7*GSEP8W,B_K Q'4*ZJ4KN1
MNN'B]ZF%#GA:&VK<JL;+M8#UZ2#I]]/OKWJC8O$%X,GCI^OKF=!)%,1TJ:6I
MI)*''F?1-EI-#!Y/<8++W=$'-)MF-2S5L:1=G)E-L JLC>P8R5%B9#( $7Q*
M3IABFL@ZQ**V\%N8="[3S)_RWUVW[=<B/_ P"_/M9?K\HWH%B^FC%\HNMA!Q
MK%:<'P$3 .F[&.D#F)UYP?N>4Z&ML[NC?=5VJ;/3L59F)=^+[_#IP* ($+6T
M,^<!);98;E,>$:IU\G"\M^-,%J>P2\GK/ZQ#R_])4H.8@]YB(FV(_I/]-VH%
MN@A"+@1-<&2)6E[FI?BBS!"NL0&,GVSMD/,5_P#X0Q933FCV%$H*-G_WQ8;K
M]%:S,DD<:R@[!MWC'R?.)_XX:EE;RRIH2)H_I#.&0W>4GBB>SH$NS[\!!]A^
MYR&5=$8'_?+\:QX<9;S\8'HMJ[U?R4^J]RUSD"%C[DLCABS/_1?Z_F9[FSJK
M9)40AM\^"CACTN5'X>7AWB%@,YAO^+P.-Q _K+8X<P?.V$?;Z:*=<8>%=@GD
M>OKX]$"+#>TW0#] H^S[)WPZ+BN+5]\BZE2@^U*K)2OK*33T%@5?4TT[7?.3
MZ("_IA3!W5ZYQ<C/%X:Q-JZM<RR1_/5C];3(Y"SQR'A)N/OY,:*F'PAGDTCJ
MT7J9QY.\8UYDH6EUGI2',QJ'N#LC%C2I)"?7CUFJ$6.QU**[8CX;.L[E"_H8
M+,SPJPX*5M:UJY;R5)'$9:NT&@^ <]?@S:%R8Y1+K._3EZ["@1*4_8;KI0QA
M+)O>-8[,U=-C,,>I9@M/+Y/Z,^ZPQ?3\7Q$[TX4HAEC!$1T^14/8Z.15IPD9
MH-7CKZZ"2K64%@FEK+4.@T^0V^4*8M#'@/C8<:#[*4V.8W.W%^/'O9(6%L[,
MA(#"%WD(--)0F8><8!R=;1*]0(7R(;94$K>HL0$W5E?L]XID\E+]WE50G7^B
M>[\(8X$;_KG2QLO7>8C6&6+%S1#-;_#E&=4:33++TAW9VM\=8R%TIT ,+6#A
MPNXGRPM/R0#7Q.*N6,'*4FO_@.<0EFVJGFH(\8[SH6YD!&+5E_:'T/)EK=5N
M&\Z[V;PFVK#"80'#57D%JA_^]M+D;L -9 +Q>$'K]JR8<_0K-0I=;A!Y6-LB
MSV^$3FI_?@;87?W$4XK8AXC0/OMPSL)D,DY'=)]H''Y4?5')^S(;5[QLB2:I
MJ<Q!_.\$-+$ZBX-.F_MDU'8AR4SFG>S]V3S9Q=HC:_G*ODW%>MWWN([=8*P,
MFZ%*RPFE>6L(9:,<6ZH1/GQLC44:&%(V9GS(%1# 2RV,;[,/MDKBBZ24YLZ<
M/AD/#<PHT^2RNI>4+EIZ#1DRH,(=8I04M8J;75T[OD>55^/8K=I\ Q;&[-Q]
MH7=WBZ]%%$J^)P-1;T"H'\3I][N%ZZ0C$[L]JY8H\_G 4I+4(;7T8AZ$R:!>
M+?B[*@-SSIM:#YO]:U>=MEBS0/:X@6M*U%L23\+]>C)X*[46K*:.%O"3!N?#
MI@F8)V%PQ)D:49@HD_NE\+?T<9!>JG63DMH3\NSHE1Q-EUO:EOZ&@H&9%?;T
MD2B^27@"+#]%?EE-X'O5*V'!/Q O,N (T[(AV0W#A#SDBB&4CRI1FPVF7U)W
M&R3O.8<P7[\2'=XXK[^"AV4Q:<G638'7,%4B6B)UM>H1'>?W\SH#N=GN\J-2
M$IH1]Y-!7/<1 XYQ8J0=55S"A_AE<K;S)JPTP#7JKZZZ=-R LZ?@^HB7QKIV
MS.@\!-$A)81O_ 0L@>Z4EEOLS3VWM<I"I.! U<!"^X$#22!<,R-Q&5C%0'Z/
MH.!9[W:)H!T]$8(BQU9<&_(D&TY0P#9T9]AY=.%T_7Z KPL!XDF2.+'"R%09
M>'J])>VZS[N:LWV;@\XB<J%[%E6UO(%=[6[DM6NB$A)%G2(5[*N78XS5S]'G
MXJ9T&3OKR"!:/BZD(DS(VI2V1GS=[%&FI9=)G66*1E'#-^S/__T7QL-E](%?
MIH=K[26HMP'*.ELG2";:V,D=AYF+LS3LSRY%NI?VRPOF^/N(R.9*PV5OR]QH
MK ",U$\Z/A7_'*R;,0?0Q6\HA=]DC-]Y;_W8@UG_.DOH@)N]6+&L_;T;_)ES
M;0P%#0%Y=C-XY_)82X)=O3I*B[5L>VQJ8\^+)Z*8[= *.<-C&AXD,O&@)I\.
M  [JWLJ:42&;C5_"2>S=*\8D/*S;6,ITM9O![M:[<3QDW5W2"-<545$8F(<J
M5J38<YPC:E%FK?7N1A;HV&S$9B3EB1T7?N'UU5QWQ=2))#=*VF)6\*V#1B81
M!G3,)QSQD:CH#-P]??P-X$L!PJL',-[,!^@I]:+6)(+P ]MV62TFAC,$Y0T(
M2\MLSZPLQ(DJOM,YYPS\>^[(-*\8=E+F1FN0M!&( $L\"?=D%\C%>QLZ6R6?
M06UWBH1GSHY8T.1B3.D8N6TQH3!?8^U+;)545L-OH3S(?%*I14!M*NV=X&+]
MDF'+B C\<#X=STR.:!-G[J3.()-+/B6<O5/BC&VZ,@23O\+LQ/BQ6]8/](Y)
MH+'_*^75&MAI\UZ_-%[ZUS 2V?N_;N@N#?8C#G#"H&:CWFHRJH'JERG#1*[R
M7%71F4>A&E_<Y8J![9+#B+,VIGSNX)P^PZ.RS9W81%,+T23#151AFJH<TL"F
MU@G\A^#;14:F#7D\W-K5 ;;(6FT=^A6DY->*R&W@=G\YVVH;HG5WA5$M9M<!
ME1/BW6YR9>O9%[YB([)W9SB>J <\B8=B)1)6J-)(5UDKJE".V1]"N^?Y"RXE
ML6?*[:2&Z DT$[8%MG<AVI]^;9^%^//IA]%;WS)1JLH3\BPK3(:0S;?V_CBH
MX&<=K%390@L>@T;9)C5<35",HR\N.,!:[-5^N@1%;(;PAH9J_%1L9NODQ6ED
MX<2)IED90(LH'<TL-,NS*RHV*].2]K+8D:3(98IO[: WC[6N^.XE3@;RKV*[
M1 @7$&-4F];5$,HP3'9V+*N)<YA).^%<DU6>;:-S</"SV)'=Y9X_W$/U.6T7
M_U;:5)Z)S79S_-TY+RM+?RY2EG4!#X/C:IK-T+=^>KFO7MS@T)R5H<#?NSYU
MU0EO_=/"AE[[[TEG*^U%YPU:W=2S;W:4O&L-GR*-Z<8UMLHM01]NRJVBM/IG
M"5A.?F0F\!%1Q7U>'>I:93L21D" FWN5[5KF"7-!XL*H7\^7;6"HJVZC(YE(
M<M=\=TM9C"]8.O$WDU[3A;56MT#]F&+,AKC'L.Y7Z ^VF%[4*ZDS>$!EILV#
M>#GA3CVID%B.RC[% T[2-I[-.@MC5'B@4-B72DL<_O9DWC&=-F[N[Z*J5+=Y
M9#;W'C);I+U'^;4[K'3JLG@6E$#+-'TLY$<%RE<*$P029-K[";X2_3_\J#9V
M>,N5FYE?]<10_&L,:2/UF25!E"0#I"^*\*=D_;B>9P5)2;ANX)!YAH8FX^]1
M'[XS^N_LT\#]0%YWB-4DQ AQ?@,PSKSP,GM6>NQ2B7F&,#^Q!1QX"!X;W^0@
M@XZ8MQ)<;7T3JYP0F^J3/KY8BIOHHC,8^TS],WKJ9B1Q9WT#5[I]X 8GNM5[
MG.CQ+E3N93+6N5?BTM!_LSP%RW-$%\IXJV_5( H1@^Y/CQ5,*"<T,Q'*.E?'
M%-#<7<^_S=TRB=Y)%<3MO$01T 1*"_HAFT68L!_ASO]Y*6D=O*<AF_[MC55Y
MS.)W!P.[IF7[I<9OUI>FL7%7FW"2:8O.:4F%+!%'17G6PT7&*=?3HK#R]=4S
MR?F!-:\!R[[-I4Q-]BJBQ22<"DP=BRO-48T"C(&;2"XU,_>S09$O*B9>99(E
M%LOL(D5C=M@3J-.M']ETTT5@!7@$V<ZU@K;D(^?3VA=#S@=GB*RC?SY&I];B
MKR7N/W>Y[Q=:ZC^HR+7;R%62ND!GDM:E+\G).'F7&L%"!Q,Z<WX/(C<;C>L;
M1)G":[J]!M?>FRV<3$W!7QPEA)]7FO /A;'\NKV*4#B;K;P*U7]G*\(B;K2&
M^?=\"J/:CR0FT](F(SMH"0V;$0LNQ&.Y*N=>*[Q#H(L\&T2H9(N1L$3R)3KP
M6QJQINYH% =O?DZB"R10-D0-@.HV4<'^P>\SM]##GV%T83EE0"D/K*&-']),
MS#549$GU9Y=&_K(ML.7/,\&EML6J>JEV1"<Y(OS1 JPU2G?T$^*0UL1OUKLF
MM"L_UX),=#F<?:@;DMK]#;0"31QV/QJ'RNG+ME;7IFWFP(-[&6%0$1%P"EDB
M!K)3:4Y4I^>90+UGY2Q*,[OM[8T_AG8E'(<5!*V2WH"?57W9-\QDSW>WX>7N
MZ;T,Y5JZLN9W>,B%RJR0<!%!1$&/HE)N\6_SD91>H.;\&2[M(*M"G=%.#\7M
M(W>< 8L89TBFZ-'9=;>AU8B8U9>$#2R^ 5#Q=.EA^)^*K-!\ CIQ:1>^TC8[
M'[OM^XM5UL,18D?1UF(.CS@$Q0';.7K$_7,L[0_>XM,4,X;MSUS'DDPY;=\U
M9AMZ6,-0S<YM!049Y.<X?6AT.E.., =\2E,B8^3L_1OF%EM5_UX)-5?,/MCD
M4]GA99?4V6 &8^W#B>,GR.#XZKW?/.^#Q_B'[6FP'U>0137I?B(-KQK\V2)^
M&&C%)((#1B;CG *^AT9+S^_4),O'S:\S29[(";R<D4HG-, \2L%VVODFG[5A
M%:[JR++K;*SHRCEP#:6M;QL'C2'7T/(^%UL^!_)RWE_()SWEZ[6N55L%.$]R
M-D<.4K!]$"'8E<?@A)'R%I_Q'8_CSB[-'_[!?5%'3^J<VM!_P.-,4]U%[*"T
MZOUM"F+#:&O6T!YE6^1.H*GBS%SC88UONX_J%RK@I-+S-Q-Y7M9]_>Q(VBB)
MK/;Q7B05]V,[A4YT"W_L$&5ID<+%PM=LOW,7Q)?N/05F>YZ0Y/&N1T^$'5])
M3ICRG*-I*]?&Z1%D"9OS_3H8I"\_;?P]SBQ?<Z]<< 8DX>4DBRQPEP7PL+0)
MD"></L\\1L6WCVN3+I4Z_!I4>#;T9[120G(N;5=!!2'K$JHP)R+1?!;1'YRI
M#Y]>$6_/$I:1A&V&+?TS9NQ.IO9+\^)^.1?\582#FHQ@FS1;JU)]9&Q27;UZ
M6DD<AQ*Y^Y+PE+L68],0% M-;-5\FNM<YAP""(P?!_YUN/,Y2%5&SVKI E83
MJ5@#NSH-<0_&$_B47%,'"R"+&:.A$9K!C= W0.MW)60\NVPPY74E\_!&L 1V
MG%,.^: R$ZTJN/*D_LN7].;*6YI&C=YJUF3+]^/&3,VLB-LX?M(S G*XY?E]
MC%H5,;+%??"]CGC!3*&Q]6$F-E'7+G#O5]UY<0X;IM_E0=#% ?>YT%"7B0?Q
M_89G[OJ/VN[. SBU@YM:%VT!_CJ;8,0_AX'T-X02G;B-WHPV+E9>Y;_NG-@,
M&R"V-H$-'OVOF_8.&0%!_E;SM#D8)-D*E^B08F$6:ZX9D@)^Q22>=0A5[*#W
MG2+&J$-0UL/["CF#+?>3-?B.&LSTO5IM"=HAYYEXE)'!U_51E^';,<\Y;)A]
M?I_0\$^7XO6G/99RG1I)? MC1@A+'>.LHF8PWN,AK=,=)KU61]U%3@&R)@0>
M:<J\>@CS_LQR]%THPV^ "PQU?ETK^ J&4[LA/CK%L/9%Q&%7(TSDL9!WX/>Q
M>MVS7\VB&!9Q\&-',020H_L>//).E8X*O:F,GVLN<RP55REE*ZKAE!+A6(O*
M^,=-I?Y7NY-3UW,%IV"GA(E&RAM0H<-"R>%\\=*:7^R,#+)S\9H5U(0,1W/L
M\]J.HNS.B(NU&AVHJ4\FZ(%8G:C@P+.74+#7TRPX?ZHJOSIB[6RK1>GS$CIJ
M /=EDF+O%T<DG$/HISKVY<)AU#H$FM>9^5*-;\@1)WQ@:CL,][PSBHBG.MQP
MG&<M4;MJ1N,RGTSC'QMLJ\21\?[V<K)"J=L\-B*3EK#*20B8.K_FM(U5/M@H
ML("\>7V%B3-V(FZ<R2-\  ^M!Z>^!5PL<<ZGM#P1[ZF\-?PUXCP/Y%ZIWI?-
ML!%BLRQZ;0QD*S-])A?2?&P\SY\\/+62[JI2V28]L/6UT+H?_OQ&Q.K%4\*D
M()80;]T2G]IGT05%=ZV]Y1WM7VU14ZL?H)HLV;?&F+YZ&3 !ZL63+WJQH[\'
M?'FDG>]\Q:<'=D87X..D/1[C1P:([_&'QCP3/^6@H\A-"XA8;3EW-"==YL8]
MW<A7.;5\@@%Z?HX#:QD_C-VJ1'[K-N2\ >[QJCOO);&JU'@A>,[U]69&/Z,<
M?0/C+1BJ"]V,G38N+[=M^;^V0?^UU0N5:<U5J%]G5O4LV=&-;<H4%FB>U&5U
M^#S;>91>BY;F(J<MR8;C.':RQM%TO^>#+!/@,<!!6;=D80;L!].Q<XA^@W-^
MF+V#-N<?SR46:6YQ*J)(=G,$C1)!H@S-XDQ@M975/<YY>'$YFTT_#-'Q2W,M
M8SN*!%=95?B$6[CM&,L*MOK$E17I.72A_&K((#$.=J\3V4H6_AQ7>A1)G4>E
MR;-9LD!4$4?7/GF_UC>;07P"P7(9ZHO<0$%1RKR4NO.UPNZ4AA6_&J('_IM*
MM9D_6HF-D2PN:@U318%[=YHOA\S,<(-@MD;#3:2N\V.EPPWT6VT4P5^" 5(L
M3&<V)P6N<=18(<H5N[ V/6@Y(2O@(O\OB%L7;1Q$YO&2TEQ4JX8BF#PR7ML/
M77OI=F\ 8D'#M+C=:^2%5O<0A80A [;<?0#L6>D W]^M9ND7F/)5*\+OV](%
M!:YV%N01:WI4OX9-F4MRG#)7<04<63DT6M1[VM4U+^8:E^$;TJ:T1XC-L:8U
M?^F$@WP&8!$1")Z7[G(PY'5Y1.=LOHZ8%.MI#W<K;G'&DO@O$PD$"N-/%./8
MHA#)?C:PLD*%251]E,+[)('M<,!+FIB^J8M5AX:_S-]?(W E?TP\01^X#_*X
M4.@$S.JM!A>Q@167#>_.DT#+M=T=-=9PT_%IUPL.I44)T;H"QU6,0E,K1CLN
M!BOL?02FAS?@M@36E>>#1&5S#R!AQ=&;%@6.SUG3/U(:^IP!</XB/*,R=GW:
MJ@>0<]"!O]^9S.2CU:?LG ^%Z9Q0>IU6* D*ICT%0]+E#T)[6N:*PYP9=)7[
M")CV$"Q9@4HD?'+G0YV7ZM=LS99H_-=-@QN!!:X+%55WIGH%U+5=VXIB"QRB
M2J3EG@N#IP6'+105XDN]DK\OT:]HJHF9/S4;^)0TCK>CD.I3G:L%UKUMJ+S&
M6L,RMW7'(QZ61P$!#)G)F@0<G $RN..HK=2JK?:9S=HX"U/7T%%I&O1@40&_
MHRMV]NT]WH+W@_%=:1E)6LTS-\>_TA>"\U-/8T8+%YRM'W?==7:>O@\67$0F
MQ=6QFT=9QZ)XR-2)XW+S(:[Y4^TCM#MJ*?1D2HI/553@'BV;0RK_=KI]CHRB
M$!VB" )+N)Y.B,3JO'8&WL;^?:6_DD51S;0Y@:B-D1M._ J@%#@&KPT(_F="
M,UQUU\1=1MR>Z1B^BTLIB#*ZPB4.H#@C!J0)2)[G ZT(!5Q1[-,2 Y?*P]3$
M,^$,0F%@QCE.=7 6>GSDCQBZ;3D/=EHC;K7P[SV4.*\D_K 0EV!E9* KR-BV
M;Z9'$2G;*!-IV/[P$94VK -/[49]/_WYM28OLP)YYP>F4R2X#N;0?@*G%XGS
M0T$U[RHXDD##,Y!_UBD[85XAB+&2<P+.O$'= ;^2O/9K'#NKZG:A51G!&0Y;
MO^.&#-!IG:5;9^D9C+.CCQI]5]Q[CG.TG7+/3_<&>(I%3UE-OEA4LH1Z4Y98
MP@<.QF*'9M7PH$3W[E]4:O]MB%SV"TI73"#[HI0R$C^;\ZA^O0/ELI)J0"A0
MXTZW*U@\QALRLZ1L:XX9<Z C'EQU.XZV3:S5(,Q^0F^T\XB.?3!Z(IO.@;_\
M^G5%>Q1A-1[ADNS5<OSZ-&?ZS+1=<;ZZ>X(]<149D'78 ,_-Z&NCK!#\&'Q<
MV!5Z+8]L;DBZE^R<22B3X_P@C'*C1B\IM)2#^OI%^<*VN,!2RS<-(73:':<X
M9@F2+J!P%0*_@(I!*?2B+@:?';PG]^6;ZO19UC0<=RP?6%+J#[X)0H8]NA_A
M7O)F>YZYVMW\F4G[->-8;V-\V_!4]^82GJM]05# =(7"7]GF^J5=S5/*VGA%
MKTO[,M_9PEPV#[%(:Q*GK RC=L!:VS(+.[OW0V'MX41)Y5+6%FLH8V__^\NY
M<<0!+=/JH@>]-T"^M3[-1FCF^?M+.$UXOC2URP^9G=>]P2[B!2:[BW--_Q49
M(DFP-BUC7K#A>CF']K"^TTL;+D*#O8_E7&< EY=;R&9GM>V^75W!E"YE&^WG
MIH\((I%Q_)@.67PY:*]?%"\R[I46+6(7OXAS7@3 R3;0H#RO;A>)= E>6,ZJ
MN&LQ&+='Z)*0@\6_9NJQEAT4T*)EO"N/03!(VRU^\/!S<'/.MJP+6=:\1<+5
M"/+PU^G'-C8BH[O?4:F DJW[F2^MK[\!IO1]+C9420T'W\0_A<_8PSGN- GR
M JAIP!D3[A@C!:'G'R;DLU^#_=T8?#H.01FS=RCIX62_==3(@F]2VP0W9='H
MMZ1VDI8(-//&9Y(-V;(-&0IKP_J P<?T>&&TEEGRVCC.9%?CYR:"\N\3@WYU
M E)E?."-__KX61GHS_HBYU%D<==PGU98.QXKFS*G[DJ&  ?.JB]N9KD9F[J*
M[TE\PNHS<Z^2Y\\..?LKDHKCW4MZ/*9T05K \L*#306]FGW\)MA2^M*9J%N%
MDB%3#F99:B^H;%?;)6$][<[*#](E:7ZNC_:SM78Q(S?D ]]"\Z\A1!8P2HJN
M6=K4P5M8=MXQ8N7:\-'?FX)M"LQ[QDW5_#-(I0G(2>N2TT#AY"VSR^M,6I];
M9BFRCJ1ZX^S"5B*MD?_&?1X7C9$D^&O8[DT<H05<KJE=:]3.0B!VMTSRLA?+
MAJ)3,I2ZD7]E/D=IO)SX-I\XI*7IHQTO\,.GC>"6,YWV-10Q>R]E)!I6?-)3
M&,8 8.;;9>2XNZT.SDVJ&[R:0B@S-U4H?(@(<"S]!5I[RDL'MC(YA,':BS<[
MC:&JJ=2);8,R [OX^!]CBKYQ8^"3)AXA%$J20-K4/ZQ*PDES+EX;J\)DD_"0
M%I/>W/-BP^B)7U-])5E$GFI-M:DHSNPX4:K-_F-:MM1OW,2.=56L #%ZN%?&
M%2**P_3S</8N)%W3@.J/E]&?4A*+?Y=)*!,*FWBP^.AGNJ'+NJ7YA\S_#3A>
ML)>08,#K3G.8$>"Q@(V4&MGCO;>ULLR4]. V"2@ZW-S$:^\4_-:.?W@I^;DR
M&R,AEBS%""[.\WE>OA,ON6* FC>.;:*)RY+C-7M+4J77C01$!FW77CA%ZPM+
M?*\'VWGT999$*2*B9A%BND%>J3W00%@XMY?M4+BR*LV(J[YI[.\]-3CIGR(8
M+LB0\SL%!Z>*R%B18]C6&<U<7[1FH&)U:=F26QTK*4W2+@UV[_<^%1+WCNM>
M3B (>]'=]VE;O6-V>[3AV#L25;S3YWD&+G*?JHJ,7"G2*.T..6)O>?UJ[?0L
M)\)=QR _$9;!1^3O)$+" >YR4:V/ VVZ1K+<3TL*DGM&$?LC"G7RS3""/SO?
ML>OFVMBL/*K&<%[PU!H\788K:FKZA'I7..',B&K<=<S #$M,D)S:1EDO#8I
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M+.BXH,3,_]'->;4UF:UA^',002G*-O024:3W 94:&(8F2B@*)G0C-004$D!
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M()[WLFN;5[Y,:(@F'RIJY(<MTU*?K2V^^HY/],QBXE><-%[7:_-8$5'S$SE
ME_I; Y4Z%2OQ9/*RS2,L1.++BC+5;,B4%''?/L)X:/%;VF-?7RPTY1R.D+3X
M!P95YJ&VFC'\:F4_KH?^2!?-YAKYD_NG]N \AK_)42_T$"RLS-](KG>VYKQX
MF.LD\U*!;\'B%2UKI99X>K_*5R'Z5Y"M&Y) +QZ !KT3L'%<A)#LZ*H\V+QK
MK[FX?X,8SUAY\VX'7]3,976ROS&:D[\=F$9=^^*A8LP_(K7NIIL%[)EU"I%T
M,,Q-Y0WK)YXH 4^1 S0M7("@0<]6@;3[&R7S?C9%?"-+4[FHP3[A<OA7UXK#
M,A/AH_[!H]H4,]&^4;@B:=%%8P>/2RR#.?\4D%_3C]Z-2&KL6DI1FUG.U)9K
M&#.U>'=1B]E+[^6^ZSYZ/+;2W8GLKCATRM+_6PC^#63%^WT),S*IG$S?,>XG
MV!UF]E4'H\_A*K<&=J^8<IW=_5B&S<!SY:-PI]:_$XY7/-W5PF5F/:6F$@6O
M!6E'&EZ709PG2]*"_QY#_]M24R K?Y_A2:+N@1VMR26P?R 9:E-T,\]'?W,W
M"PVJN+1M_OF@$0VZ' Q&524AL?HAN/PY=^Z7#US8C6S,=PABB^*MRM<6ZM0[
MR$J?6-+2#=34NF_3SL/)<+L!GUYNFYEYMQU^5- ;L<<2V/,/5I M;C=7=#YY
M_$_WD=HWEVO&""Q<'%]THJ/I2ZXZ%M[>&7ME^Q2O^D4H/<0:56('^YL >Q>+
M!@52\8A,P9Z7'00V8MAD\8<LUBZ9XPXB8BKU>U3!B+IQID"7X,+K.EB6DR:8
M!6F0<V9A<.VL^S;YK=9,+XCC><OU%'BQQ2.[(77@Z:<1R)CWLS,LK5ZV?26B
M"XELO.<O^'[0M??=2F(4<U=S,M.\EW5(G37I3F;1(]"?5%5N&F&&E?P"G[)@
M2'AO49..C#Q70(:Y.$33JYDCM;.K@Z#^:,#VK4N,1X=9Y9MM<10#)&ZY68 *
M *T4KB+;3QKF4XI-29? 'M4I9[B<S-,L]X>CW7_EZ-)YJ)VPYC^7%*5NNJE_
MEV[^@V=F*2HMG!B(9<4?@DQ.E"?O/9;I_J1/&"H$@"+J_C+)J+"V=X=T@+'
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MU/>HDTJD+>=(.+WE,N=O5D)$ F52?:5EB7RE6,<<&#-3OGRDLW^EG?9;&"%
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M9?6&@FNW8E.D(Y)_O),U7"9RX@;H+@$1/D5MXF[W-PM-44W]L/DFR/%D[VP
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M$^#_\!--1!^,LMG-N#32WO[#!?"L;*$S^2-5$"53V +KGD/C[HK7JYAE(*Q
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MT?G0[- N/_L:XKD<FX;-)LRFL9KR*NCR.U86H]Q7]:47M;@:#&9?:+?=J]K
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MB;0O,5X5DT_$Y,@@%XM\)G#\RE8W3=KHBZ:R$H_FU.:201K/)N:B.TY];5=
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MMPDLLJCI/'BQLH9*$@5YJ>I<(_E3YU<J*T./N7BY&"IDD)OP/C#4\K#Z>R)
MH^V^(H==6UA3V9A>?I6VWPGFOY(M(YPNWRO3<YU7&\S\L(%8TG1-%*S(&#>
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M(+T.PEW#WH%NM1Z17=:[I9$AMXS\.\;LK#W=+).&F.[&#GT3]$-A789YZV2
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M$,2*OIGB"FJ_BV26'#75C)[CUH3X;U_=%*[_R(E(R**/;O$X\F.A!"G.)+W
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M+U>8'^VIV:/96C/OLW1!]BZH$-3'Z+B8"ZR^5T,:7&X[]^.8T*NYU9IF1+N
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M!77>7+)$Z&B=5'XW5AK$[/ NWL/!>4FQ*OU<;2A*I2F0'(>69<J'/3=;_N$
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M4,Y7  6+P/AE_%C_RJ/4L;=EM.-#GIWVT8%YZM,[)L2#TL/PAZBH/ (EK5U
M7SPQIBRQMMA&Z!P3&I5\C+#0N&JO!3(/*4"H3'RS>_HDL9(I)S$YQQ4%A[]8
M$RT;P MXE\!GH%/*:Z7T9?YLK>RF>D#14^]*E76H4"?[1WF%8Z&L_K=YB.A
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M:$N&ECWO?WOJ^[? L(EDG6GV.QI?;CK*RKO\%:?)%/(3<W$+M*4\I_BD@0;
M"]J@OHSMRH?PB/"J]%^FG7AN78\D#KX/8#*$@;]?2XSQ[1F+UQ!6=,E9;6+-
MY.4U03Z??,PF<PIHB7J%M\6)9-\T]4P4H7^QI1'P:@3>[U:D^,U2!C:C",+\
M:H^?>5MAAS>OAYXAJ.YOIW$^Z3G+B4C5%<<YMW'"T3ZA94]>3KHP+D3LRTQ
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M&!ZK!]FZ*&F*SP8=5\YF%U"0T1&>= H3 8G-2)&F'1-9A5G2=Q'C\( ,WTZ
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M@;JK+"M:00#WLBON4)8WSJ\XHCA6X+OMIO!K:WJ;B4B50E[/2H%>'%];/:T
MA?V1]D3X&ZTJG?*\+@B;2(K8%E@9UQY7D1B-*?I% / %D+E=_V6FWSNM.^J>
MD;;AG'W^84;9>;\;<2/B^N>JCV:U/(4ULEF[H/FC8X+Z3X_Y[WA /:$P,DQ>
MR=5;OF'.IH%?U=M,"YA$$2R.A#"Q#*K&,(GCTGB2_^F?:OQ)L.++Y+>9 %7.
M_-QX4N.R06!%IM3(][O2-/ \# '52L82YC%BNPSW#-Z6+B'Y>Z!$D(1%!=)
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MVQ+]Q]P<:8IL,L4Y;V,V[PJ%0-7;2!>2/E]*O=@##X2J>0V@S87H)A<,)W\
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M27/3WR;KZAV^AUSU+"2UZ5@6G6KE=U6K+XADR_Z#)[&4:? RS!!$P15I0'<
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MH).4T3[NV;"B*17CQ!8+C2]MFZ=(3;1K!%80UMNQ]6O^&^B#>.XN,?K^F_8
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ME&PL;,4U2^V6F3S \T+)I%<]\6P@84W!W94AA<SGD8*7=.&(+@X2IQB"KC;
M D%J:7'\XHS3P)&*BUC^5_I>_^YE]77DMZ*#><SV^6 \AC1=ZA?]>_)C-"D3
M6 .G$_\Q!9D8[D3-I!<<;K1<<_XRCI=S[)LO$PP9EHIW0:(5.@:)(W?IPK^9
MC&[QN*QG+ZK"B$+B.N-*EYIO?^"@KJ;R6+&ZUEOI1QKQ,,+_%"*W*_397;3
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MHP4 P-45_]>;H\2?U?\&4$L#!!0    ( "L^;U0TJ[GHU14! .T> 0 8
M=')D82TR,#(Q,3(S,7@Q,&LP,38N:G!GM+@%5%S;LB[<08,$@KL$#YK@3B!!
M&NO@#L$#!'=/(!!< P1W=W<(P=T;=W<:EZ9Y9.^S3W;VO>>.]]\W_L688RS&
MFK.JOI*O:O;]]/TRX*FT!% "\ @. 'CT\ >XGP.\!CQ&0D)&0GR,C(R,@O(8
M%1WW"3H:&CH1-@XF+ADQ!3D9,2DI)0TK/245,S4I*0//<^87+SDY.2GH^81X
MV059.3C9?PIYA(*"@HZ&3OCD"2'[,])G[/^?G_OO *S'C][!1\ _H@+ 83V"
MQWITWP&@>+ 3\=$?#^!?SR,X> 1$).3'**AH#QNJGP+@'L'#PR' (R(B(#Q\
M]7SX#D# 0L1^]E(4"4=!'YG*%I?]4V3Z8VJQ\C8\Q=%C&@X#.Q\45'P"0B)B
M6CIZAN>,G%S</+Q\_*_?B$M(2@&EE9155-74-30-C8Q-3-^;F=L[.#HYN[BZ
M^7[V\_\2$!@4%?TU)C;N6WQ"1F96=DYN7GY!1655=4UM77W#C_:.SJ[NGMZ^
ML?&)2?#4],SLRNK:^L;FUO;.+N3D].S\XO+J^N8GKD< ^$=_/?\M+JP'7' (
M"/ (R#]Q/8)S_KD!"P'QV4LD;%$%9'U;'"KV3X]QQ2+3R]M0J#D4C_$,[$91
M\6DX5V@A/Z']@>S_#IC/_PK9OX']PC4+0(=_]! \>"R "& C/M'=HSO_"%C?
MVN3-3W)4.S&F-I[ROC'QMOLTT][;!>;P]2W<H?41Q5#HX-W:]9C"*[0_=O+P
M7(9O <4!K)LP"'1[?FE1))D6%_!_=TR.!B,+LY@D[K;]- W9ZM<F(T,^PO-!
M\RMOT3H(WORQEARZV&-B5YIH6K$0-T\S:6G&?3.]-\:_I(Z_AF-_W GP'?$]
MRWDV]V_5CF.@Y60QBL>Y =!;YYKW8-#SU]:H\GP'G2RY/EQHK:@RJUBV5K&C
M72>N'TC<$8=LYY)4=6>32[UJKF-Z6;NY?MFI5LK99I:COGA7 S9T0CFA\NC%
M$&D1,*ELA_].+:(YRL7RMEC_EUJ'L>^.E)YR+"__WQWTU[&]AN-XD>,2Z#L[
M[\E2[PLYFY@%%Q ,.!4BLI=P#]BF*^N 4G!=QX'LOS#//,C-^D/+LSUQJU?_
MO\8/*$J)'@6X3$/\XQC)SS,YAV3L'.=I3]V>>GT%'/P\,OK'_MK,G8H]S>::
MQ _;M'6>!8,]NBB]W5:, K=*^OG:TU7E?1<G5;([HP&\-*9)RJ=,)^=D5?5(
MOTSB_"G0O\$3LXW8OSE=V[RF%G^/E'G7P&9N.@\YQ';(3-[6I^D;S>+?HZ9#
MX0<E\%XMM @.UECVX25\QH%T'4BT1IX*KNB*N0=@FYWC>)H3$T%3*^+N]NR0
MED4:AW=D9L4.>28\2J88?J7CN#/ZFLTPV.?5[JL;\.>P7UBS]L:" #J_,$HS
M/'+^J5CBI]T[#']W2U;&1X(_O/F'V*C?CPF,(+L7RS'KH4#91_NV98>CBB0O
M[Y@";XVGH'>@>X"W%M2B<LI[/>K*$-;8"AO69K%?&=OP*CWE3)S$N:O8@WGE
MW@-:BV&<J1\:[@&I^?> HS7OT-?BUD;BO2TSCO< $:5[P!+X'D L_.__NA[^
M\P]B]EE?^OL9MCG6UJU=[]N;I;6W"N(1VJD'<7JGYR)W4&M(YK]>[ZPA>0P9
M/:QR%_VEUS>I,%CMU>BOUPE.!2,"^K\9;B;\FP'_4+GW2^75TII*+WP^_.[[
M^;JAE?!B?%$G]?\LQY>:J*<;7%VU@.0I(SYQKIQ">'!V_H0.NM&[34 &:ZG*
M6L-S0MW/O.AO_<,PGE\V\EQ->K8_'"YYSPP7N_LRY?G,(\-?*+/^[O,T"(&/
M(^:3':<;O\'.II&!-A$'$D;I=5,1:2XVA%U^/;^,J1)ZW]Y(0VL:I%,D6,K"
M'JUJ=$UC3#\U_"]G_5VB^5!Q=BBC.C4!N-;K Y4.>+B.SMNO^8FI#Z88Y@@X
M.%9Z.\[A[Z#?__N=!&K>LI)D9#K.6;7O9V==H^,]/'$/N(2T=L7]'A=G^K^=
M>?]WW:@,%6C1?\\6SU_O7(BX&HB]L-^R _27DO/6KO2,8,IZD5_) ?Q'Q.G^
M'BG5DSV[>T V:,*[7^)!CD^,U\V=.+ZHC77+DJ:TZNW!>58.9480 ^"_6? U
MQXISTR[6'6X;@T4\5(]C":.,$64H[@&:X*[, CD"?P\6VPLRH?/"G<=!2N9U
MH6B/?IQM*[O;:Z-:J)5O8V\'&&KQ&9\F(5['UQWM?"_D<$E52-F3J8MH:Y15
MD3'&@J:A&U*WBFI'IS^7B;^\>Z(\IBH$=]$N8TUAT1 \T\GL)NXS\.XQ=R_W
MF)UD68&;<P!]TY7W*IG)(7B2->@NZOER@&2S%@4;F5/LGK9C:K"C!9G3GGJ0
M^N#@HL>Y0Y\4ID%+DG+<(L>D(PE>>9V,2'G1#WTX+3]9WX@ZBO:4A5WA4B&<
M*>MVV]LWSL1"H5DPY'((1G%FO.E89F3&&W&]:LHNL'[8J[WA'-<2Q269&H@8
MJ'"7G'*\:N]+Y,=J([1J2;DTK$Z5>\#G-1W^_(DG'<8#%*8GLH9])W?<#@?:
M*VT&K^!3?-,*<R7,:A9:B_V>YQI..]00Z)(<PX*?77,)4:U28LHM/U>"[DRI
MEQ]?5*8_NW980.6TP=0@?&EX@SG4-"N"NQMY#S#ZX/)I3!0_MW_[<=O"GC2,
M>=(H3C5F/: FST<@=>$>\)B0Q).WJ*508&GKZAX0J3M)9FZ&S^\?OXSFNA)"
M.]Y#SP@7#R!JHXY.,H04S+:T.MKG[3407SF!#\?F^<71GWYPM\F%D_V4^GJV
MG@\JFC=LG*-)I((C1S/':5']%3+D?E8LLT1A40M6TA*8>S.>TYOK#XB2:O$K
MN/M\5-*:4TO +\  [F]OT/M2O-(X>K#:X$?7H-7H%"73/-VC^.A\[;A4 ,*L
MZ2%,W2SWW%?]Z,E30&C:1^GET[9!W7$/ZR(SIZ<:W1<::S6;\_.OR-+O 0X7
M14R-C<&W]5:'V6:F,;4"M8KFVZ-)=/.!2>.J;S@5Q!V)_' 57B'^?3GKXMP#
MHAS7,&\V6V]02O ;2U'N ;W\D"]W]GIW"&#"5-_-5O:=0YO<8ESR*M5UQ'^>
M_VLY+F$PK]1#@'7UH;J+0[/ >7X?_G>.-ZE]]<2CXUR-"U1HT\7$7 3EKNRQ
MLLE-9T(-8$>##62\B;RJY)GYSN)NGO9!&?7&L;/50C?L'Q25@/*4Q_2WT[V"
MY]U<3J?2OCI@*)EI7MOC^MC1$FMTVP!H)^!I%L8,K'H+VT(M:OO%^R)#_+=]
M)BHH/NI;^4<3DX7A>+N7Q!LU929OFFI$224X?_@1K9&U]0[:>VH":\EXH%6<
M%\'YV^2X$*Q)0=%"&>YD4[S8.)Q^*\./3%H'?6O4D_:1!\H>3W*Z5ULQET0+
MU2OG)!U8J>K$'RT$,D-\'\CD0KW$_*B[87*A>J.&><4?@CI0IO5Y(05E6#M5
M224\A,L/-J1N'+3(PGM8Z__X@I*W>T D..3\G$M$+3F5L6;IX_64DJ*HQ9J<
MZJY,\"T9TNP4UIQ6+Z%>7(2]#_N\_;4::$7FZX@'9S!9'PC.XAY@RD&_$$F(
M."]4C]34 #N1DX"YS\1RQ3JSKG+--H8K(FJ$:[4$O^;G9T<#5:&E-IXB$[8-
M+S-)?W-FR,O--3#D3![6&RV2]'<4XA"3)*I/.3GX#EM>$1$385RAK/$'^?,G
M%9,:Z!V\\]'QM?/I7RHVZ5T+M=)Q>J*_\7&A#<5/Q/'$3\AE6'.0>&%[9&OT
ME&*&/G78MG)SJ=M;GO'9E[QJ]YWK\H9(=[*+^OQ:?ZBDQ<H@S^NJQK);_GM
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M+H<03@6_LHX580$&;ZAT\6K?>?.OQI(K6M[< [YS*P'5]^"FS7P[6^AJ*WV
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MK&-V-\4P*IV2A58FWYQPX4S*,ZIF,RA/EAR$RL1""GM1B,NZ94B"BMTH)$+
MF:H,*G:CFKZB<<C*6L51T,[P'B,6-9":QIC0,,E4Q(]W-=I,RWM"/E$27AQ7
M3>&;@C@NX*^EYK@B<DVO^^*AHSRT][2$%8N&XU1H="FA]Q37/6!$3C_P2MCB
ME#5E"]5M5/3GSQ]_/_QSJ6Y]@3*YKS)8;5:G@ D/G*Z+;9^]Y4BR#S=O?VA=
MWP/-V#Y[J,:=].*EA[UDZFJ,5WO20[9'?&KCM[:NC6TU\ /L05#P?E9C8N'
MJFBRIJFFXNBQYS:XB2A_6U.H)=_AXLCZY5O!&IJ2E<BDH-$6,%0DZXI#8>3L
M.1MK5NN'098.=[A'8;YA+F<E2RHUGNZ@N/:/X>R6=+.;Z"DAQ;YW3/%3^21\
MEM[?1\78# =+FDCR9ZYTA;Q,/FKVY*WP4'"@V_!V"=Q,)*CY<+& Y.0D-/;W
MF==YP[1ZG5Q317=T:D-8HZP?NX2!J;R&]>VMS7U'&--%\KD^05[QI*9_NP>L
M4US@G;R\Y%@BJPRMVIG*%V!)]#X69Q WM]>\]*^FP)#!7LRRQ&U_"4*S"A/=
M][2@:FS\V+[<7#I;F7J >::SX&1T=M&UVW.L4C5N7CE(GFCJPK+,.NQ.-_WN
M'F!9QW?C:?%>Q2-,<?MU6#YUHMZWCTU1-H!#\\7L')T= O^A&S;&9:I&R0AI
M?R*B;K<S(?VBJ?8;[KI(,P+G2',Q_-BQ^2)V^*1\Y!)>J+BQAW(SATMQ$30
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M+A8*7]I?ZR9P!8UF8V6TO&YQ>T&X<Z1:98VXF[#@L]AQ47/<L\DK-]"(/B#
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MFNFCLH.<)*2T-)M2TF6Y62Y@O)V/$LAD5=X'08QQ1<Z:(MNK:3<+-;H_F;6
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M61-:-:,TL[A;A) ?*=/O=\^];.*Y-%U%"5V/U1]/(A6Q0GY!O9NO_P"OUK+
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MC AEQW&/UQ6+-9R^?E895A+$J2/X?K],5G.SG9K9+7N_\S:K6GR*4=%V\O\
M(V;W3;?2M,N+D3AGDC5(>>2S8SC\,URJJ7<* 23P *US%<:W>2,)!';0C[\C
M82-?\3Z#DU(TEM9$+IX9\<M</\K,?]GT _.J6ME%:GFU)*=1RBK)_@6[#0IK
M$M=3.OVJ*(RB%!N:+ ^\_88SG'7I5:ZU7;- UL9&\LAV>=0SN_<GV]JWK93<
M^$'6VN8OM$WR/%"<2,0<[6'?(&>^<5Q[*5?:ZD$'H>HHC9-M,Z?8RH0C*]W+
M6_Z%Z\UN\NY?,40VWJMO&$!^M=!;W":EX8>_OR ]G,J-\ORR9&1P.,]0:Q]
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MXU*]X0LDM;&#;WL]I(S *^1L=)%W!AZ'-:MSINF2Z=;ZE#--;Q2N8G5DWA'
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MQ]U>XYJC%??:HH[2]<M#Y@(D)RT8[X/]*;=6C262ZB')$KX8'J#ZYK/!(/\
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M2QI(67./EX#8[TES<275P\\IS(YRQQC)_"EVH8V9V(;@*H_F:L65@=3O/*@
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MI6G2-"(WO9!_RT63:OU&.M0Q72O!(DD.Z",%R <')X'-9XW'(%63(L%A*O\
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MY',,78_5NWM4%KXZUF$[;F6.^C8Y*7"!L_CUJ+QI=_;/%=ZP$7R,(PR#APH
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MM]X@=_QJM+IUS'!).\1$:D!B>Q/M^%2/82V[QEY(_*<<2*X(QWK4U'S)]/\
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MJ\]UM; 6VM\;OQ8TV\\0VNYHK#2[6.!1MC:6,&0>Y/<U!)HUO;P"2?5;4/\
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M')/K3>]+Y;E"^T[0<9QQFI$*29,K8(3"X'<#@5#ONP-'3)],CCE>]BW.  B
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M-V5[!0G&%57>C(KV?9=2)!&D*@[<*.OOS6OX;UBXM]7M+><B2,R!8]XSY9)
M!'Z5S]TT9N7:*5G7.0SC!/U%3:>(FU" S3"- ZEG/. #4RC&4'W-859*M9/2
M_P O\C+E_P!=)_O&ECB>:41QJ6<] O.:)3^^D_WC_.GVUQ+:SK-"<2+T.,U4
M;7U.$DN[22QD6.4KN*AB <XSV-(MY*EI); CRG8,1CN*C"RW,Q #/(Q)QU)J
M.J;L[QT0>I9:^D:QCM.!&K%N!RQ]357WIRE5)W+G@T*I8X&2?:I;;W!+H/DE
M>9@6(X4+P.PJ::^EDLXK3.(8LE0.Y]34TK1V5KY";))I #(_78/[H]_6L_-6
M[PT3]05@I05"8P=V?PQ245F,2K5C:+=WD<4D@B1SC>>E5JU+W5([O3;>V6!8
MWB/) &#QBM*:CJY/;\297Z%&ZA$%S)$K!PC%=P[XID1595+#(!Y'K5K2[$ZC
M>K 695()+8SBF:@EK'=,EG(\D(QAG&"3WXI-->];1AS*_*0SL'E9E "DYP.@
MJ*KFGW$5M<&2:,2+L8!2,\D<528\FE*S7-<8ZEC4-(%+  G!)[4P'FGQ@M(%
M7J>!BI FN+:2&7R_O9^Z5YW#U%3Z3IKZEJ,=JIVY/S-Z"M"SD2QNQ+)T_754
M'.^R/0X/@00-! TN80A.L. 2G,'='0*!P5V"2W#"X.XZ#.XNP=W=+;B[_?B<
M<^[]GONN]?XYLZ:?KJ=JU]Z[5O=TO]H'\NTW:.&7KP;;-,V->C$=[*A?T[==
M[HI_B5MB2*K1W[*Z]IT6U#WWMP:9O853+JA/O++?6KH'M\&L]\S#8Y;UB\[0
M+$7=$JE,>,Z/:\ EKH/J-&S+3S+\DW3)H5D/+J(M/YAN9D)[I\.06&3'>%ZB
ME"859W=0]L=W84BX/DM.\; Q8[7$$2-_GP)!^R9IW+N08FWSFW_N25:AD-3M
M_5Q%]<ODA+#VJ8" 9*\,4QBY#S&+$B9S,Z[5LS+ 1!QE.&L/G%4"$5J*&PG?
MHYC8\QD$&K$RVREI=:-5^O)MX!S/#6NWUDUF!\K"%F4_VXHOH2FK+$:QN#.B
M'5ZH63*^WY[H;E$@AFA,V26>NESM3>3&CVRL(!V3?I;<6M>XR69Y4&LD\D0Y
M9K:3_R!EP(9@0T.25]%CP>J@C-H0/[80]#3NN>4Q5:J7581M8&S.?97C8;58
MOSF1DLR3'!VI8_W6E[)^6,/OZ&C;Q5?5'NDNZ!"C!VJ47Y<&8\+[5GR[#^NC
MG"A%'W;$QOJT%1L!<MZ,E*.-(NJ9LU79Y/I4.K\O/*G\8"2<Z?!0[@J8!C<5
M-#="W%@:1FQY4*Q$XF^FM)9LYK?.^=8R\VTE^>GGO'"]^VEN_5\ >JL/H(.>
MJFZ/+_]GWC-EZ_' R&-BD^3NMM!:%C(SM"-:/*Z/-=1MI.E6^912Y8SH07"K
M8\QED;S27TJ1+ 9AV6;:*)D#>J@:V<L2= ,GW/W9'9^,/%D)* ,_)) ?&T[B
MBKOIN:6K;Z?&?P7+UM8TQ@NYV).+Z;S:!V*::#_B0FK$*36(@ZVZ.[+61@=:
M C:0);PIE>8&>NWNZ+U@9>;)58?Z>\BMH]NLIYM*#<$/B9O$PJ-?"9S '$2C
M3=XP2 :C.2]<+01Q9E.F(3CTA2YV5L#]\G8/*NVE*J]EI*O2>?,F:KVW19D:
MF)XA-;(I T$B71_((BJ7P_BIXHDQX2/)1^C^YXB(2YRFS=6W/>MSNU,7 =4%
MZIL1>&*/J>ANI)#<Z [+=2,2^;8)Z%HXL5+X[LIO;>&KN*.1^-'M4V+#N%_O
M"J9*+P]2:-#P=GBC,]AL4&<*%SOX'SOQ8YM2?[_5KIN >+AI'F^$:LP%1=R?
M:1?*98,LN8:%!-EXQ,.CMW-HX%-3+]2!,S;;==HN]<98:W0O $=T'W=5//KH
M:@./Y(\(%Q.587;N6!,>"=31I1O@I%)XV=]YDAV4)!:)#\L6W:,0T^YZ 0WX
M$Z>O1MS8LN?Y(>MI>0'':CIW)J<2_$][P[RMV2WQ@1\-MGX6,[/XKOQ&0W&4
M-(U6P(PGQ^@I'6R3#]56%\5B(3!J8^ZUL4CY: ;.SD7O_Y*PDSC^K,Z]27K5
M4FAQ75M[H:G114JTQ=3"$MGZ=/ &?V7#*909M:$=UI2!YIDB*UW$-(Y,YG1[
MU\*FRVZF'->#4$_[,YP-H4GZSJK<I1?^K,C0;^<T+?3<4B?]]DWR3=V[9:OP
M@,[<WRU5:NS#<KNR&3\I-$@)B+]K>,RP;+<VP;<)3P^OI#&%$2LNY+J$=C'!
M]9,\02F<3XA^#::+Z6IK?D4M$LOEE;QK;CY'K%&*(Z6FV5?]9<1L/EQW4HT)
M^F%Q@!>&*N*$^K$N34B-&OB;.W_9HG(T5W,.AX+<U'*WB ^CSTYU:XHJN8<(
M]"8V8!O#EI^.A<!)G[$N+2_IVT/;+@P76'9LV:\X[N!(>4%DEA!3Y6QWHG4$
ME3;+7^CZX4R2%-W<C.5P/^,96+9H/0%/UX/<;\J',G-&#/W4A68D2$?AH^+G
MT-Y;#J-UH.$NL/9+D9.BYF<_E^O><G;FER9.#LW7(.FR$K=$2T6?DL!J#BWI
M$"+'_DM/Q#&,5"$]-IT?2@_>$?_T8_PLC@N-IB7-VI0I&BCM\R9S\TT0S./X
M4QW0;"*MPB^H8_$@DJZ[9C;:BD] B3,9L.1>-A'0DLPU0:[2$ZE#SR3^H]JJ
M?E2SJ1$OHZHM:#DK4I4G-K1O<T4O/:A>'RL"4VWR@5;;H[?12)O<+//^JG10
M0_ LDI2(S[M/3GZ7T6TZHLJB;@^;YT_BW58O4J:]K/%7TSS/R$8V:W2(NHW1
MLW]A?ACN]&)NNN,X?B:][XCXYF7)WA512M)0! 6:G#U7;IOMS5O*T3C\.?\Y
M[]1)RR/2C6,DP M F_R;?$,^#%R96C!\F'DY-Y^B[ J#E0%_#[NK&ZSV(;UC
M%M,OGUE5-0U5C40-"(PCI0@O(HXRXMGRF&5S77&Z' $@X?OP ]90QDZ7ZQ:<
M"@?AML2C@']V4?&5ZY]5<3<12<%:?7^[9HM0!CXVMK9ZF3K63G39CU=^V+<5
MTZW]I5)?]SK^B15')1)P9)*%%&Y.)X](G!N!F.5Z$JW)5?07;O)NH,7$QC0^
M1K +KCQCG+\]LA>"OZ=,(R=V:/&1HN381A4?H:PU1AI;$R>#<>A-FO9>1BYP
MCR$EI34Y<9=<5E >0?1NPW<I1?L\OQ*5N!Z#(6R#3?Z//L.@3/9\28+E@?.*
M +Z'+36=]VF4ADHJ.GB"NJG>6@ER%S!3[=S8/P&'5'+X_K.X^:06J7=Y56/]
M2K%WL,(ZAY+DS8]+E!%] *=V?L0\U9;ZC^J5([BQDMWEO4!/6:O>?*T5BS $
M>]Z*& IY B5N[E(OR07.[P9""'X8%JJJQ74>]T2=SK\J#S^91/O.AJMG@L?W
MW;V#+.>:1WF%P]A3=SZ(VWJRM3_2QYT6^3]C\;+QF8JJ,WPLU7@C<1 :Z6FC
M9"7LD="4V,_R2;:7HL<=<Q)WD)-:0"5^6>X>2Z6(N_;IB/W\!?"+/.38-)8.
MQ-N_: Z<52_6&N)[:YUMQHCS[+B/@89O@'V,01;A0%^BU[.8E=K9Y;M5*..E
M:B-9'SMG44X4) I6ZF#YW6O[6$RO'%/=Q&X>5"1[H3Q]04GB1N:8(24.("[#
M\4F;0R0@G@6M-?%*P_3 $<(L5+#<][S^[4!'Q+.O,*G05.(,D<@X3B4+U,+X
MNYIJ?[FXC*%T;E0HQI50.SSI+4%)V%YT6>YYI:'.)[.''%]E'?U^%YCTS_8J
MWH3VR\O'8EUJ:5T7[<@)Q/.?,]3H\^3&?.Z382HYHXSW<4H9-=!C]R_17X*4
MGS^+2P=Z5^!X\_MLPCD\GJD< ZN:DY+Q<X/4K7%(VE\ 6HN-9P@<14\QYL@\
MEG;-7^:W&2-&/,_?T>,]2,>/T#!!Q" K3JO$P=XB?X5P,O=57"!UQNZIU6M9
M1%*O:MS.^<F3K&N, )>Z<2J9KXN2Z9/(/K_=XP&JS-3[R"*2(?]AF0U5FTWE
MFT#P?F. >UT0HS4I(&:Q?[NJ< TB6$CP>)"P[ _A[M5*=MR8W'&Q9%$EIB8S
M.SV.;.KEL,V'X659=DHR;:+KN%BZ".0:/'_MO^+"G3%7EB^[U=H5.8_+KWP!
M2-7^=/#MHA",(HMS^/#G7">7 N1LD.4!D95%[63".(P.K@$5=9M_&3I^9,L%
M93?I[7..]9I8^0\2MH(P;EROAAT(IRHL>&*K1&PUA<]VR%JBY$]A)\$H,YRU
M6C]!6PMADO6C*Y8.&5G#=C)YQ)'U7,/X$DIY7RRV<]A[IOQJ\*FS6+4ECZJM
M^%P,NZU:8]#],19L'IN2@%$<9SG?I9V!-V]*7%U$HG3'K?\$4L9SO^G@?-
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M?J G3_I4'-W]0KGL2[1:$P\M'S_8A7&XNZ23BZ>GQ7DWE;!KLDPNQ8N*!@C
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M2 WSEVSYP&)<Q4WP3?$9C1NNQII93/C43<S 'AKZ<"4NG&H02[H%F#>,B_W
M;Z_Q\#=E7]^;FLI8F,<7%MU<!?(3"CEQUYLB/1 6/-Z:DG#IMRL"^+LIJ6U]
M^U.AS862!0T=?89AE&-,IIV=*D5[9Q&O[Z[/MT2U6U?0#T![W4*CGYGM5=Z5
M/,FPZGNE(#JDO?3JF"JRHL,5R@9- ;@?RIKO0BF+0=5?\ EB)IJ;]?=ED0)T
M=-B-;^TER_0FJ#6\D%UE3<)!:,FY(71QR^>F2JZ/]",U9;CR#DZ?S-O^SOC6
MYD\I'++U2)+E&2OE;JOFD?&F71KBC^\X@/.BJ7]9.4%3FL"P=49CFZ3\[ZIT
M/.&DU:XYW]IDA<%GY*U^XDQZG"L*I#Z;!>>EAO9;)]Y#5["C=PO7J\^?[4%4
M+0$FOV($O2-]7$KVQ0L$JW?.:R+^2N$:%58?>:P\$#]W-;V5GVA,P4#W-M4D
MT=:LUY9\X\<H.30)/_?%\CX]S>(]VY\)B2+:!@T2Z0]5_4B,'[-(ZHOOKUI+
MK$FMA,V9'(*P8^J9^=$M3FA;01[Y%JD49& ,]]5?1>HJT^_RV+S6C66[HW%.
M_<O) D5/J6)99 5F+X1^;(P"S0@$_ 73E&CFU[#3$7&.I&F]@9J,VT:"*7/&
M=SMULF+V.7[5VTKJ,5-^;BL;9O$B\<80"SJ:3)\BJP)F*2) I!""K5!A8::L
MSG1LKHFT-1M:A@LUKWS!3'Q[W["]PI7O388U701L%")5OXSZ=#6ZS]^M'Y'<
M;TVY%19<"W4<V!6<B"V=Y.@:C3<'_0VV&E_8X.I"8.@ \;/HHE>YY3,^DRZ.
M.H6HNPO M;?W'23G9?4:VUH++'C]16,[M!#\L#"0'+8<\&[%H9%:OE%"?G0A
MOX:KJ%=W9(!.(7,_#W9T?NQX'VL']H*//!\@R>_VC6>>IVE8\$97F:7.M5 R
M=P]P01JJ7SOBZH-ZX<X0B<\R[MJ:U-H;IV,/]$5T(+C 9-6[.$9=AZU<;*SJ
MT\:EYE#LW<FD>N.$I!@]"H3CM,XC++RQ>!@%]&NU5@Y8WS745P;F1#I1 C](
M+N]+E-6XY7)6+>C"AIMAQ'V+<5,7R8?5HX+2$V4EV>DKFE1^WUIU?+:#>U@.
MPF>1VG=QV6EZ/M:.GM.S0K\XY#S)BGQ:+1FI +Y5Z5O$0)@T;*CG\?C#1-RS
M:1:WLV9&?GFB,+]8\^<CD1S!!\Y9@HT4JS<#E<V! 3_@6133V;1K<%K0\55C
M\ZQ+()?#5N#W)6GML0YSTQ21;&FMTR5'[ZI<X\],28HIZR[D54G@!&J$><VU
M;(#B/3)'BY$.>ZJRJR!KNC-K4*]J)=X"LO4+P E'YIST'8\GV&M7K:)Z3"[&
MYD/"B,$%EZ6!;Z0@88[YM0<XH+(A[;&!*Z:?DDX>?W0[6O/F&@KV9,?DCF>W
M+[[M$3-3FC:);23J:.;_O%;C+OB%4EF^?.SX2+?4":\Z\8UPH_5HGM!3Z TV
M4.VC@FY3ZEL1_SMB9<<G)D]Q6N=!K#LII LB!#^[WEV9#/&FVJ1-!]*M@Q!$
MG*W9KSG,6[&9N7OFRR3J04<GCOWZ\BST[) <MT2@Z!-+^J]MZD\-R,TU4V9/
M<Y1#!M!(GMGO:TV\U?&.];% *;[QEF>%KK8Z19V:X4,K.^[XB2_L#7<;7 2C
MBLH2'Z:6L.16BUJI,3"^XZTRW@M2"B,QLC>IM<5?6$[^4<)717=;J[B$1U 7
MY*,"VH>3"F3U%K3HIZ@_6,75I U)5R)24>DW%[N7M?%-_?XQD7(5+,E7$,YM
MY.SWJT!?:YQ;REIIO"JR.K-H7M">WU,F.,<MS5B,8<@6<)#<XF8[WLGP :ZB
MS57"84]7-BT];GVKIB5=W"6NLH6U?J_;S#5#U*]SSXF19]OZD-IJO2U$XUPU
M4/]K,==2LDK#Z?,,X>KYL4-%9Y%C]#*M& ,G]IQ9V;8VSQ"+UOZ[/AKMKWT1
MOR_(";IB5C]7G# 1[J_G&?JXH^WBN@^%/8A7QSC(X@^W>JL^U_R,6J267<:4
M4G3<_@<%PLUL0FS>>6_0!6=H*=KNKWB[@6QBN#U[,.*R:'M$F5<3'053B)9(
M%;X<W5:W*OT<940UCI>MT(FU?/$7_#E#)%TE-7F[(H;]NW4:,L&*N$.O5E7!
MORX3LV>)MM$JL'64N=K,MXZGUCT"E>T=7@"D72^ T-P70)!5]>ACN++W&O,+
M8 ,J">K4Z4LH#3_5[L"I%#]E,8NU=NQ=-G)'@59'YN1YH@B:/J@:#&YP=Y!@
MS/]Z >"JO0#6,RQ? %7#.6 9N:-._<J(KJL"I\^+8]ID/$NZ_*/Q^#28I=T
MXU"?-_(D#659OPZ739$$3Z-E7P ^_T20\TS0.NE\<BNY,_KD@?%,EU>[/#>:
MD9<Z$%U$C50//P&1UC0.HDWR CE4WV_"/!&\30^$7Z-'QEF]11.\+8Y]'KG>
M>3T7YI"Q^HK@^"_$Y_M\&*QK[&[0/+?;D\CF@7NN_7"T%,2DXD.XA$:FWZ+H
MW<4QGW&7F/\":#=\ 70KF6M@I-<=*>74=^2;MKYN*<BRZ@60%6KS^([L497L
M=-C9^Y+E?X+-11RE:"D$W,^.;5Y;5I%=L/S7+FI'!<__]W,F1GJ0$#X[C*A'
M?)N2+SST'M?;]$',H.N/@PGQ"Z"W_#75Q=V[AW>XERN6*Y2QJ7"^%H#V%X"O
M*I,VN-Z)CTUJ<IV#\V-=X ?QP'40%U;TXD4)-"S)&K\JO<6G'?=2=O3P 7=*
MH9<ZQ!K--IS.,]7 BZB8^BFU^CK*XB &ZNW1AW@_H0;6)4@U.EZ*2H=U'O,&
M(X2C70[+?R>B>GQKI-EO&?SD"5V1>"V&X(Y1Q@L [I]B*@L]\(E9/JR?,>S?
M]IQ4AK\ > K9DRUKH][53R/\UM%.^3'6W.0+'W==:-PL>7EG-<22X/ G<0O]
MZD3BVKK:E.&G!#=P*Z/JM8HQ_^3C.8BV[13?^TQ5KCJE7I.,GRX&PHLV58?*
MRB!-C\7Q'8X?;J?5AZS**O,%D!3I_:]\<[\ S(C,!5X (=1<+X""?PJD9C$S
M93;2(:^E0SP[;O[ HYG7'.UM([G8QSM</K YN5/8MIY2<O$"H'Q-[+\@0?CM
MY\4HKL4/)LMOFO#D27#P@FZ>!ZLQUS:5:H.N0<ZD&6;P]U-U@E5#+N%!WMAR
MW1\M7@ YZ(A/5ZIX$,\N[0R>GI0MU3X"?EGI6BZ;-P,N/;!^O<V%EH?7+8UY
M#_4*/L._;C#V>7@FW/YUPR^ NG^B5%G6:O]Y/91H )W:\D")XIL=>P&<#M?^
M%W9R_CLE*CYW6ZDSD0G.C5;]R9+^D P:_I:#9>_UE-=6^FN4\I]Z"#VE6&'H
M8X[^9X7B@"5@KB\42OKN(JRI-GG]^@18\09:C/=:6;0+?>%_@/T"&.OF_%>
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MPW\#0PEQU/#>-U4E:$>^*ICMH?FXAW=V['7=^/_"6P'9?.=XM/HS%H%MR_/
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MA3DHN5>K\JE2R2GJ'<U>%5VHUC37)2@N=N;EQOG116[-S,!@_6B5<_.5L,;
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M6F?RG)'QY;KI>:2+,-7K",Z.SE\B&@+E@T1B3, PV'-3_\6'D<J!3#Q*O="
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M][G?4K@VD;_DHU<)3@D]A/:S<_7?1*@(:;7\Y]O\"C+E")VM=T'.LZ[E]?
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M=_&)!PEJZ6=O#&[R4QAQLR_F OK(L@X;;YF\54/IYVGVKI,1T8TQCZ*C!!@
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M9\LA_?9,),KOW<N,T*6>AE[4$8E:,Y%.ST/2?G =FURN+_YB:VP33[D[*I#
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MN8LB006R)SH@!V7J;O>^C7:#H7O0%AG\6RG5?4T&:CH>]--X?:J? "Z;XP#
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MR;N'?=8$5?_RVZV_OE&+VOGM:*!V$#]:&<%"9#W)MB:D^#;$X,E(P*?HP>*
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M4+:#5>'C$:NPWEEO?"66[YFWI&8&^\E?DBIX:54=J4 =A)Z2O5Y;DK(1./]
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MB9'?. ZB!>9>@]N@OX IB=,I :$#0'2(M>W0S#!)XS/SF5/)(6KYUCJAN(;
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M0?UJ^NFW@AM$%L^ 1LPM0ID0(:IO2\TSL,HXU5+I6?D0L>S<8K:\877__E9
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MV0(D7#Z9" 6ET4G)O$UJ/+IBX @+11H\5I!H((V2@B1)-1F"2T=\4!9;*C&
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M&\Y34.++:#[\1H5_2^+ _]M:TBA$^L":M\YA45M.AUEU0M#%'%6BQ2SNK2K
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MK@7R *1' (O]SP',*PNQ#P$?&^+$8]')'(P"'_8@DV-'/*7.6_S+9A<U!YS
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MF=\?GT(V)J.LC8!%0/.0\I7S*"$5J^ 2&^R7:'^1[+\G6,#_2+)_"/:;7-,
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MI]9+K9+7):]C8L>F:=W<>=HYVG'-)I(]"C;3R4"'"=>?>6E][5M."$\(CU$
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M2"S32&&@!\":+)T<2;8Z;/CZY&9T9[&\!$R_??SIC)EQ'C8*X,Q HQ759Q0
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M+-#,V=YYG6C?G^1[5J[$>O\H;9GNSLDEL'2MA@+N)J#="_S93&<X% 6L\J.
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MS6;;PO@/GU^\O-^3OY.XO4/6;I\I_"&X8W_LQ5>: _NKK[W]-TW6V5-S:SB
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MYKN27OG7IF:O%*23/3R4/"O*]]&'47:79:$ \WEZ,<#>;ZQB$?.-!X3N4K<
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MUK'DE5Z.VAX.P.7ZJ)O$QC=X&80@I +#!:+J$5;ZAP<??.2*;,^I/$H*:%7
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M)0$C5=3>HX"=H7,4($.Y\+_V BJVB$:_4'%9&U^ CB:5>D8UHR%#U2J_K=B
MOM"[NHE3V>T$9H)X/:QAYPI3RFK$00+H_LIT$]I7CX9)M_W8WE[%820>Z% =
M"\WES [=C5)' 0U8$O<4S[U/2XS(NN8YP'=FX&\[Q20#OZ;.;2A6U_+3<7O\
M:#5! ;UOQD"[U"+'%!@+H_^#-S?_Z8(DUTJMX\+3LL2^LWTR3N1L+V4-@^U7
M]1L]MZ=QG7'1P;J0 ZN[= .JD/'PYO;"3C9RBG#<E/D8:CGP)LORH.Y::&0+
MRO#(A$R?GG"Z?9V%=<K>6$]'C<OKJ&FX-\H@\>0)!]9G.'C9X(#2T^Y*3B-@
MGNASJI(1]W'%VBO1WF';[:)W<! *8$;G@V<WZE# :%##Y;_]UOW]N$=AU!^!
M)P6B[+>[I"K<?I[LV//E_>"].3;-KLO?]/V= ]X:3BA6G'^ 5SJI8JN4X(2$
MFM^KI@E!+]"HSXJ=E8T379GP<]-46>UWO7CTS_"7FS ;(4N!@TWSW\YO&.K%
M<,<X$7K&JEQ\I)(+#JTU=.6>@LTW:?Z%S(O^V<:@&!#T/-D<@A%>\RA@DQDM
M#N?]DLS:F?7<7=?5,(O!O9PO6FYNQ!C-!TE,A@@!=;"##>B$HAP%M'Y  7<(
MG*,&8\)IP7LW4_5FUJQHHPT1MB?",(, 9J.ZG5ZA+T(E7%=/:\Y24A>X;A]#
MZ?VJK*Y<T"ET>DX"$IL=/CX1TD<_ZA<6,'TV><A751?TINFI)FX/E%*2Y?'!
M-_1T$_]/_JD!9[%89&3G.KZC_>H7*[[LPA=F$& ]J6#@[K<X/M5[L+6](/Z-
M5 '_(:X!)/U/9:OEN[36L-8BVNC*-.)>J[N70YT;ER-XQ1KR7CV=#8AG4/7Q
M^+[][9_8KU% ?>SCFU+2A,*^&SN!KPM.TLD42S'15% E* 8%O*QK^5(\R/(<
M1K2C>V]@=G;[+;O 3^,G.S=O*'YZZ/=\^$K2J_!2>SBDU$_ IF296VRHSRGO
M*8N!7H1_PD3<V#M)VS".='S+M%XF+\UF<&U=EZP0!3\%U;GXNUX&(\/" A1P
M]SYXYTMZ@O,+RV-_*</0Z(-2 <U1>9P_1VW*U&E=Y_8S5[S,_*=D@[9$UJ7W
M0BI,9K%JHZA R'N5G"7!UV_3SF<NQN^6J.#G/,?L"D&R1*3UI<A3A/\EX^,L
M,O[0*PREH5=+4%4YC9'C;FK3&KEPO340_DF35,'&FN.?JIPVJ>$MEWOJ_C+'
M79,FUE)*Q8E43MN5YKMM3N#,<'%?J?WEQ[&/?F2616TY$]#P-8:0+;^-;L4J
MJ&BIF# ]+G98K \77<#VATI]I7Q5YPAT>5 ']\WK-14WV_GM56[N1DGZU,[U
MK"1N6P.9C3HJ:3=(S'1G[A6M];+0?M 2M6:F)DI& :1/S??X5M;P(+CUJH\:
MW2_%&$F$8R?3;)(?3V_5\G_Q2./%=E:8]=VWQ@2C[?^(70T%F!*E(6CL6B 2
M<+X-<#LI"K#^N>%;OP).2&EH[$BV2M;-&,'03KRD?$5HZ+3E>!<%_+0=I"!8
MR%!UX_)0[^.YK<84;H,/@N\9X#$Q>)U2&OS:<&91@W Q6=/)IW#X,86V8 H*
MS8?$.2\P\=OPFJQ,;":Y+%BX4VHEG)E-3'(P[7-<GH05)OK&4EI4U! _E"'G
MD;DN_ % ?JT^XOZKE^THC<_P]Q^L1;U@27%?563&TU1\1J9?IF'XL7HL=B#]
M[B/CK*CY$XS59JRFB1.$WUV>2(CJ6<@'ZCVVDGP5NX"=OB]]Y9VXUP$$2Y[+
M37Z-64O/A6\NR'G9@)?V5E2/!IN3[O$X8)A+N8W=BF&.B5YN<[^(DO=N IP6
MR..&#F%!0BT&\:3V.55!-MJLA$YUKYA65P/9F83)7C.\E8ON-#F,.7C!R_)#
M;5JU9^9IB>/:E[CO.J9'PK2,+JF,\TU/T"&% [R$SO@">Y? \"<M93[#Y7,7
MC#_]'/B^67E\7<CE.S!N,,1M00%L>6THX'3C+1HKP@XVL0:0O.">YL_(D[1>
MNWZNB3^<Y::U^^R#$,LFO+]V75=$G((_F,!6"L%0)100IYNMFW3-C *BZ;60
M]8K7B4W,=84^3R\E_KK#1EW%RPYK-W&=9N;V]!$ UD\->U^PD*%NZ^TUQ%L2
M)8:\ '<7RPNZY,*SE6]=?6\-"QA'N&T@/-"&0%6BSC&WCYX/'!R=MZK[!GNW
M2M]R+1)6R&/:KKNE-/0[-NV7$LRO')P12R.U?:E?X<P^$R_K%3)!6UVTVI4-
M.S+HAVT2A<ZO=2/Y_Y*(7RZ<Q8Q9W5&J%+%XD[NOH-2ZK\+!ZJ>]#B)Y5:5V
M2PSW\ 1:IK"LMPLIS4Z42[Y)I8W?(:DDM$/]5JH']$5)C;OF!K]TC]"J'_6W
MI@:HZVJ<+M3>_KK&EV_UK1Z5DO]%T _5WAZ( [^8.E[97V(L!CJK8^M J^^;
MX<* +M@0!P5<)Y"P(-M<P'S2](A?P])6NR!000&&7?J_89-:QB\0,_U%.&[.
M3[=>L=4%B>Q4K0+(*L:SU%3EKM.R'H20":S(30>*\(5>H8"QKSSG[&'6>:HP
MI5AV5;1^?2DTT?C26-.Y<*.JA*53Q%VXU]8T]+!AA14%B.5W]9O=^;&D(#$N
M^:1P"MR##K^^+2E>9-?<:C=0@',_$L&(Y,P*7_9K(;1_7O%_FOO.L*:Z;=VE
M""B@2.^@4@41I H"$90F0J0K+2(B(DVD-V.C"P@** *A2B?2.Z&#($4IH;?0
M Y)0 X3D++Y][S[Z[7/V<_[<^YP?/$]&LEB9<XXQWC'>.<=8:=->X"<#K<9^
M%[E1HS(N SN=8JUD8.:)=_!!'&QWB0S@C;&<@G/50:%V/E?U+_V@=DJGD)5Z
M';FP=<4(*Y?R6%_=6RAG-LE7W.37U6V_5O785]D?INE^L&]2"3-QGI)#NDT*
MD0'#HV8#(T\X?I'MH&QS#V\7<O(<5KX2LC7<5R^&_J%66.0++)UH0XY(OS_0
M8T.)J02GU?N%MR:?DSZGV+U,&4PLEUW?^6XVQ&H3HZ\MO&PH\BSIKJ.1PV3G
MD&!:F.B9E'_I#Z>??6/:_SBDIA2U^G7E423>SC-VLXDR7/#EULY.X485).2!
M'&[\<=O,([_LH8F4:M9Y6X5&J;.>D74E8W6 .F[0*;X)C/+EHQ[%>]W57.R9
M$?HU0?>>WQ\<1I_"+>K=3:FM=EC3TXF^UNQVNBWE<MKFL?G85V\7!S9':ZK_
M3W$\/1GH2((<OKD,W[(N)%72_PU+4XZ'89R?"SV6JY :ZXC_C'E0$!(D!9DV
M9@.U1 ]_MDLZI">)YL581L(+]&'V/,Z?R<"Y+I>C4_P"4TH[_+7KKWK8DR3D
M+P"NH$YG<UT(9LF\I/GUPWT^HC%WS*K(;/:(7\?:TI<\ZCO-J1Q91DGGC<OH
M"?CX)<C'/%ES,#6-XGC^>B^,4OS3_8 ?6YD9?.X!%Q^S_[N,TICG$5=X!.\O
M,?-^FVL:GN,AS7O/#Z!42".W:?,.'2<NZ#4OFR@],G +V" #024M^_LM'O;K
MMKJ2S)"1Z+&;>V=K_#N]KF5[EU32^23MM>>:QA+D_"98%X[1OV$H+<8Z)Q34
M(88S6HI%OE5X7C9U-?@N"7"T4?/F7*=D2<K#5C\*I'NV8JISO+/UCM.C2]<%
MID6$7YP2_LK"DQ4JXW>H78K55;M8&.NU=ON=!G.BO-IU6P&*Z.CKW(5_QTCL
M"S09F"LE0$BUZ_ M!LM#P ?1ND[8_8F:?+\G[F/K^X?DWD^ )OVS<%#?Q#49
MB0LG*7E ]Y?Y-IYLA6W^#4-EH:$(S?\LC7F=GV=/JMXDU9"!U7"3W(*L?6SO
M_CH9*!8W2_FX^A<JLK2N3#&Z3_ ;5WY-Z%F;"RPO$1KGE6Z#UAF Z%^100;Z
M5, ,E!O,(0NU/14F+X=Y/KL6 "$I0]8R$/M<QKF;X;"P:J.SJPY<35[2KA4U
M3-AU0WC3V$_X$A\XX4AXA(JVYX6KG:Q6^"498P?:EH%+XNO\)D:?*+*=4Q@F
M\P=XM"<LC\"SZ=_TL]+X9LYQ/H]W\W!S8RG5;VOIDJ8TQN0(AVU*!.T'!N^L
M9)B06!RZ*B?F:W[^JN@54NC2.'MBEX-[!ZE?'V'[M5)3:\),CM(6R,'4>[?Z
MH%^DHP6&^.O\KOD%B*<_]E2EHT%(:-"]288"=NS,QY;+%N$,$F7FNC ]U@JF
M&_;STH%AVOI?/DHV'4_2YIAYR=M6QPB&QS5A(SP3UDNH=XU-,?G;]QU3MZM!
M4B<W@N@[/VU;U0XZB2ZVF$(X2H?PK$EVME?[OS 4Y+==[UK17K8J^SM,/WJ2
M0(I/*W7(GBBH>B\H?U&!&&B/CO.W!'TD0OYPB.2A;^HIV3+HGJ.0_I4,O-EL
MYMMBC2(1X+C<94S4:=IE <5\OUO &=!*:'#58BX/HX0/]) /_1:)PLGLH,F5
MPG>;054^L??M0>0W;2SOBBD]]BRZHT$_*[:PO[W^9FKC1!T9*,3L&>DEA%7U
M![;KE:F?$O ][6/: F%XL@\+><,JOZG*%E-01L^!-$:R$3+) #]H'&C*3%TK
MC9$WB8\GKCVQ@3?9ST+WZ2Q(-L2+>1B^LWE7+,VF6164(AW.A$W%>BI!G SW
M$),N_[SL09U70\6N67Q@2E5MTI=/22^]5GR0)Y!N!%>0M3E5'*P3L8HY E[S
M@\*B!=H5J4.F+[VQ)$UQ35(U_-;N*$Z"!]XQGPT. KILJ..6)4UBW%88%4FK
M4))$IBF)@;<H!P'+@K7>ZP^Q.*]H>1[.77?:=Z_BJ&:I>_VH_ANF;=I=W4X,
M<H%C2^"*1A6/1K*:&6.9]<UY)0EP=#L)1_+8*D,2?1K_43O:+4D&D%&',T3L
ML@.,L/GZJ!<BW\%=V3%OS3\T.RVL9>=?V[%A869E29$O7>S=X-9/=DUICJ^<
M[#Z1JV#[]%C'\KZIAP4R:INV3J+YQ\1P7=JX8*?C@5%T6HSJM Q"1(7HFGB'
M0H5GJAD^$[WS\&?<)(?95="!T]Q?O#SLFWA>-H2^-CU<%N+^R/+1ZD370E'8
MLY56C/(9(QO>Y.'"L!=*MFGX"[ G35K(>1\!(7QZV,RMFY?9 IU:'WZW+?IZ
M'&CW'2]^W9ZEI3H3ZCY\B=2O$.J1B>@^NQ?<U=!X7PZS[F85JP[X3#6Z2N*D
M:5\%N92/NUS<]?()OKJ#O%E(,0U:<F@_&1A66R0#&IQ@ KBPYD"ZX36U/4$&
MDO3S1M'$H'44%H0?Q73+<)NY1;PD&!X%]IWYMAE F@:)5<V]IIEA57W%]"YW
MWL5&:OLY(QP9R(XZ_$',K0<)[SES,K"_^QYDP+(=%2K%L%/3U"W5.U"BWK8$
MD0:._U(1LMUN4)"_<HG^CC-(+<QZ($<U1+D=>R[V*JL#H+/$6X$>, E:[$LH
M239KIO>L@R'AO6Z8DQ5):W*&@G^\BDZZ[Y5/X8.R6@G0JO7BR0#L(G')_FZU
MAW!/V4H DSJSZ?EM"H$PA?2+%\125_*EZ&?NH<T\0I)[64TPTO=)RSY[7*-E
MH@53^P<2^[_@6]1?0F-NNYN8O*OT+K#6Y.&P 0;#1#)D8H;_SA18NKU_=1D,
M*$D(%GYRD!V/4E+QJ)7.%[]T05WJW#,-J1>1Z7\5IR^:#LCH4G%URUM7R>\4
M.4;'LJK[Q-ZC/:OVZA1749O;=1"77VU=FY!N1<JBWBS@?L7L7'Y_T^5!K!#B
MNUI$&<]7M;U$#.IG'>M7&65HBQ?:L1H57%"*=;E4K'LFXS*MG ;;8W7,B<3%
MBCJ7/FIIC*6$Y9#,L&.I28E1--[3+FG&,YP[33&=9:(OT8ZC79B?2Q<G3I1?
MYFF)&QIUUW63@=M\(@[:8T[>L06,H9\=[(3GI^^CX:"],*NP5N!0;5#:=JKT
M7*O0->=O\KL:#RI5=Y]=Q?Y_)0[JU@Z\$C]*N5I+!R[S*GPZ\>+DIWH#K17J
MHGPR0+BGPG[T^!G(^A$^0L56G42WTE;GZC?32\F I0_X1P9VU/.,6\>(ZKCQ
M9Q9QM>]."8ZC*I]_-O+UXT206*%!D,4=Z %HL3/0.,N02*&(>L'=)"<6S5N#
M3K)Y++5%[VKIM.B,D/S#@ROOW?M--7M)<F0@NLL0A-OTHUV=E^9_?\/2=81/
MW)P0LPUFYX;2*F$X-#%<T>[03WBCP*SS=V'.#V$*G;9ZJ<YL<.G?;;)TH\L<
M I@TDW<6?8RYC!F55U>]:=BJA,M\XH-*^:ZU4!::W^WS^!:<Q%B0+S>T*:+
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ME[+8<Q<=G[T-QK(&>\.8R(6/JTI8D6QWA6HQ4WU" *9;6J^JOC+\IN18V\.
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M8#PPJZ*H=V<K.I TV)K&4?=Q?-S3D2V4F04A;LL+EOO=.9?JLFHL3_PC&\/
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M\KX1V7Q@M+ KT86:T$5J1[3%D3;SHB^L,O@^5Y\-.OTQH]2_=:9,$Y8%X>Z
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MKV[9K9:_,-]/\M];["Z.N30+C?((X-M2?X.\[W48,%S&$Y6$!:1G6N_4NPJ
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M,/N[$ZG?" 'F&WBFF4#;VXRIUC0H-%8TV%#9C*.32I5,#JO2^PXOSVB4,*-
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M67(04M;FH(OVB^J%'^#/^'LJ<C*?4N@E)&9VW7R>4&V!_]'K=E[]#61'DF#
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MEERS[O%GW>=.D]0>F3/?1JC&@AG_WP0 4$L#!!0    ( "L^;U3/"$UH1$0
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M #D^!C96"!8&.X!)CH%%CH%N 5C ?>)@?/\ __A@8&)AX^#BX1,0$H$=RB\
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M;R/CG%9UK4XZOA3=]#;%<[U?->M$P.B?TE:6 Z2%\OY/&U;W'02*MR9&MVH
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M.:&![:(Z+C0@IPSYF@W&*&3.Q$,-Y?<"/J.)$AG4EF-L1/(5$\![*<A.U]!
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M;:=#0AT^XLD2]I/B=]<DT@,S?].97]#OO&:[@8+XJ(-$T1.RA_T30_E'([5
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MFFB-=^C#;(.5GU;]"<ZXJJ<G:-1R\C2>[XG)N$E_6(Q_M 5 YMSJXO)G2DQ
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M4G[,9MQ.%4CI/>%;&(' )Y5]]1ZT>T04J#6J%!2NP-%(?F'F\Q58?:U%'^5
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MVZL%3_;PZ6LOK;144[37Y)BE<C8:^+?WEQ-J7GW);'U.8'ZL'^ON&O[:/RR
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MAT^.AVL#6,#[/(_WZP/\^<$[AT]PGA!"=.'B)?" RLO .3Q\_',$^.?/$Q"
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M^ <WMAN49&MSUG93GAKGQ5L&W?<MS'Y>< ()VXX*<BC>$"XR-JS%CB6//4Y
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MX$FU_<!&?#N6S-P;. B/,N+J%RZ'S>, IE5)$BR\P+9L6EYZQG+XFH(_A#A
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M8!(5WRJRMZ?S5.8QJ5-\'Z1,AP$H\=HQ*BC"G,R95?()6S+K,J_(^>>^2_<
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MF/%?>" WK7S/)"4MHL+TBS;5]-# _3/9#=8THJHO'=-"<8.#A'U_IA[>JLG
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M!&9<OK34W-GS'K7[#('#3_@O66_S5-T;^9RF<C]'N9/SU&EZ=Z9M! VS\;!
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M>I+?V'.L69W/+GY.G-OKYG[V3M&/?#^4OD&*_G#B_3IL[VNO2V[E$?7]I',
MA@-_V/I7;-<6>>B//T(4[A<Q,Q#&6C-;^70Z 5J$A(-^UO@YQ1YMDAT?/GZ_
M]JWPADBUU[0*@X!]-I#Q4@ QD_%] 7Z\-#][>@S% 5<4MYEPP  ?*0Z8!6<
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M-T8HGX9=3YN(QZLJ6ARO1YH\72YCB<>FP0?R$47XJ?W<=@QWLOL$VB3U4Z0
M(T1$$X5=,,](\?!-\>P%V0S_3KE;1*'Y0A1M0V*4:]7.]5^HXBG"+L?V*-UA
M=K!GQ6=F"$FC-WK^)&A=%C080TZ>VV('PC5GRX455N8^ RR%XYY4S.L3(7;H
M%B="71NW7<\S2NT$*SV98>63I8$YK*&'ZY\T5,"E<KP4&=CA(=20=K?#*L_R
MLLNZ+S5%SU;@+_P:6_6UQ/D8]2('QJ9V7$D^"C!=YSX3^O0TC+<^L^CQJBV&
M_ UR>FCQ:YE%_1KP18_<L-O%PES9IZ=<JYV#M4ITVDD9Q%.O?WL;%;6MK(/
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MWM'4^Q>\U>3&%B374PEBSM1R._=YXEXC#%1CE-ZLELAK$>PSS3A-..#4,V-
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MK)*YG,E7+<CL(1B<XGXX&/Q(:$_GTAR=Y8@XX#,O+0('V:,/U7^S-Y0)FC2
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MCG=WEKAAZ5DQJ/N@0JN@7BKX,[UDY/;Y8>: F1^^L%5V1MC@_$.F1]D*@8C
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MZUXKKX?IX764EA4&J&A1V'8#N>=U^A'*2@+@XMNSC.:+/RM#1J9!*H<^ 0,
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M5>8UN(2=R1UY+(C/R#+UKL..F+N8Y]8J'.MG*\I7SA7Z>H6$Z+Z**-5$?V[
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M>@A9[JLB1@E+P0]WS-!H.5P5]1!?!0%35\% 8A[J9(-PKN7[Z<62)VJ-=FD
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MZF7J\E/;6/N+D5:AP(01 ! 2%M :JU#0:%*IB01YZG)KR)D:!:D4&:N0 FP
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MO*P)N+T-NYT1,"0+NP_7:WWPDWJP32]9;;IXP%&;?8$/TL/%!TD#_G%KU:9
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MQSXQ7>RUI4S >QOK!97SW6X38\@#,-S(,$+ DQ"PWJ'XCFLBP(^Q2=O!!>Y
MQ&:,B(Q+,\V!A'X+IJ\>'^_)_;6!*/LRUYJ:>XMH#@F;0!ZW9@A1DP;W!9!%
M"0=-98F(>CP5NR^XK?!P RB<\;4.!8'T0K3&9NSKV+*2-^WT(X3W)@Z-34*
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MWAB&3!LK?(EA^>3BF/S6QXQ42I(OJ,M&]6\UZ1#)7;.\)73G5 H-J@)LCY\
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M(%:F'S%._/<DTC]=*5DR)6G9=',6^DV%:],7%I19H)/C;V2-?_<II(C\=$Z
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M_4KB,;^PCW:S,U#QM.&<9C)Q>ORA4CBH7H">C DRKWQ0N%CNE4!L8;^2GBA
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M(:J-'+V9$Y,7JUE2I!E]-XH5]RFJ54JW@VR765/)G>^28[^PU?9%2>+I@K2
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MIKS:CU=M;_@<\THWC#5?E\RK+HZAG OK<,I.4<D$?IBJ\T+:? 4+J99?[AR
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M!%.G4#&TJ?8BIM*]VMNQ3C4YE*VQE5J:,[@W*J2 86Z=C3HK72[S.R[:T?\
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MG'22L5#2:L26I9X /2F3SK@HGYU5(:,[6STI'R%!/?I6GL6I.ZV*5-<UR6"
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M9?EL@^8BOD>XJ@#6KK$7FRK-;GS8%C5=Z]L>OI64!5TI7@C6@[TT6+6[>V)
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M5<N?W7:R#^QK\2*OV=OF/![?G5F[D,,\2Q-@0QJ@(]1U_6HM4O7%\4AE<)$
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M @=*R:L6F26TTJ;EC &X<D^E((78<,/I2QDMD^U2@$#.>:?MI)*+V5]/-_\
M#(S;L]!A4CJ #[4*>>:>2-N>]1-R>*SYG)W8+4DXP.0">U(%)S3=N4(;/'0T
MR$3O\X; ]Z5@MH3A&5AA<YX ]:4D[0.W:G%)9,9E.0.NWI1M;:58@XZ'UJ>:
MZL1<B!YKT;XC9/P]\%_]>Y_] 2O.,$-S7H_Q%S_PKSP5_P!>Y_\ 0$KHI?#+
M^NIUT/AGZ?J>7@=ZG6(MP6VTY%5(P<9)YS2YR>M9.78P<K[%:1#&Y4G..]-
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M,!'8+WY-'!7&,4G%QUL3I?0&D&S++D_7K7HGQ##?\*\\%;A\WV<Y'_ $KSE
M6F . 4Y)->F^/L?\*_\ !K'DBW.#_P  2NB"2IRDWJ_^ =%)\L)^B_,\T1'5
M0K$$8_[YH8"$!L@D_=%.#G=54_ZPD<#/%<_Q/L8)7>HZ2!U0NQ!/4\U$!@9J
M>24F(J>IZFHXXVEX5<U2;MJ6F[:C*L(I6$$C&33H[5T#22(<+4W+VCDG)5P0
M?J*B4NQ$IKH0!MIYZ'@BJS+LD*]A4QY.*CE_UA]N*J)<=Q@/%20[2Q)[=*C.
M,=*4+M .>35/8IZHE;GY0>:6$!I0"5XY(-0HP0G-1NY\S<#CZ46Z!RMZ%]VP
MQ X]J8>1T_&JWVA@V3S2O,SKQ^-'LV3R-$4V&=B*B;K@$X%.8Y45&1^5:I6.
MB*';<*,YW'G\*C[\4_)(YY[4WJ?3WK25F_=*0$< D<&I H"9!;/\0]J&!943
M?N4#.!VI%"LPZBMY)4I/3I^-NEM/^ *XU@O.,_6K$5L2N'3;GG/?%-B $P7^
M G//<U;;<QSV%<DYN.QG.36B*LT2Q;#RR^F:2$J 1SGJ<CH*L2#.U<=.32!%
M*$ >^:%/W+/47-[NI5ER9 W(7UIUQC=&1C[O6IKD8BQZGI4,;!BJ;0!]*[,-
M7BJ$Z<NMG]Q<7=7)HXP5)D)8'ICBECA\N^AQ]TN"/SI6( P.E2Q@M-:^GF #
M\ZX>=N5^Y$9.Y]&?$7_DE=Y_UPC_ *5\UVLLJR!8R>>HKZ5^(AV_"V\)&?W$
M?'Y5\SO*5^6,!5([=371BE=I'9C%>27D:OGS"'9;7+N@.3D\FH1'=73?,7*C
MJ7/"U4M6(G48+ G!7U%:]_%+';!5?,([ Y -<+C&%M5=_>>5)>SDHK=C%2">
M)[:&1WE5=R''#8ZCU^GTK.BF>$D_PD88'H?8T^TG:WN%E7JIS3]5B$5ZX7A6
MPZ_0C-**M+E?4J,;2Y'LR:*2"<[ @!/W0YR,^W<5%<W)@D:*%0FWC('-5[6-
MY)5"]CU]*M75MY\K2*ZEB>@/6K<4YML;C&,[/81)6NK&8,<N@#9QR<5GCEL>
MM:=G$\-O<J5^9HR O<^]4!"[' 4D^F*<9+F9=-I.26Q/:3"*;RY1F%_E<?U_
M"IRCVL-V& W,XC! P#SDX_2F1Z5>,4)@<*W.2.U.U"0O*O4+C(!]ZAR4G:+T
M,VXRG:+]1]C?F &*91);OU4C./<5<O76QMD6S0H)UR\H;.X?W1Z"L6-&D8*J
MY)/ %;HDM+>./3KP%OD^=U.?+;_/6LZJ47=*YE6BHS32OW7ZF SG/4BK.G"2
M2ZC49Y.#3[O39HKD1QJ95895E'45(K+I<$@+_P"E.,;5YV#W/K6KDI1M'J;2
MG&4+0U;%^T6R-Y#%)53A2Z'^8.<4DT8FF>*>5(V^4J?X0,<BLC/-7KP[[N5A
MTV@G'KM%6XJ[[OK_ ,#;4;I<LM'_ %H37XB%O EHQ:W Y;'+/WS19(%M;ISU
MV;1^/_ZJHVUU);O\N"IZJPR#5Z6[83F(HH0<A0,9X[U-12>@I0E%<B*UM;M/
M* "%4<LQZ*/4TNHPA9?/CD$D;GAAV/I5JY)%D1$@2-MI('))Z\G]*CB2&.S=
M+EV5G(*J!DCWHBVY7&IN_/\ *QGQY&Z0_P (_6DAC,C#) 7/)-:0CM;:VW,&
MF$F<=JJ740)66'/E'@#^Z?2J4[FL:G,]"],/-MY(U&/)QCW%5+>(R3H@."S
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MS]TGBNQ6 Q^"O$L:L!_IT!'T.37)6L&W<"W.>M=,)<L4XNVESK;2I*SZ$SA
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M^'>LPS%ODNX-H)R!UZ5QSL%4OBNCXDO0[-7&-^WZL620*N>N>,4R*,NZM+G
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M$9#<4;=YYX&#S443E9,#IG&:JRFTVK+R_P BE$L)&KIN+,!V'K4DP$D/09'
M-+)UP![4C<1Y/'(K-59I63LGT,[ZW&YW1C.,J .!494@T\.5?('3BI&01A5;
M.",\5?*YKG;UOKVUV_4=[$(E9.$^7G)KT?XC?\DY\#_]>Q_] 2O-R@P<GFO2
M/B-_R3GP1_U[G_T!*T@WR.-]#JHVY9?UU/,DP4/."/UI14:DBI!S64G<R8C2
M,HP#TZ4T.V,'FI)-K 8'(&/K45.79.XU:PX'F@L,XR?>DII&.:0[#F.&/-*>
M*C))Y-/5^,&A@T+T%-/%.R"<"D^M(2$XVD$?-V--Q2EL4BGYN15%(7..E-SS
M4LJ;&P"#[BHC3LT[,%J2-&@W,).>PQUJ,<GF@T#K3;3V0T%*HRPHP.M XR<C
MCGGO22;T0$F#3@ !D=<U#YV!]WGZU+$P90,\Y[U#3L0TTALO^J_&JSKD\5=
M63<F-S#H>P]34$J!'X!V]O:M5'E2=]_Z_0J$K:$"J:4],4[.>@IQV"//._/X
M8JHQYKZFEQ0"L>W')YS2XQ[TX+E 03G'/-,/2LF[O0SW&MR.M26BE;R$'^^O
M/XT1H!\PYJS NZXB'HZXS]:;=G8?-9V/I7Q\R)\,;II%+*((\@'&>E?-CW4D
MO[N)!&AXVIW^I[U])?$!@OPONF*A@((^#^%?-?VF63A %4=D&*TQ4;S5ET-<
M;&]1.W0V[>TCN],CAN7DCECW%9",A5XX-9Q>TMCMA7SI,\O(/E_ 4LDL@T=
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MI#@Y[XXI?.-PD$4+$1IQ'@\ACZ_4U+J \F$2*=LSA5E4#&TXSBLE&I.+N_\
M@&=Y:QD]9#K:-K.Z66<8]/7ZU1N]/N?-+C]ZKG.]#G-5S(Y!+.3QW-017,L1
M^1B/;/%7&$EJF;PI33YD]2V(P)HX,%U!^<+_ 'J?_:$EL?*M)#&BGJ.YJ./
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M@A1C4OT1IS7,6IRR!D6*1SD8Z'TJ,:1YD8\NY@:4=8PW-4(B1(I!YR*GGE>
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M('^)$Q'N/P?POP_<*W@$1"0@,LIKU)<7ZC !K^#@X5\AP",B(B"\//WR\AR
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M-FKJ^0;4#+Y%\9JW?3-S00B,=/]5XUBT."MQ_9;<3(?TW*(RP4*B>>AX4]\
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MNK(]$R9^PAL.?=G=242/:YZX_BOHEE4_RS7).'>ZMHM7%3HWTWKWZI_ZBX_
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M^Z<ODL^F&N[?W9)V_U?&K$?]A$\F.*FK=E<$WIL+#B-HD:5>?\NOY<4H[D<
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M,V][AX1+-5X/Z;^,^)S@M]BI7W4M+?_F>$-I:U%*OO1DPE+Y4>EES17;=-D
M8WNRQL'/7B'=/A=$&R/B?J/4-B55 "J^7J'K[8LB$IYWS:Y/S%!CDNV^.&&,
M?\]JGRB)%Z@>O8A6).2!J?EDJJK,YLY'F73%:HY6CLR] P6. J^;8-B0OT S
MU$?^)154.%^UO<[E8<E_4ZGN-<A=F$JERJLBU=?5;C6^?XXZC4^397?BL%M\
M.M4A:CU*63=.C[  C%HHN2'WFH=#M#7.68V(+T(F+4U9E6&U<?=>BA0]ZU^B
MMAT^$M);T[,&J=I0)_*9-,L.$AF!6J1<(3IMTW$MC@),P7F("@#;@)(U%O^
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M"KQE^,=EF2Y=_?3S8"!=(5/5"=+QC5SV-CF3Y?(F]]NZ[.'BP]]U,?)/JA%
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M#/V+<N=RD49F#WQY?+_ KLU"/ Q%Z,5%:>KEG/"]-"D9%QPF;+Z;U/MRR,8
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M2]=E\(]##81@\I1YFFD^N@+.04^7*GKFHJW>70VH[L89(RQ,"H2ODHYA^*<
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M9F49R>/PXK5\*V\L7CBP=MS@S@9/0#%9$C?:Y$\QXXU5_FW'!^GTKH/# /\
MPF.GN3N_>!%R#NQSGOT[U-?^'+T8J[]QKR9N>)+?1TU;42TCP3W.^.0@[MW
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M.TMTS[?XUDZG:RRW/VFXC ADSE@Q^0CJ?H#6=-6T>IE326DM=0B#./+:4%&
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M)!R<GMBNK.J>'8I9FU41NV(V6!DWX91U4=3]:Y;1-,:+6($FN8E.P[85D!D
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M,Z ,!T)8<CM4-OEDGJ91E-*:>MBW\2;DP>,+H'YT*I\A/&=HY'H:Y=8S.K-
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M2<^Y]*G6:=&5H<(D?;'&/?UK6--I:ZLUC2:6NK+_ (>E5-1#V\4-L(HY-Q5
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M2BE=K=FJ@H)SCOU\Q%=MBJD9( X5>::\)#AFCX'.X\?_ *Z7SY8Y%8$C(QD
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M ([J!DU<=&B;9(K*3D\]_P :;& \C<\CVQ6\5U.B$;7DGN3VEH3:7-V1N6$
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M)\_E[]GS!<XW$<X!J!HPR C[K#(Y[4V;=/E'RJ;2I XZU+#&MK91I$%RI/\
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M0<"G1@E3B_)&U"C!0B^MD0.^^88;@\G YK9U&32VLK:6#3VBN9P5D8R90%<
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MW<IIX6TMHW'EI;#:.G7CG-=*NGR-'?!N#]FT=#X2UMKFPCAU2:"+48]L3AB
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M]W=R7&J/-G=;,J@8&-N!C/T/-7U1N[MI= <(-Q P<]J9MWRER,AA^%$SKYA
M/;H!74:=X=M9;&V:]F#708'R%;:I5C\H8_2G*<8:L=2K"C9LYZX']GW-N\R.
MT4ULA^122I!(&X=N,8J;1)IKGQ!ITD:F.W^T1]1\S?,*-1>9[F>:3(=I2I X
MV@' 'X  4[1DE@\16"Q%Y8FN8R58\I\PSSW%-_ [@E^[NS8^)$<;>,K@[5+F
M- W'48%<B!$H8A0R;U[DY]173_$L"3QS.FXQCRUWXZN-HZ>E<W)M1(@B+M!P
MJU.&_@Q]$<]!)TX^A%'(9"(UYD!VC'?'_P!:K+"-,*K90'J/IR?QJ.* 02S2
M2Q@R2?*P'8>G^-2D?*<#DC@ =JT6NIK"[5R6PLH]0NTA>7REY+2]E7U-,,%X
M\TBK8W'E#[N%)"X.,9Z?C4UD^VVNT;/EO;L6'N.15"-FV@,7\O'W-W'Y5.O,
MR?>YV/GLI(WF)E#3-R!CA3CI[TQ[5&A =RS%?FP< FI985E5@2^TX^ZY'3Z5
M ?.#;!,AVC)#+R/RII O,LO(UW%% Q"3*=BSGNN. WX\9]ZJ,71MI^5R>1W&
M.O%"M()-LVPQG^)<\>E7;NU#VL-VQ(<DQ,W?(Z?I4[#NHNQ4$BLV 3DG%'DN
M)LAD$9&3QSGZT-D*O(Z=*L# 3#8VD88>U44T-A>2+/D'+=<$\$@\ ^U7+Z.0
MZ99WC[C-)NQ$!_!G@YX]^*@M/*MW61T+Q=<$\MCL/\:L?;/MYGC-HL0&94"2
MLP/08(;I^'I64E[R:.:I&U1373<J6TCV\Q)*LI!4^C*1S3)0IF)1F4#@ \YI
M[VLB2%5*..VQMP/XBB5"'4$%2 /Y=:M6;T-[1;NBF\BV\CR2*6#?Q;20/P[4
M+<HX78CD'N1UJ<K^\'' &/QJ.=9)&,2':N,M)G]/J:JPDK; BN#G:'W'L<"I
M+J7R3-;C:T8.WIU(/4>E)&%7:"H^4<X[U4N@XFY;.3D_7K2L')[UF:NBW@EO
M1#YHA9E(@D9N/,[ ^E12V-Y"[--81.V3EEZ]:RK:-C"AP0<DD#MS6^FIW-W;
MAY-HEC&-V>7'J?>BVHE%IWW3*#W,<XCC8M&\8V@L.W]T^U3Z?%$=4M(;J:.!
M)).96;Y0,]S4$MYYV0X#D'C*BH"!(69 VP\*O3%4UI9%RIZ6CH:FIQ&*]GMD
M<-&LV-Q_B -0,J7$PC(PXZ8.#3(E::T,QPGEG85ZDGD[OH?YBI["Z:TU"*2%
MAD!@Q(S@$=>:$G8RLXQ[M"S)+;;/+XR.0W%+&RI*)&Q(Q.<L >:?>2 ON#/(
MG?)R5^F?Y5689^92K(W0BM$K[FL(J2][<OR"1PVS;T[],TOEJ5A_A+C@,>N.
MM7D2RFMI6G9EG!&Q4&"_J3FJ[(DT\4,)6*)AQY\F%0^F3ZT2FHW;V1//9W>R
M)8EC%G,=ZF3*@(R]/]H&JI 4_,1@<GZ5J0Z;,$E1;JP)<=KD=JKC1W97(OK#
M./E/VD5@L513?O$*O35_>,^5I6:,0^3Y(&26SEO\*22X@60+OQ@;=F<C=ZU>
M;2+@1,%O--+]BUR,4V+1Y$7"WFF9]!=+Q1]:I?S$^WIW^(KDM-$QCD'7MS2!
M0KD@#Z>E:"Z6T8(6XTQ7/4BY -0S6DEM"6ENK.4\#]S,&8_A36)I-VN7&O3;
MW(D82KY4K'R^<'NI]J9<VEQ8O&DL#KYHRC$8!'J/\*;Y00<G)Z@UH1ZA.-)^
MRAD,(EW,C(&!SW]JTE=:HN?-'6)BWC_Z3"Y1IG8<K]!U]*6)T9P5CD1F.T%T
MP/SJY+#!)(90CK-@*HSE,9R>.OI^55+F1EMY2OR-C@D]Z+DB-(R8VHS^NW_/
M-3%QLPH))'0<$?6F?:%#DB-B%R&P,<BB%_-9F5=@;D GG--%*5R=<R121J55
ML9"N<9'UJ.-0A$F2\F"H/H.XQ2;LR@L!L<\E3G(I3]\J.4QG<>II+<5E?7J0
M.3(Y5-RL1Q@9&*OPV\UQ8,\H57MB1(2-HVGH1GKCOC.,CUJFUO$9!Y@W$=.W
MTJ]:.LUPL<H#!SM&_D<^OXT232OV%-22NNA76$F/=G/T( -"Q1JN"O)Y.<5#
M)"CL1+(^\==QY!S^E38)0;VVGIN/'^>]46.9&.PHF1@YQT_*D#"2W4JOW"20
M.<#UIP;Y=OFE0!QVS3XV/V9@I/FY!^3@$4I:$R;6Q5W<9.Y@!C*@G\:GX+85
M@2W  IOSM(7+;6+9STJQ;(VT+\A).XG9U-4BE<=<L5M8[-,8CQ(QQ]Y__P!5
M1Y+<E<-TXXP*N:D"TT;;D9W4,P7C:1QBJ1C _>%F!Z 9X/UIQ2M<(V<;D0B\
MMCU*D]3[]S74> -O_"408Q]UL$=^#7.Q(6E9#\P"[ACI]/\ /K72^!5QXK@Z
MY"-VZ<&LL3_ GZ,FL_W4O1D/CRT2TU*WB.'F99)BZC&26_G_ (5R[Q>9&ISR
MQW?+QS].M=UXYTV.T9;LIO?SQ'YN#DJQ)"DGL,]:X7YY)A!!)$C2DJ)6P%3W
M)K#"S7L;OH+"34J-^POS372E&D(.#*BC<OIGT%,WQ>9((G4['VX!Y7'4%>H[
M5I'1Y6MS%]NTWRR025N% 8CUJLOA]HYRXOM,R1A!]J7G%"Q%*_Q%QKTDW[Q2
M6\:VDC:([-K97 RV>OI3S>&[N6DF$HG=B[,&X<G/8_RJRVCSM#A;W269AG<+
MP?+S3%\/W";G&HZ67!R UV"!G^7M2^L4+WN5[?#[WU*<I5592V,]1[U73*RJ
MZOC!R/FQ@^M:\'ANZ=B@O=.DD/9+E?Y 5*^FII\4MQ<7-C/+']R$70.]@?N_
MXU3Q5'N7+%T4M[EB^NDATVSM)C(VH+$991YGRAB,KN/<GKMR/3TK!\Z<?.SM
M+)G)<C.XX[TDRW=[>;)#%*\I\V;:N%'!S[D=..]1*)8X4S(THW$)N/)%.G!1
MW)HTE#1]2:SU:YLKE9$5').2QC'R^^X8-6;BZBU2(SQ%UN(=JS!N5D!XWJ?R
M&#5&>-0OSQ%7SP0>>E7]/MH_L]W,Z/L:W= P_O<'.?;C\Z)QC'WEN.K"G#]X
ME9E5E\N!F9@%QG"4EBP2W9V;#$D@8.1_2IGM'F*%<%/[SM@?KWJ59OL%P(8%
MCD=&&69 5'&<8[\U=^BW*YOLK<[7P;IMTFC7B; 'E>.>*.;*KMZCGC#$9..P
MVYJQ8ZU;V>N7-[J<\5M#<+';QRQEGC27+8W'&-Q&1^!Z5P<NLZD8!%]NE3<B
MAI(SLF."<9?[QZ^O2C2=>N6U"6TN9#-%(2T8D/"2X&'QT)X_G7!/"S;E*74\
MBIE]><ISG;4]+O/&UD]S+906M[),JEC(D+%4'J2!G'T%:MGKFE7MDUTMRCH,
M@R?WMH[9Y[_6O$5N)EE^1RC=<@X)/]*?+K-Z&;;>3*S+M8[CR/?U^O6F\O5M
M&-Y(FO=9ZSI.LP)+?01>4OE3,424;"RG' SWR2/QKB/%^J/]KD@2.3SIF9I7
M.!^[8@J@(Z@=,^QJG!KL$D-O/?1NTEH L.Q<$GKNY-6]173M6M9+HS&&:-L"
M7JK(>5W>A&<'W/O13HJE.\D%#"JA6YJB.=AGNK5TEM[F:%LYRC=/P[U;EMO[
M9L6O8((X[F(XN8T!_>Y_C4#H>#D4JZ?D))]KCV2/M3Y6RQ]ABMO0H8;5TQ*!
M<G(5@I"M@8VMVZ\_C75.<=X[GHU:\%[T-SC6C98MSL%4 X!(%;]M=1^&K/[1
M)$%O[R+;''R'CC/\1],UV7]D1/+<7.GZ;%=3%0V]AN,3'." 3@]#[UR-WH.L
MW^H22W%N&FD*B0*<A2!@#)[>_O4*M"K[KT1FL73K^Y+1==2U9:CHM]:3-JR>
M1<P[2%A;+3[B3P<?C[?C6O=?\([:P6+:4K37L[@LRMO:!> 6]L$_I7&R65U'
M(RRVL@D50LFU.<_YX_"NS\,:19BQNVU&>.&*XBV,P<;A_D4JL8PCS*3MV,\1
M3C"'-&;MV1R>IO-)K5Y(2V6E+;L<,.@/XC!KH/#"!M:T&6(#RO-*.<_\M 3G
M]"*DMM*T>!7M+N]@N '_ '3"3:RC'(![#.#]<U)X?>6W\4:?936^R$7!> IU
M ([G^(&JG.]-Q2V3_(TE4YJ7+%;+\+#?%:G_ (26^(X_>9XKG([.5//9<-;R
M<C!Y5QUS[8_D:[W5M+@EU;4KZ^E\N!)L  8+<>IKBM2=)EMHWMPNV0@+O^1<
MG S]!WI4JB<(I=%K]Q-*NI*,8]%J_D4;?S([N*=-OROE3O'4=./K6UJD8^UO
M\GE[L-C;CDCG'XYJHVF7*.LD=]I:D$8_TE<5<6"ZG0QW>H:=)L.Z-_M(+=?F
M4^W0CTYJ7B*:ES<PYXB"FI\U^A3M3:O'-:7(<0R,'0IC<KCN,^O2J-Q;?8M<
M:WO5D\L#:0?EWH>A'^>M:[:3(2X>YL.>.;D=*>VFK=Z4MC?W=@6AYMIA<@LA
M]/<4GB*:=T] E7I)\R=T]_\ ,RXK)9U=C=1I%"A;<V0P4#)R/IZ4UI$6./\
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MW]Z@:4HH= QQT4G[Y/:M^IUZ\VVQK7LT-]90WQDCBN+>,6\J= 5'W6]JSH1
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M/!"!>@P1]:K2K:@N=DD@Z;@,< G'OTQ5L31&W.8B6X(^<E6&.V>?UIMH)7N
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M>XCFL72!H1YQP</D*H/<X_3UJJLC^?,Q)*X3;DY .#T].,5:1S?,5DF;<B
M8R2!T.?:DDT[D+GW8ACRK.[="=QQ_*FVR; N"V\#C=U%/=)EM9XX) +AA^Z+
M= :980W 2..ZF5I@/WDF:OJ:;;EV6SW6J2(K!<X88Z'_ .O5([D2612%9$)R
M?7.!CWR:DN-4GD3R[24PQQGJAP['USV'M5ZTN8;W1;R"YPMRBJY=% ,H##K]
M/ZU#<DMC%U)J&VC=C(901Y14,&(7![TS[,D156S(0.3DC)^E:-M#;RKN&[S@
M?D)Z#UJM,58L8L@#JYXY^E:+S-DUS6:&6KF!G 4A7^\O9AZ&M%]-@6Q2>WD+
M,X),1.7C&?Y'M62952=3/\\98<CW/I5Y;D),",@@]:.6[NARA=IQT*<B2*@V
M,H.<8/\ /^51B*ZB7<CQ%6Y(;.[/L:NW4R131EU.&;:=O;CK4TMA(T)D@994
MQG"\,/PJ[KJ:77VBI:;XX$E+$O(,M['TI%@BC*I$#$KM_ <8.,Y%20$BU+'C
MYL#-,N&WB/;EG613@'I56T"458L1RRZ>#) V3C!5QN#CKAL]:35M27465[>!
M((]JYB08PV.>?K35D:ZR%@E.P9;Y<XJ[>:>C:;$RQGS%/SNK8('7GUJ7RJ2:
MW,'R1FFEJ6FX ;OD#/M56VG:X>8.JY23;D#DC'>BBM7N6_B+MDFV<R*2&"MT
MZ=*KA09<8X(P?IBBBIZLI?$RLOS1J3U/6IL\9_VL444RQY&5+=#[5GW/$MNO
M8DD^Y%%%)D2W++0I-$3(,Y..M4V9H VUV;&"-W/>BBE(&:AC$FFI*Q.X2;1Z
M $ U3ERC,@/&.]%%3'8SAL0VC-(UPCL6\M@%)ZU>MQG\\T452*6Q)*,$,.IZ
MT^*-6;GTS110MA=!25N"8G1>/XQPQ^M0LBHH50,#I114P%1W+UHY>UN8FY10
MK@'L=P'\C59U5,E0!DT441^*7]=!1_B20'Y$W#J/:H8IFD>12!A<8_&BBM#0
MOW39$2[1\J#GN>>_YU3BF8Q^9@!@>"/K114PV(I_"7-2BC@O6:- #(BNWU(!
M/X>U5T/S_C113I_ BJ7P(?(Q#,F!C9G\<XKH_!$2IXFMPN>%;_T$T45EBOX$
M_1D5?X4O1G? !M2O8' :.,(Z C[I;=G'Y5Y?XS@6UN+-XR2\KO&S-@G (;^9
M/YT45Y&7_P 7^NQYN6?Q_P"NQ@H%E0SNBEU8 #' _"HK@F..5U/*2;>>XV@_
MS-%%>RCZ!+4@N)VCCC<*I+N$((R,<?XU8U%FM+FXT^)B(@X!<_?88SR:**SE
M\:1G+XTBIMRR*3N Z9YIB.Z7!*L005_K_A116K-S2V#<T_21DVD^U5;F,(BJ
M,X '4^YHHJ)+5&;W1TF@Z1:S^(?#4KF0%;2>?"N5!.]1@X[<].^!6QXMTFVM
M;2_A1IF$(1T9Y"Q&[.1SV]J**\EM_6;>?ZGSEW]=^?ZGFC#(W'KT_#)_PK04
M#[,!V()/X#BBBO7/II;(9 -ZG^'IT^M=%X=T:VG>XN7:3?;H\B8( +!2P)X]
M:**QK-\C.?$MJF['-7<SM>L7.]I)!N9N23CK7>Z! FJZ;;PWN9@L[1;F/S;<
M@C_]=%%9XO2FK'/CU:@FOZT.AU[2K;3-)=X3(RQH(A&[G;AF&20,<^]>8:L/
ML^HSVL9;R89W1%+$\9/7U-%%8Y>[WN<V4ZR=RC#(ZNK*Q!R.G\ZL399ED)RY
M ;/<&BBO2:U/;DE<V5OI+G2+5Y4C:3]\#)MPQ VC_#\A6.PP2?;-%%9T$DGZ
MLY,,DN>W=EO2[F>+[4T<K*6A=3CN"#5-P'G>-@"H7=SUSG%%%:)+F;-K)2;'
M3S2M"(Y9I)5B&4$C%MM=!X)B \463AF5LCH?7M]***FNDJ4UY,=9)49I=G^1
M<U2=XOB#<P<-#<RF.5&Y!4BKJ:'IU_<W5NUN(HK*98T6)B-ZKR V2<_ABBBO
M.J-KDM_*CQ<1)QE"SM[J."OYY'NKMF8EC*S%B<DG<1_2N@T/1K6_\,ZCJ,N\
M3V\NR/:1@8'7&.IS1173-M4U;R.N<FJ$;/JOS.BM=,MM.C6*)-["W,WF2<MN
M8<^W3CI7G=YJ$UU=173!%>2,A@BX'!(Z?A117-1=YW.; MNO)LZ7P["C:7)?
M.-\MNR[ >F2<9JY'(-0L]1M+B*)E='7>$ 90"2 #]>:**=?XF3B_XS\K'%PI
MYEM#,S'>AVC'0A@<Y_*JLW[[56LF.(MF3C@G\:**ZV>C+J6DM@H_ULQ 8<%S
MVS^-:)LXI+O><C?$KE1TSTHHJ69SW10C)9A&22-S<GKUI^W"A<G!)XHHI]"U
MLCJ+*!+G2X[F0OY]MN$<BL00!Z^M0>(-UY::;=RNV]T*E5.%^OUHHK'[9R?\
MOOF8\ES);:>CQA?,)=&<J"67/0FKNG6$-S>PQON"-(JD#'(.?\***T^RV;O2
M$FO,ZK5[&U33KJ*.%46/:PV^N*XK1T%S<.)">C'*G!XHHK.@VX.YS8*3EAYW
M8^>)=1B>XG)\Q9-H([X&1^-,*JUG;N5&XG!([\=:**VCLCJ@[0A8AB ,C.5!
M*E2/SKM+#3[>>SNHYD\Q'^8JWKR.***SQ#LC''-K8XJ5 DTJ+P$=E'T!-6M&
M?R]0C5E252=I$J[@<^M%%;O^'\CJG_ ?I^A+K;%KOH %RJ@#  !Q@"I?#R9U
M2T0DE?.C< ]CN'2BBF_X?R%'^#'T-CXA,4\1SD=U4'/^Z*Y*(E+:.+<S!I1@
ML<E<JV0/3H***BA_!AZ(RI?P8_(;>2-""%P01@@TD:J[HNT <=***W^T:KXF
M9>BH?LMW<,[/(;DQY8]JMQO]HFE1U&(F*KCTP#S^=%%94_A1$=A!\^&8 D$#
MI[U8!_>E3R***KJ:+<C95-S;@J.%9N_7@<^M$D*0RSRH,%H%8C/&<XHHJ69O
M<BE8Q;67KP>?J:9/_P ?1]& 8CW-%%)[E/<AA0?:YQ[(/T)_K5RW11<1\<G*
MGZ8_^M113Z"Z%AU'FD8X%5;J0O=H" /+0XQ[[<YHHJF5(BAPMRIV@[SL;/I6
MI:1+#).$SAH7!SZ K114R,Y[OY$%HQ'/I1 HDTR*1N6:($_E115]367Q(H&-
M9(8F(Y$JXQ]:MH 6&>Y(-%%,IC;A1)<*K#(&,5;GD8/&H.-HXQQ115%K9$MV
M/M,%M,YPS HVT8!QT/UYK-8"-BB *OMWHHI0V,Z.WW_F36DC*[.&(.PFBXFD
M.3N(+Q8./]ZBBK":7/\ <?_94$L#!!0    ( "L^;U1R^5'T@0H! -(1 0 8
M    =')D82TR,#(Q,3(S,7@Q,&LP,C<N:G!GG+D%6!Q;ES7<!'<)[M()&H*[
MN[MK@@1WMV A!'>WH(V[.\&=-.X.P=VE/W)GYIU[YYN\OU0_]3Q]NJIV[;WV
MVNOL<QHR!UD#8,A(2$L H%X! % O'P!D$2 *0("#@X>#18"'AT=$1$!"P49%
M049&(<!ZC8Y-0DA&2D)(3$P.9*0FIV2@(B:FX:1E8&)F8V,CH^;FYV+A8V1E
M8_EM! H1$1$%&04?%16?A8*8@N7_\P'I!& B0-E!^T%#40)>84)!8T)!>@!D
M+W["0OUU /[S@'H%#0,+!X^ B(3\<D,=!N 5%#3T*QAH6%@8F)>K/B_7 3"8
ML%@4S,)PKY4_PE,Z8+/XQV0C4(E4=>&H_#P%LAHY!B BX>+A$Q"^>4M-0TO'
MQL[!R<7-(RHF+B$I)2VCJJ:NH:FEK6-L8OK)S-S"TLG9Q=7-W<,S\$O0U^!O
M(:&Q<?$)B4G)*:DYN7GY!:#"HN+JFMJZ^H;&IN8?W3V]??T#@T/@R:GIF=FY
M^87UC<VM[9W=7WO[9^<7EU?7-[=W][_C@@) 0_W7\;_&A?D2URL8&&@8^-]Q
M0;UR^WT#)@PL!3,<EK R_$>'UY0L_@C8(C'955V(5*PJISA&CC^1<(%LZV_.
M?H?V5V3_[P(+^/\5V;\"^^^X%@ HT% OR8/&! @";NYI<OR0_G"R7NV:/_(6
M-3-KZ&I+?; 77K#:%3S*4'T.T,RZ>>KH:P\]0W\,TP$]><I" -\)[S+;]-JH
M"?1VRJ_$3_YV6]3?OA?^-(AB\"*^,?WS#9(,7K#S7@]F:B\V$W:?( "[L]Q_
MC(K9E(=)NUP-GN>G!7^]\8  ?!<?S?\^L&J=K,U@V5D4GC6M;L#5N':LVT?H
MFW6_MR49+-A/??,UPZ9LI2R/5'_I>L]$[L.W[O7(GXO@IK;6]U:^FE4@JKIC
M^XY%'M 33(7@R8-O!-G?OKMI+L"VVKL7S G;O.E1T<UC^8;+']31#+_\2%-S
M.A92  '8+OCDK:PN:%7%O&T@4CY%VQ)8IKF^//+RU?%-=I1:]ZUW4;Q'-/!=
MO88 " 7_/I"G5WH>;<4C,ZYKN7/87I9LXSZ)TKE\YPD>5[(J8UR4GRS[1.AH
M(#:A4]S"P3)$5-FKMY,-3'U+6]>TN_H';YUG/J-4)[IG-T^]"8( :MH7N3$#
MM^]1W#:^>:/:%>E95.]Y?HFUN FC8HOM#:&:OVE7GEV(LI*]%]V.&8$ K/>S
M+K%:(8".HV<VW[\-V"LV%)'[<^<65A>&':\G6R0T]LGHQ#X>_;)*+0D&3O]D
MW)M/ZOACF+GBA@Q>2(=M3S7%OA,R%\\00,/MS[\/I@EIMJ,^M+S_QRM!ZVVZ
M*G$]"SH"V:X#L\H!9:P8$NLG>E>6M\;/$AGTS^T;$,!$D-A&DT%@F)LDN&ZW
M ]?VV(9-%[>^,1&7$^8U40+01B#AE_HN&;[O%CP( I@=?'E WCW9<%/LL.24
M=>C?.>RU5'7HH/]O8R*N.L3[(Z6;,P1V%J5.87B"KQ4RW.QORC"M&J$S&L=U
MDI3"Q"?K2%@U")E2V)$567AQ=MC30 H'1UI>XEZ.$(!4N^;2UI\9L^>MG\]0
MLU>EO>?073((]S LB_U&Z?I.4C2T(N]68693FK.Y;+DWCJC+,H:!-R7DH.M$
M7@TT/#+19.J%;_@'RKAHKL!6?T55?L<N3=U:%8.='69)T@_E]+0_ >9[DZ-U
M\/I-[\TBH_,<RJPK6(@OQ_42OAV-9ZKYLLRY ^I<9A?YCVF=E5MY/4DFH8@Q
M6%2K8QV#2U/(-\XKN#_EW*MV:EJ7"7(HM&#M>CWH8KOZ*68*5QHO)G"1W0!,
M7"YMS:CIA9_U)W=G#(@B]9%EP:GX<:K3U!8&9N%X7[$/(A\W@DY]ZB)!N<L]
MLZ_GA[WKSWN][+;KG7YY%N4?%1U]/)?Z-[CNLT, J!9^AON$-HM5]1T8\E!^
M=&\W.PV5Z.15?]0K[:>VK>1[VAPR;$4R+"S2F+DJV6/8PR*5<4Z>7D( 3-LQ
M@_^F=B;W[B52GK(VG&M32<0I&[XMZN%7JL5ZFF4?]<H6>@OHR@L<]KLXWM3;
M(VZCVVK@DLCDWE!&6<GSLC_YRG&;./K^ 0?EG(;M*"/&X3\I@7).I-8U<@U8
M &<?K\$ F,+(>/Q6V+:'(1:78."*_5!](PM1<,LLZ[DM[2[TNOG,86BZEI?F
M$?ZKM]A4Q=&CJ1LQ7@.S! Y3$3T-L2>T7L/U6!$$($P__O"\NJD+ 6#Y;KF]
MQ.<BF."HOC\1>JT\F3W,<9?R[S5<H[7J4/[?ZGS)"EK#UX/>9F=.C+R??(TF
M,6[T*&YPS5JHP2&&.I/Y/VL?I!DV8G6]PJ1:ZXD4):Y&C;G[&&=HW\[L$OR9
MAF9Y)$1*/QG%4K%Q[_7KLB_L"LC:+<[Z9D[&+;>=.] -#2UQ,89M'&#P'.D8
M1C&1A(\1U\[$S."]2K0(/;7*_FQ7^WT@&UM]XI:5&QS^>X&A+=VM&E?$<>I5
MD$[H09<&C^E8_MO<8FG2+ M*L2ABW;R8.3/\O7Y/F3IJ" !%0)NX_^^02OY]
MH+^2O<[/LN'#V3TS*9'48>3U[1B7O-TK+@'-\[*<LX?0-#'*LUYCUL:)SRHL
M$6"M>5QR$*5C7Z1@.XBD'$OO^T<F[DOGBT3DTYM[XEW+)3K438]T82G)G$MR
M/]%S=(O_K&@E\D&M*WW/-\N:G]$EO/-18ANJ^1(G:8;B,=^+<^D" OB#V+7A
M'G3K6&?B3;)=U@7PKM8)H_9V"I$Q<F(H&GPM[.>(<-FH/^U_I+J6-FU=+-T'
MC:/ KZQ>%:NOG9@?$D>X<$7]P6SI8.[PQT+9-[T)4_<N=5W2;\0HM.B-3YQQ
M)JW(YI-(L6TD?- 6%=ZNBP>(<4@S^/:VS$9>Y8&PIQ..912;!OZ,PHP5IL5]
M< !:/ER"J?4>2ZG(>%($#QG7?>9\.6X&)T%9$'UY_I];%1W'_LKR?Q2=EUVW
M;$BY-QEQW"BP8I=KF0I7,*4"IL+U5A\"H-0SO)J' /+M-\%JM<<VP@_]IM28
M@A.SHYH\?86,!= JK0!>WV'7J_M9<+5OL>^-O'>3"P1 YN0[*_'L$JD7M],1
MXQY<9?;OJHI]P=Q)UV(%IG4J3:ZRM5&W-T)^Z94<[:LV@CH<+^+]DZ)_-Z]/
M[R/F=#HK8DCGT89><_,-X[N+4IXBD&9.XX4Z7V5.2F/N,2T<:$*EZO+2C"\]
M8RDYLZ<6X8*WET!X2SM_5M,Y<"LSS(+IU7&5D\.'=Z92]1[<KI^.:F]Z+5;=
MB10;GJ>^DNA8,):NO_["M.Z:&=K_L"IC6P8\ND=.U$T'_;DJZB/6CB@7=1OJ
MVCM8#;LPFAKKS)UPE\QL3W3R,G$FV>GASZ"FQ,LSFD7M_0'F<V0)&,[<&Z!%
MU?95OSN@XY]DTLX=#@R^Z)6@M5G/)'LK(=:L--RY5KFG0[C %;K\IOZT4+)1
M7'"^1:[--ZE,K5A<,;8SY\@K/>J/7AK$;<@JFSIYD)1%!6XVB-^IJ"MS;4[.
M@BLA@*IWCZ*@6\_CL1E\N5B?U$,Q?PE)WDC^8BH=5%KV[TN$KDV#?V9M2;E.
MVI/G_J;\)('S'! 3+@!%XM6I-+EQZB5R&1V87WBC]:<SE[-BS5>K=$HYM)4Y
M[C&?HK%:RL2T$/%V4,*?[:Y$("MTG*(P+^B(7N]Q#F+_8 +:ETUDMJ$:3'DS
MY^GU9FN)6J%H-3(MR1("SFWTZA551Q5G:$&?6IZAMY*<1@7_2((CMCOG+$PK
M31YD<PZ-2M@8FUU_CJ$@3US;)_KXVDH;@6.B447YYC1Y::8>"O4X^.^V":5F
M>,[3*>\$MNW^U%4=>3VP._,+*K7]?&=]G->T3%+6>#Z2^"),40=*MYG(]%E(
M6OO1>_6ND]+,>G-1,53]R!3/3S)%>'9N/G ;#^D=?\R:FGG9G?%<6,U^,4U.
MN\FE2"C-]U?_RXFRB@$!#-05^\[F==Q#5:0<[#VIX)>SI0V8)8NB1/.TYOEA
MRD0K"@2TQCUCC,/9H$( B&V9Z 07.1# 1LE$URQ(FIWCHPZ:O-9%,_U/R8!6
M8D_WF<F"DZLJYZN'J=PN4@Q>ATU9U4:3S]>,DD]7^ED&V4O=\U(7J?0_T[I(
MT=675MCJD---AO$,'_9C6G'6MKGL"!>@?YF&00"AN0=3O,'5,;MJFGE94+=R
M\-1]N&ODPUDL@DD'%ZJ2_JV4KIM]KAV<RT^'>D\"E@)MDHU>'([7*[2-]:=!
ML\$S&,:9\L^VQVH.,5'>:LU1X8SL[U[+3 +]Z.:XC!XN=C8+)"U_=:PCGG[&
MAP!^6%@%<5&/AD4]>J9GPIV&?R/A,[4>4(!&I*02O)DVNTI_=[*[VZ174Q7D
ML>EAFZ;I7*.UJNR>COG6.R>#UTGCT]FE8_Y!!-KR^_??SVT9-32&TXVY?@DD
M%'HCKV/.]FET/R^(0P"]*KX_T-=1H%\@S*@8G;RI<H( HE2NYPSWURT@  V^
M-8?0(^<R#W9%_'E+-SS<9FN-:$K!# I*<>4 >.)87HVT6Z(?S+%D?1I#DM0L
M8H+7EO#^WD"1F$TB:T[1'?'Q9WYU/G7$,L.U-XB4Y7$;NMRMVN7[FN^1NMZ5
MAL XD12O?:#[3*YA]TC-LKB\=P3:F]#1GB^AJ4/3$H  VA+Y+G0%3X/<>2WL
M;N5M. (#O.<:7R+G?<:P0PB,NI4KJTDW'@FK>+I2/JILF'XV=1S9<EFVG%7'
M*"M/3I0FE>XYH3#RD27LJY PA''G3TCQMK!4]XQAT"*[O>)RQ_LACAQ%H&M#
M\CA0!0%D:X01!(=6^Z8PIC=GVHE["IV^_Y(<S6=L+<7%%<LH>+:O>"O\2"XL
M>)JRL&:OF(;W8D*W[Z=N1Z?!F&2ZLD&D-_HZP'\\_$@D,V*G-_ %0E4(8/W5
M:<'RZFFR[E&?4SN?\47^U3YRH1>'1]D_EU:NHIW/&.0QF[PJ4%T"UOJ^)\4M
M>>Z</ZX7>M.O5Q@:,LU!&E*)4H.N,"2MA"F;YHUU#L6.<E>6%U'A@N?0DQ#
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MUVWI0.J[88E*5:QOW"6QYRIN)SL+Z@^^/#C@LID1;R*C>!=%LTE 6O<RI?_
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M48^AS9)/OF1/4"7J3?MDG!A2#'C(4FBTK.*6"VT305Q'X-AX1^9TM-KX_"4
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M3AT=K)\_G^<Q(3-DA -KV!8.Y([=SLPGVT?S"KSI-P1+FL!CY \DL&S^XA.
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ML,8RVV=$( T-Y"@YX,M9+8-N)\>;RK[NL=CS 7*Z1].)Y%\(*,ZXRU[A@.6
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MR]!$R\ +BZZ$7PAH:7RJU_V&H_/Y"IEB>V<,CR&I?H2EZ]' MU!F[LHPL[M
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M83R*V?4<]U=[-U_K876-MA[P!&#\!CVFA0:"?%Y<KV"Z<Q,*0.'_]*CGY=G
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M@#>KR!SAWSKFE-7F%-&3O*%*$:+2G/"5/T#A^MX!O':=HA471]70I,D "TD
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MD;+ZW(OFJKX:PBIQCG20(WLP/.VQO ;&J?[0V1?AE:S1_9$^P,72J]5MQ7(
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M/:V"1&Z.HTG2@[A#*3*6!;)=T/F<H[U&DIV1<Q,O%^?;IBN$],2Q81577&Y
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M:Y?8D4-5OEQN&_?"\-'$8<AI,!M7[%$S?8TWAI"C"Q5_]U3QV[(<NVU-K3
MM=T776>$^N.2F?]1;[GYRN8W%WX+VA #E(7\-I$5*'E= L$_0*@+PN3A0O%Q
MD_+ZILF1-5U.V^Z^&(0N"^[_I]#>/"UZ5Z(G1*;-_@&F%'TNP0QC8?NQT/#
M/ OA^SN#FFY7@0<C7<FVWP&;^URW\SO49>@=1WM#?$YI&&N/%6T\ZJLCAJT4
MMM]2E1!=C6H#JH/0]KW?.5^$=!\GC@6[\]0("/S4"H\W<C)\UFK7E"I%7N\8
M$P:$Z&^+OU8-HS*V8L=,?)J\*5]1=IFW$M);"Y#)%+9W=FDU<7V&I-C0F2=3
MW:I[DQOUB/LKR]D4A<PEFF'+#\SP/^_.U+DJ8VQ85RF3U/8=XVGSKOU',^RQ
MD%;3":?  _NA;!/[<YKN&+L]G3G,]*O>C"R/(BUX!Z8XN2'^P.FXKKMQ2;"9
M4.1 O^=8:J?_'L::AHK^1]U8#W/ '@O_N^M"2WS"O;3#]KFZ<JIBRL#.'B/Q
M,)9\XLJ]UJ2!?+KGDC5L*C^,PH!;H6CPVN)Y 3U-11G0!)/0J0W\L^PH'(_]
M>:-*N?,78!<!_E3GA6[]*:U3.Y2S[1_@@UM"PXQ;8(N+0Y0(!SWO80%#MKJ'
MXSB:=[KS.13P6(Y*0FENG@),R@;LVD8@F^C31(7> =M9J^?*MSJHBV\,]X7[
MU!-DNJU!I6)IFO?>H&V]%>]$*QTV6WO><W5QUYP?)"L<'XFD_P%*<INE0N[+
M>X?*6RW&/$\7"N-0>:TH+:@Z'-%MFCN.$B24T2"Y!\9XWMRL0KPE,.Z%&]"3
M,O<P\38\<5"FW]Q]2[AM!$#+#R6FZ['H*X$IEEV8Z2 ?$M75I1A"G56JUT+<
M _+Y=-YO$<\=P>+'?E#U]4*MG3EL-K^N6OHFQ+37Y!2T]P6T5LO^&?]S7_6$
M7X*YSC<8@? <GC542-[]6&TKI>Z>/8%N6*^@@?^4,0KU%$M06^'A5B'(<E@#
M32#HC9'R><4\\NYI3Y8VXA\@5T'T[>C]PE?2:%7:A8I#XOVGYA/OA A*LX5@
M \QY\*#L*JXY9I,(..]]$%NP<Y&,$OZ[DL G6<O&2M/>SLR<O8'(D7>EZV[H
MA$$90_!Z<U!P:WB??H7@#XKHI?JDUXV4?5O>DEP4J[_L(Q=]@VZ%W<QT\L<9
M!^K,!"7D<G[=5+NOF>J4%Z^;U(^QQ>#]>)@562#2#\C1*TD1V"N_F1&?A\=Q
M0/UO(AK?&R/[J&QM1P@J!<7O, ]%ZD+_PL@^7U]^\W(K+[?VPKYP1AO4Q)0)
M@:)J1RF<:"FGOWNJM%_3)#6[NWN',R6T4WS,!Q^^9L9K_0/("I(]*GKI@RL'
M1('BLYKJWD1E="0N=8NX9#M4AXXBEU\$K?DJF-+1/B:^M/H*S/4\V 3WU0B+
MM+>6RZ7XWH^R2Z,%[^Y5\!OGITR8-I)9TQ,G T0]32Y\&:?MR!3V*B1=]GI,
M]MIB*VU=B\_NQI55(W]6!1>H &C J!H*(9]T=7'.>8W!(L'N&=@+AR$/!^,:
M<4SX?Q)0/MWOU!2MF;C^U%/[#<JI&%S3D34I?/*@P:?VTZ 54-I=:%XV2IE>
MX E'IQA$GU2V/N(2!W]L60'IO14@;Z+U*"283!K<3X* UCPN"I11,;?[35TD
M(H03J3-G T%M]LO\5G@\+:Y#.GG1<=16% ..[%(,AJBG:E:)-R'*PJ@Q(9&#
M6N<+-7616MZ^(-27,"VL,F*^AS<&DP=> P*[PUC53J8(5KS,?26YQX@&!E7G
M@]_W"K*<3Q5<5LP_ZV"T[C2J-9\>LE-FAL\7CC\U2:\M'4:\S5[V>[PSO?QW
MSIC&ZP]&B\$1,JNI&<I"HKB'C8A\2LN;KD6.9'SXSW-J12>,R5,EIU(OE O%
M96LV>#DW%U*6QB,#)4TK[?'SO@XJJ6J+)MX-YA(HQ1G<Y2)*T]\6[/=J(R$-
M"&%-6[@D+L ,YJN+9"L[.Z>'& ?GW3<=/O2 9VSEE"^Q?YZ.Q9Q"#5E">=PJ
M-Y#BSA#E93YTR2QM=]3=E@3/SJVLRCHXGM88%X:6RUN^"L>LZM-TL]'UQ=1L
M_T[W?"@92X&VNG!(FW4:L7_!NLER^7NMD>:-D__UH4;_'Z!<H4EN6^HA>.F<
M/,(?70=*Y*K^/1FGF#B(KFN_F%I:6LTX>C@-UVFR"J>Q$G\E6BX"P^-< ;!T
M4+<VWWJ&*<BC*"#N0%)7DW9&M0]?.:I6?[[ ?08%A(<8L>H\:_+:YJ(1Y&UC
M3H:<=N^4%>1B2T0_R4R4H0Q'=)(4D;12ZC, TQGV*V=$8[\_M]T.%QHJ?W#3
MS8H%-OM9F;I?*%L7<ZV$_&@0YS2-S?=3DRV-EG8KV>R+1)9,Z"$)CWBC.QWK
MMQ%V1XDI;P6!^M1H],.J,(#UW(R=M:(/&PJV,[M8I//59<=*]KC?4MC,@T8C
M$_S7H7SP[69R#5FI#O<U5SR,CA^_Q,8V9=/0N#3]_4DXN/,)8*P#) [T[??:
M!Y/UU%O6C]:A<..'#1/?D^5[[3LM_IW$9'WG$-3>09/TT79C:.150IJIB9-O
M:IO-ZT!R[A)+F(0K?Q5/D;A.WRD])U+?%-3"?&A[4/NS8 0Y@J_@Y;LGK9_&
M><*-LHXP._MI/Q1PGF<W&,A/:LTY:SC:'">0NPI#N+.>:L-"CGY2C9^898"V
M/^&FD;$/!^TGD$A[M:86NF4G,I?&YOM_FA>]/%<_?O%;[P"%.XK%;)+6,WUY
M*[%R/O,#W>_R]3,]V#DP2(PDV?JLUD*(CGBH[VCFREU/P>8W9"A\$8UCX'\
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MS?ZO]7IUO@94-B&]D?P5>E<W8'"X_SR[&L*V6J&3 W69PO(M7;X?8,RR9L)
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MD;<@[=6HN4;@.$S1:@R$@<:L+'*MY *7SO+8$E'<G>=NE[?'K[ UK")<"U-
MHE=521,K>#K-P56*0\HYF)]^O^P-7O4I)_(A*=8DSQJU^F1;GJ9D0=#^G/9@
MT9.QBTY_ C *='<R]B]FI5@.LU\([ZD;L4PRX#S%=6'<O(>=G(!=N7.T8@A$
MLT5*-&5' A_PFQ?!BU\$VQ -U^P#K.)@5?=TTT+,V5POK:][PGL]\PE^X'HW
M_P5%,)J"=9RR\LW(1X?2,$*ZCC[L^F79UD4"_O7/=0-A53A:AVKZ'=X=[7 3
M0N3=W</ZU2P-2PCV.&17N31V_"AR\7?EZ[>)2>B+'6M!UP$%@#?[2F?D<@VU
M1R7%-D7<]#IS>8C3K)"VLV<S\ WAH7O/&\&J]_I:#BX0Y0$77(Q8L9 C/F?9
MII2HJ^$@NP1+3K''^74-K/N0=\V9I:ESLSV_'Q%^2$)A=U-72FQA[)Z$K6^9
MXF^+S;M9/<PP:=2;,+H ^=V+/8]\%+^]0X6.)_8%T[WG!,6/)P5EWIXA%__7
MP&2'\'8>_8$+6@?A+):%\+/>5_P#>"^.M_&BGJ\.<H<&#M*UBU8.^/",<9T]
M)@KX:>I[_*S8HSC2@P3')+M;0+W"^!R1GG8#%Q1U['F]&X\V-#<2',7+^9U&
M,!0)K!?@U<<<;_Y6]^W+TB_BV9G*E3AI>)]09,F<B1D7J[DTV;8^[(IEFA#&
M,''T0LG()4]XV!'*27]5*A8C>>VZNO7U-X<I+?4/B7_8I6J)EHC5QW;PJ#EY
M.^NG$F/NZ5JP3M@5#37 ?]E7S^]PQT0LA[\')CME:,2])26 1:^D[\-#JMSF
M,C@XTEVY2U]5BSOUOEN#+<;/@1)/K*6_]?C>Q4D\UW%<\L.!\B5A#!FW92_L
M_NB(1F-"[?UZ6%>S_+A"<J&E7TK#B'KW6X"M7W58TSP-('AM\:Z#R'?N4$5U
MC*D7/8;-<TS-#A59F.R$>0/B@6#(0^979Q.#6NXS]5Z*0OJ V+7*.H&3IG1N
M3!LV2AJJ)I^JU8VFUEW%'?-KAW;, ]WMQLZL[B5JO'QA;?U#U0!$O5RH>G/;
M[%;:ZD=@AZ9RE2?U>9FIL1)B1B4G ?A@**8M0#%Z;6W8BO#<=BRSO\/ :VF(
M/(K4+6DCXC[X:?-L0J9R1VVMB=Z>4JEU_/)/ADYKB[,8SQ?$75X)!0-=&-5X
M:R:*L2,;0QS:"\V]O#K3BFJ!6P/7G6*D@ND/].$$#MY_AX__%N7P/'^BH=^N
MY:(X;A/:A;Y.\-)7_SH#84T] ?]>FN0.2))8\?_+GKB9;\?&%/%QB@1M L=1
MG5>L2,+56';M:X=\_!RH6V7T#!@!-J230JU'4XL5ZXJ:_F"IN&?F3)5.AIXF
MQFK%PQ#O1<W'W]'] V3ISRX7MW:HK4"$>=;&_:JU#QTA94R)-F:9WGVH6LG"
M,Z]?^&S%[<G9_YUA?(+F+U8.L^O2D91T'+5"=G!A34E;VP'&&ZF99O#,$J,_
M>)TE25:E4!K3ODXA,#L>4,^5F/N[5'NY#^AX2X+&>O_=MT(BKQG6[&D\^*L7
M&RPM@UDNK_:?-%.CUXCN'@^B-K #G, 8-'7OD]B_Q0H0A!(Y_#A8F)H!3 +A
MW]9A/^$3GTH76L@ 6O+_%QAYVP"-F&MI_H)&E=F_ ^:B.V2$19F% T6'S@=$
MMEC9M/>OEZG6I34JQIS[N&JY&0,08IG%J]&&F;_'C_XL@FF7^)?'=M* ,EP7
M)EARD Y-H>?H2\GF#,\5-;ZJB"3 3D'/]6TEI=%+Z\0?,$5,'*E$)<CWDW1@
MLE=J+K&\M\$UO+645-['5?('XR?/X*(4I1.443(7]SFC70IAU-EU=:C+R\8!
MR2MY47=L?CW#=%:_A+W$KV>L'G0QX6OPY:[!#6^B#9]DK_@\ONF]Y^MEC0%'
MFGP:NZ"IAJV&-KJK[XMX:?*ZX%_\,ZFO]%E2^ H$:=,@U!FTW_HS@T=5!MKY
MDN3L<W5<S\ "/M[<:]CH2+VG68'H-1#&YHX]YJ/#%^ X0JNJ/:["H ]B7$EN
MNXX+P8V[;:OCC30$+[++<!)OK7I+IGO8Z-'9;<BNSPD0.2,%XD<QRV9RZ:19
M:W4_+]<,C&%A+C*+2BEWSI2,:2 TLGK!Z&0MO8J$T5P!<QXTC@2;=,(,ZB5^
MCAQF9(?&ZN,[8'/RU!KAX4A<^X[U[YK%? <C:8,W-+8:]$8SLW1O[/D3NZS'
MA64UW(;3:^KD.O7?6>!A-=;I?&LHWM[;.$823]90P)BN[W7K@I<6*('R)O\
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M#5974P3W^C)"Q=U^JN:[T#GQB>VW735QV;.FE8'<':)5&WHKW)KC7VVN5O\
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M%W] /Z9WABDPDS!ND:R&0P>@]DNMJ5E6=ZDRN_F)7,AZV:3VDVW7J&?\-U8
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M(<]@HJS,BS'_^2^1^DW55(R"-/ 7)OI\KTZ)OV7F>80H&;>R%/X\;JO25FH
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MV: VUFSM?5=#_$SK6YO_)[H&1?F:&-I ,9(S@>HJ^AII8T(;BXD2*23[L?\
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MJ4D08JYVSTJU7-HD9>YL-M#>R<V8<Y:$^'0>9<=>DI!Q14^VCH8E?JF6?^Z
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M[@2@)8ICX1/_"!VC8U3;'@RC8[\5E[0E3 _A3GSV"&$?.Z(_3KS_DLIF&9U
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MG2=<0T=]"Q<]F]CG&#JX6Y'/'],1R1W!A_N9]%>N0]T00S9Z&",.K]8MI9$
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M+=A+\'ZM9A[B^D%I01%_K"*)>'5)?(+9>/QV&7F?V%=!O43;Q-3&N+2(7D6
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M/C=OB-:QE6I)?GT, 6J([J[0TQZQUCT&>M[!@Z9^-_CK3?DBH_7MLG?I(1
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M;Y2VAA#5_67@(_;T=,DY%/6=K1[]QF0.+2X7D**]-C1\01%S]FR:"93.'!3
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MN;T#Y61MO9[*KT, LLTL9K7E .SO131(. T)KLN4RN"5:3NG?5[% 0O:"R,
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MPF;KX#^SY:I!0%!O%L3'I_39+E,IMCMG13J/5SDR/(A,'O\4TOWR"4#(H &
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M]M^;_(8=QMN&>/10[B,#P)CG=[XHWC%ZL[LQH92_$9UYGBM5+;-(/>3^!*
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MXM4KSV_S_=( +$[5 6I:&=-($G-B>T&W03ZZLT5NZK1#!)K(":2.;PQN'P+
M8+E4^GWK#4:Q_JOFJ?L'^53C=/P96=$7M&3XET\ -..%MI_M=B>O*!P\;\?Y
M?@6SOZJFB77+^"@7N1)+.ZVT-:VRH5G!-/65.8V@09CPPN+!UI*2N1W$1\=F
M2DG#JUIC9=8H3G1DTE=$67>Z$K[QF1$;H=K7:MC1/DYZ/<L4 YEX>;R$/7>F
M<=2>_9L4\ZQKB^'.%U_G]?E]"7'5ZV]B]&G#M$GR;UY&<P.-D16%"^H#6NDT
M4B') _$51/FE'-7'30TU276(YU2CX0I2W8D60+4B]SRS^@F_U,A/P[2+>@TS
MAB%#'E>%I9&DB1\"L)@.G+DC>$JE?UCW>N14+#GP<U5/4)W:*)@4=%BJZQ7L
M5C7<A__\?5QK!@HU496W7C^*5"2RL-IE^B-O'8>PP;%5(-"SHO2>5M9I7U8H
M9-C0R[NYO=($K/F[L=[WH4_M"R^&&D^GJ456]$G.G?A@<#I*!54;Y9JBRE>"
M]8'3>K*/"/DBE:!$RV7J,$/ X8>>#=4I_4'R44561HANZ6H?>4E#Y<=-F;4Q
M?PD%=.XW<KW[.? ]0J.?:NX^D]ISIF%%/N+KB?'=VYK1U*WAL:JGCM/.F^:B
MYA%6?=UKZNVE.IO,T=1&GGE[^1%<HJ/=]J8$PPEYS8%L[$,4SF_UCM[,F-HU
MT&3!0-W+[,*-Q+''9@@U?HT2<4X,DN'AJ8)B5(GMR5Q%Z%[@1*B/&KK3S0>&
MH9(VE%O53JROJ";V7*CVR;>C-G5JLX8=!N#FEJF;&);Z6F89(X^B1?>O7L7;
MA7E(USW _%)[,]U0]"# 6C"^EDS7+UF!O7C)NL09YJQL-JWJ_2< ]6,!.D^
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M*FE<-@L5M?Z,E$H69PU^*Y%<"^+SO"IBVJBU:D><FZ)HGH!@%:^YE5AVS2Z
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M2.EF\S#=*G6G \4QAH-44T5UO*SOU_E<B7E@7#%[!G0 HK%[/M\V7OF>[,H
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M523^=1?@/:1J)WXP+"RRN0LQ6A12*/L1GW:ZISJPX%75^*C3(T)-M%#O<A#
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MAZ#\4^IT@#6Q???9:N"*3Q3'H K=GWQ^LW2X$V#PP%JP?9^5<#66KSH<E"-
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MI=-[!\D4'RS,WF:6F1K'\C9Y'(!/3OW17.:VA38RWPR:)[ -2<$<)<L^/X$
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MGP+(8T2=\Z='TD,W92]R4GBM^,V%O4WSWJ..2T4F3ZBV?A# :.K7:3][>(R
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M/#8A;&Y6 A.BWU?;_6Y?8-==Y?)\J@X_C_'KJ+SWD"A3[U!>ME$+S7, ^U$
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M2?\0I[WL-+?*5G# H5IM("IUG$5D\[A_J#W7D8&<YZN40U$*EJC72G/99 #
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M4Y5"04R8;W;39"D;][P51T8P@Y5#@'J[J8AV\ZZ>Z3+3_.V#;$QZ8DIKSA,
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M+0-K*7UEB 5J+^T\2UX+&'-*Y)."N*[@0]SK_+SK(3DO\T^H1T-W_)<#DZO
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MW@^FPQY2.H9=F*G:V0_885A_0R#2,S(5,KHH(;F*41WI9U]TL% .R9%%Q1O
M!(2&<]P^,*G7CE/=9#>Z23_BZQE/\-4[UB:X8;U6';9K+TPIC(J)G:?M?^NL
M?#<PW:G766<7U48>'NG;W,7+NI>]0/9%^_O$V'SO5)R*0C*Q-"JVIQ-85CSE
ML.30<TB+H7L$Q3V)NV24,ZXLJ4B<]ZJ.%VZI4OYIU\V@OYJR(=)RHS[AHU0]
M$S7#Q\%KY^([#P$SFU_J0A4KZB7R/Y:8U50*T%]AV[L-[XE/F#"S=J$I<FS:
MC"B(!QU8E1JIY-O#$GHU=Z&"0T53*@70*MF<C)_?WO%37E+70%<)P6?'C!Y:
M*E>FW06*=<UX^XF6/IB*--U_R&?/\U1I44<KI=N8?5\I,K= ,;AU?T8\!+K5
MEOC@$!B6.IP9C6B4^+V__#JU4\D5]6:L,J#FG(X[V!6]FU@Y:!U19^HM:TVF
M>#$IN98+S\J&;&;A3885^3*3?K7&XJ<G@,_TCXV-T>7-^R? "B'S%AAVB;MP
M?3BGI>VM("IR]Y-MM$6>+/&6L\7A^GK=M>$U0F"%'_TC"JN'4]E 1@>SKNK@
MQKC.VK5\)X:S_JDL-B)BLL>8G%>>P*E1M6L&&<K0FE?_W]>Y:[($:NHE0%1R
M "]!X%C!-'6>B[E(Z*(<<TY#%6%:WE+Z5WH,ZM.3\][+ERF%$A86U-T_ I%(
M@Q'[C(Z4K4+D*X(EPXR;ZA7Z@9$D%%SAJA_GJ_E":#A_1]:._1:'$VU%:F<?
M#3J/\:J&-5B6]K=:@OQ]D8&'9C>3BYRW1O:U>TB*4>N"R-V2 H.JNFAZ86$X
MBU>2QVCW6 ;2:?+CY E2<VPMXNU#$T"//(>QZH(^"];9&+?QQIFX6>Z9(\]M
MD@],)ED!O4RZY8O+:9#>N-W5LD\;*?X; UR. @6$0SO!/DCI41RGD1IL2T,6
MW_%DZ!/37\:^H_KIE,G(Z(+;%)=(R'ZH<J4@\X*IA=/K1[?4GI93P=?R0@7$
MWD^\*BMEY"@B'N-6*^6-D884EIBNF'^(\(YZ\,4*S4L#U)KFK':)XHX4L*@$
M9!2G'<)F$4&B,P2&6F3;H^TOCN89W63/HB115@0*Y[(BW8\!A$+016J_$>Q=
M\SEWPZ5#4Y7>'PC$<)J31 6/0C'7Y=B']0I7YQ.X-NW7#*P1(8>;5S'M3EB1
M:"8D5;"JW@;6<W) =MU$*8[O6SR0W4;YXZ=8QE,6I#HL',Z7L_@V]ZRA45YV
M77);S7EEZ<U394J*5RPZ2DR+03R,0ST&#2"GX3K(<'WBY9PS+E>IXCL1U /8
M3"$V:! D'*K]<SUZJ>9+<^*X3/BAZ YV'.W']G=D<-$+Q310<YFMZJ^:2\KZ
M!-XNNFXZL2BT;M'4B6C]WU/YY321@]'-(<8X\P2EQ_,6<]H-ZF\7YU?UV)DZ
M:E$@W1Y:5%:5"^37Z]1F%)V;L0*2.B+3[W.(637^E$8M6*/#UE,[DB<36(^H
M0X4CFN0[ <X'BZF3WK3Z8'F/(D*NWH.-!&?X 'Q\>JD*]W13P.5F2%= ".:@
MD;V^S$0O?2__4XF@VD>BR3Z6WWZ66.1D1W578VJ7*MZCZ]+_C(#(FOE"--E.
M6:\'L;]2V!>/.O#KY1;2+52P(G_8IK /.Y8O[D2\@JG_+1%"CPBRPL/ZY'UW
MF6F"C&-1GYHPAUO%$\ +M4N_HMI*=,<T4?SLG1#H0R,*N2(_@8$BS+B5L)*9
M(6(UMO*ENY]R\\6<+-2S7VT%F1_Q.(_-C8^T"$D/9,Y]^'[TSTU$5G*J+DJT
M@8(G.K(W63ZEWV6!^R/!V<%AA0M:7=2<ZNLXRGVU5[JMN\S;X;Z:JI\\P=JE
M-)S2UMD#P-\U'?WV+I!>W/^OJK>.BOJ+^D8':400') &Z59Z$ 8$I+L;I!OI
MAD$D9*2'D)9F2.F2022&[N[ND*X!7G[O<^]SU_WWK/7]GG/VV?'9>^V )D>=
MV]]\7D?^_V+>U-U!3/\;\^[(0J:_^M+P)GC'+MA_!!-#1X:>QN[#10' HE(L
M,2282C*YQXA0:5S%SD[X)S<3<$\BV$U&M@#-!9V_Q6=_N( ]*D269L(\CJ<5
M=RNA(,DKE"XJ:<.[N)?Q;"K-POZONS182_PD./#%&TI5L&WC <AI3Q54?)LQ
M/I'C^(O.CTL(B [D8;!#@G>%7*%*9U^DT5P*,-:!B:VLK_"R'3[R=KJ.6)?"
MLF;@#'CK=D[E\V VGGR!2 N8# &?ZE_6#>)E$S8*&;.HU4!L!6X.;Y(W-NUD
MW:Y3B#_73_X?X[SD[I,7>-^V)'#RSRA&!3,0\J_M03[KZ]/5E^]X2L.WXJJF
M=7L@0.'KE(K86]\G7"T=Z&O*$* 4UW4B9.R"UC6\>0KU],*+%#':B+_<('[G
M]U67@K\IAI8Q6-LKR:*W>#$W^2U/?3@V(]K\&)QT#NGD;IAN_"UA<^Q*)O0U
MW_R[R/4SAA<#;MP0]A2=QK?P%LR_P:_MR)#4',+.W R 2",")/^?S<@%>1:$
MG;^X_P^CI6-VJ^BV3C0VC6<P:Z'S&[(+$B/Y.H48>;#JM0:V\ :Z<N=WQGY=
MO""D0_AR@PN3'WI6DGF/M5"R[;7Z:4L,KBB:?@=/5-X[G:L"KP1IS)GJ6,VQ
M@K][W5 [A?4E+P(Y;9E'@)6+O23M0;?\!WS77UE%T_\*63+Z%$#8RY7;:HEQ
M"$9&6LU![3@NH8DDRQV,T$#;>.I$GO9AA1#=N4ZT6#<W>]X#)"-,*V_"@ O=
M]<57#0!.#WTN2XS=ZPI_;8.-F>3,VNHDH.QFRZ=&D_?Q2P713B$#+.;(?C&3
MCM$6F_ER12_B[PLE%3EZ1+"9"5^@>8&>?H0:F/U<NIKO4'XNF]$Q]!GHHM"K
M,.0/ 9NB39U@2@&:F>YGS32-^9[G:=(:R)@+>@Z99=YX^<@<T4@"WJ*LU&-3
M"Y2(1ALA/YW?]X^5\5%GOW&J+25##WMZ:!5N]U=/%O\] J3$ZK^K)*8[;_U2
M!JLD(Z1.]OF#A*?_.L75K2>;_,2[/47(G)270O[V3.."G:T^83->Y+8HO$]Q
MJ'7[UV_MDSSQ=:8L@C;)I#G\L.*GK84%,?L-$S8 <KOWK3$BCDO=S5>8,;;
M6'Z),D/6HZ,JJHC13Y=S7&7_!.C$9/UPO/NB.0MT@2WFA2WSH4F')J3D/DS_
M(R+ CA+6("P> 42VQN?WQG"B_TVDTJ[RNTSN;5*3<],!_\:_*K*39FR@7A<\
MKL*?VAI:B%L=^/FIF ']I'!V/I7!*Q-J$%-Y/$]3F.H*-UI ; >YQF"QN_/N
M.> [+QGMM$@\D-*.92/RX*^_!QTO"(H4<ZD>O;%F">=M6*+Y04+74),U6]$
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M&P<9+S/M0^16)C_\%[Q6^)\4Z;)+:N58_IPO?X[8L(%7YA\8MW?G:GC'.GW
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M96"O53 V+'P_V:6O*^]O_0?"#XJ]_H9DN='QS"&?&];855!'I!$T3PJ)(.V
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MM&<0A,-N[!?34Q7-!T3!0Z*ZX>CNSO/KV"T_XX"&D_7_MY-L+G3.D 0<RUM
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MMTGGU_$H%$B2$=P8MQN[:3M<I#!'Y:J:>8(3ZSHZ&E*(*_LS<Y_%,J=./<_
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MQ*^=4:_!NHQ<\C2NO 2V.3!^/CK\,/PN5_QXA>TS7T$H9<6I!X\ [ ;)>^7
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MS_C0\PQYGM=/M4<=IZ*EWIWNF:KENN9U%1C>-+=5>:JA'H_G-Y"FVW.1Q8A
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M]IL] 01_W!\;%9I_,5-_/2%E9MVJAG=,&YYQ&"<O(2K5?]A (PM2(]< W2V
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M%%%'4/FOG''NKURNMP:GN-\]$]X#3M54UZW+[2YT:XZ=J[SHCWF;\][!\Y$
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MD_?"Z%XM]KFY/4B8R7=YERS:Y*=::FAL--RB^'5&@C_EX_?.H>Q^ LG@\7)
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M<-^X"%MIGRS$T:=?4/QD9)KZ=79+-,/#S1+)%6-I?H?.(#(Z$P#)=N@)K3.
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MQ<5H]<TS_OY-Y],YND=5@Z;Y ,YVD$S8DH6"UXOB/-Z15\"Y\'BMT=4ZDZR
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M$,IQ!^!?\NH&#B_O]5];D[D3WD%\+?*C\?D+'ILK7ZZ\7DBRQ*.VZ;&^VS2
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M$M#\FS;_!J.R99C </HX:UX ?%AU$,F)!HU3G!/LSZ!)HM%VKT8RR[&XSS$
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M]Q,1''B*WG,S!/@<;HT%*^S;?70 ZZS//!_QZ^.XZI&=H]%+8WBFV(.!\5P
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M#K;XY$K8)%V@P21!),)0L,B'- JFB.OZRB\@>VWE?_%,X<6/_P=02P,$%
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MT@:@P0$/D"Z0$!^ -V@0D&@0+UT \>M[0D/\90!_'1!O(*&@86#AWL(CO-X
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M1P@EW4E9OG=R%39-X)(A^"(S"> >01MY,$\4.\CBWAU*3UK-K(P@),D32$K
M(WZ^YKFF\.%E^H_BYB:8VKN?_ASEV8UXAR:__ 6(=*Q]MI/=HGK3_?]EI I-
M,RS#?(K!M_+5-5'@#6FN#)MTRL1&;>[-0W<KABYGWQ4D^N$\T#NTI!*HE9:,
M;\,46^B > ^J[BY^  P5Y)P@8L8O7[@^TF;C)1=G\4;PQ*-(J-T+8%9(ON81
M127O/\JCZZ9?Z47<S=H:P#?*F\TVBM15<1RPU!86T/Z!)[)I2Y? $)UK]JL
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MQP)]QLV=Q[JQ:G<:N6UU.6PNUVSF?T-6U16:%R!*^P5X;G\!,N#GBVVP7B%
MF3=X[36<^K/6I^CX:H?.9V8EFI9LF!G'DH:Y-9;+\6.HP7;-S")^E:JMFTJV
M37)XGN.[8'MW01&"];&'N\HZLZ[>=P:#KFN\$_7@@O&/V]\0HZXF#]M;Y0IY
M^RY[['LES5D1^R;&H2"917VAIPPJLQ9[JFFRIT')==%I@Z<-VHFY4UE]]HY"
M.R=SYJ>/,7+,CYD0GS34N3TO1UE/Y!LL6XVX*IISV(MXJJS28?KBWK<)>:;3
M4],&Z#KD9#[[1;4&@=/.O#$H)CL3C8H[UMJL7^=OTN*,DVVKL;W3KX;.J1S=
M+6D2THS9@<)OY4H,5ODH1&/X>NZ@H;^] $C\4RY%X!Z-US5!5+'5Y.^4O2:B
M?@$JXEZ %T 8$V+IO[RFTA2(1II4)DVN];>PQ9O3.*&W\'Q^B0!(Q)Y+I8L!
MP<(MF\LZI8AV-@9;,:0_2H(ZYV>_'-\>13"PXT4/E\-%"!IN3ILWC#8@G[IA
M7JJ&HMXT_1$ 4>4WJG>JA=+YS/ZE^FR*W0E5+8A>=-X$5.DN3R)J)+_=.L0(
MPWE@YQV<M%$DA6 V ][M<?8B=&T1D#XRP_R!W,](C<S?&/%5Y8G!R PKJ@4T
M>W+=7;_O3#>7@ _EBTJ!YMK'+>K2SB,'<XVI$KZZ=(BG%!AV?.(X>!ACDV^V
MS[O'381CJ!HZ]-TE%!B>3-\M8X$X4E3QT3FTIP\/L2T[D#.5KRET*-IJC.3M
M[/EZ=&!(T/(VQI37Z;;;8N]AI(P]W!+Z)L.MA<13DL-D$K'X S;%$#=_[*WW
MC.')=3KRYD;>4_0IZ@LPFP'6;PCYDY@UU6Z(K(9KM#U<:)NY?3!+E8*)HRG
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M%Z!4W08<$MT8#.SFG;$'T)<<Z::)@*)IT*4;ROGI9393O2Q39>QC^DL#@JF
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M8PO%/K"5%SY;< @\1K=H,2XCN*G26'Z.A!*T#OU90G2:1$.6P!T@91NJW_A
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M?U ,6I'B[67:VM H.7II0MI<T[1!_GTN<5P\7\LS6*]CKHN*9MQ-Y0?<S6N
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MC&!!Q&RQ$9X;NTH<;CTFEZ\>&YM3QKP<@J=J'4ZROR)G$D,'X<=X#T$NC04
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MB/R$O'#'P!;SMI_V=R;.!+/I]IRR9K^&P ^3PQ?)#@O3\YI75\I7\%-?[N/
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M*^)&Q)0ROMKE?-9#%=\+4D1U8F5\5H,@Y0.$: [YN$H D=S&6!OH<\AB8,W
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M\WW$! RK_S+E=B&=-,J9^1(]Q#B1IPV!U=</V]RDT86Y,02M0@X>%-7][/\
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ME<Y#XG@IT\Z'A JO$CIR:E#YN]%*=*T?W*5:,XO38 ,SW_DU.!*-GO-.Z&G
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M)& 4,"T0=&-4QZ(HQ=2!P=&VO83V#KF-NM?',PGD@6%-I.Q[O8=QG!VPVK0
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M65-79MJS>:[,\. PB/0N$GH<Q0YN>,VEM:*;\B+29!F2 (:UONP.C$:Y?;U
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M.CM#9)V<[+1XQ]-[1P,Y6>CTOVW8R2Y43N2/2RXR?Q2+='*<&7OIX!6O+G8
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MB4=LXA1F3[0?DOTYP3S_+<G^*=B_Y!H$J(B)0.41TP)08'/[=*('Q=ZQBF2
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MH>/^FI"SQ@Z/U148>6O^K*YOZ8\T/#"4F9IZ$1^4;$-Z$VC)6.!N@*Z<F2<
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MMH070#1WT>RZ"J^:3PAD0BAD#5EPSB[>#.IW;/?;!^?..'2+7FQYDV95O&M
M<O\)3[%)7R>>X4<(#OI!1@_X%2P9%HW3!\.X.SA6/8,MBC($G>3YL:45?%FL
M&A@@5%;E]@<"_1IT-/[RQ;CUL6U8R,!^ L#H3E\NA)?:BGT&MCJ_]FLKTD?5
M.343NV?6*5],A8D9W\Z;E(YQS%7%,XV&@DDZ<W48(L@4=QVT4?Y)?%D3 4B
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M"-2:,%X)@8D_ZO5QJ=N)6=[QX>?'B3ROPMS5==;U:S^-W7COV=AW0>>CI\2
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M<)?&FPX>W()[8\'=W9K'S.Y_OYG]=N;M>^==3IU#G7N[;NFOJKKO?9AY^ 7
MD9>6DP8@/ $ $![_  ]S $D *C(R"O)35!04%#0TU&<8^)@8Z.@8)'C/L?$I
M2*DH*4C)R:GIV.BI7[#0DI,S\#&RO.;@YN:FHA<0X><49N/BYOQ-" (:&AH&
M.@8Q)B8Q)PTY#>?_\?'P X"+BL"&F(^(\ +P!!<!$1?AH1- ]:CG4X3?#\ _
M#X0GB$A/D5%0T9ZA/UX P0$\04!$?(*$^/0I$M+C6;_'\P DW*=X-!SBR,_5
M3%!>..%S?HS-1J65J&HC4!\]HN-Z[QR(]HR0B)B$].4K>@9&)FX>7CY^ 4')
MMU+2,K)R\AJ:6MHZNGKZIF;F%I96UC8NKF[N'IY>WD&?@D-"/X>%Q\5_34A,
M2DY)S<G-RR\H+"HNJ:ZIA=1!O]<WM'=T=G7W]/;UCXU/3$Y-S\S"EE=6U]8W
M-K>V=XY/3L_.+RZOKF]^LPL!@(CP/\=_M OWT:XG2$B(2"B_V87PQ..W"W"1
MGM)P(..)JZ&8.#U_P?D1%5\B-KNJ#8V62_V(X+WSZ#-".N[EE\>_F?:[9?^=
M88'_5Y;]R[#_SRX8  ,1X3%XB+@ ,<#E#4-.P+._(B82-O#R T"/VW9/OU2T
MYEWFR3S5I3@W@G]XGR/.;'2@]@VKS , C0)Z=YQTEH59PDSL&3W=Y!SS0[.T
M8@:J\>)>.X"'H<2Z9*9O;)GKL$M/SO2+.84NJ-KE#79.. /@?T<5*%=!14OB
MJU'R_(X.M%&*GIH) 52-1C^FFW2&EW!;U_PFX%4/@"U(^5XSO=H2])I8YTJ1
M?=]/ 1Y(!+J\;NV.^</_Q:-&/4Q[S@M)8I!S]AO4A0? TL4#@!2YJB@C-6'T
M 5"W#^=Q;*_*:V$=HXTE&"U?Q2CC1!UV,NR*SB5L7=F7[-"YL?AF3U(@NQ8^
M3Q>[-X2U?%9FHR1^)\*FJ763X75?40P:D3B$/P#XKD;_R$R+$X5R^S K<>_R
M0<.<BLW:67/5JU[M9V>*N/0\J75] (0>5;5&']B6ID4H5-!D5\W6:P#"4/VS
M OG)1W;&@(&1*3T@VQWC,YS&!T#K()S[CPS/I+4H<O29C4;??38+(53,,IK!
M5'?#9:(&A5\5@=RC#!O/*K3C9J\!E+[Y(MC5]UV"26SL+NR;C<;7>NU?JW3E
M&O"9"=#62[<' &CNSAKTNV,,'QVS\>B8,S]3(!";=,ZJ4&[\U?B&+NXH6/JT
M">-+QZXFT?)^4U+JM\+]:OTNWZD1*>O*A@JD&B+^'T.O!?C+)CWU3[3K#6)R
M^4%_$8J&%&&J@NTJ6^<=Z/0K$=X5_A%823SG]][=D=,S I[6 / A#YT/L#2E
MMH]%:L]'Z^T>6O=/JB2!P['2.?5Y@S@![+^0V\AQ!)]T^\ZZ6=\0..;#Z/#F
M0XAN"D>"G1EE_2I8305-U\;]AJ<[UL/U16N#K0Z1;..7(KK*N3G L018[@%@
M//UN+7;P=_?B_N;>_7_S-4R\8"NH'<X0(>\3MOZYBW"W:(1BT8*/A@)!@+))
MK<174 &3\WP,V%H[V[;)78V$H_AF@.G= 9+/>?Y^\>(@\,9X@SQNRPD$NTFZ
M1V)[ !R>@J*H?F<<'IE;4)2[W"\PH9+\N#SP=AGD]9XM1^CY@&1M'5G]$+9\
M=I'^UK$O_S@;;:!;4^**^(:)J"6%!V6CT_AY04E;;=S2S3UBHHS 8]YA-40M
MW3\ '(]S;XW5'P!9_^3*<^6LN*D0*=R%R&Q+;],Z[&)<*,^#W]!_W'%28U'S
M'->O5-F[JLUYY\56_D("3\I(H>3LHG"H_&S4C8CYP"7S_Z_T/QE7CBM'N8F]
MW)8QMD/,!B,I>^<DANP?[@#!V![_D/+"3[4DOC)%VW)>1<'C^^N)7BD:<=^7
MI86>N.R&4^C;%OXBKQ:@^JLD62!K<R=MR;S/QYDD';/^J4KWGO8%P\[)\X^1
MFQ\'M9/:M4E%(.N+4"_G=^&7>T[H/.I#3HU>"S^(]V4@A3YN5"Q0@=;?Q?']
MCVC9LPF'UM\\[=9@&!,J$^RK\OI6"?;#5/= &*+S3(5,?,ME>BY?SF\YV:$"
MK']RO5I3-YK;E/$V&/'I7@D^0*5^(PD2#+,2T/N;@AS7]U10FE@?8RMC*W\
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MNNAGF<H0D860;S!MJ!-^$NY,5TD/?FRMDT.;& =F9(# #Q1*B'*>!J2U=$;
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MQO5H3O@[.V]N?U &-Z-X*\ST:-Y=PANQETRH(LMICRD2JUE6./5A$5J1]1V
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MO!RSL+GMJ3I.M*S >=\<Q?O5C((TT*]]4Z7:AOH,(>>Z,J1=_)U#2F4$)@'
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M;&F-\@%@*GL5_^8!\"D>CC?JX7*Q1$\UNRCW -"K<5S:KJMI7::NY%W$UN#
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M2ETS<C%_LJVE9/Q?H4*ZE\?V<QDZ59;L0J>X*_<,^HCX6#0=OF,:ZS)!(IA
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M8V@'A:'<5D#V)G"FTR%(;I1 G(1E\$["B?#WFP-45%IHW87N)Y/J3SG/HFY
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M8THY]Q!9)C/<QGXH"B.4%/EAB):$ ^  ..,/Q3C&TS85C%3--0TM7_@M,)(
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M4TWSOC\"XH&$AX<ET @T5YO(6#,M^^=ZK"-\Q]F491S%;']>4[A"-VX50X:
M7/OG(#-EDME@"0FA\1)M^U!0A1Q8JW>(M:Z7O0B4W<?JI.2&702VR[NHJTGK
M&//-+2YW)D",\'UI57%!!V+4_=E.:;@6K?$,YTPH$9?/+$>4\8CLD;[ N\U%
M;'LL3%0>MPC'#O>'*MG3Z5',2Y]E^Z, (([]F&N949#)>H9+J4:5*1U'Y4_+
M "^_*TL3*B?3F*(_$*X0[!QW+!W*S?BH?"5@OJ_3HT2!D*_^,)25X2#3@30N
M2\.QFIC,D0!9^?*G?J-V+/KSB1E!1>4;NOQ3,-GS[3]*T03I?G(A/ \GZ+M
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M463#T .LCLK.4_@H.#=C*8B;R*AVM3SO*MM6K3 C0ZZ0WTSW#K!:+AG8++V
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M&#EEA8_V/N3S<5TH,G>W7<KA8JT\SR-&.RO__*@Z%*Z].VRAI95?]Q'9"#$
M)]N:=([)/2,!6?%<G\^EM T8^_T\M J4_"([2S5K^Q>C(2V1S,A3M&9Y7&2]
M%5Y5BLS>(K"7<VX][3;T(>()OFU$N.WWK"!%..BT7YIF-3&<1$,O9C3>07^
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M;^E!GG!+0--LOC%HT  7\O/'YW&$\;FEXS,V8=*<6"K?>"=]5-9"CC%/_G=
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MK\T]+\F8-7O QM]KR?>ZJAO%B]0*N7)(>QD&+/V8BTBV6H!>R&&B\?5&M1T
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M!X[X8>N121*ES%J)*PJ%*&!G?S_K9N".DSZX=WZ#-+ICNW_&EG2/%D\N75!
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M*]<0JFK-W)BXN$%,?Y%WN3BT$EIF=57C2ZY+6K46<1CU7[2D0.*?%Y[3^[#
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M//8^*;VG!0,"*&# %^7GY%]S4G%_(_@(+7@SE_^0+57#_? Q"CJG[?@1,S/
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M\)AP\)LHF;Q=);S>]I[[RA]_ER'"&&:SD[(O&KB,EXI9Z4F]P;SL,!>:FWO
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M96^4)E-DK$A/<(DR-C9QW:-,%O>7Y/"REG1@ QG\??PT"2/?DX@85V2/(L&
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MI<^\K^3TA5AES22H-O!.)4XI?-C$IN"U4>Q; ,O2SH=UU")LXIA/;#T*95\
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M/]EG[^^<>^Y:Y\>[UO3,]"O=;U?54_54]3.7_=BX5>.\%3T.V5HQ;1MKSYM
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M)8:-R=S+M-Q[X,WTS.R+4:;;#&L',Q3^:<?D3RNUQ:Y._TW2?_T!KGAV"LI
M(5AHUB(ZLQ,VG<G$#+E1FMR6PC%*[XDC,3JC_LF7*9<MLP3/!1(CDQ-4KA*9
M7(ES$ 63.XDB_!!*A4#<U\(LN1SV6F:*J%<] ^0UC[P*7VSDZ4_4ZMJVZW"6
M'?X81Q@I'M9G">M%C*$(K18TCZ &#TJ^@: B6&5..'\4P,..W\M&GFF%4D4N
MHL0$(D)XJ"#L]']PQ\E\[^"UGLP[1[+A>B6A&L"'LX<B_,8PL@@59O")V;]%
M17\PD\/UP UQ.= 6S^<!RV[[)?I4-0&O<-@=;22<YM^3O]EG^+#CAS3@R?AP
M#X)OY3[-N-6?7IXA[3)BXB2Q.O7:O"KJK'W29U?7>KL)&N;32+)Z3DM56-R;
MM3"?,XZN0+"S4<D_<+PJ2?P:9Q")T UWO9DI#!E8=@H=D!B3'L=OGWSR2;OX
MKI\]:3=OOZF:0>RS-,P%S.6UVA"<G+M=PVGM>:BYTVR6>R1#IO"[WE#B%SM=
M:"MZ&I8;MP^"C?B.XF%+%-P#(^C#B/\(:VG.1@2_'BN9G5^*Z@'6[!=J+ ,G
MPQ\,RB2W4![ W)Z0/@VSD-MG+?MV(+]!QJ!90Y*-.M2\/J[D3<>.&=I\_+?"
M1><KJ2'CD*I4GJKH;WJ,.4,S/?-?3:0C+EB2;YQ+\E'4)$:+DG;V& $VFR<M
MU*4;FOR"5(QUJO/?]4,KOLVH9XZJ!/7G.9)U=TK[NJ,H:3=TLP'%5&H0P4\2
M(N<<(Q-*>5JA$56/G4Y<;;Y#'7?4"S,#Z+KN)C6F%,20*_+H/3D,,T/H'4G^
M&+SZ[U#>L<WZCG;741$T&B8LZ;*HGSO1BDMKI;S2<+G >!8<_L/.8[(S;J(Z
MIZI6Q5JXX.H&^611B@<1:SU>0K%H5]4);BI#X87=5(+*4&%"0:&CA=[XF70U
M;:T0AI]+:8XBD!JKH68.MK6V(NJYZ&O%['!,6L^3=TNLI7)2+4#AQPSA,4+:
MIJ6OL>)>EWC:$2BU K5B-4!KZ]F-9K>>)A*WYH<7/]PV1?'F.K)PC%7;2:'S
M-)2&@:RN%"N5T+8IND3SD7,/Z/_,GHC^!4RSH8],X3+98,;?O@(YPFS;Z^DU
M4!972!3&\A-X7$])$+VKMMGO);@,N>NE9]2"-*B-A07BG@YQJ$NE4LV1Q0F>
M378TIO3QP7_3C!F?L,JP=8RCPT<$D[B6)"ZN]#N=\2R%)7 D#:_3Y/6EZA:E
MOL/J.YFM+-^D]A;](U+:60^Y-CA_>!:B$.Z!N[8'4)6YDHU8_--CK4&_@GLK
M9C-9FC'S;3Y+Q)&@7!3]+3D)!ALB.0FGPBG'A)(PCOZSAL:/KZ1LV?G"F325
M0.^5.;0,B-EH1#VAESNZS*%W US0@Y4&/!,_/BOOT'S+8^V]GC>[JHO^78Z#
M5A,[_4U:[H()*WP[P925\8A^(.?S%$[9V$H '?>;'>38QY\*(B H="8=9FRQ
MZ<"K' <7+;QJ>#2N3'U=O4J$2#]VF*<(XL]O/\#(7;K5D?#EM0/, 93D9-33
M*D5$YC^*V/\IIC]]Q&6@_9MK-G""CZ6(/59E+P.I[*<VN  J#Q803".155E1
ML6.[-M=[TA!&HS:^JL!0"8*HJBC_8>@X3,RBSF-KNCGUL6*35,WTSSW1#G@2
MW[$<O 8F@K^'I=H!>]KZ9&7CU?2:Q46F;TG-A,#2LLQ)'V[J]86I2VNQ!4/3
MP3Z$E9YR5 .,ANXH1<'2_>@([M1EQ''@A^7:+H7F3#X#VQCIT*Q%KW,O*9=4
M\.MKX6Y5P7:XKGJHOQ0D\!>^?)O!SG6=,I5B[88V5TID5X?A/3_/.^6K._@[
M]"!,R.&H'99*QCL#[39JDR 'D\_CK!0:IS97T.=D0KB7LB^+;5*7^7987#1^
M& >]B/GV9M#^\H[]QG%YIH3RO:D?)MK7DS89XQ]AZ+XISN.*"&COBISYN.JX
MCN,ER"V8&U/7:_/_$P[=<1IA:[1;>;:WS>S,*+T]>I)[M(Y*T^TAF5=%_*:D
M$8);J7HI^L2M7H8EU?F!8NU8SN2BGP%%TSX1K7&]23@Z*)92V+@6[@<-:&XS
MW2D3\B>G4(G_GP+V%J#T/WHT_J>3='ZESY2:%E>A%[%1K>F#2A7IR4)&4[14
M7$/9"F0XL+.A#83:?29(%7M&[M\[+?I&9'Q=.E=F6:#N![KB<05-35# ON[8
M&]YE9(NS%UPS@UR&0\'26VK^2+W8HF:T?&5Y2SF+TFQ?-6KQ.!L3DQ/*-EEW
M&$X10!83TUH2?R 66Q^/F_95I6LE2K%M";OX($-JT'<2IJ>(!6M-65I.NUN"
M*!O<6<>7? 0OC9B?76#CXIUQ6UG/]J6+34DCCM+<>$Q^^Z=?"@?DA[2GAUV]
MK3M'/?!>XP!F1W>/A\)MSH%%94]'J6BKA<I8.R2_:62R*20YGB_D.-TYE_;]
MRH]Q<9RP%L(=LN]:+,G]1.MWASD).D;IDD1H%^]W]-]-%LQ>< L6*O%I%A;0
M%0^.]()BE$3  MTL75)G>;-=MJ43)K:?';IJ9E(QC<+5% XU*&CIB@=VG0<+
MLV.?K<.=QSP8@D6B"/9)UY)_D&&EJ!@5'0M./F9+)QI-7J  D<70,_UWR@X"
M+:Z$<AY$0VKEJE8GFT.J#[KIP^:OS7?"_&PV-V?E<:/;4J4"TP):56B*WI[Z
MGKQ,4+CJOM(8-5'<5G6GI?ZCYI:6:'>F*IVRC1]F&5D48V3GBDL0[DU6&E"5
M0ET33.N2AP_1Q-#LSH7C]DC7>5EQP 7;K!A)9")7!SYE$(M_>?G0ZQWM:^^J
M21<6$7N7"X?\JUP35<9[ $8?( 2*IF\Y"+23$][[.CWWJFB'F37VTT+ G0J+
MZ>6F!E%/0NCG+Z/7YQ13/O<_!M=<& UJ\;>O'] VVND:6U"@UA_(YKE%JS17
MQU95A,U07DM58A8^)4!?@WPA<!Q+2KQE@6M(F%UKJG=+G 1;RX\01 ?,-!VE
MIKSM<B]@3T,5R<7E[R\X<!6MV63R*X-B]ZKB$)QMNW-CP?3/NS6V6Q_ARS3J
M><IQ'FUI*#5E;G$65I6C9V\4 $>[5MD*>)?:DJH*&&";7;M/M1;2@A"SJI9*
M]GO@ZK#J :L]NL-*F]%V$5HEMGCQ@@46Q9L[';GE,!KLY7-[<0>2O*5H,+B]
ML$F\>7><%X$&-C3>S6HYPNL=]F)]_4Y13YUD]^*DNAS3W+K>=A[*:R^,QWI9
M*%8K>J&=TEP!"WB^PR@0A*16(]Y2$SU] (<)#T][:\<]@-="]#[W96=@\BL%
M\',W8F$/U989;=<?H-WKC3N!L=(U85S?PV0WA;L@/>I[ /3T5X73E;:T4U:P
MT"5.VHIVVN_^K37K\]8:(:MP@",P,61YC>+=!8V/$C+M"H%7GP5,VD-'*G=!
M<K_MR/>4=>L?'=D/W<KN7CT@LZR\2Z4?<7D$&PJ5&Z77O+Z!@.D#[K9?4KC&
M94^[15$XRKI[&H'L.]R;_8 *C7S#+0GIY7D&T\R'#$Z=-DZ+Y(3:E;XL#[A<
M>SX6,W=]DBG,7\6?6>?#TLW0H@VD_>W4_K^?2OR[U5FIW-#+/R!&[S1RXJ/]
M![AYKIYR#PC?"'YXD(9./R%C].#YE&(5=+]OF3[4'8:601Y7!Y$ 8RK2TL-$
M21+%BD IV[X4.3A#^!I&X1>V>&3X,_)/U_0+=_R)'6 F63HM6U037W(/6"BK
M8@:0OU#L%'-B@($+^?H[R[]@9ZF@I39\; &MG&%4MQNS /,1143_FQH/0#,,
M9?5&C?/2,:OIZ.M%TI@L#BD%;]%:+($YHBMNZ] HA/>:/O;A4H/D'I8%;;X'
M_$,C?F:,"[-_OT;:^7[)7?<SQ1M4F%G'Z-E:WIZE0/71>QFQ$=^%;GNL7.C%
M$'XSF[;!(03<<HHQU7)H;W\/="HB:H@[I/W^NP=LC83P8"F)$'K> XC/B6_5
M &<GC:>?W%!G!<C.=@_.SALT"=H0BNVD[?)L\>LWL)\%+FJ:'=Y]9,KR+<TY
MF>V:0IZM;HLB5:K#:(0Z=@*N3AJT?^J2^-_/0YTZ@!^#<BJPR&R*V4N$*/O+
M[9JWLA/)P1L[?"B+,%'X7YNXNGSHTHTURE?K?=OUDYK]&[W5F!7<K9_.W:F0
MR738@A1J>7.F-XRR,77E@8YI^G$./VV>"B^Y?(6<2YN[\^G\))KW$J\C\W)7
M=MG2VB <C7^(P^3KN$'UB+J5\$+U+8T&;W8+.*I+K@AP)H[5$*T[S(GBPK/<
M%F:[=C2CK?'U'SM[F4?@F>31KTE\3G;(A0B0A:SX+AE/^PX3&]P#7W1;EB1O
M&3S1KD$[]\ E?<(M#:@BLRY1D&K++A83[+'\W/!]XZM8&^-A5-XC9=^V[K*'
M;2#X8-;ZU?NV0?CHZ,/O@<"(UP][W-OW'H!W^%EF[[!\5V@3[<'662PQ.$Q'
M[0M90>L(%Q"AEIJ"$,3\2&"^5'6Y!YZ>?FQTVV>LFG>P,%'L)0-7Q!EZH-OW
MI*,N_(7I?;_4/"<^19RZ!PXU'KH#'_')1(-?R['I@HVZ/_C+Q<8-D9,3F$'X
M+/_:])8OWQDS%.",<@SK^?G-FJ2C)#O8Z_TMAUGYGUDJI2@_LH56QMI]ST8W
MKB3U-_1Q;Z1\N_-^&G8Y0\=0"/]OG?6/GVD@3![SO#M,]4G9&2G693#2U-*3
M.4J-6^<HS]FIF($A2+0X>@N=V%R[K!NQ89M)=7D=$&>2\V1DKI<DS.]2N;U:
M(T$^5!G2^0+&DY.'Z$Q_2J.R2;A$M=:R(::S";*(,6S6/$&CJC//UF9?(+T[
M)@GS"3P*3BBU67U!4(BVC"U3ZZ7@EJ"17U@5BT.ACNW5184>J"6!3ZP0E+PA
MPYKZD]N)L/1W$ P?BML4VO.=>X,XQ0F6E&KYH/J=1(E^-4.U"/H<;WSKXI09
M7I7Q?K]QS%,9Y8NL^F+^7!S\?ELV\FCZA3OXY$N\U17<S\81E[ :0U;N<*/T
M]#0;E")?2C-]D!M: FQ#@.<W(H>(/QQEYC#'"VH2H;C<X])9HP_&_HG"RS_G
M3%2<S4O(<7;P(U'$S5F$:[H'VCGTY!V4+>X=A #UKI[PL0A:LN@PI.3X*>53
MEE"%):U4HJFER<YCBN%>RJHUQV<2QK:)CQ C[2,E/R4M.^E0C9])W<TAZ_:[
M$VWI?RN#LM25U=<X7J#N(LJC2H+*3_'U*!E+.T]>C>KBF]9&]=%=U?$L3!/4
M'J<_0:;YY)&:99VK)= YOJ#\8X)/%K/#/I @YCMH%$*8/]]MG/MM7D:7XD73
M.\-^0UHAFGVW(EO4'0U'?FVS$G3+)[;GP6;!0;+!CA<5W"BL(-3D53NKR+H8
ME2.!]53JD-'EE=YOSQZ%9$%D*8;K5\#<: ]0D!?OH$H.>4R\6BT()WYM18F_
MW ]41K#HB[P:4V6(<IK^1(:FJ%FG@]?LG4"R=M@Z<76]U+<,^DA6!^'66PL8
M9T9#S6^25O!Q V=S&3&]M2 ZR(H]@S"(']6=0S"Q8&Y[4G1[NDZODY!"KQ2_
MH)T>-.P_6R?W;$7/VIJ_?YK))K;7LM:42\R1Z%5P:>7^"Y5Z3;O6J'$-ZZRM
MTCPQAY.^BGF];QQ?]T.K72,1L#R =)\JF*S?\+;@RKQ/3@NQ]7_%@/XY_A 5
MQJ4&+<37#3W?,?]JS32Y/<[R:K "=IJP'6T_TIT\ML>(11BO82.$H4H-05IE
MS1GS68^:[NUW+KE61_]QY'EE7#%8)'X_^JC#!4CXF^-Y'5D,TB4B,/R:J'1'
ML_HK3)<6^R''U$^3\XR,I#6AK@G(#%9UJXLH*$E ? @]] BUQ=DUSY(V^^,'
M\LJ8_H]*[]4"Y+.?7:$Q9&6A<^-V/1@^7#[D5*LE"4B?H9.NH8J:0P<DL_5+
MGJF2A%WV.BY3Z/-SDO:@]V118N2H 7@K7GS9VUS:O9/,JCIRY>J2H72C#8=?
M$N),R,$H:&_"3$+VXD3#:  /9$";ID2C@XCY;BA69\ME^7J;AX7!ES4\_9FS
M.N!/ G(9K$. L!]4RU:/^WS)TV[G[P52Q1@6M ,9U(1;>2@*/5'4FND5]53D
M0G9?'B;TN*4=D-/2]=EOBF"W73J*<S7$CL[A3S/$S2P[TJJK)6QTV+ 2/C;!
M%GB!U$W6>,/'_8:1O*96KESB!0Q%FK*T@#3_.H3ZMR(M5Q;+L>-()N2H(<[D
M=63K&9S*9CKRI/JS).NRFHI:*)((!875VYCQB>0'F8B3A:7N4UJLM5GSW:+)
M# -5-W^^W+.<T 7*ZFD&>:X\)I%^+CG \B-^RX;7W&580J!A8E?CD>^R@/@9
MT@'F0)9?;[1[AKN+%..WUQ]QZ<E.HOPC-7!*CB$H2B%T^(6-GC0H%RK=*,(0
M?0ED&&I0S($P:A(+!3/1KJUR_77(T.%Z&+_04C.?U-/$SI0&L?6XN1:++ON8
MD/7JQU?."ICW@.F\ E4B8]6=68HS:%^Z7S(0[:#?*R_HRY>>E;(RS]J*X._B
M!*[<':'X-KK^X\1B4T?IC[FS'F F CUKO]2SI/6\@JNUNV^D1/K?WAR/0^LW
M>(J8,=R@<S=R3A%5NL(D\5R?C[]HO&"MP=6YR3@/HN_!W9HL<;,TY[J.?3:E
M/+^E]&&@:I3%@2!HX>W0 @C9<<X>=QG"^TKI01. _L-J^Z54<O2U).NRTPG0
MO5$M0 .[>\X[+:C;1*2U1Q+I"79R+D=S,AC%1UA06(Q:;E+[R=R16QUOUQ4=
ME[K8W!A?4^L*3 22)*E7Z1NEI)H^:G9N3Q5O. :3%VCJ]<B6M?1EI8JC-(N@
M6C%?>TD(.\Q+Z-:S%D.MIIUQEAJCQ_9D+<L^##^U787%*BT1(8/0N&GH3'$4
M\(LQ6./7)ST?6ZJ[4L;)UBVQ8W5K]TA>KN7'=W7W7I*E#[VZO<EE?4\Y%]YI
MZKSH@@-;M.7!P*N>X^WZ.+I67QC#&)8%\PU =(N<(#XZ)3'ZNDSZ52$^GRTY
MW+Z+[X^/6# ^OUAZ;.>1#Z:PPL^,/]FT-4+/E#^5@SK\H[S PLPCB?06ESUO
M##,>C"$^4&574;9ZS9ZZ*"\OAZ4D]:?Z4P:O?(8HTF ,3.Z!KW^KK7(B\*<T
MX^&_.=]^[]4F9UHUI8!(L*(^ 4RW&W[DQFUT,YW70R?VH]'S6#^=(7M@\D%G
M!NPU6+Y=]KE]T]'A#Q3KVN)YO(JR&\])A^OK)L+]Q1 "I7]UZ7)\H<G).S^Q
M]E51O$6F.72-Y<7VH.1M#2Z(>LUTB"!INVJ>:4K6W[0)/:N,R*H;78$%LBV\
M]1WJSPXTF*4\2S C"0^M)#SN$T;00L)U0,3E[NWVJ!=7&J^V\J:9^YB^0W#L
M;J0H^-)V"<7W'35$ 3<=_N$G :I!JX\%PII^\6IKT)5 P".FM01S0W'<2ZSP
M&UCE14V=-$4039AF-*P#G#\BE1 SZ<>P@[;3@B?-!^]M5\9]!F 'VV25D3&M
M@Z1?Z&8(L9;=L?10&/L/V>=,WP/FX&'M1&T53.N%#?ON"P=W$B?<#< ,0CK"
M'GQJ]2R0TS9>(LF 42;W?*?:P27B]>V.3$CWA'-U58.>X'>K!78SK<<8%;-,
MQSV>:"+C:5T0=NJX9#E;:W99-S*FMU>/DP.-$+E[?CRQ:R!*2AK,L@<7/%JI
MJZVE]U[7C?=\G_A6*ZL;N="_.A8UQQ-O..H,7"W NN_-_[4"K5+:->^S<?R"
MTD4PMPG=G*;SP8 S9Y)W2IABM[4UEBR*CZJG1IQ\W9"N>5HI.XR*^'"QDV9R
M.X$O^ --71)WAX^][F(< 6C(YJI8YO<4BW\-N["FG,-QY_T^A45[P,BGAX7A
M :O\8LOW0)D4PY[*U^AUN*1)35R#K_V *NK;X)O$):CPJE%BI@6K)9M(@>4;
MK67O+Z_XX*"L7E^2L0=W,2(^&@IP%^N@H6AM325TP05/ZV-'[>F_$.U!4Q-(
MR'@\3"3!IE,%0( 7"$#.3\\HFLKAN';@G!SV^&2F?<41V99#ZKOA\V\\79*Y
M7#3I")D,%OD0>"4(XFOYS/IP5XWX8[YY9NED28>/QE9^7U1EI,C0OW\WI8Y$
M_>9G 1)3FC*LTCOLQ=J!VR*<UH#/D%BQ)^HH$)SA2,RQT$"_?%MZ&X,-B3;&
MSJXP[XV*8$TG_MYOIX"[<H"AI4V94AK,.) R&3V"-)&58&-DQ8^"Y#743$XD
MS=/-L\^VT.7'/?&<6Q'H[4U':(=3/[JR>QF53K$GWMK+P^\MS4'YSSC?V"K*
MXT:CNZG[SI%M >YAH8U&&_'DP\Z"?A &63K1P&\0Q!U]<XH$(M(C?F;LHN&!
M& :&O291NT^KY@ ZKKI4!!QQ[#Y"3GVH^A''1,WF0%?\<=^DP]=&Y?5GP-(A
M6KR$H&3WU_I-*8ZYS6MV7A,)"<W9<\,G'=MU)_CU]X"0?A6P1RXCQR4;,E+S
M>:3GRVS]ZB?_Z.<""/+P%B/B /;& FGJAG+ME/49[G*P-NS15LQ+%-<7J!&-
M!0QN\/95BX:IG_W5;*KFZ&?VUNNK0[2LT[P8=J+#MX6&\G( 0S?SMB/P%YM<
MIH.U@'""9+@>YV_OWI(E']<1'K+IR6$]?9L$T(<<R3?;LU]X<"15>:(HR?33
M0EU93X\1>$A,5H^^$$*9MA<H_*QHERN3+&1-25HP8I#B%.89ITT,8[IU\73H
M:;QD&2."!UKAU8C&>A7Q2,-D EN"6?JBYD $)\*X'JY!'++-\L\GF? D*H@,
MTL(K>."PHKD()1?@,-(2W_;PE&P"60" ^%KV][M=.=LXP(@7(L=(_J1/,I\,
MPE_;]IFF:9)B[,E0&/$>%VJN+.7(8?9&[ FOI]G;Y<+^<!VE(-_GGU./# 9L
M"2LLU@WS2P.ONO7ITT?8F7$V:URTO3S68\^?9:B *V,\)=#(^<J373L9\-!"
MJV8.-&0F3^OVF)C6ZE^FCLQ/?;6>IGB! &&:VQG=FDT+MJY^']MMC/==ITXQ
MISCD6*"OH>Q6G.M&4KWFTM[^TWR/O^HSS/D50UA..CT-PO,P-"^56[$EE5)=
M\%CU<&#&CXG%QYT=<(7L/C,FB%M)Y85N1MU*->-A2@P:M37'HN8,W?A3-BX;
MQ#F  Z_O^]+,"?8/Z4=ZT.;ST7Z!*O7-"-BK5W=F:A'(PHB"U9RA*P+:!TO?
M$ERIT/9VLY6\/DB"5?EM:\>L,'WG.6:U+<[5U5/5JG.J6'&\<J-IU*2O[ ?A
M'=6)8#E=>4UR+UEGM@K!%*^YXTTE7B8<:MA'V MCS.[P'@0;*(R=SLUY4N/I
M-9^=K7Q9Y]P2F<U/!%U*4YPN5S<)%5B*:8ZS$QI)F3=60?F"2U[+^5GHEL&5
MR$_"2PG48RM>RBI51,C5C3AK%COC6R$5F;,)FP2MH7MEEXC $2SZ?\?.2=_4
MP+/N7,\H,'B\IWQBU,_:O9:9:6Y)MKHD(;VZ&B.,'_=?*BCWCZ9N6!GMY8LD
M,"!SK=M_(64[6J6:.S'*YFR8\I%F1+G7FEWK.SZ*:Z>XXI@VZYB"868(+<H_
M0CU_8)%_MO@S]Q X:_BGU0"*O#T[%#<QOK#7C'V3.&%0K@*X(M$D7J<&+/JP
MPQ@K3A95-3;26]5[Y3:Y2'V(2+ #^7F:DZ!<+%>4L@_(C^KT6).&JHS9^B=4
M-280R=;J/DWN\HC;1E,0\4^7L:D.%Y,SP^N*8R^MIU[748V-Z;%QL5'.=E9.
MAZ(13@2FEY6'C,NQ]Z//EK+9>)E#%+Q0V:9"@.),L)CTZ%[Q?,>4-)R]G(/D
M *T(1'K;?M@\63T..Z%TAUQD=.!&>\ 13^8]61N,J?J;9]U>)O;"J%,EI;M5
MLA_#6>?VGEND9QISXZZ5WVKB\GFN8'<T/4LE*:M,I94='"0K2]V@K"8ITNH8
MR5\FG&>[L$\V]A\!<ST_TJ4<US"8;9#/8NLEB#J>_/@ACF@K##2O4"OG*?=<
MOGR<R;;8FCQD?75=0_^NCA!!@9I0@0J"GZVI.RM.,35%Y3GG1Z27'3P&@B'7
M[Q-B&Y\,_[. _@O@[A^MQ%9GBHKL1F',L#':@KRSL[.B$-^H/U*T_&H:%G4D
M53 3PK"M?12RML<^'7U]OO"2B[/OTBD\MF;IX&UWP7+E^O"><V,/QSS1R6ZE
M%/*K-H&YM_C2LSZ[6?BNQN21(D7A3Q4FJL/5QY0;XYE9<2!<925=<6XFIBNH
M88]AN;O<@?Q2X9>J@Q./HZ5;NQ2* =;9>4;K+#^!.7+%POI0 C1E=P[&?Z:
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M=:&PIC7V,: ^RM$OV5UK?*YCA!:_EM:V&<HB7W<S$QXTHJ7N 9V.IYTH:T*
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MO.\8.#N*:L<7?'(Y\5@(QZ ?_NL0^"E=?)0J)G*&DQKB5@O%-?(>)Y/T;+V
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MH_1ACS'#C]45^SVLG[<=G0=-XVL3OQ":[#]E3?ZOU/7$]S/_!U!+ P04
M"  K/F]4^@5PNP"&  !?G   &    '1R9&$M,C R,3$R,S%X,3!K,#,V+FIP
M9]2[!515[=HN/)%N$9"04#H$D>X0:0'I!NE<=",L0E!:6KJ[I+L;I;N[NQ8-
M9_GN_>VM[W?TV^<?__G'^!?C&8,Y%O.>=USSNN_KF9/[R?M%X*&DJ(0H /,
M &"@/\#]#" ,("$@("+ (R$B(B(C(Z&@X:"CH:*B$3S"QL0A)B0E(28D(GI*
MP4C]E.PY.1$1#0?M<Z:7K*RLI-1<?)S,O(PLK,P_C, @(R.CH:+AHZ/C,S\C
M>L;\?_RY;P:PD& 48.-A8<B !U@PL%@P]^T *=1/>)B_/L _/S /8.'@$1"1
MD%%0H7]0\1!X  ,+^P .%AX>#@[ZK3OT>P ."_[1LY=""-ARNHAD-CC,7F&I
M2.2O2EIPY8<.*5CT;+V141[CX1,04E)1T]#2L;*Q<W!R<0N_%A$5$Y>05%!4
M4E9155/7-S T,C8Q-;.S=W!T<G9Q]?G@Z_?QDW] >$1D5'3,E]BXM/2,S*SL
MG-R\TK+RBLJJZIK:UK;VCLZN[I[>X9'1L?&)R:GII>65U;7UC<VM[:/CD],S
MR/G%Y=6/N&  6)C_^OQOX\*"QO4 #@X6#O%'7# /G'[\ 18<_+.7"(^$Y!!U
M;;#)F+V0<%Z%I9:T().SR!_BZMD.H3RF8%VB//H1VE^1_6>!>?\_BNQ?@?T[
MKFD #18&6CQ8+$  R+T'D ?\FS99["Y##]/OL).QP8-&&R>D2YJWN*<>O<G'
MQ=4GEYFSFP)+7$<<MPB6X)=W..!6NV6K*[39._T;^N2T4$/92Y59HN%]>]+#
MA(OX.Q\.@2_W ,I/)^ .#(F59M_D[V.8.G%C7LB\E[X'A.*3OX-]?SEC8S-]
M2N%.Z1R1M2X1\8::G^H>2.D;6!=H#?WY%+M3N5VHTW37/G%:_1]_<ECLAIKD
M7Z?$-$^[9^4N7]/S3"J;N\#N!_NWM(9SJRCQ^^A=*>=3Y2XYG[[V1G!S2[65
M<")U<(SH-R?HC:3L7;G$PZ4JMHNX!SYLM"^<$M3<=%W(WP/_CI=.XP6\MK:Z
M.E=#N?<^A(6A,*'@=7C.0<([XTI3UB;D'AMS8S<W-U-CXKZN*#@.-&$985W/
MYI7JGCR/MM)KWX.PGVW1_IPBM_9&?-4*3"PMU<NW:J81HDFR7)>C]C?N9FD7
M+&_#KZ4K0DSP%]11^U8_EXC-ED @J=P,VM_VCZOYW2:-?\Y5S$\947?E\&%@
M=+AE)J@PY^GCWZW!M%AEB2+*PGQZ?06K5'1*DSI4D<L0/KRIL8T,YX15=O#D
M4RO-INOB1J.I=O!NS-(Q)M@MZC>%IQN]@VOPI?9_L9LU"EHZR?H:W!.%1[ S
M^)E'7NV"S"W'OH=4Z6L5=Z3;7GIDY8;5_B+FQ'SBICI$Q]IMS>KG>K[XV?NO
M^WNK935)T[J5JEIAS5PMB BU.\5(TCEFCHZ.85-J-</*AY]WE;KRL8="/")7
M<T4GQ"5ZSEA^=K'I9T3YJ!RNQFG'F^9TN9N[&=M^#V2HX<3@]@D[6Z_%A'-V
MDYS@%<A'/0R;=1EJ UE+W,Y\73GAS*06?;FQ-C)HGEBGV?D+#GZ&O70];=WK
MX8+OR%9YLV:E4SWT&YXPS?RSRDR'<SVEXT4?AD##!JIKVK:K)3HQQP>O("_2
MKAL%+X<X?E<J^5EGNO7I86'&S'<Q1S.WF06$KRB0SWB-I\L=9%'$7.Q29[;"
MA"THA^7WMXVIS>X!EYGB+<E3GA?5#"SDO]X#_[;O7T_-ZQ2-3)*J3YEXH8]^
M%&&@JM.0..O-1]=V0><8_^::*M/4P2I'!K22B.NI DO]-&@E %R]V[AXWGL/
M_)Q&G9_KI3#!JK/+\Z'*[5HC]DZ73E#B6)4DR-T\^S DT,I]2>I;QZ#>6+'\
MKFA)?293O*C+@!GE;CJ)I9+59T:C/3OLGWR5^)EY\JN22&K&W@M1)K@J5?HQ
M@-JKGF4Q$)E/N)&X7F%*9MLL7B_99!<&0:X^$/I$5E5[A;2VY7"MV?3<T&AW
MY>EXNBW]CL84JGSA,^?B.W*V:B.-SAB,0KCP0;:"TV+R#:7TY#H5C[6?C3*\
MEGM-EOA9#(L2C]B+=V5'ABXR,5S'.CY\+N8>^"WM%?_%5:A0$O+Y70%JKF@@
MBO= E'M+'^.&T.^)%L>-#MS;N+@>8Y?R,^#D?CZCR". +TI@3<?:3JIF\.?[
M<#]T10!KH'!2F+'8>JC'CK TG$GH'=*69I2)B<XQTU;RV3G>G1^M9"273JU?
M)OV^.YL(CDI_XI((SEL8;53J]F+<YP7I<F\>B-VX==T#[1,-*M^PP441MRLW
M.T/-"D&7-5$0KIV>?-7MIB7#B^([;]I[P//H'CAB!;=^.]*YA5.X!V!6[H%E
M\_"T!E)=*6@GL#OY5C,.Y;E?OC:Y!WQCEINND++O8/^Z#J4(26L,M+EPK<WN
M@/]'TZ%_628ZWG=H.BR]48%B$><>:':^!R[B!'X]F0W/Z[2!1W&4<:4AA,=_
MQ;.AL*#,18)E(]5J2X57)+75DK7N]1#E4 5];'VV_,S>++9G[Q3O:7=!7%IV
M3V_CJM:&^:S/W6.=@'M@DRSY I/T'L 6NWG>A'L/#(H(')((W%'E+US007HG
MWH9965A2?X4O BU%QI+K'&"%CE18:EY8MCB R69DO$:NX;1*>UAR'CE9B]JZ
MU\J#5;9PSY^>7\>"_Z< U+M:JIP<V<MZP+H@ME4C*0US?\<>YI"5(,S.[- V
M>1U3;KBW,S-"=NXVK**+O>TU\LZZ06CZ5>J6G Y#[@L3NMKN7> _)W^,YP!)
M:VK+;CYS+6IB*NNAIHC5,V-?_V;$(!)WNLE#^'L@ =+U=J1C]2W!1L4)<CAE
MI\M*<MMXXM?K*?<65^_?UK;XG[5]86QY7N4(&;J]7%74R7\H4.AX%7@A)C)N
M,%AD+T'IASG7YT%EQ>/!\KF!&Y)FG8EG*=7T&D7>=3;U'D!]T0$^Q9*]00R]
M!_S3_U8(M2NP7[Q\9743WOBXNH&=BX2=ZXQ3E:Y7DDW0E=(77O0\J5SMR?KH
MKPT9]#P2%,EU)CU+/J[ZU(>I71A54ONHH_NR_\,%Y$06<PU+XR[,"?4FV[@\
M9\L_/'LFM!)BEZ#P]% YE:_@.2/H\?$RM@U\(!>V!/[&4WUB'J- W>L7U2_>
MEOP/II58#Q#G="8UM"3<]8TAI:WC/+$HY:L.740>;(ZR*-,:%W3$,E(Y'O-6
M]=E!W=:"%/B=B//[LBG+$:KV>[UU%JP;LU:_PC#T0LV#'LHT >!%7O"--(_"
M8=#(1;QBE=?STQD>'+$DT=@X&B&YT"]!X>YT>1?4<A%JY2/+2>-*]?Y9E37!
M/0%*<A$^(8VCE!_-H#W9XZ1&_\^H+ZMX@:9I>L5M%NAB[&2UX?+HB2FJBSS8
M_FA@5)E8TU0NO#;@VM\V;B[QSV[:*BJYH>CT-B[9_5\D"7?LQ6#Y$[7#S,*S
MTS0-?U2_=ZEV?D^M.;>TT&UUT 561:#%<I6]19O0T$8WB)*@G-W_V!K*=)&\
MC*XA-O9<?^0@JTK,LXP.R]M)!?D7#LY>P;SQ8SVX.K>Z1:F1A9]I<UHA9D;]
M%*Z:I,G,V4UNNDT_GHI/AR)MSV6TP!=!_#O&US(*6YP".10:+5^-]TH)E,WB
MOY4,+=^@<PSY0AI%_9&!@9&7(RL13W;(X8FWP+(^_!*)&T=:Q*!^]M*!]&CZ
M,.UM<SK_!NWOK*L3\G^T<EO96HQNU9!"97?SW\N\##))YY'-H2;U9>F, ]7'
M$%H69ZI] ;&)"U/0)-L*M=' -LF.%W)K]O+FZ[QRW]%>>_';(=TQ<$G"@;7)
M[5OR[FB9OY%CM;^?8CCRV:Y'A:4T57]7:]DWN)*YGAPS5&.0K7XGN;::)Q_S
M)*F0]#7.GN$Y8E-#K\[O1,*0.;=?Z!*?@0FL8&E=F==#+6GF=5,I&@J_O?'2
M/5#YY0W6LE0WPZL/=8&[>XR$XH-AG=N1B\,Q5"%SM<$GVA,T/X_6-#_W4>7U
MQ)1ILT;"PWH$BA"IAE>JZ[&*B#0<1,:;G/F5(\(YVT[36J'>>XRG^6(F.CTP
MQHB?G[CP2> DY.9?Y\O*0. R9]>:?ITPG?\50!(Z-WTRRDX87U.44\;L\[QV
M]&O\70,][A6"J_&.L*$S+4Q%\.X3-SZJ_I%SI]"[^EE]KR8!=EFS7&[SW;M7
MF@.Y7K\KH\;=$V[^?+/QXA2-CDSUJ3(=,VQPX:,5[R)NNR&SSL L4R:AI0;V
M#:FJ&NY16][S1P\,9.H<29>Z<)D3.><X/80E97.__3XE;'M-DP?[(+NZGJB5
M@:)Q\BN5'(T+Q@'%LL/;T^BCP@+'!Q)I'^##]]\8T)QQ(E+EI:=+4RU7'..X
MK)5QAOX6'!6@;'"K<=ZVG2B#_9="AN^ME(%(GS"8;!9J6*=N\)Y'F*Q(-09<
M$<O%ZL;HAIKJ-%236". Z< U,L,2 H+G5\Q-OU5]TN ESI61(BO6!G5T<;5N
M\MK70>FB$LWD L[&02,5 D@M63-:(NQU)FQ2)J]+ITJCMEDJ- \UDB*I14Y_
M* [P;UW>K)=;4N7]XO!JR'3:7MV>RR&0RC3$XVTZ 7507/[2 ;*&<,XFBYFK
M;ZFLZS=>QT>O-;Z'SI["01!290)#V6)F>60@-:&_*Z'*QF%#_81Z9;I+CE#F
M5MA"CQ4V?N#^NRY?N4F48J?%NGCQBE>6Z>%2G.G5P?KR(NV,-@VR%JY*V<(_
MI.)G\.]J%[S1=AV/_GIFP#GP@2K?;MGN$ONA L%.@H?#<S!FU %# ;AR46.F
M3L[&"L:WM(W@:9+/U>+P1MLTE.?WWO;\;$I%)?TB7CU9TD_-@79JQE&"//G+
MM4K<9Z5/?$(M11/0B?4S0],-ZCWPBE4Y&Y[X$0[%04W[D#94':,X055Q2F+V
M[?$"=.2EG9.Z\W9,/O\&]A4H'+I[!U'8=:G W1(XS'9X<84\#5Y@^#$\)XXV
M;5*;W@/OJR[DSFH%OI/TNH>RIS50W^'L9T)+PR-[O=8$+;I";<PMW)[ 033T
M*OQ58I<^4[(EZZ,J&5 L_VSA;SZ,;]X#3&ZT$-[I@-/D7VP(+,ELZYQBE]\#
MC1HW-%=SI.N8AOQ=Y$L,>@M"1VQ%Z?:EK"\19\F!*CHQ<*'6"*^$V;1V>OJ.
M!%M'T%IFE<.3I'G-0U%9V9/Y6M+?VZ7G4F[KF?MV)4*CJ(4"T>:M(#0,T)+-
M;>&+)!&+,/TJQH^ &TBB>#4.:OITZM9 +NNCZG<ZNU7&^SG>-N,-0=7#]M.-
MZL+BW]NGXSK\9HHQQD-P?%$FUEAW1,$1-D\94G#4'?XZS^"5)X80YP9)^<F*
M.S>?ADSX$ZD(W<=Q]M>?)H.O);:S4_GXZ Y^KA'ISW6Q6VJ*OZKP'N/!CU:?
M^,C*9RQ>,US(N*JA1E#$:-P<+O(T.%6HB^#&)*8]SJ$H-D]]:\',*%DNX'AN
M7?!EN=^SK^Y"716@/]9&=GIIIB[FK+K&S)%6:GD.A4_R1*>\HN%NLO9#UVI/
M54]P[*LR UMG8GI.Y[ANS0MYZ0A]"24\4IK+KU.7+ANGA0=_**<2T[<]L 9F
M=+:^U]A^^#V@W%CWB2G$)4D$??2!!$%1RWOC;'09^@C<_O8AC"31H626$-?;
M>;KSWV4#5[[P8[C$-UUH%3$D5U2K8EK8"9D+DDV]MR42/SV1_,K9<K:>F+UC
MK78AI33<':DY)XM3PAV"9\2=<.A<5/P'('LL8)K;.31M,TI :.=O! ,@"VTG
M4A;KU[)UV+.+0.F2Y"JI/!WJP:--B2QSR)693FR%VB/029ZO*'J=)<PFUT:#
MZ1]3K):[%#U\5VQ;J% 2D>_LT^;Z33IO7G5>*N^;!1G3RP=83_$?62(*^*I7
M'LUE5MS%DXG8K79E%"5;]^)P?]UP-?;QYAD;^$.6-]K4^X7,XB<SWNM# P29
MALLXH(L.C^F\C]'E< EB(M:_3L=EN5B08<A C)>O9<=;7UJO?CV[J1@"<.(/
M/,B&3G4\N>!!F9&[2RLH/_Z<I1 +CA/X/$?>>T"N6J-/9G^- Q1G_-ERQ[O]
M1#WZ:O;A!=V.V -=!X9EF:)ZQD$F4;N$";4_L(_9$0ZA5+R>>\(U4;;?V3=W
M=JD==TG:K-(FG^XOG0OU<E-^KBO#%<M'P=%!5WR5P?#ME<K8]<=\_;CK1G D
MB+#>Y@I_J*&_4IO$7+<9V^/NUAB%PXK$N8K^>%-WBN5+1FWS(-A'"#TBP.*M
MM)[Y^9%9TM/1%XLJJD74I@\Y6X"K"9L_^,PYD8KGH<LI??H_4!>]+)1:=?\/
M*"Y>[H],3:J1?M.RFSUY8D8_#/[%P*_UVK$'?^&+O"8!J1/BW01Q&]^Z=]P#
MJ0'[OYQ#UY]X&/^V='2/,5ZNPM#/X+-G83@L["V=84#:R+E?KLPU28D(CLH'
M1U\<.4'X]R4<5UL"\P+]C=G%3\$^5Q$\')#$;(KDVK$%KWR4][/[,_C*@5$%
M+IE_:B$JJ3]ZB.[_20 BKK*_I4%WR] 3Q-)D_=#!%ZR!CK4^:F4N[ZI#S08P
M>"?Q[0W[[ ^=?62BRM$1WX1?;7.>T6R8!R[48UCCBNGVJ?URM93W)*,M<&;1
M*2$?Z)45\C]&U(5)LF@AL>T9BPX[O, .9*L'R=P#WROL/[^((I']WGS&=9HC
ML,0\ JX@W##LBK87V+VQ(#CA<ST]S]]8O,MJCQYCD."30)/(^.4JN0IMT_W"
M%3*=G.,W7+E;5QKF;[4K^A-!$"NRA[PUH^ZSE;;EMQP=K@X9)(1B 89W?;5)
MIE$J3^DC/+-Y5]CR_X *#@6,L9JF0O!W+C-'KAF=AS-"Z>;1J08G!T4K20]4
MUF!TG+[;=3BUCN.,5Z [;L@T5":!N*9-U88*/^_"KEI[Z%ES%@C\@LW/-Y3C
M;\BP"UKUB,DI(7=:=-3<CZ:5KV^:NFT4--+[0%GATR;&0<OBL5JRJ?CDERH@
MFV)GT7M D?ML+WAG@7D_O-V7B?=+IY.K\L??LG;!SF!\71@*MA:&1Y?ZT &O
M &-P 65'.=E>44IXGS!HKN4-R;Q?L>9%?^>RM*$R\K(WB,WB^>A2/&H"'E]9
MW/ ?^"ESM(W#0_=X=-<VN&"&%*;HHS__".3$6H9?*]YF8KQ6M=[%9-J](%S+
M3/E<>3P-LTPCS2+,LQFT^JAQ.>L/9OT5VZ1<'@2+#'9]U#J\R\[8LC8?FK^<
M-G% ?N!=A20C2/VT6.AM45W&MR7L+%ZGQR=".4_J#(*L7F4<9OH/ ,G#54V_
MQWOVGC448$05/#C[-_H9V]Q)3?"C3E*9VVED%,%BL4]2\#D'R .D9/&WU#WR
MTSM N$/#I]U4(DYRZ]W'L!%!BVAC"W\80UP.QZLXSLP]A"ND=VW]"V9>>%O:
MVY:Z9VF<U2B$QIAH.IP5$/Z1Q%27340A88P)"\)].<42?TA1_H_;5OO_QHC(
M(^N7?$PV>0] [?J9%Q;HH)B47H#;QJ\LAC.*L?2T8( U_X.SPKPC>C:Z</.:
M*7B3#.?S3M)+--.%L_V%*UP;?I(Q;)&)W3,",E/YN7,<>1A>K(4=[9X5 5B!
M@ -0T>-;T(>7D=-Z"PD)5P'KX"5I*:CKT/";]>^!#I5,82P1N;<17!LRED[B
MJZQ66&U9YG%9*9#^'1><H3Q:H.@D+#E3K>P(P8LA.HD-1.)8_U70GRW!^R4-
M4?#=W=D(N#4NYLX'&J%GUST0 ,W9:-/I$]D;!($;)8UB/]<3#X,<Q5U=CG;D
M:&D]R/CLS+;KA["]6'%=''$ =4#>I2>'ZJAO[\X/5($8K?7J251U69UT_AK6
M9) [F'M+X%=??R303.<*/?L.EO2.+CS?5PO\\GB,B^9&RXD].5\X]QO?ZGGE
M-RNB K']9KW9:SM9#=_&"T?0F&?U\,&'9N-D1J&@T'2PY';3?S=K^2^SR55M
MIX[CUR]M%;>#6%;0'T..%Y3'6"6RQQ:5X,/?D<5&6G^O$),Z$BD75JD<L[\'
MN+L4;"C"9IB"VIM707NAAT7Y/Z> ]# +"I24:?#BRWM@.=?-@@U*9>^C>(@:
M[H% LF#[>'>,<2DI$+,"KX?;@=/G)"G]*KE0UR:\P!L!C!R'C,']$06&=1RI
M D&#.XB IO+ #6TN>),]^0(-?)'WM^R\W5Z*JX B:C5W<GVON-WC\1%&JLV'
M")4:57T1WMOE?;&OB 3YZL4!]5PYFX>FWS)T.G#+#4%#EJ]2WEM_1YSG.M#0
M.<Q:^[>S.=";@>W%+<+(/0 #592X8I5M54XO!@:YZ$#Z.!?Y;>'.KB-B\>)-
MCP_1OS^K0:*,J&/G3K@:55<)VBTH.!UQR/K&!XDL94@(I$$2-G[2I<TR774/
M_*F@H>:^%35-3&NYDR<$AB[KX6H8&V&!)6<4JQ-B;LN7!E"=Z+X;K6HXK(O$
MP:XT$Y3@^O#E*=L8]![[+0 U2SA=U ].'F7+V3.1=ER9F;F.K17%\Y(KEIJ0
M\.U\"*O]"N&S.<N#:+_D=HCY.#P_%32M&%X7K5OY]E9PGY-MY$^V92M:IR=N
MKE5_%+-CP;]\QIT=,O)JI(@AZ4[$S9^1$K.<=A87V$M6]RA<!F$KX3D-;X9,
M-XR2L9M2?G]9^7*=+L2NPS[Y%WC\/>.O"OW43SQT>Q1*@AU6NHLCI[34!ZBB
MKURGZY],T).=AKD99Z_)J5UT2:.G:YD1&K9?^47GX]B*,2G:$Z.B&9-?CI__
M 2[RD"\:ZO? %]NQ73O]#F[07N&>7V'VK)0AV\Z\X+O(YV%EV%%<BR%F&F#B
M2P]Z+1DITE/XBFO\,O3D.9AC;UF%!,*%OP/DYZOQ%>$UK1-!<W-V$*)]WL;M
M]P6R!PFL\R<=>,ZO&GN.<[8C*_M$HSB0M=!XU\[%45EO*GV>N9T>S6?K1/E/
M;LOM65="4<Z?^DWQ!!'4W[<M433RT[X 6]4OD*IBO0<^RJNIB5DZL+G'7M:'
MLX3+GC=LC77(15I\$8T<F3PP20LX"OF:%D #0!<LJ<:1LN]2ER];L/QT3Q9<
M)Y5[G6>GS65 +S34Y,7D*X+R@^L;^AZPJ7ZP<-O"62_X%IF^E=E=&G!/OP=0
M!5H$3EE,%\Y_,/V_#U0ZIOBSHGS(=;T0!P<1ITD/RVZP[P%A]L1[X,?8\//1
M>ZV(;9.>,U882.C-\WL [AX8[,L&_YB(?C[2P3.XBHN>GEX^UL6MMR)/ZF41
M' 9-D1J!6P<.96_1IIUN?XRF__H=]^A#SI#D4-D#Q<7/MK0U_%E>;"#,<O"2
ML3.TW8!X[OYJB3\=7-39=#+;*#\W#*#?-*B69<:UUL*T$1RN*X'(_LDI4G.K
M[,:L@\S]Q]]A4-Q(+B!Y3S13W[,/6LM:#)XB%.RZI_XY0Q6[]MT']J:9RKKV
MI7HOD_#A>TBU*^RW>M/+W^0I!K.YD&K]+KYC!DAD29^UKFU)^U%71:F,FEV<
MN4DG=:2L"XYD:3E-7P(/1I/0OKG8QYQXY6=ZIN705!=O)6O_UARKJ]@T:(^0
MFKZ6.ER%RS+8RY,KIXBUAN%I'?-#=7*2D7#F)YQ/P<&8F'+T,[(7>/"?LN:*
MBV^>D)IL-C(.\HKP?C8EK"C<+6$\%]>QD4LP&!][/W/-'OY>MN >F B_!S;U
M&L,+T%L#:%(>_/]T828)F%I=(CF[W=7(0J47I3.?6]<>PSWP#!,3/$%[#YQ2
M%".F(+;1"]-UISQ6" L+TT+(AD]*S^K*[;(FC[&<\/^H3&RCN<:X4F4I,[M!
ML,)FEA%)]/A[%))=;H_9A[0 .A24"O,<+34Q.B%:D<^Z)4HFZ3:=,HQ;7EQ<
MK'(B#U!HTCQ1ZFLSOF54)I92^<8[4WH8\G?FC#=]W"O_%I\;HQ#S+5C/2#;>
M4H-(WJ@\,J%&;\^.K% X1]K*XG.7[Q13K*H#&@)=F2]&BXP*+ZF99$Y/EZ(^
M#:U)GT)1_\FLY*'@G1M]U#MK E>L/HYK,V73-Y6'DB0*-(]HGZF>=0GTQZ:*
MAN^,8W4';(ZD&.I^%C6W7$?54E'2$*GV30OL"Q>R,B&SQC$VN3MB70O,28P_
M84N/'LF5C6-OV(V9V[C$_[J#W5KR5+R7 D2@D,!$S;MX=:5HNRTOA?O=0].L
MK#0<CQ>T%93L.JF%T?I:ZHSCP> ,7XMGV/K[ CQ@!7^#JX.BUC#G\"[5S<(0
MB>(3A1W-?,I93U<3?J?I\S>KA> =O7FU[LLXK5N+FN(+DHAK=G#WP$^X*XX'
M&RU<$IPE7QWKW**I#"L&_;NN+"( CMS_ETO3+_T(5:;D27I98TTP98+DD8@7
MT=LH-</5H+0RF+!1GY!(F(DA<:1W2*LDD>6 G @!?K\SU$]!H4VAS/_W<$N'
M:L9/##QZH["(>1Y>S\W#X__&BTQ/G^"=<W-6A&6W=$81Y&E:N7WNZ8ZINO0K
M9$9$X'4U<,>7UU^"IL(DEJN!I.=U)_> 1!]RGA?$%6&>LCH*6M<;$L']1Y J
M0L9+3W8*J:_%Z^5:RJMGVR@PA31O\5@3:5NH*:OE@A1S=+'X#SO?!'_9.H@K
M<[.?CB@(?) =A8^F4HV8>[,]JA!\D.L3L5Y13@,U">^+([<G^$B8-?HD8[!&
M LN''J-=83%IR4K9V= @V7%QZ:NM^S8*3>DV&RU#;+9=SK:UV:NE@]@B)0 C
M! -F;^M"@?'%&=<SI^HDHY!5/[TY4BO9WK+M8>WO(/[.7;3GHAQHD1L5BOHR
M!]GOHLS&J]BNM^\L($U3K28Z&F/Z#WUC&1"V8*[;G'=T1%3Z2<LB14D?FX=%
M)%::#Q3WTV]>4<R=D=%2ILA)A[_VHXY640S&*6,A A#EI0TX NLY"RLJ]E@Y
M4FMECW)IIHI@.]7WOO,_&[%H-6-2UYA7KY. K_>U5,N U37$G\;+&:#PFJY;
M% )\/KL26H2),<F1T?N^:V;J1^)"W$8'7-9#G3@@Z[&V50K?<N86=#K<+8TH
M7&PNXQ%:K>,E.V&:K^?/,FU6I'5DDMK-DK#KRZKJZ@(&WU@N6A>3PQ.@K*[$
M;:^,["XU1!_3BS_:?OM8(IJ)N'E7([=(9YGZQME$ $+R]1X82O/D(?Q!-/_!
M>GDCL>Q.WQHGM<U=T>V'NZ1HV^^.X\1&55.L=@%^':/<<()>[X9 +OV]XPN=
M)T^X>,$!J8G=A4^+>E:R,9SM@C0LQ9-N?&J"-I($11*:KZ-L(,8564+TS)N'
M7RC%]XO8"_LQM$3YM_#Q&5KZ ,O-JS1S0@.GH9G9F8P/RSQ?@BR9;+K9/*JE
M45LXS)?$G[^H0-U[&;UM_FGO=*8>U=Z14G?.IT:1M+_ &<L25%POG2V=HZW=
M99A3\+9AME'?EZES<F L&'"T_X]O6Z7,489GC=Z=&E_"MY?4TGR_(%@W.7LM
M$.# & 48V(G0<X:(Z#\!66?SR+#X''3GQ?E59)DRH&SC02"%+]OU3!_L7QEO
M"W ##2($.8TCF-,>?>O9R67@F+KUF01CDM@49.A$!M! 5V;>MQRA; FJ&'/T
ML<G.[JR87N6-A$H,3DCQ,Q#WR;6"0EE2E]2))<IS2':[P+:^B].741<7I; !
M\D8;[0EM[CN2AC$'!BGI$9E .Y# ]+ND\P$2>R.)=M\D7H/N+\]<NE"<MP1)
M6M-1$("5E#TI\70SKX1%I\P4M(&'ZM)NJ5HM\+L0F:%P(Y\GS42?D1$)MI+&
M.C9K@X07*Q(>F=G,:$NGUA6$/_J>PHCVA4 /052\6/3I0R$"Q!PVE"GUU*#,
M<CK]5_Z?FJ>S<TA\ICUY)Y96S]FY']>8ILY,FI6J]:&TV:$=$''XADD9?FDD
M$+4+03XMBGEUQ%[BM.Q?SF L6O4U]KGO,BM'DK,AHP+BFJ8MNCT$,JC^FJS*
MCU,?\1GYVQ2/!S5L]T!X%_6M)W2 E"3\S^&*,J!E)^FN5%XQ"E*_%56?E.1M
M%IC;4<==FHA601A[GGT(*;=4:+?3EG4 F;3$S<6VS#Q=79,,X7F+6#II5LF=
M/<W?9D?<7!791BYJB]L,%W05%%"CVHB7U*]%K#=RFA_,/(UP'#[O9H>,#ZR^
MR.;SJ(@X0MG?GA#_D#G6EQG/FFQ:7;DT@E429 !;(>4+=XOH"NS2%'$TNV;V
MYT.F[L;XQKRD' /4Q$AL9.?SB&Q3?*\>B3@JPIP,[%'MD>0N=8G2?2-:Q9K<
MESS<"=R)SXU3RS0*\T.UIW!5J?887CA^>'A^:YL,E0*2AZZ\74Z6VEZB,B^G
M V@>RHG@0)L(#HS #*/'  3,=9-ZP[6<DA: L#J_2^<FE5RJ63"O+E$E0!_D
M\U9.D&JD%C?>+?HI6L(B!BU-FA<\CIS@X_3R$&E^J0@'0F[V(6QC.S0'7.4
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MVST48+J>W%$NN"/>>AS7T9@/:9!WJR;B;NB8D4BP1^0343^*C%&^XAG YOJ
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MV%-E!N(-54C [*P'"Y6&S!\(UX9*!*#2YR\PSAN.%Q&@TI,$B&)()AC[W9C
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MNC[.][HI!]CAG)-M-;G:$AGC\WWDH\]_K;JB*.3[%H#]B@.,\-*_B#04HN(
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M2"LN;A49(MTO#RI0%,=Y%_BGPYE_$!3/OIZIG;<'7HA1@A3$OQ,/A5?-K21
MSIK=+VL=?SV/[T3WJ (&E">#-7MD)/9#$EEV,\'XM<]B=*2D%T/_1G5CO709
MS7'.=[T^B@JL_3P.M24WABTCM'OT9R2,,00O\8*)4VCM 4'&Z6]R"Z?GS7T\
MK_ !D'ZK,#DS3=1RJK'QO'*AO7??*B 8_E>!7JJ<_ VRQ'R6Q5NB8*PC^W6*
MTV(GXJY&;K5340%+2B7F:0D"6&6UY@Q[YU=E"6L:CG>E7(BJ@1W9E-&HV6Y*
MAD*+>Z2P,ZZ1XXH3Z9H: 52][VEA:XK6KUD?W:<@"0&'CKUK8:#:I#G:'#;Z
M N4S#%'*Z-@VS@8L#CMZ]D1\5%SKO"J'T"U%+:&[F%AGJ_83YURGW-T*':WE
M>2U2=DN"#+8C? $ <;O)[HHO/236I!*M/&\8_X>S;K4\FT G+&:#?XHG0\M4
ME:R<\Z"V;C%8#;4D'_;5<,VQ9UR))1&W>MBK[M&#I1P< Q14G".1?%*CC.2F
M7^66^-(&Q-)4QH1FMPOY*[H.2M/@-U031H'A]O09H>0^J Y]-)Q3$US5\9<*
M-VHC.8K;_(JV[/O**BIV7^?]?G!D$W0GJ1(OVV:%TK\0^QO>H4,"C%*0 2TZ
M&'@"6,Q#61%2 :^QY9,GX$^GW=Y5 7)"I:NUL81IO!.FT_;J_@,OVUY'BM-W
M%' <''KYU3<%/8/T()S,;+VV_&7/+-?!T");_^NH%HABA$MOX1=N##8/U52)
MMO/]\M>S.H>H!.X?IJIN5N]ZS]D*^X0790NU),^H7+JY67D*7]>G+4B11W^5
MRM4G[GHK;I(S7L]A)Z<9J"E[5S"2];Y-JENP"()-QW/0UB7KZ,AG8/Y6K"'-
MO*UYKL,0S;-B7^<"^SK[S%BC X[1+EY K;+P$-L@KO0Z42R]TC[6I66%+;3"
MS=#N(W>< Z8$!84@X@6.W@\[.V>3BIB8^AG:K*]TACY(0A-!C-:&T3I.2HC%
M5^/SNF(UA+-E.32#8BS8VP4E>_3KBMW,@@18?O9*>WZA=?EZXJ:\[/-4G4P=
M%+;>,+*&+G!YF=M]9I7B0^0.K7F9>)8#WJWR]NI5SO>@#P_)PANF4][[?=[G
MK/K2ZL/+@!.*Y2_LO2T4_,,*H[H9]_NU9M]<GH+^41<BRDW"/LWP)! ]7JRA
MT"031$*Z=0>AU.XV."I+&=E<34E/?K[S.]L/:4+4CS+KO+P\PT1.9<UK%()5
M%8P1+_EPT%+5*0A(UNITA5OC3[K8]J;M+=[?"=21TI_@(&RI]7V0=VOK@0GU
M&RJC,7\M:40[F!$G*'J>/ZX(:U<$+:4 ]/7E*T#]AC&<"0BZW<J$_]^=671
M?@M/0YOPN5GOUC_EV5N^.)T,UDYC>[:->]2>@/+X$KZ#R)Y>M4?*)LW_$[X8
M5E\3\G]^IXL^2U8H WLC[6_&%?KO.3E.V[^;X3Y\M_]N'MI_00S+^G/FU5%.
M'G;$3?6&CC%<V$8K#GHXQ=IFXY!!7\>PN]GMNL\ZD#UK_@W-URD;YWH*Y369
MY6Y)B&7DK')8L@1[99F^]R]<?S[6@YT$0>PSXJ[%=#7C+Y*,C2)752EVZ\)#
MEI<IGH6HF'>QGNB*XZY\CIZ*T8?U_%PF %O%!0]C3N1L02;ZG3_CD2UPQ3%3
M=KA=A:<((IR/6Z!4@Y.Z^ G(_79**Y=Z49:)D&YJAWUB2KC^H4-84>?'GSN(
M$$?\%_KAOR1#"SW&D?,(&2:A.\4@E$);,=8=I%::<9JI:LO^3X8Y^^SZKOTH
MNFA;)TYAVF:E913S$&2Z(7M[%GDSF%$PYZ+0G6K].-@:=AJW"'4>7A5) -K=
M=*XN'8-L\M[S8^8>'OO;W ??HWB>35;//(55YWA8+!RW5L']MVUGDB_JQLE'
MF!US@CB]EP\' XZER6+DW6,UEP3'G3QE9-]5CY7\*L' =?9<<GR35ECE'^Y.
M- )M_B4O\ 1-D$(FS9SC+E5(-BS,-#$'=Z@L$Q^7,F+V8_BS[>G"N>T%S3*W
M5X-K.Y#70R<W/O]Y0SM+4FS)E!+-<I069CM]3C'40H_(F(><KE?XF+(<:\()
MB9/!5Z @=%4L-9N@Q_UR>$[[48R$Y DH4WY>H=)ZZ"KY5'@DX0F(=72<120G
MC1]E4:T)2&6,M1IJ0UU+_5ZK10J6@1Q4S9*D9V&U+17R!:)>P\U4P,#0""B;
M%=:)BIN;A< F/.H<)_H7*H2R20OV-*DT0F+&-K.BD3%[$<KXU2*3-Y1W3(J8
M7= R!5N3:#$D"C?+QB1/B"X*:+,RJQ=GS2E+_O"&L2W<!M1PL6C+GKE1'CA,
M(T!4BMW-:^X,2GM)M/WJA-NE5B9-=6/8;K$8I)>DY1K.[\)7!W!7XNH?UBVZ
MFM;G:8[BU-YO2$=*XG>I9V6QV;F(]]/+#")1QK@GT69]:0^E-T3V#']/27AU
M2+=@-Y4D=T ])IC^S\DVO^47%J+^8Y^>I9(<Z1^6LJU:FR0HU#:W1-ZBLZ0O
MYB=6@7=J&? 1'LK=2]<B]/6GP54SJ\?.Q020B=)R0C=Y->X%D>W"<JG(_BF&
M0N;LZD!F2GPW5<"$9+NP\%B0%B8TH=M])>@MGI^3-[OY?&T>>R3[F7K:KC>V
M%Z4EAJZ<\2IMKJR2FC(DP9RX;L^UW*4UCSBZD+(H_&+W)^ JGWBBOL9<FK-@
MX:R'$^0A:]\NC<T-Y^[#OU;OC7 O=4(-R0P;&$98?O^3 C9F @B4$&X4'7+0
M_15<)74OG)N,OV7^=4%.:$O'@3+B-6G0@5J&J@( 0,T@ Z?Z.+K7P7I3GP0]
M$ (XI<;?U[OEJ-/%PW&M.(":3N0+\SV_Z5Z#5,(.V4L;>>G.I&;;+RXY]_%)
MXJ++S%CW@]^SO1_U]'ODGYRK6U(6IKODS4"G./F9'G*OG-'U$;PJ*$&'M<<[
M(*6,KSM+1.I^3GK]'I)^BP5)'Q)^I&\@0M9!EP%NG@#=T4_*Q98)-2?76@]8
M;K)%%3H^WJ^Z:D8_23JYN9FC!Y>3>'"II$+I?_D1!%.>"=^<U%I2*OPN"C0%
MB9 V,07+:.08,?@D4V@<"SK4<.9717<PU@<D@VVVW$S]E#O3\)KKTK;;M;X6
M,XH"X7FB0QY)OZP^J1<MZHO:O F :)MMV)9R!')E" ZAR^P]_ZBNM^"&RJ(X
MVK$H2JYGJ1J=\2>'()3OFOY+=/2'4-H2TY;&1F<-\$KW%F+NM[-N@+14?:+1
M)G_F^I4PCD049\EHYPG9:\W&;@#-E2C-*TY6X]@ZX\JY/CZVF%U_7D>6WMN,
M^*2H-Y! 8@01ABPJEU$(>^) @ Z<,2N7WZBFJ%T"O_>2+#HV8:G)5Q!Q0P'^
M*+B4N2)+M*#OU7Q(#5B9OK:5TG.3AS-PE6!5'\NU-U$!IBB3X./P+8=*/:CC
M05! J-X+@NUB;;W5R( BH-A]RDJE0(>OF *E%!4DA*;4Y?@!A:@"#RL\W3LY
M"=@3FD2XOXQZO,/V+$*_.21]N&3X]@0$FJ^2WL(^ 1N#+?>ZJN./.-<&8S,]
M=F97UL;1G5$"16*56,4=YPIBC]A0,P]_?X[V3H7T;$[X[D"=]0E 'F\7/G^6
MXWV)WM?UD>NKP8%4U?$\YU,AB\@E879TM%(K4>D0P,G;PO_10_()\ S]QS!P
M>F<_,1U#((&-+V>:!D??%9PU=6;TMP(:/C.P:=ZOTA]Q\@.\=UX^ ;'/>OK$
M$6K\GS]/4'A/=_SS,$S4$DSU-?=+2'::!!D\;#CN$11IA,YO<P,<GX!_'L.@
M=WO5<=0#M/>IB?XC<Y'N)_KCSBMG!W%+2LPV"HX*QM-H'GH1)9<3O[=VNR+$
M"7,93T#:Z!.P;! %$7T"!+/_B.]W(#TN%:!X D32[Q,3GH"P[']CY*^\L*]-
M[S[H>2:!*E$<,*O.-N;T;85,7$QYUDDN;/Z-%_S.^7S+X_P.%KVEGTQ5L5W\
MQ>(H(#(,( ,#T=I>PNTB VWX4,%[V.P)^%4!DI3&LV?YN(=F&?<;AZQW7S&G
M9VH2RG$M]_K4>2;/-AN&IU30?,] ^5=)Q1]=ZR^/!D2%/WX3=1 XGJ?L<G'S
M,@H-K%CPD;.[O'4N+72->0(D/246(@37S3F#:D"0>JE$C8EU("J9:4<29WGO
M5CRM+E\P\-[J\JB_DP&'5PF1+%*23%T@'?6>DZB47M29TAZ%I3&!*3+QIBX#
MK4YB$H:W]9>L%#P DY&;@2:YQEF50/+*)\REMCI8 9)TA"VVN:*I4CO'%XZ6
M-MG?A=-QSSI]7DQH^=ED@E"A=KPTX'V.=B(2,L+Q!@G>4I/!LQ*(0IQ;:A2B
MJ3O>0,K76M1I=;RHKS$24<.?4J[T[X/U%)<28%WW7:,H\[;:>5X^7'XC495"
MB[X#Y\,Z2>=\M#!)534GE+:8Q;K:.E+Z&UQV/P#!,S5D"U*A3\/NXXT33%8?
MT[1#XF Q"7((-LB&>>[I\Z++M2U^"=CE5,BA@,TV=4A\-MPO",X%%.!5#\O#
MC>*TWT]P[#!=1L7LP;L,>XD6+7^\]G\"1".>\2.4T1/PZF!?6&$*S'$MT.-
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M';%W 8ZO!$\FJFJM0U>J)>Q\9BBM20]2C#PPU2FCR2/2))!#V312 #H19
M> #U= NMP^'/^7><M5)5#=&4N(=\6_RSJJ&-\I)T7]#XKPY%X'K";5JJ#]<J
M%5W,KCX$/0%*J@3X]%Q'7160>I*X):T!RLN*/HX7L.%LHZRPA>>]:W51:&:W
M 5H^R2H2,3REN QOJ1=[ _P,8TG=OA9T./8T6^8U-@2U]WL,!,W"8E;%<+$'
MPE".0.OKM>7/]CDX4/>..'5+"_H0#T-LY_3#.-T@,X?-PY<[C<&JCA_QDOI;
M'Z9V5MT+;\.W,AJ;)@1DA<9BQ!_+CL:&-U]0BD!31[Y?'U03*%PG(H%,N%K*
M-E99[J>J4.R]E$<9](']0A^HICB_N;*=LEU-"^,I38^$3^EX7E*.86%G/F>X
MM3,_3$N'PF@BL1B^0;NQ7GA9"$G5>H$G;UG79I-J*(Y F!J);5HMO:_#UU-F
MJ17NPD#?533;OV?@",Q4PM2T_")W EY.UQ[1PDAVD%!/0IC4+GD//O6&=2JN
M)<K08P/UVS&!_D070Z*[NDU&KM9=!XYF:JX"Q7G,9W1M'96X5H;A1C'TPIC[
M,>8L'3:F-I>I\K_<Y\0T:$U4&>U!^.LG&8@"BN4OJ/&[F@:E'4LH67MSBLE6
M@CY>00VCNO86/;Z8YF32&L"KQNI6TU3=<-')1).2T,LXI)C'&7YK6K)G ):4
M2[4V2D*G-HUA"5^5)T'"."Y#X9K:G2#5.N<GU#@XR/2CI"]\E2_HJ@ /<O"A
MA>[ZF^.G)XGG,Y9485IR)#NH]^]E^)3@U?[#HPR'K9@$T.9),]H!1M$*),]]
M1)+(D;!> SY>'R?.L8%;NC!&ZR[%R<][4$-TYX"B%($V#]G*RLHY1]7_#@!1
M]1C(-+4V=6(,&XB^IX>7ONH2]RC6-%\S=.#+#%HLT_7X/%UL4(NXE: ];:0)
MGQ<?]1K1#[2DU=\%2LJ5)X"B1^2= PF0 %23-F33933>5>W, >UC0[3C3)1*
M&-RLP\,OZ?I@\MC0Q!T?"8\'^2A99889%C[#BDBM!LBF=F&OF&YMT\1&6H 1
M1**D:@;3M!<J& =# I7<#XA52'+0V.3DBBR=U7#'<1THP\C;-KJ]'"C"B^ZP
MT)XQG^!C+FX*3CZAX4??UV2T5CY%GGT"ZJD_34E#XT<[*Q[J[V\2N$8V83^R
MIC[&,$NA2A#&4< GR%:E=T*K>"07ZJG^S)D&?L#"P".M$SE,<)] (^[J^>::
MX];+U4HI<'R;&^>!ER3VYV*;V8W=%8&/SNG)F1>P9(R59;")UV1-X$'F(?KC
M=MU=!4LALIHQ/5IH:0<W9AEM$1@I%6A9PQ&H!_JXY;!#*Z>!8H8 HZ!9/(>5
M!!,*E_[LF$SWFO<G^RJYQV/+^V\*YONI(<WS#L1K+&>E1LA<W^8;K82#%VZ/
MH89FVDA#;*Q*RM+<\N/2MBS]GH#Z:/C#F'>$1[T1W\$PD:*]G+O5U16:K>2!
MF)+*$+$CP;X>![G(H2E<M._OR@C2;470MNYZ]CRFL/48U5/U+'G)QW-J/8P:
M%A U<4(_]J@.H$)[-IE!-5.=T&NVN1B;4J#D!"0R8PIT52VV5_DXA#^*O-1Y
M#,Z;WT^Z=@Y:>_T1*Q'V% G_O=10-^_BRSR'F9-PHJFIA%7N[Y,$B3^BI<:Z
MG!'/J"4-].B"3P 0PNXXSHA,M99<2@(*K%T.!NF%&7N%*+\$/YHM+?2$70^J
M+)%417<V<A$+<(G3[1K5V7[$]6-<\Q+E:ZAL'$^D&,M/1%LO-0H?=]/PR1TG
MR-2*+M\ETOD3<,A@/Q4K229D$#?<WY'M.T17CQ[XV-6HVX5\W_RN$"N*^E""
M2ZKOGIF/] E0!4Q=E26_3[YAAD21Z]/R^G$T0.70 OU2:*#^&X8T"4]6W<X8
M25@YRO#"5ZCQ- !R=N&2:-;N%5X8=#QCG6K[+^?74#1[DC000SU^UZSN??%:
M38Y#&:Q8-YM@=:@?I3LG,2R2JR+XM].AY!-'3*CFKG,&(49&P?179G6$:\8"
MAV0Q35)MI38(.VH5L\P%JD8Q!XGV;=HN@\Y24D2\<IF?]R1+]4>>=Z+_8-KL
M:U,[[EGLH- EO;<<7C[;/%=7I059D?B==A(5&3M%+ BK(NC_R'$K8]"M&"'M
MK.&F*P#E6]K-WIPMS*<W(!^C^OBQ3L.$KTQ;ZIFNE0I*AG!J"$/.]SWD3!C,
M?@6<'L;CA*<<$G?0=0&ZU\:.QS-]651C.EHS$LW2,?!!GF72<%\N$%(P=:DK
MGM4M+#>#0\Y#I"NN@&#.C81)WZ9^QGK%>4GZBQOWJ'!(A.EAO,TWBJJ:H#F%
M#;'P3GYW+.U\*U40[I*V4),+V-NC4-(T?Q=!*6EILIVQB-@7-BI9P!$_ Z49
M=]J*4*E^3(LP3%?&G+(Q!LFV8XO">4H/\:?31=]N@I9$5/'N*XF$/$JDPMD!
M9TK%7J3*()H8^9,;=4T14D&O,3N!A$=2VMSJ#EZ>PS,J5R:/YP7QVHVI:2@$
MU0@NB<"?R,&G3P]*Y<:J1*9IL?TK5@GB'B_V5Y6O6@T3S.4!!EO*9.$?V6=4
MM6@SP#7/R!4;D=Y2.PA2)QVG&OH$H*#Z*TR6<B$RVZR%;ME08WFYG./8MK!M
M+H1&T-8P?3:E/ZTLE]@X"2>5B<RKEUJKC>$Q/B-_<?J=6/RMC'9%C]$S2)46
ME:TZ7/3W[S8#8H!]M2-K*EQ;3;9 J=-GI>TQ*4&7-\L&YHB6#Z4MI*4[Z1V5
M(I;'=\S/[9Y7#^Y_6^=O0Q%]^#X$-J8(%Z5VG2:C:+984+HY<AOR^/- OXMO
MGK6/RP+T<,FP^^JFX=):J9EN:N("UT+XY$1?:LQC3^D997WYS^,"-9/BDIZ\
M1@5*-ET]N5CB1HT%D;T> 4!0#@ 5Z1/SOZ]OU- RM"'XTITJ193B15 N>&)=
MX@06/<2GF'T7O=!>3#I,CP.G1_-X\PE@C41SY9P0M;%9LY3U='G?5/<CS75B
M@[C5]YXYV'_!+K0APVS,/$D%MZ84KC/^Z%$VQW4F,$258-='Y)X6ZE8O>H.G
ML4G#:$)33([C0V"L.;]&N4G;_J_P-4@!#0QU[4^7SI,GP(+))RYFNA_+@#7Q
M31A6%FW%KZLH:Z$JJ":/ NU4\?.PVD2#M)^;6-O(*T1\&_:(L*0]<W7E2.;J
MF!9?Y&PK%W9'YJ)S?M+#LDC((]=?+$FP+$XO<QH(PN]I-^!63H;<O>BT[[.Q
M_]3C@]/13>34'\/B&6GY(P.1B?'PX .&5ON73OSO[_"!V%C?^1@+]W]112SI
MJ*+0]$,17XPM'54\#[FYL>UG?\;.8SB'5R:5-FO%I;+R31#,N<.W+YK:XV+,
MAH6LA>OE61<,DP !\37">>P)<&GI_% 0?AFY6?>5JRPX+L[CA[M':.]Q6=)<
M2LV/]R?#IDY/ &FH@IL+G"_#^*,6V1Q!,,(>@SLILF>LYH^FZ@EK6-RN$YLW
MPX'&;0H]7X1VVX87<<H++'#K!?UU%HBC"Y&+LN,-7%6)^P2@1' Q#7VQ.-LC
M0Y$VGH (VT?R$_%]K3 /QSMVSR)+_F!'M(I>@#5H&(I8?LT3GB]I//1HN.OE
MPNY<7$ZU2SQS9/$VL-\DK82<5MM+7K*K1UP[?J'=$'(!XV9CARRA9!:TII*"
M2^%G:S?^_3P#]5E<[!3<&J'34VA*TL4/D>?@$[%#*UR<SO\"/+CXU"4+]IRU
M.+-T] :_BQA)^9/X5+3>.JB+   \4,!<<EANJ''T45I1VU:=@.#6B]J'IQ B
MZ")>.VE#C2D3]FP[SO+4AQ7E (ZOI1 $-6[5U<'9LVV>@AN*<=Q4>E)1"TO"
M438F%T*3:,D9HOF2&UC,3&NQGEGO?2.^]RRJ":P+"O*I-0&&^WIDE6,(T8Q+
M.J?4JJ%8%1N':O9\S&OP<@Y:$C5VV%/0LGW625NJ5<T_TN&EC,GN]WW[[<[;
M$#@G+/G><T^Y4%F5'EE31B@;;01^8;!&[G3NH\XZO@RJEPLM&>VXC#A:_] ;
MHAER.AG%+V$G@ENU2#(L&]YC%2"YQ=X=T1OFH@H2OWS&N/M=3.565=O>->^R
MMU$"$8)H\4\:,WE(UNJU-CB7$0?<2KBRS9CR-;.-TH9^"2D:0-\41T;X((R/
M^1#F+'44Z%9_O1*>J]>]:.AMMGW8H,1XQ0LO>"V (8HSKF%^8GY9T4$H$,2!
M&6+,GU)  ]0HAT]H2220).3/M\7%.P92Q*P4H-,IAE<<68KY\)1Z=,7;2YNC
MXKE@SE<=T,1@=PA8X+\DQ Q"GI?N^6 QE!2VAL*_R*"8:H,[.;K2'+#Z^6/<
M!\G%:+LAP28[U5_W6-UK2_P$V@<AK/%4\?*,D2M=68!1[!D:")C6AVODZE5"
MS Z1'II0R!8.!!@5<N@"86CBK0"-]<*KPK^;@[R'WO)U]9-,S 8_9&O7JVL#
MHQ,E""[! I<W()F>*)$36*Y?UE?*TM4L:1:R5Q.P<QE8+*+HL=T.4PU)M#"!
MGGB=8S\I9.UW2A&5OO?R@75H^_80#4 $PUJ3S153-,>' 5(RRV(J]3DM#!B(
M'41^DJ#')L<J!00, >%2[9:C)8F:Z"7I%=EP/$/*'+!P1T2OYXG4'$WH^W&Z
M)FKJ@*+O"0A>@_[7#9CGBKI=V%!!4WSA)"2-5;X#.C9?1)O?IP;^R!9JL(1^
M@=#I_3%YJ/YK?R86%;N]X4LI#5NOD[?X0QY.94>AP&89QPN)VV51V<2) 0O2
M0[8XM3[6."(2=.I*ID923U,' 8Q +B87XG;<6*9O]]\#'J&B[F'5W<0!AR3J
M6"=3-^NQUF@4#Y,@:1Q?;D9-*8>;E\.\AJK&HQ>)%S2+',569[&L+]<'Y6X4
MLJ]M4TBU]LTRT%Y*C3D-",K@,]/8788([/\@I+"@!Y/=5M(I'^HN_CVP1R5W
MX@/W]OM0VS=:N%]H=><11+3'8WO*7JA.7=PQX91FUL=E>OS8Q4[3-%)#2:D@
MAK._90JOP0W6'J,BG:^HBU*(V%PDGD7@ESY@$17C@Q;<@>XNQ&VX_"DDN\C)
M/$< "Q+,Z/^)FL[X><=-CV6Q9T#[ECNHZ@'5WWSK2_2-(A*IR]?$/M7+88&-
M8P9=:7H45")[009NA:\6&/J[SMS[X )$UP]LH]:D# 8^I Z.T[8+VKOJ\>VW
MC$;"@WAIX0A"D-Y%\P2^YF:PDR>)V4I+<']=#,(BONNC62XJK_)50KI%[NHA
MOQK?9,>[:BVU?$.;2T,K W-<LYD@=KQ>IKH$_SZB*\Y=UB#,LE.4%6N*/#/H
MR(0<[5WI-U^'*2M9W(P_6=L#BBD "P @>Y6;,F?GZ&IV\&OW"1CCJO+0I:TO
ME8V*$)6\,LFEFO@BOT6X8XB$5A(-SRZ:<O!QMG+Z#&=D]Y)EM]ZI*:*6')]"
M8YPF!2JT4APPN Z3\M2:55@48)&(8:=OH-:VZ;5OO,]/47^3N0,JZ2J09,XZ
MU>P]R3EM339LO,&N:+LK34-!:]$ZIQ>!#@> 9RL.TNDZQ#_#F8S2.E3-5$UA
M#\,VVZR18 1K_>*T# 1#<C$_(B') =5YK2X6L]8_M+>V9ESCM[D9-,-,P4@0
M9Z1S6B3:JS=[7C872@OSLU$[;X]!\+X&-B >/*(K4!?6-SOX L]>BL(W/9EW
MK3X51CQF06MY46>ACQ:"V86Z\1*Z>LJ8:?(S/3PHU^8+N@(:[U;\7ST[9S:A
M+_)TS?&FD'*D'8HJ?$H*C73BL.B$A83KT=W/G_=KVO'A4;"3P+KTN%Q.:$9O
M=V];K:EO"NHT^SJ8;>Q.?Z)O6C[]]0C!&XSY7Z3&2[,?'-J&+$?W_4Z" YV:
MU-5;ZL;FAON;1Y/?QPX[P[$-NJ"B>5T XKGFW</=0J26A^!RDU=6:UU8TP8W
M^O4+TGW;1].9ZN@YKMZ=")WU0IE%*/@KXXS&58JPX8.;E_;V\$+;^[I=O^>%
MM^TO_58[DV?_)X"M!KGH3J".!N.4-E#-<?\BNL)_ E[)<8OS^=E8-KB*$B%\
M>JDEDYH[@.<M1M?W4[?8/5%%>4N4:,C7'\X !NV\?_![5AESHJ/CU 3J.VUX
ME,8KS@+P8?;QV7L,AE[GS?IPA]L3[0YT.KU;<P>DZ7 PV*EB>%0<Q[=6>4Q"
MW$GG8S<Z=C]=/MBW..& 8ZJYIB%Y4$7;["KEZK* J<2:>8@LO.ZR0$E2I(WX
M*TL'X!XZ5CVQ6CVZ61T)72._&K!:X:O]=E:F7TN3_^8;:*[[B&^QV(T@ ,>
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M3\#Z@? K(&:^B\^JF;1RRAH]&JZ/ 9_"CM)Z-\J8NH2K)@M2*3/-PL'P19N
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MUG^MW<"7(*,86I+^OPD 4$L#!!0    ( "L^;U0^S/F"G^   +X$ 0 8
M=')D82TR,#(Q,3(S,7@Q,&LP,S<N:G!GU+L%4%Q-MS:Z8? @(;A#@$ @)'C0
M( D>- 37 $$F. 1GL #!G> $=PGN$!R"N[N[^\R=O)^]R?F^]_SGW*I;_]U4
M3TU5[]V[5_=:S_.LU0-L$K8(W)<6EQ('$! !  '^!\!F@)< &@H**@HR&BHJ
M*CHZ&@8F/A;FO7N8) _P</ I2*DH*4C)R:GIGC)0/WQ"2T[.^/SQ$U8V3DY.
M*@9>01YV@:<<G.P_!T% 1T?'O(=)C(5%S$Y#3L/^/[Y@S0 N&D(I*!Z$\!!
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M-\*\>Z\N.[5L-4\5.#[5# K(YILYQ!+M6>+SBE5]>D8J>?C<R.M+1X> <<Q
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M\W23P\T8<S!R^^YFOZ[]6F__%36FA8T<S]99WJ_EVZK?ZS(*"(L#5[BN@C!
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M(4B^/7/V9:V749EH3:U')N*8,F#*,4$+FKTK_\?%Q'O99Y\W1[M>_HJ4\1<
MFCF;81Q63R@[G_C]9F/(([=3CR\I+PFM1C9*?DZ=SI@]OI4C\5T"+C6.40W
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MOBT\KUW*Z.6Y+M&2GKAB:6N:">YJX28J1S7].'-9:\)>W+?4$5<-EON=QH@
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MO';R3OB?["X->OI^(:<67)^9E&\?F3@AS,GS^O+Z6 OVA&EK.*M2,%*O)BH
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M*:."Z+BE4_K/@CM8+ (L"8H;A.H5^UM_XXJ6^I98Z+K^-UF<=VKR8UL!J3K
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MI9>DR\DU[*J85NJ0MEZ6U(^L&:9.VN)(C'&^I?J;>9.MB]B4"U7J/M,OO4I
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M1L$U$#]\7:)819+>:9 &#H"A5.OEW%WB%_,J3:S@5Y:&ZM"^4/,<[%%Q@R"
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MTKYOQ,0R>5"'"E@CQOB&>Y X7"L>1L_V6-<E"I;*K<D@-?B_ZD&,?H&!X3P
M__Z]Z@PY%$ M>0O:])IH/L2;@@)ARK<OJ-/D7NN%ND8_=/P:;05/72 8B(Q4
M'M;/P>M92U[O4MQ$&>R-4S-67(E:Z359%48R0/\UBQ1]PX;4WJ'BY"1[XFV
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M.(IG$79D<W[6C#54WWR'YC9*(Z[NPKA2J=,89KXLI+R;M[D6_;MGNO.&@$<
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MV\X,C27BY[L.5(3QPZV$PFKP[I&KWS*ZFVD*'TL<F/JSC"UB8DB< 38?/66
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M?FM-%.')WKH$SCXU(GSS^)1-QE;S].4+0LK7=0W'Y5=7.0LTQL&KB[:<OIL
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MWF\9CN<Y6W?Y6![!(O,RKU-AG6]/9\.G0:A:M6[\I#ZQGIRR'WE^1/6)/>9
M([DLU>,J=?L5'QA+&G;U$(V3VYG3?C&ZMZNU+0H%7JIIJKM#@3XUOJX/=A-V
MG9PQ6DTT4T5<Y-R9*9?@R64EE>E99&.V<(Y[R1EY0@'FLSJ2YE9T[0-5#._K
MJ^Y\(7=73[$\I@\C+N(ZUUCH># C+SZXB$0X^A!CUR$Z!R,T@Y[*<7$8&3F
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M:U*'7;/J&<N'C'3P6!\GZ\]TM#^9!:I47Y8->Y!VCMCVQ%RMXG\3ML==S\P
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M[B5P*14U&L-7V?48PIXN\\S(-]5V9;N!:VP>5WM/L_9=H*QP?<F#3<G)_=6
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MAWK#Y-QE-\.$G O89U:Z?J%;9KEFZX2*'U@0H?#U,&TX*&9@GKG*__SW_O_
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M,!7.N#/;=1)S+9!KJ,O-+OI1^^%5V;6 ^0]MJ,-3TO)U1_DXV:$EQ%\0I[[
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M*,CHJ^$3_VE7_/]#P_V]\&]02P,$%     @ *SYO5,RZ"\:*3P  XE\  !@
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M3;%UW%;=\KQL?W"&Q%/FO(;LA(,$L#(2'.%U9X:%VO_;2CBVHQ^*.ZYY/O\
MZ]<G"EW10^;4F5)J""2_K\.G\W-03TSM"S,_[<28UK"O6?*Y/D<:>_-"C2Z?
MM;]?0-&\E4>KR$TQ;DS9Y-BP:DRUSCAVGO_DVP:]Z+;R_N/AVS^-+/5[4QAU
MZ")9PVAA^?IYZB[K5.7S)IJ[@GI(7://)3<OY>*V'[]Y!5V?'.4'*8*CULG#
MX(B.U:>%0XMB:8]NV S''H*_F/9O"!5XX5$^<J T=Y-COUQD\]6N6.YIYDQX
MCI( ;X-5K@M-CKD*?S$IZ<5(J9ZS:$/>#W]4@?K3QR"FW] #1R."S:8;+(=G
M?$7>YN_T$H/6TUF8B0./OW,^5K6>S01_<B._++^3F'!7\UO!EH#@_$V9DQG/
M!WBQ IV)9S.M5\H%RU]XR=_9?W-2(E0H2 E4 :U6O5HZG?S9Q.6@?9,+MA:S
MTE/&_8YW%8H:^WYR7B@;)A0#_8T2HXU#GG3<,.%@*S&_">3='5L0SM0K[.;O
MQZ=;=XJ@\?SODTH?S4YFX(A:^:NZ,X8_](J@Q63N$PN$?N-K+VU)9%ASC)!#
MV+;MS)/T.W$JOD2M)\&<(&R2K.;$!Q'THB9%R#DIJS%1/YAH(8+H-Z<^F@8G
M1NXS>#-@_-5O58_S!):2,WG5Y_:UIV>';DWI,QWBL_74LPCJ=S:BN$VJ:,%B
MGEG^M>9NN^SZKTPW&ZWBQ N+-&X2C_@I)@>5SL:-RA-6;I&&3N\LCP=^ME:1
M#S@LER*189$5^@:)+1!!*7EP!'20?T0$H7=;80Y/%54BC2X10;QYEN!N!JC?
MXQNB[O[NU-\4U92BLA%'OE2U[M1V?UC%56 UX_HOU3)C7R^E_VM5XKNWK6M3
M[-5?93<D7CRT*>3>^O*)(//A'4B?/<)C87BK(8?Z?^B[K0-G[6^Z5Y\W['16
M&US#/M<VGU4*V=6?H5HW 7U7I'Y?#I>1TH:0:6F"0!+3>VA)"C#^N7PT-V<J
M:4-Y04/*^*YMV4&F&^6-DOROO\*4O>/+QHB@P[HBZ/UU5&U.M.YE(<E8!+V.
M$D%?]HN@#4^^+3-:8F^S(>S9P[,+NESOS;Q>YJ"T9'W8MX\=M\L&MYKOG]F\
M(?*?X5<I,3\@>,\Z1L']3>X)^^<;(UF9XUP4.!&J]UV5?[54579VA B"6T00
M9\+,\T#TW4F)7F+ZLG<=OTF]^-W+7G&>BU^,,"D&H<U0A0)IQ-&>SA(Z X<F
M 5E&O?9FMPSZ?;@NG;C@&&Z^'[@!6BO<)P',WO(LU^R^K6/YAF63T*LC7<L%
MIR2F^?[3TD/1UFZ[:%7;7M5)G#H<)-.R[$%"DMZW1]:%AFM>3!6:O=_ZC.'Q
M;#G1XY2DN:Y+QO=4J8T6 X%W ]?8,6P#TL<S7$;VETFZ#D^K-Y^:HRM]2G*U
MZY<S5[>Y83LHKJL"BK..XA\T4 6?I)'WRAG-6?Y.&[JWY_7HY.HNS),/NQ43
M?SBZ([$A(>_6XH<^SQ6RW!)V?%3P(I1&7JR8L*>'3MJ2*R;B;8&2AY'XMJ:7
MOFL?%$'5ICAA1C+:^RG[5O[-K*[!/<0HW4=;E5E]KVY,RV9E6)2KEI3;A96K
M@#.Z<[("NZ@+%I3]AG0JQ2F\]_ %;35(\6W 3*=<C<IZLB'XUM'ZCPU//D_8
MP[8%H4 Z),6W!M+X%/[^<YK P0H0#A-H.>%P\S*\F?_QTSZZ.QLJVXY%6::-
M.=I(; J@2&PB+2:T%_<AU5XPGP6JQIFS;^1A6+(D5"""9H:[1YPO-%WIS;\;
M).,C)S??P]3OZH[PHV\I&5HK$-OP0!&TNPTX 1IPR]&$=MX7I-H)'F\%WXHZ
M_'Q/[NS8WU'?'BE#A<;6HM9Z(LB+RIO9*EB82^ ^CA'R1-!P:W:]T8 Q<5EO
MV+?>3.K\._F"9:^0Z@L_VH@F>!N3N/XQ0KX8&=?CN";;XG[TX_#JUEU_=A1*
MQ<7.$&]UXG8G5NQ\/-3@]'CYZNNYK,&PT/MO>1O+L>7E]NC"KVJJ]_<.=-2
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M?ZF*;1338 \2'_U1E10J!<*B(3MG=D)K2>(;IT9XFN2$?;JRP<#__N$F;KG
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M C._$?@CC6@;R@2D$X*S"0(^: 6CZ_SO^K,O,0F7Z3I!YM2HCI+&O.")>>)
M2J.6HW.FC\Z@$X*!'FH/)L)S7!BG*A#4@)7= &=M [?SDCI.P;'+.3#F^URT
M V&-3XJ@NQX9("?^B)_3!??6GA1!H]'VLYT6WT8;@FZ-8Z_TKN\" PQ%O2X#
M+0[ _!B?)+OQY_ &9N^N>=GU5O[B[V,R1SZQ1JV6_;/C473]N8U%#FQ->;>U
M(UT)KTB%VHX.Z\E9L6\J'+GA%U@$)U/COBRPZ%]D0QW=G%SF?M!R^>WUTZ17
MIKN<#0O3UZ3:3^CL:JZ^?^HXXQ2T2#ZPQEY^]Q]Z3^2/(/FO3;7-CV6W;#Z6
MO.'2[NSI9^L7'WAE_4!F>GN1<>NFMX0 XV.9U!4OT/J5%:FO1C_7*HWJV#LN
M"WBU+WM@Y;I36Q5'(! -('%(_!\>\[Z)H)5=^R?-4O<]406345=C(XP60?GP
M@0$MW!I/PP19N)?M+%S:8ALTHDQS#6!C/ZYS[TKHV4'\@<(VB*!N3,2Y*>)]
M67QJ-$VVE&B5PY(N_E&,L4?&2+7)7.Q'DD*;(4WVPXP[O?I,FN&N^(*E*_'Z
M:7TI149G5FY;7'V8'<T_CM =/AHZ=<MF*35]E5AO,;A6*X1#J2"XQ[!?@%5J
M(KZ#Q[/P\@'8#%S5N(J;\CCN6?$,?G0W6)'8V<J:\I@S% ;'/_;XSMXC\,/
MSS6GT"8L/61[G$*XS,6]N=ZN8=6=JE'HS5;]8$MB[S?68W6E[Q4FV>S.^@WD
M#M_.*0K_%-_+-#2;H"L8F 7&I-UC"(^$7G9 '##.E:11G5&NF54[<2V+<J48
M1(>1\YA3T>UA>X9V[3SN,S_P20AN+W+-ZP:M)Z;ZR!<C8EP152GW ^[KVIVI
MZ.BNE]LOHU\$ ]7T+DP$COV.+8CE&WMXF9H1?8975^S5X$@RCXH!0W"61@X#
MUQ'>.15%2R5>S-M^&?,>/C"C?!1).RM(0.,\/!9/D3/3I@4);2/)JT;6M)N(
M(*,(:OOJOLLYAD\B:%('DXP,?6'RP&'@I/*I(1O)_ 2NZ7BF L=XBC*Z2-@D
M2"CM)Y(BF42_@V*1X0^8%?\(<A-6PM:1N_&53VS;-.D7GS#1(=34Z.ME-Y?X
MW7[M/P"4VW8<5VXLUG+.U*2%<63^@/U)]^$W9(8E<L/KAILY!JSZ:;0J7)A2
M2QK)HW8(AIWM90<Z.W#YRMQ9H:QI.0?'-(/3^T60(XO"5W%F4P]HO_5XS0X<
M\T-GA5:/)MRV$5800M=A+LV(H"OFDL)0#3XAPEWJXT&-[,EE_'W7G*Y7B 4G
MEU^_^2WH0*JQ?\IJUS; TW@Z@]Y^BJ_G_HU#RM_S1'SZG933EJIK&Y>31\,J
MT5;GL12&P3<R=^-,"J#!9!%T5/V2F6S9)M*)RW>"$]\Z(HXY''.@+N>H8.8N
MU>-2?2^  'H1>='RHRZ.78#<1)0JHD@7EG\0QCU"K9/2_$=;_#7GR0>6GD%I
MA"F'77/N-LA5H'(6'J$MA?$9P9<;@-^?YQMMONSD6XZ]!D<:R6@5A,'B4U$>
MT:ZK.(N<&=@ZLQ.^2&*[BZ @W.S9/$<U:6-H"\E^,^\Y)NU>0MOO?JJJ3<RP
M"KXT2DYRNA/XV7L9N4=3D!#) KYR>]%.>.^["%KM'>\],2].JG4_)S]3F$5B
M+I(;9V*U*I *2G6H(*RG8>Q.83/R@CQBS//*)/HA^);7LPV0]A"F[#(+?-4)
M_0K[GKWN*KG7"NA!ZKL%@4\:Z_B-A4%#]L/-X?4%5KS^M<ZI%.?4MU/X.$H%
M]EW LB1,GT"B<T2Q<V2'5M"0G;C\4"82-+$II\V<Z$Q*+V%A9AP%"31!T)!C
MT^@6S$40JY,-.MO,7[ZHT/UC@A5W=/=]BI,(.N);)>P7#'"10GJ$ U>N<9I2
M(4N.=K-JEI7,.FK^[V2RS;\DP^;X@BFG6\N]+KJMGQ79]DCJ35 >+]X4SX^Z
ME3 6CG1(UB%T-<0.<QB0[U;-ET388J]JS+#!4/W:YHLW_I,8UQR%,7U4+X)^
M"FY.9 _0DGOB-NW*:!2^L=(5XZ9)/F &O\HW:=S@*Z"URC$21W:GK'F2N$9V
M]R==2D<L4%[KH;^CN+/*ZZ=U<BVZLL;ZG@C"-+*!3;28K:WS,G4M75'I>3;Q
MZ1W^#:$(&J28X4,T4H9/NW CHY*4/;<EJKX6Q'[D257&<XW=T4PW\<F%2^HT
MX"XY33C,-;P_C0DQG7HW([2;/3%84DZJ?0?.J<6F&^8^P<]-&B.,A_G\D=W]
M;HOG6)>CSDC"N)7I&=T3E/%K:@Y5RT[J70WM,^NBTM6N EP&VY1# 0A#VJJ$
MH1E/O\Y0?G] E9!EYE59/$T,(0XP'Q*M4@+O)ZW>K<M:Q=I0_I$7-JCNJ%U?
MFGK)VU%Y9 ]RJV# Q,\;UJ()'^]F!9PY,\C=^F!M4_W]&75$+"6E5@@[.CO*
M\WI=+\ O@W\O?O=8-2Y!!%T(XF<2'^#'ZD>MNS13R=65RG??^WFQA/5F867G
M8ASZV/TOV4M2N/WP;IP6P3CJB;*4GL6>S3U(OB(XE)#4<PAM-]</^^&F"-(J
M[U?L)[D21A?#U8<+1= -0_$).-[S@&9$6K.DB=[#J!NIVK!&]JOP#8[[4.<5
M*=@\SD+^726=(8*>&PCNNY';KE*9+P2EM[-Y 946'U_@0Z1OL%,T=EL.:<7X
M1+8\V?J[2?<H4M?<KLJQ X?C0?Y)9CVL!&>.$5=-I2BWXS]S:=:P'.X2M9L"
MCL3QT8/D/P2Q:&/>-+Z29 -O9N^=4KME(.QP*<FUZ34BEEY&[+MX"@S3J^J#
M;T*MY]?N;0A[8V2Q)7[UMBB-XEHJJP)X^Q\7)OQ5/K0>&0_[=4V);U$="GE"
M&AD&8P^:HOR\)KNB*_6(:U$NY==U*,OG+[CD\:^6A]6'&U:8"S>F F,P?PI(
MF)YJ%*"^ZH/P G5SZN3V-QNME]@6W"/UKF[V*6D.N).3UNA=8OIDZY[GY=F&
MNJNG?1OO_\U]>,SJ[V&-6.46J9J:Z6X1U*D>PH8YU/'X(4_=*\Q/O+3RLQ74
MZ;UGR#:(/JO;Z3:V>/W%Z_C@"CZ&3^<T8T">X('RDIS3J=$8@+"B5Z>,E K>
MX4'6T -81^P/F",Q1*C(5^89C@I*^+N1':YZ%Q9$/G3W=F>9%]<54Z,O?QJ>
M?T'FKGLCVHCAW+]>*]-PA6>)W69(V7!;OV*K".I8VSI-&5TRS#.5RBP7?L5U
M6*,3<>RC(LB*4.T/9HI :"!EJJ8,FF#%]3'V)/Y'TB4,$#YR?KMGZQ5F&.61
MMH0>]HW3W+C !XMZ'S<CH_Z8<2E^?_:?VY\'PDK?W$Z^L]7<1J3*ZP'@NJ Z
M$Z1S#=R#X=1@?EX).T50,!>U(%?^)X1,!GJ*$2=X<S#SVL'LN?>>.<+\H_ X
M^B"Y!G%T6]+YR65JZ9SL6.12E;"$:];49,29UG@7%3JN9DW-M :YYH =6D_B
MBZ W[T30+,90&*3*D6)8> WG1<=R-@DI&(X(TL&Q'R-TX3(-_G;"&*:2-/(2
MR464X)M=NW"YXZ/K0%K%VS"\)55JOG,1:B,YG:S#5Q+C"@KNF)S]8VGB0MU-
MV@G^ZQ5+58Y>Z[59%_VYDMY>PJ=Q_> ,7PZ9M=JC$L\=HH?(&B$T,T&"3T=5
MWH=1FRZ*\!4,#/8%A;\?<1-!N\T+WP*S3>(:,A0$,X#7.:I\_0OJ[8$[DGF<
M_0GH;"/QB>-:1D[W-9+W!IW<&^2^N^QM>#U0:UL1E &,CP;^XAH7\JG<;XJL
M,9!H/DPHY(>Z<38*R2@-$ 182&:<_"&@T I IUO]:;E6Q+*?#20T%"\YZR:[
MK>GLNII(>'+2RID)-)BVPBIHPDJ/_BG_X?/?*2.>"/UBSL<\_NGN\*^6PLRK
M-*<H/^5N[8F_P?)GF7Z?U(IS*[X13SO)6)T RQ16S;^ #B0'$0*H7^6:L;HB
MB)2' #OI.8M<=RP-[KW]AN>T<Y?M24!+=.MFL9117WY4IB ;_5;/R.&L"<TD
M6>/CS5#D_;^3DNP!V]>GT[Y+]Y)&%\K+=42P#X^?"2NM9G/NK;J7*KMQM0[_
M"+,)N(;+.0'K*URWNYFRM+07/PG^UFFQ[P;ADNPT\:E'ZT'A&]<AD(+BV/=I
M<< <:^"$IC$;8<:?*$[H^<1_Q*>'E"[ESD0R58AX<<Y:ES<#<]HI0S,'?=FU
MJ[B8F2EU]?U_[BZ[M: "=L_0D.(R, SCCJ&RK70[W6NXC0^&,H1Y@%-H@1R9
MJFYOXLU@Y$V^+)/K_,8P"MZ4*7@L+$'=<%S#7(2F*(*4ZM"N;+"&OX&;#H-S
M=E&9?\*<?K(ZGJ%5ZT#^;#N&857"E0&S5<Q\V8P<P80O*JC_9P]JKB;HJ?XX
MP?VSIJRKU@'6AZJO+91IR6$[E0-V>RK4+#OWT9L59??+-';>D9N,QUH2Q)GQ
MM/W^6HLB>)7%'8N05O4FXID"8?AUM)6)^U'M@MMUA/:)RJFG5/FC7MO$Z2P^
M/93EA9DX 6<X(+3/PF%!#7VDDP1H-IQQ%0:,?,D_D+(_N[!C&Z'.)>A"Y#)8
M$'(@OY4;3FW/P8QZW7R;OB<J3NNNA,LOJ&.ZMSQ?B[";[Y.3Y?I-KC*D&\4M
M.+AT0#%/3U_X@%O>0MK/:RHV<B=7DG9HXQF6.3CRG4"W_[U8M\Y*WNKZ3$)+
MSHJ%B!LGW</465QLEC1">;:KQWJYQ^*7N9W&!Y[L:PH=W8>2HS'V.=-"1;26
MA+I3^WY=E3<VCEF[$TO^,T*Q"/OU%\!=X>.BBT&?S+]AJ9>FQ<E#!#!"G C2
M)DRM'B OW&4DM8*07K![WXL^)%LY1K)BM/?RC2]<[<(K-&M@;P.T=W_WG0BL
M_N0\O A:M#WA?N_H,XZ8F]T:%$$%O-8+20.I%2D.*E?;UN0']SKC7S1C1O;#
MS$GJ>!BWXJ(]"YZRS9(]\.&#8BX-KQ/1#7,0"PV\D-Z2K_H+!J=^ 0L%W$BQ
M@U<6GG<<&>Z7XBI\EQF;[: ^'QE#L^J1"Q]$$!P "&F]T%=2@&H(6;@68$5Z
MOCRN#ZJ'2JZ*+;N4MTQ!TLF$?X#72BF)[O@4;;5P;+D7/P76#^)C:>B]"82N
M'E5MO?H2*;CLNDS"106CB)&><%E[]LT9P J&K4*%9.#)#GV'P3UEC( H@)$4
MLO#\$[=L5=DS!/@]"Y^1DH2Q)5A,4T?X,$_RP^S=_+-.9NME3&>S)TA]:K=F
M>!_G)KY?_B(.SDBD,M^&U-])/GCVH*/+T_(%3#FEW9'*(7Q+F-5F;K/A6=+R
M.]T8VZ!>1?./1Z-/QR@0.5UIP@@;L)KR%/Z!*M1=SQ1ME1*PI8G)&.Z(LI5%
M1/N0AR5FJIS'??ZC]6#$]@Q"TU.B=GP%)OV1E%4"*M^7R3J8RLZ%&:09UJYW
M$;:%3K=I5YKH[74BZ YJ>E2S]_FA1ZK574M-R1E4P312&V59,2Q756[SK/R$
M28FZ=$CFF($P0HI# @G@#;@'#M%EWP:-D[CU/Z]-P+OO+D>3+X+%F]B&UOKR
MRT&0.( 9QU1&\0\"SX\3#/RZ%J#G19#Y;H3V?2505!UA+]=LQ,-,?OW :W-M
MMNUL<RV.>)=-=V^]W\]O5O%/8&=K[K:$K1:YTB8.GJL:/LJ8258874N@._.'
M2)GG$"*@1.0XN'\_-94I$$$^!YW^/08+8N,+^)\8LZ2Q2,7LJ+CUM<=28+YN
M*Z<3Y5%J\K6X#5+GFR(7#-4>>:ZKJ>SJ)4DAYA/&%!BXSFCTFY<I$VO3*N"$
MHGQ*M9@C3XF?'F/:J_(P0]/\E-QIYQP#X2=!+/\&M0M?6<C\!^:&6RB!U4/@
MCY%&&%UP\R"'<'V ?C64_XAK_L9S<ZY;H8Y78CR429LG3",<Y/[$%OFPW>S#
M2_-37LJE\B6/:@+&[7_VPH12A*[RB*G6\QOR\3EIT^>D#:W2.O[N&RMWEB>S
MZ9T:[5K"J.,"ZNB&Z'X+G@CJS5J3=7-_ZTUH\^-[K@K[ 8%KQF1U(;1"),3S
MTD"Q+6K[J=:_'^FWYSXOIGX?E;5)24$/GB$[BG=4[X! @FV]+H*PDZBI;*D(
M.DX"ZO#NOT%-/-8*?V>K\BYM>)*U*7KX2+C^72DEAQB!O(Z0S.]KU?RF//@@
M8_/NJ(B$]SPS<[ &0ZUI!G/6&Y](]LW"J3Z.*\VJ&X._;L4 &Z5O)WT_YLN'
M.17)F-$&$733#BQ#MT4C_\"F #CC3=M_P8DAXJ-G<K7 _=5O<D_W[9:#6K79
M=DBQPVBP@HFM'J%JX9Y]C_N3D?-@>+ J,/F6B6!%7'M/B_;.?7LB5X91*C-G
M=A?72 'R>=D7D%@D56P1H<"=V:$?0' BH-P$7C7\@LZ_2)Y2S1-!+P/$S=OQ
MU6"Z>H;09ZU 0 7.C+V4P )* UHYX\N29)?"?017$;1WT_EC;5I_9/J,D2Q"
M:XJ!8NT2042S3'>U4Y_3W48Z3UXS3[*8>C.#"?DC;<5@;.1MHP-&]6Z63$'G
M./<;X/JR3AS!)#"(?"DEC"'@B#I#L!+Y*C68/#IB[DIF.5.9_@C=Q"V'SBH%
MYC*@%4O$,7 A4K&"6/8P5X?OL;KK'TW9[=P;,K_SW3%T(FFV,:-G/G>;]R01
M Z<+-?WC2!&ZIH(=7AICMMR]P.;S$?H1TG:$R\'S!TP%*9S82A'D'M.!+6\6
MGL14BR"I*46W_X@CV?$EF[X*:!,B:*MO$"S@QPBGE>[W[>$*DDONO5<O"D%G
MC/.-&FT.R6UR&&RZK7G]A6*^NP8U=. Q00EOS*UGZ TA!YJF.OE1I%W4?&7$
MP8UPRNHR(40A3C P]78&CG!P<Q+6XY[3NZ4]3O&\67L$<=IXIM4'OA9%U?^F
MT2<15$Y*$:I9L&!Q]1;LW!T$Z2$W"'F#C R;GXSN"ZQY_&'J5'!6G?A5PP*I
M5W\[F#JVC(^V6C69I'[.#Y:%.]1Q_*.=_)*I1.IO0\>*MS6;5YU4W;X)*-1E
M$>0 HKI6KR# LR\U-*B.&W=^?/M(;?@//.7')=F6;P1SF9@^.[2)A+J5<S>0
MX]WV>,7T_5<<-JZO9,CK>$J*0D>6_;9'&CM,U\_KR/"J4A!,P2$WU]QRCCMB
M&[!<PXEK[I<A](4Y&)2;_.(;Y80BUO?X=<.WP1O;>HM_@#$V0:@;2&TP(\!A
MY<ZJ<1M07V#NXV&(E:]+<=%RYB;V&9@9"/SD3C+K,VH*DM(+-&'YK)V4D/DD
M<3"=&;@ME:*3=S_JT\5G%R=[E0Z0W-N 1MPPW72Q;3#M4T/!ITT/)9TM*O@W
M"*QI>B EL$7X;4@%1^#XQS78(/F*8JRY!GN RARDRN$Z0;).?B<(4$TXADV0
M>RL6&H: -,%YM!ZA-7H=)>6 1 $^ >8A:3,O,:"S/K_2QI3K-^G'1&G7![?A
MG>^0#BC5UNI]/:;5\IPC3GB2M9HR5;2:;NPN%@,PMKG3S[)O4P63TLX(]]L.
MOOTM3$ZH]<81CNPS0[8'24_9UD.< 1V=K4MR4ODPRF@KYVN7OPW1>*D(.0UH
M.QK, LZ,+6</:<8;]W=C#$O4M^UHR@Y3;7(.5P5<2:L= 1PHDQ>VCVR,UQE.
MP8[\*.FO APJ(*9)+%);0BN0VD< -.EJN^?G' U)=6/[&767]H\Z/L/&VID'
MKE$_<7K^+#;BU3-4DU1?%7N3-(D2UN.R 7&+0(&L$:^!6S6@R JM,QR7F"UR
M]WT_O>2;TQ\D+DL$M;<4EM02#EN]F= NN1-J. \%!(=],RF5PW[(<KV)'S+=
MU3FCW>"GF&(I&/CUAL'_]. 2K!HV(RL<KIYQ:74A%Z#MB2)HQ!$95Q5.GLUG
M=.>VSFP^&WA3Y8XX*$EEGT4\IE/"0O0+::X,AE'*7I#E!C@+&4"#%-&R'%0<
M<E=[C#ZG]P@5^38Y'*H^V=Z\VJHEY26.OX'.KP(*9OBK@A*G<Q>UB&?(KG(>
M]PKVT"^^,.K O1^6]7B[(O"><GYI;, M\Y&]IL?3/W_J+,^'+8Z+D]G%-65C
MXZX:&PN*JA ',C^&I4:,1\;(U<T_I'L!,]+:X:*ZQ45U*[TC!AT4U&!F8>K&
M&@CKX^-9D.;:IT <6;BLZ]0BD]\2C]&T$Z1& #52%R3<$H9?)+Y=5^9EN;0_
M]JHX/8L!%C>T\KKWL;$W"NOD_> +_JA;"@/7!D),I"/7=+2%SA*GG6J_P$G$
MMX4U18F%E?\52>DPJ-9.+*QN'VWHD'RY0F?SY\VF4J.:1&2R]ZS&M[6I+ZV?
M9H1\L4YRA2^!F!5Y.3_6I797]7!);.TNVJ2*"+*O&@99]@8XDS$#_&6 $7\;
M30"FXQD3=0NCMS<>T Y1&2@0QJBFH%IV:&-HJPB253<8"859U?5L S*WWXY]
MHZ3=:,R?VN$B)B%E6?4:6],4GBYS16;[<SHG_\?#4[)O<%/)[I./C1C8(-\=
MC<9QSJI-!$7W,*TW0_:=L=V6'-MFE_?.P=HG9$_-J(TV78T:T3RO42G[+O+M
MUM[U;[OUI7/4R"\-]> ;MX GU> ;W\)8[,-8F.FRCO]+P4Z?,.L<OGF<8,F5
M[V2C7M12K.$I2FU$QV:LQ Y9A2;J,- >6XN.^T516H+ZJB%7JG6/793?C)3/
MW_;]YUJ=6-\V'>M-:BJB=JJ3V<[.#9GJ;0SLEJ94&BG+0+R909MZA[)::_2*
M;>-8JYQ?#F$NLX%&:^0,XD(T.)$D)>=Q[1-TEZM\W_8BJCZV9I1GR#@A9%(J
MP_DT7?JU@K'3WAI_?'RVP,,DW 9EF? \=SK53NAU]R1Q,2->(32EYT$XM2&+
M$^L+@-0PFS"N;N\&!,'B4PBV>=6H8;BX<".0FH4&HN6#N-E3UN%1P^IA?<_<
MVWF8W65>(:0_P2KY3"4Y;]!C&S@>71)06R+>X<(/<EO3_HS9T6"$R_*)40HV
M"<SX :0L CF)).,TO0/!UY)&X1CF.>Q'6WQS_Y6O,%.\@X_0#G/---CD1A9%
MW$K]R':,^<N$@XFGM.[YK%Y?G@32!'LR]QLY0I<]J3K6N>ZJE%KX!79"@#KF
MT=H-^O#*[6@CS"J%#\"9-,$DOO9-IU36Q@OL>(;OQ;PM;>'\X\#VI 4#/T&^
M5[!-3KX=3T[?6G[LUJ^:A>E[%?>7'75OL6HC)NB:LI/GE$G8&NT^*S>P9SYE
MQU0R/6X[FR,8Z.D101%[KT0^"$AWWU#[F6=E[T::+=O826>]<PJJJ\_&Z^@^
M=36H]@+PH=&X!3*!M2=L1X/JFOE'UBS5A/IF$H=V+2^4(6>VIEDSIJ4]B[V#
MW)$[AD5PH?(2V>C6IU35UQ10'M[(_Q@P*/RJZSW\F1!:9Q[K^5NY0#[_"<P4
M;]593(T"F=@M!W\/-?P@*902%W9*"4S<\DH(AG&#O,A!76GS5"^7OYLG>)8G
MJY$[><^E@6$W47GKXS>^10>3R:?]ZH9O]U%A^R!8E7\TSFT?0@< Y3Z%,Z[:
M4D\B;E9/[[ZM)VP\.@CG.SI69* B"-7$!=D*19# ):93Y1/_9EMIMP+GA+BU
MI)3M-+X(^LZ0/4$&T7&R4CM]1+;[EF)']9JMFRI?3<>A]1C!C'I ?"KIU,U'
MQ<>7WHJW<N21:[---%LU7&U\F9:M78/%8HP:,0KF#CF^9!&:T!MN*8#Y(:8L
M3+-G;?CH"K#DQK@..:!_[_+(ZD(\$Q>&QK H0\479@B[(]7M^K,R-W(N=*8T
MY(YOAQT&L[;9-_QN[K4H<3Q=!#5B&HJN[ PYH*^A[2D?HJ2OL:?PA3!VRIJ=
M1/@A)?VXY&NG']!._P]"TA6?3KE]BL8UEM!)=U.J(KBA#9YU+]ZXK=FY>OV"
M6&(R,H:^"RN<T55N:EZK10'1PVZ*))B,1QS)?&H<9110J-LS:B['O"IM:+.5
M9S$.Y XF.CYDQP=^JEMX0N:9E,T>YC.$&6 ?=\IOC^3<5&PKS$&,S^Z02=H0
M471(VU$IS:$52_(U^7H@C.#<1'9Q]]-0B(WUC$/R "4P$-):TM+'B+A,\A0Z
MOS.HR3!/6U=GMIBD1!CSRCQS6\H>9@@6Y2C$QBB-K;?2-9^*1IG#9J\OR)PE
M0/WO]*MT+(Q<0MXF^EB[&Z85*>$UM75E01_^Q>7X;=@^CXT- 0&#1FX50XHL
MT/CM-LT='+FVGI A9&XP:=70&<P44P1E)+GYOHJ,*C+X<L4/W=YT2 [5FF49
ML1JC*YB7T[P_-&4,>&2!K#=N8HONCW?V_J>'9)7%S/3PMTTG#GDNR<,1V#7
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M7B ( NZ>(IY%1V*9E'.*#3R]"VR;M)5'+ZKG1S?QLDK?("=L8TB'6^:5S^A
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MN2SWO>S=IJ<HXT*H**M6UMG6V9*D@SE'3YBY_6F=F:M/E@_!(EZ3;W X@0T
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M5V*G2XN[U#C$*YJ4E SNWUEB>>E>##E$VN/[*M;5M30Y-AJ5E[?9M:<16\$
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M#@8XWUL[I8=^81H!X,?SO +9*CF;\+8.U:OIY!]'I] 4ZLV6:.MIMD]ON%B
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MEE]0M);K\L.@I/:JJL >9V*LEG\6<.27:;-I2^T@'CJ>/E)/= ?]MN0^$7"
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M8DQ<FSE&#@3L@!6?2WCX(8, 0/!Q:4/K47)J3!+[QMS;YT2 K NC#+A:&V+
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M4UY[DU3^WSSV/VY*.-[ZAMQ5'I&X<WV6W.:$Q,Z[BA/:(NY]-*\^O2L1SX^
MI1SZGC,DF+4J1%CE8[E:G:C/Q%[%,A?*/UC,&..$]YHKP6 S,?VH<+ :C%1N
M9\:<M\#0ICYS[;A[49W!(CKW9 5=HOMI#U60_8#3GT]5C;AR>I!1[%BZ0 E\
M!(2]&TS_WXLZPZL J:WR9UEC[Y)-08[7'Z56K1>JP'V)-9W.0QI%*W5^-0%.
M;#N*C$H(#<SA2P<__ 1J+K*NDD!.J=J:[':8SI<X03]!*@J@Q=XG_"W<I,_%
M!XRO1%]<),ILB$_2)$;08%!#0CBHT0C((MX+\D63WH^$4,/F_)+QL#WN+H\
M15DSB7K>I)BPCO3JT#5#$G SH%/Z[T$S7<ADA=2NAPZ$VE*;3+M:/D1 7DFP
MTH'I^B[RK(CVIX7D"VL;U]?V_+B&%518Y)-9-H(WM[HW6^ S[#RLS8&\'7JE
M^)JGBN%C(2Q2]Q4YX*&UY$R#L@"))H<'DHU/)[4AL^G#U$6"#[/C)8\ 2<3G
MJ/F9.@E#V)H^=E.)<^[">49>W.AQ114>&VZ)88F> UD13%63[G\ZL5453Q"B
M7"XRC*M.2 :4=OK*U]#<C0J4<$HEL'S;P_DD7KWK+Z!IA0&U6%EI ,MW6(Q)
M-_UFR*HR$)KW=GV\$C4E:/&)N8AXP:#MV[+FM>2WA70MQ[N!+@\Q5NLSN>)<
MY7(IUI(_[IJ8LC=D&@(N!QS+_],1AB5SJ5!56A:]LJ FRE:A9I L6:.<55Q1
M[0N)@*-=]O$%'NQ!_NE7V:8X3<9)6%^M*7 YQ8A"S-(D,-[O.9B[$DYBAZ[<
MTDGY_VR3[-T+W/C@*=A9A4&].MBN/*2=C@G\5U:W6>J5BIN^,JHXA6.6NR%_
M(HSEZYCFC #!5WH_!7PF2]R?U+K&MQA=TD.HO4S"E22],MK337@6'TQZ6CJY
M.]D:(!SAY<\R0F;I(E:4.F@/%#(]]:N"VY'#7H?!&S@3'1*/*MK]I(ASD0L*
M?&NNWAIE..LRF\*()OLC9!PT^0MB@-8:^1Z!B)EEM/R)7;*4(LKCS;OH(<##
MJ$B="!Y@@#(9/):.YJ<?Y2&GJ)OF^8AK*+9RSB%X#L($8M8,"5\4+[YV;QXZ
MW%/#5J2E!DR\\N@=C7P8SV\[H?SY?\E)--U'(&Q_:@)\AJYN7&!J]@B<$-7>
M%#UXTW$V,F$6:7PN.A4H0KO#=67J%AY6>&XG<_<IW\).CA_%E>/KG<]^TRZ4
M[5_JV+KBGYFA72/.@:<H'MXTY,>O)J?QY4^M^.L%4!>E\ G]LU(J=S:0=KOJ
M_8A+[DM;_87@59-5_K+1_ D&R1TZ9WW?UIA:.SC)Y2ACVG:$+N&3.&"EGB9/
M7=V44^XZ>'U>XRX7>X^AS!"F_5U0KRP?(0V!+.%4NBKBRC.2XAU..R(]J:V#
M_0VUM##)/*OU6C\UGQ=?!A$'HI<_K'HMRH%$,*&-C%F$OAW@(8][1INC)R3'
M*L$G!S/UCY%MJ,;JI_"$SYNNI_[U(T!% SF\1>AX!%):A(@K?NM%S)0Z!:G2
MPU)PMPPL6:%L'LI%<C[3E/FKE%\_Y'OGGUW_D8*%SL)(G67,QTMC1750_R*V
M/O5)Y.O[(<$H6\7.-^FF^--;2?C6$GU2<>RJ/(:09RX.\($OONA7J"^1)LU@
MC4Q^9WE>&._3\"U/U#XQPSN NJ#?^Q_LPC_;D)EP>\QP?)D,ZE69&5L[*$X"
M$G?]ENY("3'<0.J-F)/[F>.'[#T<XH6%WT5[5>Z-5>!86N]R;8$>7+[G9HKM
MIZ+V;GG2/1=?O3)%3&8):;'F;\<Q8-:($<P$6SFKHJ=P;'8T$C026P+PTJOE
M7ER:$Y#4 7!K7*2)"\=!<HBJOR\^YA=?N B 2"(%/BU/PQ3;Z8+&S<0.<[+P
MJ7JXEP*(-.$!(6WTO(!-TVMC]'"_Z)78]!"<5VM5:@?@DAPJN%;I#+O+X=H-
MU07UO\*]T#-HWS"$'S:SW*?03-G1KL1%.^/[YOD:ENP^@_GL.YR04\=SUM!]
MM+X08Z#O<G/A>?.7@D)_!"6@C7J^_OOY$3_XX6V5KO(C,"QB-!G=!(WXN:+<
M1V#K59G9*HM@9W+>W5!>VR. 0!QX KV_A!-V>"I=#=PM,/=0PW2"M4F56B1:
M#$TSCZI[6]TUNIF>1IX;LIZ!S[C14+=X ]O^3Z/2P*1]U3BD\J0P;M;,I/VX
M.YLD++^:]*(-?S1?%TNM)WO+5O,=D]1K5/H%Y= I.VJZ'38A/'R$>.,LLS!U
M<*L0DZ7%RQ^9V<&PI.$M1A8-/+AX'8X<FV"TK-J2R7,/G-M7U,MH%[&,!>%D
M(3Q/E$]BE><1FQ?:B+.XB][] 1:K\.%U5S:Y/1=YWZ(7R5Z&4"&5)GC"'D?4
M;Q+M-(5:[:T?720:4O0S6:"<!YH.']Y&Y\_' FLO2=U44WGIO\F/LR:E^@G_
M_*%'X1^,>ES1*-]]Q@[:%,"+UZTZ(N/R+;!@5+Q565//G,\/#Q1DN< 42.2\
MZ+!;!")5XE>7_),UO1=1WFV77)?,\=B3[-AX>Y1<3570YE(K ]2X #+P[R6D
MTKEF+/U97>"WDD;V[N[NO*AX"-HU2 <\Q7;7 =@*'L7L))]U/5P] KMC%,=&
M6?32Q%=3UIWK[]'/-HIO1Y3@=U%T3F5B,[P5HV][[WRN5$+O*/&S[ED>@4;!
MFW,O$<"QD7CJT(%!O$4PIJR/X:00590NMQ"V9>F$0/"\HRG3Z9P>)NWVG>#I
MA.!AJL)4G"1B(A5).SC16K\D%*7/T"WQQWO:=JZ"?(>R+5>#RY_+0YX#->FH
MS-*ZIPP#<ZG.%[AO5JT[69T+86%'@Y#/BE[Q!'V8"V8O:FPZ0I-1>RJAH=@0
M4CHE5%+9J.GC2(1>16\0@E8SQ%'/^)(<1(L!GL7:J":.X@^]^V+A_ A$]]QU
MZ)"P!#,Y)K(7WH9K@F@*308O3OB)H1"=SL?\+[I?6,1V7J)%J(F,"=.LFC&N
M /.^H%31KB%#KB:S:M(P_EI^;7YXT#B6/:NM15'14!.RR.K'(;TN!=-OZT0B
M$X46E%H;-SMA46A%!NIQ+EB.G91[PNT8N"D\E:65A&)XQU3K<TMY^%Z:9N^
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M*G:,)O",#6]G%[JU/C"6'K_#B+=W-OI*;*"@S\W_A"R[\"M[G)FHQ=-.FXW
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MT'>5/M/X*T$5O3RJV&P71-Y:E26&T?0D-UYT$(\IY.X2B*IZ!)Y:M<O>4-%
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MJXU;>=Y!W[094];MD26&\=+Y5LSJ$WWD7"X8@*+4P]=XX2I9N>'*;L6L/+'
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M]?+[%&X^?=ES,;KUQV XYYEZMO0A8Z>59 PILGD\4$!S5"=P()9:&/,/^]N
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M1G7UE&]*U9JS>M4J0:W=,!P_F>%[ ,TN]ZX93VUHK;)^A"IF0B9F%]Z^6I=
M2,?*2E C),5^1PCA(X0H7=M)ILV1UFG"T@P>=PO^X1$+9:J]CBVI](,DT>&A
M">>'CZ=GNAYB9,AVIF(\UJ$A 4BC5D6"'SS[*-<,Z"#_S\^=__+<L/?YCE02
MB>#1^_TIL".?R/I#P9WPN%H1P/GM9MWM03"Y3[L@J?=V&W1$%WB]//)FIB_W
M1.3IVQ/RW.Y[P N5E&ZH0@I6YO VOTV/R(<<(4)5GU7B*0!3&TH-  ) (>]?
M3O?>/YYN_;YOL1&"^-@@(]H[[U8B!740TZQ+N#1$?(]T>]N19:85;9CB,SV6
M]2(F3*=+$M]$_,)EZTSG= *&ZN=7XX1!8(.*K]61/;5S:*0\TB.X0GV3@R^:
M@JD#&MXZYBQHSS0<-59 BR?"5[1WX>RO$"1KM.L9N8*L/ZZNUQ\@;HWW&^!]
M CXMF,:4"O0-6:AL/#'0GW1A04ABF_9D\2!4,;VV,7VLT47/JW4[?BA)]"1
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MUU0VCM$O,5%@M0N)G,NW>'%OX*_PY,\_^A[?R?MR^C+PC7]QQ9:NT0DY'$F
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M=F((]^.Q!BG[,V O8@6=Y3S)GNL-H$EHS>KHUJNMGS+P7D_(L4H]',KY5'!
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MX8M(.+BUEC]\,<K'$9?# /UH;S\4(7N?L.%.\H1TI15S#>N?RO^K7C\703E
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MHG^;=6*N=XT5>L=IK9;F(3YN?472S 76\*.R!<#UW8U("D>6W-.]0V8DC55
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MQ+.J3C?CB"494EFHI(P0R(](;[X 3PJY!BW_U $BN'9X_<&4V_V__AMC\P+
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M_,/'I=<<OI)IUH?4V #$-_3-_PG9.42+56PP5T/M [_%'Q,Q^N)E$F@&@HY
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M>3Q2>YA.=@/\';O*#4 T@]4R,F',EX2FNRAHBS?K<(-L<8.S$2*H2SV".QL
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M'X\6(K#;S#,)E7T+(RVN4")M>,06(71?1^,)P.A+PTNM07@S\3]02P,$%
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MLY</B"55L4U=GC#POG](\CHFN_H'#B.?VC&IF>O$(S(F_A7FD[^@_1NR_W?
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MS3EZ_7- 58KD7Q9U"Q2@@0(.4STP+4S&L1GS1OS0<^?TI%RED^QU:<TIP%#
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MDRBC?_DK^US$4<?T?58)O1M]IMTK9 X64D$;8V4$/.('+*-("!FQU'ZX!D
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M%6/<XD[QW824-:OG7)EFK +;7^5)N\,)&!&9.G8'O0_MV:GW-'ZOTZR]DN7
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M:\52CB!M8X1.^8IU5(+I>/$HU(/1SKTEUS[9"F,C)D F^YRFE+*],*?%]-N
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MMOVG9@Y#NQ3"%(67I*7X8::Y1D(33\@DBWF5E.TLM)G"<0"(Q/KUZW1[IUD
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MY-FPXED(0OVR?M^K\Z]D&JW4^&,]F9*&5'Z(V7;J"5XC"COP$"2_7Y">[)%
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MY48GM&434M#J6[K3W=2?DX1&+9UJ%]18-YYLQ\(=NH8R)%XE?/#CT[LG]A]
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M+7RLOH?,*S*Q^]KKM&RB&N!^%,#;+,P)S4J!K7&87WYT?F10XI)T%]ANE"Z
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M3LHO@W#AJ1UW<'D*K2/E,*&&79B9<7W4OL\N@;W"WQLY1J!I+Q2_?ZA*A02
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MVLD3N+-HG66$VN=93(5VOSKJ4D,=O,GV/64UDD%OTI^@UW%.7_6R7L(P#=\
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M[%3O,+'39YNOG"[VG,_D67HL2FON!&+JV6+*WQ6L[JQ>PMS4914S\$1)?:J
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M[6OJCX4XUT$XPI'&%F2 W._R_7_[\OT+S/IJ5^CVAU3*-(8T-1YD:P/;5.T
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M-(]@I=V(?AGG\C5%+0P]X=B<6EB=-;:IW-65MQFX?$=2C8HY>?I*8$=@M8T
M8BGYX)'!'*WL:-G,0O\5D\$]PR#NF0Y=TQ\#OLTK-B(51O\6K2C^4R[[EW;]
M3]9[SGXP;P%_@BSL3H]9X>]L4!-_)3G:C=P6P(?U'7A5KQ(!0*Q_?2939Y!!
MC #BC+K@#9FWV%/S_Z5P0JJ/0]@]*]+L"R<CIV!: M(^?//K9;F9==^%SMV=
M6Z&"[/W+$TYA]3!H:ZI%'M1PBQQ:>B^U*)*"VE<N!8=L(@0+W0$+_2&]D(P.
MG-+X1Y=+$=X+R!R?#+[YZ\GRF\@B[J>*'VFX84I( ZV[\8>&7^CICG.SO/=(
M86&B2GJ8)[ORYNE@>VQD\/GFH-6-:-UD3JJV5]94>;7'$;P7LX8W?MG$X1A[
M-?')T=)=K[ZL.T?AQ_L1*_KJF(-NA5M@BYJ 4I,\6]^^+TP8&DLWI7VL#4NN
M@S:^RA/<G+X$[O;<=%1FBDQ>S'Z0N.:B,IDM81;KA0 QZG\R_ <A)8N>_KU?
M1V9 YXW-U&9Y589&+#U*@I_E#=$$U4BK'%P6&E35NZ&%H:VL%Q37*ET45ZQQ
M;H+#-6F7#;I#PK2\4H^DZ6!(-Y$9T2%9Z'J]S,(5_[A]$##(*0;;SGK7W1XK
MG)77E8(7^5'<PXOI<ATYP\.-76@(D\I'L#)NGB$ TP($T,1Z;+14VG+Q"=ZD
MB@#<U7_6=&B@Z+DB#0;'&#RM"W]9JILN!9?56SR=!'_,(G0GU>"(N(B!V(K2
M)8($4]\\CUN?Z6:JE1_S"5+E:**:+"J6&=R)'BM&XH[>LVSD$OI(>&1T@  N
M#,S8D;GR"WCQ(Y)(>>EYWGW8'-V8BQF[9[&FT-<CU;2! =KYM"X^%F&G< '^
M=()!MO0$1A$>AK32?Q]T'F%M71LVL_8)A761C"\H>MWL'@6^W*7V2%(X6Y%H
MX/_J94>#>:@H)/W%LMB \?7QJZMWZG9HG.H<%%;BP>H?EUR^NND.>'[I@M:6
M%VU<14<5S1J:@<:4^Z>)J'2#"CIYL7=3@.*E()A8J8K8; 7Q9DIMS/VVO8R%
MP5P/";2[ZE7?VG\V*<-\B9<S[UZ\9"OCJ4G%:^%C9#3(^?*HKV6NU8-<W"J&
M$@+]WSCT_\,?[>9*N]QB+@D6$<#T]\PKXBQ<G5]>Y9$3?8*R\Z<_OO14@,O9
M$5[]!)\P&[L"FG*D?]]TP=4[4NMGBW!XQ<6D(:1\]<-G.[N[F4OZH6\O T$S
MR?RATYV-U+:+4+L"8[ST++2UJ*P0;AH>Z=F/Z?-V+RN-=N6NG@KLSW_\%#9/
MJ*%S9^%G6:\SJF(9=,GICO*7KT&7^*,O=9\B@#S;T3]62GR^1:7(+B^#5<XT
MKO[")B<<\_=XX37]E<"L7T5]!\?>[=,J,8$\R+7R[6Y.6,==9':%TEAD<&0?
M1"?<3RR<!2\S3;IY\C!&*[8N]+L_I$)_H: A[[*I<Z.Y)"RN4%R;XU:NKN;^
M1= %3TC.D&G.X/U<X<1D!=:%%S^'GH&X7)'M5/Y=MJ2?EG&,.#TD-G1=!Z0H
M=<6@)*.O[Y)$@QM-C :B#J7D.]#]LW0HC# 3?)R=):8RT8],9B,,(R.:?*7C
MB8)Z^)3*V=E0DQ)S-Z_NQWX9MV>JK9LSM[0HI<L[9[E*69)D />I7R!CL+F^
MU!6N?H%^BJ\T,D1G'FS#6R'@$](L0F5:C)?;](=GF7N$/^UL7,DBRL"]4'"]
MU*<L_"NDO7 :@GMWI/9Q-[;3D!5.S QX@6STO^'"9.M@"O JE@62(=9?Q<M&
M8/,^;/\F8 >\O8H -C AF=W1SSRNFV/H<\(YBBZ=]?=QK]R'X>+(E *QNPGV
M[6[SU!^OS3Q<)[QU,5_EH)XGM&9; /-,I(0O<;>R_9CU_.$K#+6_K&<?6 TE
M3#MR0'&/W&73=W$8EBO-$+D( BW%.7"7%]Q>]Y"_BKQDH4#I61XZ:'AMD::'
M5>WNJB_A!MNVD\)3@.&<W,J+R=]+?X;V/4SD=J5(G!O3LZ]CTW"!Z'#'G_U@
MHK%,U'Z%G]@A]@F=GA*O4C13-SESC,RWGP%B[!PA!R'=J3P4=A2-?N7Y?;S/
MVH5#@Z-YLX(87]N_G$U&DW)O^BV'0X1ZS8FX?._6PK:@CHO-+U[9]+T+7!*>
M$UF@X(IT":\J]80M*A^$>P::BFFH>)'&L@1]K!<SDL9ASUO)4/_.AP&XZ>CS
M+&=2?86IX]':+JHW6T43?=62.AVBX*RR#)QY#5'CD[/V? +338YP*]T5G1I;
MK;X;2_-4^A=#W,XU$0XF^+=08,\&@J9]D6M=<#%$3RB9[CN-3_M,%M4J[G/.
M8\JA*3V,(27*V2&.5BP&&HMM:;Q?,,X$'+78':>:/[#<\,)K8@[K2_SR2R&J
MT&!FIZ[7+^GI)F?T258&_-1H%62F^8=W!J&OOSA2!P_'AGR/>7Y9Z;4M329.
MF^,9H3)M;UG?.'F_*E7U+A(YV"QR+LU7T7/:2N[-"2J**3+3<HS8#?O3R\$D
M4 G$NAJ[1?G=1V>;9 _,DE/,4]UEB?C:A%A\])*[W=T.;C/.W"KME2=L\?,"
MN)H[VIQI@C<S7X]@O9#SB@XKZO:G,0?%%+=DUT=HV(N"M)1H.:?D=1-B/@;K
MF7CT/-*ZN&O<Y(=F4C/R?+Q"-6\T/QV&%7AOS$+V:QA7_VJ@@O;%",;M?XJ;
M_5,KW2XW1@=M-RR"U'ZE>,:+K#L>!-S+-8^;G"AW8XHK=/XO0QU%12#>"0/@
M(AO:S! ^V*LJE4RU*G["U<Y.A(4UV)\DYM773G/2 8NY4/,5NVVYC;HMQ(+"
M]X0B'1>_#&RG7^Y&IXU@R?W:3=6$6V,_ M%4UJO:*VK@TC,#]%AF6\X]DY(J
MEU]3&I=0X"0C& $PG:4B +,J\ 9JJQVMW:8J'ESN5@C>\A()]# LC"V]+]6_
M,LN&LY41.OT.48\00*@W]N3I;&WM(4'^AQ5%U*.I/=:CP:)4+Q>FN+K[[AG-
MUE.-4CB>6EQHNI,59?Z]F)_\UOR2QOJ4>TI*P)X_5GP<=GL B#;,E=S9,T!%
M*)+K1&'"=6I\];VJ!$2EVR2^.^@(OU:(QL\.W*Y?AWFL,59XJ%O;=(8>+75B
MAX(K[75/)? )G:A[;PO@P:^'%=IL:+7<P 5+@1YM>8TIZ=U3[*J,YL5KZ*/!
MCWFCAF'0<O@@W6H9)"YO"7(]K:50'HU,EN7CO2,B0HI2808Z1(,K@[LJKJX:
M_@%O6UBUDK5K0/GCCIS8K['W C%?!+P1K%I)6?XS[FI@Y=\)K'*+N;A6/\<Z
M%J@6Q?TZ);6R*S5'_WT$TP]I >2<;2MG].?!KFY#_QYO-]"&_1^ (>/@^83+
M<B?=A3\B;A%0*@J^>5?>MHVLWA[IEOQ6AVA@->$>MT6T':%5(3%WPJ\SH1,9
M,X]##[BTN]3I$?@$35\=IO! ['9!(694CFS"M[[T/-A/#(0 Z)S TP)PV=:7
MYLT<F[-2%\=!\(:*([(HAY O'QREDK=<M&]$#P9[ZFZ+'WQ"4]0]SY8)<7<#
M\Z8Y+. >N+2SZ+81>_+('?+'#189,9O(6\P*?GV%&TUO_1T;JMAQBMF(RX$&
M?;1Z4!OR_S3WG6%-;5N[BRZ]2.]2!*1(1R 0D V"=*2')D5 C(!T1$(14'H1
M4'H1 >F]B]0(2$=*Z$4Z@=",E'"S]SGG.^[]G?.5>__<'^MYYOJQ5N:<8[SO
M?,>8<ZS<C*&(/W-H<1X!OZ.KLN@M2[S7[[NMRW;KP^LE*-'=T8)Q:.EH?A:.
MZ[-=P'G"/N#<C;@#M-(LQX^7/@HBSG%B?H,(BWDIX'98F]#<6[(6KFH054N9
M2IK!>JCM^>:?VSNL6+]K9<A#9ZZFZM6J-4;#ZZ&17^E8%8??4N%P$\4J%UJB
M991:1[G&.+2#S)0;.Z@L2H4^7_13J*FMQMXIV^;'(]4X"'R=[U2]95RO7]9Z
M4&K"R**%UDY/9V3B?*8F871LC>L+4Y[X,"'TY(9F1'*6M.FW@'A]O;P]O.^=
M&T2@1)>"O"!9R'"$%5/[)*QV8YS3V53=P2#HM65_YJY[BQM"5)FQK[R(C(SD
M[PJQ]<>*5T;2O!.#<,'T=GW*N-:XF=5\#ZY&L\)'F%\'9Z(_\_&M+RB*Y)QM
M>G+W%5)!P2A-*>>H^5XV6R!@<%B' /"#=T81C7L1A!^IU#!< 8X.4'47:DMU
M:O59&DZ>/(+/JW&I:2<KXJ+^)N3+3*UXT@6L6:SCI66N#I$J++RO@Q>D;"I"
M#'T$X194[I:#P,W1>#=Q?@ G2%3 Z?^'N.ZE/76BQ):>A?4,X@XDO>B&K3A^
MXJU$\'5#I%0)6.A%NL%XPT:V])(=1W"AK<5*PR.*L(,-[1&0KD\Y9-Y*JJ<#
M'_GN->Q-^!$QN'4@8"XXA/#W358/+)XZ7:X 8C!B7W$J>F,(.MO@N.^(A/Z4
MMF,L8XEYD5.?J _+;U(5KK5XYHYXCYEQ/2-V6D1C^SJ5]S4.>MT[<BC*?/RB
MX*A.D%("7:_3>"'^>+YMO@Y1 [%0%7T08N<V?5%L6L??]DY*6O<$>BRY_21[
M>W;3B?^GYTE>Z&3DGJ+H[QQ)9'[VX"YV_#"LAJHP;3_&L9:*K3O^\#OG8O[!
MN55EU0H!A2L)N:JTQD2-?]*K#-U;!@/=A^I2YVP*%<<>=D(FTM>'S,5W-06B
MJ2@5+N6,VSLSM1VK&\=M)FI+2B!W5JGA#PNU76ID\1O>$JZX3_@,N52BZ-LH
M(SSSGPN)#PURJ9!1VWDFRA,8X<<3:FSK$.@=M$=SH80254X%ROAB$2R)L=M+
MI>D1^#YDT13NXPK\>(*]S3<KI%L<2[:,.5P%'WK9\7 Y1!>_$9GZV<A)';J8
M=3PU*L7BBMNU["QYS<NIS'/6RTYX.E;^'6W,:.PJBP^N+XA"L#4O"/3CMX/
M7,7@BNF6!5_O6;U6L]*EVD9"R&\X$N'X87/]&L !N?M9ZLM'!PT]E+@_/]WX
M=@*KM=2.VR.^&+[]N&+^>,COC.3'K3_'NF]PME1R2BWM,(KCEQT7@]!?F%@2
M)QN[_!%$W49?1EPN6[)YI%BCSBG/.YOE_J^S/G^6LVU4)ID7EEA0L,5=!F1?
M M_&T0E]L5> 3\+JL;ZJ%X?(K<ME:YT9;,":P7$R"(NO>)OZ9\%K!\G=_<XR
M_/TL25^5+GCO#W+S(XJ^L%[9DX&GI/@[M-:8"242>-4D<6Q_LGG@LW]*F?T=
M7FA^<A:SMYSHM.Z;[VS;%S.C+) 0&CK+%03:68EXY77)T5DYD/^.QZ\L8ZC/
MA4M<A.%'GM:*D".R7F-(WC@YI;UB\.!LQ[#Q54<I=[QP;+J@WY-KN KI#1I;
MK:P>6=]FAO%E1$$2W8G=JV2)_ X/D93F\0 AL!($:EF.>QV@70ISNME EM+'
M8B&IO+>6*KP>WS4X-'?C)Z[7JFSI/K%O5P\B(@XI5'>--[;GZXT":8.]WLG9
M5P./*$7M$V=Z%_U/-J'+]7?C55GOFU89ZN4D/M-EZ\L57H[UNZF>;^;P.:$S
M:#CVG0(J#4C\:Y1=$Z#RI"&+;0*:U5$Q"?%1>5R-+X$K5BNV='W'W*CO0FF"
M,'MY*Z;[S- \H'*0=05C=MV/W_O6[MK:"5Z&9PX%9'D%_?0VK04D:N_%A3+M
M,[&:R?<+(R5T"_V&4)X]BXQ$);KMNG4.RI/KSJ4J^=T!=&RM]?O\<<H)"P\:
M7(7<XU8PW$EHYN._G1;\SP19_I]9%!#\4V1=\:R"?!*\)@/#Z@9QV*9:D, ?
M4?)"I/P(4?6OH;777].Q1E+"]Z?4*Q//3M5B$4(,;M'GRG?Z2(CAQ;NR4D\_
M/C:'EE<\Y$W>?:3I)]:&5XT$-O!#*!3N!88'B07(K\9P=Z?Q( K2M6R#2;_F
MW7R6Z4N@3#;-U+EVJ. ,DEHM8^AY,-_UH1]Y.K0]?5?9B)-PCI#0HS.I)11.
M^XG]0#%AN8T>*C[ZZ!!YW7Z7U_[V5#QM4"$1DP4[40%?^ 5I'MI\!?E"CEY#
MQ'+@87]0J3)ID)M[+/%&TB!P+S] ::1N/G#U7G6:<=/+()S7X8$6]6KB;T%L
MZ(W([9+DT4\<3N;L[>ZE9EU<<_W*!@ZNJ=\1,[(#&\7S67[E'__(:(!@6,1%
ME,)V9K&+GM2&7\5OZ!8L/F<YSDZO@)E!OWFO<;3^(7KQQVM"IT%:(];@M)/A
ME^!#L@G83C5L\V9K;)O',N5%J!3'V6[V&;FJ]4OD0/L"P_"A M??]+#7'\PM
MU?]"X'!K1Y6HC X18/.[62C^RM#_&U7\'<,Y2*9(U2Q#XRQ(*BX452(H24'Z
M8KQAO6]7S<V%9=FP_IYF<RR\4SNWFTDC4X6Q?!@L+A&T1NG>Z_OA0F-*)V2R
M[&9%L3D6%8RJY5DUI3H\3$E"A>L=>*X/8F6+ ]D?-YC'K+]/=#'O+<-W9C*K
MJ/U>IVH+N=7.+^1&Z 'G"I+?_A]GPTV;X1<O"L]#?Z8A?DD5..$I8A%'2O\/
MPMSXAX+UQ-GXE2WW?Q&QAL OR8"/?]V!\EOL6?R),XV% E8\C)#[<U;(_VY(
M3GF.LY_@,YR20A1W$AMFGQN^F1>YK6AA=-[Y*;/F"HB[ ]Y)P]K;6NSV MWQ
M7O:%7\<58#'UDZ2W066F7R9[X(0&N2TO:-*8ZMW=ZQV=U5CZ&J1MLT20N*PP
M*7;Y>/$5;(W(X]CZ\IH)GK7".[N/R]O\*H_:OY[M4M!D.LEJ/L]T0K%5O/7P
M\*C!XVC6VL@X/3/<6GE.8"$QM#'1"RYP]S1)9YVE:@D$KWNW?HI2D"9.6;FV
MKK7G12:Q^?A^<0%V<;@YCFFL."RY?C_^[N$7MU<%;U<K*XI>[A/P31\XL&CW
M4.9597<CW"S>1\/''W*,Y5T!+S^,WT$$MF(%B@UJVN%T]&.G"<PA?<)8*)!O
M?)H-V0^;YSLSSBQ8DQGQ&Q&S[V/BIBL#J=XJ'TE\\GJTF,!/-<]?36_;<(-H
M9"5=H%OGG@7S4<4>R_[/B\8KH+T,(S4< []'ZL#[//VA6W6%=V:I3Q)$K>(:
M0>]&Q^6J9\>/$NK.!!H3;]V2ZQ<[0T.Y_N[I34.R'*V@P%J8TR)L^#O\\M(5
M52'K2)O4SK?F#:K/-UY7X(KL.*@]TG64T!;\\MM;@ND,]WW(M]V1TI('1C1U
MP^)U,O>?4N9@5["JMR;@51>QYTOS1@S:H?KOA+/4A==?J3,K%3YE:#KSL"3P
M8)>MJD]72M=KF3B)8I3<?-\(VVU)(FTD3:2LT.''"T<_=RG>PL@^U_CL&U8;
M/4P8P9;A0)EBZRIF2#_'>/$.GTYV2'!:L.\3NW4OAC>$J0*D](-F=H[CYI$Y
M9/I-[Q>*N]'V$08LA3P>5C7_FZ-FOD^QP=0-K#>>_?RC7!=IM(Q%1?C^%;"S
MKGMY;83@UN]PDA^]YP^<ZE[#VKSL(=8)AS$O79Y6@;BQ)%$7<>D!/J,N:P:Z
M4=Z%'OF^5J>8D9PLJG2?\N6!(M +XHI;6'/GKX#W$5? 8ARFS5^W&_R36@K\
M'G8FYO*YQ%]?^[%O4[+_F^T"8JG"GYF%%\(<6!4:.(6Y@)UL_OE1=T_CC(1=
MOT5(Q<7N'GC9"1UW?MK^8Q6+:7-FCF[+YWI3M>>R6;/]62MW%JF6EBJ)VOSF
M7= F&+5Y;DP[%Q9[87S79FVW5DIDWZ_]4(S)BQ1\<Q8*QXA@A^4-Q[2UGWI8
M^5B]Q@:4*O7@D[TKH";MJ'FG\"#_.ZI]GP;+R$5K)+\RK-2:UT[V-=@:4Q$6
MVO;8US^^=<'G;8DY^ 1+V**= 7]K&!DOKH:5N.:6/]C23=4UYU=P*A]?_7U!
M![PJ"B1O_V0X7CP[B;H"E.B.3'>L[SM9'][>:C_98< $"3+/<D_U!PHP8W6P
MS?/@7X\PB*V^?>KJ></!P1^Z_OR5N3Y=?Y?@71YV&S4>F[TARCJ; ,G1$TOQ
M*\ (,YJX8D_=0Z+K7GQ9^M4H6YR_;SJ:)+,P8[WL0FM,$C[*89:M7#-Q^\;A
M\G6+V=K.:U$70_J*CXSPZPGL+VYD]:]9:Q9N21L?L#R'B6]/CNYU#1[MWV79
MM\.IOL."4F(.O#-1)[%"*LP%UV\<7\4,M7SR@W8B?:)%>@;P#D,TN-MI!R$]
M_MD7MTC9O(D.I5BFA6G[BRA3QJH%18GB5G@"Z<9](SK3'%\'A :(T*BKY&FZ
MRO]VSOIP)!E4 H@K?)1O)W+Z43^&&"3[,*0I64,_("&D_NI9@2%'<G OH\?G
MXQP*G_LH[<FP0G2N%^6>L*T"_>7#EW"JQ!7U>;W@X* >3?87@N&H>W&P^@N[
M94O;Q<X%'G7)UQ\2O1*[R#HZ@QOP0T=.N-K254:>U))JV-0<90P*I#D7ONGC
M*7<CE6#7^(RW*?B %F?=;E4A!;RFCW+$D,*O #JS'XOTPN4?3'2)T>^!QO7/
M,)31SMM\6IQ5<I3:O&&-KTGWLE+?37@A1D$?$F!6V=9@MA<@LR*[_&0O45"T
MWQV.+RTXO;_T/$9QA1%SD2!>KB/+&6RQWP6CM/:%?/;WCBGV@SUN.)+YJ=L4
MZ,P43LGV*H>":W&EH-6$^,9!=J3Z@RPA\/FM22PLAAVP<(V+ A]8@=$?C[_J
M1P('%0P!=ZVI%/+-T9#NXK4(\O5I.UFXUO4MBZD+'AF.8V%L/(C&=]DJ-:!.
M@!_E4*;NM9K>UL^:NCM9J&H;/6J.Q(G0<_,_-QJPIADFF!-O" ]0,F(S#;;W
MZ*BP14.7,U4ZSV[F.Q?[64%["Z3&_ R>LG \E?B\$6J9Q8_W]0I8]IB!C>2O
M#%\PQ&%N-5FS7BA;7]^:G#P-I$<)N=(N/)0PM:&NC>T^FVJQC7Z@,[09^6;5
M0(1F)IOO1?45@ F;=[T"@+2<4-.4=8W\4-5O!;Z0)Q]3>B(Y[A*IG%24??D=
MY1:.(1=B19M67"B'D_WDM>W4SN<P$6VXZ^"/\#N@R'87[JAS"<J9RXU@TH$#
MV)KE%/B N&3:!MWG2$O=&\"]TOHQR+TPMNMR^X1,/_*=]H!'7CA])NFA%RC;
M$-WD\J)0TY7C9:LA&RH$X0O7@[59#%_P69\(HK&\",#.3O:G\^FZ7GT>[=9,
M^["1?X_!(-K/)N TF[KL?7/B-Q"XHJY;B8D+HF2IO*D^I(H-=XFG+N]C>*Z
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MZD0_*>5II*X;B(V4V(<W+7E8R;)]VX@"&1["H44X'_.TGCQZ^U(C=_GE==B
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MSMNJ;RB!N3ZJG&?QJA<1)X[Q,P(MK4Y5M#F-J@)T)@83-\9J!\KN;L 2?E_
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M*^6FF)/Q,X$LS9+9B*-RY/?SHR]JQ,< !6XL .@11ANG' Q+HI29M15!4T;
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MF3G3W7.ZSYD[]SGGOW<^GGH>]O[V7GNM=[UKK;T*X#/P[X!G\M)RT@"$!P
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MKJ&20/,=8<=*1@?3@(#S^4,=)7&RK#K"H$WHK<Q&/[$T"]0OGW_.4:EB@L=
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MQVKGZ69WFNPK#5-P@&-LP;9:<REZH16EIR8V$DCY0H<+%#BS\:5VM'S_U+N
M/@&!^[AK!_0%A:BXV)2_=\MKZN!W?/56YNA_0LCGO7N]I3'%LO1Z='^/VKB<
M6PH'\D+10AS_HS$D#!<VQ$ST$&G_!X=>\V_44563TW9N/U%(WA.C1K]0GEQ2
MK9I@39X>CISO9FIVV^<?$BE: $V+3K38X1E*HQ\PNQW8@[/_=K;GWZ :U5;
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MZA>)R[ULW0)2?Z#CZ-^1S7]"2^97M)$7?K@2#@?T_(8<WNR1P#7Y^QM!%&R
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M9@@\1'[:+"!)73&+3<K8_V8>*<$E7%X7ZQR"K;7J$3T%"&_83%881RD%4A<
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M5Z=, 7WIMA:_XCM;_,4^#$3R\XEX'O:+R/.UL*P3%/-B#1X#Z5!KI%RDHQ>
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M1TV(8'J?0P ,NK%R1>A].?;#_#,@P"9FZ4$V G_D>]I*W>(M\S, _T?1OHW
M\1D_#EO;'-57"/)12B)XF2*YJ0'NVY84(K.#M]U+O5)%3D:I6=J+A5_I5I.
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MG'N_L$^\02]IZKONYV 8N\OD[;AI*<K,-E31*LZ A$JYWA=#@KJ-?H?CX.#
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M#9##*1%GI\9(+*8#M9VJG@'\V"0_\2$0R"SBCX5$(H+9+#_KOPHLT7>DQEN
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M/G3/_+%6KABT7RY5;T1U4B"OCC2,S5DA)4\UT/Q#\2Q$[&CL+96P2-L#P="
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M7ENDVU>V]A1"O+_?^#<]4&2(SRK""C%(!7SL\5 >R^):D$PS5@!U4LZ)%8G
MMQWI?;Y0>JI3M12*Z_P5)+W-7P[0WWX9_Q/KM1G&(9$-T>=02T^A\*6X;(8<
MG%%T3YYAO_<KUXD/Q]>CR\JNM3(=>EWU_^JP+WW9JJ]^<X3[AAW>IY1VV=WU
M@$H+0V.^(JZJ<+6<&RU_*>#@'"R@_X5LVIE $D"EW]*QEY)&T9J9FQ,&V&4;
M6??\&QB2K-2?&A33_FU@J^],H51;5Z)EM< J]*K.!ZIGHO#:![1_(L_W?T+6
M<E5^E:#%1U/G>+)L!_Z8^"]02P,$%     @ *SYO5 GMN_5- P  *PX  !@
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M5SNJDN04)YSR&%2<JX:_ %!+ P04    "  K/F]41>MK#=H#  !&#P  &
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MV)(!EX72M=*DN5\@WX!F"ZP#;!1PJ>5PM=$Q?+5X\;=]P_MSI2OXZ@W@4OF
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MP)0)2H%S($'()>3T0 99O@).P!8(+$H8$U7@Q[K_@DEF!T$!9EQ!ZHGJ-U6
M9"ICH680Q\T,]D(!*P]*&2^K:G@!U\Z!RW^VX&)DPE,P7T3"VEQK@"P@A]NR
M<I^G$QP?RR+X'28%1@: 1,4V:P G+I,ER<"B$8P(4BAK5VBSAJZVI@9 1[K>
MJB%%D0 !0$P #O1T2O,34A6322(6JL2?9%.N( C!1!0;#=_ 9:T"(U4R<XO;
M%R3M')):NXZDT8;9O7[E=[K*(L5FZ^C4Q63"X7)?'6B+/"%4,FW[8,L<+0N3
M+:9PU3AD^M #R680TS"NX77$59@(54 _C'92) 8$F10ABZ!9D7VP^8@!B(QA
M#V_"F*932. @D%P4"5#H0K6]SPP7NE+%JX-5KE<%$%!@?AC<#XJ7XN,6;MJM
MW< -W77<#)B"*[!4G1D];-TU3-I"6JAO[X+9TY@!).Q,)A\3A80!(!1@G8\!
M!JA8JL?!LGH=FJKAS>SZ 0QM0K;&2<V&/KS)(4P!+THD/-*[LZH8*QYQ*CD*
MP$W:J -NBB,5"E,Y[2R4SOMT.!** 4,YA#_LE%$TAB*A&$5!+,W$.B6$'B;!
MK.;%\&O,D! "'?0'&WX);+L&T/&N W3_G$HZ!1EB72NA.6>%5 7&!K#=RV&?
M7# H6L!:3X6J$]]W#IO^H>NWG-:[SN%;#49L]#M-W=CQ/?_@Q1)WSA+#7;?$
MX9PFA?:GZ/C89 (% Y^S%"KTVXF_S<"^(3J8R[LK 1TEH"-X=F7JC3&L\OWS
M?TO\HBMJAL74Y.'*GHS+,DU'/&;T /QT<?#GB:3&+XRD:->1-#!F>MO<<>/,
M5@OZSAV(XO@<)36U.1HX09.ME.QF)).>0!HEPK"0:-*5G.76F#.A<FC%9S0P
MD@+UD[\*2'A@X/T[.TP EWF\36M9#C$6X6X?;@3J/6O#TX'A**9JE=Q!+D4U
MCEFD$TNM":I$"I:X) F_9HG=^MNBKSU2.0\@]^Z*JJS%GUM!]4OM1+1W'=P_
MN!.AGP%%I6.HK6,.AL J0-?A!T'VS19?NUTS6=XH5$VYD"92(H5N@ %G.M]D
M]P;WL:!21]"( V]ZB'T ,<12A;$:OK%R*[T.^ZO@P+KV,44:ZOW#@Y==C><8
M8'=^5Z.7) 1W&SB # LEW(X+.0-(V(1SM;NP8/0:,TBFRO!E]BGTLZERG_N[
M@&8W LS.XAVQC$;04;%5*+L'E.;H W8 ;(%EU$P2JR"#5<4,# MTI$6QJ<.=
MSP->$M2=Q,_.;SKT( ^=2(@#-;!FIF,7X$$_(;7 J9EDCJ=SD<P99G0IG=H'
MO=*&.S;+$K%D<'<1"Q/@Z 8L 49/D.C6'Y7'/<WY(7M<"'^3RO_V6O[4,TU/
MRU,EWGZ3%S!\O(7Y8F-L>)(3EQ),I 2V/BA*BUR4#>:4J&[9.$Q:/:)E:+"E
M@OT]HNWW_9XY9Z;Q7_)IY_>L7UAA;@O)QN_805N=>L?_K7H*;(70^KLV*M)^
MK75:L;7*C&BT^&RTU&UY[:"'",80(:Z=!2CRP3.Q%;>X(J5C)9(B9QN:* W;
M?F[ZF:_)W*AWVK^^R-I7Z[Y^W6OME+RWA2P3QR=9WU:[WGF[4P(_9H&UG]\,
M\O<>8GUBI/_#IV8WCIX.(-X&Y N5D%)Z;7W(KZG]\=;"_Y#LWX_XGRGZZU?>
MVT;W,<(^!NL_4](/R^#)UM2BW ;G\F6&[(;HQZ'D54/_[9(J'C@E[BK76$+E
M"/9:6_\2-_!X+/RK@#^#P)2P9X']K[[L46K"OJ[Q]/Y!E];/V#E\57L;#J.J
MPA>G\>(T'A#VQ6D\LG388;]P+IGB$;.'*_LQ9Q,RO&%A@24*.3-/9G;E';FO
M";)_+GD::B]WB_^#.UQ>N2WV#^Q\_?C&4K6RB^7]RK:QJ?)N\.8-6Z#B:[L)
M3YECKQL;FTWV!>2-[:;-MM4+SQF=,L<4LW0"ZQ+0N>#EAO.[3MU?!5'K'G69
M:MZCUB]F'_\-4$L#!!0    ( "L^;U1T&67.T D  (0^   8    =')D82TR
M,#(Q,3(S,7AE>#,Q9#(N:'1M[5M_<]HX$_XJ>M.Y7C*#,<;0!D@S0PE]F[DV
MR1 R=_>GL&6LB;%\D@WA_?3OKB2#R8^F;=([TB,S 2ROI%WI>797LGST'\<9
MIC%- Q:2C^//GT@H@F+&TIP$DM$<2A<\C\E89!E-R6<F)4\2\E[R<,H(Z=0]
MK]ZH'[8=Y_@(FAK8.B+M$M_UVFZST6P2S^OZ;[OPH_^9[%^-!P=:^N1\,/[S
M8FAZO;AZ_^ET0/8<U_W='[CNR?C$W&C5&QX92YHJGG.1TL1UAV=[9"_.\ZSK
MNHO%HK[PZT).W?'(C?-9TG(3(12KAWFX=WR$)?#):'A\-&,Y)4%,I6+YN[VK
M\0?G$"1RGB?L^,@MOXWL1(3+XZ.0SXG*EPE[MS>C<LI3)Q=9UV]D>0]JNG#[
MELR-L^!A'G>]1N.77D;#D*=3)V%1#B5UO[TNDWP:KPN%,:XK64)S/F?8>J7=
M(&%4=B<BCWNWN[BO9E;6BT2:.Q&=\639_77,9TR1,[8@(S&CZ:\U4P+?BDD>
M_=K3THK_CT'38&"I*72;BUG7:T)9SFYRAR9\"AVB 3TS*ET[().-CA=,VS@1
M20@WAS<QG_"<^%Z]>>1.8/2RBJ83&EQ/I2C2T E$(F3W5:3_>D\RH:)N (AF
M\AOT'0Q'X],/IX/^^/3\#. YNKSJGXW)^/PE*#^Z^C2\))Y/':^U3P_(^8AX
M[=!>7)V=#$=D_'%(+H>#J]'I^!1DAW\,/O;/_CLD_<&8G'\@7L=OU5Z"J?U+
MTC\YOQ@/3ZJ3A*;IB?,;331'6]L?O>^?#2^=\S\^#?\L#6TV&O?@\8>90_ ?
MN42L;5CW0?/F7 %I$IXONS$/0Y9"C=>O#IL-OW?DHO1SJFV5]$HM#U=*GM;(
M;T(NR>]@S4+(/*Z1@,F<1TN2QS3O:B5R.DD8F0@9,OENK[$'(DEBG<CJ6F4T
M**]+2.D:"*>$9HIURQ]/@Y1UU]9Y':Y+T('K24)UG80N19%W(W[#PE[%KQJE
M2OSE$O[#4F$K=FB#0!Y6;WY1Z=M*SG$0 YI8L&C<@'Z]1<QSYN!8L6XJ%I)F
MO4JG=DRM<E[]M@J;]^\"['N'U%QB0Z"4G-&D5\6K+:I@'\,>@H?$=,Z(9'/.
M%I :Y#%7Y -($Z_A_$8B(:&(D7Z:%C0A%]"U",DP#4'TA 5L-F$2@D8-B-KT
MB(C@5BYI2,DX9C PK( 15#5RF@;U-2=P0%R<-5=/\PZ<_Q XF]L.SO=4Z6R5
MS);D&JQ)&*2U-8-1R3+P=9 /@R*I@'P8&J0\)31=D@) 6##0'+)=G2P#,"F9
MP97D@.*(!E DB9A!QI,+(W='( 5X*T7!L8+(C%XS3815FPK*0E &NDS0"NP#
M!0(N(4,',<C9%6@"6" P*4%,5($?Z_H+)IEM! V8<06)) Z_R>DE4QD+M(+8
M;F:H%PB8>1B4R;(Z##MN;1NW_!?++48BG@)ZD0AKM-: 6" .MV7E/D\C;!_7
M./ [2 J,"\"("C1KP"8NDR7) -#(1>0HK%%79+,X5[>Z!CZ'>O%40XDB 0%@
MF  :Z.Z4UB>@*B91(A:JI)]D4ZX@!$%'% N-WJ!EK<(B52IS1]L=D;:-2*UM
M)])X W6O7_F=GK)$L6DXNG0111PN]]6!!N0IH9)IZ .4.0(+,RVF<-:XBK$&
MBLT@HF%4P^N0JR 1JH!Z&.ND2 P',BD"%D*Q(OL ^9 !APRNAS=!3-,I9&\0
M1D9% A)ZT=G>9T8+O>K$JX-5HE?E#TA@<MC=<<)RHMW:#D[0;>?$"5-P!2C4
M.<_CR*UA.A;00GU]%<R+)@S@;GLRF98H)#0 7A[7YA@[0(JENAU<"Z^C3C5R
MF=TYH)A-M=8<J-FHAC<Y1"#018F$AWH75143Q4-.)4<#N$D(=2Q-L:5"89*F
M'8'2&9V.-$(Q4"B'R(:5,HI@*!** 1+,TDJLDSVH85+':L8+OR8,!2&&07W
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MG^%5>*?(5%18B#^@[7PB<X&6:-589X"M$ 32 ,25BL@L >B=D5]5CZ'TSK]
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M>[_3HR91A2<@"&7+R#A409IV#,[R!#0!X[%4B;G)%4$:N4=2&3%1"3*GI$V
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M? [I\F6+UA01^D?(2H"A2.:(G)\(/5L+31*,&P*O8H;_OTVXAE:+7A:08&K
M0K!#S@2AA9'^0OWQN%Y9(?T"3@0<D;L=TW6KJ7=(<L%M9D3.-EO[/#T3- 'Y
M48($3904L6KZIS4>I55WQC!X9:<TPLJ5M#9 "-Q=\S#\J$^PTF(Z!$%#2TYJ
M&$<#Z!7XNI8@/ZN$CTV9DD=OB]$)2:_%^&3KP>Y4+A$_Q[3N2[XZ#63;A"8.
M4W VI<,\G.[FY+'09(RB41@.C$;D\2=EJ#(S"QY+@.WU.,6-.M&?5:(GQL0<
M1M!X_$.DG3Z"*>?&0;J;2O]+,4.)U+U.!_+:,B5E]B8<VOIAE=:@>%1H<RJ1
M2YJ%F)[ $1H2"[H[<C;"D8^@US!ON36)%YY;:*A"D9)<<4:U[:'!A;DAXPH=
MIBPYA=A1$T3A;::8J/AA,\DTTA@TU'BKK4GJ3D#WV@/Y61DP1'%.ZIK5:"WD
MO-!*?E]9&3B%&4$\\"2I8WNVV#^?KETE*=DK$L3H1FZ,[G/"N@]>I(P%R( N
MF6F6$> 6W1H 2,$HYWD\@E9 1NP\T2P DQ1%IQ!;ZTA3&JIH5<= ;VR0 !4I
M9&PYL:*Y5QD0!>1L,LG0Z:9J#-B-8R:3VI .@A0FWHU RH=>'V/7\N&X:AT3
M9'"(F??&@>"]OR5$AKL\T3O$5%0E9O$H-KI&%S>KGKZ'V=*3?:3(=(0,/HD5
M_8(K#J(Y?@W.#N?ROV4$#@K\^7%7?T^V^!#Q\;661?H!>N X!?;XF:L]V*".
M.J5%"*N4B!)*H# 8FE/JE<OQF)8YZ?/V4DG+(5?+:7CJ'@*5PP=4 HW"[43X
MX-W,/5R/!K@F47:<(IA0<[D C?^=6"^YH8P^CZV!$+"Q!!"4D=4_<+-VT)C%
M?3<];7@D-U.N>W.7PIHV=ZE6TM8LEYO)L6H/(4K\W*;,N2^3A5QF1US+]OR7
MSM/G/QX-C05L<?5M^XTBN']"<=UCH<5]#*72;A>[6S4%0$7F$6)M-(Y(%IGR
M(73*UR$SHQ1N--*TZC)7-2XRB,/SA6E#J&3CK$R_/&')81HU&A(NU!"6#Z1L
M),XFRXYVQ&M.$[$Q3D/FA&)+X8+R5=-%VF>AT$^8*"K(1[:<7^" VK< /2H2
M<IKL)E.\"_0THV";N@V3MADC6B1&EI'">#!AOG.3M"3<_R=EP;[-:D)(,IBZ
MPG,1LUU"CT2BLHQ=HA1_%<864\ZC"%T8.YHBPZQYK,B7$AAQ+C0%'\&9+":<
M..TRJ0,>33KF<I[5FGMWT2)BM!Z(3"5EFQ .TS3'&OL-TB0M"I-XG&67P5"5
M5^";-@IVJWTT)"U_6.3U4W#4:>:$?16*[#OSSP_-9=W.5W-949*$VN3RVLR5
M&V%8RS@"]H?1(=%(FY=*'-)(SOE046<JPM6#J5+,A3#R(5L0/H9FCBLH^ K"
MH(JS6KBIC-Q4@@DG6A7.W+E95W% 1DAM)2H=D\$34I1KGU01$HZ*WK=V^-#-
M!>4(+O)W+4& /@UH<I=-T&K$&HM?0[F5[!S^SFCI!D'T46W9:9N-] ,/.MN9
MYOH$U5DIVPIYP+IS0W6<*J0=LVMB[(;30].(R.+K9IDU=8]3:GPK*&NFJA53
M1?X'G)[SWV"T.JJ@H-ZL#X)\NHMQ$)D8UB\BYX=HL?+0BAE\K R-+1Q?-2PR
MF-C,H5CUHKB@YFLXM*%E+H(*AX=)M;(8;4"(#PH#;8[0^;*P'=1LLU6>Q'-B
M6"]X6B\9*IFEW7+#=!J&%83#1&<3Y,A)%D[%03<B%1<89%/49]48S0W7- /_
M4=$RG-> UKE2N]1,=4G^@Q6F,3+=+F4N0W,( X/U>RM2Z':EZN2&&[H9FG#3
MV03TC>][#5<JZUT_ABE, WE^$!A8Q5C/&4[0)[NA\:JO9\4S!>%]CK7-,ZN1
M"C"A[:!5>KK7,^A(] ;A1<?7_R7+EK].+V_YSOH^N;4%,G5>Z(#<0L_ W-47
M%164%S#L<?UO%>B_W!<QI,=PU:50=+5WX"[7>@XY1H90DFI<,,&!>6Z;AE#'
M%T]^S+!OY-PK*L*I%X'=B#,8&UJ7)#%@V1UA+_*(P=IW.*EN2Y.31SG'M=80
M#[$7Q-35,(\2L2&F; S0#'P!SMTEG-MR,"RC/9B9V_KM+4;)$XS+FQ'PM7(A
M6V43&E(9JB4R9-@,9C9E_RA7/:HB=G@PP5)@>XLZ6'HW+2IS-<FU'4#%7ZG]
MR%:)%),V\@ J/+E-4_ )D9/,6JXTS*O?A/^2[VD!CD5JEC-2KV0?C#,E*Q]Z
MF]5\IN6D&W #+-R*ML V?47-L@394&)U$ V9J*^77\M5T-RYY3N+LX;"+EST
MNP=NS2@QL[T^N%ZIG@LIH96XF3O".YRP-T1&?VV7OD[R;KF_Y+)(5A!IC!-U
M7PU<'U>4<0S/N0^'^/>5C&3[5! +05J(9YO6YQ2665!Q9RGQNC=F433[?P-]
M_##: GK+HT7R]D;5V>[ X%-09BY6R^2^JP#@?DX?HO5<446;ZD,\V5Y8.8,6
M'Z1^[6Z+BD%E6K![86-Q"I/XZ@MNE_05H-5CPR+'174L?+NF#0)FE5*M]"9^
MQ6!QK-^H@Z$R+YQ39C2DFH5Z10#8ZE1)KE] YL^.E6W5UOVQY,U\67(& !#H
MJP 6.E,=+)Z!44G<O$A0XMQ)7.!@E8W@)FP:MRR.=%P I.(^4TAHQXRUK4TC
M62A+F^5BA>NLH'..'EZM.,",#>'2O7J(G=2XXU^YC2.K588;WLE%&+PBMGD6
M. MTD^79TUJ,0[!(VY9JA8E8*LB*-:)2BZ"B(L<S3V19>8@,$AH8]"TI&+L]
MQI6/5$5WSO%AR7SL2C]P\BR\/RM@0M-Z]^K+-0)7CV=4W48U3TPCM&Z.I<?0
M97S_>E$.K9&Q*]T#@54L1E OR.6353EEW2;PTS4VL5L2WRV)WPOFUP)S6,JY
MV?(9'V+EEHSK:SD@Q92,FE(PWD%0W]L"R)Q;/>1]"V 4P3KZ^OULC;Z5<?G:
M:MG0J-#LLG )O%%HS*"154OY/NR_H0 MOTO!:O$]1ET/N UN8EQ.\1I7Z;>Y
MW#'(5$.ZM@7X3#G*0H6KH0$92QE#6.:!$4D"6I1R6C!"R7$Q]2F>68"WG-+Y
M9+9,#U8W6(.Q\$8>:MXD7+X"N6$""9UOE;<00]I+._")IH%,0$\Y>GO2^YFW
MKRGRR?B4HW])M4VDF"_UW+8O/5'PZE%+/#GX.5P51FNWWA3P)=A=!'O>#"^#
MT"<N,/%9.,XG7:T+:;GTW=--$+TE9JD4Q79%YKFF>CSSY/"&_DBK,RKXQ#)+
MF9;[[;%<]1:^WKV4=0!>][3V.MRS@?$60 )FK[,9LN,*MVQ'%/R$(9S"?;4Z
M#GBVN[P89^[9#4.EZ D"F3$&B6E%75 7<3,Y8*;4@'FQB0".4W7DE3HNZXA:
M5<)+05%)*SC=PW"3QNFY%8H9.8)Q_7("YV-1\OI!*'3VB:V=A=+87F >P>)&
M*J827G9+T"5,&ZJ(\E-*)<!D?MD=; [\F$GF7)B\Y'--(.W(ZS-%(?;MI=41
MR/5RM3)*COB!)6HS2# +PV+,2H+R9^R"SP4H'*\?9%..*E9JRG0#><"*+W)K
M'RAI5Z%!?I.'6[%-?M&C>9V<JD:24X7G&42&4I.T8<94*4(KRDT3]VLLG@_%
M',2&6H\[%]W;H8=+0!SH^$C.P9"&B?)E+M6>']QIS].-+V6HPI(NVEXK_BSB
M,2_<\(062>Z8*+_M!!]=W1)C,5J!672G"$%'>1EI,5&NU+M2NX:H2'<:-N(
MN]JW29 "9EIM1[I&MJ[>?74-<HN#$G_^TL'^8;DCP;O-30>9;''@\H>BNK&
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M-QO9GJ]XX!VK95WT>YV16!^G0O%Q]E$TO[PCT1E_ASI-[87,8OF7>).8(<#
M!VD_JSRHBL:OQR4]6TY!8KXX<'!Y=M)QM8"/H0D^>G=^JV[:#ZL0 Y]PGHS]
MZ1:7])VC5MHU:K&:48WHS]$_4U\&OA0!)2!+"=A2 B.W/Z*I5'@>=($'Z5 \
M.;!X=('[[H"6N.B<=+Y%<GK_3'1N='Q3(MH=FG@)/R;Y-'GU_U!+ 0(4 Q0
M   ( "L^;U2SF(U0FP\  ).K   1              "  0    !T<F1A+3(P
M,C$Q,C,Q+GAS9%!+ 0(4 Q0    ( "L^;U3>G6TI! P  %R>   5
M      "  <H/  !T<F1A+3(P,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4    "  K
M/F]4R#FC;D<E   ]L ( %0              @ $!'   =')D82TR,#(Q,3(S
M,5]D968N>&UL4$L! A0#%     @ *SYO5 0#17ZJ8   /: & !4
M     ( !>T$  '1R9&$M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( "L^
M;U1NAKA=\$,  '5=!0 5              "  5BB  !T<F1A+3(P,C$Q,C,Q
M7W!R92YX;6Q02P$"% ,4    "  K/F]4.&(Z,F:C!  (""0 %0
M    @ %[Y@  =')D82TR,#(Q,3(S,7@Q,&LN:'1M4$L! A0#%     @ *SYO
M5$<)JY8V8P  ?YX  !@              ( !%(H% '1R9&$M,C R,3$R,S%X
M,3!K,# V+FIP9U!+ 0(4 Q0    ( "L^;U3 F.P650 ! -<( 0 8
M      "  8#M!0!T<F1A+3(P,C$Q,C,Q>#$P:S P-RYJ<&=02P$"% ,4
M"  K/F]4]WW5]I![  !BAP  &               @ $+[@8 =')D82TR,#(Q
M,3(S,7@Q,&LP,#@N:G!G4$L! A0#%     @ *SYO5(A)*'? W@  "OL  !@
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M,RYJ<&=02P$"% ,4    "  K/F]4#8 M [9A   6=0  &
M@ $830H =')D82TR,#(Q,3(S,7@Q,&LP,30N:G!G4$L! A0#%     @ *SYO
M5.J9^#BI@   3Y,  !@              ( !!*\* '1R9&$M,C R,3$R,S%X
M,3!K,#$U+FIP9U!+ 0(4 Q0    ( "L^;U0TJ[GHU14! .T> 0 8
M      "  >,O"P!T<F1A+3(P,C$Q,C,Q>#$P:S Q-BYJ<&=02P$"% ,4
M"  K/F]4E#'X]0DV   %3   &               @ 'N10P =')D82TR,#(Q
M,3(S,7@Q,&LP,3<N:G!G4$L! A0#%     @ *SYO5$D!5*FW2P   E0  !@
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M,BYJ<&=02P$"% ,4    "  K/F]4R;7!H<A+   @6   &
M@ %_[PT =')D82TR,#(Q,3(S,7@Q,&LP,C,N:G!G4$L! A0#%     @ *SYO
M5&^AX7^ 60  <FD  !@              ( !?3L. '1R9&$M,C R,3$R,S%X
M,3!K,#(T+FIP9U!+ 0(4 Q0    ( "L^;U3@(>XGU;(  $ZX   8
M      "  3.5#@!T<F1A+3(P,C$Q,C,Q>#$P:S R-2YJ<&=02P$"% ,4
M"  K/F]4,W\"@_'Y  !#_P  &               @ $^2 \ =')D82TR,#(Q
M,3(S,7@Q,&LP,C8N:G!G4$L! A0#%     @ *SYO5'+Y4?2!"@$ TA$! !@
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M,2YJ<&=02P$"% ,4    "  K/F]4UK#1S*\D   7+P  &
M@ $;E1, =')D82TR,#(Q,3(S,7@Q,&LP,S(N:G!G4$L! A0#%     @ *SYO
M5!+RQ%EU/   SF4  !@              ( ! +H3 '1R9&$M,C R,3$R,S%X
M,3!K,#,S+FIP9U!+ 0(4 Q0    ( "L^;U0 8N^@\Y\   "L   8
M      "  :OV$P!T<F1A+3(P,C$Q,C,Q>#$P:S S-"YJ<&=02P$"% ,4
M"  K/F]4< [6+VAP  "&B0  &               @ '4EA0 =')D82TR,#(Q
M,3(S,7@Q,&LP,S4N:G!G4$L! A0#%     @ *SYO5/H%<+L A@  7YP  !@
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M,"YJ<&=02P$"% ,4    "  K/F]4;S#<+B%>   :9   &
M@ &6E1< =')D82TR,#(Q,3(S,7@Q,&LP-#$N:G!G4$L! A0#%     @ *SYO
M5%MR[MC!-P  "CX  !@              ( ![?,7 '1R9&$M,C R,3$R,S%X
M,3!K,#0R+FIP9U!+ 0(4 Q0    ( "L^;U3D40U()%(  -EA   8
M      "  >0K& !T<F1A+3(P,C$Q,C,Q>#$P:S T,RYJ<&=02P$"% ,4
M"  K/F]4L1$[ATQJ  "'>P  &               @ $^?A@ =')D82TR,#(Q
M,3(S,7@Q,&LP-#0N:G!G4$L! A0#%     @ *SYO5.09_/->G   V\0  !@
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M,BYH=&U02P$"% ,4    "  K/F]4ULTN7\@&  #F-@  &
M@ 'FH!D =')D82TR,#(Q,3(S,7AE>#,R9#$N:'1M4$L! A0#%     @ *SYO
M5&8ZMT7W%@  \8   !<              ( !Y*<9 '1R9&$M,C R,3$R,S%X
?97@T9#,N:'1M4$L%!@     T #0 (0X  !"_&0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
